,drug_name,pubmed_id,title,authors,mesh_terms,paper_url
0,Amoxapine,36786368,Preparation and characterization of amoxapine- and naringin-loaded solid lipid nanoparticles: drug-release and molecular-docking studies.,"['Jat S', 'Bhatt M', 'Roychowdhury S', 'Dixit VA', 'Pawar SD', 'Kulhari H', 'Alexander A', 'Kumar P']","['*Amoxapine', 'Molecular Docking Simulation', 'Cytochrome P-450 CYP2D6', 'Cytochrome P-450 CYP3A', 'Lipids/chemistry', '*Nanoparticles/chemistry', 'Particle Size', 'Drug Carriers/chemistry']",https://pubmed.ncbi.nlm.nih.gov/36786368/
1,Amoxapine,3345021,Amoxapine cardiotoxicity.,"['Munger MA', 'Effron BA']","['Adult', 'Amoxapine/*poisoning', 'Dibenzoxazepines/*poisoning', 'Electrocardiography', 'Emergencies', 'Female', 'Heart Arrest/*chemically induced', 'Humans', 'Tachycardia/chemically induced/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/3345021/
2,Amoxapine,423094,"GLC analysis of loxapine, amoxapine, and their metabolites in serum and urine.","['Cooper TB', 'Kelly RG']","['Amoxapine/*blood/*urine', 'Chromatography, Gas', 'Dibenzoxazepines/*blood/*urine', 'Humans', 'Hydroxylation', 'Loxapine/*blood/*urine', 'Methods']",https://pubmed.ncbi.nlm.nih.gov/423094/
3,Amoxapine,6749828,Amoxapine and amitriptyline: serum levels and clinical response in patients with primary unipolar depression.,"['Click MA Jr', 'Zisook S']","['Adolescent', 'Adult', 'Ambulatory Care', 'Amitriptyline/*blood/therapeutic use', 'Amoxapine/*blood/therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/blood/*drug therapy/psychology', 'Dibenzoxazepines/*blood', 'Double-Blind Method', 'Humans', 'Middle Aged', 'Nortriptyline/blood', 'Psychiatric Status Rating Scales']",https://pubmed.ncbi.nlm.nih.gov/6749828/
4,Amoxapine,23780763,Development and validation of a sensitive spectrofluorimetric method for the determination of amoxapine in human plasma and urine.,"['Karasakal A', 'Ulu ST']","['Amoxapine/*blood/*urine', 'Antidepressive Agents/*blood/*urine', 'Humans', 'Limit of Detection', 'Male', 'Spectrometry, Fluorescence/*methods']",https://pubmed.ncbi.nlm.nih.gov/23780763/
5,Amoxapine,21082678,Determination of amoxapine and nortriptyline in blood plasma and serum by salt-assisted liquid-liquid microextraction and high-performance liquid chromatography.,"['Gupta M', 'Jain A', 'Verma KK']","['Amoxapine/*blood', 'Chromatography, High Pressure Liquid/*methods', 'Humans', 'Indicators and Reagents', 'Limit of Detection', 'Nortriptyline/*blood', 'Reference Standards', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/21082678/
6,Amoxapine,9631933,Concurrent high-performance liquid chromatographic measurement of loxapine and amoxapine and of their hydroxylated metabolites in plasma.,"['Hue B', 'Palomba B', 'Giacardy-Paty M', 'Bottai T', 'Alric R', 'Petit P']","['Amoxapine/*blood', 'Antidepressive Agents, Tricyclic/*blood', 'Antipsychotic Agents/*blood', '*Chromatography, High Pressure Liquid/methods', 'Drug Monitoring/*methods/*statistics & numerical data', 'Humans', 'Hydroxylation', 'Linear Models', 'Loxapine/*blood', 'Sensitivity and Specificity']",https://pubmed.ncbi.nlm.nih.gov/9631933/
7,Amoxapine,28152454,"Simultaneous quantification of loxapine, loxapine N-oxide, amoxapine, 8-hydroxyloxapine and 7-hydroxyloxapine in human plasma using LC-MS/MS.","['Meng M', 'Zhao N', 'Pederson CC', 'Harrison E', 'Green C', 'Gorman SH', 'Reuschel S']","['Adolescent', 'Antipsychotic Agents/blood/pharmacokinetics/therapeutic use', 'Child', 'Chromatography, High Pressure Liquid/*methods', 'Humans', 'Limit of Detection', 'Linear Models', 'Loxapine/*analogs & derivatives/*blood/pharmacokinetics/therapeutic use', 'Reproducibility of Results', 'Tandem Mass Spectrometry/*methods']",https://pubmed.ncbi.nlm.nih.gov/28152454/
8,Amoxapine,7621219,Successful treatment of amoxapine-induced refractory status epilepticus with propofol (diprivan).,"['Merigian KS', 'Browning RG', 'Leeper KV']","['Adult', 'Amoxapine/*adverse effects', 'Drug Overdose', 'Female', 'Humans', 'Infusions, Intravenous', 'Propofol/administration & dosage/*therapeutic use', 'Status Epilepticus/*chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7621219/
9,Amoxapine,6680730,Analysis of blood and tissue for amoxapine and trimipramine.,"['Wu Chen NB', 'Schaffer MI', 'Lin RL', 'Hadac JP', 'Stein RJ']","['Amoxapine/*blood/poisoning', 'Chromatography, Gas', 'Dibenzazepines/*blood', 'Dibenzoxazepines/*blood', '*Forensic Medicine', 'Gas Chromatography-Mass Spectrometry', 'Humans', 'Trimipramine/*blood/poisoning']",https://pubmed.ncbi.nlm.nih.gov/6680730/
10,Disopyramide,11720625,Torsades de pointes due to drug interaction between disopyramide and clarithromycin.,"['Choudhury L', 'Grais IM', 'Passman RS']","['Aged', 'Anti-Arrhythmia Agents/*adverse effects', 'Anti-Bacterial Agents/*adverse effects', 'Clarithromycin/*adverse effects', 'Disopyramide/*adverse effects', 'Drug Interactions', 'Female', 'Humans', 'Torsades de Pointes/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/11720625/
11,Disopyramide,746466,Clinical and electrophysiological observations with disopyramide in drug-resistant and recurrent symptomatic arrhythmias.,"['Myers JB', 'Millar RN', 'Obel IW']","['Adult', 'Aged', 'Arrhythmias, Cardiac/*drug therapy', 'Depression, Chemical', 'Disopyramide/pharmacology/*therapeutic use', 'Drug Resistance', 'Electrophysiology/methods', 'Female', 'Heart/physiopathology', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Pyridines/*therapeutic use', 'Syncope/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/746466/
12,Disopyramide,37688422,Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide.,"['Willeford A', 'Silva Enciso J']","['Humans', '*Disopyramide/therapeutic use', '*Cardiomyopathy, Hypertrophic/drug therapy/chemically induced', 'Benzylamines/adverse effects', 'Adrenergic beta-Antagonists']",https://pubmed.ncbi.nlm.nih.gov/37688422/
13,Disopyramide,884018,Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods.,"['Birkhead JS', 'Vaughan Williams EM']","['Adolescent', 'Adult', 'Aged', 'Arrhythmias, Cardiac/physiopathology', 'Atrioventricular Node/*drug effects', 'Atropine/pharmacology', 'Disopyramide/*pharmacology', 'Female', 'Heart/innervation', 'Heart Atria/*drug effects', 'Heart Conduction System/*drug effects', 'Heart Ventricles/drug effects', 'Humans', 'Male', 'Middle Aged', 'Neural Conduction/*drug effects', 'Parasympathetic Nervous System/drug effects/physiology', 'Pyridines/*pharmacology', 'Refractory Period, Electrophysiological/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/884018/
14,Disopyramide,3304965,"Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.","['Brogden RN', 'Todd PA']","['Arrhythmias, Cardiac/*drug therapy', 'Disopyramide/metabolism/*pharmacology/therapeutic use', 'Humans', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/3304965/
15,Disopyramide,10824133,"Enantioselective binding of propranolol, disopyramide, and verapamil to human alpha(1)-acid glycoprotein.","['Hanada K', 'Ohta T', 'Hirai M', 'Arai M', 'Ogata H']","['Disopyramide/*metabolism', 'Humans', 'Orosomucoid/*metabolism', 'Propranolol/*metabolism', 'Protein Binding', 'Stereoisomerism', 'Verapamil/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/10824133/
16,Disopyramide,4061965,The anticholinergic side effects of disopyramide and controlled-release disopyramide.,['Teichman S'],"['Delayed-Action Preparations', 'Disopyramide/administration & dosage/*adverse effects/metabolism/therapeutic use', 'Drug Interactions', 'Drug Therapy, Combination', 'Humans', 'Pyridostigmine Bromide/administration & dosage/metabolism/therapeutic use', 'Tachycardia/drug therapy', 'Urination Disorders/drug therapy/etiology/prevention & control', 'Xerostomia/drug therapy/etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/4061965/
17,Disopyramide,4006374,Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.,"['Chiang WT', 'von Bahr C', 'Calissendorff B', 'Dahlqvist R', 'Emilsson H', 'Magnusson A', 'Schenck-Gustafsson K']","['Adult', 'Chromatography, High Pressure Liquid', 'Disopyramide/*analogs & derivatives/blood/*metabolism', 'Double-Blind Method', 'Drug Evaluation', 'Electrocardiography', 'Female', 'Heart Rate/drug effects', 'Humans', 'Infusions, Parenteral', 'Kinetics', 'Male', 'Pupil/drug effects', 'Salivation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/4006374/
18,Disopyramide,7299695,Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.,"['Lima JJ', 'Boudoulas H', 'Blanford M']","['Binding Sites', 'Blood Proteins/metabolism', 'Disopyramide/*blood/pharmacology', 'Heart Rate/drug effects', 'Humans', 'In Vitro Techniques', 'Kinetics', 'Myocardial Contraction/drug effects', 'Orosomucoid/metabolism', 'Protein Binding', 'Pyridines/*blood']",https://pubmed.ncbi.nlm.nih.gov/7299695/
19,Disopyramide,1724233,Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease.,"['Tanabe T', 'Takahashi K', 'Yoshioka K', 'Goto Y']","['Administration, Oral', 'Adult', 'Aged', 'Cardiac Complexes, Premature/complications/*drug therapy', 'Cardiomyopathy, Dilated/physiopathology', 'Cardiomyopathy, Hypertrophic/physiopathology', 'Disopyramide/administration & dosage/adverse effects/blood/*therapeutic use', 'Drug Combinations', 'Drug Evaluation', 'Electrocardiography, Ambulatory/drug effects', 'Female', 'Heart Diseases/complications/*physiopathology', 'Humans', 'Hypertension/physiopathology', 'Male', 'Mexiletine/administration & dosage/adverse effects/blood/*therapeutic use', 'Middle Aged', 'Myocardial Infarction/physiopathology', 'Pulmonary Heart Disease/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/1724233/
20,Disopyramide,22687589,A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.,"['Sherrid MV', 'Arabadjian M']","['Anti-Arrhythmia Agents/*therapeutic use', 'Cardiomyopathy, Hypertrophic/*drug therapy/etiology', 'Disopyramide/*therapeutic use', 'Heart Failure/prevention & control', 'Humans', 'Ventricular Outflow Obstruction/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22687589/
21,Disopyramide,885947,High-pressure liquid chromatographic analysis of drugs in biological fluids. III. Analysis of disopyramide and its mono-N-dealkylated metabolite in plasma and urine.,"['Meffin PJ', 'Harpat SR', 'Harrison DC']","['Chromatography, High Pressure Liquid/methods', 'Dealkylation', 'Disopyramide/*analysis/blood/urine', 'Humans', 'Pyridines/*analysis']",https://pubmed.ncbi.nlm.nih.gov/885947/
22,Disopyramide,11758636,Enantioselective binding of disopyramide to alpha1-acid glycoprotein and its variants.,"['Kishino S', 'Itoh S', 'Nakagawa T', 'Miyazaki K']","['Anti-Arrhythmia Agents/*chemistry', 'Binding Sites', 'Chromatography, High Pressure Liquid', 'Disopyramide/*chemistry', 'Humans', 'In Vitro Techniques', 'Orosomucoid/*chemistry', 'Protein Binding', 'Protein Isoforms', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/11758636/
23,Iodixanol,27378442,Purification of infectious and non-infectious chlamydial particles using iodixanol for density gradient preparation.,"['Beder T', 'Scheven MT', 'Praetzsch D', 'Westermann M', 'Saluz HP']","['Cell Line', 'Chlamydia/classification/*isolation & purification', 'Colony Count, Microbial', 'Contrast Media/*chemistry', 'Humans', 'RNA, Bacterial/*isolation & purification', 'RNA, Ribosomal, 16S/isolation & purification', 'Triiodobenzoic Acids/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/27378442/
24,Iodixanol,29048268,Density separation of quiescent yeast using iodixanol.,"['Quasem I', 'Luby CJ', 'Mace CR', 'Fuchs SM']","['Cell Separation/economics/*methods', 'Centrifugation, Density Gradient/economics/*methods', 'Cost-Benefit Analysis', '*Resting Phase, Cell Cycle/drug effects', 'Saccharomyces cerevisiae/drug effects/*isolation & purification/physiology', 'Time Factors', 'Triiodobenzoic Acids/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29048268/
25,Iodixanol,32015003,Enrichment of Fully Packaged Virions in Column-Purified Recombinant Adeno-Associated Virus (rAAV) Preparations by Iodixanol Gradient Centrifugation Followed by Anion-Exchange Column Chromatography.,"['Sena-Esteves M', 'Gao G']","['Anions', 'Centrifugation/*methods', 'Chromatography, Ion Exchange/instrumentation/*methods', 'Dependovirus/genetics/*isolation & purification', 'Genetic Vectors/genetics/*isolation & purification', 'Hydrogen-Ion Concentration', 'Recombination, Genetic', 'Reproducibility of Results', 'Temperature', 'Triiodobenzoic Acids/*chemistry', 'Viral Genome Packaging', 'Virion/*genetics']",https://pubmed.ncbi.nlm.nih.gov/32015003/
26,Iodixanol,14665738,Iodixanol development of a laboratory-scale technique to monitor the persistence of Mycobacterium avium subsp. paratuberculosis in Cheddar cheese.,"['Donaghy JA', 'Totton NL', 'Rowe MT']","['Cheese/analysis/*microbiology', 'Food Microbiology', 'Humans', 'Mycobacterium avium/classification/growth & development/*isolation & purification', 'Mycobacterium avium subsp. paratuberculosis/classification/growth & development/*isolation & purification', '*Triiodobenzoic Acids']",https://pubmed.ncbi.nlm.nih.gov/14665738/
27,Iodixanol,12805920,Formation of self-generated gradients of iodixanol.,['Graham JM'],"['Centrifugation, Density Gradient/*instrumentation/*methods', 'Reproducibility of Results', 'Solutions', 'Time Factors', '*Triiodobenzoic Acids/chemistry', 'Ultracentrifugation']",https://pubmed.ncbi.nlm.nih.gov/12805920/
28,Iodixanol,25363067,Acute generalized exanthematous pustulosis induced by iodixanol (Visipaque): a serious reaction to a commonly used drug.,"['Ozturk U', 'Sungur MA', 'Karakas T', 'Mulayim K', 'Ozturk P']","['Acute Generalized Exanthematous Pustulosis/diagnosis/drug therapy/*etiology', 'Anti-Inflammatory Agents/administration & dosage/therapeutic use', 'Biopsy', 'Contrast Media/administration & dosage/*adverse effects', 'Coronary Angiography/methods', 'Female', 'Humans', 'Methylprednisolone/administration & dosage/therapeutic use', 'Middle Aged', 'Treatment Outcome', 'Triiodobenzoic Acids/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25363067/
29,Iodixanol,37220640,Ioxaglate Versus IoDixanol for the Prevention of Contrast-Induced Nephropathy: The IDPC Trial.,"['Freitas RAP', 'Tanajura LF', 'Mehran R', 'Chamie D', 'Chaves A', 'Centemero M', 'Braga S', 'Costa R', 'Cao D', 'Sousa A', 'Feres F', 'Costa JR Jr']","['Aged', 'Humans', 'Contrast Media/adverse effects', 'Coronary Angiography/adverse effects/methods', 'Creatinine', '*Ioxaglic Acid/adverse effects', '*Kidney Diseases/chemically induced', 'Risk Factors', 'Triiodobenzoic Acids/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37220640/
30,Iodixanol,35422982,Iopromide and Iodixanol in the Development of Postoperative Contrast Nephropathy in Patients with Renal Insufficiency: A Meta-Analysis.,"['Feng Y', 'Qiu G', 'Xu C', 'Duan Z', 'Wang M', 'Wang L', 'Hu W', 'Li P', 'Zhou H']","['Contrast Media/adverse effects', 'Creatinine/adverse effects', 'Female', 'Humans', 'Iohexol/analogs & derivatives', '*Kidney Diseases/chemically induced', 'Male', '*Renal Insufficiency/chemically induced/complications/epidemiology', 'Retrospective Studies', 'Triiodobenzoic Acids']",https://pubmed.ncbi.nlm.nih.gov/35422982/
31,Iodixanol,29718868,Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.,"['Zhang J', 'Jiang Y', 'Rui Q', 'Chen M', 'Zhang N', 'Yang H', 'Zhou Y']","['Contrast Media/*adverse effects', 'Coronary Angiography/*methods', 'Creatinine/blood', 'Humans', 'Iohexol/adverse effects/*analogs & derivatives', 'Kidney Diseases/blood/*chemically induced', '*Percutaneous Coronary Intervention', 'Renal Insufficiency/*complications', 'Triiodobenzoic Acids/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/29718868/
32,Iodixanol,35618562,Image quality and diagnostic accuracy of different dosages of iodixanol in computed tomography angiography and perfusion of overweight patients with coronary artery stenosis: A feasibility study.,"['Tang X', 'Zhang Y', 'Wang T', 'Ma Y', 'Shi H', 'Yin R', 'Zou P', 'Cao J', 'Pan C']","['Humans', 'Computed Tomography Angiography', 'Feasibility Studies', 'Overweight', 'Coronary Angiography/methods', '*Myocardial Perfusion Imaging/methods', '*Coronary Stenosis', '*Coronary Artery Disease/complications/diagnostic imaging', 'Tomography, X-Ray Computed/methods', 'Perfusion']",https://pubmed.ncbi.nlm.nih.gov/35618562/
33,Iodixanol,36307737,A multiple-metabolites model to predict preliminary renal injury induced by iodixanol based on UHPLC/Q-Orbitrap-MS and (1)H-NMR.,"['Cheng L', 'Wang L', 'Chen B', 'Wang C', 'Wang M', 'Li J', 'Gao X', 'Zhang Z', 'Han L']","['Humans', 'Chromatography, High Pressure Liquid/methods', '*Metabolomics/methods', 'Kynurenic Acid/adverse effects/metabolism', 'Leucine/adverse effects/metabolism', 'Proton Magnetic Resonance Spectroscopy', 'Tryptophan/metabolism', 'Kidney/metabolism', '*Acute Kidney Injury/chemically induced/diagnosis/metabolism', 'Biomarkers/metabolism', 'Indoles/adverse effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/36307737/
34,Rofecoxib,11087881,Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.,"['Bombardier C', 'Laine L', 'Reicin A', 'Shapiro D', 'Burgos-Vargas R', 'Davis B', 'Day R', 'Ferraz MB', 'Hawkey CJ', 'Hochberg MC', 'Kvien TK', 'Schnitzer TJ']","['Adult', 'Arthritis, Rheumatoid/*drug therapy/mortality', 'Cardiovascular Diseases/mortality', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*therapeutic use', 'Duodenal Obstruction/chemically induced', 'Female', 'Gastric Outlet Obstruction/chemically induced', 'Gastrointestinal Diseases/*chemically induced', 'Gastrointestinal Hemorrhage/chemically induced', 'Humans', 'Isoenzymes/*antagonists & inhibitors', 'Lactones/*adverse effects/therapeutic use', 'Male', 'Membrane Proteins', 'Middle Aged', 'Naproxen/*adverse effects/therapeutic use', 'Peptic Ulcer/chemically induced', 'Proportional Hazards Models', 'Prostaglandin-Endoperoxide Synthases', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11087881/
35,Rofecoxib,17106714,Rofecoxib inhibits heterotopic ossification after total hip arthroplasty.,"['van der Heide HJ', 'Koorevaar RC', 'Lemmens JA', 'van Kampen A', 'Schreurs BW']","['Adult', 'Aged', 'Aged, 80 and over', 'Arthroplasty, Replacement, Hip/*adverse effects', 'Cyclooxygenase 2 Inhibitors/*therapeutic use', 'Female', 'Follow-Up Studies', 'Humans', 'Lactones/*therapeutic use', 'Male', 'Middle Aged', 'Ossification, Heterotopic/*prevention & control', 'Prospective Studies', 'Research Design', 'Sulfones/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17106714/
36,Rofecoxib,11898894,Gastrointestinal bleeds associated with rofecoxib.,"['Foral PA', 'Wilson AF', 'Nystrom KK']","['Aged', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Cyclooxygenase Inhibitors/*adverse effects/therapeutic use', 'Gastrointestinal Hemorrhage/*chemically induced', 'Hematemesis/chemically induced', 'Humans', 'Ibuprofen/adverse effects/therapeutic use', 'Lactones/*adverse effects/therapeutic use', 'Laminectomy/adverse effects', 'Male', 'Melena/chemically induced', 'Middle Aged', 'Pain, Postoperative/drug therapy/etiology', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11898894/
37,Rofecoxib,32179835,Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.,"['Buzharevski A', 'Paskas S', 'Sarosi MB', 'Laube M', 'Lonnecke P', 'Neumann W', 'Murganic B', 'Mijatovic S', 'Maksimovic-Ivanic D', 'Pietzsch J', 'Hey-Hawkins E']","['*Antineoplastic Agents', 'Boron Compounds/*chemistry', 'Carcinogenesis/genetics', 'Cell Line, Tumor', 'Colonic Neoplasms/*etiology/*pathology', 'Cyclooxygenase 2/*physiology', 'Cyclooxygenase 2 Inhibitors/*chemical synthesis/*pharmacology', 'Drug Design', 'Humans', 'Hydrophobic and Hydrophilic Interactions', 'Lactones/*chemical synthesis/*pharmacology', 'Melanoma/*etiology/*pathology', 'Sulfones/*chemical synthesis/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32179835/
38,Rofecoxib,15566132,Effect of rofecoxib on pain caused by osteoid osteoma.,"['Carpintero-Benitez P', 'Aguirre MA', 'Serrano JA', 'Lluch M']","['Adolescent', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage', 'Bone Neoplasms/complications/diagnostic imaging', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Follow-Up Studies', 'Humans', 'Lactones/*administration & dosage', 'Male', 'Osteoma, Osteoid/complications/diagnostic imaging', 'Pain Measurement', 'Pain, Intractable/*drug therapy/etiology', 'Prospective Studies', 'Radionuclide Imaging', 'Risk Assessment', 'Severity of Illness Index', 'Sulfones/*administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15566132/
39,Rofecoxib,15485938,Lessons from the withdrawal of rofecoxib.,"['Dieppe PA', 'Ebrahim S', 'Martin RM', 'Juni P']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Cyclooxygenase Inhibitors/*adverse effects', '*Drug Approval', 'Humans', 'Lactones/*adverse effects', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/15485938/
40,Rofecoxib,16408954,Synthesis of a NO-releasing prodrug of rofecoxib.,"['Engelhardt FC', 'Shi YJ', 'Cowden CJ', 'Conlon DA', 'Pipik B', 'Zhou G', 'McNamara JM', 'Dolling UH']","['Carbon Dioxide', 'Cyclooxygenase Inhibitors/*chemical synthesis/chemistry', 'Indicators and Reagents', 'Lactones/*chemical synthesis/chemistry', 'Models, Molecular', 'Molecular Conformation', 'Nitric Oxide/*analysis', 'Prodrugs/chemical synthesis/chemistry', 'Sulfones/*chemical synthesis/chemistry']",https://pubmed.ncbi.nlm.nih.gov/16408954/
41,Rofecoxib,14741079,Efficacy of rofecoxib and nimesulide in controlling postextraction pain in oral surgery: a randomised comparative study.,"['Bracco P', 'Debernardi C', 'Coscia D', 'Pasqualini D', 'Pasqualicchio F', 'Calabrese N']","['Adolescent', 'Adult', 'Analgesics/administration & dosage/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use', 'Female', 'Humans', 'Lactones/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', 'Molar, Third', 'Pain, Postoperative/*drug therapy', 'Sulfonamides/administration & dosage/*therapeutic use', 'Sulfones', '*Tooth Extraction', 'Tooth, Impacted/surgery']",https://pubmed.ncbi.nlm.nih.gov/14741079/
42,Rofecoxib,15663617,Intracranial hypertension induced by rofecoxib.,"['Jacob S', 'Rajabally YA']","['Aged', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Cyclooxygenase Inhibitors/*adverse effects/therapeutic use', 'Humans', 'Intracranial Hypertension/*chemically induced', 'Lactones/*adverse effects/therapeutic use', 'Male', 'Sulfones/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15663617/
43,Rofecoxib,14633764,"Metformin lactic acidosis, acute renal failure and rofecoxib.",['Price G'],"['Acidosis, Lactic/*chemically induced', 'Acute Kidney Injury/*chemically induced', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Cyclooxygenase Inhibitors/*adverse effects', 'Drug Interactions', 'Female', 'Humans', 'Hypoglycemic Agents/*adverse effects', 'Lactones/*adverse effects', 'Metformin/*adverse effects', 'Middle Aged', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/14633764/
44,Rofecoxib,35179314,Development of Rofecoxib-Based Fluorophores from ACQ to AIE by Positional Regioisomerization.,"['Wang X', 'Chen L', 'Li R', 'Xie Z', 'Hu M', 'Sun S', 'Li Z', 'Hao J', 'Lin B', 'Chen X', 'Xie L']","['*Fluorescent Dyes/chemistry', 'Lactones', 'Luminescence', '*Sulfones']",https://pubmed.ncbi.nlm.nih.gov/35179314/
45,Rofecoxib,25246044,Rofecoxib does not appear to increase the risk of venous thromboembolism: a systematic review of the literature.,"['Goy J', 'Paikin J', 'Crowther M']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Cyclooxygenase 2 Inhibitors/*adverse effects', 'Humans', 'Lactones/*adverse effects', 'Risk Factors', 'Sulfones/*adverse effects', 'Venous Thromboembolism/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25246044/
46,Rofecoxib,12550797,Ab initio structure determination of rofecoxib from powder diffraction data using molecular packing analysis method and direct space method.,"['Kiang YH', 'Xu W', 'Kaufman MJ']","['Crystallization', 'Lactones/analysis/*chemistry', 'Molecular Structure', 'Monte Carlo Method', 'Powder Diffraction/*methods', 'Sulfones', 'X-Ray Diffraction/methods']",https://pubmed.ncbi.nlm.nih.gov/12550797/
47,Rofecoxib,12151676,Fatal haemorrhagic pulmonary oedema and associated angioedema after the ingestion of rofecoxib.,"['Kumar NP', 'Wild G', 'Ramasamy KA', 'Snape J']","['Angioedema/*chemically induced', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Cyclooxygenase Inhibitors/*adverse effects', 'Fatal Outcome', 'Hemorrhage/chemically induced', 'Humans', 'Lactones/*adverse effects', 'Lung Diseases/chemically induced', 'Male', 'Middle Aged', 'Pulmonary Edema/*chemically induced', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/12151676/
48,Rofecoxib,12234159,Fixed drug eruption to rofecoxib.,"['Nedorost ST', 'Florentino FT', 'Gilliam AC']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Drug Eruptions/*etiology', 'Dysmenorrhea/complications/drug therapy', 'Erythema/chemically induced', 'Female', 'Humans', 'Lactones/*adverse effects', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/12234159/
49,Rofecoxib,35188774,"New Rofecoxib-Based Mechanochromic Luminescent Materials and Investigations on Their Aggregation-Induced Emission, Acidochromism, and LD-Specific Bioimaging.","['Chen L', 'Li R', 'Wang X', 'Wang Z', 'Lin X', 'Yang L', 'Yao Y', 'Sun S', 'Li Z', 'Hao J', 'Lin B', 'Chen X', 'Xie L']","['*Fluorescent Dyes/chemistry', 'Lactones', '*Luminescence', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/35188774/
50,Rofecoxib,12782779,Recurrent aseptic meningitis due to different non-steroidal anti-inflammatory drugs including rofecoxib.,"['Ashwath ML', 'Katner HP']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Female', 'Humans', 'Lactones/*adverse effects', 'Meningitis, Aseptic/*chemically induced', 'Recurrence', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/12782779/
51,meprobamate,14076165,"OBSERVATIONS ON THE ANTIHYPERTENSIVE AND SEDATIVE EFFECTS OF MEBUTAMATE, MEPROBAMATE AND RESERPINE.","['MORIN Y', 'TURMEL L', 'GRANTHAM H', 'FORTIER J']","['*Anti-Anxiety Agents', '*Antihypertensive Agents', '*Antipsychotic Agents', '*Blood Pressure Determination', '*Carbamates', '*Double-Blind Method', 'Humans', '*Hydrochlorothiazide', '*Hypnotics and Sedatives', '*Meprobamate', '*Placebos', '*Reserpine', '*Toxicology']",https://pubmed.ncbi.nlm.nih.gov/14076165/
52,meprobamate,22417833,Postmortem carisoprodol and meprobamate concentrations in blood and liver: lack of significant redistribution.,"['McIntyre IM', 'Sherrard J', 'Lucas J']","['Carisoprodol/blood/pharmacokinetics/*poisoning', 'Diagnosis', 'Forensic Toxicology/methods', 'Gas Chromatography-Mass Spectrometry', 'Humans', 'Liver/metabolism', 'Meprobamate/blood/pharmacokinetics/*poisoning', 'Muscle Relaxants, Central/blood/pharmacokinetics/*poisoning', 'Postmortem Changes', 'Substance Abuse Detection/*methods', 'Substance-Related Disorders/blood/*diagnosis', 'Suicide', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/22417833/
53,meprobamate,26660179,Quantitation of Carisoprodol and Meprobamate in Urine and Plasma Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).,"['Slawson MH', 'Johnson-Davis KL']","['Carisoprodol/*blood/*urine', 'Chromatography, Liquid/methods', 'Humans', 'Meprobamate/*blood/*urine', 'Muscle Relaxants, Central/*blood/*urine', 'Tandem Mass Spectrometry/*methods']",https://pubmed.ncbi.nlm.nih.gov/26660179/
54,meprobamate,27798072,Impact of Expanding ELISA Screening in DUID Investigations to Include Carisoprodol/Meprobamate and Zolpidem.,"['Lu A', 'Scott KS', 'Chan-Hosokawa A', 'Logan BK']","['*Automobile Driving', 'Carisoprodol/*blood', 'Central Nervous System Depressants/*blood', 'Driving Under the Influence/legislation & jurisprudence/*statistics & numerical data', 'Enzyme-Linked Immunosorbent Assay', 'Government Regulation', 'Humans', 'Meprobamate/*blood', 'Pyridines/*blood', 'Retrospective Studies', '*Substance Abuse Detection/legislation & jurisprudence/methods/statistics & numerical data', 'United States', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/27798072/
55,meprobamate,6747621,Impaired brain functions due to diazepam and meprobamate abuse in a 53-year-old-male.,"['Brooker AE', 'Wiens AN', 'Wiens DA']","['Cognition Disorders/chemically induced/diagnosis', '*Diazepam', 'Humans', 'MMPI', 'Male', 'Memory Disorders/chemically induced/diagnosis', '*Meprobamate', 'Middle Aged', 'Motor Skills', '*Psychological Tests', 'Substance-Related Disorders/*complications/*diagnosis/etiology/psychology', 'Wechsler Scales']",https://pubmed.ncbi.nlm.nih.gov/6747621/
56,meprobamate,12826989,"Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.","['Zawertailo LA', 'Busto UE', 'Kaplan HL', 'Greenblatt DJ', 'Sellers EM']","['Adult', 'Analysis of Variance', 'Barbiturates/blood/*pharmacology', 'Behavior, Addictive/blood/*psychology', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Male', 'Meprobamate/blood/*pharmacology', 'Psychomotor Performance', 'Substance-Related Disorders/blood/psychology', 'Triazolam/blood/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12826989/
57,meprobamate,22511696,Evaluating the relationship between carisoprodol concentrations and meprobamate formation and inter-subject and intra-subject variability in urinary excretion data of pain patients.,"['Tse SA', 'Atayee RS', 'Best BM', 'Pesce AJ']","['Carisoprodol/*pharmacokinetics/urine', 'Chromatography, High Pressure Liquid', 'Chronic Pain/*drug therapy/metabolism', 'Drug Monitoring', 'Female', 'Humans', 'Male', 'Meprobamate/*urine', 'Models, Biological', 'Muscle Relaxants, Central/*pharmacokinetics/urine', 'Reference Values', 'Reproducibility of Results', 'Tandem Mass Spectrometry', 'Urinalysis']",https://pubmed.ncbi.nlm.nih.gov/22511696/
58,meprobamate,1113782,"Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality.","['Hartz SC', 'Heinonen OP', 'Shapiro S', 'Siskind V', 'Slone D']","['Abnormalities, Drug-Induced/*etiology', '*Child Development', 'Child, Preschool', 'Chlordiazepoxide/*adverse effects', 'Congenital Abnormalities/epidemiology', 'Female', 'Fetal Death/chemically induced', 'Fetus/*drug effects', 'Follow-Up Studies', 'Humans', 'Infant', '*Infant Mortality', 'Infant, Newborn', 'Intelligence', 'Maternal-Fetal Exchange', 'Meprobamate/*adverse effects', 'Motor Skills', 'Pregnancy', 'Pregnancy Trimester, First', 'United States']",https://pubmed.ncbi.nlm.nih.gov/1113782/
59,meprobamate,3694540,Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability.,"['Roache JD', 'Griffiths RR']","['Adult', 'Affect/drug effects', 'Analysis of Variance', 'Behavior/*drug effects', 'Dose-Response Relationship, Drug', 'Humans', 'Lorazepam/*pharmacology', 'Meprobamate/*pharmacology', 'Sleep/drug effects', '*Substance-Related Disorders', 'Task Performance and Analysis/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3694540/
60,meprobamate,24790060,"Quantification of five compounds with heterogeneous physicochemical properties (morphine, 6-monoacetylmorphine, cyamemazine, meprobamate and caffeine) in 11 fluids and tissues, using automated solid-phase extraction and gas chromatography-tandem mass spectrometry.","['Bevalot F', 'Bottinelli C', 'Cartiser N', 'Fanton L', 'Guitton J']","['Caffeine/*analysis', 'Gas Chromatography-Mass Spectrometry/*methods', 'Limit of Detection', 'Meprobamate/*analysis', 'Morphine/*analysis', 'Morphine Derivatives/*analysis', 'Phenothiazines/*analysis', 'Solid Phase Extraction/*methods', 'Tandem Mass Spectrometry/*methods']",https://pubmed.ncbi.nlm.nih.gov/24790060/
61,meprobamate,16217659,"Incidence, causes and prognosis of hypotension related to meprobamate poisoning.","['Charron C', 'Mekontso-Dessap A', 'Chergui K', 'Rabiller A', 'Jardin F', 'Vieillard-Baron A']","['Adult', 'Anti-Anxiety Agents/blood/*poisoning', 'Charcoal/therapeutic use', 'Female', 'Gastric Emptying', 'Humans', 'Hypotension/*chemically induced', 'Incidence', 'Intensive Care Units', 'Male', 'Meprobamate/blood/*poisoning', 'Middle Aged', 'Prognosis', 'Respiration, Artificial', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/16217659/
62,meprobamate,20870445,"Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate.","['Pok PR', 'Mauras M', 'De Saint Leger MN', 'Kuhlmann E', 'Charpenel-Durat C', 'Navarette C', 'Duval ML', 'De Meo P']","['Aged', 'Anticonvulsants/*blood/poisoning', 'Autopsy', 'Benzodiazepines/*blood/poisoning', 'Clobazam', 'Clorazepate Dipotassium/*blood/poisoning', 'Drug Overdose', 'Fatal Outcome', 'Female', 'Humans', 'Meprobamate/*blood/poisoning']",https://pubmed.ncbi.nlm.nih.gov/20870445/
63,meprobamate,3381792,Fatal meprobamate self-poisoning.,"['Kintz P', 'Tracqui A', 'Mangin P', 'Lugnier AA']","['Adult', 'Bile/analysis', 'Chromatography, Gas', 'Humans', 'Liver/analysis', 'Male', 'Meprobamate/analysis/*poisoning', 'Muscles/analysis', 'Myocardium/analysis', '*Suicide']",https://pubmed.ncbi.nlm.nih.gov/3381792/
64,meprobamate,3379924,A rapid and sensitive gas chromatographic analysis of meprobamate or carisoprodol in urine and plasma.,"['Kintz P', 'Mangin P', 'Lugnier AA', 'Chaumont AJ']","['Carisoprodol/*analysis', 'Chromatography, Gas/methods', 'Humans', 'Meprobamate/*analysis']",https://pubmed.ncbi.nlm.nih.gov/3379924/
65,meprobamate,1186258,Drug interactions: the effects of alcohol and meprobamate applied singly and jointly in human subjects. III. The concentrations of alcohol and meprobamate in the blood and their effects on performance; application of mathematical models.,"['Ashford JR', 'Cobby JM']","['Drug Combinations', 'Drug Interactions', 'Ethanol/blood/*pharmacology', 'Humans', 'Meprobamate/blood/*pharmacology', 'Models, Biological', 'Motor Activity/drug effects', 'Visual Perception/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1186258/
66,meprobamate,16200657,Simultaneous determination of carisoprodol and meprobamate in human hair using solid-phase extraction and gas chromatography/mass spectrometry of the trimethylsilyl derivatives.,"['Kim JY', 'In MK', 'Paeng KJ', 'Chung BC']","['Adult', 'Carisoprodol/*analysis/chemistry', 'Gas Chromatography-Mass Spectrometry/*methods', 'Hair/*chemistry', 'Humans', 'Male', 'Meprobamate/*analysis/chemistry', 'Muscle Relaxants, Central/*analysis/chemistry', 'Substance Abuse Detection/*methods', 'Trimethylsilyl Compounds/chemistry']",https://pubmed.ncbi.nlm.nih.gov/16200657/
67,meprobamate,1186261,Drug interactions: the effects of alcohol and meprobamate applied singly and jointly in human subjects. II. Five experiments.,"['Carpenter JA', 'Gibbins RJ', 'Marshman JA']","['Adult', 'Dose-Response Relationship, Drug', 'Drug Combinations', 'Drug Interactions', 'Ethanol/administration & dosage/blood/*pharmacology', 'Humans', 'Male', 'Meprobamate/administration & dosage/blood/*pharmacology', 'Middle Aged', 'Models, Biological', 'Motor Activity/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1186261/
68,meprobamate,947653,"Subjective and physiologic effects of morphine, pentobarbital, and meprobamate.","['McClane TK', 'Martin WR']","['Electrooculography', 'Humans', 'Hypnotics and Sedatives', 'Meprobamate/*pharmacology', 'Morphine/*pharmacology', 'Pentobarbital/*pharmacology', 'Saccades/drug effects', 'Surveys and Questionnaires']",https://pubmed.ncbi.nlm.nih.gov/947653/
69,Pyridostigmine,33423527,Supine Parasympathetic Withdrawal and Upright Sympathetic Activation Underly Abnormalities of the Baroreflex in Postural Tachycardia Syndrome: Effects of Pyridostigmine and Digoxin.,"['Stewart JM', 'Warsy IA', 'Visintainer P', 'Terilli C', 'Medow MS']","['Adult', 'Baroreflex/drug effects/physiology', 'Blood Pressure/drug effects/physiology', 'Cardiotonic Agents/administration & dosage', 'Cholinesterase Inhibitors/administration & dosage', 'Digoxin/*administration & dosage', 'Dizziness/physiopathology', 'Female', 'Heart Rate/drug effects/physiology', 'Humans', 'Hypovolemia/etiology/physiopathology', 'Outcome Assessment, Health Care', 'Patient Positioning/methods', '*Postural Orthostatic Tachycardia Syndrome/diagnosis/physiopathology', 'Pyridostigmine Bromide/*administration & dosage', 'Sympathetic Nervous System/drug effects/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/33423527/
70,Pyridostigmine,37132128,Pyridostigmine in chronic intestinal pseudo-obstruction - a systematic review.,"['Wilkie BD', 'Noori J', 'Johnston M', 'Woods R', 'Keck JO', 'Behrenbruch C']","['Adult', 'Humans', '*Pyridostigmine Bromide/therapeutic use/pharmacology', 'Gastrointestinal Motility', '*Intestinal Pseudo-Obstruction/drug therapy/diagnosis', 'Cholinesterase Inhibitors/therapeutic use/pharmacology', 'Chronic Disease']",https://pubmed.ncbi.nlm.nih.gov/37132128/
71,Pyridostigmine,28794253,Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension.,"['Byun JI', 'Moon J', 'Kim DY', 'Shin H', 'Sunwoo JS', 'Lim JA', 'Kim TJ', 'Lee WJ', 'Lee HS', 'Jun JS', 'Park KI', 'Lee ST', 'Jung KH', 'Jung KY', 'Lee SK', 'Chu K']","['Adrenergic alpha-1 Receptor Agonists/administration & dosage/adverse effects', 'Blood Pressure/drug effects', 'Cholinesterase Inhibitors/administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Hypotension, Orthostatic/*drug therapy', 'Male', 'Middle Aged', 'Midodrine/*administration & dosage/adverse effects', 'Pyridostigmine Bromide/*administration & dosage/adverse effects', 'Self Report', 'Time Factors', 'Treatment Outcome', 'Vasoconstrictor Agents/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28794253/
72,Pyridostigmine,21815707,Treatment of myasthenia gravis: focus on pyridostigmine.,"['Maggi L', 'Mantegazza R']","['Cholinesterase Inhibitors/*therapeutic use', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Myasthenia Gravis/*drug therapy/surgery', 'Pyridostigmine Bromide/*therapeutic use', 'Thymectomy']",https://pubmed.ncbi.nlm.nih.gov/21815707/
73,Pyridostigmine,39708173,Effect of pyridostigmine on growth hormone and IGF-1 levels and outcomes of controlled ovarian stimulation cycle in women with poor ovarian response.,"['Karimi R', 'Hadavi F', 'Jafarabadi M']","['Humans', 'Female', '*Pyridostigmine Bromide/therapeutic use', 'Adult', '*Ovulation Induction/methods', '*Insulin-Like Growth Factor I/analysis/metabolism', 'Cholinesterase Inhibitors/therapeutic use', 'Human Growth Hormone/blood', 'Oocyte Retrieval', 'Fertilization in Vitro/methods']",https://pubmed.ncbi.nlm.nih.gov/39708173/
74,Pyridostigmine,36083490,"Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis.","['Caifeng S', 'Jingsheng Z', 'Yi L', 'Xueshi H', 'Zhanyou W', 'Haiou P', 'Wenjun Q']","['Drug Tapering', 'Drugs, Chinese Herbal', 'Hormones/therapeutic use', 'Humans', '*Myasthenia Gravis/drug therapy', 'Prednisone/therapeutic use', 'Pyridostigmine Bromide/therapeutic use', 'Tablets/therapeutic use', '*Tacrolimus/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36083490/
75,Pyridostigmine,8513959,Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome.,"['Lee EJ', 'Lee BS', 'Lee HC', 'Park KH', 'Song CH', 'Huh KB']","['Adolescent', 'Adult', 'Female', 'Glucose Tolerance Test', 'Growth Hormone/blood/*metabolism', 'Humans', 'Insulin/*blood', 'Insulin-Like Growth Factor I/metabolism', 'Levodopa/*pharmacology', 'Polycystic Ovary Syndrome/blood/*metabolism', 'Premedication', 'Pyridostigmine Bromide/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8513959/
76,Pyridostigmine,34600060,Monitoring the weight and dimensional expansion of pyridostigmine bromide tablets under dynamic vapor sorption and impact of deliquescence on tablet strength and drug release.,"['Partheniadis I', 'Kopanelou D', 'Gamlen M', 'Nikolakakis I']","['Drug Liberation', 'Humidity', '*Pyridostigmine Bromide', 'Tablets', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/34600060/
77,Pyridostigmine,17036555,"Pyridostigmine, diethyltoluamide, permethrin, and stress: a double-blind, randomized, placebo-controlled trial to assess safety.","['Roy MJ', 'Kraus PL', 'Seegers CA', 'Young SY', 'Kamens DR', 'Law WA', 'Cherstniakova SA', 'Chang DN', 'Cooper JA', 'Sato PA', 'Matulich W', 'Krantz DS', 'Cantilena LR', 'Deuster PA']","['Adult', 'Blood Pressure/drug effects', 'Blood Proteins/analysis', 'Cholinesterase Inhibitors/administration & dosage/*adverse effects/blood', 'DEET/administration & dosage/*adverse effects/blood', 'Environmental Exposure', 'Female', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Military Personnel', 'Permethrin/administration & dosage/*adverse effects/blood', 'Pesticides/*adverse effects/blood', 'Physical Exertion/*drug effects/physiology', 'Prospective Studies', 'Pyridostigmine Bromide/administration & dosage/adverse effects/blood', 'Regression Analysis', '*Stress, Psychological', 'United States']",https://pubmed.ncbi.nlm.nih.gov/17036555/
78,Pyridostigmine,36184373,The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study.,"['Remijn-Nelissen L', 'Verschuuren JJGM', 'Tannemaat MR']","['Humans', '*Pyridostigmine Bromide/adverse effects', 'Cross-Sectional Studies', '*Myasthenia Gravis/drug therapy/chemically induced', 'Muscle Weakness/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/36184373/
79,Pyridostigmine,1620385,"Effects of heat-exercise stress, NBC clothing, and pyridostigmine treatment on psychomotor and subjective measures of performance.","['Arad M', 'Varssano D', 'Moran D', 'Arnon R', 'Vazina A', 'Epstein Y']","['*Exercise', '*Heat Exhaustion', 'Humans', 'Male', '*Military Personnel', '*Protective Clothing', '*Psychomotor Performance', 'Pyridostigmine Bromide/*therapeutic use', 'Stress, Physiological/*etiology']",https://pubmed.ncbi.nlm.nih.gov/1620385/
80,Pyridostigmine,9270671,Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome.,"['Oh SJ', 'Kim DS', 'Head TC', 'Claussen GC']","['Adult', 'Aged', 'Cholinesterase Inhibitors/*administration & dosage/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Electrophysiology', 'Female', 'Guanidine', 'Guanidines/*administration & dosage/adverse effects/therapeutic use', 'Humans', 'Lambert-Eaton Myasthenic Syndrome/complications/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Neoplasms/complications/therapy', 'Pyridostigmine Bromide/*administration & dosage/adverse effects/therapeutic use', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9270671/
81,Duloxetine,36194493,Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis.,"['Chow R', 'Novosel M', 'So OW', 'Bellampalli S', 'Xiang J', 'Boldt G', 'Winquist E', 'Lock M', 'Lustberg M', 'Prsic E']","['Humans', 'Duloxetine Hydrochloride/adverse effects', '*Peripheral Nervous System Diseases/chemically induced/drug therapy/prevention & control', '*Antineoplastic Agents/adverse effects', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36194493/
82,Duloxetine,30877484,Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial.,"['Bidari A', 'Moazen-Zadeh E', 'Ghavidel-Parsa B', 'Rahmani S', 'Hosseini S', 'Hassankhani A']","['Adult', 'Chronic Pain/*drug therapy', 'Depression/*drug therapy', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/*administration & dosage/therapeutic use', 'Female', 'Fibromyalgia/complications/*drug therapy', 'Humans', 'Medication Adherence', 'Middle Aged', 'Pregabalin/*administration & dosage/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30877484/
83,Duloxetine,37601081,Takotsubo Cardiomyopathy Related to Duloxetine-Atomoxetine Combination in an Adolescent with ADHD and Comorbid GAD.,"['Naguy A', 'Alamiri B']","['Adolescent', 'Humans', 'Atomoxetine Hydrochloride/adverse effects', '*Attention Deficit Disorder with Hyperactivity/drug therapy', 'Duloxetine Hydrochloride/adverse effects', '*Takotsubo Cardiomyopathy/chemically induced', 'Comorbidity']",https://pubmed.ncbi.nlm.nih.gov/37601081/
84,Duloxetine,30871298,Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis.,"['Osani MC', 'Bannuru RR']","['Aged', 'Antirheumatic Agents/adverse effects/*therapeutic use', 'Duloxetine Hydrochloride/adverse effects/*therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Osteoarthritis, Knee/diagnosis/*drug therapy/immunology', 'Quality of Life', 'Remission Induction', 'Risk Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30871298/
85,Duloxetine,37198620,Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis.,"['Ma X', 'Zhou S', 'Sun W', 'Sun J', 'Li G', 'Wang L', 'Guo Y']","['Humans', 'Duloxetine Hydrochloride/adverse effects', '*Musculoskeletal Pain/diagnosis/drug therapy', 'Analgesics/adverse effects', '*Chronic Pain/diagnosis/drug therapy', 'Antidepressive Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37198620/
86,Duloxetine,32135389,Duloxetine and cardiovascular adverse events: A systematic review and meta-analysis.,"['Park K', 'Kim S', 'Ko YJ', 'Park BJ']","['Blood Pressure', '*Cardiovascular Diseases', 'Duloxetine Hydrochloride/adverse effects', 'Humans', '*Hypertension', '*Myocardial Infarction', '*Stroke']",https://pubmed.ncbi.nlm.nih.gov/32135389/
87,Duloxetine,37378482,Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study.,"['Salaffi F', 'Farah S', 'Sarzi-Puttini P', 'Di Carlo M']","['Humans', '*Fibromyalgia/diagnosis/drug therapy', 'Duloxetine Hydrochloride/adverse effects', 'Pregabalin/adverse effects', 'Acetylcarnitine/adverse effects', 'Treatment Outcome', 'Analgesics/adverse effects', 'Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37378482/
88,Duloxetine,38618021,"Fixed dose combination of low dose pregabalin and duloxetine, or pregabalin monotherapy for neuropathic pain: A double-blind, randomized, parallel-group study.","['K K', 'Dutt S', 'Rattan P', 'Dadhania A', 'Gupta R', 'Joshi D', 'Kakkad A', 'Makwana A', 'Jha P']","['Adult', 'Humans', '*Dizziness', 'Duloxetine Hydrochloride/adverse effects', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Sleepiness', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/38618021/
89,Duloxetine,25004984,Total synthesis of fluoxetine and duloxetine through an in situ imine formation/borylation/transimination and reduction approach.,"['Calow AD', 'Fernandez E', 'Whiting A']","['Chemistry, Organic/*methods', 'Duloxetine Hydrochloride', 'Fluoxetine/*chemical synthesis/chemistry', 'Imines/*chemical synthesis/chemistry', 'Thiophenes/*chemical synthesis/chemistry']",https://pubmed.ncbi.nlm.nih.gov/25004984/
90,Duloxetine,21449618,A chemoenzymatic dynamic kinetic resolution approach to enantiomerically pure (R)- and (S)-duloxetine.,"['Traff A', 'Lihammar R', 'Backvall JE']","['Duloxetine Hydrochloride', 'Fungal Proteins', 'Kinetics', 'Lipase/*metabolism', 'Ruthenium/chemistry', 'Stereoisomerism', 'Thiophenes/*chemical synthesis/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/21449618/
91,Duloxetine,38481321,Duloxetine reduces opioid consumption and pain after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.,"['Lin Y', 'Jiang M', 'Liao C', 'Wu Q', 'Zhao J']","['Female', 'Humans', 'Male', '*Analgesics, Opioid/therapeutic use', '*Arthroplasty, Replacement, Hip/adverse effects', '*Arthroplasty, Replacement, Knee/adverse effects', '*Duloxetine Hydrochloride/therapeutic use', '*Pain, Postoperative/drug therapy/prevention & control', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38481321/
92,Duloxetine,32075794,Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study.,"['Huybrechts KF', 'Bateman BT', 'Pawar A', 'Bessette LG', 'Mogun H', 'Levin R', 'Li H', 'Motsko S', 'Scantamburlo Fernandes MF', 'Upadhyaya HP', 'Hernandez-Diaz S']","['Abnormalities, Drug-Induced/epidemiology/etiology', 'Adolescent', 'Adult', 'Cohort Studies', 'Duloxetine Hydrochloride/*adverse effects/therapeutic use', 'Female', 'Heart Defects, Congenital/chemically induced/epidemiology', 'Humans', 'Infant, Small for Gestational Age', 'Middle Aged', 'Postpartum Hemorrhage/chemically induced/epidemiology', 'Pre-Eclampsia/chemically induced', 'Pregnancy', 'Pregnancy Complications/*drug therapy/epidemiology', 'Pregnancy Outcome/*epidemiology', 'Premature Birth/chemically induced/epidemiology', 'Prenatal Exposure Delayed Effects/chemically induced/epidemiology', 'Serotonin and Noradrenaline Reuptake Inhibitors/*adverse effects/therapeutic use', 'United States/epidemiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32075794/
93,Duloxetine,31689755,The short-term effect and safety of duloxetine in osteoarthritis: A systematic review and meta-analysis.,"['Gao SH', 'Huo JB', 'Pan QM', 'Li XW', 'Chen HY', 'Huang JH']","['Analgesics/adverse effects/*therapeutic use', 'Duloxetine Hydrochloride/adverse effects/*therapeutic use', 'Humans', 'Ontario', 'Osteoarthritis/*drug therapy', 'Pain Measurement', 'Patient Acuity', 'Physical Functional Performance', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/31689755/
94,Duloxetine,32641165,Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews.,"['de Farias AD', 'Eberle L', 'Amador TA', 'da Silva Dal Pizzol T']","['Amitriptyline/adverse effects/*therapeutic use', 'Antidepressive Agents/adverse effects/*therapeutic use', 'Duloxetine Hydrochloride/adverse effects/*therapeutic use', 'Fibromyalgia/*drug therapy', 'Humans', 'Syndrome', '*Systematic Reviews as Topic']",https://pubmed.ncbi.nlm.nih.gov/32641165/
95,Duloxetine,38285030,Co-treatment with Oral Duloxetine and Intraarticular Injection of Corticosteroid plus Hyaluronic Acid Reduces Pain in the Treatment of Knee Osteoarthritis.,"['Li D', 'Hang R', 'Meng L', 'Zhao Z', 'Zhao C', 'Luo F']","['Humans', 'Aged', '*Hyaluronic Acid/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', '*Osteoarthritis, Knee/complications/drug therapy', 'Prospective Studies', 'Quality of Life', 'Injections, Intra-Articular', 'Pain/drug therapy/etiology', 'Adrenal Cortex Hormones']",https://pubmed.ncbi.nlm.nih.gov/38285030/
96,Duloxetine,37653762,The efficacy and safety of duloxetine for the treatment of patients after TKA or THA: A systematic review and meta-analysis.,"['Zhou Y', 'Chen X', 'Chen C', 'Cao Y']","['Humans', '*Arthroplasty, Replacement, Hip/adverse effects', 'Duloxetine Hydrochloride/adverse effects', '*Arthroplasty, Replacement, Knee/adverse effects', 'Pain Management', 'Knee Joint', '*Drug-Related Side Effects and Adverse Reactions', 'Analgesics, Opioid', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37653762/
97,Duloxetine,38995181,PPARgamma and AKt gene modulation following pregabalin and duloxetine combination for painful diabetic polyneuropathy.,"['Saxena AK', 'Thanikkal N', 'Chilkoti GT', 'Gondode PG', 'Sharma T', 'Banerjee BD']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Analgesics/administration & dosage/pharmacology', '*Diabetic Neuropathies/drug therapy', '*Drug Therapy, Combination', '*Duloxetine Hydrochloride/administration & dosage/therapeutic use', 'Neuralgia/drug therapy/genetics', 'Pain Measurement', '*PPAR gamma/genetics', '*Pregabalin/administration & dosage/pharmacology/therapeutic use', '*Proto-Oncogene Proteins c-akt/metabolism/genetics', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/38995181/
98,Duloxetine,26435496,First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review.,"['Lassen D', 'Ennis ZN', 'Damkier P']","['Abnormalities, Drug-Induced/epidemiology/*etiology', 'Cohort Studies', 'Depressive Disorder, Major/drug therapy', 'Duloxetine Hydrochloride/administration & dosage/*adverse effects/therapeutic use', 'Female', 'Humans', 'Pregnancy', 'Pregnancy Trimester, First', 'Prenatal Exposure Delayed Effects/*chemically induced/epidemiology', 'Serotonin and Noradrenaline Reuptake Inhibitors/administration & dosage/*adverse effects/therapeutic use', 'Venlafaxine Hydrochloride/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26435496/
99,Duloxetine,36945033,Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials.,"['Wu CS', 'Huang YJ', 'Ko YC', 'Lee CH']","['Humans', 'Duloxetine Hydrochloride/therapeutic use', '*Diabetic Neuropathies/drug therapy/chemically induced', 'Quality of Life', 'Randomized Controlled Trials as Topic', 'Pain/drug therapy', '*Diabetes Mellitus']",https://pubmed.ncbi.nlm.nih.gov/36945033/
100,Methylphenidate,12558545,Methylphenidate and intracortical excitability: opposite effects in healthy subjects and attention-deficit hyperactivity disorder.,"['Moll GH', 'Heinrich H', 'Rothenberger A']","['Adult', 'Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Central Nervous System Stimulants/*pharmacology/*therapeutic use', 'Cerebral Cortex/*drug effects', 'Female', 'Humans', 'Male', 'Methylphenidate/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12558545/
101,Methylphenidate,10628897,Pharmacokinetics and clinical effectiveness of methylphenidate.,"['Kimko HC', 'Cross JT', 'Abernethy DR']","['Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Central Nervous System Stimulants/*pharmacokinetics/*therapeutic use', 'Child', 'Humans', 'Methylphenidate/*pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10628897/
102,Methylphenidate,32715789,"An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations.","['Shellenberg TP', 'Stoops WW', 'Lile JA', 'Rush CR']","['Abuse-Deterrent Formulations', 'Adult', 'Attention Deficit Disorder with Hyperactivity/drug therapy', 'Central Nervous System Stimulants/*administration & dosage/adverse effects/pharmacology', 'Child', 'Humans', 'Methylphenidate/*administration & dosage/adverse effects/pharmacology', 'Substance-Related Disorders/*epidemiology']",https://pubmed.ncbi.nlm.nih.gov/32715789/
103,Methylphenidate,27438788,Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects.,['Dinis-Oliveira RJ'],"['Humans', '*Metabolomics', 'Methylphenidate/*adverse effects/*analogs & derivatives/metabolism/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/27438788/
104,Methylphenidate,35108133,Translating methylphenidate's efficacy on selective and sustained attentional deficits to those reported in childhood cancer survivors: A qualitative review.,"['Hagan AJ', 'Verity SJ']","['Child', 'Humans', '*Attention Deficit Disorder with Hyperactivity/diagnosis', '*Central Nervous System Stimulants/pharmacology', '*Cancer Survivors', '*Neoplasms/complications/drug therapy', '*Methylphenidate/pharmacology', 'Attention']",https://pubmed.ncbi.nlm.nih.gov/35108133/
105,Methylphenidate,32629693,Methylphenidate has mild hyperglycemic and hypokalemia effects and increases leukocyte and neutrophil counts.,"['Charach G', 'Karniel E', 'Grosskopf I', 'Rabinovich A', 'Charach L']","['Adolescent', 'Adult', 'Attention Deficit Disorder with Hyperactivity/blood/*drug therapy', 'Central Nervous System Stimulants/pharmacology/*therapeutic use', 'Child', 'Cohort Studies', 'Female', 'Humans', 'Hypoglycemia/chemically induced', 'Leukocytes/drug effects', 'Male', 'Methylphenidate/pharmacology/*therapeutic use', 'Neutrophils/drug effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32629693/
106,Methylphenidate,40102913,Bioethical evaluation of methylphenidate and atomoxetine for pediatric ADHD and cognitive enhancement.,"['Burguete E', 'Peydro L', 'Ventura I']","['Humans', '*Methylphenidate/adverse effects/therapeutic use', '*Atomoxetine Hydrochloride/therapeutic use/adverse effects', '*Attention Deficit Disorder with Hyperactivity/drug therapy', 'Child', 'Central Nervous System Stimulants/adverse effects', 'Nootropic Agents/therapeutic use/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/40102913/
107,Methylphenidate,35714551,Withdrawing methylphenidate in relation to serum levels of ferritin and zinc in children and adolescents with attention-deficit/hyperactivity disorder.,"['Rosenau PT', 'van den Hoofdakker BJ', 'Matthijssen AM', 'van de Loo-Neus GHH', 'Buitelaar JK', 'Hoekstra PJ', 'Dietrich A']","['Adolescent', '*Attention Deficit Disorder with Hyperactivity/complications', '*Central Nervous System Stimulants/pharmacology/therapeutic use', 'Child', 'Ferritins', 'Humans', '*Methylphenidate/pharmacology/therapeutic use', 'Zinc/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35714551/
108,Methylphenidate,28388850,Auditory and Visual Executive Functions in Children and Response to Methylphenidate: A Randomized Controlled Trial.,"['Hadar Y', 'Hocherman S', 'Lamm O', 'Tirosh E']","['*Attention Deficit Disorder with Hyperactivity/drug therapy', '*Central Nervous System Stimulants/pharmacology/therapeutic use', 'Child', 'Double-Blind Method', 'Executive Function', 'Humans', 'Male', '*Methylphenidate/pharmacology/therapeutic use', 'Reaction Time', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28388850/
109,Methylphenidate,30504928,Methylphenidate's effects on thalamic metabolism and functional connectivity in cannabis abusers and healthy controls.,"['Demiral SB', 'Tomasi D', 'Wiers CE', 'Manza P', 'Shokri-Kojori E', 'Studentsova Y', 'Wang GJ', 'Volkow ND']","['Adult', 'Cerebellum/metabolism/*physiology', 'Female', 'Fluorodeoxyglucose F18/metabolism', 'Functional Neuroimaging', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Marijuana Abuse/*physiopathology', 'Methylphenidate/*pharmacology', 'Neural Pathways/physiology', 'Nucleus Accumbens/*physiology', 'Positron-Emission Tomography', 'Single-Blind Method', 'Thalamus/*metabolism/*physiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30504928/
110,Methylphenidate,12014596,Methylphenidate-related growth impairment.,"['Holtkamp K', 'Peters-Wallraf B', 'Wuller S', 'Pfaaffle R', 'Herpertz-Dahlmann B']","['Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Body Height/drug effects', 'Central Nervous System Stimulants/*adverse effects/*therapeutic use', 'Child', 'Growth Disorders/*chemically induced', 'Humans', 'Male', 'Methylphenidate/*adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12014596/
111,Methylphenidate,26695166,Misuse of Methylphenidate.,['Clemow DB'],"['Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Central Nervous System Stimulants/*therapeutic use', 'Humans', 'Malingering', 'Methylphenidate/*therapeutic use', 'Prescription Drug Diversion', '*Substance-Related Disorders']",https://pubmed.ncbi.nlm.nih.gov/26695166/
112,Methylphenidate,15613514,"Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy.","['Tan M', 'Appleton R']","['Attention Deficit Disorder with Hyperactivity/complications/*drug therapy', 'Central Nervous System Stimulants/adverse effects/*therapeutic use', 'Child', 'Epilepsy/*complications', 'Humans', 'Methylphenidate/adverse effects/*therapeutic use', 'Risk Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15613514/
113,Methylphenidate,31786618,Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers.,"['Arvidsson M', 'Dahl ML', 'Beck O', 'Ackehed G', 'Nordin K', 'Rosenborg S']","['Administration, Oral', 'Adult', 'Area Under Curve', 'Breath Tests/methods', 'Central Nervous System Stimulants/administration & dosage/*pharmacokinetics', 'Chromatography, Liquid', 'Female', 'Humans', 'Male', 'Medication Adherence', 'Methylphenidate/administration & dosage/analogs & derivatives/*pharmacokinetics', 'Stereoisomerism', 'Tandem Mass Spectrometry', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31786618/
114,Methylphenidate,20167695,Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma.,"['Marchei E', 'Farre M', 'Pardo R', 'Garcia-Algar O', 'Pellegrini M', 'Pacifici R', 'Pichini S']","['Adult', 'Chromatography, Liquid', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Methylphenidate/*analogs & derivatives/*blood/*cerebrospinal fluid/pharmacokinetics', 'Reference Values', 'Spectrometry, Mass, Electrospray Ionization', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/20167695/
115,Methylphenidate,17339864,Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.,"['Patrick KS', 'Straughn AB', 'Minhinnett RR', 'Yeatts SD', 'Herrin AE', 'DeVane CL', 'Malcolm R', 'Janis GC', 'Markowitz JS']","['Adult', 'Area Under Curve', 'Biotransformation', 'Blood Pressure/drug effects', 'Body Temperature/drug effects', 'Central Nervous System Depressants/*pharmacokinetics/*pharmacology', 'Central Nervous System Stimulants/*pharmacokinetics/*pharmacology', 'Cross-Over Studies', 'Drug Interactions', 'Ethanol/*pharmacokinetics/*pharmacology', 'Female', 'Heart Rate/drug effects', 'Humans', 'Male', 'Methylphenidate/analogs & derivatives/metabolism/*pharmacokinetics/*pharmacology', 'Pharmacogenetics', 'Respiratory Mechanics/drug effects', 'Sex Characteristics', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/17339864/
116,Moexipril,8793166,Moexipril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension.,"['Stimpel M', 'Koch B', 'Dickstein K']","['Administration, Oral', 'Adult', 'Aged', 'Analysis of Variance', 'Angiotensin-Converting Enzyme Inhibitors/*administration & dosage/adverse effects', 'Blood Pressure/drug effects', 'Diuretics', 'Double-Blind Method', 'Drug Therapy, Combination', 'Drug Tolerance', 'Female', 'Follow-Up Studies', 'Humans', 'Hydrochlorothiazide/*administration & dosage/adverse effects', 'Hypertension/*drug therapy/physiopathology', 'Isoquinolines/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Posture', 'Sodium Chloride Symporter Inhibitors/*administration & dosage/adverse effects', '*Tetrahydroisoquinolines', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/8793166/
117,Moexipril,10376852,Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women.,"['Koch B', 'Oparil S', 'Stimpel M']","['Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Blood Pressure/physiology', 'Double-Blind Method', 'Drug Combinations', 'Female', '*Hormone Replacement Therapy', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Isoquinolines/*therapeutic use', 'Middle Aged', '*Postmenopause', '*Tetrahydroisoquinolines']",https://pubmed.ncbi.nlm.nih.gov/10376852/
118,Moexipril,8803515,"Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients.","['Persson B', 'Stimpel M']","['Aged', 'Analysis of Variance', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Blood Pressure/*drug effects', 'Double-Blind Method', 'Female', 'Humans', 'Hydrochlorothiazide/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Isoquinolines/adverse effects/*therapeutic use', 'Male', 'Prodrugs/adverse effects/*therapeutic use', 'Single-Blind Method', '*Tetrahydroisoquinolines']",https://pubmed.ncbi.nlm.nih.gov/8803515/
119,Moexipril,8583466,Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension.,"['White WB', 'Stimpel M']","['Aged', 'Aged, 80 and over', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Hydrochlorothiazide/administration & dosage/adverse effects/*therapeutic use', 'Hypertension/*drug therapy/physiopathology', 'Isoquinolines/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Prognosis', '*Tetrahydroisoquinolines']",https://pubmed.ncbi.nlm.nih.gov/8583466/
120,Moexipril,25272934,Electrochemistry of moexipril: experimental and computational approach and voltammetric determination.,"['Tasdemir HI', 'Kilic E']","['Angiotensin-Converting Enzyme Inhibitors/*chemistry', 'Electrochemistry', 'Electrodes', 'Electrolysis', 'Glass/chemistry', 'Hydrogen-Ion Concentration', 'Indicators and Reagents', 'Mercury/chemistry', 'Reference Standards', 'Solutions', 'Tablets/analysis', 'Tetrahydroisoquinolines/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/25272934/
121,Moexipril,10379633,Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. MADAM study group. Moexipril as Antihypertensive Drug After Menopause.,"['Agabiti-Rosei E', 'Ambrosioni E', 'Pirelli A', 'Stimpel M', 'Zanchetti A']","['Aged', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Blood Pressure', 'Calcium Channel Blockers/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Isoquinolines/adverse effects/*therapeutic use', 'Middle Aged', 'Nitrendipine/adverse effects/*therapeutic use', '*Postmenopause/physiology', 'Prodrugs/*therapeutic use', '*Tetrahydroisoquinolines']",https://pubmed.ncbi.nlm.nih.gov/10379633/
122,Moexipril,22594252,"First order derivative spectrophotometric and HPLC methods for determination of moexipril hydrochloride in the pure form, pharmeceutical formulations and evaluation of its stability.","['Stanisz B', 'Regulska K', 'Ratajczak T']","['Angiotensin-Converting Enzyme Inhibitors/analysis', 'Chemistry, Pharmaceutical/*methods', 'Chromatography, High Pressure Liquid/*methods', 'Drug Stability', 'Spectrophotometry/*methods', 'Spectrophotometry, Ultraviolet/methods', 'Tablets/analysis', 'Tetrahydroisoquinolines/*analysis']",https://pubmed.ncbi.nlm.nih.gov/22594252/
123,Moexipril,7619356,"Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients.","['Chrysant SG', 'Fox AA', 'Stimpel M']","['Aged', 'Aldosterone/blood', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Delayed-Action Preparations', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hydrochlorothiazide/administration & dosage/*therapeutic use', 'Hypertension/*drug therapy/physiopathology', 'Isoquinolines/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Renin/blood', '*Tetrahydroisoquinolines', 'Verapamil/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7619356/
124,Moexipril,24954754,Comparative study between univariate spectrophotometry and multivariate calibration as analytical tools for simultaneous quantitation of Moexipril and Hydrochlorothiazide.,"['Tawakkol SM', 'Farouk M', 'Elaziz OA', 'Hemdan A', 'Shehata MA']","['Antihypertensive Agents/*analysis', 'Calibration', 'Hydrochlorothiazide/*analysis', 'Least-Squares Analysis', 'Limit of Detection', 'Spectrophotometry/methods', 'Tablets', 'Tetrahydroisoquinolines/*analysis']",https://pubmed.ncbi.nlm.nih.gov/24954754/
125,Moexipril,14550868,Simultaneous determination of moexipril hydrochloride and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromatographic methods.,"['Erturk S', 'Cetin SM', 'Atmaca S']","['Chromatography, High Pressure Liquid/methods', 'Hydrochlorothiazide/*analysis/chemistry', 'Spectrophotometry, Ultraviolet/methods', 'Tablets', 'Technology, Pharmaceutical/*methods', 'Tetrahydroisoquinolines/*analysis/chemistry']",https://pubmed.ncbi.nlm.nih.gov/14550868/
126,Moexipril,7493088,"Simultaneous determination of moexipril and moexiprilat, its active metabolite, in human plasma by gas chromatography-negative-ion chemical ionization mass spectrometry.","['Hammes W', 'Hammes B', 'Buchsler U', 'Paar F', 'Bokens H']","['Angiotensin-Converting Enzyme Inhibitors/*blood/pharmacokinetics', 'Gas Chromatography-Mass Spectrometry/*methods', 'Humans', 'Isoquinolines/*blood/pharmacokinetics', 'Reproducibility of Results', '*Tetrahydroisoquinolines']",https://pubmed.ncbi.nlm.nih.gov/7493088/
127,Moexipril,11837383,Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.,"['Cawello W', 'Boekens H', 'Waitzinger J', 'Miller U']","['Adult', 'Aged', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/adverse effects/*pharmacokinetics/*pharmacology', 'Area Under Curve', 'Chromatography, High Pressure Liquid', 'Cross-Over Studies', 'Food-Drug Interactions', 'Half-Life', 'Humans', 'Isoquinolines/administration & dosage/adverse effects/blood/*pharmacokinetics/*pharmacology', 'Kinetics', 'Male', 'Middle Aged', 'Peptidyl-Dipeptidase A/blood', '*Tetrahydroisoquinolines']",https://pubmed.ncbi.nlm.nih.gov/11837383/
128,Moexipril,2362911,"Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation.","['Gu L', 'Strickley RG', 'Chi LH', 'Chowhan ZT']","['Angiotensin-Converting Enzyme Inhibitors/*analysis', 'Chemistry, Pharmaceutical', 'Chromatography, High Pressure Liquid', 'Drug Incompatibility', 'Excipients', 'Humidity', 'Isoquinolines/*analysis', 'Lactose', 'Powders', '*Tetrahydroisoquinolines', 'Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/2362911/
129,Moexipril,14728069,ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.,"['Pines A', 'Fisman EZ']","['Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Humans', 'Hypertension/*drug therapy', 'Randomized Controlled Trials as Topic', 'Renal Insufficiency/drug therapy', 'Tetrahydroisoquinolines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14728069/
130,Moexipril,22419504,"A rapid and sensitive liquid chromatography-tandem mass spectrometric assay for moexipril, an angiotensin-converting enzyme inhibitor in human plasma.","['Karra VK', 'Mullangi R', 'Pilli NR', 'Inamadugu JK', 'Ravi VB', 'Seshagiri Rao JV']","['Angiotensin-Converting Enzyme Inhibitors/*blood/chemistry/pharmacokinetics', 'Chromatography, High Pressure Liquid/*methods', 'Drug Stability', 'High-Throughput Screening Assays/methods', 'Humans', 'Least-Squares Analysis', 'Liquid-Liquid Extraction', 'Male', 'Reproducibility of Results', 'Sensitivity and Specificity', 'Tandem Mass Spectrometry/*methods', 'Tetrahydroisoquinolines/*blood/chemistry/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/22419504/
131,Moexipril,9617599,Moexipril. A review of its use in the management of essential hypertension.,"['Brogden RN', 'Wiseman LR']","['Age Factors', 'Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics/*therapeutic use', 'Antihypertensive Agents/pharmacokinetics/*therapeutic use', 'Delayed-Action Preparations', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Isoquinolines/pharmacokinetics/*therapeutic use', 'Male', 'Prodrugs/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', '*Tetrahydroisoquinolines']",https://pubmed.ncbi.nlm.nih.gov/9617599/
132,Ganciclovir,34596243,"Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation.","['Franck B', 'Autmizguine J', 'Marquet P', 'Ovetchkine P', 'Woillard JB']","['Adult', 'Antiviral Agents/pharmacokinetics', 'Bayes Theorem', 'Child', 'Drug Monitoring', '*Ganciclovir/adverse effects/pharmacokinetics', 'Humans', '*Organ Transplantation', 'Valganciclovir']",https://pubmed.ncbi.nlm.nih.gov/34596243/
133,Ganciclovir,11926748,Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation.,['Tzakis AG'],"['Adult', 'Antiviral Agents/administration & dosage/*therapeutic use', 'Child', 'Cytomegalovirus/drug effects/*isolation & purification', 'Cytomegalovirus Infections/drug therapy/*prevention & control', 'Drug Therapy, Combination', 'Ganciclovir/administration & dosage/*therapeutic use', 'Humans', 'Immunoglobulins/administration & dosage/*therapeutic use', 'Immunoglobulins, Intravenous', 'Intestines/*transplantation/virology', 'Liver Transplantation/*adverse effects', 'Organ Transplantation/adverse effects', 'Risk Factors', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/11926748/
134,Ganciclovir,33755191,"A systematic overview of the spermatotoxic and genotoxic effects of methotrexate, ganciclovir and mycophenolate mofetil.","['Jensen NB', 'Justesen SD', 'Larsen A', 'Ernst E', 'Pedersen LH']","['DNA Damage/drug effects', 'Ganciclovir/pharmacology/*toxicity', 'Humans', 'Immunosuppressive Agents/pharmacology/*toxicity', 'Male', 'Methotrexate/pharmacology/*toxicity', 'Mycophenolic Acid/pharmacology/*toxicity', 'Spermatozoa/drug effects']",https://pubmed.ncbi.nlm.nih.gov/33755191/
135,Ganciclovir,16313481,HHV-6-related acute liver failure in two immunocompetent adults: favourable outcome after liver transplantation and/or ganciclovir therapy.,"['Cacheux W', 'Carbonell N', 'Rosmorduc O', 'Wendum D', 'Paye F', 'Poupon R', 'Chazouilleres O', 'Gozlan J']","['Administration, Oral', 'Adult', 'Antiviral Agents/*therapeutic use', 'Female', 'Ganciclovir/analogs & derivatives/*therapeutic use', '*Herpesvirus 6, Human', 'Humans', 'Immunocompetence', 'Liver Failure, Acute/drug therapy/surgery/*virology', 'Liver Transplantation/*methods', 'Roseolovirus Infections/drug therapy/surgery/*therapy', 'Treatment Outcome', 'Valganciclovir']",https://pubmed.ncbi.nlm.nih.gov/16313481/
136,Ganciclovir,33421169,Dose banding of intravenous ganciclovir: Banding scheme proposal and audit of toxicity and efficiency.,"['Rodriguez-Reyes M', 'Lopez-Cabezas C', 'Calvo-Cidoncha E', 'Soy-Muner D']","['Administration, Intravenous', 'Aged', 'Antiviral Agents/*administration & dosage/adverse effects', 'Body Weight', 'Dose-Response Relationship, Drug', 'Female', 'Ganciclovir/*administration & dosage/adverse effects', 'Humans', 'Kidney Function Tests', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/33421169/
137,Ganciclovir,33373493,Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients.,"['Franck B', 'Woillard JB', 'Theoret Y', 'Bittencourt H', 'Demers E', 'Briand A', 'Marquet P', 'Lapeyraque AL', 'Ovetchkine P', 'Autmizguine J']","['Antiviral Agents', 'Child', '*Ganciclovir', 'Humans', 'Retrospective Studies', 'Stem Cell Transplantation', '*Transplant Recipients', 'Valganciclovir']",https://pubmed.ncbi.nlm.nih.gov/33373493/
138,Ganciclovir,36880779,Limited Sampling Strategies to Predict Ganciclovir Exposure after Valganciclovir Administration and to Reduce Monitoring Constraints in Renal Transplant Children.,"['Facchin A', 'Benyoub N', 'Elie V', 'Magreault S', 'Jacqz-Aigrain E']","['Humans', 'Child', 'Valganciclovir/therapeutic use/pharmacokinetics', 'Ganciclovir/pharmacokinetics', '*Kidney Transplantation', 'Retrospective Studies', 'Antiviral Agents/pharmacokinetics', '*Cytomegalovirus Infections/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/36880779/
139,Ganciclovir,39085138,Contribution of Adsorption and Hematocrit Levels to Ganciclovir Clearance in an in Vitro Continuous Hemodiafiltration Model.,"['Roongpairoj Y', 'Uchida M', 'Yamazaki S', 'Sawada M', 'Suzuki T', 'Kawasaki K', 'Niibe Y', 'Goto Y', 'Suzuki T', 'Ishikawa M', 'Ishii I']","['Humans', '*Hemodiafiltration/methods', 'Adsorption', '*Ganciclovir/pharmacokinetics/blood/administration & dosage', 'Hematocrit', '*Acrylic Resins/chemistry', 'Antiviral Agents/blood/pharmacokinetics', 'Polymethyl Methacrylate/chemistry', 'Polymers/chemistry', 'Membranes, Artificial']",https://pubmed.ncbi.nlm.nih.gov/39085138/
140,Ganciclovir,33318012,Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens.,"['Nguyen T', 'Oualha M', 'Briand C', 'Bendavid M', 'Beranger A', 'Benaboud S', 'Treluyer JM', 'Zheng Y', 'Foissac F', 'Winter S', 'Gana I', 'Boujaafar S', 'Lopez V', 'Berthaud R', 'Demir Z', 'Bouazza N', 'Hirt D']","['Administration, Oral', 'Antiviral Agents/therapeutic use', 'Child', '*Cytomegalovirus Infections/drug therapy', '*Ganciclovir/therapeutic use', 'Humans', 'Valganciclovir/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33318012/
141,Ganciclovir,40063966,"Dosing, Toxicity and Drug Concentrations for Ganciclovir/Valganciclovir in Preterm and Low Birthweight Infants Treated for Cytomegalovirus.","['Abu Bakar A', 'Payne H', 'Tickner N', 'Muhd Helmi MA', 'Jacobs TG', 'Lyall H']","['Humans', '*Cytomegalovirus Infections/drug therapy', 'Male', '*Antiviral Agents/pharmacokinetics/administration & dosage/adverse effects/therapeutic use', '*Valganciclovir/pharmacokinetics/therapeutic use/administration & dosage', '*Ganciclovir/pharmacokinetics/analogs & derivatives/administration & dosage/adverse effects/therapeutic use', 'Infant, Newborn', 'Female', '*Infant, Premature', '*Infant, Low Birth Weight', 'Infant', 'Administration, Oral', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/40063966/
142,Ganciclovir,11557492,"Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir.","['McSharry JJ', 'McDonough A', 'Olson B', 'Hallenberger S', 'Reefschlaeger J', 'Bender W', 'Drusano GL']","['Antiviral Agents/*pharmacology', 'Cytomegalovirus/*drug effects/physiology', 'Ganciclovir/pharmacology', 'Humans', 'Microbial Sensitivity Tests', 'Naphthalenesulfonates/*pharmacology', 'Virus Replication/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11557492/
143,Ganciclovir,11363015,FDA approves oral ganciclovir as first drug to prevent CMV disease. Food and Drug Administration.,['Baker R'],"['AIDS-Related Opportunistic Infections/*drug therapy', 'Administration, Oral', 'Antiviral Agents/administration & dosage/*therapeutic use', 'Cytomegalovirus Infections/complications/*drug therapy', 'Cytomegalovirus Retinitis/complications/*drug therapy', '*Drug Approval', 'Drug Costs', 'Ganciclovir/administration & dosage/*therapeutic use', 'Humans', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/11363015/
144,Ganciclovir,14565309,"Synthesis and fluorescent properties of 6-(4-biphenylyl)-3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purine analogues of acyclovir and ganciclovir.","['Goslinski T', 'Wenska G', 'Golankiewicz B', 'Balzarini J', 'De Clercq E']","['Acyclovir/*analogs & derivatives/chemical synthesis/*chemistry/pharmacology', 'Antiviral Agents/*chemical synthesis/pharmacology', 'Cell Line', 'Ganciclovir/*analogs & derivatives/chemical synthesis/*chemistry/pharmacology', 'Herpesvirus 1, Human/drug effects', 'Herpesvirus 2, Human/drug effects', 'Humans', 'Imidazoles', 'Indicators and Reagents', 'Models, Molecular', 'Molecular Conformation', 'Molecular Structure', 'Spectrometry, Fluorescence', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/14565309/
145,Ganciclovir,30354026,Pediatric Dosing of Ganciclovir and Valganciclovir: How Model-Based Simulations Can Prevent Underexposure and Potential Treatment Failure.,"['Jorga K', 'Reigner B', 'Chavanne C', 'Alvaro G', 'Frey N']","['Adolescent', 'Algorithms', 'Antiviral Agents/*administration & dosage/pharmacokinetics', 'Child', 'Child, Preschool', 'Computer Simulation', 'Cytomegalovirus Infections/prevention & control', 'Ganciclovir/*administration & dosage/pharmacokinetics', 'Humans', 'Infant', 'Infant, Newborn', '*Models, Biological', 'Treatment Failure', 'Valganciclovir/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/30354026/
146,Ganciclovir,26538506,Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?,"['Billat PA', 'Woillard JB', 'Essig M', 'Sauvage FL', 'Picard N', 'Alain S', 'Neely M', 'Marquet P', 'Saint-Marcoux F']","['Adult', 'Aged', 'Antiviral Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Cytomegalovirus Infections/drug therapy', 'Cytoplasm/*chemistry', 'Female', 'Ganciclovir/administration & dosage/adverse effects/*pharmacokinetics', 'Humans', '*Kidney Transplantation', 'Leukocyte Count', 'Male', 'Middle Aged', 'Neutropenia/*chemically induced', 'Plasma/*chemistry', '*Transplant Recipients']",https://pubmed.ncbi.nlm.nih.gov/26538506/
147,Anagrelide,36183610,Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population.,"['Bieniaszewska M', 'Sobieralski P', 'Leszczynska A', 'Dutka M']","['Child', 'Humans', 'Erythropoietin/blood', '*Platelet Aggregation Inhibitors/therapeutic use', '*Primary Myelofibrosis/drug therapy/genetics', '*Quinazolines/therapeutic use', '*Thrombocythemia, Essential/drug therapy/genetics']",https://pubmed.ncbi.nlm.nih.gov/36183610/
148,Anagrelide,35342135,Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review.,"['Sugawara M', 'Okada S', 'Kanda M', 'Iseki T', 'Sakaida E', 'Kobayashi Y']","['Humans', 'Middle Aged', '*Thrombocythemia, Essential/complications/drug therapy', 'Platelet Aggregation Inhibitors/adverse effects', '*Cardiomyopathies', '*Heart Failure/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/35342135/
149,Anagrelide,22689919,Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis.,"['Chen YG', 'Lin CS', 'Shen CH', 'Chian CF']","['Adenocarcinoma/*complications/drug therapy', 'Adenocarcinoma of Lung', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Femoral Vein', 'Humans', 'Lung Neoplasms/*complications/drug therapy', 'Male', 'Middle Aged', 'Paraneoplastic Syndromes/drug therapy', 'Platelet Aggregation Inhibitors/*therapeutic use', 'Platelet Count', 'Quinazolines/*therapeutic use', 'Thrombocytosis/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/22689919/
150,Anagrelide,26368319,Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.,"['Antelo ML', 'de Las Heras N', 'Gonzalez Porras JR', 'Kerguelen A', 'Raya JM']","['Female', 'Fibrinolytic Agents/administration & dosage/*therapeutic use', 'Fusion Proteins, bcr-abl/*adverse effects', 'Humans', 'Male', 'Myeloproliferative Disorders/*drug therapy', 'Quinazolines/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26368319/
151,Anagrelide,32557810,"Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.","['Kellner A', 'Dombi P', 'Illes A', 'Demeter J', 'Homor L', 'Ercsei I', 'Simon Z', 'Karadi E', 'Herczeg J', 'Gy Korom V', 'Gasztonyi Z', 'Szerafin L', 'Udvardy M', 'Egyed M']","['Aspirin/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Health Care Surveys', 'Humans', 'Hungary', 'Hydroxyurea/administration & dosage/therapeutic use', 'Quinazolines/administration & dosage/therapeutic use', 'Registries', 'Thrombocythemia, Essential/*complications/epidemiology/*mortality', 'Thrombosis/epidemiology/*etiology/*mortality/prevention & control', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32557810/
152,Anagrelide,35924546,SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.,"['Verstovsek S', 'Komatsu N', 'Gill H', 'Jin J', 'Lee SE', 'Hou HA', 'Sato T', 'Qin A', 'Urbanski R', 'Shih W', 'Zagrijtschuk O', 'Zimmerman C', 'Mesa RA']","['Clinical Trials, Phase III as Topic', 'Humans', '*Hydroxyurea/adverse effects', 'Multicenter Studies as Topic', 'Quinazolines/adverse effects', 'Randomized Controlled Trials as Topic', '*Thrombocythemia, Essential/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35924546/
153,Anagrelide,35272575,"Interaction of Anagrelide drug molecule on pristine and doped boron nitride nanocages: a DFT, RDG, PCM and QTAIM investigation.","['Nishat M', 'Hossain MR', 'Hasan MM', 'Hossain MK', 'Hossain MA', 'Ahmed F']","['*Quinazolines/administration & dosage/chemistry', '*Boron Compounds/chemistry', '*Nanostructures/chemistry', '*Drug Carriers/chemistry', 'Adsorption', 'Density Functional Theory', 'Quantum Theory']",https://pubmed.ncbi.nlm.nih.gov/35272575/
154,Anagrelide,35717689,Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.,"['Rippel N', 'Tremblay D', 'Zubizarreta N', 'Podoltsev N', 'Gotlib J', 'Heaney M', 'Kuykendall A', ""O'Connell C"", 'Shammo JM', 'Fleischman A', 'Kremyanskaya M', 'Hoffman R', 'Mesa R', 'Yacoub A', 'Mascarenhas J']","['Cytoreduction Surgical Procedures', 'Humans', '*Polycythemia Vera/drug therapy', 'Quinazolines', '*Thrombocythemia, Essential/drug therapy', '*Thrombocytosis/therapy', '*Thrombosis']",https://pubmed.ncbi.nlm.nih.gov/35717689/
155,Anagrelide,35624199,"Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose.","['Komatsu N', 'Hashimoto Y', 'Baba T', 'Otsuka M', 'Akimoto T', 'Fernandez J']","['*Cytoreduction Surgical Procedures', 'Headache/chemically induced/epidemiology', 'Humans', 'Japan/epidemiology', 'Platelet Aggregation Inhibitors', '*Product Surveillance, Postmarketing', 'Quinazolines']",https://pubmed.ncbi.nlm.nih.gov/35624199/
156,Anagrelide,21082965,Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.,['Griesshammer M'],"['Blood Platelets/*drug effects', 'Humans', 'Platelet Aggregation Inhibitors/therapeutic use', '*Platelet Count', 'Quinazolines/*therapeutic use', 'Risk Factors', 'Thrombocythemia, Essential/*blood/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21082965/
157,Anagrelide,22943924,Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (>/= 65 years) patients with essential thrombocythemia.,"['Besses C', 'Zeller W', 'Alvarez-Larran A', 'Coll R', 'Troy S', 'Purkayastha J', 'Martin P', 'Freitag C']","['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Area Under Curve', 'Biotransformation', 'Europe', 'Female', 'Half-Life', 'Hematologic Agents/administration & dosage/adverse effects/blood/*pharmacokinetics', 'Humans', 'Hydroxylation', 'Male', 'Metabolic Clearance Rate', 'Middle Aged', 'Models, Biological', 'Platelet Count', 'Quinazolines/administration & dosage/adverse effects/blood/*pharmacokinetics', 'Thrombocythemia, Essential/blood/diagnosis/*drug therapy', 'Thrombopoiesis/*drug effects', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/22943924/
158,Anagrelide,25850727,Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study.,"['Tortorella G', 'Piccin A', 'Tieghi A', 'Marcheselli L', 'Steurer M', 'Gastl G', 'Codeluppi K', 'Fama A', 'Santoro U', 'Birtolo C', 'Gugliotta G', 'Cortelazzo S', 'Gugliotta L']","['Adult', 'Aged', '*Cardiovascular Diseases/blood/physiopathology/prevention & control', 'Electrocardiography', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', '*Monitoring, Physiologic', 'Natriuretic Peptide, Brain/blood', 'Peptide Fragments/blood', 'Platelet Aggregation Inhibitors/*administration & dosage/adverse effects', 'Prospective Studies', 'Quinazolines/*administration & dosage/adverse effects', '*Thrombocythemia, Essential/blood/drug therapy/physiopathology', 'Troponin I/blood']",https://pubmed.ncbi.nlm.nih.gov/25850727/
159,Anagrelide,25604267,Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.,"['Espasandin YR', 'Glembotsky AC', 'Grodzielski M', 'Lev PR', 'Goette NP', 'Molinas FC', 'Marta RF', 'Heller PG']","['Blood Platelets/*drug effects/metabolism', 'Case-Control Studies', 'Cell Adhesion Molecules/metabolism', 'Cells, Cultured', 'Cyclic AMP/metabolism', 'Dose-Response Relationship, Drug', 'Fetal Blood/cytology', 'Hematopoietic Stem Cells/*drug effects/metabolism', 'Heterocyclic Compounds, 4 or More Rings/pharmacology', 'Humans', 'Megakaryocytes/*drug effects/metabolism', 'Microfilament Proteins/metabolism', 'Myosins/metabolism', 'Phosphodiesterase 3 Inhibitors/pharmacology', 'Phosphoproteins/metabolism', 'Phosphorylation', 'Platelet Aggregation Inhibitors/*pharmacology', 'Quinazolines/*pharmacology', 'Signal Transduction/drug effects', 'Thrombocythemia, Essential/blood/diagnosis/*drug therapy', 'Thrombopoiesis/*drug effects', 'Time Factors', 'Transcription Factors/metabolism', 'Vasodilator-Stimulated Phosphoprotein']",https://pubmed.ncbi.nlm.nih.gov/25604267/
160,Anagrelide,33691325,Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.,"['Kwiatkowski J', 'Kuliszkiewicz-Janus M', 'Rymer W', 'Jazwiec B', 'Malecki R']","['Aged', 'Calreticulin/genetics', 'Creatinine/blood', 'Disease Progression', 'Female', 'Humans', 'Hydroxyurea/adverse effects/therapeutic use', 'Janus Kinase 2/genetics', 'Kidney Diseases/blood/*chemically induced/genetics', 'Male', 'Middle Aged', 'Mutation', 'Platelet Aggregation Inhibitors/*adverse effects/therapeutic use', 'Quinazolines/*adverse effects/therapeutic use', 'Retrospective Studies', 'Risk Factors', 'Thrombocythemia, Essential/blood/*drug therapy/genetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33691325/
161,Anagrelide,15270658,Anagrelide: an update on its mechanisms of action and therapeutic potential.,"['Dingli D', 'Tefferi A']","['Clinical Trials as Topic', 'Drug Costs', 'Fibrinolytic Agents/adverse effects/*pharmacology/*therapeutic use', 'Humans', 'Quinazolines/adverse effects/*pharmacology/*therapeutic use', 'Thrombocytosis/*drug therapy/*etiology']",https://pubmed.ncbi.nlm.nih.gov/15270658/
162,Tramadol,29369473,Comparative pharmacology and toxicology of tramadol and tapentadol.,"['Faria J', 'Barbosa J', 'Moreira R', 'Queiros O', 'Carvalho F', 'Dinis-Oliveira RJ']","['Analgesics, Opioid/*pharmacology/therapeutic use/toxicity', 'Humans', 'Pain/*drug therapy', 'Quality of Life', 'Tapentadol/*pharmacology/therapeutic use/toxicity', 'Tramadol/*pharmacology/therapeutic use/toxicity']",https://pubmed.ncbi.nlm.nih.gov/29369473/
163,Tramadol,29752906,Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures.,"['Hassamal S', 'Miotto K', 'Dale W', 'Danovitch I']","['Analgesics, Opioid/*adverse effects', 'Anticonvulsants/therapeutic use', 'Humans', 'Risk Factors', 'Seizures/*chemically induced', 'Serotonin Syndrome/*chemically induced/complications/diagnosis/drug therapy', 'Tramadol/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/29752906/
164,Tramadol,34319855,Hepatotoxic effect of tramadol and O-desmethyltramadol in HepG2 cells and potential role of PI3K/AKT/mTOR.,"['Helmy MA', 'Abdalla HA', 'Abd El Rahman HA', 'Ahmed DAM']","['Hep G2 Cells', 'Humans', 'Phosphatidylinositol 3-Kinases', '*Proto-Oncogene Proteins c-akt', 'TOR Serine-Threonine Kinases', '*Tramadol/analogs & derivatives/toxicity']",https://pubmed.ncbi.nlm.nih.gov/34319855/
165,Tramadol,7618427,Efficacy and safety of oral tramadol and pentazocine for postoperative pain following prolapsed intervertebral disc repair.,"['Kupers R', 'Callebaut V', 'Debois V', 'Camu F', 'Verborgh C', 'Coppejans H', 'Adriaensen H']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Double-Blind Method', 'Female', 'Humans', 'Intervertebral Disc Displacement/*surgery', 'Male', 'Middle Aged', 'Pain Measurement', 'Pain, Postoperative/diagnosis/*drug therapy', 'Pentazocine/administration & dosage/adverse effects/*therapeutic use', 'Tramadol/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7618427/
166,Tramadol,22840860,Efficacy and safety of tramadol for premature ejaculation: a systematic review and meta-analysis.,"['Wu T', 'Yue X', 'Duan X', 'Luo D', 'Cheng Y', 'Tian Y', 'Wang K']","['Ejaculation/*drug effects', 'Humans', 'Male', 'Sexual Dysfunction, Physiological/*drug therapy', 'Tramadol/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22840860/
167,Tramadol,25258277,Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study.,"['Allegaert K', 'Holford N', 'Anderson BJ', 'Holford S', 'Stuber F', 'Rochette A', 'Troconiz IF', 'Beier H', 'de Hoon JN', 'Pedersen RS', 'Stamer U']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Analgesics, Opioid/administration & dosage/*pharmacokinetics', 'Child', 'Child, Preschool', 'Cytochrome P-450 CYP2D6/genetics/metabolism', 'Female', 'Genotype', 'Humans', 'Infant', 'Male', 'Middle Aged', 'Models, Biological', 'Polymorphism, Genetic', 'Tramadol/administration & dosage/*analogs & derivatives/*pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25258277/
168,Tramadol,28953949,Effect of tramadol as an adjuvant to local anesthetics for brachial plexus block: A systematic review and meta-analysis.,"['Shin HW', 'Ju BJ', 'Jang YK', 'You HS', 'Kang H', 'Park JY']","['*Adjuvants, Pharmaceutic', 'Anesthetics, Local/*pharmacology', '*Brachial Plexus Block', 'Humans', 'Tramadol/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/28953949/
169,Tramadol,9881825,Venlafaxine-tramadol similarities.,"['Markowitz JS', 'Patrick KS']","['Analgesics, Opioid/chemistry/*therapeutic use', 'Antidepressive Agents, Second-Generation/chemistry/*therapeutic use', 'Cyclohexanols/chemistry/*therapeutic use', 'Depressive Disorder/*drug therapy', 'Humans', 'Models, Biological', 'Models, Psychological', 'Molecular Structure', 'Pain/*drug therapy', 'Structure-Activity Relationship', 'Tramadol/chemistry/*therapeutic use', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/9881825/
170,Tramadol,34649173,HPLC-UV assay of tramadol and O-desmethyltramadol in human plasma containing other drugs potentially co-administered to participants in a paediatric population pharmacokinetic study.,"['Yoo O', 'Tang EKY', 'Nguyen MN', 'Salman S', 'Hua AJ', 'von Ungern Sternberg BS', 'Lim LY']","['Adult', 'Child', 'Chromatography, High Pressure Liquid/*methods', 'Humans', 'Limit of Detection', 'Linear Models', 'Reproducibility of Results', 'Spectrophotometry, Ultraviolet', 'Tramadol/*analogs & derivatives/*blood/chemistry/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/34649173/
171,Tramadol,31162528,"Tramadol, Methadone and Benzodiazepines added to Alcoholic Beverages.","['Ghadirzadeh MR', 'Nazari SSH', 'Mirtorabi D', 'Fattahi A']","['Alcoholic Beverages/adverse effects/*analysis', 'Analgesics, Opioid/adverse effects/*analysis', 'Benzodiazepines/adverse effects/*analysis', 'Chromatography, High Pressure Liquid/methods', 'Cross-Sectional Studies', 'Gas Chromatography-Mass Spectrometry/methods', 'Humans', 'Iran', 'Methadone/adverse effects/*analysis', 'Random Allocation', 'Tramadol/adverse effects/*analysis']",https://pubmed.ncbi.nlm.nih.gov/31162528/
172,pemoline,6121837,"Determination of the psychostimulants pemoline, fenozolone and thozalinone in human urine by gas chromatography/mass spectrometry and thin layer chromatography.",['Gielsdorf W'],"['Central Nervous System Stimulants/urine', 'Chromatography, Thin Layer', 'Gas Chromatography-Mass Spectrometry', 'Humans', 'Hydrolysis', 'Male', 'Oxazoles/*urine', 'Pemoline/*analogs & derivatives/*urine', 'Trimethylsilyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/6121837/
173,pemoline,12132793,Inappropriate pemoline therapy leading to acute liver failure and liver transplantation.,"['Abbiati C', 'Vecchi M', 'Rossi G', 'Donata MF', 'de Franchis R']","['Adult', 'Central Nervous System Stimulants/*adverse effects', 'Female', 'Humans', 'Liver Failure, Acute/*chemically induced', '*Liver Transplantation', 'Pemoline/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/12132793/
174,pemoline,1204741,Antagonistic effects of pemoline to colchicine and caffeine.,['Roper W'],"['Caffeine/*antagonists & inhibitors/pharmacology', 'Colchicine/*antagonists & inhibitors/pharmacology', 'Mitosis/*drug effects', 'Pemoline/*pharmacology', 'Plants/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/1204741/
175,pemoline,8855756,Pemoline-induced autoimmune hepatitis.,"['Sterling MJ', 'Kane M', 'Grace ND']","['Antibodies, Antinuclear/analysis', 'Autoantibodies/analysis', 'Autoimmune Diseases/*chemically induced/drug therapy', 'Central Nervous System Stimulants/*adverse effects/therapeutic use', 'Chemical and Drug Induced Liver Injury/drug therapy/*immunology', 'Female', 'Glucocorticoids/therapeutic use', 'Humans', 'Immunoglobulin A/analysis', 'Immunoglobulin M/analysis', 'Middle Aged', 'Multiple Sclerosis/drug therapy', 'Pemoline/*adverse effects/therapeutic use', 'Prednisone/therapeutic use', 'Thyroid Gland/immunology']",https://pubmed.ncbi.nlm.nih.gov/8855756/
176,pemoline,12932798,"Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans.","['Pohl R', 'Balon R', 'Jayaraman A', 'Doll RG', 'Yeragani V']","['Adult', 'Anxiety Disorders/complications/drug therapy', 'Cardiac Output/*drug effects', 'Central Nervous System Stimulants/*pharmacology', 'Death, Sudden, Cardiac', 'Depressive Disorder/complications/drug therapy', 'Electroencephalography', 'Female', 'Fluoxetine/*pharmacology', 'Heart Rate/*drug effects', 'Humans', 'Male', 'Pemoline/*pharmacology', 'Placebos', 'Selective Serotonin Reuptake Inhibitors/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12932798/
177,pemoline,7437258,Wakefullness and reduced rapid eye movement sleep: studies with prolintane and pemoline.,"['Nicholson AN', 'Stone BM', 'Jones MM']","['Adult', 'Humans', 'Male', 'Pemoline/*pharmacology', 'Pyrrolidines/*pharmacology', 'Sleep, REM/*drug effects', 'Time Factors', 'Wakefulness/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/7437258/
178,pemoline,2420216,Pemoline and urinary excretion of catecholamines and indoleamines in children with attention deficit disorder.,"['Zametkin AJ', 'Linnoila M', 'Karoum F', 'Sallee R']","['Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology/urine', 'Child', 'Dextroamphetamine/therapeutic use', 'Humans', 'Hydroxyindoleacetic Acid/*urine', 'Male', 'Methylphenidate/therapeutic use', 'Norepinephrine/metabolism', 'Pemoline/*therapeutic use', 'Phenethylamines/*urine', 'Serotonin/*urine']",https://pubmed.ncbi.nlm.nih.gov/2420216/
179,pemoline,24574157,"Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole.","['Hess C', 'Ritke N', 'Sydow K', 'Mehling LM', 'Ruehs H', 'Madea B', 'Musshoff F']","['Administration, Oral', 'Adult', 'Aminorex/*analysis/metabolism', 'Anthelmintics/administration & dosage/analysis/pharmacokinetics', 'Area Under Curve', 'Chromatography, Liquid/*methods', 'Half-Life', 'Humans', 'Levamisole/administration & dosage/analysis/*pharmacokinetics', 'Limit of Detection', 'Male', 'Mass Spectrometry/*methods', 'Models, Biological', 'Pemoline/analysis']",https://pubmed.ncbi.nlm.nih.gov/24574157/
180,pemoline,4017397,Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity.,"['Collier CP', 'Soldin SJ', 'Swanson JM', 'MacLeod SM', 'Weinberg F', 'Rochefort JG']","['Aging', 'Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Child', 'Child, Preschool', 'Female', 'Follow-Up Studies', 'Humans', 'Kinetics', 'Learning/drug effects', 'Male', 'Pemoline/adverse effects/*metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4017397/
181,pemoline,9685452,Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy.,"['Rao JK', 'Julius JR', 'Breen TJ', 'Blethen SL']","['Attention Deficit Disorder with Hyperactivity/complications/*drug therapy', 'Central Nervous System Stimulants/*therapeutic use', 'Child', 'Female', 'Growth/drug effects', 'Growth Disorders/complications/physiopathology/*therapy', 'Growth Hormone/deficiency/*therapeutic use', 'Humans', 'Male', 'Methylphenidate/*therapeutic use', 'Pemoline/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9685452/
182,pemoline,4021028,Pemoline abuse.,"['Polchert SE', 'Morse RM']","['Adult', 'Hallucinations/chemically induced', 'Humans', 'Male', 'Paranoid Disorders/*chemically induced', 'Pemoline/*adverse effects', 'Psychoses, Substance-Induced/*etiology', 'Substance-Related Disorders/*complications/psychology']",https://pubmed.ncbi.nlm.nih.gov/4021028/
183,pemoline,6472603,EEG and clinical findings during pemoline treatment in children and adults with attention deficit disorder. An 8-week open trial.,"['Caresia L', 'Pugnetti L', 'Besana R', 'Barteselli F', 'Guareschi Cazzullo A', 'Musetti L', 'Scarone S']","['Adolescent', 'Adult', 'Anxiety Disorders/drug therapy', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology', 'Child', 'Depressive Disorder/drug therapy', '*Electroencephalography', 'Evoked Potentials/drug effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pemoline/*therapeutic use', 'Personality Disorders/drug therapy', 'Phobic Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6472603/
184,pemoline,881457,"Gas chromatographic determination of pemoline as 5-phenyl-2,4-oxazolidinedione in human urine.","['Vermeulen NP', 'de Roode D', 'Breimer DD']","['Chromatography, Gas/methods', 'Humans', 'Hydrolysis', 'Mass Screening', 'Methods', 'Microchemistry', 'Oxazoles/urine', 'Pemoline/*urine']",https://pubmed.ncbi.nlm.nih.gov/881457/
185,Fosphenytoin,32203691,"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.","['Chamberlain JM', 'Kapur J', 'Shinnar S', 'Elm J', 'Holsti M', 'Babcock L', 'Rogers A', 'Barsan W', 'Cloyd J', 'Lowenstein D', 'Bleck TP', 'Conwit R', 'Meinzer C', 'Cock H', 'Fountain NB', 'Underwood E', 'Connor JT', 'Silbergleit R']","['Adolescent', 'Adult', 'Age Distribution', 'Age Factors', 'Aged', 'Aged, 80 and over', 'Anticonvulsants/*administration & dosage/adverse effects', 'Child', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Infant', 'Levetiracetam/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Phenytoin/administration & dosage/adverse effects/*analogs & derivatives', 'Status Epilepticus/*drug therapy', 'Valproic Acid/*administration & dosage/adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32203691/
186,Fosphenytoin,36207063,Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial.,"['Nakamura K', 'Marushima A', 'Takahashi Y', 'Mochizuki M', 'Kimura A', 'Fukuda Y', 'Asami M', 'Nakamoto H', 'Egawa S', 'Kaneko J', 'Unemoto K', 'Kondo Y', 'Yonekawa C', 'Uchida M', 'Hoshiyama E', 'Yamada T', 'Maruo K', 'Ishikawa E', 'Matsumaru Y', 'Inoue Y']","['Humans', 'Adult', 'Levetiracetam/therapeutic use/adverse effects', '*Phenytoin/therapeutic use/adverse effects', 'Diazepam/therapeutic use', 'Anticonvulsants/adverse effects', '*Status Epilepticus/drug therapy', 'Seizures/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36207063/
187,Fosphenytoin,38149403,Efficacy and safety of intravenous fosphenytoin for patients with acute herpes zoster-associated pain: A placebo-controlled randomized trial.,"['Iseki M', 'Yamamoto T', 'Ogawa Y', 'Majima Y', 'Abe Y', 'Watanabe D', 'Amaya F', 'Hasegawa T', 'Inafuku K', 'Kosugi T', 'Nomura Y', 'Deguchi T', 'Hamada T', 'Shimizu K', 'Arai S', 'Takahashi M', 'Hamada I', 'Ishikawa Y', 'Kawashima M']","['Adult', 'Aged', 'Humans', 'Middle Aged', 'Young Adult', 'Analgesics', 'Analgesics, Non-Narcotic/pharmacology', 'Double-Blind Method', '*Herpes Zoster/complications/drug therapy', 'Herpesvirus 3, Human', '*Pain/drug therapy/etiology', '*Phenytoin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38149403/
188,Fosphenytoin,33157214,Intranasal fosphenytoin: The promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs.,"['Pires PC', 'Santos LT', 'Rodrigues M', 'Alves G', 'Santos AO']","['Administration, Intranasal', '*Anticonvulsants/therapeutic use', 'Brain', 'Esters', '*Phenytoin/analogs & derivatives', 'Phosphates']",https://pubmed.ncbi.nlm.nih.gov/33157214/
189,Fosphenytoin,36866990,Efficacy of single dose of phenytoin/fosphenytoin in benign convulsions with mild gastroenteritis.,"['Lee KS', 'Lee BL']","['Child', 'Humans', 'Infant', '*Phenytoin/therapeutic use', 'Retrospective Studies', 'Seizures/drug therapy/etiology', '*Gastroenteritis/complications/drug therapy', 'Sodium']",https://pubmed.ncbi.nlm.nih.gov/36866990/
190,Fosphenytoin,33710073,Levetiracetam Versus Phenytoin or Fosphenytoin for Second-Line Treatment of Pediatric Status Epilepticus: A Meta-Analysis.,"['Klowak JA', 'Hewitt M', 'Catenacci V', 'Duffett M', 'Rochwerg B', 'Jones K', 'Choong K']","['Anticonvulsants/adverse effects', 'Child', 'Humans', 'Levetiracetam/therapeutic use', '*Phenytoin/adverse effects/analogs & derivatives', '*Status Epilepticus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33710073/
191,Fosphenytoin,34284302,Efficacy and safety of levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials.,"['Feng Y', 'Chen Y', 'Jia Y', 'Wang Z', 'Wang X', 'Jiang L', 'Ai C', 'Li W', 'Liu Y']","['Anticonvulsants/therapeutic use', 'Humans', 'Levetiracetam/therapeutic use', '*Phenytoin/therapeutic use', 'Randomized Controlled Trials as Topic', '*Status Epilepticus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34284302/
192,Fosphenytoin,39237847,Effectiveness of Fosphenytoin and Levetiracetam to Prevent Posttraumatic Seizures in Young Children with Accidental or Abusive Traumatic Brain Injury.,"['McNamara CR', 'Menchaca CI', 'Abel TJ', 'Horvat CM', 'Berger RP', 'Fink EL', 'Kochanek PM', 'Simon DW']","['Humans', '*Levetiracetam/therapeutic use/pharmacology', '*Phenytoin/analogs & derivatives/pharmacology/therapeutic use', 'Male', 'Female', '*Brain Injuries, Traumatic/complications/drug therapy', '*Anticonvulsants/therapeutic use/pharmacology', '*Seizures/etiology/prevention & control/drug therapy', 'Retrospective Studies', 'Infant', 'Child, Preschool', '*Child Abuse/prevention & control', 'Accidental Injuries/prevention & control/etiology']",https://pubmed.ncbi.nlm.nih.gov/39237847/
193,Fosphenytoin,35879140,Fosphenytoin dosing regimen including optimal timing for the measurement of serum phenytoin concentration in pediatric patients.,"['Okamoto G', 'Furuya E', 'Terada K', 'Yasukawa K', 'Takanashi JI', 'Kobayashi E']","['Humans', 'Child', '*Phenytoin/therapeutic use', '*Anticonvulsants', 'Retrospective Studies', 'Bayes Theorem']",https://pubmed.ncbi.nlm.nih.gov/35879140/
194,Fosphenytoin,30522345,Evaluation of Intravenous Phenytoin and Fosphenytoin Loading Doses: Influence of Obesity and Sex.,"['DasGupta R', 'Alaniz C', 'Burghardt D']","['Administration, Intravenous', 'Adult', 'Aged', 'Anticonvulsants/administration & dosage/pharmacokinetics', 'Body Mass Index', 'Dose-Response Relationship, Drug', '*Drug Dosage Calculations', 'Epilepsy/complications/*drug therapy/epidemiology/metabolism', 'Female', 'Humans', 'Infusions, Intravenous', 'Male', 'Middle Aged', 'Obesity/*complications/drug therapy/epidemiology/metabolism', 'Phenytoin/administration & dosage/*analogs & derivatives/pharmacokinetics', 'Retrospective Studies', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/30522345/
195,Fosphenytoin,26135797,Purple Glove Syndrome after Phenytoin or Fosphenytoin Administration: Review of Reported Cases and Recommendations for Prevention.,"['Garbovsky LA', 'Drumheller BC', 'Perrone J']","['Anticonvulsants/*adverse effects', 'Humans', 'Male', 'Middle Aged', 'Phenytoin/*adverse effects/*analogs & derivatives', 'Risk Factors', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/26135797/
196,Fosphenytoin,8840370,"The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.","['Boucher BA', 'Feler CA', 'Dean JC', 'Michie DD', 'Tipton BK', 'Smith KR Jr', 'Kramer RE', 'Young B', 'Parks BR Jr', 'Kugler AR']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anticonvulsants/administration & dosage/*adverse effects/*pharmacokinetics', 'Brain Injuries/drug therapy/*metabolism', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Male', 'Middle Aged', 'Phenytoin/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics', 'Prodrugs/administration & dosage/*adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8840370/
197,Fosphenytoin,35469443,Intravenous fosphenytoin as treatment for acute exacerbation of trigeminal neuralgia: A prospective systematic study of 15 patients.,"['Andersen ASS', 'Heinskou TB', 'Asghar MS', 'Rossen B', 'Noory N', 'Smilkov EA', 'Bendtsen L', 'Maarbjerg S']","['Follow-Up Studies', 'Humans', '*Phenytoin/analogs & derivatives/therapeutic use', 'Prospective Studies', '*Trigeminal Neuralgia/drug therapy/surgery']",https://pubmed.ncbi.nlm.nih.gov/35469443/
198,Fosphenytoin,31672614,Nanoemulsions and thermosensitive nanoemulgels of phenytoin and fosphenytoin for intranasal administration: Formulation development and in vitro characterization.,"['Pires PC', 'Peixoto D', 'Teixeira I', 'Rodrigues M', 'Alves G', 'Santos AO']","['Administration, Intranasal', 'Anticonvulsants/*chemistry', 'Drug Compounding', '*Drug Delivery Systems', 'Drug Liberation', 'Emulsions', 'Gels', 'Nanostructures/*chemistry', 'Phenytoin/*analogs & derivatives/chemistry', 'Temperature']",https://pubmed.ncbi.nlm.nih.gov/31672614/
199,Fosphenytoin,32198860,"Efficacy, Tolerability and Serum Phenytoin Levels after Intravenous Fosphenytoin Loading Dose in Children with Status Epilepticus.","['Srivastava K', 'Bhartiya S', 'Gavli V', 'Patil R', 'Rajadhyaksha S']","['Administration, Intravenous', 'Adolescent', 'Anticonvulsants/*administration & dosage/pharmacokinetics/therapeutic use', 'Biomarkers/blood', 'Child', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Infant', 'Linear Models', 'Male', 'Phenytoin/administration & dosage/*analogs & derivatives/blood/pharmacokinetics/therapeutic use', 'Prospective Studies', 'Status Epilepticus/blood/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32198860/
200,Fosphenytoin,32420641,"The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus.","['Sathe AG', 'Elm JJ', 'Cloyd JC', 'Chamberlain JM', 'Silbergleit R', 'Kapur J', 'Cock HR', 'Fountain NB', 'Shinnar S', 'Lowenstein DH', 'Conwit RA', 'Bleck TP', 'Coles LD']","['Adolescent', 'Adult', 'Anticonvulsants/*administration & dosage', 'Body Weight/*drug effects/physiology', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Levetiracetam/*administration & dosage', 'Male', 'Phenytoin/administration & dosage/*analogs & derivatives', 'Single-Blind Method', 'Status Epilepticus/*drug therapy/physiopathology', 'Treatment Outcome', 'Valproic Acid/*administration & dosage', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32420641/
201,Fosphenytoin,33894096,Comparison of levetiracetam versus phenytoin/fosphenytoin for busulfan seizure prophylaxis at a pediatric institution.,"['Hughes K', 'Garrity L', 'Nelson AS', 'Lane A', 'Teusink-Cross A']","['Adolescent', 'Adult', 'Anticonvulsants/*therapeutic use', 'Busulfan/*adverse effects', 'Child', 'Child, Preschool', 'Drug Administration Schedule', 'Female', 'Hematopoietic Stem Cell Transplantation', 'Humans', 'Incidence', 'Infant', 'Levetiracetam/*therapeutic use', 'Male', 'Myeloablative Agonists/*adverse effects', 'Phenytoin/*therapeutic use', 'Retrospective Studies', 'Seizures/chemically induced/epidemiology/*prevention & control', 'Transplantation Conditioning/*adverse effects/methods', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33894096/
202,Ibuprofen,34443379,Recent Advances in the Synthesis of Ibuprofen and Naproxen.,"['Ha MW', 'Paek SM']","['Electrochemistry', 'Humans', 'Hydrogenation', 'Ibuprofen/*chemical synthesis/chemistry', 'Naproxen/*chemical synthesis/chemistry', 'Oxidation-Reduction', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/34443379/
203,Ibuprofen,391117,Ibuprofen.,['Kantor TG'],"['Analgesics', 'Anti-Inflammatory Agents', 'Arthritis/drug therapy', 'Digestive System/drug effects', 'Drug Interactions', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/391117/
204,Ibuprofen,21992864,Ibuprofen lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates.,"['De Carolis MP', 'Bersani I', 'De Rosa G', 'Cota F', 'Romagnoli C']","['Cyclooxygenase Inhibitors/*therapeutic use', 'Ductus Arteriosus, Patent/*drug therapy', 'Humans', 'Ibuprofen/administration & dosage/*analogs & derivatives/*therapeutic use', 'Infant, Newborn', 'Infant, Premature, Diseases/*drug therapy', 'Lysine/administration & dosage/*analogs & derivatives/therapeutic use', 'Retrospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21992864/
205,Ibuprofen,36903343,Ibuprofen: Toxicology and Biodegradation of an Emerging Contaminant.,"['Jan-Roblero J', 'Cruz-Maya JA']","['Humans', 'Ibuprofen/chemistry', 'Bacteria', 'Biodegradation, Environmental', '*Drug-Related Side Effects and Adverse Reactions', 'Technology', '*Water Pollutants, Chemical/analysis']",https://pubmed.ncbi.nlm.nih.gov/36903343/
206,Ibuprofen,11501788,Solubility and dissolution rate of ibuprofen in ionic and non-ionic micellar systems.,"['Kokot Z', 'Zmidzinska H']","['Anti-Inflammatory Agents, Non-Steroidal/*chemistry', 'Ibuprofen/administration & dosage/*chemistry', 'Micelles', 'Sodium Chloride/pharmacology', 'Sodium Dodecyl Sulfate/pharmacology', 'Solubility']",https://pubmed.ncbi.nlm.nih.gov/11501788/
207,Ibuprofen,799991,Response of osteoarthritis to ibuprofen or flurbiprofen.,"['Mena HR', 'Ehrlich GE', 'Giansiracusa J', 'Ward J', 'Gray J']","['Aged', 'Clinical Trials as Topic', 'Drug Evaluation', 'Female', 'Flurbiprofen/adverse effects/*therapeutic use', 'Humans', 'Ibuprofen/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Osteoarthritis/*drug therapy', 'Phenylpropionates/*therapeutic use', 'Propionates/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/799991/
208,Ibuprofen,8179987,Ibuprofen-induced thrombocytopenia.,['Jain S'],"['Female', 'Humans', 'Ibuprofen/*adverse effects', 'Middle Aged', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/8179987/
209,Ibuprofen,9876608,"Preparation, characterization, and dissolution studies of ibuprofen solid dispersions using polyethylene glycol (PEG), talc, and PEG-talc as dispersion carriers.","['Khan GM', 'Jiabi Z']","['Calorimetry, Differential Scanning', 'Chemistry, Pharmaceutical', 'Drug Compounding', 'Humans', 'Ibuprofen/administration & dosage/chemistry/*isolation & purification', 'In Vitro Techniques', 'Microscopy, Electron, Scanning', 'Particle Size', 'Pharmaceutical Vehicles', 'Polyethylene Glycols', 'Solubility', 'Talc', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/9876608/
210,Ibuprofen,38276584,Silver and Copper Complexes with Ibuprofen and Caffeine-Preparation and Evaluation of Their Selected Biological Effects.,"['Borowka A', 'Sieroslawska A', 'Baier A', 'Rymuszka A', 'Olszewska E']","['Humans', '*Silver/chemistry', '*Ibuprofen/pharmacology/chemistry', 'Copper/chemistry', 'Caffeine/pharmacology', 'Spectroscopy, Fourier Transform Infrared', 'Anti-Bacterial Agents/chemistry', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/38276584/
211,Ibuprofen,1518683,Acetaminophen and ibuprofen: fever control and overdose.,['Murphy KA'],"['Acetaminophen/blood/poisoning/*therapeutic use', 'Child', 'Fever/*drug therapy/nursing/physiopathology', 'Humans', 'Ibuprofen/blood/poisoning/*therapeutic use', 'Poisoning/blood/nursing/therapy']",https://pubmed.ncbi.nlm.nih.gov/1518683/
212,Ibuprofen,14742809,Antipyretic efficacy and safety of ibuprofen and acetaminophen in children.,"['Goldman RD', 'Ko K', 'Linett LJ', 'Scolnik D']","['Acetaminophen/administration & dosage/*adverse effects/*therapeutic use', 'Child', 'Child, Preschool', 'Drug Administration Schedule', 'Fever/*drug therapy', 'Humans', 'Ibuprofen/administration & dosage/*adverse effects/*therapeutic use', 'Infant', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/14742809/
213,Ibuprofen,15449966,Ibuprofen and increased morbidity in children with asthma: fact or fiction?,"['Kauffman RE', 'Lieh-Lai M']","['Asthma/*chemically induced/drug therapy/*epidemiology', 'Child', 'Humans', 'Ibuprofen/*adverse effects/therapeutic use', 'Morbidity']",https://pubmed.ncbi.nlm.nih.gov/15449966/
214,Ibuprofen,26633347,Determination of Solubility Parameters of Ibuprofen and Ibuprofen Lysinate.,"['Kitak T', 'Dumicic A', 'Planinsek O', 'Sibanc R', 'Srcic S']","['Anti-Inflammatory Agents, Non-Steroidal/*chemistry', 'Chromatography, Gas', 'Drug Carriers', 'Excipients/*chemistry', 'Ibuprofen/*analogs & derivatives/*chemistry', 'Lysine/*analogs & derivatives/chemistry', 'Solvents/*chemistry', 'Technology, Pharmaceutical/*methods']",https://pubmed.ncbi.nlm.nih.gov/26633347/
215,Ibuprofen,27806251,Onset of Action and Efficacy of Ibuprofen Liquigel as Compared to Solid Tablets: A Systematic Review and Meta-Analysis.,"['Lawati HA', 'Jamali F']","['Gels', 'Humans', 'Ibuprofen/*administration & dosage/*chemistry/therapeutic use', 'Pain/*drug therapy', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/27806251/
216,Ibuprofen,36833369,Biodegradation of Microtoxic Phenylpropanoids (Phenylpropanoic Acid and Ibuprofen) by Bacteria and the Relevance for Their Removal from Wastewater Treatment Plants.,"['Wittich RM', 'Haidour A', 'Aguilar-Romero I', 'de la Torre-Zuniga J', 'van Dillewijn P']","['*Ibuprofen/chemistry/metabolism', 'Anti-Inflammatory Agents, Non-Steroidal', 'Bacteria/metabolism', 'Biodegradation, Environmental', '*Water Purification']",https://pubmed.ncbi.nlm.nih.gov/36833369/
217,Ibuprofen,35491716,"Theoretical insights of the drug-drug interaction between favipiravir and ibuprofen: a DFT, QTAIM and drug-likeness investigation.","['Parlak C', 'Alver O', 'Baglayan O', 'Ramasami P']","['*Ibuprofen/pharmacology/chemistry', '*Amides/pharmacology', 'Pyrazines/pharmacology', 'Drug Interactions']",https://pubmed.ncbi.nlm.nih.gov/35491716/
218,Isoniazid,26631576,Preparation and characterization of isoniazid and lamivudine co-loaded polymeric microspheres.,"['Pandey G', 'Yadav SK', 'Mishra B']","['Caco-2 Cells', '*Drug Carriers/chemistry/pharmacokinetics/pharmacology', 'Humans', '*Isoniazid/chemistry/pharmacokinetics/pharmacology', '*Lamivudine/chemistry/pharmacokinetics/pharmacology', 'Materials Testing', '*Microspheres']",https://pubmed.ncbi.nlm.nih.gov/26631576/
219,Isoniazid,30922765,"Eosinophil peroxidase oxidizes isoniazid to form the active metabolite against M. tuberculosis, isoniazid-NAD().","['Babu D', 'Morgan AG', 'Reiz B', 'Whittal RM', 'Almas S', 'Lacy P', 'Siraki AG']","['Asthma/metabolism/pathology', 'Chromatography, High Pressure Liquid', 'Electron Spin Resonance Spectroscopy', 'Eosinophil Peroxidase/*metabolism', 'Eosinophils/chemistry/drug effects/*enzymology', 'Humans', 'Isoniazid/*analogs & derivatives/blood/chemistry/*metabolism/pharmacology', 'Mass Spectrometry', 'Mycobacterium tuberculosis/drug effects/pathogenicity', 'NAD/*analogs & derivatives/blood/chemistry/*metabolism', 'Oxidation-Reduction', 'Platelet Activating Factor/pharmacology', 'Superoxide Dismutase/metabolism']",https://pubmed.ncbi.nlm.nih.gov/30922765/
220,Isoniazid,24705055,"Cinnamic acid hydrogen bonds to isoniazid and N'-(propan-2-ylidene)isonicotinohydrazide, an in situ reaction product of isoniazid and acetone.","['Sarcevica I', 'Orola L', 'Veidis MV', 'Belyakov S']","['Acetone/*chemistry', 'Cinnamates/*chemistry', 'Hydrogen Bonding', 'Isoniazid/*analogs & derivatives/*chemical synthesis/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/24705055/
221,Isoniazid,21517721,Isoniazid-induced pellagra.,"['Bilgili SG', 'Karadag AS', 'Calka O', 'Altun F']","['Antitubercular Agents/administration & dosage/*adverse effects/therapeutic use', 'Child', 'Drug Therapy, Combination', 'Humans', 'Isoniazid/administration & dosage/*adverse effects/therapeutic use', 'Male', 'Niacinamide/administration & dosage/therapeutic use', 'Pellagra/*chemically induced/complications/diagnosis/drug therapy', 'Treatment Outcome', 'Tuberculosis, Pulmonary/complications/drug therapy', 'Vitamin B Complex/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21517721/
222,Isoniazid,36099255,Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia.,"['Getahun M', 'Blumberg HM', 'Ameni G', 'Beyene D', 'Kempker RR']","['Ethiopia', 'Humans', 'Isoniazid/pharmacology/therapeutic use', 'Microbial Sensitivity Tests', '*Mycobacterium tuberculosis', 'Rifabutin', 'Rifampin/pharmacology/therapeutic use', '*Tuberculosis, Multidrug-Resistant/drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/36099255/
223,Isoniazid,21753138,Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.,"['Sotsuka T', 'Sasaki Y', 'Hirai S', 'Yamagishi F', 'Ueno K']","['Adult', 'Aged', 'Alanine Transaminase/blood', 'Arylamine N-Acetyltransferase/*genetics', 'Aspartate Aminotransferases/blood', 'Biotransformation', 'Cytochrome P-450 CYP2E1/*genetics', 'Female', 'Genetic Association Studies', 'Genotype', 'Glutathione Transferase/*genetics', 'Humans', 'Isoniazid/*adverse effects/pharmacokinetics/therapeutic use', 'Liver/*drug effects/enzymology', 'Male', 'Middle Aged', 'Polymorphism, Genetic', 'Tuberculosis, Pulmonary/blood/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21753138/
224,Isoniazid,31761544,Vibrational spectra of pyrazinamide and isoniazid studied by terahertz spectroscopy and density functional theory.,"['Liang J', 'Zhang X', 'Wang N', 'Chang T', 'Cui HL']","['Crystallization', '*Density Functional Theory', 'Dimerization', 'Isoniazid/*chemistry', 'Molecular Conformation', 'Pyrazinamide/*chemistry', 'Quantum Theory', '*Terahertz Spectroscopy', '*Vibration']",https://pubmed.ncbi.nlm.nih.gov/31761544/
225,Isoniazid,34981576,Thermodynamic integration combined with molecular dynamic simulations to explore the cross-resistance mechanism of isoniazid and ethionamide.,"['Zhang Q', 'Yang Y', 'Gong X', 'Zhao N', 'Zhang Y', 'Liu H']","['Bacterial Proteins/chemistry', 'Ethionamide/metabolism/pharmacology', 'Humans', 'Isoniazid/metabolism/pharmacology', 'Molecular Dynamics Simulation', 'Mutation', '*Mycobacterium tuberculosis/metabolism', 'Oxidoreductases/metabolism', 'Thermodynamics', '*Tuberculosis']",https://pubmed.ncbi.nlm.nih.gov/34981576/
226,Isoniazid,28667670,"Preparation, characterization, and in vitro evaluation of isoniazid and rifampicin-loaded archaeosomes.","['Attar A', 'Bakir C', 'Yuce-Dursun B', 'Demir S', 'Cakmakci E', 'Danis O', 'Birbir M', 'Ogan A']","['Archaea/*metabolism', 'Calorimetry, Differential Scanning', 'Drug Liberation', 'Hydrogen-Ion Concentration', 'Isoniazid/*chemistry/metabolism', 'Microscopy, Atomic Force', 'Particle Size', 'Rifampin/*chemistry/metabolism', 'Unilamellar Liposomes/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/28667670/
227,Isoniazid,9876514,Effects of drug concentration in inner aqueous phase and additives in oleaginous phase on release and bioavailability of isoniazid from multiple emulsion.,"['Khopade AJ', 'Jain NK']","['Administration, Oral', 'Adult', 'Biological Availability', 'Emulsions', 'Humans', 'Isoniazid/*pharmacokinetics/urine', 'Male', '*Oils', 'Reference Values', 'Water/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/9876514/
228,Isoniazid,773583,Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.,['Ellard GA'],"['Acetylation', 'Homozygote', 'Humans', 'Isoniazid/administration & dosage/*metabolism/therapeutic use/toxicity', 'Kinetics', 'Tuberculosis, Pulmonary/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/773583/
229,Isoniazid,7153283,"Determination of rifampicin, desacetylrifampicin, isoniazid and acetylisoniazid by high-performance liquid chromatography: application to human serum extracts, polymorphonucleocytes and alveolar macrophages.","['Guillaumont M', 'Leclercq M', 'Frobert Y', 'Guise B', 'Harf R']","['Chromatography, High Pressure Liquid/methods', 'Humans', 'Isoniazid/*analogs & derivatives/*analysis/blood/therapeutic use', 'Macrophages/*analysis', 'Neutrophils/*analysis', 'Rifampin/*analogs & derivatives/*analysis/blood/therapeutic use', 'Tuberculosis, Pulmonary/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7153283/
230,Isoniazid,30617660,3D-Printed Isoniazid Tablets for the Treatment and Prevention of Tuberculosis-Personalized Dosing and Drug Release.,"['Oblom H', 'Zhang J', 'Pimparade M', 'Speer I', 'Preis M', 'Repka M', 'Sandler N']","['Antitubercular Agents/administration & dosage/*chemistry/*pharmacokinetics', 'Drug Compounding/methods', 'Drug Delivery Systems/methods', '*Drug Liberation', 'Isoniazid/administration & dosage/*chemistry/*pharmacokinetics', '*Printing, Three-Dimensional', 'Tablets', 'Technology, Pharmaceutical/methods', 'Tuberculosis/metabolism/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/30617660/
231,Isoniazid,35876096,"Isonicotinic acid N-oxide, from isoniazid biotransformation by Aspergillus niger, as an InhA inhibitor antituberculous agent against multiple and extensively resistant strains supported by in silico docking and ADME prediction.","['Ragab AE', 'Badawy ET', 'Aboukhatwa SM', 'Abdel-Aziz MM', 'Kabbash A', 'Abo Elseoud KA']","['*Isoniazid/pharmacology/chemistry/metabolism', 'Antitubercular Agents/pharmacology/chemistry', 'Aspergillus niger/metabolism', 'Isonicotinic Acids/metabolism', 'Oxides', '*Mycobacterium tuberculosis', 'Microbial Sensitivity Tests', 'Biotransformation', 'Bacterial Proteins/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35876096/
232,Isoniazid,31758837,"Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data.","['Otero L', 'Battaglioli T', 'Rios J', 'De la Torre Z', 'Trocones N', 'Ordonez C', 'Seas C', 'Van der Stuyft P']","['Adolescent', 'Antitubercular Agents/administration & dosage/*therapeutic use', 'Child', 'Child Health Services', 'Child, Preschool', '*Contact Tracing', '*Family Characteristics', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Isoniazid/administration & dosage/*therapeutic use', 'Male', 'Peru/epidemiology', 'Tuberculosis, Pulmonary/drug therapy/*epidemiology/prevention & control', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31758837/
233,Isoniazid,22846601,Isoniazid as a substrate and inhibitor of myeloperoxidase: identification of amine adducts and the influence of superoxide dismutase on their formation.,"['Forbes LV', 'Furtmuller PG', 'Khalilova I', 'Turner R', 'Obinger C', 'Kettle AJ']","['Amines/*chemistry', 'Benzidines', 'Chromatography, High Pressure Liquid', 'Humans', 'Hydrogen Peroxide', 'Hypochlorous Acid/metabolism', 'Immunity, Innate/drug effects', 'Isoniazid/analogs & derivatives/chemistry/*pharmacology', 'Mass Spectrometry', 'Molecular Structure', 'Neutrophils/drug effects/metabolism', 'Oxidation-Reduction', 'Peroxidase/*antagonists & inhibitors/*metabolism', 'Superoxide Dismutase/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/22846601/
234,Racemethorphan,8120122,Chiral differentiation of the optical isomers of racemethorphan and racemorphan in urine by capillary zone electrophoresis.,"['Aumatell A', 'Wells RJ']","['Dextromethorphan/*urine', 'Electrophoresis/*methods', 'Humans', 'Levorphanol/*urine', 'Male', 'Spectrophotometry, Ultraviolet', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/8120122/
235,thiotepa,26524264,Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.,"['Pasqualini C', 'Dufour C', 'Goma G', 'Raquin MA', 'Lapierre V', 'Valteau-Couanet D']","['Adolescent', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'Autografts', 'Busulfan/administration & dosage/adverse effects', 'Child', 'Child, Preschool', 'Disease-Free Survival', 'Female', 'Humans', 'Infant', 'Male', 'Melphalan/administration & dosage/adverse effects', '*Neuroblastoma/mortality/therapy', 'Retrospective Studies', '*Stem Cell Transplantation', 'Survival Rate', 'Thiotepa/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/26524264/
236,thiotepa,27132696,"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.","['Ferreri AJ', 'Cwynarski K', 'Pulczynski E', 'Ponzoni M', 'Deckert M', 'Politi LS', 'Torri V', 'Fox CP', 'Rosee PL', 'Schorb E', 'Ambrosetti A', 'Roth A', 'Hemmaway C', 'Ferrari A', 'Linton KM', 'Ruda R', 'Binder M', 'Pukrop T', 'Balzarotti M', 'Fabbri A', 'Johnson P', 'Gorlov JS', 'Hess G', 'Panse J', 'Pisani F', 'Tucci A', 'Stilgenbauer S', 'Hertenstein B', 'Keller U', 'Krause SW', 'Levis A', 'Schmoll HJ', 'Cavalli F', 'Finke J', 'Reni M', 'Zucca E', 'Illerhaus G']","['Acute Kidney Injury/chemically induced', 'Anemia/chemically induced', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects/*therapeutic use', 'Central Nervous System Neoplasms/diagnostic imaging/mortality/*therapy', 'Chemical and Drug Induced Liver Injury/epidemiology', 'Combined Modality Therapy/*adverse effects/*methods', 'Comparative Effectiveness Research', 'Cytarabine/*adverse effects/*therapeutic use', 'Death, Sudden/epidemiology', 'Denmark', 'Dexamethasone/therapeutic use', 'Disease-Free Survival', 'Female', 'Follow-Up Studies', 'Gastrointestinal Diseases/chemically induced', 'Germany', 'Heart Injuries/chemically induced', 'Hematopoietic Stem Cell Transplantation/adverse effects/*methods', 'Humans', 'Hyperglycemia/chemically induced', 'Induction Chemotherapy/adverse effects/*methods', 'Infections/chemically induced', 'Intraocular Lymphoma/diagnostic imaging/therapy', 'Italy', 'Kaplan-Meier Estimate', 'Lymphoma, B-Cell/diagnostic imaging/mortality/*therapy', 'Magnetic Resonance Imaging', 'Male', 'Methotrexate/*adverse effects/*therapeutic use', 'Middle Aged', 'Mucositis/chemically induced', 'Neurotoxicity Syndromes/epidemiology', 'Neutropenia/chemically induced', 'Optic Nerve Neoplasms/diagnostic imaging/therapy', 'Poisoning/epidemiology', 'Radiotherapy, Adjuvant/adverse effects/*methods', 'Remission Induction/methods', 'Rituximab/*adverse effects/*therapeutic use', 'Stroke/chemically induced', 'Switzerland', 'Thiotepa/*adverse effects/*therapeutic use', 'Thrombocytopenia/chemically induced', 'Thrombosis/chemically induced', 'Transplantation Conditioning/adverse effects/methods', 'Transplantation, Autologous/adverse effects', 'Treatment Outcome', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/27132696/
237,thiotepa,11313694,"Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature.","['Mileshkin L', 'Prince HM', 'Rischin D', 'Zimet A']","['Adult', 'Anti-Inflammatory Agents/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects', 'Breast Neoplasms/complications/drug therapy/pathology', 'Cyclophosphamide/administration & dosage/adverse effects', 'Docetaxel', 'Female', 'Hematopoietic Stem Cell Transplantation', 'Humans', 'Lung Diseases, Interstitial/*chemically induced/drug therapy', 'Methylprednisolone/administration & dosage', 'Middle Aged', 'Paclitaxel/administration & dosage/adverse effects/analogs & derivatives', '*Taxoids', 'Thiotepa/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11313694/
238,thiotepa,35008101,"Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML.","['Ramaswamy K', 'Steinherz PG', 'Agrawal AK', 'Forlenza CJ', 'Mauguen A', 'Roshal M', 'Trippett T', 'Kernan NA', 'Sulis ML', 'Shukla N']","['Anthracyclines', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Child', 'Clofarabine/therapeutic use', 'Humans', '*Leukemia, Myeloid, Acute/etiology', 'Recurrence', '*Thiotepa/adverse effects', 'Topotecan/adverse effects', 'Vinorelbine/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/35008101/
239,thiotepa,39674707,De-escalated Induction Therapy and Thiotepa/Busulfan-based Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma.,"['Puckrin R', 'Stewart C', 'Owen C', 'Street LE', 'Perry S', 'Duggan P', 'Shafey M', 'Chua N', 'Stewart DA']","['Humans', '*Thiotepa/administration & dosage/therapeutic use/pharmacology', 'Middle Aged', 'Male', 'Female', 'Adult', '*Central Nervous System Neoplasms/therapy/mortality/drug therapy', '*Transplantation, Autologous/methods', 'Aged', 'Retrospective Studies', '*Hematopoietic Stem Cell Transplantation/methods', '*Busulfan/therapeutic use/administration & dosage', 'Lymphoma/therapy/mortality/drug therapy', 'Induction Chemotherapy/methods', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Transplantation Conditioning/methods']",https://pubmed.ncbi.nlm.nih.gov/39674707/
240,thiotepa,38036843,Measurement of ThioTEPA and Its Metabolite TEPA in Plasma and Cerebrospinal Fluid by Turbulent Flow Chromatography-Tandem Mass Spectrometry.,"['Schofield RC', 'Scordo M', 'Shah G', 'Carlow DC']","['*Thiotepa/chemistry/metabolism', '*Triethylenephosphoramide/chemistry/metabolism', 'Tandem Mass Spectrometry', 'Chromatography, Liquid', 'Gas Chromatography-Mass Spectrometry']",https://pubmed.ncbi.nlm.nih.gov/38036843/
241,thiotepa,3110433,Generalized hypersensitivity reaction to intravesical thiotepa and doxorubicin.,"['Lee M', 'Sharifi R']","['Administration, Intravesical', 'Aged', 'Aged, 80 and over', 'Carcinoma, Transitional Cell/drug therapy', 'Doxorubicin/administration & dosage/*adverse effects', 'Drug Hypersensitivity/*etiology', 'Female', 'Humans', 'Pruritus/chemically induced', 'Sweating/drug effects', 'Thiotepa/administration & dosage/*adverse effects', 'Urinary Bladder Neoplasms/drug therapy', 'Urticaria/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/3110433/
242,thiotepa,37046407,"Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders.","['Fraser A', 'Castillo P', 'Cascio E', 'Moore-Higgs G', 'Farhadfar N', 'Fort J', 'Slayton W', 'Lamba J', 'Horn B']","['Child', 'Humans', 'Busulfan/therapeutic use', 'Thiotepa/therapeutic use', '*Hematopoietic Stem Cell Transplantation/adverse effects', 'Feasibility Studies', 'Prospective Studies', '*Anemia, Sickle Cell/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37046407/
243,thiotepa,24491026,Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma.,"['Kokolo MB', 'Fergusson D', ""O'Neill J"", 'Tay J', 'Tinmouth AT', 'Stewart D', 'Bredeson C']","['Central Nervous System Neoplasms/complications/pathology/*therapy', 'Hematopoietic Stem Cell Mobilization/methods', '*Hematopoietic Stem Cell Transplantation/adverse effects', 'Humans', 'Lymphoma/complications/pathology/*therapy', 'Myeloablative Agonists/administration & dosage/adverse effects/*therapeutic use', 'Neoplasm Recurrence, Local', 'Publication Bias', 'Thiotepa/administration & dosage/adverse effects/*therapeutic use', '*Transplantation Conditioning', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24491026/
244,thiotepa,31673080,Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.,"['Peric Z', 'Mohty R', 'Bastos J', 'Brissot E', 'Battipaglia G', 'Belhocine R', 'Sestili S', 'Giannotti F', 'Vekhoff A', 'Ledraa T', 'Legrand O', 'Lapusan S', 'Isnard F', 'Labopin M', 'Bonnin A', 'Mediavilla C', 'Rubio MT', 'Ruggeri A', 'Dulery R', 'Malard F', 'Mohty M']","['Antilymphocyte Serum', 'Cyclophosphamide', '*Graft vs Host Disease/prevention & control', '*Hematologic Neoplasms/therapy', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Middle Aged', 'Neoplasm Recurrence, Local', 'Thiotepa', 'Transplantation Conditioning', 'Transplantation, Haploidentical']",https://pubmed.ncbi.nlm.nih.gov/31673080/
245,thiotepa,30989325,"Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.","['Hyung J', 'Hong JY', 'Yoon DH', 'Kim S', 'Park JS', 'Park CS', 'Lee SW', 'Kim JH', 'Ryu JS', 'Huh J', 'Suh C']","['Aged', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage', 'Autografts', 'Busulfan/administration & dosage', '*Central Nervous System Neoplasms/mortality/therapy', 'Consolidation Chemotherapy', 'Cyclophosphamide/administration & dosage', 'Disease-Free Survival', 'Etoposide/administration & dosage', 'Female', 'Follow-Up Studies', 'Humans', '*Induction Chemotherapy', '*Lymphoma/mortality/therapy', 'Male', 'Middle Aged', 'Prospective Studies', '*Registries', '*Stem Cell Transplantation', 'Survival Rate', 'Thiotepa/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/30989325/
246,thiotepa,32736010,Addition of Thiotepa to Total Body Irradiation and Cyclophosphamide Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia.,"['Chinnabhandar V', 'Tran S', 'Sutton R', 'Shaw PJ', 'Mechinaud F', 'Cole C', 'Tapp H', 'Teague L', 'Fraser C', ""O'Brien TA"", 'Mitchell R']","['Child', 'Cyclophosphamide/therapeutic use', 'Disease-Free Survival', '*Hematopoietic Stem Cell Transplantation', 'Humans', '*Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy', 'Retrospective Studies', 'Thiotepa', 'Transplantation Conditioning', 'Whole-Body Irradiation']",https://pubmed.ncbi.nlm.nih.gov/32736010/
247,thiotepa,35550442,"Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning.","['Kulkarni UP', 'Pai AA', 'Kavitha ML', 'Selvarajan S', 'Lionel S', 'Devasia AJ', 'Korula A', 'Fouzia NA', 'Sindhuvi E', 'Abraham A', 'Srivastava A', 'Mathews V', 'George B', 'Balasubramanian P']","['Adolescent', 'Adult', 'Busulfan/analogs & derivatives', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Male', 'Retrospective Studies', '*Thiotepa/therapeutic use', 'Vidarabine/analogs & derivatives', 'Young Adult', '*beta-Thalassemia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35550442/
248,thiotepa,22492714,"Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma.","['Saarinen-Pihkala UM', 'Hovi L', 'Koivusalo A', 'Jahnukainen K', 'Karikoski R', 'Sariola H', 'Wikstrom S']","['Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'Child', 'Child, Preschool', 'Combined Modality Therapy', 'Disease-Free Survival', 'Female', 'Humans', 'Infant', 'Male', 'Melphalan/*administration & dosage/adverse effects', 'Neuroblastoma/mortality/*therapy', '*Peripheral Blood Stem Cell Transplantation', 'Remission Induction', 'Survival Rate', 'Thiotepa/*administration & dosage/adverse effects', 'Transplantation, Autologous', 'Whole-Body Irradiation']",https://pubmed.ncbi.nlm.nih.gov/22492714/
249,thiotepa,29625929,Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation.,"['El-Cheikh J', 'Massoud R', 'Moukalled N', 'Haffar B', 'Assi H', 'Zahreddine A', 'Mahfouz R', 'Bazarbachi A']","['Adult', 'Dose-Response Relationship, Drug', 'Female', 'Hematologic Neoplasms/mortality/*therapy', '*Hematopoietic Stem Cell Transplantation/mortality', 'Humans', 'Male', 'Middle Aged', 'Myeloablative Agonists/*administration & dosage', 'Remission Induction', 'Retrospective Studies', 'Survival Analysis', 'Thiotepa/*administration & dosage', 'Transplantation Conditioning/*methods', 'Transplantation, Homologous', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29625929/
250,thiotepa,29035395,Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma.,"['Joffe E', 'Rosenberg D', 'Rozovski U', 'Perry C', 'Kirgner I', 'Trestman S', 'Gur O', 'Aviv F', 'Sarid N', 'Kolomansky A', 'Gepstein L', 'Herishanu Y', 'Naparstek E']","['Adult', 'Antineoplastic Agents, Alkylating/pharmacology/*therapeutic use', 'Carmustine/pharmacology/*therapeutic use', 'Cyclophosphamide/pharmacology/*therapeutic use', 'Female', 'Hematopoietic Stem Cell Transplantation/*methods', 'Hodgkin Disease/mortality/*therapy', 'Humans', 'Lymphoma, Non-Hodgkin/mortality/*therapy', 'Male', 'Middle Aged', 'Progression-Free Survival', 'Retrospective Studies', 'Thiotepa/pharmacology/*therapeutic use', 'Transplantation, Autologous/*methods']",https://pubmed.ncbi.nlm.nih.gov/29035395/
251,thiotepa,12407434,"Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.","['de Jonge ME', 'Mathot RA', 'Dalesio O', 'Huitema AD', 'Rodenhuis S', 'Beijnen JH']","['Adolescent', 'Adult', 'Alopecia/*chemically induced/etiology', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects', 'Area Under Curve', 'Carboplatin/pharmacokinetics/pharmacology', 'Cyclophosphamide/*analogs & derivatives/blood/metabolism/pharmacokinetics/pharmacology', 'Drug Evaluation', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/complications/drug therapy', 'Thiotepa/metabolism/pharmacokinetics/pharmacology', 'Triethylenephosphoramide/blood']",https://pubmed.ncbi.nlm.nih.gov/12407434/
252,thiotepa,37816471,Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.,"['Battipaglia G', 'Labopin M', 'Mielke S', 'Ruggeri A', 'Nur Ozkurt Z', 'Bourhis JH', 'Rabitsch W', 'Yakoub-Agha I', 'Grillo G', 'Sanz J', 'Arcese W', 'Novis Y', 'Fegueux N', 'Spyridonidis A', 'Giebel S', 'Nagler A', 'Ciceri F', 'Mohty M']","['Aged', 'Humans', 'Thiotepa/therapeutic use', 'Retrospective Studies', 'Whole-Body Irradiation/adverse effects', 'Bone Marrow', '*Leukemia, Myeloid, Acute/therapy', '*Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy', 'Acute Disease', '*Graft vs Host Disease/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/37816471/
253,thiotepa,28369839,"High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.","['DeFilipp Z', 'Li S', 'El-Jawahri A', 'Armand P', 'Nayak L', 'Wang N', 'Batchelor TT', 'Chen YB']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Bacterial Infections/etiology', 'Busulfan/administration & dosage', 'Central Nervous System Neoplasms/*therapy', 'Cyclophosphamide/administration & dosage', 'Cytarabine/administration & dosage', 'Dacarbazine/administration & dosage/analogs & derivatives', 'Disease-Free Survival', 'Female', 'Follow-Up Studies', 'Humans', 'Kaplan-Meier Estimate', 'Lymphoma/*therapy', 'Male', 'Methotrexate/administration & dosage', 'Middle Aged', 'Mucositis/etiology', 'Remission Induction', 'Retrospective Studies', 'Rituximab/administration & dosage', 'Stem Cell Transplantation/adverse effects/*methods', 'Temozolomide', 'Thiotepa/administration & dosage', 'Transplantation Conditioning', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/28369839/
254,Trimipramine,1573122,Trimipramine: acute and lasting effects on sleep in healthy and major depressive subjects.,"['Feuillade P', 'Pringuey D', 'Belugou JL', 'Robert P', 'Darcourt G']","['Adult', 'Depressive Disorder/*drug therapy/psychology', 'Dose-Response Relationship, Drug', 'Electroencephalography/drug effects', 'Female', 'Humans', 'Long-Term Care', 'Male', 'Middle Aged', 'Sleep Stages/*drug effects', 'Sleep, REM/drug effects', 'Trimipramine/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/1573122/
255,Trimipramine,21484238,Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters.,"['Haenisch B', 'Hiemke C', 'Bonisch H']","['*Antidepressive Agents/metabolism/pharmacology', 'Biogenic Monoamines/*metabolism', 'Cell Culture Techniques', 'Data Interpretation, Statistical', 'HEK293 Cells', 'Humans', 'Molecular Structure', 'Neurotransmitter Transport Proteins/*antagonists & inhibitors/genetics', 'Organic Cation Transport Proteins/*antagonists & inhibitors/genetics', 'Regression Analysis', 'Transfection', '*Trimipramine/metabolism/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/21484238/
256,Trimipramine,6113683,"Normal and disturbed motility pattern in the duodenum of man. The effect of l-hyoscyamine, trimipramine and ranitidine on the maximal pressure waves.","['Myren J', 'Bohman T', 'Osnes M', 'Larssen S']","['Adult', 'Atropine/*pharmacology', 'Bile Reflux', 'Dibenzazepines/*pharmacology', 'Duodenum/*drug effects', 'Furans/*pharmacology', 'Gastrointestinal Motility/*drug effects', 'Histamine H2 Antagonists/*pharmacology', 'Humans', 'Ranitidine', 'Transducers, Pressure', 'Trimipramine/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6113683/
257,Trimipramine,6743780,Pharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers.,"['Caille G', 'du Souich P', 'Spenard J', 'Lacasse Y', 'Vezina M']","['Adolescent', 'Adult', 'Azabicyclo Compounds', 'Biological Availability', 'Dibenzazepines/*metabolism', 'Drug Interactions', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*metabolism', 'Kinetics', 'Piperazines/administration & dosage/*metabolism', 'Saliva/metabolism', 'Tablets', 'Trimipramine/administration & dosage/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/6743780/
258,Trimipramine,2857709,"A comparative trial of the antidepressant, anxiolytic, and cardiovascular effects of trimipramine and doxepin in depressed hospitalized patients.","['Assalian P', 'Rosengarten MD', 'Phillips R']","['Anorexia/chemically induced', 'Anti-Anxiety Agents', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Dibenzazepines/*therapeutic use', 'Dizziness/chemically induced', 'Double-Blind Method', 'Doxepin/adverse effects/*therapeutic use', 'Electrocardiography', 'Female', 'Heart/drug effects', 'Heart Rate/drug effects', '*Hospitalization', 'Humans', 'Male', 'Middle Aged', 'Personality Inventory', 'Placebos', 'Psychiatric Status Rating Scales', 'Trimipramine/adverse effects/*therapeutic use', 'Xerostomia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/2857709/
259,Trimipramine,17692337,Metabolism in adipose tissue in response to citalopram and trimipramine treatment--an in situ microdialysis study.,"['Flechtner-Mors M', 'Jenkinson CP', 'Alt A', 'Adler G', 'Ditschuneit HH']","['Adipose Tissue/*metabolism', 'Adrenergic Uptake Inhibitors/*adverse effects/therapeutic use', 'Body Mass Index', 'Cholesterol/blood', 'Citalopram/*adverse effects/therapeutic use', 'Depressive Disorder, Major/*drug therapy/epidemiology/*psychology', 'Female', 'Glycerol/metabolism', 'Humans', 'Male', 'Middle Aged', 'Obesity/*chemically induced/epidemiology/*metabolism', 'Selective Serotonin Reuptake Inhibitors/*adverse effects/therapeutic use', 'Triglycerides/blood', 'Trimipramine/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17692337/
260,Trimipramine,14646691,"Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.","['Kirchheiner J', 'Sasse J', 'Meineke I', 'Roots I', 'Brockmoller J']","['Administration, Oral', 'Antidepressive Agents, Tricyclic/administration & dosage/blood/*pharmacokinetics', 'Chromatography, High Pressure Liquid', 'Cytochrome P-450 CYP2D6/*genetics', 'Genotype', 'Humans', 'Infusions, Intravenous', 'Trimipramine/administration & dosage/*analogs & derivatives/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/14646691/
261,Trimipramine,9160649,Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression.,"['Sonntag A', 'Rothe B', 'Guldner J', 'Yassouridis A', 'Holsboer F', 'Steiger A']","['Adult', 'Aged', 'Antidepressive Agents, Tricyclic/adverse effects/*therapeutic use', 'Cerebral Cortex/*drug effects/physiopathology', 'Depressive Disorder/*drug therapy/physiopathology/psychology', 'Dopamine D2 Receptor Antagonists', 'Double-Blind Method', 'Electroencephalography/*drug effects', 'Human Growth Hormone/*blood', 'Humans', 'Hydrocortisone/*blood', 'Hypothalamo-Hypophyseal System/drug effects/physiopathology', 'Imipramine/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Personality Inventory', 'Pituitary-Adrenal System/drug effects/physiopathology', 'Polysomnography/*drug effects', 'Prolactin/*blood', 'Receptors, Dopamine D2/physiology', 'Sleep Stages/drug effects/physiology', 'Testosterone/blood', 'Trimipramine/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9160649/
262,Trimipramine,27855951,"Initial fate assessment of teratogenic drug trimipramine and its photo-transformation products - Role of pH, concentration and temperature.","['Khaleel NDH', 'Mahmoud WMM', 'Olsson O', 'Kummerer K']","['Humans', 'Hydrogen-Ion Concentration', 'Photolysis', 'Temperature', '*Teratogens', '*Trimipramine', 'Water Pollutants, Chemical/chemistry']",https://pubmed.ncbi.nlm.nih.gov/27855951/
263,Trimipramine,10774635,"Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients.","['Eap CB', 'Bender S', 'Gastpar M', 'Fischer W', 'Haarmann C', 'Powell K', 'Jonzier-Perey M', 'Cochard N', 'Baumann P']","['Adult', 'Aged', 'Antidepressive Agents, Tricyclic/*blood', '*Aryl Hydrocarbon Hydroxylases', 'Cytochrome P-450 CYP2C19', 'Cytochrome P-450 CYP2D6/*physiology', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme System/*physiology', 'Female', 'Humans', 'Male', 'Middle Aged', 'Mixed Function Oxygenases/*physiology', 'Phenotype', 'Stereoisomerism', 'Trimipramine/*blood/metabolism']",https://pubmed.ncbi.nlm.nih.gov/10774635/
264,Trimipramine,21298415,Electrospray ionization-ion mobility spectrometry as a detection system for three-phase hollow fiber microextraction technique and simultaneous determination of trimipramine and desipramine in urine and plasma samples.,"['Jafari MT', 'Saraji M', 'Sherafatmand H']","['Antidepressive Agents/*blood/isolation & purification/*urine', 'Desipramine/*blood/isolation & purification/*urine', 'Humans', 'Solid Phase Microextraction/instrumentation/*methods', 'Spectrometry, Mass, Electrospray Ionization/*methods', 'Trimipramine/*blood/isolation & purification/*urine']",https://pubmed.ncbi.nlm.nih.gov/21298415/
265,Trimipramine,2859273,"Trimipramine and maprotiline: antidepressant, anxiolytic, and cardiotoxic comparison.","['Pecknold JC', 'Familamiri P', 'McClure DJ', 'Elie R', 'Chang H']","['Adult', 'Ambulatory Care', 'Anthracenes/*therapeutic use', 'Anti-Anxiety Agents', 'Blood Pressure/drug effects', 'Body Weight/drug effects', 'Cardiovascular System/drug effects', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Dibenzazepines/*therapeutic use', 'Electrocardiography', 'Female', 'Heart Rate/drug effects', 'Humans', 'Male', 'Maprotiline/adverse effects/*therapeutic use', 'Personality Inventory', 'Psychiatric Status Rating Scales', 'Pulse/drug effects', 'Sleep/drug effects', 'Trimipramine/adverse effects/*therapeutic use', 'Xerostomia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/2859273/
266,Trimipramine,8458903,Simultaneous determination of trimipramine and desmethyl- and hydroxytrimipramine in plasma and red blood cells by capillary gas chromatography with nitrogen-selective detection.,"['Jourdil N', 'Pinteur B', 'Vincent F', 'Marka C', 'Bessard G']","['Chromatography, Gas/*methods', 'Erythrocytes/*chemistry', 'Humans', 'Nitrogen/chemistry', 'Reproducibility of Results', 'Sensitivity and Specificity', 'Trimipramine/analogs & derivatives/*blood']",https://pubmed.ncbi.nlm.nih.gov/8458903/
267,Trimipramine,23324861,"Adsorptive stripping voltammetric determination of imipramine, trimipramine and desipramine employing titanium dioxide nanoparticles and an Amberlite XAD-2 modified glassy carbon paste electrode.","['Sanghavi BJ', 'Srivastava AK']","['Adsorption', 'Antidepressive Agents, Tricyclic/*analysis/blood/urine', 'Carbon/chemistry', 'Desipramine/*analysis/blood/urine', 'Electrochemical Techniques/*methods', 'Electrodes', 'Humans', 'Imipramine/*analysis/blood/urine', 'Limit of Detection', 'Nanoparticles/chemistry', 'Pharmaceutical Preparations/chemistry', 'Reproducibility of Results', 'Resins, Synthetic/chemistry', 'Titanium/chemistry', 'Trimipramine/*analysis/blood/urine']",https://pubmed.ncbi.nlm.nih.gov/23324861/
268,Trimipramine,2251340,"Effects of scopolamine, trimipramine and diazepam on explicit memory and repetition priming in healthy volunteers.","['Danion JM', 'Zimmermann MA', 'Willard-Schroeder D', 'Grange D', 'Welsch M', 'Imbs JL', 'Singer L']","['Adult', 'Diazepam/*pharmacology', 'Female', 'Humans', 'Male', 'Memory/*drug effects', 'Scopolamine/*pharmacology', 'Trimipramine/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2251340/
269,Trimipramine,373073,Serum concentration of trimipramine (Surmontil) and gastric secretion of acid and pepsin following peroral administration of the drug in healthy humans.,"['Myren J', 'Schrumpf E', 'Bohman T', 'Skaug OE', 'Larsen S']","['Administration, Oral', 'Adult', 'Clinical Trials as Topic', 'Dibenzazepines/*blood', 'Double-Blind Method', 'Gastric Juice/*metabolism', 'Humans', 'Pepsin A/*metabolism', 'Secretory Rate/drug effects', 'Trimipramine/administration & dosage/*blood/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/373073/
270,Trimipramine,8014234,Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry.,"['Eap CB', 'Koeb L', 'Baumann P']","['Biotransformation', 'Chromatography, High Pressure Liquid', 'Dealkylation', 'Gas Chromatography-Mass Spectrometry', 'Glucuronates/metabolism', 'Humans', 'Hydroxylation', 'Trimipramine/*blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8014234/
271,Trimipramine,6372066,Comparative study of cimetidine and trimipramine in the short-term treatment of duodenal and gastric ulcer.,"['Valnes K', 'Wetterhus S', 'Myren J', 'Arva P', 'Larsen S']","['Cimetidine/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Dibenzazepines/*therapeutic use', 'Double-Blind Method', 'Duodenal Ulcer/*drug therapy', 'Female', 'Gastroscopy', 'Humans', 'Male', 'Middle Aged', 'Random Allocation', 'Stomach Ulcer/*drug therapy', 'Trimipramine/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6372066/
272,Trimipramine,6680730,Analysis of blood and tissue for amoxapine and trimipramine.,"['Wu Chen NB', 'Schaffer MI', 'Lin RL', 'Hadac JP', 'Stein RJ']","['Amoxapine/*blood/poisoning', 'Chromatography, Gas', 'Dibenzazepines/*blood', 'Dibenzoxazepines/*blood', '*Forensic Medicine', 'Gas Chromatography-Mass Spectrometry', 'Humans', 'Trimipramine/*blood/poisoning']",https://pubmed.ncbi.nlm.nih.gov/6680730/
273,Pamidronic acid,33449911,Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study.,"['Pijnenburg L', 'Salem JE', 'Lebrun-Vignes B', 'Sibilia J', 'Javier RM', 'Arnaud L']","['Administration, Intravenous', 'Aged', 'Aged, 80 and over', 'Atrial Fibrillation/*chemically induced/*epidemiology', 'Databases, Factual', 'Drug-Related Side Effects and Adverse Reactions/*epidemiology', 'Europe/epidemiology', 'Female', 'Humans', 'Male', 'North America/epidemiology', 'Pamidronate/administration & dosage/*adverse effects', 'Pharmacoepidemiology', 'Pharmacovigilance', 'World Health Organization', 'Zoledronic Acid/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33449911/
274,Pamidronic acid,36432069,"Preparation, Optimisation, and In Vitro Evaluation of [(18)F]AlF-NOTA-Pamidronic Acid for Bone Imaging PET.","['Hassan H', 'Othman MF', 'Abdul Razak HR', 'Zakaria ZA', 'Ahmad Saad FF', 'Osman MA', 'Yi LH', 'Ashhar Z', 'Idris J', 'Abdul Hamid MHN', 'Safee ZM']","['Humans', '*Fluorine Radioisotopes', 'Pamidronate', 'Sodium Fluoride', 'Chromatography, Liquid', '*Heterocyclic Compounds/chemistry', 'Oligopeptides/chemistry', 'Tandem Mass Spectrometry', 'Positron-Emission Tomography/methods']",https://pubmed.ncbi.nlm.nih.gov/36432069/
275,Pamidronic acid,1820495,Intravenous pamidronic acid in hypercalcemia due to parathyroid carcinoma.,"['Vega EM', 'Mautalen CA']","['Adult', 'Diphosphonates/*therapeutic use', 'Female', 'Humans', 'Hypercalcemia/*drug therapy/etiology', 'Infusions, Intravenous', 'Male', 'Middle Aged', 'Pamidronate', 'Parathyroid Neoplasms/*complications', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/1820495/
276,Pamidronic acid,16679782,Long-term survival after second-line therapy with docetaxel and carboplatin and monthly pamidronic acid in a woman with metastatic non-small cell lung cancer.,"['Andritzky B', 'Schuch G', 'Thoem I', 'Goern M', 'Brandl S', 'Bokemeyer C', 'Laack E']","['Adult', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage', 'Carboplatin/administration & dosage', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/*secondary', 'Diphosphonates/administration & dosage', 'Docetaxel', 'Female', 'Humans', 'Longitudinal Studies', 'Lung Neoplasms/*drug therapy', 'Lymphatic Metastasis', 'Pamidronate', 'Taxoids/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16679782/
277,Pamidronic acid,8091148,Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis.,"['Maccagno A', 'Di Giorgio E', 'Roldan EJ', 'Caballero LE', 'Perez Lloret A']","['Administration, Oral', 'Adult', 'Arthritis, Rheumatoid/*diagnostic imaging/drug therapy', 'Cartilage, Articular/diagnostic imaging', 'Diphosphonates/*administration & dosage', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Foot/diagnostic imaging', 'Hand/diagnostic imaging', 'Humans', 'Male', 'Middle Aged', 'Pamidronate', 'Radiography', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/8091148/
278,Ciclopirox,12895184,Interdigital tinea pedis (dermatophytosis simplex and complex) and treatment with ciclopirox 0.77% gel.,"['Gupta AK', 'Skinner AR', 'Cooper EA']","['Administration, Topical', 'Antifungal Agents/*administration & dosage', 'Ciclopirox', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Follow-Up Studies', 'Gels/therapeutic use', 'Humans', 'Male', 'Pyridones/*administration & dosage', 'Randomized Controlled Trials as Topic', 'Severity of Illness Index', 'Tinea Pedis/*diagnosis/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12895184/
279,Ciclopirox,782504,Ciclopirox: a new topical pyrodonium antimycotic agent. A double-blind study in superficial dermatomycoses.,['Sehgal VN'],"['Adult', 'Antifungal Agents/*therapeutic use', 'Clinical Trials as Topic', 'Drug Evaluation', 'Female', 'Humans', 'Male', 'Placebos', 'Pyridones/*therapeutic use', 'Tinea/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/782504/
280,Ciclopirox,35331268,Ciclopirox targets cellular bioenergetics and activates ER stress to induce apoptosis in non-small cell lung cancer cells.,"['Lu J', 'Li Y', 'Gong S', 'Wang J', 'Lu X', 'Jin Q', 'Lu B', 'Chen Q']","['Apoptosis', '*Carcinoma, Non-Small-Cell Lung/pathology', 'Cell Line, Tumor', 'Cell Proliferation', 'Ciclopirox/pharmacology/therapeutic use', 'Energy Metabolism', 'Humans', '*Lung Neoplasms/pathology', 'Reactive Oxygen Species/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35331268/
281,Ciclopirox,15334279,Ciclopirox shampoo for treating seborrheic dermatitis.,"['Gupta AK', 'Bluhm R']","['Administration, Cutaneous', 'Adult', 'Aged', 'Ciclopirox', 'Dermatitis, Seborrheic/diagnosis/*drug therapy', 'Female', 'Follow-Up Studies', '*Hair Preparations', 'Humans', 'Male', 'Middle Aged', 'Pyridones/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Risk Assessment', 'Scalp Dermatoses/diagnosis/*drug therapy', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15334279/
282,Ciclopirox,35563420,Giving Drugs a Second Chance: Antibacterial and Antibiofilm Effects of Ciclopirox and Ribavirin against Cystic Fibrosis Pseudomonas aeruginosa Strains.,"['Di Bonaventura G', 'Lupetti V', 'De Fabritiis S', 'Piccirilli A', 'Porreca A', 'Di Nicola M', 'Pompilio A']","['Anti-Bacterial Agents/chemistry/pharmacology', '*Biofilms/drug effects', '*Ciclopirox/pharmacology', '*Cystic Fibrosis/drug therapy/microbiology', 'Dactinomycin/pharmacology', 'Drug Repositioning', 'Extracellular Polymeric Substance Matrix', 'Fluorouracil/pharmacology', 'Humans', 'Microbial Sensitivity Tests', '*Pseudomonas Infections/microbiology', 'Pseudomonas aeruginosa', '*Ribavirin/pharmacology', 'Tobramycin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/35563420/
283,Ciclopirox,31001967,"Efficacy and tolerability of 1% ciclopirox shampoo in the treatment of moderate-to-severe scalp seborrheic dermatitis: a multicenter, prospective, assessor-blinded trial.","['Veraldi S', 'Barbareschi M', 'Martella A', 'Milani M']","['Adult', 'Antifungal Agents/*administration & dosage/adverse effects', 'Ciclopirox/*administration & dosage/adverse effects', 'Dermatitis, Seborrheic/*drug therapy', 'Female', '*Hair Preparations', 'Humans', 'Male', 'Prospective Studies', 'Severity of Illness Index', 'Single-Blind Method', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31001967/
284,Ciclopirox,16428154,Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.,"['Avner S', 'Nir N', 'Henri T']","['Administration, Oral', 'Administration, Topical', 'Adult', 'Antifungal Agents/*administration & dosage', 'Ciclopirox', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Naphthalenes/*administration & dosage', 'Onychomycosis/*drug therapy', 'Pyridones/*administration & dosage', 'Terbinafine', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16428154/
285,Ciclopirox,31603527,Effects of the antifungal agent ciclopirox in HPV-positive cancer cells: Repression of viral E6/E7 oncogene expression and induction of senescence and apoptosis.,"['Braun JA', 'Herrmann AL', 'Blase JI', 'Frensemeier K', 'Bulkescher J', 'Scheffner M', 'Galy B', 'Hoppe-Seyler K', 'Hoppe-Seyler F']","['Antifungal Agents/pharmacology/therapeutic use', 'Apoptosis/drug effects', 'Cellular Senescence/drug effects', 'Ciclopirox/*pharmacology/therapeutic use', 'DNA-Binding Proteins/*antagonists & inhibitors/metabolism', 'Female', 'HCT116 Cells', 'HeLa Cells', 'Humans', 'Iron Chelating Agents/pharmacology/therapeutic use', 'Oncogene Proteins, Viral/*antagonists & inhibitors/metabolism', 'Papillomavirus E7 Proteins/*antagonists & inhibitors/metabolism', 'Papillomavirus Infections/*drug therapy/pathology/virology', 'Repressor Proteins/*antagonists & inhibitors/metabolism', 'Spheroids, Cellular', 'Uterine Cervical Neoplasms/*drug therapy/pathology/virology']",https://pubmed.ncbi.nlm.nih.gov/31603527/
286,Ciclopirox,29328472,Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.,"['Yuan B', 'Ji W', 'Xia H', 'Li J']","['Antifungal Agents/therapeutic use', 'Antineoplastic Agents/*therapeutic use', 'Bone Neoplasms/blood supply/*drug therapy/genetics/pathology', 'Cell Line, Tumor', 'Ciclopirox', 'Collagen Type I/genetics/metabolism', 'Collagen Type I, alpha 1 Chain', 'Databases, Genetic', 'Drug Repositioning', 'Gene Expression Profiling', '*Gene Expression Regulation, Neoplastic', 'Gene Ontology', 'Gene Regulatory Networks', '*Genome, Human', 'Humans', 'Molecular Sequence Annotation', 'N-Myc Proto-Oncogene Protein/genetics/metabolism', 'Oncogene Proteins, Fusion/antagonists & inhibitors/*genetics/metabolism', 'Protein Binding', 'Protein Interaction Mapping', 'Proto-Oncogene Protein c-fli-1/antagonists & inhibitors/*genetics/metabolism', 'Pyridones/*therapeutic use', 'RNA-Binding Protein EWS/antagonists & inhibitors/*genetics/metabolism', 'Sarcoma, Ewing/blood supply/*drug therapy/genetics/pathology', 'Signal Transduction', 'Transforming Growth Factor beta1/genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/29328472/
287,Ciclopirox,32506716,In vitro antidermatophytic synergism of double and triple combination of clioquinol with ciclopirox and terbinafine.,"['da Costa B', 'Pippi B', 'Andrzejewski Kaminski TF', 'Andrade SF', 'Fuentefria AM']","['Antifungal Agents/*pharmacology', 'Arthrodermataceae/*drug effects', 'Cell Survival/drug effects', 'Ciclopirox/*pharmacology', 'Clioquinol/*pharmacology', 'Drug Combinations', 'Drug Synergism', 'Fungi/classification/*drug effects', 'Humans', 'Leukocytes/drug effects', 'Microbial Sensitivity Tests', 'Terbinafine/*pharmacology', 'Tinea/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32506716/
288,Ciclopirox,37781969,A density functional theory study on the potential application of Ni and Co doped ZnO nanosheets as a carrier for ciclopirox anticancer drug.,"['Taha A', 'Kadhim MM', 'Naser ST', 'Majdi A', 'Abdullaha SAH', 'Hachim SK', 'Abdulwahid Abdulhussain M', 'Mahdi Rheima A']","['Ciclopirox/pharmacology', '*Zinc Oxide', 'Density Functional Theory', 'Metals', '*Antineoplastic Agents']",https://pubmed.ncbi.nlm.nih.gov/37781969/
289,Pilocarpine,6252317,"Complexes between pilocarpine and cobalt(II), nickel(II), copper(II), and zinc(II) ions.","['Canti G', 'Scozzafava A', 'Ciciani G', 'Renzi G']","['Cobalt', 'Copper', 'Electron Spin Resonance Spectroscopy', 'Magnetic Resonance Spectroscopy', '*Metals', 'Nickel', '*Pilocarpine/analysis', 'Spectrophotometry, Atomic', 'Zinc']",https://pubmed.ncbi.nlm.nih.gov/6252317/
290,Pilocarpine,31520497,Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation.,"['Farag AM', 'Holliday C', 'Cimmino J', 'Roomian T', 'Papas A']","['Adult', 'Aged', 'Female', 'Follow-Up Studies', 'Humans', 'Middle Aged', 'Muscarinic Agonists/*therapeutic use', 'Pilocarpine/administration & dosage/*therapeutic use', 'Quinuclidines/administration & dosage/*therapeutic use', 'Retrospective Studies', 'Thiophenes/administration & dosage/*therapeutic use', 'Time Factors', 'Xerostomia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31520497/
291,Pilocarpine,7229939,"Quantitative determination of pilocarpine, isopilocarpine, pilocarpic acid, and isopilocarpic acid in clinical ophthalmic pilocarpine formulations by reversed-phase liquid chromatography.","['Noordam A', 'Maat L', 'Beyerman HC']","['Chromatography, High Pressure Liquid', 'Isomerism', 'Ophthalmic Solutions', 'Pilocarpine/administration & dosage/*analogs & derivatives/*analysis']",https://pubmed.ncbi.nlm.nih.gov/7229939/
292,Pilocarpine,26563850,Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis.,"['Cheng CQ', 'Xu H', 'Liu L', 'Wang RN', 'Liu YT', 'Li J', 'Zhou XK']","['Head and Neck Neoplasms/*radiotherapy', 'Humans', 'Muscarinic Agonists/adverse effects/*therapeutic use', 'Pilocarpine/adverse effects/*therapeutic use', 'Treatment Outcome', 'Xerostomia/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/26563850/
293,Pilocarpine,39033941,Pretreatment of microneedles enhances passive transdermal administration of pilocarpine and pilocarpine-induced sweat production in humans.,"['Amano T', 'Fujii N', 'Kenny GP', 'Mundel T', 'Yokoyama S', 'Yamashita H', 'Quan YS']","['*Pilocarpine/administration & dosage', 'Humans', '*Administration, Cutaneous', '*Sweating/drug effects', 'Male', '*Needles', 'Adult', '*Iontophoresis/methods', 'Female', 'Young Adult', 'Drug Delivery Systems/instrumentation', 'Muscarinic Agonists/administration & dosage', 'Sweat', 'Skin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/39033941/
294,Pilocarpine,8198156,Combined timolol and pilocarpine vs pilocarpine alone and timolol alone in the treatment of glaucoma.,"['Zadok D', 'Geyer O', 'Zadok J', 'Lazar M', 'Krakowski D', 'Nemet P']","['Administration, Topical', 'Adult', 'Drug Therapy, Combination', 'Female', 'Glaucoma, Open-Angle/*drug therapy', 'Humans', 'Intraocular Pressure', 'Male', 'Ocular Hypertension/*drug therapy', 'Ophthalmic Solutions', 'Pilocarpine/*administration & dosage/therapeutic use', 'Timolol/*administration & dosage/therapeutic use', 'Tonometry, Ocular']",https://pubmed.ncbi.nlm.nih.gov/8198156/
295,Pilocarpine,20963353,Pilocarpine used to treat xerostomia in patients submitted to radioactive iodine therapy: a pilot study.,"['Almeida JP', 'Kowalski LP']","['Adult', 'Aged', 'Aged, 80 and over', 'Dose-Response Relationship, Drug', 'Drug Therapy', 'Humans', 'Iodine Radioisotopes/*adverse effects', 'Middle Aged', 'Pilocarpine/adverse effects/*therapeutic use', 'Pilot Projects', 'Prospective Studies', 'Radionuclide Imaging', 'Salivary Glands/diagnostic imaging/physiopathology', 'Salivation/drug effects', 'Thyroid Neoplasms/*radiotherapy', 'Treatment Outcome', 'Xerostomia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20963353/
296,Pilocarpine,2653044,Timolol-pilocarpine combined vs timolol and pilocarpine given separately.,"['Soderstrom MB', 'Wallin O', 'Granstrom PA', 'Thorburn W']","['Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Drug Therapy, Combination', 'Glaucoma, Open-Angle/drug therapy/physiopathology', 'Humans', 'Intraocular Pressure/drug effects', 'Multicenter Studies as Topic', 'Ophthalmic Solutions', 'Pilocarpine/*administration & dosage/adverse effects', 'Pulse/drug effects', 'Random Allocation', 'Sweden', 'Time Factors', 'Timolol/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2653044/
297,Pilocarpine,32196472,Low-dose Pilocarpine Spray to Treat Xerostomia.,['Zur E'],"['*Head and Neck Neoplasms', 'Humans', 'Muscarinic Agonists/administration & dosage/*therapeutic use', 'Pilocarpine/administration & dosage/therapeutic use', 'Quality of Life', '*Xerostomia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32196472/
298,Pilocarpine,35858231,Vitreofoveal Traction Associated With Pilocarpine for Presbyopia.,"['Amarikwa L', 'Michalak SM', 'Caul S', 'Mruthyunjaya P', 'Rahimy E']","['Female', 'Humans', 'Pilocarpine/adverse effects', '*Presbyopia', '*Retinal Diseases/diagnosis', 'Tomography, Optical Coherence', 'Traction', '*Vitreous Detachment/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/35858231/
299,Naproxen,31925484,"Naproxen in the environment: its occurrence, toxicity to nontarget organisms and biodegradation.","['Wojcieszynska D', 'Guzik U']","['Anti-Inflammatory Agents, Non-Steroidal/analysis/metabolism/toxicity', 'Aquatic Organisms/drug effects/metabolism', 'Bacillus thuringiensis/metabolism', 'Bacterial Proteins/metabolism', 'Biodegradation, Environmental', 'Environmental Exposure/*adverse effects', 'Metabolic Networks and Pathways/drug effects', 'Naproxen/analogs & derivatives/analysis/*metabolism/*toxicity', 'Water Pollutants, Chemical/analysis/*metabolism/*toxicity']",https://pubmed.ncbi.nlm.nih.gov/31925484/
300,Naproxen,34443379,Recent Advances in the Synthesis of Ibuprofen and Naproxen.,"['Ha MW', 'Paek SM']","['Electrochemistry', 'Humans', 'Hydrogenation', 'Ibuprofen/*chemical synthesis/chemistry', 'Naproxen/*chemical synthesis/chemistry', 'Oxidation-Reduction', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/34443379/
301,Naproxen,32368976,Anticancer and Antimicrobial Activities of Naproxen and Naproxen Derivatives.,"['Han MI', 'Kucukguzel SG']","['Anti-Infective Agents/*chemistry/pharmacology', 'Anti-Inflammatory Agents, Non-Steroidal/chemistry/pharmacology/therapeutic use', 'Antineoplastic Agents/*chemistry/pharmacology/therapeutic use', 'Bacteria/drug effects', 'Cyclooxygenase 2/chemistry/metabolism', 'Fungi/drug effects', 'Humans', 'Naproxen/*analogs & derivatives/pharmacology/therapeutic use', 'Neoplasms/drug therapy/pathology', 'Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32368976/
302,Naproxen,9113437,Clinical pharmacokinetics of naproxen.,"['Davies NM', 'Anderson KE']","['Absorption', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Aging/metabolism', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/blood/*pharmacokinetics/urine', 'Child', 'Child, Preschool', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Food-Drug Interactions', 'Humans', 'Middle Aged', 'Naproxen/administration & dosage/blood/*pharmacokinetics/urine', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/9113437/
303,Naproxen,15495091,Single dose oral naproxen and naproxen sodium for acute postoperative pain.,"['Mason L', 'Edwards JE', 'Moore RA', 'McQuay HJ']","['Acute Disease', 'Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Humans', 'Naproxen/analogs & derivatives/*therapeutic use', 'Pain, Postoperative/*drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/15495091/
304,Naproxen,19160232,Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults.,"['Derry C', 'Derry S', 'Moore RA', 'McQuay HJ']","['Acute Disease', 'Administration, Oral', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage', 'Humans', 'Naproxen/*administration & dosage/analogs & derivatives', 'Pain, Postoperative/*drug therapy', 'Randomized Controlled Trials as Topic', 'Sodium/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/19160232/
305,Naproxen,30986596,Experimental and theoretical investigation on photodegradation mechanisms of naproxen and its photoproducts.,"['Tu N', 'Liu Y', 'Li R', 'Lv W', 'Liu G', 'Ma D']","['Naproxen/*chemistry', '*Photolysis', 'Reactive Oxygen Species/chemistry', 'Ultraviolet Rays', 'Water Pollutants, Chemical/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/30986596/
306,Naproxen,31145329,Naproxen for the treatment of neoplastic fever: A PRISMA-compliant systematic review and meta-analysis.,"['Zhang H', 'Wu Y', 'Lin Z', 'Zhong X', 'Liu T', 'Huang Z', 'Yang Y']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Cross-Sectional Studies', 'Dose-Response Relationship, Drug', 'Fever/*drug therapy/*etiology', 'Humans', 'Naproxen/administration & dosage/adverse effects/*therapeutic use', 'Neoplasms/*complications', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/31145329/
307,Naproxen,28392278,Improvement of the physicochemical properties of Co-amorphous naproxen-indomethacin by naproxen-sodium.,"['Beyer A', 'Grohganz H', 'Lobmann K', 'Rades T', 'Leopold CS']","['Calorimetry, Differential Scanning', 'Drug Stability', 'Indomethacin/*chemistry', 'Naproxen/*chemistry', 'Solubility', 'Transition Temperature']",https://pubmed.ncbi.nlm.nih.gov/28392278/
308,Naproxen,27130786,Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin.,"['Beyer A', 'Radi L', 'Grohganz H', 'Lobmann K', 'Rades T', 'Leopold CS']","['Anti-Inflammatory Agents, Non-Steroidal/*chemistry', 'Crystallization', 'Indomethacin/*chemistry', 'Naproxen/*chemistry', 'Powder Diffraction']",https://pubmed.ncbi.nlm.nih.gov/27130786/
309,Naproxen,33211618,Spray drying of naproxen and naproxen sodium for improved tableting and dissolution - physicochemical characterization and compression performance.,"['Al-Zoubi N', 'Odeh F', 'Partheniadis I', 'Gharaibeh S', 'Nikolakakis I']","['Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/chemistry', '*Chemistry, Pharmaceutical', 'Crystallization', 'Drug Compounding/methods', 'Drug Liberation', 'Excipients/chemistry', 'Hypromellose Derivatives/*chemistry', 'Naproxen/*administration & dosage/chemistry', 'Solubility', 'Spray Drying', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/33211618/
310,Naproxen,11389025,Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen.,"['Bougie D', 'Aster R']","['Acetaminophen/administration & dosage/*adverse effects/*analogs & derivatives/immunology/metabolism/urine', 'Adult', 'Aged', 'Antibodies/blood/drug effects', 'Blood Platelets/immunology', 'Female', 'Glucuronides/immunology/urine', 'Humans', 'Male', 'Middle Aged', 'Naproxen/administration & dosage/*adverse effects/analogs & derivatives/immunology/metabolism/urine', 'Platelet Glycoprotein GPIIb-IIIa Complex/immunology', 'Purpura, Thrombocytopenic, Idiopathic/*chemically induced/immunology']",https://pubmed.ncbi.nlm.nih.gov/11389025/
311,Naproxen,7025178,Naproxen and sulindac in the treatment of osteoarthritis of the hip and knee.,"['Liyanage SP', 'Macauley DI', 'English JR']","['Aged', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', '*Hip Joint', 'Humans', 'Indenes/*therapeutic use', '*Knee Joint', 'Male', 'Middle Aged', 'Naproxen/adverse effects/*therapeutic use', 'Osteoarthritis/*drug therapy', 'Random Allocation', 'Sulindac/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7025178/
312,Naproxen,33272098,"Antimicrobial, cytotoxicity, molecular modeling and DNA cleavage/binding studies of zinc-naproxen complex: switching DNA binding mode of naproxen by coordination to zinc ion.","['Khandar AA', 'Mirzaei-Kalar Z', 'Shahabadi N', 'Hadidi S', 'Abolhasani H', 'Hosseini-Yazdi SA', 'Jouyban A']","['Anti-Bacterial Agents/pharmacology', '*Anti-Infective Agents/pharmacology', '*Coordination Complexes/chemistry/pharmacology', 'DNA/chemistry', 'DNA Cleavage', 'HEK293 Cells', 'Humans', 'Molecular Docking Simulation', 'Naproxen/chemistry/pharmacology', 'Zinc/chemistry']",https://pubmed.ncbi.nlm.nih.gov/33272098/
313,Naproxen,31862555,Sustainable and efficient electrosynthesis of naproxen using carbon dioxide and ionic liquids.,"['Mena S', 'Santiago S', 'Gallardo I', 'Guirado G']","['Carbon Dioxide/*chemistry', 'Electrochemical Techniques/methods', 'Electrodes', 'Electrolytes', 'Ionic Liquids/*chemistry', 'Naproxen/*chemistry', 'Organic Chemicals', 'Solvents/chemistry']",https://pubmed.ncbi.nlm.nih.gov/31862555/
314,tolcapone,29427081,Effects of tolcapone and bromocriptine on cognitive stability and flexibility.,"['Cameron IGM', 'Wallace DL', 'Al-Zughoul A', 'Kayser AS', ""D'Esposito M""]","['Adult', 'Attention/*drug effects', 'Bromocriptine/*pharmacology', 'Catechol O-Methyltransferase/genetics', 'Catechol O-Methyltransferase Inhibitors/*pharmacology', 'Cognition/*drug effects', 'Dopamine Agonists/*pharmacology', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Prefrontal Cortex/*drug effects', 'Reaction Time/drug effects', 'Saccades/drug effects', 'Tolcapone/*pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29427081/
315,tolcapone,32247076,"Effects of caspofungin, tolcapone and other FDA-approved medications on MRSA susceptibility to vancomycin.","['Moore JA', 'Meakin M', 'Earl MH', 'Kummer TM', 'McAleer JP', 'Long TE']","['Caspofungin', 'Drug Synergism', 'Humans', '*Methicillin-Resistant Staphylococcus aureus', 'Staphylococcus aureus', 'Tolcapone', '*Vancomycin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32247076/
316,tolcapone,12588182,In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.,"['Smith KS', 'Smith PL', 'Heady TN', 'Trugman JM', 'Harman WD', 'Macdonald TL']","['Acetylation', 'Amines/chemistry/metabolism', 'Benzophenones/*metabolism/pharmacokinetics/*toxicity', 'Catechol O-Methyltransferase Inhibitors', 'Cells, Cultured', '*Chemical and Drug Induced Liver Injury', 'Cytochrome P-450 Enzyme Inhibitors', 'Cytochrome P-450 Enzyme System/metabolism', 'Electrochemistry/methods', 'Enzyme Inhibitors/*metabolism/pharmacokinetics/pharmacology/*toxicity', 'Glutathione/chemistry/metabolism', 'Half-Life', 'Hepatocytes/drug effects/enzymology/pathology', 'Horseradish Peroxidase/metabolism', 'Humans', 'Microsomes, Liver/drug effects', 'Nitrophenols', 'Nuclear Magnetic Resonance, Biomolecular', 'Oxidation-Reduction', 'Peroxidase/metabolism', 'Reactive Oxygen Species/metabolism', 'Spectrometry, Mass, Electrospray Ionization/methods', 'Tolcapone']",https://pubmed.ncbi.nlm.nih.gov/12588182/
317,tolcapone,10047930,Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.,"['Napolitano A', 'Del Dotto P', 'Petrozzi L', ""Dell'Agnello G"", 'Bellini G', 'Gambaccini G', 'Bonuccelli U']","['Antiparkinson Agents/blood/metabolism/*pharmacokinetics/pharmacology', 'Benzophenones/pharmacology/*therapeutic use', 'Drug Interactions', 'Enzyme Inhibitors/pharmacology/*therapeutic use', 'Female', 'Humans', 'Levodopa/blood/metabolism/*pharmacokinetics/pharmacology', 'Male', 'Middle Aged', 'Motor Activity/drug effects', 'Nitrophenols', 'Parkinson Disease/blood/drug therapy/*metabolism', 'Tolcapone', 'Tyrosine/analogs & derivatives/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/10047930/
318,tolcapone,9591521,Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.,"['Waters CH', 'Kurth M', 'Bailey P', 'Shulman LM', 'LeWitt P', 'Dorflinger E', 'Deptula D', 'Pedder S']","['Aged', 'Antiparkinson Agents/administration & dosage/adverse effects/*therapeutic use', 'Benzophenones/administration & dosage/adverse effects/*therapeutic use', '*Catechol O-Methyltransferase Inhibitors', 'Dopamine Agents/therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Enzyme Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Humans', 'Levodopa/therapeutic use', 'Male', 'Middle Aged', 'Nitrophenols', 'Parkinson Disease/*drug therapy/enzymology', 'Time Factors', 'Tolcapone', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9591521/
319,tolcapone,10830415,Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.,"['Welsh MD', 'Dorflinger E', 'Chernik D', 'Waters C']","['*Adaptation, Psychological', 'Adult', 'Aged', 'Antiparkinson Agents/adverse effects/*therapeutic use', 'Benzophenones/adverse effects/*therapeutic use', 'Carbidopa/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Levodopa/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Nitrophenols', 'Parkinson Disease/*drug therapy/psychology', 'Quality of Life', '*Sick Role', '*Sickness Impact Profile', 'Tolcapone', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10830415/
320,tolcapone,9754991,"Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy.","['Jorga KM', 'Fotteler B', 'Heizmann P', 'Zurcher G']","['Administration, Oral', 'Adult', 'Antiparkinson Agents/*pharmacokinetics/*pharmacology', 'Benzophenones/*pharmacokinetics/*pharmacology', 'Biological Availability', 'Body Fluid Compartments', 'Catechol O-Methyltransferase/blood', 'Catechol O-Methyltransferase Inhibitors', 'Cross-Over Studies', 'Erythrocytes/enzymology', 'Humans', 'Infusions, Intravenous', 'Male', 'Nitrophenols', 'Tolcapone']",https://pubmed.ncbi.nlm.nih.gov/9754991/
321,tolcapone,26037113,Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV.,"['Lee TT', 'Chana G', 'Gorry PR', 'Ellett A', 'Bousman CA', 'Churchill MJ', 'Gray LR', 'Everall IP']","['Benzophenones/*pharmacology', 'Catechol O-Methyltransferase/*metabolism', 'Catechol O-Methyltransferase Inhibitors/*pharmacology', 'Cell Line', 'Fluorescent Antibody Technique', 'HIV/drug effects/*enzymology', 'Humans', 'Microtubule-Associated Proteins/*metabolism', 'Neurons/*metabolism/virology', 'Nitrophenols/*pharmacology', 'Real-Time Polymerase Chain Reaction', 'Synaptophysin/*metabolism', 'Tolcapone', 'Transcriptome']",https://pubmed.ncbi.nlm.nih.gov/26037113/
322,tolcapone,14975680,"Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.","['Korlipara LV', 'Cooper JM', 'Schapira AH']","['Benzophenones/pharmacology/*toxicity', 'Catechol O-Methyltransferase/metabolism', '*Catechol O-Methyltransferase Inhibitors', 'Catechols/pharmacology/*toxicity', 'Cell Survival/drug effects/physiology', 'DNA, Mitochondrial/metabolism', 'Dose-Response Relationship, Drug', 'Enzyme Inhibitors/pharmacology/*toxicity', 'Humans', 'Neuroblastoma/*enzymology', 'Nitriles', 'Nitrophenols', 'Tolcapone', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/14975680/
323,tolcapone,7768073,Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans.,"['Dingemanse J', 'Jorga KM', 'Schmitt M', 'Gieschke R', 'Fotteler B', 'Zurcher G', 'Da Prada M', 'van Brummelen P']","['Administration, Oral', 'Adult', 'Benzophenones/adverse effects/*pharmacokinetics/pharmacology', '*Catechol O-Methyltransferase Inhibitors', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Half-Life', 'Humans', 'Intestinal Absorption', 'Male', 'Nitrophenols', 'Tolcapone']",https://pubmed.ncbi.nlm.nih.gov/7768073/
324,Metoprolol,7059440,Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros delivery system.,"['Kendall MJ', 'Jack DB', 'Woods KL', 'Laugher SJ', 'Quarterman CP', 'John VA']","['Adult', 'Blood Pressure/drug effects', 'Delayed-Action Preparations', 'Double-Blind Method', 'Heart Rate/drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Kinetics', 'Male', 'Metoprolol/*administration & dosage/metabolism/pharmacology', 'Physical Exertion', 'Propanolamines/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/7059440/
325,Metoprolol,37307170,Pharmacogenomic markers of metoprolol and alpha-OH-metoprolol concentrations: a genome-wide association study.,"['Laverdiere J', 'Meloche M', 'Provost S', 'Leclair G', 'Oussaid E', 'Jutras M', 'Perreault LL', 'Valois D', 'Mongrain I', 'Busseuil D', 'Rouleau JL', 'Tardif JC', 'Dube MP', 'Denus S']","['Humans', '*Metoprolol/therapeutic use/pharmacokinetics', '*Genome-Wide Association Study', 'Cytochrome P-450 CYP2D6/genetics', 'Pharmacogenetics', 'Cross-Sectional Studies']",https://pubmed.ncbi.nlm.nih.gov/37307170/
326,Metoprolol,34067394,Metoprolol and Its Degradation and Transformation Products Using AOPs-Assessment of Aquatic Ecotoxicity Using QSAR.,"['Voigt M', 'Bartels I', 'Schmiemann D', 'Votel L', 'Hoffmann-Jacobsen K', 'Jaeger M']","['Algorithms', 'Bioreactors', 'Chromatography, High Pressure Liquid', '*Ecotoxicology/methods', 'Environmental Monitoring/methods', 'Hydrogen Peroxide/chemistry', 'Hydrogen-Ion Concentration', 'Kinetics', 'Metoprolol/*analysis/chemistry', 'Oxygen/chemistry', 'Ozone/*chemistry', 'Photochemistry', 'Photolysis', '*Quantitative Structure-Activity Relationship', 'Sewage/*chemistry', 'Software', 'Ultraviolet Rays', 'Wastewater/*chemistry', 'Water Pollutants, Chemical/*analysis/chemistry']",https://pubmed.ncbi.nlm.nih.gov/34067394/
327,Metoprolol,35764772,Clinical Pharmacokinetics of Metoprolol: A Systematic Review.,"['Zamir A', 'Hussain I', 'Ur Rehman A', 'Ashraf W', 'Imran I', 'Saeed H', 'Majeed A', 'Alqahtani F', 'Rasool MF']","['Administration, Oral', 'Area Under Curve', 'Female', 'Food-Drug Interactions', 'Humans', '*Liver', '*Metoprolol/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/35764772/
328,Metoprolol,34781150,Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: A meta-analysis.,"['Lan Q', 'Wu F', 'Han B', 'Ma L', 'Han J', 'Yao Y']","['Administration, Intravenous', 'Atrial Fibrillation/*drug therapy', 'Blood Pressure/drug effects', 'Diltiazem/administration & dosage/*therapeutic use', 'Heart Rate/*drug effects', 'Humans', 'Metoprolol/administration & dosage/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34781150/
329,Metoprolol,7318502,Metoprolol and alopecia.,"['Graeber CW', 'Lapkin RA']","['Adolescent', 'Alopecia/*chemically induced', 'Humans', 'Male', 'Metoprolol/*adverse effects', 'Propanolamines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7318502/
330,Metoprolol,34915981,Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.,"['Dybro AM', 'Rasmussen TB', 'Nielsen RR', 'Andersen MJ', 'Jensen MK', 'Poulsen SH']","['Adrenergic beta-1 Receptor Antagonists/pharmacology/*therapeutic use', 'Aged', 'Cardiomyopathy, Hypertrophic/complications/*drug therapy', 'Cross-Over Studies', 'Double-Blind Method', 'Exercise Tolerance/drug effects', 'Female', 'Humans', 'Male', 'Metoprolol/pharmacology/*therapeutic use', 'Middle Aged', 'Ventricular Outflow Obstruction/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/34915981/
331,Metoprolol,25917170,Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulations.,"['Gesquiere I', 'Darwich AS', 'Van der Schueren B', 'de Hoon J', 'Lannoo M', 'Matthys C', 'Rostami A', 'Foulon V', 'Augustijns P']","['Administration, Oral', 'Adult', 'Biological Availability', 'Computer Simulation', 'Delayed-Action Preparations/*administration & dosage/*pharmacokinetics', 'Female', '*Gastric Bypass', 'Humans', 'Male', 'Metoprolol/*administration & dosage/*pharmacokinetics', '*Models, Biological']",https://pubmed.ncbi.nlm.nih.gov/25917170/
332,Metoprolol,27977472,Cost-effectiveness of nitrendipine and hydrochlorothiazide or metoprolol to treat hypertension in rural community health centers in China.,"['Wang Z', 'Chen Z', 'Wang X', 'Hao G', 'Ma L', 'Zhao X', 'Li Y', 'Zhang L', 'Zhu M']","['Adolescent', 'Adult', 'Aged', 'Antihypertensive Agents/economics/*therapeutic use', 'Beijing', 'Blood Pressure/drug effects', '*Community Health Centers', 'Cost-Benefit Analysis', 'Drug Therapy, Combination/economics', 'Female', 'Health Care Costs', 'Humans', 'Hydrochlorothiazide/economics/*therapeutic use', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Metoprolol/economics/pharmacology/*therapeutic use', 'Middle Aged', 'Nitrendipine/economics/*therapeutic use', 'Prospective Studies', '*Rural Health Services', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27977472/
333,Metoprolol,32829137,Simultaneous time-course measurements of metoprolol and alpha-hydroxyl metoprolol in fingermarks after oral administration by liquid chromatography tandem mass spectrometry.,['Zhang WJ'],"['Administration, Oral', 'Adult', 'Chromatography, High Pressure Liquid/*methods', 'Female', 'Fingers/*physiology', 'Humans', 'Limit of Detection', 'Linear Models', 'Male', 'Metoprolol/administration & dosage/*analogs & derivatives/*analysis/pharmacokinetics', 'Middle Aged', 'Reproducibility of Results', 'Specimen Handling', 'Tandem Mass Spectrometry/*methods', 'Tissue Distribution', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32829137/
334,Metoprolol,3654886,Determination of metoprolol and two major metabolites in plasma and urine by column liquid chromatography and fluorometric detection.,"['Balmer K', 'Zhang YY', 'Lagerstrom PO', 'Persson BA']","['Chromatography, Liquid', 'Humans', 'Indicators and Reagents', 'Metoprolol/*analysis/blood/urine', 'Spectrometry, Fluorescence']",https://pubmed.ncbi.nlm.nih.gov/3654886/
335,Metoprolol,25291152,Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients.,"['Antunes Nde J', 'Cavalli RC', 'Marques MP', 'Moises EC', 'Lanchote VL']","['Adult', 'Antihypertensive Agents/*blood/chemistry/metabolism/therapeutic use', 'Diabetes, Gestational/blood/drug therapy/*metabolism', 'Female', 'Fetal Blood/chemistry', 'Humans', 'Hypertension/blood/complications/*drug therapy/metabolism', 'Infant, Newborn', 'Metoprolol/*blood/chemistry/metabolism/therapeutic use', 'Parturition', 'Placenta/*metabolism', 'Pregnancy', 'Stereoisomerism', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/25291152/
336,Metoprolol,2940080,"Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.","['Benfield P', 'Clissold SP', 'Brogden RN']","['Adult', 'Age Factors', 'Aged', 'Arrhythmias, Cardiac/drug therapy', 'Cardiomegaly/drug therapy', 'Coronary Disease/drug therapy', 'Drug Interactions', 'Drug Therapy, Combination', 'Female', 'Heart Failure/drug therapy', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/drug therapy', 'Hypotension, Controlled', 'Kinetics', 'Lung/drug effects', 'Metoprolol/metabolism/pharmacology/*therapeutic use', 'Myocardial Infarction/drug therapy', 'Pregnancy', 'Substance Withdrawal Syndrome']",https://pubmed.ncbi.nlm.nih.gov/2940080/
337,Metoprolol,21989963,Identification and characterization of stressed degradation products of metoprolol using LC/Q-TOF-ESI-MS/MS and MS(n) experiments.,"['Borkar RM', 'Raju B', 'Srinivas R', 'Patel P', 'Shetty SK']","['Chromatography, Liquid/*methods', 'Drug Stability', 'Hydrolysis', 'Ions/analysis/chemistry', 'Metoprolol/*analysis/*chemistry', 'Oxidation-Reduction', 'Photolysis', 'Reproducibility of Results', 'Tandem Mass Spectrometry/*methods']",https://pubmed.ncbi.nlm.nih.gov/21989963/
338,Metoprolol,2076733,A comparison of diltiazem and metoprolol in hypertension. Swedish Diltiazem-Metoprolol Multicentre Study Group.,"['Hedner T', 'Thulin T', 'Gustafsson S', 'Olsson SO']","['Blood Pressure/drug effects', 'Diltiazem/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Lipids/blood', 'Male', 'Metoprolol/adverse effects/*therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2076733/
339,Metoprolol,26211655,"Derivation of water quality standards for carbamazepine, metoprolol, and metformin and comparison with monitoring data.","['Moermond CT', 'Smit CE']","['Carbamazepine/*analysis/toxicity', 'Ecosystem', 'Ecotoxicology', '*Environmental Monitoring', 'Metformin/*analysis/toxicity', 'Metoprolol/*analysis/toxicity', 'Toxicity Tests, Acute', 'Toxicity Tests, Chronic', 'Water Pollutants, Chemical/*analysis', 'Water Quality/*standards']",https://pubmed.ncbi.nlm.nih.gov/26211655/
340,ertapenem,39550069,Synergistic approach of ertapenem and flucloxacillin or cefazolin for addressing persistent methicillin susceptible Staphylococcus aureus bacteremia.,"['Bakthavatchalam YD', 'Karthik R', 'Ashok A', 'Walia K', 'Ragothaman H', 'Krishnamoorthy S', 'Manokaran Y', 'Veeraraghavan B']","['*Ertapenem/pharmacology', '*Floxacillin/pharmacology', '*Cefazolin/pharmacology', 'Drug Synergism', '*Staphylococcus aureus/drug effects/isolation & purification', '*Bacteremia/drug therapy/microbiology', '*Methicillin/pharmacology', 'Humans', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/39550069/
341,ertapenem,26552970,Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.,"['Cprek JB', 'Gallagher JC']","['Aged', 'Anti-Bacterial Agents/*therapeutic use', 'Bacteremia/drug therapy/microbiology/mortality/pathology', 'Carbapenems/*therapeutic use', 'Ertapenem', 'Female', 'Humans', 'Intraabdominal Infections/drug therapy/microbiology/mortality/pathology', 'Klebsiella Infections/*drug therapy/microbiology/mortality/pathology', 'Klebsiella pneumoniae/*drug effects/growth & development/isolation & purification/pathogenicity', 'Length of Stay', 'Male', 'Middle Aged', 'Pneumonia, Bacterial/drug therapy/microbiology/mortality/pathology', 'Survival Analysis', 'Treatment Outcome', 'Urinary Tract Infections/drug therapy/microbiology/mortality/pathology', 'beta-Lactams/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26552970/
342,ertapenem,19029330,CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.,"['Girlich D', 'Poirel L', 'Nordmann P']","['Anti-Bacterial Agents/*pharmacology', 'Bacterial Outer Membrane Proteins/genetics', 'Bacterial Proteins/biosynthesis/genetics', 'DNA Primers', 'Drug Resistance, Bacterial', 'Ertapenem', 'Escherichia coli/*drug effects', 'Klebsiella pneumoniae/*drug effects', 'Microbial Sensitivity Tests', 'Mutation', 'beta-Lactamases/*biosynthesis/genetics', 'beta-Lactams/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/19029330/
343,ertapenem,36401791,Treatment of persistent methicillin-susceptible Staphylococcus aureus bacteremia and presumed osteomyelitis with oxacillin and ertapenem in a premature neonate.,"['Hitchins M', ""O'Mara K"", 'Edwards L', 'Bouchard J']","['Infant, Newborn', 'Humans', 'Oxacillin/therapeutic use', 'Staphylococcus aureus', 'Ertapenem', 'Anti-Bacterial Agents/therapeutic use', 'Methicillin/pharmacology/therapeutic use', '*Staphylococcal Infections/drug therapy', '*Osteomyelitis/drug therapy', '*Bacteremia/drug therapy', '*Methicillin-Resistant Staphylococcus aureus']",https://pubmed.ncbi.nlm.nih.gov/36401791/
344,ertapenem,32867678,Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution.,"['Gonzalo X', 'Satta G', 'Ortiz Canseco J', 'McHugh TD', 'Drobniewski F']","['Amoxicillin-Potassium Clavulanate Combination/pharmacology', 'Antitubercular Agents/pharmacology', 'Drug Resistance, Bacterial', 'Ertapenem/administration & dosage/*pharmacology', 'Humans', 'Microbial Sensitivity Tests/*methods', 'Mycobacterium tuberculosis/*drug effects/isolation & purification', 'Tuberculosis/microbiology', 'Tuberculosis, Multidrug-Resistant/microbiology', 'beta-Lactams/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32867678/
345,ertapenem,34599521,Cefazolin plus ertapenem and heart transplantation as salvage therapy for refractory LVAD infection due to methicillin-susceptible Staphylococcus aureus: A case series.,"['Cardenas-Alvarez JL', 'Suarez J', 'Motoa G', 'Anjan S', 'Natori Y', 'Loebe M', 'Breda JR', 'Thakkar-Rivera N', 'Phancao A', 'Ghodsizad A', 'Bauerlein JE', 'Munagala MR', 'Simkins J']","['Anti-Bacterial Agents/therapeutic use', '*Bacteremia', 'Cefazolin', 'Ertapenem', '*Heart Transplantation', '*Heart-Assist Devices', 'Humans', 'Methicillin', 'Salvage Therapy', '*Staphylococcal Infections/drug therapy', 'Staphylococcus aureus']",https://pubmed.ncbi.nlm.nih.gov/34599521/
346,ertapenem,17512703,"In vitro activities of faropenem, ertapenem, imipenem and meropenem against Borrelia burgdorferi s.l.","['Rodel R', 'Freyer A', 'Bittner T', 'Schafer V', 'Hunfeld KP']","['Anti-Bacterial Agents/*pharmacology', 'Borrelia burgdorferi Group/*drug effects', 'Colony Count, Microbial', 'Microbial Sensitivity Tests', 'Microbial Viability/drug effects', 'Time Factors', 'beta-Lactams/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/17512703/
347,ertapenem,16870780,Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae.,"['Szabo D', 'Silveira F', 'Hujer AM', 'Bonomo RA', 'Hujer KM', 'Marsh JW', 'Bethel CR', 'Doi Y', 'Deeley K', 'Paterson DL']","['Anti-Bacterial Agents/*pharmacology', 'Bacterial Outer Membrane Proteins/*metabolism', 'Drug Resistance, Microbial/genetics', 'Enterobacter cloacae/*drug effects/genetics/isolation & purification', 'Ertapenem', 'Gene Expression Regulation, Bacterial', 'Genes, Bacterial', 'Humans', 'Membrane Transport Proteins/*metabolism', 'Microbial Sensitivity Tests', 'Transcription, Genetic', 'beta-Lactams/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/16870780/
348,ertapenem,27164625,Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-Mediated Hypersensitivity to beta-Lactams.,"['Buonomo A', 'Pascolini L', 'Rizzi A', 'Aruanno A', 'Pecora V', 'Ricci AG', 'Mezzacappa S', 'Di Rienzo A', 'Centrone M', 'Nucera E', 'Schiavino D']","['Adult', 'Aged', 'Anti-Bacterial Agents/*adverse effects', 'Cross Reactions', 'Drug Hypersensitivity/blood/*diagnosis/etiology/immunology', 'Ertapenem', 'Female', 'Humans', 'Imipenem/*adverse effects', 'Immunoglobulin E/blood', 'Male', 'Meropenem', 'Middle Aged', 'Skin Tests', 'Thienamycins/*adverse effects', 'beta-Lactams/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27164625/
349,ertapenem,32618479,Ertapenem Neurotoxicity in Hemodialysis Patients-Safe and Effective Dosing Is Still Needed: A Retrospective Study and Literature Review.,"['El Nekidy WS', 'Elrefaei H', 'St John TJL', 'Attallah NM', 'Kablaoui F', 'Nusair A', 'Piechowski-Jozwiak B', 'Phillips J', 'Ghazi IM']","['Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/*administration & dosage/adverse effects/therapeutic use', 'Ertapenem/*administration & dosage/adverse effects/therapeutic use', 'Female', 'Humans', 'Incidence', 'Male', 'Middle Aged', '*Neurotoxicity Syndromes/epidemiology/etiology', '*Renal Dialysis', 'Renal Insufficiency, Chronic/*drug therapy/therapy', 'Retrospective Studies', 'Seizures/epidemiology/etiology']",https://pubmed.ncbi.nlm.nih.gov/32618479/
350,ertapenem,31127290,Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in Klebsiella pneumoniae ST258.,"['Iovleva A', 'Mettus RT', 'McElheny CL', 'Mustapha MM', 'Van Tyne D', 'Shields RK', 'Pasculle AW', 'Cooper VS', 'Doi Y']","['Anti-Bacterial Agents/*pharmacology', 'Ceftazidime/*pharmacology', 'Drug Resistance, Bacterial/genetics', 'Ertapenem/*pharmacology', 'Humans', 'Kinetics', 'Klebsiella Infections/microbiology', 'Klebsiella pneumoniae/*drug effects/enzymology/*genetics', 'Microbial Sensitivity Tests', 'beta-Lactamases/*genetics']",https://pubmed.ncbi.nlm.nih.gov/31127290/
351,ertapenem,10952584,"Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.","['Goldstein EJ', 'Citron DM', 'Vreni Merriam C', 'Warren Y', 'Tyrrell KL']","['Abdominal Abscess/*microbiology', 'Bacteria, Anaerobic/classification/*drug effects/isolation & purification', 'Brazil', 'Carbapenems/*pharmacology', 'Humans', 'Microbial Sensitivity Tests', 'Russia', 'South Africa', 'Spain']",https://pubmed.ncbi.nlm.nih.gov/10952584/
352,ertapenem,27851857,Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.,"['Solomkin J', 'Evans D', 'Slepavicius A', 'Lee P', 'Marsh A', 'Tsai L', 'Sutcliffe JA', 'Horn P']","['Abdominal Abscess/*drug therapy/microbiology/surgery', 'Adult', 'Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/adverse effects/*therapeutic use', 'Appendicitis/complications', 'Bacterial Infections/complications/*drug therapy', 'Double-Blind Method', 'Ertapenem', 'Female', '*Gram-Negative Bacteria', 'Humans', 'Intention to Treat Analysis', 'Male', 'Middle Aged', 'Peritonitis/*drug therapy/microbiology', 'Tetracyclines/adverse effects/*therapeutic use', 'Treatment Outcome', 'Young Adult', 'beta-Lactams/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27851857/
353,ertapenem,34806574,Interaction between valproic acid and meropenem or ertapenem in patients with epilepsy: clinical relevance and results from pharmaceutical intervention.,"['Hernandez-Ramos JA', 'Caro-Telle JM', 'Bruni-Montero MA', 'Canales-Siguero D', 'Ferrari-Piquero JM']","['Aged', 'Anti-Bacterial Agents/therapeutic use', 'Anticonvulsants/therapeutic use', 'Drug Interactions', '*Epilepsy/drug therapy', 'Ertapenem/therapeutic use', 'Humans', 'Male', 'Meropenem/therapeutic use', '*Pharmaceutical Preparations', 'Retrospective Studies', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34806574/
354,ertapenem,38353987,Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa.,"['Nosrati A', ""Ch'en PY"", 'Torpey ME', 'Shokrian N', 'Ball G', 'Benesh G', 'Andriano TM', 'Zhu TR', 'Heibel HD', 'Hosgood HD', 'Campton KL', 'Cohen SR']","['Humans', 'Female', 'Adult', 'Male', 'Ertapenem/therapeutic use', '*Hidradenitis Suppurativa/diagnosis/drug therapy', 'Interleukin-6', 'Retrospective Studies', '*Antimicrobial Stewardship', 'C-Reactive Protein', 'Anti-Bacterial Agents/therapeutic use', 'Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38353987/
355,ertapenem,28249572,Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.,"['Rattanaumpawan P', 'Werarak P', 'Jitmuang A', 'Kiratisin P', 'Thamlikitkul V']","['Adult', 'Aged', 'Anti-Bacterial Agents/therapeutic use', 'Carbapenems/*therapeutic use', 'Enterobacteriaceae/genetics/*pathogenicity', 'Enterobacteriaceae Infections/*drug therapy/microbiology', 'Ertapenem', 'Female', 'Humans', 'Male', 'Middle Aged', 'Treatment Outcome', 'Urinary Tract Infections/drug therapy', 'beta-Lactamases/metabolism', 'beta-Lactams/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28249572/
356,Perindopril,17765963,Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.,"['Patel A', 'MacMahon S', 'Chalmers J', 'Neal B', 'Woodward M', 'Billot L', 'Harrap S', 'Poulter N', 'Marre M', 'Cooper M', 'Glasziou P', 'Grobbee DE', 'Hamet P', 'Heller S', 'Liu LS', 'Mancia G', 'Mogensen CE', 'Pan CY', 'Rodgers A', 'Williams B']","['Aged', 'Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Blood Pressure/drug effects', 'Diabetes Mellitus, Type 2/complications/*drug therapy/physiopathology', 'Diuretics/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy/etiology', 'Indapamide/*therapeutic use', 'Male', 'Middle Aged', 'Perindopril/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17765963/
357,Perindopril,37325939,Utilization of erythrosine B in spectrofluorimetric quenching analysis of amlodipine and perindopril in pharmaceutical and biological matrices.,"['Badr El-Din KM', 'Salem H', 'Derayea S', 'Abdelaziz A', 'Nagy DM']","['Humans', '*Amlodipine', 'Perindopril', 'Erythrosine', 'Spectrometry, Fluorescence', 'Pharmaceutical Preparations', '*Leukemia, Myeloid, Acute']",https://pubmed.ncbi.nlm.nih.gov/37325939/
358,Perindopril,37661180,Perindopril and losartan attenuate pro-coagulation factors in human adipocytes exposed to SARS-CoV-2 spike protein.,"['Ardiana M', 'Suryawan IGR', 'Hermawan HO', 'Harsoyo PM', 'Sufiyah IM', 'Muhammad AR', 'Zaini BSI']","['Humans', 'Male', 'Perindopril/pharmacology', 'Spike Glycoprotein, Coronavirus', 'Losartan/pharmacology', 'Plasminogen Activator Inhibitor 1', 'Angiotensin-Converting Enzyme 2', 'Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology', '*COVID-19', 'SARS-CoV-2', 'Blood Coagulation Factors', 'Adipocytes', 'Thromboplastin', '*Cardiovascular Agents', 'Obesity/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37661180/
359,Perindopril,36287359,Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis.,"['Mostafa S', 'Shabana H', 'Khalil F', 'Mancy IME', 'Zedan HA', 'Elmoursi A', 'Ramadan IG', 'Mohamed SED', 'Kassem A', 'Kamel IS']","['Humans', '*Perindopril/adverse effects', 'Amlodipine/adverse effects', 'Antihypertensive Agents/adverse effects', 'Drug Combinations', '*Hypertension/diagnosis/drug therapy', 'Blood Pressure', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36287359/
360,Perindopril,30790132,Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension.,"['Tsioufis K', 'Douma S', 'Kallistratos MS', 'Manolis AJ']","['Adult', 'Aged', 'Amlodipine/*administration & dosage', 'Antihypertensive Agents/*administration & dosage', 'Blood Pressure/drug effects/physiology', 'Drug Combinations', 'Female', 'Greece/epidemiology', 'Humans', 'Hypertension/diagnosis/*drug therapy/epidemiology', 'Indapamide/*administration & dosage', 'Male', '*Medication Adherence', 'Middle Aged', 'Perindopril/*administration & dosage', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/30790132/
361,Perindopril,34907764,"Rosuvastatin, Perindopril and Ezetimibe loaded instant release buccal films: Development and in vitro characterization.","['Anwar S', 'Zaman M', 'Raja MAG', 'Mahmood A', 'Amjad MW']","['Ezetimibe/pharmacology', 'Hypromellose Derivatives/chemistry', '*Perindopril/pharmacology', 'Rosuvastatin Calcium/pharmacology', 'Solvents']",https://pubmed.ncbi.nlm.nih.gov/34907764/
362,Perindopril,24741317,Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.,"['Wang JG', 'Pimenta E', 'Chwallek F']","['Angiotensin II Type 1 Receptor Blockers/adverse effects/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Benzimidazoles/adverse effects/*therapeutic use', 'Benzoates/adverse effects/*therapeutic use', 'Blood Pressure/*drug effects', 'Humans', 'Hypertension/diagnosis/*drug therapy/physiopathology', 'Perindopril/adverse effects/*therapeutic use', 'Preventive Health Services', 'Risk Assessment', 'Risk Factors', 'Telmisartan', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24741317/
363,Perindopril,36799308,The Efficacy and Tolerability of a Fixed Combination of Perindopril and Indapamide in the Treatment of Unregulated Essential Hypertension - a Postmarketing Study.,"['Sukalo A', 'Dzananovic Jaganjac J', 'Tanovic Avdic A', 'Glamoclija U', 'Popovic Z', 'Boloban A', 'Tiric Campara M', 'Mehic M']","['Humans', 'Antihypertensive Agents/therapeutic use/adverse effects', 'Blood Pressure', 'Drug Combinations', 'Essential Hypertension/drug therapy/chemically induced', '*Hypertension/drug therapy/chemically induced', '*Indapamide/therapeutic use/adverse effects', 'Perindopril/therapeutic use/adverse effects', 'Prospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36799308/
364,Perindopril,37730949,"Comparing Cardiovascular Outcomes and Costs of Perindopril-, Enalapril- or Losartan-Based Antihypertensive Regimens in South Africa: Real-World Medical Claims Database Analysis.","['Snyman JR', 'Gumedze F', 'Jones ESW', 'Alaba OA', 'Tsabedze N', 'Vira A', 'Ntusi NAB']","['Humans', '*Losartan/therapeutic use/pharmacology', 'Antihypertensive Agents/therapeutic use', 'Enalapril/therapeutic use/pharmacology', 'Perindopril/therapeutic use', 'South Africa/epidemiology', 'Angiotensin-Converting Enzyme Inhibitors/therapeutic use/pharmacology', '*Hypertension/complications', 'Blood Pressure']",https://pubmed.ncbi.nlm.nih.gov/37730949/
365,Perindopril,23933903,Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.,"['Dinicolantonio JJ', 'Lavie CJ', ""O'Keefe JH""]","['Angiotensin-Converting Enzyme Inhibitors/pharmacology/*therapeutic use', 'Cardiovascular Diseases/*drug therapy', 'Cardiovascular System/drug effects', 'Coronary Disease/drug therapy', 'Heart Failure/drug therapy', 'Humans', 'Hypertension/drug therapy', 'Myocardial Infarction/drug therapy', 'Perindopril/pharmacology/*therapeutic use', 'Ramipril/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23933903/
366,Perindopril,8804953,Perindopril-associated pneumonitis.,"['Benard A', 'Melloni B', 'Gosselin B', 'Bonnaud F', 'Wallaert B']","['Aged', 'Alveolitis, Extrinsic Allergic/*chemically induced/diagnosis', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use', 'Diagnosis, Differential', 'Humans', 'Indoles/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Perindopril', 'Tomography, X-Ray Computed']",https://pubmed.ncbi.nlm.nih.gov/8804953/
367,Perindopril,37029871,Effectiveness and Tolerability of Bisoprolol/Perindopril Single-Pill Combination in Patients with Arterial Hypertension and a History of Myocardial Infarction: The PRIDE Observational Study.,"['Kobalava Z', 'Kvasnikov B', 'Burtsev Y']","['Male', 'Humans', 'Middle Aged', 'Aged', 'Female', 'Perindopril/adverse effects', 'Bisoprolol/adverse effects', 'Antihypertensive Agents/adverse effects', 'Retrospective Studies', '*Hypertension/complications/drug therapy', 'Blood Pressure', '*Myocardial Infarction/complications/drug therapy', 'Angina Pectoris', 'Drug Combinations', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37029871/
368,Perindopril,26407654,Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients.,"['Derosa G', 'Mugellini A', 'Pesce RM', ""D'Angelo A"", 'Maffioli P']","['Antihypertensive Agents/*therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Hypolipidemic Agents/*therapeutic use', 'Male', 'Nifedipine/*analogs & derivatives/therapeutic use', 'Non-alcoholic Fatty Liver Disease/*drug therapy', 'Obesity/drug therapy', 'Perindopril/*therapeutic use', 'Simvastatin/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26407654/
369,Perindopril,37322624,Comparison of antihypertensive drugs amlodipine and perindopril on blood pressure variability after long-term treatment of hypertension induced by apatinib and bevacizumab.,"['Zhao W', 'Liu L', 'Chen L']","['Humans', '*Antihypertensive Agents/therapeutic use/pharmacology', 'Perindopril/therapeutic use/pharmacology', 'Amlodipine/therapeutic use/pharmacology', 'Blood Pressure', 'Bevacizumab/adverse effects', '*Hypertension/chemically induced/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37322624/
370,Perindopril,34774433,Advanced chemometric methods as powerful tools for impurity profiling of drug substances and drug products: Application on bisoprolol and perindopril binary mixture.,"['Hassan SA', 'Nashat NW', 'Elghobashy MR', 'Abbas SS', 'Moustafa AA']","['Bisoprolol', 'Chemometrics', 'Least-Squares Analysis', '*Perindopril', '*Pharmaceutical Preparations']",https://pubmed.ncbi.nlm.nih.gov/34774433/
371,Perindopril,37341634,"Chromatographic Techniques for Assessment of Bisoprolol Fumarate and Perindopril Arginine in Solid Formulations under Various Stress Conditions and Application to Six Sigma, Content Uniformity, and Comparative Dissolution Approaches.","['Mahmoud OA', 'Omran AA', 'Binsaleh AY', 'Almalki MA', 'Mohamed MA']","['Arginine', '*Bisoprolol/analysis', '*Perindopril/analysis', 'Solubility', 'Total Quality Management']",https://pubmed.ncbi.nlm.nih.gov/37341634/
372,mefloquine,36508338,"Prevalence and characterization of piperaquine, mefloquine and artemisinin derivatives triple-resistant Plasmodium falciparum in Cambodia.","['Mairet-Khedim M', 'Roesch C', 'Khim N', 'Srun S', 'Bouillon A', 'Kim S', 'Ke S', 'Kauy C', 'Kloeung N', 'Eam R', 'Khean C', 'Kul C', 'Chy S', 'Leang R', 'Ringwald P', 'Barale JC', 'Witkowski B']","['Humans', 'Mefloquine/pharmacology/therapeutic use', 'Plasmodium falciparum/genetics', '*Antimalarials/pharmacology/therapeutic use', 'Artesunate', 'Cambodia/epidemiology', 'Prevalence', '*Artemisinins/pharmacology/therapeutic use', '*Quinolines/pharmacology', '*Malaria, Falciparum/drug therapy/epidemiology/parasitology', 'Drug Resistance/genetics']",https://pubmed.ncbi.nlm.nih.gov/36508338/
373,mefloquine,38147482,"Synthesis, antiproliferative and antiplasmodial evaluation of new chloroquine and mefloquine-based harmiquins.","['Pavic K', 'Poje G', 'Carvalho LP', 'Held J', 'Rajic Z']","['Humans', '*Antimalarials/pharmacology', 'Cell Line, Tumor', '*Chloroquine/pharmacology', '*Mefloquine/pharmacology', 'Parasitic Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/38147482/
374,mefloquine,30836914,Synthesis and Antibacterial Activity of Mefloquine-Based Analogs Against Sensitive and Resistant Mycobacterium tuberculosis Strains.,"['da Silva Araujo A', 'Moraes AM', 'Lourenco MCS', 'Pessoa CO', 'da Silva ET', 'de Souza MVN']","['Antitubercular Agents/chemical synthesis/chemistry/*pharmacology', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Drug Resistance, Bacterial/*drug effects', 'Humans', 'Mefloquine/chemical synthesis/chemistry/*pharmacology', 'Microbial Sensitivity Tests', 'Molecular Structure', 'Mycobacterium tuberculosis/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/30836914/
375,mefloquine,26424621,Malaria Chemoprophylaxis and Self-Reported Impact on Ability to Work: Mefloquine Versus Doxycycline.,"['Terrell AG', 'Forde ME', 'Firth R', 'Ross DA']","['Antimalarials/*adverse effects', 'Chemoprevention', 'Cohort Studies', 'Doxycycline/*adverse effects', 'Humans', 'Kenya', 'Malaria/*prevention & control', 'Mefloquine/*adverse effects', 'Military Personnel', 'Self Report', 'United Kingdom', 'Work']",https://pubmed.ncbi.nlm.nih.gov/26424621/
376,mefloquine,35446430,A Cross-sectional Cohort Study to Assess Long-term Neurocognitive and Psychiatric Symptoms of Mefloquine Use in Veterans.,"['Reinhard MJ', 'Chester JE', 'Breneman CB', 'Samuel IBH', 'Prisco MK', 'Vincent TD', 'Rumm PD', 'Smith SR', 'Barrett JP']","['Humans', 'Mefloquine/adverse effects', '*Antimalarials/adverse effects', '*Veterans/psychology', 'Cross-Sectional Studies', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/35446430/
377,mefloquine,36892247,"Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments.","['Akazawa D', 'Ohashi H', 'Hishiki T', 'Morita T', 'Iwanami S', 'Kim KS', 'Jeong YD', 'Park ES', 'Kataoka M', 'Shionoya K', 'Mifune J', 'Tsuchimoto K', 'Ojima S', 'Azam AH', 'Nakajima S', 'Park H', 'Yoshikawa T', 'Shimojima M', 'Kiga K', 'Iwami S', 'Maeda K', 'Suzuki T', 'Ebihara H', 'Takahashi Y', 'Watashi K']","['Humans', 'Atovaquone/pharmacology/therapeutic use', '*Mefloquine/pharmacology/therapeutic use', '*Monkeypox virus/drug effects', 'Mpox, Monkeypox']",https://pubmed.ncbi.nlm.nih.gov/36892247/
378,mefloquine,36821622,Prediction of improved antimalarial chemotherapy of artesunate-mefloquine in combination with mefloquine sensitive and resistant Plasmodium falciparum malaria.,"['Saeheng T', 'Na-Bangchang K']","['Humans', '*Antimalarials/pharmacology/therapeutic use', 'Mefloquine/pharmacology/therapeutic use', 'Artesunate/therapeutic use', '*Artemisinins/pharmacology/therapeutic use', '*Malaria, Falciparum/drug therapy/parasitology', 'Plasmodium falciparum', 'Drug Therapy, Combination', '*Sesquiterpenes/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/36821622/
379,mefloquine,31987860,Mefloquine binding to human acyl-CoA binding protein leads to redox stress-mediated apoptotic death of human neuroblastoma cells.,"['Kumar A', 'Ghosh DK', 'Ranjan A']","['Antimalarials/metabolism/*toxicity', 'Apoptosis/*drug effects', 'Cell Line, Tumor', 'Diazepam Binding Inhibitor/*metabolism', 'Humans', 'Mefloquine/metabolism/*toxicity', 'Oxidation-Reduction', 'Oxidative Stress/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/31987860/
380,mefloquine,31844010,Association of Lipid Levels with Mefloquine and Carboxy-Mefloquine Concentrations in Patients with Uncomplicated Falciparum Malaria.,"['Vieira JLF', 'Rivera JGB', 'de Sena LWP', 'Ferreira MVD']","['Adult', 'Antimalarials/*blood/pharmacokinetics/pharmacology', 'Artesunate/*blood/pharmacokinetics/pharmacology', 'Biotransformation', 'Brazil', 'Cholesterol, HDL/blood', 'Cholesterol, LDL/blood', 'Cholesterol, VLDL/blood', 'Drug Therapy, Combination', 'Erythrocytes/drug effects/metabolism/parasitology', 'Humans', 'Malaria, Falciparum/blood/*drug therapy/parasitology', 'Male', 'Mefloquine/*analogs & derivatives/*blood/pharmacokinetics/pharmacology', 'Plasmodium falciparum/*drug effects/growth & development/metabolism', 'Severity of Illness Index', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/31844010/
381,mefloquine,31691964,Combination mode of antimalarial drug mefloquine and human serum albumin: Insights from spectroscopic and docking approaches.,"['Musa KA', 'Ridzwan NFW', 'Mohamad SB', 'Tayyab S']","['Antimalarials/*chemistry', 'Circular Dichroism', 'Humans', 'Mefloquine/*chemistry', '*Molecular Docking Simulation', 'Serum Albumin, Human/*chemistry', 'Spectrometry, Fluorescence']",https://pubmed.ncbi.nlm.nih.gov/31691964/
382,Carvedilol,36897563,Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.,"['Turco L', 'Reiberger T', 'Vitale G', 'La Mura V']","['Humans', 'Carvedilol/therapeutic use', 'Propranolol', '*Esophageal and Gastric Varices/etiology/complications', 'Ascites/etiology/complications', 'Gastrointestinal Hemorrhage/drug therapy/etiology', 'Adrenergic beta-Antagonists/therapeutic use', '*Hypertension, Portal/complications/drug therapy', 'Liver Cirrhosis']",https://pubmed.ncbi.nlm.nih.gov/36897563/
383,Carvedilol,37221930,Enantioselective binding of carvedilol to human serum albumin and alpha-1-acid glycoprotein.,"['Toma CM', 'Imre S', 'Farczadi L', 'Ion V', 'Marc G']","['Humans', 'Albumins', 'Carbazoles/chemistry', '*Carvedilol/chemistry', 'Chromatography, Liquid/methods', 'Molecular Docking Simulation', '*Orosomucoid/chemistry', '*Serum Albumin, Human/chemistry', 'Stereoisomerism', 'Tandem Mass Spectrometry/methods', 'Protein Binding', 'Binding, Competitive', '*Adrenergic beta-Antagonists/chemistry']",https://pubmed.ncbi.nlm.nih.gov/37221930/
384,Carvedilol,37110635,Synthesis and Characterization of Carvedilol-Etched Halloysite Nanotubes Composites with Enhanced Drug Solubility and Dissolution Rate.,"['Maggi L', 'Urru C', 'Friuli V', 'Ferrara C', 'Conti DM', 'Bruni G', 'Capsoni D']","['Carvedilol/chemistry', 'Solubility', 'Clay', 'Spectroscopy, Fourier Transform Infrared', '*Nanotubes/chemistry']",https://pubmed.ncbi.nlm.nih.gov/37110635/
385,Carvedilol,15342304,Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation.,"['Kanoupakis EM', 'Manios EG', 'Mavrakis HE', 'Tzerakis PG', 'Mouloudi HK', 'Vardas PE']","['Aged', 'Amiodarone/*therapeutic use', 'Anti-Arrhythmia Agents/*therapeutic use', 'Atrial Fibrillation/*drug therapy/prevention & control', 'Carbazoles/*therapeutic use', 'Carvedilol', 'Electric Countershock/methods', 'Female', 'Humans', 'Male', 'Middle Aged', 'Propanolamines/*therapeutic use', 'Prospective Studies', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/15342304/
386,Carvedilol,36854819,Effect of Roux-En-Y Gastric Bypass in the Pharmacokinetics of (R)-Carvedilol and (S)-Carvedilol.,"['Yamamoto PA', 'Cristofoletti R', 'Vozmediano V', 'de Gaitani CM', 'da Silva RM', 'Kemp R', 'Sankarankutty AK', 'Salgado Junior W', 'Santos JSD', 'de Moraes NV']","['Humans', '*Gastric Bypass/methods', '*Obesity, Morbid/surgery', 'Carvedilol', 'Obesity/surgery', 'Comorbidity']",https://pubmed.ncbi.nlm.nih.gov/36854819/
387,Carvedilol,30927739,"Magnetic solid phase extraction with carbon-coated Fe(3)O(4) nanoparticles coupled to HPLC-UV for the simultaneous determination of losartan, carvedilol, and amlodipine besylate in plasma samples.","['Heidari H', 'Limouei-Khosrowshahi B']","['Amlodipine/*blood', 'Carvedilol/*blood', 'Chromatography, High Pressure Liquid/*methods', 'Humans', 'Limit of Detection', 'Linear Models', 'Losartan/*blood', 'Magnetite Nanoparticles/*chemistry', 'Reproducibility of Results', 'Solid Phase Extraction/*methods']",https://pubmed.ncbi.nlm.nih.gov/30927739/
388,Carvedilol,32655020,"Effects of Carvedilol on Cardiovascular Events and Mortality in Hemodialysis Patients, A Systematic Review and Meta-Analysis.","['Tan Z', 'Ke G', 'Huang J', 'Yang D', 'Pi M', 'Li L', 'Liu X', 'Tao S', 'Chen L', 'Liang G', 'Liu S']","['*Cardiovascular Diseases', 'Carvedilol/*therapeutic use', 'Humans', 'Observational Studies as Topic', '*Renal Dialysis', 'Stroke Volume', 'Ventricular Function, Left']",https://pubmed.ncbi.nlm.nih.gov/32655020/
389,Carvedilol,37762145,"Differential Effects of the Betablockers Carvedilol, Metoprolol and Bisoprolol on Cardiac K(v)4.3 (I(to)) Channel Isoforms.","['Rahm AK', 'Hackbarth J', 'Muller ME', 'Pfeiffer J', 'Gampp H', 'Petersenn F', 'Rivinius R', 'Frey N', 'Lugenbiel P', 'Thomas D']","['Humans', '*Metoprolol/pharmacology', 'Bisoprolol/pharmacology', 'Carvedilol/pharmacology', 'Heart', '*Heart Failure/drug therapy', 'Protein Isoforms']",https://pubmed.ncbi.nlm.nih.gov/37762145/
390,Carvedilol,32991355,Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites.,"['Kalambokis GN', 'Christaki M', 'Tsiakas I', 'Despotis G', 'Fillipas-Ntekouan S', 'Fotopoulos A', 'Tsiouris S', 'Xourgia X', 'Lakkas L', 'Pappas K', 'Michalis LK', 'Sergianiti F', 'Baltayiannis G', 'Christodoulou D', 'Koustousi C', 'Aggelis N', 'Milionis H']","['*Ascites/drug therapy', 'Carvedilol', 'Humans', 'Kidney/physiology', 'Liver Cirrhosis/complications/drug therapy', 'Perfusion', '*Propranolol']",https://pubmed.ncbi.nlm.nih.gov/32991355/
391,Carvedilol,35661713,Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.,"['Villanueva C', 'Torres F', 'Sarin SK', 'Shah HA', 'Tripathi D', 'Brujats A', 'Rodrigues SG', 'Bhardwaj A', 'Azam Z', 'Hayes PC', 'Jindal A', 'Abid S', 'Alvarado E', 'Bosch J']","['Adrenergic beta-Antagonists/therapeutic use', 'Ascites/complications', 'Carvedilol/therapeutic use', '*Esophageal and Gastric Varices/complications/prevention & control', 'Humans', '*Hypertension, Portal/complications/drug therapy', 'Liver Cirrhosis/complications/drug therapy', 'Portal Pressure', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/35661713/
392,Carvedilol,37989396,"Which should you choose for post operative atrial fibrillation, carvedilol or metoprolol? A systemic review and meta-analysis.","['Abouzid MR', 'Vyas A', 'Eldahtoury S', 'Anwar J', 'Naccour S', 'Elshafei S', 'Memon A', 'Subramaniam V', 'Bennett W', 'Morin DP', 'Lavie CJ', 'Nwaukwa C']","['Humans', 'Metoprolol/therapeutic use', 'Carvedilol/therapeutic use', '*Atrial Fibrillation/epidemiology/etiology/prevention & control', 'Bradycardia/complications/drug therapy', '*Propanolamines/therapeutic use', 'Carbazoles/therapeutic use', 'Adrenergic beta-Antagonists/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37989396/
393,Carvedilol,18996664,Reaction between drug substances and pharmaceutical excipients: formation of citric acid esters and amides of carvedilol in the solid state.,"['Larsen J', 'Cornett C', 'Jaroszewski JW', 'Hansen SH']","['Amides/*chemistry', 'Carbazoles/*chemistry', 'Carvedilol', 'Chemical Phenomena', 'Chromatography, High Pressure Liquid/methods', 'Chromatography, Liquid/methods', 'Citric Acid/*chemistry', 'Esters/*chemistry', 'Excipients/*chemistry', 'Kinetics', 'Magnetic Resonance Spectroscopy', 'Mass Spectrometry/methods', 'Molecular Structure', 'Propanolamines/*chemistry', 'Temperature', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/18996664/
394,Carvedilol,39407632,Characterization and Crystal Structural Analysis of Novel Carvedilol Adipate and Succinate Ethanol-Solvated Salts.,"['Ye L', 'Furuishi T', 'Yamashita T', 'Yonemochi E']","['*Carvedilol/chemistry', '*Adipates/chemistry', '*Ethanol/chemistry', '*Solubility', 'Spectroscopy, Fourier Transform Infrared', 'Crystallography, X-Ray', 'X-Ray Diffraction', 'Calorimetry, Differential Scanning', 'Succinic Acid/chemistry', 'Salts/chemistry', 'Thermogravimetry', 'Molecular Structure', 'Crystallization', 'Propanolamines/chemistry']",https://pubmed.ncbi.nlm.nih.gov/39407632/
395,Carvedilol,12972122,Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation.,"['Merritt JC', 'Niebauer M', 'Tarakji K', 'Hammer D', 'Mills RM']","['Adult', 'Aged', 'Anti-Arrhythmia Agents/*therapeutic use', 'Atenolol/*therapeutic use', 'Atrial Fibrillation/*etiology/*prevention & control', 'Carbazoles/*therapeutic use', 'Carvedilol', 'Coronary Artery Bypass/*adverse effects', 'Coronary Artery Disease/*surgery', 'Female', 'Heart Valve Diseases/*surgery', 'Heart Valve Prosthesis Implantation/*adverse effects', 'Humans', 'Male', 'Metoprolol/*therapeutic use', 'Middle Aged', 'Outcome Assessment, Health Care', '*Postoperative Complications', 'Propanolamines/*therapeutic use', 'Retrospective Studies', 'Vasodilator Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12972122/
396,Zaleplon,32323442,"Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death.","['Harbourt K', 'Nevo ON', 'Zhang R', 'Chan V', 'Croteau D']","['Acetamides/*adverse effects', 'Adult', 'Adverse Drug Reaction Reporting Systems', 'Aged', 'Drug Labeling', 'Eszopiclone/*adverse effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Parasomnias/*chemically induced/mortality/physiopathology', 'Pyrimidines/*adverse effects', 'Retrospective Studies', 'Risk Assessment', 'Risk Factors', 'Sleep/*drug effects', 'Sleep Aids, Pharmaceutical/*adverse effects', 'Sleep Initiation and Maintenance Disorders/diagnosis/*drug therapy/physiopathology', 'Somnambulism/chemically induced/mortality/physiopathology', 'Time Factors', 'Treatment Outcome', 'Wounds and Injuries/*chemically induced/mortality/physiopathology', 'Zolpidem/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32323442/
397,Zaleplon,15005637,"Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.",['Drover DR'],"['Acetamides/chemistry/pharmacokinetics/*pharmacology', 'Aged', 'Azabicyclo Compounds', 'Humans', 'Hypnotics and Sedatives/chemistry/pharmacokinetics/*pharmacology', 'Liver Failure/metabolism', 'Piperazines/chemistry/pharmacokinetics/*pharmacology', 'Pyridines/chemistry/pharmacokinetics/*pharmacology', 'Pyrimidines/chemistry/pharmacokinetics/*pharmacology', 'Renal Insufficiency/metabolism', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/15005637/
398,Zaleplon,24931450,"The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis.","['Stranks EK', 'Crowe SF']","['Acetamides/*adverse effects', 'Attention/*drug effects', 'Azabicyclo Compounds/*adverse effects', 'Eszopiclone', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Memory/*drug effects', 'Piperazines/*adverse effects', 'Psychomotor Performance/*drug effects', 'Pyridines/*adverse effects', 'Pyrimidines/*adverse effects', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/24931450/
399,Zaleplon,19968019,"Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem.","['Joya FL', 'Kripke DF', 'Loving RT', 'Dawson A', 'Kline LE']","['Acetamides/adverse effects', 'Azabicyclo Compounds/adverse effects', 'Eszopiclone', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Indenes/adverse effects', 'Infections/*chemically induced', 'Piperazines/adverse effects', 'Pyridines/adverse effects', 'Pyrimidines/adverse effects', 'Randomized Controlled Trials as Topic', 'Risk', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/19968019/
400,Zaleplon,26016724,"A facile environment-friendly one-pot two-step regioselective synthetic strategy for 3,7-diarylpyrazolo[1,5-a]pyrimidines related to zaleplon and 3,6-diarylpyrazolo[1,5-a]pyrimidine-7-amines assisted by KHSO(4) in aqueous media.","['Devi AS', 'Kaping S', 'Vishwakarma JN']","['Acetamides/chemistry', 'Amines/chemistry', 'Hydrazines/chemistry', 'Molecular Conformation', 'Molecular Structure', 'Pyrazoles/*chemical synthesis', 'Pyrimidines/*chemical synthesis/chemistry']",https://pubmed.ncbi.nlm.nih.gov/26016724/
401,Zaleplon,10445371,Zaleplon and triazolam in humans: acute behavioral effects and abuse potential.,"['Rush CR', 'Frey JM', 'Griffiths RR']","['Acetamides/*pharmacokinetics', 'Adolescent', 'Adult', 'Behavior/*drug effects', 'Behavior, Addictive/psychology', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*pharmacokinetics', 'Illicit Drugs/*pharmacokinetics', 'Male', 'Observer Variation', 'Pyrimidines/*pharmacokinetics', 'Triazolam/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/10445371/
402,Zaleplon,17557470,"Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening.","['Zammit GK', 'Corser B', 'Doghramji K', 'Fry JM', 'James S', 'Krystal A', 'Mangano RM']","['Acetamides/*therapeutic use', 'Adolescent', 'Adult', 'Aged', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Male', 'Middle Aged', 'Polysomnography', 'Pyridines/*therapeutic use', 'Pyrimidines/*therapeutic use', 'Sleep Disorders, Circadian Rhythm/*diagnosis/*drug therapy', 'Treatment Outcome', '*Wakefulness', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/17557470/
403,Zaleplon,10831020,"Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.","['Troy SM', 'Lucki I', 'Unruh MA', 'Cevallos WH', 'Leister CA', 'Martin PT', 'Furlan PM', 'Mangano R']","['Acetamides/adverse effects/*pharmacology', 'Adolescent', 'Adult', 'Affect/drug effects', 'Association Learning/drug effects', 'Attention/drug effects', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/adverse effects/*pharmacology', 'Learning/*drug effects', 'Male', 'Memory/*drug effects', 'Mental Recall/drug effects', 'Middle Aged', 'Psychomotor Performance/*drug effects', 'Pyridines/adverse effects/*pharmacology', 'Pyrimidines/adverse effects/*pharmacology', 'Sex Characteristics', 'Surveys and Questionnaires', 'Triazolam/adverse effects/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/10831020/
404,Zaleplon,17076453,Usefulness of temazepam and zaleplon to induce afternoon sleep.,"['Simons R', 'Koerhuis CL', 'Valk PJ', 'Van den Oord MH']","['Acetamides/*pharmacology', 'Adult', 'Attention', 'Benzodiazepines/*pharmacology', 'Cognition', 'Double-Blind Method', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', 'Military Personnel/*psychology', 'Pyrimidines/*pharmacology', 'Safety', 'Sleep/*drug effects', 'Sleep Deprivation/*drug therapy', 'Temazepam/*pharmacology', 'Time Factors', 'Treatment Outcome', 'Wakefulness/drug effects']",https://pubmed.ncbi.nlm.nih.gov/17076453/
405,Zaleplon,9834048,"Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.","['Greenblatt DJ', 'Harmatz JS', 'von Moltke LL', 'Ehrenberg BL', 'Harrel L', 'Corbett K', 'Counihan M', 'Graf JA', 'Darwish M', 'Mertzanis P', 'Martin PT', 'Cevallos WH', 'Shader RI']","['Acetamides/administration & dosage/blood/pharmacokinetics/*pharmacology', 'Adult', 'Anti-Anxiety Agents/agonists', 'Benzodiazepines', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Electroencephalography/drug effects', 'GABA-A Receptor Agonists', 'Humans', 'Hypnotics and Sedatives/administration & dosage/blood/pharmacokinetics/*pharmacology', 'Male', 'Memory/drug effects', 'Pyridines/administration & dosage/blood/pharmacokinetics/*pharmacology', 'Pyrimidines/administration & dosage/blood/pharmacokinetics/*pharmacology', 'Reference Values', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/9834048/
406,Zaleplon,11192136,"Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem.","['Drover D', 'Lemmens H', 'Naidu S', 'Cevallos W', 'Darwish M', 'Stanski D']","['Acetamides/*pharmacokinetics/*pharmacology', 'Adult', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*pharmacokinetics/*pharmacology', 'Male', 'Mental Recall/drug effects', 'Pyridines/*pharmacokinetics/*pharmacology', 'Pyrimidines/*pharmacokinetics/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/11192136/
407,Zaleplon,22898722,Comparative analysis of zaleplon complexation with cyclodextrins and hydrophilic polymers in solution and in solid state.,"['Jablan J', 'Szalontai G', 'Jug M']","['Acetamides/*analysis/chemistry', 'Calorimetry, Differential Scanning/methods', 'Cellulose/chemistry', 'Chemistry, Pharmaceutical/methods', 'Excipients/analysis/chemistry', 'Hydrophobic and Hydrophilic Interactions', 'Hypromellose Derivatives', 'Magnetic Resonance Spectroscopy/methods', 'Methylcellulose/*analogs & derivatives/analysis/chemistry', 'Microscopy, Electron, Scanning/methods', 'Pharmaceutical Solutions/chemistry', 'Povidone/*analysis/chemistry', 'Pyrimidines/*analysis/chemistry', 'Solubility', 'Tablets/chemistry', 'Water/chemistry', 'X-Ray Diffraction/methods', 'beta-Cyclodextrins/*analysis/chemistry']",https://pubmed.ncbi.nlm.nih.gov/22898722/
408,Zaleplon,32393528,"In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate.","['Tan WK', 'Tan ARY', 'Sivanandam P', 'Goh EJH', 'Yap ZP', 'Saburulla NF', 'Austin-Muttitt K', 'Mullins JGL', 'Lau AJ']","['Acetamides/*metabolism', 'Aldehyde Oxidase/*antagonists & inhibitors/chemistry/metabolism', 'Dose-Response Relationship, Drug', 'Enzyme Inhibitors/metabolism/pharmacology', 'Erlotinib Hydrochloride/metabolism/*pharmacology', 'Gefitinib/metabolism/*pharmacology', 'Humans', 'Liver/*drug effects/metabolism', 'Methotrexate/*metabolism', '*Molecular Docking Simulation', 'Protein Conformation', 'Pyrimidines/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/32393528/
409,Zaleplon,21259378,"Long-term use of zopiclone, zolpidem and zaleplon among Danish elderly and the association with sociodemographic factors and use of other drugs.","['Andersen AB', 'Frydenberg M']","['Acetamides/administration & dosage/*therapeutic use', 'Age Factors', 'Aged', 'Aged, 80 and over', 'Azabicyclo Compounds/administration & dosage/*therapeutic use', 'Denmark', 'Female', 'Follow-Up Studies', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*therapeutic use', 'Logistic Models', 'Male', 'Piperazines/administration & dosage/*therapeutic use', 'Pyridines/administration & dosage/*therapeutic use', 'Pyrimidines/administration & dosage/*therapeutic use', 'Registries', 'Sex Factors', 'Socioeconomic Factors', 'Time Factors', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/21259378/
410,Zaleplon,15034230,"Effects of zolpidem and zaleplon on sleep, respiratory patterns and performance at a simulated altitude of 4,000 m.","['Beaumont M', 'Batejat D', 'Coste O', 'Van Beers P', 'Colas A', 'Clere JM', 'Pierard C']","['Acetamides/*pharmacology/therapeutic use', 'Adult', 'Altitude Sickness/prevention & control', 'Atmosphere Exposure Chambers', 'Attention/drug effects', 'Cognition/drug effects', 'Cross-Over Studies', 'Double-Blind Method', 'Electroencephalography/methods', 'Humans', 'Hypnotics and Sedatives/*pharmacology/therapeutic use', 'Male', 'Neuropsychological Tests', 'Physical Fitness', 'Polysomnography/methods', 'Psychomotor Performance/drug effects', 'Pyridines/*pharmacology/therapeutic use', 'Pyrimidines/*pharmacology/therapeutic use', 'Respiration/*drug effects', 'Sleep/*drug effects', 'Sleep Apnea Syndromes/etiology/*physiopathology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/15034230/
411,Bimatoprost,37615697,MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.,"['Stalmans I', 'Lim KS', 'Oddone F', 'Fichtl M', 'Belda JI', 'Hommer A', 'Laganovska G', 'Schweitzer C', 'Voykov B', 'Zarnowski T', 'Hollo G']","['Humans', '*Glaucoma, Open-Angle/diagnosis/drug therapy', 'Timolol/adverse effects', 'Bimatoprost/therapeutic use', 'Latanoprost/adverse effects', 'Prospective Studies', 'Intraocular Pressure', 'Antihypertensive Agents/adverse effects', 'Tonometry, Ocular', '*Ocular Hypertension/diagnosis/drug therapy', 'Ophthalmic Solutions', 'Treatment Outcome', 'Double-Blind Method', '*Benzoates', 'beta-Alanine/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/37615697/
412,Bimatoprost,18076345,Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension.,"['Martinez A', 'Sanchez M']","['Amides/adverse effects/pharmacokinetics/*therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Bimatoprost', 'Blood Pressure/drug effects', 'Cloprostenol/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Drug Combinations', 'Glaucoma/*drug therapy/metabolism/physiopathology', 'Humans', 'Lipids/adverse effects/pharmacokinetics/*therapeutic use', 'Ocular Hypertension/*drug therapy/metabolism/physiopathology', 'Timolol/adverse effects/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18076345/
413,Bimatoprost,38499140,"A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study.","['Fechtner R', 'Mansberger S', 'Branch J', 'Mulaney J', 'Ziebell S', 'Lopez K', 'Hubatsch D']","['Humans', '*Glaucoma, Open-Angle/drug therapy/physiopathology', '*Latanoprost/therapeutic use', '*Intraocular Pressure/drug effects/physiology', '*Ocular Hypertension/drug therapy/physiopathology', 'Double-Blind Method', '*Bimatoprost/therapeutic use', 'Male', 'Prospective Studies', 'Female', '*Antihypertensive Agents/therapeutic use/administration & dosage', 'Middle Aged', 'Aged', '*Ophthalmic Solutions', '*Tonometry, Ocular', '*Prostaglandins F, Synthetic/therapeutic use', 'Nitric Oxide Donors/therapeutic use/administration & dosage', 'Treatment Outcome', 'Amides/therapeutic use/adverse effects', 'Adult', 'Cloprostenol/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38499140/
414,Bimatoprost,38146971,Comparison of safety and efficacy of Netarsudil 0.02% and Bimatoprost 0.01% monotherapy and combination therapy in primary open-angle glaucoma and ocular hypertension.,"['Shahid S', 'Rizvi SWA', 'Khan AA', 'Ashraf H', 'Akhter A']","['Humans', 'Infant', 'Bimatoprost/therapeutic use', '*Glaucoma, Open-Angle/drug therapy', 'Prospective Studies', 'Intraocular Pressure', 'Antihypertensive Agents/therapeutic use', '*Ocular Hypertension/drug therapy', '*Glaucoma/drug therapy', 'Treatment Outcome', 'Ophthalmic Solutions', '*Benzoates', 'beta-Alanine/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/38146971/
415,Bimatoprost,34724172,"Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).","['Bacharach J', 'Tatham A', 'Ferguson G', 'Belalcazar S', 'Thieme H', 'Goodkin ML', 'Chen MY', 'Guo Q', 'Liu J', 'Robinson MR', 'Bejanian M', 'Wirta DL']","['Adult', 'Aged', 'Aged, 80 and over', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Bimatoprost/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Implants/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Glaucoma, Open-Angle/*drug therapy', 'Humans', 'Intraocular Pressure/drug effects', 'Male', 'Middle Aged', 'Ocular Hypertension/*drug therapy', 'Ophthalmic Solutions', 'Timolol/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34724172/
416,Bimatoprost,30917168,Decreased orbital fat and enophthalmos due to bimatoprost: Quantitative analysis using magnetic resonance imaging.,"['Higashiyama T', 'Minamikawa T', 'Kakinoki M', 'Sawada O', 'Ohji M']","['Adipose Tissue/*diagnostic imaging', 'Adult', 'Aged', 'Aged, 80 and over', 'Bimatoprost/administration & dosage/*adverse effects', 'Cross-Sectional Studies', '*Enophthalmos/chemically induced/diagnostic imaging', 'Female', '*Glaucoma/diagnostic imaging/drug therapy', 'Humans', '*Magnetic Resonance Imaging', 'Male', 'Middle Aged', 'Orbit/*diagnostic imaging']",https://pubmed.ncbi.nlm.nih.gov/30917168/
417,Bimatoprost,37517060,Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial.,"['Zaky MS', 'Hashem OA', 'Mahfouz SM', 'Elsaie ML']","['Humans', 'Male', 'Female', 'Bimatoprost/adverse effects', '*Minoxidil/adverse effects', 'Eyebrows', '*Hypotrichosis/drug therapy', 'Administration, Topical', 'Treatment Outcome', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37517060/
418,Bimatoprost,37219580,"Screening, characterization, and determination of suspected additives bimatoprost and latanoprost in cosmetics using NMR and LC-MS methods.","['Lu Y', 'He Y', 'Wang X', 'Wang H', 'Qiu Q', 'Wu B', 'Wu X']","['Chromatography, Liquid/methods', '*Tandem Mass Spectrometry/methods', 'Latanoprost', 'Bimatoprost', 'Reproducibility of Results', 'Chromatography, High Pressure Liquid/methods', 'Magnetic Resonance Spectroscopy', '*Cosmetics']",https://pubmed.ncbi.nlm.nih.gov/37219580/
419,Bimatoprost,26956170,"Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases.","['Yamada H', 'Yoneda M', 'Gosho M', 'Kato T', 'Zako M']","['Antihypertensive Agents/*pharmacology', 'Bimatoprost/pharmacology', 'Cell Line', 'Ciliary Body/*drug effects/metabolism', 'Dose-Response Relationship, Drug', 'Epithelial Cells/drug effects/metabolism', 'Gene Expression Regulation, Enzymologic/*physiology', 'Humans', 'Latanoprost', 'Matrix Metalloproteinases/*genetics', 'Prostaglandins F/pharmacology', 'Prostaglandins F, Synthetic/pharmacology', 'RNA, Messenger/genetics', 'Real-Time Polymerase Chain Reaction', 'Tissue Inhibitor of Metalloproteinases/*genetics']",https://pubmed.ncbi.nlm.nih.gov/26956170/
420,Bimatoprost,34610257,Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost.,"['Wu JH', 'Wang TH', 'Huang JY', 'Su CC']","['Adult', 'Aged', 'Benzalkonium Compounds/adverse effects/*therapeutic use', 'Bimatoprost/adverse effects/*therapeutic use', 'Comorbidity', 'Conjunctivitis/chemically induced', 'Female', 'Glaucoma/*drug therapy', 'Humans', 'Intraocular Pressure/drug effects', 'Latanoprost/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Ophthalmic Solutions/adverse effects/*therapeutic use', 'Preservatives, Pharmaceutical/adverse effects/*therapeutic use', 'Prospective Studies', 'Tears/drug effects']",https://pubmed.ncbi.nlm.nih.gov/34610257/
421,Bimatoprost,21790301,Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma.,"['Sato S', 'Hirooka K', 'Baba T', 'Mizote M', 'Fujimura T', 'Tenkumo K', 'Ueda H', 'Shiraga F']","['Administration, Ophthalmic', 'Aged', 'Aged, 80 and over', 'Amides/administration & dosage/adverse effects/*therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Bimatoprost', 'Cloprostenol/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Epithelium, Corneal/drug effects/pathology', 'Female', 'Follow-Up Studies', 'Humans', 'Hyperemia/chemically induced', 'Intraocular Pressure/drug effects', 'Japan', 'Latanoprost', 'Low Tension Glaucoma/*drug therapy', 'Male', 'Middle Aged', 'Prospective Studies', 'Prostaglandins F, Synthetic/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21790301/
422,Bimatoprost,36430590,"Cytotoxicity, Mitochondrial Functionality, and Redox Status of Human Conjunctival Cells after Short and Chronic Exposure to Preservative-Free Bimatoprost 0.03% and 0.01%: An In Vitro Comparative Study.","['Petricca S', 'Celenza G', 'Costagliola C', 'Tranfa F', 'Iorio R']","['Humans', 'Bimatoprost/pharmacology', '*Preservatives, Pharmaceutical/pharmacology', '*Conjunctiva', 'Oxidation-Reduction']",https://pubmed.ncbi.nlm.nih.gov/36430590/
423,Bimatoprost,17057169,Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.,['Noecker R'],"['Amides/*therapeutic use', 'Bimatoprost', 'Cloprostenol/*analogs & derivatives/therapeutic use', 'Glaucoma/*drug therapy', 'Humans', 'Intraocular Pressure/*drug effects', 'Lipids/*therapeutic use', 'Ocular Hypertension/drug therapy', 'Patient Selection', 'Travoprost', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17057169/
424,Bimatoprost,21214361,Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension.,"['Katsanos A', 'Dastiridou AI', 'Fanariotis M', 'Kotoula M', 'Tsironi EE']","['Aged', 'Amides/*administration & dosage/adverse effects', 'Antihypertensive Agents/*administration & dosage/adverse effects', 'Bimatoprost', 'Circadian Rhythm', 'Cloprostenol/administration & dosage/adverse effects/*analogs & derivatives', 'Drug Combinations', 'Exfoliation Syndrome/*drug therapy/physiopathology', 'Female', 'Glaucoma, Open-Angle/*drug therapy/physiopathology', 'Humans', 'Intraocular Pressure/drug effects', 'Male', 'Middle Aged', 'Ocular Hypertension/*drug therapy/physiopathology', 'Ophthalmic Solutions', 'Single-Blind Method', 'Timolol/*administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21214361/
425,Bimatoprost,36054045,"Enhanced Uptake and Retention of 0.03% Bimatoprost, 0.5% 5-Fluorouracil, and 5% Minoxidil After 1,550-nm or 1,927-nm Nonablative Laser Pretreatment.","['Wang JV', 'Friedman PM', 'Agron S', 'Konda A', 'Parker C', 'Geronemus RG']","['Bimatoprost', 'Erbium', 'Fluorouracil', 'Humans', '*Laser Therapy/methods', '*Lasers, Solid-State/therapeutic use', 'Minoxidil', 'Thulium']",https://pubmed.ncbi.nlm.nih.gov/36054045/
426,Salmeterol,37549393,Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.,"['Feldman WB', 'Kesselheim AS', 'Avorn J', 'Russo M', 'Wang SV']","['Adult', 'Humans', 'Fluticasone-Salmeterol Drug Combination/adverse effects', 'Bronchodilator Agents/adverse effects', 'Cohort Studies', '*Pulmonary Disease, Chronic Obstructive/drug therapy/diagnosis', 'Salmeterol Xinafoate/therapeutic use', 'Fluticasone/therapeutic use', '*Asthma/drug therapy', 'Administration, Inhalation', '*Pneumonia/drug therapy', 'Drug Combinations', 'Androstadienes/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37549393/
427,Salmeterol,12926383,"Potassium trimethylsilanolate induced cleavage of 1,3-oxazolidin-2- and 5-ones, and application to the synthesis of (R)-salmeterol.","['Coe DM', 'Perciaccante R', 'Procopiou PA']","['Adrenergic beta-Agonists/*chemical synthesis', 'Albuterol/*analogs & derivatives/*chemical synthesis', 'Molecular Structure', 'Oxazolidinones/*chemistry', 'Salmeterol Xinafoate', 'Stereoisomerism', 'Trimethylsilyl Compounds/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/12926383/
428,Salmeterol,37620110,Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol.,"['Pitrez PM', 'Nanthapisal S', 'Castro APBM', 'Teli C', 'P G A']","['Adult', 'Humans', 'Child', 'Fluticasone-Salmeterol Drug Combination', '*Asthma/drug therapy', 'Databases, Factual', 'Emergency Service, Hospital', 'Hospitalization']",https://pubmed.ncbi.nlm.nih.gov/37620110/
429,Salmeterol,34784306,Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis.,"['Zhou XJ', 'Qin Z', 'Lu J', 'Hong JG']","['Acetates', 'Administration, Inhalation', 'Adolescent', 'Adrenal Cortex Hormones/therapeutic use', 'Albuterol/therapeutic use', '*Anti-Asthmatic Agents/therapeutic use', '*Asthma/drug therapy', 'Child', 'Cyclopropanes', 'Drug Therapy, Combination', 'Fluticasone/therapeutic use', 'Humans', 'Quinolines', 'Salmeterol Xinafoate/therapeutic use', 'Sulfides']",https://pubmed.ncbi.nlm.nih.gov/34784306/
430,Salmeterol,33353582,"A generic fluticasone propionate and salmeterol dry powder inhaler: Evidence of usability, function, and robustness.","['Tashkin DP', 'Koltun A', 'Wallace R']","['Asthma/*drug therapy', 'Bronchodilator Agents/*therapeutic use', 'Drug-Related Side Effects and Adverse Reactions', 'Drugs, Generic/*therapeutic use', 'Dry Powder Inhalers/*instrumentation/methods', 'Fluticasone-Salmeterol Drug Combination/*therapeutic use', 'Humans', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33353582/
431,Salmeterol,38671158,Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability.,"['Li S', 'Feng K', 'Lee J', 'Gong Y', 'Wu F', 'Newman B', 'Yoon M', 'Fang L', 'Zhao L', 'Gobburu JVS']","['Humans', 'Administration, Inhalation', '*Cross-Over Studies', 'Male', 'Adult', '*Fluticasone-Salmeterol Drug Combination/pharmacokinetics/administration & dosage', '*Models, Biological', '*Therapeutic Equivalency', 'Young Adult', '*Dry Powder Inhalers', '*Bronchodilator Agents/pharmacokinetics/administration & dosage/blood', 'Female', 'Middle Aged', 'Fluticasone/pharmacokinetics/administration & dosage', 'Salmeterol Xinafoate/pharmacokinetics/administration & dosage', 'Healthy Volunteers']",https://pubmed.ncbi.nlm.nih.gov/38671158/
432,Salmeterol,27196484,Chinese Herbal Medicine and Salmeterol and Fluticasone Propionate for Chronic Obstructive Pulmonary Disease: Systematic Review and Network Meta-Analysis.,"['Chung VCH', 'Wu X', 'Ma PHX', 'Ho RST', 'Poon SK', 'Hui DS', 'Wong SYS', 'Wu JCY']","['Bronchodilator Agents/therapeutic use', 'Drug Therapy, Combination', 'Drugs, Chinese Herbal/*therapeutic use', 'Fluticasone/therapeutic use', 'Forced Expiratory Volume', 'Humans', 'Network Meta-Analysis', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology', 'Salmeterol Xinafoate/therapeutic use', 'Walk Test']",https://pubmed.ncbi.nlm.nih.gov/27196484/
433,Salmeterol,37054881,Safety and Effectiveness of As-Needed Formoterol in Asthma Patients Taking Inhaled Corticosteroid (ICS)-Formoterol or ICS-Salmeterol Maintenance Therapy.,"['Reddel HK', 'Brusselle G', 'Lamarca R', 'Gustafson P', 'Anderson GP', 'Jorup C']","['Humans', 'Formoterol Fumarate/therapeutic use', 'Salmeterol Xinafoate/therapeutic use', '*Bronchodilator Agents/therapeutic use', 'Budesonide/therapeutic use', 'Ethanolamines/adverse effects', 'Drug Combinations', '*Asthma/drug therapy/chemically induced', 'Albuterol/therapeutic use', 'Adrenal Cortex Hormones/therapeutic use', 'Administration, Inhalation']",https://pubmed.ncbi.nlm.nih.gov/37054881/
434,Salmeterol,33720401,"Determination of salmeterol, alpha-hydroxysalmeterol and fluticasone propionate in human urine and plasma for doping control using UHPLC-QTOF-MS.","['Sakellariou P', 'Petrou M', 'Lyris E', 'Tsivou M', 'Fragkaki A', 'Kiousi P', 'Angelis YS', 'Pistos C']","['Albuterol/*analogs & derivatives/blood', 'Chromatography, High Pressure Liquid/*methods', '*Doping in Sports', '*Fluticasone/blood/urine', 'Humans', 'Linear Models', 'Reproducibility of Results', '*Salmeterol Xinafoate/blood/urine', 'Sensitivity and Specificity', 'Substance Abuse Detection']",https://pubmed.ncbi.nlm.nih.gov/33720401/
435,Salmeterol,33210444,Pharmacokinetics of salmeterol and its main metabolite alpha-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control.,"['Jessen S', 'Becker V', 'Rzeppa S', 'Backer V', 'Bengtsen KH', 'Hullstein I', 'Dehnes Y', 'Hostrup M']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/administration & dosage/analysis/*pharmacokinetics', 'Adult', 'Albuterol/*analogs & derivatives/analysis/pharmacokinetics', 'Chromatography, High Pressure Liquid', 'Doping in Sports/prevention & control', 'Dry Powder Inhalers', 'Humans', 'Male', 'Salmeterol Xinafoate/administration & dosage/analysis/*pharmacokinetics', 'Substance Abuse Detection/*methods', 'Tandem Mass Spectrometry', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33210444/
436,Salmeterol,22192967,Effects of intranasal salmeterol and fluticasone given alone and in combination in persistent allergic rhinitis.,"['Lipworth BJ', 'Short P', 'Burns P', 'Nair A']","['Adenosine Monophosphate/administration & dosage', 'Administration, Intranasal', 'Adrenergic beta-2 Receptor Agonists/*administration & dosage', 'Adult', 'Albuterol/administration & dosage/*analogs & derivatives', 'Androstadienes/*administration & dosage', 'Anti-Allergic Agents/*administration & dosage', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Fluticasone', 'Fluticasone-Salmeterol Drug Combination', 'Glucocorticoids/*administration & dosage', 'Humans', 'Male', 'Rhinitis, Allergic, Perennial/*drug therapy', 'Salmeterol Xinafoate', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22192967/
437,Salmeterol,33852162,Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.,"[""O'Shea O"", 'Stovold E', 'Cates CJ']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Anti-Asthmatic Agents/administration & dosage/*adverse effects', 'Asthma/*drug therapy/mortality', 'Beclomethasone/administration & dosage/adverse effects', 'Bronchodilator Agents/administration & dosage/adverse effects', 'Budesonide/administration & dosage/adverse effects', 'Child', 'Chronic Disease', 'Drug Therapy, Combination/adverse effects', 'Fluticasone/administration & dosage/adverse effects', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Glucocorticoids/administration & dosage/*adverse effects', 'Humans', 'Mometasone Furoate/administration & dosage/adverse effects', 'Randomized Controlled Trials as Topic', 'Salmeterol Xinafoate/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33852162/
438,Salmeterol,37740997,Efficacy and safety of fluticasone propionate/salmeterol and fluticasone propionate monotherapy in step-up treatment of childhood asthma: A systematic review and meta-analysis.,"['Li H', 'Dong T', 'Luan J']","['Adult', 'Child', 'Humans', 'Fluticasone/therapeutic use', 'Fluticasone-Salmeterol Drug Combination/therapeutic use', '*Androstadienes/adverse effects', '*Asthma/drug therapy', 'Albuterol/adverse effects', 'Salmeterol Xinafoate/therapeutic use', 'Treatment Outcome', 'Bronchodilator Agents/adverse effects', 'Administration, Inhalation', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37740997/
439,Salmeterol,20303247,Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms.,"['van Noord JA', 'Aumann JL', 'Janssens E', 'Smeets JJ', 'Zaagsma J', 'Mueller A', 'Cornelissen PJ']","['Adult', 'Airway Obstruction/*drug therapy/physiopathology', 'Albuterol/administration & dosage/*analogs & derivatives', 'Bronchodilator Agents/*administration & dosage', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Dyspnea/*drug therapy/physiopathology', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology', 'Salmeterol Xinafoate', 'Scopolamine Derivatives/*administration & dosage', 'Spirometry', 'Tiotropium Bromide', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20303247/
440,Salmeterol,8096416,Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma.,"['Smyth ET', 'Pavord ID', 'Wong CS', 'Wisniewski AF', 'Williams J', 'Tattersfield AE']","['Adolescent', 'Adrenergic beta-Agonists/*pharmacokinetics/pharmacology', 'Adult', 'Albuterol/*analogs & derivatives/*pharmacokinetics/pharmacology', 'Asthma/*drug therapy', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Interactions', 'Female', 'Forced Expiratory Volume/drug effects', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Potassium/blood', 'Salmeterol Xinafoate', 'Stimulation, Chemical', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/8096416/
441,Salmeterol,17879293,Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment.,"['Westmeier R', 'Steckel H']","['Administration, Inhalation', 'Aerosols', 'Albuterol/administration & dosage/*analogs & derivatives/chemistry', 'Androstadienes/administration & dosage/*chemistry', 'Anti-Asthmatic Agents/administration & dosage/*chemistry', 'Chemical Precipitation', 'Chemistry, Pharmaceutical', '*Drug Carriers', 'Drug Combinations', 'Drug Compounding', 'Excipients/chemistry', 'Fluticasone-Salmeterol Drug Combination', 'Hypromellose Derivatives', 'Methylcellulose/*analogs & derivatives/chemistry', 'Nebulizers and Vaporizers', 'Particle Size', 'Polysorbates/*chemistry', 'Powders', 'Solvents/chemistry', 'Surface Properties', 'Technology, Pharmaceutical/methods']",https://pubmed.ncbi.nlm.nih.gov/17879293/
442,Salmeterol,36715079,Simultaneous Quantitative Analysis of Salmeterol and Fluticasone in Inhalation Spray Using HPLC and a Fast Spectrophotometric Technique Combined with a Time Series Neural Network and Multivariate Calibration Methods.,"['Valizadeh M', 'Ameri Braki Z', 'Smiley E', 'Arghand A', 'Dastafkan P']","['Fluticasone', 'Salmeterol Xinafoate', 'Calibration', 'Chromatography, High Pressure Liquid', 'Time Factors', 'Spectrophotometry/methods', '*Neural Networks, Computer', 'Least-Squares Analysis']",https://pubmed.ncbi.nlm.nih.gov/36715079/
443,Salmeterol,30556939,The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age.,"['Yoshihara S', 'Tsubaki T', 'Ikeda M', 'Lenney W', 'Tomiak R', 'Hattori T', 'Hashimoto K', 'Soutome T', 'Kato S']","['Administration, Inhalation', 'Asthma/*drug therapy', 'Bronchodilator Agents/adverse effects/*therapeutic use', 'Child, Preschool', 'Double-Blind Method', 'Fluticasone-Salmeterol Drug Combination/adverse effects/*therapeutic use', 'Follow-Up Studies', 'Humans', 'Infant', 'Japan', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30556939/
444,Salmeterol,35730239,"The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler(R) in the treatment of asthma in the daily clinical practice.","['Doniec Z', 'Olszanecka-Glinianowicz M', 'Hantulik P', 'Almgren-Rachtan A', 'Chudek J']","['Adult', 'Humans', '*Asthma/drug therapy/chemically induced', 'Fluticasone/adverse effects', 'Salmeterol Xinafoate', 'Patient Satisfaction', 'Fluticasone-Salmeterol Drug Combination/therapeutic use', 'Treatment Outcome', 'Bronchodilator Agents/adverse effects', 'Androstadienes/adverse effects', 'Albuterol']",https://pubmed.ncbi.nlm.nih.gov/35730239/
445,Dioxidophosphinecarboxylate oxide,24898625,"Nanostructured manganese oxide/carbon nanotubes, graphene and graphene oxide as water-oxidizing composites in artificial photosynthesis.","['Najafpour MM', 'Rahimi F', 'Fathollahzadeh M', 'Haghighi B', 'Holynska M', 'Tomo T', 'Allakhverdiev SI']","['Catalysis', 'Graphite/*chemistry', 'Manganese Compounds/*chemistry', 'Microscopy, Electron, Transmission', 'Nanotubes, Carbon/*chemistry', 'Oxidation-Reduction', 'Oxides/*chemistry', 'Photosynthesis', 'Surface Properties', 'Water/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/24898625/
446,Dioxidophosphinecarboxylate oxide,21850343,Nano-size amorphous calcium-manganese oxide as an efficient and biomimetic water oxidizing catalyst for artificial photosynthesis: back to manganese.,"['Najafpour MM', 'Nayeri S', 'Pashaei B']","['Biomimetic Materials/*chemistry', 'Calcium/*chemistry', 'Catalysis', 'Cerium/chemistry', 'Manganese Compounds/*chemistry', 'Nanostructures/chemistry', 'Nitrates/chemistry', 'Oxidants/*chemistry', 'Oxidation-Reduction', 'Oxides/*chemistry', '*Photosynthesis', 'Water/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/21850343/
447,Dioxidophosphinecarboxylate oxide,14511116,Nitric oxide and Fenton/Haber-Weiss chemistry: nitric oxide is a potent antioxidant at physiological concentrations.,"['Sharpe MA', 'Robb SJ', 'Clark JB']","['Antioxidants/*chemistry', 'Cobalt/chemistry', 'Fluorescein/chemistry', 'Hydrogen Peroxide/*chemistry', 'Hydroxyl Radical/chemistry', 'Iron/*chemistry', 'Nitric Oxide/*chemistry', 'Oxidants/chemistry', 'Oxidation-Reduction', 'Spectrum Analysis']",https://pubmed.ncbi.nlm.nih.gov/14511116/
448,Dioxidophosphinecarboxylate oxide,32448965,Prooxidant and antimicrobic effects of iron and titanium oxide nanoparticles and thalicarpine.,"['Pavlova EL', 'Toshkovska RD', 'Doncheva TE', 'Ivanova IA']","['Anti-Infective Agents/pharmacology', 'Aporphines/*pharmacology', 'Bacteria/*drug effects', 'Hydrogen Peroxide/chemistry/pharmacology', 'Iron/chemistry', '*Nanoparticles', 'Oxidants/pharmacology', 'Oxidation-Reduction', 'Reactive Oxygen Species', 'Titanium/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32448965/
449,Dioxidophosphinecarboxylate oxide,36463743,Graphdiyne oxide elicits a minor foreign-body response and generates quantum dots due to fast degradation.,"['Wang L', 'Zhang Y', 'Li L', 'Geng X', 'Dou D', 'Yu L', 'Jing H', 'Fan Y']","['*Oxides/toxicity/chemistry', '*Quantum Dots/toxicity', 'Carbon/chemistry', 'Oxidation-Reduction']",https://pubmed.ncbi.nlm.nih.gov/36463743/
450,Dioxidophosphinecarboxylate oxide,26887904,Production of Metal-Free Composites Composed of Graphite Oxide and Oxidized Carbon Nitride Nanodots and Their Enhanced Photocatalytic Performances.,"['Kim SY', 'Oh J', 'Park S', 'Shim Y', 'Park S']","['Catalysis', 'Graphite/*chemistry', 'Nanoparticles/*chemistry', 'Nitrites/*chemistry', 'Oxidants, Photochemical/*chemistry', 'Oxidation-Reduction', 'Oxides/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/26887904/
451,Dioxidophosphinecarboxylate oxide,31967629,Crossover between anti- and pro-oxidant activities of different manganese oxide nanoparticles and their biological implications.,"['Jiang X', 'Gray P', 'Patel M', 'Zheng J', 'Yin JJ']","['Antioxidants/chemistry/*pharmacology', 'Caco-2 Cells', 'Cell Survival/drug effects', 'Electron Spin Resonance Spectroscopy', 'Humans', 'Hydrogen Peroxide/antagonists & inhibitors/pharmacology', 'Manganese Compounds/chemistry/*pharmacology', 'Oxidation-Reduction', 'Oxides/chemistry/*pharmacology', 'Particle Size', 'Surface Properties', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/31967629/
452,Dioxidophosphinecarboxylate oxide,26046320,Developments in Synthetic Application of Selenium(IV) Oxide and Organoselenium Compounds as Oxygen Donors and Oxygen-Transfer Agents.,"['Mlochowski J', 'Wojtowicz-Mlochowska H']","['Anhydrides/chemistry', 'Carboxylic Acids/chemistry', 'Catalysis', 'Epoxy Compounds/chemistry', '*Green Chemistry Technology', 'Hydrogen Peroxide/chemistry', 'Lactones/chemistry', 'Nitrogen Oxides/chemistry', 'Organoselenium Compounds/*chemistry', 'Oxidation-Reduction', 'Oxygen/*chemistry', 'Selenium Oxides/*chemistry', 'Sulfides/chemistry', 'Sulfoxides/chemistry']",https://pubmed.ncbi.nlm.nih.gov/26046320/
453,Dioxidophosphinecarboxylate oxide,21648436,Competitive microbially and Mn oxide mediated redox processes controlling arsenic speciation and partitioning.,"['Ying SC', 'Kocar BD', 'Griffis SD', 'Fendorf S']","['Arsenic/*chemistry/*metabolism', 'Geologic Sediments/*analysis', 'Models, Chemical', 'Oxidation-Reduction', 'Oxides/*chemistry', 'Shewanella/*metabolism', 'Soil/*analysis', 'Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/21648436/
454,Dioxidophosphinecarboxylate oxide,35351451,Development of reduced graphene oxide-supported novel hybrid nanomaterials (Bi(2)WO(6)@rGO and Cu-WO(4)@rGO) for green and efficient oxidative desulfurization of model fuel oil for environmental depollution.,"['Riaz A', 'Saeed M', 'Munir M', 'Intisar A', 'Haider S', 'Tariq S', 'Hussain N', 'Kousar R', 'Bilal M']","['*Fuel Oils', 'Graphite', 'Kinetics', '*Nanocomposites', 'Oxidants', 'Oxidative Stress', 'Spectroscopy, Fourier Transform Infrared']",https://pubmed.ncbi.nlm.nih.gov/35351451/
455,Dioxidophosphinecarboxylate oxide,31648133,Graphene oxide size and structure pro-oxidant and antioxidant activity and photoinduced cytotoxicity relation on three cancer cell lines.,"['Markovic ZM', 'Jovanovic SP', 'Maskovic PZ', 'Mojsin MM', 'Stevanovic MJ', 'Danko M', 'Micusik M', 'Jovanovic DJ', 'Kleinova A', 'Spitalsky Z', 'Pavlovic VB', 'Todorovic Markovic BM']","['Antioxidants/*chemistry', 'Carbon/chemistry', 'Cell Line, Tumor', 'Cell Survival/drug effects', 'Graphite/*chemistry/toxicity', 'Humans', 'Microscopy, Confocal', 'Oxidants/*chemistry', 'Quantum Dots/chemistry/toxicity', 'Singlet Oxygen/chemistry/metabolism']",https://pubmed.ncbi.nlm.nih.gov/31648133/
456,Dioxidophosphinecarboxylate oxide,33485578,Simple paper-based colorimetric and fluorescent glucose sensor using N-doped carbon dots and metal oxide hybrid structures.,"['Ngo YT', 'Nguyen PL', 'Jana J', 'Choi WM', 'Chung JS', 'Hur SH']","['*Carbon', '*Colorimetry', 'Glucose', 'Hydrogen Peroxide', 'Limit of Detection', 'Oxides']",https://pubmed.ncbi.nlm.nih.gov/33485578/
457,Carbachol,15387366,"Cholelithiatic human gallbladders in vitro fail to respond to cholecystokinin but are responsive to carbachol, histamine, or electrical stimulation.","['Deshpande SB', 'Gupta NK', 'Shukla VK']","['Atropine/pharmacology', 'Carbachol/*pharmacology', 'Cholecystokinin/*pharmacology', 'Cholecystolithiasis/*physiopathology', 'Cholinergic Agonists/*pharmacology', 'Electric Stimulation', 'Gallbladder/*drug effects', 'Histamine/*pharmacology', 'Humans', 'In Vitro Techniques', 'Muscle Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/15387366/
458,Carbachol,262106,Airway response to carbachol in normal and asthmatic subjects: distinction between bronchial sensitivity and reactivity.,"['Orehek J', 'Gayrard P', 'Smith AP', 'Grimaud C', 'Charpin J']","['Asthma/diagnosis/*physiopathology', 'Bronchi/*drug effects/physiopathology', 'Bronchial Provocation Tests', 'Carbachol/*pharmacology', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/262106/
459,Carbachol,6832249,Airway response of asthmatics to carbachol and to deep inspiration.,"['Beaupre A', 'Badier M', 'Delpierre S', 'Orehek J', 'Grimaud C']","['Adult', 'Airway Resistance/*drug effects', 'Asthma/*physiopathology', 'Bronchial Provocation Tests', 'Carbachol/*pharmacology', 'Female', 'Forced Expiratory Volume', 'Humans', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/6832249/
460,Metronidazole,3280909,Metronidazole.,['Scully BE'],"['Bacteria, Anaerobic', 'Bacterial Infections/*drug therapy', 'Humans', '*Metronidazole/adverse effects/therapeutic use', 'Protozoan Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3280909/
461,Metronidazole,19633614,Synthesis and antibacterial activities of new metronidazole and imidazole derivatives.,['Atia AJ'],"['Anti-Bacterial Agents/*chemical synthesis/chemistry/*pharmacology', 'Escherichia coli/drug effects', 'Imidazoles/*chemical synthesis/chemistry/*pharmacology', 'Metronidazole/*chemical synthesis/chemistry/*pharmacology', 'Proteus mirabilis/drug effects', 'Staphylococcus aureus/drug effects']",https://pubmed.ncbi.nlm.nih.gov/19633614/
462,Metronidazole,35296432,Metronidazole-resistant Clostridioides difficile: genomic and transcriptomic traits acquired under in-vitro metronidazole induction.,"['Xu T', 'Zhou F', 'Wang L', 'Wu S', 'Huang H']","['Anti-Bacterial Agents/pharmacology/therapeutic use', 'Clostridioides', '*Clostridioides difficile/genetics', '*Clostridium Infections/drug therapy', 'Genomics', 'Humans', 'Metronidazole/pharmacology/therapeutic use', 'Microbial Sensitivity Tests', 'Transcriptome']",https://pubmed.ncbi.nlm.nih.gov/35296432/
463,Metronidazole,39843250,"(15)N SABRE-SHEATH and NMR/DFT Characterization of Amino-Metronidazole, a Metabolic Product of the Antibiotic and Prospective Hypoxia Contrast Agent Metronidazole.","['Senanayake IM', 'Alam MS', 'Kabir MSH', 'Petrilla AF', 'Siraj Z', 'Theis T', 'Chekmenev EY', 'Goodson BM']","['*Metronidazole/chemistry/metabolism', '*Magnetic Resonance Spectroscopy', '*Density Functional Theory', '*Contrast Media/chemistry/metabolism', '*Anti-Bacterial Agents/chemistry/metabolism', 'Nitrogen Isotopes/chemistry']",https://pubmed.ncbi.nlm.nih.gov/39843250/
464,Metronidazole,35446232,"Metronidazole, acyclovir and tetrahydrobiopterin may be promising to treat COVID-19 patients, through interaction with interleukin-12.","['Farasati Far B', 'Bokov D', 'Widjaja G', 'Setia Budi H', 'Kamal Abdelbasset W', 'Javanshir S', 'Seif F', 'Pazoki-Toroudi H', 'Dey SK']","['Humans', '*Metronidazole/pharmacology/therapeutic use/chemistry', 'Interleukin-12', 'Molecular Docking Simulation', '*COVID-19', 'Cytokines']",https://pubmed.ncbi.nlm.nih.gov/35446232/
465,Metronidazole,32059495,"Metronidazole and Secnidazole Carbamates: Synthesis, Antiprotozoal Activity, and Molecular Dynamics Studies.","['Rocha-Garduno G', 'Hernandez-Martinez NA', 'Colin-Lozano B', 'Estrada-Soto S', 'Hernandez-Nunez E', 'Prieto-Martinez FD', 'Medina-Franco JL', 'Chale-Dzul JB', 'Moo-Puc R', 'Navarrete-Vazquez G']","['Antiprotozoal Agents/chemical synthesis/chemistry/*pharmacology', 'Carbamates/chemical synthesis/*chemistry/pharmacology', 'Giardia lamblia/drug effects/pathogenicity', 'Giardiasis/drug therapy/parasitology', 'Metronidazole/*analogs & derivatives/chemical synthesis/*chemistry/pharmacology', 'Trichomonas Infections/drug therapy/parasitology', 'Trichomonas vaginalis/drug effects/pathogenicity']",https://pubmed.ncbi.nlm.nih.gov/32059495/
466,Metronidazole,25924732,Formulation and evaluation of different floating tablets containing metronidazole to target stomach.,"['Loh ZC', 'Elkordy AA']","['Administration, Oral', 'Anti-Infective Agents/administration & dosage/*chemistry/metabolism', 'Calorimetry, Differential Scanning', 'Chemistry, Pharmaceutical', 'Delayed-Action Preparations', 'Drug Carriers', 'Excipients/chemistry', '*Gastric Absorption', 'Gastric Mucosa/*metabolism', 'Humans', 'Kinetics', 'Metronidazole/administration & dosage/*chemistry/metabolism', 'Microscopy, Electron, Scanning', 'Powders', 'Rheology', 'Solubility', 'Spectroscopy, Fourier Transform Infrared', 'Tablets', 'Technology, Pharmaceutical/methods']",https://pubmed.ncbi.nlm.nih.gov/25924732/
467,Metronidazole,35988858,"Effects of metronidazole on mesophilic and thermophilic fermentation: Biodegradation mechanisms, microbial communities, and reversibility.","['Zhao W', 'Zhang X', 'Cai Y', 'Zhao S', 'Wang S']","['Fermentation', 'Glucose', 'Hydrogen', '*Metronidazole/analysis/pharmacology', '*Microbiota']",https://pubmed.ncbi.nlm.nih.gov/35988858/
468,Metronidazole,24341948,Concentrations of metronidazole in human plasma and saliva after tablet or gel administration.,"['de C Bergamaschi C', 'Berto LA', 'Venancio PC', 'Cogo K', 'Franz-Montan M', 'Motta RH', 'Santamaria MP', 'Groppo FC']","['Administration, Oral', 'Adult', 'Area Under Curve', 'Cross-Over Studies', 'Gels/*administration & dosage/pharmacokinetics', 'Humans', 'Male', 'Metronidazole/*administration & dosage/*blood/pharmacokinetics', 'Saliva/*metabolism', 'Tablets/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/24341948/
469,Metronidazole,30022596,Preparation and biological evaluation of metronidazole derivatives with monoterpenes and eugenol.,"['Bkhaitan MM', 'Alarjah M', 'Mirza AZ', 'Abdalla AN', 'El-Said HM', 'Faidah HS']","['Anti-Bacterial Agents/chemical synthesis/*chemistry/pharmacology', 'Cell Line', 'Cell Survival/drug effects', 'Clostridium perfringens/drug effects', 'Eugenol/*chemistry', 'Helicobacter pylori/drug effects', 'Humans', 'Metronidazole/*analogs & derivatives/chemical synthesis/pharmacology', 'Microbial Sensitivity Tests', 'Monoterpenes/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/30022596/
470,Metronidazole,31622182,Case 271: Metronidazole-induced Encephalopathy.,"['Sun Y', 'Overby PJ', 'Mehta H']","['Anti-Bacterial Agents/*adverse effects/therapeutic use', 'Brain/diagnostic imaging', 'Brain Diseases/*chemically induced/diagnostic imaging', 'Child', 'Fusobacterium Infections/drug therapy', 'Humans', 'Magnetic Resonance Imaging/methods', 'Male', 'Meningitis, Bacterial/drug therapy', 'Metronidazole/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31622182/
471,Metronidazole,6854509,Blood and milk concentrations of metronidazole in mothers and infants.,"['Heisterberg L', 'Branebjerg PE']","['*Breast Feeding', 'Endometritis/drug therapy', 'Female', 'Humans', 'Infant, Newborn', 'Metronidazole/*analysis/*blood/therapeutic use', 'Milk, Human/*analysis', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/6854509/
472,Metronidazole,32457109,Chromosomal Resistance to Metronidazole in Clostridioides difficile Can Be Mediated by Epistasis between Iron Homeostasis and Oxidoreductases.,"['Deshpande A', 'Wu X', 'Huo W', 'Palmer KL', 'Hurdle JG']","['Clostridioides', '*Clostridioides difficile/genetics', 'Drug Resistance, Bacterial', 'Epistasis, Genetic', 'Homeostasis', 'Iron/*metabolism', '*Metronidazole/pharmacology', '*Oxidoreductases']",https://pubmed.ncbi.nlm.nih.gov/32457109/
473,Metronidazole,29439963,In Vitro Study of the Susceptibility of Clinical Isolates of Trichomonas vaginalis to Metronidazole and Secnidazole.,"['Ghosh AP', 'Aycock C', 'Schwebke JR']","['Antiprotozoal Agents/*pharmacology', 'Metronidazole/*analogs & derivatives/*pharmacology', 'Nitroimidazoles/pharmacology', 'Trichomonas vaginalis/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/29439963/
474,Metronidazole,7324776,Metronidazole and appendicitis. Can a preoperative prophylaxis be changed to a peroperative treatment in high risk patients?,"['Gottrup F', 'Sakso P']","['Adolescent', 'Adult', 'Appendectomy/*adverse effects', 'Appendicitis/*surgery', 'Child', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Metronidazole/*therapeutic use', 'Middle Aged', 'Surgical Wound Infection/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/7324776/
475,Droperidol,27745766,"Midazolam-Droperidol, Droperidol, or Olanzapine for Acute Agitation: A Randomized Clinical Trial.","['Taylor DM', 'Yap CYL', 'Knott JC', 'Taylor SE', 'Phillips GA', 'Karro J', 'Chan EW', 'Kong DCM', 'Castle DJ']","['Acute Disease', 'Adult', 'Benzodiazepines/*therapeutic use', 'Conscious Sedation/*methods', 'Double-Blind Method', 'Droperidol/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Emergency Service, Hospital', 'Female', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*therapeutic use', 'Injections, Intravenous', 'Male', 'Midazolam/administration & dosage/*therapeutic use', 'Olanzapine', 'Psychomotor Agitation/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27745766/
476,Droperidol,7396141,Droperidol and endotracheal intubation. Attenuation of pressor response to laryngoscopy and intubation.,"['Curran J', 'Crowley M', ""O'Sullivan G""]","['Adult', '*Anesthesia, Intravenous', 'Blood Pressure/*drug effects', '*Droperidol/pharmacology', 'Heart Rate/drug effects', 'Humans', '*Intubation, Intratracheal', '*Laryngoscopy', 'Pulse/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7396141/
477,Droperidol,36925442,Droperidol Use in the Emergency Department: A Clinical Review.,"['Siegel RB', 'Motov SM', 'Marcolini EG']","['Humans', 'Analgesics/therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Anti-Anxiety Agents/therapeutic use', 'Antiemetics/therapeutic use', '*Droperidol/therapeutic use', '*Emergency Service, Hospital', 'Hypnotics and Sedatives/therapeutic use', 'Ondansetron/therapeutic use', 'Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36925442/
478,Droperidol,33046432,Safety and effectiveness of olanzapine and droperidol for chemical restraint for non-consenting adults: a systematic review and meta-analysis.,"['Muir-Cochrane E', 'Grimmer K', 'Gerace A', 'Bastiampillai T', 'Oster C']","['Antipsychotic Agents/adverse effects/standards/therapeutic use', 'Droperidol/adverse effects/*standards/therapeutic use', 'Humans', 'Olanzapine/adverse effects/*standards/therapeutic use', 'Tranquilizing Agents/adverse effects/standards/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33046432/
479,Droperidol,36999520,Comparison of Droperidol and Midazolam Versus Haloperidol and Lorazepam for Acute Agitation Management in the Emergency Department.,"['Allen PJ', 'Johanson KE', 'Reveles KR', 'Neff LA', 'Lock AE']","['Humans', '*Haloperidol/adverse effects', 'Midazolam/therapeutic use', 'Lorazepam', 'Droperidol/therapeutic use', 'Retrospective Studies', 'Psychomotor Agitation/drug therapy', 'Injections, Intramuscular', '*Antipsychotic Agents/therapeutic use', 'Emergency Service, Hospital']",https://pubmed.ncbi.nlm.nih.gov/36999520/
480,Droperidol,22632989,To add or not to add? An empirical study on droperidol and intravenous patient-controlled analgesia.,"['Kuo YM', 'Tsou MY', 'Chang WK', 'Chan KH', 'Chang KY']","['Adult', 'Aged', '*Analgesia, Patient-Controlled', 'Antiemetics/*administration & dosage', 'Droperidol/*administration & dosage', 'Female', 'Humans', 'Logistic Models', 'Male', 'Middle Aged', 'Morphine/administration & dosage', 'Postoperative Nausea and Vomiting/*prevention & control', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/22632989/
481,Droperidol,37277099,Comparative Efficacy of Granisetron and Droperidol After Orthognathic Surgery for Prophylaxis of Postoperative Nausea and Vomiting: A Retrospective Study.,"['Maeda K', 'Higashibeppu N', 'Yamamoto S', 'Takenobu T', 'Taniike N']","['Humans', 'Droperidol/therapeutic use', 'Granisetron/therapeutic use', 'Postoperative Nausea and Vomiting/prevention & control', 'Retrospective Studies', '*Antiemetics/therapeutic use', '*Orthognathic Surgery', 'Vomiting/drug therapy/prevention & control', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37277099/
482,Droperidol,10875717,"Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting.","['Henzi I', 'Sonderegger J', 'Tramer MR']","['Adult', 'Antiemetics/*therapeutic use', 'Child', 'Dose-Response Relationship, Drug', 'Droperidol/adverse effects/*therapeutic use', 'Humans', 'Postoperative Nausea and Vomiting/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/10875717/
483,Droperidol,32569560,Droperidol Reduces Postoperative Nausea and Vomiting and Supports the Continuation of Intravenous Patient-Controlled Analgesia with Fentanyl.,"['Hirata I', 'Iwamoto M', 'Matsui H', 'Yoshinuma H', 'Funakoshi R']","['Adjuvants, Anesthesia/adverse effects/*therapeutic use', '*Analgesia, Patient-Controlled', 'Cohort Studies', 'Droperidol/adverse effects/*therapeutic use', 'Female', 'Fentanyl/adverse effects/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Postoperative Nausea and Vomiting/*drug therapy/surgery', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/32569560/
484,Droperidol,10357347,"Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis.","['Domino KB', 'Anderson EA', 'Polissar NL', 'Posner KL']","['Adult', 'Antiemetics/adverse effects/*therapeutic use', 'Child', 'Droperidol/adverse effects/*therapeutic use', 'Female', 'Humans', 'Male', 'Metoclopramide/adverse effects/*therapeutic use', 'Ondansetron/adverse effects/*therapeutic use', 'Postoperative Nausea and Vomiting/physiopathology/*prevention & control', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/10357347/
485,Droperidol,28160494,"Intravenous midazolam-droperidol combination, droperidol or olanzapine monotherapy for methamphetamine-related acute agitation: subgroup analysis of a randomized controlled trial.","['Yap CYL', 'Taylor DM', 'Knott JC', 'Taylor SE', 'Phillips GA', 'Karro J', 'Chan EW', 'Kong DCM', 'Castle DJ']","['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Akathisia, Drug-Induced/*drug therapy', 'Australia', 'Benzodiazepines/administration & dosage/*therapeutic use', 'Dopamine D2 Receptor Antagonists/therapeutic use', 'Double-Blind Method', 'Droperidol/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypnotics and Sedatives/therapeutic use', 'Injections, Intravenous', 'Male', 'Methamphetamine/*adverse effects', 'Midazolam/administration & dosage/*therapeutic use', 'Middle Aged', 'Olanzapine', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28160494/
486,Droperidol,24460451,Comparison of droperidol and haloperidol for use by paramedics: assessment of safety and effectiveness.,"['Macht M', 'Mull AC', 'McVaney KE', 'Caruso EH', 'Johnston JB', 'Gaither JB', 'Shupp AM', 'Marquez KD', 'Haukoos JS', 'Colwell CB']","['Adult', 'Allied Health Personnel', 'Antipsychotic Agents/administration & dosage/adverse effects', 'Cohort Studies', 'Colorado', 'Confidence Intervals', 'Dose-Response Relationship, Drug', 'Droperidol/*administration & dosage/adverse effects', 'Drug Administration Schedule', 'Electrocardiography/methods', 'Emergency Medical Services/*methods', 'Female', 'Haloperidol/*administration & dosage/adverse effects', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Long QT Syndrome/*diagnosis/epidemiology', 'Male', 'Middle Aged', 'Patient Safety', 'Psychomotor Agitation/diagnosis/*drug therapy', 'Retrospective Studies', 'Risk Assessment', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24460451/
487,Droperidol,16805932,Ondansetron or droperidol for prophylaxis of nausea and vomiting after intrathecal morphine.,"['Peixoto AJ', 'Celich MF', 'Zardo L', 'Peixoto Filho AJ']","['Adult', 'Cesarean Section', 'Double-Blind Method', 'Droperidol/*administration & dosage', 'Female', 'Follow-Up Studies', 'Humans', 'Injections, Intravenous', 'Injections, Spinal', 'Morphine/*administration & dosage/adverse effects', 'Ondansetron/*administration & dosage', 'Placebos', 'Postoperative Nausea and Vomiting/chemically induced/*prevention & control', 'Pregnancy', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16805932/
488,Droperidol,22488335,Low-dose droperidol (</=1 mg or </=15 mug kg-1) for the prevention of postoperative nausea and vomiting in adults: quantitative systematic review of randomised controlled trials.,"['Schaub I', 'Lysakowski C', 'Elia N', 'Tramer MR']","['Adult', 'Antiemetics/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Droperidol/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Postoperative Nausea and Vomiting/*prevention & control', 'Randomized Controlled Trials as Topic', 'Statistics as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22488335/
489,Droperidol,7200016,A comparison of droperidol and metoclopramide in the treatment of nausea and vomiting during cis-platinum polichemotherapy in ovarian carcinoma.,"['Bolis PF', 'Guaschino S', 'Paganelli AM', 'Sampaolo P']","['Antineoplastic Agents/*adverse effects', 'Cisplatin/*adverse effects', 'Droperidol/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Metoclopramide/therapeutic use', 'Middle Aged', 'Nausea/chemically induced/*drug therapy', 'Ovarian Neoplasms/*drug therapy', 'Vomiting/chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7200016/
490,Droperidol,12755651,A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients.,"['Shale JH', 'Shale CM', 'Mastin WD']","['Adolescent', 'Adult', 'Adverse Drug Reaction Reporting Systems', 'Aged', 'Antipsychotic Agents/administration & dosage/*adverse effects/*therapeutic use', 'Arrhythmias, Cardiac/chemically induced/epidemiology', 'Child', 'Child, Preschool', 'Death, Sudden, Cardiac/epidemiology', 'Droperidol/administration & dosage/*adverse effects/*therapeutic use', 'Drug Monitoring', 'Humans', 'Injections, Intramuscular', 'Mental Disorders/*drug therapy/psychology', 'Middle Aged', 'Psychomotor Agitation/drug therapy/*prevention & control', 'United States/epidemiology', 'Violence/*prevention & control/psychology']",https://pubmed.ncbi.nlm.nih.gov/12755651/
491,Droperidol,3375905,Cardiovascular and respiratory effects of oral premedication with trimeprazine and droperidol in children.,"['Butt AD', 'Mets B']","['Administration, Oral', 'Blood Pressure/*drug effects', 'Child', 'Child, Preschool', 'Droperidol/administration & dosage/*pharmacology', 'Drug Therapy, Combination', 'Humans', 'Infant', 'Premedication', 'Prospective Studies', 'Pulse/*drug effects', 'Respiration/*drug effects', 'Trimeprazine/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3375905/
492,Droperidol,33846015,A Prospective Study of Intramuscular Droperidol or Olanzapine for Acute Agitation in the Emergency Department: A Natural Experiment Owing to Drug Shortages.,"['Cole JB', 'Stang JL', 'DeVries PA', 'Martel ML', 'Miner JR', 'Driver BE']","['Adult', 'Antipsychotic Agents/*administration & dosage', 'Droperidol/*administration & dosage', 'Emergency Service, Hospital/statistics & numerical data', 'Female', 'Humans', 'Injections, Intramuscular', 'Male', 'Middle Aged', 'Olanzapine/*administration & dosage', 'Pharmaceutical Preparations/supply & distribution', 'Prospective Studies', 'Psychomotor Agitation/*drug therapy/epidemiology', 'Quality Improvement', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/33846015/
493,Droperidol,39137114,Coma After Droperidol Administration: A Case Report.,"['Vetter C', 'Biedermann C', 'Berger-Estilita J', 'Butikofer A']","['Humans', 'Female', 'Adult', '*Droperidol/adverse effects/administration & dosage', '*Coma/chemically induced', '*Uterine Myomectomy/adverse effects', 'Antiemetics/adverse effects/administration & dosage', 'Switzerland']",https://pubmed.ncbi.nlm.nih.gov/39137114/
494,Apomorphine,37210460,Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.,"['Jenner P', 'Falup-Pecurariu C', 'Leta V', 'Verin M', 'Auffret M', 'Bhidayasiri R', 'Weiss D', 'Borovecki F', 'Jost WH']","['Humans', '*Apomorphine/pharmacology/therapeutic use', 'Levodopa/pharmacology/therapeutic use', '*Parkinson Disease/drug therapy', 'Antiparkinson Agents/pharmacology/therapeutic use', 'Dopamine']",https://pubmed.ncbi.nlm.nih.gov/37210460/
495,Apomorphine,10192792,Electrophysiological and clinical desensitization to apomorphine administration in parkinsonian patients undergoing stereotaxic neurosurgery.,"['Stefani A', 'Mazzone P', 'Bassi A', 'Bernardi G', 'Altibrandi MG', 'Peppe A', 'Pierantozzi M', 'Stanzione P']","['Apomorphine/administration & dosage/*pharmacology', 'Dopamine Agonists/administration & dosage/*pharmacology', 'Electrophysiology', 'Globus Pallidus/physiopathology', 'Humans', 'Middle Aged', 'Parkinson Disease/*physiopathology/*surgery', 'Stereotaxic Techniques', 'Synaptic Transmission/drug effects']",https://pubmed.ncbi.nlm.nih.gov/10192792/
496,Apomorphine,35070491,Necrotic Ulcers Secondary to Apomorphine Infusion.,"['Llamas-Osorio Y', 'McLoughlin C', 'Maguire M', 'Lynch T']","['Antiparkinson Agents/adverse effects', '*Apomorphine/adverse effects', 'Dopamine Agonists/adverse effects', 'Humans', 'Injections, Subcutaneous', '*Ulcer/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35070491/
497,Apomorphine,27282537,Apomorphine and its esters: Differences in Caco-2 cell permeability and chylomicron affinity.,"['Borkar N', 'Chen Z', 'Saaby L', 'Mullertz A', 'Hakansson AE', 'Schonbeck C', 'Yang M', 'Holm R', 'Mu H']","['Apomorphine/*chemistry/*metabolism', 'Caco-2 Cells', 'Cell Line, Tumor', 'Chylomicrons/*chemistry/*metabolism', 'Esters/*chemistry/*metabolism', 'Humans', 'Hydrolysis', 'Intestinal Absorption/*physiology', 'Permeability', 'Prodrugs/chemistry/metabolism']",https://pubmed.ncbi.nlm.nih.gov/27282537/
498,Apomorphine,12404888,Studies of interferences of apomorphine and its metabolites or decomposition products with immunochemical screening tests for legal and illicit drugs after therapeutic doses of apomorphine.,"['Schutz H', 'Erdmann F', 'Risse M', 'Weiler G']","['Apomorphine/pharmacokinetics/therapeutic use/*urine', 'Biomarkers/analysis', 'Cross Reactions', 'Enzyme-Linked Immunosorbent Assay', 'False Positive Reactions', 'Fluorescence Polarization Immunoassay', 'Humans', 'Immunochemistry', 'Substance Abuse Detection/*methods']",https://pubmed.ncbi.nlm.nih.gov/12404888/
499,Apomorphine,7885353,Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans.,"['Przedborski S', 'Levivier M', 'Raftopoulos C', 'Naini AB', 'Hildebrand J']","['3,4-Dihydroxyphenylacetic Acid/cerebrospinal fluid', 'Aged', 'Apomorphine/blood/cerebrospinal fluid/*pharmacokinetics', 'Chromatography, High Pressure Liquid', 'Dopamine/cerebrospinal fluid/*metabolism', 'Female', 'Homovanillic Acid/cerebrospinal fluid', 'Humans', 'Hydrolysis', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/7885353/
500,Apomorphine,32795778,LC-MS/MS simultaneous quantification of apomorphine and its major metabolites in human plasma: Application to clinical comparative bioavailability evaluation for the apomorphine sublingual film and a subcutaneous product.,"['Chen YL', 'Shi L', 'Agbo F', 'Yong SH', 'Tan PS', 'Ngounou Wetie AG']","['*Apomorphine/blood', 'Biological Availability', 'Chromatography, Liquid', 'Humans', 'Plasma', 'Reproducibility of Results', '*Tandem Mass Spectrometry']",https://pubmed.ncbi.nlm.nih.gov/32795778/
501,Paracetamol,7039926,Clinical pharmacokinetics of paracetamol.,"['Forrest JA', 'Clements JA', 'Prescott LF']","['Acetaminophen/analysis/*metabolism/poisoning', 'Administration, Oral', 'Age Factors', 'Body Weight', 'Drug Interactions', 'Food', 'Humans', 'Injections, Intravenous', 'Intestinal Absorption', 'Kinetics', 'Liver Diseases/metabolism', 'Protein Binding', 'Racial Groups', 'Rectum/metabolism', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/7039926/
502,Paracetamol,29473717,Interventions for paracetamol (acetaminophen) overdose.,"['Chiew AL', 'Gluud C', 'Brok J', 'Buckley NA']","['Acetaminophen/pharmacokinetics/*poisoning', 'Acetylcysteine/therapeutic use', 'Analgesics, Non-Narcotic/pharmacokinetics/*poisoning', 'Antidotes/therapeutic use', 'Charcoal/therapeutic use', 'Cysteamine/therapeutic use', 'Dimercaprol/therapeutic use', 'Drug Overdose/mortality/therapy', 'Gastric Lavage', 'Humans', 'Intestinal Absorption', 'Liver Failure, Acute/chemically induced/epidemiology/surgery', 'Liver Transplantation', 'Methionine/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29473717/
503,Paracetamol,24128822,Acetaminophen (paracetamol).,"['Twycross R', 'Pace V', 'Mihalyo M', 'Wilcock A']","['Acetaminophen/*administration & dosage/*adverse effects', 'Analgesics, Non-Narcotic/administration & dosage/adverse effects', 'Chemical and Drug Induced Liver Injury/*etiology/*prevention & control', 'Dose-Response Relationship, Drug', 'Humans', 'Pain/*complications/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24128822/
504,Paracetamol,2100601,Application of solid-phase extraction to the isolation and determination of paracetamol and its metabolites.,"['el Mouelhi M', 'Buszewski B']","['Acetaminophen/analysis/*isolation & purification', 'Chemical Phenomena', 'Chemistry, Physical', 'Electrochemistry', 'Humans', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/2100601/
505,Paracetamol,37042928,Interaction between escitalopram and ibuprofen or paracetamol: DFT and molecular docking on the drug-drug interactions.,"['Daboe M', 'Parlak C', 'Direm A', 'Alver O', 'Ramasami P']","['Humans', '*Acetaminophen/pharmacology/therapeutic use', '*Ibuprofen/pharmacology', 'Molecular Docking Simulation', 'Escitalopram', 'Drug Interactions']",https://pubmed.ncbi.nlm.nih.gov/37042928/
506,Paracetamol,11878655,"Rectal and parenteral paracetamol, and paracetamol in combination with NSAIDs, for postoperative analgesia.","['Romsing J', 'Moiniche S', 'Dahl JB']","['Acetaminophen/administration & dosage/*therapeutic use', 'Administration, Rectal', 'Analgesics, Non-Narcotic/administration & dosage/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Pain, Postoperative/*drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/11878655/
507,Paracetamol,18497418,Does paracetamol cause hypertension?,['Montgomery B'],"['Acetaminophen/*adverse effects', 'Analgesics, Non-Narcotic/*adverse effects', 'Humans', 'Hypertension/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/18497418/
508,Paracetamol,22845052,Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum.,"['Kulo A', 'Peeters MY', 'Allegaert K', 'Smits A', 'de Hoon J', 'Verbesselt R', 'Lewi L', 'van de Velde M', 'Knibbe CA']","['Acetaminophen/administration & dosage/analogs & derivatives/*pharmacokinetics', 'Administration, Intravenous', 'Adult', 'Analgesics, Non-Narcotic/administration & dosage/*pharmacokinetics', '*Delivery, Obstetric', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Metabolic Clearance Rate', 'Pain/drug therapy', 'Pain Measurement', 'Postpartum Period/*metabolism', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/22845052/
509,Paracetamol,25429980,"Acetaminophen/paracetamol: A history of errors, failures and false decisions.","['Brune K', 'Renner B', 'Tiegs G']","['Acetaminophen/*adverse effects/history/pharmacology/*therapeutic use', 'Adult', 'Analgesics, Non-Narcotic/*adverse effects/history/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', 'Child', 'History, 19th Century', 'History, 20th Century', 'History, 21st Century', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/25429980/
510,Paracetamol,29179598,Serum paracetamol-protein adducts in ambulatory subjects: Relationship to recent reported paracetamol use.,"['Heard K', 'Anderson VE', 'Lavonas EJ', 'Dart RC', 'Green JL']","['Acetaminophen/administration & dosage/blood/*chemistry/therapeutic use', 'Adult', 'Analgesics, Non-Narcotic', 'Blood Proteins/analysis/*chemistry', 'Cross-Sectional Studies', 'Dose-Response Relationship, Drug', 'Drug Overdose', 'Female', 'Humans', 'Male', 'Middle Aged', 'Walking', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29179598/
511,Paracetamol,33989641,"Efficacy of Intravenous Paracetamol and Ibuprofen on Postoperative Pain and Morphine Consumption in Lumbar Disc Surgery: Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.","['Akbas S', 'Ozkan AS', 'Durak MA', 'Yologlu S']","['*Acetaminophen/therapeutic use', 'Humans', '*Ibuprofen/therapeutic use', 'Morphine', 'Pain Measurement', 'Pain, Postoperative/drug therapy/prevention & control', 'Prospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33989641/
512,Paracetamol,22471366,Investigating paracetamol pharmacokinetics using venous and capillary blood and saliva sampling.,"['Rittau AM', 'McLachlan AJ']","['Acetaminophen/analogs & derivatives/*pharmacokinetics', 'Adult', 'Area Under Curve', 'Capillaries/*metabolism', 'Chromatography, High Pressure Liquid/*methods', 'Female', 'Humans', 'Middle Aged', 'Reference Values', 'Reproducibility of Results', 'Saliva/*metabolism', 'Veins/*metabolism', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/22471366/
513,Terazosin,38896813,"Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men.","['Hart A', 'Aldridge G', 'Zhang Q', 'Narayanan NS', 'Simmering JE']","['Humans', 'Male', '*Doxazosin/therapeutic use', 'Aged', '*Prazosin/analogs & derivatives/therapeutic use', '*Lewy Body Disease/drug therapy', '*Adrenergic alpha-1 Receptor Antagonists/therapeutic use', '*Quinazolines/therapeutic use/adverse effects', 'Aged, 80 and over', 'Tamsulosin/therapeutic use', 'Prostatic Hyperplasia/drug therapy', 'Neuroprotective Agents/therapeutic use/pharmacology', 'Middle Aged', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/38896813/
514,Terazosin,16493591,"Identification, preparation, and characterization of several polymorphs and solvates of terazosin hydrochloride.","['Bauer J', 'Morley J', 'Spanton S', 'Leusen FJ', 'Henry R', 'Hollis S', 'Heitmann W', 'Mannino A', 'Quick J', 'Dziki W']","['Antineoplastic Agents/chemical synthesis/*chemistry', 'Calorimetry, Differential Scanning', 'Computer Simulation', 'Crystallography, X-Ray', 'Drug Stability', 'Humidity', 'Magnetic Resonance Spectroscopy', 'Methanol/chemistry', 'Models, Molecular', 'Molecular Structure', 'Phase Transition', 'Prazosin/*analogs & derivatives/chemical synthesis/chemistry', 'Solvents/*chemistry', 'Water/chemistry']",https://pubmed.ncbi.nlm.nih.gov/16493591/
515,Terazosin,16683008,More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study.,"['Paick JS', 'Lee SC', 'Ku JH']","['Adrenergic alpha-Antagonists/therapeutic use', 'Adult', 'Combined Modality Therapy/methods', 'Humans', 'Magnetics/*therapeutic use', 'Male', 'Middle Aged', 'Pelvic Pain/*drug therapy/*radiotherapy', 'Pilot Projects', 'Prazosin/*analogs & derivatives/therapeutic use', 'Prostatitis/drug therapy/radiotherapy', 'Syndrome', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16683008/
516,Terazosin,7686794,"Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.","['Wilde MI', 'Fitton A', 'Sorkin EM']","['Adrenergic alpha-Antagonists/pharmacokinetics/*pharmacology/therapeutic use', 'Adult', 'Aged', 'Humans', 'Male', 'Middle Aged', 'Prazosin/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7686794/
517,Terazosin,8665000,Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension.,['Pisarik P'],"['Adrenergic alpha-Antagonists/*therapeutic use', '*Beverages', 'Blood Pressure/*drug effects', 'Calcium Channel Blockers/*therapeutic use', '*Citrus', 'Food-Drug Interactions', 'Humans', 'Hypertension, Renovascular/*drug therapy', 'Male', 'Middle Aged', 'Nifedipine/*therapeutic use', 'Prazosin/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8665000/
518,Terazosin,1678920,Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.,"['Somberg JC', 'Achari R', 'Laddu AR']","['Adrenergic alpha-Antagonists/*adverse effects/*pharmacokinetics/therapeutic use', 'Age Factors', 'Antihypertensive Agents/therapeutic use', 'Dose-Response Relationship, Drug', 'Half-Life', 'Humans', 'Hypertension/*drug therapy', 'Kidney Failure, Chronic/metabolism', 'Meta-Analysis as Topic', 'Prazosin/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1678920/
519,Terazosin,1678923,Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.,['Cohen JD'],"['Adrenergic alpha-Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Female', 'Follow-Up Studies', 'Humans', 'Hypertension/*drug therapy/epidemiology', 'Male', 'Middle Aged', 'Prazosin/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1678923/
520,Terazosin,9824790,"Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin.","['Vashi V', 'Chung M', 'Hilbert J', 'Lawrence V', 'Phillips K']","['Adrenergic alpha-Antagonists/*pharmacokinetics/pharmacology', 'Adult', 'Area Under Curve', 'Doxazosin/blood/*pharmacokinetics/pharmacology', 'Drug Interactions', 'Enzyme Inhibitors/*pharmacokinetics/pharmacology', 'Finasteride/blood/*pharmacokinetics/pharmacology', 'Humans', 'Male', 'Middle Aged', 'Prazosin/*analogs & derivatives/blood/pharmacokinetics/pharmacology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/9824790/
521,Terazosin,33429127,Simple and fast LC-MS/MS method for quantification of terazosin in human plasma and application to bioequivalence study.,"['Loh GOK', 'Wong EYL', 'Tan YTF', 'Ong LM', 'Ng RS', 'Wee HC', 'Peh KK']","['Administration, Oral', 'Adolescent', 'Adult', 'Chromatography, High Pressure Liquid/*methods', 'Cross-Over Studies', 'High-Throughput Screening Assays', 'Humans', 'Linear Models', 'Male', 'Middle Aged', 'Prazosin/administration & dosage/*analogs & derivatives/blood/pharmacokinetics', 'Reproducibility of Results', 'Sensitivity and Specificity', 'Tandem Mass Spectrometry/*methods', 'Therapeutic Equivalency', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33429127/
522,Terazosin,33840085,A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia.,"['Farshi A', 'DalirAkbari N', 'Zomorrodi A', 'Khalili M', 'Mahmoudinezhad M']","['Adrenergic alpha-1 Receptor Antagonists/*administration & dosage', 'Aged', 'Antihypertensive Agents/*administration & dosage', 'Carvedilol/*administration & dosage', 'Cross-Over Studies', 'Drug Therapy, Combination', 'Enalapril/*administration & dosage', 'Humans', 'Hypertension/complications', 'Male', 'Middle Aged', 'Pilot Projects', 'Prazosin/administration & dosage/*analogs & derivatives', 'Prostatic Hyperplasia/complications', 'Single-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/33840085/
523,Terazosin,8607228,The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia.,"['Hillman AL', 'Schwartz JS', 'Willian MK', 'Peskin E', 'Roehrborn CG', 'Oesterling JE', 'Mason MF', 'Maurath CJ', 'Deverka PA', 'Padley RJ']","['Adrenergic alpha-Antagonists/*economics/therapeutic use', 'Aged', 'Aged, 80 and over', 'Analysis of Variance', 'Cost-Benefit Analysis', 'Diagnosis-Related Groups/economics/statistics & numerical data', 'Health Resources/economics/statistics & numerical data', 'Humans', 'Male', 'Middle Aged', 'Prazosin/*analogs & derivatives/economics/therapeutic use', 'Prospective Studies', 'Prostatic Hyperplasia/drug therapy/*economics', 'Regression Analysis', 'Treatment Outcome', 'United States']",https://pubmed.ncbi.nlm.nih.gov/8607228/
524,Terazosin,2875651,"The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure.","['Leier CV', 'Patterson SE', 'Huss P', 'Parrish D', 'Unverferth DV']","['Adrenergic alpha-Antagonists/blood/*pharmacology', 'Adult', 'Aged', 'Dose-Response Relationship, Drug', 'Exercise Test', 'Female', 'Heart Failure/*physiopathology', 'Hemodynamics/*drug effects', 'Humans', 'Male', 'Middle Aged', 'Prazosin/*analogs & derivatives/blood/pharmacology', 'Rest', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2875651/
525,Terazosin,15533470,"Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.","['Cheah PY', 'Liong ML', 'Yuen KH', 'Teh CL', 'Khor T', 'Yang JR', 'Yap HW', 'Krieger JN']","['Adrenergic alpha-Antagonists/*therapeutic use', 'Adult', 'Chronic Disease', 'Double-Blind Method', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', 'Pelvic Pain/*drug therapy', 'Prazosin/*analogs & derivatives/therapeutic use', 'Prostatitis/*drug therapy', 'Quality of Life', 'Research Design', 'Syndrome', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/15533470/
526,Terazosin,7755941,Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions.,"['Lenz ML', 'Pool JL', 'Laddu AR', 'Varghese A', 'Johnston W', 'Taylor AA']","['Adult', 'Blood Pressure/*drug effects/physiology', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Heart Rate/*drug effects/physiology', 'Humans', 'Hypertension/*drug therapy/metabolism/physiopathology', 'Male', 'Middle Aged', 'Posture', 'Prazosin/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Verapamil/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7755941/
527,Terazosin,17376305,Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.,"['Yang Y', 'Zhao XF', 'Li HZ', 'Wang W', 'Zhang Y', 'Xiao H', 'Zhang X']","['Adrenergic alpha-Antagonists/*administration & dosage', 'Aged', 'Benzhydryl Compounds/*administration & dosage/adverse effects', 'Cresols/*administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Humans', 'Male', 'Middle Aged', 'Muscarinic Antagonists/*administration & dosage', 'Phenylpropanolamine/*administration & dosage/adverse effects', 'Prazosin/administration & dosage/adverse effects/*analogs & derivatives', 'Prospective Studies', 'Prostatic Hyperplasia/complications/*drug therapy', 'Tolterodine Tartrate', 'Urination Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17376305/
528,Terazosin,2872809,Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension.,['Deger G'],"['Adrenergic alpha-Antagonists/*administration & dosage/adverse effects', 'Adult', 'Aged', 'Blood Pressure/drug effects', 'Body Weight/drug effects', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Piperazines/*administration & dosage/adverse effects/pharmacology', 'Posture', 'Prazosin/*administration & dosage/adverse effects/pharmacology', 'Pulse/drug effects', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/2872809/
529,Deferoxamine,9745687,The gallium-deferoxamine complex: stability with different deferoxamine concentrations and incubation conditions.,"['Caraco C', 'Aloj L', 'Eckelman WC']","['Chromatography, Thin Layer', 'Deferoxamine/*chemistry', 'Gallium/chemistry', 'Gallium Radioisotopes/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/9745687/
530,Deferoxamine,38784214,Combination Effect of Deferoxamine and Arsenic Trioxide on Viability and Vitality of APL Like Cell Line.,"['Ghaffari K', 'Bayat A', 'Ghasemi A']","['*Arsenic Trioxide/pharmacology', 'Humans', '*Arsenicals/pharmacology', '*Leukemia, Promyelocytic, Acute/drug therapy', '*Deferoxamine/pharmacology', '*Cell Survival/drug effects', 'Cell Line, Tumor', '*Apoptosis/drug effects', '*Telomerase/metabolism', '*Oxides/pharmacology', 'Antineoplastic Agents/pharmacology', 'Cell Proliferation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/38784214/
531,Deferoxamine,11099897,Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).,"['Kontoghiorghes GJ', 'Pattichi K', 'Hadjigavriel M', 'Kolnagou A']","['Deferiprone', 'Deferoxamine/*therapeutic use', 'Humans', 'Iron Chelating Agents/*therapeutic use', 'Iron Overload/*drug therapy/*etiology', 'Pyridones/*therapeutic use', '*Transfusion Reaction']",https://pubmed.ncbi.nlm.nih.gov/11099897/
532,Deferoxamine,27083844,Synthesis and evaluation of oxidation-responsive alginate-deferoxamine conjugates with increased stability and low toxicity.,"['Tian M', 'Chen X', 'Gu Z', 'Li H', 'Ma L', 'Qi X', 'Tan H', 'You C']","['Alginates/*chemistry', 'Cell Survival/drug effects', 'Chemistry Techniques, Synthetic', 'Deferoxamine/*chemical synthesis/*chemistry/metabolism/toxicity', 'Drug Stability', 'Glucuronic Acid/chemistry', 'Hexuronic Acids/chemistry', 'Human Umbilical Vein Endothelial Cells/cytology/drug effects', 'Humans', 'Iron/chemistry', 'Models, Molecular', 'Molecular Conformation', 'Molecular Weight', 'Oxidation-Reduction', 'Water/chemistry']",https://pubmed.ncbi.nlm.nih.gov/27083844/
533,Deferoxamine,30676731,Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1alpha Inhibitor Impairs Pancreatic Tumor Growth.,"['Lang J', 'Zhao X', 'Wang X', 'Zhao Y', 'Li Y', 'Zhao R', 'Cheng K', 'Li Y', 'Han X', 'Zheng X', 'Qin H', 'Geranpayehvaghei M', 'Shi J', 'Anderson GJ', 'Hao J', 'Ren H', 'Nie G']","['Administration, Oral', 'Antineoplastic Agents/administration & dosage/chemistry/*pharmacology', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Deferoxamine/administration & dosage/chemistry/*pharmacology', '*Drug Delivery Systems', 'Drug Screening Assays, Antitumor', 'Humans', 'Hypoxia-Inducible Factor 1, alpha Subunit/*antagonists & inhibitors/metabolism', 'Iron Chelating Agents/administration & dosage/chemistry/*pharmacology', 'Nanoparticles/administration & dosage/chemistry', 'Pancreatic Neoplasms/*drug therapy/metabolism/pathology']",https://pubmed.ncbi.nlm.nih.gov/30676731/
534,Deferoxamine,36286552,Synergistic Effect of the Combination of Deferoxamine and Fluconazole In Vitro and In Vivo against Fluconazole-Resistant Candida Spp.,"['An L', 'Tan J', 'Wang Y', 'Liu S', 'Li Y', 'Yang L']","['Humans', '*Fluconazole/pharmacology', '*Candida', 'Antifungal Agents/pharmacology', 'Deferoxamine/pharmacology', 'Drug Resistance, Fungal', 'Drug Synergism', 'Microbial Sensitivity Tests', 'Candida albicans', 'Candida glabrata']",https://pubmed.ncbi.nlm.nih.gov/36286552/
535,Deferoxamine,10709159,Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis.,"['Nakamura H', 'Rose PG', 'Blumer JL', 'Reed MD']","['Acute Disease', 'Aged', 'Aged, 80 and over', 'Alum Compounds/*adverse effects/therapeutic use', 'Deferoxamine/administration & dosage/*therapeutic use', 'Delirium/chemically induced/drug therapy/*therapy', 'Female', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Renal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/10709159/
536,Deferoxamine,21523808,Iron chelation adherence to deferoxamine and deferasirox in thalassemia.,"['Trachtenberg F', 'Vichinsky E', 'Haines D', 'Pakbaz Z', 'Mednick L', 'Sobota A', 'Kwiatkowski J', 'Thompson AA', 'Porter J', 'Coates T', 'Giardina PJ', 'Olivieri N', 'Yamashita R', 'Neufeld EJ']","['Adolescent', 'Adult', 'Age Factors', 'Benzoates/adverse effects/*therapeutic use', '*Chelation Therapy/adverse effects', 'Child', 'Child, Preschool', 'Deferasirox', 'Deferoxamine/adverse effects/*therapeutic use', 'Female', 'Humans', 'Iron Chelating Agents/adverse effects/*therapeutic use', 'Male', 'Medical Records', '*Medication Adherence', 'Middle Aged', 'North America', 'Retrospective Studies', 'Self Report', 'Thalassemia/*drug therapy', 'Triazoles/adverse effects/*therapeutic use', 'United Kingdom', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21523808/
537,Deferoxamine,26893541,"Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.","['Kontoghiorghe CN', 'Kontoghiorghes GJ']","['Benzoates/adverse effects/therapeutic use', 'Chelation Therapy/methods', 'Deferasirox', 'Deferiprone', 'Deferoxamine/adverse effects/therapeutic use', 'Humans', 'Iron Chelating Agents/adverse effects/*therapeutic use', 'Iron Overload/*drug therapy/etiology', 'Pyridones/adverse effects/therapeutic use', 'Syndrome', 'Thalassemia/complications/*drug therapy', 'Triazoles/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26893541/
538,Deferoxamine,2093286,Mucorales and deferoxamine: from saprophytic to pathogenic state.,"['Vandevelde L', 'Bondewel C', 'Dubois M', 'De Vuyst M']","['Deferoxamine/*adverse effects', 'Ethmoid Sinusitis/diagnostic imaging/*microbiology/surgery', 'Humans', 'Intracranial Embolism and Thrombosis/*etiology', 'Male', 'Middle Aged', 'Mucormycosis/*diagnosis/surgery', 'Prognosis', 'Renal Dialysis/adverse effects', 'Sinus Thrombosis, Intracranial/*etiology', 'Tomography, X-Ray Computed']",https://pubmed.ncbi.nlm.nih.gov/2093286/
539,Deferoxamine,12825969,Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.,"['Kontoghiorghes GJ', 'Neocleous K', 'Kolnagou A']","['Deferoxamine/adverse effects/*therapeutic use', 'Erythrocyte Transfusion/adverse effects', 'Humans', 'Iron Chelating Agents/adverse effects/*therapeutic use', 'Iron Overload/*drug therapy/etiology', 'Risk', 'Thalassemia/*complications/epidemiology/therapy']",https://pubmed.ncbi.nlm.nih.gov/12825969/
540,Deferoxamine,16373663,Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.,"['Borgna-Pignatti C', 'Cappellini MD', 'De Stefano P', 'Del Vecchio GC', 'Forni GL', 'Gamberini MR', 'Ghilardi R', 'Piga A', 'Romeo MA', 'Zhao H', 'Cnaan A']","['Adolescent', 'Adult', 'Child', 'Deferiprone', 'Deferoxamine/adverse effects/*therapeutic use', 'Female', 'Ferritins/blood', 'Heart Diseases/*etiology/mortality/prevention & control', 'Humans', 'Iron Chelating Agents/adverse effects/*therapeutic use', 'Italy/epidemiology', 'Male', 'Pyridones/adverse effects/*therapeutic use', 'beta-Thalassemia/blood/*complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16373663/
541,Chlorambucil,28355112,Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.,"['Zucca E', 'Conconi A', 'Martinelli G', 'Bouabdallah R', 'Tucci A', 'Vitolo U', 'Martelli M', 'Pettengell R', 'Salles G', 'Sebban C', 'Guillermo AL', 'Pinotti G', 'Devizzi L', 'Morschhauser F', 'Tilly H', 'Torri V', 'Hohaus S', 'Ferreri AJM', 'Zachee P', 'Bosly A', 'Haioun C', 'Stelitano C', 'Bellei M', 'Ponzoni M', 'Moreau A', 'Jack A', 'Campo E', 'Mazzucchelli L', 'Cavalli F', 'Johnson P', 'Thieblemont C']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Chlorambucil/administration & dosage/adverse effects/*therapeutic use', 'Disease-Free Survival', 'Endpoint Determination', 'Female', 'Humans', 'Kaplan-Meier Estimate', 'Lymphoma, B-Cell, Marginal Zone/*drug therapy', 'Male', 'Middle Aged', 'Rituximab/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28355112/
542,Chlorambucil,37944541,"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.","['Niemann CU', 'Munir T', 'Moreno C', 'Owen C', 'Follows GA', 'Benjamini O', 'Janssens A', 'Levin MD', 'Robak T', 'Simkovic M', 'Voloshin S', 'Vorobyev V', 'Yagci M', 'Ysebaert L', 'Qi K', 'Qi Q', 'Sinet P', 'Parisi L', 'Srinivasan S', 'Schuier N', 'Baeten K', 'Howes A', 'Caces DB', 'Kater AP']","['Female', 'Humans', 'Male', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Chlorambucil/adverse effects/therapeutic use', 'Follow-Up Studies', '*Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy', '*Pneumonia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37944541/
543,Chlorambucil,3596472,"OPEC chemotherapy (vincristine, prednisolone, etoposide and chlorambucil) for refractory and recurrent Hodgkin's disease.","['Barnett MJ', 'Man AM', 'Richards MA', 'Waxman JH', 'Wrigley PF', 'Lister TA']","['Adolescent', 'Adult', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Bone Marrow/drug effects', 'Chlorambucil/administration & dosage/adverse effects/therapeutic use', 'Etoposide/administration & dosage/adverse effects/therapeutic use', 'Hodgkin Disease/*drug therapy', 'Humans', 'Leukocyte Count', 'Mechlorethamine/therapeutic use', 'Middle Aged', 'Prednisolone/administration & dosage/adverse effects/therapeutic use', 'Procarbazine/therapeutic use', 'Prognosis', 'Vinblastine/therapeutic use', 'Vincristine/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3596472/
544,Chlorambucil,20190437,"Novel melphalan and chlorambucil derivatives of 2,2,6,6-tetramethyl-1-piperidinyloxy radicals: synthesis, characterization, and biological evaluation in vitro.","['Zhao H', 'Meng X', 'Yuan H', 'Lan M']","['Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Chlorambucil/chemical synthesis/chemistry/*pharmacology', 'Cyclic N-Oxides/chemical synthesis/chemistry/*pharmacology', 'Dose-Response Relationship, Drug', 'Drug Screening Assays, Antitumor', 'Free Radicals/chemical synthesis/chemistry/pharmacology', 'Humans', 'Hydrolysis', 'Kinetics', 'Melphalan/chemical synthesis/chemistry/*pharmacology', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/20190437/
545,Chlorambucil,29131242,Synergistic effects of chlorambucil and TRAIL on apoptosis and proliferation of Raji cells.,"['Guo JX', 'Zhou YH', 'Huang YQ', 'Liu GJ', 'Pan JX']","['Apoptosis/*drug effects', 'Caspase 3/metabolism', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Chlorambucil/*pharmacology', 'Drug Synergism', 'Humans', 'Ki-67 Antigen/metabolism', 'Receptors, TNF-Related Apoptosis-Inducing Ligand/metabolism', 'TNF-Related Apoptosis-Inducing Ligand/*pharmacology', 'Up-Regulation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/29131242/
546,Chlorambucil,6142995,Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative.,"['Palmer RG', 'Dore CJ', 'Denman AM']","['Adult', 'Behcet Syndrome/drug therapy', 'Chlorambucil/*adverse effects', 'Chromosomes, Human/*drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Leukemia, Myeloid, Acute/chemically induced', 'Male', 'Metaphase', 'Sister Chromatid Exchange/drug effects', 'Time Factors', 'Uveitis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6142995/
547,Chlorambucil,2912022,A phase II trial of intermittent leukocyte interferon and high dose chlorambucil in the treatment of non-Hodgkin's lymphoma resistant to conventional therapy.,"['Clark RH', 'Dimitrov NV', 'Axelson JA', 'Charamella LJ', 'Stott PB']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Chlorambucil/*administration & dosage/adverse effects', 'Drug Administration Schedule', 'Drug Evaluation', 'Drug Interactions', 'Humans', 'Interferon Type I/*administration & dosage/adverse effects', 'Lymphoma, Non-Hodgkin/*therapy', 'Middle Aged', 'Remission Induction', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2912022/
548,Chlorambucil,22574508,Amino and chlorambucil analogues of pentamidine--synthesis and biological examinations.,"['Puckowska A', 'Drozdowska D', 'Rusak M', 'Bielawski T', 'Bruzgo I', 'Midura-Nowaczek K']","['*Antifibrinolytic Agents/chemical synthesis/pharmacology', '*Antineoplastic Agents, Alkylating/chemical synthesis/pharmacology', 'Apoptosis/drug effects', 'Breast Neoplasms/genetics/pathology', 'Cell Line, Tumor', '*Chlorambucil/analogs & derivatives/chemical synthesis/pharmacology', 'DNA/drug effects/metabolism', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Inhibitory Concentration 50', 'Molecular Structure', '*Pentamidine/analogs & derivatives/chemical synthesis/pharmacology', 'Structure-Activity Relationship', '*Topoisomerase I Inhibitors/chemical synthesis/pharmacology', '*Topoisomerase II Inhibitors/chemical synthesis/pharmacology', '*Trypsin Inhibitors/chemical synthesis/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/22574508/
549,Chlorambucil,34068372,HPLC-UV and GC-MS Methods for Determination of Chlorambucil and Valproic Acid in Plasma for Further Exploring a New Combined Therapy of Chronic Lymphocytic Leukemia.,"['Lipska K', 'Gumieniczek A', 'Pietras R', 'Filip AA']","['Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use', 'Calibration', 'Chlorambucil/*blood/chemistry/pharmacology/*therapeutic use', 'Chromatography, High Pressure Liquid', '*Gas Chromatography-Mass Spectrometry', 'Humans', 'Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy', 'Valproic Acid/*blood/chemistry/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34068372/
550,Chlorambucil,37866554,ROS/pH dual-sensitive emodin-chlorambucil co-loaded micelles enhance anti-tumor effect through combining oxidative damage and chemotherapy.,"['Liang W', 'Fan Y', 'Liu Y', 'Fang T', 'Zhang J', 'Xu Y', 'Li J', 'Wang D']","['Humans', 'Chlorambucil/pharmacology/therapeutic use', 'Micelles', 'Reactive Oxygen Species', '*Emodin/pharmacology', '*Neoplasms/drug therapy', 'Oxidative Stress', 'Glutathione/metabolism', 'Hydrogen-Ion Concentration']",https://pubmed.ncbi.nlm.nih.gov/37866554/
551,Chlorambucil,24401022,Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.,"['Goede V', 'Fischer K', 'Busch R', 'Engelke A', 'Eichhorst B', 'Wendtner CM', 'Chagorova T', 'de la Serna J', 'Dilhuydy MS', 'Illmer T', 'Opat S', 'Owen CJ', 'Samoylova O', 'Kreuzer KA', 'Stilgenbauer S', 'Dohner H', 'Langerak AW', 'Ritgen M', 'Kneba M', 'Asikanius E', 'Humphrey K', 'Wenger M', 'Hallek M']","['Adult', 'Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects', 'Antibodies, Monoclonal, Murine-Derived/administration & dosage', 'Antigens, CD20/*immunology', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Chlorambucil/*administration & dosage/adverse effects', 'Comorbidity', 'Disease-Free Survival', 'Humans', 'Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy', 'Middle Aged', 'Remission Induction', 'Rituximab']",https://pubmed.ncbi.nlm.nih.gov/24401022/
552,Chlorambucil,4009365,Chylous effusions due to neuroblastoma resolved by intrapleural chlorambucil coupled to father's antibodies.,"['Melino G', 'Tabara ZB', 'Hobbs JR']","['Antibodies, Neoplasm/*administration & dosage/therapeutic use', 'Child, Preschool', 'Chlorambucil/*administration & dosage/therapeutic use', 'Chyle', 'Combined Modality Therapy', 'Drug Combinations', 'Fathers', 'Humans', 'Immunoglobulin G/*administration & dosage/therapeutic use', 'Immunotherapy', 'Male', 'Neuroblastoma/*complications/therapy', 'Pleural Effusion/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/4009365/
553,Chlorambucil,621613,Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome.,"['Guesry P', 'Lenoir G', 'Broyer M']","['Adolescent', 'Cell Count', 'Child', 'Chlorambucil/*adverse effects/therapeutic use', 'Follicle Stimulating Hormone/blood', 'Humans', 'Luteinizing Hormone/blood', 'Male', 'Nephrotic Syndrome/*drug therapy', 'Oligospermia/chemically induced', 'Penis/pathology', '*Puberty', 'Spermatogenesis/drug effects', 'Spermatozoa', 'Testis/*drug effects/pathology/physiopathology', 'Testosterone/blood']",https://pubmed.ncbi.nlm.nih.gov/621613/
554,Bupivacaine,12032040,Predicting the density of bupivacaine and bupivacaine-opioid combinations.,"['Hallworth SP', 'Fernando R', 'Stocks GM']","['Analgesics, Opioid/*chemistry', 'Anesthetics, Local/*chemistry', 'Bupivacaine/*chemistry', 'Calibration', 'Drug Compounding', 'Glucose Solution, Hypertonic', 'Reproducibility of Results', 'Solutions']",https://pubmed.ncbi.nlm.nih.gov/12032040/
555,Bupivacaine,33372953,Perineural Liposomal Bupivacaine Is Not Superior to Nonliposomal Bupivacaine for Peripheral Nerve Block Analgesia.,"['Hussain N', 'Brull R', 'Sheehy B', 'Essandoh MK', 'Stahl DL', 'Weaver TE', 'Abdallah FW']","['Analgesia/*methods', 'Anesthetics, Local/administration & dosage/*therapeutic use', 'Bupivacaine/administration & dosage/*therapeutic use', 'Humans', 'Liposomes', 'Nerve Block/*methods', 'Pain Management/*methods', 'Peripheral Nerves/drug effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33372953/
556,Bupivacaine,937750,Arterial and venous plasma levels of bupivacaine following epidural and intercostal nerve blocks.,"['Moore DC', 'Mather LE', 'Bridenbaugh PO', 'Bridenbaugh LD', 'Balfour RI', 'Lysons DF', 'Horton WG']","['Adult', 'Aged', '*Anesthesia, Epidural', 'Body Weight', 'Bupivacaine/administration & dosage/adverse effects/*blood', 'Epinephrine/administration & dosage', 'Female', 'Humans', 'Male', 'Middle Aged', '*Nerve Block', 'Preanesthetic Medication', 'Shivering', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/937750/
557,Bupivacaine,32541292,Bupivacaine Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine Administered After Cesarean Birth.,"['Mustafa HJ', 'Wong HL', 'Al-Kofahi M', 'Schaefer M', 'Karanam A', 'Todd MM']","['Adult', 'Anesthetics, Local/administration & dosage/blood/*pharmacokinetics', 'Area Under Curve', 'Bupivacaine/administration & dosage/blood/*pharmacokinetics', '*Cesarean Section', 'Cohort Studies', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Infant, Newborn', 'Milk, Human/*metabolism', '*Nerve Block', 'Pregnancy', 'Prenatal Care', 'Prospective Studies', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32541292/
558,Bupivacaine,25207707,"Comparative Evaluation of Intrathecal Bupivacaine Alone, Bupivacaine-fentanyl, and Bupivacaine-dexmedetomidine in Caesarean Section.","['Sun Y', 'Xu Y', 'Wang GN']","['Adult', 'Anesthesia, Spinal/*methods', 'Anesthetics, Local/administration & dosage/adverse effects/therapeutic use', 'Apgar Score', 'Bupivacaine/*administration & dosage/adverse effects/*therapeutic use', 'Cesarean Section/*methods', 'Dexmedetomidine/*administration & dosage/adverse effects/*therapeutic use', 'Drug Therapy, Combination/adverse effects', 'Female', 'Fentanyl/*administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Infant, Newborn', 'Injections, Spinal', 'Pain, Postoperative/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25207707/
559,Bupivacaine,24992382,New formulations of bupivacaine for the treatment of postoperative pain: liposomal bupivacaine and SABER-Bupivacaine.,"['Skolnik A', 'Gan TJ']","['Analgesics, Opioid/pharmacokinetics/therapeutic use', 'Anesthetics, Local/*administration & dosage/pharmacokinetics', 'Bupivacaine/*administration & dosage/pharmacokinetics', 'Chemistry, Pharmaceutical', 'Humans', 'Pain, Postoperative/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24992382/
560,Bupivacaine,7845278,"Epidural anaesthesia for caesarean section: a comparison of 0.5% bupivacaine plain, 0.5% bupivacaine plus 100 micrograms fentanyl and 0.5% bupivacaine plus 50 micrograms fentanyl.","['Wang CY', 'Ong GS', 'Delilkan AE']","['Adult', '*Anesthesia, Epidural', '*Anesthesia, Obstetrical', 'Apgar Score', '*Bupivacaine/administration & dosage/adverse effects', '*Cesarean Section', 'Ethnicity', 'Female', '*Fentanyl/administration & dosage/adverse effects', 'Humans', 'Infant, Newborn', 'Malaysia', 'Pregnancy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/7845278/
561,Bupivacaine,31422655,"Comparing Bupivacaine, Lidocaine, and a Combination of Bupivacaine and Lidocaine for Labor Epidural Activation: A Prospective, Randomized, Double-Blind Study.","['Powell MF', 'Jarzombek KW', 'Venhuizen KJ', 'Tubinis MD', 'Morgan CJ', 'Frolich MA']","['Analgesia, Epidural/*methods', 'Analgesia, Obstetrical/*methods', 'Anesthetics, Local/*pharmacology', 'Bupivacaine/administration & dosage/*pharmacology', 'Double-Blind Method', 'Female', 'Humans', 'Lidocaine/administration & dosage/*pharmacology', 'Phenylephrine/pharmacology', 'Pregnancy', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/31422655/
562,Bupivacaine,3190969,Spinal anaesthesia with 0.5% bupivacaine 3 ml: comparison of plain and hyperbaric solutions administered to seated patients.,['Alston RP'],"['Aged', '*Anesthesia, Spinal', 'Bupivacaine/*administration & dosage/pharmacokinetics', 'Double-Blind Method', 'Humans', 'Male', 'Posture', 'Prostatectomy', 'Specific Gravity', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3190969/
563,Bupivacaine,12207874,Comparative efficacy and pharmacokinetics of racemic bupivacaine and S-bupivacaine in third molar surgery.,"['Fawcett JP', 'Kennedy JM', 'Kumar A', 'Ledger R', 'Kumara GM', 'Patel MJ', 'Zacharias M']","['Adult', '*Anesthesia, Local', 'Anesthetics, Local/chemistry/*pharmacokinetics', 'Area Under Curve', 'Bupivacaine/blood/chemistry/*pharmacokinetics', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Molar, Third/*surgery', 'Stereoisomerism', '*Tooth Extraction']",https://pubmed.ncbi.nlm.nih.gov/12207874/
564,Bupivacaine,28157791,Addition of Liposome Bupivacaine to Bupivacaine HCl Versus Bupivacaine HCl Alone for Interscalene Brachial Plexus Block in Patients Having Major Shoulder Surgery.,"['Vandepitte C', 'Kuroda M', 'Witvrouw R', 'Anne L', 'Bellemans J', 'Corten K', 'Vanelderen P', 'Mesotten D', 'Leunen I', 'Heylen M', 'Van Boxstael S', 'Golebiewski M', 'Van de Velde M', 'Knezevic NN', 'Hadzic A']","['Aged', 'Ambulatory Surgical Procedures/adverse effects', 'Anesthetics, Local/*administration & dosage', 'Brachial Plexus Block/*methods', 'Bupivacaine/*administration & dosage/chemistry', 'Double-Blind Method', 'Female', 'Humans', 'Liposomes', 'Male', 'Middle Aged', 'Pain Measurement/*drug effects/methods', 'Pain, Postoperative/diagnosis/*prevention & control', 'Prospective Studies', 'Shoulder/*surgery']",https://pubmed.ncbi.nlm.nih.gov/28157791/
565,Bupivacaine,2803882,Comparison of bupivacaine and bupivacaine with fentanyl in continuous extradural analgesia during labour.,"['Jones G', 'Paul DL', 'Elton RA', 'McClure JH']","['Adult', '*Analgesia, Epidural/adverse effects', '*Anesthesia, Obstetrical/adverse effects', 'Apgar Score', 'Bupivacaine/*administration & dosage/adverse effects', 'Delivery, Obstetric', 'Female', 'Fentanyl/*administration & dosage/adverse effects', 'Humans', 'Infant, Newborn', '*Labor, Obstetric', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/2803882/
566,Sumatriptan,17955173,Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment.,['Tfelt-Hansen P'],"['Administration, Oral', 'Biological Availability', 'Humans', 'Infusions, Parenteral', 'Injections, Subcutaneous', 'Migraine Disorders/*drug therapy/physiopathology', 'Piperidines/*administration & dosage/blood/pharmacokinetics', 'Serotonin Receptor Agonists/*administration & dosage/blood/pharmacokinetics', 'Sumatriptan/*administration & dosage/blood/pharmacokinetics', 'Time Factors', 'Treatment Outcome', 'Tryptamines/*administration & dosage/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/17955173/
567,Sumatriptan,7488309,"Screening and identification of sumatriptan and its main metabolite by means of thin-layer chromatography, ultraviolet spectroscopy and gas chromatography/mass spectrometry.","['Rochholz G', 'Ahrens B', 'Konig F', 'Schutz HW', 'Schutz H', 'Seno H']","['Biotransformation', 'Chromatography, Thin Layer', 'Densitometry', 'Gas Chromatography-Mass Spectrometry', 'Humans', 'Spectrophotometry, Ultraviolet', 'Sumatriptan/*analysis/urine']",https://pubmed.ncbi.nlm.nih.gov/7488309/
568,Sumatriptan,24442762,Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERS.,"['Nguyen TQ', 'Lewis JH']","['*Adverse Drug Reaction Reporting Systems', 'Colitis, Ischemic/*chemically induced/diagnosis/epidemiology', 'Colonoscopy', 'Humans', 'Intestinal Mucosa/drug effects/pathology', 'Serotonin 5-HT1 Receptor Agonists/administration & dosage/*adverse effects/therapeutic use', 'Sumatriptan/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24442762/
569,Sumatriptan,25078720,"Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein.","['Labruijere S', 'Chan KY', 'de Vries R', 'van den Bogaerdt AJ', 'Dirven CM', 'Danser AJ', 'Kori SH', 'MaassenVanDenBrink A']","['Adolescent', 'Adult', 'Aged', 'Coronary Vessels/*drug effects', 'Dihydroergotamine/*pharmacology', 'Female', 'Humans', 'Male', 'Meningeal Arteries/*drug effects', 'Middle Aged', 'Organ Culture Techniques', 'Saphenous Vein/*drug effects', 'Sumatriptan/*pharmacology', 'Vasoconstriction/drug effects', 'Vasoconstrictor Agents/*pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25078720/
570,Sumatriptan,26659468,OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics.,"['Matthaei J', 'Kuron D', 'Faltraco F', 'Knoch T', 'Dos Santos Pereira JN', 'Abu Abed M', 'Prukop T', 'Brockmoller J', 'Tzvetkov MV']","['Alleles', 'Biological Availability', 'Cell Membrane Permeability/drug effects', 'Enzyme Inhibitors/pharmacology', 'Genotype', 'HEK293 Cells', 'Hepatocytes/metabolism', 'Humans', 'Liver/*drug effects/*metabolism', 'Migraine Disorders/drug therapy', 'Octamer Transcription Factor-1/antagonists & inhibitors/*genetics/*metabolism', '*Polymorphism, Genetic', 'Serotonin Receptor Agonists/blood/*pharmacokinetics', 'Sumatriptan/blood/*pharmacokinetics', 'Tryptamines/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26659468/
571,Sumatriptan,8873693,Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response.,"['Visser WH', 'Burggraaf J', 'Muller LM', 'Schoemaker RC', 'Fowler PA', 'Cohen AF', 'Ferrari MD']","['Adolescent', 'Adult', 'Aged', 'Female', 'Half-Life', 'Humans', 'Male', 'Metabolic Clearance Rate', 'Middle Aged', 'Migraine Disorders/*drug therapy/*metabolism', 'Recurrence', 'Sumatriptan/*pharmacokinetics/*therapeutic use', 'Vasoconstrictor Agents/*pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8873693/
572,Sumatriptan,33368986,Spectrofluorimetric investigation for determination of sumatriptan succinate: application to tablets and spiked human plasma.,"['Abo Zaid MH', 'Abo El Abass S', 'El-Enany N', 'Aly F']","['Humans', '*Plasma', 'Spectrometry, Fluorescence', '*Sumatriptan', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/33368986/
573,Sumatriptan,23657930,Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine.,"['Maghbooli M', 'Golipour F', 'Moghimi Esfandabadi A', 'Yousefi M']","['Administration, Oral', 'Adult', 'Analgesics/*therapeutic use', 'Antiemetics/therapeutic use', 'Double-Blind Method', 'Female', 'Zingiber officinale/*chemistry', 'Humans', 'Male', 'Migraine without Aura/*drug therapy', 'Patient Satisfaction', 'Plant Preparations/*therapeutic use', 'Sumatriptan/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23657930/
574,Sumatriptan,9209775,"Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.","['Kunka RL', 'Hussey EK', 'Shaw S', 'Warner P', 'Aubert B', 'Richard I', 'Fowler PA', 'Pakes GE']","['Adolescent', 'Adult', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Male', 'Middle Aged', 'Reference Values', 'Serotonin Receptor Agonists/*adverse effects/pharmacokinetics', 'Sumatriptan/*adverse effects/pharmacokinetics', 'Suppositories']",https://pubmed.ncbi.nlm.nih.gov/9209775/
575,Sumatriptan,38730542,Development and Evaluation of Chemometric Models for the Estimation of Sumatriptan in the Presence of Naproxen and a Degradation Product Using UV Spectrophotometry.,"['Michael AM', 'Lotfy HM', 'Rezk MR', 'Nessim CK']","['*Sumatriptan/analysis/chemistry', '*Naproxen/analysis/chemistry', '*Spectrophotometry, Ultraviolet/methods', 'Least-Squares Analysis', 'Drug Stability', 'Principal Component Analysis']",https://pubmed.ncbi.nlm.nih.gov/38730542/
576,Sumatriptan,27020929,Development and validation of an LC-ESI-MS/MS method for the simultaneous quantification of naproxen and sumatriptan in human plasma: application to a pharmacokinetic study.,"['Bretas JM', 'Cesar IC', 'Bretas CM', 'Teixeira Lde S', 'Bellorio KB', 'Mundim IM', 'Pianetti GA']","['Chromatography, Liquid/*methods', 'Humans', 'Naproxen/*blood/pharmacokinetics', 'Plasma/chemistry', 'Sumatriptan/*blood/pharmacokinetics', 'Tandem Mass Spectrometry/*methods']",https://pubmed.ncbi.nlm.nih.gov/27020929/
577,Sumatriptan,9827244,"Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat.",['Tfelt-Hansen P'],"['Administration, Intranasal', 'Administration, Oral', 'Double-Blind Method', 'Humans', 'Injections, Subcutaneous', 'Migraine Disorders/*drug therapy', 'Randomized Controlled Trials as Topic', 'Safety', 'Serotonin Receptor Agonists/administration & dosage/adverse effects/*therapeutic use', 'Sumatriptan/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome', 'Vasoconstrictor Agents/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9827244/
578,Sumatriptan,10570730,Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data.,['Gaist D'],"['Cluster Headache/drug therapy', 'Denmark', '*Drug Prescriptions', 'Female', 'Humans', '*Interviews as Topic', 'Male', 'Migraine Disorders/drug therapy', '*Pharmacoepidemiology', ""*Practice Patterns, Physicians'"", 'Registries', 'Serotonin Receptor Agonists/adverse effects/*therapeutic use', 'Sumatriptan/adverse effects/*therapeutic use', 'Tension-Type Headache/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10570730/
579,Sumatriptan,10849042,Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial.,"['Mathew NT', 'Kailasam J', 'Gentry P', 'Chernyshev O']","['Administration, Oral', 'Cross-Over Studies', 'Drug Resistance', 'Humans', 'Migraine Disorders/*drug therapy', 'Oxazoles/adverse effects/*therapeutic use', '*Oxazolidinones', 'Retreatment', 'Serotonin Receptor Agonists/adverse effects/*therapeutic use', 'Sumatriptan/adverse effects/*therapeutic use', 'Triazoles/adverse effects/*therapeutic use', 'Tryptamines', 'Vasoconstrictor Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10849042/
580,Sumatriptan,26975891,Systematic review: Is Metoclopramide more effective than Sumatriptan in relieving pain from migraine in adults in the Emergency Department (ED) setting?,['Barleycorn D'],"['Adult', 'Analgesics/pharmacology/therapeutic use', 'Emergency Service, Hospital/organization & administration', 'Female', 'Humans', 'Male', 'Metoclopramide/*pharmacology/therapeutic use', 'Migraine Disorders/*drug therapy', 'Pain Management/*methods', 'Sumatriptan/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26975891/
581,Sumatriptan,7828190,"Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences.","['Ferrari MD', 'James MH', 'Bates D', 'Pilgrim A', 'Ashford E', 'Anderson BA', 'Nappi G']","['Administration, Oral', 'Adult', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Middle Aged', 'Migraine Disorders/*drug therapy/prevention & control', 'Recurrence', 'Sumatriptan/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7828190/
582,Azelastine,39212082,Generic competition and prices for azelastine-fluticasone nasal spray.,"['Bhat AM', 'Soler ZM', 'Schlosser RJ', 'Scangas GA', 'Workman AD', 'Rathi VK']","['Humans', '*Drugs, Generic/economics', '*Phthalazines/economics', '*Fluticasone/administration & dosage', '*Nasal Sprays', 'United States', 'Drug Combinations', 'Economic Competition', 'Anti-Allergic Agents/economics', 'Drug Costs']",https://pubmed.ncbi.nlm.nih.gov/39212082/
583,Azelastine,30961435,Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis.,"['Debbaneh PM', 'Bareiss AK', 'Wise SK', 'McCoul ED']","['Administration, Intranasal', 'Anti-Allergic Agents/*administration & dosage', 'Drug Combinations', 'Fluticasone/*administration & dosage', 'Humans', 'Phthalazines/*administration & dosage', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30961435/
584,Azelastine,32605694,Treatment with azelastine hydrochloride and fluticasone propionate in a single delivery device of young children and adolescents with allergic rhinitis.,"['Berger WE', 'Mustakov TB', 'Kralimarkova TZ', 'Christoff G', 'Popov TA']","['Administration, Intranasal', 'Adolescent', 'Anti-Allergic Agents/*therapeutic use', 'Child', 'Child, Preschool', 'Drug Combinations', 'Fluticasone/*therapeutic use', 'Humans', 'Infant', 'Phthalazines/*therapeutic use', 'Rhinitis, Allergic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32605694/
585,Azelastine,12383290,A study of intranasal distribution of azelastine hydrochloride aqueous nasal spray with different spray techniques.,"['Bateman ND', 'Whymark AD', 'Clifton NJ', 'Woolford TJ']","['Administration, Intranasal', 'Aerosols', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacokinetics', 'Humans', 'Nasal Mucosa/*chemistry', 'Phthalazines/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/12383290/
586,Azelastine,34813682,Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy.,"['Watts AM', 'West NP', 'Smith PK', 'Zhang P', 'Cripps AW', 'Cox AJ']","['Fluticasone/therapeutic use', 'Gene Expression', 'Humans', 'Phthalazines/therapeutic use', '*Rhinitis, Allergic, Seasonal']",https://pubmed.ncbi.nlm.nih.gov/34813682/
587,Azelastine,36053218,Efficacy of Topical Azelastine and Fluticasone Dipropionate Combination in Children With Adenoid Hypertrophy.,"['Bilgili AM', 'Durmaz HO', 'Dilber M']","['Child', 'Humans', 'Child, Preschool', 'Fluticasone', '*Nasal Sprays']",https://pubmed.ncbi.nlm.nih.gov/36053218/
588,Azelastine,24383318,"Identification and determination of ketotifen hydrogen fumarate, azelastine hydrochloride, dimetindene maleate and promethazine hydrochloride by densitometric method.","['Wyszomirska E', 'Czerwinska K', 'Kublin E', 'Mazurek AP']","['Calibration', '*Chromatography, Thin Layer/standards', '*Densitometry/standards', 'Dimethindene/*analysis', 'Histamine H1 Antagonists/*analysis', 'Ketotifen/analysis', 'Limit of Detection', 'Phthalazines/*analysis', 'Promethazine/*analysis', 'Regression Analysis', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/24383318/
589,Azelastine,37100830,Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.,"['Klussmann JP', 'Grosheva M', 'Meiser P', 'Lehmann C', 'Nagy E', 'Szijarto V', 'Nagy G', 'Konrat R', 'Flegel M', 'Holzer F', 'Gross D', 'Steinmetz C', 'Scherer B', 'Gruell H', 'Schlotz M', 'Klein F', 'de Aragao PA', 'Morr H', 'Al Saleh H', 'Bilstein A', 'Russo B', 'Muller-Scholtz S', 'Acikel C', 'Sahin H', 'Werkhauser N', 'Allekotte S', 'Mosges R']","['Humans', '*SARS-CoV-2', '*COVID-19', 'Nasal Sprays', 'Viral Load', 'Double-Blind Method', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37100830/
590,Azelastine,37195751,Anti-chlamydial effects of azelastine hydrochloride and the impact of the histamine H1 receptor on chlamydial development.,"['Kuratli J', 'Leonard CA', 'Schoborg R', 'Borel N']","['Humans', 'Chlamydia trachomatis', 'HeLa Cells', 'Histamine H1 Antagonists/pharmacology', '*Phthalazines/pharmacology', '*Receptors, Histamine H1/metabolism', '*Chlamydia Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37195751/
591,Azelastine,12776442,Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis.,"['Lieberman PL', 'Settipane RA']","['Anti-Inflammatory Agents, Non-Steroidal/metabolism/*pharmacology/therapeutic use', 'Europe', 'Histamine H1 Antagonists/metabolism/*pharmacology/therapeutic use', 'Humans', 'Japan', 'Phthalazines/metabolism/*pharmacology/therapeutic use', 'Respiratory Hypersensitivity/drug therapy/metabolism', 'Rhinitis/drug therapy/metabolism', 'Treatment Outcome', 'United States']",https://pubmed.ncbi.nlm.nih.gov/12776442/
592,Azelastine,33180014,"Maraviroc, celastrol and azelastine alter Chlamydia trachomatis development in HeLa cells.","['Kuratli J', 'Leonard CA', 'Nufer L', 'Marti H', 'Schoborg R', 'Borel N']","['Chlamydia trachomatis/*drug effects/growth & development/ultrastructure', 'Cytokines/*antagonists & inhibitors', 'HeLa Cells', 'Humans', 'Indicators and Reagents', 'Maraviroc/*pharmacology', 'Microbial Sensitivity Tests', 'Oxazines', 'Pentacyclic Triterpenes', 'Phthalazines/*pharmacology', 'Triterpenes/*pharmacology', 'Xanthenes']",https://pubmed.ncbi.nlm.nih.gov/33180014/
593,Azelastine,35344122,Synchronous Fluorescence as a Green and Selective Method for the Simultaneous Determination of Cetirizine and Azelastine in Aqueous Humor.,"['Abd-AlGhafar WN', 'Aly FA', 'Sheribah ZA', 'Saad S']","['*Aqueous Humor', '*Cetirizine', 'Ophthalmic Solutions', 'Phthalazines', 'Spectrometry, Fluorescence/methods']",https://pubmed.ncbi.nlm.nih.gov/35344122/
594,Azelastine,1981189,Azelastine and desmethylazelastine suppress acetylcholine-induced contraction and depolarization in human airway smooth muscle.,"['Richards IS', 'Miller L', 'Solomon D', 'Kulkarni A', 'Brooks S', 'Sperelakis N']","['Acetylcholine/*antagonists & inhibitors/pharmacology', 'Electrophysiology', 'Histamine H1 Antagonists/*pharmacology', 'Humans', 'In Vitro Techniques', 'Isometric Contraction', 'Membrane Potentials/drug effects', 'Microelectrodes', 'Muscle Contraction/drug effects', 'Muscle, Smooth/*drug effects', 'Phthalazines/*pharmacology', 'Trachea/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1981189/
595,solifenacin,30350884,Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.,"['Wang J', 'Zhou Z', 'Cui Y', 'Li Y', 'Yuan H', 'Gao Z', 'Zhu Z', 'Wu J']","['Acetanilides/adverse effects/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Solifenacin Succinate/adverse effects/*therapeutic use', 'Thiazoles/adverse effects/*therapeutic use', 'Urinary Bladder, Overactive/*drug therapy', 'Urological Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30350884/
596,solifenacin,36336627,Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review.,"['Raman G', 'Tunnicliffe D', 'Lai E', 'Bennett T', 'Caldwell P']","['Child', 'Adolescent', 'Humans', 'Solifenacin Succinate/adverse effects', '*Urinary Bladder, Overactive/drug therapy', 'Treatment Outcome', 'Cholinergic Antagonists/adverse effects', '*Xerostomia/chemically induced/drug therapy', 'Constipation', 'Muscarinic Antagonists/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/36336627/
597,solifenacin,28506854,Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder.,"['Newgreen D', 'Bosman B', 'Hollestein-Havelaar A', 'Dahler E', 'Besuyen R', 'Snijder R', 'Sawyer W', 'Rittig S', 'Bolduc S']","['Adolescent', 'Child', 'Double-Blind Method', 'Humans', 'Muscarinic Antagonists/*therapeutic use', 'Solifenacin Succinate/*therapeutic use', 'Treatment Outcome', 'Urinary Bladder, Overactive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28506854/
598,solifenacin,36344629,Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study.,"['Tang QL', 'Zhou S', 'Liu YQ', 'Wu J', 'Tao RZ']","['Humans', '*Solifenacin Succinate/adverse effects', '*Urinary Bladder, Overactive/drug therapy/diagnosis', 'Prospective Studies', 'Quality of Life', 'Treatment Outcome', 'Drug Therapy, Combination', 'Acetanilides/adverse effects', 'Stents', 'Muscarinic Antagonists/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36344629/
599,solifenacin,28550362,"The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis.","['Wang J', 'Zhang X', 'Zhang T', 'Mu J', 'Bai B', 'Lei Y']","['Adrenergic alpha-1 Receptor Antagonists/*therapeutic use', 'Drug Therapy, Combination', 'Flank Pain/drug therapy/etiology', 'Health Status', 'Hematuria/drug therapy/etiology', 'Humans', 'Lower Urinary Tract Symptoms/*drug therapy/etiology', 'Muscarinic Antagonists/*therapeutic use', 'Postoperative Complications/*drug therapy/etiology', 'Quality of Life', 'Solifenacin Succinate/*therapeutic use', 'Stents/*adverse effects', 'Sulfonamides/*therapeutic use', 'Tamsulosin', 'Ureter/*surgery', 'Xerostomia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/28550362/
600,solifenacin,28150436,Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment.,"['Chua ME', 'See MC 4th', 'Esmena EB', 'Balingit JC', 'Morales ML Jr']","['Adolescent', 'Adult', 'Aged', 'Amines/*administration & dosage/adverse effects', 'Cyclohexanecarboxylic Acids/*administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Gabapentin', 'Humans', 'Male', 'Middle Aged', 'Muscarinic Antagonists/*administration & dosage/adverse effects', 'Prospective Studies', 'Quality of Life', 'Solifenacin Succinate/*administration & dosage/adverse effects', 'Treatment Outcome', 'Urinary Bladder, Overactive/*drug therapy', 'Urological Agents/*administration & dosage/adverse effects', 'Young Adult', 'gamma-Aminobutyric Acid/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28150436/
601,solifenacin,37871329,Efficacy and Safety of High-Dose Vitamin D Supplementation vs Solifenacin or Standard Urotherapy for Overactive Bladder Dry in Children: A Randomized Clinical Trial.,"['Chen H', 'Zhang Z', 'Wu S', 'Zhang D', 'Zhong X', 'Liu X', 'Wei G']","['Child', 'Humans', 'Dietary Supplements', 'Muscarinic Antagonists', 'Quality of Life', '*Solifenacin Succinate', 'Treatment Outcome', '*Urinary Bladder, Overactive/drug therapy', 'Vitamin D/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37871329/
602,solifenacin,34161360,Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study.,"['Zhang Y', 'Wang S', 'Zu S', 'Zhang C']","['Adolescent', 'Adult', 'Aged', 'Combined Modality Therapy', 'Double-Blind Method', 'Female', 'Follow-Up Studies', 'Humans', 'Middle Aged', 'Muscarinic Antagonists/*pharmacology', 'Prognosis', 'Prospective Studies', 'Solifenacin Succinate/*pharmacology', 'Transcutaneous Electric Nerve Stimulation/*methods', 'Urinary Bladder, Overactive/pathology/*therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34161360/
603,solifenacin,29140559,Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.,"['Nazir J', 'Kelleher C', 'Aballea S', 'Maman K', 'Hakimi Z', 'Mankowski C', 'Odeyemi I']","['Benzhydryl Compounds/adverse effects/therapeutic use', 'Benzilates/adverse effects/therapeutic use', 'Humans', 'Mandelic Acids/adverse effects/therapeutic use', 'Muscarinic Antagonists/adverse effects/*therapeutic use', 'Network Meta-Analysis', 'Solifenacin Succinate/adverse effects/*therapeutic use', 'Tolterodine Tartrate/adverse effects/therapeutic use', 'Treatment Outcome', 'Urinary Bladder, Overactive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29140559/
604,solifenacin,39469916,Safety and Efficacy of Trospium Chloride and Solifenacin in Stroke-Induced Neurogenic Lower Urinary Tract Dysfunction: A Randomized Controlled Trial.,"['Hajebrahimi S', 'Pourmohammad A', 'Konstantinidis C', 'Samarinas M', 'Morsali S', 'Mostafaei H', 'Farhoudi M', ""Rahnama'i MS"", 'Beheshti R', 'Salehi-Pourmehr H']","['Humans', '*Nortropanes/adverse effects/administration & dosage', 'Male', '*Benzilates/adverse effects', '*Solifenacin Succinate/administration & dosage/adverse effects', 'Female', 'Aged', 'Middle Aged', '*Stroke/complications', '*Quality of Life', 'Treatment Outcome', '*Muscarinic Antagonists/adverse effects/administration & dosage', 'Lower Urinary Tract Symptoms/drug therapy/physiopathology/diagnosis/etiology', 'Double-Blind Method', 'Urological Agents/adverse effects/therapeutic use/administration & dosage', 'Urinary Bladder, Neurogenic/drug therapy/physiopathology/diagnosis/etiology']",https://pubmed.ncbi.nlm.nih.gov/39469916/
605,solifenacin,26757270,"Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women--a multicenter, randomized, open-label, controlled comparison study.","['Jiang F', 'Zhu L', 'Xu T', 'Gong MY', 'Huang YL', 'Li HF', 'Wang JJ', 'Tong XW', 'Cheng XX', 'Bai WP', 'Li X', 'Xu XX', 'Xu HC']","['Administration, Intravaginal', 'Aged', 'China', 'Estrogens/*administration & dosage/adverse effects', 'Female', 'Humans', 'Middle Aged', 'Muscarinic Antagonists/therapeutic use', '*Postmenopause', 'Quality of Life', 'Solifenacin Succinate/adverse effects/*therapeutic use', 'Surveys and Questionnaires', 'Treatment Outcome', 'Urinary Bladder, Overactive/*drug therapy', '*Urological Agents']",https://pubmed.ncbi.nlm.nih.gov/26757270/
606,solifenacin,32749655,Comparison of the effects of trospium and solifenacin on intraocular pressure and tear secretion in patients with overactive bladder.,"['Turkoglu AR', 'Parmak Yener N', 'Guzelsoy M', 'Coban S', 'Demirci H']","['Adult', 'Aged', 'Humans', 'Intraocular Pressure', 'Middle Aged', 'Muscarinic Antagonists', 'Prospective Studies', '*Solifenacin Succinate', 'Treatment Outcome', '*Urinary Bladder, Overactive/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32749655/
607,solifenacin,39913092,Efficacy and Safety of Mirabegron Compared to Solifenacin in Treatment of Non-neurogenic Overactive Bladder in Children: A Randomized Controlled Trial.,"['Mansour I', 'Laymon M', 'Abdelhalim A', 'Dawaba MS', 'El-Hefnawy AS']","['Humans', '*Solifenacin Succinate/therapeutic use', '*Acetanilides/therapeutic use/adverse effects', '*Urinary Bladder, Overactive/drug therapy', '*Thiazoles/therapeutic use/adverse effects', 'Child', 'Male', 'Female', 'Treatment Outcome', 'Urological Agents/therapeutic use/adverse effects', 'Adrenergic beta-3 Receptor Agonists/therapeutic use/adverse effects', 'Muscarinic Antagonists/therapeutic use/adverse effects', 'Adolescent', 'Surveys and Questionnaires', 'Time Factors', 'Statistics, Nonparametric', 'Child, Preschool']",https://pubmed.ncbi.nlm.nih.gov/39913092/
608,solifenacin,34308834,The bioequivalence of a single dose of a generic solifenacin succinate tablet or Vesicare in fasting or postprandial healthy Chinese adults.,"['Jin H', 'Shi L', 'Yin J', 'Yu J', 'Jiang M', 'Liu F', 'Zhang J', 'Zhu Y', 'Zou C', 'Yang H']","['Adult', 'Area Under Curve', 'China', 'Cross-Over Studies', '*Fasting', 'Healthy Volunteers', 'Humans', '*Solifenacin Succinate', 'Tablets', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/34308834/
609,solifenacin,32374123,"The relation between the storage symptoms before and after transurethral resection of the prostate, analysis of the risk factors and the prevention of the symptoms with solifenacin.","['Sipal T', 'Akdere H']","['Aged', 'Humans', 'Male', 'Middle Aged', '*Prostatic Hyperplasia/drug therapy/surgery', 'Risk Factors', 'Solifenacin Succinate/therapeutic use', '*Transurethral Resection of Prostate', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32374123/
610,solifenacin,29866467,"Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).","['Gratzke C', 'van Maanen R', 'Chapple C', 'Abrams P', 'Herschorn S', 'Robinson D', 'Ridder A', 'Stoelzel M', 'Paireddy A', 'Yoon SJ', 'Al-Shukri S', 'Rechberger T', 'Mueller ER']","['*Acetanilides/administration & dosage/adverse effects', 'Drug Monitoring/methods', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', '*Solifenacin Succinate/administration & dosage/adverse effects', 'Symptom Assessment', '*Thiazoles/administration & dosage/adverse effects', 'Time', 'Treatment Outcome', 'Urinary Bladder, Overactive/diagnosis/*drug therapy/physiopathology', 'Urinary Incontinence/diagnosis', 'Urination/drug effects', 'Urological Agents/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/29866467/
611,solifenacin,23234618,Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.,"['Kaplan SA', 'McCammon K', 'Fincher R', 'Fakhoury A', 'He W']","['Adrenergic alpha-Antagonists/therapeutic use', 'Aged', 'Aged, 80 and over', 'Double-Blind Method', 'Humans', 'Male', 'Middle Aged', 'Muscarinic Antagonists/adverse effects/*therapeutic use', 'Quinuclidines/adverse effects/*therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/adverse effects/*therapeutic use', 'Urinary Bladder, Overactive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/23234618/
612,solifenacin,34346046,Evaluation of the Clinical Efficacy and Complications of Duloxetine in Comparison to Solifenacin in the Treatment of Overactive Bladder Disease in Women: A Randomized Clinical Trial.,"['Mirzaei M', 'Daneshpajooh A', 'Anvari SO', 'Dozchizadeh S', 'Teimorian M']","['Duloxetine Hydrochloride/adverse effects', 'Female', 'Humans', 'Muscarinic Antagonists', '*Solifenacin Succinate', 'Treatment Outcome', '*Urinary Bladder, Overactive/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34346046/
613,solifenacin,28418102,Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).,"['Herschorn S', 'Chapple CR', 'Abrams P', 'Arlandis S', 'Mitcheson D', 'Lee KS', 'Ridder A', 'Stoelzel M', 'Paireddy A', 'van Maanen R', 'Robinson D']","['Acetanilides/*administration & dosage/adverse effects', 'Adult', 'Aged', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Internationality', 'Male', 'Maximum Tolerated Dose', 'Middle Aged', 'Multivariate Analysis', 'Risk Assessment', 'Single-Blind Method', 'Solifenacin Succinate/*administration & dosage/adverse effects', 'Thiazoles/*administration & dosage/adverse effects', 'Time Factors', 'Treatment Outcome', 'Urinary Bladder, Overactive/diagnosis/*drug therapy', 'Urinary Incontinence/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/28418102/
614,solifenacin,31662524,"Comparison of Solifenacin and Bilateral Apical Fixation in the Treatment of Mixed and Urgency Urinary Incontinence in Women: URGE 1 Study, A Randomized Clinical Trial.","['Ludwig S', 'Becker I', 'Mallmann P', 'Jager W']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Genital Diseases, Female/drug therapy/therapy', 'Humans', 'Middle Aged', 'Solifenacin Succinate/*therapeutic use', 'Urinary Bladder/drug effects', 'Urinary Incontinence/*drug therapy/*therapy', 'Urination Disorders/drug therapy/therapy']",https://pubmed.ncbi.nlm.nih.gov/31662524/
615,Cimetidine,1592416,Conformational studies on cimetidine and ranitidine by PCILO calculations and NMR spectroscopy.,"['Saran A', 'Srivastava S', 'Kulkarni VM', 'Coutinho E']","['Cimetidine/*chemistry', '*Magnetic Resonance Spectroscopy', 'Molecular Conformation', '*Quantum Theory', 'Ranitidine/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/1592416/
616,Cimetidine,6869120,Determination of submicrogram quantities of cimetidine and its biotransformation and degradation products.,"['Jenko B', 'Kosak A', 'Milivojevic D', 'Kralj B']","['Biotransformation', 'Cimetidine/analysis/*metabolism', 'Guanidines/*metabolism', 'Humans', 'Mass Spectrometry']",https://pubmed.ncbi.nlm.nih.gov/6869120/
617,Cimetidine,4057034,"Cimetidine as pre-anesthetic agent for cesarean section: perinatal effects on the infant, the placental transfer of cimetidine and its elimination in the infants.","['Qvist N', 'Storm K', 'Holmskov A']","['*Cesarean Section', 'Cimetidine/adverse effects/*blood/therapeutic use', 'Double-Blind Method', 'Female', 'Humans', '*Infant, Newborn', '*Maternal-Fetal Exchange', '*Preanesthetic Medication', 'Pregnancy', 'Prospective Studies', 'Umbilical Veins']",https://pubmed.ncbi.nlm.nih.gov/4057034/
618,Cimetidine,6375965,Cimetidine for stress-ulcer prophylaxis.,"['Greene WL', 'Bollinger RR']","['Antacids/adverse effects/therapeutic use', 'Cimetidine/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Gastric Juice/drug effects/metabolism', 'Gastric Mucosa/drug effects/metabolism', 'Humans', 'Peptic Ulcer/physiopathology/*prevention & control', 'Random Allocation', 'Stress, Physiological/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/6375965/
619,Cimetidine,6733633,Cimetidine-induced fever.,"['Landolfo K', 'Low DE', 'Rogers AG']","['Administration, Oral', 'Aged', 'Cimetidine/administration & dosage/*adverse effects', 'Duodenal Ulcer/drug therapy', 'Female', 'Fever/*chemically induced', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/6733633/
620,Cimetidine,4020559,Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children.,"['Lloyd CW', 'Martin WJ', 'Taylor BD', 'Hauser AR']","['Adolescent', 'Brain Injuries/*drug therapy', 'Child', 'Child, Preschool', 'Cimetidine/analysis/metabolism/*therapeutic use', 'Critical Care', 'Female', 'Humans', 'Kinetics', 'Male', 'Stomach/analysis']",https://pubmed.ncbi.nlm.nih.gov/4020559/
621,Cimetidine,1570516,The fasciitis-panniculitis syndrome: clinical spectrum and response to cimetidine.,"['Naschitz JE', 'Yeshurun D', 'Zuckerman E', 'Rosner I', 'Shajrawi I', 'Missellevitch I', 'Boss JH']","['Cimetidine/*therapeutic use', 'Eosinophilia', 'Fasciitis/*drug therapy', 'Humans', 'Panniculitis/*drug therapy', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/1570516/
622,Cimetidine,2355107,Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients.,"['Sandborn WJ', 'Forland SC', 'Cutler RE', 'Strong RM']","['Administration, Oral', 'Adult', 'Aged', 'Biological Availability', 'Cimetidine/administration & dosage/blood/*pharmacokinetics/pharmacology', 'Female', 'Gastric Acidity Determination', 'Gastritis/drug therapy', 'Hospitals, Veterans', 'Humans', 'Hydrogen-Ion Concentration', 'Injections, Intravenous', 'Male', 'Middle Aged', 'Peptic Ulcer/drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2355107/
623,Cimetidine,2066715,Cimetidine and ranitidine may not cross-react to cause thrombocytopenia.,"['Shalev O', 'Seror D']","['Aged', 'Cimetidine/*adverse effects/therapeutic use', 'Duodenal Ulcer/complications/*drug therapy', 'Humans', 'Male', 'Peptic Ulcer Hemorrhage/etiology', 'Ranitidine/*therapeutic use', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/2066715/
624,Cimetidine,6691563,Effect of preanesthetic glycopyrrolate and cimetidine on gastric fluid pH and volume in outpatients.,"['Manchikanti L', 'Roush JR']","['Adult', '*Ambulatory Surgical Procedures', 'Cimetidine/administration & dosage/*pharmacology', 'Gastric Acidity Determination', 'Gastric Juice/*drug effects/metabolism', 'Glycopyrrolate/administration & dosage/*pharmacology', 'Humans', 'Hydrogen-Ion Concentration', '*Preanesthetic Medication', 'Pyrrolidines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6691563/
625,Cimetidine,4033072,Quantitation of cimetidine and cimetidine sulfoxide in serum by solid-phase extraction and solvent-recycled liquid chromatography.,"['Lin Q', 'Lensmeyer GL', 'Larson FC']","['Chromatography, High Pressure Liquid/methods', 'Cimetidine/*analogs & derivatives/*blood', 'Humans', 'Middle Aged', 'Solvents']",https://pubmed.ncbi.nlm.nih.gov/4033072/
626,Cimetidine,3063727,Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine.,"['Pritchett EL', 'Smith WM', 'Kirsten EB']","['Adult', 'Cimetidine/adverse effects/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Electrocardiography', 'Humans', 'Male', 'Propafenone/adverse effects/pharmacokinetics/*pharmacology', 'Renin/blood', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3063727/
627,Cimetidine,7226705,"Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients.","['Schentag JJ', 'Cerra FB', 'Calleri GM', 'Leising ME', 'French MA', 'Bernhard H']","['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Blood-Brain Barrier', 'Chronic Disease/*metabolism', 'Cimetidine/cerebrospinal fluid/*metabolism', 'Guanidines/*metabolism', 'Half-Life', 'Humans', 'Metabolic Clearance Rate', 'Middle Aged', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/7226705/
628,Cimetidine,6344228,Interaction of cimetidine with other drugs.,['Feely J'],"['Aged', 'Chlormethiazole/metabolism', 'Cimetidine/metabolism/*pharmacology', 'Diazepam/metabolism', 'Drug Interactions', 'Guanidines/*pharmacology', 'Humans', 'Lidocaine/metabolism', 'Liver/metabolism', 'Liver Circulation', 'Phenytoin/metabolism', 'Propranolol/metabolism', 'Tissue Distribution', 'Warfarin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/6344228/
629,Cimetidine,25497893,Qualitative and simultaneous quantitative analysis of cimetidine polymorphs by ultraviolet-visible and shortwave near-infrared diffuse reflectance spectroscopy and multivariate calibration models.,"['Feng Y', 'Li X', 'Xu K', 'Zou H', 'Li H', 'Liang B']","['Calibration', 'Cimetidine/*analysis/chemistry', 'Crystallization/methods', 'Photoelectron Spectroscopy/methods', 'Spectroscopy, Near-Infrared/methods', 'X-Ray Diffraction/methods']",https://pubmed.ncbi.nlm.nih.gov/25497893/
630,Zafirlukast,31670489,Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast.,"['Schierle S', 'Helmstadter M', 'Schmidt J', 'Hartmann M', 'Horz M', 'Kaiser A', 'Weizel L', 'Heitel P', 'Proschak A', 'Hernandez-Olmos V', 'Proschak E', 'Merk D']","['Binding Sites', 'Catalytic Domain', 'Cholesterol 7-alpha-Hydroxylase/genetics/metabolism', 'Drug Evaluation, Preclinical', 'Epoxide Hydrolases/*antagonists & inhibitors/genetics/metabolism', 'Gene Expression Regulation/drug effects', 'Hep G2 Cells', 'Humans', 'Indoles', 'Membrane Transport Proteins/genetics/metabolism', 'Molecular Docking Simulation', 'Non-alcoholic Fatty Liver Disease/metabolism/pathology', 'Phenylcarbamates', 'Receptors, Cytoplasmic and Nuclear/*agonists/genetics/metabolism', 'Structure-Activity Relationship', 'Sulfonamides', 'Tosyl Compounds/*chemistry/metabolism/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/31670489/
631,Zafirlukast,9463793,Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.,"['Adkins JC', 'Brogden RN']","['Anti-Asthmatic Agents/economics/pharmacokinetics/*therapeutic use', 'Asthma/*drug therapy/economics', 'Clinical Trials as Topic', 'Humans', 'Indoles', '*Leukotriene Antagonists', 'Phenylcarbamates', 'Sulfonamides', 'Tosyl Compounds/economics/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9463793/
632,Zafirlukast,35408930,Zafirlukast Induces VHL- and HIF-2alpha-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells.,"['Wolf C', 'Smith S', 'van Wijk SJL']","['Basic Helix-Loop-Helix Transcription Factors/metabolism', '*Carcinoma, Renal Cell/drug therapy/genetics/pathology', 'Cell Death', 'Cell Line, Tumor', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Hypoxia-Inducible Factor 1, alpha Subunit/genetics/metabolism', 'Indoles', '*Kidney Neoplasms/drug therapy/genetics/metabolism', 'Oxidative Stress', 'Phenylcarbamates', 'Sulfonamides', 'Von Hippel-Lindau Tumor Suppressor Protein/genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35408930/
633,Zafirlukast,33977464,Zafirlukast promotes mitochondrial respiration by stimulating mitochondrial biogenesis in human bronchial epithelial cells.,"['Ren P', 'Gong F', 'Chang L', 'Hong X', 'Xing L', 'Zhang H']","['Blotting, Western', 'Bronchi/*cytology', 'CREB-Binding Protein/metabolism', 'Cell Respiration/drug effects/physiology', 'DNA, Mitochondrial/metabolism', 'DNA-Binding Proteins/genetics/metabolism', 'Epithelial Cells/*drug effects/metabolism', 'Humans', 'Indoles/*pharmacology', 'Leukotriene Antagonists/*pharmacology', 'Microscopy, Electron', 'Mitochondria/*drug effects/metabolism', 'Mitochondrial Proteins/genetics/metabolism', 'Nuclear Respiratory Factor 1/genetics/metabolism', 'Organelle Biogenesis', 'Oxygen Consumption/physiology', 'Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/genetics/metabolism', 'Phenylcarbamates/*pharmacology', 'Phosphorylation', 'RNA, Messenger/genetics', 'Real-Time Polymerase Chain Reaction', 'Sulfonamides/*pharmacology', 'Transcription Factors/genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/33977464/
634,Zafirlukast,39737528,Antiviral and Immunomodulatory Effects of Zafirlukast Against Flaviviruses via Inhibition of the TNF Signaling Pathway.,"['Komarasamy TV', 'Gilbert-Jaramillo J', 'Adnan NAA', 'James WS', 'Balasubramaniam VR']","['Humans', '*Antiviral Agents/pharmacology', '*Signal Transduction/drug effects', '*Zika Virus/drug effects/immunology/physiology', '*Phenylcarbamates/pharmacology', '*Indoles/pharmacology', '*Tosyl Compounds/pharmacology', '*Dengue Virus/drug effects/immunology/physiology', '*Sulfonamides/pharmacology', 'Tumor Necrosis Factor-alpha/metabolism', 'Immunomodulating Agents/pharmacology', 'Cell Line', 'Immunologic Factors/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/39737528/
635,Zafirlukast,27260089,Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors.,"['Madsen CM', 'Boyd B', 'Rades T', 'Mullertz A']","['Anti-Asthmatic Agents/*chemistry', 'Chemical Precipitation', 'Excipients/chemistry', '*Fasting', 'Hypromellose Derivatives/chemistry', 'Indoles', 'Intestinal Secretions/*chemistry', 'Leukotriene Antagonists/*chemistry', 'Phenylcarbamates', 'Povidone/chemistry', 'Solubility', 'Sulfonamides', 'Tosyl Compounds/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/27260089/
636,Temazepam,24878116,Experimental and solid-state computational study of structural and dynamic properties in the equilibrium form of temazepam.,"['Pajzderska A', 'Druzbicki K', 'Gonzalez MA', 'Jenczyk J', 'Peplinska B', 'Jarek M', 'Mielcarek J', 'Wasicki J']","['Magnetic Resonance Spectroscopy', 'Models, Molecular', 'Neutron Diffraction', 'Temazepam/*chemistry', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/24878116/
637,Temazepam,8071389,The influence of ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of temazepam in the young and elderly.,"['Kamali F', 'Herd B', 'Edwards C', 'Nicholson E', 'Wynne H']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Aging/*metabolism', 'Ciprofloxacin/*pharmacology', 'Drug Evaluation', 'Female', 'Humans', 'Male', 'Middle Aged', 'Temazepam/administration & dosage/*pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8071389/
638,Temazepam,21298417,Reduction of temazepam to diazepam and lorazepam to delorazepam during enzymatic hydrolysis.,"['Fu S', 'Molnar A', 'Bowron P', 'Lewis J', 'Wang H']","['Benzodiazepines/*metabolism', 'Chromatography, Liquid', 'Diazepam/*metabolism', 'Glucuronidase/*metabolism', 'Humans', 'Hydrolysis', 'Lorazepam/*metabolism', 'Mass Spectrometry', 'Nordazepam/*analogs & derivatives/metabolism', 'Reference Standards', 'Temazepam/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/21298417/
639,Temazepam,913857,Temazepam (Euhypnos) as a hypnotic: a multicentre trial in general practice.,['Fowler LK'],"['Adolescent', 'Adult', 'Aged', 'Diazepam/administration & dosage/*analogs & derivatives/therapeutic use', 'Drug Evaluation', 'Family Practice', 'Female', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', 'Sleep Wake Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/913857/
640,Temazepam,15163440,Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study.,"['Voshaar RC', 'van Balkom AJ', 'Zitman FG']","['Adolescent', 'Adult', 'Anti-Anxiety Agents/*therapeutic use', 'Double-Blind Method', 'Drug Tolerance', 'Female', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Male', 'Middle Aged', 'Pyridines/*therapeutic use', 'Reaction Time/drug effects', 'Sleep/drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Temazepam/*therapeutic use', 'Time Factors', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/15163440/
641,Temazepam,41542,"Effects of temazepam, flurazepam and quinalbarbitone on sleep: psychomotor and cognitive function.","['Roth T', 'Piccione P', 'Salis P', 'Kramer M', 'Kaffeman M']","['Adult', 'Anti-Anxiety Agents/*pharmacology', 'Cognition/*drug effects', 'Emotions/drug effects', 'Flurazepam/*pharmacology', 'Humans', 'Male', 'Memory/drug effects', 'Motor Skills/*drug effects', 'Secobarbital/*pharmacology', 'Sleep/*drug effects', 'Sleep, REM/drug effects', 'Temazepam/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/41542/
642,Temazepam,14572503,The interactive effects of alcohol and temazepam on P300 and reaction time.,"['Martin FH', 'Siddle DA']","['Adolescent', 'Adult', '*Alcohol Drinking', 'Anticonvulsants/administration & dosage/*pharmacology', 'Central Nervous System Depressants/administration & dosage/*pharmacology', 'Drug Administration Schedule', 'Electroencephalography', 'Ethanol/administration & dosage/*pharmacology', 'Event-Related Potentials, P300/*drug effects', 'Female', 'Humans', 'Male', 'Reaction Time/*drug effects', 'Temazepam/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/14572503/
643,Temazepam,8690830,"Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers.","['Rush CR', 'Griffiths RR']","['Adult', 'Anti-Anxiety Agents/*pharmacology', 'Arousal/drug effects', 'Attention/*drug effects', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', 'Mental Recall/*drug effects', 'Middle Aged', 'Neuropsychological Tests', 'Psychomotor Performance/*drug effects', 'Pyridines/*pharmacology', 'Serial Learning/*drug effects', 'Temazepam/*pharmacology', 'Triazolam/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/8690830/
644,Temazepam,17076453,Usefulness of temazepam and zaleplon to induce afternoon sleep.,"['Simons R', 'Koerhuis CL', 'Valk PJ', 'Van den Oord MH']","['Acetamides/*pharmacology', 'Adult', 'Attention', 'Benzodiazepines/*pharmacology', 'Cognition', 'Double-Blind Method', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', 'Military Personnel/*psychology', 'Pyrimidines/*pharmacology', 'Safety', 'Sleep/*drug effects', 'Sleep Deprivation/*drug therapy', 'Temazepam/*pharmacology', 'Time Factors', 'Treatment Outcome', 'Wakefulness/drug effects']",https://pubmed.ncbi.nlm.nih.gov/17076453/
645,Temazepam,1304807,A study to compare the effectiveness of temazepam and a chloral hydrate/hydroxyzine combination in sedating paediatric dental patients.,"['Tsinidou KG', 'Curzon ME', 'Sapsford DJ']","['Anesthesia, Dental/*methods', '*Child Behavior', 'Child, Preschool', '*Chloral Hydrate', 'Conscious Sedation/*methods', 'Dental Anxiety/prevention & control', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Humans', '*Hydroxyzine', 'Infant', 'Male', '*Temazepam']",https://pubmed.ncbi.nlm.nih.gov/1304807/
646,Temazepam,30295409,"Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia.","['Lahteenmaki R', 'Neuvonen PJ', 'Puustinen J', 'Vahlberg T', 'Partinen M', 'Raiha I', 'Kivela SL']","['Aged', 'Aged, 80 and over', 'Azabicyclo Compounds/*administration & dosage/adverse effects', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects', 'Male', 'Melatonin/administration & dosage', 'Middle Aged', 'Piperazines/*administration & dosage/adverse effects', 'Quality of Life', 'Sleep/drug effects/*physiology', 'Sleep Aids, Pharmaceutical/administration & dosage/adverse effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy/psychology', 'Substance Withdrawal Syndrome/*psychology', 'Surveys and Questionnaires', 'Temazepam/*administration & dosage/agonists', 'Zolpidem/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30295409/
647,Temazepam,6149491,A comparison of temazepam and flurazepam in terms of sleep quality and residual changes in performance.,"['Wesnes K', 'Warburton DM']","['Adult', 'Anti-Anxiety Agents/*therapeutic use', 'Attention/*drug effects', 'Cognition/*drug effects', 'Discrimination Learning/drug effects', 'Female', 'Flicker Fusion/drug effects', 'Flurazepam/adverse effects/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Sensory Thresholds', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Sleep Stages/*drug effects', 'Temazepam/adverse effects/*therapeutic use', 'Visual Perception/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6149491/
648,Temazepam,1860930,Determination of diazepam and nordazepam in milk and plasma in the presence of oxazepam and temazepam.,"['Stebler T', 'Guentert TW']","['Chromatography, High Pressure Liquid/*methods/statistics & numerical data', 'Diazepam/*analysis/blood', 'Flurazepam/analysis/blood', 'Humans', 'Hydrogen-Ion Concentration', 'Milk, Human/*chemistry', 'Nordazepam/*analysis/blood', 'Oxazepam/*analysis/blood', 'Temazepam/*analysis/blood']",https://pubmed.ncbi.nlm.nih.gov/1860930/
649,Temazepam,2892863,Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three months.,"['Allen RP', 'Mendels J', 'Nevins DB', 'Chernik DA', 'Hoddes E']","['Adolescent', 'Adult', 'Aged', 'Anti-Anxiety Agents/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Tolerance', 'Female', 'Humans', 'Male', 'Midazolam/*therapeutic use', 'Middle Aged', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Temazepam/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2892863/
650,Temazepam,10672632,"Effect of zopiclone and temazepam on sleep EEG parameters, psychomotor and memory functions in healthy elderly volunteers.","['Hemmeter U', 'Muller M', 'Bischof R', 'Annen B', 'Holsboer-Trachsler E']","['Aged', 'Arousal/drug effects', 'Attention/drug effects', 'Azabicyclo Compounds', 'Double-Blind Method', 'Electroencephalography/*drug effects', 'Female', 'Flicker Fusion/drug effects', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', 'Memory/*drug effects', 'Memory, Short-Term/drug effects', 'Middle Aged', 'Piperazines/*pharmacology', 'Polysomnography/drug effects', 'Psychomotor Performance/*drug effects', 'Reaction Time/drug effects', 'Sleep/*drug effects', 'Sleep, REM/drug effects', 'Temazepam/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10672632/
651,Temazepam,6127821,"Rapid gas chromatographic measurement of diazepam and its metabolites desmethyldiazepam, oxazepam, and 3-hydroxydiazepam (temazepam) in small samples of plasma.",['Loscher W'],"['Anti-Anxiety Agents/*blood', 'Biotransformation', 'Chromatography, Gas/methods', 'Diazepam/blood', 'Humans', 'Nordazepam/blood', 'Oxazepam/blood', 'Temazepam/blood']",https://pubmed.ncbi.nlm.nih.gov/6127821/
652,Temazepam,9882760,Daytime melatonin and temazepam in young adult humans: equivalent effects on sleep latency and body temperatures.,"['Gilbert SS', 'van den Heuvel CJ', 'Dawson D']","['Adolescent', 'Adult', 'Anti-Anxiety Agents/*pharmacology', 'Body Temperature/*drug effects', 'Body Temperature Regulation/drug effects', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Melatonin/*pharmacology', 'Polysomnography', 'Sex Characteristics', 'Sleep/*drug effects', 'Temazepam/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9882760/
653,Temazepam,1898301,"Effects of temazepam on sleep, performance, and rhythmic 6-sulphatoxymelatonin and cortisol excretion after transmeridian travel.","['Donaldson E', 'Kennaway DJ']","['Adult', '*Aerospace Medicine', 'Body Temperature/drug effects', 'Circadian Rhythm/drug effects', 'Double-Blind Method', 'Humans', 'Hydrocortisone/*urine', 'Male', 'Melatonin/*analogs & derivatives/urine', 'Middle Aged', 'Pineal Gland/physiology', 'Psychomotor Performance', 'Sleep/*drug effects', 'Temazepam/administration & dosage/*pharmacology', '*Travel']",https://pubmed.ncbi.nlm.nih.gov/1898301/
654,Temazepam,6120717,Hypnotic activity and effects on performance of lormetazepam and camazepam--analogues of temazepam.,"['Nicholson AN', 'Stone BM']","['Adolescent', 'Adult', 'Anti-Anxiety Agents/*pharmacology', '*Benzodiazepines', 'Cognition/drug effects', 'Emotions/drug effects', 'Humans', '*Hypnotics and Sedatives', 'Lorazepam/analogs & derivatives/*pharmacology', 'Male', 'Motor Skills/*drug effects', 'Sleep/drug effects', 'Sleep Stages/drug effects', 'Structure-Activity Relationship', 'Temazepam/analogs & derivatives/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6120717/
655,EPICAPTOPRIL,8138187,Reactions of captopril and epicaptopril with transition metal ions and hydroxyl radicals: an EPR spectroscopy study.,"['Misik V', 'Mak IT', 'Stafford RE', 'Weglicki WB']","['Captopril/*chemistry/pharmacology', 'Cations/chemistry', 'Copper/chemistry', 'Cyclic N-Oxides', 'Electron Spin Resonance Spectroscopy', 'Free Radical Scavengers', 'Free Radicals', 'Hydroxyl Radical/*chemistry', 'In Vitro Techniques', 'Iron/chemistry', 'Metals/*chemistry', 'Oxidation-Reduction', 'Spin Labels', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/8138187/
656,Triazolam,6135296,Triazolam as a hypnotic for geriatric patients. A double-blind cross-over comparison of nitrazepam and triazolam regarding effects on sleep and psychomotor performance.,"['Dehlin O', 'Bjornson G']","['Aged', 'Anti-Anxiety Agents/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Motor Skills/*drug effects', 'Nitrazepam/adverse effects/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Sleep Stages/*drug effects', 'Triazolam/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6135296/
657,Triazolam,1487483,"Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature.",['Rothschild AJ'],"['Amnesia/*chemically induced', 'Benzodiazepines/adverse effects/therapeutic use', 'Delirium/*chemically induced', 'Double-Blind Method', 'Humans', 'Placebos', 'Randomized Controlled Trials as Topic', 'Sleep Initiation and Maintenance Disorders/chemically induced/*drug therapy', 'Substance Withdrawal Syndrome/*etiology', 'Triazolam/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1487483/
658,Triazolam,2262904,Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.,"['Evans SM', 'Funderburk FR', 'Griffiths RR']","['Adult', 'Behavior/drug effects', 'Cognition/drug effects', 'Dose-Response Relationship, Drug', 'Humans', 'Male', 'Psychomotor Performance/drug effects', 'Pyridines/adverse effects/*pharmacology', 'Substance-Related Disorders/metabolism', 'Time Factors', 'Triazolam/adverse effects/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/2262904/
659,Triazolam,8824695,Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity.,"['Kinirons MT', 'Lang CC', 'He HB', 'Ghebreselasie K', 'Shay S', 'Robin DW', 'Wood AJ']","['Adult', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme System/*metabolism', 'Double-Blind Method', 'Half-Life', 'Humans', 'Hypnotics and Sedatives/*pharmacokinetics/pharmacology', 'India/ethnology', 'Male', 'Mixed Function Oxygenases/*metabolism', 'Postural Balance/drug effects', 'Triazolam/*pharmacokinetics/pharmacology', 'United States', 'White People']",https://pubmed.ncbi.nlm.nih.gov/8824695/
660,Triazolam,10773013,Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences.,"['Greenblatt DJ', 'Harmatz JS', 'von Moltke LL', 'Wright CE', 'Durol AL', 'Harrel-Joseph LM', 'Shader RI']","['Adult', 'Affect/drug effects', 'Area Under Curve', 'Chromatography, Gas', 'Cross-Over Studies', 'Double-Blind Method', 'Electroencephalography/drug effects', 'Female', 'GABA Agonists/*pharmacokinetics/*pharmacology', 'GABA Modulators/*pharmacokinetics/*pharmacology', '*GABA-A Receptor Agonists', 'Half-Life', 'Humans', 'Hypnotics and Sedatives/pharmacology', 'Male', 'Middle Aged', 'Psychomotor Performance/drug effects', 'Pyridines/*pharmacokinetics/*pharmacology', 'Sex Characteristics', 'Triazolam/*pharmacokinetics/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/10773013/
661,Triazolam,8690830,"Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers.","['Rush CR', 'Griffiths RR']","['Adult', 'Anti-Anxiety Agents/*pharmacology', 'Arousal/drug effects', 'Attention/*drug effects', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', 'Mental Recall/*drug effects', 'Middle Aged', 'Neuropsychological Tests', 'Psychomotor Performance/*drug effects', 'Pyridines/*pharmacology', 'Serial Learning/*drug effects', 'Temazepam/*pharmacology', 'Triazolam/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/8690830/
662,Triazolam,15536461,"Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate.","['Greenblatt DJ', 'Harmatz JS', 'von Moltke LL', 'Wright CE', 'Shader RI']","['Adult', 'Aged', 'Aging/*metabolism', 'Area Under Curve', 'Aryl Hydrocarbon Hydroxylases/*metabolism', 'Cross-Over Studies', 'Cytochrome P-450 CYP3A', 'Double-Blind Method', 'Electroencephalography/drug effects', 'Female', 'GABA Modulators/*pharmacokinetics/*pharmacology', 'Half-Life', 'Humans', 'Hypnotics and Sedatives', 'Male', 'Mental Recall/drug effects', 'Middle Aged', 'Oxidoreductases, N-Demethylating/*metabolism', 'Sex Characteristics', 'Triazolam/*pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/15536461/
663,Triazolam,2864320,"Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects.","['Pourbaix S', 'Desager JP', 'Hulhoven R', 'Smith RB', 'Harvengt C']","['Adult', 'Alprazolam', 'Anti-Anxiety Agents/administration & dosage/*metabolism', 'Benzodiazepines/administration & dosage/*metabolism', 'Cimetidine/administration & dosage/*pharmacology', 'Drug Interactions', 'Female', 'Half-Life', 'Humans', 'Kinetics', 'Male', 'Time Factors', 'Triazolam/administration & dosage/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/2864320/
664,Triazolam,10579141,"Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam.","['Yuan R', 'Flockhart DA', 'Balian JD']","['Alprazolam/pharmacokinetics/*pharmacology', 'Anti-Anxiety Agents/pharmacokinetics/*pharmacology', 'Data Collection', 'Drug Interactions', 'Enzyme Induction/*drug effects', 'Enzyme Inhibitors/*pharmacology', 'Humans', 'Itraconazole/pharmacology', 'Ketoconazole/pharmacology', 'Midazolam/pharmacokinetics/*pharmacology', 'Triazolam/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10579141/
665,Triazolam,7635997,Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men.,"['Derry CL', 'Kroboth PD', 'Pittenger AL', 'Kroboth FJ', 'Corey SE', 'Smith RB']","['Adolescent', 'Adult', 'Dose-Response Relationship, Drug', 'Humans', 'Male', 'Obesity/*drug therapy/psychology', 'Psychological Tests', 'Psychomotor Performance/*drug effects', 'Triazolam/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/7635997/
666,Triazolam,9832970,"Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers.","['Mintzer MZ', 'Frey JM', 'Yingling JE', 'Griffiths RR']","['Adult', 'Cognition/*drug effects', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', 'Mental Recall/drug effects', 'Psychomotor Performance/*drug effects', 'Pyridines/*pharmacology', 'Time Perception/drug effects', 'Triazolam/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/9832970/
667,Triazolam,31930237,Kinetic analysis of sequential metabolism of triazolam and its extrapolation to humans using an entero-hepatic two-organ microphysiological system.,"['Arakawa H', 'Sugiura S', 'Kawanishi T', 'Shin K', 'Toyoda H', 'Satoh T', 'Sakai Y', 'Kanamori T', 'Kato Y']","['Caco-2 Cells', 'Humans', 'Kinetics', '*Lab-On-A-Chip Devices', 'Liver/*metabolism/pathology', '*Microfluidic Analytical Techniques/instrumentation', 'Models, Biological', 'Triazolam/blood/*metabolism/pharmacokinetics', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/31930237/
668,Triazolam,10445371,Zaleplon and triazolam in humans: acute behavioral effects and abuse potential.,"['Rush CR', 'Frey JM', 'Griffiths RR']","['Acetamides/*pharmacokinetics', 'Adolescent', 'Adult', 'Behavior/*drug effects', 'Behavior, Addictive/psychology', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*pharmacokinetics', 'Illicit Drugs/*pharmacokinetics', 'Male', 'Observer Variation', 'Pyrimidines/*pharmacokinetics', 'Triazolam/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/10445371/
669,Triazolam,10379619,Triazolam and zolpidem: effects on human memory and attentional processes.,"['Mintzer MZ', 'Griffiths RR']","['Adult', 'Analysis of Variance', 'Attention/*drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*pharmacology', 'Male', 'Memory/*drug effects', 'Middle Aged', 'Psychomotor Performance/drug effects', 'Pyridines/administration & dosage/*pharmacology', 'Time Factors', 'Triazolam/administration & dosage/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/10379619/
670,Triazolam,1929688,Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration's Spontaneous Reporting System.,"['Wysowski DK', 'Barash D']","['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Aged, 80 and over', 'Child', 'Cognition Disorders/*chemically induced', 'Female', 'Humans', 'Male', 'Middle Aged', '*Product Surveillance, Postmarketing', 'Temazepam/*adverse effects', 'Triazolam/*adverse effects', 'United States', '*United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/1929688/
671,Bethanechol,3903644,Effect of metoclopramide and bethanechol on gastric emptying in infants.,"['Hyman PE', 'Abrams C', 'Dubois A']","['Bethanechol Compounds/*pharmacology', 'Clinical Trials as Topic', 'Double-Blind Method', 'Gastric Acid/metabolism', 'Gastric Emptying/*drug effects', 'Humans', 'Infant', 'Metoclopramide/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3903644/
672,Bethanechol,7351606,Use of bethanechol for the treatment of gastroesophageal reflux.,['Euler AR'],"['Adolescent', 'Bethanechol Compounds/*therapeutic use', 'Child', 'Child, Preschool', 'Double-Blind Method', 'Esophagus/physiopathology', 'Evaluation Studies as Topic', 'Gastroesophageal Reflux/*drug therapy/physiopathology', 'Gastrointestinal Motility/drug effects', 'Humans', 'Hydrogen-Ion Concentration', 'Infant', 'Infant, Newborn', 'Pressure']",https://pubmed.ncbi.nlm.nih.gov/7351606/
673,Bethanechol,1166898,The use of bethanechol chloride with tricyclic antidepressants.,['Everett HC'],"['Adult', 'Antidepressive Agents, Tricyclic/*administration & dosage/adverse effects', 'Bethanechol Compounds/*administration & dosage', 'Constipation/prevention & control', 'Depression/drug therapy', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Urination Disorders/prevention & control', 'Xerostomia/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/1166898/
674,Bethanechol,37207874,Efficacy of bethanechol chloride in the treatment of radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis.,"['Moral Nakamura D', 'da Graca Pinto H', 'Baena Elchin C', 'Thomazotti Berard L', 'Abreu Alves F', 'Azeredo Alves Antunes L', 'Pena Coto N']","['Humans', '*Bethanechol/therapeutic use', 'Head and Neck Neoplasms/radiotherapy/drug therapy', '*Radiation Injuries/drug therapy/etiology/prevention & control', 'Salivary Glands', '*Xerostomia/drug therapy/etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/37207874/
675,Bethanechol,327652,Action of oral and parenteral bethanechol on decompensated bladder.,"['Diokno AC', 'Lapides J']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Bethanechol Compounds/administration & dosage/*pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Subcutaneous', 'Male', 'Middle Aged', 'Muscles/drug effects', 'Sweating/drug effects', 'Urinary Bladder/*drug effects', 'Urination Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/327652/
676,Bethanechol,4087006,Bethanechol decreases reaction time in senile dementia of the Alzheimer type.,"['Davous P', 'Lamour Y']","['Adult', 'Aged', 'Alzheimer Disease/*drug therapy', 'Bethanechol Compounds/*therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Middle Aged', 'N-Methylscopolamine', 'Parasympatholytics/therapeutic use', 'Psychomotor Performance/drug effects', 'Reaction Time/*drug effects', 'Scopolamine Derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4087006/
677,Bethanechol,7114318,Reversal by bethanechol of sexual dysfunction caused by anticholinergic antidepressants.,['Gross MD'],"['Adult', 'Amoxapine/adverse effects', 'Antidepressive Agents/*adverse effects', 'Bethanechol Compounds/*therapeutic use', 'Female', 'Humans', 'Isocarboxazid/adverse effects', 'Male', 'Middle Aged', 'Sexual Dysfunctions, Psychological/*chemically induced/drug therapy', 'Tranylcypromine/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7114318/
678,Bethanechol,501834,Malacoplakia of the bladder: efficacy of bethanechol chloride therapy.,"['Zornow DH', 'Landes RR', 'Morganstern SL', 'Fried FA']","['Adult', 'Bethanechol Compounds/*therapeutic use', 'Female', 'Humans', 'Malacoplakia/*drug therapy', 'Middle Aged', 'Urinary Bladder Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/501834/
679,Bethanechol,34954424,"Bethanechol used to prevent salivary gland dysfunction in patients submitted to radioactive iodine therapy: A double blind, placebo-controlled, randomized study.","['Campanha D', 'PereiraLIMA EN', 'Alves FA', 'Jaguar GC']","['Bethanechol/therapeutic use', 'Humans', 'Iodine Radioisotopes/adverse effects', 'Quality of Life', 'Salivary Glands', '*Thyroid Neoplasms/complications/drug therapy', '*Xerostomia/epidemiology/etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/34954424/
680,Bethanechol,6934321,Positive bethanechol chloride supersensitivity test in hereditary sensory neuropathy.,"['Harris JD', 'Benson GS']","['*Bethanechol Compounds', 'Child', 'Female', 'Hereditary Sensory and Autonomic Neuropathies/*diagnosis/physiopathology', 'Humans', 'Urinary Bladder, Neurogenic/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/6934321/
681,Bethanechol,355661,The effect of oral bethanechol chloride on the cystometrogram of the normal male adult.,"['Wein AJ', 'Hanno PM', 'Dixon DO', 'Raezer DM', 'Benson GS']","['Administration, Oral', 'Adult', 'Aged', 'Bethanechol Compounds/administration & dosage/*pharmacology', 'Clinical Trials as Topic', 'Humans', 'Male', 'Middle Aged', 'Muscle Contraction/*drug effects', 'Muscle, Smooth/drug effects', 'Placebos', 'Postoperative Complications/drug therapy', 'Urinary Bladder/*drug effects', 'Urination Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/355661/
682,Bethanechol,513222,Further observations on the cystometric and uroflowmetric effects of bethanechol chloride on the human bladder.,"['Sonda LP', 'Gershon C', 'Diokno AC', 'Lapides J']","['Bethanechol Compounds/administration & dosage/*pharmacology', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Pressure', 'Urinary Bladder/*drug effects', 'Urination Disorders/drug therapy/physiopathology', 'Urodynamics/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/513222/
683,Bethanechol,7354516,Failure of bethanechol denervation supersensitivity as a diagnostic aid.,"['Blaivas JG', 'Labib KB', 'Michalik SJ', 'Zayed AA']","['Adult', 'Aged', '*Bethanechol Compounds', 'Diagnosis, Differential', 'Diagnostic Errors', 'Female', 'Humans', 'Male', 'Middle Aged', 'Urinary Bladder Diseases/*diagnosis', 'Urinary Bladder, Neurogenic/*diagnosis']",https://pubmed.ncbi.nlm.nih.gov/7354516/
684,Bethanechol,11052511,Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects.,"['Carapeti EA', 'Kamm MA', 'Phillips RK']","['Administration, Topical', 'Adult', 'Aged', 'Anal Canal/*drug effects/physiology', 'Bethanechol/*administration & dosage/adverse effects', 'Calcium Channel Blockers/*administration & dosage/adverse effects', 'Diltiazem/*administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Female', 'Fissure in Ano/*drug therapy', 'Humans', 'Male', 'Manometry', 'Middle Aged', 'Pain/drug therapy', 'Parasympathomimetics/*administration & dosage/adverse effects', 'Pilot Projects', 'Pressure']",https://pubmed.ncbi.nlm.nih.gov/11052511/
685,Bethanechol,841412,Diabetic visceral neuropathy: treatment with bethanechol chloride.,"['LoIUDICE TA', 'Buhac I']","['Aged', 'Bethanechol Compounds/*therapeutic use', 'Diabetic Neuropathies/*drug therapy', 'Humans', 'Male', 'Vagus Nerve']",https://pubmed.ncbi.nlm.nih.gov/841412/
686,Ticlopidine,37023582,Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39.,"['Bi C', 'Schakel L', 'Mirza S', 'Sylvester K', 'Pelletier J', 'Lee SY', 'Pillaiyar T', 'Sevigny J', 'Muller CE']","['*Adenosine Triphosphate', '*Ticlopidine', 'Adenosine', 'Blood Platelets', 'Structure-Activity Relationship', ""5'-Nucleotidase/metabolism""]",https://pubmed.ncbi.nlm.nih.gov/37023582/
687,Ticlopidine,1761070,Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration.,"['DiPerri T', 'Pasini FL', 'Frigerio C', 'Blardi P', 'Centini F', 'Messa GL', 'Ghezzi A', 'Volpi L']","['Adult', 'Blood Platelets/metabolism', 'Dose-Response Relationship, Drug', 'Erythrocytes/metabolism', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neutrophils/metabolism', 'Platelet Aggregation/drug effects', 'Platelet Aggregation Inhibitors/blood/pharmacokinetics/*pharmacology', 'Ticlopidine/blood/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/1761070/
688,Ticlopidine,19948947,"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.","['Farid NA', 'Kurihara A', 'Wrighton SA']","['Acute Coronary Syndrome/drug therapy', 'Aryl Hydrocarbon Hydroxylases/genetics/metabolism', 'Blood Platelets/drug effects', 'Clopidogrel', 'Cytochrome P-450 CYP2C19', 'Drug Interactions', 'Humans', 'Piperazines/*metabolism/therapeutic use', 'Platelet Aggregation/*drug effects', 'Platelet Aggregation Inhibitors/metabolism/therapeutic use', 'Polymorphism, Genetic', 'Prasugrel Hydrochloride', 'Pyridines/*metabolism/therapeutic use', 'Thiophenes/*metabolism/therapeutic use', 'Ticlopidine/*analogs & derivatives/*metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19948947/
689,Ticlopidine,6396655,"The effect of 5-(2-chlorobenzyl)-5,6,7,7a-tetrahydro 4H-thieno (3.2-C)-pyridine-2-one hydrochloride (PCR 3787), a metabolite of ticlopidine, on the aggregation of human platelets in vitro and on the aggregation inhibiting action of PGI2 and PGD2.","['Vincent JE', 'Zijlstra FJ', 'de Wit CM', 'Bonta IL']","['Collagen/pharmacology', 'Epoprostenol/*pharmacology', 'Humans', 'Platelet Aggregation/*drug effects', 'Prostaglandin D2', 'Prostaglandins D/*pharmacology', 'Thiophenes/metabolism/*pharmacology', 'Ticlopidine']",https://pubmed.ncbi.nlm.nih.gov/6396655/
690,Ticlopidine,9874086,Bone marrow suppression and klebsiella pneumonia septicemia due to ticlopidine and successful treatment with filgrastim; a case report.,"['Korkmaz ME', 'Cekin AH']","['Biopsy, Needle', 'Bone Marrow/*drug effects', 'Female', 'Filgrastim', 'Follow-Up Studies', 'Granulocyte Colony-Stimulating Factor/*therapeutic use', 'Humans', 'Klebsiella Infections/*chemically induced/drug therapy/microbiology', 'Klebsiella pneumoniae/isolation & purification', 'Leukocyte Count', 'Middle Aged', 'Neutropenia/*chemically induced/drug therapy/microbiology', 'Platelet Aggregation Inhibitors/*adverse effects', 'Recombinant Proteins', 'Sepsis/*chemically induced/drug therapy/microbiology', 'Ticlopidine/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/9874086/
691,Ticlopidine,10718778,Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin.,"['Wittke B', 'Ensor H', 'Chung J', 'Birnbock H', 'Lausecker B', 'Ertel SI', 'MacKie IJ', 'Machin SJ']","['Adult', 'Aspirin/adverse effects/pharmacokinetics/pharmacology', 'Drug Interactions', 'Humans', 'Male', 'Oximes/adverse effects/*pharmacokinetics/pharmacology', 'Piperidines/adverse effects/*pharmacokinetics/pharmacology', 'Platelet Aggregation Inhibitors/adverse effects/*pharmacokinetics/pharmacology', 'Prodrugs', 'Ticlopidine/adverse effects/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10718778/
692,Ticlopidine,35889200,Repurposing the Antiplatelet Agent Ticlopidine to Counteract the Acute Phase of ER Stress Condition: An Opportunity for Fighting Coronavirus Infections and Cancer.,"['Tesei A', 'Cortesi M', 'Bedeschi M', 'Marino N', 'Rossino G', 'Listro R', 'Rossi D', 'Linciano P', 'Collina S']","['Drug Repositioning', 'Endoplasmic Reticulum Stress', 'Humans', '*Neoplasms/pathology', 'Platelet Aggregation Inhibitors/pharmacology/therapeutic use', 'SARS-CoV-2', 'Ticlopidine/pharmacology', 'Unfolded Protein Response', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/35889200/
693,Ticlopidine,3304967,"Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.","['Saltiel E', 'Ward A']","['Blood Platelets/*physiology', 'Hematologic Diseases/blood/*drug therapy', 'Humans', 'Kinetics', 'Platelet Aggregation', 'Ticlopidine/adverse effects/metabolism/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3304967/
694,Ticlopidine,23086541,"Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR).","['Moore TJ', 'Bennett CL']","['Adverse Drug Reaction Reporting Systems/*standards', 'Clopidogrel', 'Hemorrhage/*chemically induced', 'Humans', 'Thalidomide/administration & dosage/*adverse effects', 'Thrombosis/*chemically induced', 'Ticlopidine/administration & dosage/*adverse effects/*analogs & derivatives', 'United States', 'United States Food and Drug Administration', 'Warfarin/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/23086541/
695,Ticlopidine,15136063,Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.,"['Nomura S', 'Takahashi N', 'Inami N', 'Kajiura T', 'Yamada K', 'Nakamori H', 'Tsuda N']","['Aged', 'Analysis of Variance', 'Biomarkers/analysis', 'Diabetes Mellitus, Type 2/blood/complications/*diagnosis', 'Drug Therapy, Combination', 'E-Selectin/analysis', 'Female', 'Humans', 'Hyperlipidemias/blood/complications/*drug therapy', 'Male', 'Malondialdehyde/analysis', 'Middle Aged', 'Monocytes/drug effects', 'P-Selectin/analysis', 'Platelet Activation/drug effects', 'Probability', 'Probucol/*administration & dosage', 'Prospective Studies', 'Reference Values', 'Sensitivity and Specificity', 'Ticlopidine/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/15136063/
696,Ticlopidine,15632883,"Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials.","['Schleinitz MD', 'Olkin I', 'Heidenreich PA']","['Anticoagulants/therapeutic use', 'Aspirin/therapeutic use', 'Cilostazol', 'Clopidogrel', 'Coronary Thrombosis/*prevention & control', 'Drug Therapy, Combination', 'Humans', 'Odds Ratio', 'Platelet Aggregation Inhibitors/*therapeutic use', 'Randomized Controlled Trials as Topic', '*Stents', 'Tetrazoles/*therapeutic use', 'Ticlopidine/*analogs & derivatives/*therapeutic use', 'Warfarin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15632883/
697,Ticlopidine,15077098,A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation.,"['Juergens CP', 'Wong AM', 'Leung DY', 'Lowe HC', 'Lo S', 'Fernandes C', 'Newland EF', 'Hopkins AP']","['Angioplasty, Balloon, Coronary', 'Aspirin/*therapeutic use', 'Clopidogrel', 'Coronary Stenosis/*therapy', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Platelet Aggregation Inhibitors/*therapeutic use', '*Stents', 'Ticlopidine/*analogs & derivatives/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15077098/
698,Ticlopidine,8996289,Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures.,"['Gregorini L', 'Marco J', 'Fajadet J', 'Bernies M', 'Cassagneau B', 'Brunel P', 'Bossi IM', 'Mannucci PM']","['*Angioplasty, Balloon, Coronary', 'Antifibrinolytic Agents/administration & dosage/therapeutic use', 'Aspirin/*administration & dosage/therapeutic use', '*Atherectomy, Coronary', 'Coronary Disease/blood/*therapy', 'Drug Therapy, Combination', 'Female', 'Hemostasis/*drug effects', 'Heparin/administration & dosage/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Platelet Activation/*drug effects', 'Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use', '*Premedication', 'Serotonin/blood', '*Stents', 'Ticlopidine/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8996289/
699,Ticlopidine,23099620,"Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction.","['Hagelberg NM', 'Saarikoski T', 'Saari TI', 'Neuvonen M', 'Neuvonen PJ', 'Turpeinen M', 'Scheinin M', 'Laine K', 'Olkkola KT']","['Adult', 'Analgesics, Opioid/administration & dosage/blood/*pharmacokinetics/urine', 'Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors', 'Biotransformation', 'Cross-Over Studies', 'Cytochrome P-450 CYP2B6', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 CYP3A Inhibitors', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Drug Therapy, Combination', 'Female', 'Humans', 'Itraconazole/administration & dosage/*pharmacology', 'Kidney/*metabolism', 'Male', 'Metabolic Clearance Rate', 'Oxidoreductases, N-Demethylating/antagonists & inhibitors', 'Ticlopidine/administration & dosage/*pharmacology', 'Tramadol/administration & dosage/*analogs & derivatives/blood/pharmacokinetics/urine', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/23099620/
700,Ticlopidine,10318654,Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.,"['Moussa I', 'Oetgen M', 'Roubin G', 'Colombo A', 'Wang X', 'Iyer S', 'Maida R', 'Collins M', 'Kreps E', 'Moses JW']","['Aged', 'Aspirin/administration & dosage/adverse effects/*therapeutic use', 'Clopidogrel', 'Coronary Angiography', 'Coronary Disease/*surgery', 'Coronary Thrombosis/*prevention & control', 'Diarrhea/chemically induced', 'Drug Eruptions/etiology', 'Drug Therapy, Combination', 'Female', 'Hemorrhage/chemically induced', 'Humans', 'Male', 'Middle Aged', 'Neutropenia/chemically induced', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Postoperative Complications/*prevention & control', 'Safety', '*Stents', 'Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10318654/
701,Fentanyl,37788600,"Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl.","['Bird HE', 'Huhn AS', 'Dunn KE']","['Humans', 'Analgesics, Opioid', '*Chronic Pain/drug therapy', 'Clinical Relevance', '*Drug Overdose/drug therapy', 'Fentanyl']",https://pubmed.ncbi.nlm.nih.gov/37788600/
702,Fentanyl,8452277,An analysis of the duration of fentanyl and its metabolites in urine and saliva.,"['Silverstein JH', 'Rieders MF', 'McMullin M', 'Schulman S', 'Zahl K']","['Adult', 'Female', 'Fentanyl/*analogs & derivatives/*urine', 'Gas Chromatography-Mass Spectrometry', 'Humans', 'Saliva/*chemistry', 'Substance Abuse Detection/*methods', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8452277/
703,Fentanyl,34030211,The anomalous pharmacology of fentanyl.,"['Kelly E', 'Sutcliffe K', 'Cavallo D', 'Ramos-Gonzalez N', 'Alhosan N', 'Henderson G']","['Humans', '*Fentanyl/pharmacology', 'Analgesics, Opioid/pharmacology/therapeutic use', 'Narcotic Antagonists', 'Naloxone/pharmacology', '*Drug Overdose/drug therapy/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/34030211/
704,Fentanyl,29120973,Acute Intoxications and Fatalities From Illicit Fentanyl and Analogues: An Update.,"['Pichini S', 'Solimini R', 'Berretta P', 'Pacifici R', 'Busardo FP']","['Analgesics, Opioid/adverse effects', '*Cause of Death', 'Drug Contamination', 'Fentanyl/*adverse effects/analogs & derivatives/*pharmacokinetics', 'Humans', 'Illicit Drugs/*adverse effects/*pharmacokinetics', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/29120973/
705,Fentanyl,30305277,The Fentanyl Epidemic and Evolution of Fentanyl Analogs in the United States and the European Union.,"['Jannetto PJ', 'Helander A', 'Garg U', 'Janis GC', 'Goldberger B', 'Ketha H']","['Analgesics, Opioid/*administration & dosage/adverse effects/analysis', 'Europe/epidemiology', 'Fentanyl/*administration & dosage/adverse effects/analogs & derivatives', 'Humans', 'Respiratory Insufficiency/etiology', 'Substance-Related Disorders/epidemiology/mortality/*pathology', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/30305277/
706,Fentanyl,32435865,Treating Fentanyl Withdrawal.,"['Neimark G', 'Tjoa C']","['Analgesics, Opioid/*administration & dosage/*adverse effects', 'Buprenorphine/*therapeutic use', 'Fentanyl/*administration & dosage/*adverse effects', 'Humans', 'Narcotic Antagonists/*therapeutic use', 'Substance Withdrawal Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32435865/
707,Fentanyl,22770488,Fentanyl (transmucosal).,"['Twycross R', 'Prommer EE', 'Mihalyo M', 'Wilcock A']","['Administration, Mucosal', 'Analgesics, Opioid/pharmacology/*therapeutic use', 'Fentanyl/pharmacology/*therapeutic use', 'Humans', 'Pain/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22770488/
708,Fentanyl,35041405,Proton Affinity Values of Fentanyl and Fentanyl Analogues Pertinent to Ambient Ionization and Detection.,"['Denis EH', 'Bade JL', 'Renslow RS', 'Morrison KA', 'Nims MK', 'Govind N', 'Ewing RG']","['Atmospheric Pressure', '*Fentanyl/analogs & derivatives/analysis/chemistry', 'Gases/analysis/chemistry', 'Limit of Detection', 'Mass Spectrometry/*methods', 'Protons', 'Reproducibility of Results', 'Substance Abuse Detection/methods']",https://pubmed.ncbi.nlm.nih.gov/35041405/
709,Fentanyl,34957817,In Vitro and In Vivo Analysis of Fentanyl and Fentalog Metabolites using Hyphenated Chromatographic Techniques: A Review.,"['Patel JC', 'Parveen S']","['Body Fluids/chemistry', 'Chromatography', 'Fentanyl/analogs & derivatives/*analysis/metabolism', 'Humans', 'Illicit Drugs/*analysis/metabolism', 'Molecular Structure', '*Substance Abuse Detection']",https://pubmed.ncbi.nlm.nih.gov/34957817/
710,Fentanyl,39873905,Fentanyl and Fentanyl Analog Screening Using ASAP-MS With LiveID Confirmation.,"['Reyes Monroy KA', 'Koerber R', 'Verbeck GF']","['*Fentanyl/analogs & derivatives/analysis/chemistry', '*Mass Spectrometry/methods', '*Analgesics, Opioid/analysis/chemistry', 'Software', 'Atmospheric Pressure']",https://pubmed.ncbi.nlm.nih.gov/39873905/
711,Fentanyl,39455665,Field and laboratory perspectives on fentanyl and carfentanil decontamination.,"['Linden P', 'Moren L', 'Qvarnstrom J', 'Forsgren N', 'Engdahl CS', 'Engqvist M', 'Henych J', 'Tengel T', 'Osterlund L', 'Thors L', 'Larsson A', 'Johansson S']","['*Fentanyl/analogs & derivatives/pharmacology', '*Decontamination/methods', 'Humans', 'Microsomes, Liver/metabolism', 'Analgesics, Opioid/pharmacology', 'Receptors, Opioid, mu/metabolism']",https://pubmed.ncbi.nlm.nih.gov/39455665/
712,Fentanyl,31286476,Spinal and epidural sufentanil and fentanyl in early labour.,"['Vaananen A', 'Kuukasjarvi M', 'Tekay A', 'Ahonen J']","['Analgesia, Epidural/*methods', 'Analgesia, Obstetrical/*methods', 'Female', 'Fentanyl/*administration & dosage', 'Heart Rate, Fetal', 'Humans', 'Pregnancy', 'Sufentanil/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/31286476/
713,Fentanyl,37498626,Fentanyl and the Fluorinated Fentanyl Derivative NFEPP Elicit Distinct Hydrogen-Bond Dynamics of the Opioid Receptor.,"['Lesnik S', 'Bren U', 'Domratcheva T', 'Bondar AN']","['Humans', '*Fentanyl/pharmacology/chemistry', '*Receptors, Opioid', 'Analgesics, Opioid/pharmacology', 'Receptors, Opioid, mu/metabolism', 'Pain', 'Hydrogen']",https://pubmed.ncbi.nlm.nih.gov/37498626/
714,Fentanyl,30653482,"Overdose Deaths Involving Fentanyl and Fentanyl Analogs - New York City, 2000-2017.","['Colon-Berezin C', 'Nolan ML', 'Blachman-Forshay J', 'Paone D']","['Drug Overdose/*mortality', 'Fentanyl/*analogs & derivatives/*poisoning', 'Humans', 'New York City/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/30653482/
715,Fentanyl,29902699,Abuse of fentanyl: An emerging problem to face.,"['Kuczynska K', 'Grzonkowski P', 'Kacprzak L', 'Zawilska JB']","['Analgesics, Opioid/*adverse effects', 'Dosage Forms', 'Drug Contamination', 'Drug Overdose/drug therapy', 'Drug Trafficking/trends', 'Fentanyl/*adverse effects', 'Humans', 'Illicit Drugs/adverse effects', 'Naloxone/therapeutic use', 'Narcotic Antagonists/therapeutic use', 'Opioid-Related Disorders/*epidemiology', 'Transdermal Patch']",https://pubmed.ncbi.nlm.nih.gov/29902699/
716,Fentanyl,36168915,Vapor detection and vapor pressure measurements of fentanyl and fentanyl hydrochloride salt at ambient temperatures.,"['Ewing RG', 'Nims MK', 'Morrison KA', 'Hart GL', 'Avalos NM', 'Denis EH']","['*Fentanyl/analysis', 'Vapor Pressure', 'Temperature', '*Illicit Drugs', 'Analgesics, Opioid/analysis', 'Gases']",https://pubmed.ncbi.nlm.nih.gov/36168915/
717,Fentanyl,35932759,"Knowledge, attitudes, and behaviors related to the fentanyl-adulterated drug supply among people who use drugs in Oregon.","['LaForge K', 'Stack E', 'Shin S', 'Pope J', 'Larsen JE', 'Leichtling G', 'Leahy JM', 'Seaman A', 'Hoover D', 'Byers M', 'Barrie C', 'Chisholm L', 'Korthuis PT']","['Analgesics, Opioid', '*Drug Overdose/prevention & control', 'Fentanyl', 'Health Knowledge, Attitudes, Practice', 'Humans', '*Methamphetamine', 'Oregon']",https://pubmed.ncbi.nlm.nih.gov/35932759/
718,Dobutamine,34347952,Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.,"['Mathew R', 'Di Santo P', 'Jung RG', 'Marbach JA', 'Hutson J', 'Simard T', 'Ramirez FD', 'Harnett DT', 'Merdad A', 'Almufleh A', 'Weng W', 'Abdel-Razek O', 'Fernando SM', 'Kyeremanteng K', 'Bernick J', 'Wells GA', 'Chan V', 'Froeschl M', 'Labinaz M', 'Le May MR', 'Russo JJ', 'Hibbert B']","['Adrenergic beta-Agonists/therapeutic use', 'Aged', 'Cardiotonic Agents/adverse effects/*therapeutic use', 'Comorbidity', 'Dobutamine/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Hospital Mortality', 'Humans', 'Male', 'Middle Aged', 'Milrinone/adverse effects/*therapeutic use', 'Phosphodiesterase 3 Inhibitors/therapeutic use', 'Shock, Cardiogenic/*drug therapy/mortality']",https://pubmed.ncbi.nlm.nih.gov/34347952/
719,Dobutamine,35700546,Venoarterial extracorporeal membrane oxygenation flow or dobutamine to improve microcirculation during ECMO for refractory cardiogenic shock.,"['Chommeloux J', 'Montero S', 'Franchineau G', 'Lebreton G', 'Brechot N', 'Barhoum P', 'Lefevre L', 'de Chambrun MP', 'Hekimian G', 'Luyt CE', 'Combes A', 'Schmidt M']","['Dobutamine/pharmacology/therapeutic use', '*Extracorporeal Membrane Oxygenation', 'Humans', 'Microcirculation', 'Prospective Studies', 'Retrospective Studies', '*Shock, Cardiogenic/therapy']",https://pubmed.ncbi.nlm.nih.gov/35700546/
720,Dobutamine,31228965,Efficacy of milrinone and dobutamine in low cardiac output states: Systematic review and meta-analysis.,"['Mathew R', 'Visintini SM', 'Ramirez FD', 'DiSanto P', 'Simard T', 'Labinaz M', 'Hibbert BM']","['Cardiac Output, Low/drug therapy', 'Cardiotonic Agents/therapeutic use', '*Dobutamine/therapeutic use', 'Humans', 'Length of Stay', '*Milrinone/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/31228965/
721,Dobutamine,30175599,Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock.,"['Lewis TC', 'Aberle C', 'Altshuler D', 'Piper GL', 'Papadopoulos J']","['Aged', 'Aged, 80 and over', 'Cardiotonic Agents/*pharmacology', 'Dobutamine/*pharmacology', 'Female', 'Hemodynamics/drug effects', 'Humans', 'Male', 'Middle Aged', 'Milrinone/*pharmacology', 'Retrospective Studies', 'Shock, Cardiogenic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30175599/
722,Dobutamine,25689169,Differing autonomic responses to dobutamine stress in the presence and absence of myocardial ischaemia.,"['Sharma R', ""O'Driscoll JM"", 'Saha A', 'Sritharan M', 'Sutton R', 'Rosen SD']","['Adrenergic beta-1 Receptor Agonists/*pharmacology', 'Aged', 'Autonomic Nervous System/*drug effects/physiology', 'Case-Control Studies', 'Dobutamine/*pharmacology', 'Echocardiography, Stress', 'Female', 'Heart Rate', 'Humans', 'Male', 'Middle Aged', 'Myocardial Ischemia/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/25689169/
723,Dobutamine,22129568,Dopamine and dobutamine use in preterm or low birth weight neonates in the premier 2008 database.,"['Lasky T', 'Greenspan J', 'Ernst FR', 'Gonzalez L']","['Cardiovascular Agents/adverse effects/*therapeutic use', 'Cardiovascular Diseases/*drug therapy/mortality/physiopathology', 'Chi-Square Distribution', 'Databases as Topic', 'Dobutamine/adverse effects/*therapeutic use', 'Dopamine/adverse effects/*therapeutic use', 'Drug Utilization', 'Female', 'Humans', 'Infant Mortality', '*Infant, Low Birth Weight', 'Infant, Newborn', '*Infant, Premature', 'Male', ""*Practice Patterns, Physicians'/statistics & numerical data"", 'Proportional Hazards Models', 'Retrospective Studies', 'Risk Assessment', 'Risk Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22129568/
724,Dobutamine,1466438,Cimetidine-dobutamine interaction?,"['Baraka A', 'Nauphal M', 'Arab W']","['Anesthesia, Intravenous', 'Cimetidine/*adverse effects', 'Coronary Artery Bypass', 'Dobutamine/*adverse effects', 'Drug Interactions', 'Humans', 'Hypertension/*chemically induced', 'Intraoperative Complications/*chemically induced', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/1466438/
725,Dobutamine,37195621,Blood pressure control with phenylephrine or dobutamine: a randomized controlled trial comparing effects on cerebral and paravertebral tissue oxygen saturation measured with near-infrared spectroscopy.,"['Vanpeteghem CM', 'De Hert SG', 'Moerman AT']","['Humans', 'Phenylephrine/pharmacology', 'Blood Pressure/physiology', '*Dobutamine/pharmacology', '*Spectroscopy, Near-Infrared', 'Oxygen Saturation', 'Oxygen']",https://pubmed.ncbi.nlm.nih.gov/37195621/
726,Dobutamine,3510774,Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.,"['Colucci WS', 'Wright RF', 'Jaski BE', 'Fifer MA', 'Braunwald E']","['Aged', 'Blood Pressure/drug effects', 'Cardiac Output/drug effects', 'Cardiotonic Agents/administration & dosage/*pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Dobutamine/administration & dosage/*pharmacology/therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'Heart Failure/*drug therapy', 'Heart Rate/drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Male', 'Middle Aged', 'Milrinone', 'Myocardial Contraction/drug effects', 'Nitroprusside/pharmacology', 'Norepinephrine/blood', 'Pyridones/administration & dosage/*pharmacology/therapeutic use', 'Stimulation, Chemical', 'Vascular Resistance/drug effects', 'Vasodilation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/3510774/
727,Dobutamine,679437,Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure.,"['Leier CV', 'Heban PT', 'Huss P', 'Bush CA', 'Lewis RP']","['Adult', 'Aged', 'Blood Pressure/drug effects', 'Cardiac Output/drug effects', 'Catecholamines/*therapeutic use', 'Dobutamine/adverse effects/*therapeutic use', 'Dopamine/adverse effects/*therapeutic use', 'Dyspnea/drug therapy', 'Heart Failure/*drug therapy', 'Hemodynamics/*drug effects', 'Humans', 'Kidney/physiopathology', 'Lung/physiopathology', 'Middle Aged', 'Regional Blood Flow']",https://pubmed.ncbi.nlm.nih.gov/679437/
728,Dobutamine,18211120,"Pharmacokinetic-pharmacodynamic relationship of dobutamine and heart rate, stroke volume and cardiac output in healthy volunteers.","['Ahonen J', 'Aranko K', 'Iivanainen A', 'Maunuksela EL', 'Paloheimo M', 'Olkkola KT']","['Adult', 'Area Under Curve', 'Cardiac Output/*drug effects/physiology', 'Cardiotonic Agents/administration & dosage/pharmacokinetics/pharmacology', 'Cross-Over Studies', 'Dobutamine/blood/*pharmacokinetics/pharmacology', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Echocardiography', 'Female', 'Heart Rate/*drug effects/physiology', 'Humans', 'Infusions, Intravenous', 'Male', 'Myocardial Contraction/drug effects', 'Stroke Volume/*drug effects/physiology', 'Therapeutic Equivalency', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18211120/
729,vincristine,3596472,"OPEC chemotherapy (vincristine, prednisolone, etoposide and chlorambucil) for refractory and recurrent Hodgkin's disease.","['Barnett MJ', 'Man AM', 'Richards MA', 'Waxman JH', 'Wrigley PF', 'Lister TA']","['Adolescent', 'Adult', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Bone Marrow/drug effects', 'Chlorambucil/administration & dosage/adverse effects/therapeutic use', 'Etoposide/administration & dosage/adverse effects/therapeutic use', 'Hodgkin Disease/*drug therapy', 'Humans', 'Leukocyte Count', 'Mechlorethamine/therapeutic use', 'Middle Aged', 'Prednisolone/administration & dosage/adverse effects/therapeutic use', 'Procarbazine/therapeutic use', 'Prognosis', 'Vinblastine/therapeutic use', 'Vincristine/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3596472/
730,vincristine,6794311,Infusion of vincristine-loaded platelets in acute ITP refractory to steroids: an alternative to splenectomy.,"['Nenci GG', 'Agnelli G', 'De Cunto M', 'Gresele P']","['Acute Disease', 'Adult', '*Blood Transfusion', 'Humans', 'Male', 'Platelet Count', '*Platelet Transfusion', 'Purpura, Thrombocytopenic/*therapy', 'Splenectomy', 'Vincristine/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6794311/
731,vincristine,22126626,Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.,"['Moriyama B', 'Henning SA', 'Leung J', 'Falade-Nwulia O', 'Jarosinski P', 'Penzak SR', 'Walsh TJ']","['Adolescent', 'Antifungal Agents/*adverse effects/therapeutic use', 'Antineoplastic Agents, Phytogenic/*adverse effects/therapeutic use', 'Azoles/*adverse effects/therapeutic use', 'Child', 'Child, Preschool', 'Drug Interactions', 'Female', 'Humans', 'Infant', 'Male', 'Vincristine/*adverse effects/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/22126626/
732,vincristine,37459833,Simultaneous quantification and pharmacokinetics of vincristine and its major metabolite M1 in Chinese pediatric ALL patients by LC-MS/MS.,"['Yuan Y', 'Chen C', 'You G', 'Yao R', 'Zhu X', 'Wu X', 'Wu J', 'Zhao W', 'Li Z', 'Zhang S']","['Child', 'Humans', 'Chromatography, High Pressure Liquid/methods', 'Chromatography, Liquid', 'East Asian People', 'Methanol', '*Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy', '*Tandem Mass Spectrometry/methods', '*Vincristine/metabolism/pharmacokinetics/therapeutic use', 'China']",https://pubmed.ncbi.nlm.nih.gov/37459833/
733,vincristine,26500149,Modulation of vincristine and doxorubicin binding and release from silk films.,"['Coburn JM', 'Na E', 'Kaplan DL']","['Antibiotics, Antineoplastic/chemistry/*metabolism', 'Antineoplastic Agents, Phytogenic/chemistry/*metabolism', 'Crystallization', 'Delayed-Action Preparations', 'Doxorubicin/chemistry/*metabolism', '*Drug Carriers', 'Drug Compounding', 'Fibroins/chemistry/*metabolism', 'Kinetics', 'Molecular Structure', 'Protein Binding', 'Solubility', 'Structure-Activity Relationship', 'Surface Properties', 'Technology, Pharmaceutical/methods', 'Vincristine/chemistry/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/26500149/
734,vincristine,38975633,Co-delivery of oncolytic virus and chemotherapeutic modality: Vincristine against prostate cancer treatment: A potent viro-chemotherapeutic approach.,"['Anjum S', 'Naseer F', 'Ahmad T', 'Liaquat A', 'Abduh MS', 'Kousar K']","['Humans', 'Male', '*Prostatic Neoplasms/therapy/drug therapy', '*Vincristine/pharmacology/administration & dosage', '*Oncolytic Viruses', '*Oncolytic Virotherapy/methods', 'Cell Line, Tumor', 'Measles virus/drug effects', 'Cell Survival/drug effects', 'Antineoplastic Agents/pharmacology/administration & dosage', 'Drug Delivery Systems', 'Nanoparticles/chemistry', 'PC-3 Cells']",https://pubmed.ncbi.nlm.nih.gov/38975633/
735,vincristine,33751022,Immune-mediated vincristine-induced neuropathy: Unlocking therapies.,"['Savelieff MG', 'Feldman EL']","['Humans', '*Neoplasms/drug therapy', '*Peripheral Nervous System Diseases/chemically induced', 'Vincristine/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33751022/
736,vincristine,26156322,The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo.,"['Chao MW', 'Lai MJ', 'Liou JP', 'Chang YL', 'Wang JC', 'Pan SL', 'Teng CM']","['Antineoplastic Agents, Phytogenic/administration & dosage/*therapeutic use', 'Cell Line, Tumor', 'Cell Survival', 'Drug Synergism', 'Humans', 'Hydroxamic Acids/administration & dosage/*therapeutic use', 'Leukemia/*drug therapy', 'Vincristine/administration & dosage/*therapeutic use', 'Vorinostat']",https://pubmed.ncbi.nlm.nih.gov/26156322/
737,vincristine,35643614,"DAT and PRX1 gene expression modulates vincristine production in Catharanthus roseus L. propagates using Cu, Fe and Zn nano structures.","['Perveen S', 'Safdar N', 'Yasmin A', 'Bibi Y']","['Calcium/metabolism', '*Catharanthus/genetics/metabolism', 'Copper/metabolism', 'Gene Expression', 'Iron/metabolism', '*Metal Nanoparticles', 'Vincristine/metabolism/pharmacology', 'Zinc/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35643614/
738,vincristine,29115708,CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.,"['Skiles JL', 'Chiang C', 'Li CH', 'Martin S', 'Smith EL', 'Olbara G', 'Jones DR', 'Vik TA', 'Mostert S', 'Abbink F', 'Kaspers GJ', 'Li L', 'Njuguna F', 'Sajdyk TJ', 'Renbarger JL']","['Adolescent', 'Child', 'Child, Preschool', '*Cytochrome P-450 CYP3A/biosynthesis/genetics', 'Female', '*Genotype', 'Humans', 'Infant', 'Kenya', 'Male', '*Neoplasms/drug therapy/enzymology/genetics', '*Peripheral Nervous System Diseases/chemically induced/enzymology/genetics', 'Pharmacogenomic Testing', '*Vincristine/administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/29115708/
739,Hydroxyurea,38256385,Adherence to Hydroxyurea and Patients' Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study.,"['Madkhali MA', 'Abusageah F', 'Hakami F', 'Zogel B', 'Hakami KM', 'Alfaifi S', 'Alhazmi E', 'Zaalah S', 'Trabi S', 'Alhazmi AH', 'Mohrag M', 'Malhan H']","['Humans', 'Male', 'Young Adult', 'Adult', 'Female', 'Cross-Sectional Studies', '*Hydroxyurea/adverse effects', '*Anemia, Sickle Cell/drug therapy', 'Emotions', 'Health Personnel']",https://pubmed.ncbi.nlm.nih.gov/38256385/
740,Hydroxyurea,37638133,Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine.,"['Kilonzi M', 'Mlyuka H', 'Jonathan A', 'Tutuba H', 'Chirande L', 'Rugajo P', 'Kida I', 'Balandya E', 'Makani J', 'Sirili N']","['Humans', '*Hydroxyurea/therapeutic use', '*Anemia, Sickle Cell/drug therapy', 'Commerce', 'Government', 'National Health Programs']",https://pubmed.ncbi.nlm.nih.gov/37638133/
741,Hydroxyurea,35506261,Treatment with Hydroxyurea Leads to Fetal Hemoglobin Reactivation through CA1 and LIN28B Genes: An In Vitro Study.,"['Parsasefat M', 'Safarpour H', 'Nomiri S', 'Miri-Moghaddam E']","['Adult', '*Fetal Hemoglobin/analysis', 'Humans', 'Hydroxyurea/pharmacology/therapeutic use', 'RNA-Binding Proteins/therapeutic use', 'beta-Globins/genetics', '*beta-Thalassemia/genetics', 'gamma-Globins/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35506261/
742,Hydroxyurea,16000122,Synthesis and X-ray crystal structure study of the hydroxyurea and hydantoin derivatives of L-valine.,"['Opacic N', 'Zorc B', 'Cetina M', 'Mrvos-Sermek D', 'Raic-Malic S', 'Mintas M']","['Crystallography, X-Ray', 'Hydantoins/chemical synthesis/*chemistry/pharmacology', 'Hydrogen Bonding', 'Hydroxyurea/*analogs & derivatives/chemical synthesis/*chemistry/pharmacology', 'Models, Molecular', 'Molecular Conformation', 'Molecular Structure', 'Stereoisomerism', 'Structure-Activity Relationship', 'Valine/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/16000122/
743,Hydroxyurea,37728912,Treatment of Hydroxyurea-Induced Ulcers With Timolol.,"['Hwang AS', 'Hoss E', 'Pittelkow MR', 'Yang YW']","['Humans', '*Hydroxyurea/adverse effects', 'Ulcer', 'Timolol/adverse effects', '*Leg Ulcer/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37728912/
744,Hydroxyurea,16990003,"Synthesis, aerobic cytotoxicity, and radiosensitizing activity of novel 2,4-dinitrophenylamine tethered 5-fluorouracil and hydroxyurea.","['Khalaj A', 'Doroudi AR', 'Ostad SN', 'Khoshayand MR', 'Babai M', 'Adibpour N']","['Aerobiosis', 'Cell Survival/drug effects/radiation effects', 'Fluorouracil/*analogs & derivatives/*chemical synthesis/chemistry/*toxicity', 'HT29 Cells', 'Humans', 'Hydroxyurea/*analogs & derivatives/*chemical synthesis/chemistry/*toxicity', 'Molecular Structure', 'Nitro Compounds/*chemical synthesis/chemistry/*toxicity', 'Radiation-Sensitizing Agents/*chemical synthesis/chemistry/*toxicity', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/16990003/
745,Hydroxyurea,34353779,Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.,"['Altomare I', 'Parasuraman S', 'Paranagama D', 'Kish J', 'Lord K', 'Yu J', 'Colucci P']","['Aged', 'Drug Resistance, Neoplasm', 'Female', 'Humans', 'Hydroxyurea/pharmacology/*therapeutic use', 'Male', 'Middle Aged', 'Nitriles/pharmacology/*therapeutic use', 'Polycythemia Vera/*drug therapy', 'Pyrazoles/pharmacology/*therapeutic use', 'Pyrimidines/pharmacology/*therapeutic use', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/34353779/
746,Hydroxyurea,31106898,Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.,"['McGann PT', 'Niss O', 'Dong M', 'Marahatta A', 'Howard TA', 'Mizuno T', 'Lane A', 'Kalfa TA', 'Malik P', 'Quinn CT', 'Ware RE', 'Vinks AA']","['Adolescent', 'Anemia, Sickle Cell/blood/*drug therapy', 'Antisickling Agents/*administration & dosage/*blood/therapeutic use', 'Area Under Curve', 'Child', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Drug Monitoring', 'Female', 'Humans', 'Hydroxyurea/*administration & dosage/blood/therapeutic use', 'Infant', 'Male', 'Maximum Tolerated Dose', '*Models, Biological', 'Practice Guidelines as Topic', 'Prospective Studies', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31106898/
747,Hydroxyurea,15639238,Synthesis and NMR characterization of hydroxyurea and mesylglycol glycoconjugates as drug candidates for targeted cancer chemotherapy.,"['Sorg BL', 'Hull WE', 'Kliem HC', 'Mier W', 'Wiessler M']","['Antineoplastic Agents/*chemical synthesis/chemistry', 'Drug Delivery Systems/*methods', 'Glycoconjugates/*chemical synthesis/chemistry', 'Hydroxyurea/*analogs & derivatives/*chemistry', 'Magnetic Resonance Spectroscopy', 'Mesylates/*chemistry', 'Molecular Structure', 'Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15639238/
748,Hydroxyurea,19860305,Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia.,"['Ballas SK', 'McCarthy WF', 'Guo N', 'DeCastro L', 'Bellevue R', 'Barton BA', 'Waclawiw MA']","['Anemia, Sickle Cell/*drug therapy', 'Antisickling Agents/pharmacology/*therapeutic use', 'Female', 'Fetus/drug effects', 'Humans', 'Hydroxyurea/pharmacology/*therapeutic use', 'Male', 'Pregnancy', 'Pregnancy Complications, Hematologic/*drug therapy', '*Pregnancy Outcome', 'Prenatal Exposure Delayed Effects']",https://pubmed.ncbi.nlm.nih.gov/19860305/
749,Hydroxyurea,34272726,Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.,"['Heitzer AM', 'Longoria J', 'Okhomina V', 'Wang WC', 'Raches D', 'Potter B', 'Jacola LM', 'Porter J', 'Schreiber JE', 'King AA', 'Kang G', 'Hankins JS']","['Adolescent', 'Age Factors', 'Anemia, Sickle Cell/complications/*drug therapy', 'Antisickling Agents/administration & dosage/*adverse effects/therapeutic use', 'Case-Control Studies', 'Child', 'Cross-Sectional Studies', 'Female', 'Fetal Hemoglobin/analysis', 'Hemoglobin, Sickle', 'Humans', 'Hydroxyurea/administration & dosage/*adverse effects/therapeutic use', 'Male', 'Neurocognitive Disorders/diagnosis/etiology/*prevention & control', 'Social Vulnerability', 'Thalassemia/complications', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34272726/
750,Hydroxyurea,25023087,The effect and side effect of hydroxyurea therapy on patients with beta-thalassemia: a systematic review to December 2012.,"['Kosaryan M', 'Zafari M', 'Alipur A', 'Hedayatizadeh-Omran A']","['Blood Transfusion', 'Erythrocyte Indices/drug effects', 'Humans', 'Hydroxyurea/*adverse effects/*therapeutic use', 'Treatment Outcome', 'beta-Thalassemia/blood/*drug therapy/therapy']",https://pubmed.ncbi.nlm.nih.gov/25023087/
751,Bosentan,29393580,Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta-analysis.,"['Chen X', 'Zhai Z', 'Huang K', 'Xie W', 'Wan J', 'Wang C']","['Antihypertensive Agents/therapeutic use', 'Bosentan', 'Chronic Disease', 'Hemodynamics/*drug effects', 'Humans', 'Hypertension, Pulmonary/*drug therapy/etiology/physiopathology', 'Pulmonary Embolism/complications/*drug therapy/physiopathology', 'Sulfonamides/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29393580/
752,Bosentan,33856119,Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension.,"['Chen T', 'Chen J', 'Chen C', 'Zheng H', 'Chen Y', 'Liu M', 'Zheng B']","['Bosentan', 'Child', 'Cost-Benefit Analysis', 'Humans', '*Hypertension, Pulmonary/drug therapy', '*Pharmaceutical Preparations', '*Pulmonary Arterial Hypertension', 'Quality of Life', 'Sildenafil Citrate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33856119/
753,Bosentan,38368315,"Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention-prospective, single-center, randomized, parallel-group study.","['Kashiwada T', 'Tanaka Y', 'Tanaka T', 'Okano T', 'Saito Y', 'Seike M', 'Hino M', 'Kimura H', 'Gemma A']","['Humans', 'Bosentan/therapeutic use', '*Hypertension, Pulmonary/etiology/complications', 'Pulmonary Artery', 'Activities of Daily Living', 'Prospective Studies', 'Endothelin Receptor Antagonists/therapeutic use', 'Sulfonamides', '*Pulmonary Disease, Chronic Obstructive/complications/drug therapy', '*Respiratory Insufficiency/complications', 'Disease Progression', 'Antihypertensive Agents/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38368315/
754,Bosentan,34319626,Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.,"['Zhao Q', 'Guo N', 'Chen J', 'Parks D', 'Tian Z']","['Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Bosentan/administration & dosage/adverse effects/*therapeutic use', 'Endothelin Receptor Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Liver Function Tests', 'Phenylpropionates/administration & dosage/adverse effects/*therapeutic use', 'Pulmonary Arterial Hypertension/*drug therapy', 'Pyridazines/administration & dosage/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Walk Test']",https://pubmed.ncbi.nlm.nih.gov/34319626/
755,Bosentan,28424444,"A successful cesarean delivery without fetal or maternal morbidity in an Eisenmenger patient with cor triatriatum sinistrum, double-orifice mitral valve, large ventricular septal defect, and single ventricle who was under long-term bosentan treatment.","['Tokgoz HC', 'Kaymaz C', 'Poci N', 'Akbal OY', 'Ozturk S']","['Adult', 'Bosentan', 'Cardiovascular Agents/therapeutic use', '*Cesarean Section', 'Cor Triatriatum/*complications/drug therapy', 'Eisenmenger Complex/complications/drug therapy', 'Female', 'Heart Septal Defects, Ventricular/*complications', 'Humans', '*Infant, Extremely Premature', 'Infant, Newborn', 'Sulfonamides/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28424444/
756,Bosentan,27716320,Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study.,"['Corallo C', 'Cutolo M', 'Kahaleh B', 'Pecetti G', 'Montella A', 'Chirico C', 'Soldano S', 'Nuti R', 'Giordano N']","['Adult', 'Aged', 'Blotting, Western', 'Bosentan', 'Cell Transdifferentiation/*drug effects', 'Cells, Cultured', 'Coculture Techniques', 'Endothelial Cells/drug effects/pathology', 'Endothelin Receptor Antagonists/*pharmacology', 'Female', 'Fibroblasts/drug effects/pathology', 'Humans', 'In Vitro Techniques', 'Middle Aged', 'Myofibroblasts/drug effects/pathology', 'Pyrimidines/*pharmacology', 'Real-Time Polymerase Chain Reaction', 'Scleroderma, Systemic/*pathology', 'Sulfonamides/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/27716320/
757,Bosentan,32918210,Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.,"['Kuang HY', 'Li Q', 'Du HA', 'Chen M', 'Yin YH']","['Antihypertensive Agents/*therapeutic use', 'Bosentan/*therapeutic use', 'Connective Tissue Diseases/epidemiology', 'Exercise/physiology', 'Familial Primary Pulmonary Hypertension/drug therapy', 'HIV Infections/epidemiology', 'Heart Defects, Congenital/epidemiology', 'Hemodynamics/drug effects', 'Humans', 'Observational Studies as Topic', 'Pulmonary Arterial Hypertension/*drug therapy/epidemiology/mortality']",https://pubmed.ncbi.nlm.nih.gov/32918210/
758,Bosentan,17239133,Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?,"['Brancaccio G', 'Toscano A', 'Bevilacqua M', 'Di Chiara L', 'Parisi F']","['Antihypertensive Agents/*therapeutic use', 'Bosentan', 'Child', 'Drug Therapy, Combination', 'Epoprostenol/administration & dosage/*therapeutic use', 'Female', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Infusions, Intravenous', 'Lung Transplantation/*physiology', 'Piperazines/*therapeutic use', 'Purines/therapeutic use', 'Sildenafil Citrate', 'Sulfonamides/*therapeutic use', 'Sulfones/*therapeutic use', 'Vasodilator Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17239133/
759,Bosentan,28805809,X-ray structures of endothelin ET(B) receptor bound to clinical antagonist bosentan and its analog.,"['Shihoya W', 'Nishizawa T', 'Yamashita K', 'Inoue A', 'Hirata K', 'Kadji FMN', 'Okuta A', 'Tani K', 'Aoki J', 'Fujiyoshi Y', 'Doi T', 'Nureki O']","['Bosentan', 'Crystallography, X-Ray', 'Endothelin Receptor Antagonists/*chemistry/*metabolism', 'Humans', 'Models, Molecular', 'Protein Binding', 'Protein Conformation', 'Receptor, Endothelin B/*chemistry/*metabolism', 'Sulfonamides/*chemistry/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/28805809/
760,Bosentan,32290885,Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.,"['Aypar E', 'Alehan D', 'Karagoz T', 'Aykan H', 'Ertugrul I']","['Administration, Oral', 'Adolescent', 'Adult', 'Antihypertensive Agents/administration & dosage', 'Bosentan', 'Child', 'Endothelin A Receptor Antagonists/administration & dosage', 'Female', 'Humans', 'Male', 'Prospective Studies', 'Pulmonary Arterial Hypertension/*drug therapy/physiopathology', 'Pyrimidines/*administration & dosage', 'Sulfonamides/*administration & dosage', 'Time Factors', 'Treatment Outcome', 'Walk Test', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32290885/
761,Bosentan,21256048,Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.,"['Barst RJ', 'Oudiz RJ', 'Beardsworth A', 'Brundage BH', 'Simonneau G', 'Ghofrani HA', 'Sundin DP', 'Galie N']","['Adult', 'Aged', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Bosentan', 'Carbolines/adverse effects/*therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Male', 'Middle Aged', 'Sulfonamides/adverse effects/*therapeutic use', 'Tadalafil', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21256048/
762,Bosentan,29233198,Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.,"['Aypar E', 'Alehan D', 'Karagoz T', 'Aykan HH', 'Ertugrul I']","['Administration, Oral', 'Adolescent', 'Adult', 'Antihypertensive Agents/administration & dosage', 'Bosentan', 'Child', 'Dose-Response Relationship, Drug', 'Endothelin A Receptor Antagonists/administration & dosage', 'Female', 'Humans', 'Hypertension, Pulmonary/*drug therapy/physiopathology', 'Male', 'Prospective Studies', 'Pulmonary Wedge Pressure/drug effects/*physiology', 'Pyrimidines/*administration & dosage', 'Sulfonamides/*administration & dosage', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29233198/
763,Bosentan,12047483,Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.,"['van Giersbergen PL', 'Halabi A', 'Dingemanse J']","['Adult', 'Antifungal Agents/administration & dosage/*pharmacology', 'Antihypertensive Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Area Under Curve', 'Bosentan', 'Cross-Over Studies', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme Inhibitors', 'Drug Administration Schedule', 'Drug Interactions', 'Humans', 'Ketoconazole/administration & dosage/*pharmacology', 'Male', 'Sulfonamides/*administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/12047483/
764,Bosentan,10620203,Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A.,"['Binet I', 'Wallnofer A', 'Weber C', 'Jones R', 'Thiel G']","['Adult', 'Blood Pressure/drug effects', 'Bosentan', 'Cyclosporine/*administration & dosage', 'Double-Blind Method', 'Endothelin Receptor Antagonists', 'Humans', 'Kidney/*drug effects/physiology', 'Male', 'Placebos', 'Reference Values', 'Sulfonamides/administration & dosage/adverse effects/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10620203/
765,Bosentan,26631100,Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.,"['Bellando-Randone S', 'Lepri G', 'Bruni C', 'Blagojevic J', 'Radicati A', 'Cometi L', 'De Paulis A', 'Matucci-Cerinic M', 'Guiducci S']","['Adult', 'Aged', 'Bosentan', 'Capillaries/physiopathology', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Microscopic Angioscopy', 'Microvessels/*drug effects', 'Middle Aged', 'Nails/blood supply', 'Raynaud Disease/*drug therapy', 'Retrospective Studies', 'Scleroderma, Systemic/*drug therapy', 'Sildenafil Citrate/*administration & dosage', 'Sulfonamides/*administration & dosage', 'Treatment Outcome', 'Vasodilator Agents/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/26631100/
766,Oxaprozin,1603605,Oxaprozin: a new NSAID.,"['al-Faks MA', 'Pugh MC']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Double-Blind Method', 'Half-Life', 'Humans', 'Osteoarthritis/*drug therapy', 'Oxaprozin', 'Propionates/adverse effects/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/1603605/
767,Oxaprozin,36144490,Application of CO(2) Supercritical Fluid to Optimize the Solubility of Oxaprozin: Development of Novel Machine Learning Predictive Models.,"['Alshahrani SM', 'Saqr AA', 'Alfadhel MM', 'Alshetaili AS', 'Almutairy BK', 'Alsubaiyel AM', 'Almari AH', 'Alamoudi JA', 'Abourehab MAS']","['*Artificial Intelligence', '*Carbon Dioxide/chemistry', 'Machine Learning', 'Oxaprozin', 'Solubility']",https://pubmed.ncbi.nlm.nih.gov/36144490/
768,Oxaprozin,20206429,"Analgesic and anti-inflammatory effects of oxaprozin and naproxen sodium after removal of impacted lower third molars: a randomized, double-blind, placebo-controlled crossover study.","['Kara IM', 'Polat S', 'Inci MF', 'Gumus C']","['Adolescent', 'Anti-Inflammatory Agents/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Cross-Over Studies', 'Double-Blind Method', 'Edema/prevention & control', 'Face', 'Female', 'Humans', 'Male', 'Mandible/physiopathology', 'Molar, Third/*surgery', 'Naproxen/*therapeutic use', 'Oxaprozin', 'Pain, Postoperative/prevention & control', 'Placebos', 'Propionates/*therapeutic use', 'Prospective Studies', 'Range of Motion, Articular/physiology', 'Tooth, Impacted/*surgery', 'Trismus/prevention & control', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/20206429/
769,Oxaprozin,8565037,Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee.,"['Weaver A', 'Rubin B', 'Caldwell J', 'McMahon FG', 'Lee D', 'Makarowski W', 'Offenberg H', 'Sack M', 'Sikes D', 'Trapp R', 'et al.']","['Aged', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Butanones/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Knee/pathology', 'Male', 'Middle Aged', 'Nabumetone', 'Osteoarthritis/*drug therapy/pathology', 'Oxaprozin', 'Pain/etiology', 'Propionates/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8565037/
770,Oxaprozin,21439375,"Improvement of oxaprozin solubility and permeability by the combined use of cyclodextrin, chitosan, and bile components.","['Maestrelli F', 'Cirri M', 'Mennini N', 'Zerrouk N', 'Mura P']","['Anti-Inflammatory Agents, Non-Steroidal/*chemistry', 'Bile/*chemistry/metabolism', 'Caco-2 Cells', 'Chitosan/*chemistry', 'Cholagogues and Choleretics/chemistry', 'Dehydrocholic Acid/chemistry', 'Drug Carriers', 'Drug Compounding/*methods', 'Drug Delivery Systems', 'Drug Synergism', 'Excipients/chemistry', 'Humans', 'L-Lactate Dehydrogenase/drug effects', 'Oxaprozin', 'Permeability', 'Propionates/*chemistry', 'Solubility', 'Ursodeoxycholic Acid/chemistry', 'beta-Cyclodextrins/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/21439375/
771,Oxaprozin,6863578,Effects of oxaprozin alone or in combination with aspirin on hemostasis and plasma protein binding.,"['Kahn SB', 'Hubsher JA']","['Adult', 'Anti-Inflammatory Agents/administration & dosage/*pharmacology', 'Aspirin/administration & dosage/metabolism/*pharmacology', 'Bleeding Time', 'Blood Proteins/*metabolism', 'Collagen/pharmacology', 'Epinephrine/pharmacology', 'Female', 'Hemostasis/*drug effects', 'Humans', 'Male', 'Oxaprozin', 'Platelet Aggregation/drug effects', 'Propionates/administration & dosage/metabolism/*pharmacology', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/6863578/
772,Oxaprozin,9916614,"Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis.","['Simon LS', 'Zhao SZ', 'Arguelles LM', 'Lefkowith JB', 'Dedhiya SD', 'Fort JG', 'Johnson KE']","['Adult', 'Aged', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*economics/*therapeutic use', 'Arthritis/*drug therapy/*economics', 'Butanones/adverse effects/*economics/*therapeutic use', 'Costs and Cost Analysis', 'Data Interpretation, Statistical', 'Databases, Factual', 'Etodolac/adverse effects/*economics/*therapeutic use', 'Female', 'Humans', 'Insurance, Pharmaceutical Services/economics', 'Male', 'Middle Aged', 'Nabumetone', 'Oxaprozin', 'Propionates/adverse effects/*economics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9916614/
773,Oxaprozin,2497096,Indomethacin and oxaprozin lower seminal prostaglandin levels but do not influence sperm motion characteristics and serum hormones of young healthy men in a placebo-controlled double-blind trial.,"['Knuth UA', 'Kuhne J', 'Crosby J', 'Bals-Pratsch M', 'Kelly RW', 'Nieschlag E']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/blood/*pharmacology', 'Double-Blind Method', 'Estradiol/*blood', 'Follicle Stimulating Hormone/blood', 'Humans', 'Indomethacin/blood/*pharmacology', 'Luteinizing Hormone/blood', 'Male', 'Oxaprozin', 'Pituitary Hormones, Anterior/*blood', 'Prolactin/blood', 'Propionates/blood/*pharmacology', 'Prostaglandins/analysis/*metabolism', 'Random Allocation', 'Semen/analysis', 'Sperm Motility/drug effects', 'Spermatozoa/*drug effects/metabolism', 'Testosterone/*blood', 'Thyrotropin/blood']",https://pubmed.ncbi.nlm.nih.gov/2497096/
774,Oxaprozin,8851458,"The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee.","['Makarowski W', 'Weaver A', 'Rubin B', 'Caldwell J', 'McMahon FG', 'Noveck RJ', 'Lee D', 'Offenberg H', 'Sack M', 'Sikes D', 'Trapp R', 'Rush S', 'Kuss M', 'Ganju J', 'Bocanegra TS', 'Ratliff JM']","['Adult', 'Aged', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Butanones/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', '*Knee Joint', 'Male', 'Middle Aged', 'Nabumetone', 'Osteoarthritis/*drug therapy', 'Oxaprozin', 'Propionates/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8851458/
775,Oxaprozin,15132714,"Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.","['Brinker A', 'Goldkind L', 'Bonnel R', 'Beitz J']","['Adult', 'Adverse Drug Reaction Reporting Systems/*statistics & numerical data', 'Aged', 'Aged, 80 and over', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Butanones/*adverse effects', 'Celecoxib', 'Clinical Trials as Topic', 'Cyclooxygenase 2', 'Female', 'Hospitalization/statistics & numerical data', 'Humans', 'Hypertension/*chemically induced', 'Isoenzymes/antagonists & inhibitors', 'Lactones/*adverse effects', 'Male', 'Membrane Proteins', 'Middle Aged', 'Nabumetone', 'Oxaprozin', 'Propionates/*adverse effects', 'Prostaglandin-Endoperoxide Synthases', 'Pyrazoles', 'Sulfonamides/*adverse effects', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/15132714/
776,Oxaprozin,3439193,Interactions between oxaprozin glucuronide and human serum albumin.,"['Wells DS', 'Janssen FW', 'Ruelius HW']","['Binding Sites', 'Chemical Phenomena', 'Chemistry', 'Chromatography, High Pressure Liquid', 'Humans', 'Propionates/*blood', 'Protein Binding', 'Serum Albumin/*metabolism', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3439193/
777,Oxaprozin,8973987,Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.,['Karim A'],"['Adult', 'Age Factors', 'Aged', 'Anti-Inflammatory Agents, Non-Steroidal/blood/*pharmacokinetics', 'Blood Proteins/metabolism', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Half-Life', 'Humans', 'Male', 'Middle Aged', 'Oxaprozin', 'Propionates/blood/*pharmacokinetics', 'Protein Binding', 'Sex Factors', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/8973987/
778,Oxaprozin,8708989,The effect of co-administered drugs on oxaprozin binding to human serum albumin.,"['Aubry AF', 'Markoglou N', 'Adams MH', 'Longstreth J', 'Wainer IW']","['Angiotensin-Converting Enzyme Inhibitors/metabolism', 'Anti-Inflammatory Agents, Non-Steroidal/*metabolism', 'Binding Sites', 'Drug Interactions', 'Humans', 'Hypoglycemic Agents/metabolism', 'Oxaprozin', 'Propionates/*metabolism', 'Protein Binding', 'Serum Albumin/*metabolism', 'Tamoxifen/metabolism', 'Warfarin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/8708989/
779,Oxaprozin,27454086,Analysis of physicochemical properties of ternary systems of oxaprozin with randomly methylated-ss-cyclodextrin and l-arginine aimed to improve the drug solubility.,"['Mennini N', 'Maestrelli F', 'Cirri M', 'Mura P']","['Amino Acids/chemistry', 'Anti-Inflammatory Agents/chemistry', 'Arginine/*chemistry', 'Calorimetry, Differential Scanning/methods', 'Chemical Phenomena', 'Oxaprozin', 'Pharmaceutical Solutions/*chemistry', 'Powders/chemistry', 'Propionates/*chemistry', 'Solubility', 'X-Ray Diffraction/methods', 'X-Rays', 'beta-Cyclodextrins/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/27454086/
780,Oxaprozin,3220091,Pharmacokinetics of oxaprozin in women receiving conjugated estrogen.,"['Scavone JM', 'Ochs HR', 'Greenblatt DJ', 'Matlis R']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics', 'Drug Interactions', 'Estrogens/*adverse effects', 'Female', 'Half-Life', 'Humans', 'Male', 'Middle Aged', 'Oxaprozin', 'Propionates/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/3220091/
781,Aminophylline,38059379,Aminophylline in pain and migraine.,"['Phillips BL', 'Phillips MC']","['Humans', '*Aminophylline/administration & dosage/adverse effects', '*Migraine Disorders/drug therapy', '*Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38059379/
782,Aminophylline,36251063,The diuretic effect of adding aminophylline or theophylline to furosemide in pediatric populations: a systematic review.,"['Van Siang Lian Mang P', 'Hui JC', 'Tan RSJ', 'Hasan MS', 'Choo YM', 'Abosamak MF', 'Ng KT']","['Child', 'Humans', '*Diuretics/pharmacology/therapeutic use', '*Theophylline', 'Aminophylline/pharmacology/therapeutic use', 'Furosemide/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36251063/
783,Aminophylline,28857147,Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia.,"['Schroeder T', 'Piantadosi CA', 'Natoli MJ', 'Autmizguine J', 'Cohen-Wolkowieczs M', 'Hamilton KL', 'Bell C', 'Klawitter J', 'Christians U', 'Irwin DC', 'Noveck RJ']","['Adenosine/metabolism', 'Adolescent', 'Adult', 'Altitude', 'Aminophylline/*adverse effects/*therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination/adverse effects', 'Endothelins/*drug effects/metabolism', 'Exercise/*physiology', 'Female', 'Humans', 'Hypoxia/*drug therapy/metabolism', 'Male', 'Middle Aged', 'Phenylpropionates/*adverse effects/*therapeutic use', 'Pyridazines/*adverse effects/*therapeutic use', 'Signal Transduction/drug effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28857147/
784,Aminophylline,25585842,"Salbutamol or aminophylline for acute severe asthma: how to choose which one, when and why?","['Neame M', 'Aragon O', 'Fernandes RM', 'Sinha I']","['Acute Disease', 'Albuterol/adverse effects/pharmacology/*therapeutic use', 'Aminophylline/adverse effects/pharmacology/*therapeutic use', 'Asthma/*drug therapy/physiopathology', 'Bronchodilator Agents/adverse effects/pharmacology/*therapeutic use', 'Child', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/25585842/
785,Aminophylline,28474588,Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (</=34 weeks) Neonates: A Randomized Controlled Trial.,"['Shivakumar M', 'Jayashree P', 'Najih M', 'Lewis LES', 'Bhat Y R', 'Kamath A', 'Shashikala -']","['Aminophylline/*therapeutic use', 'Apnea/*drug therapy', 'Caffeine/*therapeutic use', 'Female', 'Humans', 'Infant, Newborn', 'Infant, Premature, Diseases/*drug therapy', 'Male']",https://pubmed.ncbi.nlm.nih.gov/28474588/
786,Aminophylline,16462032,Effects of dexamethasone and aminophylline on survival of Jurkat and HL-60 cells.,"['Kizawa Y', 'Furuya M', 'Saito K', 'Masuko T', 'Kusama T']","['Aminophylline/administration & dosage/*pharmacology', 'Anti-Inflammatory Agents/administration & dosage/*pharmacology', 'Apoptosis/*drug effects', 'Dexamethasone/administration & dosage/*pharmacology', 'Dose-Response Relationship, Drug', 'Drug Synergism', 'HL-60 Cells', 'Histones/metabolism', 'Humans', 'Intracellular Signaling Peptides and Proteins', 'Jurkat Cells', 'Protein Serine-Threonine Kinases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/16462032/
787,Aminophylline,22005755,Additive diuretic response of concurrent aminophylline and furosemide in children: a case series and a brief literature review.,"['da Silva PS', 'de Aguiar VE', 'Fonseca MC']","['Aminophylline/*pharmacology', 'Child, Preschool', 'Diuretics/*pharmacology', 'Drug Synergism', 'Female', 'Furosemide/*pharmacology', 'Humans', 'Infant', 'Male']",https://pubmed.ncbi.nlm.nih.gov/22005755/
788,Aminophylline,3533371,The hemodynamic effects of aminophylline and salbutamol alone and in combination.,"['Burgess CD', 'Crane J', 'Graham AN', 'Maling TJ']","['Adult', 'Albuterol/administration & dosage/*pharmacology/therapeutic use', 'Aminophylline/administration & dosage/*pharmacology/therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Drug Therapy, Combination', 'Female', 'Heart Rate/drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Lung Diseases, Obstructive/*drug therapy', 'Male', 'Middle Aged', 'Myocardial Contraction/drug effects', 'Random Allocation', 'Stimulation, Chemical', 'Stroke Volume/drug effects', 'Theophylline/blood']",https://pubmed.ncbi.nlm.nih.gov/3533371/
789,Aminophylline,6504688,Pulsed proton NMR and solid-liquid fat ratio determinations in suppository vehicles and aminophylline suppositories.,"['De Blaey CJ', 'Varkevisser FA', 'Kalk A']","['Aminophylline/administration & dosage/*analysis', 'Chemical Phenomena', 'Chemistry, Physical', 'Drug Stability', 'Drug Storage', 'Fats/*analysis', 'Magnetic Resonance Spectroscopy', 'Molecular Conformation', 'Particle Size', 'Pharmaceutical Vehicles', 'Suppositories', 'Temperature']",https://pubmed.ncbi.nlm.nih.gov/6504688/
790,Aminophylline,20193253,Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules.,"['Liu HY', 'Pi XT', 'Zheng XL', 'Hou WS', 'Cui JG']","['Adult', 'Aminophylline/*administration & dosage/*pharmacokinetics', 'Capsules/*administration & dosage/*pharmacokinetics', 'Colon/*metabolism', 'Humans', 'Intestine, Small/*metabolism', 'Male', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/20193253/
791,Aminophylline,656345,The value of a scoring system in predicting outcome of pre-term labour and comparing the efficacy of treatment with aminophylline and salbutamol.,"['Liu DT', 'Blackwell RJ']","['Albuterol/*therapeutic use', 'Aminophylline/*therapeutic use', 'Female', 'Fetal Membranes, Premature Rupture/complications', 'Humans', 'Methods', 'Obstetric Labor, Premature/*diagnosis/drug therapy', 'Pregnancy', 'Uterine Contraction']",https://pubmed.ncbi.nlm.nih.gov/656345/
792,Aminophylline,2595106,Failure of aminophylline and salbutamol to improve respiratory muscle function and exercise tolerance in healthy humans.,"['Violante B', 'Pellegrino R', 'Vinay C', 'Selleri R', 'Ghinamo G']","['Adult', 'Albuterol/*pharmacology', 'Aminophylline/*pharmacology', 'Exercise/*physiology', 'Exercise Test', 'Humans', 'Male', 'Physical Endurance/drug effects', 'Pulmonary Gas Exchange/drug effects', 'Respiratory Muscles/*drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/2595106/
793,Aminophylline,340945,Bronchodilator effects of terbutaline and aminophylline alone and in combination in asthmatic patients.,"['Wolfe JD', 'Tashkin DP', 'Calvarese B', 'Simmons M']","['Adolescent', 'Adult', 'Aged', 'Aminophylline/*administration & dosage/adverse effects/therapeutic use', 'Asthma/*drug therapy', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Synergism', 'Drug Therapy, Combination', 'Female', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Pulmonary Ventilation/drug effects', 'Terbutaline/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/340945/
794,Aminophylline,7011349,The metabolic actions of intravenous salbutamol and aminophylline singly and in combination.,"['Jenkins CR', 'Marlin GE']","['Adult', 'Albuterol/administration & dosage/*pharmacology', 'Aminophylline/administration & dosage/*pharmacology', 'Blood Glucose/metabolism', 'Drug Interactions', 'Heart Rate/drug effects', 'Humans', 'Injections, Intravenous', 'Insulin/*blood', 'Male', 'Potassium/blood']",https://pubmed.ncbi.nlm.nih.gov/7011349/
795,Aminophylline,28636149,Photocatalytic interaction of aminophylline-riboflavin leads to ROS-mediated DNA damage and cell death: A novel phototherapeutic mechanism for cancer.,"['Khan S', 'Naseem I']","['Aminophylline/*chemistry/metabolism', 'Apoptosis/radiation effects', 'Cell Line, Tumor', 'Cell Proliferation/radiation effects', 'DNA Damage/radiation effects', 'Humans', 'Light', 'Lipid Peroxidation/radiation effects', 'Neoplasms/pathology/*therapy', 'Oxidative Stress/radiation effects', 'Photochemical Processes/radiation effects', '*Photochemotherapy', 'Reactive Oxygen Species/*chemistry/radiation effects', 'Riboflavin/*chemistry/metabolism']",https://pubmed.ncbi.nlm.nih.gov/28636149/
796,Aminophylline,15889197,Aminophylline: exploring cardiovascular benefits versus medical malcontent.,['Rudusky BM'],"['Aminophylline/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Cardiotonic Agents/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Humans', 'Lung Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15889197/
797,Aminophylline,6620175,Pharmacodynamics of the diuretic effects of aminophylline and acetazolamide alone and combined with furosemide in normal subjects.,"['Brater DC', 'Kaojarern S', 'Chennavasin P']","['Acetazolamide/administration & dosage/*pharmacology', 'Aminophylline/administration & dosage/*pharmacology', '*Diuretics', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Furosemide/*administration & dosage', 'Humans', 'Kidney/*drug effects', 'Kidney Tubules, Proximal/drug effects', 'Male', 'Renal Circulation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6620175/
798,Aminophylline,9282234,Effects of high-dose ipratropium bromide and oral aminophylline on spirometry and exercise tolerance in COPD.,"['Shivaram U', 'Cash ME', 'Mateo F', 'Shim C']","['Administration, Oral', 'Aged', 'Aminophylline/*administration & dosage/therapeutic use', 'Bronchodilator Agents/*administration & dosage/therapeutic use', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Administration Schedule', 'Exercise Tolerance/*drug effects', 'Heart/physiopathology', 'Heart Function Tests', 'Humans', 'Ipratropium/*administration & dosage/therapeutic use', 'Lung/*drug effects/physiopathology', 'Lung Diseases, Obstructive/*drug therapy/physiopathology', 'Spirometry']",https://pubmed.ncbi.nlm.nih.gov/9282234/
799,Bicalutamide,35032336,Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know.,"['Carvalho RM', 'Santos LDN', 'Ramos PM', 'Machado CJ', 'Acioly P', 'Frattini SC', 'Barcaui CB', 'Donda ALV', 'Melo DF']","['Female', 'Humans', '*Quality of Life', '*Dermatologists', 'Alopecia/therapy', 'Minoxidil']",https://pubmed.ncbi.nlm.nih.gov/35032336/
800,Bicalutamide,33926033,Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.,"['Kim GY', 'Song CW', 'Yang YS', 'Lee NR', 'Yoo HS', 'Son SH', 'Lee SJ', 'Park JS', 'Lee JK', 'Inn KS', 'Kim NJ']","['Androgen Antagonists/chemical synthesis/*chemistry/pharmacology', 'Anilides/*chemistry/pharmacology', 'Binding Sites', 'Cell Line', 'Chemistry Techniques, Synthetic', 'Humans', 'Models, Biological', 'Models, Molecular', 'Molecular Conformation', 'Molecular Structure', 'Nitriles/*chemistry/pharmacology', 'Protein Binding', 'Proteolysis/drug effects', 'Receptors, Androgen/*chemistry/metabolism', 'Structure-Activity Relationship', 'Thalidomide/*chemistry/pharmacology', 'Tosyl Compounds/*chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33926033/
801,Bicalutamide,38427963,Toward Bicalutamide Analogues with High Structural Diversity Using Catalytic Asymmetric Oxohydroxylation.,"['Chen X', 'Tian J', 'Wang S', 'Wang C', 'Zong L']","['Male', 'Humans', 'Molecular Structure', 'Stereoisomerism', 'Structure-Activity Relationship', '*Prostatic Neoplasms', '*Anilides', '*Nitriles', '*Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/38427963/
802,Bicalutamide,36075260,"Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.","['Gu W', 'Han W', 'Luo H', 'Zhou F', 'He D', 'Ma L', 'Guo H', 'Liang C', 'Chong T', 'Jiang J', 'Chen Z', 'Wang Y', 'Zou Q', 'Tian Y', 'Xiao J', 'Huang J', 'Zhu S', 'Dong Q', 'Zhang X', 'Li H', 'Yang X', 'Chen C', 'Li J', 'Jin C', 'Zhang X', 'Ye D']","['*Androgen Antagonists/adverse effects', 'Androgens', 'Anilides', '*Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Disease-Free Survival', 'Humans', 'Male', 'Nitriles', '*Prostatic Neoplasms/drug therapy/pathology', 'Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/36075260/
803,Bicalutamide,9037299,Fulminant hepatic failure associated with bicalutamide.,"['Dawson LA', 'Chow E', 'Morton G']","['Adenocarcinoma/drug therapy', 'Androgen Antagonists/*adverse effects', 'Anilides/*adverse effects', 'Hepatic Encephalopathy/*chemically induced', 'Humans', 'Male', 'Middle Aged', 'Nitriles', 'Prostatic Neoplasms/drug therapy', 'Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/9037299/
804,Bicalutamide,17102802,Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.,"['Wirth M', 'Tyrrell C', 'Delaere K', 'Sanchez-Chapado M', 'Ramon J', 'Wallace DM', 'Hetherington J', 'Pina F', 'Heyns CF', 'Navani S', 'Armstrong J']","['Anilides/*administration & dosage/adverse effects', 'Antineoplastic Agents/administration & dosage/adverse effects', 'Carcinoma/*drug therapy/mortality', 'Chemotherapy, Adjuvant', 'Combined Modality Therapy', 'Disease-Free Survival', 'Double-Blind Method', 'Follow-Up Studies', 'Humans', 'Male', 'Nitriles/*administration & dosage/adverse effects', 'Placebos', 'Prostatectomy', 'Prostatic Neoplasms/*drug therapy/mortality', 'Radiotherapy', 'Survival Analysis', 'Tosyl Compounds/*administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17102802/
805,Bicalutamide,31849389,A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.,"['Muramatsu T', 'Funahashi Y', 'Yamamoto A', 'Sassa N', 'Matsukawa Y', 'Gotoh M']","['Aged', 'Anilides/*therapeutic use', 'Disease Progression', 'Flutamide/*therapeutic use', 'Humans', 'Male', 'Nitriles/*therapeutic use', 'Prostatic Neoplasms/*drug therapy', 'Prostatic Neoplasms, Castration-Resistant/*drug therapy', 'Temperature', 'Tosyl Compounds/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31849389/
806,Bicalutamide,14682722,Nucleophilic aromatic substitution of methacrylamide anion and its application to the synthesis of the anticancer drug bicalutamide.,"['Chen BC', 'Zhao R', 'Gove S', 'Wang B', 'Sundeen JE', 'Salvati ME', 'Barrish JC']","['Acrylamides/*chemistry', 'Anilides/*chemical synthesis/chemistry', 'Anions/chemistry', 'Antineoplastic Agents/*chemical synthesis/chemistry', 'Nitriles', 'Stereoisomerism', 'Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/14682722/
807,Bicalutamide,16954109,Characteristics of bicalutamide solid dispersions and improvement of the dissolution.,"['Ren F', 'Jing Q', 'Tang Y', 'Shen Y', 'Chen J', 'Gao F', 'Cui J']","['Anilides/*administration & dosage/chemistry', 'Calorimetry, Differential Scanning', 'Drug Carriers', 'Drug Stability', 'Nitriles', 'Polyvinyls/*administration & dosage', 'Powders', 'Pyrrolidines/*administration & dosage', 'Solubility', 'Spectroscopy, Fourier Transform Infrared', 'Tosyl Compounds', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/16954109/
808,Bicalutamide,37143720,Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer.,"['Li Y', 'Wang H', 'Pan Y', 'Wang S', 'Zhang Z', 'Zhou H', 'Xu M', 'Liu X']","['Male', 'Humans', '*Prostatic Neoplasms/drug therapy/genetics/pathology', 'Androgen Antagonists/therapeutic use', 'Prognosis', 'Anilides/pharmacology/therapeutic use', 'Tumor Microenvironment', 'Repressor Proteins', 'Trans-Activators', '*Vacuolar Proton-Translocating ATPases', 'Nuclear Proteins']",https://pubmed.ncbi.nlm.nih.gov/37143720/
809,Bicalutamide,9498983,Eosinophilic lung disease induced by bicalutamide: a case report and review of the medical literature.,"['Wong PW', 'Macris N', 'DiFabrizio L', 'Seriff NS']","['Aged', 'Androgen Antagonists/*adverse effects', 'Anilides/*adverse effects', 'Anti-Inflammatory Agents/therapeutic use', 'Antineoplastic Agents, Hormonal/*adverse effects', 'Biopsy', 'Dyspnea/chemically induced', 'Glucocorticoids/therapeutic use', 'Humans', 'Lung Diseases, Interstitial/chemically induced', 'Male', 'Methylprednisolone Hemisuccinate/therapeutic use', 'Nitriles', 'Prostatic Neoplasms/drug therapy', 'Pulmonary Eosinophilia/*chemically induced/drug therapy', 'Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/9498983/
810,Bicalutamide,36421730,Bicalutamide Anticancer Activity Enhancement by Formulation of Soluble Inclusion Complexes with Cyclodextrins.,"['De Gaetano F', 'Cristiano MC', 'Paolino D', 'Celesti C', 'Iannazzo D', 'Pistara V', 'Iraci N', 'Ventura CA']","['Male', 'Humans', '*Cyclodextrins/pharmacology/chemistry', 'Nitriles/pharmacology', 'Solubility', '2-Hydroxypropyl-beta-cyclodextrin/pharmacology', 'Water/chemistry']",https://pubmed.ncbi.nlm.nih.gov/36421730/
811,Bicalutamide,38523017,"Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.","['Parikh M', 'Tangen C', 'Hussain MHA', 'Gupta S', 'Callis S', 'Jo Y', 'Harzstark A', 'Paller CJ', 'George S', 'Zibelman MR', 'Cheng HH', 'Maughan BL', 'Zhang J', 'Pachynski RK', 'Bryce AH', 'Lin DW', 'Quinn DI', 'Lerner SP', 'Thompson IM', 'Dorff TB', 'Lara PN', 'Agarwal N']","['Humans', 'Male', '*Prostate-Specific Antigen/blood', '*Tosyl Compounds/therapeutic use', '*Anilides/therapeutic use', '*Nitriles/therapeutic use', '*Prostatic Neoplasms/drug therapy/mortality/pathology/blood', '*Androgen Antagonists/therapeutic use', 'Aged', 'Prognosis', 'Middle Aged', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Biomarkers, Tumor/blood', 'Neoplasm Metastasis', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/38523017/
812,Bicalutamide,30661420,Co-crystallization for enhanced dissolution rate of bicalutamide: preparation and evaluation of rapidly disintegrating tablets.,"['Essa EA', 'Elbasuony AR', 'Abdelaziz AE', 'El Maghraby GM']","['Anilides/*chemistry', 'Calorimetry, Differential Scanning/methods', 'Chemistry, Pharmaceutical/methods', 'Crystallization/methods', 'Excipients/chemistry', 'Nitriles/*chemistry', 'Solubility/*drug effects', 'Spectroscopy, Fourier Transform Infrared/methods', 'Sucrose/analogs & derivatives/chemistry', 'Tablets/*chemistry', 'Tosyl Compounds/*chemistry', 'X-Ray Diffraction/methods']",https://pubmed.ncbi.nlm.nih.gov/30661420/
813,Bicalutamide,18062751,Treatment of bicalutamide-induced breast events.,['Sieber PR'],"['Androgen Antagonists/*adverse effects', 'Anilides/*adverse effects', 'Clinical Trials as Topic', 'Estrogen Receptor Modulators/therapeutic use', 'Gynecomastia/*chemically induced/*therapy', 'Humans', 'Male', 'Nitriles/*adverse effects', 'Pain/chemically induced', 'Pain Management', 'Prostatic Neoplasms/drug therapy', 'Tamoxifen/therapeutic use', 'Tosyl Compounds/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18062751/
814,MALTULOSE,15220094,"Golgi endomannosidase inhibitor, alpha-D-glucopyranosyl-(1 --> 3)-1-deoxymannojirimycin: a five-step synthesis from maltulose and examples of N-modified derivatives.","['Spreitz J', 'Stutz AE']","['1-Deoxynojirimycin/*analogs & derivatives/*chemistry', 'Carbohydrate Sequence', 'Catalysis', 'Enzyme Inhibitors/*pharmacology', 'Fructose/chemistry', 'Glucosides/*chemistry', 'Golgi Apparatus/*enzymology/metabolism', 'Hydrogen/chemistry', 'Magnetic Resonance Spectroscopy', 'Mannitol/chemistry', 'Mannosidases/*antagonists & inhibitors/*chemistry', 'Methanol/chemistry/pharmacology', 'Models, Chemical', 'Molecular Sequence Data', 'Pyrans/chemistry', 'Temperature']",https://pubmed.ncbi.nlm.nih.gov/15220094/
815,MALTULOSE,15506809,Ratio of maltose to maltulose and furosine as quality parameters for infant formula.,"['Morales V', 'Olano A', 'Corzo N']","['Chromatography, Gas', 'Infant Formula/*chemistry', 'Lysine/*analogs & derivatives/*analysis', 'Maltose/*analysis/*chemistry', 'Quality Control']",https://pubmed.ncbi.nlm.nih.gov/15506809/
816,MALTULOSE,5690932,"Crypticity of Myrothecium verrucaria spores to maltose and induction of transport by maltulose, a common maltose contaminant.","['Parrish FW', 'Hahn WB', 'Mandels GR']","['Biological Transport', 'Carbohydrates/pharmacology', '*Enzyme Induction', 'Maltose/analysis/*metabolism', 'Membrane Transport Proteins/*metabolism', '*Mitosporic Fungi', 'Molecular Biology', 'Spores']",https://pubmed.ncbi.nlm.nih.gov/5690932/
817,hydroxychloroquine,32634079,The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.,"['Martinez GP', 'Zabaleta ME', 'Di Giulio C', 'Charris JE', 'Mijares MR']","['Autoimmune Diseases/drug therapy', 'Betacoronavirus', 'COVID-19', 'Chloroquine/*pharmacology/therapeutic use', 'Coronavirus Infections', 'Humans', 'Hydroxychloroquine/*pharmacology/therapeutic use', 'Immune System/*drug effects', 'Pandemics', 'Pneumonia, Viral', 'SARS-CoV-2']",https://pubmed.ncbi.nlm.nih.gov/32634079/
818,hydroxychloroquine,32726238,Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.,"['Lebin JA', 'LeSaint KT']","['Betacoronavirus/*drug effects', 'COVID-19', 'Chloroquine/adverse effects/*therapeutic use', 'Coronavirus Infections/*drug therapy', 'Humans', 'Hydroxychloroquine/adverse effects/*therapeutic use', 'Pandemics', 'Pneumonia, Viral/*drug therapy', 'SARS-CoV-2', 'COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/32726238/
819,hydroxychloroquine,33725851,Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure: Case report and literature review.,"['Lu J', 'Huang Y', 'Ye Q', 'Shang F', 'Ming M', 'Xu H', 'Li Z']","['Adolescent', 'Female', 'Humans', 'Hydroxychloroquine/*adverse effects/pharmacokinetics/therapeutic use', 'Lupus Erythematosus, Systemic/drug therapy', 'Vision, Low/*chemically induced', 'Visual Acuity']",https://pubmed.ncbi.nlm.nih.gov/33725851/
820,hydroxychloroquine,28282061,Hydroxychloroquine retinopathy.,"['Yusuf IH', 'Sharma S', 'Luqmani R', 'Downes SM']","['Antirheumatic Agents/adverse effects', 'Connective Tissue Diseases/drug therapy', 'Diagnostic Techniques, Ophthalmological', 'Global Health', 'Humans', 'Hydroxychloroquine/*adverse effects', 'Incidence', 'Retina/*drug effects/pathology', 'Retinal Diseases/*chemically induced/diagnosis/epidemiology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/28282061/
821,hydroxychloroquine,33028485,Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.,['Carafoli E'],"['COVID-19/prevention & control', 'Chloroquine/chemistry/pharmacology/*therapeutic use', 'Humans', 'Hydroxychloroquine/chemistry/pharmacology/*therapeutic use', 'Primary Prevention', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33028485/
822,hydroxychloroquine,32687630,Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.,"['Nicol MR', 'Joshi A', 'Rizk ML', 'Sabato PE', 'Savic RM', 'Wesche D', 'Zheng JH', 'Cook J']","['Age Factors', 'Aging', 'Antiviral Agents/administration & dosage/adverse effects/*therapeutic use', 'Chloroquine/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Drug Interactions', 'Drug Therapy, Combination', 'Humans', 'Hydroxychloroquine/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Liver Failure/epidemiology', 'Malaria/drug therapy', 'Prospective Studies', 'Renal Insufficiency/epidemiology', 'SARS-CoV-2', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/32687630/
823,hydroxychloroquine,36112387,Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares.,"['Jorge AM', 'Mancini C', 'Zhou B', 'Ho G', 'Zhang Y', 'Costenbader K', 'Choi HK']","['*Antirheumatic Agents/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', '*Eye Diseases/chemically induced', 'Humans', '*Hydroxychloroquine/administration & dosage/adverse effects', '*Lupus Erythematosus, Systemic/drug therapy/prevention & control', '*Ophthalmology/standards', 'Practice Guidelines as Topic/standards', 'Risk', '*Symptom Flare Up']",https://pubmed.ncbi.nlm.nih.gov/36112387/
824,hydroxychloroquine,32885373,Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis.,"['Elavarasi A', 'Prasad M', 'Seth T', 'Sahoo RK', 'Madan K', 'Nischal N', 'Soneja M', 'Sharma A', 'Maulik SK', 'Shalimar', 'Garg P']","['Bias', 'Chloroquine/administration & dosage/adverse effects', 'Humans', 'Hydroxychloroquine/*administration & dosage/adverse effects', 'Research Design/standards', 'SARS-CoV-2', 'Treatment Outcome', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/32885373/
825,hydroxychloroquine,33236703,The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19.,"['Lee Z', 'Rayner CR', 'Forrest JI', 'Nachega JB', 'Senchaudhuri E', 'Mills EJ']","['Antimalarials/adverse effects/*therapeutic use', 'Antiviral Agents/adverse effects/therapeutic use', 'COVID-19/prevention & control', 'Cardiovascular Diseases/chemically induced', 'Humans', 'Hydroxychloroquine/adverse effects/*therapeutic use', 'Politics', '*SARS-CoV-2', 'Treatment Outcome', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33236703/
826,hydroxychloroquine,37881891,"Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review.","['Garcia MC', 'Tsang K', 'Lohit S', 'Deng J', 'Schneider T', 'Matos Silva J', 'Mbuagbaw L', 'Holbrook A']","['Humans', 'Arrhythmias, Cardiac/chemically induced', '*Chloroquine/adverse effects', '*Hydroxychloroquine/adverse effects/therapeutic use/administration & dosage', '*Long QT Syndrome/chemically induced', 'Randomized Controlled Trials as Topic', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/37881891/
827,hydroxychloroquine,34296811,Maternal exposure to hydroxychloroquine and birth defects.,"['Howley MM', 'Werler MM', 'Fisher SC', 'Van Zutphen AR', 'Carmichael SL', 'Broussard CS', 'Heinke D', 'Ailes EC', 'Pruitt SM', 'Reefhuis J', 'Mitchell AA', 'Browne ML']","['Female', 'Humans', 'Hydroxychloroquine/adverse effects', 'Maternal Exposure/adverse effects', 'Pregnancy', '*Pregnancy Complications, Infectious', 'SARS-CoV-2', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/34296811/
828,hydroxychloroquine,32715647,Hydroxychloroquine in rheumatic autoimmune disorders and beyond.,"['Nirk EL', 'Reggiori F', 'Mauthe M']","['*Arthritis, Rheumatoid/drug therapy', '*Autoimmune Diseases/drug therapy', 'Chloroquine', 'Humans', 'Hydroxychloroquine/therapeutic use', '*Lupus Erythematosus, Systemic']",https://pubmed.ncbi.nlm.nih.gov/32715647/
829,hydroxychloroquine,39899183,Safety of Hydroxychloroquine: What a Dermatologist Should Know.,"['Rapparini L', 'Cedirian S', 'La Placa M', 'Piraccini BM', 'Raschi E', 'Starace M']","['*Hydroxychloroquine/adverse effects/therapeutic use', 'Humans', 'Antirheumatic Agents/adverse effects', 'COVID-19', 'Retinal Diseases/chemically induced/diagnosis', 'Skin Diseases/chemically induced', 'SARS-CoV-2', 'Dermatologists']",https://pubmed.ncbi.nlm.nih.gov/39899183/
830,hydroxychloroquine,33775862,Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms.,"['Ferreira PMP', 'Sousa RWR', 'Ferreira JRO', 'Militao GCG', 'Bezerra DP']","['Antineoplastic Agents/pharmacology', 'Autophagy/*drug effects', 'Chloroquine/*pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Drug Resistance, Neoplasm', 'Humans', 'Hydroxychloroquine/*pharmacology/therapeutic use', 'Immunomodulating Agents/pharmacology', 'Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33775862/
831,hydroxychloroquine,32880032,"Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.","['Misra DP', 'Gasparyan AY', 'Zimba O']","['Antirheumatic Agents/*therapeutic use', '*Betacoronavirus', 'COVID-19', 'Colchicine/adverse effects/*therapeutic use', 'Coronavirus Infections/*drug therapy', '*Drug Repositioning', 'Hydroxychloroquine/adverse effects/*therapeutic use', 'Methotrexate/adverse effects/*therapeutic use', 'Pandemics', 'Pneumonia, Viral/*drug therapy', 'SARS-CoV-2', 'COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/32880032/
832,hydroxychloroquine,32947506,Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients.,"['Yang TH', 'Chou CY', 'Yang YF', 'Chien CS', 'Yarmishyn AA', 'Yang TY', 'Liu CH', 'Chang KJ', 'Yang YP', 'Chang YL']","['Azithromycin/administration & dosage', 'COVID-19/mortality/virology', 'Electrocardiography/drug effects', 'Humans', 'Hydroxychloroquine/administration & dosage/pharmacology/*therapeutic use', 'Publication Bias', 'Randomized Controlled Trials as Topic', '*SARS-CoV-2', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/32947506/
833,Amphetamine,33216112,Use of Lisdexamfetamine or Amphetamine? Interpretation of Chiral Amphetamine Analyses.,"['Cherma MD', 'Nilsson GH', 'Johansson A', 'Jonsson AK', 'Ahlner J']","['Amphetamine', '*Central Nervous System Stimulants', 'Dextroamphetamine', 'Humans', '*Lisdexamfetamine Dimesylate', 'Sweden']",https://pubmed.ncbi.nlm.nih.gov/33216112/
834,Amphetamine,31931669,Amphetamine-Dextroamphetamine and Pregnancy: Neonatal Outcomes After Prenatal Prescription Mixed Amphetamine Exposure.,"['Rose SJ', 'Hathcock MA', 'White WM', 'Borowski K', 'Rivera-Chiauzzi EY']","['*Amphetamine', '*Attention Deficit Disorder with Hyperactivity/drug therapy/epidemiology', 'Dextroamphetamine/adverse effects', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Pregnancy', 'Prescriptions', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/31931669/
835,Amphetamine,7580171,Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.,"['Lurie S', ""O'Quinn A""]","['Adolescent', 'Adult', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology', 'Central Nervous System Stimulants/adverse effects/*therapeutic use', 'Child', 'Dextroamphetamine/adverse effects/*therapeutic use', 'Growth Disorders/chemically induced', 'Humans', 'Methylphenidate/adverse effects/*therapeutic use', 'Neurosecretory Systems/*drug effects/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7580171/
836,Amphetamine,27518755,"Method validation and determination of lisdexamfetamine and amphetamine in oral fluid, plasma and urine by LC-MS/MS.","['Comiran E', 'Barreto F', 'Meneghini LZ', 'Carlos G', 'Froehlich PE', 'Limberger RP']","['Amphetamine/*analysis/blood/urine', '*Chromatography, Liquid', 'Clinical Chemistry Tests/*methods/standards', 'Humans', 'Lisdexamfetamine Dimesylate/*analysis/blood/urine', 'Reproducibility of Results', 'Saliva/chemistry', '*Tandem Mass Spectrometry']",https://pubmed.ncbi.nlm.nih.gov/27518755/
837,Amphetamine,19243715,"The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.",['Najib J'],"['Adult', 'Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Central Nervous System Stimulants/*administration & dosage/adverse effects/pharmacokinetics', 'Child', 'Clinical Trials as Topic', 'Dextroamphetamine/*administration & dosage/adverse effects/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Humans', 'Lisdexamfetamine Dimesylate', 'Prodrugs', 'Substance-Related Disorders/etiology']",https://pubmed.ncbi.nlm.nih.gov/19243715/
838,Amphetamine,36919514,Priming effects of a slot machine game and amphetamine on probabilistic risk-taking in people with gambling disorder and healthy controls.,"['Zack M', 'Lobo D', 'Biback C', 'Fang T', 'Smart K', 'Tatone D', 'Kalia A', 'Digiacomo D', 'Kennedy JL']","['Humans', '*Amphetamine/adverse effects', '*Gambling/psychology', 'Haloperidol/pharmacology/therapeutic use', 'Dextroamphetamine', 'Fluphenazine', 'Dopamine', 'Risk-Taking']",https://pubmed.ncbi.nlm.nih.gov/36919514/
839,Amphetamine,36562920,Detection of lisdexamfetamine and its metabolite d-amphetamine in urine and gastric contents collected from a cadaver at forensic autopsy.,"['Torimitsu S', 'Saka K', 'Noritake K', 'Namera A', 'Makino Y', 'Yamaguchi R', 'Iwase H']","['Humans', '*Lisdexamfetamine Dimesylate', 'Amphetamine', 'Dextroamphetamine', 'Autopsy', 'Chromatography, Liquid', 'Tandem Mass Spectrometry', '*Prodrugs', 'Cadaver']",https://pubmed.ncbi.nlm.nih.gov/36562920/
840,Amphetamine,11557168,Human response to repeated low-dose d-amphetamine: evidence for behavioral enhancement and tolerance.,"['Strakowski SM', 'Sax KW', 'Rosenberg HL', 'DelBello MP', 'Adler CM']","['Adolescent', 'Adult', 'Behavior/*drug effects', 'Central Nervous System Stimulants/administration & dosage/*pharmacology', 'Databases, Factual', 'Dextroamphetamine/administration & dosage/*pharmacology', 'Double-Blind Method', 'Drug Tolerance', 'Euphoria/drug effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Sex Characteristics']",https://pubmed.ncbi.nlm.nih.gov/11557168/
841,Ketoprofen,7506182,Tolerability of nimesulide and ketoprofen in paediatric patients with traumatic or surgical fractures.,"['Facchini R', 'Selva G', 'Peretti G']","['Adolescent', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Child', 'Female', 'Fractures, Bone/*drug therapy', 'Humans', 'Ketoprofen/adverse effects/*therapeutic use', 'Male', 'Pain/*drug therapy', 'Sulfonamides/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7506182/
842,Ketoprofen,3913556,Correlation between ketoprofen plasma levels and analgesic effect in acute lumbar pain and radicular pain.,"['Kohler G', 'Primbs P', 'Morand J', 'Rubelt C']","['Acute Disease', '*Analgesia', 'Brachial Plexus Neuritis/*drug therapy', 'Clinical Trials as Topic', 'Female', 'Humans', 'Ketoprofen/*blood/therapeutic use', '*Lumbar Vertebrae', 'Male', 'Pain/*drug therapy', 'Phenylpropionates/*blood', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3913556/
843,Ketoprofen,18313878,"Separation and determination of ketoprofen, methylparaben and propylparaben in pharmaceutical preparation by micellar electrokinetic chromatography.","['Safra J', 'Pospisilova M']","['Chromatography, Micellar Electrokinetic Capillary/*methods', 'Ketoprofen/*analysis', 'Parabens/*analysis']",https://pubmed.ncbi.nlm.nih.gov/18313878/
844,Ketoprofen,17203858,Ketoprofen ion-selective electrode and its application to pharmaceutical analysis.,"['Lenik J', 'Wardak C', 'Marczewska B']","['Anti-Inflammatory Agents, Non-Steroidal/*chemistry', 'Calibration', 'Chemistry, Pharmaceutical', 'Electrodes', 'Hydrogen-Ion Concentration', 'Ketoprofen/*chemistry', 'Solutions']",https://pubmed.ncbi.nlm.nih.gov/17203858/
845,Ketoprofen,1403487,Preparation and in vitro evaluation of slow release ketoprofen microcapsules formulated into tablets and capsules.,"['el Khodairy KA', 'Eshra AG', 'Nada AH', 'Mortada SA']","['Acrylic Resins', 'Capsules', 'Delayed-Action Preparations', 'Drug Compounding', 'Humans', 'In Vitro Techniques', 'Ketoprofen/*administration & dosage', 'Polymers', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/1403487/
846,Ketoprofen,37659631,Ketoprofen exposure perturbs nitrogen assimilation and ATP synthesis in rice roots: An integrated metabolome and microbiome analysis.,"['Wang H', 'Li Z', 'Shen L', 'Zhang P', 'Lin Y', 'Huang X', 'Du S', 'Liu H']","['Nitrogen/metabolism', '*Oryza/metabolism', '*Ketoprofen/metabolism/pharmacology', 'Plant Roots/metabolism', 'Amino Acids/metabolism', 'Metabolome', 'Proton-Translocating ATPases/metabolism/pharmacology', 'Adenosine Triphosphate/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37659631/
847,Ketoprofen,29635176,Mechanism and kinetics of photochemical transformation of ketoprofen and its degradation intermediates.,"['Hykrdova L', 'Bajt O', 'Jirkovsky J']","['Anti-Inflammatory Agents, Non-Steroidal/chemistry/*radiation effects', 'Hydrogen-Ion Concentration', 'Ketoprofen/chemistry/*radiation effects', 'Kinetics', 'Photolysis', '*Ultraviolet Rays', 'Water Pollutants, Chemical/chemistry/*radiation effects']",https://pubmed.ncbi.nlm.nih.gov/29635176/
848,Ketoprofen,31022092,Effect of Ketoprofen and ATB-352 on the Immature Human Intestine: Identification of Responders and Non-responders.,"['Thibault MP', 'Tremblay E', 'Wallace JL', 'Beaulieu JF']","['Anti-Inflammatory Agents, Non-Steroidal/*pharmacology', 'Cyclooxygenase 2/drug effects', 'Humans', 'Indomethacin/*pharmacology', 'Intestine, Small/*drug effects/embryology', 'Ketoprofen/analogs & derivatives/*pharmacology', 'Signal Transduction/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/31022092/
849,Ketoprofen,19856108,Encapsulation of ketoprofen and ketoprofen lysinate by prilling for controlled drug release.,"['Del Gaudio P', 'Russo P', 'Rosaria Lauro M', 'Colombo P', 'Aquino RP']","['Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage', 'Calorimetry, Differential Scanning', 'Delayed-Action Preparations', 'Ketoprofen/*administration & dosage/*analogs & derivatives/chemistry', 'Lysine/administration & dosage/*analogs & derivatives/chemistry', 'Solubility', 'Spectroscopy, Fourier Transform Infrared', 'Technology, Pharmaceutical']",https://pubmed.ncbi.nlm.nih.gov/19856108/
850,Ketoprofen,30298560,Efficacy of ketoprofen lysine salt and paracetamol/acetaminophen to reduce pain during rapid maxillary expansion: A randomized controlled clinical trial.,"['Cossellu G', 'Lanteri V', 'Lione R', 'Ugolini A', 'Gaffuri F', 'Cozza P', 'Farronato M']","['Acetaminophen/*therapeutic use', 'Analgesics, Non-Narcotic/*therapeutic use', 'Child', 'Female', 'Humans', 'Ketoprofen/*analogs & derivatives/therapeutic use', 'Lysine/*analogs & derivatives/therapeutic use', 'Male', 'Pain Management/*methods', 'Pain Perception/drug effects', '*Palatal Expansion Technique', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/30298560/
851,Ketoprofen,19122547,"Compatibility and stability of binary mixtures of acetaminophen, nefopam, ketoprofen and ketamine in infusion solutions.","['Hamdi M', 'Lentschener C', 'Bazin C', 'Ozier Y', 'Havard L']","['Acetaminophen/*analysis', 'Humans', 'Ketamine/*analysis', 'Ketoprofen/*analysis', 'Nefopam/*analysis', 'Solutions']",https://pubmed.ncbi.nlm.nih.gov/19122547/
852,Formoterol,35230437,Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis.,"['Beasley R', 'Harrison T', 'Peterson S', 'Gustafson P', 'Hamblin A', 'Bengtsson T', 'Fageras M']","['Administration, Inhalation', 'Adolescent', 'Adrenal Cortex Hormones/therapeutic use', 'Adult', '*Anti-Asthmatic Agents/therapeutic use', '*Asthma/drug therapy', 'Budesonide/therapeutic use', 'Budesonide, Formoterol Fumarate Drug Combination/therapeutic use', 'Drug Combinations', 'Female', 'Formoterol Fumarate/therapeutic use', 'Humans', 'Male', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/35230437/
853,Formoterol,33929661,Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.,"['Bourdin A', 'Molinari N', 'Ferguson GT', 'Singh B', 'Siddiqui MK', 'Holmgren U', 'Ouwens M', 'Jenkins M', 'De Nigris E']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/therapeutic use', 'Bayes Theorem', 'Bronchodilator Agents/adverse effects', 'Budesonide/adverse effects', 'Drug Combinations', 'Formoterol Fumarate/therapeutic use', 'Fumarates/therapeutic use', '*Glycopyrrolate/adverse effects', 'Humans', 'Muscarinic Antagonists/therapeutic use', 'Network Meta-Analysis', '*Pulmonary Disease, Chronic Obstructive/drug therapy', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/33929661/
854,Formoterol,31605923,A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 mug and 160/18/9.6 mug using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.,"['Rabe KF', 'Martinez FJ', 'Ferguson GT', 'Wang C', 'Singh D', 'Wedzicha JA', 'Trivedi R', 'St Rose E', 'Ballal S', 'McLaren J', 'Darken P', 'Reisner C', 'Dorinsky P']","['Administration, Inhalation', 'Adult', 'Aged', 'Aged, 80 and over', 'Budesonide/*administration & dosage', '*Drug Delivery Systems', 'Female', 'Formoterol Fumarate/*administration & dosage', 'Glycopyrrolate/*administration & dosage', 'Humans', 'Male', '*Metered Dose Inhalers', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31605923/
855,Formoterol,29768149,Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.,"[""O'Byrne PM"", 'FitzGerald JM', 'Bateman ED', 'Barnes PJ', 'Zhong N', 'Keen C', 'Jorup C', 'Lamarca R', 'Ivanov S', 'Reddel HK']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Aged', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/adverse effects', 'Budesonide/*administration & dosage/adverse effects', 'Child', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Combinations', 'Female', 'Forced Expiratory Volume', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Glucocorticoids/administration & dosage', 'Humans', 'Maintenance Chemotherapy', 'Male', 'Medication Adherence', 'Middle Aged', 'Surveys and Questionnaires', 'Terbutaline/*administration & dosage/adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29768149/
856,Formoterol,37818789,Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real-world effectiveness and economic assessment.,"['Yu Y', 'Cao W', 'Xiao Y', 'Li A', 'Huang H', 'Liu K', 'Hu L', 'Hou X', 'Xiang L', 'Wang X']","['Humans', 'Child', 'Adolescent', 'Budesonide/therapeutic use', 'Ethanolamines/therapeutic use', 'Drug Combinations', '*Asthma/drug therapy', 'Budesonide, Formoterol Fumarate Drug Combination/therapeutic use', 'Adrenal Cortex Hormones/therapeutic use', 'Administration, Inhalation', 'Formoterol Fumarate/therapeutic use', '*Anti-Asthmatic Agents/therapeutic use', 'Bronchodilator Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37818789/
857,Formoterol,16570304,Thermodynamic stability and crystal structures for polymorphs and solvates of formoterol fumarate.,"['Jarring K', 'Larsson T', 'Stensland B', 'Ymen I']","['2-Propanol', 'Benzyl Alcohol', 'Calorimetry, Differential Scanning', 'Crystallization', 'Drug Stability', 'Ethanol', 'Ethanolamines/*chemistry', 'Formoterol Fumarate', 'Isomerism', 'Kinetics', 'Models, Molecular', 'Solvents', 'Thermodynamics', 'Thermogravimetry', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/16570304/
858,Formoterol,30232048,"Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.","['Ferguson GT', 'Rabe KF', 'Martinez FJ', 'Fabbri LM', 'Wang C', 'Ichinose M', 'Bourne E', 'Ballal S', 'Darken P', 'DeAngelis K', 'Aurivillius M', 'Dorinsky P', 'Reisner C']","['Administration, Inhalation', 'Adult', 'Aged', 'Aged, 80 and over', 'Budesonide/*administration & dosage', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Forced Expiratory Volume/drug effects', 'Formoterol Fumarate/*administration & dosage', 'Glycopyrrolate/*administration & dosage', 'Humans', 'Male', 'Metered Dose Inhalers', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Respiratory Function Tests', 'Respiratory System Agents/*administration & dosage', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30232048/
859,Formoterol,34342835,Budesonide/Glycopyrronium/Formoterol: A Review in COPD.,['Heo YA'],"['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/*therapeutic use', 'Bronchodilator Agents/therapeutic use', 'Budesonide/*therapeutic use', 'Drug Combinations', 'Formoterol Fumarate/*therapeutic use', 'Glucocorticoids/*therapeutic use', 'Glycopyrrolate/*therapeutic use', 'Humans', 'Metered Dose Inhalers', 'Muscarinic Antagonists/*therapeutic use', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/34342835/
860,Formoterol,29768147,As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma.,"['Bateman ED', 'Reddel HK', ""O'Byrne PM"", 'Barnes PJ', 'Zhong N', 'Keen C', 'Jorup C', 'Lamarca R', 'Siwek-Posluszna A', 'FitzGerald JM']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/adverse effects', 'Budesonide/*administration & dosage/adverse effects', 'Child', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Combinations', 'Female', 'Forced Expiratory Volume', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Glucocorticoids/administration & dosage', 'Humans', 'Maintenance Chemotherapy', 'Male', 'Medication Adherence', 'Middle Aged', 'Proportional Hazards Models', 'Severity of Illness Index', 'Surveys and Questionnaires', 'Terbutaline/*administration & dosage/adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29768147/
861,Formoterol,31983228,Budesonide/formoterol therapy: effective and appropriate use in asthma and chronic obstructive pulmonary disease.,"['Mapel DW', 'Roberts MH', 'Davis J']","['Asthma/*drug therapy', 'Bronchodilator Agents/*therapeutic use', 'Budesonide/*therapeutic use', 'Drug Combinations', 'Fluticasone-Salmeterol Drug Combination/therapeutic use', 'Formoterol Fumarate/*therapeutic use', 'Humans', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Randomized Controlled Trials as Topic', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/31983228/
862,Formoterol,31112386,Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.,"['Beasley R', 'Holliday M', 'Reddel HK', 'Braithwaite I', 'Ebmeier S', 'Hancox RJ', 'Harrison T', 'Houghton C', 'Oldfield K', 'Papi A', 'Pavord ID', 'Williams M', 'Weatherall M']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/administration & dosage/adverse effects', 'Adult', 'Aged', 'Albuterol/*administration & dosage/adverse effects', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/adverse effects', 'Budesonide/*administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Female', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Humans', 'Male', 'Metered Dose Inhalers', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/31112386/
863,Formoterol,33252985,"Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.","['Martinez FJ', 'Rabe KF', 'Ferguson GT', 'Wedzicha JA', 'Singh D', 'Wang C', 'Rossman K', 'St Rose E', 'Trivedi R', 'Ballal S', 'Darken P', 'Aurivillius M', 'Reisner C', 'Dorinsky P']","['Aged', 'Bronchodilator Agents/*therapeutic use', 'Budesonide/*therapeutic use', 'Cause of Death', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Forced Expiratory Volume', 'Formoterol Fumarate/*therapeutic use', 'Glucocorticoids/*therapeutic use', 'Glycopyrrolate/*therapeutic use', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', '*Mortality', 'Muscarinic Antagonists/*therapeutic use', 'Proportional Hazards Models', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/33252985/
864,Formoterol,36639054,The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review.,"['Beasley R', 'Bruce P', 'Houghton C', 'Hatter L']","['Adult', 'Adolescent', 'Humans', 'Formoterol Fumarate/therapeutic use', 'Budesonide/therapeutic use', 'Bronchodilator Agents/therapeutic use', '*Anti-Asthmatic Agents/therapeutic use', '*Asthma/drug therapy', 'Adrenal Cortex Hormones/therapeutic use', 'Drug Therapy, Combination', 'Administration, Inhalation', 'Ethanolamines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36639054/
865,Formoterol,34478483,Extrafine HFA-beclomethasone-formoterol vs. nonextrafine combination of an inhaled corticosteroid and a long acting beta2-agonist in patients with persistent asthma: A systematic review and meta-analysis.,"['Liu T', 'Yang D', 'Liu C']","['Administration, Inhalation', 'Adolescent', 'Adrenal Cortex Hormones/administration & dosage/adverse effects/*therapeutic use', 'Adrenergic beta-2 Receptor Agonists/adverse effects/*therapeutic use', 'Adult', 'Aged', 'Asthma/*drug therapy', 'Beclomethasone/adverse effects/*therapeutic use', 'Female', 'Formoterol Fumarate/adverse effects/*therapeutic use', 'Humans', 'Hydrocarbons, Fluorinated/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Outcome Assessment, Health Care', 'Publication Bias', 'Risk', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34478483/
866,Formoterol,39420338,Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial.,"['Watz H', 'Kirsten AM', 'Ludwig-Sengpiel A', 'Krull M', 'Mroz RM', 'Georges G', 'Varoli G', 'Charretier R', 'Cortellini M', 'Vele A', 'Galkin D']","['Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Administration, Inhalation', '*Beclomethasone/administration & dosage', 'Bronchodilator Agents/administration & dosage', '*Cross-Over Studies', 'Double-Blind Method', '*Drug Combinations', '*Exercise Tolerance/drug effects/physiology', '*Formoterol Fumarate/administration & dosage', '*Glycopyrrolate/administration & dosage', 'Lung/drug effects/physiopathology', '*Pulmonary Disease, Chronic Obstructive/drug therapy/physiopathology/diagnosis', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39420338/
867,Formoterol,32401744,Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture.,"['Ngim K', 'Patel J']","['Administration, Inhalation', '*Adrenergic beta-2 Receptor Agonists/chemistry/pharmacology', 'Benzamides/chemistry/*pharmacology', 'Carbamates/chemistry/*pharmacology', 'Drug Therapy, Combination', 'Formoterol Fumarate/*pharmacology', 'Humans', '*Pulmonary Disease, Chronic Obstructive']",https://pubmed.ncbi.nlm.nih.gov/32401744/
868,Formoterol,33852162,Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.,"[""O'Shea O"", 'Stovold E', 'Cates CJ']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Anti-Asthmatic Agents/administration & dosage/*adverse effects', 'Asthma/*drug therapy/mortality', 'Beclomethasone/administration & dosage/adverse effects', 'Bronchodilator Agents/administration & dosage/adverse effects', 'Budesonide/administration & dosage/adverse effects', 'Child', 'Chronic Disease', 'Drug Therapy, Combination/adverse effects', 'Fluticasone/administration & dosage/adverse effects', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Glucocorticoids/administration & dosage/*adverse effects', 'Humans', 'Mometasone Furoate/administration & dosage/adverse effects', 'Randomized Controlled Trials as Topic', 'Salmeterol Xinafoate/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33852162/
869,Formoterol,34865628,Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma.,"['Buendia JA', 'Patino DG']","['Adrenal Cortex Hormones/economics', 'Anti-Asthmatic Agents/*economics/*therapeutic use', 'Asthma/*drug therapy/*economics', 'Budesonide, Formoterol Fumarate Drug Combination/*economics/*therapeutic use', 'Colombia', 'Cost-Benefit Analysis', 'Humans', 'Markov Chains', 'Models, Econometric', 'Nebulizers and Vaporizers/economics', 'Quality-Adjusted Life Years']",https://pubmed.ncbi.nlm.nih.gov/34865628/
870,Formoterol,38518866,Assessing Inhaled Corticosteroid Adherence and Responsiveness in Severe Asthma Using Beclometasone Dipropionate/Formoterol NEXThaler Dose-Counting and Nitric Oxide Monitoring.,"['Aung HWW', 'Boddy CE', 'Hampson E', 'Bell M', 'Parnell LA', 'Balasundaram K', 'Murphy AC', 'Naveed S', 'Bradding P']","['Humans', '*Asthma/drug therapy', 'Male', '*Formoterol Fumarate/administration & dosage/therapeutic use', 'Female', '*Beclomethasone/administration & dosage/therapeutic use', 'Middle Aged', '*Nitric Oxide/metabolism/analysis', 'Adult', 'Administration, Inhalation', '*Anti-Asthmatic Agents/therapeutic use/administration & dosage', 'Medication Adherence', 'Ethanolamines/therapeutic use/administration & dosage', 'Adrenal Cortex Hormones/therapeutic use/administration & dosage', 'Aged', 'Drug Combinations', 'Treatment Outcome', 'Eosinophils/immunology', 'Respiratory Function Tests']",https://pubmed.ncbi.nlm.nih.gov/38518866/
871,Formoterol,32843176,Comparing the efficacy and safety of formoterol/budesonide pMDI versus its mono-components and other LABA/ICS in patients with asthma.,"['Mukhopadhyay A', 'Waked M', 'Gogtay J', 'Gaur V']","['Administration, Inhalation', 'Adrenal Cortex Hormones/*administration & dosage', 'Adrenergic beta-2 Receptor Agonists/*administration & dosage', 'Age Factors', 'Anti-Asthmatic Agents', 'Asthma/*drug therapy', 'Budesonide/*administration & dosage', 'Budesonide, Formoterol Fumarate Drug Combination/*administration & dosage', 'Child', 'Dose-Response Relationship, Drug', 'Drug Combinations', 'Female', 'Formoterol Fumarate/*administration & dosage', 'Humans', 'Maintenance', 'Male', 'Metered Dose Inhalers', 'Practice Guidelines as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32843176/
872,LEVOBUNOLOL,3062529,Levobunolol and betaxolol. A double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure.,"['Long DA', 'Johns GE', 'Mullen RS', 'Bowe RG', 'Alexander D', 'Epstein DL', 'Weiss MJ', 'Masi RJ', 'Charap AD', 'Eto CY', 'et al.']","['Betaxolol', 'Clinical Trials as Topic', 'Double-Blind Method', 'Glaucoma/drug therapy/physiopathology', 'Humans', 'Intraocular Pressure/*drug effects', 'Levobunolol/*therapeutic use', 'Ocular Hypertension/drug therapy/physiopathology', 'Propanolamines/*therapeutic use', 'Visual Fields/drug effects']",https://pubmed.ncbi.nlm.nih.gov/3062529/
873,LEVOBUNOLOL,3881033,Minimum concentration of levobunolol required to control intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.,"['Long D', 'Zimmerman T', 'Spaeth G', 'Novack G', 'Burke PJ', 'Duzman E']","['Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Glaucoma, Open-Angle/*drug therapy', 'Humans', 'Levobunolol/*administration & dosage', 'Ocular Hypertension/*drug therapy', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3881033/
874,LEVOBUNOLOL,2883990,"Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort.","['Krieglstein GK', 'Novack GD', 'Voepel E', 'Schwarzbach G', 'Lange U', 'Schunck KP', 'Lue JC', 'Glavinos EP']","['Administration, Topical', 'Adult', 'Aged', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Glaucoma, Open-Angle/*drug therapy', 'Heart Rate/drug effects', 'Humans', 'Intraocular Pressure/drug effects', 'Levobunolol/administration & dosage/*therapeutic use', 'Metipranolol/administration & dosage/adverse effects/*therapeutic use', 'Middle Aged', 'Ocular Hypertension/*drug therapy', 'Propanolamines/*therapeutic use', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/2883990/
875,LEVOBUNOLOL,9916610,Efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD compared with 0.5% levobunolol hydrochloride BID in patients with open-angle glaucoma or ocular hypertension.,"['Walters TR', 'Maloney S', 'Slater D', 'Liss C', 'Wilson H', 'Hartenbaum D']","['Adrenergic beta-Antagonists/administration & dosage/*adverse effects/*therapeutic use', 'Aged', 'Double-Blind Method', 'Female', 'Glaucoma/*drug therapy/physiopathology', 'Heart Rate/drug effects', 'Humans', 'Intraocular Pressure/drug effects', 'Levobunolol/administration & dosage/*adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Ocular Hypertension/*drug therapy/physiopathology', 'Timolol/administration & dosage/*adverse effects/*therapeutic use', 'Vision Tests']",https://pubmed.ncbi.nlm.nih.gov/9916610/
876,LEVOBUNOLOL,9379380,Levobunolol 0.5% and timolol 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy.,"['Rakofsky S', 'Koch DD', 'Faulkner JD', 'Terry SA', 'Mandell AI', 'Gross RL', 'Kelley EP', 'Iacono TL', 'Lue J']","['Adrenergic beta-Antagonists/*administration & dosage', 'Adult', 'Aged', 'Aged, 80 and over', 'Cataract/pathology', 'Double-Blind Method', 'Female', 'Humans', 'Intraocular Pressure/drug effects', 'Laser Therapy/*adverse effects', 'Lens Capsule, Crystalline/pathology/*surgery', 'Levobunolol/*administration & dosage', 'Male', 'Middle Aged', 'Ocular Hypertension/etiology/*prevention & control', 'Ophthalmic Solutions', 'Premedication', 'Prospective Studies', 'Timolol/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/9379380/
877,LEVOBUNOLOL,18465723,An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes.,"['Ciancaglini M', 'Carpineto P', 'Agnifili L', 'Nubile M', 'Fasanella V', 'Lanzini M', 'Calienno R', 'Mastropasqua L']","['Adrenergic beta-Antagonists/*therapeutic use', 'Cell Count', 'Conjunctiva/*drug effects/pathology', 'Female', 'Glaucoma, Open-Angle/*drug therapy', 'Goblet Cells/*pathology', 'Humans', 'Intraocular Pressure/drug effects', 'Levobunolol/*therapeutic use', 'Male', 'Microscopy, Confocal', 'Middle Aged', 'Ocular Hypertension/drug therapy', 'Preservatives, Pharmaceutical/*therapeutic use', 'Single-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/18465723/
878,LEVOBUNOLOL,12002664,A comparison of the efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD and 0.5% levobunolol hydrochloride BID in patients with ocular hypertension or open-angle glaucoma.,"['Halper LK', 'Johnson-Pratt L', 'Dobbins T', 'Hartenbaum D']","['Adrenergic beta-Antagonists/*administration & dosage/adverse effects', 'Adult', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Gels', 'Glaucoma, Open-Angle/*drug therapy/physiopathology', 'Heart Rate/drug effects', 'Humans', 'Intraocular Pressure/drug effects', 'Levobunolol/adverse effects/*therapeutic use', 'Male', 'Ocular Hypertension/*drug therapy/physiopathology', 'Ophthalmic Solutions', 'Timolol/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/12002664/
879,LEVOBUNOLOL,37861808,Levobunolol-imprinted polymer: a theoretical study.,"['Maia PP', 'Guimaraes L', 'Nascimento CS Jr']","['Humans', 'Polymers/chemistry', '*Levobunolol', 'Solvents/chemistry', 'Drug Delivery Systems', 'Molecularly Imprinted Polymers', 'Models, Theoretical', '*Molecular Imprinting/methods']",https://pubmed.ncbi.nlm.nih.gov/37861808/
880,LEVOBUNOLOL,8145982,A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol.,"['Behrens-Baumann W', 'Kimmich F', 'Walt JG', 'Lue J']","['Administration, Topical', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Carteolol/administration & dosage/adverse effects/*therapeutic use', 'Child', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Glaucoma, Open-Angle/*drug therapy', 'Humans', 'Intraocular Pressure', 'Levobunolol/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Ocular Hypertension/*drug therapy', 'Ocular Hypotension/chemically induced', 'Ophthalmic Solutions', 'Visual Fields']",https://pubmed.ncbi.nlm.nih.gov/8145982/
881,LEVOBUNOLOL,3293726,Efficacy of twice-daily levobunolol in the treatment of elevated intraocular pressure.,"['Seamone C', 'LeBlanc R', 'Saheb N', 'Novack G']","['Aged', 'Blood Pressure/drug effects', 'Chronic Disease', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Glaucoma, Open-Angle/*drug therapy/physiopathology', 'Heart Rate/drug effects', 'Humans', 'Intraocular Pressure/drug effects', 'Levobunolol/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Ocular Hypertension/*drug therapy/physiopathology', 'Random Allocation', 'Timolol/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3293726/
882,LEVOBUNOLOL,3535611,Levobunolol compared with timolol for the control of elevated intraocular pressure.,"['Geyer O', 'Lazar M', 'Novack GD', 'Lue JC', 'Duzman E']","['Clinical Trials as Topic', 'Glaucoma, Open-Angle/drug therapy', 'Humans', 'Intraocular Pressure/*drug effects', 'Levobunolol/*therapeutic use', 'Ocular Hypertension/drug therapy', 'Timolol/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3535611/
883,Tirofiban,31471774,Ticagrelor and tirofiban in pregnancy and delivery: beyond labels.,"['Argentiero D', 'Savonitto S', ""D'Andrea P"", 'Iacovelli F']","['Adult', 'Cesarean Section', 'Female', 'Humans', '*Live Birth', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy', 'ST Elevation Myocardial Infarction/*drug therapy', 'Ticagrelor/*administration & dosage', 'Tirofiban/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/31471774/
884,Tirofiban,37256974,Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.,"['Zi W', 'Song J', 'Kong W', 'Huang J', 'Guo C', 'He W', 'Yu Y', 'Zhang B', 'Geng W', 'Tan X', 'Tian Y', 'Liu Z', 'Cao M', 'Cheng D', 'Li B', 'Huang W', 'Liu J', 'Wang P', 'Yu Z', 'Liang H', 'Yang S', 'Tang M', 'Liu W', 'Huang X', 'Liu S', 'Tang Y', 'Wu Y', 'Yao L', 'Shi Z', 'He P', 'Zhao H', 'Chen Z', 'Luo J', 'Wan Y', 'Shi Q', 'Wang M', 'Yang D', 'Chen X', 'Huang F', 'Mu J', 'Li H', 'Li Z', 'Zheng J', 'Xie S', 'Cai T', 'Peng Y', 'Xie W', 'Qiu Z', 'Liu C', 'Yue C', 'Li L', 'Tian Y', 'Yang D', 'Miao J', 'Yang J', 'Hu J', 'Nogueira RG', 'Wang D', 'Saver JL', 'Li F', 'Yang Q']","['Humans', 'Aspirin/adverse effects', 'Brain Ischemia/drug therapy/etiology', '*Fibrinolytic Agents/adverse effects/therapeutic use', 'Intracranial Hemorrhages/chemically induced', '*Ischemic Stroke/diagnosis/drug therapy/etiology', 'Platelet Aggregation Inhibitors/adverse effects/therapeutic use', '*Tirofiban/adverse effects/therapeutic use', 'Treatment Outcome', 'Cerebral Arterial Diseases/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/37256974/
885,Tirofiban,38390817,Adjunct Intraarterial or Intravenous Tirofiban Versus No Tirofiban After Successful Recanalization of Basilar Artery Occlusion Stroke: The BASILAR Registry.,"['Li H', 'Ju D', 'Tao Z', 'Wang J', 'Nguyen TN', 'Saver JL', 'Nogueira RG', 'Liu C', 'Yang Q', 'Qiu Z', 'Yin C', 'Sun D', 'Liu S']","['Humans', 'Tirofiban/therapeutic use', 'Basilar Artery/diagnostic imaging', 'Prospective Studies', 'Thrombolytic Therapy/adverse effects/methods', 'Treatment Outcome', '*Stroke', 'Intracranial Hemorrhages/etiology', '*Arterial Occlusive Diseases/diagnostic imaging/drug therapy', 'Registries', '*Endovascular Procedures/adverse effects', 'Thrombectomy']",https://pubmed.ncbi.nlm.nih.gov/38390817/
886,Tirofiban,37423089,Safety and efficacy of tirofiban in the management of stroke: A systematic review and meta-analysis of randomized controlled trials.,"['Al-Salihi MM', 'Ayyad A', 'Al-Jebur MS', 'Al-Salihi Y', 'Saha R', 'Morsi RZ', 'Kass-Hout T', 'Kasab SA', 'Spiotta AM']","['Humans', 'Tirofiban/adverse effects', 'Platelet Aggregation Inhibitors/adverse effects', '*Brain Ischemia/complications', 'Treatment Outcome', 'Randomized Controlled Trials as Topic', '*Stroke/complications', 'Intracranial Hemorrhages/chemically induced/complications']",https://pubmed.ncbi.nlm.nih.gov/37423089/
887,Tirofiban,34167477,Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke.,"['Tao C', 'Zhu Y', 'Zhang C', 'Song J', 'Liu T', 'Yuan X', 'Luo W', 'Chen C', 'Liu D', 'Zhu Y', 'Liu J', 'Hu W']","['Aspirin/administration & dosage/adverse effects/therapeutic use', 'China', 'Clopidogrel/administration & dosage/adverse effects/therapeutic use', '*Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Intracranial Hemorrhages/chemically induced/epidemiology', '*Ischemic Stroke/drug therapy/mortality', 'Prospective Studies', '*Tirofiban/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34167477/
888,Tirofiban,15307109,Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment.,"['Mulot A', 'Moulin F', 'Fohlen-Walter A', 'Angioi M', 'Sghaier M', 'Carteaux JP', 'Lecompte T', 'de Maistre E']","['Aged', 'Disease Management', 'Female', 'Heparin/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Platelet Aggregation Inhibitors/adverse effects', 'Platelet Count', 'Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors', 'Thrombocytopenia/*chemically induced/diagnosis/drug therapy', 'Tirofiban', 'Tyrosine/*adverse effects/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/15307109/
889,Tirofiban,39072930,Preoperative and intraoperative tirofiban during endovascular thrombectomy in large vessel occlusion stroke due to large artery atherosclerosis.,"['Sun Z', 'Huang S', 'Li W', 'Yang Y', 'Wu Y', 'Ma X', 'Nie X', 'Jin W', 'Liu C', 'Li X', 'Xu Y', 'Dong J', 'Liao Y', 'Sun B', 'Han W', 'Zhao Q', 'Chi H', 'Wang Y', 'Liu L', 'Zhang M']","['Humans', 'Male', '*Tirofiban/administration & dosage/therapeutic use', 'Female', 'Aged', 'Middle Aged', 'Retrospective Studies', '*Thrombectomy/methods', '*Endovascular Procedures/methods', 'Preoperative Care/methods', 'Atherosclerosis/complications', 'Aged, 80 and over', 'Ischemic Stroke/surgery/drug therapy', 'Intraoperative Care/methods', 'Fibrinolytic Agents/administration & dosage', 'Stroke/etiology/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39072930/
890,Tirofiban,38648030,Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.,"['Zhao W', 'Li S', 'Li C', 'Wu C', 'Wang J', 'Xing L', 'Wan Y', 'Qin J', 'Xu Y', 'Wang R', 'Wen C', 'Wang A', 'Liu L', 'Wang J', 'Song H', 'Feng W', 'Ma Q', 'Ji X']","['Humans', '*Tirofiban/administration & dosage/therapeutic use', 'Male', 'Female', 'Middle Aged', 'Aged', '*Ischemic Stroke/drug therapy', '*Platelet Aggregation Inhibitors/therapeutic use/administration & dosage', '*Aspirin/therapeutic use/administration & dosage', 'Adult', 'Treatment Outcome', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/38648030/
891,Tirofiban,17655948,Treatment of acute myocardial infarction in pregnancy with coronary artery balloon angioplasty and stenting: use of tirofiban and clopidogrel.,"['Boztosun B', 'Olcay A', 'Avci A', 'Kirma C']","['Adult', 'Angioplasty, Balloon, Coronary/instrumentation/*methods', 'Clopidogrel', 'Drug Therapy, Combination', '*Drug-Eluting Stents', 'Female', 'Humans', 'Myocardial Infarction/physiopathology/*therapy', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/physiopathology/*therapy', 'Ticlopidine/administration & dosage/*analogs & derivatives', 'Tirofiban', 'Tyrosine/administration & dosage/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/17655948/
892,Tirofiban,22767141,Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.,"['Elcioglu OC', 'Ozkok A', 'Akpinar TS', 'Tufan F', 'Sezer M', 'Umman S', 'Besisik SK']","['Acute Coronary Syndrome/complications/drug therapy', 'Aged', 'Hemorrhage/*chemically induced/diagnosis/therapy', 'Humans', 'Male', 'Middle Aged', 'Platelet Count', 'Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors', 'Pulmonary Alveoli/*pathology', 'Thrombocytopenia/*chemically induced/diagnosis/therapy', 'Tirofiban', 'Tyrosine/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22767141/
893,Tirofiban,28456813,Early Thrombosuction and Tirofiban Use in Knee and Below-Knee Arterial Thrombosis.,"['Bildirici U', 'Celikyurt U', 'Yavuz S', 'Dervis E', 'Adina Q', 'Ural D']","['Aged', 'Aged, 80 and over', 'Arteries', 'Embolism/therapy', 'Female', 'Hemorrhage/etiology', 'Humans', 'Knee Joint/blood supply', 'Leg/blood supply', 'Male', 'Middle Aged', 'Myocardial Infarction/etiology', 'Percutaneous Coronary Intervention/adverse effects', 'Platelet Aggregation Inhibitors/therapeutic use', 'Retrospective Studies', 'Thrombectomy/*methods', 'Thromboembolism/*therapy', 'Tirofiban', 'Treatment Outcome', 'Tyrosine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28456813/
894,Tirofiban,37021200,Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol.,"['Medina-Rodriguez M', 'Moniche F', 'de Alboniga-Chindurza A', 'Ortega-Quintanilla J', 'Ainz-Gomez L', 'Pardo-Galiana B', 'Cabezas-Rodriguez JA', 'Aguilar-Perez M', 'Zamora A', 'Delgado-Acosta F', 'Jimenez-Gomez E', 'Bravo Rey I', 'Oteros Fernandez R', 'Freijo Guerrero MDM', 'Gonzalez Diaz E', 'Escudero-Martinez I', 'Morales Caba L', 'Vielba-Gomez I', 'Mosteiro S', 'Castellanos Rodrigo MDM', 'Amaya Pascasio L', 'Hidalgo C', 'Fernandez Prudencio L', 'Ramirez Moreno JM', 'Diaz Perez J', 'Sanz-Fernandez G', 'Baena-Palomino P', 'Gamero-Garcia MA', 'Jimenez Jorge S', 'Rosso Fernandez C', 'Montaner J', 'Gonzalez Garcia A', 'Zapata-Arriaza E']","['Humans', 'Tirofiban/therapeutic use', '*Ischemic Stroke/drug therapy', 'Platelet Aggregation Inhibitors/adverse effects', 'Prospective Studies', '*Brain Ischemia/chemically induced', 'Treatment Outcome', 'Aspirin/adverse effects', 'Thrombectomy/adverse effects', '*Thrombosis/drug therapy', 'Randomized Controlled Trials as Topic', 'Multicenter Studies as Topic', 'Clinical Trials, Phase IV as Topic']",https://pubmed.ncbi.nlm.nih.gov/37021200/
895,Tirofiban,37992511,Efficacy and safety of tirofiban in patients with acute ischemic stroke treated with endovascular thrombectomy: A frequentist and Bayesian meta-analysis.,"['Lu WZ', 'Lin HA', 'Hou SK', 'Bai CH', 'Lin SF']","['Humans', 'Tirofiban/adverse effects', '*Stroke/diagnostic imaging/therapy', '*Ischemic Stroke/diagnostic imaging/drug therapy', 'Bayes Theorem', '*Brain Ischemia/diagnostic imaging/drug therapy', 'Treatment Outcome', 'Thrombectomy/adverse effects/methods', 'Intracranial Hemorrhages/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37992511/
896,Tirofiban,36162161,Early tirofiban administration for patients with acute ischemic stroke treated with intravenous thrombolysis or bridging therapy: Systematic review and meta-analysis.,"['Liu Q', 'Lu X', 'Yang H', 'Deng S', 'Zhang J', 'Chen S', 'Shi S', 'Xun W', 'Peng R', 'Lin B', 'Li T', 'Pan L', 'Weng B']","['Humans', 'Tirofiban/therapeutic use/adverse effects', '*Brain Ischemia/drug therapy/complications', 'Thrombectomy/methods', '*Ischemic Stroke/drug therapy', '*Stroke/complications', 'Treatment Outcome', 'Thrombolytic Therapy/methods', 'Intracranial Hemorrhages/etiology', 'Administration, Intravenous', 'Fibrinolytic Agents']",https://pubmed.ncbi.nlm.nih.gov/36162161/
897,Tirofiban,37800797,Systematic review and meta-analysis of the efficacy and safety of adjunctive use of tirofiban in patients treated with endovascular therapy for acute ischemic stroke at different embolic sites.,"['Liu C', 'Yang X', 'Liu M', 'Wang J', 'Li G']","['Humans', 'Tirofiban/therapeutic use', '*Ischemic Stroke/drug therapy', '*Brain Ischemia', 'Treatment Outcome', '*Stroke', 'Intracranial Hemorrhages/chemically induced', '*Endovascular Procedures/adverse effects', 'Thrombectomy']",https://pubmed.ncbi.nlm.nih.gov/37800797/
898,Tirofiban,33560898,Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention.,"['Revilla-Marti P', 'Linares-Vicente JA', 'Martinez Labuena A', 'Jimenez Melo O', 'Morlanes Gracia P', 'Meseguer Gonzalez D', 'Lukic A', 'Simo Sanchez B', 'Ruiz Arroyo JR']","['Abciximab/pharmacology/*therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Percutaneous Coronary Intervention/*methods', 'Platelet Aggregation Inhibitors/pharmacology/*therapeutic use', 'ST Elevation Myocardial Infarction/*drug therapy/pathology', 'Ticagrelor/pharmacology/*therapeutic use', 'Tirofiban/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33560898/
899,Tirofiban,28449419,Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.,"['Zhou X', 'Wu X', 'Sun H', 'Li J']","['Acute Coronary Syndrome/*drug therapy', 'Eptifibatide', 'Humans', 'Myocardial Infarction/drug therapy', 'Peptides/*therapeutic use', 'Platelet Aggregation Inhibitors/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Tirofiban', 'Treatment Outcome', 'Tyrosine/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28449419/
900,Tirofiban,32795098,"Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.","['Gargiulo G', 'Esposito G', 'Avvedimento M', 'Nagler M', 'Minuz P', 'Campo G', 'Gragnano F', 'Manavifar N', 'Piccolo R', 'Tebaldi M', 'Cirillo P', 'Hunziker L', 'Vranckx P', 'Leonardi S', 'Heg D', 'Windecker S', 'Valgimigli M']","['Adenosine Diphosphate/pharmacology', 'Adenosine Monophosphate/administration & dosage/*analogs & derivatives/blood/pharmacology/therapeutic use', 'Administration, Oral', 'Aged', 'Aged, 80 and over', 'Area Under Curve', 'Aspirin/therapeutic use', 'Cardiac Catheterization', 'Comorbidity', 'Female', 'Heart/physiopathology', 'Humans', 'Infusions, Intravenous', 'Male', 'Mastication', 'Middle Aged', 'Percutaneous Coronary Intervention', 'Platelet Aggregation/*drug effects', 'Polypharmacy', 'Prasugrel Hydrochloride/administration & dosage/blood/pharmacology/*therapeutic use', 'Proportional Hazards Models', 'Purinergic P2Y Receptor Antagonists/administration & dosage/blood/pharmacology/*therapeutic use', 'ST Elevation Myocardial Infarction/*drug therapy/therapy', 'Tablets', 'Tirofiban/administration & dosage/blood/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32795098/
901,Tirofiban,39053321,Safety and efficacy of tirofiban combined with intravenous thrombolysis and endovascular treatment in acute large vessel occlusion stroke.,"['Su S', 'Bai X', 'Li Q', 'Yue C', 'Yang J', 'Huang J', 'Kong W', 'Guo C', 'Hu J', 'Liu S', 'Yang D', 'Song J', 'Peng Z', 'Li L', 'Tian Y', 'Li F', 'Zi W', 'Liu X']","['Humans', '*Tirofiban/therapeutic use/administration & dosage', 'Female', 'Male', 'Middle Aged', 'Aged', '*Endovascular Procedures/methods', '*Thrombolytic Therapy/methods', 'Treatment Outcome', '*Fibrinolytic Agents/therapeutic use/administration & dosage', 'Stroke/drug therapy', 'Ischemic Stroke/drug therapy', 'Aged, 80 and over', 'Administration, Intravenous', 'Intracranial Hemorrhages/etiology/chemically induced', 'Platelet Aggregation Inhibitors/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39053321/
902,Tirofiban,34780001,Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies.,"['Liu J', 'Yang Y', 'Liu H']","['*Brain Ischemia/drug therapy', 'Eptifibatide', 'Humans', '*Ischemic Stroke', 'Prospective Studies', '*Stroke/drug therapy', 'Tirofiban/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34780001/
903,Flutamide,37958610,Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications.,"['Mora-Rodriguez JM', 'Sanchez BG', 'Sebastian-Martin A', 'Diaz-Yuste A', 'Sanchez-Chapado M', 'Palacin AM', 'Sanchez-Rodriguez C', 'Bort A', 'Diaz-Laviada I']","['Male', 'Humans', '*Flutamide/pharmacology', 'Down-Regulation', '*Prostatic Neoplasms/drug therapy/genetics/metabolism', 'Androgen Antagonists/pharmacology', 'Cell Line, Tumor', 'Transferases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37958610/
904,Flutamide,21446829,Lyophilized flutamide dispersions with polyols and amino acids: preparation and in vitro evaluation.,"['Elgindy N', 'Elkhodairy K', 'Molokhia A', 'Elzoghby A']","['Amino Acids/*chemistry', 'Calorimetry, Differential Scanning', 'Flutamide/chemistry', 'Freeze Drying', 'Particle Size', 'Polymers/*chemistry', 'Solubility', 'Spectroscopy, Fourier Transform Infrared', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/21446829/
905,Flutamide,11804262,Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review.,"['Chakrapee-Sirisuk S', 'Amornpichetkul K', 'Visudhiphan S', 'Sangruchi T', 'Srimuninnimit V', 'Sinlarat P']","['Antifungal Agents/*therapeutic use', 'Antineoplastic Agents, Hormonal/*therapeutic use', 'Disseminated Intravascular Coagulation/*drug therapy/etiology', 'Drug Therapy, Combination', 'Flutamide/*therapeutic use', 'Humans', 'Ketoconazole/*therapeutic use', 'Male', 'Middle Aged', 'Prostatic Neoplasms/*complications']",https://pubmed.ncbi.nlm.nih.gov/11804262/
906,Flutamide,37919464,The effect of Ganoderma lucidum polysaccharide extract on sensitizing prostate cancer cells to flutamide and docetaxel: an in vitro study.,"['Rahimnia R', 'Akbari MR', 'Yasseri AF', 'Taheri D', 'Mirzaei A', 'Ghajar HA', 'Farashah PD', 'Baghdadabad LZ', 'Aghamir SMK']","['Male', 'Humans', 'Docetaxel/pharmacology/therapeutic use', '*Reishi', 'Prostate/metabolism', 'Flutamide/pharmacology', '*Prostatic Neoplasms/drug therapy/metabolism', 'Cell Line, Tumor', 'Polysaccharides/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37919464/
907,Flutamide,19337013,"A comparison between finasteride, flutamide, and finasteride plus flutamide combination in the treatment of hirsutism.","['Unluhizarci K', 'Ozel D', 'Tanriverdi F', 'Karaca Z', 'Kelestimur F']","['Adult', 'Androgen Antagonists/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Finasteride/*therapeutic use', 'Flutamide/*therapeutic use', 'Hirsutism/*drug therapy', 'Humans', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/19337013/
908,Flutamide,22446520,Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver.,"['Kobayashi Y', 'Fukami T', 'Shimizu M', 'Nakajima M', 'Yokoi T']","['Androgen Antagonists/*metabolism', 'Carboxylesterase/*metabolism', 'Carboxylic Ester Hydrolases/*metabolism', 'Flutamide/*metabolism', 'Humans', 'Hydrolysis', 'Liver/enzymology', 'Microsomes, Liver/*enzymology']",https://pubmed.ncbi.nlm.nih.gov/22446520/
909,Flutamide,31170526,How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions.,"['Pacult J', 'Rams-Baron M', 'Chmiel K', 'Jurkiewicz K', 'Antosik A', 'Szafraniec J', 'Kurek M', 'Jachowicz R', 'Paluch M']","['Acrylates/chemistry', 'Anilides/*chemistry', 'Crystallization/methods', 'Drug Delivery Systems/methods', 'Drug Stability', 'Excipients/chemistry', 'Flutamide/*chemistry', 'Methylmethacrylate/chemistry', 'Nitriles/*chemistry', 'Polymers/chemistry', 'Povidone/chemistry', 'Solubility/drug effects', 'Tosyl Compounds/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/31170526/
910,Flutamide,2670515,"Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.","['Brogden RN', 'Clissold SP']","['Anilides/*pharmacology', 'Flutamide/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Male', 'Prostatic Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2670515/
911,Flutamide,27055586,"The effects of pH, temperature and protein concentration on the in vitro binding of flutamide to human serum albumin.","['Esmaeilzadeh S', 'Valizadeh H', 'Zakeri-Milani P']","['Flutamide/*metabolism', 'Humans', 'Hydrogen-Ion Concentration', 'Protein Binding', 'Serum Albumin/*metabolism', 'Spectrometry, Fluorescence', 'Temperature', 'Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/27055586/
912,Flutamide,16868063,"Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.","['Gambineri A', 'Patton L', 'Vaccina A', 'Cacciari M', 'Morselli-Labate AM', 'Cavazza C', 'Pagotto U', 'Pasquali R']","['Adipose Tissue/metabolism', 'Adult', '*Diet, Reducing', 'Drug Therapy, Combination', 'Energy Intake', 'Female', 'Flutamide/administration & dosage/*therapeutic use', 'Gonadal Steroid Hormones/blood', 'Humans', 'Insulin Resistance', 'Metformin/administration & dosage/*therapeutic use', 'Obesity/*complications/metabolism', 'Polycystic Ovary Syndrome/*drug therapy/metabolism', 'Prospective Studies', 'Sex Hormone-Binding Globulin/analysis']",https://pubmed.ncbi.nlm.nih.gov/16868063/
913,Norfloxacin,3056259,"Double-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in the therapy of complicated urinary tract infection.","['Sheehan GJ', 'Harding GK', 'Haase DA', 'Thomson MJ', 'Urias B', 'Kennedy JK', 'Hoban DJ', 'Ronald AR']","['Bacteriuria/drug therapy', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Norfloxacin/administration & dosage/adverse effects/*therapeutic use', 'Prospective Studies', 'Random Allocation', 'Urinary Tract Infections/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3056259/
914,Norfloxacin,36464023,Evaluation of rice straw and its transformation products on norfloxacin degradation and antibiotic resistome attenuation during soil incorporation.,"['Tian S', 'Sun X', 'Xiao H', 'Zhou Y', 'Huang X', 'An XL', 'Liu C', 'Su JQ']","['*Anti-Bacterial Agents/pharmacology', 'Soil', 'Norfloxacin/pharmacology', '*Oryza/genetics', 'Soil Microbiology', 'Genes, Bacterial']",https://pubmed.ncbi.nlm.nih.gov/36464023/
915,Norfloxacin,39031314,Performance and mechanism of sulfadiazine and norfloxacin adsorption from aqueous solution by magnetic coconut shell biochar.,"['He Y', 'Liu Z', 'Chen J', 'Deng Y']","['*Norfloxacin/chemistry', 'Adsorption', '*Sulfadiazine/chemistry', '*Charcoal/chemistry', '*Cocos/chemistry', '*Water Pollutants, Chemical/chemistry', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/39031314/
916,Norfloxacin,36592587,The different toxicological effects and removal efficiencies of norfloxacin and sulfadiazine in culturing Arthrospira (Spirulina) platensis.,"['Jiang X', 'Wang D', 'Wu W', 'Li F']","['*Spirulina', 'Norfloxacin/toxicity/metabolism', 'Sulfadiazine/toxicity/metabolism', 'Ecosystem', 'Biomass', 'Anti-Bacterial Agents/toxicity/metabolism']",https://pubmed.ncbi.nlm.nih.gov/36592587/
917,Norfloxacin,35318022,Interaction of norfloxacin and hexavalent chromium with ferrihydrite nanoparticles: Synergistic adsorption and antagonistic aggregation behavior.,"['Chen Y', 'Li Z']","['Adsorption', 'Chromium', 'Ferric Compounds', '*Nanoparticles', 'Norfloxacin', '*Water Pollutants, Chemical']",https://pubmed.ncbi.nlm.nih.gov/35318022/
918,Norfloxacin,39115052,"Design, synthesis and evaluation of novel norfloxacin analogs as potent anticancer and antioxidant agents.","['Qurban F', 'Shahzad SA', 'Khaskheli MS', 'Khan SU', 'Khan SA', 'Rauf W', 'Islam S', 'Mannan A']","['*Norfloxacin/pharmacology/chemical synthesis', 'Humans', '*Antineoplastic Agents/pharmacology/chemical synthesis/chemistry', '*Drug Design', '*Antioxidants/pharmacology/chemical synthesis/chemistry', '*Cell Proliferation/drug effects', '*Molecular Docking Simulation', 'Drug Screening Assays, Antitumor', 'HeLa Cells', 'Cell Survival/drug effects', 'Structure-Activity Relationship', 'Molecular Structure']",https://pubmed.ncbi.nlm.nih.gov/39115052/
919,Norfloxacin,24388445,Sorption and solubility of ofloxacin and norfloxacin in water-methanol cosolvent.,"['Peng H', 'Li H', 'Wang C', 'Zhang D', 'Pan B', 'Xing B']","['Adsorption', 'Anti-Bacterial Agents/*chemistry', 'Hydrogen Bonding', 'Methanol/*chemistry', 'Nanotubes, Carbon', 'Norfloxacin/*chemistry', 'Ofloxacin/*chemistry', 'Solubility', 'Solvents/chemistry', 'Water/*chemistry', 'Water Pollutants, Chemical/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/24388445/
920,Norfloxacin,30769240,Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation.,"['Wang LL', 'Battini N', 'Bheemanaboina RRY', 'Zhang SL', 'Zhou CH']","['Anti-Infective Agents/chemical synthesis/*chemistry/pharmacology', 'Bacteria/drug effects', 'Cell Membrane Permeability/drug effects', 'Chitin Synthase/antagonists & inhibitors', 'DNA Gyrase/drug effects', 'DNA Replication/drug effects', 'Drug Design', 'Fungi/drug effects', 'Intercalating Agents/pharmacology', 'Molecular Docking Simulation', 'Norfloxacin/*analogs & derivatives/chemical synthesis/*pharmacology', 'Quantum Theory', 'Structure-Activity Relationship', 'Thiazoles/chemistry']",https://pubmed.ncbi.nlm.nih.gov/30769240/
921,Norfloxacin,30189811,Binary and ternary complexes of norfloxacin to improve the solubility of the active pharmaceutical ingredient.,"['Ponce-Ponte M', 'Aloisio C', 'Romero-Guerra DM', 'Gracia-Vasquez S', 'Garnero C', 'Longhi M']","['2-Hydroxypropyl-beta-cyclodextrin/chemistry', 'Anti-Bacterial Agents/administration & dosage/chemistry/*pharmacokinetics', 'Biological Availability', 'Calorimetry, Differential Scanning', 'Chemistry, Pharmaceutical', 'Drug Carriers/*chemistry', 'Drug Compounding/*methods', 'Drug Liberation', 'Freeze Drying', 'Glutamic Acid/chemistry', 'Norfloxacin/administration & dosage/chemistry/*pharmacokinetics', 'Solubility', 'beta-Cyclodextrins/chemistry']",https://pubmed.ncbi.nlm.nih.gov/30189811/
922,Norfloxacin,38547361,Rational Design and Synthesis of Fe-Doped Co-Based Coordination Polymer Composite Photocatalysts for the Degradation of Norfloxacin and Ciprofloxacin.,"['Li YX', 'Chen X', 'Jiang ZY', 'Luan J', 'Guo F']","['*Norfloxacin/chemistry/radiation effects', '*Ciprofloxacin', 'Anti-Bacterial Agents/chemistry', 'Light', 'Catalysis']",https://pubmed.ncbi.nlm.nih.gov/38547361/
923,Norfloxacin,19842796,Stability of ciprofloxacin and norfloxacin in the presence and absence of metal ions in acidic solution.,"['Hubicka U', 'Krzek J', 'Walczak M']","['Anti-Infective Agents/*chemistry', 'Chromatography, Thin Layer', 'Ciprofloxacin/*chemistry', 'Densitometry', 'Drug Stability', 'Hydrogen-Ion Concentration', 'Ions', 'Metals/*chemistry', 'Norfloxacin/*chemistry', 'Solutions', 'Temperature']",https://pubmed.ncbi.nlm.nih.gov/19842796/
924,Amiloride,22589079,Strong and selective binding of amiloride to an abasic site in RNA duplexes: thermodynamic characterization and microRNA detection.,"['Sato Y', 'Ichihashi T', 'Nishizawa S', 'Teramae N']","['Amiloride/*chemistry', 'Base Sequence', 'MicroRNAs/*analysis/chemistry', 'Models, Molecular', 'Nucleic Acid Conformation', 'RNA/*chemistry', '*Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/22589079/
925,Amiloride,36923593,Antifungal activity of 6-substituted amiloride and hexamethylene amiloride (HMA) analogs.,"['Vu K', 'Buckley BJ', 'Bujaroski RS', 'Blumwald E', 'Kelso MJ', 'Gelli A']","['Humans', 'Amiloride/pharmacology', 'Antifungal Agents/pharmacology', 'Fungi', '*Mycoses/drug therapy', 'Microbial Sensitivity Tests', '*Cryptococcus neoformans']",https://pubmed.ncbi.nlm.nih.gov/36923593/
926,Amiloride,37560772,Amiloride evokes significant natriuresis and weight loss in kidney transplant recipients with and without albuminuria.,"['Hinrichs GR', 'Nielsen JR', 'Birn H', 'Bistrup C', 'Jensen BL']","['Humans', 'Amiloride/pharmacology/therapeutic use', 'Albuminuria', 'Natriuresis', '*Kidney Transplantation/adverse effects', 'Renin', 'Aldosterone', 'Angiotensin II', 'Blood Pressure Monitoring, Ambulatory', '*Hypertension', 'Sodium/metabolism', '*Water-Electrolyte Imbalance', 'Weight Loss', 'Body Weight', 'Water', 'Epithelial Sodium Channels']",https://pubmed.ncbi.nlm.nih.gov/37560772/
927,Amiloride,38067419,"Study of Amiloride Binding to Human Serum Albumin: Insights from Thermodynamic, Spectroscopic, and Molecular Docking Investigations.","['Rahman S', 'Iram S', 'Rehman MT', 'Hussain A', 'Jan AT', 'Kim J']","['Humans', '*Serum Albumin, Human/chemistry', 'Molecular Docking Simulation', 'Amiloride/pharmacology', 'Protein Binding', 'Binding Sites', 'Circular Dichroism', 'Thermodynamics', '*Leukemia, Myeloid, Acute', 'Spectrometry, Fluorescence']",https://pubmed.ncbi.nlm.nih.gov/38067419/
928,Amiloride,33804289,Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors.,"['Buckley BJ', 'Kumar A', 'Aboelela A', 'Bujaroski RS', 'Li X', 'Majed H', 'Fliegel L', 'Ranson M', 'Kelso MJ']","['Amiloride/chemical synthesis/chemistry/*pharmacology', 'Breast Neoplasms/*drug therapy/genetics/pathology', 'Cell Line, Tumor', 'Diuretics/chemical synthesis/chemistry/pharmacology', 'Female', 'Humans', 'Models, Molecular', 'Neoplasm Invasiveness/genetics/pathology', 'Sodium-Hydrogen Exchanger 1/antagonists & inhibitors/*genetics', 'Structure-Activity Relationship', 'Urokinase-Type Plasminogen Activator/antagonists & inhibitors/*genetics']",https://pubmed.ncbi.nlm.nih.gov/33804289/
929,Amiloride,9085317,Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis.,"['Jones KM', 'Liao E', 'Hohneker K', 'Turpin S', 'Henry MM', 'Selinger K', 'Hsyu PH', 'Boucher RC', 'Knowles MR', 'Dukes GE']","['Administration, Inhalation', 'Administration, Oral', 'Adolescent', 'Adult', 'Aerosols', 'Amiloride/administration & dosage/adverse effects/*pharmacokinetics', 'Child', 'Cross-Over Studies', 'Cystic Fibrosis/*drug therapy/metabolism', 'Diuretics/administration & dosage/adverse effects/*pharmacokinetics', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9085317/
930,Amiloride,18264941,Amiloride-sensitive and amiloride-insensitive kaliuresis in advanced chronic kidney disease.,"['Levy Yeyati N', 'Fellet A', 'Arranz C', 'Balaszczuk AM', 'Adrogue HJ']","['Adult', 'Aged', 'Amiloride/*pharmacology', 'Chronic Disease', 'Epithelial Sodium Channels/physiology', 'Female', 'Humans', 'Kidney Diseases/*metabolism', 'Male', 'Middle Aged', 'Potassium/*urine']",https://pubmed.ncbi.nlm.nih.gov/18264941/
931,Amiloride,7004473,Effect of tienilic acid and amiloride in healthy volunteers and in hypertensives with normal renal function.,"['Myers JB', 'Gillies A', 'Waga S', 'Morgan TO']","['Adolescent', 'Adult', 'Aged', 'Amiloride/administration & dosage/*pharmacology/therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Diuretics/adverse effects', 'Drug Therapy, Combination', 'Electrolytes/blood', 'Female', 'Glycolates/*pharmacology', 'Humans', 'Hydrochlorothiazide/administration & dosage/pharmacology/therapeutic use', 'Hypertension/*drug therapy', 'Kidney/*drug effects', 'Male', 'Middle Aged', 'Pyrazines/*pharmacology', 'Ticrynafen/administration & dosage/*pharmacology/therapeutic use', 'Uric Acid/blood']",https://pubmed.ncbi.nlm.nih.gov/7004473/
932,Amiloride,10318954,"Mutations conferring resistance to phenamil and amiloride, inhibitors of sodium-driven motility of Vibrio parahaemolyticus.","['Jaques S', 'Kim YK', 'McCarter LL']","['Amiloride/*analogs & derivatives/*pharmacology', 'Amino Acid Sequence', 'Bacterial Outer Membrane Proteins/genetics', 'Bacterial Proteins/chemistry/genetics', 'Cell Movement/drug effects/*genetics', 'Conserved Sequence', 'Membrane Proteins/genetics', 'Molecular Sequence Data', 'Mutation', 'Phenotype', 'Sodium/metabolism', 'Vibrio parahaemolyticus/drug effects/*genetics']",https://pubmed.ncbi.nlm.nih.gov/10318954/
933,Emtricitabine,32711800,"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.","['Mayer KH', 'Molina JM', 'Thompson MA', 'Anderson PL', 'Mounzer KC', 'De Wet JJ', 'DeJesus E', 'Jessen H', 'Grant RM', 'Ruane PJ', 'Wong P', 'Ebrahimi R', 'Zhong L', 'Mathias A', 'Callebaut C', 'Collins SE', 'Das M', 'McCallister S', 'Brainard DM', 'Brinson C', 'Clarke A', 'Coll P', 'Post FA', 'Hare CB']","['Adenine/adverse effects/*analogs & derivatives/therapeutic use', 'Adult', 'Anti-HIV Agents/adverse effects/*therapeutic use', 'Double-Blind Method', 'Emtricitabine/adverse effects/*therapeutic use', 'Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/adverse effects/*therapeutic use', 'Europe/epidemiology', 'Female', 'HIV Infections/*drug therapy/epidemiology/prevention & control', 'HIV-1/drug effects', 'Homosexuality, Male/ethnology', 'Humans', 'Male', 'North America/epidemiology', 'Placebos/administration & dosage', 'Pre-Exposure Prophylaxis/methods', 'Prevalence', 'Safety', 'Sexual and Gender Minorities', 'Tenofovir/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32711800/
934,Emtricitabine,37567205,"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.","['Ramgopal MN', 'Castagna A', 'Cazanave C', 'Diaz-Brito V', 'Dretler R', 'Oka S', 'Osiyemi O', 'Walmsley S', 'Sims J', 'Di Perri G', 'Sutton K', 'Sutherland-Phillips D', 'Berni A', 'Latham CL', 'Zhang F', ""D'Amico R"", 'Pascual Bernaldez M', 'Van Solingen-Ristea R', 'Van Eygen V', 'Patel P', 'Chounta V', 'Spreen WR', 'Garges HP', 'Smith K', 'van Wyk J']","['Infant, Newborn', 'Adult', 'Humans', 'Female', 'Adolescent', 'Young Adult', 'Middle Aged', 'Aged', 'Male', 'Emtricitabine/adverse effects', 'Rilpivirine/adverse effects', '*HIV Infections/drug therapy', 'Tenofovir/adverse effects', 'Injection Site Reaction/drug therapy', 'Adenine/adverse effects', 'Anti-Retroviral Agents/therapeutic use', '*HIV Seropositivity/drug therapy', 'Heterocyclic Compounds, 4 or More Rings/adverse effects', '*HIV-1/physiology', 'RNA/therapeutic use', '*Anti-HIV Agents/adverse effects', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/37567205/
935,Emtricitabine,36423244,Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide.,"['Maggiolo F , MD', 'Valenti D , BSc', 'Teocchi R , BSc', 'Comi L , MD', 'Di Filippo E , MD', 'Rizzi M , MD']","['Adult', 'Humans', 'Emtricitabine/therapeutic use', '*Forgiveness', '*HIV-1', '*HIV Infections/drug therapy', 'Adenine/therapeutic use', 'Heterocyclic Compounds, 4 or More Rings/therapeutic use/pharmacology', 'Drug Combinations', 'RNA/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/36423244/
936,Emtricitabine,28867497,"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.","['Gallant J', 'Lazzarin A', 'Mills A', 'Orkin C', 'Podzamczer D', 'Tebas P', 'Girard PM', 'Brar I', 'Daar ES', 'Wohl D', 'Rockstroh J', 'Wei X', 'Custodio J', 'White K', 'Martin H', 'Cheng A', 'Quirk E']","['Adenine/administration & dosage/*analogs & derivatives', 'Adult', 'Alanine', 'Amides', 'Anti-Retroviral Agents/pharmacology/therapeutic use', 'Dideoxynucleosides/*administration & dosage', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', 'Emtricitabine/*administration & dosage', 'Female', 'HIV Infections/diagnosis/*drug therapy', 'Heterocyclic Compounds, 3-Ring/*administration & dosage', 'Heterocyclic Compounds, 4 or More Rings/*administration & dosage', 'Humans', 'Internationality', 'Lamivudine/*administration & dosage', 'Male', 'Middle Aged', 'Oxazines', 'Piperazines', 'Prognosis', 'Pyridones', 'Risk Assessment', 'Survival Rate', 'Tenofovir/analogs & derivatives', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28867497/
937,Emtricitabine,33010240,"Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.","['Venter WDF', 'Sokhela S', 'Simmons B', 'Moorhouse M', 'Fairlie L', 'Mashabane N', 'Serenata C', 'Akpomiemie G', 'Masenya M', 'Qavi A', 'Chandiwana N', 'McCann K', 'Norris S', 'Chersich M', 'Maartens G', 'Lalla-Edward S', 'Vos A', 'Clayden P', 'Abrams E', 'Arulappan N', 'Hill A']","['Adenine/administration & dosage/analogs & derivatives', 'Adolescent', 'Adult', 'Alanine', 'Alkynes', 'Anti-HIV Agents/administration & dosage/adverse effects/*therapeutic use', '*Antiretroviral Therapy, Highly Active', 'Benzoxazines/administration & dosage', 'Body Composition', 'Body Weight', 'Cyclopropanes', 'Duration of Therapy', 'Emtricitabine/administration & dosage', 'Female', 'HIV Infections/*drug therapy/*virology', 'HIV-1/*drug effects', 'Heterocyclic Compounds, 3-Ring/administration & dosage', 'Humans', 'Male', 'Middle Aged', 'Oxazines', 'Piperazines', 'Pyridones', 'Tenofovir/administration & dosage', 'Treatment Outcome', 'Viral Load', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33010240/
938,Emtricitabine,34197772,"Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.","['Ogbuagu O', 'Ruane PJ', 'Podzamczer D', 'Salazar LC', 'Henry K', 'Asmuth DM', 'Wohl D', 'Gilson R', 'Shao Y', 'Ebrahimi R', 'Cox S', 'Kintu A', 'Carter C', 'Das M', 'Baeten JM', 'Brainard DM', 'Whitlock G', 'Brunetta JM', 'Kronborg G', 'Spinner CD']","['Adenine/adverse effects/*analogs & derivatives/therapeutic use', 'Adult', 'Aged', 'Alanine/adverse effects/*therapeutic use', 'Anti-HIV Agents/adverse effects/*therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination/adverse effects', 'Emtricitabine/adverse effects/*therapeutic use', 'Female', 'Follow-Up Studies', 'HIV Infections/*prevention & control/virology', 'HIV-1/drug effects/physiology', 'Humans', 'Male', 'Middle Aged', 'Organophosphonates/adverse effects/*therapeutic use', 'Pre-Exposure Prophylaxis', 'Tenofovir/adverse effects/*therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34197772/
939,Emtricitabine,33812487,"Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.","['Lockman S', 'Brummel SS', 'Ziemba L', 'Stranix-Chibanda L', 'McCarthy K', 'Coletti A', 'Jean-Philippe P', 'Johnston B', 'Krotje C', 'Fairlie L', 'Hoffman RM', 'Sax PE', 'Moyo S', 'Chakhtoura N', 'Stringer JS', 'Masheto G', 'Korutaro V', 'Cassim H', 'Mmbaga BT', 'Joao E', 'Hanley S', 'Purdue L', 'Holmes LB', 'Momper JD', 'Shapiro RL', 'Thoofer NK', 'Rooney JF', 'Frenkel LM', 'Amico KR', 'Chinula L', 'Currier J']","['Adenine/administration & dosage/adverse effects/*analogs & derivatives', 'Adult', 'Alanine', 'Anti-HIV Agents/*administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Emtricitabine/*administration & dosage/adverse effects', 'Female', 'Gestational Age', 'HIV Infections/*drug therapy/prevention & control', 'Heterocyclic Compounds, 3-Ring/*administration & dosage/adverse effects', 'Humans', 'Infant, Newborn', 'Infectious Disease Transmission, Vertical/prevention & control', 'Oxazines/*administration & dosage/adverse effects', 'Piperazines/*administration & dosage/adverse effects', 'Pregnancy', 'Pregnancy Complications, Infectious/drug therapy', 'Pregnancy Outcome', 'Pyridones/*administration & dosage/adverse effects', 'Tenofovir/*administration & dosage/adverse effects', 'Ultrasonography, Prenatal']",https://pubmed.ncbi.nlm.nih.gov/33812487/
940,Emtricitabine,30420123,"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.","['Cahn P', 'Madero JS', 'Arribas JR', 'Antinori A', 'Ortiz R', 'Clarke AE', 'Hung CC', 'Rockstroh JK', 'Girard PM', 'Sievers J', 'Man C', 'Currie A', 'Underwood M', 'Tenorio AR', 'Pappa K', 'Wynne B', 'Fettiplace A', 'Gartland M', 'Aboud M', 'Smith K']","['Adult', 'Anti-HIV Agents/adverse effects/*therapeutic use', 'Anti-Retroviral Agents/adverse effects/*therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Emtricitabine/adverse effects/therapeutic use', 'Female', 'HIV Infections/*drug therapy/virology', 'HIV-1/*isolation & purification', 'Heterocyclic Compounds, 3-Ring/adverse effects/*therapeutic use', 'Humans', 'Lamivudine/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Oxazines', 'Piperazines', 'Pyridones', 'RNA, Viral/blood', 'Tenofovir/adverse effects/therapeutic use', 'Viral Load/drug effects']",https://pubmed.ncbi.nlm.nih.gov/30420123/
941,Emtricitabine,35616112,Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir Alafenamide.,"['Scevola S', 'Imaz A', 'Cottrell ML', 'Niubo J', 'Van Horne B', 'Tiraboschi J', 'Saumoy M', 'Morenilla S', 'Soriano I', 'Kashuba ADM', 'Podzamczer D']","['Adult', 'Humans', '*HIV-1/genetics', '*Anti-HIV Agents/therapeutic use', '*HIV Infections/drug therapy', 'Emtricitabine/therapeutic use', 'RNA/therapeutic use', 'Genitalia']",https://pubmed.ncbi.nlm.nih.gov/35616112/
942,Emtricitabine,37952550,Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.,"['Landovitz RJ', 'Hanscom BS', 'Clement ME', 'Tran HV', 'Kallas EG', 'Magnus M', 'Sued O', 'Sanchez J', 'Scott H', 'Eron JJ', 'Del Rio C', 'Fields SD', 'Marzinke MA', 'Eshleman SH', 'Donnell D', 'Spinelli MA', 'Kofron RM', 'Berman R', 'Piwowar-Manning EM', 'Richardson PA', 'Sullivan PA', 'Lucas JP', 'Anderson PL', 'Hendrix CW', 'Adeyeye A', 'Rooney JF', 'Rinehart AR', 'Cohen MS', 'McCauley M', 'Grinsztejn B']","['Male', 'Female', 'Humans', 'Adolescent', '*HIV Infections/drug therapy', 'Tenofovir/adverse effects', 'Emtricitabine/adverse effects', '*Anti-HIV Agents/adverse effects', '*Transgender Persons', 'Retrospective Studies', '*HIV-1', '*Acquired Immunodeficiency Syndrome/drug therapy', '*Pre-Exposure Prophylaxis']",https://pubmed.ncbi.nlm.nih.gov/37952550/
943,Emtricitabine,38860279,Emtricitabine/tenofovir alafenamide and doravirine in a virologically suppressed adult with HIV and on chronic ambulatory peritoneal dialysis: A case report.,"['Bickenbach E', 'Pan J', 'King M']","['Humans', 'Male', 'Adenine/analogs & derivatives/therapeutic use', '*Alanine/analogs & derivatives/therapeutic use', '*Anti-HIV Agents/therapeutic use', 'Drug Combinations', '*Emtricitabine/therapeutic use', '*HIV Infections/drug therapy', 'HIV-1/drug effects', 'Kidney Failure, Chronic/therapy/complications', 'Peritoneal Dialysis, Continuous Ambulatory', 'Pyrazoles/therapeutic use', '*Pyridones/therapeutic use', '*Tenofovir/therapeutic use/analogs & derivatives', 'Treatment Outcome', 'Triazoles', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/38860279/
944,Emtricitabine,37494280,Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study.,"['Knobel H', 'Canas-Ruano E', 'Guelar A', 'Knobel P', 'Villar-Garcia J', 'Gonzalez-Mena A', 'Canepa C', 'Arrieta-Aldea I', 'Marcos A', 'Abalat-Torrres A', 'Guerri-Fernandez R']","['Humans', '*Lamivudine/adverse effects', '*HIV Infections/drug therapy', 'Retrospective Studies', 'Adenine', 'Treatment Outcome', 'Emtricitabine', 'Drug Combinations', 'Heterocyclic Compounds, 4 or More Rings/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37494280/
945,Emtricitabine,30451698,Community and activists demand for tenofovir/emtricitabine or lamivudine/dolutegravir and routine viral load testing.,"['Baptiste SL', 'Taro TB', ""Etya'ale HM""]","['Anti-HIV Agents/*therapeutic use', 'Drug Monitoring', 'Emtricitabine/*therapeutic use', 'HIV Infections/*drug therapy/virology', 'HIV-1/drug effects/physiology', 'Heterocyclic Compounds, 3-Ring/*therapeutic use', 'Humans', 'Lamivudine/*therapeutic use', 'Oxazines', 'Piperazines', 'Pyridones', 'Residence Characteristics', 'Tenofovir/*therapeutic use', 'Viral Load/drug effects']",https://pubmed.ncbi.nlm.nih.gov/30451698/
946,Emtricitabine,38349226,Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.,"['Orkin C', 'Antinori A', 'Rockstroh JK', 'Moreno-Guillen S', 'Martorell CT', 'Molina JM', 'Lazzarin A', 'Maggiolo F', 'Yazdanpanah Y', 'Andreatta K', 'Huang H', 'Hindman JT', 'Martin H', 'Pozniak A']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Young Adult', 'Adenine/analogs & derivatives/therapeutic use/adverse effects', 'Alanine/therapeutic use', 'Amides/therapeutic use', '*Anti-HIV Agents/therapeutic use/adverse effects', 'CD4 Lymphocyte Count', 'Double-Blind Method', 'Drug Substitution', 'Drug-Related Side Effects and Adverse Reactions', '*Emtricitabine/therapeutic use/administration & dosage/adverse effects', 'Heterocyclic Compounds, 3-Ring/adverse effects/therapeutic use/administration & dosage', 'Heterocyclic Compounds, 4 or More Rings/therapeutic use/adverse effects/administration & dosage', '*HIV Infections/drug therapy', '*HIV-1/drug effects', '*Oxazines', '*Piperazines', 'Pyridones', '*Tenofovir/therapeutic use/adverse effects/administration & dosage/analogs & derivatives', 'Treatment Outcome', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/38349226/
947,Emtricitabine,33315694,Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.,"['Perez-Valero I', 'Llibre JM', 'Castagna A', 'Pulido F', 'Molina JM', 'Esser S', 'Margot N', 'Shao Y', 'Temme L', 'Piontkowsky D', 'McNicholl IR', 'Haubrich R']","['Adult', 'Aged', 'Alanine/administration & dosage/therapeutic use', 'Anti-HIV Agents/administration & dosage/*therapeutic use', 'Cobicistat/administration & dosage/therapeutic use', 'Drug Combinations', 'Drug Resistance, Viral/*genetics', 'Emtricitabine/administration & dosage/therapeutic use', 'Female', 'HIV Infections/*drug therapy', 'HIV-1/*drug effects/genetics', 'Humans', 'Male', 'Middle Aged', 'Mutation', 'Quinolones/administration & dosage', 'Tenofovir/administration & dosage/analogs & derivatives/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33315694/
948,Emtricitabine,30767719,Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics.,"['Gini J', 'Olagunju A', 'Dickinson L', 'Waitt C', 'Neary M', 'Else LJ', 'Siccardi M', 'Khoo S']","['Adolescent', 'Adult', 'Anti-HIV Agents/administration & dosage/pharmacokinetics', 'Emtricitabine/*administration & dosage/adverse effects/pharmacokinetics', 'Female', 'Genotype', 'HIV Infections/*drug therapy/genetics/transmission/virology', 'Humans', 'Infectious Disease Transmission, Vertical', 'Leukocytes, Mononuclear/drug effects', 'Multidrug Resistance-Associated Protein 2', 'Multidrug Resistance-Associated Proteins/*genetics', 'Polymorphism, Single Nucleotide/genetics', 'Pregnancy', 'Tenofovir/*administration & dosage/adverse effects/pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30767719/
949,Emtricitabine,33599173,Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.,"['Tabak F', 'Zerdali E', 'Altuntas O', 'Gunduz A', 'Bolukcu S', 'Mete B', 'Nakir IY', 'Kumbasar Karaosmanoglu H', 'Yildiz DS', 'Meric Koc M', 'Dokmetas I']","['Adult', 'Alanine', 'Cobicistat', 'Emtricitabine/adverse effects', '*HIV Infections/drug therapy', 'Homosexuality, Male', 'Humans', 'Male', 'Quinolones', '*Sexual and Gender Minorities', 'Tenofovir/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/33599173/
950,Emtricitabine,39676239,Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.,"['Tan DHS', 'Antinori A', 'Eu B', 'Galindo Puerto MJ', 'Kinder C', 'Sweet D', 'Van Dam CN', 'Sutton K', 'Sutherland-Phillips D', 'Berni A', 'Zhang F', 'Urbaityte R', 'Baugh B', 'Spreen W', 'van Wyk J', 'Garges HP', 'Patel P', 'Batterham R', ""D'Amico R""]","['Humans', '*HIV Infections/drug therapy', 'Male', 'Female', '*Emtricitabine/therapeutic use/administration & dosage', '*Tenofovir/therapeutic use/administration & dosage/analogs & derivatives', '*Anti-HIV Agents/therapeutic use/administration & dosage', 'Middle Aged', 'Adult', '*Pyridones/administration & dosage/therapeutic use', '*Rilpivirine/therapeutic use/administration & dosage', '*Alanine/administration & dosage', 'Heterocyclic Compounds, 4 or More Rings/administration & dosage/therapeutic use', 'Body Weight', 'Heterocyclic Compounds, 3-Ring/administration & dosage/therapeutic use', 'Drug Combinations', 'Adenine/analogs & derivatives/administration & dosage/therapeutic use', 'Amides', 'Piperazines/administration & dosage', 'Carbamates/administration & dosage/therapeutic use', 'Pyridines/administration & dosage/therapeutic use', 'Diketopiperazines']",https://pubmed.ncbi.nlm.nih.gov/39676239/
951,Emtricitabine,38621393,"Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.","['Rodriguez CA', 'Natukunda E', 'Strehlau R', 'Venter EL', 'Rungmaitree S', 'Cunningham CK', 'Lalloo U', 'Kosalaraksa P', 'HellstrOm E', 'Liberty A', 'McGrath EJ', 'Kaur M', 'Leisegang R', 'Hindman JT', 'Vieira VA', 'Kersey K', 'Cotton MF', 'Rakhmanina N', 'Gaur AH']","['Humans', '*Emtricitabine/pharmacokinetics/administration & dosage/therapeutic use/adverse effects', '*HIV Infections/drug therapy/virology', '*Tenofovir/pharmacokinetics/administration & dosage/adverse effects/therapeutic use/*analogs & derivatives', 'Child', 'Male', 'Female', '*Anti-HIV Agents/pharmacokinetics/adverse effects/administration & dosage/therapeutic use', 'Child, Preschool', '*Alanine/pharmacokinetics/adverse effects', '*Heterocyclic Compounds, 4 or More Rings/pharmacokinetics/adverse effects/administration & dosage', '*Amides/pharmacokinetics', 'Adolescent', '*Pyridones/pharmacokinetics/adverse effects', '*Heterocyclic Compounds, 3-Ring/pharmacokinetics/adverse effects/administration & dosage', '*Piperazines/adverse effects/pharmacokinetics', '*Adenine/analogs & derivatives/pharmacokinetics/adverse effects/administration & dosage/therapeutic use', 'Thailand', 'United States', 'South Africa', 'Drug Combinations', 'Uganda', 'Viral Load/drug effects']",https://pubmed.ncbi.nlm.nih.gov/38621393/
952,Loxapine,30721526,Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change.,"['Pacciardi B', 'Calcedo A', 'Messer T']","['Administration, Inhalation', 'Antipsychotic Agents/*administration & dosage', 'Bipolar Disorder/*drug therapy/psychology', 'Humans', 'Loxapine/*administration & dosage', 'Psychomotor Agitation/*drug therapy/psychology', 'Randomized Controlled Trials as Topic', 'Schizophrenia/*drug therapy', 'Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/30721526/
953,Loxapine,28510296,Pharmacokinetics and Safety of Single-Dose Inhaled Loxapine in Children and Adolescents.,"['Selim S', 'Riesenberg R', 'Cassella J', 'Kunta J', 'Hellriegel E', 'Smith MA', 'Vinks AA', 'Rabinovich-Guilatt L']","['Administration, Inhalation', 'Adolescent', 'Antipsychotic Agents/adverse effects/blood/*pharmacokinetics', 'Child', 'Female', 'Humans', 'Loxapine/adverse effects/blood/*pharmacokinetics', 'Male']",https://pubmed.ncbi.nlm.nih.gov/28510296/
954,Loxapine,28335658,Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline.,"['Hellings JA', 'Arnold LE', 'Han JC']","['Adolescent', 'Adult', 'Amitriptyline/pharmacology/*therapeutic use', 'Antipsychotic Agents/therapeutic use', 'Aripiprazole/therapeutic use', 'Autism Spectrum Disorder/*drug therapy', 'Brain-Derived Neurotrophic Factor/metabolism', 'Child', 'Dopamine Antagonists/therapeutic use', 'Humans', 'Irritable Mood/drug effects', 'Loxapine/*therapeutic use', 'Risperidone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28335658/
955,Loxapine,25782098,Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability.,"['Hellings JA', 'Reed G', 'Cain SE', 'Zhou X', 'Barth FX', 'Aman MG', 'Palaguachi GI', 'Mikhnev D', 'Teng R', 'Andridge R', 'Logan M', 'Butler MG', 'Han JC']","['Adolescent', 'Adult', 'Antipsychotic Agents/*administration & dosage', 'Autism Spectrum Disorder/blood/*drug therapy/*psychology', 'Brain-Derived Neurotrophic Factor/blood', 'Drug Therapy, Combination', 'Female', 'Humans', 'Irritable Mood/*drug effects', 'Loxapine/*administration & dosage', 'Male', 'Prospective Studies', 'Psychiatric Status Rating Scales', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25782098/
956,Loxapine,28152454,"Simultaneous quantification of loxapine, loxapine N-oxide, amoxapine, 8-hydroxyloxapine and 7-hydroxyloxapine in human plasma using LC-MS/MS.","['Meng M', 'Zhao N', 'Pederson CC', 'Harrison E', 'Green C', 'Gorman SH', 'Reuschel S']","['Adolescent', 'Antipsychotic Agents/blood/pharmacokinetics/therapeutic use', 'Child', 'Chromatography, High Pressure Liquid/*methods', 'Humans', 'Limit of Detection', 'Linear Models', 'Loxapine/*analogs & derivatives/*blood/pharmacokinetics/therapeutic use', 'Reproducibility of Results', 'Tandem Mass Spectrometry/*methods']",https://pubmed.ncbi.nlm.nih.gov/28152454/
957,Loxapine,8251682,Potential interaction between carbamazepine and loxapine: case report and retrospective review.,"['Collins DM', 'Gidal BE', 'Pitterle ME']","['Adult', 'Carbamazepine/analogs & derivatives/blood/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Drug Monitoring', 'Female', 'Humans', 'Loxapine/*pharmacology', 'Male', 'Middle Aged', 'Prospective Studies', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/8251682/
958,Loxapine,423094,"GLC analysis of loxapine, amoxapine, and their metabolites in serum and urine.","['Cooper TB', 'Kelly RG']","['Amoxapine/*blood/*urine', 'Chromatography, Gas', 'Dibenzoxazepines/*blood/*urine', 'Humans', 'Hydroxylation', 'Loxapine/*blood/*urine', 'Methods']",https://pubmed.ncbi.nlm.nih.gov/423094/
959,Loxapine,28205038,Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents.,"['Dong M', 'Fukuda T', 'Selim S', 'Smith MA', 'Rabinovich-Guilatt L', 'Cassella JV', 'Vinks AA']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Age Factors', 'Antipsychotic Agents/*administration & dosage/*pharmacokinetics', 'Area Under Curve', 'Child', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Loxapine/*administration & dosage/*pharmacokinetics', 'Male', '*Models, Biological']",https://pubmed.ncbi.nlm.nih.gov/28205038/
960,Loxapine,3512535,A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients.,['Tuason VB'],"['Acute Disease', 'Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Aggression/*drug effects', 'Clinical Trials as Topic', 'Dibenzoxazepines/*therapeutic use', 'Double-Blind Method', 'Female', 'Haloperidol/administration & dosage/pharmacology/*therapeutic use', 'Hostility/*drug effects', 'Humans', 'Injections, Intramuscular', 'Loxapine/administration & dosage/pharmacology/*therapeutic use', 'Male', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Schizophrenia/diagnosis/*drug therapy', 'Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/3512535/
961,Loxapine,24745666,Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.,"['Gross N', 'Greos LS', 'Meltzer EO', 'Spangenthal S', 'Fishman RS', 'Spyker DA', 'Cassella JV']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Aerosols', 'Aged', 'Albuterol/administration & dosage', 'Antipsychotic Agents/*administration & dosage/adverse effects', 'Asthma/diagnosis/*drug therapy/physiopathology', 'Bronchial Spasm/chemically induced/drug therapy/physiopathology', 'Bronchodilator Agents/administration & dosage', 'Double-Blind Method', 'Female', 'Forced Expiratory Volume', 'Humans', 'Loxapine/*administration & dosage/adverse effects', 'Lung/*drug effects/physiopathology', 'Male', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy/physiopathology', 'Respiratory System Agents/*administration & dosage/adverse effects', 'Time Factors', 'Treatment Outcome', 'United States', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24745666/
962,Loxapine,28376877,Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.,"['San L', 'Estrada G', 'Oudovenko N', 'Vieta E']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Aged', 'Aggression/*drug effects', 'Antipsychotic Agents/administration & dosage/adverse effects/therapeutic use', 'Aripiprazole/administration & dosage/adverse effects/*therapeutic use', 'Bipolar Disorder/complications/*drug therapy', '*Clinical Protocols', 'Humans', 'Injections, Intramuscular', 'Loxapine/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Psychomotor Agitation/complications/*drug therapy', 'Schizophrenia/complications/drug therapy', '*Schizophrenic Psychology', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28376877/
963,Loxapine,417377,Clinical and plasma level characteristics of intramuscular and oral loxapine.,"['Simpson GM', 'Cooper TB', 'Lee JH', 'Young MA']","['Administration, Oral', 'Adult', 'Clinical Trials as Topic', 'Dibenzoxazepines/*blood', 'Double-Blind Method', 'Humans', 'Hypnotics and Sedatives', 'Injections, Intramuscular', 'Kinetics', 'Loxapine/administration & dosage/*blood/therapeutic use', 'Male', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Schizophrenia/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/417377/
964,Loxapine,29724638,PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.,"['San L', 'Estrada G', 'Oudovenko N', 'Montanes F', 'Dobrovolskaya N', 'Bukhanovskaya O', 'Popov M', 'Vieta E']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Aged', 'Antipsychotic Agents/*administration & dosage', 'Aripiprazole/*administration & dosage', 'Bipolar Disorder/complications', 'Female', 'Humans', 'Injections, Intramuscular', 'Loxapine/*administration & dosage', 'Male', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Psychomotor Agitation/*drug therapy/etiology', 'Schizophrenia/complications', 'Single-Blind Method', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29724638/
965,Loxapine,10340687,"Low-dose loxapine in the treatment of schizophrenia: is it more effective and more ""atypical"" than standard-dose loxapine?","['Meltzer HY', 'Jayathilake K']","['Adult', 'Antipsychotic Agents/*administration & dosage/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Humans', 'Loxapine/*administration & dosage/therapeutic use', 'Male', 'Retrospective Studies', 'Schizophrenia/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10340687/
966,Loxapine,494666,Determination of loxapine in human plasma and urine and identification of three urinary metabolites.,"['Cooper SF', 'Dugal R', 'Bertrand MJ']","['Adult', 'Chromatography, Gas/methods', 'Dibenzoxazepines/*blood/*urine', 'Gas Chromatography-Mass Spectrometry/methods', 'Humans', 'Kinetics', 'Loxapine/analogs & derivatives/*blood/therapeutic use/*urine', 'Male', 'Middle Aged', 'Models, Chemical', 'Psychotic Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/494666/
967,Aciclovir,20447128,Aciclovir-resistant herpes keratitis.,"['Choong K', 'Walker NJ', 'Apel AJ', 'Whitby M']","['Acyclovir/administration & dosage/*therapeutic use', 'Administration, Oral', 'Administration, Topical', 'Aged, 80 and over', 'Antiviral Agents/administration & dosage/*therapeutic use', 'Blindness/virology', '*Drug Resistance, Viral', 'Humans', 'Keratitis, Herpetic/complications/*drug therapy', 'Male', 'Middle Aged', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20447128/
968,Aciclovir,38775304,Population pharmacokinetics and dose rationale for aciclovir in term and pre-term neonates with herpes.,"[""D'Agate S"", 'Ruiz Gabarre D', 'Della Pasqua O']","['Humans', '*Acyclovir/pharmacokinetics/administration & dosage', 'Infant, Newborn', '*Antiviral Agents/pharmacokinetics/administration & dosage', '*Herpes Simplex/drug therapy', 'Female', 'Male', 'Models, Biological', 'Creatinine/blood', 'Dose-Response Relationship, Drug', 'Metabolic Clearance Rate', 'Computer Simulation']",https://pubmed.ncbi.nlm.nih.gov/38775304/
969,Aciclovir,33264148,Herpes Simplex Virus-Related Conjunctivitis Resistant to Aciclovir: A Case Report and Review of the Literature.,"['Esra N', 'Hollhumer R']","['Acyclovir/*pharmacology', 'Adult', 'Antiviral Agents/pharmacology', 'Conjunctivitis/*drug therapy/virology', '*Drug Resistance, Viral', 'Eye Infections, Viral/*drug therapy/virology', 'Herpes Simplex/*drug therapy/virology', 'Herpesvirus 1, Human/genetics', 'Humans', 'Male', 'Microbial Sensitivity Tests', 'RNA, Viral/analysis']",https://pubmed.ncbi.nlm.nih.gov/33264148/
970,Aciclovir,36601749,Aciclovir-induced neurotoxicity.,"['Vonberg FW', 'Dawson A', 'Scott G', 'Davies N']","['Female', 'Humans', 'Aged', 'Acyclovir/adverse effects', 'Antiviral Agents/adverse effects', '*Neurotoxicity Syndromes/etiology/therapy', 'Seizures/drug therapy', '*Encephalitis, Viral', 'Confusion']",https://pubmed.ncbi.nlm.nih.gov/36601749/
971,Aciclovir,17303480,Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples.,"['Perrottet N', 'Beguin A', 'Meylan P', 'Pascual M', 'Manuel O', 'Buclin T', 'Biollaz J', 'Decosterd LA']","['Acyclovir/*blood', 'Antiviral Agents/*blood', 'Calibration', 'Chromatography, High Pressure Liquid/*methods', 'Ganciclovir/*blood', 'Humans', 'Organ Transplantation', 'Reproducibility of Results', 'Sensitivity and Specificity', 'Spectrometry, Fluorescence/*methods']",https://pubmed.ncbi.nlm.nih.gov/17303480/
972,Aciclovir,11389118,Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients.,"['Hoglund M', 'Ljungman P', 'Weller S']","['Acyclovir/*analogs & derivatives/*metabolism/*pharmacokinetics/therapeutic use', 'Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Antiviral Agents/metabolism/*pharmacokinetics/therapeutic use', 'Female', 'Herpes Simplex/drug therapy/etiology/metabolism', 'Humans', 'Immunocompromised Host', 'Infusions, Intravenous', 'Male', 'Middle Aged', 'Neoplasms/complications/*metabolism/virology', 'Opportunistic Infections/drug therapy/metabolism/virology', 'Valacyclovir', 'Valine/*analogs & derivatives/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/11389118/
973,Aciclovir,24010876,Evaluation of the activity and safety of CS21 barrier genital gel(R) compared to topical aciclovir and placebo in symptoms of genital herpes recurrences: a randomized clinical trial.,"['Khemis A', 'Duteil L', 'Tillet Y', 'Dereure O', 'Ortonne JP']","['Acyclovir/*administration & dosage', 'Administration, Topical', 'Adult', 'Aged', 'Antiviral Agents/*administration & dosage', 'Female', 'Gels', 'Herpes Genitalis/*drug therapy', 'Humans', 'Male', 'Middle Aged', 'Prospective Studies', 'Recurrence', 'Single-Blind Method', 'Triglycerides/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24010876/
974,Aciclovir,17428641,"Development, evaluation and application of an isocratic high-performance liquid chromatography (HPLC) assay for the simultaneous determination of aciclovir and its metabolite 9-carboxymethoxymethylguanine in human serum and cerebrospinal fluid.","['Darville JM', 'Lovering AM', 'MacGowan AP']","['Acyclovir/*analysis', 'Analysis of Variance', 'Cerebrospinal Fluid/*chemistry', 'Chromatography, High Pressure Liquid/*methods', 'Guanine/*analogs & derivatives/analysis', 'Humans', 'Reproducibility of Results', 'Sensitivity and Specificity', 'Serum/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/17428641/
975,Aciclovir,29730641,PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer.,"['Bate J', 'Baker S', 'Breuer J', 'Chisholm JC', 'Gray J', 'Hambleton S', 'Houlton A', 'Jit M', 'Lowis S', 'Makin G', ""O'Sullivan C"", 'Patel SR', 'Phillips R', 'Ransinghe N', 'Ramsay ME', 'Skinner R', 'Wheatley K', 'Heath PT']","['Acyclovir/*therapeutic use', 'Adolescent', 'Antiviral Agents/therapeutic use', 'Child', 'Child, Preschool', 'England', 'Female', 'Herpesvirus 3, Human/drug effects/isolation & purification', 'Humans', '*Immune Sera', 'Immunization, Passive/methods', 'Male', '*Neoplasms/complications/therapy', 'Pilot Projects', 'Post-Exposure Prophylaxis/*methods', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29730641/
976,Aciclovir,16540518,The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.,"['Hellden A', 'Lycke J', 'Vander T', 'Svensson JO', 'Odar-Cederlof I', 'Stahle L']","['Acyclovir/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Antiviral Agents/*adverse effects/pharmacokinetics/therapeutic use', 'Guanine/*analogs & derivatives/cerebrospinal fluid', 'Humans', 'Mental Disorders/cerebrospinal fluid/*chemically induced', 'Neurotoxicity Syndromes/cerebrospinal fluid/*etiology', 'Retrospective Studies', 'Valacyclovir', 'Valine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16540518/
977,Aciclovir,15244498,Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects.,"['Gimenez F', 'Foeillet E', 'Bourdon O', 'Weller S', 'Garret C', 'Bidault R', 'Singlas E']","['Acyclovir/*analogs & derivatives/*pharmacokinetics/*pharmacology', 'Adult', 'Antiviral Agents/*pharmacokinetics/*pharmacology', 'Area Under Curve', 'Chromatography, Liquid', 'Cross-Over Studies', 'Drug Interactions', 'Glucuronides/metabolism', 'Half-Life', 'Humans', 'Immunosuppressive Agents/*pharmacokinetics/*pharmacology', 'Male', 'Middle Aged', 'Mycophenolic Acid/*analogs & derivatives/*pharmacokinetics/*pharmacology', 'Valacyclovir', 'Valine/*analogs & derivatives/*pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/15244498/
978,Aciclovir,19244470,Economic evaluation of early administration of prednisolone and/or aciclovir for the treatment of Bell's palsy.,"['Hernandez RA', 'Sullivan F', 'Donnan P', 'Swan I', 'Vale L']","['Acyclovir/*administration & dosage/*economics', 'Adult', 'Anti-Inflammatory Agents/*administration & dosage/*economics', 'Antiviral Agents/*administration & dosage/*economics', 'Bell Palsy/*drug therapy/*economics', 'Cost-Benefit Analysis/statistics & numerical data', 'Decision Trees', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Health Resources/economics/statistics & numerical data', 'Humans', 'Male', 'Middle Aged', 'Prednisolone/*administration & dosage/*economics', 'State Medicine/economics', 'Treatment Outcome', 'United Kingdom', 'Utilization Review/statistics & numerical data']",https://pubmed.ncbi.nlm.nih.gov/19244470/
979,Aciclovir,19155993,Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.,"['Delany S', 'Mlaba N', 'Clayton T', 'Akpomiemie G', 'Capovilla A', 'Legoff J', 'Belec L', 'Stevens W', 'Rees H', 'Mayaud P']","['Acyclovir/*pharmacology/therapeutic use', 'Adult', 'Antiviral Agents/*pharmacology/therapeutic use', 'CD4 Lymphocyte Count', 'Cervix Uteri/virology', 'DNA, Viral/analysis', 'Double-Blind Method', 'Female', 'Follow-Up Studies', 'HIV Infections/*complications/immunology/virology', 'HIV-1/*drug effects/genetics/isolation & purification', 'Herpes Genitalis/*complications/drug therapy/virology', 'Herpesvirus 2, Human/drug effects/genetics/isolation & purification', 'Humans', 'Middle Aged', 'RNA, Viral/analysis/blood', 'Sexual Behavior', 'Specimen Handling/methods', 'Treatment Outcome', 'Vagina/virology', 'Virus Shedding/drug effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19155993/
980,Aciclovir,10602752,Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.,"['Steingrimsdottir H', 'Gruber A', 'Palm C', 'Grimfors G', 'Kalin M', 'Eksborg S']","['Acyclovir/*analogs & derivatives/*pharmacokinetics', 'Administration, Oral', 'Antiviral Agents/*pharmacokinetics', 'Biological Availability', 'Humans', 'Leukopenia/drug therapy/*metabolism', 'Prodrugs/*pharmacokinetics', 'Valacyclovir', 'Valine/*analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/10602752/
981,Aciclovir,21981375,Evaluation of the efficacy and safety of a CS20(R) protective barrier gel containing OGT compared with topical aciclovir and placebo on functional and objective symptoms of labial herpes recurrences: a randomized clinical trial.,"['Khemis A', 'Duteil L', 'Coudert AC', 'Tillet Y', 'Dereure O', 'Ortonne JP']","['Acyclovir/administration & dosage/adverse effects/*therapeutic use', 'Adult', 'Antiviral Agents/administration & dosage/adverse effects/*therapeutic use', 'Female', '*Gels', 'Herpes Labialis/*drug therapy/physiopathology', 'Humans', 'Male', 'Middle Aged', 'Placebos', 'Prospective Studies', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/21981375/
982,Aciclovir,19282055,Varicella zoster exposure on paediatric wards between 2000 and 2007: safe and effective post-exposure prophylaxis with oral aciclovir.,"['Shinjoh M', 'Takahashi T']","['Acyclovir/administration & dosage/adverse effects/*therapeutic use', 'Administration, Oral', 'Chemoprevention/adverse effects/*methods', 'Chickenpox/*prevention & control/transmission', 'Cross Infection/*prevention & control/transmission', 'Herpes Zoster/*prevention & control/transmission', 'Humans', 'Infant']",https://pubmed.ncbi.nlm.nih.gov/19282055/
983,Candesartan,28841231,Noncholestatic acute hepatocellular injury following candesartan administration.,"['Lammel-Lindemann JA', 'Flores-Villalba E', 'Martagon AJ', 'DeObeso-Gonzalez E', 'Puente-Gallegos F']","['Adult', 'Amlodipine/therapeutic use', 'Angiotensin II Type 1 Receptor Blockers/administration & dosage/*adverse effects', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/administration & dosage/*adverse effects', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Chemical and Drug Induced Liver Injury/blood/*diagnosis/etiology', 'Dose-Response Relationship, Drug', 'Humans', 'Hypertension/blood/*drug therapy', 'Liver Function Tests', 'Male', 'Tetrazoles/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28841231/
984,Candesartan,13678871,Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.,"['Yusuf S', 'Pfeffer MA', 'Swedberg K', 'Granger CB', 'Held P', 'McMurray JJ', 'Michelson EL', 'Olofsson B', 'Ostergren J']","['Adolescent', 'Adult', 'Aged', 'Angiotensin Receptor Antagonists', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/*therapeutic use', 'Biphenyl Compounds', 'Cardiovascular Diseases/mortality', 'Double-Blind Method', 'Female', 'Follow-Up Studies', 'Heart Failure/*drug therapy/mortality', 'Hospitalization', 'Humans', 'Male', 'Middle Aged', 'Outcome Assessment, Health Care', 'Placebos', 'Stroke Volume/physiology', 'Tetrazoles/*therapeutic use', 'Treatment Outcome', 'Ventricular Function, Left/*physiology']",https://pubmed.ncbi.nlm.nih.gov/13678871/
985,Candesartan,18854846,Candesartan and renal protection: more than blocking angiotensin type 1 receptor?,"['Macconi D', 'Remuzzi G']","['Angiotensin II Type 1 Receptor Blockers/pharmacology', 'Antioxidants/pharmacology', 'Benzimidazoles/*pharmacology', 'Biphenyl Compounds', 'Humans', 'Inflammation/prevention & control', 'Kidney Diseases/pathology/*prevention & control', 'Protective Agents/pharmacology', 'Tetrazoles/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/18854846/
986,Candesartan,38418298,Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure.,"['Hanna SM', 'Rabea HM', 'Abdelrahim MEA', 'Mahmoud HB']","['Humans', '*Amlodipine/adverse effects', 'Valsartan/pharmacology/therapeutic use', 'Blood Pressure', '*Hypertension/drug therapy', 'Prospective Studies', 'Valine/pharmacology/therapeutic use', 'Antihypertensive Agents/adverse effects', 'Tetrazoles/adverse effects', 'Drug Therapy, Combination', '*Benzimidazoles', '*Biphenyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/38418298/
987,Candesartan,38663908,CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine.,"['Garcia-Azorin D', 'Martinez-Badillo C', 'Camina Muniz J', 'Gago-Veiga AB', 'Morollon Sanchez N', 'Gonzalez-Quintanilla V', 'Porta-Etessam J', 'Sierra-Mencia A', 'Gonzalez-Garcia N', 'Gonzalez-Osorio Y', 'Polanco-Fernandez M', 'Recio-Garcia A', 'Belvis Nieto R', 'Guerrero-Peral AL']","['Humans', '*Migraine Disorders/drug therapy', 'Female', '*Biphenyl Compounds', 'Male', '*Benzimidazoles/therapeutic use/adverse effects', 'Adult', '*Tetrazoles/therapeutic use/adverse effects', 'Middle Aged', 'Treatment Outcome', 'Prospective Studies', 'Angiotensin II Type 1 Receptor Blockers/therapeutic use/adverse effects', 'Spain/epidemiology', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/38663908/
988,Candesartan,18046913,Candesartan in heart failure.,"['Ripley TL', 'Chonlahan JS', 'Germany RE']","['Angiotensin II Type 1 Receptor Blockers/adverse effects/pharmacokinetics/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacokinetics/*therapeutic use', 'Biphenyl Compounds', 'Death, Sudden', 'Heart Failure/*drug therapy/physiopathology', 'Heart Failure, Systolic/drug therapy', 'Humans', 'Hyperkalemia/chemically induced/epidemiology', 'Kidney Diseases/chemically induced/epidemiology', 'Tetrazoles/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18046913/
989,Candesartan,21421652,A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension.,"['Zhenfeng Zheng', 'Huilan Shi', 'Junya Jia', 'Dong Li', 'Shan Lin']","['Antihypertensive Agents/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/*therapeutic use', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Losartan/adverse effects/pharmacology/*therapeutic use', 'Publication Bias', 'Regression Analysis', 'Tetrazoles/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21421652/
990,Candesartan,34895036,Effect of Soluplus((R)) on gamma-cyclodextrin solubilization of irbesartan and candesartan and their nanoaggregates formation.,"['Soe HMSH', 'Sripetch S', 'Loftsson T', 'Stefansson E', 'Jansook P']","['Benzimidazoles', 'Biphenyl Compounds', 'Calorimetry, Differential Scanning', 'Irbesartan', 'Polyethylene Glycols', 'Polyvinyls', 'Solubility', 'Spectroscopy, Fourier Transform Infrared/methods', 'Tetrazoles', 'X-Ray Diffraction', '*gamma-Cyclodextrins/chemistry']",https://pubmed.ncbi.nlm.nih.gov/34895036/
991,Candesartan,29701105,A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure.,"['de Denus S', 'Dube MP', 'Fouodjio R', 'Huynh T', 'LeBlanc MH', 'Lepage S', 'Sheppard R', 'Giannetti N', 'Lavoie J', 'Mansour A', 'Provost S', 'Normand V', 'Mongrain I', 'Langlois M', ""O'Meara E"", 'Ducharme A', 'Racine N', 'Guertin MC', 'Turgeon J', 'Phillips MS', 'Rouleau JL', 'Tardif JC', 'White M']","['Aged', 'Angiotensin II Type 1 Receptor Blockers/pharmacokinetics/*therapeutic use', 'Benzimidazoles/pharmacokinetics/*therapeutic use', 'Biomarkers/blood', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Female', 'Heart Failure/blood/*drug therapy/genetics', 'Humans', 'Kidney Function Tests', 'Male', 'Natriuretic Peptide, Brain/blood', 'Peptide Fragments/blood', 'Pharmacogenetics', '*Polymorphism, Single Nucleotide', 'Prospective Studies', 'Receptor, Angiotensin, Type 1/*genetics', 'Renin-Angiotensin System/*drug effects/genetics', 'Tetrazoles/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29701105/
992,Candesartan,11825094,Clinical pharmacokinetics of candesartan.,"['Gleiter CH', 'Morike KE']","['*Angiotensin Receptor Antagonists', 'Antihypertensive Agents/administration & dosage/metabolism/*pharmacokinetics', 'Benzimidazoles/administration & dosage/metabolism/*pharmacokinetics', 'Biological Availability', 'Biphenyl Compounds/administration & dosage/metabolism/*pharmacokinetics', 'Blood Proteins/metabolism', 'Humans', 'Intestinal Absorption', 'Kidney Diseases/metabolism', 'Prodrugs/administration & dosage/metabolism/*pharmacokinetics', 'Receptor, Angiotensin, Type 1', 'Tetrazoles/metabolism/*pharmacokinetics', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/11825094/
993,Candesartan,15013936,Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials.,['Doggrell SA'],"['*Angiotensin II Type 1 Receptor Blockers', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/*therapeutic use', 'Biphenyl Compounds', 'Clinical Trials as Topic', 'Humans', 'Stroke/*drug therapy/mortality/*prevention & control', 'Tetrazoles/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15013936/
994,Candesartan,34550434,Impeding Virulence of Candida albicans by Candesartan and Domperidone.,"['Abbas HA', 'Gad AI', 'El-Sayed MA', 'El-Ganiny AM']","['Benzimidazoles', 'Biphenyl Compounds', '*Candida albicans', '*Domperidone/pharmacology', 'Humans', 'Tetrazoles/pharmacology', 'Virulence']",https://pubmed.ncbi.nlm.nih.gov/34550434/
995,Candesartan,34699047,"Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.","['Gandotra C', 'Clark J', 'Liu Q', 'Senatore FF', 'Rose M', 'Zhang J', 'Stockbridge NL']","['Aminobutyrates', 'Angiotensin Receptor Antagonists/therapeutic use', 'Benzimidazoles', 'Biphenyl Compounds', '*Heart Failure/drug therapy/epidemiology', 'Humans', '*Spironolactone/therapeutic use', 'Stroke Volume/physiology', 'Tetrazoles', 'United States', 'United States Food and Drug Administration', 'Valsartan/therapeutic use', 'Ventricular Function, Left/physiology']",https://pubmed.ncbi.nlm.nih.gov/34699047/
996,Candesartan,36629645,Effect of candesartan treatment on echocardiographic indices of cardiac remodeling in post-myocardial infarction patients.,"['Tezcan H', 'Tuncez A', 'Demir K', 'Altunkeser BB', 'Aygul N', 'Yalcin MU', 'Ates MS', 'Aydogan C', 'Polat OC', 'Toprak AM']","['Humans', 'Prospective Studies', '*Ventricular Remodeling', '*Myocardial Infarction/drug therapy', 'Echocardiography']",https://pubmed.ncbi.nlm.nih.gov/36629645/
997,Benazepril,19052124,Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.,"['Jamerson K', 'Weber MA', 'Bakris GL', 'Dahlof B', 'Pitt B', 'Shi V', 'Hester A', 'Gupte J', 'Gatlin M', 'Velazquez EJ']","['Aged', 'Amlodipine/adverse effects/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Antihypertensive Agents/adverse effects/therapeutic use', 'Benzazepines/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Calcium Channel Blockers/*therapeutic use', 'Cardiovascular Diseases/epidemiology/mortality/*prevention & control', 'Diuretics/*therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hydrochlorothiazide/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/19052124/
998,Benazepril,17395288,Benazepril induced isolated visceral angioedema: a rare and under diagnosed adverse effect of angiotensin converting enzyme inhibitors.,"['Khan MU', 'Baig MA', 'Javed RA', 'Ali S', 'Qamar UR', 'Vasavada BC', 'Khan IA']","['Adult', 'Angioedema/*chemically induced/*diagnosis', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects', 'Benzazepines/*adverse effects', 'Diagnosis, Differential', 'Female', 'Humans', 'Hypertension/complications/drug therapy', 'Intestinal Diseases/diagnosis', 'Viscera']",https://pubmed.ncbi.nlm.nih.gov/17395288/
999,Benazepril,17971736,Formal synthesis of the ACE inhibitor benazepril x HCl via an asymmetric aza-Michael reaction.,"['Yu LT', 'Huang JL', 'Chang CY', 'Yang TK']","['Angiotensin-Converting Enzyme Inhibitors/*chemical synthesis/chemistry', 'Benzazepines/*chemical synthesis/chemistry', '*Models, Chemical', 'Solvents/chemistry']",https://pubmed.ncbi.nlm.nih.gov/17971736/
1000,Benazepril,39056339,Acute Declines in Estimated Glomerular Filtration Rate in Patients Treated With Benazepril and Hydrochlorothiazide Versus Amlodipine and Risk of Cardiovascular Outcomes.,"['Ku E', 'Jamerson K', 'Copeland TP', 'McCulloch CE', 'Tighiouart H', 'Sarnak MJ']","['Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Amlodipine/therapeutic use/adverse effects', '*Angiotensin-Converting Enzyme Inhibitors/therapeutic use/adverse effects', '*Antihypertensive Agents/therapeutic use/adverse effects', '*Benzazepines/therapeutic use/adverse effects', 'Calcium Channel Blockers/therapeutic use/adverse effects', 'Cardiovascular Diseases/prevention & control/epidemiology', '*Drug Therapy, Combination', '*Glomerular Filtration Rate/drug effects', '*Hydrochlorothiazide/therapeutic use/adverse effects', '*Hypertension/drug therapy/physiopathology/diagnosis', 'Kidney/physiopathology/drug effects', 'Risk Assessment', 'Risk Factors', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39056339/
1001,Benazepril,1893639,Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide.,['DeQuattro V'],"['Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Benzazepines/administration & dosage/*therapeutic use', 'Drug Combinations', 'Humans', 'Hydrochlorothiazide/administration & dosage/*therapeutic use', 'Hypertension/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1893639/
1002,Benazepril,34260595,"Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.","['Ruggenenti P', 'Cortinovis M', 'Parvanova A', 'Trillini M', 'Iliev IP', 'Bossi AC', 'Belviso A', 'Aparicio MC', 'Trevisan R', 'Rota S', 'Perna A', 'Peracchi T', 'Rubis N', 'Martinetti D', 'Prandini S', 'Gaspari F', 'Carrara F', 'De Cosmo S', 'Tonolo G', 'Mangili R', 'Remuzzi G']","['Aged', 'Albuminuria/*etiology/*prevention & control', 'Angiotensin II Type 1 Receptor Blockers/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Benzazepines/*therapeutic use', 'Diabetes Mellitus, Type 2/*complications', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Valsartan/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34260595/
1003,Benazepril,1619382,A 3-month double-blind cross-over study of the effect of benazepril and hydrochlorothiazide on functional class in symptomatic mild heart failure.,"['Nordrehaug JE', 'Omsjo IH', 'Vollset SE']","['Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Benzazepines/*therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Female', 'Heart Failure/*drug therapy', 'Humans', 'Hydrochlorothiazide/*therapeutic use', 'Male', 'Middle Aged', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1619382/
1004,folinic acid,26615328,"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.","['Wang-Gillam A', 'Li CP', 'Bodoky G', 'Dean A', 'Shan YS', 'Jameson G', 'Macarulla T', 'Lee KH', 'Cunningham D', 'Blanc JF', 'Hubner RA', 'Chiu CF', 'Schwartsmann G', 'Siveke JT', 'Braiteh F', 'Moyo V', 'Belanger B', 'Dhindsa N', 'Bayever E', 'Von Hoff DD', 'Chen LT']","['Aged', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Camptothecin/administration & dosage/adverse effects/analogs & derivatives', 'Carcinoma, Pancreatic Ductal/*drug therapy/mortality', 'Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives', 'Diarrhea/chemically induced', 'Fatigue/chemically induced', 'Female', 'Fluorouracil/administration & dosage/adverse effects', 'Humans', 'Irinotecan', 'Kaplan-Meier Estimate', 'Leucovorin/administration & dosage/adverse effects', 'Liposomes', 'Male', 'Middle Aged', 'Neoplasm Metastasis', 'Neutropenia/chemically induced', 'Pancreatic Neoplasms/*drug therapy/mortality', 'Treatment Outcome', 'Vomiting/chemically induced', 'Gemcitabine']",https://pubmed.ncbi.nlm.nih.gov/26615328/
1005,folinic acid,35204698,"Folic Acid, Folinic Acid, 5 Methyl TetraHydroFolate Supplementation for Mutations That Affect Epigenesis through the Folate and One-Carbon Cycles.","['Menezo Y', 'Elder K', 'Clement A', 'Clement P']","['Carbon Cycle', 'Dietary Supplements', 'Female', '*Folic Acid/metabolism', 'Humans', 'Infant', 'Leucovorin', 'Mutation', 'Pregnancy', '*Tetrahydrofolates/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35204698/
1006,folinic acid,23728635,Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.,"['Shea B', 'Swinden MV', 'Tanjong Ghogomu E', 'Ortiz Z', 'Katchamart W', 'Rader T', 'Bombardier C', 'Wells GA', 'Tugwell P']","['Abdominal Pain/chemically induced/prevention & control', 'Adult', 'Antirheumatic Agents/*adverse effects/therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Folic Acid/administration & dosage/*therapeutic use', 'Folic Acid Antagonists/*adverse effects/therapeutic use', 'Gastrointestinal Diseases/chemically induced/prevention & control', 'Hematologic Diseases/chemically induced/prevention & control', 'Humans', 'Leucovorin/administration & dosage/*therapeutic use', 'Methotrexate/*adverse effects/therapeutic use', 'Nausea/chemically induced/prevention & control', 'Vomiting/chemically induced/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/23728635/
1007,folinic acid,35276810,"Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial.","['Bumrungpert A', 'Pavadhgul P', 'Piromsawasdi T', 'Mozafari MR']","['*Anemia, Iron-Deficiency/blood/drug therapy', 'Biomarkers/blood', 'Female', '*Ferrous Compounds/therapeutic use', 'Glycine/therapeutic use', 'Humans', '*Iron Deficiencies/blood/drug therapy', 'Leucovorin/therapeutic use', 'Pregnancy', '*Pregnancy Complications/blood/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35276810/
1008,folinic acid,27752075,Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial.,"['Frye RE', 'Slattery J', 'Delhey L', 'Furgerson B', 'Strickland T', 'Tippett M', 'Sailey A', 'Wynne R', 'Rose S', 'Melnyk S', 'Jill James S', 'Sequeira JM', 'Quadros EV']","['Autism Spectrum Disorder/drug therapy', 'Autistic Disorder/drug therapy', 'Child', 'Child Development Disorders, Pervasive/drug therapy', 'Child, Preschool', 'Double-Blind Method', 'Female', 'Folate Receptor 1/metabolism', 'Humans', 'Language Development Disorders/drug therapy', 'Language Disorders/drug therapy', 'Leucovorin/metabolism/*pharmacology', 'Male', 'Placebo Effect', 'Receptors, Peptide/metabolism', 'Treatment Outcome', 'Verbal Behavior/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/27752075/
1009,folinic acid,39703043,Folinic acid as a treatment for autism in children: A within-subjects open-label study on safety and efficacy.,"['Wong CM', 'Tan CS', 'Koh HC', 'Gan X', 'Hie SL', 'Saffari SE', 'Yeo JG', 'Lam JCM']","['Humans', 'Male', 'Female', 'Child', '*Leucovorin/therapeutic use/adverse effects', '*Autistic Disorder/drug therapy', 'Child, Preschool', 'Pilot Projects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39703043/
1010,folinic acid,38056998,The effects of folinic acid and l-methylfolate supplementation on serum total homocysteine levels in healthy adults.,"['Mazokopakis EE', 'Papadomanolaki MG', 'Papadakis JA']","['Adult', 'Male', 'Humans', 'Female', 'Middle Aged', 'Leucovorin', '*Folic Acid/pharmacology', '*Methylenetetrahydrofolate Reductase (NADPH2)/genetics', 'Dietary Supplements', 'Homocysteine']",https://pubmed.ncbi.nlm.nih.gov/38056998/
1011,folinic acid,35929573,Leucovorin (folinic acid) rescue for high-dose methotrexate: A review.,"['Jiang R', 'Mei S', 'Zhao Z']","['*Drug-Related Side Effects and Adverse Reactions/drug therapy', 'Humans', 'Leucovorin/therapeutic use', 'Methotrexate', '*Neoplasms/drug therapy', 'Renal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/35929573/
1012,folinic acid,33029705,Folinic Acid as Adjunctive Therapy in Treatment of Inappropriate Speech in Children with Autism: A Double-Blind and Placebo-Controlled Randomized Trial.,"['Batebi N', 'Moghaddam HS', 'Hasanzadeh A', 'Fakour Y', 'Mohammadi MR', 'Akhondzadeh S']","['*Antipsychotic Agents/therapeutic use', '*Autism Spectrum Disorder/drug therapy', '*Autistic Disorder/drug therapy', 'Child', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Iran', 'Leucovorin/therapeutic use', 'Male', 'Speech', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33029705/
1013,folinic acid,1919655,Cyclophosphamide plus epidoxorubicin and 5-fluorouracil with folinic acid as a novel treatment in metastatic breast cancer: preliminary results of a phase II study.,"['Palmeri S', 'Gebbia V', 'Russo A', 'Gebbia N', 'Meli M', 'Rausa L']","['Adult', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Breast Neoplasms/*drug therapy', 'Cyclophosphamide/administration & dosage/adverse effects', 'Drug Evaluation', 'Epirubicin/administration & dosage', 'Female', 'Fluorouracil/administration & dosage/adverse effects', 'Humans', 'Infusions, Intravenous', 'Leucovorin/administration & dosage/adverse effects', 'Middle Aged', 'Neoplasm Metastasis', 'Remission Induction']",https://pubmed.ncbi.nlm.nih.gov/1919655/
1014,folinic acid,24737913,Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.,"['Shea B', 'Swinden MV', 'Ghogomu ET', 'Ortiz Z', 'Katchamart W', 'Rader T', 'Bombardier C', 'Wells GA', 'Tugwell P']","['Adult', 'Antirheumatic Agents/*adverse effects/therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Female', 'Folic Acid/adverse effects/*therapeutic use', 'Humans', 'Leucovorin/adverse effects/*therapeutic use', 'Male', 'Methotrexate/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24737913/
1015,folinic acid,38996519,Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial.,"['Ballhausen A', 'Karthaus M', 'Fruehauf S', 'Graeven U', 'Muller L', 'Konig AO', 'von Weikersthal LF', 'Sommerhauser G', 'Jelas I', 'Alig AHS', 'Kurreck A', 'Stahler A', 'Goekkurt E', 'Held S', 'Kasper S', 'Heinrich K', 'Heinemann V', 'Stintzing S', 'Trarbach T', 'Modest DP']","['Humans', '*Quality of Life', '*Fluorouracil/therapeutic use/pharmacology', '*Colorectal Neoplasms/drug therapy/pathology', 'Male', 'Female', '*Leucovorin/therapeutic use/pharmacology/adverse effects', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/pharmacology', '*Panitumumab/therapeutic use/pharmacology', 'Middle Aged', 'Aged', 'Adult', 'Organoplatinum Compounds/therapeutic use/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/38996519/
1016,folinic acid,39243316,"Efficacy of oral folinic acid supplementation in children with autism spectrum disorder: a randomized double-blind, placebo-controlled trial.","['Panda PK', 'Sharawat IK', 'Saha S', 'Gupta D', 'Palayullakandi A', 'Meena K']","['Humans', '*Autism Spectrum Disorder/drug therapy', 'Double-Blind Method', 'Male', 'Female', '*Leucovorin/administration & dosage/therapeutic use', 'Child', 'Child, Preschool', 'Administration, Oral', 'Treatment Outcome', 'Dietary Supplements', 'Vitamin B Complex/administration & dosage/therapeutic use', 'Folic Acid/administration & dosage/therapeutic use', 'Autoantibodies/blood']",https://pubmed.ncbi.nlm.nih.gov/39243316/
1017,folinic acid,10796393,Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.,"['Ortiz Z', 'Shea B', 'Suarez Almazor M', 'Moher D', 'Wells G', 'Tugwell P']","['Antirheumatic Agents/*adverse effects/therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Folic Acid/*therapeutic use', 'Folic Acid Antagonists/*adverse effects/therapeutic use', 'Gastrointestinal Diseases/chemically induced/prevention & control', 'Hematologic Diseases/chemically induced/prevention & control', 'Humans', 'Leucovorin/*therapeutic use', 'Methotrexate/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10796393/
1018,folinic acid,35641554,Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma.,"['Machover D', 'Goldschmidt E', 'Almohamad W', 'Castagne V', 'Dairou J', 'Desterke C', 'Gomez L', 'Gaston-Mathe Y', 'Boucheix C']","['Antineoplastic Combined Chemotherapy Protocols', '*Breast Neoplasms/pathology', 'Doxorubicin', 'Female', '*Fluorouracil/therapeutic use', 'Humans', '*Leucovorin/therapeutic use', 'Pilot Projects', '*Pyridoxine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35641554/
1019,folinic acid,2788577,"Cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC) as first-line chemotherapy for advanced breast cancer: preliminary results.","['Zaniboni A', 'Simoncini E', 'Marpicati P', 'Montini E', 'Ferrari V', 'Ferragni A', 'Boari L', 'Marini G']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy', 'Cyclophosphamide/administration & dosage', 'Epirubicin/administration & dosage', 'Fluorouracil/administration & dosage', 'Humans', 'Leucovorin/administration & dosage', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2788577/
1020,Gabapentin,34819636,"Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale.","['Hong JSW', 'Atkinson LZ', 'Al-Juffali N', 'Awad A', 'Geddes JR', 'Tunbridge EM', 'Harrison PJ', 'Cipriani A']","['Amines/therapeutic use', 'Anxiety/drug therapy', '*Bipolar Disorder/drug therapy', 'Calcium Channels', '*Cyclohexanecarboxylic Acids/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', 'Pregabalin/therapeutic use', 'Randomized Controlled Trials as Topic', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'gamma-Aminobutyric Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34819636/
1021,Gabapentin,29023146,Is there a role for combined use of gabapentin and pregabalin in pain control? Too good to be true?,"['Senderovich H', 'Jeyapragasan G']","['Analgesics/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Gabapentin/*administration & dosage', 'Humans', 'Neuralgia/*drug therapy', 'Pregabalin/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29023146/
1022,Gabapentin,39163072,Gabapentin-induced Multifocal Myoclonus.,"['Priya L', 'Alamanda VA', 'Javali M', 'Acharya P', 'Rangaiah P', 'Nagabushana D']","['Humans', '*Gabapentin/adverse effects', 'Male', '*Myoclonus/chemically induced', '*Analgesics/adverse effects', 'Neuralgia/drug therapy', 'Aged', 'gamma-Aminobutyric Acid/adverse effects', 'Amines/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39163072/
1023,Gabapentin,36409473,"Trends in the Concurrent Prescription of Opioids and Gabapentin in the US, 2006 to 2018.","['Peet ED', 'Dana B', 'Sheng FY', 'Powell D', 'Shetty K', 'Stein BD']","['Humans', '*Analgesics, Opioid/therapeutic use', 'Gabapentin/therapeutic use', '*Opioid Epidemic', 'Prescriptions']",https://pubmed.ncbi.nlm.nih.gov/36409473/
1024,Gabapentin,11353278,Gabapentin and gabapentin monohydrate.,['Ibers JA'],"['Acetates/*chemistry', '*Amines', 'Anticonvulsants/*chemistry', 'Crystallography, X-Ray', '*Cyclohexanecarboxylic Acids', 'Gabapentin', 'Hydrogen Bonding', 'Molecular Structure', 'Water/chemistry', '*gamma-Aminobutyric Acid']",https://pubmed.ncbi.nlm.nih.gov/11353278/
1025,Gabapentin,39173895,Efficacy and Safety of Pregabalin and Gabapentin for Pruritus: A Systematic Review and Meta-Analysis.,"['Xu W', 'Dong H', 'Ran H', 'Liu H', 'Wang L', 'Li H', 'Tan C']","['Humans', 'Anticonvulsants/therapeutic use/adverse effects', '*Gabapentin/administration & dosage/adverse effects', '*Pregabalin/administration & dosage/adverse effects', '*Pruritus/diagnosis/drug therapy', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39173895/
1026,Gabapentin,27206565,Gabapentin for the hemodynamic response to intubation: systematic review and meta-analysis.,"['Doleman B', 'Sherwin M', 'Lund JN', 'Williams JP']","['Airway Management/*methods', 'Amines/*therapeutic use', 'Cyclohexanecarboxylic Acids/*therapeutic use', 'GABA Agents/*therapeutic use', 'Gabapentin', 'Hemodynamics/*drug effects', 'Humans', 'Intubation, Intratracheal/*adverse effects', 'Randomized Controlled Trials as Topic', 'gamma-Aminobutyric Acid/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27206565/
1027,Gabapentin,35583872,Association of Gabapentin Use With Pain Control and Feeding Tube Placement Among Patients With Head and Neck Cancer Receiving Chemoradiotherapy.,"['Ma SJ', 'Wang K', 'Iovoli AJ', 'Attwood K', 'Hermann G', 'Farrugia M', 'Singh AK']","['Chemoradiotherapy/adverse effects', 'Gabapentin/therapeutic use', '*Head and Neck Neoplasms/therapy', 'Humans', '*Intubation, Gastrointestinal', 'Pain/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/35583872/
1028,Gabapentin,36930339,Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis.,"['Smith LE', 'Murphy BA', 'Smith DK']","['Humans', 'Gabapentin/therapeutic use', 'Analgesics', 'gamma-Aminobutyric Acid/therapeutic use', 'Amines/therapeutic use', '*Cyclohexanecarboxylic Acids/therapeutic use', '*Head and Neck Neoplasms/drug therapy', 'Analgesics, Opioid/therapeutic use', 'Pain/drug therapy', 'Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/36930339/
1029,Gabapentin,35427982,An algorithm to identify gabapentin misuse and/or abuse in administrative claims data.,"['Zhao D', 'Nunes AP', 'Baek J', 'Lapane KL']","['Algorithms', 'Analgesics, Opioid/therapeutic use', 'Gabapentin/adverse effects', 'Humans', 'Male', 'Odds Ratio', '*Prescription Drug Misuse', '*Substance-Related Disorders/diagnosis/drug therapy/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/35427982/
1030,Gabapentin,36402053,Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.,"['Mattle AG', 'McGrath P', 'Sanu A', 'Kunadharaju R', 'Kersten B', 'Zammit K', 'Mammen MJ']","['Humans', '*Substance Withdrawal Syndrome/drug therapy', '*Alcoholism/drug therapy', 'Gabapentin/therapeutic use', 'Retrospective Studies', 'Benzodiazepines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36402053/
1031,Gabapentin,37548889,Concurrent Gabapentin and Opioid Use and Risk of Mortality in Medicare Recipients with Non-Cancer Pain.,"['Corriere MA', 'Daniel LL', 'Dickson AL', 'Nepal P', 'Hall K', 'Plummer WD', 'Dupont WD', 'Murray KT', 'Stein CM', 'Ray WA', 'Chung CP']","['Humans', '*Gabapentin/therapeutic use/adverse effects', '*Medicare', 'Aged', 'Male', '*Analgesics, Opioid/adverse effects/therapeutic use/administration & dosage', 'Female', 'United States/epidemiology', 'Aged, 80 and over', 'Retrospective Studies', '*Duloxetine Hydrochloride/therapeutic use/adverse effects', '*Chronic Pain/drug therapy/mortality', 'Analgesics/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/37548889/
1032,Gabapentin,34951456,State-level response to gabapentin misuse in the United States: Implications and future direction.,"['Karavolis ZA', 'Su AB', 'Peckham AM']","['Gabapentin/therapeutic use', 'Humans', '*Prescription Drug Misuse/prevention & control', '*Public Policy', 'United States']",https://pubmed.ncbi.nlm.nih.gov/34951456/
1033,Gabapentin,34799138,Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup.,"['Bouchard J', 'Yates C', 'Calello DP', 'Gosselin S', 'Roberts DM', 'Lavergne V', 'Hoffman RS', 'Ostermann M', 'Peng A', 'Ghannoum M']","['*Drug Overdose', '*Frailty', 'Gabapentin', 'Humans', '*Poisoning', 'Pregabalin', 'Renal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/34799138/
1034,Gabapentin,36069804,Gabapentin Use During Pregnancy and Lactation With and Without Concurrent Opioid Exposure: Considerations and Future Directions.,"['DeLisle A', 'Jones HE', 'Jansson LM']","['Female', 'Pregnancy', 'Infant, Newborn', 'Humans', 'Gabapentin/adverse effects', 'Analgesics, Opioid/adverse effects', 'Prospective Studies', 'gamma-Aminobutyric Acid/adverse effects', '*Cyclohexanecarboxylic Acids/adverse effects', 'Amines/adverse effects', '*Opioid-Related Disorders/drug therapy', 'Lactation']",https://pubmed.ncbi.nlm.nih.gov/36069804/
1035,Gabapentin,37556139,Different Gabapentin and Pregabalin Dosages for Perioperative Pain Control in Patients Undergoing Spine Surgery: A Systematic Review and Network Meta-Analysis.,"['Tsai SHL', 'Hu CW', 'El Sammak S', 'Durrani S', 'Ghaith AK', 'Lin CCJ', 'Krzyz EZ', 'Bydon M', 'Fu TS', 'Lin TY']","['Humans', 'Female', 'Middle Aged', 'Gabapentin/therapeutic use', 'Pregabalin/therapeutic use', '*Analgesics/therapeutic use', '*Analgesics, Opioid/therapeutic use', 'Network Meta-Analysis', 'Pain, Postoperative/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37556139/
1036,Ketamine,37488280,Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms.,"['Krystal JH', 'Kavalali ET', 'Monteggia LM']","['Humans', '*Ketamine/pharmacology/therapeutic use', 'Receptors, N-Methyl-D-Aspartate', 'Antidepressive Agents/pharmacology/therapeutic use', 'Synapses', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Depression/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37488280/
1037,Ketamine,37729028,Ketamine: Mechanisms and Relevance to Treatment of Depression.,"['Kim JW', 'Suzuki K', 'Kavalali ET', 'Monteggia LM']","['Humans', '*Ketamine/therapeutic use', 'Depression/drug therapy', '*Depressive Disorder, Major/drug therapy', 'Antidepressive Agents/therapeutic use', 'Amines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37729028/
1038,Ketamine,33022440,Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.,"['Bahji A', 'Vazquez GH', 'Zarate CA Jr']","['Antidepressive Agents/therapeutic use', 'Depression', '*Depressive Disorder, Major/drug therapy', 'Humans', '*Ketamine/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33022440/
1039,Ketamine,35092901,Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence.,"['Subramanian S', 'Haroutounian S', 'Palanca BJA', 'Lenze EJ']","['Antidepressive Agents/therapeutic use', '*Chronic Pain/drug therapy', 'Depression/drug therapy', 'Humans', '*Ketamine/therapeutic use', 'Receptors, N-Methyl-D-Aspartate']",https://pubmed.ncbi.nlm.nih.gov/35092901/
1040,Ketamine,35231204,Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.,"['Bahji A', 'Zarate CA', 'Vazquez GH']","['Antidepressive Agents/adverse effects', 'Depression/drug therapy', '*Depressive Disorder, Major/drug therapy', 'Female', 'Humans', '*Ketamine/adverse effects', 'Male']",https://pubmed.ncbi.nlm.nih.gov/35231204/
1041,Ketamine,33569971,Ketamine for depression.,"['Jelen LA', 'Stone JM']","['Antidepressive Agents/*therapeutic use', 'Depression/drug therapy', 'Depressive Disorder, Treatment-Resistant/*drug therapy', 'Humans', 'Ketamine/*therapeutic use', 'Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/33569971/
1042,Ketamine,38537759,Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.,"['Seshadri A', 'Prokop LJ', 'Singh B']","['*Ketamine/administration & dosage/adverse effects', 'Humans', '*Administration, Intranasal', '*Depressive Disorder, Major/drug therapy', '*Antidepressive Agents/administration & dosage/therapeutic use/adverse effects', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Administration, Intravenous', 'Treatment Outcome', 'Dose-Response Relationship, Drug', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/38537759/
1043,Ketamine,37949235,"Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.","['Terao I', 'Tsuge T', 'Endo K', 'Kodama W']","['Adult', 'Humans', '*Ketamine/adverse effects', 'Aripiprazole/adverse effects', 'Antidepressive Agents/adverse effects', 'Lithium/therapeutic use', 'Network Meta-Analysis', '*Depressive Disorder/drug therapy', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Depression/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37949235/
1044,Ketamine,37149345,Pharmacotherapy: Ketamine and Esketamine.,"['Feeney A', 'Papakostas GI']","['Humans', '*Ketamine/adverse effects', 'Antidepressive Agents/adverse effects', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Administration, Intranasal']",https://pubmed.ncbi.nlm.nih.gov/37149345/
1045,Ketamine,35416105,Long-term safety of ketamine and esketamine in treatment of depression.,"['Nikayin S', 'Murphy E', 'Krystal JH', 'Wilkinson ST']","['Antidepressive Agents/adverse effects', 'Depression/drug therapy', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Humans', '*Ketamine/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35416105/
1046,Ketamine,34699848,"Patterns of use, clinical efficacy, safety and tolerability of Ketamine and Esketamine in treatment-resistant depression: Towards registry-based surveillance systems.","['Lopez-Diaz A', 'Rendon de Lope L', 'de la Vega Sanchez D']","['Antidepressive Agents/adverse effects', 'Depression', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Humans', '*Ketamine/adverse effects', 'Registries', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34699848/
1047,Ketamine,33370729,Therapeutic Mechanisms of Ketamine.,"['Mihaljevic S', 'Pavlovic M', 'Reiner K', 'Cacic M']","['Antidepressive Agents/*pharmacology/*therapeutic use', 'Depressive Disorder, Major/*drug therapy/genetics/metabolism', 'Drug Interactions', 'Epigenesis, Genetic/drug effects', 'Glutamic Acid/metabolism', 'Humans', 'Ketamine/adverse effects/chemistry/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33370729/
1048,Ketamine,31213212,Toward specific ways to combine ketamine and psychotherapy in treating depression.,['Hasler G'],"['Antidepressive Agents/pharmacology/*therapeutic use', 'Brain/drug effects/metabolism/physiology', 'Depressive Disorder, Major/*drug therapy/therapy', 'Humans', 'Ketamine/pharmacology/*therapeutic use', 'Neuronal Plasticity', 'Psychotherapy/*methods']",https://pubmed.ncbi.nlm.nih.gov/31213212/
1049,Ketamine,38573154,Acute Dissociation and Ketamine's Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial.,"['Sajid S', 'Galfalvy HC', 'Keilp JG', 'Burke AK', 'Mann JJ', 'Grunebaum MF']","['Humans', '*Ketamine/administration & dosage/blood/pharmacology/*analogs & derivatives', '*Suicidal Ideation', 'Male', 'Adult', '*Midazolam/administration & dosage/pharmacology/blood', 'Female', '*Antidepressive Agents/blood/administration & dosage/pharmacology', '*Dissociative Disorders/chemically induced/blood', 'Middle Aged', 'Young Adult', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/38573154/
1050,Propofol,20816571,Propofol.,"['Lundstrom S', 'Twycross R', 'Mihalyo M', 'Wilcock A']","['Anesthetics, Intravenous/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Death', 'Delirium/drug therapy/psychology', 'Drug Interactions', 'Humans', 'Propofol/administration & dosage/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20816571/
1051,Propofol,30217361,Propofol: Milk of Amnesia.,['Walsh CT'],"['Anesthesia/history/methods', 'Awards and Prizes', 'History, 21st Century', 'Humans', 'Propofol/history/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30217361/
1052,Propofol,29992157,Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects.,['Dinis-Oliveira RJ'],"['Anesthesia', 'Anesthetics, Intravenous/adverse effects/*pharmacokinetics', 'Humans', 'Hypnotics and Sedatives', '*Metabolome', 'Propofol/adverse effects/*analogs & derivatives/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/29992157/
1053,Propofol,35390580,The superiority of ketofol and etomidate against propofol or thiopental anesthesia for ECT.,"['Gurel SC', 'Ozden HC', 'Karahan S', 'Ayhan Y']","['*Anesthesia', '*Electroconvulsive Therapy/adverse effects', '*Etomidate/adverse effects', 'Humans', '*Propofol/pharmacology/therapeutic use', 'Retrospective Studies', 'Seizures/chemically induced', 'Thiopental/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35390580/
1054,Propofol,38105166,"Changes in information integration and brain networks during propofol-, dexmedetomidine-, and ketamine-induced unresponsiveness.","['Liang Z', 'Chang Y', 'Liu X', 'Cao S', 'Chen Y', 'Wang T', 'Xu J', 'Li D', 'Zhang J']","['Humans', '*Propofol/pharmacology', '*Ketamine/pharmacology', '*Dexmedetomidine/pharmacology', 'Electroencephalography', 'Brain']",https://pubmed.ncbi.nlm.nih.gov/38105166/
1055,Propofol,29661412,Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation.,"['Eleveld DJ', 'Colin P', 'Absalom AR', 'Struys MMRF']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anesthesia/*methods', 'Anesthetics, Intravenous/administration & dosage/pharmacokinetics/*pharmacology', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Infusions, Intravenous', 'Male', 'Middle Aged', '*Models, Biological', 'Propofol/administration & dosage/pharmacokinetics/*pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29661412/
1056,Propofol,36309382,"Effect of Propofol and Etomidate on the Proliferation, Cell-cycle Distribution, Apoptosis and Necrosis of Pancreatic Tumour Cells.","['Malsy M', 'Graf B', 'Hofer V', 'Bitzinger D', 'Bundscherer A']","['Humans', '*Etomidate/pharmacology/therapeutic use', '*Propofol/pharmacology/therapeutic use', 'Apoptosis', 'Necrosis', '*Pancreatic Neoplasms/pathology', 'Cell Cycle', 'Cell Proliferation']",https://pubmed.ncbi.nlm.nih.gov/36309382/
1057,Propofol,27294779,Adaptive pharmacokinetic and pharmacodynamic modelling to predict propofol effect using BIS-guided anesthesia.,"['Martin-Mateos I', 'Mendez Perez JA', 'Reboso Morales JA', 'Gomez-Gonzalez JF']","['Adult', 'Anesthesia/*methods', 'Female', 'Humans', 'Male', '*Models, Biological', 'Propofol/*administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/27294779/
1058,Propofol,34885756,Continuous Flow Synthesis of Propofol.,"['Mougeot R', 'Jubault P', 'Legros J', 'Poisson T']","['Anesthesia, Intravenous', 'Humans', '*Hypnosis, Anesthetic', 'Propofol/*chemical synthesis/chemistry/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34885756/
1059,Propofol,1911015,Comparison of arterial and arterialized venous concentrations of propofol during infusion of propofol.,"['Okell RW', 'Mapleson WW', 'Vickers MD']","['Arteries/*physiology', 'Humans', 'Infusions, Intravenous', 'Propofol/administration & dosage/*blood/pharmacokinetics', 'Veins/*physiology']",https://pubmed.ncbi.nlm.nih.gov/1911015/
1060,Propofol,26290263,Propofol: a review of its role in pediatric anesthesia and sedation.,"['Chidambaran V', 'Costandi A', ""D'Mello A""]","['Anesthetics, Intravenous/*administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Child', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Propofol/*administration & dosage/adverse effects/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/26290263/
1061,Propofol,27832555,Driving impairment due to propofol at effect-site concentrations relevant after short propofol-only sedation.,"['Telles JL', 'Agarwal S', 'Monagle J', 'Stough C', 'King R', 'Downey L']","['Adult', '*Automobile Driving', 'Ethanol/blood', 'Female', 'Humans', 'Hypnotics and Sedatives/*adverse effects/blood', 'Male', 'Propofol/*adverse effects/blood']",https://pubmed.ncbi.nlm.nih.gov/27832555/
1062,Propofol,37213151,Examination of ADRB2 gene expression and influence of Dexmedetomidine and Propofol on Hemodynamics after Abdominal Surgery.,"['Lin Z', 'Bu H', 'Huang X']","['Humans', '*Propofol/pharmacology/therapeutic use', '*Dexmedetomidine/pharmacology/therapeutic use', 'Hemodynamics', 'Heart Rate', 'Gene Expression', 'Receptors, Adrenergic, beta-2/genetics']",https://pubmed.ncbi.nlm.nih.gov/37213151/
1063,Propofol,28259866,Verification of propofol sulfate as a further human propofol metabolite using LC-ESI-QQQ-MS and LC-ESI-QTOF-MS analysis.,"['Maas A', 'Maier C', 'Michel-Lauter B', 'Broecker S', 'Madea B', 'Hess C']","['Chromatography, High Pressure Liquid', 'Humans', 'Molecular Structure', 'Propofol/*analogs & derivatives/*metabolism/urine', 'Spectrometry, Mass, Electrospray Ionization']",https://pubmed.ncbi.nlm.nih.gov/28259866/
1064,Propofol,38049909,Remimazolam besylate versus propofol for deep sedation in critically ill patients: a randomized pilot study.,"['Tang Y', 'Gao X', 'Xu J', 'Ren L', 'Qi H', 'Li R', 'Shu H', 'Zou X', 'Yuan S', 'Yang X', 'Shang Y']","['Humans', 'Critical Illness/therapy', '*Deep Sedation', 'Hypnotics and Sedatives/pharmacology/therapeutic use', 'Pilot Projects', '*Propofol/pharmacology/therapeutic use', 'Prospective Studies', 'Respiration, Artificial']",https://pubmed.ncbi.nlm.nih.gov/38049909/
1065,Propofol,39805976,Comparative effective dose of ciprofol and propofol in suppressing cardiovascular responses to tracheal intubation.,"['Liao M', 'Wu XR', 'Hu JN', 'Lin XZ', 'Zhao TY', 'Sun H']","['Humans', '*Propofol/administration & dosage/adverse effects/pharmacology', '*Intubation, Intratracheal/adverse effects/methods', 'Male', 'Female', 'Middle Aged', 'Adult', 'Dose-Response Relationship, Drug', 'Heart Rate/drug effects', 'Blood Pressure/drug effects', 'Aged', 'Pilot Projects', 'Cardiovascular System/drug effects', 'Cyclopropanes']",https://pubmed.ncbi.nlm.nih.gov/39805976/
1066,Efavirenz,32667979,Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.,"['Haas DW', 'Acosta EP']","['Alkynes', '*Anti-HIV Agents/therapeutic use', 'Benzoxazines/therapeutic use', 'Cyclopropanes/therapeutic use', 'Cytochrome P-450 CYP2B6/genetics', '*HIV Infections/drug therapy', 'Heterocyclic Compounds, 3-Ring', 'Humans', 'Oxazines', 'Pharmacogenetics', 'Piperazines', 'Pyridones']",https://pubmed.ncbi.nlm.nih.gov/32667979/
1067,Efavirenz,22715849,Efavirenz-induced exfoliative dermatitis.,"['Zhang JC', 'Sun YT']","['Adult', 'Alkynes', 'Anti-HIV Agents/*adverse effects/*therapeutic use', 'Benzoxazines/*adverse effects/*therapeutic use', 'Cyclopropanes', 'Dermatitis, Exfoliative/*chemically induced/pathology', 'HIV Infections/*drug therapy', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/22715849/
1068,Efavirenz,17516877,Efavirenz.,['Maggiolo F'],"['Alkynes', 'Anti-HIV Agents/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Antiretroviral Therapy, Highly Active', 'Benzoxazines/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Cyclopropanes', 'Drug Interactions', '*Drug Resistance, Viral', 'Drug Therapy, Combination', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/therapeutic use', 'Humans', 'Immunocompromised Host', 'Mutation', 'Patient Compliance']",https://pubmed.ncbi.nlm.nih.gov/17516877/
1069,Efavirenz,28230617,Acute Kidney Injury After Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (Atripla) Overdose.,"['Havenith T', 'Burger D', 'Visschers MJ', 'Schippers J', 'Oude Lashof A']","['Acute Kidney Injury/*chemically induced', 'Alkynes', 'Anti-HIV Agents/adverse effects/therapeutic use', 'Benzoxazines/*adverse effects/therapeutic use', 'Cyclopropanes', 'Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/*adverse effects/therapeutic use', 'Emtricitabine/*adverse effects/therapeutic use', 'HIV Infections/drug therapy', 'HIV-1/drug effects', 'Humans', 'Male', 'Middle Aged', 'Tenofovir/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28230617/
1070,Efavirenz,36671473,"Efavirenz: History, Development and Future.","['Costa B', 'Vale N']","['Humans', '*Anti-HIV Agents/pharmacology/therapeutic use', 'Reverse Transcriptase Inhibitors/therapeutic use/adverse effects', 'Benzoxazines/adverse effects', '*HIV Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36671473/
1071,Efavirenz,23640958,Efavirenz intoxication due to a new CYP2B6 constellation.,"['Anagnostopoulos A', 'Rotger M', 'Aouri M', 'Kuster SP', 'Telenti A', 'Decosterd LA', 'Gunthard HF']","['Adult', 'Alkynes', 'Alleles', 'Anti-HIV Agents/*pharmacokinetics/therapeutic use', 'Aryl Hydrocarbon Hydroxylases/genetics/*metabolism', 'Benzoxazines/*metabolism', 'Cyclopropanes', 'Cytochrome P-450 CYP2B6', 'Genotype', 'HIV Infections/drug therapy/enzymology/genetics', 'HIV-1', 'Humans', 'Male', 'Pharmacogenetics', 'Polymorphism, Single Nucleotide', 'Reverse Transcriptase Inhibitors/*pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23640958/
1072,Efavirenz,9878993,Efavirenz.,"['Adkins JC', 'Noble S']","['Administration, Oral', 'Alkynes', 'Antiviral Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Benzoxazines', 'Cyclopropanes', 'Drug Administration Schedule', 'Drug Interactions', 'Drug Therapy, Combination', 'HIV Infections/*drug therapy', '*HIV-1', 'Humans', 'Oxazines/adverse effects/pharmacokinetics/*therapeutic use', 'Reverse Transcriptase Inhibitors/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9878993/
1073,Efavirenz,29868159,HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.,"['Drury A', 'Gleadow-Ware S', 'Gilfillan S', 'Ahrens J']","['Adult', 'Alkynes', 'Anti-HIV Agents/*adverse effects/*therapeutic use', 'Benzoxazines/adverse effects/*therapeutic use', 'Cyclopropanes', 'Female', 'HIV Infections/*drug therapy/psychology', 'Humans', 'Male', 'Mental Disorders/*chemically induced/psychology']",https://pubmed.ncbi.nlm.nih.gov/29868159/
1074,Efavirenz,32061245,Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients.,"['Hasan M', 'Yunihastuti E', 'Teguh H K', 'Abdullah M']","['Alkynes', '*Anti-HIV Agents/adverse effects', 'Benzoxazines', 'CD4 Lymphocyte Count', '*Coinfection/complications/drug therapy', 'Cyclopropanes', '*Exanthema/chemically induced/drug therapy/epidemiology', 'Female', '*HIV Infections/complications/drug therapy', '*Hepatitis C/drug therapy', 'Humans', 'Incidence', 'Indonesia/epidemiology', 'Male', 'Nevirapine/adverse effects', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/32061245/
1075,Efavirenz,33155233,Efavirenz as a psychotropic drug.,"['Zareifopoulos N', 'Lagadinou M', 'Karela A', 'Pouliasi F', 'Economou I', 'Tsigkou A', 'Velissaris D']","['Alkynes/*therapeutic use', 'Benzoxazines/*therapeutic use', 'Cyclopropanes/*therapeutic use', 'Humans', 'Psychotic Disorders/*drug therapy', 'Psychotropic Drugs/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33155233/
1076,Efavirenz,32829410,Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.,"['Leonard MA', 'Cindi Z', 'Bradford Y', 'Bourgi K', 'Koethe J', 'Turner M', 'Norwood J', 'Woodward B', 'Erdem H', 'Basham R', 'Baker P', 'Rebeiro PF', 'Sterling TR', 'Hulgan T', 'Daar ES', 'Gulick R', 'Riddler SA', 'Sinxadi P', 'Ritchie MD', 'Haas DW']","['Alkynes', 'Benzoxazines/adverse effects', 'Cyclopropanes', '*HIV Infections/drug therapy', '*HIV Integrase Inhibitors/adverse effects', 'Humans', 'Pharmacogenetics', 'Weight Gain/genetics']",https://pubmed.ncbi.nlm.nih.gov/32829410/
1077,Efavirenz,21633320,Absence seizures associated with efavirenz initiation.,"['Strehlau R', 'Martens L', 'Coovadia A', 'Dandara C', 'Norman J', 'Maisel J', 'Kuhn L', 'Abrams EJ']","['Alkynes', 'Anti-HIV Agents/*adverse effects/blood', 'Aryl Hydrocarbon Hydroxylases/deficiency/*genetics', 'Benzoxazines/*adverse effects/blood', 'Child, Preschool', 'Cyclopropanes', 'Cytochrome P-450 CYP2B6', 'Epilepsy, Absence/blood/chemically induced/*genetics/physiopathology/virology', 'Female', 'Genetic Predisposition to Disease', 'Genotype', 'HIV/drug effects/*physiology', 'HIV Infections/blood/drug therapy/*genetics/physiopathology/virology', 'Homozygote', 'Humans', 'Oxidoreductases, N-Demethylating/deficiency/*genetics', 'Polymorphism, Genetic', 'South Africa', 'Viral Load/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21633320/
1078,Efavirenz,33722117,A Concise Analytical Profile of Efavirenz: Analytical Methodologies.,"['Ambhore JP', 'Chaudhari SR', 'Cheke RS', 'Kharkar PS']","['Alkynes', 'Benzoxazines', 'Cyclopropanes', '*HIV Infections/chemically induced/drug therapy', 'Humans', 'Pharmaceutical Preparations', 'RNA', 'RNA-Directed DNA Polymerase/therapeutic use', '*Reverse Transcriptase Inhibitors/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33722117/
1079,Efavirenz,11365572,Efavirenz and Fortovase.,['Baker R'],"['Alkynes', 'Benzoxazines', 'Cyclopropanes', '*Drug Interactions', 'Drug Therapy, Combination', 'Gels', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Oxazines/administration & dosage/adverse effects/*pharmacology', 'Reverse Transcriptase Inhibitors/administration & dosage/adverse effects/*pharmacology', 'Saquinavir/administration & dosage/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11365572/
1080,Efavirenz,27599655,Rethinking the risk-benefit ratio of efavirenz in HIV-infected children.,"['Van de Wijer L', 'Schellekens AFA', 'Burger DM', 'Homberg JR', 'de Mast Q', 'van der Ven AJAM']","['Africa', 'Alkynes', 'Benzoxazines/metabolism/*therapeutic use/toxicity', 'Central Nervous System Diseases/chemically induced', 'Child', 'Cognition/drug effects', 'Cyclopropanes', 'HIV Infections/blood/*drug therapy', 'HIV-1/*drug effects', 'Humans', 'Odds Ratio', 'Reverse Transcriptase Inhibitors/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27599655/
1081,Erlotinib,38244939,"Design, synthesis and bioactivity evaluation of the combination of evodiamine and erlotinib linked by indolequinone.","['Wei B', 'Ma J', 'Guo H', 'Wang Y', 'Guo D', 'Tang Y']","['Erlotinib Hydrochloride/pharmacology', '*Antineoplastic Agents/chemistry', 'Quinazolines/pharmacology', 'Apoptosis', '*Indolequinones/chemistry', 'Drug Screening Assays, Antitumor', 'Cell Line, Tumor', 'Cell Proliferation', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/38244939/
1082,Erlotinib,38604999,PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway.,"['Ma Y', 'Fang Z', 'Zhang H', 'Qi Y', 'Mao Y', 'Zheng J']","['Humans', '*Antineoplastic Agents/pharmacology', 'Cell Line, Tumor', '*ErbB Receptors/metabolism', 'Erlotinib Hydrochloride/pharmacology/therapeutic use', '*Membrane Proteins/therapeutic use', 'Protein Kinase Inhibitors/pharmacology/therapeutic use', '*Triple Negative Breast Neoplasms/drug therapy/genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/38604999/
1083,Erlotinib,37421702,Electrochemical and theoretical study on interaction between erlotinib and DNA.,"['Jovanovic M', 'Nikolic K', 'Carapic M', 'Aleksic MM']","['Erlotinib Hydrochloride', 'Hydrogen-Ion Concentration', 'Molecular Docking Simulation', '*Carbon/chemistry', '*DNA/chemistry', 'Electrodes', 'Oxidation-Reduction', 'Electrochemical Techniques']",https://pubmed.ncbi.nlm.nih.gov/37421702/
1084,Erlotinib,37463100,Homoharringtonine sensitizes pancreatic cancer to erlotinib by direct targeting and miRNA-130b-3p-mediated EphB4-JAK2-STAT3 axis.,"['Sarwar A', 'Zhu Z', 'Zhu M', 'Tang X', 'Su Q', 'Yang T', 'Tang W', 'Zhang Y']","['Humans', 'Homoharringtonine/pharmacology', '*MicroRNAs/metabolism', 'Erlotinib Hydrochloride/pharmacology', 'Cell Line, Tumor', '*Pancreatic Neoplasms/drug therapy/genetics', 'Cell Proliferation', 'Janus Kinase 2/metabolism/pharmacology', 'STAT3 Transcription Factor/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37463100/
1085,Erlotinib,28225456,Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.,"['Ariyasu R', 'Horiike A', 'Koyama J', 'Saiki M', 'Sonoda T', 'Kawashima Y', 'Takano N', 'Oguri T', 'Nishikawa S', 'Kitazono S', 'Yanagitani N', 'Ohyanagi F', 'Nishio M']","['Adenocarcinoma/*drug therapy/pathology', 'Adenocarcinoma of Lung', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bevacizumab/administration & dosage', 'Brain Neoplasms/drug therapy/secondary', 'Erlotinib Hydrochloride/administration & dosage', 'Humans', 'Lung Neoplasms/*drug therapy/pathology', 'Male', 'Meningeal Carcinomatosis/*drug therapy/pathology', 'Middle Aged', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/28225456/
1086,Erlotinib,35514158,Antioxidant activity of erlotinib and gefitinib: theoretical and experimental insights.,"['K P SH', 'Babu TD', 'C M P', 'Joshy G', 'Mathew D', 'Thayyil MS']","['*Antioxidants/chemistry/pharmacology', 'Erlotinib Hydrochloride/pharmacology', 'Gefitinib', 'Molecular Docking Simulation', '*Protons', 'Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/35514158/
1087,Erlotinib,28152323,Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.,"['Rossi A', 'La Salvia A', 'Di Maio M']","['Antineoplastic Agents/*therapeutic use', 'Carcinoma, Non-Small-Cell Lung/*drug therapy', 'Erlotinib Hydrochloride/*therapeutic use', 'Gefitinib', 'Humans', 'Lung Neoplasms/*drug therapy', 'Prospective Studies', 'Quinazolines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28152323/
1088,Erlotinib,34296544,Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial.,"['Lim SH', 'Yun J', 'Lee MY', 'Kim HJ', 'Kim KH', 'Kim SH', 'Lee SC', 'Bae SB', 'Kim CK', 'Lee N', 'Lee KT', 'Park SK', 'Lee YN', 'Moon JH']","['*Adenocarcinoma/drug therapy', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Deoxycytidine/analogs & derivatives', 'Erlotinib Hydrochloride/adverse effects', 'Humans', 'Oxaliplatin/therapeutic use', '*Pancreatic Neoplasms/drug therapy', 'Treatment Outcome', 'Gemcitabine']",https://pubmed.ncbi.nlm.nih.gov/34296544/
1089,Erlotinib,28295308,"Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.","['Yang Z', 'Hackshaw A', 'Feng Q', 'Fu X', 'Zhang Y', 'Mao C', 'Tang J']","['Afatinib', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics', 'Diarrhea/chemically induced', 'Disease-Free Survival', 'ErbB Receptors/genetics', 'Erlotinib Hydrochloride/adverse effects/*therapeutic use', 'Exanthema/chemically induced', 'Gefitinib', 'Humans', 'Lung Neoplasms/*drug therapy/genetics', 'Mutation', 'Outcome Assessment, Health Care/methods/statistics & numerical data', 'Proportional Hazards Models', 'Protein Kinase Inhibitors/adverse effects/therapeutic use', 'Quinazolines/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/28295308/
1090,Erlotinib,38642796,EGFR Inhibition by Erlotinib Rescues Desmosome Ultrastructure and Keratin Anchorage and Protects against Pemphigus Vulgaris IgG-Induced Acantholysis in Human Epidermis.,"['Egu DT', 'Schmitt T', 'Ernst N', 'Ludwig RJ', 'Fuchs M', 'Hiermaier M', 'Moztarzadeh S', 'Moron CS', 'Schmidt E', 'Beyersdorfer V', 'Spindler V', 'Steinert LS', 'Vielmuth F', 'Sigmund AM', 'Waschke J']","['Humans', '*Pemphigus/drug therapy/pathology/metabolism', '*Erlotinib Hydrochloride/pharmacology/administration & dosage', '*ErbB Receptors/antagonists & inhibitors/metabolism', '*Desmosomes/drug effects/ultrastructure/metabolism', '*Epidermis/drug effects/pathology/metabolism/ultrastructure', '*Acantholysis/drug therapy/pathology/metabolism', '*Immunoglobulin G', '*Keratins/metabolism', 'Phosphorylation', 'Desmoglein 3/metabolism/immunology', 'Protein Kinase Inhibitors/pharmacology/therapeutic use', 'Signal Transduction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/38642796/
1091,Erlotinib,34388377,"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.","['Zhou Q', 'Xu CR', 'Cheng Y', 'Liu YP', 'Chen GY', 'Cui JW', 'Yang N', 'Song Y', 'Li XL', 'Lu S', 'Zhou JY', 'Ma ZY', 'Yu SY', 'Huang C', 'Shu YQ', 'Wang Z', 'Yang JJ', 'Tu HY', 'Zhong WZ', 'Wu YL']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects', 'Bevacizumab/*administration & dosage/adverse effects', 'Brain Neoplasms/*drug therapy/genetics/*secondary', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics', 'ErbB Receptors/genetics', 'Erlotinib Hydrochloride/*administration & dosage/adverse effects', 'Female', 'Humans', 'Lung Neoplasms/*drug therapy/genetics', 'Male', 'Middle Aged', 'Mutation', 'Random Allocation', 'Survival Analysis', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34388377/
1092,Erlotinib,36070882,Arsenic trioxide and Erlotinib loaded in RGD-modified nanoliposomes for targeted combination delivery to PC3 and PANC-1 cell lines.,"['Khosravani F', 'Mir H', 'Mirzaei A', 'Kobarfard F', 'Bardania H', 'Hosseini E']","['Humans', 'Arsenic Trioxide/pharmacology', 'Erlotinib Hydrochloride/pharmacology', 'PC-3 Cells', 'Oxides/pharmacology', '*Arsenicals/pharmacology/chemistry/therapeutic use', 'Cell Line, Tumor', 'Apoptosis', 'Oligopeptides/pharmacology/chemistry', '*Antineoplastic Agents/pharmacology/chemistry']",https://pubmed.ncbi.nlm.nih.gov/36070882/
1093,Erlotinib,37432652,Solid amorphous formulations for enhancing solubility and inhibiting Erlotinib crystallization during gastric-to-intestinal transfer.,"['Mugnier L', 'Espitalier F', 'Menegotto J', 'Bell S', 'Re MI']","['Solubility', 'Crystallization', 'Drug Compounding/methods', '*Chemistry, Pharmaceutical/methods', 'Erlotinib Hydrochloride', '*Polymers/chemistry', 'Water']",https://pubmed.ncbi.nlm.nih.gov/37432652/
1094,Erlotinib,35985780,Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials.,"['Deng W', 'Wang K', 'Jiang Y', 'Li D', 'Bao C', 'Luo J', 'Liu L', 'Huang B', 'Kong J']","['*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Bevacizumab/adverse effects', '*Carcinoma, Non-Small-Cell Lung/drug therapy', '*ErbB Receptors/genetics', 'Erlotinib Hydrochloride/adverse effects/therapeutic use', 'Humans', 'Lung Neoplasms/drug therapy', 'Protein Kinase Inhibitors', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/35985780/
1095,Erlotinib,30069756,Erlotinib.,"['Steins M', 'Thomas M', 'Geissler M']","['Adenocarcinoma/drug therapy', 'Antineoplastic Agents/*pharmacology', 'Carcinoma/*drug therapy', 'Carcinoma, Hepatocellular/drug therapy', 'Carcinoma, Non-Small-Cell Lung/drug therapy', 'ErbB Receptors/*antagonists & inhibitors', 'Erlotinib Hydrochloride/*pharmacology', 'Humans', 'Liver Neoplasms/drug therapy', 'Lung Neoplasms/drug therapy', 'Pancreatic Neoplasms/drug therapy', 'Protein Kinase Inhibitors/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30069756/
1096,Citalopram,34048796,Early Developmental Exposure to Fluoxetine and Citalopram Results in Different Neurodevelopmental Outcomes.,"['Liu K', 'Garcia A', 'Park JJ', 'Toliver AA', 'Ramos L', 'Aizenman CD']","['Anxiety', '*Citalopram/toxicity', 'Female', '*Fluoxetine/toxicity', 'Humans', 'Patch-Clamp Techniques', 'Pregnancy', 'Selective Serotonin Reuptake Inhibitors/toxicity']",https://pubmed.ncbi.nlm.nih.gov/34048796/
1097,Citalopram,9988363,Co-administration of citalopram and clozapine: effect on plasma clozapine levels.,"['Taylor D', 'Ellison Z', 'Ementon Shaw L', 'Wickham H', 'Murray R']","['Adolescent', 'Adult', 'Antidepressive Agents, Second-Generation/administration & dosage/*pharmacology', 'Antipsychotic Agents/administration & dosage/*pharmacokinetics', 'Citalopram/administration & dosage/*pharmacology', 'Clozapine/administration & dosage/*pharmacokinetics', 'Depressive Disorder/*drug therapy', 'Drug Interactions', 'Drug Therapy, Combination', 'Humans', 'Middle Aged', 'Pilot Projects', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9988363/
1098,Citalopram,26928394,Pharmaceutical-Oriented Selective Synthesis of Mononitriles and Dinitriles Directly from Methyl(hetero)arenes: Access to Chiral Nitriles and Citalopram.,"['Liu J', 'Zheng HX', 'Yao CZ', 'Sun BF', 'Kang YB']","['Antidepressive Agents, Second-Generation/chemical synthesis', 'Chemistry, Pharmaceutical', 'Citalopram/*chemical synthesis', 'Nitriles/*chemical synthesis', 'Stereoisomerism', 'Xylenes/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/26928394/
1099,Citalopram,27736049,High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death.,"['Ray WA', 'Chung CP', 'Murray KT', 'Hall K', 'Stein CM']","['Adult', 'Aged', '*Ambulatory Care', 'Citalopram/*adverse effects/therapeutic use', 'Cohort Studies', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Female', 'Humans', 'Long QT Syndrome/*chemically induced/*mortality', 'Male', 'Mental Disorders/*drug therapy/*mortality', 'Middle Aged', 'Out-of-Hospital Cardiac Arrest/*mortality', 'Retrospective Studies', 'Selective Serotonin Reuptake Inhibitors/adverse effects/therapeutic use', 'Tennessee']",https://pubmed.ncbi.nlm.nih.gov/27736049/
1100,Citalopram,31288974,When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram.,['Aga VM'],"['Aged', 'Alzheimer Disease/*psychology', 'Citalopram/*therapeutic use', 'Female', 'Humans', 'Mental Status and Dementia Tests', 'Psychomotor Agitation/*drug therapy', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31288974/
1101,Citalopram,1831396,No crossover reactions to citalopram or paroxetine among patients hypersensitive to zimeldine.,"['Bengtsson BO', 'Lundmark J', 'Walinder J']","['Aged', 'Aged, 80 and over', '*Antidepressive Agents', 'Citalopram/*adverse effects/therapeutic use', 'Combined Modality Therapy', 'Depressive Disorder/*drug therapy/psychology', 'Drug Hypersensitivity/diagnosis/*etiology', 'Female', 'Follow-Up Studies', 'Humans', 'Liver Function Tests', 'Male', 'Paroxetine', 'Piperidines/*adverse effects/therapeutic use', '*Serotonin Antagonists', 'Zimeldine/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1831396/
1102,Citalopram,31273200,Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.,"['Bhattacharyya S', 'Ahmed AT', 'Arnold M', 'Liu D', 'Luo C', 'Zhu H', 'Mahmoudiandehkordi S', 'Neavin D', 'Louie G', 'Dunlop BW', 'Frye MA', 'Wang L', 'Weinshilboum RM', 'Krishnan RR', 'Rush AJ', 'Kaddurah-Daouk R']","['Adult', 'Citalopram/*pharmacology', 'Depressive Disorder, Major/*drug therapy/metabolism/physiopathology', 'Female', 'Follow-Up Studies', 'Gastrointestinal Microbiome/drug effects', 'Humans', 'Male', 'Metabolome/*drug effects', 'Metabolomics', 'Middle Aged', 'Selective Serotonin Reuptake Inhibitors/*pharmacology', 'Severity of Illness Index', 'Signal Transduction/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/31273200/
1103,Citalopram,38776603,Design and synthesis of S-citalopram-imprinted polymeric sorbent: Characterization and application in enantioselective separation.,"['Alharbi HY', 'Alnoman RB', 'Aljohani MS', 'Monier M', 'Tawfik EH']","['*Citalopram/chemistry/isolation & purification/chemical synthesis', 'Stereoisomerism', '*Molecular Imprinting', 'Adsorption', 'Polymers/chemistry/chemical synthesis', 'Chromatography, High Pressure Liquid/methods']",https://pubmed.ncbi.nlm.nih.gov/38776603/
1104,Citalopram,34280395,Contributions of S- and R-citalopram to the citalopram-induced modulation of the function of Nav1.5 voltage-gated sodium channels.,"['Nakatani Y', 'Amano T']","['*Citalopram/pharmacology', 'Humans', '*NAV1.5 Voltage-Gated Sodium Channel/metabolism', 'HEK293 Cells', 'Selective Serotonin Reuptake Inhibitors/pharmacology', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/34280395/
1105,Citalopram,24528284,Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.,"['Ji Y', 'Schaid DJ', 'Desta Z', 'Kubo M', 'Batzler AJ', 'Snyder K', 'Mushiroda T', 'Kamatani N', 'Ogburn E', 'Hall-Flavin D', 'Flockhart D', 'Nakamura Y', 'Mrazek DA', 'Weinshilboum RM']","['Adult', 'Aged', 'Aged, 80 and over', 'Biotransformation', 'Citalopram/*blood/metabolism/therapeutic use', 'Cytochrome P-450 CYP2C19/*genetics', 'Cytochrome P-450 CYP2D6/*genetics', 'Depressive Disorder, Major/drug therapy/*metabolism', 'Female', 'Genome-Wide Association Study', 'Humans', 'Male', 'Middle Aged', 'Molecular Sequence Data', 'Polymorphism, Single Nucleotide', 'Selective Serotonin Reuptake Inhibitors/*blood/metabolism/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24528284/
1106,Citalopram,37952772,The efficacy of citalopram or escitalopram in patients with asthma and major depressive disorder.,"['Agarwal CD', 'Palka JM', 'Gajewski AJ', 'Khan DA', 'Brown ES']","['Humans', 'Adrenal Cortex Hormones/therapeutic use', 'Antidepressive Agents/therapeutic use', '*Asthma/drug therapy', '*Citalopram/therapeutic use', '*Depressive Disorder, Major/drug therapy', '*Escitalopram/therapeutic use', 'Treatment Outcome', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37952772/
1107,Citalopram,37147306,Effects of prenatal exposure to (es)citalopram and maternal depression during pregnancy on DNA methylation and child neurodevelopment.,"['Olstad EW', 'Nordeng HME', 'Sandve GK', 'Lyle R', 'Gervin K']","['Pregnancy', 'Infant, Newborn', 'Female', 'Humans', 'Child', '*DNA Methylation', 'Citalopram/adverse effects', '*Prenatal Exposure Delayed Effects/genetics', 'Cohort Studies', 'Depression']",https://pubmed.ncbi.nlm.nih.gov/37147306/
1108,Citalopram,38286546,Supramolecular assemblies of citalopram and escitalopram in beta-cyclodextrin dimeric cavity: Crystallographic and theoretical insights.,['Aree T'],"['Escitalopram', 'Citalopram', '*beta-Cyclodextrins/chemistry', 'Crystallography, X-Ray', '*Cyclodextrins/chemistry']",https://pubmed.ncbi.nlm.nih.gov/38286546/
1109,Citalopram,28467792,Assessment of citalopram and escitalopram on neuroblastoma cell lines. Cell toxicity and gene modulation.,"['Sakka L', 'Deletage N', 'Chalus M', 'Aissouni Y', 'Sylvain-Vidal V', 'Gobron S', 'Coll G']","['Citalopram/*pharmacology', 'Gene Regulatory Networks/*drug effects', 'Humans', 'Neural Stem Cells/*drug effects', 'Neuroblastoma/*drug therapy/genetics/pathology', 'Selective Serotonin Reuptake Inhibitors/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/28467792/
1110,Citalopram,8634772,Simplified high-performance liquid chromatographic method for the determination of citalopram and desmethylcitalopram in serum without interference from commonly used psychotropic drugs and their metabolites.,"['Olesen OV', 'Linnet K']","['Artifacts', 'Chromatography, High Pressure Liquid/*methods', 'Citalopram/*analogs & derivatives/*blood', 'Humans', 'Psychotropic Drugs/blood', 'Reference Standards', 'Reproducibility of Results', 'Selective Serotonin Reuptake Inhibitors/*blood', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/8634772/
1111,Citalopram,33422834,"Interaction of citalopram and escitalopram with calf Thymus DNA: A spectrofluorometric, voltammetric, and liquid chromatographic approach.","['Dindar CK', 'Erkmen C', 'Yildirim S', 'Bozal-Palabiyik B', 'Uslu B']","['*Citalopram', '*DNA', 'Selective Serotonin Reuptake Inhibitors', 'Spectrometry, Fluorescence', 'Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/33422834/
1112,phenytoin,7213507,Prediction of phenytoin dosage in relation to the variability of phenytoin plasma concentration.,"['Van der Velde EA', 'Driessen O']","['Humans', 'Kinetics', 'Models, Biological', 'Phenytoin/*administration & dosage/blood']",https://pubmed.ncbi.nlm.nih.gov/7213507/
1113,phenytoin,3992622,Carbamazepine-phenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication.,"['Zielinski JJ', 'Haidukewych D', 'Leheta BJ']","['Adult', 'Carbamazepine/*administration & dosage', 'Drug Interactions', 'Drug Therapy, Combination', 'Epilepsy/drug therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Monitoring, Physiologic', 'Phenytoin/administration & dosage/adverse effects/*blood']",https://pubmed.ncbi.nlm.nih.gov/3992622/
1114,phenytoin,32376339,"Phenytoin - An anti-seizure drug: Overview of its chemistry, pharmacology and toxicology.","['Patocka J', 'Wu Q', 'Nepovimova E', 'Kuca K']","['Anticonvulsants/*chemistry/*pharmacology/toxicity', 'Carcinogenicity Tests', 'Humans', 'Mutagenicity Tests', 'Phenytoin/*chemistry/*pharmacology/toxicity', 'Teratogens/toxicity']",https://pubmed.ncbi.nlm.nih.gov/32376339/
1115,phenytoin,791565,Absorption and metabolism of phenytoin from tablets and capsules.,"['Smith TC', 'Kinkel A']","['Adult', 'Biological Availability', 'Capsules', 'Clinical Trials as Topic', 'Humans', '*Intestinal Absorption', 'Male', 'Phenytoin/administration & dosage/*metabolism', 'Solubility', 'Tablets', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/791565/
1116,phenytoin,3150279,Phenytoin-induced thrombocytopenia.,"['Brown JJ', 'Chun RW']","['Adolescent', 'Epilepsy, Tonic-Clonic/*drug therapy', 'Humans', 'Male', 'Phenytoin/*adverse effects/therapeutic use', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/3150279/
1117,phenytoin,2815228,Time for phenytoin concentration to peak: consequences of first-order and zero-order absorption.,"['McCauley DL', 'Tozer TN', 'Winter ME']","['Administration, Oral', 'Half-Life', 'Humans', 'Intestinal Absorption', 'Models, Biological', 'Phenytoin/administration & dosage/blood/*pharmacokinetics', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2815228/
1118,phenytoin,38479432,Topical phenytoin improves wound healing with analgesic and antibacterial properties and minimal side effects: a systematic review.,"['Sadiq KO', 'Shivakumar YM', 'Burra EK', 'Shahid K', 'Tamene YT', 'Mody SP', 'Nath TS']","['*Phenytoin/pharmacology', '*Wound Healing/drug effects', 'Humans', '*Anti-Bacterial Agents/pharmacology/administration & dosage', '*Administration, Topical', 'Analgesics/pharmacology', 'Wounds and Injuries/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38479432/
1119,phenytoin,2967311,Cutaneous and immunologic reactions to phenytoin.,"['Silverman AK', 'Fairley J', 'Wong RC']","['Carcinogens', 'Drug Eruptions/*etiology', 'Drug Hypersensitivity/*etiology', 'Female', 'Humans', 'Phenytoin/*adverse effects/immunology', 'Pregnancy', 'Teratogens']",https://pubmed.ncbi.nlm.nih.gov/2967311/
1120,phenytoin,31672614,Nanoemulsions and thermosensitive nanoemulgels of phenytoin and fosphenytoin for intranasal administration: Formulation development and in vitro characterization.,"['Pires PC', 'Peixoto D', 'Teixeira I', 'Rodrigues M', 'Alves G', 'Santos AO']","['Administration, Intranasal', 'Anticonvulsants/*chemistry', 'Drug Compounding', '*Drug Delivery Systems', 'Drug Liberation', 'Emulsions', 'Gels', 'Nanostructures/*chemistry', 'Phenytoin/*analogs & derivatives/chemistry', 'Temperature']",https://pubmed.ncbi.nlm.nih.gov/31672614/
1121,phenytoin,6157786,A comparison between microcrystalline and conventional phenytoin preparations: relative bioavailability and steady-state plasma concentrations.,"['Boreus LO', 'Nergardh A', 'Ehrnebo M', 'Theorell K']","['Biological Availability', 'Crystallization', 'Humans', 'Male', 'Phenytoin/administration & dosage/blood/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/6157786/
1122,phenytoin,33970810,"Design, synthesis, structural and molecular characterization, toxicity, psychotropic activity and molecular docking evaluation of a novel phenytoin derivative: 3-decyl-5,5-diphenylimidazolidine-2,4-dione.","['Guerrab W', 'El Jemli M', 'Akachar J', 'Demirtas G', 'Mague JT', 'Taoufik J', 'Ibrahimi A', 'Ansar M', 'Alaoui K', 'Ramli Y']","['Molecular Docking Simulation', '*Phenytoin/pharmacology', 'Models, Molecular', 'Hydrogen Bonding', 'Static Electricity']",https://pubmed.ncbi.nlm.nih.gov/33970810/
1123,phenytoin,1527539,Bioavailability and dissolution of proprietary and generic formulations of phenytoin.,"['Soryal I', 'Richens A']","['Adolescent', 'Adult', 'Biological Availability', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Epilepsy/*blood/drug therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Phenytoin/administration & dosage/adverse effects/*blood', 'Single-Blind Method', 'Therapeutic Equivalency', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/1527539/
1124,phenytoin,4082246,Phenytoin/clonazepam interaction.,"['Saavedra IN', 'Aguilera LI', 'Faure E', 'Galdames DG']","['Adult', 'Benzodiazepinones/*pharmacology', 'Clonazepam/administration & dosage/blood/*pharmacology/therapeutic use', 'Drug Interactions', 'Drug Therapy, Combination', 'Epilepsy/blood/drug therapy', 'Humans', 'Male', 'Phenytoin/administration & dosage/*blood/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4082246/
1125,phenytoin,32166473,Effects of Diluents on Physical and Chemical Stability of Phenytoin and Phenytoin Sodium.,"['Rahman Z', 'Dharani S', 'Barakh Ali SF', 'Nutan MTH', 'Khan MA']","['Anticonvulsants/*chemistry', 'Drug Compounding', '*Drug Stability', 'Excipients', 'Lactose', 'Mannitol', 'Phenytoin/*chemistry', 'Solubility']",https://pubmed.ncbi.nlm.nih.gov/32166473/
1126,phenytoin,9620116,Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.,"['Doak KK', 'Haas CE', 'Dunnigan KJ', 'Reiss RA', 'Reiser JR', 'Huntress J', 'Altavela JL']","['Adult', 'Anticonvulsants/administration & dosage/*pharmacokinetics', 'Biological Availability', '*Enteral Nutrition', 'Female', 'Food-Drug Interactions', 'Humans', 'Injections, Intravenous', 'Male', 'Phenytoin/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/9620116/
1127,Cetirizine,19635371,Development and validation of a stability-indicating RP-HPLC method for the determination of paracetamol with dantrolene or/and cetirizine and pseudoephedrine in two pharmaceutical dosage forms.,"['Hadad GM', 'Emara S', 'Mahmoud WM']","['Acetaminophen/*analysis', 'Analgesics, Non-Narcotic', 'Anti-Allergic Agents', 'Cetirizine/analysis', 'Chromatography, High Pressure Liquid/*methods', 'Dantrolene/analysis', 'Drug Combinations', 'Drug Stability', 'Muscle Relaxants, Central', 'Nasal Decongestants', 'Pharmaceutical Preparations/*analysis', 'Pseudoephedrine/analysis']",https://pubmed.ncbi.nlm.nih.gov/19635371/
1128,Cetirizine,34474941,Unintentional cetirizine overdose causing anticholinergic syndrome.,"['Renko A', 'Cortese T', 'Karagiannis P', 'Salzman M']","['Anti-Allergic Agents/administration & dosage/*poisoning', 'Anticholinergic Syndrome/*etiology', 'Cetirizine/administration & dosage/*poisoning', 'Child', 'Drug Overdose/complications', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/34474941/
1129,Cetirizine,36756861,Separation and identification of cetirizine enantiomers in human urine by capillary electrophoresis and circular dichroism independent of their standards.,"['Chen L', 'Tian T', 'Yang S', 'Dong Y', 'Cui H', 'Li X']","['Humans', '*Cetirizine/analysis/pharmacokinetics', 'Circular Dichroism', 'Reference Standards', '*Electrophoresis, Capillary/methods', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/36756861/
1130,Cetirizine,36368368,"Application of the C-C(3)N(4)/Li(2)CoMn(3)O(8)//IL nanocomposite for design a sensitive electrochemical sensor inorder to detection of cetirizine, acetaminophen and phenylephrine in biological and pharmaceuticals samples.","['Ziaie N', 'Shabani-Nooshabadi M']","['Humans', '*Acetaminophen', 'Electrochemical Techniques', 'Cetirizine', 'Phenylephrine', 'Spectroscopy, Fourier Transform Infrared', '*Nanocomposites/chemistry', 'Lithium', 'Ions', 'Pharmaceutical Preparations']",https://pubmed.ncbi.nlm.nih.gov/36368368/
1131,Cetirizine,26971810,"Oxidation of cetirizine, fexofenadine and hydrochlorothiazide during ozonation: Kinetics and formation of transformation products.","['Borowska E', 'Bourgin M', 'Hollender J', 'Kienle C', 'McArdell CS', 'von Gunten U']","['Cetirizine/*chemistry', 'Chromatography, Liquid', 'Hydrochlorothiazide/*chemistry', 'Hydrogen-Ion Concentration', 'Kinetics', 'Oxidation-Reduction', 'Ozone/*chemistry', 'Tandem Mass Spectrometry', 'Terfenadine/*analogs & derivatives/chemistry', 'Wastewater/chemistry', 'Water Pollutants, Chemical/*chemistry', 'Water Purification/*methods']",https://pubmed.ncbi.nlm.nih.gov/26971810/
1132,Cetirizine,35344122,Synchronous Fluorescence as a Green and Selective Method for the Simultaneous Determination of Cetirizine and Azelastine in Aqueous Humor.,"['Abd-AlGhafar WN', 'Aly FA', 'Sheribah ZA', 'Saad S']","['*Aqueous Humor', '*Cetirizine', 'Ophthalmic Solutions', 'Phthalazines', 'Spectrometry, Fluorescence/methods']",https://pubmed.ncbi.nlm.nih.gov/35344122/
1133,Cetirizine,15841664,"Double-blind, crossover comparison of olopatadine and cetirizine versus placebo: suppressive effects on skin response to histamine iontophoresis.","['Morita E', 'Matsuo H', 'Zhang Y']","['Administration, Oral', 'Adult', 'Cetirizine/*administration & dosage', 'Cross-Over Studies', 'Dibenzoxepins/*administration & dosage', 'Double-Blind Method', 'Female', 'Histamine', 'Histamine H1 Antagonists/*administration & dosage', 'Humans', 'Hypersensitivity, Immediate/chemically induced/*drug therapy/pathology', 'Iontophoresis', 'Male', 'Olopatadine Hydrochloride', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15841664/
1134,Cetirizine,20354769,Isolation and characterization of cetirizine degradation product: mechanism of cetirizine oxidation.,"['Dyakonov T', 'Muir A', 'Nasri H', 'Toops D', 'Fatmi A']","['Cetirizine/*chemistry/isolation & purification', 'Chromatography, Liquid', 'Histamine H1 Antagonists, Non-Sedating/chemistry', 'Hydrogen Peroxide/chemistry', 'Hydrogen-Ion Concentration', 'Magnetic Resonance Spectroscopy', 'Mass Spectrometry', 'Molecular Structure', 'Oxidation-Reduction', 'Polyethylene Glycols/chemistry']",https://pubmed.ncbi.nlm.nih.gov/20354769/
1135,Cetirizine,35732105,"Simple and rapid quantification of cetirizine, venlafaxine, and O-desmethylvenlafaxine in human breast milk, and metformin in human milk and plasma with UHPLC-MS/MS.","['Wegler C', 'Saleh A', 'Lindqvist A', 'Nordeng H', 'Smeraglia J', 'Baranczewski P']","['Cetirizine', 'Chromatography, High Pressure Liquid/methods', 'Desvenlafaxine Succinate', 'Female', 'Humans', 'Infant', '*Metformin', 'Milk, Human', 'Pregnancy', 'Reproducibility of Results', '*Tandem Mass Spectrometry/methods', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/35732105/
1136,Cetirizine,37811726,Transfer of cetirizine/levocetirizine into human breast milk and estimation of drug exposure to infants through breastfeeding: A human lactation study from the ConcePTION project.,"['Nordeng H', 'Wegler C', 'Lindqvist A', 'Melander E', 'Magnusson M', 'Gandia P', 'Panchaud A', 'Baranczewski P', 'Spigset O']","['Infant', 'Humans', 'Female', '*Cetirizine/adverse effects', '*Breast Feeding', 'Milk, Human', 'Lactation']",https://pubmed.ncbi.nlm.nih.gov/37811726/
1137,Cetirizine,38674305,Comparing the Risk of Infusion-Related Reactions and Tolerability in Patients Given Cetirizine or Diphenhydramine Prior to Ocrelizumab Infusion (PRECEPT).,"['Smoot K', 'Marginean H', 'Gervasi-Follmar T', 'Chen C']","['Humans', '*Diphenhydramine/administration & dosage/therapeutic use', '*Cetirizine/adverse effects/administration & dosage/therapeutic use', 'Female', 'Male', 'Adult', 'Middle Aged', '*Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use/administration & dosage', 'Infusions, Intravenous/adverse effects', 'Multiple Sclerosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38674305/
1138,Cetirizine,34989925,Comparison of Carbon Dots Prepared in Deep Eutectic Solvent and Water/Deep Eutectic Solvent: Study of Fluorescent Detection of Fe(3+) and Cetirizine and their Photocatalytic Antibacterial Activity.,"['Tabaraki R', 'Nazari F']","['Anti-Bacterial Agents/pharmacology', 'Carbon/*chemistry/pharmacology', 'Cetirizine/*analysis/pharmacology', '*Deep Eutectic Solvents', 'Ferric Compounds/*analysis/pharmacology', 'Hydrogen-Ion Concentration', 'Limit of Detection', 'Microscopy, Electron, Transmission', 'Microwaves', 'Quantum Dots/*chemistry', 'Spectrometry, Fluorescence/*methods', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/34989925/
1139,Cetirizine,21874559,Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans.,['Church MK'],"['Adult', 'Anti-Allergic Agents/*administration & dosage/blood/pharmacokinetics', 'Benzimidazoles/*administration & dosage/blood/pharmacokinetics', 'Cetirizine/*administration & dosage/blood/pharmacokinetics', 'Cross-Over Studies', 'Double-Blind Method', 'Histamine', 'Histamine H1 Antagonists/*administration & dosage/blood/pharmacokinetics', 'Humans', 'Male', 'Piperidines/*administration & dosage/blood/pharmacokinetics', 'Skin Tests', 'Urticaria/blood/chemically induced/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21874559/
1140,Sibutramine,17266632,Currently available drugs for the treatment of obesity: Sibutramine and orlistat.,"['Chaput JP', 'St-Pierre S', 'Tremblay A']","['Anti-Obesity Agents/adverse effects/*therapeutic use', 'Body Weight', 'Cyclobutanes/adverse effects/*therapeutic use', 'Energy Metabolism', 'Exercise', 'Humans', 'Lactones/adverse effects/*therapeutic use', 'Obesity/*drug therapy', 'Orlistat']",https://pubmed.ncbi.nlm.nih.gov/17266632/
1141,Sibutramine,23444775,Rapid identification of sibutramine in dietary supplements using a stepwise approach.,"['Csupor D', 'Boros K', 'Danko B', 'Veres K', 'Szendrei K', 'Hohmann J']","['Appetite Depressants/*analysis', 'Chromatography, High Pressure Liquid', 'Chromatography, Thin Layer', 'Color', 'Cyclobutanes/*analysis', 'Dietary Supplements/*analysis', 'Drug Contamination', 'Magnetic Resonance Spectroscopy', 'Spectrometry, Mass, Electrospray Ionization', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/23444775/
1142,Sibutramine,20731270,Myocardial infarction associated with sibutramine use: case report and discussion.,"['Fernandez WG', 'Biswas AK']","['Adult', 'Afghanistan', 'Appetite Depressants/*adverse effects', 'Cyclobutanes/*adverse effects', 'Diagnosis, Differential', 'Electrocardiography', 'Female', 'Humans', 'Myocardial Infarction/*chemically induced/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/20731270/
1143,Sibutramine,11916103,The importance of obesity in diabetes and its treatment with sibutramine.,"['Van Gaal LF', 'Peiffer FW']","['Appetite Depressants/pharmacology/*therapeutic use', 'Cyclobutanes/pharmacology/*therapeutic use', 'Diabetes Mellitus, Type 2/complications/*prevention & control', 'Glycated Hemoglobin/drug effects', 'Humans', 'Obesity/complications/*prevention & control', 'Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/11916103/
1144,Sibutramine,15957900,Control of diastereoselectivity by solvent effects in the addition of Grignard reagents to enantiopure t-butylsulfinimine: syntheses of the stereoisomers of the hydroxyl derivatives of sibutramine.,"['Lu BZ', 'Senanayake C', 'Li N', 'Han Z', 'Bakale RP', 'Wald SA']","['Cyclobutanes/*chemical synthesis/chemistry', 'Hydroxyl Radical/chemistry', 'Indicators and Reagents', 'Molecular Structure', 'Solvents', 'Stereoisomerism', 'Sulfinic Acids/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/15957900/
1145,Sibutramine,21892560,"Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.","['Garcia Diaz E', 'Martin Folgueras T']","['Adolescent', 'Anti-Obesity Agents/adverse effects/*therapeutic use', 'Appetite Depressants/adverse effects/*therapeutic use', 'Cyclobutanes/adverse effects/*therapeutic use', 'Diet', 'Female', 'Humans', 'Lactones/adverse effects/*therapeutic use', 'Male', 'Obesity/diet therapy/*drug therapy/*psychology', 'Orlistat', '*Quality of Life', 'Randomized Controlled Trials as Topic', 'Weight Loss/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/21892560/
1146,Sibutramine,19845869,Variegate porphyria in a 46-year-old patient taking sibutramine for weight loss.,"['Reiser M', 'Eickmann S', 'Haverkamp T', 'Finckh U']","['Appetite Depressants/*adverse effects', 'Cyclobutanes/*adverse effects', 'Female', 'Flavoproteins/metabolism', 'Genetic Predisposition to Disease', 'Humans', 'Mitochondrial Proteins/metabolism', 'Mutation', 'Porphyria, Variegate/*chemically induced/*genetics', 'Porphyrins/urine', 'Protoporphyrinogen Oxidase/genetics/metabolism', 'Weight Loss/drug effects']",https://pubmed.ncbi.nlm.nih.gov/19845869/
1147,Sibutramine,28724846,Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects.,"['Al-Tahami BAM', 'Al-Safi Ismail AA', 'Sanip Z', 'Yusoff Z', 'Shihabudin TMT', 'Singh TSP', 'Rasool AHG']","['Adiponectin/metabolism', 'Adolescent', 'Adult', 'Aged', 'Asian People', 'Blood Glucose/metabolism', 'Body Fat Distribution', 'Body Mass Index', 'C-Reactive Protein/metabolism', 'Cardiovascular Diseases/etiology/prevention & control', 'Cyclobutanes/*administration & dosage/pharmacology', 'Fasting/blood', 'Humans', 'Insulin/metabolism', 'Insulin Resistance', 'Intra-Abdominal Fat/metabolism', 'Lactones/*administration & dosage/pharmacology', 'Malaysia', 'Middle Aged', 'Obesity/complications/*drug therapy/*metabolism/physiopathology', 'Orlistat', 'Risk', 'Treatment Outcome', 'Waist Circumference', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28724846/
1148,Sibutramine,18398902,"Crystal chemistry of sibutramine: thermal, diffractometric and spectroscopic characterization.","['Maccaroni E', 'Alberti E', 'Malpezzi L', 'Masciocchi N', 'Pellegatta C']","['Appetite Depressants/*chemistry', 'Crystallography, X-Ray/*methods', 'Cyclobutanes/*chemistry', 'Magnetic Resonance Spectroscopy/*methods', 'Molecular Structure']",https://pubmed.ncbi.nlm.nih.gov/18398902/
1149,Sibutramine,19475780,The use of sibutramine in the management of obesity and related disorders: an update.,"['Tziomalos K', 'Krassas GE', 'Tzotzas T']","['Adult', 'Appetite Depressants/adverse effects/*therapeutic use', 'Biomarkers/blood', 'Blood Glucose/drug effects', 'Cardiovascular Diseases/etiology/mortality/*prevention & control', 'Child', 'Cyclobutanes/adverse effects/*therapeutic use', 'Eating/drug effects', 'Humans', 'Inflammation Mediators/blood', 'Lipids/blood', 'Obesity/blood/complications/*drug therapy/mortality', 'Risk Reduction Behavior', 'Treatment Outcome', 'Weight Loss/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/19475780/
1150,Sibutramine,9130039,Sibutramine--a review of clinical efficacy.,['Lean ME'],"['Anti-Obesity Agents/pharmacology/standards/*therapeutic use', 'Antidepressive Agents/pharmacology/standards/*therapeutic use', 'Appetite Depressants/pharmacology/standards/therapeutic use', 'Body Weight/drug effects/physiology', 'Cardiovascular Physiological Phenomena', 'Cardiovascular System/drug effects', 'Clinical Trials as Topic', 'Cyclobutanes/pharmacology/standards/*therapeutic use', 'Dose-Response Relationship, Drug', 'Fenfluramine/pharmacology/standards/therapeutic use', 'Humans', 'Obesity/*drug therapy/physiopathology', 'Weight Loss/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/9130039/
1151,Sibutramine,15013931,Sibutramine and the management of obesity.,"['Poston WS', 'Foreyt JP']","['Adolescent', 'Adrenergic Uptake Inhibitors/adverse effects/pharmacology/therapeutic use', 'Appetite Depressants/adverse effects/pharmacology/*therapeutic use', 'Cardiovascular System/drug effects', 'Clinical Trials as Topic', 'Cyclobutanes/adverse effects/pharmacology/*therapeutic use', 'Diabetes Mellitus, Type 2/complications/drug therapy', 'Humans', 'Obesity/complications/*drug therapy', 'Racial Groups', 'Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15013931/
1152,Sibutramine,18374423,"Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.","['Baptista T', 'Uzcategui E', 'Rangel N', 'El Fakih Y', 'Galeazzi T', 'Beaulieu S', 'de Baptista EA']","['Adult', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Appetite Depressants/*therapeutic use', 'Benzodiazepines/*adverse effects/therapeutic use', 'Body Mass Index', 'Chronic Disease', 'Cyclobutanes/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Male', 'Metabolic Syndrome/*chemically induced/*drug therapy', 'Metformin/*therapeutic use', 'Middle Aged', 'Obesity/*chemically induced/*drug therapy', 'Olanzapine', 'Pilot Projects', 'Placebos', 'Schizophrenia/diagnosis/*drug therapy', 'Schizophrenic Psychology', 'Waist-Hip Ratio', 'Weight Gain/drug effects', 'Weight Loss/drug effects']",https://pubmed.ncbi.nlm.nih.gov/18374423/
1153,Sibutramine,25149468,Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?,"['Antel J', 'Albayrak O', 'Heusch G', 'Banaschewski T', 'Hebebrand J']","['Adolescent', 'Adult', 'Antidepressive Agents/*adverse effects', 'Attention Deficit Disorder with Hyperactivity/drug therapy', 'Blood Pressure/drug effects', 'Cardiovascular Diseases/*chemically induced', 'Central Nervous System Stimulants/*adverse effects', 'Child', 'Child, Preschool', 'Cohort Studies', 'Cyclobutanes/*adverse effects', 'Female', 'Heart Rate/drug effects', 'Humans', 'Male', 'Methylphenidate/*adverse effects', 'Middle Aged', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25149468/
1154,Sibutramine,12637112,Weight management and current options in pharmacotherapy: orlistat and sibutramine.,"['Leung WY', 'Thomas GN', 'Chan JC', 'Tomlinson B']","['Anti-Obesity Agents/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Body Mass Index', 'Cyclobutanes/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Humans', 'Lactones/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Obesity/*drug therapy', 'Orlistat', 'Randomized Controlled Trials as Topic', 'Weight Loss/drug effects']",https://pubmed.ncbi.nlm.nih.gov/12637112/
1155,pyrazinamide,34074731,"Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug.","['Hussain Z', 'Zhu J', 'Ma X']","['Antitubercular Agents/pharmacology/toxicity', 'Chemical and Drug Induced Liver Injury/*etiology', 'Humans', '*Liver/drug effects/enzymology', '*Pyrazinamide/pharmacology/toxicity', 'Tuberculosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34074731/
1156,pyrazinamide,32571824,How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide.,"['Koser CU', 'Cirillo DM', 'Miotto P']","['Amidohydrolases/genetics', 'Antitubercular Agents/pharmacology/therapeutic use', 'Humans', 'Microbial Sensitivity Tests', 'Mutation', '*Mycobacterium tuberculosis/genetics', '*Pharmaceutical Preparations', 'Pyrazinamide/pharmacology', '*Tuberculosis, Multidrug-Resistant/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32571824/
1157,pyrazinamide,8161767,"Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis.","['Turktas H', 'Unsal M', 'Tulek N', 'Oruc O']","['Acute Disease', 'Adolescent', 'Adult', 'Chemical and Drug Induced Liver Injury/*diagnosis/etiology', 'Diagnosis, Differential', 'Drug Therapy, Combination', 'Female', 'Hepatitis B/diagnosis', 'Hepatitis C/diagnosis', 'Hepatitis, Viral, Human/*diagnosis', 'Humans', 'Isoniazid/*adverse effects', 'Male', 'Middle Aged', 'Pyrazinamide/*adverse effects', 'Rifampin/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8161767/
1158,pyrazinamide,30858213,Introducing RpsA Point Mutations Delta438A and D123A into the Chromosome of Mycobacterium tuberculosis Confirms Their Role in Causing Resistance to Pyrazinamide.,"['Shi W', 'Cui P', 'Niu H', 'Zhang S', 'Tonjum T', 'Zhu B', 'Zhang Y']","['Antitubercular Agents/*pharmacology', 'Chromosomes, Bacterial/*genetics', 'Microbial Sensitivity Tests', 'Mycobacterium tuberculosis/drug effects/*genetics', 'Point Mutation/genetics', 'Pyrazinamide/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30858213/
1159,pyrazinamide,37690869,Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan.,"['Huang HT', 'Lin WH', 'Chan TH', 'Jou R']","['Humans', 'Pyrazinamide/pharmacology/therapeutic use', 'Antitubercular Agents/pharmacology/therapeutic use', '*Mycobacterium tuberculosis', 'Fluoroquinolones/pharmacology/therapeutic use', 'Microbial Sensitivity Tests', 'Taiwan', 'Retrospective Studies', 'Drug Resistance, Multiple, Bacterial', 'Amidohydrolases/genetics', '*Tuberculosis/drug therapy/microbiology', '*Tuberculosis, Multidrug-Resistant/drug therapy/epidemiology/microbiology', 'Mutation', 'Moxifloxacin/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37690869/
1160,pyrazinamide,39034578,Pyrazinamide-induced Toxic Epidermal Necrolysis.,"['Datta A', 'Sivasankar R', 'Kar BR']","['Humans', '*Stevens-Johnson Syndrome/etiology', 'Male', '*Pyrazinamide/adverse effects', 'Aged', '*Antitubercular Agents/adverse effects', 'Treatment Outcome', 'Tuberculosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39034578/
1161,pyrazinamide,21795116,Pyrazinamide pharmacokinetics and efficacy in adults and children.,"['Donald PR', 'Maritz JS', 'Diacon AH']","['Adolescent', 'Adult', 'Antitubercular Agents/administration & dosage/*pharmacokinetics', 'Area Under Curve', 'Child', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Male', 'Maximum Tolerated Dose', 'Practice Guidelines as Topic', 'Pyrazinamide/administration & dosage/*pharmacokinetics', 'Treatment Outcome', 'Tuberculosis, Pulmonary/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21795116/
1162,pyrazinamide,39609447,"Bifidobacterium adolescentis is resistant to pyrazinamide, isoniazid, and streptomycin.","['Nellikka A', 'Cheruvari A', 'Vasu P', 'Mutturi S', 'Rajagopal K']","['*Isoniazid/pharmacology', '*Streptomycin/pharmacology', '*Pyrazinamide/pharmacology', '*Antitubercular Agents/pharmacology', '*Bifidobacterium adolescentis/drug effects/genetics', '*Microbial Sensitivity Tests', 'Drug Resistance, Bacterial', 'Whole Genome Sequencing', 'Genome, Bacterial']",https://pubmed.ncbi.nlm.nih.gov/39609447/
1163,pyrazinamide,36377952,Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.,['Lyons MA'],"['Humans', 'Pyrazinamide/pharmacology/therapeutic use', 'Antitubercular Agents/pharmacology/therapeutic use', 'Diarylquinolines/pharmacology/therapeutic use', '*Tuberculosis, Pulmonary/drug therapy', '*Nitroimidazoles/pharmacology', '*Tuberculosis/drug therapy', '*Tuberculosis, Multidrug-Resistant/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36377952/
1164,pyrazinamide,27919887,"Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010.","['Pang Y', 'Zhang Z', 'Wang Y', 'Wang S', 'Song Y', 'Zhao B', 'Zhou Y', 'Ou X', 'Li Q', 'Xia H', 'Zheng Y', 'Fang X', 'Zhao Y']","['Antitubercular Agents/*pharmacology', 'China', 'Drug Resistance, Multiple, Bacterial/genetics', 'Fluoroquinolones/*pharmacology', 'Genotype', 'Microbial Sensitivity Tests', 'Moxifloxacin', 'Mycobacterium tuberculosis/drug effects/*pathogenicity', 'Prevalence', 'Pyrazinamide/*pharmacology', 'Tuberculosis, Multidrug-Resistant/*drug therapy/*genetics']",https://pubmed.ncbi.nlm.nih.gov/27919887/
1165,pyrazinamide,31761544,Vibrational spectra of pyrazinamide and isoniazid studied by terahertz spectroscopy and density functional theory.,"['Liang J', 'Zhang X', 'Wang N', 'Chang T', 'Cui HL']","['Crystallization', '*Density Functional Theory', 'Dimerization', 'Isoniazid/*chemistry', 'Molecular Conformation', 'Pyrazinamide/*chemistry', 'Quantum Theory', '*Terahertz Spectroscopy', '*Vibration']",https://pubmed.ncbi.nlm.nih.gov/31761544/
1166,pyrazinamide,34183327,"Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.","['Ruslami R', 'Gafar F', 'Yunivita V', 'Parwati I', 'Ganiem AR', 'Aarnoutse RE', 'Wilffert B', 'Alffenaar JC', 'Nataprawira HM']","['Adolescent', 'Antitubercular Agents/adverse effects/pharmacokinetics/therapeutic use', 'Area Under Curve', 'Chemical and Drug Induced Liver Injury/epidemiology', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Indonesia', 'Infant', 'Infant, Newborn', 'Isoniazid/blood/cerebrospinal fluid/*pharmacokinetics/therapeutic use', 'Male', 'Prospective Studies', 'Pyrazinamide/blood/cerebrospinal fluid/*pharmacokinetics/therapeutic use', 'Rifampin/blood/cerebrospinal fluid/*pharmacokinetics/therapeutic use', 'Tuberculosis, Meningeal/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34183327/
1167,Adapalene,34674160,"Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.","['Stein Gold L', 'Baldwin H', 'Kircik LH', 'Weiss JS', 'Pariser DM', 'Callender V', 'Lain E', 'Gold M', 'Beer K', 'Draelos Z', 'Sadick N', 'Pillai R', 'Bhatt V', 'Tanghetti EA']","['Acne Vulgaris/*drug therapy', 'Adapalene/*administration & dosage', 'Administration, Topical', 'Adolescent', 'Adult', 'Benzoyl Peroxide/*administration & dosage', 'Child', 'Clindamycin/administration & dosage/*analogs & derivatives', 'Dermatologic Agents/*administration & dosage', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Humans', 'Male', 'Middle Aged', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34674160/
1168,Adapalene,38734769,Rx -to- OTC switch increased access and lowered cost of topical adapalene.,"['Fix W', 'Desai S', 'Nussbaum D', 'Friedman A']","['Humans', '*Adapalene/administration & dosage/economics', '*Nonprescription Drugs/economics/administration & dosage', '*Acne Vulgaris/drug therapy/economics', '*Dermatologic Agents/economics/administration & dosage', 'United States', 'Administration, Topical', 'Prescription Drugs/economics/administration & dosage', 'Drug Costs', 'Medicare/economics', 'Health Services Accessibility/economics', 'Cost Savings']",https://pubmed.ncbi.nlm.nih.gov/38734769/
1169,Adapalene,38834226,Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne in Adult and Pediatric Participants.,"['Baldwin H', 'Gold LS', 'Harper JC', 'Alexis AF', 'Callender VD', 'Kircik L', 'Guenin E', 'Eichenfield LF']","['Humans', '*Acne Vulgaris/drug therapy', '*Clindamycin/administration & dosage/adverse effects/analogs & derivatives', 'Child', 'Double-Blind Method', 'Adolescent', 'Female', 'Male', '*Gels', 'Adult', '*Drug Combinations', '*Benzoyl Peroxide/administration & dosage/adverse effects', 'Treatment Outcome', 'Young Adult', '*Dermatologic Agents/administration & dosage/adverse effects', '*Quality of Life', 'Administration, Cutaneous', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/38834226/
1170,Adapalene,36622889,Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies.,['Draelos ZD'],"['Adult', 'Humans', 'Adapalene', '*Dermatologic Agents/adverse effects', 'Naphthalenes', 'Retinoids', '*Acne Vulgaris/drug therapy', 'Emollients', 'Double-Blind Method', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36622889/
1171,Adapalene,18848668,A review of adapalene in the treatment of acne vulgaris.,"['Irby CE', 'Yentzer BA', 'Feldman SR']","['Acne Vulgaris/*drug therapy', 'Adapalene', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use', 'Humans', 'Naphthalenes/pharmacology/*therapeutic use', 'Retinoids/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18848668/
1172,Adapalene,36949579,Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study.,"['Eichenfield LF', 'Stein Gold L', 'Kircik LH', 'Werschler WP', 'Beer K', 'Draelos ZD', 'Tanghetti EA', 'Papp KA', 'Baldwin H', 'Lain E', 'Sadick N', 'Gooderham MJ', 'Konda A']","['Humans', 'Child', 'Adolescent', 'Infant, Newborn', 'Adapalene/therapeutic use', '*Dermatologic Agents/adverse effects', 'Benzoyl Peroxide/adverse effects', 'Quality of Life', 'Peroxides/therapeutic use', 'Drug Combinations', 'Severity of Illness Index', '*Acne Vulgaris/drug therapy', 'Clindamycin/adverse effects', 'Treatment Outcome', 'Gels/therapeutic use', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/36949579/
1173,Adapalene,37665181,Evaluation of the efficacy of maintenance therapy for acne vulgaris using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel for 24 weeks and assessment of atrophic acne scars using three-dimensional image analysis.,"['Tanizaki H', 'Hayashi N', 'Abe M']","['Humans', 'Adapalene/therapeutic use', 'Benzoyl Peroxide/therapeutic use', 'Cicatrix/drug therapy/etiology/pathology', '*Dermatologic Agents/therapeutic use', 'Imaging, Three-Dimensional', 'Administration, Cutaneous', 'Gels/therapeutic use', '*Acne Vulgaris/complications/drug therapy/chemically induced', '*Adapalene, Benzoyl Peroxide Drug Combination/adverse effects', 'Treatment Outcome', '*Connective Tissue Diseases/chemically induced/complications/drug therapy', 'Atrophy/chemically induced', 'Drug Combinations']",https://pubmed.ncbi.nlm.nih.gov/37665181/
1174,Adapalene,39496135,Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey.,"['Baldwin H', 'Harper JC', 'Zeichner JA', 'Draelos ZD', 'Eichenfield LF', 'Gold M', 'Gold LS', 'Kircik LH']","['Adolescent', 'Adult', 'Child', 'Female', 'Humans', 'Male', 'Young Adult', '*Acne Vulgaris/drug therapy', '*Administration, Cutaneous', '*Benzoyl Peroxide/administration & dosage/adverse effects', '*Dermatologic Agents/administration & dosage/adverse effects', 'Double-Blind Method', '*Drug Combinations', '*Gels', '*Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39496135/
1175,Adapalene,36566399,Comparison Of Efficacy Of Topical Adapalene Plus Oral Azithromycin And Topical Adapalene Plus Oral Doxycycline In Treatment Of Acne Vulgaris.,"['Ullah G', 'Ali F', 'Paracha MM', 'Noor SM', 'Naeem J']","['Humans', 'Adapalene/therapeutic use', 'Doxycycline/therapeutic use', 'Azithromycin/therapeutic use', 'Treatment Outcome', '*Acne Vulgaris/drug therapy', 'Gels/therapeutic use', '*Dermatologic Agents']",https://pubmed.ncbi.nlm.nih.gov/36566399/
1176,Adapalene,33683070,Tolerability and Efficacy of Clindamycin/Tretinoin versus Adapalene/Benzoyl Peroxide in the Treatment of Acne Vulgaris.,"['Aschoff R', 'Moller S', 'Haase R', 'Kuske M']","['Acne Vulgaris/diagnosis/*drug therapy', 'Adapalene, Benzoyl Peroxide Drug Combination/*administration & dosage/adverse effects', 'Administration, Cutaneous', 'Adolescent', 'Adult', 'Clindamycin/*administration & dosage/adverse effects', 'Dermatologic Agents/*administration & dosage/adverse effects', 'Drug Combinations', 'Erythema/chemically induced/epidemiology', 'Female', 'Gels', 'Humans', 'Male', 'Patient Satisfaction/statistics & numerical data', 'Pilot Projects', 'Pruritus/chemically induced/epidemiology', 'Severity of Illness Index', 'Skin/drug effects', 'Treatment Outcome', 'Tretinoin/*administration & dosage/adverse effects', 'Water Loss, Insensible/drug effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33683070/
1177,Adapalene,39630680,Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and Adolescents.,"['Eichenfield LF', 'Hebert AA', 'Harper JC', 'Baldwin H', 'Bhatia N', 'Gold LS', 'Kircik LH', 'Graber E', 'Tanghetti EA', 'Alexis AF', 'Del Rosso JQ']","['Humans', '*Acne Vulgaris/drug therapy/diagnosis', '*Clindamycin/administration & dosage/adverse effects/analogs & derivatives', 'Adolescent', 'Child', 'Female', 'Male', '*Gels', 'Double-Blind Method', '*Drug Combinations', '*Benzoyl Peroxide/administration & dosage/adverse effects', 'Treatment Outcome', '*Severity of Illness Index', '*Dermatologic Agents/administration & dosage/adverse effects', '*Administration, Cutaneous']",https://pubmed.ncbi.nlm.nih.gov/39630680/
1178,Adapalene,9074847,Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne.,"['Brogden RN', 'Goa KE']","['Acne Vulgaris/*drug therapy', 'Adapalene', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use', 'Humans', 'Naphthalenes/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9074847/
1179,Adapalene,26947815,Recent advances in the use of adapalene 0.1%/benzoyl peroxide 2.5% to treat patients with moderate to severe acne.,['Leyden J'],"['Acne Vulgaris/*drug therapy', 'Adapalene/*administration & dosage', 'Anti-Bacterial Agents/administration & dosage', 'Benzoyl Peroxide/*administration & dosage', 'Dermatologic Agents/administration & dosage', 'Doxycycline/administration & dosage/therapeutic use', 'Drug Combinations', 'Gels', 'Humans', 'Inflammation/drug therapy', 'Isotretinoin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26947815/
1180,Adapalene,20415678,"Efficacy, safety, and tolerability of microsphere adapalene vs. conventional adapalene for acne vulgaris.","['Rao GR', 'Ghosh S', 'Dhurat R', 'Sharma A', 'Dongre P', 'Baliga VP']","['Acne Vulgaris/*drug therapy', 'Adapalene', 'Adolescent', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects', 'Child', 'Dermatologic Agents/*administration & dosage', 'Female', 'Humans', '*Microspheres', 'Naphthalenes/*administration & dosage/adverse effects', 'Prospective Studies', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/20415678/
1181,Adapalene,23725303,"Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single-center, randomized, double-blinded, placebo-controlled clinical trial on Mexican patients (skin type III-IV).","['Tirado-Sanchez A', 'Espindola YS', 'Ponce-Olivera RM', 'Bonifaz A']","['Acne Vulgaris/*drug therapy', 'Adapalene', 'Adolescent', 'Adult', 'Child', 'Dermatitis, Irritant/etiology', 'Dermatologic Agents/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Gels', 'Humans', 'Hyperpigmentation/chemically induced', 'Keratolytic Agents/adverse effects/*therapeutic use', 'Male', 'Mexico', 'Naphthalenes/adverse effects/*therapeutic use', 'Pruritus/chemically induced', 'Tretinoin/adverse effects/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/23725303/
1182,Adapalene,37098185,Efficacy and safety of adapalene gel as a reactive treatment for cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck: A historical cohort comparison study.,"['Uozumi S', 'Enokida T', 'Suzuki S', 'Nishizawa A', 'Kamata H', 'Okano T', 'Kawasaki T', 'Fujisawa T', 'Ueda Y', 'Okano S', 'Tahara M', 'Yamaguchi M']","['Humans', 'Cetuximab/adverse effects', 'Adapalene/therapeutic use', 'Squamous Cell Carcinoma of Head and Neck/drug therapy', 'Prospective Studies', 'Retrospective Studies', '*Paronychia/chemically induced/drug therapy', 'Neoplasm Recurrence, Local/drug therapy', '*Skin Diseases/chemically induced', '*Head and Neck Neoplasms/drug therapy', 'Steroids', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37098185/
1183,Zolpidem,36260747,Heteroarylation of Congested alpha-Bromoamides with Imidazo-Heteroarenes and Indolizines via Aza-Oxyallyl Cations: Enroute to Dibenzoazepinone and Zolpidem Analogues.,"['Sathish E', 'Gupta AK', 'Deeksha', 'Mishra SK', 'Sawant DM', 'Singh R']","['*Indolizines', 'Zolpidem', 'Molecular Structure', 'Cations']",https://pubmed.ncbi.nlm.nih.gov/36260747/
1184,Zolpidem,35985088,Zolpidem use and risk of suicide: A systematic review and meta-analysis.,"['Khan H', 'Garg A', 'Yasmeen', 'Agarwal NB', 'Yadav DK', 'Ashif Khan M', 'Hussain S']","['Humans', 'Risk Assessment', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Suicidal Ideation', '*Suicide, Attempted', 'Zolpidem/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35985088/
1185,Zolpidem,35286569,Effect of Zolpidem on nocturnal arousals and susceptibility to central sleep apnea.,"['Ahmad B', 'Sankari A', 'Eshraghi M', 'Aldwaikat A', 'Yarandi H', 'Zeineddine S', 'Salloum A', 'Badr MS']","['Humans', 'Arousal', 'Carbon Dioxide', '*Sleep Apnea Syndromes', '*Sleep Apnea, Central/drug therapy', 'Zolpidem', 'Cross-Over Studies']",https://pubmed.ncbi.nlm.nih.gov/35286569/
1186,Zolpidem,27105645,Zolpidem use and risk of fractures: a systematic review and meta-analysis.,"['Park SM', 'Ryu J', 'Lee DR', 'Shin D', 'Yun JM', 'Lee J']","['Fractures, Bone/*epidemiology', 'Humans', 'Pyridines/*adverse effects', 'Risk', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/27105645/
1187,Zolpidem,19584967,Novel zolpidem formulations.,['Owen RT'],"['Administration, Oral', 'Administration, Sublingual', 'Aerosols', 'Delayed-Action Preparations', 'Dosage Forms', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*pharmacokinetics/*pharmacology', 'Pyridines/administration & dosage/*pharmacokinetics/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/19584967/
1188,Zolpidem,3413207,Variations of cyclic alternating pattern rate and homeostasis of sleep organization: a controlled study on the effects of white noise and zolpidem.,"['Terzano MG', 'Parrino L', 'Fioriti G', 'Farolfi A', 'Spaggiari MC', 'Anelli S', 'Arcelloni T']","['Adult', 'Female', '*Homeostasis', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', '*Noise', 'Pyridines/*pharmacology', 'Sleep Stages/*drug effects', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/3413207/
1189,Zolpidem,37477771,"Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem.","['Di Marco T', 'Scammell TE', 'Meinel M', 'Seboek Kinter D', 'Datta AN', 'Zammit G', 'Dauvilliers Y']","['Adult', 'Humans', 'Zolpidem', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Pyridines/therapeutic use', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37477771/
1190,Zolpidem,34032717,Effectiveness and safety profiling of zolpidem and acupressure in CKD associated pruritus: An interventional study.,"['Rehman IU', 'Ahmed R', 'Rahman AU', 'Wu DBC', 'Munib S', 'Shah Y', 'Khan NA', 'Rehman AU', 'Lee LH', 'Chan KG', 'Khan TM']","['Acupressure/adverse effects/*methods', 'Acupuncture Points', 'Adolescent', 'Adult', 'Female', 'Foot', 'Humans', 'Male', 'Middle Aged', 'Pruritus/diagnosis/etiology/psychology/*therapy', 'Quality of Life', 'Renal Dialysis/adverse effects', 'Renal Insufficiency, Chronic/*complications/therapy', 'Severity of Illness Index', 'Sleep Initiation and Maintenance Disorders/etiology/psychology/*therapy', 'Treatment Outcome', 'Visual Analog Scale', 'Young Adult', 'Zolpidem/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34032717/
1191,Zolpidem,37269133,Maternal exposure to zolpidem and risk of specific birth defects.,"['Howley MM', 'Werler MM', 'Fisher SC', 'Tracy M', 'Van Zutphen AR', 'Papadopoulos EA', 'Hansen C', 'Ailes EC', 'Reefhuis J', 'Wood ME', 'Browne ML']","['Pregnancy', 'Female', 'Humans', '*Maternal Exposure', 'Zolpidem/adverse effects', '*Gastroschisis/epidemiology', 'Logistic Models', 'Case-Control Studies', 'Risk Factors', 'Odds Ratio']",https://pubmed.ncbi.nlm.nih.gov/37269133/
1192,Zolpidem,34635802,"The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial.","['Louzada LL', 'Machado FV', 'Quintas JL', 'Ribeiro GA', 'Silva MV', 'Mendonca-Silva DL', 'Goncalves BSB', 'Nobrega OT', 'Camargos EF']","['Aged, 80 and over', '*Alzheimer Disease/complications/drug therapy', 'Azabicyclo Compounds', 'Double-Blind Method', 'Humans', 'Hypnotics and Sedatives/adverse effects', 'Piperazines', '*Sleep Initiation and Maintenance Disorders/complications/drug therapy', 'Zolpidem/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34635802/
1193,Zolpidem,2226217,Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.,"['Langtry HD', 'Benfield P']","['Drug Interactions', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Premedication', 'Pyridines/pharmacokinetics/pharmacology/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/2226217/
1194,Zolpidem,39496046,"Zolpidem-related euphoria, addiction and detoxification: A case report and review of the literature.","['Xie F', 'Liu B', 'Yang L', 'Huang J', 'Li B', 'Li Y']","['Humans', '*Zolpidem/therapeutic use/administration & dosage', 'Female', 'Middle Aged', '*Sleep Initiation and Maintenance Disorders/drug therapy', '*Substance-Related Disorders/psychology', '*Hypnotics and Sedatives/adverse effects/therapeutic use', '*Substance Withdrawal Syndrome/drug therapy', 'Pyridines/adverse effects/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39496046/
1195,Zolpidem,29750249,Zolpidem and Zolpidem Carboxylic Acid Results from Medication Monitoring.,"['Feng S', 'Cummings OT', 'McIntire G']","['Administration, Oral', 'Biotransformation', 'Chromatography, Liquid', 'Drug Dosage Calculations', 'Drug Monitoring/*methods', 'Female', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*urine', 'Male', 'Pyridines/*urine', 'Reproducibility of Results', 'Sex Factors', 'Tablets', 'Tandem Mass Spectrometry', 'Urinalysis', 'Zolpidem/administration & dosage/*urine']",https://pubmed.ncbi.nlm.nih.gov/29750249/
1196,Zolpidem,31880796,Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.,"['Rosenberg R', 'Murphy P', 'Zammit G', 'Mayleben D', 'Kumar D', 'Dhadda S', 'Filippov G', 'LoPresti A', 'Moline M']","['Aged', 'Delayed-Action Preparations', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Male', 'Middle Aged', 'Polysomnography', 'Pyridines/*therapeutic use', 'Pyrimidines/*therapeutic use', 'Sleep Aids, Pharmaceutical/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31880796/
1197,Zolpidem,29961838,"Zolpidem and Eszopiclone Pre-medication for PSG: Effects on Staging, Titration, and Adherence.","['Holley AB', 'Londeree WA', 'Sheikh KL', 'Andrada TF', 'Powell TA', 'Khramtsov A', 'Hostler JM']","['Adult', 'Analysis of Variance', 'Body Mass Index', 'Continuous Positive Airway Pressure/*methods/standards', 'Eszopiclone/*pharmacology/therapeutic use', 'Female', 'Humans', 'Hypnotics and Sedatives/pharmacology/therapeutic use', 'Male', 'Middle Aged', 'Polysomnography/*methods', 'Retrospective Studies', 'Sleep Initiation and Maintenance Disorders/drug therapy/prevention & control', 'Statistics, Nonparametric', 'Treatment Adherence and Compliance', 'Zolpidem/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29961838/
1198,Zolpidem,30912258,Zolpidem and zolpidem phenyl-4-carboxylic acid pharmacokinetics in oral fluid after a single dose.,"['Feng X', 'Chen H', 'Xiang P', 'Shen M']","['Administration, Oral', 'Adult', 'Chromatography, Liquid', 'Female', 'GABA-A Receptor Agonists/administration & dosage/*pharmacokinetics', 'Humans', 'Male', 'Pyridines/administration & dosage/*pharmacokinetics', 'Saliva/*metabolism', 'Sleep Aids, Pharmaceutical/administration & dosage/*pharmacokinetics', 'Tandem Mass Spectrometry', 'Zolpidem/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/30912258/
1199,Zolpidem,35139209,"Simultaneous Analysis of Zolpidem, Four Hydroxyzolpidems and Two Zolpidem Carboxylic Acids in Postmortem Urine Using Liquid Chromatography--Tandem Mass Spectrometry.","['Yamaguchi K', 'Ohno Y', 'Kanawaku Y']","['Zolpidem', '*Tandem Mass Spectrometry/methods', '*Cysteine', 'Chromatography, Liquid', 'Hypnotics and Sedatives', 'Chromatography, High Pressure Liquid/methods']",https://pubmed.ncbi.nlm.nih.gov/35139209/
1200,Zolpidem,28810070,"The Appearance, Taste, and Concentrations of Zolpidem Dissolved in Still Water and Carbonated Beverages.","['Heide G', 'Hjelmeland K', 'Brochmann GW', 'Karinen R', 'Hoiseth G']","['*Carbonated Beverages', 'Chromatography, High Pressure Liquid', '*Drinking Water', 'Humans', 'Hypnotics and Sedatives/*analysis/chemistry', 'Pyridines/*analysis/chemistry', 'Tandem Mass Spectrometry', '*Taste', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/28810070/
1201,Zolpidem,33440032,Determination of zolpidem phenyl-4-carboxylic acid and zolpidem 6-carboxylic acid in hair using gas chromatography-electron ionization-tandem mass spectrometry.,"['Kwon NH', 'Kim SY', 'Suh SI', 'Kim JY']","['Gas Chromatography-Mass Spectrometry/*methods', 'Hair/*chemistry', 'Humans', 'Limit of Detection', 'Linear Models', '*Pyridines/analysis/metabolism', 'Reproducibility of Results', 'Spectrometry, Mass, Electrospray Ionization', 'Zolpidem/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/33440032/
1202,Zolpidem,29414005,Evaluation of benzodiazepines and zolpidem in nails and their stability after prolonged exposure to chlorinated water.,"['Moretti M', 'Andrello L', 'Visona S', 'Vignali C', 'Groppi A', 'Freni F', 'Osculati A', 'Tajana L', 'Morini L']","['Benzodiazepines/*chemistry', 'Bromazepam/chemistry', 'Chlorine/*adverse effects', 'Chromatography, Liquid/methods', 'Diazepam/chemistry', 'Female', 'Forensic Toxicology/methods', 'Humans', 'Limit of Detection', 'Male', 'Nails/*chemistry', 'Pyridines/*chemistry', 'Tandem Mass Spectrometry/methods', 'Water/*adverse effects', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/29414005/
1203,Chloroquine,32634079,The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.,"['Martinez GP', 'Zabaleta ME', 'Di Giulio C', 'Charris JE', 'Mijares MR']","['Autoimmune Diseases/drug therapy', 'Betacoronavirus', 'COVID-19', 'Chloroquine/*pharmacology/therapeutic use', 'Coronavirus Infections', 'Humans', 'Hydroxychloroquine/*pharmacology/therapeutic use', 'Immune System/*drug effects', 'Pandemics', 'Pneumonia, Viral', 'SARS-CoV-2']",https://pubmed.ncbi.nlm.nih.gov/32634079/
1204,Chloroquine,32726238,Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.,"['Lebin JA', 'LeSaint KT']","['Betacoronavirus/*drug effects', 'COVID-19', 'Chloroquine/adverse effects/*therapeutic use', 'Coronavirus Infections/*drug therapy', 'Humans', 'Hydroxychloroquine/adverse effects/*therapeutic use', 'Pandemics', 'Pneumonia, Viral/*drug therapy', 'SARS-CoV-2', 'COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/32726238/
1205,Chloroquine,32147496,Of chloroquine and COVID-19.,"['Touret F', 'de Lamballerie X']","['Antiviral Agents/adverse effects/pharmacology/standards/*therapeutic use', 'Betacoronavirus/drug effects', 'COVID-19', 'China', 'Chloroquine/adverse effects/pharmacology/standards/*therapeutic use', 'Clinical Trials as Topic/standards', 'Coronavirus Infections/*drug therapy', 'Humans', 'Hydroxychloroquine/adverse effects/pharmacology/standards/therapeutic use', 'Pandemics', 'Pneumonia, Viral/*drug therapy', 'SARS-CoV-2']",https://pubmed.ncbi.nlm.nih.gov/32147496/
1206,Chloroquine,33028485,Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.,['Carafoli E'],"['COVID-19/prevention & control', 'Chloroquine/chemistry/pharmacology/*therapeutic use', 'Humans', 'Hydroxychloroquine/chemistry/pharmacology/*therapeutic use', 'Primary Prevention', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33028485/
1207,Chloroquine,37846548,Pharmacogenomics of chloroquine and hydroxychloroquine: current evidence and future implications.,"['Biswas M', 'Sukasem C']","['Humans', '*Hydroxychloroquine/adverse effects', '*Chloroquine/adverse effects', 'Cytochrome P-450 CYP2C8', 'Cytochrome P-450 CYP2D6/genetics', 'Pharmacogenetics']",https://pubmed.ncbi.nlm.nih.gov/37846548/
1208,Chloroquine,32687630,Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.,"['Nicol MR', 'Joshi A', 'Rizk ML', 'Sabato PE', 'Savic RM', 'Wesche D', 'Zheng JH', 'Cook J']","['Age Factors', 'Aging', 'Antiviral Agents/administration & dosage/adverse effects/*therapeutic use', 'Chloroquine/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Drug Interactions', 'Drug Therapy, Combination', 'Humans', 'Hydroxychloroquine/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Liver Failure/epidemiology', 'Malaria/drug therapy', 'Prospective Studies', 'Renal Insufficiency/epidemiology', 'SARS-CoV-2', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/32687630/
1209,Chloroquine,33775862,Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms.,"['Ferreira PMP', 'Sousa RWR', 'Ferreira JRO', 'Militao GCG', 'Bezerra DP']","['Antineoplastic Agents/pharmacology', 'Autophagy/*drug effects', 'Chloroquine/*pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Drug Resistance, Neoplasm', 'Humans', 'Hydroxychloroquine/*pharmacology/therapeutic use', 'Immunomodulating Agents/pharmacology', 'Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33775862/
1210,Chloroquine,35137072,Chloroquine-susceptible and -resistant Plasmodium falciparum strains survive high chloroquine concentrations by becoming dormant but are eliminated by prolonged exposure.,"['Ursing J', 'Johns R', 'Aydin-Schmidt B', 'Calcada C', 'Kofoed PE', 'Ghanchi NK', 'Veiga MI', 'Rombo L']","['*Antimalarials/pharmacology/therapeutic use', 'Chloroquine/pharmacology/therapeutic use', 'Drug Resistance', 'Humans', '*Malaria, Falciparum/drug therapy', 'Plasmodium falciparum']",https://pubmed.ncbi.nlm.nih.gov/35137072/
1211,Chloroquine,33617702,Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: Review and Appraisal of Current Evidence.,"['Powell-Young YM', 'Alzaghari O', 'Reyes-Miranda C', 'Coleman B', 'Strickland OL', 'Gordon Y', 'Aroke E', 'Lewis Iii H', 'Giger JN']","['*Chloroquine/therapeutic use', 'Humans', '*Hydroxychloroquine/therapeutic use', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33617702/
1212,Chloroquine,33316045,Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.,"['Nadeem U', 'Raafey M', 'Kim G', 'Treger J', 'Pytel P', 'N Husain A', 'Schulte JJ']","['Antimalarials/*adverse effects/therapeutic use', 'Antiviral Agents/adverse effects/therapeutic use', 'COVID-19/diagnosis', 'Cardiomyopathies/*etiology', 'Chloroquine/*adverse effects/pharmacology', 'Humans', 'Hydroxychloroquine/*adverse effects/pharmacology', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33316045/
1213,Chloroquine,1952637,Chloroquine and hydroxychloroquine retinopathy: how to follow affected patients.,"['Ruiz RS', 'Saatci OA']","['Chloroquine/*adverse effects', 'Follow-Up Studies', 'Fundus Oculi', 'Humans', 'Hydroxychloroquine/*adverse effects', 'Photography', 'Retinal Diseases/*chemically induced', 'Visual Fields']",https://pubmed.ncbi.nlm.nih.gov/1952637/
1214,Chloroquine,35390060,Chloroquine and COVID-19-A systems biology model uncovers the drug's detrimental effect on autophagy and explains its failure.,"['Kapuy O', 'Korcsmaros T']","['Autophagy', 'Chloroquine/pharmacology/therapeutic use', 'Humans', 'Hydroxychloroquine/adverse effects', 'Pandemics', 'SARS-CoV-2', 'Systems Biology', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/35390060/
1215,Chloroquine,2110509,"Chloroquine's modulation of endothelial cell activity induced with basic fibroblast growth factor and human serum: effect on mitogenesis, protease production and cell migration.","['Inyang AL', 'Bikfalvi A', 'Lu H', 'Tobelem G']","['Blood Proteins/*pharmacology', 'Cell Division/drug effects', 'Cells, Cultured', 'Chloroquine/*pharmacology', 'Endopeptidases/*metabolism', 'Endothelium, Vascular/*cytology/drug effects/enzymology', 'Fibroblast Growth Factors/*pharmacology', 'Humans', 'Tissue Plasminogen Activator/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/2110509/
1216,Chloroquine,36753782,Affinity binding of COVID-19 drug candidates (chloroquine/hydroxychloroquine) and serum albumin: Based on photochemistry and molecular docking.,"['Hu LY', 'Yuan Y', 'Wen ZX', 'Hu YY', 'Yin MM', 'Hu YJ']","['Humans', 'Antiviral Agents/chemistry/pharmacology', '*Chloroquine/chemistry/pharmacology', 'Computer Simulation', '*COVID-19', 'COVID-19 Drug Treatment', '*Hydroxychloroquine/chemistry/pharmacology', 'Molecular Docking Simulation', 'Photochemistry', 'SARS-CoV-2']",https://pubmed.ncbi.nlm.nih.gov/36753782/
1217,Fluorouracil,3275485,5-Fluorouracil-associated cardiotoxicity.,"['Freeman NJ', 'Costanza ME']","['Electrocardiography', 'Fluorouracil/*adverse effects/pharmacokinetics', 'Heart/*drug effects', 'Humans', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/3275485/
1218,Fluorouracil,33573546,Chemistry and Anticancer Activity of Hybrid Molecules and Derivatives based on 5-Fluorouracil.,"['Cardona-G W', 'Herrera-R A', 'Castrillon-L W', 'Ramirez-Malule H']","['*Antineoplastic Agents/pharmacology/therapeutic use', 'Drug Discovery', 'Fluorouracil/pharmacology/therapeutic use', 'Humans', '*Neoplasms/drug therapy', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/33573546/
1219,Fluorouracil,2656050,Clinical pharmacology of 5-fluorouracil.,"['Diasio RB', 'Harris BE']","['Female', 'Fluorouracil/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/2656050/
1220,Fluorouracil,2295446,5-Fluorouracil neurotoxicity.,"['Moore DH', 'Fowler WC Jr', 'Crumpler LS']","['Adult', 'Carcinoma, Squamous Cell/drug therapy', 'Female', 'Fluorouracil/*adverse effects/metabolism', 'Humans', 'Middle Aged', 'Nervous System Diseases/*chemically induced', 'Thiamine Deficiency/complications', 'Uterine Cervical Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2295446/
1221,Fluorouracil,630214,Fluorouracil cardiotoxicity.,"['Pottage A', 'Holt S', 'Ludgate S', 'Langlands AO']","['Adult', 'Aged', 'Coronary Disease/*chemically induced', 'Electrocardiography', 'Female', 'Fluorouracil/*adverse effects/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/630214/
1222,Fluorouracil,2604390,19F nuclear magnetic resonance analysis of 5-fluorouracil metabolism in wild-type and 5-fluorouracil-resistant Nectria haematococca.,"['Parisot D', 'Malet-Martino MC', 'Crasnier P', 'Martino R']","['Agar', 'Culture Media', 'Drug Resistance, Microbial', 'Fluorouracil/*metabolism/pharmacology', 'Hypocreales/drug effects/genetics/*metabolism', 'Magnetic Resonance Spectroscopy', 'Mutation', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2604390/
1223,Fluorouracil,16990003,"Synthesis, aerobic cytotoxicity, and radiosensitizing activity of novel 2,4-dinitrophenylamine tethered 5-fluorouracil and hydroxyurea.","['Khalaj A', 'Doroudi AR', 'Ostad SN', 'Khoshayand MR', 'Babai M', 'Adibpour N']","['Aerobiosis', 'Cell Survival/drug effects/radiation effects', 'Fluorouracil/*analogs & derivatives/*chemical synthesis/chemistry/*toxicity', 'HT29 Cells', 'Humans', 'Hydroxyurea/*analogs & derivatives/*chemical synthesis/chemistry/*toxicity', 'Molecular Structure', 'Nitro Compounds/*chemical synthesis/chemistry/*toxicity', 'Radiation-Sensitizing Agents/*chemical synthesis/chemistry/*toxicity', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/16990003/
1224,Fluorouracil,37570864,"Synthesis and Characterization of Methoxy-Exfoliated Montmorillonite Nanosheets as Potential Carriers of 5-Fluorouracil Drug with Enhanced Loading, Release, and Cytotoxicity Properties.","['Alqahtani MD', 'Bin Jumah MN', 'Al-Hashimi A', 'Allam AA', 'Abukhadra MR', 'Bellucci S']","['*Fluorouracil/pharmacology/chemistry', '*Bentonite/chemistry', 'Drug Carriers/chemistry', 'Drug Liberation', 'Ions']",https://pubmed.ncbi.nlm.nih.gov/37570864/
1225,Fluorouracil,23582737,"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.","['Polk A', 'Vaage-Nilsen M', 'Vistisen K', 'Nielsen DL']","['Capecitabine', 'Deoxycytidine/adverse effects/*analogs & derivatives/therapeutic use', 'Fluorouracil/*adverse effects/*analogs & derivatives/therapeutic use', 'Heart Diseases/*chemically induced', 'Humans', 'Prospective Studies', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/23582737/
1226,Fluorouracil,32592630,"Systemic exposure to 5-fluorouracil and its metabolite, 5,6-dihydrofluorouracil, and development of a limited sampling strategy for therapeutic drug management of 5-fluorouracil in patients with gastrointestinal malignancy.","['Jacob J', 'Mathew SK', 'Chacko RT', 'Aruldhas BW', 'Singh A', 'Prabha R', 'Mathew BS']","['Fluorouracil/adverse effects/analogs & derivatives', '*Gastrointestinal Neoplasms/drug therapy', 'Humans', '*Pharmaceutical Preparations', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/32592630/
1227,Fluorouracil,15169811,Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.,"['Rich TA', 'Shepard RC', 'Mosley ST']","['Antimetabolites, Antineoplastic/administration & dosage/pharmacology/*therapeutic use', 'Capecitabine', 'Combined Modality Therapy', 'Deoxycytidine/*analogs & derivatives/therapeutic use', 'Drug Administration Schedule', 'Drug Combinations', 'Fluorouracil/administration & dosage/analogs & derivatives/pharmacology/*therapeutic use', 'Humans', 'Neoplasms/*drug therapy/*radiotherapy', 'Pyrimidines/administration & dosage', 'Radiation-Sensitizing Agents/administration & dosage/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15169811/
1228,Modafinil,33242419,"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.","['Nourbakhsh B', 'Revirajan N', 'Morris B', 'Cordano C', 'Creasman J', 'Manguinao M', 'Krysko K', 'Rutatangwa A', 'Auvray C', 'Aljarallah S', 'Jin C', 'Mowry E', 'McCulloch C', 'Waubant E']","['Adult', 'Amantadine/administration & dosage/adverse effects/*pharmacology', 'Central Nervous System Stimulants/administration & dosage/adverse effects/*pharmacology', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Administration Schedule', '*Drug-Related Side Effects and Adverse Reactions', 'Fatigue/*drug therapy/*etiology', 'Female', 'Humans', 'Male', 'Methylphenidate/administration & dosage/adverse effects/*pharmacology', 'Middle Aged', 'Modafinil/administration & dosage/adverse effects/*pharmacology', 'Multiple Sclerosis/*complications', '*Outcome Assessment, Health Care', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/33242419/
1229,Modafinil,33074297,Pregnancy and Fetal Outcomes Following Exposure to Modafinil and Armodafinil During Pregnancy.,"['Kaplan S', 'Braverman DL', 'Frishman I', 'Bartov N']","['Abnormalities, Drug-Induced/*epidemiology', 'Female', 'Humans', 'Modafinil/*adverse effects', 'Narcolepsy/drug therapy', 'Pregnancy', 'Registries', 'United States/epidemiology', 'Wakefulness-Promoting Agents/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33074297/
1230,Modafinil,35670369,"Cognitive enhancement: Effects of methylphenidate, modafinil, and caffeine on latent memory and resting state functional connectivity in healthy adults.","['Becker M', 'Repantis D', 'Dresler M', 'Kuhn S']","['Adult', 'Brain/diagnostic imaging', 'Brain Mapping/methods', 'Caffeine/pharmacology', '*Central Nervous System Stimulants/pharmacology', 'Cognition', 'Double-Blind Method', 'Humans', 'Magnetic Resonance Imaging/methods', 'Male', '*Methylphenidate/pharmacology', 'Modafinil/pharmacology', 'Neural Pathways/diagnostic imaging']",https://pubmed.ncbi.nlm.nih.gov/35670369/
1231,Modafinil,31990303,First-Trimester Pregnancy Exposure to Modafinil and Risk of Congenital Malformations.,"['Damkier P', 'Broe A']","['Abnormalities, Drug-Induced/*epidemiology/etiology', 'Adult', 'Central Nervous System Stimulants/*adverse effects', 'Denmark/epidemiology', 'Female', 'Humans', 'Logistic Models', 'Methylphenidate/*adverse effects', 'Modafinil/*adverse effects', 'Pregnancy', 'Pregnancy Trimester, First', 'Product Surveillance, Postmarketing', 'Registries']",https://pubmed.ncbi.nlm.nih.gov/31990303/
1232,Modafinil,32870289,Incidence of Malformations After Early Pregnancy Exposure to Modafinil in Sweden and Norway.,"['Cesta CE', 'Engeland A', 'Karlsson P', 'Kieler H', 'Reutfors J', 'Furu K']","['Abnormalities, Drug-Induced/*epidemiology/etiology', 'Adult', 'Central Nervous System Stimulants/*adverse effects', 'Cohort Studies', 'Female', 'Humans', 'Incidence', 'Modafinil/*adverse effects', 'Norway/epidemiology', 'Odds Ratio', 'Pregnancy', 'Pregnancy Trimester, First', 'Registries', 'Sweden/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/32870289/
1233,Modafinil,31951804,Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects.,"['Sousa A', 'Dinis-Oliveira RJ']","['Anxiety', 'Diarrhea', 'Drug Eruptions/etiology', 'Drug Interactions', 'Erythema Multiforme/chemically induced', 'Forensic Sciences', 'Headache', 'Humans', 'Modafinil/analogs & derivatives/chemistry/*pharmacology/therapeutic use', 'Narcolepsy/drug therapy', 'Nootropic Agents/chemistry/*pharmacology/therapeutic use', 'Sleep Apnea, Obstructive/drug therapy', 'Sleep Disorders, Circadian Rhythm/drug therapy', 'Sleep Initiation and Maintenance Disorders', 'Stevens-Johnson Syndrome/etiology']",https://pubmed.ncbi.nlm.nih.gov/31951804/
1234,Modafinil,36142172,"Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration.","['Wagener N', 'Lehmann W', 'Weiser L', 'Jackle K', 'Di Fazio P', 'Schilling AF', 'Boker KO']","['Adult', 'Atomoxetine Hydrochloride/pharmacology', '*Attention Deficit Disorder with Hyperactivity/drug therapy', 'Cell Differentiation', '*Central Nervous System Stimulants/pharmacology', 'Child', 'Guanfacine/pharmacology', 'Humans', 'Ligands', '*Methylphenidate/therapeutic use', 'Modafinil/pharmacology/therapeutic use', '*Nootropic Agents/therapeutic use', 'Osteoprotegerin/therapeutic use', 'Receptor Activator of Nuclear Factor-kappa B']",https://pubmed.ncbi.nlm.nih.gov/36142172/
1235,Modafinil,37839272,Pitolisant-supported bridging during drug holidays to deal with tolerance to modafinil in patients with narcolepsy.,"['Winter Y', 'Lang C', 'Kallweit U', 'Apel D', 'Fleischer V', 'Ellwardt E', 'Groppa S']","['Humans', 'Modafinil/therapeutic use', 'Quality of Life', '*Narcolepsy/drug therapy/chemically induced', 'Piperidines/adverse effects', '*Disorders of Excessive Somnolence/drug therapy', 'Benzhydryl Compounds/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37839272/
1236,Modafinil,23877512,False-positive 123I-FP-CIT scintigraphy and suggested dopamine transporter upregulation due to chronic modafinil treatment.,"['Borghammer P', 'Knudsen K', 'Danielsen E', 'Ostergaard K']","['Aged', 'Benzhydryl Compounds/*pharmacology', 'Dopamine Plasma Membrane Transport Proteins/*metabolism', 'False Positive Reactions', 'Humans', 'Male', 'Modafinil', 'Neostriatum/diagnostic imaging/drug effects/metabolism', 'Radionuclide Imaging', '*Tropanes', 'Up-Regulation/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/23877512/
1237,Modafinil,30117329,"Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis.","['Stuhec M', 'Lukic P', 'Locatelli I']","['Adult', 'Amphetamine/chemistry/*therapeutic use', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/epidemiology', 'Central Nervous System Stimulants/therapeutic use', 'Double-Blind Method', 'Humans', 'Lisdexamfetamine Dimesylate/*therapeutic use', 'Methylphenidate/*therapeutic use', 'Modafinil/*therapeutic use', 'Salts/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30117329/
1238,Exemestane,36521078,Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.,"['Pagani O', 'Walley BA', 'Fleming GF', 'Colleoni M', 'Lang I', 'Gomez HL', 'Tondini C', 'Burstein HJ', 'Goetz MP', 'Ciruelos EM', 'Stearns V', 'Bonnefoi HR', 'Martino S', 'Geyer CE Jr', 'Chini C', 'Puglisi F', 'Spazzapan S', 'Ruhstaller T', 'Winer EP', 'Ruepp B', 'Loi S', 'Coates AS', 'Gelber RD', 'Goldhirsch A', 'Regan MM', 'Francis PA']","['Adult', 'Female', 'Humans', 'Adjuvants, Immunologic/therapeutic use', 'Antineoplastic Agents, Hormonal/therapeutic use', '*Breast Neoplasms/drug therapy', 'Chemotherapy, Adjuvant', 'Disease-Free Survival', 'Follow-Up Studies', 'Premenopause', 'Tamoxifen/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36521078/
1239,Exemestane,24881463,Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.,"['Pagani O', 'Regan MM', 'Walley BA', 'Fleming GF', 'Colleoni M', 'Lang I', 'Gomez HL', 'Tondini C', 'Burstein HJ', 'Perez EA', 'Ciruelos E', 'Stearns V', 'Bonnefoi HR', 'Martino S', 'Geyer CE Jr', 'Pinotti G', 'Puglisi F', 'Crivellari D', 'Ruhstaller T', 'Winer EP', 'Rabaglio-Poretti M', 'Maibach R', 'Ruepp B', 'Giobbie-Hurder A', 'Price KN', 'Bernhard J', 'Luo W', 'Ribi K', 'Viale G', 'Coates AS', 'Gelber RD', 'Goldhirsch A', 'Francis PA']","['Adult', 'Androstadienes/adverse effects/*therapeutic use', 'Antineoplastic Agents, Hormonal/adverse effects/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Aromatase Inhibitors/adverse effects/therapeutic use', 'Breast Neoplasms/*drug therapy/radiotherapy/surgery', 'Chemotherapy, Adjuvant', 'Disease-Free Survival', 'Estradiol/blood', 'Female', 'Follow-Up Studies', 'Humans', 'Kaplan-Meier Estimate', 'Mastectomy', 'Middle Aged', 'Osteoporosis/chemically induced', 'Premenopause', 'Quality of Life', 'Tamoxifen/adverse effects/*therapeutic use', 'Triptorelin Pamoate/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24881463/
1240,Exemestane,33722897,"Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR(+)/HER2(-) Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).","['Bardia A', 'Hurvitz SA', 'DeMichele A', 'Clark AS', 'Zelnak A', 'Yardley DA', 'Karuturi M', 'Sanft T', 'Blau S', 'Hart L', 'Ma C', 'Rugo HS', 'Purkayastha D', 'Moulder S']","['Adult', 'Aged', 'Aged, 80 and over', 'Aminopyridines/*therapeutic use', 'Androstadienes/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Breast Neoplasms/chemistry/*drug therapy/pathology', 'Cyclin-Dependent Kinase 4/antagonists & inhibitors', 'Cyclin-Dependent Kinase 6/antagonists & inhibitors', 'Disease Progression', 'Everolimus/*therapeutic use', 'Female', 'Humans', 'Middle Aged', 'Purines/*therapeutic use', 'Receptor, ErbB-2/analysis']",https://pubmed.ncbi.nlm.nih.gov/33722897/
1241,Exemestane,24158787,Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.,"['Yardley DA', 'Noguchi S', 'Pritchard KI', 'Burris HA 3rd', 'Baselga J', 'Gnant M', 'Hortobagyi GN', 'Campone M', 'Pistilli B', 'Piccart M', 'Melichar B', 'Petrakova K', 'Arena FP', 'Erdkamp F', 'Harb WA', 'Feng W', 'Cahana A', 'Taran T', 'Lebwohl D', 'Rugo HS']","['Adult', 'Aged', 'Aged, 80 and over', 'Androstadienes/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bone Neoplasms/drug therapy/secondary', 'Breast Neoplasms/*drug therapy/metabolism/pathology', 'Disease-Free Survival', 'Double-Blind Method', 'Everolimus', 'Female', 'Humans', 'Liver Neoplasms/drug therapy/secondary', 'Lung Neoplasms/drug therapy/secondary', 'Middle Aged', 'Postmenopause', 'Receptors, Estrogen/metabolism', 'Receptors, Progesterone/metabolism', 'Sirolimus/administration & dosage/analogs & derivatives', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24158787/
1242,Exemestane,25231953,"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger.","['Piccart M', 'Hortobagyi GN', 'Campone M', 'Pritchard KI', 'Lebrun F', 'Ito Y', 'Noguchi S', 'Perez A', 'Rugo HS', 'Deleu I', 'Burris HA 3rd', 'Provencher L', 'Neven P', 'Gnant M', 'Shtivelband M', 'Wu C', 'Fan J', 'Feng W', 'Taran T', 'Baselga J']","['Androstadienes/adverse effects/*therapeutic use', 'Breast Neoplasms', 'Double-Blind Method', 'ErbB Receptors/metabolism', 'Everolimus', 'Female', 'Humans', 'Placebos', 'Sirolimus/adverse effects/*analogs & derivatives/therapeutic use', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/25231953/
1243,Exemestane,8300790,"Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection.","['Breda M', 'Pianezzola E', 'Benedetti MS']","['Androstadienes/*blood', '*Aromatase Inhibitors', 'Chromatography, High Pressure Liquid/*methods', 'Humans', 'Male', 'Reproducibility of Results', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/8300790/
1244,Exemestane,28167101,Quinone-related hexacyclic by-products in the production process of exemestane.,"['Giovenzana GB', 'Masciocchi N', 'Negri R', 'Palmisano G', 'Penoni A', 'Toma L']","['Androstadienes/*chemistry', 'Benzoquinones/*chemistry', 'Magnetic Resonance Spectroscopy', 'Mass Spectrometry', 'Molecular Structure', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/28167101/
1245,Exemestane,18340242,Intergroup Exemestane Study mature analysis: overall survival data.,['Jassem J'],"['Androstadienes/*therapeutic use', 'Antineoplastic Agents/*therapeutic use', 'Aromatase Inhibitors/*therapeutic use', 'Breast Neoplasms/*drug therapy/metabolism/mortality', 'Chemotherapy, Adjuvant', 'Female', 'Humans', 'Neoplasms, Hormone-Dependent/*drug therapy/metabolism/mortality', 'Postmenopause', 'Receptors, Estrogen/metabolism', 'Selective Estrogen Receptor Modulators/therapeutic use', 'Survival Rate', 'Tamoxifen/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18340242/
1246,Exemestane,38503755,Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.,"['Gomez Tejeda Zanudo J', 'Barroso-Sousa R', 'Jain E', 'Jin Q', 'Li T', 'Buendia-Buendia JE', 'Pereslete A', 'Abravanel DL', 'Ferreira AR', 'Wrabel E', 'Helvie K', 'Hughes ME', 'Partridge AH', 'Overmoyer B', 'Lin NU', 'Tayob N', 'Tolaney SM', 'Wagle N']","['Humans', 'Female', '*Breast Neoplasms/drug therapy/genetics/metabolism', 'Everolimus/therapeutic use', 'Transcriptome', 'Proto-Oncogene Proteins B-raf/genetics', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Receptor, ErbB-2/metabolism', 'Gene Expression Profiling', 'Genomics', 'Cyclin-Dependent Kinase 4/metabolism', '*Androstadienes', '*Piperazines', '*Pyridines']",https://pubmed.ncbi.nlm.nih.gov/38503755/
1247,Exemestane,27017970,"Exemestane encapsulated vitamin E-TPGS-polymeric nanoparticles: preparation, optimization, characterization, and in vitro cytotoxicity assessment.","['Mishra B', 'Padaliya R', 'Patel RR']","['Androstadienes/chemistry/*pharmacology', 'Antineoplastic Agents, Phytogenic/chemistry/*pharmacology', 'Biological Transport', 'Cell Survival/drug effects', 'Dose-Response Relationship, Drug', 'Drug Carriers', 'Drug Compounding', 'Drug Liberation', 'Factor Analysis, Statistical', 'Female', 'Humans', 'Hydrogen-Ion Concentration', 'Kinetics', 'MCF-7 Cells', 'Nanoparticles/*chemistry/ultrastructure', 'Particle Size', 'Polyesters/*chemistry/metabolism', 'Vitamin E/*chemistry/metabolism']",https://pubmed.ncbi.nlm.nih.gov/27017970/
1248,Exemestane,27687081,Falsely elevated serum oestradiol due to exemestane therapy.,"['Mandic S', 'Kratzsch J', 'Mandic D', 'Debeljak Z', 'Lukic I', 'Horvat V', 'Gaudl A', 'Seric V']","['Androstadienes/*blood/therapeutic use', 'Antineoplastic Agents/*blood/therapeutic use', 'Aromatase Inhibitors/*blood/therapeutic use', 'Breast Neoplasms/blood/*drug therapy/pathology', 'Contraindications', 'Drug Dosage Calculations', 'Estradiol/*blood', 'False Positive Reactions', 'Female', 'Humans', '*Immunoassay', 'Middle Aged', 'Molecular Mimicry', 'Monitoring, Physiologic']",https://pubmed.ncbi.nlm.nih.gov/27687081/
1249,Exemestane,26992705,Unravelling exemestane: From biology to clinical prospects.,"['Sobral AF', 'Amaral C', 'Correia-da-Silva G', 'Teixeira N']","['Anastrozole', 'Androstadienes/metabolism/*therapeutic use', 'Antineoplastic Agents/*therapeutic use', 'Apoptosis/drug effects', 'Aromatase Inhibitors/*therapeutic use', 'Autophagy/drug effects', 'Biotransformation', 'Breast Neoplasms/*drug therapy/metabolism/pathology', 'Cell Cycle Checkpoints/drug effects', 'Cell Line, Tumor', 'Clinical Trials as Topic', 'Drug Resistance, Neoplasm', 'Female', 'Humans', 'Nitriles/therapeutic use', 'Tamoxifen/therapeutic use', 'Triazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26992705/
1250,Exemestane,32756099,Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane.,"['Krasniqi E', 'Barchiesi G', 'Mazzotta M', 'Pizzuti L', 'Villa A', 'Barba M', 'Vici P']","['Androstadienes/administration & dosage/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols', 'Breast Neoplasms/*diagnosis/drug therapy/mortality/pathology', 'Carcinoma, Lobular/*diagnosis/drug therapy/mortality/pathology', 'Everolimus/administration & dosage/therapeutic use', 'Female', 'Humans', 'Liver Neoplasms/*diagnosis/drug therapy/mortality/secondary', 'Middle Aged', 'Premenopause', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/32756099/
1251,Exemestane,34989983,Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence.,"['Wang Y', 'Jing F', 'Wang H']","['Androstadienes/therapeutic use', 'Aromatase Inhibitors/therapeutic use', '*Breast Neoplasms/pathology', 'Chemotherapy, Adjuvant', 'Estrogens', 'Female', 'Humans', 'Postmenopause']",https://pubmed.ncbi.nlm.nih.gov/34989983/
1252,Exemestane,22515450,Complete response to exemestane in a patient with a desmoid tumor.,"['Debled M', 'Le Loarer F', 'Callonnec F', 'Soubeyran I', 'Cambon-Michot C', 'Dujardin F', 'Italiano A']","['Aged', 'Androstadienes/*therapeutic use', 'Antineoplastic Agents/*therapeutic use', 'Aromatase Inhibitors/*therapeutic use', 'Female', 'Desmoid Tumors/diagnosis/*drug therapy', 'Humans', 'Magnetic Resonance Imaging', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22515450/
1253,Exemestane,16918105,The evolving role of exemestane in the management of breast cancer.,['Bundred N'],"['Androstadienes/*therapeutic use', 'Antineoplastic Agents/*therapeutic use', 'Aromatase Inhibitors/*therapeutic use', 'Breast Neoplasms/*drug therapy', 'Drug Evaluation', 'Female', 'Humans', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16918105/
1254,Exemestane,34048027,Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.,"['Cairns J', 'Kalari KR', 'Ingle JN', 'Shepherd LE', 'Ellis MJ', 'Goss PE', 'Barman P', 'Carlson EE', 'Goodnature B', 'Goetz MP', 'Weinshilboum RM', 'Gao H', 'Wang L']","['Anastrozole/*therapeutic use', 'Androstadienes/*therapeutic use', 'Antigens, CD/genetics', 'Antineoplastic Agents, Hormonal/therapeutic use', 'Aromatase Inhibitors/*therapeutic use', 'Breast Neoplasms/*drug therapy/genetics/pathology', 'Chemotherapy, Adjuvant', 'Epithelial-Mesenchymal Transition/genetics', 'Female', 'Humans', 'Lectins, C-Type/genetics', 'Minor Histocompatibility Antigens/genetics', 'Neoplasm Staging', 'Patient Selection', 'Pharmacogenomic Variants', 'Polymorphism, Single Nucleotide', 'Receptors, Cell Surface/genetics', 'Receptors, G-Protein-Coupled/genetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34048027/
1255,Exemestane,39384801,Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.,"['Fullana B', 'Morales S', 'Petit A', 'Alay A', 'Verdaguer H', 'Climent F', 'Navarro-Perez V', 'Cejuela M', 'Galvan P', 'Guma A', 'Llombart-Cussac A', 'Cordero D', 'Casanovas O', 'Prat A', 'Gil-Gil M', 'Pernas S']","['Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Middle Aged', '*Androstadienes/administration & dosage/therapeutic use/adverse effects', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Biomarkers, Tumor/metabolism', '*Breast Neoplasms/drug therapy/metabolism/pathology', '*Neoadjuvant Therapy', 'Neoplasm Staging', '*Postmenopause', '*Receptor, ErbB-2/metabolism/genetics', '*Receptors, Estrogen/metabolism', 'Receptors, Progesterone/metabolism', '*Sunitinib/therapeutic use/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39384801/
1256,Pyrimethamine,6386210,Plasmodium falciparum in Haiti: susceptibility to pyrimethamine and sulfadoxine-pyrimethamine.,"['Nguyen-Dinh P', 'Zevallos-Ipenza A', 'Magloire R']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Drug Resistance', 'Drug Therapy, Combination', 'Female', 'Haiti', 'Humans', 'Infant', 'Malaria/*drug therapy/parasitology', 'Male', 'Plasmodium falciparum/*drug effects', 'Pyrimethamine/*pharmacology', 'Sulfadoxine/*pharmacology', 'Sulfanilamides/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6386210/
1257,Pyrimethamine,7036438,"The in vivo sensitivity of Plasmodium falciparum to chloroquine and to sulphadoxine-pyrimethamine combination in Ibadan, Nigeria.","['Olatunde A', 'Salako LA', 'Walker O']","['Antimalarials/*therapeutic use', 'Child', 'Child, Preschool', 'Chloroquine/*therapeutic use', 'Drug Combinations/therapeutic use', 'Drug Resistance, Microbial', 'Humans', 'Infant', 'Malaria/*drug therapy', 'Nigeria', 'Plasmodium falciparum', 'Pyrimethamine/*therapeutic use', 'Sulfadoxine/*therapeutic use', 'Sulfanilamides/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7036438/
1258,Pyrimethamine,38761813,Plasmodium ovale spp dhfr mutations associated with reduced susceptibility to pyrimethamine in sub-Saharan Africa: a retrospective genetic epidemiology and functional study.,"['Joste V', 'Coppee R', 'Bailly J', 'Rakotoarivony Y', 'Toko Tchokoteu FG', 'Achache S', 'Pradines B', 'Cottrell G', 'Ariey F', 'Khim N', 'Popovici J', 'Mita T', 'Groger M', 'Ramharter M', 'Egbo T', 'Juma DW', 'Akala H', 'Houze S', 'Clain J']","['*Tetrahydrofolate Dehydrogenase/genetics/metabolism', '*Pyrimethamine/pharmacology/therapeutic use', '*Drug Resistance/genetics', '*Antimalarials/pharmacology/therapeutic use', '*Mutation', '*Plasmodium ovale/genetics/drug effects', 'Humans', '*Malaria/epidemiology', 'Retrospective Studies', 'Africa South of the Sahara/epidemiology', 'Protozoan Proteins/genetics', 'Kenya/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/38761813/
1259,Pyrimethamine,37147353,In vitro and in vivo susceptibility to sulfadiazine and pyrimethamine of Toxoplasma gondii strains isolated from Brazilian free wild birds.,"['de Lima Bessa G', 'Vitor RWA', 'Lobo LMS', 'Rego WMF', 'de Souza GCA', 'Lopes REN', 'Costa JGL', 'Martins-Duarte ES']","['Sulfadiazine/pharmacology/therapeutic use', 'Pyrimethamine/pharmacology/therapeutic use', '*Toxoplasma', '*Antiprotozoal Agents/therapeutic use', 'Brazil']",https://pubmed.ncbi.nlm.nih.gov/37147353/
1260,Pyrimethamine,28597978,Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery.,"['de Kock M', 'Tarning J', 'Workman L', 'Nyunt MM', 'Adam I', 'Barnes KI', 'Denti P']","['Adult', 'Africa', 'Antimalarials/blood/*pharmacokinetics/therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Malaria/prevention & control', '*Models, Biological', 'Postpartum Period/blood/metabolism', 'Pregnancy/blood/metabolism', 'Pyrimethamine/blood/*pharmacokinetics/therapeutic use', 'Sulfadoxine/blood/*pharmacokinetics/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28597978/
1261,Pyrimethamine,36108988,Pyrimethamine induces phototoxicity in human keratinocytes via lysosomal and mitochondrial dependent signaling pathways under environmental UVA and UVB exposure.,['Yadav N'],"['*Dermatitis, Phototoxic/etiology/metabolism', '*HIV Infections', 'Humans', 'Keratinocytes', 'Lysosomes', 'Phosphatidylserines/metabolism', 'Pyrimethamine/metabolism/pharmacology', 'Reactive Oxygen Species/metabolism', 'Signal Transduction', 'Sunlight', 'Ultraviolet Rays/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/36108988/
1262,Pyrimethamine,9695976,The use of the anti-malaria drug Fansidar (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency.,"['van der Werff ten Bosch JE', 'Demanet C', 'Balduck N', 'Bakkus MH', 'De Raeve H', 'Desprechins B', 'Otten J', 'Thielemans K']","['Antimalarials/*therapeutic use', 'Autoimmune Diseases/*drug therapy', 'Drug Combinations', 'Humans', 'Infant', 'Lymphoproliferative Disorders/*drug therapy', 'Pyrimethamine/*therapeutic use', 'Sulfadoxine/*therapeutic use', 'Syndrome', 'Tomography, X-Ray Computed', 'fas Receptor/*blood']",https://pubmed.ncbi.nlm.nih.gov/9695976/
1263,Pyrimethamine,32310062,"Nationwide Monitoring for Plasmodium falciparum Drug-Resistance Alleles to Chloroquine, Sulfadoxine, and Pyrimethamine, Haiti, 2016-2017.","['Rogier E', 'Herman C', 'Huber CS', 'Hamre KES', 'Pierre B', 'Mace KE', 'Presume J', 'Mondelus G', 'Romilus I', 'Elisme T', 'Eisele TP', 'Druetz T', 'Existe A', 'Boncy J', 'Lemoine JF', 'Udhayakumar V', 'Chang MA']","['Alleles', '*Antimalarials/pharmacology/therapeutic use', 'Chloroquine/pharmacology/therapeutic use', 'Drug Resistance/genetics', 'Haiti/epidemiology', 'Humans', '*Malaria, Falciparum/drug therapy/epidemiology', 'Mutation', 'Plasmodium falciparum/genetics', 'Pyrimethamine/pharmacology/therapeutic use', 'Sulfadoxine/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32310062/
1264,Pyrimethamine,35815526,"Key interactions of pyrimethamine derivatives specific to wild-type and mutant P. falciparum dihydrofolate reductase based on 3D-QSAR, MD simulations and quantum chemical calculations.","['Seetin S', 'Saparpakorn P', 'Vanichtanankul J', 'Vitsupakorn D', 'Yuthavong Y', 'Kamchonwongpaisan S', 'Hannongbua S']","['Humans', 'Pyrimethamine/pharmacology/chemistry', '*Antimalarials/chemistry', 'Quantitative Structure-Activity Relationship', 'Tetrahydrofolate Dehydrogenase/chemistry', 'Plasmodium falciparum', '*Folic Acid Antagonists/chemistry']",https://pubmed.ncbi.nlm.nih.gov/35815526/
1265,Pyrimethamine,33621328,Simultaneous Determination of Chloroquine and Pyrimethamine with Cetirizine in an Active Form and Human Serum by RP-HPLC.,"['Shamshad H', 'Sayqal A', 'Zeb J', 'Mirza AZ']","['*Cetirizine', 'Chloroquine', 'Chromatography, High Pressure Liquid', 'Humans', '*Pyrimethamine', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/33621328/
1266,Pyrimethamine,36307852,"Molecular surveillance for anti-malarial drug resistance and genetic diversity of Plasmodium falciparum after chloroquine and sulfadoxine-pyrimethamine withdrawal in Quibdo, Colombia, 2018.","['Guerra AP', 'Olivera MJ', 'Cortes LJ', 'Chenet SM', 'Macedo de Oliveira A', 'Lucchi NW']","['Humans', 'Sulfadoxine/pharmacology/therapeutic use', 'Pyrimethamine/pharmacology/therapeutic use', '*Antimalarials/pharmacology/therapeutic use', 'Plasmodium falciparum', 'Chloroquine/pharmacology/therapeutic use', 'Colombia', '*Malaria, Falciparum/epidemiology', 'Artemether/therapeutic use', 'Artemether, Lumefantrine Drug Combination/therapeutic use', 'Drug Combinations', 'Drug Resistance/genetics', 'Polymorphism, Genetic', 'Codon']",https://pubmed.ncbi.nlm.nih.gov/36307852/
1267,Haloperidol,27023437,Possible biomarkers modulating haloperidol efficacy and/or tolerability.,"['Porcelli S', 'Crisafulli C', 'Calabro M', 'Serretti A', 'Rujescu D']","['Antipsychotic Agents/adverse effects/pharmacology/*therapeutic use', 'Biomarkers/analysis', 'Epigenesis, Genetic', 'Gene Expression Profiling', 'Genetic Markers', 'Genotype', 'Haloperidol/adverse effects/pharmacology/*therapeutic use', 'Humans', 'Organ Specificity', 'Psychotic Disorders/*drug therapy/genetics']",https://pubmed.ncbi.nlm.nih.gov/27023437/
1268,Haloperidol,2277853,Measurement of haloperidol reductase activity in red blood cells and reduced haloperidol/haloperidol ratios in plasma in oriental psychiatric patients.,"['Shibasaki M', 'Someya T', 'Kato T', 'Noguchi T', 'Ishida N', 'Takahashi S']","['Adult', 'Alcohol Oxidoreductases/*blood', 'Delusions/*blood/drug therapy', 'Erythrocytes/*enzymology', 'Female', 'Haloperidol/*blood/therapeutic use', 'Humans', 'Kinetics', 'Male', 'Reference Values', 'Schizophrenia/*blood/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2277853/
1269,Haloperidol,8821369,Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.,"['Chang WH', 'Jann MW', 'Chiang TS', 'Lin HN', 'Hu WH', 'Chien CP']","['Adult', 'Age Factors', 'Aged', 'Aged, 80 and over', 'Antipsychotic Agents/administration & dosage/*pharmacokinetics', 'Bipolar Disorder/blood/drug therapy/psychology', 'Dementia/*blood/drug therapy/psychology', 'Dose-Response Relationship, Drug', 'Female', 'Haloperidol/administration & dosage/*analogs & derivatives/*pharmacokinetics', 'Humans', 'Male', 'Metabolic Clearance Rate/physiology', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Schizophrenia/*blood/drug therapy', '*Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/8821369/
1270,Haloperidol,6527751,Effects of high and low dosage of haloperidol on the brain in relation to schizophrenic thought disorder.,"['Winter M', 'Lehmann E', 'Scholz OB']","['Hallucinations/drug therapy', 'Haloperidol/administration & dosage/*therapeutic use', 'Hostility', 'Humans', 'Hypochondriasis/drug therapy', 'Schizophrenia/*drug therapy', 'Schizophrenia, Paranoid/drug therapy', 'Schizophrenic Psychology', 'Syndrome', 'Thinking']",https://pubmed.ncbi.nlm.nih.gov/6527751/
1271,Haloperidol,6736272,Haloperidol plasma and red blood cell levels and clinical antipsychotic response.,"['Garver DL', 'Hirschowitz J', 'Glicksteen GA', 'Kanter DR', 'Mavroidis ML']","['Erythrocytes/*metabolism', 'Haloperidol/*blood/therapeutic use', 'Humans', 'Plasma/analysis', 'Schizophrenia/blood/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6736272/
1272,Haloperidol,8208983,Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia.,"['Leroux JM', 'Elia E', 'Jacquet M', 'Pommery J', 'Levron JC', 'Bouhours P', 'Erb F', 'Sechter D']","['Adult', 'Chromatography, High Pressure Liquid', 'Female', 'Haloperidol/*analogs & derivatives/*blood/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Schizophrenia, Paranoid/*drug therapy', 'Schizophrenic Psychology', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/8208983/
1273,Haloperidol,34610953,Haloperidol-induced isolated lingual dystonia.,"['Jin JW', 'Chapa A', 'Kockara N', 'Helminiak A']","['Adult', '*Dystonia/chemically induced', '*Dystonic Disorders', 'Female', 'Haloperidol/adverse effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/34610953/
1274,Haloperidol,16261544,Rapid determination of haloperidol and its metabolites in human plasma by HPLC using monolithic silica column and solid-phase extraction.,"['Aboul-Enein HY', 'Ali I', 'Hoenen H']","['Chemical Fractionation/methods', 'Chromatography, High Pressure Liquid/*methods', 'Haloperidol/*blood/metabolism', 'Humans', 'Reproducibility of Results', 'Sensitivity and Specificity', 'Silicon Dioxide']",https://pubmed.ncbi.nlm.nih.gov/16261544/
1275,Haloperidol,2566628,Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid.,"['Straw GM', 'Bigelow LB', 'Kirch DG']","['Ascorbic Acid/*therapeutic use', 'Haloperidol/pharmacokinetics/*therapeutic use', 'Humans', 'Male', 'Neurotransmitter Agents/metabolism', 'Oxidation-Reduction', 'Psychiatric Status Rating Scales', 'Schizophrenia/blood/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2566628/
1276,Haloperidol,8430218,Relation of plasma and red blood cells reduced haloperidol concentrations to haloperidol reductase activity assayed in red blood cells in psychiatric population.,"['Shibasaki M', 'Someya T', 'Takahashi S']","['Adolescent', 'Adult', 'Alcohol Oxidoreductases/*blood', 'Erythrocytes/enzymology/*metabolism', 'Female', 'Haloperidol/*analogs & derivatives/blood', 'Humans', 'Japan', 'Male', 'Middle Aged', 'Psychotic Disorders/*blood']",https://pubmed.ncbi.nlm.nih.gov/8430218/
1277,Haloperidol,3545764,Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.,"['Beresford R', 'Ward A']","['Haloperidol/*analogs & derivatives/therapeutic use', 'Humans', 'Psychotic Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3545764/
1278,Haloperidol,8861178,Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate.,"['Jann MW', 'Wei FC', 'Lin HN', 'Piao-Chien C', 'Chang WH']","['Adult', 'Antipsychotic Agents/*administration & dosage/metabolism', 'Female', 'Haloperidol/*administration & dosage/*analogs & derivatives/*metabolism', 'Humans', 'Male', 'Middle Aged', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8861178/
1279,Haloperidol,1549652,Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol.,"['Eyles DW', 'Whiteford HA', 'Stedman TJ', 'Pond SM']","['Chromatography, High Pressure Liquid', 'Delayed-Action Preparations', 'Erythrocytes/enzymology/metabolism', 'Haloperidol/administration & dosage/*blood/pharmacokinetics', 'Humans', 'Ketone Oxidoreductases/blood', 'Oxidation-Reduction', 'Radioligand Assay', 'Schizophrenia/blood']",https://pubmed.ncbi.nlm.nih.gov/1549652/
1280,Haloperidol,3680566,The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients.,"['Nayak RK', 'Doose DR', 'Nair NP']","['Adult', 'Aged', 'Biological Availability', 'Chromatography, High Pressure Liquid', 'Haloperidol/administration & dosage/*pharmacokinetics', 'Humans', 'Injections, Intramuscular', 'Middle Aged', 'Schizophrenia/drug therapy/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/3680566/
1281,Haloperidol,1984711,Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.,"['Goldberg TE', 'Bigelow LB', 'Weinberger DR', 'Daniel DG', 'Kleinman JE']","['Adult', 'Affect/drug effects', 'Blinking/drug effects', 'Cerebral Ventricles/anatomy & histology', 'Chronic Disease', 'Cognition/*drug effects', 'Concept Formation/drug effects', 'Dextroamphetamine/administration & dosage/pharmacology/*therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Haloperidol/administration & dosage/pharmacology/*therapeutic use', 'Hospitalization', 'Humans', 'Male', 'Middle Aged', 'Psychological Tests', 'Radiography', 'Schizophrenia/diagnosis/diagnostic imaging/*drug therapy', '*Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/1984711/
1282,Haloperidol,2742942,Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.,"['Chang WH', 'Lin SK', 'Jann MW', 'Lam YW', 'Chen TY', 'Chen CT', 'Hu WH', 'Yeh EK']","['Adult', 'Biological Availability', 'Brain/drug effects', 'Chronic Disease', 'Haloperidol/*pharmacokinetics/therapeutic use', 'Homovanillic Acid/blood', 'Humans', 'Male', 'Metabolic Clearance Rate', 'Middle Aged', 'Oxidation-Reduction', 'Receptors, Dopamine/drug effects', 'Schizophrenia/*blood/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2742942/
1283,Haloperidol,1933763,Haloperidol-induced bronchospasm.,"['Sethna R', 'Notkin R']","['Administration, Oral', 'Adult', 'Bronchial Spasm/*chemically induced', 'Female', 'Haloperidol/administration & dosage/*adverse effects', '*Hospitalization', 'Humans', 'Psychotic Disorders/*drug therapy/psychology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/1933763/
1284,Celecoxib,37867289,Durable and dramatic response to checkpoint inhibition combined with COX-2 inhibitor celecoxib in a patient with p16+ metastatic sinonasal undifferentiated carcinoma: A case study.,"['Trinh JQ', 'Acosta C', 'Easwar A', 'Galamaga R', 'Tan A']","['Female', 'Humans', 'Middle Aged', 'Celecoxib/pharmacology', 'Cyclooxygenase 2 Inhibitors/pharmacology', '*Maxillary Sinus Neoplasms/pathology/therapy', '*Carcinoma/pathology']",https://pubmed.ncbi.nlm.nih.gov/37867289/
1285,Celecoxib,30362840,Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain.,"['Angeli F', 'Trapasso M', 'Signorotti S', 'Verdecchia P', 'Reboldi G']","['Amlodipine/*administration & dosage/adverse effects/pharmacology', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/pharmacology', 'Antihypertensive Agents/administration & dosage/adverse effects/pharmacology', 'Celecoxib/*administration & dosage/adverse effects/pharmacology', 'Drug Combinations', 'Humans', 'Hypertension/*drug therapy/etiology', 'Osteoarthritis/complications/*drug therapy', 'Pain/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/30362840/
1286,Celecoxib,27959716,"Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.","['Nissen SE', 'Yeomans ND', 'Solomon DH', 'Luscher TF', 'Libby P', 'Husni ME', 'Graham DY', 'Borer JS', 'Wisniewski LM', 'Wolski KE', 'Wang Q', 'Menon V', 'Ruschitzka F', 'Gaffney M', 'Beckerman B', 'Berger MF', 'Bao W', 'Lincoff AM']","['Aged', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Arthritis/*drug therapy', 'Cardiovascular Diseases/*chemically induced/mortality', 'Celecoxib/*adverse effects/therapeutic use', 'Cyclooxygenase 2 Inhibitors/*adverse effects/therapeutic use', 'Female', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Ibuprofen/*adverse effects/therapeutic use', 'Intention to Treat Analysis', 'Kidney Diseases/chemically induced', 'Male', 'Middle Aged', 'Naproxen/*adverse effects/therapeutic use', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/27959716/
1287,Celecoxib,33586981,"Copper-Catalyzed Reductive Ring-Cleavage of Isoxazoles: Synthesis of Fluoroalkylated Enaminones and Application for the Preparation of Celecoxib, Deracoxib, and Mavacoxib.","['Wan C', 'Pang JY', 'Jiang W', 'Zhang XW', 'Hu XG']","['Catalysis', 'Celecoxib', '*Copper', '*Isoxazoles', 'Pyrazoles', 'Sulfonamides']",https://pubmed.ncbi.nlm.nih.gov/33586981/
1288,Celecoxib,37935204,Effects of Resveratrol Co-Administration on Celecoxib Disposition and Pharmacokinetics in Healthy Volunteers.,"['Helal NI', 'El-Khodary NM', 'Omran GA', 'El-Masry SM']","['Humans', 'Male', 'Celecoxib/pharmacology', 'Resveratrol', 'Healthy Volunteers', 'Area Under Curve', '*Anti-Inflammatory Agents', 'Administration, Oral']",https://pubmed.ncbi.nlm.nih.gov/37935204/
1289,Celecoxib,33200341,Cytotoxic and Apoptotic Effects of Celecoxib and Topotecan on AGS and HEK 293 Cell Lines.,"['Badalanloo K', 'Naji T', 'Ahmadi R']","['*Antineoplastic Agents/pharmacology', 'Apoptosis', 'Celecoxib/pharmacology', 'Cell Line, Tumor', 'HEK293 Cells', 'Humans', '*Topotecan/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33200341/
1290,Celecoxib,34932581,Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis.,"['Cheng BR', 'Chen JQ', 'Zhang XW', 'Gao QY', 'Li WH', 'Yan LJ', 'Zhang YQ', 'Wu CJ', 'Xing JL', 'Liu JP']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy/pathology', 'Cardiovascular System/*drug effects', 'Celecoxib/*therapeutic use', 'Humans', 'Osteoarthritis/*drug therapy/pathology', 'Patient Safety/*standards']",https://pubmed.ncbi.nlm.nih.gov/34932581/
1291,Celecoxib,35882305,Celecoxib alleviates denervation-induced muscle atrophy by suppressing inflammation and oxidative stress and improving microcirculation.,"['Zhang L', 'Li M', 'Wang W', 'Yu W', 'Liu H', 'Wang K', 'Chang M', 'Deng C', 'Ji Y', 'Shen Y', 'Qi L', 'Sun H']","['Celecoxib/pharmacology/therapeutic use', 'Humans', 'Inflammation/metabolism', 'Microcirculation', '*Muscle Denervation/methods', 'Muscle, Skeletal', '*Muscular Atrophy/drug therapy/metabolism', 'Oxidative Stress']",https://pubmed.ncbi.nlm.nih.gov/35882305/
1292,Celecoxib,34636290,"Celecoxib and Dimethylcelecoxib Block Oxidative Phosphorylation, Epithelial-Mesenchymal Transition and Invasiveness in Breast Cancer Stem Cells.","['Gallardo-Perez JC', 'Adan-Ladron de Guevara A', 'Garcia-Amezcua MA', 'Robledo-Cadena DX', 'Pacheco-Velazquez SC', 'Belmont-Diaz JA', 'Vargas-Navarro JL', 'Moreno-Sanchez R', 'Rodriguez-Enriquez S']","['Adenosine Triphosphate/metabolism', '*Breast Neoplasms/pathology', 'Celecoxib/pharmacology/therapeutic use', 'Cell Line, Tumor', 'Epithelial-Mesenchymal Transition', 'Female', 'Humans', 'Neoplastic Stem Cells/metabolism', '*Oxidative Phosphorylation']",https://pubmed.ncbi.nlm.nih.gov/34636290/
1293,Celecoxib,29441879,Development and validation of a LC-FL method for the simultaneous determination of doxorubicin and celecoxib in nanoparticulate fixed dose combination (NanoFDC).,"['Kozlu S', 'Sahin A', 'Calis S', 'Capan Y']","['Antibiotics, Antineoplastic/*analysis', 'Antineoplastic Combined Chemotherapy Protocols/*analysis', 'Celecoxib/*analysis', 'Chromatography, High Pressure Liquid/*methods', 'Cyclooxygenase 2 Inhibitors/*analysis', 'Doxorubicin/*analysis', 'Drug Combinations', 'Limit of Detection', 'Nanoparticles', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/29441879/
1294,Celecoxib,39986574,Exploring the potential antidepressant mechanisms of ibuprofen and celecoxib based on network pharmacology and molecular docking.,"['Zhang Q', 'Yang L', 'Li C', 'Zhang Y', 'Li R', 'Jia F', 'Wang L', 'Ma X', 'Yao K', 'Tian H', 'Zhuo C']","['Humans', '*Ibuprofen/pharmacology/therapeutic use', '*Celecoxib/pharmacology/therapeutic use', '*Molecular Docking Simulation', '*Antidepressive Agents/pharmacology/therapeutic use', '*Depressive Disorder/drug therapy', 'Network Pharmacology', 'Protein Interaction Maps/drug effects', 'PPAR gamma/metabolism', 'Female', 'ErbB Receptors/metabolism']",https://pubmed.ncbi.nlm.nih.gov/39986574/
1295,Celecoxib,36800138,Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis.,"['Guo Y', 'Jiang D', 'Mai Z', 'Chen Y', 'Li T', 'Gao G']","['Humans', 'Celecoxib/therapeutic use', 'Sacroiliac Joint/pathology', 'Core Binding Factor Alpha 1 Subunit', 'Vascular Endothelial Growth Factor A', 'beta Catenin/therapeutic use', '*Sacroiliitis', '*Spondylarthritis/drug therapy', '*Axial Spondyloarthritis', 'Magnetic Resonance Imaging/methods', 'Inflammation/drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/36800138/
1296,Celecoxib,36135051,The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.,"['Ye SY', 'Li JY', 'Li TH', 'Song YX', 'Sun JX', 'Chen XW', 'Zhao JH', 'Li Y', 'Wu ZH', 'Gao P', 'Huang XZ']","['*Carcinoma, Non-Small-Cell Lung', 'Celecoxib/therapeutic use', 'Cyclooxygenase 2', 'ErbB Receptors', 'Humans', '*Lung Neoplasms', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36135051/
1297,Celecoxib,39243988,Long-term characterisation of the relationship between change in depression severity and change in inflammatory markers following inflammation-stratified treatment with vortioxetine augmented with celecoxib or placebo.,"['Sampson E', 'Mills NT', 'Hori H', 'Cearns M', 'Schwarte K', 'Hohoff C', 'Oliver Schubert K', 'Fourrier C', 'Baune BT']","['Humans', '*Celecoxib/therapeutic use/pharmacology', '*Vortioxetine/pharmacology/therapeutic use', 'Male', '*Depressive Disorder, Major/drug therapy', 'Female', 'Adult', 'Double-Blind Method', 'Middle Aged', '*Inflammation/drug therapy/metabolism', '*Antidepressive Agents/therapeutic use/pharmacology', '*Biomarkers/blood', 'Treatment Outcome', 'Drug Therapy, Combination', 'C-Reactive Protein/metabolism/analysis', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/39243988/
1298,Riluzole,22596264,Riluzole: what it does to spinal and brainstem neurons and how it does it.,"['Cifra A', 'Mazzone GL', 'Nistri A']","['Amyotrophic Lateral Sclerosis/*drug therapy/metabolism', 'Brain Stem/*drug effects/metabolism', 'Excitatory Amino Acid Antagonists/*pharmacology/therapeutic use', 'Glutamic Acid/metabolism', 'Humans', 'Motor Neurons/*drug effects/metabolism', 'Neuroprotective Agents/*pharmacology/therapeutic use', 'Riluzole/*pharmacology/therapeutic use', 'Spinal Cord/*drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/22596264/
1299,Riluzole,31254879,Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis.,"['de Boer JN', 'Vingerhoets C', 'Hirdes M', 'McAlonan GM', 'Amelsvoort TV', 'Zinkstok JR']","['Adult', 'Autistic Disorder/drug therapy', 'Depressive Disorder/*drug therapy', 'Female', 'Humans', 'Male', 'Mental Disorders/*drug therapy', 'Neuroprotective Agents/*therapeutic use', 'Obsessive-Compulsive Disorder/*drug therapy', 'Randomized Controlled Trials as Topic', 'Riluzole/*therapeutic use', 'Schizophrenia/drug therapy', 'Substance-Related Disorders/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31254879/
1300,Riluzole,31958711,Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.,"['Yao R', 'Wang H', 'Yuan M', 'Wang G', 'Wu C']","['Adult', 'Antidepressive Agents/*therapeutic use', 'Citalopram/therapeutic use', 'Depressive Disorder/*drug therapy', 'Female', 'Humans', 'Ketamine/therapeutic use', 'Male', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Riluzole/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31958711/
1301,Riluzole,22419278,Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).,"['Miller RG', 'Mitchell JD', 'Moore DH']","['Age Factors', 'Amyotrophic Lateral Sclerosis/*drug therapy/mortality', 'Excitatory Amino Acid Antagonists/adverse effects/*therapeutic use', 'Humans', 'Life Expectancy', 'Neuroprotective Agents/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Riluzole/adverse effects/*therapeutic use', 'Tracheostomy']",https://pubmed.ncbi.nlm.nih.gov/22419278/
1302,Riluzole,32891672,Neuroprotective effects of Riluzole and Curcumin in human astrocytes and spinal cord white matter hypoxia.,"['Daverey A', 'Agrawal SK']","['Apoptosis/drug effects', 'Astrocytes/*drug effects/metabolism', 'Cell Line', 'Curcumin/*pharmacology', 'Glial Fibrillary Acidic Protein/metabolism', 'Humans', 'Hydrogen Peroxide/pharmacology', 'Hypoxia/*metabolism', 'Neuroprotective Agents/*pharmacology', 'Oxidative Stress/drug effects', 'Riluzole/*pharmacology', 'Spinal Cord/*drug effects/metabolism', 'White Matter/*drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/32891672/
1303,Riluzole,37130044,"Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial.","['Chow DS', 'Nguyen A', 'Park J', 'Wu L', 'Toups EG', 'Harrop JS', 'Guest JD', 'Schmitt KM', 'Aarabi B', 'Fehlings MG', 'Boakye M', 'Grossman RG']","['Male', 'Middle Aged', 'Humans', 'Riluzole/adverse effects', '*Neuroprotective Agents/adverse effects/pharmacokinetics', '*Amyotrophic Lateral Sclerosis/drug therapy', '*Cervical Cord', '*Spinal Cord Injuries/drug therapy', '*Neck Injuries/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37130044/
1304,Riluzole,31280619,Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.,"['Mora JS', 'Genge A', 'Chio A', 'Estol CJ', 'Chaverri D', 'Hernandez M', 'Marin S', 'Mascias J', 'Rodriguez GE', 'Povedano M', 'Paipa A', 'Dominguez R', 'Gamez J', 'Salvado M', 'Lunetta C', 'Ballario C', 'Riva N', 'Mandrioli J', 'Moussy A', 'Kinet JP', 'Auclair C', 'Dubreuil P', 'Arnold V', 'Mansfield CD', 'Hermine O']","['Adolescent', 'Adult', 'Aged', 'Amyotrophic Lateral Sclerosis/*drug therapy', 'Benzamides', 'Disease Progression', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', 'Piperidines', 'Pyridines', 'Riluzole/*therapeutic use', 'Thiazoles/*therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31280619/
1305,Riluzole,38904964,Riluzole for Degenerative Cervical Myelopathy: A Secondary Analysis of the CSM-PROTECT Trial.,"['Fehlings MG', 'Pedro KM', 'Alvi MA', 'Badhiwala JH', 'Ahn H', 'Farhadi HF', 'Shaffrey CI', 'Nassr A', 'Mummaneni P', 'Arnold PM', 'Jacobs WB', 'Riew KD', 'Kelly M', 'Brodke DS', 'Vaccaro AR', 'Hilibrand AS', 'Wilson J', 'Harrop JS', 'Yoon ST', 'Kim KD', 'Fourney DR', 'Santaguida C', 'Massicotte EM', 'Huang P']","['Humans', '*Riluzole/therapeutic use', 'Male', 'Female', 'Middle Aged', 'Double-Blind Method', '*Cervical Vertebrae/surgery', 'Aged', 'Spinal Cord Diseases/surgery/drug therapy', 'Spondylosis/surgery/drug therapy', 'Treatment Outcome', 'Neuroprotective Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38904964/
1306,Riluzole,32847483,Riluzole for the treatment of amyotrophic lateral sclerosis.,"['Saitoh Y', 'Takahashi Y']","['Amyotrophic Lateral Sclerosis/*drug therapy', 'Excitatory Amino Acid Antagonists/*therapeutic use', 'Humans', 'Neuroprotective Agents/*therapeutic use', 'Riluzole/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32847483/
1307,Telithromycin,25801573,ClpP-independent function of ClpX interferes with telithromycin resistance conferred by Msr(A) in Staphylococcus aureus.,"['Vimberg V', 'Lenart J', 'Janata J', 'Balikova Novotna G']","['Anti-Bacterial Agents/*pharmacology', 'Bacterial Proteins/genetics/metabolism', 'Ketolides/*pharmacology', 'Macrolides/pharmacology', 'Mutation', 'Staphylococcus aureus/*drug effects/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/25801573/
1308,Telithromycin,10543769,"Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.","['Goldstein EJ', 'Citron DM', 'Merriam CV', 'Warren Y', 'Tyrrell K']","['Anti-Bacterial Agents/*pharmacology', 'Azithromycin/pharmacology', 'Bacteria, Anaerobic/*drug effects', 'Bacterial Infections/microbiology', 'Clarithromycin/pharmacology', 'Humans', '*Ketolides', '*Macrolides', 'Microbial Sensitivity Tests', 'Roxithromycin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10543769/
1309,Telithromycin,15264209,Telithromycin-induced acute interstitial nephritis: a first case report.,"['Tintillier M', 'Kirch L', 'Almpanis C', 'Cosyns JP', 'Pochet JM', 'Cuvelier C']","['Acute Disease', 'Adolescent', 'Humans', 'Ketolides/*adverse effects/therapeutic use', 'Kidney/*pathology', 'Male', 'Methylprednisolone/therapeutic use', 'Nephritis, Interstitial/*chemically induced/drug therapy/pathology', 'Respiratory Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15264209/
1310,Telithromycin,12821495,Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infections.,"['Bingen E', 'Doit C', 'Loukil C', 'Brahimi N', 'Bidet P', 'Deforche D', 'Geslin P']","['Amoxicillin/pharmacology', 'Anti-Bacterial Agents/*pharmacology', 'Azithromycin/pharmacology', 'Ceftizoxime/*analogs & derivatives/pharmacology', 'Ceftriaxone/pharmacology', 'Child', 'Drug Resistance, Bacterial', 'Erythromycin/pharmacology', 'France', 'Humans', 'In Vitro Techniques', 'Josamycin/pharmacology', '*Ketolides', '*Macrolides', 'Penicillin G/pharmacology', 'Penicillin Resistance', 'Penicillins/pharmacology', 'Pneumococcal Infections/*drug therapy', 'Streptococcus pneumoniae/*drug effects', 'Cefpodoxime']",https://pubmed.ncbi.nlm.nih.gov/12821495/
1311,Telithromycin,12232662,Telithromycin inhibition of protein synthesis and 50S ribosomal subunit formation in Streptococcus pneumoniae cells.,"['Champney WS', 'Pelt J']","['Anti-Bacterial Agents/metabolism/*pharmacology', 'Inhibitory Concentration 50', '*Ketolides', '*Macrolides', 'Protein Synthesis Inhibitors/metabolism/*pharmacology', 'Ribosomes/drug effects/*metabolism', 'Staphylococcus aureus/drug effects/metabolism', 'Streptococcus pneumoniae/*drug effects/growth & development/*metabolism', 'Uridine/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12232662/
1312,Telithromycin,10602744,In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials.,"['Fernandez-Roblas R', 'Esteban J', 'Cabria F', 'Lopez JC', 'Jimenez MS', 'Soriano F']","['Anti-Bacterial Agents/*pharmacology', '*Ketolides', '*Macrolides', 'Microbial Sensitivity Tests', 'Mycobacterium/*drug effects/growth & development']",https://pubmed.ncbi.nlm.nih.gov/10602744/
1313,Telithromycin,15616322,"Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.","['Goldstein EJ', 'Citron DM', 'Merriam CV', 'Warren YA', 'Tyrrell KL', 'Fernandez HT', 'Bryskier A']","['Actinobacteria/drug effects', 'Anti-Bacterial Agents/*pharmacology', 'Bacteria, Anaerobic/*drug effects', 'Gram-Positive Bacteria/*drug effects', 'Humans', 'Lactobacillus/drug effects', 'Microbial Sensitivity Tests', 'Streptogramins/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/15616322/
1314,Telithromycin,15851496,Telithromycin: the first ketolide for the treatment of respiratory infections.,"['Kasbekar N', 'Acharya PS']","['*Anti-Bacterial Agents/adverse effects/pharmacokinetics/therapeutic use', 'Biological Availability', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme Inhibitors', 'Half-Life', 'Humans', 'Intestinal Absorption', '*Ketolides/adverse effects/pharmacokinetics/therapeutic use', 'Microbial Sensitivity Tests', 'Multicenter Studies as Topic', 'Randomized Controlled Trials as Topic', 'Respiratory Tract Infections/*drug therapy', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/15851496/
1315,Telithromycin,10858366,"Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.","['Bebear CM', 'Renaudin H', 'Bryskier A', 'Bebear C']","['Anti-Bacterial Agents/*pharmacology/therapeutic use', 'Anti-Infective Agents/*pharmacology/therapeutic use', 'Humans', '*Ketolides', '*Levofloxacin', '*Macrolides', 'Microbial Sensitivity Tests', 'Mycoplasma/*drug effects', 'Mycoplasma Infections/drug therapy', 'Ofloxacin/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10858366/
1316,Telithromycin,37081393,The antimicrobial activity of cethromycin against Staphylococcus aureus and compared with erythromycin and telithromycin.,"['Hu Y', 'Ouyang L', 'Li D', 'Deng X', 'Xu H', 'Yu Z', 'Fang Y', 'Zheng J', 'Chen Z', 'Zhang H']","['Humans', 'Staphylococcus aureus', 'Erythromycin/pharmacology', '*Methicillin-Resistant Staphylococcus aureus', 'Multilocus Sequence Typing', 'Drug Resistance, Multiple, Bacterial/genetics', '*Ketolides/pharmacology', 'Anti-Bacterial Agents/pharmacology', '*Staphylococcal Infections/microbiology', 'Lincosamides/pharmacology', 'Streptogramin B/pharmacology', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/37081393/
1317,Telithromycin,17065627,Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe.,"['Al-Lahham A', 'Appelbaum PC', 'van der Linden M', 'Reinert RR']","['Anti-Bacterial Agents/*pharmacology', 'Drug Resistance, Bacterial/genetics', 'Europe', 'Genotype', 'Humans', 'Ketolides/*pharmacology', 'Microbial Sensitivity Tests', 'Molecular Sequence Data', 'Phenotype', 'Pneumococcal Infections/*microbiology', 'Reverse Transcriptase Polymerase Chain Reaction', 'Streptococcus pneumoniae/*drug effects/genetics']",https://pubmed.ncbi.nlm.nih.gov/17065627/
1318,Telithromycin,11897601,"Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones.","['Braback M', 'Riesbeck K', 'Forsgren A']","['Acetamides/*pharmacology', 'Anti-Bacterial Agents/*pharmacology', 'Fluoroquinolones', 'Humans', '*Ketolides', 'Linezolid', '*Macrolides', 'Microbial Sensitivity Tests', 'Mycobacterium Infections, Nontuberculous/microbiology', 'Mycobacterium marinum/*drug effects/growth & development', 'Oxazolidinones/*pharmacology', 'Virginiamycin/analogs & derivatives/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11897601/
1319,Telithromycin,12487505,Efficacy and safety of telithromycin in community-acquired pneumonia.,"['Van Rensburg DJ', 'Matthews PA', 'Leroy B']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/*therapeutic use', 'Community-Acquired Infections/*drug therapy', 'Female', 'Humans', '*Ketolides', '*Macrolides', 'Male', 'Middle Aged', 'Pneumonia, Bacterial/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12487505/
1320,Telithromycin,15273149,High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.,"['Kresken M', 'Henrichfreise B', 'Bagel S', 'Brauers J', 'Wiedemann B']","['Anti-Bacterial Agents/*pharmacology', 'Bacterial Proteins/*genetics', 'Drug Resistance, Bacterial', 'Electrophoresis, Gel, Pulsed-Field', 'Erythromycin/*pharmacology', 'Genotype', 'Germany/epidemiology', '*Ketolides', 'Macrolides/*pharmacology', 'Membrane Proteins/genetics', 'Methyltransferases/*genetics', 'Pneumococcal Infections/epidemiology/microbiology', 'Reverse Transcriptase Polymerase Chain Reaction', 'Streptococcus pneumoniae/*drug effects/*genetics']",https://pubmed.ncbi.nlm.nih.gov/15273149/
1321,Telithromycin,15980387,Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22.,"['Reinert RR', 'Al-Lahham A']","['Anti-Bacterial Agents/*pharmacology', '*Drug Resistance, Bacterial', 'Humans', 'Ketolides/*pharmacology', 'Macrolides/*pharmacology', 'Microbial Sensitivity Tests/standards', 'Mutation', 'RNA, Ribosomal, 23S/genetics', 'Ribosomal Proteins/genetics/metabolism', 'Streptococcus pneumoniae/*drug effects/genetics/growth & development', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/15980387/
1322,Telithromycin,14602368,"In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.","['Kucukbasmaci O', 'Gonullu N', 'Aktas Z', 'Gurol D', 'Berkiten R']","['Anti-Bacterial Agents/*pharmacology', 'Erythromycin/analogs & derivatives/*pharmacology', 'Fluoroquinolones/*pharmacology', 'Haemophilus influenzae/*drug effects', 'Humans', 'In Vitro Techniques', '*Ketolides', 'Macrolides/*pharmacology', 'Microbial Sensitivity Tests', 'Moraxella catarrhalis/*drug effects', 'Streptococcus pneumoniae/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/14602368/
1323,Telithromycin,18195060,Selection for high-level telithromycin resistance in Staphylococcus aureus yields mutants resulting from an rplB-to-rplV gene conversion-like event.,"['Gentry DR', 'Holmes DJ']","['Amino Acid Sequence', 'Anti-Bacterial Agents/*pharmacology', 'Base Sequence', 'Drug Resistance, Bacterial/*genetics', '*Gene Conversion', 'Ketolides/*pharmacology', 'Microbial Sensitivity Tests', 'Molecular Sequence Data', '*Mutation', 'Ribosomal Proteins/*genetics', 'Staphylococcus aureus/*drug effects/genetics']",https://pubmed.ncbi.nlm.nih.gov/18195060/
1324,Lamotrigine,33573557,"Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications.","['Kaplan YC', 'Demir O']","['Anticonvulsants/adverse effects', 'Breast Feeding', 'Carbamazepine/adverse effects', '*Epilepsy/drug therapy', 'Female', 'Humans', 'Lamotrigine/adverse effects', 'Levetiracetam/adverse effects', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Pregnancy', '*Pregnancy Complications/drug therapy', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33573557/
1325,Lamotrigine,33838757,"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.","['Marson A', 'Burnside G', 'Appleton R', 'Smith D', 'Leach JP', 'Sills G', 'Tudur-Smith C', 'Plumpton C', 'Hughes DA', 'Williamson P', 'Baker GA', 'Balabanova S', 'Taylor C', 'Brown R', 'Hindley D', 'Howell S', 'Maguire M', 'Mohanraj R', 'Smith PE']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Anticonvulsants/*adverse effects', 'Child', '*Cost-Benefit Analysis', 'Epilepsies, Partial/*drug therapy', 'Female', 'Humans', 'Lamotrigine/*therapeutic use', 'Levetiracetam/*therapeutic use', 'Male', 'Middle Aged', '*Treatment Outcome', 'Young Adult', 'Zonisamide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33838757/
1326,Lamotrigine,34931602,Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.,"['Marson AG', 'Burnside G', 'Appleton R', 'Smith D', 'Leach JP', 'Sills G', 'Tudur-Smith C', 'Plumpton CO', 'Hughes DA', 'Williamson PR', 'Baker G', 'Balabanova S', 'Taylor C', 'Brown R', 'Hindley D', 'Howell S', 'Maguire M', 'Mohanraj R', 'Smith PE']","['Child, Preschool', 'Female', 'Humans', 'Cost-Benefit Analysis', '*Epilepsies, Partial/drug therapy', '*Epilepsy/drug therapy', '*Lamotrigine/therapeutic use', '*Levetiracetam/therapeutic use', 'Quality of Life', '*Valproic Acid/therapeutic use', '*Zonisamide/therapeutic use', 'Child', 'Adolescent', 'Young Adult', 'Adult', 'Middle Aged', 'Aged', 'Aged, 80 and over', 'Male']",https://pubmed.ncbi.nlm.nih.gov/34931602/
1327,Lamotrigine,38507750,"Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure.","['Hernandez-Diaz S', 'Straub L', 'Bateman BT', 'Zhu Y', 'Mogun H', 'Wisner KL', 'Gray KJ', 'Lester B', 'McDougle CJ', 'DiCesare E', 'Pennell PB', 'Huybrechts KF']","['Child', 'Female', 'Humans', 'Pregnancy', '*Anticonvulsants/adverse effects/therapeutic use', '*Autism Spectrum Disorder/chemically induced/epidemiology/etiology', 'Autistic Disorder/chemically induced/epidemiology/etiology', '*Lamotrigine/adverse effects/therapeutic use', '*Prenatal Exposure Delayed Effects/epidemiology/chemically induced/drug therapy', '*Topiramate/adverse effects/therapeutic use', '*Valproic Acid/adverse effects/therapeutic use', 'Epilepsy/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38507750/
1328,Lamotrigine,35129410,Quality control concerns in relation to lamotrigine and their impact.,"['Parker G', 'Jenner A']","['Anticonvulsants/adverse effects', '*Drug-Related Side Effects and Adverse Reactions', 'Drugs, Generic/adverse effects', '*Epilepsy/drug therapy', 'Humans', 'Lamotrigine/adverse effects', 'Quality Control', 'Tablets/therapeutic use', 'Triazines/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35129410/
1329,Lamotrigine,35240475,Rational therapy with lamotrigine or levetiracetam: Which one to select?,"['Asadi-Pooya AA', 'Farazdaghi M']","['Anticonvulsants/therapeutic use', '*Epilepsies, Partial/drug therapy', '*Epilepsy/drug therapy', '*Epilepsy, Generalized', 'Humans', 'Immunoglobulin E', 'Lamotrigine/therapeutic use', 'Levetiracetam/therapeutic use', 'Longitudinal Studies', 'Retrospective Studies', 'Seizures/drug therapy', 'Treatment Outcome', 'Triazines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35240475/
1330,Lamotrigine,33475151,"Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.","['Brigo F', 'Igwe SC', 'Lattanzi S']","['Adolescent', 'Anticonvulsants/adverse effects/*therapeutic use', 'Child', 'Epilepsy, Absence/*drug therapy/prevention & control', 'Ethosuximide/adverse effects/*therapeutic use', 'Female', 'Humans', 'Lamotrigine/adverse effects/*therapeutic use', 'Male', 'Randomized Controlled Trials as Topic', 'Seizures/prevention & control', 'Treatment Failure', 'Valproic Acid/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33475151/
1331,Lamotrigine,30734919,"Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.","['Brigo F', 'Igwe SC', 'Lattanzi S']","['Adolescent', 'Anticonvulsants/adverse effects/*therapeutic use', 'Child', 'Epilepsy, Absence/*drug therapy', 'Ethosuximide/adverse effects/*therapeutic use', 'Humans', 'Lamotrigine/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Valproic Acid/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30734919/
1332,Lamotrigine,33012875,Efficacy and Tolerability of Lamotrigine in Borderline Personality Disorder: A Systematic Review and Meta-Analysis.,"['Pahwa M', 'Nunez NA', 'Joseph B', 'Seshadri A', 'Gerberi DJ', 'Frye MA', 'Singh B']","['Anticonvulsants/therapeutic use', '*Antipsychotic Agents/therapeutic use', '*Borderline Personality Disorder/drug therapy', 'Humans', 'Lamotrigine/adverse effects', 'Mood Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33012875/
1333,Lamotrigine,34092825,Lamotrigine and Stevens-Johnson Syndrome Prevention.,"['Edinoff AN', 'Nguyen LH', 'Fitz-Gerald MJ', 'Crane E', 'Lewis K', 'Pierre SS', 'Kaye AD', 'Kaye AM', 'Kaye JS', 'Kaye RJ', 'Gennuso SA', 'Varrassi G', 'Viswanath O', 'Urits I']","['*Anticonvulsants/adverse effects', 'Carbamazepine', 'HLA-B Antigens', 'Humans', 'Lamotrigine/*adverse effects', '*Stevens-Johnson Syndrome/genetics/prevention & control', 'United States']",https://pubmed.ncbi.nlm.nih.gov/34092825/
1334,Lamotrigine,33367908,Lamotrigine and lithium in primary care psychiatric consultation: adoption and adverse effects.,"['Phelps JR', 'Pipitone OR', 'Squires K', 'Bale JD']","['Adult', '*Antimanic Agents/adverse effects', 'Humans', 'Lamotrigine/adverse effects', '*Lithium/adverse effects', 'Primary Health Care', 'Referral and Consultation']",https://pubmed.ncbi.nlm.nih.gov/33367908/
1335,Lamotrigine,38945077,Seizure control and adverse outcomes of lamotrigine use during pregnancy: A systematic review and meta-analysis.,"['Wan X', 'Wu Y', 'Zou Q', 'Yuan B', 'Huang L', 'Hu M']","['Humans', 'Pregnancy', 'Female', '*Anticonvulsants/adverse effects/therapeutic use', '*Lamotrigine/therapeutic use/adverse effects', '*Pregnancy Complications/drug therapy', '*Seizures/drug therapy/chemically induced', '*Epilepsy/drug therapy', 'Pregnancy Outcome/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/38945077/
1336,Lamotrigine,39217754,"Cognitive outcomes after fetal exposure to carbamazepine, lamotrigine, valproate or levetiracetam monotherapy: Data from the EURAP neurocognitive extension protocol.","['Stjerna S', 'Huber-Mollema Y', 'Tomson T', 'Perucca E', 'Battino D', 'Craig J', 'Sabers A', 'Thomas S', 'Vajda F', 'Gaily E']","['Adult', 'Child', 'Female', 'Humans', 'Male', 'Pregnancy', '*Anticonvulsants/adverse effects', '*Carbamazepine/adverse effects', 'Cognition/drug effects', 'Cohort Studies', '*Epilepsy/drug therapy', 'Intelligence/drug effects', '*Lamotrigine/adverse effects/therapeutic use', '*Levetiracetam/adverse effects', 'Neuropsychological Tests', 'Piracetam/analogs & derivatives/adverse effects', '*Prenatal Exposure Delayed Effects/chemically induced', 'Prospective Studies', 'Triazines/adverse effects', '*Valproic Acid/adverse effects', 'Multicenter Studies as Topic', 'Observational Studies as Topic']",https://pubmed.ncbi.nlm.nih.gov/39217754/
1337,Lamotrigine,28862044,Acute lamotrigine overdose: a systematic review of published adult and pediatric cases.,"['Alyahya B', 'Friesen M', 'Nauche B', 'Laliberte M']","['Adult', 'Anticonvulsants/blood/*poisoning', 'Child', 'Drug Overdose/blood/*therapy', 'Humans', 'Lamotrigine/blood/*poisoning', 'Renal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/28862044/
1338,Lamotrigine,21242744,Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications.,"['Seo HJ', 'Chiesa A', 'Lee SJ', 'Patkar AA', 'Han C', 'Masand PS', 'Serretti A', 'Pae CU']","['Adult', 'Antimanic Agents/*adverse effects/*therapeutic use', 'Bipolar Disorder/*drug therapy', 'Exanthema/chemically induced', 'Humans', 'Lamotrigine', 'Randomized Controlled Trials as Topic', 'Stevens-Johnson Syndrome/chemically induced', 'Triazines/*adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21242744/
1339,Lamotrigine,36030754,"Simultaneous determination of plasma lamotrigine, lamotrigine N2-glucuronide and lamotrigine N2-oxide by UHPLC-MS/MS in epileptic patients.","['Yang H', 'Zhang D', 'Mei S', 'Zhao Z']","['Anticonvulsants', 'Chromatography, High Pressure Liquid', '*Epilepsy/drug therapy', '*Glucuronides', 'Humans', 'Lamotrigine/therapeutic use', 'Organic Chemicals', 'Oxides', 'Tandem Mass Spectrometry/methods', 'Triazines', 'Valproic Acid']",https://pubmed.ncbi.nlm.nih.gov/36030754/
1340,Lamotrigine,37916262,Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediate release absorption process.,"['Caleffi-Marchesini ER', 'Herling AA', 'Macente J', 'Bonan RH', 'de Freitas Lima P', 'Moreno R', 'Alexandre V', 'Charbe NB', 'Borghi-Pangoni FB', 'Cristofoletti R', 'Diniz A']","['Adult', 'Humans', 'Child', 'Child, Preschool', '*Biopharmaceutics', 'Lamotrigine', '*Intestinal Absorption/physiology', 'Solubility', 'Drug Compounding', 'Administration, Oral', 'Models, Biological']",https://pubmed.ncbi.nlm.nih.gov/37916262/
1341,Lamotrigine,10417037,Lamotrigine-induced blepharospasm.,"['Verma A', 'Miller P', 'Carwile ST', 'Husain AM', 'Radtke RA']","['Anticonvulsants/*adverse effects/therapeutic use', 'Blepharospasm/*chemically induced', 'Humans', 'Lamotrigine', 'Male', 'Middle Aged', 'Seizures/drug therapy', 'Triazines/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10417037/
1342,Brimonidine,36410471,Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials.,"['Tanihara H', 'Yamamoto T', 'Aihara M', 'Kawakita K', 'Kojima S', 'Kanazawa M', 'Nojima T', 'Suganami H']","['Humans', 'Brimonidine Tartrate/adverse effects', '*Glaucoma, Open-Angle/drug therapy', 'Prospective Studies', 'Antihypertensive Agents', 'Quinoxalines/therapeutic use/adverse effects', 'Treatment Outcome', 'Randomized Controlled Trials as Topic', '*Ocular Hypertension', 'Intraocular Pressure', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/36410471/
1343,Brimonidine,37330927,Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine.,"['Tanihara H', 'Yamamoto T', 'Aihara M', 'Koizumi N', 'Minami H', 'Kojima S', 'Isobe T', 'Kanazawa M', 'Suganami H']","['Male', 'Adult', 'Humans', 'Brimonidine Tartrate/pharmacology/therapeutic use', '*Glaucoma, Open-Angle/drug therapy', '*Ocular Hypertension/drug therapy', 'Prospective Studies', '*Hyperemia/chemically induced/drug therapy', 'Endothelial Cells', 'Intraocular Pressure', 'Ophthalmic Solutions/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Quinoxalines/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37330927/
1344,Brimonidine,35642327,The benefit of scratch patch testing to demonstrate ocular contact allergy to brimonidine tartrate.,"['Ringuet J', 'Lajoie C', 'Bourgault S', 'Simonyan D', 'Houle MC']","['Adrenergic alpha-Agonists/adverse effects', 'Brimonidine Tartrate/adverse effects', '*Dermatitis, Allergic Contact/diagnosis/drug therapy/etiology', 'Humans', 'Patch Tests', 'Quinoxalines/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35642327/
1345,Brimonidine,38430227,"Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study.","['Tanihara H', 'Yamamoto T', 'Aihara M', 'Koizumi N', 'Fukushima A', 'Kawakita K', 'Kojima S', 'Nakamura T', 'Suganami H']","['Humans', '*Intraocular Pressure/drug effects/physiology', '*Ocular Hypertension/drug therapy/physiopathology/diagnosis', 'Male', 'Female', 'Prospective Studies', 'Aged', '*Sulfonamides/administration & dosage/adverse effects', '*Isoquinolines/administration & dosage/adverse effects', '*Brimonidine Tartrate/administration & dosage', 'Treatment Outcome', 'Middle Aged', '*Antihypertensive Agents/administration & dosage/adverse effects', 'Follow-Up Studies', 'Ophthalmic Solutions', 'Time Factors', 'Dose-Response Relationship, Drug', 'Tonometry, Ocular', 'Drug Combinations', 'Glaucoma, Open-Angle/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/38430227/
1346,Brimonidine,36178959,"Cytotoxic, Apoptotic, and Oxidative Effects of Preserved and Preservative-Free Brimonidine in a Corneal Epithelial Cell Line.","['Kucukoduk A', 'Durmus IM', 'Aksoy M', 'Karakurt S']","['Humans', 'Caspase 3/metabolism/pharmacology', 'bcl-2-Associated X Protein/genetics/metabolism/pharmacology', 'Reactive Oxygen Species/metabolism', 'Caspase 9/metabolism/pharmacology', 'Brimonidine Tartrate/pharmacology', 'Annexin A5/metabolism', 'Caspase 12/metabolism', '*Proto-Oncogene Proteins c-bcl-2/genetics/metabolism/pharmacology', '*Apoptosis', 'Epithelial Cells', 'Preservatives, Pharmaceutical/pharmacology', 'Oxidative Stress', 'RNA, Messenger/metabolism']",https://pubmed.ncbi.nlm.nih.gov/36178959/
1347,Brimonidine,36799023,Efficacy and safety of a fixed combination of 1% brinzolamide and 0.1% brimonidine as treatment for glaucoma: a retrospective study focusing on the number of ingredients.,"['Aoki R', 'Terao E', 'Dote S', 'Shiraishi M', 'Oogi S', 'Ueda K', 'Kimura Y', 'Nagata Y', 'Nakakura S']","['Humans', 'Brimonidine Tartrate/adverse effects', 'Retrospective Studies', '*Glaucoma, Open-Angle/drug therapy', '*Ocular Hypertension/drug therapy', 'Antihypertensive Agents/adverse effects', 'Drug Combinations', '*Glaucoma/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36799023/
1348,Brimonidine,33438819,"The effect of brimonidine and proparacaine on metabolic enzymes: Glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and glutathione reductase.","['Caliskan B', 'Ozturk Kesebir A', 'Demir Y', 'Akyol Salman I']","['Brimonidine Tartrate/pharmacology', 'Glucose-6-Phosphate', '*Glucosephosphate Dehydrogenase/metabolism', 'Glutathione', 'Glutathione Reductase/metabolism', 'Humans', 'Molecular Docking Simulation', 'Pentose Phosphate Pathway', '*Phosphogluconate Dehydrogenase/metabolism', 'Propoxycaine']",https://pubmed.ncbi.nlm.nih.gov/33438819/
1349,Brimonidine,40149925,"Effects of Brimonidine, Latanoprost, and Omidenepag on Tunicamycin-Induced Endoplasmic Reticulum Stress and Fibrosis in Human Trabecular Meshwork Cells.","['Liu M', 'Honjo M', 'Yamagishi R', 'Aihara M']","['Humans', '*Endoplasmic Reticulum Stress/drug effects', '*Trabecular Meshwork/drug effects/metabolism/pathology', '*Endoplasmic Reticulum Chaperone BiP', '*Tunicamycin/pharmacology', '*Fibrosis', '*Brimonidine Tartrate/pharmacology', '*Latanoprost/pharmacology', 'Cells, Cultured', 'Actins/metabolism/genetics', 'Collagen Type I/metabolism/genetics', 'Collagen Type I, alpha 1 Chain', 'Connective Tissue Growth Factor/metabolism/genetics']",https://pubmed.ncbi.nlm.nih.gov/40149925/
1350,Brimonidine,23820229,Dilute brimonidine to improve patient comfort and subconjunctival hemorrhage after LASIK.,"['Pasquali TA', 'Aufderheide A', 'Brinton JP', 'Avila MR', 'Stahl ED', 'Durrie DS']","['Adrenergic alpha-2 Receptor Agonists/*therapeutic use', 'Adrenergic alpha-Agonists/therapeutic use', 'Adult', 'Brimonidine Tartrate', 'Conjunctival Diseases/*drug therapy/etiology', 'Double-Blind Method', 'Drug Therapy, Combination', 'Eye Hemorrhage/*drug therapy/etiology', 'Female', 'Histamine H1 Antagonists/therapeutic use', 'Humans', 'Hyperemia/drug therapy/etiology', '*Keratomileusis, Laser In Situ', 'Lasers, Excimer/therapeutic use', 'Male', 'Middle Aged', 'Naphazoline/therapeutic use', 'Patient Satisfaction', 'Pheniramine/therapeutic use', '*Postoperative Complications', 'Prospective Studies', 'Quinoxalines/*therapeutic use', 'Refraction, Ocular/physiology', '*Refractive Surgical Procedures', 'Visual Acuity/physiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/23820229/
1351,Brimonidine,37029145,"Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.","['Kim KE', 'Lee CK', 'Shin J', 'Kim Y', 'Rho S']","['Humans', 'Brimonidine Tartrate/adverse effects', '*Glaucoma, Open-Angle/drug therapy', 'Quinoxalines/therapeutic use', '*Glaucoma/drug therapy/chemically induced', '*Ocular Hypertension', 'Intraocular Pressure', 'Preservatives, Pharmaceutical/adverse effects', 'Treatment Outcome', 'Antihypertensive Agents/adverse effects', 'Double-Blind Method', 'Ophthalmic Solutions/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37029145/
1352,Brimonidine,37061271,Brimonidine.,"['Bakheit AH', 'Alomar AM', 'Darwish H', 'Alkahtani HM']","['Humans', 'Brimonidine Tartrate/pharmacology/therapeutic use', '*Glaucoma, Open-Angle/drug therapy', 'Adrenergic alpha-Agonists/pharmacology/therapeutic use', 'Quinoxalines/pharmacology/therapeutic use', 'Ophthalmic Solutions/therapeutic use', '*Glaucoma/drug therapy', 'Antihypertensive Agents/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37061271/
1353,Brimonidine,26114331,Effects of Switching from Timolol to Brimonidine in Prostaglandin Analog and Timolol Combination Therapy.,"['Aihara M', 'Adachi M', 'Hamada N', 'Honda N', 'Koseki N', 'Matsuo H', 'Miyata K', 'Otani S', 'Unoki K']","['Aged', 'Antihypertensive Agents/*administration & dosage/adverse effects', 'Brimonidine Tartrate/*administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Glaucoma, Open-Angle/*drug therapy/physiopathology', 'Humans', 'Intraocular Pressure/drug effects', 'Male', 'Manometry/methods/trends', 'Middle Aged', 'Ocular Hypertension/*drug therapy/physiopathology', 'Prospective Studies', 'Prostaglandins, Synthetic/adverse effects/*therapeutic use', 'Timolol/*administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26114331/
1354,Brimonidine,12690374,Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.,"['Mungan NK', 'Wilson TW', 'Nischal KK', 'Koren G', 'Levin AV']","['Administration, Topical', 'Adrenergic alpha-Agonists/*administration & dosage/*adverse effects', 'Adrenergic beta-Antagonists/*administration & dosage/*adverse effects', 'Bradycardia/*chemically induced', 'Brimonidine Tartrate', 'Female', 'Glaucoma/*drug therapy/physiopathology', 'Humans', 'Hypotension/*chemically induced', 'Infant', 'Infant, Newborn', 'Intraocular Pressure/drug effects', 'Quinoxalines/*administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/12690374/
1355,Trimethoprim,10405706,Trimethoprim-sulfamethoxazole.,['Smilack JD'],"['*Anti-Infective Agents/pharmacology/therapeutic use', 'Humans', '*Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10405706/
1356,Trimethoprim,31892256,"Trimethoprim: An Old Antibacterial Drug as a Template to Search for New Targets. Synthesis, Biological Activity and Molecular Modeling Study of Novel Trimethoprim Analogs.","['Wrobel A', 'Maliszewski D', 'Baradyn M', 'Drozdowska D']","['Anti-Bacterial Agents/*chemistry', 'Bacteriophage T4/chemistry', 'DNA/chemistry', 'DNA, Viral/chemistry', 'Folic Acid Antagonists/*chemistry', '*Molecular Docking Simulation', 'Tetrahydrofolate Dehydrogenase/*chemistry', '*Trimethoprim/analogs & derivatives/chemistry']",https://pubmed.ncbi.nlm.nih.gov/31892256/
1357,Trimethoprim,833727,NMR determination of trimethoprim and sulfamethoxazole in tablets and powders.,"['Rodriguez MR', 'Pizzorno MT', 'Albonico SM']","['Drug Combinations', 'Magnetic Resonance Spectroscopy', 'Powders', 'Sulfamethoxazole/*analysis', 'Tablets', 'Trimethoprim/*analysis']",https://pubmed.ncbi.nlm.nih.gov/833727/
1358,Trimethoprim,670346,Determination of trimethoprim and sulfamethoxazole (co-trimoxazole) in body fluids of man by means of high-performance liquid chromatography.,"['Vree TB', 'Hekster YA', 'Baars AM', 'Damsma JE', 'Kleijin EV']","['Chromatography, High Pressure Liquid/methods', 'Drug Combinations', 'Humans', 'Sulfamethoxazole/*analysis/blood/urine', 'Trimethoprim/*analysis/blood/urine']",https://pubmed.ncbi.nlm.nih.gov/670346/
1359,Trimethoprim,6483946,Simultaneous solubility and dissolution rate of sulfamethoxazole and trimethoprim in binary mixture.,"['Meshali M', 'el-Sabbagh H', 'Ramadan I']","['Drug Combinations', 'Hydrogen-Ion Concentration', 'Kinetics', 'Solubility', 'Sulfamethoxazole/*analysis', 'Trimethoprim/*analysis']",https://pubmed.ncbi.nlm.nih.gov/6483946/
1360,Trimethoprim,7113690,Levels of trimethoprim and sulfamethoxazole in human oviduct mucosa and plasma.,"['Brihmer C', 'Brundin J', 'Dornbusch K']","['Drug Combinations', 'Fallopian Tubes/*metabolism', 'Female', 'Humans', 'Mucous Membrane/metabolism', 'Sulfamethoxazole/blood/*metabolism', 'Trimethoprim/blood/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/7113690/
1361,Trimethoprim,34064068,"Photodegradation of Ciprofloxacin, Clarithromycin and Trimethoprim: Influence of pH and Humic Acids.","['Rodriguez-Lopez L', 'Cela-Dablanca R', 'Nunez-Delgado A', 'Alvarez-Rodriguez E', 'Fernandez-Calvino D', 'Arias-Estevez M']","['Anti-Bacterial Agents/chemistry/*radiation effects', 'Ciprofloxacin/chemistry/*radiation effects', 'Clarithromycin/chemistry/*radiation effects', 'Darkness', 'Half-Life', '*Humic Substances', '*Hydrogen-Ion Concentration', 'Kinetics', '*Light', 'Trimethoprim/chemistry/*radiation effects']",https://pubmed.ncbi.nlm.nih.gov/34064068/
1362,Trimethoprim,389808,"The effect of trimethoprim-sulphonamide, trimethoprim and sulphonamide on the occurrence of resistant enterobacteriaceae in human intestinal flora.",['Knothe H'],"['Adult', 'Drug Synergism', 'Drug Therapy, Combination', 'Enterobacteriaceae/drug effects/isolation & purification', 'Enterobacteriaceae Infections/*drug therapy', 'Escherichia coli/isolation & purification', 'Female', 'Humans', 'Intestine, Large/microbiology', 'Male', 'Sulfonamides/pharmacology/*therapeutic use', 'Trimethoprim/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/389808/
1363,Trimethoprim,7051228,"Mechanisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulfamethoxazole.",['Then RL'],"['4-Aminobenzoic Acid/metabolism', 'Bacteria/*drug effects', 'Drug Combinations', 'Drug Resistance, Microbial', 'Drug Synergism', 'Mutation', 'Sulfamethoxazole/*pharmacology', 'Sulfonamides/*pharmacology', 'Thymine/metabolism', 'Trimethoprim/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7051228/
1364,Trimethoprim,1454814,Drug design by machine learning: the use of inductive logic programming to model the structure-activity relationships of trimethoprim analogues binding to dihydrofolate reductase.,"['King RD', 'Muggleton S', 'Lewis RA', 'Sternberg MJ']","['*Artificial Intelligence', '*Drug Design', 'Escherichia coli/enzymology', '*Folic Acid Antagonists', 'Molecular Structure', 'Structure-Activity Relationship', 'Trimethoprim/*analogs & derivatives/chemistry']",https://pubmed.ncbi.nlm.nih.gov/1454814/
1365,Trimethoprim,12151067,Simultaneous determination of binary mixtures of trimethoprim and sulfamethoxazole or sulphamethoxypyridazine by the bivariate calibration spectrophotometric method.,"['Lopez-Martinez L', 'Lopez-de-Alba PL', 'de-Leon-Rodriguez LM', 'Yepez-Murrieta ML']","['Algorithms', 'Calibration', 'Drug Combinations', 'Hydrogen-Ion Concentration', 'Indicators and Reagents', 'Linear Models', 'Spectrophotometry, Ultraviolet', 'Sulfamethoxypyridazine/*analysis', 'Trimethoprim/*analysis', 'Trimethoprim, Sulfamethoxazole Drug Combination/*analysis']",https://pubmed.ncbi.nlm.nih.gov/12151067/
1366,Trimethoprim,6991695,"2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 4. 6-Substituted trimethoprim derivatives from phenolic Mannich intermediates. Application to the synthesis of trimethoprim and 3,5-dialkylbenzyl analogues.","['Roth B', 'Aig E', 'Lane K', 'Rauckman BS']","['Alkylation', 'Bacteria/drug effects', 'Escherichia coli/enzymology', 'Folic Acid Antagonists', 'Mannich Bases', 'Methods', 'Models, Molecular', 'Trimethoprim/*analogs & derivatives/*chemical synthesis']",https://pubmed.ncbi.nlm.nih.gov/6991695/
1367,Trimethoprim,6985448,"Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications.","['Gleckman R', 'Blagg N', 'Joubert DW']","['Bacterial Infections/drug therapy', 'Drug Combinations/therapeutic use', 'Drug Resistance, Microbial', 'Female', 'Humans', 'Pregnancy', 'Sulfamethoxazole/therapeutic use', 'Trimethoprim/adverse effects/metabolism/*pharmacology/therapeutic use', 'Trimethoprim, Sulfamethoxazole Drug Combination', 'Urinary Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6985448/
1368,hydralazine,25405892,Covalent adduct formation between the antihypertensive drug hydralazine and abasic sites in double- and single-stranded DNA.,"['Melton D', 'Lewis CD', 'Price NE', 'Gates KS']","['Antihypertensive Agents/*chemistry', 'Base Sequence', 'DNA/*chemistry', 'DNA, Single-Stranded/*chemistry', 'Hydralazine/*chemistry', 'Mass Spectrometry']",https://pubmed.ncbi.nlm.nih.gov/25405892/
1369,hydralazine,33400322,Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review.,"['Cawoski JR', 'DeBiasio KA', 'Donnachie SW', 'Timanus EA', 'Zimmerman DE', 'Guarascio AJ', 'Montepara CA', 'Covvey JR', 'Nemecek BD']","['Administration, Intravenous', 'Antihypertensive Agents/adverse effects', 'Humans', 'Hydralazine/adverse effects', '*Hypertension/drug therapy', '*Labetalol/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33400322/
1370,hydralazine,26073215,Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review.,"['Farag M', 'Mabote T', 'Shoaib A', 'Zhang J', 'Nabhan AF', 'Clark AL', 'Cleland JG']","['Chronic Disease', 'Drug Therapy, Combination', 'Heart Failure/*drug therapy/mortality', 'Humans', 'Hydralazine/*therapeutic use', 'Mortality', 'Nitrates/*therapeutic use', 'Vasodilator Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26073215/
1371,hydralazine,37273965,"Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial.","['S D', 'Novri DA', 'Hamidy Y', 'Savira M']","['Female', 'Humans', 'Pregnancy', '*Labetalol/therapeutic use', 'Nifedipine/therapeutic use', '*Pre-Eclampsia/drug therapy/chemically induced', 'Antihypertensive Agents/therapeutic use', 'Hydralazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37273965/
1372,hydralazine,6479540,Hydralazine-induced cholangitis.,"['Myers JL', 'Augur NA Jr']","['Acute Disease', 'Chemical and Drug Induced Liver Injury/etiology/pathology', 'Cholangitis/*chemically induced/pathology', 'Cholecystitis/chemically induced/pathology', 'Female', 'Humans', 'Hydralazine/*adverse effects', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/6479540/
1373,hydralazine,16292990,Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety.,['Ferdinand KC'],"['*Black or African American', 'Cardiac Output, Low/*drug therapy/*ethnology', 'Drug Combinations', 'Humans', 'Hydralazine/adverse effects/*therapeutic use', 'Isosorbide Dinitrate/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16292990/
1374,hydralazine,11942883,Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia.,"['Aali BS', 'Nejad SS']","['Adolescent', 'Adult', 'Antihypertensive Agents/*therapeutic use', 'Blood Pressure/drug effects', 'Female', 'Humans', 'Hydralazine/*therapeutic use', 'Nifedipine/*therapeutic use', 'Pre-Eclampsia/*drug therapy', 'Pregnancy', 'Single-Blind Method', 'Vasodilator Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11942883/
1375,hydralazine,24702251,Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.,"['Garces-Eisele SJ', 'Cedillo-Carvallo B', 'Reyes-Nunez V', 'Estrada-Marin L', 'Vazquez-Perez R', 'Juarez-Calderon M', 'Guzman-Garcia MO', 'Duenas-Gonzalez A', 'Ruiz-Arguelles A']","['Acetylation', 'Adult', 'Area Under Curve', 'Arylamine N-Acetyltransferase/*genetics', 'Chromatography, High Pressure Liquid/*methods', 'Dose-Response Relationship, Drug', 'Female', 'Genotype', 'Humans', 'Hydralazine/administration & dosage/*pharmacokinetics', 'Male', 'Mexico', 'Middle Aged', 'Pilot Projects', 'Polymorphism, Single Nucleotide', 'Tablets', 'Tandem Mass Spectrometry/methods', 'Valproic Acid/administration & dosage/*pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24702251/
1376,hydralazine,32927458,Genotype-Guided Hydralazine Therapy.,"['Collins KS', 'Raviele ALJ', 'Elchynski AL', 'Woodcock AM', 'Zhao Y', 'Cooper-DeHoff RM', 'Eadon MT']","['Antihypertensive Agents/pharmacokinetics/*therapeutic use', 'Arylamine N-Acetyltransferase/*genetics/metabolism', 'Dose-Response Relationship, Drug', 'Drug Resistance/genetics', 'Humans', 'Hydralazine/pharmacokinetics/*therapeutic use', 'Hypertension/*drug therapy/genetics', 'Nephrology/methods/standards', 'Pharmacogenomic Testing/standards', 'Pharmacogenomic Variants', 'Practice Guidelines as Topic', 'Precision Medicine/*methods/standards', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32927458/
1377,hydralazine,39522185,Comparative efficacy and safety between intravenous labetalol and intravenous hydralazine for hypertensive disorders in pregnancy: A systematic review and meta-analysis of 19 randomized controlled trials.,"['Goncalves OR', 'Bendaham LCAR', 'Simoni GH', 'Kojima GSA', 'Faria HS', 'de Abreu VS', 'da Silva Junior AB', 'Soares VG', 'Ribeiro BL', 'de Azevedo BB', 'de Araujo Melo KCD', 'de Macedo Lins CD']","['Humans', '*Labetalol/administration & dosage/therapeutic use', '*Hydralazine/administration & dosage/therapeutic use/adverse effects', 'Pregnancy', 'Female', '*Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', '*Hypertension, Pregnancy-Induced/drug therapy', '*Randomized Controlled Trials as Topic', 'Administration, Intravenous', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39522185/
1378,hydralazine,1136859,Acetylator phenotype and the antihypertensive response to hydralazine.,"['Jounela AJ', 'Pasanen M', 'Mattila MJ']","['Acetylation', 'Adult', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Hydralazine/blood/*therapeutic use', 'Hypertension/blood/*drug therapy/urine', 'Male', 'Middle Aged', 'Oxprenolol/*therapeutic use', 'Phenotype', 'Polymorphism, Genetic', 'Sulfamethazine/*urine']",https://pubmed.ncbi.nlm.nih.gov/1136859/
1379,hydralazine,7298112,Plasma concentration and acetylator phenotype determine response to oral hydralazine.,"['Shepherd AM', 'McNay JL', 'Ludden TM', 'Lin MS', 'Musgrave GE']","['Acetylation', 'Administration, Oral', 'Aged', 'Blood Pressure/*drug effects', 'Dose-Response Relationship, Drug', 'Humans', 'Hydralazine/*blood/pharmacology', 'Hypertension/blood/*drug therapy', 'Male', 'Middle Aged', 'Phenotype', 'Sulfamethazine/administration & dosage/metabolism']",https://pubmed.ncbi.nlm.nih.gov/7298112/
1380,hydralazine,8710038,Hydralazine-induced constrictive pericarditis.,"['Franssen CF', 'el Gamal MI', 'Gans RO', 'Hoorntje SJ']","['Antibodies, Antineutrophil Cytoplasmic', 'Antihypertensive Agents/*adverse effects/therapeutic use', 'Autoantibodies/*analysis', 'Autoimmune Diseases/*chemically induced/physiopathology', 'Humans', 'Hydralazine/*adverse effects/therapeutic use', 'Hypertension/drug therapy', 'Male', 'Middle Aged', 'Pericarditis, Constrictive/*chemically induced/diagnosis', 'Peroxidase/immunology', 'Thoracotomy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8710038/
1381,indometacin,10490532,Congenital nephrotic syndrome responsive to captopril and indometacin.,"['Heaton PA', 'Smales O', 'Wong W']","['Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Captopril/*therapeutic use', 'Female', 'Humans', 'Indomethacin/*therapeutic use', 'Infant', 'Nephrotic Syndrome/*congenital/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10490532/
1382,indometacin,27133971,"Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography: a multicentre, single-blinded, randomised controlled trial.","['Luo H', 'Zhao L', 'Leung J', 'Zhang R', 'Liu Z', 'Wang X', 'Wang B', 'Nie Z', 'Lei T', 'Li X', 'Zhou W', 'Zhang L', 'Wang Q', 'Li M', 'Zhou Y', 'Liu Q', 'Sun H', 'Wang Z', 'Liang S', 'Guo X', 'Tao Q', 'Wu K', 'Pan Y', 'Guo X', 'Fan D']","['Acute Disease', 'Administration, Rectal', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage', 'Cholangiopancreatography, Endoscopic Retrograde/*methods', 'Female', 'Humans', 'Indomethacin/*administration & dosage', 'Male', 'Middle Aged', 'Pancreatitis/*prevention & control', 'Postoperative Care/methods', 'Preoperative Care/methods', 'Single-Blind Method', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27133971/
1383,indometacin,8901151,Modelling of indometacin and diclofenac sodium binding to the molecule of human serum albumin.,"['Russeva V', 'Mihailova D']","['Amino Acid Sequence', 'Anti-Inflammatory Agents, Non-Steroidal/*metabolism', 'Diclofenac/*metabolism', 'Humans', 'Hydrogen-Ion Concentration', 'Indomethacin/*metabolism', 'Models, Chemical', 'Molecular Sequence Data', 'Protein Binding', 'Serum Albumin/*metabolism', 'Spectrophotometry, Infrared', 'Urea/metabolism']",https://pubmed.ncbi.nlm.nih.gov/8901151/
1384,indometacin,17270079,A theoretical and spectroscopic study of gamma-crystalline and amorphous indometacin.,"['Strachan CJ', 'Rades T', 'Gordon KC']","['Crystallization', 'Dimerization', 'Indomethacin/*chemistry', 'Models, Molecular', 'Molecular Structure', 'Phase Transition', 'Spectrophotometry, Infrared', 'Spectrum Analysis, Raman']",https://pubmed.ncbi.nlm.nih.gov/17270079/
1385,indometacin,22888516,Preparation and study of poly(vinyl acetate) and poly(styrene) nanosized latex with indometacin.,"['Andonova V', 'Georgiev G', 'Toncheva V', 'Kassarova M']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*chemistry', 'Drug Carriers', 'Indicators and Reagents', 'Indomethacin/administration & dosage/*chemistry', 'Kinetics', 'Microscopy, Atomic Force', 'Microscopy, Electron, Scanning', 'Microscopy, Electron, Transmission', '*Microspheres', 'Nanoparticles/*chemistry', 'Ophthalmic Solutions', 'Particle Size', 'Polystyrenes/*chemistry', 'Polyvinyls/*chemistry', 'Solubility', 'Spectrophotometry, Ultraviolet', 'Spectroscopy, Fourier Transform Infrared']",https://pubmed.ncbi.nlm.nih.gov/22888516/
1386,indometacin,3562200,Incompatibility of indometacin and benzalkonium in eye drops due to ion-pair formation.,"['Dreijer-van der Glas SM', 'Bult A']","['Benzalkonium Compounds/*administration & dosage/antagonists & inhibitors', 'Chemical Phenomena', 'Chemistry', 'Humans', 'Hydrogen-Ion Concentration', 'Indomethacin/*administration & dosage/antagonists & inhibitors', '*Ophthalmic Solutions']",https://pubmed.ncbi.nlm.nih.gov/3562200/
1387,indometacin,17963427,Alkylation activity and molecular properties of two antineoplastic agents that utilise indometacin and a conjugate of aspirin with 2-aminonicotinic acid to transport nitrogen mustard groups.,['Bartzatt R'],"['Alkylation', 'Anti-Inflammatory Agents, Non-Steroidal/*chemistry', 'Antineoplastic Agents, Alkylating/*chemistry/pharmacokinetics/*pharmacology', 'Aspirin/*chemistry', 'Chemical Phenomena', 'Chemistry, Physical', 'Drug Design', 'Hydrolysis', 'Indicators and Reagents', 'Indomethacin/*chemistry', 'Mechlorethamine/*chemistry', 'Models, Molecular', 'Nicotinic Acids/*chemistry', 'Skin Absorption', 'Software']",https://pubmed.ncbi.nlm.nih.gov/17963427/
1388,indometacin,10431478,Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study.,"['de Leval X', 'Dogne JM', 'Neven P', 'Labasse A', 'Delarge J', 'Reginster JY', 'Henrotin Y']","['Cyclooxygenase 1', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*pharmacology', 'Indomethacin/*pharmacology', 'Isoenzymes/*metabolism', 'Prostaglandin-Endoperoxide Synthases/*metabolism', 'Substrate Specificity', 'Sulfonamides/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10431478/
1389,indometacin,3700558,Quantitative determination of acemetacin and its metabolite indometacin in blood and plasma by column liquid chromatography.,"['Schollnhammer G', 'Dell HD', 'Doersing K', 'Kamp R']","['Biological Availability', 'Chromatography, Liquid', 'Erythrocytes/metabolism', 'Humans', 'Hydrogen-Ion Concentration', 'Indicators and Reagents', 'Indomethacin/*analogs & derivatives/*blood/metabolism', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/3700558/
1390,Pimecrolimus,25802354,Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.,"['Sigurgeirsson B', 'Boznanski A', 'Todd G', 'Vertruyen A', 'Schuttelaar ML', 'Zhu X', 'Schauer U', 'Qaqundah P', 'Poulin Y', 'Kristjansson S', 'von Berg A', 'Nieto A', 'Boguniewicz M', 'Paller AS', 'Dakovic R', 'Ring J', 'Luger T']","['Adrenal Cortex Hormones/adverse effects/therapeutic use', 'Child, Preschool', 'Dermatitis, Atopic/diagnosis/*drug therapy', 'Dermatologic Agents/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Humans', 'Infant', 'Long-Term Care', 'Tacrolimus/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25802354/
1391,Pimecrolimus,36370744,"Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.","['Devasenapathy N', 'Chu A', 'Wong M', 'Srivastava A', 'Ceccacci R', 'Lin C', 'MacDonald M', 'Wen A', 'Steen J', 'Levine M', 'Pyne L', 'Schneider L', 'Chu DK']","['Adult', 'Child', 'Humans', 'Infant', '*Asthma', 'Bayes Theorem', 'Calcineurin Inhibitors/adverse effects', '*Dermatitis, Atopic/drug therapy/epidemiology', '*Hypersensitivity', '*Neoplasms/drug therapy', 'Tacrolimus/adverse effects', 'Controlled Clinical Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36370744/
1392,Pimecrolimus,33818985,Response of pruritic scrotal epidermolytic acanthomas to pimecrolimus 1% cream.,"['Martinez-Domenech A', 'Garcia-Legaz Martinez M', 'Partarrieu-Mejias F', 'Magdaleno-Tapial J', 'Valenzuela-Onate C', 'Casanova-Esquembre A', 'Lorca-Sprohnle J', 'Perez-Ferriols A']","['Acanthoma/complications/*drug therapy', 'Dermatologic Agents/*administration & dosage', 'Dosage Forms', 'Humans', 'Male', 'Middle Aged', 'Pruritus/*drug therapy/etiology', '*Scrotum', 'Skin Neoplasms/complications/*drug therapy', 'Tacrolimus/administration & dosage/*analogs & derivatives', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33818985/
1393,Pimecrolimus,37394952,Safety and efficacy of Pimecrolimus in atopic dermatitis among Chinese infants: a sub-group analysis of a five-year open-label study.,"['Dou X', 'Liu L', 'Zhu X', 'Wen W', 'Ni C', 'Zhao Y', 'He Z', 'Li H', 'Sun Q', 'Yang Q', 'Sun X', 'Guo Y']","['Humans', 'Infant', '*Dermatitis, Atopic/drug therapy', '*Dermatologic Agents/administration & dosage/adverse effects/therapeutic use', 'East Asian People', '*Tacrolimus/administration & dosage/adverse effects/analogs & derivatives/therapeutic use', 'Treatment Outcome', 'Administration, Topical', 'Glucocorticoids/administration & dosage/adverse effects/therapeutic use', 'Skin Cream']",https://pubmed.ncbi.nlm.nih.gov/37394952/
1394,Pimecrolimus,38297923,Pimecrolimus 1% cream for mild-to-moderate atopic dermatitis: a systematic review and meta-analysis with a focus on children and sensitive skin areas.,"['Luger T', 'Chu CY', 'Elgendy A', 'Ibrahim SBBK', 'Murashkin N', 'Ranjan S', 'Zhao Z']","['Child', 'Humans', 'Tacrolimus/adverse effects', '*Dermatitis, Atopic/drug therapy', '*Dermatologic Agents/adverse effects', 'Immunoglobulin A', 'Treatment Outcome', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/38297923/
1395,Pimecrolimus,22571582,Clinical effects of topical pimecrolimus in a patient with Fox-Fordyce disease.,"['Milcic D', 'Nikolic M']","['Child', 'Dermatologic Agents/*therapeutic use', 'Female', 'Fox-Fordyce Disease/*drug therapy/pathology', 'Humans', 'Tacrolimus/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22571582/
1396,Pimecrolimus,27653808,Annular Lichenoid Dermatitis of Youth: A Chronic Case Managed Using Pimecrolimus.,"['Malachowski SJ', 'Creasey M', 'Kinkley N', 'Heaphy MR Jr']","['Child', 'Chronic Disease', 'Dermatologic Agents/administration & dosage/*therapeutic use', 'Humans', 'Lichenoid Eruptions/*drug therapy/pathology', 'Male', 'Tacrolimus/administration & dosage/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27653808/
1397,Pimecrolimus,33834524,Topical therapy of atopic dermatitis with a focus on pimecrolimus.,"['Luger T', 'Paller AS', 'Irvine AD', 'Sidbury R', 'Eichenfield LF', 'Werfel T', 'Bieber T']","['Adult', 'Calcineurin Inhibitors/therapeutic use', 'Child', '*Dermatitis, Atopic/drug therapy', 'Humans', 'Quality of Life', 'Tacrolimus/adverse effects/analogs & derivatives', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33834524/
1398,Pimecrolimus,24281309,"Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial.","['Siepmann D', 'Lotts T', 'Blome C', 'Braeutigam M', 'Phan NQ', 'Butterfass-Bahloul T', 'Augustin M', 'Luger TA', 'Stander S']","['Administration, Cutaneous', 'Adult', 'Aged', 'Anti-Inflammatory Agents/therapeutic use', 'Biomarkers/metabolism', 'Calcitonin Gene-Related Peptide/metabolism', 'Dermatologic Agents/*administration & dosage', 'Double-Blind Method', 'Female', 'Humans', 'Hydrocortisone/therapeutic use', 'Male', 'Middle Aged', 'Neuropeptides/*metabolism', 'Prurigo/complications/*drug therapy/metabolism', 'Pruritus/*drug therapy/etiology/metabolism', 'Quality of Life', 'Tacrolimus/administration & dosage/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/24281309/
1399,Pimecrolimus,25557211,Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants.,"['Luger T', 'Boguniewicz M', 'Carr W', 'Cork M', 'Deleuran M', 'Eichenfield L', 'Eigenmann P', 'Folster-Holst R', 'Gelmetti C', 'Gollnick H', 'Hamelmann E', 'Hebert AA', 'Muraro A', 'Oranje AP', 'Paller AS', 'Paul C', 'Puig L', 'Ring J', 'Siegfried E', 'Spergel JM', 'Stingl G', 'Taieb A', 'Torrelo A', 'Werfel T', 'Wahn U']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Child, Preschool', 'Consensus', 'Dermatitis, Atopic/*drug therapy', 'Humans', 'Infant', 'Practice Guidelines as Topic', 'Tacrolimus/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25557211/
1400,Pimecrolimus,23876065,"Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.","['Prucha H', 'Schnopp C', 'Akdis C', 'Lauener R', 'Wollenberg A', 'Ring J', 'Traidl-Hoffmann C']","['Calcineurin/*drug effects/metabolism', 'Dermatitis, Atopic/*drug therapy', 'Dermatologic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Drug Evaluation, Preclinical', 'Enzyme Inhibitors/*administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Randomized Controlled Trials as Topic', 'Skin/drug effects/pathology', 'Tacrolimus/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/23876065/
1401,Pimecrolimus,21810396,Letter: Generalized lichen nitidus successfully treated with pimecrolimus 1 percent cream.,"['Farshi S', 'Mansouri P']","['Administration, Cutaneous', 'Child', 'Dermatologic Agents/*administration & dosage/therapeutic use', 'Drug Administration Schedule', 'Humans', 'Lichen Nitidus/*drug therapy/*pathology', 'Male', 'Tacrolimus/administration & dosage/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21810396/
1402,Pimecrolimus,19943858,Topical tacrolimus and pimecrolimus in the treatment of oral lichen planus: an update.,"['Lopez-Jornet P', 'Camacho-Alonso F', 'Salazar-Sanchez N']","['Administration, Topical', '*Calcineurin Inhibitors', 'Humans', 'Immunosuppressive Agents/administration & dosage/*therapeutic use', 'Lichen Planus, Oral/*drug therapy', 'Peptidylprolyl Isomerase/*antagonists & inhibitors', 'Randomized Controlled Trials as Topic', 'Safety', 'Tacrolimus/administration & dosage/*analogs & derivatives/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19943858/
1403,Pimecrolimus,19706108,Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo.,"['Hui-Lan Y', 'Xiao-Yan H', 'Jian-Yong F', 'Zong-Rong L']","['Administration, Cutaneous', 'Adolescent', 'Child', 'Combined Modality Therapy', 'Dermatologic Agents/*administration & dosage/adverse effects', 'Female', 'Humans', 'Lasers, Excimer/adverse effects/*therapeutic use', '*Low-Level Light Therapy/adverse effects', 'Male', 'Single-Blind Method', 'Skin Pigmentation', 'Tacrolimus/administration & dosage/adverse effects/*analogs & derivatives', 'Vitiligo/*therapy']",https://pubmed.ncbi.nlm.nih.gov/19706108/
1404,Pimecrolimus,22068766,Zoon's plasma cell balanitis: a report of two cases treated with pimecrolimus.,"['Delgado L', 'Brandt HR', 'Ortolan DG', 'Patriota RC', 'Criado PR', 'Belda Junior W']","['Administration, Topical', 'Adult', 'Balanitis/*drug therapy/pathology', 'Dermatologic Agents/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Plasma Cells', 'Tacrolimus/*analogs & derivatives/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22068766/
1405,Pimecrolimus,17958783,Molluscum contagiosum infection associated with pimecrolimus use in pityriasis alba.,"['Goksugur N', 'Ozbostanci B', 'Goksugur SB']","['Administration, Topical', 'Adolescent', 'Humans', 'Immunosuppressive Agents/administration & dosage/*adverse effects', 'Male', 'Molluscum Contagiosum/*etiology/pathology', '*Molluscum contagiosum virus', 'Pityriasis/*drug therapy', 'Tacrolimus/administration & dosage/adverse effects/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/17958783/
1406,Pimecrolimus,24185493,Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm.,"['Luger T', 'De Raeve L', 'Gelmetti C', 'Kakourou T', 'Katsarou A', 'Lambert J', 'Morren MA', 'Oranje A', 'Ruer M', 'Serdaroglu S', 'Torrelo A', 'Werfel T']","['Adrenal Cortex Hormones/adverse effects', '*Algorithms', 'Anti-Inflammatory Agents/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Atrophy/chemically induced', 'Dermatitis, Atopic/*drug therapy', 'Humans', 'Medication Adherence', 'Quality of Life', 'Severity of Illness Index', 'Skin/*pathology', 'Skin Cream/*therapeutic use', 'Tacrolimus/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24185493/
1407,Azelaic acid,32356369,"Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne.","['Liu H', 'Yu H', 'Xia J', 'Liu L', 'Liu GJ', 'Sang H', 'Peinemann F']","['Acne Vulgaris/*drug therapy', 'Adapalene/adverse effects/therapeutic use', 'Adolescent', 'Adult', 'Anti-Bacterial Agents/therapeutic use', 'Benzoyl Peroxide/therapeutic use', 'Bias', 'Child', 'Clindamycin/adverse effects/therapeutic use', 'Dermatologic Agents/adverse effects/*therapeutic use', 'Dicarboxylic Acids/adverse effects/therapeutic use', 'Erythromycin/adverse effects/therapeutic use', 'Female', 'Glycolates/therapeutic use', 'Humans', 'Keratolytic Agents/therapeutic use', 'Male', 'Mandelic Acids/therapeutic use', 'Niacinamide/adverse effects/therapeutic use', 'Patient Dropouts/statistics & numerical data', 'Pyruvic Acid/adverse effects/therapeutic use', 'Quality of Life', 'Salicylic Acid/therapeutic use', 'Sulfur/therapeutic use', 'Tretinoin/therapeutic use', 'Young Adult', 'Zinc/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32356369/
1408,Azelaic acid,24280644,Azelaic acid: Properties and mode of action.,"['Sieber MA', 'Hegel JK']","['Acne Vulgaris/drug therapy/metabolism', 'Anti-Bacterial Agents/*pharmacology/therapeutic use', 'Anti-Inflammatory Agents/*pharmacology/therapeutic use', 'Dermatologic Agents/*pharmacology/therapeutic use', 'Dicarboxylic Acids/*pharmacology/therapeutic use', 'Humans', 'Melanins/metabolism', 'Skin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/24280644/
1409,Azelaic acid,26355614,Azelaic Acid: Evidence-based Update on Mechanism of Action and Clinical Application.,"['Schulte BC', 'Wu W', 'Rosen T']","['Acne Vulgaris/drug therapy', 'Alopecia Areata/drug therapy', 'Dermatitis, Perioral/drug therapy', 'Dermatologic Agents/pharmacology/*therapeutic use', 'Dicarboxylic Acids/pharmacology/*therapeutic use', 'Facial Dermatoses/*drug therapy', 'Humans', ""Hutchinson's Melanotic Freckle/*drug therapy"", 'Melanosis/drug therapy', 'Psoriasis/drug therapy', 'Rosacea/drug therapy', 'Skin Diseases/*drug therapy', 'Skin Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26355614/
1410,Azelaic acid,1712709,Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders.,"['Fitton A', 'Goa KL']","['Acne Vulgaris/*drug therapy', 'Dermatologic Agents/pharmacokinetics/*pharmacology/therapeutic use', 'Dicarboxylic Acids/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Pigmentation Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1712709/
1411,Azelaic acid,37550898,"A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging.","['King S', 'Campbell J', 'Rowe R', 'Daly ML', 'Moncrieff G', 'Maybury C']","['Humans', '*Skin Aging', '*Acne Vulgaris/drug therapy', '*Rosacea/drug therapy/pathology', 'Erythema/drug therapy', 'Treatment Outcome', '*Melanosis/drug therapy', '*Dermatologic Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37550898/
1412,Azelaic acid,32730109,The versatility of azelaic acid in dermatology.,"['Searle T', 'Ali FR', 'Al-Niaimi F']","['*Acne Vulgaris/drug therapy', '*Dermatologic Agents/therapeutic use', '*Dermatology', 'Dicarboxylic Acids/therapeutic use', 'Humans', 'Male', '*Rosacea/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32730109/
1413,Azelaic acid,23652891,Retinoids and azelaic acid to treat acne and hyperpigmentation in skin of color.,"['Woolery-Lloyd HC', 'Keri J', 'Doig S']","['Humans', 'Acne Vulgaris/drug therapy/pathology', 'Dermatologic Agents/adverse effects/therapeutic use', '*Dicarboxylic Acids/adverse effects/therapeutic use', '*Hyperpigmentation/drug therapy/pathology', '*Retinoids/adverse effects/therapeutic use', 'Ethnic and Racial Minorities']",https://pubmed.ncbi.nlm.nih.gov/23652891/
1414,Azelaic acid,2528256,Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne.,"['Cunliffe WJ', 'Holland KT']","['Acne Vulgaris/*drug therapy/microbiology/physiopathology', 'Administration, Topical', 'Anti-Bacterial Agents', 'Clinical Trials as Topic', 'Dicarboxylic Acids/administration & dosage/*therapeutic use', 'Double-Blind Method', 'Fatty Acids, Nonesterified/metabolism', 'Female', 'Humans', 'Male', 'Micrococcaceae/drug effects', 'Propionibacterium/drug effects', 'Sebum/drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/2528256/
1415,Azelaic acid,9392765,Azelaic acid 20% cream (AZELEX) and the medical management of acne vulgaris.,['Gibson JR'],"['Acne Vulgaris/*drug therapy/nursing', 'Clinical Trials as Topic', 'Dermatologic Agents/*therapeutic use', 'Dicarboxylic Acids/*therapeutic use', 'Humans', 'Ointments']",https://pubmed.ncbi.nlm.nih.gov/9392765/
1416,Azelaic acid,34731527,Long-term effect of azelaic acid peel on sebum production in acne.,"['Szymanska A', 'Budzisz E', 'Erkiert-Polguj A']","['*Acne Vulgaris/diagnosis/drug therapy/pathology', 'Adult', '*Chemexfoliation/methods', 'Dicarboxylic Acids/therapeutic use', 'Female', 'Humans', 'Male', 'Sebum', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34731527/
1417,Azelaic acid,30156481,Underground Azelaic Acid-Conferred Resistance to Pseudomonas syringae in Arabidopsis.,"['Cecchini NM', 'Roychoudhry S', 'Speed DJ', 'Steffes K', 'Tambe A', 'Zodrow K', 'Konstantinoff K', 'Jung HW', 'Engle NL', 'Tschaplinski TJ', 'Greenberg JT']","['*Arabidopsis/microbiology', 'Arabidopsis Proteins/genetics/immunology', '*Dicarboxylic Acids/pharmacology', '*Plant Immunity/drug effects', '*Pseudomonas syringae/physiology']",https://pubmed.ncbi.nlm.nih.gov/30156481/
1418,Azelaic acid,16924055,Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials.,"['Liu RH', 'Smith MK', 'Basta SA', 'Farmer ER']","['Administration, Cutaneous', 'Dermatologic Agents/administration & dosage/adverse effects/*therapeutic use', 'Dicarboxylic Acids/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Rosacea/*drug therapy/pathology', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/16924055/
1419,Azelaic acid,3718862,Apparent progression of lentigo maligna to invasive melanoma during treatment with topical azelaic acid.,"['McLean DI', 'Peter KK']","['Aged', 'Dicarboxylic Acids/*therapeutic use', 'Female', 'Humans', 'Melanoma/*etiology/pathology', 'Middle Aged', 'Neoplasm Invasiveness', 'Nevus, Pigmented/complications/*drug therapy/pathology', 'Skin Neoplasms/*drug therapy/etiology/pathology']",https://pubmed.ncbi.nlm.nih.gov/3718862/
1420,Azelaic acid,23545911,Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea.,"['Jackson JM', 'Kircik LH', 'Lorenz DJ']","['Administration, Cutaneous', 'Administration, Oral', 'Delayed-Action Preparations', 'Dermatologic Agents/administration & dosage/*therapeutic use', 'Dicarboxylic Acids/administration & dosage/*therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Minocycline/administration & dosage/*therapeutic use', 'Rosacea/*drug therapy/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23545911/
1421,Azelaic acid,35112652,"Azelaic acid loaded chitosan and HPMC based hydrogels for treatment of acne: formulation, characterization, in vitro-ex vivo evaluation.","['Arpa MD', 'Secen IM', 'Erim UC', 'Hos A', 'Ustundag Okur N']","['*Acne Vulgaris/drug therapy', '*Chitosan', 'Dicarboxylic Acids/chemistry', 'Humans', 'Hydrogels']",https://pubmed.ncbi.nlm.nih.gov/35112652/
1422,Azelaic acid,27346659,A prodrug approach to enhance azelaic acid percutaneous availability.,"['Al-Marabeh S', 'Khalil E', 'Khanfar M', 'Al-Bakri AG', 'Alzweiri M']","['Acne Vulgaris/drug therapy', 'Administration, Cutaneous', 'Dermatologic Agents/administration & dosage/*pharmacokinetics/pharmacology', 'Dicarboxylic Acids/administration & dosage/*pharmacokinetics/pharmacology', 'Gram-Positive Bacterial Infections/drug therapy', 'Humans', 'Prodrugs/administration & dosage/*pharmacokinetics/pharmacology', 'Propionibacterium acnes/drug effects', 'Skin/*metabolism', 'Skin Absorption', 'Staphylococcal Infections/drug therapy', 'Staphylococcus aureus/drug effects']",https://pubmed.ncbi.nlm.nih.gov/27346659/
1423,Azelaic acid,38656631,"755-nm picosecond laser plus topical 20% azelaic acid compared to topical 20% azelaic acid alone for the treatment of melasma: a randomized, split-face and controlled trial.","['Lai D', 'Cheng S', 'Zhou S', 'Hao J', 'Chen H', 'Jia K', 'Liu H', 'Cui Y']","['Humans', '*Melanosis/therapy/radiotherapy', 'Female', '*Dicarboxylic Acids/therapeutic use/administration & dosage', 'Adult', 'Middle Aged', '*Lasers, Solid-State/therapeutic use', 'Male', 'Treatment Outcome', 'Low-Level Light Therapy/methods', 'Dermatologic Agents/therapeutic use/administration & dosage', 'Combined Modality Therapy', 'Patient Satisfaction', 'Administration, Topical', 'Single-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/38656631/
1424,Famotidine,37196883,Crystalline and amorphous famotidine malate as pathways to prevent polymorphic transformation with improved dissolution.,"['Russo MG', 'Brusau EV', 'Ellena J', 'Narda GE']","['*Famotidine/chemistry', 'Solubility', '*Malates', 'Histamine H2 Antagonists', 'X-Ray Diffraction', 'Calorimetry, Differential Scanning', 'Drug Stability', 'Spectroscopy, Fourier Transform Infrared']",https://pubmed.ncbi.nlm.nih.gov/37196883/
1425,Famotidine,37415425,"GC Analysis of Metformin, Ranitidine and Famotidine from Pharmaceuticals and Human Serum.","['Zounr RA', 'Khuhawar MY', 'Khuhawar TMJ', 'Lanjwani MF', 'Khuhawar MY']","['Humans', '*Famotidine', 'Ranitidine', '*Metformin', 'Chromatography, Gas/methods', 'Pharmaceutical Preparations']",https://pubmed.ncbi.nlm.nih.gov/37415425/
1426,Famotidine,33263203,Design of multicomponent indomethacin-paracetamol and famotidine loaded nanoparticles for sustained and effective anti-inflammatory therapy.,"['Assali M', 'Zohud N']","['Acetaminophen/*chemistry', 'Anti-Inflammatory Agents, Non-Steroidal/*chemistry', 'Drug Compounding', 'Emulsions', 'Famotidine/*chemistry', 'Fibroblasts/drug effects', 'HeLa Cells', 'Histamine H2 Antagonists/*chemistry', 'Humans', 'Indomethacin/*chemistry', 'Molecular Structure', 'Nanoparticles/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/33263203/
1427,Famotidine,24258773,Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.,"['Madani S', 'Kauffman R', 'Simpson P', 'Lehr VT', 'Lai ML', 'Sarniak A', 'Tolia V']","['Child', 'Child, Preschool', '*Critical Illness', 'Famotidine/administration & dosage/blood/*pharmacokinetics/pharmacology', 'Female', 'Gastric Acid/chemistry/metabolism', 'Gastric Acidity Determination', 'Gastritis/drug therapy/metabolism', 'Histamine H2 Antagonists/administration & dosage/blood/pharmacokinetics/pharmacology', 'Humans', 'Hydrogen-Ion Concentration/drug effects', 'Infant', 'Infusions, Intravenous', 'Ranitidine/administration & dosage/blood/*pharmacokinetics/pharmacology', 'Single-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/24258773/
1428,Famotidine,37327698,"Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study.","['Momtazmanesh S', 'Ansari S', 'Izadi Z', 'Shobeiri P', 'Vatankhah V', 'Seifi A', 'Ghiasvand F', 'Bahrami M', 'Salehi M', 'Noorbala AA', 'Akhondzadeh S']","['Humans', '*Famotidine/adverse effects', '*COVID-19/complications', 'Iran', 'Histamine H2 Antagonists/adverse effects', 'Cognition', 'Double-Blind Method', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37327698/
1429,Famotidine,33625613,"Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.","['Sun C', 'Chen Y', 'Hu L', 'Wu Y', 'Liang M', 'Ayaz Ahmed M', 'Bhan C', 'Guo Z', 'Yang H', 'Zuo Y', 'Yan Y', 'Zhou Q']","['COVID-19/mortality/*pathology', 'Famotidine/*therapeutic use', 'Histamine H2 Antagonists/therapeutic use', 'Humans', '*Intubation, Intratracheal', '*SARS-CoV-2', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33625613/
1430,Famotidine,28625018,No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole.,"['Feng HP', 'Vaddady P', 'Guo Z', 'Liu F', 'Panebianco D', 'Levine V', 'Caro L', 'Butterton JR', 'Iwamoto M', 'Yeh WW']","['2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects/*pharmacokinetics/pharmacology', 'Adult', 'Amides', 'Antiviral Agents/adverse effects/*pharmacokinetics/pharmacology', 'Benzofurans/adverse effects/blood/*pharmacokinetics/pharmacology', 'Carbamates', 'Cyclopropanes', 'Demography', 'Drug Interactions', 'Famotidine/adverse effects/*pharmacokinetics/pharmacology', 'Female', 'Hepacivirus/*drug effects', 'Humans', 'Imidazoles/adverse effects/blood/*pharmacokinetics/pharmacology', 'Male', 'Middle Aged', 'Pantoprazole', 'Quinoxalines/adverse effects/blood/*pharmacokinetics/pharmacology', 'Sulfonamides', 'Time Factors', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28625018/
1431,Famotidine,23881568,Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy.,['Deeks ED'],"['Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage', 'Drug Combinations', 'Drug Interactions', 'Duodenal Ulcer/*prevention & control', 'Famotidine/*administration & dosage/adverse effects/pharmacokinetics', 'Histamine H2 Antagonists/*administration & dosage', 'Humans', 'Ibuprofen/*administration & dosage/adverse effects/pharmacokinetics', 'Stomach Ulcer/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/23881568/
1432,Famotidine,2573505,"Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.","['Langtry HD', 'Grant SM', 'Goa KL']","['Famotidine/pharmacokinetics/*pharmacology/therapeutic use', 'Histamine H2 Antagonists/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Peptic Ulcer/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/2573505/
1433,Famotidine,25197930,Hydrogel polysaccharides of tamarind and xanthan to formulate hydrodynamically balanced matrix tablets of famotidine.,"['Razavi M', 'Nyamathulla S', 'Karimian H', 'Moghadamtousi SZ', 'Noordin MI']","['Calorimetry, Differential Scanning', 'Delayed-Action Preparations/chemistry', 'Famotidine/*chemistry', 'Hydrogels/*chemistry', 'Hydrogen-Ion Concentration', 'Kinetics', 'Plant Preparations/chemistry', 'Polysaccharides, Bacterial/*chemistry', 'Spectroscopy, Fourier Transform Infrared', 'Tamarindus/*chemistry', 'Viscosity', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/25197930/
1434,Famotidine,22149579,HZT-501 (DUEXIS((R)); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis.,"['Schiff M', 'Peura D']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology/*therapeutic use', 'Anti-Ulcer Agents/*pharmacology', 'Arthritis, Rheumatoid/*drug therapy', 'Drug Combinations', 'Drug-Related Side Effects and Adverse Reactions', 'Famotidine/adverse effects/pharmacology/*therapeutic use', 'Female', 'Gastrointestinal Diseases/chemically induced/*prevention & control', 'Gastrointestinal Tract/drug effects', 'Histamine H2 Antagonists/adverse effects/pharmacology/*therapeutic use', 'Humans', 'Ibuprofen/adverse effects/pharmacology/*therapeutic use', 'Male', 'Osteoarthritis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22149579/
1435,Famotidine,36524974,"An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter pylori.","['Ragab MAA', 'Maher HM', 'Tarek S', 'Mahgoub H']","['Humans', 'Famotidine/analysis', 'Metronidazole', 'Amoxicillin', '*Helicobacter Infections', '*Helicobacter pylori', 'Tablets', 'Gastric Juice', 'Chromatography, Thin Layer/methods']",https://pubmed.ncbi.nlm.nih.gov/36524974/
1436,Famotidine,22936406,"""Development and evaluation of sodium alginate-polyacrylamide graft-co-polymer-based stomach targeted hydrogels of famotidine"".","['Tripathi R', 'Mishra B']","['Acrylic Resins/*chemistry', 'Alginates/*chemistry', 'Anti-Ulcer Agents/administration & dosage/chemistry', 'Calorimetry, Differential Scanning/methods', 'Delayed-Action Preparations/chemistry', 'Drug Carriers/*chemistry', 'Drug Delivery Systems/methods', 'Famotidine/*administration & dosage/*chemistry', 'Gastric Mucosa/*metabolism', 'Glucuronic Acid/chemistry', 'Hexuronic Acids/chemistry', 'Hydrogel, Polyethylene Glycol Dimethacrylate/*chemistry', 'Hydrogen Bonding', 'Hydrogen-Ion Concentration', 'Models, Biological', 'Spectroscopy, Fourier Transform Infrared', 'Stomach/drug effects', 'X-Ray Diffraction/methods']",https://pubmed.ncbi.nlm.nih.gov/22936406/
1437,Famotidine,7650081,Stability and compatibility of anakinra with intravenous cimetidine hydrochloride or famotidine in 0.9% sodium chloride injection.,"['Nahata MC', 'Morosco RS', 'Sabados BK', 'Weber TR']","['Chromatography, High Pressure Liquid', 'Cimetidine/chemistry/*metabolism', 'Drug Combinations', 'Drug Interactions', 'Drug Stability', 'Famotidine/chemistry/*metabolism', 'Hydrogen-Ion Concentration', 'Interleukin 1 Receptor Antagonist Protein', 'Light', 'Recombinant Proteins/chemistry/metabolism', 'Sialoglycoproteins/chemistry/*metabolism', 'Sodium Chloride/chemistry/metabolism', 'Temperature']",https://pubmed.ncbi.nlm.nih.gov/7650081/
1438,Famotidine,1746996,"Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.","['Sabesin SM', 'Berlin RG', 'Humphries TJ', 'Bradstreet DC', 'Walton-Bowen KL', 'Zaidi S']","['Adult', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Esophagoscopy', 'Famotidine/*administration & dosage/adverse effects', 'Female', 'Gastroesophageal Reflux/complications/*drug therapy/pathology', 'Heartburn/etiology', 'Humans', 'Male', 'Middle Aged', 'Patient Compliance']",https://pubmed.ncbi.nlm.nih.gov/1746996/
1439,Famotidine,30727781,"Inhibition of alpha-, beta-, gamma-, delta-, zeta- and eta-class carbonic anhydrases from bacteria, fungi, algae, diatoms and protozoans with famotidine.","['Angeli A', 'Pinteala M', 'Maier SS', 'Del Prete S', 'Capasso C', 'Simionescu BC', 'Supuran CT']","['Bacteria/enzymology', 'Carbonic Anhydrase Inhibitors/chemical synthesis/chemistry/*pharmacology', 'Carbonic Anhydrases/*metabolism', 'Chlorophyta/enzymology', 'Diatoms/enzymology', 'Famotidine/chemical synthesis/chemistry/*pharmacology', 'Fungi/enzymology', 'Humans', 'Molecular Structure', 'Plasmodium falciparum/enzymology', 'Trypanosoma cruzi/enzymology']",https://pubmed.ncbi.nlm.nih.gov/30727781/
1440,Trazodone,34994734,Treatment of insomnia - effect of trazodone and hypnotics on sleep.,"['Wichniak A', 'Wierzbicka AE', 'Jarema M']","['Humans', 'Hypnotics and Sedatives/therapeutic use', 'Sleep', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Sleep Quality', '*Trazodone/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34994734/
1441,Trazodone,11603256,Fatal overdose with trazodone: case report and literature review.,"['de Meester A', 'Carbutti G', 'Gabriel L', 'Jacques JM']","['Adult', 'Antidepressive Agents, Second-Generation/*poisoning', 'Arrhythmias, Cardiac/chemically induced', 'Electrocardiography', 'Humans', 'Male', 'Suicide', 'Trazodone/*poisoning']",https://pubmed.ncbi.nlm.nih.gov/11603256/
1442,Trazodone,39307154,"Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial.","['Pal S', 'Chataway J', 'Swingler R', 'Macleod MR', 'Carragher NO', 'Hardingham G', 'Selvaraj BT', 'Smith C', 'Wong C', 'Newton J', 'Lyle D', 'Stenson A', 'Dakin RS', 'Ihenacho A', 'Colville S', 'Mehta AR', 'Stallard N', 'Carpenter JR', 'Parker RA', 'Keerie C', 'Weir CJ', 'Virgo B', 'Morris S', 'Waters N', 'Gray B', 'MacDonald D', 'MacDonald E', 'Parmar MKB', 'Chandran S']","['Humans', '*Trazodone/therapeutic use/pharmacology', 'Male', 'Middle Aged', 'Female', 'Aged', '*Memantine/therapeutic use', 'Double-Blind Method', '*Motor Neuron Disease/drug therapy', 'Treatment Outcome', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/39307154/
1443,Trazodone,38769018,Allosteric Inhibition and Pharmacochaperoning of the Serotonin Transporter by the Antidepressant Drugs Trazodone and Nefazodone.,"['El-Kasaby A', 'Boytsov D', 'Kasture A', 'Krumpl G', 'Hummel T', 'Freissmuth M', 'Sandtner W']","['*Serotonin Plasma Membrane Transport Proteins/metabolism/genetics', '*Trazodone/pharmacology/metabolism', 'Humans', '*Antidepressive Agents/pharmacology/metabolism', '*Piperazines/pharmacology/metabolism', 'Allosteric Regulation/drug effects', 'HEK293 Cells', 'Selective Serotonin Reuptake Inhibitors/pharmacology/metabolism', 'Triazoles/pharmacology', 'Protein Folding/drug effects', 'Vilazodone Hydrochloride/pharmacology/metabolism']",https://pubmed.ncbi.nlm.nih.gov/38769018/
1444,Trazodone,37979502,The effects of atomoxetine and trazodone combination on obstructive sleep apnea and sleep microstructure: A double-blind randomized clinical trial study.,"['Shahbazi M', 'Heidari R', 'Tafakhori A', 'Samadi S', 'Nikeghbalian Z', 'Amirifard H', 'Najafi A']","['Adult', 'Humans', 'Male', 'Middle Aged', 'Female', '*Trazodone/therapeutic use', 'Atomoxetine Hydrochloride/therapeutic use/pharmacology', 'Sleep', '*Sleep Apnea, Obstructive', 'Polysomnography/methods', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37979502/
1445,Trazodone,27744763,A review of trazodone use in psychiatric and medical conditions.,['Khouzam HR'],"['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antidepressive Agents, Second-Generation/adverse effects/*therapeutic use', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Male', 'Mental Disorders/*drug therapy', 'Middle Aged', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use', 'Trazodone/*pharmacology/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27744763/
1446,Trazodone,38287895,Analysis of Factors Affecting Concentrations and Concentration-To-Dose Ratios of Trazodone.,"['Song Y', 'Chang L', 'Lun Y', 'Chen C', 'Fu R', 'Wang D', 'Zhou C']","['Humans', 'Female', 'Middle Aged', 'Male', '*Trazodone/adverse effects', 'Fluoxetine', 'Duloxetine Hydrochloride', 'Reference Values', 'Smoking']",https://pubmed.ncbi.nlm.nih.gov/38287895/
1447,Trazodone,33731232,Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action.,"['Albert U', 'Lamba P', 'Stahl SM']","['Depressive Disorder, Major/*drug therapy', 'Drug Administration Schedule', 'Humans', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/*therapeutic use', 'Trazodone/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33731232/
1448,Trazodone,36988041,Biochemical and Biophysical in Vitro Studies and Systematic Literature Review on the Antioxidant and Antiglycation Activities of Trazodone.,"['Nesterowicz M', 'Zendzian-Piotrowska M', 'Ladny JR', 'Zalewska A', 'Maciejczyk M']","['*Antioxidants/metabolism', '*Trazodone/pharmacology', 'Glycosylation', 'Advanced Oxidation Protein Products/metabolism', 'Molecular Docking Simulation', 'Glycation End Products, Advanced/metabolism', 'Serum Albumin, Bovine/chemistry/metabolism', 'Glyoxal/chemistry', 'Glucose']",https://pubmed.ncbi.nlm.nih.gov/36988041/
1449,Trazodone,2692763,Clinical assessment and performance tasks in depression: a comparison of amitriptyline and trazodone.,"['Botros WA', 'Ankier SI', 'Priest RG', 'McManus IC', 'Steinert J', 'Samir ZY']","['Adolescent', 'Adult', 'Aged', 'Amitriptyline/*therapeutic use', 'Depressive Disorder/*drug therapy/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', 'Problem Solving/*drug effects', 'Psychiatric Status Rating Scales', 'Psychomotor Performance/*drug effects', 'Randomized Controlled Trials as Topic', 'Reaction Time/*drug effects', 'Trazodone/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2692763/
1450,Trazodone,35658904,"Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines.","['Amari DT', 'Juday T', 'Frech FH', 'Wang W', 'Wu Z', 'Atkins N Jr', 'Wickwire EM']","['Accidental Falls', 'Aged', 'Benzodiazepines/therapeutic use', 'Delivery of Health Care', 'Female', 'Health Care Costs', 'Humans', 'Male', 'Medicare', 'Retrospective Studies', '*Sleep Initiation and Maintenance Disorders/drug therapy/epidemiology', '*Trazodone/adverse effects', 'United States/epidemiology', 'Zolpidem/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35658904/
1451,Trazodone,6624973,Trazodone and priapism.,"['Scher M', 'Krieger JN', 'Juergens S']","['Combined Modality Therapy', 'Depressive Disorder/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Male', 'Middle Aged', 'Piperazines/*adverse effects', 'Priapism/*chemically induced/therapy', 'Trazodone/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6624973/
1452,Trazodone,31379379,Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice.,"['Cuomo A', 'Ballerini A', 'Bruni AC', 'Decina P', 'Di Sciascio G', 'Fiorentini A', 'Scaglione F', 'Vampini C', 'Fagiolini A']","['*Antidepressive Agents, Second-Generation/adverse effects/metabolism/pharmacology/therapeutic use', 'Anxiety/drug therapy', 'Bulimia/drug therapy', 'Delayed-Action Preparations', 'Depressive Disorder, Major/*drug therapy', 'Drug Interactions', 'Fibromyalgia/drug therapy', 'Humans', 'Neurocognitive Disorders/drug therapy', 'Randomized Controlled Trials as Topic', 'Sexual Dysfunction, Physiological/drug therapy', 'Sleep Initiation and Maintenance Disorders/drug therapy', 'Stress Disorders, Post-Traumatic/drug therapy', 'Substance-Related Disorders/drug therapy', '*Trazodone/adverse effects/metabolism/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31379379/
1453,Trazodone,7021449,Trazodone in depression.,['Wheatley D'],"['Adult', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Imipramine/therapeutic use', 'Male', 'Middle Aged', 'Piperazines/*administration & dosage', 'Sleep Stages/drug effects', 'Trazodone/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7021449/
1454,Trazodone,32888664,Trazodone-induced delirium: case report.,"['Pereira AT', 'Mota D', 'Ribeiro L', 'Rodrigues JD']","['Adult', 'Antidepressive Agents, Second-Generation/administration & dosage/*adverse effects', 'Delirium/*chemically induced', 'Female', 'Hospitalization', 'Humans', 'Trazodone/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32888664/
1455,Ibandronate,27870311,Does Local Ibandronate and/or Pamidronate Delivery Enhance Osseointegration? A Systematic Review.,"['Kellesarian SV', 'Abduljabbar T', 'Vohra F', 'Gholamiazizi E', 'Malmstrom H', 'Romanos GE', 'Javed F']","['Administration, Topical', 'Bone Density Conservation Agents/*administration & dosage', 'Humans', 'Ibandronic Acid/*administration & dosage', 'Osseointegration/*drug effects', 'Pamidronate/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27870311/
1456,Ibandronate,35787482,Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study.,"['Kobayakawa T', 'Miyazaki A', 'Takahashi J', 'Nakamura Y']","['Antibodies, Monoclonal', 'Bone Density', '*Bone Density Conservation Agents/adverse effects', 'Denosumab/adverse effects', 'Female', 'Humans', 'Ibandronic Acid/pharmacology/therapeutic use', '*Osteoporosis, Postmenopausal/complications', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/35787482/
1457,Ibandronate,36731043,Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.,"['Mendes D', 'Penedones A', 'Alves C', 'Oliveira T', 'Donato A', 'Batel-Marques F']","['Female', 'Humans', 'Alendronate/adverse effects', '*Bone Density Conservation Agents', 'Diphosphonates', 'Ibandronic Acid/therapeutic use', '*Osteoporosis, Postmenopausal/chemically induced/drug therapy', '*Osteoporotic Fractures/prevention & control', 'Risedronic Acid/therapeutic use', 'Observational Studies as Topic']",https://pubmed.ncbi.nlm.nih.gov/36731043/
1458,Ibandronate,26038356,Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.,"['Geng CJ', 'Liang Q', 'Zhong JH', 'Zhu M', 'Meng FY', 'Wu N', 'Liang R', 'Yuan BY']","['Bone Density Conservation Agents/therapeutic use', 'Bone Neoplasms/*complications/secondary', 'Bone Resorption/*drug therapy/etiology', 'Diphosphonates/*therapeutic use', 'Europe', 'Humans', 'Ibandronic Acid', 'Multiple Myeloma/*complications/secondary', 'Musculoskeletal Pain/*drug therapy/etiology', 'Randomized Controlled Trials as Topic/*statistics & numerical data', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26038356/
1459,Ibandronate,37751449,Osteoprotegerin genetic polymorphisms and their influence on therapeutic response to ibandronate in postmenopausal osteoporotic females.,"['Tariq S', 'Tariq S', 'Abualhamael SA', 'Baig M', 'Malik AA', 'Shahzad M']","['Humans', 'Female', 'Ibandronic Acid', '*Osteoprotegerin/genetics', 'Case-Control Studies', 'Postmenopause/genetics', 'Polymorphism, Single Nucleotide', '*Bone Diseases, Metabolic']",https://pubmed.ncbi.nlm.nih.gov/37751449/
1460,Ibandronate,35716279,Risks of serious adverse events and kidney injury in patients treated with ibandronate: A systematic review and meta-analysis.,"['Mitsuboshi S', 'Kotake K']","['Adult', '*Bone Density Conservation Agents', 'Diphosphonates', 'Humans', 'Ibandronic Acid', 'Kidney', '*Osteoporosis']",https://pubmed.ncbi.nlm.nih.gov/35716279/
1461,Ibandronate,20631479,Ibandronate and nonvertebral fracture efficacy: results of a recent pooled analysis.,['Sunyecz JA'],"['Bone Density Conservation Agents/*administration & dosage', 'Diphosphonates/*administration & dosage', 'Female', 'Fractures, Bone/*prevention & control', 'Humans', 'Osteoporosis, Postmenopausal/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20631479/
1462,Ibandronate,15606328,Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.,"['Heidenreich A', 'Ohlmann CH']","['Administration, Oral', 'Bone Density Conservation Agents/administration & dosage/*pharmacology/*therapeutic use', 'Bone Neoplasms/*drug therapy/physiopathology/*secondary', 'Bone Resorption', 'Diphosphonates/administration & dosage/*pharmacology/*therapeutic use', 'Humans', 'Hypercalcemia/*drug therapy/*etiology', 'Ibandronic Acid', 'Infusions, Intravenous', 'Neoplasms/complications', 'Osteoporosis/*drug therapy/*etiology', 'Product Surveillance, Postmarketing', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/15606328/
1463,Ibandronate,22722461,Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate.,['Sittig HB'],"['Arthralgia/*drug therapy/etiology', 'Bone Density Conservation Agents/*therapeutic use', 'Bone Neoplasms/complications/*drug therapy/*secondary', 'Diphosphonates/*therapeutic use', 'Humans', 'Ibandronic Acid']",https://pubmed.ncbi.nlm.nih.gov/22722461/
1464,Ibandronate,16046205,Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis.,"['Epstein S', 'Zaidi M']","['Bone Resorption/*prevention & control', 'Bone and Bones/drug effects', 'Diphosphonates/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Drug Administration Schedule', 'Humans', 'Ibandronic Acid', 'Osteoporosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16046205/
1465,Ibandronate,22016595,Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.,"['Lee YH', 'Song GG']","['Administration, Oral', 'Alendronate/administration & dosage', 'Bone Density/drug effects', 'Bone Density Conservation Agents/*administration & dosage/adverse effects', 'Bone and Bones/diagnostic imaging/drug effects', 'Diphosphonates/*administration & dosage/adverse effects', 'Drug Administration Schedule', 'Evidence-Based Medicine', 'Female', 'Humans', 'Ibandronic Acid', 'Osteoporosis, Postmenopausal/diagnostic imaging/*drug therapy', 'Patient Preference', 'Radiography', 'Randomized Controlled Trials as Topic', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22016595/
1466,Ibandronate,21253392,Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.,"['Klaus J', 'Reinshagen M', 'Herdt K', 'Schroter C', 'Adler G', 'von Boyen GB', 'von Tirpitz C']","['Absorptiometry, Photon', 'Adult', 'Bone Density/drug effects', 'Bone Density Conservation Agents/pharmacology/*therapeutic use', 'Calcium Citrate/pharmacology/*therapeutic use', 'Cholecalciferol/pharmacology/therapeutic use', 'Crohn Disease/*drug therapy', 'Diphosphonates/pharmacology/*therapeutic use', 'Female', 'Fractures, Bone/drug therapy/epidemiology', 'Humans', 'Ibandronic Acid', 'Male', 'Middle Aged', 'Sodium Fluoride/pharmacology/*therapeutic use', 'Vitamin D/pharmacology/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21253392/
1467,Ibandronate,37493978,"Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.","['Everts-Graber J', 'Bonel H', 'Lehmann D', 'Gahl B', 'Hauselmann H', 'Studer U', 'Ziswiler HR', 'Reichenbach S', 'Lehmann T']","['Humans', 'Female', 'Aged', 'Middle Aged', 'Male', 'Alendronate/therapeutic use', 'Ibandronic Acid/therapeutic use', 'Zoledronic Acid/therapeutic use', 'Denosumab/adverse effects', 'Cohort Studies', '*Bone Density Conservation Agents/adverse effects', 'Diphosphonates/therapeutic use', '*Osteoporosis/drug therapy', '*Hip Fractures/complications', '*Spinal Fractures/complications', 'Registries', '*Osteoporosis, Postmenopausal/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37493978/
1468,Ibandronate,21150819,Preparation and properties of new co-crystals of ibandronate with gluco- or galactopyranoside derivatives.,"['Oktabec Z', 'Kos J', 'Mandelova Z', 'Havelkova L', 'Pekarek T', 'Rezacova A', 'Placek L', 'Tkadlecova M', 'Havlicek J', 'Dohnal J', 'Jampilek J']","['Crystallization', 'Diphosphonates/*chemistry', 'Galactosides/*chemistry', 'Glucose/*analogs & derivatives/*chemistry', 'Ibandronic Acid', 'Spectroscopy, Fourier Transform Infrared/methods', 'Spectrum Analysis, Raman/methods']",https://pubmed.ncbi.nlm.nih.gov/21150819/
1469,Ibandronate,24389416,"Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women.","['Gonnelli S', 'Caffarelli C', 'Tanzilli L', 'Pondrelli C', 'Lucani B', 'Franci BM', 'Nuti R']","['Administration, Intravenous', 'Aged', 'Aged, 80 and over', 'Bone Density/drug effects', 'Bone Density Conservation Agents/*administration & dosage', '*Carotid Intima-Media Thickness', 'Diphosphonates/*administration & dosage', 'Female', 'Fibroblast Growth Factor-23', 'Fibroblast Growth Factors/blood', 'Humans', 'Ibandronic Acid', 'Imidazoles/*administration & dosage', 'Lipids/blood', 'Middle Aged', 'Osteoporosis, Postmenopausal/*drug therapy', 'Zoledronic Acid']",https://pubmed.ncbi.nlm.nih.gov/24389416/
1470,BLAH,22231605,Pupil-BLAH-metry: cognitive effort in speech planning reflected by pupil dilation.,"['Papesh MH', 'Goldinger SD']","['Adolescent', 'Adult', '*Attention', 'Automatism/psychology', '*Cognition', 'Cues', 'Female', 'Humans', 'Male', 'Phonetics', 'Pitch Discrimination', 'Reaction Time', '*Reading', '*Reflex, Pupillary', 'Semantics', '*Verbal Behavior', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/22231605/
1471,Etiracetam,7006304,"Influence of piracetam and etiracetam compared to placebo, on rCBF and parameters of brain metabolism.","['Van Aken J', 'Rolly G']","['Acid-Base Equilibrium/drug effects', 'Adult', '*Anesthesia, Intravenous', 'Cerebrovascular Circulation/*drug effects', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Hemodynamics/drug effects', 'Humans', 'Kinetics', 'Levetiracetam', 'Male', 'Middle Aged', 'Piracetam/analogs & derivatives/*pharmacology', 'Placebos', 'Pyrrolidinones/*pharmacology', 'Pyruvates/blood', 'Thiopental/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7006304/
1472,Etiracetam,23873062,The importance of screening solid-state phases of a racemic modification of a chiral drug: thermodynamic and structural characterization of solid-state phases of etiracetam.,"['Herman C', 'Vermylen V', 'Norberg B', 'Wouters J', 'Leyssens T']","['Calorimetry, Differential Scanning', 'Crystallography, X-Ray', 'Levetiracetam', 'Models, Molecular', 'Molecular Structure', 'Piracetam/*analogs & derivatives/chemistry', 'Powder Diffraction', 'Stereoisomerism', '*Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/23873062/
1473,Fenofibrate,38905569,Effect of Fenofibrate on Progression of Diabetic Retinopathy.,"['Preiss D', 'Logue J', 'Sammons E', 'Zayed M', 'Emberson J', 'Wade R', 'Wallendszus K', 'Stevens W', 'Cretney R', 'Harding S', 'Leese G', 'Currie G', 'Armitage J']","['Humans', '*Fenofibrate/therapeutic use/pharmacology', '*Diabetic Retinopathy/drug therapy', 'Male', 'Female', 'Middle Aged', '*Disease Progression', '*Hypolipidemic Agents/therapeutic use/administration & dosage', 'Aged', 'Adult', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/38905569/
1474,Fenofibrate,32239031,Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD).,"['Wang Z', 'Ma C', 'Shang Y', 'Yang L', 'Zhang J', 'Yang C', 'Ren C', 'Liu J', 'Fan G', 'Liu J']","['Fenofibrate/chemistry/*pharmacology', 'Humans', 'Inflammation/*drug therapy/metabolism', 'Ketoprofen/chemistry/*pharmacology', 'Lipid Metabolism/drug effects', 'Molecular Structure', 'Non-alcoholic Fatty Liver Disease/*drug therapy/metabolism', 'Peptides/chemical synthesis/chemistry/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32239031/
1475,Fenofibrate,35389455,Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy.,"['Meer E', 'Bavinger JC', 'Yu Y', 'VanderBeek BL']","['Aged', 'Cohort Studies', '*Diabetes Mellitus, Type 2/complications', '*Diabetic Retinopathy/diagnosis/drug therapy/epidemiology', 'Female', '*Fenofibrate/adverse effects', 'Humans', '*Macular Edema/complications/diagnosis/drug therapy', 'Male', 'Middle Aged', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/35389455/
1476,Fenofibrate,33949176,Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.,"['Wang L', 'Sun K', 'Tian A', 'Liu Y', 'Zhang M', 'Zhou X', 'Han Y']","['Humans', 'Cholagogues and Choleretics/therapeutic use', '*Fenofibrate/therapeutic use', '*Liver Cirrhosis, Biliary/drug therapy', 'Retrospective Studies', 'Ursodeoxycholic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33949176/
1477,Fenofibrate,39171747,Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate.,"['Januszewski AS', 'Young HK', 'Ong KL', 'Li L', ""O'Connell RL"", 'Lyons TJ', 'Kelly C', 'Zaharieva DP', 'Sullivan DR', 'Scott RS', 'Keech AC', 'Jenkins AJ']","['Humans', '*Fenofibrate/therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy/blood', 'Male', 'Female', '*Haptoglobins', 'Middle Aged', '*Phenotype', '*Hypolipidemic Agents/therapeutic use', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/39171747/
1478,Fenofibrate,27367040,Drug disposition before and after gastric bypass: fenofibrate and posaconazole.,"['Gesquiere I', 'Hens B', 'Van der Schueren B', 'Mols R', 'de Hoon J', 'Lannoo M', 'Matthys C', 'Foulon V', 'Augustijns P']","['Administration, Oral', '*Area Under Curve', 'Fenofibrate/administration & dosage/blood/*pharmacokinetics', '*Gastric Bypass', 'Triazoles/administration & dosage/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/27367040/
1479,Fenofibrate,35941297,Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail.,"['Alkhayyat SS', 'Al-Kuraishy HM', 'Al-Gareeb AI', 'El-Bouseary MM', 'AboKamer AM', 'Batiha GE', 'Simal-Gandara J']","['Humans', 'Angiotensin-Converting Enzyme 2', 'SARS-CoV-2', '*Fenofibrate/therapeutic use', 'Antioxidants/metabolism', 'Peptidyl-Dipeptidase A/metabolism', '*Thrombosis', 'Protein Binding', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/35941297/
1480,Fenofibrate,2226216,Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.,"['Balfour JA', 'McTavish D', 'Heel RC']","['Clinical Trials as Topic', 'Fenofibrate/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', 'Hyperlipidemias/*drug therapy', 'Lipids/blood', 'Lipoproteins/blood']",https://pubmed.ncbi.nlm.nih.gov/2226216/
1481,Fenofibrate,36202222,Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels.,"['Kim KS', 'Hong S', 'Han K', 'Park CY']","['Humans', '*Fenofibrate/therapeutic use', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', '*Cardiovascular Diseases/epidemiology/complications', 'Triglycerides', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/36202222/
1482,Fenofibrate,36632973,Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.,"['Ding D', 'Ren P', 'Guo G', 'Liu Y', 'Yang C', 'Zheng L', 'Jia G', 'Deng J', 'Sun R', 'Wang X', 'Zhou X', 'Shang Y', 'Han Y']","['Humans', 'Ursodeoxycholic Acid/therapeutic use', '*Fenofibrate/therapeutic use', '*Liver Cirrhosis, Biliary', 'Alkaline Phosphatase', 'Retrospective Studies', 'Cholagogues and Choleretics/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36632973/
1483,Fenofibrate,30159817,Fenofibrate and Dyslipidemia: Still a Place in Therapy?,"['Tarantino N', 'Santoro F', 'Correale M', 'De Gennaro L', 'Romano S', 'Di Biase M', 'Brunetti ND']","['Cardiovascular Diseases/prevention & control', 'Dyslipidemias/*drug therapy', 'Fenofibrate/*therapeutic use', 'Humans', 'Hypolipidemic Agents/*therapeutic use', 'Risk Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30159817/
1484,Fenofibrate,24691799,Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?,"['Winsemius A', 'Ansquer JC', 'Olbrich M', 'van Amsterdam P', 'Aubonnet P', 'Beckmann K', 'Driessen S', 'van Assche H', 'Piskol G', 'Lehnick D', 'Mihara K']","['Cholesterol/blood', 'Cross-Over Studies', 'Drug Administration Schedule', 'Drug Interactions', 'Drug Therapy, Combination', 'Female', 'Fenofibrate/*administration & dosage/blood/*pharmacokinetics', 'Humans', 'Hypolipidemic Agents/*administration & dosage/blood/*pharmacokinetics', 'Liver-Specific Organic Anion Transporter 1', 'Male', 'Organic Anion Transporters/genetics', 'Polymorphism, Single Nucleotide', 'Simvastatin/*administration & dosage/blood/*pharmacokinetics', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/24691799/
1485,Fenofibrate,38011686,Efficacy and safety of fenofibrate in combination with phototherapy for the treatment of neonatal hyperbilirubinemia: a systematic review and meta-analyses.,"['Abdellatif M', 'Abozaid AAF', 'Shah PS', 'Dhouibi N', 'Nguyen-Khac T', 'Khleif R', 'Luu MN', 'Quyen DK', 'Mohareb A', 'Vaghela G', 'Khan ZA', 'Pham HN', 'Makram AM', 'Huy NT']","['Humans', 'Infant, Newborn', 'Bilirubin/blood', 'Combined Modality Therapy', '*Fenofibrate/adverse effects/therapeutic use', '*Hyperbilirubinemia, Neonatal/therapy', '*Phototherapy/methods/adverse effects', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38011686/
1486,Nimodipine,30450691,Nimodipine improves vocal fold and facial motion recovery after injury: A systematic review and meta-analysis.,"['Lin RJ', 'Klein-Fedyshin M', 'Rosen CA']","['Calcium Channel Blockers/*therapeutic use', 'Cranial Nerve Injuries/*drug therapy', 'Face/physiology', 'Humans', 'Nimodipine/*therapeutic use', 'Recovery of Function', 'Treatment Outcome', 'Vocal Cords/physiology']",https://pubmed.ncbi.nlm.nih.gov/30450691/
1487,Nimodipine,33710143,Perioperative Nimodipine to Improve Cranial Nerve Function: A Systematic Review and Meta-Analysis.,"['Chorath K', 'Go BC', 'Kaufman A', 'Brant J', 'Moreira A', 'Rajasekaran K']","['Cochlear Nerve', '*Facial Nerve', 'Hearing', 'Hearing Tests', 'Humans', '*Nimodipine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33710143/
1488,Nimodipine,31560289,Nimodipine Reappraised: An Old Drug With a Future.,"['Carlson AP', 'Hanggi D', 'Macdonald RL', 'Shuttleworth CW']","['Brain Injuries/*drug therapy', 'Brain Injuries, Traumatic/drug therapy', 'Brain Ischemia/drug therapy', 'Calcium Channel Blockers/*therapeutic use', 'Humans', 'Nimodipine/pharmacology/*therapeutic use', 'Stroke/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31560289/
1489,Nimodipine,33855653,Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial.,"['Salvadori E', 'Poggesi A', 'Donnini I', 'Rinnoci V', 'Chiti G', 'Squitieri M', 'Tudisco L', 'Fierini F', 'Melone A', 'Pescini F', 'Pantoni L']","['Aged', 'Aged, 80 and over', '*Cerebral Small Vessel Diseases', '*Cognitive Dysfunction/drug therapy', 'Glycerylphosphorylcholine/adverse effects/*therapeutic use', 'Humans', 'Nimodipine/adverse effects/*therapeutic use', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/33855653/
1490,Nimodipine,8249618,Pharmacokinetics and relative bioavailability of nimodipine capsules and tablets in 8 Chinese healthy men.,"['Guo LQ', 'Tan HS', 'Chen G']","['Adult', 'Biological Availability', 'Capsules', 'Chromatography, High Pressure Liquid', 'Humans', 'Male', 'Nimodipine/administration & dosage/*pharmacokinetics', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/8249618/
1491,Nimodipine,28344178,Systemic and Cerebral Concentration of Nimodipine During Established and Experimental Vasospasm Treatment.,"['Albanna W', 'Weiss M', 'Conzen C', 'Clusmann H', 'Schneider T', 'Reinsch M', 'Muller M', 'Wiesmann M', 'Hollig A', 'Schubert GA']","['Aged', 'Cerebral Cortex/*metabolism', 'Chromatography, Liquid', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Male', 'Middle Aged', '*Nimodipine/blood/cerebrospinal fluid/therapeutic use', 'Retrospective Studies', 'Statistics, Nonparametric', 'Subarachnoid Hemorrhage/complications', 'Tandem Mass Spectrometry', '*Vasodilator Agents/blood/cerebrospinal fluid/therapeutic use', 'Vasospasm, Intracranial/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/28344178/
1492,Nimodipine,29738666,Co-Stabilization of Amorphous Pharmaceuticals-The Case of Nifedipine and Nimodipine.,"['Knapik-Kowalczuk J', 'Tu W', 'Chmiel K', 'Rams-Baron M', 'Paluch M']","['Calorimetry, Differential Scanning', 'Chemistry, Pharmaceutical', 'Crystallization', 'Dielectric Spectroscopy', 'Drug Compounding/*methods', 'Drug Stability', 'Molecular Dynamics Simulation', 'Nifedipine/*chemistry', 'Nimodipine/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/29738666/
1493,Nimodipine,35335371,"Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-beta-cyclodextrin and Nimodipine-methyl-beta-cyclodextrin Inclusion Complexes.","['Novac M', 'Musuc AM', 'Ozon EA', 'Sarbu I', 'Mitu MA', 'Rusu A', 'Gheorghe D', 'Petrescu S', 'Atkinson I', 'Lupuliasa D']","['2-Hydroxypropyl-beta-cyclodextrin', '*Chemistry, Pharmaceutical/methods', '*Nimodipine/chemistry', 'Solubility', 'Tablets', 'beta-Cyclodextrins']",https://pubmed.ncbi.nlm.nih.gov/35335371/
1494,Nimodipine,7858806,Nimodipine.,"['Whitfield PC', 'Pickard JD']","['Brain Ischemia/etiology/*prevention & control', 'Humans', 'Nimodipine/*pharmacology/therapeutic use', 'Subarachnoid Hemorrhage/*complications']",https://pubmed.ncbi.nlm.nih.gov/7858806/
1495,Nimodipine,31404696,Does Nimodipine Interruption due to High Catecholamine Doses Lead to a Greater Incidence of Delayed Cerebral Ischemia in the Setting of Aneurysmal Subarachnoid Hemorrhage?,"['Hernandez-Duran S', 'Mielke D', 'Rohde V', 'Malinova V']","['Adult', 'Aged', 'Aged, 80 and over', 'Arterial Pressure/drug effects', 'Brain Ischemia/*epidemiology/*etiology/prevention & control', 'Catecholamines/*metabolism', 'Cerebrovascular Circulation/drug effects', 'Female', 'Humans', 'Incidence', 'Male', 'Middle Aged', 'Neuroprotective Agents/*administration & dosage/adverse effects/*therapeutic use', 'Nimodipine/*administration & dosage/adverse effects/*therapeutic use', 'Retrospective Studies', 'Subarachnoid Hemorrhage/*surgery']",https://pubmed.ncbi.nlm.nih.gov/31404696/
1496,Nimodipine,36790504,ISSLS PRIZE in basic science 2023: Lactate in lumbar discs-metabolic waste or energy biofuel? Insights from in vivo MRS and T2r analysis following exercise and nimodipine in healthy volunteers.,"['Pushpa BT', 'Rajasekaran S', 'Easwaran M', 'Murugan C', 'Algeri R', 'Sri Vijay Anand KS', 'Mugesh Kanna R', 'Shetty AP']","['Humans', 'Nimodipine/pharmacology/metabolism', '*Intervertebral Disc/metabolism', '*Intervertebral Disc Degeneration/metabolism', 'Biofuels', 'Magnetic Resonance Imaging', 'Lactic Acid/metabolism', 'Healthy Volunteers', 'Lumbar Vertebrae/metabolism', 'Proteoglycans/metabolism', '*Awards and Prizes']",https://pubmed.ncbi.nlm.nih.gov/36790504/
1497,Nimodipine,27623621,Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trial.,"['Wang S', 'Yang H', 'Zhang J', 'Zhang B', 'Liu T', 'Gan L', 'Zheng J']","['*Acupuncture Therapy/adverse effects/methods', 'Aged', 'Cerebral Infarction/*complications', 'Cognitive Dysfunction/etiology/*therapy', 'Female', 'Humans', 'Male', 'Middle Aged', '*Nimodipine/adverse effects/therapeutic use', '*Vasodilator Agents/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27623621/
1498,Nimodipine,29782805,Maintaining Supersaturation of Nimodipine by PVP with or without the Presence of Sodium Lauryl Sulfate and Sodium Taurocholate.,"['Pui Y', 'Chen Y', 'Chen H', 'Wang S', 'Liu C', 'Tonnis W', 'Chen L', 'Serno P', 'Bracht S', 'Qian F']","['Biological Availability', 'Drug Delivery Systems/*methods', 'Drug Liberation', 'Excipients/*chemistry', 'Hydrophobic and Hydrophilic Interactions', 'Magnetic Resonance Spectroscopy', 'Nimodipine/administration & dosage/*chemistry/pharmacokinetics', 'Polyvinyls/chemistry', 'Pyrrolidines/chemistry', 'Sodium Dodecyl Sulfate/chemistry', 'Solubility', 'Surface-Active Agents/*chemistry', 'Taurocholic Acid/chemistry']",https://pubmed.ncbi.nlm.nih.gov/29782805/
1499,Torasemide,8852525,Benefits and risks of torasemide in congestive heart failure and essential hypertension.,['Brater DC'],"['Antihypertensive Agents/*therapeutic use', 'Diuretics/*therapeutic use', 'Drug Interactions', 'Half-Life', 'Heart Failure/*drug therapy', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Sulfonamides/*adverse effects/*therapeutic use', 'Torsemide']",https://pubmed.ncbi.nlm.nih.gov/8852525/
1500,Torasemide,25222231,"Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure.","['Han LN', 'Guo SL', 'Lin XM', 'Shi XM', 'Zang CB', 'Yang LM', 'Ding GL']","['Aged', 'Arrhythmias, Cardiac/*complications/diagnosis/epidemiology', 'Cardiomyopathy, Dilated/diagnosis/*drug therapy/*etiology', 'Disease Progression', 'Diuretics/*therapeutic use', 'Echocardiography, Doppler, Color', 'Female', 'Follow-Up Studies', 'Heart Failure/diagnosis/*drug therapy/*etiology', 'Heart Ventricles/drug effects/pathology/physiopathology', 'Humans', 'Incidence', 'Male', 'Middle Aged', 'Prognosis', 'Sulfonamides/*therapeutic use', 'Torsemide', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25222231/
1501,Torasemide,7506334,Pharmacokinetics and pharmacodynamics of torasemide in health and disease.,['Brater DC'],"['Diuretics/*pharmacokinetics/*pharmacology', 'Heart Failure/*drug therapy/metabolism', 'Humans', 'Kidney Diseases/*drug therapy/metabolism', 'Sulfonamides/*pharmacokinetics/*pharmacology', 'Torsemide']",https://pubmed.ncbi.nlm.nih.gov/7506334/
1502,Torasemide,28114980,"The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial.","['Balsam P', 'Ozieranski K', 'Tyminska A', 'Glowczynska R', 'Peller M', 'Fojt A', 'Cacko A', 'Sieradzki B', 'Bakula E', 'Markulis M', 'Kowalik R', 'Huczek Z', 'Filipiak KJ', 'Opolski G', 'Grabowski M']","['Biomarkers/blood', 'Chronic Disease', 'Clinical Protocols', 'Echocardiography', 'Electrocardiography, Ambulatory', 'Furosemide/adverse effects/*therapeutic use', 'Heart Failure/blood/diagnosis/*drug therapy/physiopathology', 'Hemodynamics/*drug effects', 'Humans', 'Neurotransmitter Agents/*blood', 'Poland', 'Quality of Life', 'Recovery of Function', 'Research Design', 'Sodium Potassium Chloride Symporter Inhibitors/adverse effects/*therapeutic use', 'Sulfonamides/adverse effects/*therapeutic use', 'Surveys and Questionnaires', 'Time Factors', 'Torsemide', 'Treatment Outcome', 'Ventricular Remodeling/*drug effects', 'Walk Test']",https://pubmed.ncbi.nlm.nih.gov/28114980/
1503,Torasemide,8912147,Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.,"['Gentilini P', 'La Villa G', 'Marra F', 'Carloni V', 'Melani L', 'Foschi M', 'Cotrozzi G', 'Quartini M', 'Chibbaro G', 'Tommasi AC', 'Bernareggi A', 'Simoni A', 'Buzzelli G', 'Laffi G']","['Adult', 'Aged', 'Ascites/etiology/*metabolism', 'Diuretics/*pharmacokinetics/pharmacology', 'Drug Resistance', 'Female', 'Furosemide/*pharmacokinetics/pharmacology', 'Gas Chromatography-Mass Spectrometry', 'Glomerular Filtration Rate/drug effects', 'Humans', 'Infusions, Intravenous', 'Kidney/drug effects/physiopathology', 'Liver Cirrhosis/complications/*metabolism', 'Male', 'Middle Aged', 'Potassium/blood/urine', 'Prostaglandins/urine', 'Sodium/blood/urine', 'Sulfonamides/*pharmacokinetics/pharmacology', 'Torsemide']",https://pubmed.ncbi.nlm.nih.gov/8912147/
1504,Torasemide,3370062,Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.,['Lesne M'],"['Administration, Oral', 'Adult', 'Biological Availability', 'Diuretics/*pharmacokinetics/pharmacology', 'Electrolytes/blood/urine', 'Furosemide/*pharmacokinetics/pharmacology', 'Half-Life', 'Humans', 'Injections, Intravenous', 'Male', 'Reference Values', 'Sulfonamides/*pharmacokinetics/pharmacology', 'Torsemide']",https://pubmed.ncbi.nlm.nih.gov/3370062/
1505,Torasemide,29488197,Development and Performance of a Highly Sensitive Model Formulation Based on Torasemide to Enhance Hot-Melt Extrusion Process Understanding and Process Development.,"['Evans RC', 'Kyeremateng SO', 'Asmus L', 'Degenhardt M', 'Rosenberg J', 'Wagner KG']","['Antihypertensive Agents/chemistry/*pharmacokinetics', 'Chemistry, Pharmaceutical/*methods', '*Hot Temperature', 'Polymers', 'Sulfonamides/*chemistry/pharmacokinetics', 'Torsemide', 'X-Ray Diffraction/methods']",https://pubmed.ncbi.nlm.nih.gov/29488197/
1506,Torasemide,38609117,"PERIOCULAR HIGH RISK BCCS AFTER ADDITIONAL/PARALLEL INTAKE OF TORASEMIDE, MOXONIDINE AND MIRABEGRON: IMPORTANT LINKS TO SKIN CANCER RELATED (PHOTO-) NITROSOGENESIS IN THE CONTEXT OF PHARMACO-ONCOGENESIS.","['Tchernev G', 'Dimova D']","['Humans', 'Torsemide', 'Prospective Studies', 'Retrospective Studies', 'Tumor Suppressor Protein p53', 'Carcinogenesis', 'Cell Transformation, Neoplastic', '*Skin Neoplasms/chemically induced', '*Carcinoma, Basal Cell/chemically induced', '*Nitrosamines/toxicity', '*Acetanilides', '*Imidazoles', '*Thiazoles']",https://pubmed.ncbi.nlm.nih.gov/38609117/
1507,Torasemide,26273191,"Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.","['Ballester MR', 'Roig E', 'Gich I', 'Puntes M', 'Delgadillo J', 'Santos B', 'Antonijoan RM']","['Aged', 'Aged, 80 and over', 'Chemistry, Pharmaceutical', 'Chronic Disease', 'Cross-Over Studies', 'Delayed-Action Preparations', 'Furosemide/*administration & dosage/adverse effects/chemistry/pharmacokinetics', 'Heart Failure/diagnosis/*drug therapy/physiopathology', 'Humans', 'Middle Aged', 'Natriuresis/drug effects', 'Sodium Potassium Chloride Symporter Inhibitors/*administration & dosage/adverse effects/chemistry/pharmacokinetics', 'Spain', 'Sulfonamides/*administration & dosage/adverse effects/chemistry/pharmacokinetics', 'Time Factors', 'Torsemide', 'Treatment Outcome', 'Urination/drug effects']",https://pubmed.ncbi.nlm.nih.gov/26273191/
1508,Torasemide,16344009,Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites.,"['Engelhardt S', 'Meineke I', 'Brockmoller J']","['Aryl Hydrocarbon Hydroxylases/metabolism', 'Biotransformation', 'Chemical Fractionation/methods', 'Chromatography, High Pressure Liquid/*methods', 'Cytochrome P-450 CYP2C9', 'Diuretics/isolation & purification/metabolism', 'Humans', 'Reproducibility of Results', 'Sulfonamides/*isolation & purification/metabolism', 'Torsemide']",https://pubmed.ncbi.nlm.nih.gov/16344009/
1509,Torasemide,38422674,Application of electron paramagnetic resonance spectroscopy to examine free radicals formed in indapamide and torasemide storage under UV irradiation and at the higher temperatures which appear under light exposition.,"['Orlinska K', 'Ramos P', 'Komosinska-Vassev K', 'Olczyk K', 'Stojko J', 'Rzepecka-Stojko A', 'Kiselova-Kaneva Y', 'Ivanova D', 'Olczyk P', 'Pilawa B']","['*Hot Temperature', '*Indapamide', 'Torsemide', 'Temperature', 'Electron Spin Resonance Spectroscopy/methods', 'Ultraviolet Rays', 'Free Radicals/chemistry', 'Diuretics']",https://pubmed.ncbi.nlm.nih.gov/38422674/
1510,Torasemide,3780841,Study of the tolerance and diuretic properties of torasemide following oral or intravenous administration to healthy volunteers.,"['Lambe R', 'Kennedy O', 'Kenny M', 'Darragh A']","['Administration, Oral', 'Adolescent', 'Adult', 'Chlorides/urine', 'Diuretics/administration & dosage/adverse effects/*metabolism', 'Humans', 'Injections, Intravenous', 'Kinetics', 'Male', 'Potassium/urine', 'Sodium/urine', 'Sulfonamides/administration & dosage/adverse effects/*metabolism', 'Torsemide', 'Urine']",https://pubmed.ncbi.nlm.nih.gov/3780841/
1511,Torasemide,7954550,Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide.,"['Knauf H', 'Mutschler E']","['Ascites/etiology', 'Diuretics/administration & dosage/*therapeutic use', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Female', 'Furosemide/*administration & dosage', 'Humans', 'Liver Cirrhosis/complications/*drug therapy', 'Male', 'Middle Aged', 'Prospective Studies', 'Spironolactone/*administration & dosage', 'Sulfonamides/administration & dosage/*therapeutic use', 'Torsemide', 'Xipamide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7954550/
1512,Torasemide,2076715,Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure.,"['Spahn H', 'Knauf H', 'Mutschler E']","['Diuretics/chemistry/*pharmacokinetics', 'Half-Life', 'Humans', 'Kidney/*metabolism', 'Kidney Failure, Chronic/*metabolism', 'Metabolic Clearance Rate', 'Sulfonamides/chemistry/*pharmacokinetics', 'Torsemide']",https://pubmed.ncbi.nlm.nih.gov/2076715/
1513,Furosemide,34851962,Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: An updated systematic review and meta-analysis.,"['Lee TH', 'Kuo G', 'Chang CH', 'Huang YT', 'Yen CL', 'Lee CC', 'Fan PC', 'Chen JJ']","['Albumins/*administration & dosage/therapeutic use', 'Diuretics/*administration & dosage/therapeutic use', 'Drug Combinations', 'Furosemide/*administration & dosage/therapeutic use', 'Humans', 'Nephrotic Syndrome/*drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34851962/
1514,Furosemide,27238657,Furosemide.,"['Carone L', 'Oxberry SG', 'Twycross R', 'Charlesworth S', 'Mihalyo M', 'Wilcock A']","['Diuretics/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Drug Interactions', 'Furosemide/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Hospice Care', 'Humans', 'Internet', 'Palliative Care']",https://pubmed.ncbi.nlm.nih.gov/27238657/
1515,Furosemide,3511654,Disposition and response to bumetanide and furosemide.,['Brater DC'],"['Adult', 'Aged', 'Biological Availability', '*Bumetanide/metabolism/pharmacology', '*Diuretics/metabolism/pharmacology', '*Furosemide/metabolism/pharmacology', 'Heart Failure/metabolism', 'Humans', 'Kidney Diseases/metabolism', 'Kidney Transplantation', 'Kinetics', 'Liver Cirrhosis/metabolism', 'Middle Aged', 'Nephrotic Syndrome/metabolism']",https://pubmed.ncbi.nlm.nih.gov/3511654/
1516,Furosemide,2185908,Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).,"['Ponto LL', 'Schoenwald RD']","['Acute Kidney Injury/drug therapy', 'Furosemide/metabolism/*pharmacokinetics/pharmacology/therapeutic use', 'Heart Failure/drug therapy', 'Humans', 'Hypertension/drug therapy', 'Liver Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2185908/
1517,Furosemide,37260062,Il-6 and UGT1A1 variations may related to furosemide resistance in heart failure patients.,"['Koprululu Kucuk G', 'Guney AI', 'Sunbul M', 'Guctekin T', 'Koc G', 'Kirac D']","['Humans', '*Furosemide/pharmacology/therapeutic use', 'Interleukin-6/genetics', 'Glucuronosyltransferase/genetics/therapeutic use', '*Heart Failure/drug therapy/genetics', 'Diuretics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37260062/
1518,Furosemide,36251063,The diuretic effect of adding aminophylline or theophylline to furosemide in pediatric populations: a systematic review.,"['Van Siang Lian Mang P', 'Hui JC', 'Tan RSJ', 'Hasan MS', 'Choo YM', 'Abosamak MF', 'Ng KT']","['Child', 'Humans', '*Diuretics/pharmacology/therapeutic use', '*Theophylline', 'Aminophylline/pharmacology/therapeutic use', 'Furosemide/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36251063/
1519,Furosemide,20085566,Benefits and risks of furosemide in acute kidney injury.,"['Ho KM', 'Power BM']","['Acute Kidney Injury/*drug therapy/mortality/physiopathology', 'Diuretics/adverse effects/*therapeutic use', 'Evidence-Based Medicine/methods', 'Furosemide/adverse effects/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/20085566/
1520,Furosemide,7752014,Furosemide-associated fever.,"['Clegg HW', 'Riopel DA']","['Child, Preschool', 'Female', 'Fever of Unknown Origin/*chemically induced/diagnosis', 'Follow-Up Studies', 'Furosemide/*adverse effects/therapeutic use', 'Heart Failure/*drug therapy', 'Humans', 'Recurrence', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7752014/
1521,Furosemide,34118718,"Design, synthesis, and biological evaluation of furosemide analogs as therapeutics for the proteopathy and immunopathy of Alzheimer's disease.","['Wang Z', 'Wang Y', 'Pasangulapati JP', 'Stover KR', 'Liu X', 'Schier SW', 'Weaver DF']","['Alzheimer Disease/drug therapy/metabolism', 'Amyloid beta-Peptides/antagonists & inhibitors/metabolism', 'Anti-Inflammatory Agents/chemical synthesis/chemistry/*pharmacology', 'Dose-Response Relationship, Drug', '*Drug Design', 'Furosemide/chemical synthesis/chemistry/*pharmacology', 'Humans', 'Molecular Structure', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/34118718/
1522,Furosemide,2654356,Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.,"['Hammarlund-Udenaes M', 'Benet LZ']","['Disease/metabolism', 'Furosemide/*pharmacokinetics/pharmacology', 'Health', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/2654356/
1523,Furosemide,37233136,New Delivery Route for Furosemide in Heart Failure.,['Aschenbrenner DS'],"['Adult', 'Humans', 'Furosemide/therapeutic use', 'Diuretics/therapeutic use', '*Heart Failure/drug therapy', '*Water-Electrolyte Imbalance']",https://pubmed.ncbi.nlm.nih.gov/37233136/
1524,Furosemide,8720807,Formulation and in vitro examination of furosemide containing suppositories and preliminary experiences of their clinical use.,"['Regdon G', 'Fazekas T', 'Regdon G Jr', 'Selmeczi B']","['Biological Availability', 'Chemical Phenomena', 'Chemistry, Physical', 'Cross-Over Studies', 'Diuretics/administration & dosage/*pharmacokinetics/therapeutic use', 'Double-Blind Method', 'Excipients', 'Furosemide/administration & dosage/*pharmacokinetics/therapeutic use', 'Humans', 'Prospective Studies', 'Suppositories', 'Therapeutic Equivalency', 'Urodynamics/drug effects']",https://pubmed.ncbi.nlm.nih.gov/8720807/
1525,Furosemide,902453,Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man.,"['Homeida M', 'Roberts C', 'Branch RA']","['Adult', 'Drug Interactions', 'Furosemide/*metabolism/pharmacology', 'Humans', 'Kinetics', 'Male', 'Natriuresis/drug effects', 'Probenecid/*pharmacology', 'Spironolactone/*pharmacology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/902453/
1526,Furosemide,8444517,"Pharmacokinetics and interactions of digoxin, theophylline and furosemide in diseases with edema.","['Macolic V', 'Vrhovac B']","['Digoxin/*pharmacokinetics/pharmacology', 'Drug Interactions', 'Edema/*metabolism', 'Furosemide/*pharmacokinetics/pharmacology', 'Humans', 'Theophylline/*pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8444517/
1527,Furosemide,3935455,Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man.,"['Marone C', 'Muggli F', 'Lahn W', 'Frey FJ']","['Calcium/urine', 'Diuretics/*pharmacology', 'Drug Synergism', 'Furosemide/*metabolism/pharmacology', 'Humans', 'Kinetics', 'Metolazone/*pharmacology', 'Sodium/urine']",https://pubmed.ncbi.nlm.nih.gov/3935455/
1528,Furosemide,12856384,Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.,"['Klausner EA', 'Lavy E', 'Stepensky D', 'Cserepes E', 'Barta M', 'Friedman M', 'Hoffman A']","['Adult', 'Cross-Over Studies', 'Delayed-Action Preparations', 'Diuresis/drug effects', 'Diuretics/administration & dosage/*pharmacokinetics/*pharmacology', 'Furosemide/administration & dosage/*pharmacokinetics/*pharmacology', 'Humans', 'Male', 'Sodium/urine']",https://pubmed.ncbi.nlm.nih.gov/12856384/
1529,Furosemide,8064072,The preventive effect of nedocromil or furosemide alone or in combination on exercise-induced asthma in children.,"['Novembre E', 'Frongia G', 'Lombardi E', 'Veneruso G', 'Vierucci A']","['Administration, Inhalation', 'Adolescent', 'Asthma, Exercise-Induced/*prevention & control', 'Child', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Furosemide/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Male', 'Nebulizers and Vaporizers', 'Nedocromil/administration & dosage/adverse effects/*pharmacology', 'Respiratory Function Tests']",https://pubmed.ncbi.nlm.nih.gov/8064072/
1530,Dipyridamole,36030623,Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke.,"['Lim ST', 'Murphy SJX', 'Murphy SM', 'Coughlan T', ""O'Neill D"", 'Tierney S', 'Egan B', 'Collins DR', 'McCarthy AJ', 'Lim SY', 'Smith DR', 'Cox D', 'McCabe DJH']","['Adenosine Diphosphate/metabolism/pharmacology', 'Aspirin/pharmacology/therapeutic use', 'Blood Platelets', '*Brain Ischemia/metabolism', 'Dipyridamole/metabolism/pharmacology/therapeutic use', 'Humans', '*Ischemic Attack, Transient/drug therapy', '*Ischemic Stroke', 'Platelet Activation', 'Platelet Aggregation Inhibitors/pharmacology/therapeutic use', 'Prospective Studies', '*Stroke']",https://pubmed.ncbi.nlm.nih.gov/36030623/
1531,Dipyridamole,10099046,Dipyridamole in the nephritides.,['Wardle EN'],"['Antioxidants/pharmacology/*therapeutic use', 'Dipyridamole/pharmacology/*therapeutic use', 'Erythrocyte Deformability/drug effects', 'Glomerulonephritis/blood/*drug therapy/immunology', 'Humans', 'Lipid Peroxidation/drug effects', 'Phosphodiesterase Inhibitors/pharmacology/*therapeutic use', 'Platelet Aggregation/drug effects', 'Platelet Aggregation Inhibitors/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10099046/
1532,Dipyridamole,38143309,Enzyme-Induced Shape-Shifting Peptide Nanocarrier Coloaded with Paclitaxel and Dipyridamole Inhibits Platelet Function and Tumor Metastasis.,"['Meng F', 'Zhai X', 'Ma J', 'Li A', 'Wang X', 'Bai J']","['Humans', 'Paclitaxel', 'Platelet Aggregation Inhibitors/pharmacology', 'Dipyridamole/pharmacology', 'Peptides/pharmacology/chemistry', '*Neoplastic Cells, Circulating', '*Nanoparticles/chemistry', 'Cell Line, Tumor']",https://pubmed.ncbi.nlm.nih.gov/38143309/
1533,Dipyridamole,8808777,Combined dipyridamole and aspirin pellet formulation for improved oral drug delivery. Part 2: In-vivo evaluation and stability.,"['Murtagh PW', 'Deasy PB']","['Aspirin/*administration & dosage/adverse effects/*pharmacokinetics', 'Capsules', 'Dipyridamole/*administration & dosage/adverse effects/*pharmacokinetics', 'Drug Combinations', 'Drug Stability', 'Drug Storage', 'Humans', 'Platelet Aggregation Inhibitors/*administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8808777/
1534,Dipyridamole,39510145,Evaluation of aspartame as a co-former in the preparation of co-amorphous formulations of dipyridamole using spray drying.,"['Kamruzzaman M', 'Cathcart H', 'McLoughlin P', ""O'Reilly NJ""]","['*Aspartame/chemistry', '*Dipyridamole/chemistry', '*Drug Stability', 'Drug Compounding/methods', 'Spray Drying', 'Chemistry, Pharmaceutical/methods', 'Solubility', 'Hydrogen Bonding', 'Transition Temperature', 'X-Ray Diffraction/methods']",https://pubmed.ncbi.nlm.nih.gov/39510145/
1535,Dipyridamole,18214761,Melt extrusion and spray drying of carbamazepine and dipyridamole with polyvinylpyrrolidone/vinyl acetate copolymers.,"['Patterson JE', 'James MB', 'Forster AH', 'Rades T']","['Carbamazepine/administration & dosage/*chemistry', 'Dipyridamole/administration & dosage/*chemistry', 'Drug Stability', 'Pyrrolidines/*chemistry', 'Solubility', 'Technology, Pharmaceutical', 'Vinyl Compounds/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/18214761/
1536,Dipyridamole,32442630,Physiologically based pharmacokinetic model outputs depend on dissolution data and their input: Case examples glibenclamide and dipyridamole.,"['Klumpp L', 'Dressman J']","['Computer Simulation', '*Dipyridamole', '*Glyburide', 'Models, Biological', 'Software', 'Solubility']",https://pubmed.ncbi.nlm.nih.gov/32442630/
1537,Dipyridamole,3501902,Failure of combined acetylsalicylic acid and dipyridamole to prevent occlusion of aortocoronary venous bypass graft.,"['Thaulow E', 'Froysaker T', 'Dale J', 'Vatne K']","['Aspirin/administration & dosage/therapeutic use', 'Coronary Angiography', '*Coronary Artery Bypass', 'Dipyridamole/administration & dosage/*therapeutic use', 'Drug Combinations', 'Graft Occlusion, Vascular/*prevention & control', 'Humans', 'Middle Aged', 'Postoperative Complications', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3501902/
1538,Dipyridamole,21656246,Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET.,"['Goudarzi B', 'Fukushima K', 'Bravo P', 'Merrill J', 'Bengel FM']","['Coronary Circulation/*drug effects', 'Dipyridamole/administration & dosage/adverse effects/*pharmacology', 'Female', 'Hemodynamics/drug effects', 'Humans', 'Injections', 'Male', 'Middle Aged', '*Myocardial Perfusion Imaging', '*Positron-Emission Tomography', 'Purinergic P1 Receptor Agonists/administration & dosage/adverse effects/*pharmacology', 'Purines/administration & dosage/adverse effects/*pharmacology', 'Pyrazoles/administration & dosage/adverse effects/*pharmacology', 'Retrospective Studies', '*Rubidium Radioisotopes', 'Stress, Physiological/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21656246/
1539,Dipyridamole,7904639,Partitioning and thermodynamics of dipyridamole in the n-octanol/buffer and liposome systems.,"['Betageri GV', 'Dipali SR']","['Buffers', 'Dipyridamole/*chemistry', 'Liposomes', 'Octanols', 'Phospholipids/chemistry', 'Solubility', 'Temperature', 'Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/7904639/
1540,Dipyridamole,25025699,"Effect of surfactants, gastric emptying, and dosage form on supersaturation of dipyridamole in an in vitro model simulating the stomach and duodenum.","['Mitra A', 'Fadda HM']","['Area Under Curve', 'Chromatography, High Pressure Liquid', 'Dipyridamole/*administration & dosage/*chemistry', 'Dose-Response Relationship, Drug', 'Duodenum/*drug effects/physiology', '*Gastric Emptying', 'Humans', 'Micelles', 'Poloxamer/chemistry', 'Polysorbates/chemistry', 'Sodium Dodecyl Sulfate/chemistry', 'Stomach/*drug effects/physiology', 'Surface Tension', 'Surface-Active Agents/*chemistry', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/25025699/
1541,Dipyridamole,9260666,Spectrofluorometric estimation of aspirin and dipyridamole in pure admixtures and in dosage forms.,"['Umapathi P', 'Parimoo P', 'Thomas SK', 'Agarwal V']","['Aspirin/*analysis', 'Dipyridamole/*analysis', 'Drug Combinations', 'Spectrometry, Fluorescence', 'Vasodilator Agents/*analysis']",https://pubmed.ncbi.nlm.nih.gov/9260666/
1542,Dipyridamole,893681,Binding of dipyridamole to human platelets and to alpha1 acid glycoprotein and its significance for the inhibition of adenosine uptake.,"['Subbarao K', 'Rucinski B', 'Rausch MA', 'Schmid K', 'Niewiarowski S']","['Adenine Nucleotides/blood', 'Adenosine/*blood', 'Binding, Competitive', 'Biological Transport/drug effects', 'Blood Platelets/*drug effects/metabolism', 'Dipyridamole/blood/*pharmacology', 'Glycoproteins/*blood', 'Humans', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/893681/
1543,Potassium chloride,714831,"Electrolyte studies. 2. Potassium, chloride, and acid-base.",['Burke MD'],"['*Acid-Base Imbalance/physiopathology', 'Acidosis/physiopathology', 'Alkalosis/physiopathology', 'Bicarbonates/blood', 'Carbon Dioxide/blood', 'Chlorides/*blood', 'Humans', 'Hyperkalemia/etiology/physiopathology', 'Hypokalemia/etiology/physiopathology', 'Potassium/*blood']",https://pubmed.ncbi.nlm.nih.gov/714831/
1544,Potassium chloride,33831443,Funic potassium chloride injection during intact dilation and evacuation.,"['Nippita S', 'Carranza ASO', 'Paul ME']","['*Abortion, Induced', 'Dilatation', 'Female', 'Fetal Death', 'Humans', 'Injections', 'Potassium Chloride', 'Pregnancy', 'Pregnancy Trimester, Second']",https://pubmed.ncbi.nlm.nih.gov/33831443/
1545,Potassium chloride,37846572,Potassium Magnesium Citrate Is Superior to Potassium Chloride in Reversing Metabolic Side Effects of Chlorthalidone.,"['Vongpatanasin W', 'Giacona JM', 'Pittman D', 'Murillo A', 'Khan G', 'Wang J', 'Johnson T', 'Ren J', 'Moe OW', 'Pak CCY']","['Aged', 'Humans', 'Middle Aged', 'Antihypertensive Agents/adverse effects/therapeutic use', 'Blood Glucose', 'Blood Pressure', 'Chlorthalidone/adverse effects', 'Citrates/pharmacology', '*Hyperglycemia/chemically induced', '*Hypertension/chemically induced/drug therapy', 'Potassium/pharmacology', 'Potassium Chloride/pharmacology', 'Sodium Chloride Symporter Inhibitors/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37846572/
1546,Potassium chloride,38685685,A potassium-chloride co-transporter with altered genome architecture functions as a suppressor in glioma.,"['Liu H', 'Pan Z', 'Lin X', 'Chen L', 'Yang Q', 'Zhang W', 'Dai L', 'Zhang Y', 'Li W', 'Chen Y', 'Peng K', 'Wanggou S', 'Zeng F', 'Li X']","['Humans', '*Glioma/genetics/pathology/metabolism', '*Gene Expression Regulation, Neoplastic', '*Cell Proliferation/genetics', 'Cell Line, Tumor', '*Brain Neoplasms/genetics/pathology/metabolism', '*Symporters/genetics/metabolism', 'Cell Movement/genetics', 'Prognosis', 'Receptors, GABA-A/metabolism/genetics', '*K Cl- Cotransporters']",https://pubmed.ncbi.nlm.nih.gov/38685685/
1547,Potassium chloride,34380745,"Narrative review of neuraxial potassium chloride administration errors: clinical features, human factors, and prevention measures.","['Patel S', 'Dexter F']","['*Analgesia', '*Anesthesia, Epidural/adverse effects', 'Anesthetics, Local', 'Humans', 'Injections, Spinal/adverse effects', 'Potassium Chloride/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34380745/
1548,Potassium chloride,2183776,"Antimutagenesis in yeast by sodium chloride, potassium chloride, and sodium saccharin.","['Parker KR', 'von Borstel RC']","['Depression, Chemical', 'Mutagenicity Tests', '*Mutation', 'Osmolar Concentration', 'Potassium Chloride/*pharmacology', 'Saccharin/*pharmacology', 'Saccharomyces cerevisiae/*drug effects/growth & development', 'Sodium Chloride/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2183776/
1549,Potassium chloride,14232192,SMALL BOWEL ULCERATION ASSOCIATED WITH ENTERIC-COATED POTASSIUM CHLORIDE AND HYDROCHLOROTHIAZIDE.,"['BUCHAN DJ', 'HOUSTON CS']","['*Chlorides', '*Delayed-Action Preparations', '*Drug Therapy', '*Enteritis', '*Geriatrics', 'Humans', '*Hydrochlorothiazide', '*Ileitis', '*Intestinal Diseases', '*Intestinal Obstruction', '*Intestine, Small', '*Jejunum', '*Pathology', '*Potassium', '*Potassium Chloride', '*Radiography', '*Toxicology', '*Ulcer']",https://pubmed.ncbi.nlm.nih.gov/14232192/
1550,Potassium chloride,33310850,Structures and an activation mechanism of human potassium-chloride cotransporters.,"['Xie Y', 'Chang S', 'Zhao C', 'Wang F', 'Liu S', 'Wang J', 'Delpire E', 'Ye S', 'Guo J']","['Cell Membrane/metabolism', '*Chlorides/metabolism', 'Humans', '*Potassium/metabolism', '*Symporters/metabolism', 'K Cl- Cotransporters']",https://pubmed.ncbi.nlm.nih.gov/33310850/
1551,Potassium chloride,1963175,"Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside.","['Schaaf LJ', 'Tremel LC', 'Wulf BG', 'Vernon KK']","['Critical Care/methods', 'Dobutamine/administration & dosage', 'Dopamine/administration & dosage', 'Drug Combinations', 'Drug Incompatibility', 'Enalaprilat/administration & dosage/*chemistry', 'Heparin/administration & dosage', 'Hydrogen-Ion Concentration', 'Infusions, Intravenous', 'Nitroglycerin/administration & dosage', 'Nitroprusside/administration & dosage', 'Potassium Chloride/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/1963175/
1552,Almotriptan,20819011,Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study.,"['Leone M', 'Vila C', 'McGown C']","['Acute Disease', 'Europe', 'Humans', 'Migraine Disorders/*drug therapy/*etiology', 'Primary Health Care/*methods', 'Serotonin Receptor Agonists/*therapeutic use', 'Tryptamines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20819011/
1553,Almotriptan,16556240,"Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.","['Dahlof CG', 'Pascual J', 'Dodick DW', 'Dowson AJ']","['Acute Disease', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Headache/diagnosis/*drug therapy/*epidemiology', 'Humans', 'Migraine Disorders/diagnosis/*drug therapy/*epidemiology', 'Pain Measurement', 'Placebo Effect', 'Randomized Controlled Trials as Topic/*statistics & numerical data', 'Serotonin Receptor Agonists/therapeutic use', 'Treatment Outcome', 'Tryptamines/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16556240/
1554,Almotriptan,12749502,A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine.,['Mondell BE'],"['Clinical Trials as Topic', 'Humans', 'Indoles/adverse effects/*therapeutic use', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/adverse effects/*therapeutic use', 'Treatment Outcome', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12749502/
1555,Almotriptan,16236092,Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine.,"['Sandrini G', 'Dahlof CG', 'Mathew N', 'Nappi G']","['Acute Disease', 'Humans', 'Migraine Disorders/*drug therapy', 'Product Surveillance, Postmarketing', 'Randomized Controlled Trials as Topic/methods', 'Serotonin Receptor Agonists/adverse effects/*therapeutic use', 'Treatment Outcome', 'Tryptamines/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16236092/
1556,Almotriptan,18484981,"Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial.","['Linder SL', 'Mathew NT', 'Cady RK', 'Finlayson G', 'Ishkanian G', 'Lewis DW']","['Adolescent', 'Child', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Male', 'Migraine Disorders/*drug therapy', 'Placebos', 'Serotonin Receptor Agonists/*administration & dosage/adverse effects', 'Tryptamines/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18484981/
1557,Almotriptan,18644036,Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia.,"['Schoenen J', 'De Klippel N', 'Giurgea S', 'Herroelen L', 'Jacquy J', 'Louis P', 'Monseu G', 'Vandenheede M']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage', 'Diclofenac/administration & dosage/*analogs & derivatives', 'Drug Therapy, Combination', 'Female', 'Humans', 'Logistic Models', 'Male', 'Middle Aged', 'Migraine Disorders/complications/*drug therapy/epidemiology', 'Multivariate Analysis', 'Physical Stimulation', 'Pilot Projects', 'Prevalence', 'Serotonin Receptor Agonists/*administration & dosage', 'Somatosensory Disorders/*drug therapy/epidemiology/etiology', 'Treatment Outcome', 'Tryptamines/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/18644036/
1558,Almotriptan,18234046,Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.,"['Diamond ML', 'Cady RK', 'Mao L', 'Biondi DM', 'Finlayson G', 'Greenberg SJ', 'Wright P']","['Adolescent', 'Adult', 'Disability Evaluation', 'Double-Blind Method', 'Drug Evaluation', 'Female', 'Humans', 'Male', 'Menstruation/*physiology/psychology', 'Middle Aged', 'Migraine Disorders/diagnosis/*drug therapy/*etiology', 'Serotonin Receptor Agonists/adverse effects/*therapeutic use', 'Tryptamines/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18234046/
1559,Almotriptan,15030538,A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults.,"['Baldwin JR', 'Fleishaker JC', 'Azie NE', 'Carel BJ']","['Adolescent', 'Adult', 'Age Factors', 'Area Under Curve', 'Child', 'Chromatography, High Pressure Liquid', 'Female', 'Half-Life', 'Humans', 'Indoles/*adverse effects/analysis/*pharmacokinetics', 'Male', 'Migraine Disorders/drug therapy', 'Serotonin Receptor Agonists/*adverse effects/analysis/*pharmacokinetics', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/15030538/
1560,Almotriptan,22592864,"Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study.","['Bartolini M', 'Giamberardino MA', 'Lisotto C', 'Martelletti P', 'Moscato D', 'Panascia B', 'Savi L', 'Pini LA', 'Sances G', 'Santoro P', 'Zanchin G', 'Omboni S', 'Ferrari MD', 'Fierro B', 'Brighina F']","['Adult', 'Carbazoles/*therapeutic use', 'Cross-Over Studies', 'Disability Evaluation', 'Double-Blind Method', 'Female', 'Humans', 'Italy', 'Menstruation Disturbances/*complications', 'Middle Aged', 'Migraine Disorders/*drug therapy/*etiology', 'Proportional Hazards Models', 'Serotonin Receptor Agonists/*therapeutic use', 'Severity of Illness Index', 'Time Factors', 'Treatment Outcome', 'Tryptamines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22592864/
1561,Almotriptan,12133045,"Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.","['Dowson AJ', 'Massiou H', 'Lainez JM', 'Cabarrocas X']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Double-Blind Method', 'Female', 'Humans', 'Indoles/*administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Migraine Disorders/*drug therapy', 'Multicenter Studies as Topic', 'Recurrence', 'Serotonin Receptor Agonists/*administration & dosage/*adverse effects', 'Sumatriptan/administration & dosage/adverse effects', 'Treatment Outcome', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12133045/
1562,Almotriptan,17445101,Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).,"['Freitag FG', 'Finlayson G', 'Rapoport AM', 'Elkind AH', 'Diamond ML', 'Unger JR', 'Fisher AC', 'Armstrong RB', 'Hulihan JF', 'Greenberg SJ']","['Adolescent', 'Adult', 'Aged', 'Cluster Analysis', 'Double-Blind Method', 'Early Diagnosis', 'Female', 'Humans', 'Male', 'Middle Aged', 'Migraine Disorders/*drug therapy/*physiopathology', 'Multivariate Analysis', 'Pain Measurement/methods', 'Prospective Studies', 'Serotonin Receptor Agonists/*therapeutic use', 'Severity of Illness Index', 'Time Factors', 'Treatment Outcome', 'Tryptamines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17445101/
1563,Almotriptan,11219473,"Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan.","['Colman SS', 'Brod MI', 'Krishnamurthy A', 'Rowland CR', 'Jirgens KJ', 'Gomez-Mancilla B']","['Adolescent', 'Adult', 'Aged', 'Double-Blind Method', 'Female', 'Humans', 'Indoles/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Migraine Disorders/*drug therapy/psychology', 'Patient Satisfaction', 'Quality of Life', 'Serotonin Receptor Agonists/*therapeutic use', 'Sumatriptan/adverse effects/*therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/11219473/
1564,Almotriptan,28977362,Stability-Indicating Reversed-Phase UHPLC Method Development and Characterization of Degradation Products of Almotriptan Maleate by LC-QTOF-MS/MS.,"['Saibaba B', 'Vishnuvardhan C', 'Johnsi Rani P', 'Satheesh Kumar N']","['Chromatography, High Pressure Liquid/*methods', 'Chromatography, Reverse-Phase/*methods', 'Drug Stability', 'Hydrolysis', 'Limit of Detection', 'Linear Models', 'Reproducibility of Results', 'Tandem Mass Spectrometry/*methods', 'Tryptamines/*analysis/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/28977362/
1565,Almotriptan,24656544,An integrated quality by design and mixture-process variable approach in the development of a capillary electrophoresis method for the analysis of almotriptan and its impurities.,"['Orlandini S', 'Pasquini B', 'Stocchero M', 'Pinzauti S', 'Furlanetto S']","['1-Butanol', 'Chromatography, Micellar Electrokinetic Capillary/methods', '*Drug Contamination', 'Electrophoresis, Capillary/methods', 'Emulsions', 'Heptanes', 'Monte Carlo Method', 'Regression Analysis', 'Serotonin 5-HT1 Receptor Agonists/*analysis', 'Sodium Dodecyl Sulfate', 'Surface-Active Agents', 'Tablets', 'Tryptamines/*analysis']",https://pubmed.ncbi.nlm.nih.gov/24656544/
1566,mitomycin C,37345314,Applications of Mitomycin C in Cornea and External Disease.,"['Crespo MA', 'Rapuano CJ', 'Syed ZA']","['Humans', '*Mitomycin/therapeutic use', '*Photorefractive Keratectomy/methods', 'Lasers, Excimer', 'Cornea/surgery']",https://pubmed.ncbi.nlm.nih.gov/37345314/
1567,mitomycin C,23839191,Mitomycin C in the treatment of keloids: a case and review.,"['Kleinerman R', 'Kilmer SL', 'Chotzen VA']","['Adult', 'Alkylating Agents/administration & dosage/*therapeutic use', 'Female', 'Follow-Up Studies', 'Humans', 'Keloid/*drug therapy/pathology', 'Mitomycin/administration & dosage/*therapeutic use', 'Off-Label Use']",https://pubmed.ncbi.nlm.nih.gov/23839191/
1568,mitomycin C,34995523,Effects of Mitomycin-C and 5-Fluorouracil on Ocular Adnexal Sebaceous Carcinoma Cells.,"['Gallo RA', 'Lang SH', 'Gomez A', 'Sabater AL', 'Tse DT', 'Pelaez D', 'Rong AJ']","['*Carcinoma', 'Cell Survival', 'Cells, Cultured', '*Eye Neoplasms', 'Fluorouracil/pharmacology', 'Humans', 'Mitomycin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34995523/
1569,mitomycin C,27716885,Mitomycin C from birth to adulthood.,"['Serretta V', 'Scalici Gesolfo C', 'Alonge V', 'Di Maida F', 'Caruana G']","['Adult', 'Antibiotics, Antineoplastic/*therapeutic use', 'Child', 'Humans', 'Mitomycin/*therapeutic use', 'Urinary Bladder Neoplasms/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27716885/
1570,mitomycin C,9787230,The results of trabeculectomy with and without mitomycin C in young patients.,"['Yalvac IS', 'Nurozler A', 'Kahraman C', 'Kasim R', 'Duman S']","['Adolescent', 'Adult', 'Glaucoma/*drug therapy/physiopathology/*surgery', 'Humans', 'Intraocular Pressure/physiology', 'Mitomycin/*therapeutic use', 'Nucleic Acid Synthesis Inhibitors/*therapeutic use', '*Postoperative Care', '*Trabeculectomy/methods', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9787230/
1571,mitomycin C,38308850,A Secreted BBE-Like Enzyme Acting as a Drug-Binding Efflux Carrier Confers Microbial Self-Resistance to Mitomycin C.,"['Chen X', 'He R', 'Sun A', 'Pu J', 'Pan HX', 'Tang GL']","['*Mitomycin/pharmacology/metabolism', '*NAD(P)H Dehydrogenase (Quinone)/metabolism', 'Oxidoreductases/metabolism', 'Oxidoreductases, N-Demethylating/metabolism']",https://pubmed.ncbi.nlm.nih.gov/38308850/
1572,mitomycin C,33315724,"History, presence, and future of mitomycin C in glaucoma filtration surgery.","['Wolters JEJ', 'van Mechelen RJS', 'Al Majidi R', 'Pinchuk L', 'Webers CAB', 'Beckers HJM', 'Gorgels TGMF']","['Alkylating Agents/*administration & dosage/*history', 'Drug Delivery Systems', 'Fibrosis/prevention & control', '*Filtering Surgery', 'Glaucoma/physiopathology/*surgery', 'History, 20th Century', 'History, 21st Century', 'Humans', 'Intraocular Pressure/physiology', 'Mitomycin/*administration & dosage/*history', 'Sclera/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/33315724/
1573,mitomycin C,37530590,Effects of cyclophosphamide and mitomycin C on radiation-induced transcriptional biomarkers in human lymphoblastoid cells.,"['Li S', 'Cai TJ', 'Lu X', 'Tian M', 'Liu QJ']","['Humans', '*Mitomycin/pharmacology', 'Cyclophosphamide/pharmacology', 'Gamma Rays', 'Biomarkers', 'RNA, Messenger/metabolism', 'Dose-Response Relationship, Radiation']",https://pubmed.ncbi.nlm.nih.gov/37530590/
1574,mitomycin C,22517516,Mitomycin C in the therapy of recurrent esophageal strictures: hype or hope?,"['Berger M', 'Ure B', 'Lacher M']","['Administration, Topical', 'Child', 'Child, Preschool', 'Drug-Eluting Stents', 'Endoscopy', 'Esophageal Stenosis/*drug therapy/etiology', 'Female', 'Humans', 'Infant', 'Male', 'Mitomycin/administration & dosage/*therapeutic use', 'Recurrence', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22517516/
1575,mitomycin C,37208150,Physicochemical stability of ready-to-administer mitomycin C solutions for intravesical instillation.,"['Almasi J', 'Thiesen J', 'Kraemer I']","['*Mitomycin/administration & dosage/chemistry/analysis', '*Drug Stability', 'Administration, Intravesical', 'Antibiotics, Antineoplastic/administration & dosage/chemistry', 'Hydrogen-Ion Concentration', 'Drug Storage/standards/methods', 'Excipients/chemistry', 'Chromatography, High Pressure Liquid/methods', 'Urea/chemistry/administration & dosage', 'Osmolar Concentration']",https://pubmed.ncbi.nlm.nih.gov/37208150/
1576,mitomycin C,27666201,Mitomycin C and decarbamoyl mitomycin C induce p53-independent p21WAF1/CIP1 activation.,"['Cheng SY', 'Seo J', 'Huang BT', 'Napolitano T', 'Champeil E']","['Antibiotics, Antineoplastic/chemistry/pharmacology', 'Apoptosis/drug effects', 'Blotting, Western', 'Cell Cycle/drug effects', 'Cell Proliferation/drug effects', 'Cyclin-Dependent Kinase Inhibitor p21/*metabolism', 'Gene Expression Regulation, Neoplastic/*drug effects', 'Humans', 'K562 Cells', 'MCF-7 Cells', 'Mitomycin/*chemistry/*pharmacology', 'Tumor Suppressor Protein p53/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/27666201/
1577,mitomycin C,22029538,Intraoperative mitomycin C versus intraoperative 5-fluorouracil for trabeculectomy: a systematic review and meta-analysis.,"['Lin ZJ', 'Li Y', 'Cheng JW', 'Lu XH']","['Controlled Clinical Trials as Topic', 'Fluorouracil/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Intraocular Pressure/drug effects', 'Intraoperative Care/*methods', 'Mitomycin/administration & dosage/adverse effects/*therapeutic use', 'Trabeculectomy/*methods', 'Treatment Outcome', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/22029538/
1578,mitomycin C,21239066,Management of subglottic cysts with Mitomycin-C-A case series and literature review.,"['Steehler MK', 'Groblewski JC', 'Milmoe GJ', 'Harley EH']","['Alkylating Agents/*therapeutic use', 'Bronchoscopy', 'Cysts/*therapy', 'Female', 'Humans', 'Infant', 'Laryngeal Diseases/*therapy', 'Laryngoscopy', 'Male', 'Mitomycin/*therapeutic use', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/21239066/
1579,mitomycin C,36352754,Endophthalmitis and blebitis following deep sclerectomy and trabeculectomy with routine use of mitomycin C.,"['Kankainen T', 'Harju M']","['Humans', 'Mitomycin/therapeutic use', '*Trabeculectomy/adverse effects', '*Glaucoma/complications', 'Retrospective Studies', 'Cohort Studies', '*Endophthalmitis/epidemiology/etiology/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36352754/
1580,Ranitidine,1958166,Ranitidine and depression.,['Stocky A'],"['Aged', 'Depressive Disorder/*chemically induced/diagnosis/*psychology', 'Esophagitis, Peptic/*drug therapy/*psychology', 'Female', 'Humans', 'Life Change Events', 'Ranitidine/administration & dosage/*adverse effects', 'Recurrence', 'Risk Factors', 'Sick Role', 'Stomach Ulcer/*drug therapy/*psychology', 'Substance Withdrawal Syndrome/*diagnosis/*psychology']",https://pubmed.ncbi.nlm.nih.gov/1958166/
1581,Ranitidine,35420703,Ranitidine decreases human sperm motility and vitality and increases the activity of seminal creatine kinase.,"['Banihani SA', 'Al-Natsheh AJ']","['Creatine Kinase', 'Humans', 'Male', '*Ranitidine/pharmacology', 'Semen', '*Sperm Motility', 'Spermatozoa']",https://pubmed.ncbi.nlm.nih.gov/35420703/
1582,Ranitidine,24258773,Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.,"['Madani S', 'Kauffman R', 'Simpson P', 'Lehr VT', 'Lai ML', 'Sarniak A', 'Tolia V']","['Child', 'Child, Preschool', '*Critical Illness', 'Famotidine/administration & dosage/blood/*pharmacokinetics/pharmacology', 'Female', 'Gastric Acid/chemistry/metabolism', 'Gastric Acidity Determination', 'Gastritis/drug therapy/metabolism', 'Histamine H2 Antagonists/administration & dosage/blood/pharmacokinetics/pharmacology', 'Humans', 'Hydrogen-Ion Concentration/drug effects', 'Infant', 'Infusions, Intravenous', 'Ranitidine/administration & dosage/blood/*pharmacokinetics/pharmacology', 'Single-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/24258773/
1583,Ranitidine,1592416,Conformational studies on cimetidine and ranitidine by PCILO calculations and NMR spectroscopy.,"['Saran A', 'Srivastava S', 'Kulkarni VM', 'Coutinho E']","['Cimetidine/*chemistry', '*Magnetic Resonance Spectroscopy', 'Molecular Conformation', '*Quantum Theory', 'Ranitidine/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/1592416/
1584,Ranitidine,34170952,"Design, development and optimization of sustained release floating, bioadhesive and swellable matrix tablet of ranitidine hydrochloride.","['Nigusse B', 'Gebre-Mariam T', 'Belete A']","['Cellulose/*chemistry', 'Delayed-Action Preparations/chemistry/pharmacokinetics', 'Drug Liberation', 'Ranitidine/*chemistry/*pharmacokinetics', 'Sodium Bicarbonate/*chemistry', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/34170952/
1585,Ranitidine,8971288,Effervescent and standard formulations of ranitidine--a comparison of their pharmacokinetics and pharmacology.,"['Watson RG', 'Johnston BT', 'Tham TC', 'Kersey K']","['Adolescent', 'Adult', 'Antacids/*administration & dosage/*pharmacokinetics/pharmacology', 'Chemistry, Pharmaceutical', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Gastric Acid/metabolism', 'Gastric Mucosa/drug effects/metabolism', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Ranitidine/*administration & dosage/*pharmacokinetics/pharmacology', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/8971288/
1586,Ranitidine,37917074,Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment.,"['Huntjens DW', 'Vanhommerig JW', 'van de Veen W', 'Crul M']","['Humans', '*Paclitaxel/adverse effects', '*Ranitidine/adverse effects', 'Dexamethasone/therapeutic use', 'Infusions, Intravenous', 'Premedication']",https://pubmed.ncbi.nlm.nih.gov/37917074/
1587,Ranitidine,8864319,Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate.,"['Koch KM', 'Kerr BM', 'Gooding AE', 'Davis IM']","['Adult', 'Area Under Curve', 'Bismuth/administration & dosage/*pharmacokinetics', 'Half-Life', 'Histamine H2 Antagonists/*pharmacokinetics', 'Humans', 'Male', 'Metabolic Clearance Rate', 'Middle Aged', 'Ranitidine/administration & dosage/*analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8864319/
1588,Ranitidine,7888296,Ranitidine bismuth citrate and ranitidine do not affect gastric emptying of a radio-labelled liquid meal.,"['Parikh R', 'Sweetland J', 'Forster ER', 'Bedding AW', 'Farr SJ', 'Smith JT']","['Adult', 'Bismuth/*pharmacology', 'Citrates/*pharmacology', 'Cross-Over Studies', 'Double-Blind Method', 'Food, Formulated', 'Gastric Emptying/*drug effects', 'Histamine H2 Antagonists/*pharmacology', 'Humans', 'Male', 'Ranitidine/*analogs & derivatives/pharmacology', 'Technetium Tc 99m Pentetate']",https://pubmed.ncbi.nlm.nih.gov/7888296/
1589,Ranitidine,4076334,Ranitidine-associated hallucinations.,"['Price W', 'Coli L', 'Brandstetter RD', 'Gotz VP']","['Aged', 'Duodenal Ulcer/drug therapy', 'Female', 'Hallucinations/*chemically induced', 'Humans', 'Ranitidine/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4076334/
1590,Ranitidine,3118861,Enprostil and ranitidine: comparative efficacy and safety in patients with duodenal ulcer.,"['Mackinnon M', 'Alp M', 'Austad WI', 'Byrnes D', 'Cowen A', 'Duggan J', 'Pirola R', 'Thomas M', 'Ward M']","['Clinical Trials as Topic', 'Double-Blind Method', 'Duodenal Ulcer/*drug therapy', 'Duodenoscopy', 'Enprostil', 'Female', 'Humans', 'Male', 'Middle Aged', 'Prostaglandins E, Synthetic/administration & dosage/adverse effects/*therapeutic use', 'Random Allocation', 'Ranitidine/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3118861/
1591,Ranitidine,12604553,ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate.,"['Pletz MW', 'Preechachatchaval V', 'Bulitta J', 'Allewelt M', 'Burkhardt O', 'Lode H']","['Adult', 'Anti-Ulcer Agents/adverse effects/*pharmacology', 'Area Under Curve', 'Biological Assay', 'Chromatography, Liquid', 'Cross-Over Studies', 'Drug Interactions', 'Erythromycin/adverse effects/*analogs & derivatives/*pharmacokinetics/*pharmacology', 'Female', 'Humans', '*Ketolides', 'Male', 'Mass Spectrometry', 'Microbial Sensitivity Tests', 'Ranitidine/adverse effects/*pharmacokinetics/*pharmacology', 'Sucralfate/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12604553/
1592,Ranitidine,34803007,Fabrication and evaluation for the novel ranitidine hydrochloride resinates and calculation of the kinetics and thermodynamics parameter for the ion exchange process.,"['Yang Y', 'Du Y', 'He H', 'Yu Y', 'Li D', 'Liu H']","['Calorimetry, Differential Scanning', 'Drug Liberation', '*Ion Exchange Resins', 'Kinetics', 'Osmolar Concentration', 'Ranitidine/*chemistry/*pharmacokinetics', 'Temperature', 'Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/34803007/
1593,Ranitidine,8437966,"Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison.","['Bisson C', 'St-Laurent M', 'Michaud JT', 'LeBel M']","['Aged', 'Chromatography, High Pressure Liquid', 'Double-Blind Method', 'Drug Administration Schedule', 'Famotidine/administration & dosage/*pharmacokinetics/*pharmacology', 'Female', 'Gastric Acidity Determination', 'Humans', 'Male', 'Ranitidine/administration & dosage/*pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8437966/
1594,Ranitidine,2643037,Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer.,"['Walan A', 'Bader JP', 'Classen M', 'Lamers CB', 'Piper DW', 'Rutgersson K', 'Eriksson S']","['Adult', 'Aged', 'Analysis of Variance', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', 'Multicenter Studies as Topic', 'Omeprazole/administration & dosage/pharmacology/*therapeutic use', 'Ranitidine/administration & dosage/pharmacology/*therapeutic use', 'Recurrence', 'Stomach Ulcer/*drug therapy/physiopathology', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2643037/
1595,Aminocaproic acid,35843769,Effectiveness and Safety of E-aminocaproic Acid in Overall and Less-Invasive Cardiac Surgeries.,"['Kelava M', 'Mehta A', 'Sale S', 'Gillinov M', 'Johnston D', 'Thuita L', 'Kumar N', 'Blackstone EH']","['Adult', 'Aminocaproic Acid/adverse effects', '*Antifibrinolytic Agents/adverse effects', 'Blood Loss, Surgical/prevention & control', '*Cardiac Surgical Procedures/adverse effects', 'Cardiopulmonary Bypass/adverse effects', 'Humans', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/35843769/
1596,Aminocaproic acid,31321578,Epsilon-aminocaproic acid versus tranexamic acid in total knee arthroplasty: a meta-analysis study.,"['Riaz O', 'Aqil A', 'Asmar S', 'Vanker R', 'Hahnel J', 'Brew C', 'Grogan R', 'Radcliffe G']","['Aminocaproic Acid/*therapeutic use', 'Antifibrinolytic Agents/adverse effects/*therapeutic use', 'Arthroplasty, Replacement, Knee/*adverse effects', 'Blood Loss, Surgical/*prevention & control', 'Blood Transfusion', 'Female', 'Humans', 'Male', 'Postoperative Hemorrhage/etiology/*prevention & control/therapy', 'Tranexamic Acid/*therapeutic use', 'Venous Thromboembolism/etiology']",https://pubmed.ncbi.nlm.nih.gov/31321578/
1597,Aminocaproic acid,34777729,Tranexamic Acid versus Epsilon-Aminocaproic Acid in Total Knee Arthroplasty: A Meta-Analysis.,"['Li Z', 'Sun X', 'Li W', 'Zhang M']","['Aminocaproic Acid', '*Antifibrinolytic Agents', '*Arthroplasty, Replacement, Knee', 'Blood Loss, Surgical/prevention & control', 'Humans', 'Multicenter Studies as Topic', 'Randomized Controlled Trials as Topic', '*Tranexamic Acid']",https://pubmed.ncbi.nlm.nih.gov/34777729/
1598,Aminocaproic acid,12141409,Epsilon-aminocaproic acid and renal complications: case report and review of the literature.,"['Manjunath G', 'Fozailoff A', 'Mitcheson D', 'Sarnak MJ']","['Acute Kidney Injury/*chemically induced', 'Aged', 'Aminocaproic Acid/*adverse effects/therapeutic use', 'Antifibrinolytic Agents/*adverse effects/therapeutic use', 'Creatinine/blood', 'Female', 'Hematuria', 'Humans', 'Hydronephrosis/diagnostic imaging/etiology', 'Kidney/diagnostic imaging', 'Nephrostomy, Percutaneous', 'Radiography', 'Thrombosis/drug therapy', 'Ultrasonography']",https://pubmed.ncbi.nlm.nih.gov/12141409/
1599,Aminocaproic acid,33814604,Clinical and Hematological Outcomes of Aminocaproic Acid Use During Pediatric Cardiac ECMO.,"['Coleman M', 'Davis J', 'Maher KO', 'Deshpande SR']","['Aminocaproic Acid', 'Blood Transfusion', 'Child', '*Extracorporeal Membrane Oxygenation', 'Hemorrhage/chemically induced', 'Humans', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/33814604/
1600,Aminocaproic acid,32954969,Comparison between epsilon-aminocaproic acid and tranexamic acid for total hip and knee arthroplasty: A meta-analysis.,"['Liu WB', 'Li GS', 'Shen P', 'Zhang FJ']","['Administration, Intravenous', 'Aminocaproic Acid/*administration & dosage', 'Antifibrinolytic Agents/administration & dosage', 'Arthroplasty, Replacement, Hip/*methods', 'Arthroplasty, Replacement, Knee/*methods', 'Blood Loss, Surgical/*prevention & control', 'Blood Transfusion', 'Humans', 'Length of Stay', 'Tranexamic Acid/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/32954969/
1601,Aminocaproic acid,3898514,Comparison of epsilon aminocaproic acid and normal saline for postoperative bladder irrigation following transurethral resection of prostate.,"['Flanigan RC', 'Butler KM', ""O'Neal W"", 'Rapp RP', 'Casale AJ', 'Allen DC', 'McRoberts JW']","['Aminocaproates/*therapeutic use', 'Aminocaproic Acid/*therapeutic use', 'Clinical Trials as Topic', 'Hemostasis, Surgical', 'Humans', 'Male', 'Postoperative Care', 'Prospective Studies', '*Prostatectomy', 'Random Allocation', 'Saline Solution, Hypertonic/*therapeutic use', 'Sodium Chloride/*therapeutic use', '*Therapeutic Irrigation', 'Time Factors', 'Urinary Bladder']",https://pubmed.ncbi.nlm.nih.gov/3898514/
1602,Aminocaproic acid,37321717,An aminocaproic acid-grafted chitosan derivative with superior antibacterial and hemostatic properties for the prevention of secondary bleeding.,"['Chen XJ', 'Lei ZY', 'Liu P', 'Lei MJ', 'Xu H', 'Yu LJ', 'Ao MZ']","['Humans', '*Hemostatics/chemistry', '*Chitosan/chemistry', 'Aminocaproic Acid/pharmacology', 'Hemorrhage/drug therapy/prevention & control', 'Hemostasis', 'Anti-Bacterial Agents/chemistry']",https://pubmed.ncbi.nlm.nih.gov/37321717/
1603,Aminocaproic acid,30926553,The Efficacy and Safety of Epsilon-Aminocaproic Acid for Blood Loss and Transfusions in Spinal Deformity Surgery: A Meta-Analysis.,"['Chen R', 'Xiang Z', 'Gong M']","['Aminocaproic Acid/*therapeutic use', 'Antifibrinolytic Agents/*therapeutic use', 'Blood Loss, Surgical/*prevention & control', 'Blood Transfusion/statistics & numerical data', 'Humans', 'Neurosurgical Procedures/methods', 'Postoperative Hemorrhage/*prevention & control', 'Spinal Curvatures/*surgery', 'Spinal Fusion/*methods']",https://pubmed.ncbi.nlm.nih.gov/30926553/
1604,Aminocaproic acid,29328639,The use of hyaluronic and aminocaproic acid in the treatment of alveolar osteitis.,"['Dubovina D', 'Mihailovic B', 'Bukumiric Z', 'Vlahovic Z', 'Miladinovic M', 'Mikovic N', 'Lazic Z']","['Adult', 'Aminocaproic Acid/adverse effects/*therapeutic use', 'Analgesics/adverse effects/*therapeutic use', 'Curettage/adverse effects', 'Drug Combinations', 'Dry Socket/diagnosis/*drug therapy', 'Eugenol/adverse effects/*therapeutic use', 'Facial Pain/diagnosis/etiology/physiopathology/*prevention & control', 'Female', 'Humans', 'Hyaluronic Acid/adverse effects/*therapeutic use', 'Hydrocarbons, Iodinated/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Oils, Volatile/adverse effects/*therapeutic use', 'Pain Measurement', 'Pain Perception/drug effects', 'Pain Threshold/drug effects', 'Prospective Studies', 'Serbia', 'Therapeutic Irrigation', 'Time Factors', 'Treatment Outcome', 'para-Aminobenzoates/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29328639/
1605,Aminocaproic acid,22202494,Use of topical tranexamic acid or aminocaproic acid to prevent bleeding after major surgical procedures.,"['Ipema HJ', 'Tanzi MG']","['Administration, Topical', 'Aminocaproates/administration & dosage/adverse effects/*therapeutic use', 'Antifibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use', 'Cardiac Surgical Procedures', 'Clinical Trials as Topic', 'Humans', 'Orthopedic Procedures', 'Postoperative Hemorrhage/etiology/*prevention & control', 'Practice Guidelines as Topic', 'Tranexamic Acid/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22202494/
1606,Aminocaproic acid,7411206,Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial.,"['Shucart WA', 'Hussain SK', 'Cooper PR']","['Aminocaproates/*therapeutic use', 'Aminocaproic Acid/*therapeutic use', 'Drug Evaluation', 'Humans', 'Intracranial Aneurysm/complications/surgery', 'Recurrence', 'Subarachnoid Hemorrhage/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/7411206/
1607,Aminocaproic acid,11302475,Epsilon-aminocaproic acid promotes the release of alpha2-antiplasmin during and after cardiopulmonary bypass.,"['Ray MJ', 'Hales M', 'Marsh N']","['Aminocaproic Acid/*administration & dosage', 'Antifibrinolytic Agents/*administration & dosage', 'Aprotinin/administration & dosage', '*Cardiopulmonary Bypass', 'Double-Blind Method', 'Fibrin Fibrinogen Degradation Products/metabolism', 'Fibrinolysis/drug effects', 'Heart Valve Diseases/surgery', 'Hemostatics/administration & dosage', 'Humans', 'Tissue Plasminogen Activator/metabolism', 'alpha-2-Antiplasmin/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/11302475/
1608,Aminocaproic acid,31474134,Tranexamic acid or epsilon-aminocaproic acid in total joint arthroplasty? A randomized controlled trial.,"['Bradley KE', 'Ryan SP', 'Penrose CT', 'Grant SA', 'Wellman SS', 'Attarian DE', 'Green CL', 'Risoli T Jr', 'Bolognesi MP']","['Administration, Intravenous', 'Aged', 'Aminocaproic Acid/*administration & dosage/therapeutic use', 'Antifibrinolytic Agents/*administration & dosage/therapeutic use', 'Arthroplasty, Replacement/*adverse effects', 'Arthroplasty, Replacement, Hip/adverse effects', 'Arthroplasty, Replacement, Knee/adverse effects', 'Blood Loss, Surgical/*prevention & control', 'Blood Transfusion', 'Female', 'Humans', 'Intraoperative Period', 'Male', 'Middle Aged', 'Postoperative Complications/chemically induced/etiology', 'Postoperative Hemorrhage/etiology/*prevention & control/therapy', 'Prospective Studies', 'Tranexamic Acid/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31474134/
1609,Aminocaproic acid,29471157,The effectiveness and safety of aminocaproic acid for reducing blood loss in total knee and hip arthroplasty: A meta-analysis.,"['Dong Q', 'Zhang Y', 'Sun X', 'Hu F']","['Administration, Intravenous', 'Aminocaproic Acid/adverse effects/*therapeutic use', 'Antifibrinolytic Agents/adverse effects/*therapeutic use', 'Arthroplasty, Replacement, Hip/*adverse effects', 'Arthroplasty, Replacement, Knee/*adverse effects', 'Blood Loss, Surgical/*prevention & control', 'Blood Transfusion/statistics & numerical data', 'Female', 'Hemoglobins/analysis', 'Humans', 'Male', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29471157/
1610,Aminocaproic acid,37400783,Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs.,"['Yusufu A', 'Haibier A', 'Ren Z', 'Qin Q', 'Zhang Z', 'Zhou Y', 'Ran J']","['Humans', 'Aged', 'Aminocaproic Acid/adverse effects', '*Tranexamic Acid/adverse effects', 'Postoperative Hemorrhage/etiology', 'Blood Loss, Surgical/prevention & control', '*Antifibrinolytic Agents/adverse effects', 'Postoperative Period', '*Hip Fractures/drug therapy/surgery/complications']",https://pubmed.ncbi.nlm.nih.gov/37400783/
1611,Aminocaproic acid,35870172,Comparison of trauma-dosed tranexamic acid versus aminocaproic acid in cardiac surgery in the setting of drug shortage.,"['Dannemiller RE', 'Knowles DM', 'Cook BM', 'Goodberlet MZ', 'Kelly JM', 'Malloy R']","['Aminocaproic Acid', '*Antifibrinolytic Agents/adverse effects', 'Blood Loss, Surgical/prevention & control', '*Cardiac Surgical Procedures/adverse effects', 'Humans', 'Retrospective Studies', '*Tranexamic Acid/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35870172/
1612,Aminocaproic acid,28183556,Blood loss and transfusion requirements with epsilon-aminocaproic acid use during cranial vault reconstruction surgery.,"['Thompson ME', 'Saadeh C', 'Watkins P', 'Nagy L', 'Demke J']","['Aminocaproic Acid/administration & dosage/*therapeutic use', 'Antifibrinolytic Agents/administration & dosage/*therapeutic use', 'Blood Loss, Surgical/*prevention & control', 'Blood Transfusion/*methods', 'Bone Transplantation', 'Child, Preschool', 'Craniosynostoses/*surgery', 'Craniotomy/adverse effects/methods', 'Drug Administration Schedule', 'Humans', 'Infant', 'Infant, Newborn', 'Intraoperative Period', 'Length of Stay/statistics & numerical data', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/28183556/
1613,Aminocaproic acid,1174902,Aminocaproic acid and menstrual loss in women using intrauterine devices.,"['Kasonde JM', 'Bonnar J']","['Aminocaproates/adverse effects/*therapeutic use', 'Female', 'Fibrinolysis', 'Headache/chemically induced', 'Humans', 'Intrauterine Devices/*adverse effects', 'Menorrhagia/*drug therapy/etiology', 'Nausea/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/1174902/
1614,acetazolamide,36027559,Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.,"['Mullens W', 'Dauw J', 'Martens P', 'Verbrugge FH', 'Nijst P', 'Meekers E', 'Tartaglia K', 'Chenot F', 'Moubayed S', 'Dierckx R', 'Blouard P', 'Troisfontaines P', 'Derthoo D', 'Smolders W', 'Bruckers L', 'Droogne W', 'Ter Maaten JM', 'Damman K', 'Lassus J', 'Mebazaa A', 'Filippatos G', 'Ruschitzka F', 'Dupont M']","['*Acetazolamide/adverse effects/therapeutic use', 'Acute Disease', '*Carbonic Anhydrase Inhibitors/adverse effects', '*Diuretics/adverse effects/therapeutic use', 'Double-Blind Method', '*Heart Failure/drug therapy', 'Humans', 'Natriuretic Peptide, Brain/analysis', 'Sodium', 'Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Stroke Volume', 'Symptom Flare Up', 'Treatment Outcome', 'Ventricular Function, Left', '*Water-Electrolyte Imbalance/drug therapy/etiology/therapy']",https://pubmed.ncbi.nlm.nih.gov/36027559/
1615,acetazolamide,36802203,The Impact of Acetazolamide and Methazolamide on Exercise Performance in Normoxia and Hypoxia.,"['Doherty CJ', 'Chang JC', 'Thompson BP', 'Swenson ER', 'Foster GE', 'Dominelli PB']","['Humans', '*Acetazolamide/pharmacology/therapeutic use', 'Methazolamide/pharmacology/therapeutic use', 'Carbonic Anhydrase Inhibitors/pharmacology/therapeutic use', 'Hypoxia/drug therapy', '*Altitude Sickness/drug therapy/prevention & control', 'Acute Disease']",https://pubmed.ncbi.nlm.nih.gov/36802203/
1616,acetazolamide,37197845,Natriuretic Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload.,"['Verbrugge FH', 'Martens P', 'Dauw J', 'Nijst P', 'Meekers E', 'Augusto SN Jr', 'Ter Maaten JM', 'Damman K', 'Filippatos G', 'Lassus J', 'Mebazaa A', 'Ruschitzka F', 'Dupont M', 'Mullens W']","['Humans', 'Male', 'Acetazolamide/therapeutic use', 'Prospective Studies', 'Diuretics', '*Heart Failure', '*Water-Electrolyte Imbalance', 'Sodium']",https://pubmed.ncbi.nlm.nih.gov/37197845/
1617,acetazolamide,37754779,Treatment of Acute Heart Failure with Acetazolamide.,"['Veasaw K', 'Mahmood U', 'Fishkin T', 'Frishman WH', 'Aronow WS']","['Humans', '*Acetazolamide/therapeutic use', '*Heart Failure/drug therapy', 'Acute Disease', '*Diuretics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37754779/
1618,acetazolamide,38078375,"Acetazolamide and human carbonic anhydrases: retrospect, review and discussion of an intimate relationship.",['Tsikas D'],"['Humans', '*Acetazolamide/pharmacology/chemistry', 'Nitrites', 'Nitrates', '*Carbonic Anhydrases/metabolism', 'Amino Acids']",https://pubmed.ncbi.nlm.nih.gov/38078375/
1619,acetazolamide,24388201,Recurrent shock and pulmonary edema due to acetazolamide medication after cataract surgery.,"['Zimmermann S', 'Achenbach S', 'Wolf M', 'Janka R', 'Marwan M', 'Mahler V']","['Acetazolamide/administration & dosage/*adverse effects', 'Aged', 'Carbonic Anhydrase Inhibitors/administration & dosage/*adverse effects', '*Cataract Extraction', 'Humans', 'Male', 'Ocular Hypertension/prevention & control', 'Postoperative Complications/prevention & control', 'Pulmonary Edema/*chemically induced', 'Shock/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/24388201/
1620,acetazolamide,7315930,Separate and combined effects of timolol maleate and acetazolamide in open-angle glaucoma.,"['Berson FG', 'Epstein DL']","['Acetazolamide/pharmacology/*therapeutic use', 'Aged', 'Drug Synergism', 'Drug Therapy, Combination', 'Female', 'Glaucoma, Open-Angle/diagnosis/*drug therapy', 'Humans', 'Intraocular Pressure/*drug effects', 'Male', 'Middle Aged', 'Propanolamines/*therapeutic use', 'Timolol/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7315930/
1621,acetazolamide,37598873,Ocular pharmacokinetics and toxicity of nanoparticular acetazolamide: In vivo distribution and safety of PHBV-ACZ nanoparticle.,"['Erdal E', 'Bakici C', 'Arslan A', 'Batur B', 'Yaman ME', 'Alcigir ME', 'Akyol M', 'Ekim O', 'Salih B', 'Ugurlu N']","['Humans', 'Acetazolamide/pharmacokinetics', '*Glaucoma', '*Macular Edema', '*Diabetic Retinopathy', 'Intraocular Pressure', 'Carbonic Anhydrase Inhibitors', '*Nanoparticles', 'Polyesters']",https://pubmed.ncbi.nlm.nih.gov/37598873/
1622,acetazolamide,21190500,Acetazolamide and sulfonamide allergy: a not so simple story.,"['Kelly TE', 'Hackett PH']","['Acetazolamide/*adverse effects/chemistry', 'Anemia, Hemolytic/complications', 'Carbonic Anhydrase Inhibitors/*adverse effects/chemistry', 'Cross Reactions', 'Drug Hypersensitivity/*etiology', '*Drug Interactions', 'Glucosephosphate Dehydrogenase Deficiency/complications', 'Humans', 'Molecular Structure', 'Stevens-Johnson Syndrome/chemically induced/etiology', 'Sulfonamides/*adverse effects/chemistry']",https://pubmed.ncbi.nlm.nih.gov/21190500/
1623,acetazolamide,27397528,Myopic Changes in a Climber after Taking Acetazolamide and the Use of Corrective Lenses to Temporize Symptoms: A Case Report from Mount Kilimanjaro.,['Hill AD'],"['Acetazolamide/*adverse effects/*therapeutic use', 'Adult', 'Altitude Sickness/*prevention & control', 'Eyeglasses', 'Female', 'Humans', '*Mountaineering', 'Myopia/*chemically induced', 'Tanzania']",https://pubmed.ncbi.nlm.nih.gov/27397528/
1624,acetazolamide,32332024,Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence.,"['Schmickl CN', 'Owens RL', 'Orr JE', 'Edwards BA', 'Malhotra A']","['Acetazolamide/administration & dosage/*adverse effects', 'Adult', 'Dose-Response Relationship, Drug', 'Dysgeusia/*etiology', 'Fatigue/*etiology', 'Humans', 'Paresthesia/*etiology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/32332024/
1625,acetazolamide,29951658,Versatile coordination of acetazolamide to ruthenium(ii) p-cymene complexes and preliminary cytotoxicity studies.,"['Biancalana L', 'Batchelor LK', 'Ciancaleoni G', 'Zacchini S', 'Pampaloni G', 'Dyson PJ', 'Marchetti F']","['*Acetazolamide/chemistry/pharmacology', '*Antineoplastic Agents/chemistry/pharmacology', 'Cell Line, Tumor', 'Cell Survival/drug effects', '*Coordination Complexes/chemistry/pharmacology', 'Cymenes', 'HEK293 Cells', 'Humans', '*Monoterpenes/chemistry/pharmacology', '*Ruthenium/chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29951658/
1626,acetazolamide,29792554,Effect of acetazolamide and methazolamide on diaphragm and dorsiflexor fatigue: a randomized controlled trial.,"['Dominelli PB', 'McNeil CJ', 'Vermeulen TD', 'Stuckless TJR', 'Brown CV', 'Dominelli GS', 'Swenson ER', 'Teppema LJ', 'Foster GE']","['Acetazolamide/*pharmacology', 'Adult', 'Carbonic Anhydrase Inhibitors/*pharmacology', 'Diaphragm/drug effects', 'Electric Stimulation', 'Electromyography', 'Exercise', 'Healthy Volunteers', 'Humans', 'Male', 'Methazolamide/*pharmacology', 'Muscle Contraction', 'Muscle Fatigue/*drug effects', 'Respiratory Muscles/*drug effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29792554/
1627,acetazolamide,36356042,Effect of altitude and acetazolamide on sleep and nocturnal breathing in healthy lowlanders 40 y of age or older. Data from a randomized trial.,"['Graf LC', 'Furian M', 'Bitos K', 'Mademilov M', 'Abdraeva A', 'Buenzli J', 'Buenzli S', 'Aidaralieva S', 'Sheraliev U', 'Mayer LC', 'Schneider SR', 'Sooronbaev TM', 'Ulrich S', 'Bloch KE']","['Humans', 'Female', 'Male', '*Acetazolamide/therapeutic use', '*Altitude', 'Sleep', 'Respiration']",https://pubmed.ncbi.nlm.nih.gov/36356042/
1628,acetazolamide,7950830,Acetazolamide-induced nephrocalcinosis.,"['Parikh JR', 'Nolan RL']","['Acetazolamide/*pharmacology', 'Humans', 'Kidney/diagnostic imaging', 'Kidney Calculi/*chemically induced/diagnostic imaging', 'Male', 'Middle Aged', 'Radiography']",https://pubmed.ncbi.nlm.nih.gov/7950830/
1629,acetazolamide,31063956,Structure and spectroscopic characterization of pharmaceutical co-crystal formation between acetazolamide and 4-hydroxybenzoic acid.,"['Wang Y', 'Xue J', 'Qin J', 'Liu J', 'Du Y']","['Acetazolamide/*chemistry', 'Carbonic Anhydrase Inhibitors/*chemistry', 'Crystallization', 'Models, Molecular', 'Parabens/*chemistry', 'Spectrum Analysis, Raman', 'Terahertz Spectroscopy']",https://pubmed.ncbi.nlm.nih.gov/31063956/
1630,acetazolamide,21983315,Acetazolamide: a forgotten diuretic agent.,"['Kassamali R', 'Sica DA']","['Acetazolamide/pharmacology/*therapeutic use', 'Diuretics/pharmacology/*therapeutic use', 'Drug Interactions', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/21983315/
1631,acetazolamide,23817276,Cutaneous adverse drug reaction to oral acetazolamide and skin tests.,"['Jachiet M', 'Bellon N', 'Assier H', 'Amsler E', 'Gaouar H', 'Pecquet C', 'Bourrain JL', 'Begon E', 'Chosidow O', 'Frances C', 'Ingen-Housz-Oro S', 'Soria A']","['Acetazolamide/administration & dosage/*adverse effects', 'Aged', 'Carbonic Anhydrase Inhibitors/administration & dosage/*adverse effects', 'Drug Eruptions/*etiology', 'Female', 'Humans', 'Intradermal Tests', 'Middle Aged', 'Patch Tests', 'Retrospective Studies', 'Sulfonamides/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/23817276/
1632,Minoxidil,30155952,Minoxidil in the treatment of androgenetic alopecia.,"['Goren A', 'Naccarato T']","['Alopecia/*drug therapy', 'Humans', 'Minoxidil/*therapeutic use', 'Vasodilator Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30155952/
1633,Minoxidil,34159872,Minoxidil: a comprehensive review.,"['Gupta AK', 'Talukder M', 'Venkataraman M', 'Bamimore MA']","['Administration, Topical', 'Alopecia/drug therapy', '*Alopecia Areata', 'Female', 'Hair', 'Humans', 'Male', '*Minoxidil/therapeutic use', 'Sulfotransferases/metabolism/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34159872/
1634,Minoxidil,32622136,Oral minoxidil treatment for hair loss: A review of efficacy and safety.,"['Randolph M', 'Tosti A']","['Administration, Oral', 'Alopecia/*drug therapy', 'Drug Administration Schedule', 'Humans', 'Medication Adherence', 'Minoxidil/*administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32622136/
1635,Minoxidil,37665358,Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis.,"['Abdi P', 'Awad C', 'Anthony MR', 'Farkouh C', 'Kenny B', 'Maibach HI', 'Ogunyemi B']","['Female', 'Humans', 'Male', '*Alopecia/drug therapy', 'Hair', '*Minoxidil/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37665358/
1636,Minoxidil,31403367,Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation.,"['Ghonemy S', 'Alarawi A', 'Bessar H']","['Administration, Topical', 'Adult', 'Alopecia/*drug therapy', 'Double-Blind Method', 'Hair/growth & development', 'Humans', 'Male', 'Minoxidil/*therapeutic use', 'Patient Satisfaction', 'Placebo Effect', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31403367/
1637,Minoxidil,12196747,A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.,"['Olsen EA', 'Dunlap FE', 'Funicella T', 'Koperski JA', 'Swinehart JM', 'Tschen EH', 'Trancik RJ']","['Administration, Topical', 'Adolescent', 'Adult', 'Alopecia/*drug therapy/psychology', 'Double-Blind Method', 'Drug Tolerance', 'Humans', 'Middle Aged', 'Minoxidil/*administration & dosage/adverse effects', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/12196747/
1638,Minoxidil,38598226,Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial.,"['Penha MA', 'Miot HA', 'Kasprzak M', 'Muller Ramos P']","['Humans', '*Minoxidil/administration & dosage/adverse effects', 'Male', '*Alopecia/drug therapy', 'Adult', 'Double-Blind Method', 'Administration, Oral', 'Middle Aged', 'Treatment Outcome', 'Young Adult', 'Administration, Topical', 'Adolescent', 'Hair/drug effects', 'Brazil', 'Scalp']",https://pubmed.ncbi.nlm.nih.gov/38598226/
1639,Minoxidil,6108737,Minoxidil.,"['Linas SL', 'Nies AS']","['Adrenergic beta-Antagonists/therapeutic use', 'Angina Pectoris/chemically induced', 'Diuretics/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Hypertension/*drug therapy', 'Hypertrichosis/chemically induced', 'Kidney/drug effects', 'Minoxidil/adverse effects/*therapeutic use', 'Natriuresis/drug effects', 'Pyrimidines/*therapeutic use', 'Receptors, Adrenergic/drug effects', 'Sodium Chloride/metabolism']",https://pubmed.ncbi.nlm.nih.gov/6108737/
1640,Minoxidil,39133327,To evaluate hypertrichosis with low dose oral minoxidil and spironolactone combination therapy for alopecia.,"['Nohria A', 'Desai D', 'Sikora M', 'Mandal S', 'Caplan A', 'Shapiro J', 'Lo Sicco KI']","['Humans', '*Minoxidil/administration & dosage/adverse effects', 'Female', '*Spironolactone/administration & dosage/adverse effects', '*Alopecia/drug therapy/diagnosis', '*Hypertrichosis/chemically induced/diagnosis', 'Adult', 'Retrospective Studies', '*Drug Therapy, Combination/methods', 'Middle Aged', 'Treatment Outcome', 'Administration, Oral', 'Young Adult', 'Adolescent']",https://pubmed.ncbi.nlm.nih.gov/39133327/
1641,Minoxidil,34133836,SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth.,"['Dhurat R', 'Daruwalla S', 'Pai S', 'Kovacevic M', 'McCoy J', 'Shapiro J', 'Sinclair R', 'Vano-Galvan S', 'Goren A']","['Administration, Topical', 'Alopecia/drug therapy', 'Arylsulfotransferase/therapeutic use', 'Hair', 'Humans', 'Male', '*Minoxidil', '*Sulfotransferases/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34133836/
1642,Minoxidil,27391640,"Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.","['Blume-Peytavi U', 'Shapiro J', 'Messenger AG', 'Hordinsky MK', 'Zhang P', 'Quiza C', 'Doshi U', 'Olsen EA']","['Adult', 'Aged', 'Alopecia/*diagnosis/*drug therapy', 'Dermatitis, Irritant/diagnosis/etiology', 'Drug Administration Schedule', 'Drug Compounding', 'Female', 'Humans', 'Middle Aged', 'Minoxidil/*administration & dosage/adverse effects/*chemistry', 'Pharmaceutical Solutions/administration & dosage/adverse effects/chemistry', 'Single-Blind Method', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27391640/
1643,Minoxidil,25807073,5% Minoxidil: treatment for female pattern hair loss.,"['Gupta AK', 'Foley KA']","['Alopecia/*drug therapy', 'Canada', 'Drug Administration Schedule', 'Female', 'Humans', 'Minoxidil/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/25807073/
1644,Minoxidil,35107565,Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis.,"['Gupta AK', 'Venkataraman M', 'Talukder M', 'Bamimore MA']","['*5-alpha Reductase Inhibitors', 'Adult', 'Alopecia/diagnosis', 'Bayes Theorem', 'Dutasteride', 'Finasteride', 'Humans', 'Male', '*Minoxidil/therapeutic use', 'Network Meta-Analysis', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/35107565/
1645,Minoxidil,39789748,"Fractional CO(2) Laser and Minoxidil in the Treatment of Alopecia Areata, A Comparative Study.","['Elhawary EE', 'Abdelnaby NM', 'Rezk GF', 'Qandil AM']","['Humans', '*Minoxidil/therapeutic use/administration & dosage', '*Alopecia Areata/drug therapy', '*Lasers, Gas/therapeutic use', 'Female', 'Adult', 'Male', 'Treatment Outcome', 'Adolescent', 'Middle Aged', 'Young Adult', 'Combined Modality Therapy', 'Administration, Topical', 'Vasodilator Agents/therapeutic use/administration & dosage', 'Low-Level Light Therapy/methods']",https://pubmed.ncbi.nlm.nih.gov/39789748/
1646,Minoxidil,37645625,New Target for Minoxidil in the Treatment of Androgenetic Alopecia.,"['Shen Y', 'Zhu Y', 'Zhang L', 'Sun J', 'Xie B', 'Zhang H', 'Song X']","['Humans', '*Minoxidil/pharmacology/therapeutic use', 'Molecular Docking Simulation', '*Alopecia/drug therapy', 'Dietary Supplements', 'Estradiol']",https://pubmed.ncbi.nlm.nih.gov/37645625/
1647,Ziprasidone,30346242,Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.,"['Girard TD', 'Exline MC', 'Carson SS', 'Hough CL', 'Rock P', 'Gong MN', 'Douglas IS', 'Malhotra A', 'Owens RL', 'Feinstein DJ', 'Khan B', 'Pisani MA', 'Hyzy RC', 'Schmidt GA', 'Schweickert WD', 'Hite RD', 'Bowton DL', 'Masica AL', 'Thompson JL', 'Chandrasekhar R', 'Pun BT', 'Strength C', 'Boehm LM', 'Jackson JC', 'Pandharipande PP', 'Brummel NE', 'Hughes CG', 'Patel MB', 'Stollings JL', 'Bernard GR', 'Dittus RS', 'Ely EW']","['Aged', 'Antipsychotic Agents/adverse effects/*therapeutic use', 'Critical Illness/mortality/*psychology/therapy', 'Delirium/*drug therapy', 'Dopamine Antagonists/*therapeutic use', 'Double-Blind Method', 'Female', 'Haloperidol/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Piperazines/administration & dosage/adverse effects/*therapeutic use', 'Respiratory Insufficiency/psychology', 'Shock/psychology', 'Thiazoles/administration & dosage/adverse effects/*therapeutic use', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/30346242/
1648,Ziprasidone,29885904,"Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department.","['Klein LR', 'Driver BE', 'Miner JR', 'Martel ML', 'Hessel M', 'Collins JD', 'Horton GB', 'Fagerstrom E', 'Satpathy R', 'Cole JB']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antipsychotic Agents/administration & dosage/*therapeutic use', 'Cohort Studies', 'Emergency Medical Services', 'Female', 'Haloperidol/administration & dosage/therapeutic use', 'Humans', 'Injections, Intramuscular', 'Male', 'Mental Status and Dementia Tests', 'Midazolam/administration & dosage/therapeutic use', 'Middle Aged', 'Olanzapine/administration & dosage/therapeutic use', 'Piperazines/administration & dosage/therapeutic use', 'Prospective Studies', 'Psychomotor Agitation/*drug therapy', 'Thiazoles/administration & dosage/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29885904/
1649,Ziprasidone,19164500,Ziprasidone-induced spontaneous orgasm.,"['Boora K', 'Chiappone K', 'Dubovsky S', 'Xu J']","['Antipsychotic Agents/adverse effects/therapeutic use', 'Bipolar Disorder/*drug therapy', 'Female', 'Humans', 'Middle Aged', '*Orgasm', 'Piperazines/*adverse effects/therapeutic use', 'Sexual Dysfunctions, Psychological/*chemically induced', 'Thiazoles/*adverse effects/therapeutic use', 'Torticollis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/19164500/
1650,Ziprasidone,34678557,Identification of Novel Impurity of Ziprasidone.,"['Murkute SR', 'Singh GP', 'Vasantharaju SG', 'Bhat K', 'Godbole HM', 'Upadhyay PR', 'Trivedi A']","['Chromatography, High Pressure Liquid', '*Drug Contamination', '*Piperazines', 'Thiazoles']",https://pubmed.ncbi.nlm.nih.gov/34678557/
1651,Ziprasidone,15965308,Use of ziprasidone in parkinsonian patients with psychosis.,"['Gomez-Esteban JC', 'Zarranz JJ', 'Velasco F', 'Lezcano E', 'Lachen MC', 'Rouco I', 'Barcena J', 'Boyero S', 'Ciordia R', 'Allue I']","['Aged', 'Aged, 80 and over', 'Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Humans', 'Hypotension, Orthostatic/physiopathology', 'Male', 'Middle Aged', 'Parkinson Disease/*complications/psychology', 'Piperazines/administration & dosage/adverse effects/*therapeutic use', 'Psychiatric Status Rating Scales', 'Psychotic Disorders/*drug therapy/psychology', 'Thiazoles/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15965308/
1652,Ziprasidone,37240267,"Human Hemoglobin and Antipsychotics Clozapine, Ziprasidone and Sertindole: Friends or Foes?","['Platanic Arizanovic L', 'Gligorijevic N', 'Cvijetic I', 'Mijatovic A', 'Ristivojevic MK', 'Minic S', 'Kokic AN', 'Miljevic C', 'Nikolic M']","['Humans', '*Antipsychotic Agents/pharmacology', '*Clozapine/pharmacology', 'Molecular Docking Simulation', 'Olanzapine', 'Benzodiazepines']",https://pubmed.ncbi.nlm.nih.gov/37240267/
1653,Ziprasidone,15799011,Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?,"['Oechsner M', 'Korchounov A']","['Aged', 'Antiparkinson Agents/therapeutic use', 'Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Electrocardiography', 'Emergency Medical Services', 'Female', 'Humans', 'Injections, Intramuscular', 'Male', 'Middle Aged', 'Parkinson Disease/*complications/drug therapy/psychology', 'Piperazines/administration & dosage/adverse effects/*therapeutic use', 'Psychiatric Status Rating Scales', 'Psychomotor Agitation/drug therapy/etiology', 'Psychotic Disorders/*drug therapy/*etiology/psychology', 'Thiazoles/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15799011/
1654,Ziprasidone,23698184,"Acute dystonia, akathisia, and parkinsonism induced by ziprasidone.","['Praharaj SK', 'Jana AK', 'Sarkhel S', 'Sinha VK']","['Acute Disease', 'Adult', 'Akathisia, Drug-Induced/*etiology', 'Antipsychotic Agents/administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Dystonia/*chemically induced', 'Humans', 'Male', 'Parkinsonian Disorders/*chemically induced', 'Piperazines/administration & dosage/*adverse effects', 'Thiazoles/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/23698184/
1655,Ziprasidone,38918237,Ziprasidone population pharmacokinetics and co-medication effects in Chinese patients.,"['Bao S', 'Yang S', 'Hua Z', 'Li J', 'Zang Y', 'Li X']","['Adolescent', 'Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Young Adult', '*Antipsychotic Agents/pharmacokinetics/administration & dosage/blood', 'China', 'Drug Interactions', 'Drug Therapy, Combination', 'East Asian People', '*Mental Disorders/drug therapy/blood', '*Models, Biological', 'Nonlinear Dynamics', 'Piperazines/pharmacokinetics/administration & dosage/blood', 'Retrospective Studies', '*Thiazoles/pharmacokinetics/administration & dosage/blood']",https://pubmed.ncbi.nlm.nih.gov/38918237/
1656,Ziprasidone,22249643,Adolescent female with withdrawal psychosis following abrupt termination of ziprasidone.,"['Jacob MK', 'Ash P', 'Craighead WE']","['Depressive Disorder/*drug therapy', 'Female', 'Hallucinations/*chemically induced/drug therapy', 'Humans', 'Piperazines/*adverse effects', 'Psychoses, Substance-Induced/*diagnosis/drug therapy', 'Substance Withdrawal Syndrome/diagnosis/drug therapy', 'Thiazoles/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/22249643/
1657,Ziprasidone,23302449,A case of recurrent psychosis during sickle cell disease crisis treated successfully with ziprasidone.,"['Spiegel DR', 'Messerschmidt C', 'Morewitz J', 'Akintola M']","['Adult', 'Analgesics, Opioid/therapeutic use', 'Anemia, Sickle Cell/*complications/therapy', 'Antipsychotic Agents/*therapeutic use', 'Blood Transfusion/methods', 'Diagnosis, Differential', 'Fluid Therapy/methods', 'Hospitalization', 'Humans', 'Male', 'Pain/etiology', 'Pain Management/methods', 'Piperazines/*therapeutic use', 'Psychotic Disorders/complications/diagnosis/*drug therapy', 'Recurrence', 'Thiazoles/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23302449/
1658,Ziprasidone,15079855,Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge.,['Gray NS'],"['Antipsychotic Agents/*adverse effects/therapeutic use', 'Female', 'Humans', 'Middle Aged', 'Neuroleptic Malignant Syndrome/*etiology', 'Parkinson Disease/*drug therapy', 'Piperazines/*adverse effects/therapeutic use', 'Thiazoles/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15079855/
1659,Ziprasidone,19703644,A failed case of weaning from a mechanical ventilator with lorazepam successfully accomplished by ziprasidone.,"['Spiegel DR', 'Ramdath N']","['Anti-Anxiety Agents/*therapeutic use', 'Antipsychotic Agents/*therapeutic use', 'Female', 'Humans', 'Lorazepam/*therapeutic use', 'Middle Aged', 'Piperazines/*therapeutic use', 'Pulmonary Disease, Chronic Obstructive/therapy', 'Thiazoles/*therapeutic use', 'Treatment Outcome', 'Ventilator Weaning/*methods']",https://pubmed.ncbi.nlm.nih.gov/19703644/
1660,Ziprasidone,35212782,Ziprasidone suppresses pancreatic adenocarcinoma cell proliferation by targeting GOT1 to trigger glutamine metabolism reprogramming.,"['Yang Y', 'Zheng M', 'Han F', 'Shang L', 'Li M', 'Gu X', 'Li H', 'Chen L']","['*Adenocarcinoma/pathology', 'Aspartate Aminotransferase, Cytoplasmic/pharmacology/therapeutic use', '*Carcinoma, Pancreatic Ductal/drug therapy/pathology', 'Cell Line, Tumor', 'Cell Proliferation', 'Glutamine/metabolism', 'Humans', '*Pancreatic Neoplasms/metabolism', 'Piperazines', 'Thiazoles']",https://pubmed.ncbi.nlm.nih.gov/35212782/
1661,Ziprasidone,14870962,Ziprasidone in Huntington's disease: the first case reports.,"['Bonelli RM', 'Mayr BM', 'Niederwieser G', 'Reisecker F', 'Kapfhammer HP']","['Adult', 'Dopamine Antagonists/*therapeutic use', 'Female', 'Humans', 'Huntington Disease/*drug therapy/genetics', 'Male', 'Middle Aged', 'Piperazines/*therapeutic use', 'Thiazoles/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14870962/
1662,Ziprasidone,18597173,"A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic.",['Bastiaens L'],"['Adolescent', 'Aggression/*drug effects/psychology', 'Antipsychotic Agents/*therapeutic use', 'Aripiprazole', 'Child', 'Community Mental Health Centers', 'Female', 'Humans', 'Male', 'Piperazines/*therapeutic use', 'Quinolones/*therapeutic use', 'Thiazoles/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18597173/
1663,Econazole,27764679,Clotrimazole and econazole inhibit Streptococcus mutans biofilm and virulence in vitro.,"['Qiu W', 'Ren B', 'Dai H', 'Zhang L', 'Zhang Q', 'Zhou X', 'Li Y']","['Anti-Bacterial Agents/pharmacology', 'Antifungal Agents/*pharmacology', 'Biofilms/*drug effects', 'Clotrimazole/*pharmacology', 'Econazole/*pharmacology', 'Humans', 'Hydrogen-Ion Concentration', 'In Vitro Techniques', 'Microbial Sensitivity Tests', 'Microscopy, Electron, Scanning', 'Real-Time Polymerase Chain Reaction', 'Streptococcus mutans/*drug effects/*pathogenicity', 'Virulence Factors']",https://pubmed.ncbi.nlm.nih.gov/27764679/
1664,Econazole,2490540,Analysis of miconazole and econazole in pharmaceutical formulations by derivative UV spectroscopy and liquid chromatography (HPLC).,"['Cavrini V', 'Di Pietra AM', 'Gatti R']","['Chromatography, High Pressure Liquid', 'Econazole/*analysis', 'Indicators and Reagents', 'Miconazole/*analysis', 'Ointments', 'Powders', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/2490540/
1665,Econazole,31003121,Stability and toxicity studies for duloxetine and econazole on Spirodela polyrhiza using chiral capillary electrophoresis.,"['Valimana-Traverso J', 'Amariei G', 'Boltes K', 'Garcia MA', 'Marina ML']","['Araceae/*drug effects', 'Buffers', 'Chlorophyll/chemistry', 'Dose-Response Relationship, Drug', 'Drug Stability', 'Duloxetine Hydrochloride/*toxicity', 'Econazole/*toxicity', 'Electrophoresis, Capillary', 'Stereoisomerism', 'Temperature', 'Toxicity Tests']",https://pubmed.ncbi.nlm.nih.gov/31003121/
1666,Econazole,25376919,Antifungal efficiency of miconazole and econazole and the interaction with transport protein: a comparative study.,"['Hu Z', 'Zhang J', 'Cheng X']","['Antifungal Agents/administration & dosage/chemistry/*pharmacology', 'Candida albicans/*drug effects/growth & development/metabolism/ultrastructure', 'Carrier Proteins/*chemistry', 'Dose-Response Relationship, Drug', 'Econazole/administration & dosage/chemistry/*pharmacology', 'Humans', 'Miconazole/administration & dosage/chemistry/*pharmacology', 'Microscopy, Electron, Transmission', 'Molecular Docking Simulation', 'Protein Binding', 'Serum Albumin/*chemistry', 'Spectrometry, Fluorescence']",https://pubmed.ncbi.nlm.nih.gov/25376919/
1667,Econazole,32376018,Enantiomeric determination of econazole and sulconazole by electrokinetic chromatography using hydroxypropyl-beta-cyclodextrin combined with ionic liquids based on L-lysine and L-glutamic acid.,"['Salido-Fortuna S', 'Marina ML', 'Castro-Puyana M']","['2-Hydroxypropyl-beta-cyclodextrin/*chemistry', 'Chromatography, Micellar Electrokinetic Capillary/*methods', 'Econazole/*analysis', 'Glutamic Acid/*chemistry', 'Imidazoles/*analysis', 'Ionic Liquids/*chemistry', 'Lysine/*chemistry', 'Quaternary Ammonium Compounds', 'Stereoisomerism', 'Temperature', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/32376018/
1668,Econazole,20308390,"In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.","['Vera-Cabrera L', 'Campos-Rivera MP', 'Escalante-Fuentes WG', 'Pucci MJ', 'Ocampo-Candiani J', 'Welsh O']","['Anti-Bacterial Agents/chemistry/pharmacology', 'Clavulanic Acid/*pharmacology', 'Drug Therapy, Combination', 'Econazole/*pharmacology', 'Humans', 'Imipenem/*pharmacology', 'In Vitro Techniques', 'Meropenem', 'Mycetoma/drug therapy/microbiology', 'Nocardia/*drug effects', 'Nocardia Infections/drug therapy/microbiology', 'Quinolones/chemistry/*pharmacology', 'Thiazoles/chemistry/*pharmacology', 'Thienamycins/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/20308390/
1669,Econazole,12895182,"Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria.","['Kokjohn K', 'Bradley M', 'Griffiths B', 'Ghannoum M']","['Antifungal Agents/*pharmacology', 'Arthrodermataceae/*drug effects/isolation & purification', 'Bacteria/*drug effects/isolation & purification', 'Benzylamines/pharmacology', 'Ciclopirox', 'Drug Resistance, Fungal', 'Econazole/pharmacology', 'Humans', 'Microbial Sensitivity Tests', 'Naphthalenes/pharmacology', 'Pyridones/*pharmacology', 'Sensitivity and Specificity', 'Yeasts/*drug effects/isolation & purification']",https://pubmed.ncbi.nlm.nih.gov/12895182/
1670,Nicotinate,28533213,A Novel N-Methyltransferase in Arabidopsis Appears to Feed a Conserved Pathway for Nicotinate Detoxification among Land Plants and Is Associated with Lignin Biosynthesis.,"['Li W', 'Zhang F', 'Wu R', 'Jia L', 'Li G', 'Guo Y', 'Liu C', 'Wang G']","['Alkaloids/metabolism', 'Arabidopsis/*enzymology', 'Arabidopsis Proteins/*metabolism', 'Biocatalysis', 'Inactivation, Metabolic', 'Lignin/*biosynthesis/chemistry', 'NAD/metabolism', 'Niacin/*metabolism', 'Phylogeny', 'Plant Roots/metabolism', 'Structural Homology, Protein', 'Subcellular Fractions/metabolism']",https://pubmed.ncbi.nlm.nih.gov/28533213/
1671,Nicotinate,3582710,Hexyl-nicotinate-induced vasodilation in normal human skin.,"['Dowd PM', 'Whitefield M', 'Greaves MW']","['Administration, Topical', 'Adult', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nicotinic Acids/*pharmacology', 'Skin/*blood supply', 'Vasodilation/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/3582710/
1672,Nicotinate,18042392,Nicotinate riboside salvage in plants: presence of nicotinate riboside kinase in mungbean seedlings.,"['Matsui A', 'Ashihara H']","['Cotyledon/enzymology', 'Fabaceae/*enzymology', 'NAD/*biosynthesis', 'Phosphotransferases/*metabolism', 'Plant Proteins/*metabolism', 'Ribonucleosides/*metabolism', 'Seedlings/enzymology']",https://pubmed.ncbi.nlm.nih.gov/18042392/
1673,Nicotinate,20578699,Complexes of bacterial nicotinate mononucleotide adenylyltransferase with inhibitors: implication for structure-based drug design and improvement.,"['Huang N', 'Kolhatkar R', 'Eyobo Y', 'Sorci L', 'Rodionova I', 'Osterman AL', 'Mackerell AD', 'Zhang H']","['Bacillus anthracis/*enzymology', 'Bacterial Proteins/antagonists & inhibitors/*chemistry', 'Binding Sites', 'Crystallography, X-Ray', 'Enzyme Inhibitors/*chemistry', 'Hydrazines/chemical synthesis/chemistry', 'Hydrazones/chemical synthesis/chemistry', 'Models, Molecular', 'Naphthalenes/chemical synthesis/chemistry', 'Nicotinamide-Nucleotide Adenylyltransferase/antagonists & inhibitors/*chemistry', 'Propionates/chemical synthesis/chemistry']",https://pubmed.ncbi.nlm.nih.gov/20578699/
1674,Nicotinate,19716475,Targeting NAD biosynthesis in bacterial pathogens: Structure-based development of inhibitors of nicotinate mononucleotide adenylyltransferase NadD.,"['Sorci L', 'Pan Y', 'Eyobo Y', 'Rodionova I', 'Huang N', 'Kurnasov O', 'Zhong S', 'MacKerell AD Jr', 'Zhang H', 'Osterman AL']","['Anti-Bacterial Agents/*chemistry/pharmacology', 'Bacillus anthracis/enzymology', 'Binding Sites', 'Computational Biology', 'Crystallography, X-Ray', 'Enzyme Inhibitors/*chemistry/pharmacology', 'Escherichia coli/enzymology', 'Kinetics', 'NAD/*biosynthesis/chemistry', 'Nicotinamide-Nucleotide Adenylyltransferase/*antagonists & inhibitors/metabolism', 'Protein Structure, Tertiary']",https://pubmed.ncbi.nlm.nih.gov/19716475/
1675,Nicotinate,7184475,Rapid radial transport of methyl nicotinate in the dermis.,"['Guy RH', 'Maibach HI']","['Biological Transport', 'Humans', 'Mathematics', 'Models, Biological', 'Nicotinic Acids/*metabolism', '*Skin Absorption', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7184475/
1676,Nicotinate,34582709,Genome organization and evolution of a eukaryotic nicotinate co-inducible pathway.,"['Bokor E', 'Flipphi M', 'Kocsube S', 'Amon J', 'Vagvolgyi C', 'Scazzocchio C', 'Hamari Z']","['Aspergillus nidulans/drug effects/*metabolism', 'Eukaryota/*metabolism', '*Evolution, Molecular', 'Fungal Proteins/genetics/*metabolism', 'Gene Duplication', 'Gene Expression Regulation, Fungal/*drug effects', 'Multigene Family', 'Niacin/*pharmacology', '*Phylogeny']",https://pubmed.ncbi.nlm.nih.gov/34582709/
1677,Nicotinate,35639810,Topical Application of Methyl Nicotinate Solution Enhances Peripheral Blood Collection.,"['Zhu Y', 'Xu W', 'OuYang L', 'Wang H', 'Mao W', 'Zhou H', 'Shen C', 'Hu Z', 'Tan Y']","['Humans', '*Nicotinic Acids']",https://pubmed.ncbi.nlm.nih.gov/35639810/
1678,Nicotinate,23732332,"Synthesis and antifungal evaluation of (1,2,3-triazol-4-yl)methyl nicotinate chitosan.","['Qin Y', 'Liu S', 'Xing R', 'Li K', 'Yu H', 'Li P']","['Antifungal Agents/*chemistry/*pharmacology', 'Chitosan/analogs & derivatives/*chemistry/*pharmacology', 'Microbial Sensitivity Tests', 'Nuclear Magnetic Resonance, Biomolecular', 'Spectroscopy, Fourier Transform Infrared']",https://pubmed.ncbi.nlm.nih.gov/23732332/
1679,Nicotinate,36959213,"Sources, Components, Structure, Catalytic Mechanism and Applications: a Critical Review on Nicotinate Dehydrogenase.","['Chen Z', 'Xu X', 'Ju X', 'Yan L', 'Li L', 'Yang L']","['*Oxidoreductases Acting on CH-NH Group Donors/chemistry/genetics/metabolism', 'Plasmids']",https://pubmed.ncbi.nlm.nih.gov/36959213/
1680,Nicotinate,881094,Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud's phenomena.,"['Ring EF', 'Bacon PA']","['Adult', 'Female', 'Hand', 'Humans', 'Inositol/*analogs & derivatives/pharmacology/therapeutic use', 'Male', 'Middle Aged', 'Nicotinic Acids/pharmacology/*therapeutic use', 'Raynaud Disease/*drug therapy', '*Thermography/methods', 'Vasomotor System/drug effects']",https://pubmed.ncbi.nlm.nih.gov/881094/
1681,Nicotinate,35083643,"Expression, Purification, and Biophysical Characterization of Klebsiella Pneumoniae Nicotinate Nucleotide Adenylyltransferase.","['Daya T', 'Jeje O', 'Maake R', 'Aloke C', 'Khoza T', 'Achilonu I']","['Crystallography, X-Ray', 'Escherichia coli/metabolism', 'Humans', '*Klebsiella pneumoniae/enzymology/genetics', '*Nicotinamide-Nucleotide Adenylyltransferase/chemistry/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35083643/
1682,Nicotinate,31777124,Skin blood flow response to topically applied methyl nicotinate: Possible mechanisms.,"['Elawa S', 'Mirdell R', 'Farnebo S', 'Tesselaar E']","['Administration, Topical', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology', 'Case-Control Studies', 'Female', 'Humans', 'Iontophoresis/instrumentation', 'Male', 'Microcirculation/*drug effects', 'Neurons, Afferent/drug effects', 'Nicotinic Acids/administration & dosage/*pharmacology', 'Nitric Oxide Synthase/drug effects', 'Prostaglandins/pharmacology', 'Regional Blood Flow/drug effects', 'Skin/*blood supply/drug effects/innervation', 'Tissue Survival/drug effects/radiation effects', 'Vasodilation/drug effects/physiology', 'Vitamin B Complex/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/31777124/
1683,Nicotinate,39423351,Nicotinate-Modified Lanthanide-Substituted Selenotungstate and Its Catalase-like Activity for the Detection of H(2)O(2) and Ascorbic Acid.,"['Liu L', 'Cui L', 'Jiang J', 'Chen L', 'Zhao J']","['*Ascorbic Acid/chemistry/analysis', '*Hydrogen Peroxide/analysis/chemistry', '*Tungsten Compounds/chemistry', 'Lanthanoid Series Elements/chemistry', 'Niacin/chemistry/analysis', 'Catalase/chemistry/metabolism', 'Molecular Structure', 'Oxidation-Reduction', 'Organoselenium Compounds/chemistry', 'Colorimetry/methods']",https://pubmed.ncbi.nlm.nih.gov/39423351/
1684,Midodrine,26630543,Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis.,"['Guo TT', 'Yang Y', 'Song Y', 'Ren Y', 'Liu ZX', 'Cheng G']","['Bias', 'Data Interpretation, Statistical', 'Humans', 'Liver Cirrhosis/*drug therapy', 'Midodrine/*therapeutic use', 'Sensitivity and Specificity', 'Vasoconstrictor Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26630543/
1685,Midodrine,38973543,"Impacts of rifaximin and midodrine on morbidity, mortality, and quality of life in patients with decompensated liver cirrhosis.","['Elsabaawy MM', 'Assem M', 'Badran H', 'Mahmoud A', 'Elsabaawy D', 'Ragab A']","['Humans', '*Rifaximin/therapeutic use', '*Quality of Life', 'Female', '*Midodrine/therapeutic use/adverse effects', 'Male', '*Liver Cirrhosis/complications/mortality/drug therapy', 'Middle Aged', '*Rifamycins/therapeutic use/adverse effects', 'Treatment Outcome', 'Drug Therapy, Combination', 'Adult', 'Ascites/etiology/drug therapy/mortality', 'Hepatic Encephalopathy/drug therapy/etiology', 'Aged', 'Surveys and Questionnaires', 'Peritonitis/mortality', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/38973543/
1686,Midodrine,38374552,Midodrine reduces new-onset acute kidney injury and hyponatremia in children with cirrhosis and ascites awaiting liver transplantation: Results from an open-label RCT.,"['Ashritha A', 'Lal BB', 'Khanna R', 'Sood V', 'Sood AK', 'Alam S']","['Adult', 'Humans', 'Child', 'Adolescent', '*Midodrine/therapeutic use', '*Liver Transplantation/adverse effects', 'Ascites/drug therapy/etiology', '*Hyponatremia/complications/drug therapy', 'Treatment Outcome', 'Liver Cirrhosis/complications/surgery', '*Acute Kidney Injury/etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/38374552/
1687,Midodrine,10762185,Midodrine hydrochloride and the treatment of orthostatic hypotension in tetraplegia: two cases and a review of the literature.,"['Barber DB', 'Rogers SJ', 'Fredrickson MD', 'Able AC']","['Adrenergic alpha-Agonists/*therapeutic use', 'Adult', 'Drug Resistance', 'Fludrocortisone/therapeutic use', 'Humans', 'Hypotension, Orthostatic/*drug therapy/*etiology', 'Male', 'Middle Aged', 'Midodrine/*therapeutic use', 'Mineralocorticoids/therapeutic use', 'Quadriplegia/*complications', 'Retreatment']",https://pubmed.ncbi.nlm.nih.gov/10762185/
1688,Midodrine,28794253,Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension.,"['Byun JI', 'Moon J', 'Kim DY', 'Shin H', 'Sunwoo JS', 'Lim JA', 'Kim TJ', 'Lee WJ', 'Lee HS', 'Jun JS', 'Park KI', 'Lee ST', 'Jung KH', 'Jung KY', 'Lee SK', 'Chu K']","['Adrenergic alpha-1 Receptor Agonists/administration & dosage/adverse effects', 'Blood Pressure/drug effects', 'Cholinesterase Inhibitors/administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Hypotension, Orthostatic/*drug therapy', 'Male', 'Middle Aged', 'Midodrine/*administration & dosage/adverse effects', 'Pyridostigmine Bromide/*administration & dosage/adverse effects', 'Self Report', 'Time Factors', 'Treatment Outcome', 'Vasoconstrictor Agents/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28794253/
1689,Midodrine,31030630,Midodrine as an Adjuvant to Intravenous Vasopressor Agents in Adults With Resolving Shock: Systematic Review and Meta-Analysis.,"['Hammond DA', 'Smith MN', 'Peksa GD', 'Trivedi AP', 'Balk RA', 'Menich BE']","['Administration, Intravenous', 'Adult', 'Humans', 'Intensive Care Units', '*Midodrine', '*Shock/drug therapy', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31030630/
1690,Midodrine,28902695,Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol.,"['Patrick K', 'Martin T']","['Antiparkinson Agents/*therapeutic use', 'Blood Pressure/*physiology', 'Droxidopa/*therapeutic use', 'Humans', 'Hypotension, Orthostatic/*drug therapy', 'Midodrine/*therapeutic use', 'Systematic Reviews as Topic', 'Vasoconstrictor Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28902695/
1691,Midodrine,27614145,Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study.,"['Rai N', 'Singh B', 'Singh A', 'Vijayvergiya R', 'Sharma N', 'Bhalla A', 'Singh V']","['Adult', 'Ascites/*drug therapy/etiology', 'Benzazepines/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'India', 'Liver Cirrhosis/complications/*drug therapy', 'Male', 'Middle Aged', 'Midodrine/*therapeutic use', 'Pilot Projects', 'Sodium/urine', 'Tertiary Care Centers', 'Time Factors', 'Tolvaptan', 'Vasoconstrictor Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27614145/
1692,Midodrine,15280522,Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review.,"['Prakash S', 'Garg AX', 'Heidenheim AP', 'House AA']","['Adrenergic alpha-Agonists/adverse effects/*therapeutic use', 'Humans', 'Hypotension/*drug therapy/*etiology', 'Midodrine/adverse effects/*therapeutic use', 'Renal Dialysis/*adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15280522/
1693,Midodrine,25644760,Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.,"['Cavallin M', 'Kamath PS', 'Merli M', 'Fasolato S', 'Toniutto P', 'Salerno F', 'Bernardi M', 'Romanelli RG', 'Colletta C', 'Salinas F', 'Di Giacomo A', 'Ridola L', 'Fornasiere E', 'Caraceni P', 'Morando F', 'Piano S', 'Gatta A', 'Angeli P']","['Aged', 'Albumins/*administration & dosage', 'Analysis of Variance', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Hepatorenal Syndrome/diagnosis/*drug therapy/*mortality', 'Humans', 'Infusions, Intravenous', 'Kaplan-Meier Estimate', 'Kidney Function Tests', 'Liver Function Tests', 'Lypressin/administration & dosage/*analogs & derivatives', 'Male', 'Middle Aged', 'Midodrine/*administration & dosage', 'Octreotide/*administration & dosage', 'Predictive Value of Tests', 'Survival Analysis', 'Terlipressin', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25644760/
1694,Midodrine,34034268,Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites.,"['Sharma P', 'Puri P', 'Bansal N', 'Singla V', 'Kumar A', 'ShriHari AA', 'Arora A']","['*Acute Kidney Injury/diagnosis/etiology/prevention & control', 'Albumins/adverse effects', 'Ascites/drug therapy', '*Hepatorenal Syndrome/drug therapy', 'Humans', 'Liver Cirrhosis/complications/diagnosis/drug therapy', '*Midodrine/adverse effects', 'Pilot Projects', 'Vasoconstrictor Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34034268/
1695,Midodrine,27417951,Severe Hypertension and Bradycardia Secondary to Midodrine Overdose.,"['Wong LY', 'Wong A', 'Robertson T', 'Burns K', 'Roberts M', 'Isbister GK']","['Adrenergic alpha-1 Receptor Antagonists/*poisoning', 'Blood Pressure/drug effects', 'Bradycardia/*chemically induced/therapy', 'Drug Overdose/physiopathology/*therapy', 'Female', 'Glasgow Coma Scale', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*chemically induced/therapy', 'Midodrine/analogs & derivatives/blood/*poisoning', 'Nitroglycerin/therapeutic use', 'Vasodilator Agents/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27417951/
1696,Midodrine,37001276,Studying the kinetic of midodrine degradations using TLC stability approach: Application to dosage form and human plasma.,"['Nagi DM', 'Abdelgaleel M', 'Derayea SM', 'Khashaba PY']","['Humans', '*Midodrine', 'Tablets/chemistry', 'Methanol', 'Kinetics', 'Drug Stability', 'Chromatography, Thin Layer/methods']",https://pubmed.ncbi.nlm.nih.gov/37001276/
1697,Midodrine,33689731,Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.,"['Aminorroaya A', 'Tavolinejad H', 'Sadeghian S', 'Jalali A', 'Alaeddini F', 'Emkanjoo Z', 'Mollazadeh R', 'Bozorgi A', 'Oraii S', 'Kiarsi M', 'Shahabi J', 'Akbarzadeh MA', 'Rahimi B', 'Joharimoghadam A', 'Mohsenizade A', 'Mohammadi R', 'Oraii A', 'Ariannejad H', 'Apakuppakul S', 'Ngarmukos T', 'Tajdini M']","['Adrenergic alpha-1 Receptor Agonists/therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Drug Therapy, Combination', 'Fludrocortisone/*therapeutic use', 'Humans', 'Midodrine/*therapeutic use', 'Quality of Life', 'Recurrence', 'Surveys and Questionnaires', 'Syncope, Vasovagal/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33689731/
1698,Midodrine,27622998,"Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival.","['Hanafy AS', 'Hassaneen AM']","['Aldosterone/metabolism', 'Anti-Infective Agents/*therapeutic use', 'Ascites/*drug therapy/etiology/metabolism/physiopathology', 'Blood Pressure', 'Body Weight', 'Diuretics/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Glomerular Filtration Rate', 'Humans', 'Kidney/metabolism/physiopathology', 'Liver Cirrhosis/complications', 'Male', 'Middle Aged', 'Midodrine/*therapeutic use', 'Paracentesis/statistics & numerical data', 'Renin/metabolism', 'Rifamycins/*therapeutic use', 'Rifaximin', 'Single-Blind Method', 'Treatment Outcome', 'Vasoconstrictor Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27622998/
1699,Midodrine,32885276,Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial.,"['Santer P', 'Anstey MH', 'Patrocinio MD', 'Wibrow B', 'Teja B', 'Shay D', 'Shaefi S', 'Parsons CS', 'Houle TT', 'Eikermann M']","['Adult', 'Australia', 'Humans', '*Hypotension/drug therapy', 'Intensive Care Units', '*Midodrine', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32885276/
1700,Midodrine,21749847,Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.,"['Singh V', 'Dhungana SP', 'Singh B', 'Vijayverghia R', 'Nain CK', 'Sharma N', 'Bhalla A', 'Gupta PK']","['Adrenergic alpha-1 Receptor Agonists/administration & dosage', 'Adult', 'Ascites/*drug therapy/*etiology', 'Female', 'Hemodynamics/drug effects', 'Humans', 'Kidney/drug effects/physiopathology', 'Liver Cirrhosis/*complications/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Midodrine/*administration & dosage', 'Pilot Projects', 'Prospective Studies', 'Recurrence', 'Splanchnic Circulation/drug effects', 'Treatment Outcome', 'Vasoconstrictor Agents/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/21749847/
1701,Midodrine,22801062,The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis.,"['Bari K', 'Minano C', 'Shea M', 'Inayat IB', 'Hashem HJ', 'Gilles H', 'Heuman D', 'Garcia-Tsao G']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Ascites/*prevention & control/*therapy', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', 'Midodrine/*administration & dosage', 'Octreotide/*administration & dosage', 'Paracentesis', 'Placebos/administration & dosage', 'Prospective Studies', 'Secondary Prevention', 'Serum Albumin/*administration & dosage', 'Serum Albumin, Human', 'Treatment Outcome', 'Vasoconstrictor Agents/*administration & dosage', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/22801062/
1702,Ketorolac,37097781,What is the analgesic ceiling dose of ketorolac for treating acute pain in the ED?,"['Jaglal R', 'Nemec EC 2nd']","['Humans', '*Ketorolac/therapeutic use', '*Acute Pain/drug therapy', 'Analgesics/adverse effects', 'Pain Management', 'Pain, Postoperative/drug therapy', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37097781/
1703,Ketorolac,35738193,Dexamethasone and ketorolac compare with ketorolac alone in acute renal colic: A randomized clinical trial.,"['Razi A', 'Farrokhi E', 'Lotfabadi P', 'Hosseini SS', 'Saadati H', 'Haghighi R', 'Rameshrad M']","['Analgesics, Opioid/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', '*Antiemetics/therapeutic use', 'Dexamethasone/therapeutic use', 'Double-Blind Method', 'Humans', 'Ketorolac/therapeutic use', 'Pain/drug therapy', '*Renal Colic/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35738193/
1704,Ketorolac,38273276,Synergistic use of anti-inflammatory ketorolac and gentamicin to target staphylococcal biofilms.,"['Sekar A', 'Gil D', 'Tierney P', 'McCanne M', 'Daesety V', 'Trendafilova D', 'Muratoglu OK', 'Oral E']","['Humans', '*Gentamicins/pharmacology/therapeutic use', 'Ketorolac/pharmacology/therapeutic use', 'Anti-Bacterial Agents/pharmacology/therapeutic use', 'Staphylococcus aureus', 'Biofilms', '*Staphylococcal Infections/drug therapy/microbiology/prevention & control', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/38273276/
1705,Ketorolac,34383010,Prednisolone and Ketorolac vs Ketorolac Monotherapy or Sub-Tenon Prophylaxis for Macular Thickening in Cataract Surgery: A Randomized Clinical Trial.,"['Erichsen JH', 'Holm LM', 'Forslund Jacobsen M', 'Forman JL', 'Kessel L']","['Aged', 'Anti-Inflammatory Agents/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', '*Cataract/etiology', '*Cataract Extraction/adverse effects', 'Female', 'Humans', 'Ketorolac/therapeutic use', '*Macular Edema/drug therapy', 'Male', 'Ophthalmic Solutions', '*Phacoemulsification/adverse effects', 'Postoperative Complications/prevention & control', 'Prednisolone/therapeutic use', 'Vision Disorders/etiology']",https://pubmed.ncbi.nlm.nih.gov/34383010/
1706,Ketorolac,34952188,"An Injectable Containing Morphine, Ropivacaine, Epinephrine, and Ketorolac Is Not Cytotoxic to Articular Cartilage Explants From Degenerative Knees.","['Baumann JR', 'Stoker AM', 'Bozynski CC', 'Sherman SL', 'Cook JL']","['Anesthetics, Local', '*Cartilage, Articular', 'Dinoprostone/therapeutic use', 'Epinephrine/pharmacology', 'Humans', 'Injections, Intra-Articular', '*Ketorolac/pharmacology', 'Matrix Metalloproteinase 7/therapeutic use', 'Matrix Metalloproteinase 8/therapeutic use', 'Morphine', 'Pain, Postoperative/drug therapy', 'Ropivacaine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34952188/
1707,Ketorolac,28602319,Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery.,"['Donnenfeld ED', 'Whitaker JS', 'Jackson MA', 'Wittpenn J']","['*Cataract Extraction/adverse effects', '*Eye Pain/drug therapy', 'Humans', '*Ketorolac/therapeutic use', 'Mydriasis', '*Mydriatics/therapeutic use', 'Pain, Postoperative/drug therapy', '*Phenylephrine/therapeutic use', 'Pupil/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28602319/
1708,Ketorolac,37399631,A multimodal intraosseous infusion of morphine and ketorolac decreases early postoperative pain and opioid consumption following total knee arthroplasty.,"['McNamara CA', 'Laurita J', 'Lambert BS', 'Sullivan TC', 'Clyburn TA', 'Incavo SJ', 'Park KJ']","['Humans', '*Analgesics, Opioid/therapeutic use', 'Morphine/therapeutic use', 'Ketorolac/therapeutic use', '*Arthroplasty, Replacement, Knee/adverse effects/methods', 'Prospective Studies', 'Infusions, Intraosseous', 'Pain, Postoperative/drug therapy/etiology/prevention & control', 'Nausea/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37399631/
1709,Ketorolac,38467207,Resorbable nanofibrous membranes for local and sustained co-delivery of acyclovir and ketorolac in herpes therapy.,"['Shen SJ', 'Feng PC', 'Wu RC', 'Kuo YH', 'Liu SJ', 'Ito H']","['Humans', '*Ketorolac', '*Nanofibers/chemistry', 'Acyclovir', 'Blister', 'Pain']",https://pubmed.ncbi.nlm.nih.gov/38467207/
1710,desvenlafaxine,37450377,Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper.,"['Sampogna G', 'Caraci F', 'Carmassi C', ""Dell'Osso B"", 'Ferrari S', 'Martinotti G', 'Sani G', 'Serafini G', 'Signorelli MS', 'Fiorillo A']","['Adult', 'Humans', 'Aged', '*Depressive Disorder, Major/drug therapy', 'Desvenlafaxine Succinate/adverse effects', 'Depression', 'Cyclohexanols/therapeutic use', 'Antidepressive Agents/adverse effects', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/37450377/
1711,desvenlafaxine,37227402,Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study.,"['McIntyre RS', 'Florea I', 'Pedersen MM', 'Christensen MC']","['Adult', 'Humans', 'Vortioxetine/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/adverse effects', '*Depressive Disorder, Major/drug therapy/diagnosis', 'Desvenlafaxine Succinate/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/adverse effects', 'Quality of Life', 'Double-Blind Method', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37227402/
1712,desvenlafaxine,27622824,"Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects.","['Cooper JM', 'Brown JA', 'Cairns R', 'Isbister GK']","['Adolescent', 'Adult', 'Aged', 'Antidepressive Agents/*poisoning', 'Desvenlafaxine Succinate/*poisoning', 'Drug Overdose', 'Female', 'Glasgow Coma Scale', 'Humans', 'Hypertension/*chemically induced/epidemiology', 'Male', 'Middle Aged', 'Retrospective Studies', 'Seizures/*chemically induced/epidemiology', 'Tachycardia/*chemically induced/epidemiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27622824/
1713,desvenlafaxine,25183927,Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies.,"['Berhan Y', 'Berhan A']","['Chemotherapy, Adjuvant', 'Cyclohexanols/adverse effects/*therapeutic use', 'Desvenlafaxine Succinate', 'Double-Blind Method', 'Female', 'Hot Flashes/*drug therapy', 'Humans', 'Menopause/*drug effects', 'Neurotransmitter Uptake Inhibitors/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Regression Analysis']",https://pubmed.ncbi.nlm.nih.gov/25183927/
1714,desvenlafaxine,34741760,Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study.,"['Cardoner N', 'Sicras-Mainar A', 'Rejas J', 'Armada B']","['Antidepressive Agents/therapeutic use', '*Depressive Disorder, Major/drug therapy', 'Desvenlafaxine Succinate/therapeutic use', 'Humans', 'Retrospective Studies', 'Selective Serotonin Reuptake Inhibitors/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34741760/
1715,desvenlafaxine,37243511,The Pharmacokinetics and Bioequivalence of Desvenlafaxine Succinate in Chinese Healthy Subjects Under Fasting and Fed States.,"['Wang M', 'Yang Y', 'Hu W', 'Wang Y', 'Chen Y', 'Zhang X']","['Humans', 'Area Under Curve', 'Cross-Over Studies', '*Depressive Disorder, Major', 'Desvenlafaxine Succinate', 'East Asian People', 'Fasting', 'Healthy Volunteers', 'Selective Serotonin Reuptake Inhibitors', 'Therapeutic Equivalency', 'Feeding Behavior']",https://pubmed.ncbi.nlm.nih.gov/37243511/
1716,desvenlafaxine,24611442,Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder.,"['Findling RL', 'Groark J', 'Chiles D', 'Ramaker S', 'Yang L', 'Tourian KA']","['Adolescent', 'Antidepressive Agents/administration & dosage/*adverse effects/therapeutic use', 'Child', 'Cyclohexanols/administration & dosage/*adverse effects/therapeutic use', 'Depressive Disorder, Major/*drug therapy', 'Desvenlafaxine Succinate', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Male', 'Severity of Illness Index', '*Suicidal Ideation', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/24611442/
1717,desvenlafaxine,30419989,"Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials.","['Atkinson S', 'Thurman L', 'Ramaker S', 'Buckley G', 'Jones SR', 'England R', 'Wajsbrot D']","['Adolescent', 'Antidepressive Agents/administration & dosage/*adverse effects/therapeutic use', 'Child', 'Depressive Disorder, Major/*drug therapy', 'Desvenlafaxine Succinate/administration & dosage/*adverse effects/therapeutic use', 'Drug Tolerance', 'Female', 'Humans', 'Long Term Adverse Effects/*epidemiology', 'Male', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30419989/
1718,desvenlafaxine,23334675,"Efficacy and safety of desvenlafaxine 25 and 5050% shaded blockmg/day in a randomized, placebo-controlled study of depressed outpatients.","['Iwata N', 'Tourian KA', 'Hwang E', 'Mele L', 'Vialet C']","['Adolescent', 'Adult', 'Aged', 'Antidepressive Agents/adverse effects/*therapeutic use', 'Cyclohexanols/adverse effects/*therapeutic use', 'Depressive Disorder, Major/*drug therapy', 'Desvenlafaxine Succinate', 'Double-Blind Method', 'Electrocardiography/drug effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/23334675/
1719,desvenlafaxine,27779571,Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study.,"['Bousman CA', 'Muller DJ', 'Ng CH', 'Byron K', 'Berk M', 'Singh AB']","['ATP Binding Cassette Transporter, Subfamily B/genetics/metabolism', 'Adult', 'Antidepressive Agents/*administration & dosage/pharmacokinetics', 'Depressive Disorder, Major/*drug therapy/genetics', 'Desvenlafaxine Succinate/*administration & dosage/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Glucuronosyltransferase/genetics/metabolism', 'Humans', 'Male', 'Middle Aged', 'Multidrug Resistance-Associated Proteins/genetics/metabolism', 'Pharmacogenomic Variants', 'Prospective Studies', 'Psychiatric Status Rating Scales', 'Treatment Outcome', 'White People/genetics']",https://pubmed.ncbi.nlm.nih.gov/27779571/
1720,desvenlafaxine,28718346,Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.,"['Lam RW', 'Wajsbrot DB', 'Meier E', 'Pappadopulos E', 'Mackell JA', 'Boucher M']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antidepressive Agents/*therapeutic use', 'Depressive Disorder, Major/*drug therapy', 'Desvenlafaxine Succinate/*therapeutic use', 'Double-Blind Method', 'Fatigue/*drug therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28718346/
1721,desvenlafaxine,27428303,Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.,"['Findling RL', 'Groark J', 'Tourian KA', 'Ramaker SA', 'Chiles D', 'Yang L', 'Nichols AI']","['Adolescent', 'Antidepressive Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Area Under Curve', 'Body Weight', 'Child', 'Depressive Disorder, Major/*drug therapy', 'Desvenlafaxine Succinate/*administration & dosage/adverse effects/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Electrocardiography', 'Female', 'Humans', 'Male', 'Psychiatric Status Rating Scales', 'Severity of Illness Index', 'Suicide/*psychology']",https://pubmed.ncbi.nlm.nih.gov/27428303/
1722,desvenlafaxine,26091569,"In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.","['Franek F', 'Jarlfors A', 'Larsen F', 'Holm P', 'Steffansen B']","['Cell Line, Tumor', 'Delayed-Action Preparations', 'Desvenlafaxine Succinate/administration & dosage/*pharmacokinetics', 'Humans', 'In Vitro Techniques', '*Intestinal Absorption', '*Models, Biological', 'Permeability', 'Serotonin and Noradrenaline Reuptake Inhibitors/administration & dosage/*pharmacokinetics', 'Solubility']",https://pubmed.ncbi.nlm.nih.gov/26091569/
1723,desvenlafaxine,22646219,Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms.,"['Cheng RJ', 'Dupont C', 'Archer DF', 'Bao W', 'Racketa J', 'Constantine G', 'Pickar JH']","['Adult', 'Affective Symptoms/*drug therapy', 'Aged', 'Anger/drug effects', 'Anxiety/drug therapy', 'Back Pain/drug therapy', 'Confusion/drug therapy', 'Cyclohexanols/pharmacology/*therapeutic use', 'Depression/drug therapy', 'Desvenlafaxine Succinate', 'Double-Blind Method', 'Fatigue/drug therapy', 'Female', 'Hot Flashes/drug therapy', 'Humans', 'Hyperhidrosis/drug therapy', 'Irritable Mood/drug effects', 'Menopause/*drug effects', 'Middle Aged', 'Neurotransmitter Uptake Inhibitors/pharmacology/*therapeutic use', '*Patient Satisfaction', 'Sexual Behavior/drug effects', 'Surveys and Questionnaires']",https://pubmed.ncbi.nlm.nih.gov/22646219/
1724,desvenlafaxine,25097285,"Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial.","['Maity N', 'Ghosal MK', 'Gupta A', 'Sil A', 'Chakraborty S', 'Chatterjee S']","['Adult', 'Antidepressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Anxiety/*drug therapy/psychology', 'Citalopram/administration & dosage/adverse effects/*therapeutic use', 'Cyclohexanols/administration & dosage/adverse effects/*therapeutic use', 'Depressive Disorder, Major/*drug therapy/psychology', 'Desvenlafaxine Succinate', 'Humans', 'Test Anxiety Scale']",https://pubmed.ncbi.nlm.nih.gov/25097285/
1725,desvenlafaxine,38019131,Sertraline with desvenlafaxine and sertraline with mirtazapine as treatment initiation in MDD patients with moderate to severe depression and effect on inflammatory markers.,"['Arockiaraj N', 'Gupta R', 'Ahmad R', 'Halder S', 'Bhatia MS']","['Humans', '*Sertraline/administration & dosage/pharmacology', '*Mirtazapine/pharmacology/administration & dosage', 'Adult', '*Desvenlafaxine Succinate/administration & dosage/pharmacology/blood', 'Male', 'Female', '*Depressive Disorder, Major/drug therapy/blood', 'Middle Aged', 'Young Adult', '*Antidepressive Agents/pharmacology/administration & dosage', '*Tumor Necrosis Factor-alpha/blood', '*Interleukin-6/blood', '*Drug Therapy, Combination', 'Adolescent', 'Outcome Assessment, Health Care', 'Biomarkers/blood']",https://pubmed.ncbi.nlm.nih.gov/38019131/
1726,desvenlafaxine,31978524,The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.,"['Sun Y', 'Drevets W', 'Turecki G', 'Li QS']","['*Citalopram/therapeutic use', '*Depressive Disorder, Major/drug therapy', 'Desvenlafaxine Succinate', 'Humans', 'Kynurenic Acid', 'Kynurenine', 'Plasma', 'Serotonin']",https://pubmed.ncbi.nlm.nih.gov/31978524/
1727,desvenlafaxine,21812735,Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders.,"['Guico-Pabia CJ', 'Jiang Q', 'Ninan PT', 'Thase ME']","['Adolescent', 'Adult', 'Aged', 'Algorithms', 'Cyclohexanols/*administration & dosage/adverse effects', 'Delayed-Action Preparations/administration & dosage/adverse effects', 'Depressive Disorder, Major/*drug therapy', 'Desvenlafaxine Succinate', 'Double-Blind Method', 'Drug Resistance/drug effects', '*Drug Substitution', 'Female', 'Humans', 'Male', 'Middle Aged', 'Placebos', 'Treatment Outcome', 'Venlafaxine Hydrochloride', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21812735/
1728,Pirbuterol,22216500,"Effects of oral salbutamol and pirbuterol on FEV1, heart rate and blood pressure in asthmatics.","['Willey RF', 'Grant IW', 'Pocock SJ']","['Administration, Oral', 'Aged', 'Albuterol/adverse effects/pharmacology/*therapeutic use', 'Asthma/*drug therapy/physiopathology', 'Blood Pressure/*drug effects', 'Bronchodilator Agents/*therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Ethanolamines/adverse effects/pharmacology/*therapeutic use', 'Female', 'Forced Expiratory Volume/*drug effects', 'Heart Rate/*drug effects', 'Humans', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/22216500/
1729,Pirbuterol,6113543,Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.,"['Colucci WS', 'Alexander RW', 'Williams GH', 'Rude RE', 'Holman BL', 'Konstam MA', 'Wynne J', 'Mudge GH Jr', 'Braunwald E']","['Adrenergic beta-Agonists/*pharmacology', 'Adult', 'Aged', 'Blood Pressure/drug effects', 'Chronic Disease', 'Drug Tolerance', 'Ethanolamines/*pharmacology', 'Female', 'Heart Failure/*blood/physiopathology', 'Heart Rate/drug effects', 'Humans', 'Lymphocytes/*analysis', 'Male', 'Middle Aged', 'Norepinephrine/blood', 'Receptors, Adrenergic/*analysis', 'Receptors, Adrenergic, beta/*analysis', 'Renin/blood', 'Stroke Volume/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6113543/
1730,Pirbuterol,6142748,Effects of oral and inhaled salbutamol and oral pirbuterol on right and left ventricular function in chronic bronchitis.,"['Winter RJ', 'Langford JA', 'Rudd RM']","['Administration, Intranasal', 'Administration, Oral', 'Adrenergic beta-Agonists/*pharmacology', 'Albuterol/administration & dosage/*pharmacology', 'Bronchitis/*physiopathology', 'Cardiac Output/*drug effects', 'Chronic Disease', 'Ethanolamines/administration & dosage/*pharmacology', 'Humans', 'Stroke Volume/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/6142748/
1731,Pirbuterol,387417,Comparison of pirbuterol and pirbuterol and hydroxyzine in patients with reversible airway obstruction.,"['Poppius H', 'Lehti H', 'Stenius-Aarniala B']","['Adult', 'Aged', 'Airway Obstruction/*drug therapy/physiopathology', 'Bronchodilator Agents/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Drug Combinations', 'Ethanolamines/adverse effects/*therapeutic use', 'Female', 'Humans', 'Hydroxyzine/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Pyridines/adverse effects/therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/387417/
1732,Pirbuterol,1680327,Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler.,"['Volkl KP', 'Kroll VM', 'Wiesemann HG', 'Schneider B']","['Administration, Inhalation', 'Adrenergic beta-Agonists/administration & dosage/*therapeutic use', 'Albuterol/administration & dosage/adverse effects/*therapeutic use', 'Asthma/*drug therapy/physiopathology', 'Child', 'Ethanolamines/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Humans', 'Male', 'Nebulizers and Vaporizers', 'Respiratory Function Tests']",https://pubmed.ncbi.nlm.nih.gov/1680327/
1733,Pirbuterol,4086446,Fluorometric and spectrophotometric determination of pirbuterol hydrochloride in authentic and dosage forms.,"['Mohamed ME', 'Aboul-Enein HY']","['Capsules', 'Drug Stability', 'Ethanolamines/*analysis', 'Potentiometry', 'Spectrometry, Fluorescence', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/4086446/
1734,Pirbuterol,3085906,The acute hemodynamic response to pirbuterol at rest and exercise in patients with heart failure with observations on long-term response.,"['Uretsky BF', 'Seecof RM', 'Reddy PS']","['Cardiotonic Agents/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Administration Schedule', 'Ethanolamines/*therapeutic use', '*Exercise Test', 'Female', 'Follow-Up Studies', 'Heart Failure/*drug therapy', 'Hemodynamics/*drug effects', 'Humans', 'Long-Term Care', 'Male', 'Middle Aged', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3085906/
1735,Pirbuterol,2484663,"Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy.","['Chodosh S', 'Crooks LA', 'Tuck J']","['Adult', 'Aerosols', 'Aged', 'Asthma/drug therapy/physiopathology', 'Bronchitis/drug therapy/physiopathology', 'Bronchodilator Agents/therapeutic use', 'Cardiac Complexes, Premature/*chemically induced', 'Electrocardiography', 'Electrocardiography, Ambulatory', 'Emphysema/drug therapy/physiopathology', 'Ethanolamines/adverse effects/*therapeutic use', 'Female', 'Heart Rate/drug effects', 'Humans', 'Lung/*drug effects/physiopathology', 'Male', 'Metaproterenol/*therapeutic use', 'Middle Aged', 'Placebos', 'Pulse/drug effects', 'Respiratory Function Tests']",https://pubmed.ncbi.nlm.nih.gov/2484663/
1736,Pirbuterol,555600,Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol.,"['Ence TJ', 'Tashkin DP', 'Ho D', 'Child JS']","['Acute Disease', 'Adult', 'Aged', 'Airway Obstruction/*drug therapy', 'Asthma/*drug therapy', '*Bronchodilator Agents', 'Cardiovascular System/drug effects', 'Ethanolamines/adverse effects/*therapeutic use', 'Female', 'Forced Expiratory Volume', 'Heart Rate/drug effects', 'Humans', 'Male', 'Metaproterenol/adverse effects/therapeutic use', 'Middle Aged', 'Respiratory Function Tests']",https://pubmed.ncbi.nlm.nih.gov/555600/
1737,Pirbuterol,6359846,Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial.,"['Pamelia FX', 'Gheorghiade M', 'Beller GA', 'Bishop HL', 'Olukotun AY', 'Taylor CR', 'Watson DD', 'Grunwald AM', 'Sirowatka J', 'Carabello BA']","['Administration, Oral', 'Adult', 'Aged', 'Bronchodilator Agents/*administration & dosage', 'Chronic Disease', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Evaluation', 'Ethanolamines/*administration & dosage', 'Heart Failure/*drug therapy', 'Humans', 'Middle Aged', 'Placebos', 'Random Allocation', 'Stroke Volume']",https://pubmed.ncbi.nlm.nih.gov/6359846/
1738,Pirbuterol,8108632,Maximum bronchodilator effect of pirbuterol and procaterol administered as sprays with and without an aerochamber.,"['Sole D', 'Villalba SR', 'Sestelo MR', 'Scalabrin DM', 'Soares FJ', 'Naspitz CK']","['Administration, Inhalation', 'Adolescent', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/pharmacology', 'Child', 'Ethanolamines/*administration & dosage/pharmacology', 'Humans', 'Procaterol/*administration & dosage/pharmacology', 'Prospective Studies', 'Spirometry', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8108632/
1739,Pirbuterol,2563321,The effect of six months of daily treatment with the beta-2 agonist oral pirbuterol on pulmonary hemodynamics in patients with chronic hypoxic cor pulmonale receiving long-term oxygen therapy.,"['Biernacki W', 'Prince K', 'Whyte K', 'MacNee W', 'Flenley DC']","['Adrenergic beta-Agonists/*administration & dosage', 'Aged', 'Bronchodilator Agents/*administration & dosage', 'Chronic Disease', 'Combined Modality Therapy', 'Double-Blind Method', 'Drug Evaluation', 'Ethanolamines/*administration & dosage', 'Female', 'Hemodynamics/drug effects', 'Humans', 'Hypoxia/*drug therapy/physiopathology', 'Male', 'Middle Aged', '*Oxygen Inhalation Therapy', 'Pulmonary Circulation/*drug effects', 'Pulmonary Heart Disease/*drug therapy/physiopathology', 'Random Allocation', 'Stroke Volume/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2563321/
1740,Pirbuterol,1972557,A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.,"['Windom H', 'Grainger J', 'Burgess C', 'Crane J', 'Pearce N', 'Beasley R']","['Administration, Inhalation', 'Adrenergic beta-Agonists/*pharmacology', 'Adult', 'Albuterol/*pharmacology', 'Bronchodilator Agents/*pharmacology', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Ethanolamines/*pharmacology', 'Female', 'Hemodynamics/*drug effects', 'Humans', 'Hypokalemia/*chemically induced', 'Male', 'Reference Values']",https://pubmed.ncbi.nlm.nih.gov/1972557/
1741,Pirbuterol,3828194,Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure.,"['Canepa-Anson R', 'Dawson JR', 'Kuan P', 'Poole-Wilson PA', 'Sutton GC', 'Cockrill B', 'Reuben SR']","['Adult', 'Aged', 'Blood Glucose/metabolism', 'Ethanolamines/adverse effects/blood/*therapeutic use', 'Fasting', 'Fatty Acids, Nonesterified/blood', 'Female', 'Heart Failure/*drug therapy', 'Hemodynamics/drug effects', 'Humans', 'Hydrocortisone/blood', 'Lactates/blood', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/3828194/
1742,Pirbuterol,6128086,"Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure.","['Weber KT', 'Andrews V', 'Janicki JS', 'Likoff M', 'Reichek N']","['Adrenergic beta-Agonists/*therapeutic use', 'Adult', 'Aged', 'Arrhythmias, Cardiac/chemically induced', 'Chronic Disease', 'Dose-Response Relationship, Drug', 'Echocardiography', 'Ethanolamines/adverse effects/blood/*therapeutic use', 'Exercise Test', 'Female', 'Heart Failure/diagnosis/*drug therapy/physiopathology', 'Hemodynamics/drug effects', 'Humans', 'Male', 'Middle Aged', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/6128086/
1743,Pirbuterol,8244913,"Ease-of-use study of pirbuterol acetate in the Autohaler actuator in three countries: the United States, Germany, and France.","['Bronsky EA', 'Debelic M', 'Pujet JC', 'Hahn M']","['Adult', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/therapeutic use', 'Ethanolamines/*administration & dosage/therapeutic use', 'Evaluation Studies as Topic', 'Female', 'France', 'Germany', 'Humans', 'Male', 'Middle Aged', '*Nebulizers and Vaporizers', 'Patient Satisfaction', 'United States']",https://pubmed.ncbi.nlm.nih.gov/8244913/
1744,Labetalol,26344738,A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy.,"['Clark SM', 'Dunn HE', 'Hankins GD']","['Administration, Oral', 'Adult', 'Antihypertensive Agents/*administration & dosage/pharmacokinetics', 'Blood Pressure', 'Female', 'Humans', 'Hypertension, Pregnancy-Induced/*drug therapy', 'Labetalol/*administration & dosage/pharmacokinetics', 'Nifedipine/*administration & dosage/pharmacokinetics', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy', 'Treatment Outcome', 'Vasodilator Agents/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26344738/
1745,Labetalol,38973651,Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms.,"['Liu XI', 'Green DJ', 'van den Anker J', 'Calderon J', 'Ahmadzia H', 'Burckart GJ', 'Dallmann A']","['Humans', 'Male', 'Female', '*Polymorphism, Genetic', '*Cytochrome P-450 CYP2C19/genetics', '*Labetalol/administration & dosage/pharmacology', 'Alleles', 'Pregnancy', 'Blood Pressure/drug effects', 'Genotype', 'Clinical Studies as Topic']",https://pubmed.ncbi.nlm.nih.gov/38973651/
1746,Labetalol,33400322,Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review.,"['Cawoski JR', 'DeBiasio KA', 'Donnachie SW', 'Timanus EA', 'Zimmerman DE', 'Guarascio AJ', 'Montepara CA', 'Covvey JR', 'Nemecek BD']","['Administration, Intravenous', 'Antihypertensive Agents/adverse effects', 'Humans', 'Hydralazine/adverse effects', '*Hypertension/drug therapy', '*Labetalol/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33400322/
1747,Labetalol,791332,Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine.,"['Johnson BF', 'LaBrooy J', 'Munro-Faure AD']","['Adult', 'Aged', '*Antihypertensive Agents', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Evaluation', 'Drug Synergism', 'Drug Therapy, Combination', 'Ethanolamines/*therapeutic use', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/physiopathology', 'Labetalol/pharmacology/*therapeutic use', 'Male', 'Middle Aged', 'Oxprenolol/adverse effects/pharmacology/*therapeutic use', 'Phentolamine/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/791332/
1748,Labetalol,37273965,"Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial.","['S D', 'Novri DA', 'Hamidy Y', 'Savira M']","['Female', 'Humans', 'Pregnancy', '*Labetalol/therapeutic use', 'Nifedipine/therapeutic use', '*Pre-Eclampsia/drug therapy/chemically induced', 'Antihypertensive Agents/therapeutic use', 'Hydralazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37273965/
1749,Labetalol,3624360,Combined use of an automated sample processor and a polymer-based high-performance liquid chromatographic column to determine the pharmacokinetics of labetalol in man.,"['Bates J', 'Carey PF', 'Godward RE']","['Autoanalysis', 'Chromatography, High Pressure Liquid', 'Humans', 'Hydrogen-Ion Concentration', 'Kinetics', 'Labetalol/*analysis/blood']",https://pubmed.ncbi.nlm.nih.gov/3624360/
1750,Labetalol,8124849,Labetalol and other agents that block both alpha- and beta-adrenergic receptors.,"['Pearce CJ', 'Wallin JD']","['Humans', '*Labetalol/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8124849/
1751,Labetalol,10951,Combined alpha- and beta-adrenoreceptors blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise.,['Koch G'],"['Administration, Oral', '*Adrenergic alpha-Antagonists', '*Adrenergic beta-Antagonists', 'Adult', 'Blood Pressure/drug effects', 'Female', 'Follow-Up Studies', 'Hemodynamics/*drug effects', 'Humans', 'Hypertension/drug therapy/*physiopathology', 'Labetalol/administration & dosage/pharmacology/therapeutic use', 'Male', 'Middle Aged', '*Physical Exertion', 'Pulse/drug effects', 'Renin/blood']",https://pubmed.ncbi.nlm.nih.gov/10951/
1752,Labetalol,35744047,In Vitro Toxicological Profile of Labetalol-Folic Acid/Folate Co-Administration in H9c2(2-1) and HepaRG Cells.,"['Rednic R', 'Marcovici I', 'Dragoi R', 'Pinzaru I', 'Dehelean CA', 'Tomescu M', 'Arnautu DA', 'Craina M', 'Gluhovschi A', 'Valcovici M', 'Manea A']","['Dietary Supplements', 'Female', 'Folic Acid/pharmacology', 'Humans', '*Hypertension', '*Labetalol/pharmacology', '*Neural Tube Defects', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/35744047/
1753,Labetalol,7093094,Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.,"['Opie LH', 'White D', 'Lee J', 'Lubbe WF']","['Angina Pectoris/complications/*drug therapy', 'Blood Pressure', 'Drug Therapy, Combination', 'Ethanolamines/*therapeutic use', 'Exercise Test', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/complications/*drug therapy', 'Labetalol/adverse effects/*therapeutic use', 'Nifedipine/*therapeutic use', 'Pyridines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7093094/
1754,Labetalol,32697618,Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial.,"['Rezk M', 'Emarh M', 'Masood A', 'Dawood R', 'El-Shamy E', 'Gamal A', 'Badr H']","['Adult', 'Antihypertensive Agents/pharmacology/*therapeutic use', 'Blood Pressure/*drug effects', 'Female', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Labetalol/pharmacology/*therapeutic use', 'Methyldopa/pharmacology/*therapeutic use', 'Pregnancy', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32697618/
1755,Labetalol,20495503,Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children.,"['Thomas CA', 'Moffett BS', 'Wagner JL', 'Mott AR', 'Feig DI']","['Analysis of Variance', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Chi-Square Distribution', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Infant', 'Infusions, Intravenous', 'Labetalol/administration & dosage/adverse effects/*therapeutic use', 'Linear Models', 'Male', 'Nicardipine/therapeutic use', 'Nitroprusside/therapeutic use', 'Retrospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20495503/
1756,Labetalol,465259,Labetalol in controlled hypotension: administration of labetalol when adequate hypotension is difficult to achieve.,"['Cope DH', 'Crawford MC']","['Adolescent', 'Adult', 'Aged', 'Child', 'Drug Administration Schedule', '*Ethanolamines/administration & dosage', 'Female', 'Humans', '*Hypotension, Controlled', '*Labetalol/administration & dosage', 'Male', 'Middle Aged', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/465259/
1757,Labetalol,2663413,"Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.","['Goa KL', 'Benfield P', 'Sorkin EM']","['Coronary Disease/*drug therapy', 'Humans', 'Hypertension/*drug therapy', 'Labetalol/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2663413/
1758,Labetalol,3908121,Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.,"['Ohman KP', 'Weiner L', 'von Schenck H', 'Karlberg BE']","['Adult', 'Aged', 'Blood Glucose/metabolism', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/metabolism', 'Labetalol/administration & dosage/adverse effects/*therapeutic use', 'Lipids/blood', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/adverse effects/*therapeutic use', 'Random Allocation', 'Renin/blood', 'Renin-Angiotensin System/drug effects']",https://pubmed.ncbi.nlm.nih.gov/3908121/
1759,Labetalol,2908732,"Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.",['Frishman WH'],"['Adrenergic alpha-Antagonists/*therapeutic use', 'Adrenergic beta-Antagonists/*therapeutic use', 'Coronary Disease/*drug therapy/physiopathology', 'Humans', 'Labetalol/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2908732/
1760,Labetalol,1884570,Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.,"['Donnelly R', 'Macphee GJ']","['Dose-Response Relationship, Drug', 'Humans', 'Labetalol/*pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/1884570/
1761,Labetalol,8119456,Effect of labetalol infusion on uterine and fetal hemodynamics and fetal cardiac function.,"['Jouppila P', 'Rasanen J']","['Blood Pressure/drug effects', 'Female', 'Fetal Heart/*drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Hypertension/etiology/*physiopathology', 'Infusions, Intravenous', 'Labetalol/*administration & dosage', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*physiopathology', 'Uterus/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/8119456/
1762,Balsalazide,18683049,Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.,"['Rahimi R', 'Nikfar S', 'Rezaie A', 'Abdollahi M']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Colitis, Ulcerative/*drug therapy', 'Female', 'Humans', 'Male', 'Mesalamine/adverse effects/*therapeutic use', 'Phenylhydrazines/adverse effects/*therapeutic use', 'Remission Induction']",https://pubmed.ncbi.nlm.nih.gov/18683049/
1763,Balsalazide,18806701,Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.,['Tursi A'],"['Clinical Trials as Topic', 'Colitis, Ulcerative/drug therapy/therapy', '*Diverticulitis, Colonic/drug therapy/therapy', 'Drug Therapy, Combination', 'Gastrointestinal Agents/administration & dosage/therapeutic use', 'Humans', 'Mesalamine/*administration & dosage/therapeutic use', 'Phenylhydrazines/*administration & dosage/therapeutic use', 'Probiotics/administration & dosage/*therapeutic use', 'Prodrugs/administration & dosage/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18806701/
1764,Balsalazide,11600468,"Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.","['Lowry PW', 'Franklin CL', 'Weaver AL', 'Szumlanski CL', 'Mays DC', 'Loftus EV', 'Tremaine WJ', 'Lipsky JJ', 'Weinshilboum RM', 'Sandborn WJ']","['Adult', 'Aminosalicylic Acids/adverse effects', 'Analysis of Variance', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Azathioprine/adverse effects', 'Binomial Distribution', 'Chromatography, High Pressure Liquid', 'Confidence Intervals', 'Drug Interactions', 'Female', 'Humans', 'Immunosuppressive Agents/*adverse effects', 'Leukopenia/*chemically induced/metabolism', 'Male', 'Mercaptopurine/adverse effects', 'Mesalamine/adverse effects', 'Methyltransferases/blood', 'Phenylhydrazines', 'Sulfasalazine/adverse effects', 'Thioguanine/analysis']",https://pubmed.ncbi.nlm.nih.gov/11600468/
1765,Balsalazide,15507864,Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.,"['Tursi A', 'Brandimarte G', 'Giorgetti GM', 'Forti G', 'Modeo ME', 'Gigliobianco A']","['Adult', 'Aged', 'Aminosalicylic Acids/administration & dosage/*therapeutic use', 'Colitis, Ulcerative/*drug therapy', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Mesalamine/therapeutic use', 'Middle Aged', 'Phenylhydrazines', 'Probiotics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15507864/
1766,Balsalazide,11709512,Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.,"['Kruis W', 'Schreiber S', 'Theuer D', 'Brandes JW', 'Schutz E', 'Howaldt S', 'Krakamp B', 'Hamling J', 'Monnikes H', 'Koop I', 'Stolte M', 'Pallant D', 'Ewald U']","['Aminosalicylic Acids/*administration & dosage/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects', 'Colitis, Ulcerative/*drug therapy/pathology/urine', 'Colon/pathology', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Mesalamine/*administration & dosage/adverse effects/urine', 'Phenylhydrazines', 'Prodrugs/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11709512/
1767,Balsalazide,12094857,"A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.","['Levine DS', 'Riff DS', 'Pruitt R', 'Wruble L', 'Koval G', 'Sales D', 'Bell JK', 'Johnson LK']","['Adult', 'Aged', 'Aged, 80 and over', 'Aminosalicylic Acids/*administration & dosage/adverse effects/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects/blood/therapeutic use', 'Anti-Ulcer Agents/*administration & dosage/adverse effects/blood/therapeutic use', 'Colitis, Ulcerative/*drug therapy/physiopathology', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Homeostasis', 'Humans', 'Male', 'Mesalamine/*administration & dosage/adverse effects/blood/therapeutic use', 'Middle Aged', 'Phenylhydrazines', 'Safety', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/12094857/
1768,Balsalazide,17889383,Balsalazide-induced myocarditis.,"['Robertson E', 'Austin D', 'Jamieson N', 'Hogg KJ']","['Adult', 'Colitis, Ulcerative/*drug therapy', 'Gastrointestinal Agents/*adverse effects', 'Humans', 'Male', 'Mesalamine/*adverse effects', 'Myocarditis/*chemically induced', 'Phenylhydrazines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/17889383/
1769,Balsalazide,12492193,Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.,"['Pruitt R', 'Hanson J', 'Safdi M', 'Wruble L', 'Hardi R', 'Johanson J', 'Koval G', 'Riff D', 'Winston B', 'Cross A', 'Doty P', 'Johnson LK']","['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Aminosalicylic Acids/adverse effects/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Anti-Ulcer Agents/adverse effects/*therapeutic use', 'Child', 'Colitis, Ulcerative/*drug therapy/*physiopathology', 'Double-Blind Method', 'Humans', 'Mesalamine/adverse effects/*therapeutic use', 'Middle Aged', 'Phenylhydrazines', 'Safety', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12492193/
1770,Balsalazide,17117598,A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis.,['Mackowiak JI'],"['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*economics', 'Colitis, Ulcerative/*drug therapy', '*Decision Support Techniques', 'Humans', 'Mesalamine/administration & dosage/*economics', 'Phenylhydrazines/administration & dosage/*economics', 'Treatment Failure', 'United States']",https://pubmed.ncbi.nlm.nih.gov/17117598/
1771,Balsalazide,19633577,"Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.","['Quiros JA', 'Heyman MB', 'Pohl JF', 'Attard TM', 'Pieniaszek HJ', 'Bortey E', 'Walker K', 'Forbes WP']","['Adolescent', 'Aminosalicylic Acids/adverse effects/pharmacokinetics/therapeutic use', 'Anti-Inflammatory Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Child', 'Colitis, Ulcerative/*drug therapy/pathology', 'Colon/*drug effects/pathology', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Mesalamine/adverse effects/pharmacokinetics/*therapeutic use', 'Phenylhydrazines/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19633577/
1772,Balsalazide,11856079,"A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.","['Green JR', 'Mansfield JC', 'Gibson JA', 'Kerr GD', 'Thornton PC']","['Administration, Oral', 'Adrenal Cortex Hormones/therapeutic use', 'Adult', 'Aged', 'Aminosalicylic Acids/administration & dosage/adverse effects/*pharmacology', 'Anti-Ulcer Agents/administration & dosage/adverse effects/*pharmacology', 'Colitis, Ulcerative/*drug therapy/pathology', 'Double-Blind Method', 'Female', 'Gastrointestinal Agents/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Male', 'Mesalamine', 'Middle Aged', 'Phenylhydrazines', 'Severity of Illness Index', 'Sigmoidoscopy', 'Sulfasalazine/administration & dosage/adverse effects/*pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11856079/
1773,Balsalazide,17390144,"Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon.","['Tursi A', 'Brandimarte G', 'Giorgetti GM', 'Elisei W', 'Aiello F']","['Acute Disease', 'Adult', 'Aged', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Bifidobacterium/metabolism/physiology', 'Diverticulitis, Colonic/*drug therapy', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Gastrointestinal Agents/adverse effects/*therapeutic use', 'Humans', 'Lacticaseibacillus casei/metabolism/*physiology', 'Male', 'Mesalamine/adverse effects/*therapeutic use', 'Middle Aged', 'Phenylhydrazines/adverse effects/*therapeutic use', 'Pilot Projects', 'Probiotics/*chemistry/*therapeutic use', 'Recurrence', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17390144/
1774,Balsalazide,16099600,"Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients.","['Jahraus CD', 'Bettenhausen D', 'Malik U', 'Sellitti M', 'St Clair WH']","['Acute Disease', 'Aged', 'Aminosalicylic Acids/*therapeutic use', 'Anti-Ulcer Agents/*therapeutic use', 'Colon, Sigmoid/radiation effects', 'Double-Blind Method', 'Humans', 'Male', 'Mesalamine', 'Phenylhydrazines', 'Pilot Projects', 'Proctocolitis/etiology/*prevention & control', 'Prostatic Neoplasms/*radiotherapy', 'Radiation Injuries/*prevention & control', 'Rectum/radiation effects']",https://pubmed.ncbi.nlm.nih.gov/16099600/
1775,Balsalazide,35259244,Balsalazide Exposure During the Development of Fertilizing Sperm May Be Associated With Offspring Birth Defects.,"['Wensink MJ', 'Streett SE', 'Damkier P', 'Lindahl-Jacobsen R', 'Kjeldsen J', 'Eisenberg ML']","['*Congenital Abnormalities', 'Humans', 'Male', 'Mesalamine', 'Phenylhydrazines', '*Semen', 'Spermatozoa']",https://pubmed.ncbi.nlm.nih.gov/35259244/
1776,Balsalazide,24689504,"Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates.","['Coman RM', 'Glover SC', 'Gjymishka A']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Colitis, Ulcerative/*drug therapy', 'Fever/chemically induced/*diagnosis', 'Humans', 'Male', 'Mesalamine/adverse effects/*therapeutic use', 'Pericarditis/chemically induced/*diagnosis', 'Phenylhydrazines/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24689504/
1777,Balsalazide,19072352,Balsalazide disodium for the treatment of ulcerative colitis.,"['Patil SA', 'Moss AC']","['Colitis, Ulcerative/*drug therapy', 'Gastrointestinal Agents/*therapeutic use', 'Humans', 'Mesalamine/*therapeutic use', 'Phenylhydrazines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19072352/
1778,Balsalazide,14871283,Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study.,"['Green JR', 'Swan CH', 'Gibson JA', 'Kerr GD', 'Swarbrick ET', 'Thornton PC']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Aminosalicylic Acids/*administration & dosage/adverse effects', 'Cohort Studies', 'Colitis, Ulcerative/*drug therapy', 'Female', 'Humans', 'Male', 'Mesalamine', 'Middle Aged', 'Patient Participation', 'Phenylhydrazines', 'Prognosis', 'Prospective Studies', 'Recurrence', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/14871283/
1779,Balsalazide,9664201,Balsalazide.,"['Prakash A', 'Spencer CM']","['Aminosalicylic Acids/pharmacokinetics/pharmacology/*therapeutic use', 'Anti-Ulcer Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Colitis, Ulcerative/drug therapy', 'Drug Tolerance', 'Humans', 'Mesalamine/therapeutic use', 'Phenylhydrazines']",https://pubmed.ncbi.nlm.nih.gov/9664201/
1780,Balsalazide,19743890,Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.,"['Wiggins JB', 'Rajapakse R']","['Clinical Trials as Topic', 'Colitis, Ulcerative/*drug therapy', 'Delayed-Action Preparations', 'Gastrointestinal Agents/adverse effects/pharmacology/*therapeutic use', 'Humans', 'Mesalamine/adverse effects/pharmacology/*therapeutic use', 'Phenylhydrazines/adverse effects/pharmacology/*therapeutic use', 'Prodrugs', 'Remission Induction/methods']",https://pubmed.ncbi.nlm.nih.gov/19743890/
1781,Amifostine,18328585,Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy.,"['Valeyrie-Allanore L', 'Poulalhon N', 'Fagot JP', 'Sekula P', 'Davidovici B', 'Sidoroff A', 'Mockenhaupt M']","['Adult', 'Adverse Drug Reaction Reporting Systems', 'Aged', 'Amifostine/*adverse effects', 'Europe', 'Female', 'Head and Neck Neoplasms/*radiotherapy', 'Humans', 'Male', 'Middle Aged', 'Prospective Studies', 'Radiation-Protective Agents/*adverse effects', 'Stevens-Johnson Syndrome/*chemically induced/*etiology']",https://pubmed.ncbi.nlm.nih.gov/18328585/
1782,Amifostine,16020136,"Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.","['Sastry J', 'Kellie SJ']","['Adolescent', 'Amifostine/administration & dosage/*adverse effects/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects/therapeutic use', 'Carcinoma/*drug therapy', 'Cisplatin/administration & dosage/*adverse effects/therapeutic use', 'Drug Administration Schedule', 'Fatal Outcome', 'Female', 'Hearing/*drug effects', 'Humans', 'Injections, Intravenous', 'Kidney/*drug effects', 'Nervous System/*drug effects', 'Ovarian Neoplasms/*drug therapy', 'Recurrence', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16020136/
1783,Amifostine,8612469,"Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.","['Spencer CM', 'Goa KL']","['Amifostine/administration & dosage/*pharmacokinetics/*pharmacology', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Clinical Trials as Topic', 'Humans', 'Neoplasms/therapy', 'Radiation-Protective Agents/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8612469/
1784,Amifostine,24788761,Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials.,"['Gu J', 'Zhu S', 'Li X', 'Wu H', 'Li Y', 'Hua F']","['Amifostine/*pharmacology/therapeutic use', 'Carcinoma, Squamous Cell/*drug therapy/*radiotherapy', 'Combined Modality Therapy', 'Head and Neck Neoplasms/*drug therapy/*radiotherapy', 'Humans', 'Radiation Injuries/*prevention & control', 'Randomized Controlled Trials as Topic/*methods', 'Squamous Cell Carcinoma of Head and Neck']",https://pubmed.ncbi.nlm.nih.gov/24788761/
1785,Amifostine,31028720,The effects of radioprotectant and potential antioxidant agent amifostine on the structure and dynamics of DPPC and DPPG liposomes.,"['Cakmak Arslan G', 'Severcan F']","['1,2-Dipalmitoylphosphatidylcholine/chemistry/*metabolism', 'Amifostine/*pharmacology', 'Antioxidants/*pharmacology', '*Liposomes', 'Phosphatidylglycerols/chemistry/*metabolism', 'Radiation-Protective Agents/*pharmacology', 'Temperature']",https://pubmed.ncbi.nlm.nih.gov/31028720/
1786,Amifostine,31868611,Fluorometric determination of amifostine and alkaline phosphatase on amphiprotic molecularly imprinted silica crosslinked with binary functional silanes and carbon dots.,"['Ke CB', 'Lu TL', 'Chen JL']","['Alkaline Phosphatase/*analysis', 'Amifostine/*analysis', 'Biosensing Techniques', 'Carbon/chemistry', 'Cross-Linking Reagents/chemistry', 'Fluorescent Dyes/*chemistry', 'Humans', 'Ionic Liquids/chemistry', 'Limit of Detection', 'Molecular Imprinting/methods', 'Quantum Dots/*chemistry', 'Serum/chemistry', 'Silanes/chemistry', 'Silicon Dioxide/*chemistry', 'Spectrometry, Fluorescence', 'Surface Properties']",https://pubmed.ncbi.nlm.nih.gov/31868611/
1787,Amifostine,8995515,Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.,"['Korst AE', 'Gall HE', 'Vermorken JB', 'van der Vijgh WJ']","['Adenocarcinoma/*metabolism', 'Amifostine/metabolism/*pharmacokinetics', 'Ascites/*metabolism', 'Chromatography, High Pressure Liquid', 'Disulfides/blood', 'Half-Life', 'Humans', 'Infusions, Intravenous', 'Male', 'Mercaptoethylamines/pharmacokinetics', 'Middle Aged', 'Radiation-Protective Agents/metabolism/*pharmacokinetics', 'Stomach Neoplasms/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/8995515/
1788,Amifostine,15337569,Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP).,"['Boccia R', 'Anne PR', 'Bourhis J', 'Brizel D', 'Daly C', 'Holloway N 3rd', 'Hymes S', 'Koukourakis M', 'Kozloff M', 'Turner M', 'Wasserman T']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Amifostine/*adverse effects', 'Blister/chemically induced/epidemiology', 'Child', 'Child, Preschool', 'Drug Eruptions/epidemiology/*etiology', 'Erythema Multiforme/chemically induced/epidemiology', 'Humans', 'Incidence', 'Middle Aged', '*Product Surveillance, Postmarketing', 'Radiation-Protective Agents/*adverse effects', 'Stevens-Johnson Syndrome/chemically induced/epidemiology/etiology']",https://pubmed.ncbi.nlm.nih.gov/15337569/
1789,Amifostine,19744802,"Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.","['Koukourakis MI', 'Tsoutsou PG', 'Karpouzis A', 'Tsiarkatsi M', 'Karapantzos I', 'Daniilidis V', 'Kouskoukis C']","['Adult', 'Aged', 'Aged, 80 and over', 'Amifostine/administration & dosage/adverse effects', 'Antibodies, Monoclonal/administration & dosage', 'Antibodies, Monoclonal, Humanized', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Carcinoma/*drug therapy/pathology/*radiotherapy', 'Cetuximab', 'Cisplatin/administration & dosage', 'Combined Modality Therapy/adverse effects/methods', 'Disease-Free Survival', 'Dose Fractionation, Radiation', 'Drug Administration Schedule', 'Feasibility Studies', 'Female', 'Head and Neck Neoplasms/*drug therapy/pathology/*radiotherapy', 'Humans', 'Male', 'Middle Aged', 'Mucositis/etiology', 'Mycoses/etiology', 'Prospective Studies', 'Radiodermatitis/pathology', 'Xerostomia/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/19744802/
1790,Amifostine,11849797,Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.,"['Antonadou D', 'Pepelassi M', 'Synodinou M', 'Puglisi M', 'Throuvalas N']","['Aged', 'Amifostine/*therapeutic use', 'Antineoplastic Agents/*adverse effects', 'Carboplatin/*adverse effects', 'Carcinoma, Squamous Cell/drug therapy/*radiotherapy', 'Combined Modality Therapy', 'Female', 'Head and Neck Neoplasms/drug therapy/*radiotherapy', 'Humans', 'Male', 'Middle Aged', 'Mouth Mucosa/drug effects/radiation effects', 'Radiation Injuries/complications/*prevention & control', 'Radiation-Protective Agents/*therapeutic use', 'Stomatitis/etiology/*prevention & control', 'Xerostomia/etiology/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/11849797/
1791,Amifostine,15726523,Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.,"['Werner-Wasik M', 'Langer C', 'Movsas B']","['Amifostine/administration & dosage/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Carboplatin/administration & dosage', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/radiotherapy', 'Clinical Trials as Topic', 'Combined Modality Therapy', 'Follow-Up Studies', 'Humans', 'Injections, Subcutaneous', 'Lung Neoplasms/*drug therapy/radiotherapy', 'Mucous Membrane/radiation effects', 'Radiation-Protective Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15726523/
1792,Alprazolam,28777203,"A Review of Alprazolam Use, Misuse, and Withdrawal.","['Ait-Daoud N', 'Hamby AS', 'Sharma S', 'Blevins D']","['Alprazolam/*adverse effects/therapeutic use', 'Anxiety Disorders/drug therapy', 'Benzodiazepines/*adverse effects/therapeutic use', 'Female', 'Humans', 'Panic Disorder/drug therapy', 'Pregnancy', '*Prescription Drug Misuse', 'Substance Withdrawal Syndrome/*therapy']",https://pubmed.ncbi.nlm.nih.gov/28777203/
1793,Alprazolam,36946233,Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction.,['Burkat PM'],"['Humans', 'Alprazolam/pharmacology', '*Anti-Anxiety Agents/pharmacology', '*Substance-Related Disorders', 'Anxiety/drug therapy', 'gamma-Aminobutyric Acid']",https://pubmed.ncbi.nlm.nih.gov/36946233/
1794,Alprazolam,39394685,"Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial.","['Dunbar J', 'Walling DP', 'Hassman HA', 'Jain R', 'Czysz A', 'Nandy I', 'Ona V', 'Moseley MK', 'Levin S', 'Maruff P']","['Humans', '*Alprazolam/administration & dosage/pharmacokinetics/adverse effects/pharmacology', 'Female', 'Adult', 'Male', 'Double-Blind Method', '*Cross-Over Studies', '*Ethanol/administration & dosage/adverse effects/pharmacology/pharmacokinetics', '*Cognition/drug effects', 'Young Adult', 'Drug Interactions', 'Middle Aged', 'Adolescent']",https://pubmed.ncbi.nlm.nih.gov/39394685/
1795,Alprazolam,1982881,"The effects of alprazolam, quazepam and diazepam on saccadic eye movements, parameters of psychomotor function and the EEG.","['Blom MW', 'Bartel PR', 'de Sommers K', 'Van der Meyden CH', 'Becker PJ']","['Administration, Oral', 'Adult', 'Affect/drug effects', 'Alprazolam/*pharmacology', 'Anti-Anxiety Agents/*pharmacology', 'Benzodiazepines/*pharmacology', 'Diazepam/*pharmacology', 'Electroencephalography/*drug effects', 'Flicker Fusion/drug effects', 'Humans', 'Male', 'Psychomotor Performance/*drug effects', 'Saccades/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1982881/
1796,Alprazolam,35537772,Alprazolam and lorazepam overdose and the absence of brainstem reflexes.,"['Thumtecho S', 'Wainipitapong S', 'Chunamchai S', 'Suteparuk S']","['Aged', '*Alprazolam', 'Benzodiazepines', 'Brain Stem', 'Female', 'Humans', '*Lorazepam', 'Unconsciousness']",https://pubmed.ncbi.nlm.nih.gov/35537772/
1797,Alprazolam,9618738,Photosensitivity reaction to fluoxetine and alprazolam.,"['Pazzagli L', 'Banfi R', 'Borselli G', 'Semmola MV']","['Adult', 'Alprazolam/administration & dosage/*adverse effects', 'Antidepressive Agents, Second-Generation/administration & dosage/*adverse effects', 'Depression/drug therapy', 'Ethiopia/ethnology', 'Fluoxetine/administration & dosage/*adverse effects', 'Humans', 'Male', 'Photosensitivity Disorders/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/9618738/
1798,Alprazolam,7921715,"Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure.","['Basoglu M', 'Marks IM', 'Kilic C', 'Swinson RP', 'Noshirvani H', 'Kuch K', ""O'Sullivan G""]","['Adult', 'Agoraphobia/psychology/*therapy', 'Alprazolam/*therapeutic use', 'Anxiety Disorders/psychology/*therapy', 'Arousal/drug effects', 'Combined Modality Therapy', '*Desensitization, Psychologic', 'Female', 'Humans', 'Male', 'Middle Aged', 'Panic/drug effects', 'Panic Disorder/psychology/*therapy', 'Personality Inventory', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/7921715/
1799,Alprazolam,1687613,"Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam.","['DeVane CL', 'Ware MR', 'Lydiard RB']","['Alprazolam/*pharmacokinetics/pharmacology/therapeutic use', 'Anti-Anxiety Agents/*pharmacokinetics/pharmacology/therapeutic use', 'Benzodiazepines/*pharmacokinetics/pharmacology/therapeutic use', 'Clonazepam/*pharmacokinetics/pharmacology/therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/1687613/
1800,Alprazolam,24629629,Circumstances and toxicology of sudden or unnatural deaths involving alprazolam.,"['Darke S', 'Torok M', 'Duflou J']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Alprazolam/blood/*toxicity', 'Cause of Death/trends', 'Death, Sudden/*epidemiology/*etiology', 'Female', 'Humans', 'Male', 'Middle Aged', 'New South Wales/epidemiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24629629/
1801,Alprazolam,27416838,"Postmortem Brain and Blood Reference Concentrations of Alprazolam, Bromazepam, Chlordiazepoxide, Diazepam, and their Metabolites and a Review of the Literature.","['Skov L', 'Holm KM', 'Johansen SS', 'Linnet K']","['Alprazolam/*metabolism', 'Blood-Brain Barrier/*metabolism', 'Bromazepam/*metabolism', 'Chlordiazepoxide/*metabolism', 'Diazepam/*metabolism', 'Forensic Toxicology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/27416838/
1802,Alprazolam,29022858,Formulation and characterization of alprazolam-loaded nanoliposomes: screening of process variables and optimizing characteristics using RSM.,"['Hashemi SH', 'Montazer M', 'Naghdi N', 'Toliyat T']","['Administration, Cutaneous', 'Alprazolam/administration & dosage/*chemistry', 'Chemistry, Pharmaceutical/*methods', 'Cholesterol/chemistry', 'Delayed-Action Preparations', 'Drug Liberation', 'Drug Stability', 'Liposomes/*chemistry', 'Microscopy, Electron, Transmission', 'Nanoparticles/*chemistry', 'Particle Size', 'Phospholipids/chemistry', 'Solvents', 'Surface Properties']",https://pubmed.ncbi.nlm.nih.gov/29022858/
1803,Alprazolam,37724443,"Acute administration of alprazolam, alcohol and their combination on cognitive performance and mood: A randomised, double-blind, placebo-controlled study.","['Aitken B', 'Hayley AC', 'Ford TC', 'Geier L', 'Shiferaw BA', 'Downey LA']","['Humans', 'Female', 'Adult', 'Male', '*Alprazolam/pharmacology', '*Blood Alcohol Content', 'Hypnotics and Sedatives/adverse effects', 'Ethanol/adverse effects', 'Cognition', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37724443/
1804,Alprazolam,10579141,"Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam.","['Yuan R', 'Flockhart DA', 'Balian JD']","['Alprazolam/pharmacokinetics/*pharmacology', 'Anti-Anxiety Agents/pharmacokinetics/*pharmacology', 'Data Collection', 'Drug Interactions', 'Enzyme Induction/*drug effects', 'Enzyme Inhibitors/*pharmacology', 'Humans', 'Itraconazole/pharmacology', 'Ketoconazole/pharmacology', 'Midazolam/pharmacokinetics/*pharmacology', 'Triazolam/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10579141/
1805,Alprazolam,33264914,Optimized Photo-Fenton degradation of psychoactive pharmaceuticals alprazolam and diazepam using a chemometric approach-Structure and toxicity of transformation products.,"['Mitsika EE', 'Christophoridis C', 'Kouinoglou N', 'Lazaridis N', 'Zacharis CK', 'Fytianos K']","['Alprazolam/toxicity', 'Diazepam/toxicity', 'Hydrogen Peroxide', 'Oxidation-Reduction', '*Pharmaceutical Preparations', 'Tandem Mass Spectrometry', '*Water Pollutants, Chemical/analysis']",https://pubmed.ncbi.nlm.nih.gov/33264914/
1806,Alprazolam,22365897,Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers.,"['Zacny JP', 'Paice JA', 'Coalson DW']","['Adult', 'Alprazolam/*pharmacology', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Interactions', 'Female', 'GABA Modulators/*pharmacology', 'Humans', 'Male', 'Memory/*drug effects', 'Narcotics/*pharmacology', 'Neuropsychological Tests', 'Oxycodone/*pharmacology', 'Psychomotor Performance/*drug effects', 'Reaction Time/drug effects', 'Thinking/drug effects']",https://pubmed.ncbi.nlm.nih.gov/22365897/
1807,Alprazolam,37611483,"Driving impairment and altered ocular activity under the effects of alprazolam and alcohol: A randomized, double-blind, placebo-controlled study.","['Aitken B', 'Hayley AC', 'Ford TC', 'Geier L', 'Shiferaw BA', 'Downey LA']","['Humans', 'Female', 'Adult', 'Male', '*Alprazolam/pharmacology', 'Blood Alcohol Content', 'Ethanol/adverse effects', 'Double-Blind Method', 'Accidents, Traffic', '*Automobile Driving']",https://pubmed.ncbi.nlm.nih.gov/37611483/
1808,Alprazolam,8262888,"A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature.","['Jonas JM', 'Cohon MS']","['Alprazolam/adverse effects/*therapeutic use', 'Antidepressive Agents/therapeutic use', 'Anxiety Disorders/*drug therapy', 'Benzodiazepines/therapeutic use', 'Buspirone/therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Humans', 'Panic Disorder/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8262888/
1809,Alprazolam,9597554,Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects.,"['Kaplan GB', 'Greenblatt DJ', 'Ehrenberg BL', 'Goddard JE', 'Harmatz JS', 'Shader RI']","['Adult', 'Age Factors', 'Aged', 'Alprazolam/*pharmacokinetics/pharmacology', 'Anti-Anxiety Agents/*pharmacokinetics', 'Cross-Over Studies', 'Double-Blind Method', 'Electroencephalography/drug effects', 'Female', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/9597554/
1810,Indapamide,35404993,"Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide.","['Ernst ME', 'Fravel MA']","['Antihypertensive Agents', 'Chlorthalidone', 'Diuretics', 'Humans', 'Hydrochlorothiazide', '*Hypertension/diagnosis/drug therapy', '*Indapamide', 'Thiazides']",https://pubmed.ncbi.nlm.nih.gov/35404993/
1811,Indapamide,25733245,Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects.,"['Roush GC', 'Ernst ME', 'Kostis JB', 'Tandon S', 'Sica DA']","['Blood Pressure/*drug effects', 'Chlorthalidone/*therapeutic use', 'Diuretics/therapeutic use', 'Humans', 'Hydrochlorothiazide/*therapeutic use', 'Hypertension/blood/*drug therapy', 'Hypokalemia/blood/chemically induced/prevention & control', 'Indapamide/*therapeutic use', 'Potassium/*blood', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25733245/
1812,Indapamide,17765963,Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.,"['Patel A', 'MacMahon S', 'Chalmers J', 'Neal B', 'Woodward M', 'Billot L', 'Harrap S', 'Poulter N', 'Marre M', 'Cooper M', 'Glasziou P', 'Grobbee DE', 'Hamet P', 'Heller S', 'Liu LS', 'Mancia G', 'Mogensen CE', 'Pan CY', 'Rodgers A', 'Williams B']","['Aged', 'Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Blood Pressure/drug effects', 'Diabetes Mellitus, Type 2/complications/*drug therapy/physiopathology', 'Diuretics/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy/etiology', 'Indapamide/*therapeutic use', 'Male', 'Middle Aged', 'Perindopril/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17765963/
1813,Indapamide,39426836,"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.","['Rodgers A', 'Salam A', 'Schutte AE', 'Cushman WC', 'de Silva HA', 'Di Tanna GL', 'Grobbee DE', 'Narkiewicz K', 'Ojji DB', 'Poulter NR', 'Schlaich MP', 'Oparil S', 'Spiering W', 'Williams B', 'Wright JT Jr', 'Lakshman P', 'Uluwattage W', 'Hay P', 'Pereira T', 'Amarasena N', 'Ranasinghe G', 'Gianacas C', 'Shanthakumar M', 'Liu X', 'Wang N', 'Gnanenthiran SR', 'Whelton PK']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Amlodipine/administration & dosage/adverse effects', '*Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', '*Hypertension/drug therapy', '*Indapamide/administration & dosage/adverse effects/therapeutic use', '*Telmisartan/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39426836/
1814,Indapamide,37814929,Pharmacokinetics and Drug-Drug Interaction of Allisartan Isoproxil and Indapamide Sustained-Release Formulation.,"['Yi W', 'Lin S', 'Hao R', 'Shao Y', 'Wang Y', 'Yu J', 'Fang L', 'Zhu J', 'Wang A', 'Wu Y', 'Huang H', 'Deng C', 'Sun J', 'Zhao H', 'Wang Y', 'Tong X']","['Humans', '*Indapamide/adverse effects/pharmacokinetics', 'Delayed-Action Preparations', 'Drug Interactions', '*Hypotension/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37814929/
1815,Indapamide,30790132,Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension.,"['Tsioufis K', 'Douma S', 'Kallistratos MS', 'Manolis AJ']","['Adult', 'Aged', 'Amlodipine/*administration & dosage', 'Antihypertensive Agents/*administration & dosage', 'Blood Pressure/drug effects/physiology', 'Drug Combinations', 'Female', 'Greece/epidemiology', 'Humans', 'Hypertension/diagnosis/*drug therapy/epidemiology', 'Indapamide/*administration & dosage', 'Male', '*Medication Adherence', 'Middle Aged', 'Perindopril/*administration & dosage', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/30790132/
1816,Indapamide,26301858,Molecular Dynamics and Physical Stability of Coamorphous Ezetimib and Indapamide Mixtures.,"['Knapik J', 'Wojnarowska Z', 'Grzybowska K', 'Jurkiewicz K', 'Tajber L', 'Paluch M']","['Calorimetry, Differential Scanning', 'Crystallization', 'Dielectric Spectroscopy', 'Drug Combinations', 'Drug Stability', 'Ezetimibe/*chemistry', 'Indapamide/*chemistry', 'Spectroscopy, Fourier Transform Infrared', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/26301858/
1817,Indapamide,6386023,"Effect of indapamide on the renin-aldosterone system, and urinary excretion of potassium and calcium in essential hypertension.","['Danielsen H', 'Pedersen EB', 'Spencer ES']","['Adult', 'Aldosterone/blood', 'Calcium/blood/*urine', 'Creatinine/blood', 'Diuretics/*therapeutic use', 'Female', 'Humans', 'Hypertension/*drug therapy/metabolism', 'Indapamide/*therapeutic use', 'Male', 'Middle Aged', 'Potassium/blood/*urine', 'Renin/blood', 'Renin-Angiotensin System/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/6386023/
1818,Indapamide,7033950,Echocardiographic evaluation of left ventricular function in patients showing an antihypertensive and biochemical response to indapamide.,"['Horgan JH', ""O'Donovan A"", 'Teo KK']","['Adult', 'Antihypertensive Agents/*therapeutic use', 'Clinical Trials as Topic', 'Diuretics/*therapeutic use', 'Echocardiography', 'Female', 'Heart/*physiopathology', 'Heart Ventricles/physiopathology', 'Humans', 'Hypertension/blood/physiopathology', 'Indapamide/*therapeutic use', 'Male', 'Middle Aged', 'Potassium/blood', 'Uric Acid/blood']",https://pubmed.ncbi.nlm.nih.gov/7033950/
1819,Indapamide,36799308,The Efficacy and Tolerability of a Fixed Combination of Perindopril and Indapamide in the Treatment of Unregulated Essential Hypertension - a Postmarketing Study.,"['Sukalo A', 'Dzananovic Jaganjac J', 'Tanovic Avdic A', 'Glamoclija U', 'Popovic Z', 'Boloban A', 'Tiric Campara M', 'Mehic M']","['Humans', 'Antihypertensive Agents/therapeutic use/adverse effects', 'Blood Pressure', 'Drug Combinations', 'Essential Hypertension/drug therapy/chemically induced', '*Hypertension/drug therapy/chemically induced', '*Indapamide/therapeutic use/adverse effects', 'Perindopril/therapeutic use/adverse effects', 'Prospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36799308/
1820,Indapamide,30251403,"Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.","['Roush GC', 'Abdelfattah R', 'Song S', 'Ernst ME', 'Sica DA', 'Kostis JB']","['Antihypertensive Agents/therapeutic use', 'Blood Pressure/drug effects', 'Chlorthalidone/administration & dosage/*pharmacology/therapeutic use', 'Diuretics, Potassium Sparing/administration & dosage/*pharmacology/therapeutic use', 'Drug Therapy, Combination/methods', 'Female', 'Humans', 'Hydrochlorothiazide/administration & dosage/*pharmacology/therapeutic use', 'Hypertension/complications/*drug therapy/physiopathology', 'Hypertrophy, Left Ventricular/*drug therapy/epidemiology/physiopathology/prevention & control', 'Indapamide/administration & dosage/*pharmacology/therapeutic use', 'Male', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Sodium Chloride Symporter Inhibitors/pharmacology', 'Thiazides/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30251403/
1821,Indapamide,26948252,"Addition of indapamide to frusemide increases natriuresis and creatinine clearance, but not diuresis, in fluid overloaded ICU patients.","['Bihari S', 'Holt AW', 'Prakash S', 'Bersten AD']","['Aged', 'Aged, 80 and over', 'Creatinine/blood', 'Critical Care', 'Diuresis/drug effects', 'Diuretics/administration & dosage/pharmacology/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Furosemide/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Hypernatremia/blood/*drug therapy/urine', 'Indapamide/administration & dosage/pharmacology/*therapeutic use', 'Intensive Care Units', 'Male', 'Middle Aged', 'Natriuresis/drug effects', 'Prospective Studies', 'Sodium/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26948252/
1822,Indapamide,33314205,"Determination of amlodipine, indapamide and perindopril in human plasma by a novel LC-MS/MS method: Application to a bioequivalence study.","['Rezk MR', 'Badr KA']","['Adult', '*Amlodipine/blood/pharmacokinetics', '*Antihypertensive Agents/blood/pharmacokinetics', 'Chromatography, High Pressure Liquid/*methods', 'Humans', '*Indapamide/blood/pharmacokinetics', 'Limit of Detection', 'Middle Aged', '*Perindopril/blood/pharmacokinetics', 'Specimen Handling', 'Tandem Mass Spectrometry/*methods', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/33314205/
1823,Indapamide,15038948,"A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension.","['Kang S', 'Wu YF', 'An N', 'Ren M']","['Adult', 'Aged', 'Aged, 80 and over', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Drug Combinations', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Indapamide/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Perindopril/administration & dosage/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15038948/
1824,Indapamide,12197195,Comparison of indapamide and low-dose hydrochlorothiazide monotherapy in black patients with mild to moderate hypertension.,"['Radevski IV', 'Valtchanova ZP', 'Candy GP', 'Wald AM', 'Ngcezula T', 'Sareli P']","['Adult', 'Aged', 'Analysis of Variance', '*Black People', 'Blood Pressure Determination', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Follow-Up Studies', 'Humans', 'Hydrochlorothiazide/*administration & dosage', 'Hypertension/diagnosis/*drug therapy/ethnology', 'Indapamide/*administration & dosage', 'Male', 'Middle Aged', 'Pilot Projects', 'Probability', 'Prospective Studies', 'Severity of Illness Index', 'South Africa', 'Statistics, Nonparametric', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12197195/
1825,Indapamide,3395370,Binding of indapamide to serum proteins and erythrocytes.,"['Urien S', 'Riant P', 'Renouard A', 'Coulomb B', 'Rocher I', 'Tillement JP']","['Blood Platelets/metabolism', 'Blood Proteins/*metabolism', 'Diuretics/*pharmacokinetics', 'Erythrocytes/*metabolism', 'Humans', 'In Vitro Techniques', 'Indapamide/*pharmacokinetics', 'Lipoproteins/metabolism', 'Orosomucoid/metabolism', 'Serum Albumin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/3395370/
1826,melphalan,30664726,High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators.,"['Phull P', 'Sanchorawala V', 'Brauneis D', 'Sloan JM', 'Siddiqi OK', 'Quillen K', 'Sarosiek S']","['Adult', 'Amyloidosis/complications/*drug therapy/*therapy', 'Antineoplastic Agents, Alkylating/pharmacology/*therapeutic use', 'Defibrillators/*standards', 'Female', 'Heart/physiopathology', 'Humans', 'Male', 'Melphalan/pharmacology/*therapeutic use', 'Middle Aged', 'Peripheral Blood Stem Cell Transplantation/*methods']",https://pubmed.ncbi.nlm.nih.gov/30664726/
1827,melphalan,36404519,Correlation of Engraftment and Time from Melphalan Administration to Stem Cell Infusion.,"['Shuman K', 'Palmer S', 'Anders B', 'Moore D', 'Ptachcinski J', 'Grgic T', 'Alexander M', 'Hill L', 'Sung AD', 'Armistead PM', 'Kennedy L', 'Shaw JR']","['Adult', 'Humans', '*Melphalan/therapeutic use', '*Hematopoietic Stem Cell Transplantation/methods', 'Retrospective Studies', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/36404519/
1828,melphalan,37596331,Curcumin and melphalan cotreatment induces cell cycle arrest and apoptosis in MDA-MB-231 breast cancer cells.,"['Passos CLA', 'Polinati RM', 'Ferreira C', 'Dos Santos NAN', 'Lima DGV', 'da Silva JL', 'Fialho E']","['Female', 'Humans', 'Melphalan/pharmacology', '*Curcumin/pharmacology', '*Breast Neoplasms/drug therapy', 'Cell Cycle Checkpoints', 'Apoptosis']",https://pubmed.ncbi.nlm.nih.gov/37596331/
1829,melphalan,32583431,"Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).","['Maruyama D', 'Iida S', 'Ogawa G', 'Fukuhara N', 'Seo S', 'Miyazaki K', 'Yoshimitsu M', 'Kuroda J', 'Tsukamoto N', 'Tsujimura H', 'Hangaishi A', 'Yamauchi T', 'Utsumi T', 'Mizuno I', 'Takamatsu Y', 'Nagata Y', 'Minauchi K', 'Ohtsuka E', 'Hanamura I', 'Yoshida S', 'Yamasaki S', 'Suehiro Y', 'Kamiyama Y', 'Tsukasaki K', 'Nagai H']","['Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use', 'Bortezomib/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Humans', 'Male', 'Melphalan/administration & dosage/adverse effects/*therapeutic use', 'Multiple Myeloma/*drug therapy', 'Prednisolone/administration & dosage/adverse effects/*therapeutic use', 'Survival Analysis', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32583431/
1830,melphalan,35522968,Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning.,"['Kutzke JL', 'Merten JA', 'Pawlenty AG', 'Barreto EF', 'Bartoo GT', 'Mara KC', 'Litzow MR', 'Hogan WJ', 'Shah MV', 'Mangaonkar AA', 'Leung N', 'Alkhateeb HB']","['Creatinine', '*Graft vs Host Disease/etiology', 'Humans', 'Iothalamic Acid', '*Melphalan/therapeutic use', 'Retrospective Studies', 'Vidarabine/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/35522968/
1831,melphalan,20190437,"Novel melphalan and chlorambucil derivatives of 2,2,6,6-tetramethyl-1-piperidinyloxy radicals: synthesis, characterization, and biological evaluation in vitro.","['Zhao H', 'Meng X', 'Yuan H', 'Lan M']","['Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Chlorambucil/chemical synthesis/chemistry/*pharmacology', 'Cyclic N-Oxides/chemical synthesis/chemistry/*pharmacology', 'Dose-Response Relationship, Drug', 'Drug Screening Assays, Antitumor', 'Free Radicals/chemical synthesis/chemistry/pharmacology', 'Humans', 'Hydrolysis', 'Kinetics', 'Melphalan/chemical synthesis/chemistry/*pharmacology', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/20190437/
1832,melphalan,26802176,"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.","['Zweegman S', 'van der Holt B', 'Mellqvist UH', 'Salomo M', 'Bos GM', 'Levin MD', 'Visser-Wisselaar H', 'Hansson M', 'van der Velden AW', 'Deenik W', 'Gruber A', 'Coenen JL', 'Plesner T', 'Klein SK', 'Tanis BC', 'Szatkowski DL', 'Brouwer RE', 'Westerman M', 'Leys MR', 'Sinnige HA', 'Haukas E', 'van der Hem KG', 'Durian MF', 'Mattijssen EV', 'van de Donk NW', 'Stevens-Kroef MJ', 'Sonneveld P', 'Waage A']","['Aged', 'Aged, 80 and over', 'Disease-Free Survival', 'Female', 'Humans', 'Lenalidomide', 'Maintenance Chemotherapy', 'Male', 'Melphalan/adverse effects/*therapeutic use', 'Middle Aged', 'Multiple Myeloma/*drug therapy', 'Prednisone', 'Thalidomide/adverse effects/*analogs & derivatives/*therapeutic use', 'Treatment Outcome', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/26802176/
1833,melphalan,2018366,Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines.,"['Lewensohn R', 'Ehrsson H', 'Hansson J', 'Ringborg U']","['Cell Line', 'Cell Survival/drug effects', 'Cross-Linking Reagents/*pharmacology', 'DNA, Neoplasm/*drug effects', 'Drug Interactions', 'Drug Screening Assays, Antitumor', 'Humans', 'Melanoma', 'Melphalan/*analogs & derivatives/*pharmacology', 'Peptichemio/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2018366/
1834,melphalan,34344638,"Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.","['Mateos MV', 'Dimopoulos MA', 'Cavo M', 'Suzuki K', 'Knop S', 'Doyen C', 'Lucio P', 'Nagy Z', 'Pour L', 'Grosicki S', 'Crepaldi A', 'Liberati AM', 'Campbell P', 'Yoon SS', 'Iosava G', 'Fujisaki T', 'Garg M', 'Iida S', 'Blade J', 'Ukropec J', 'Pei H', 'Van Rampelbergh R', 'Kudva A', 'Qi M', 'San-Miguel J']","['Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal/pharmacology/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use', 'Bortezomib/pharmacology/*therapeutic use', 'Female', 'Humans', 'Male', 'Melphalan/pharmacology/*therapeutic use', 'Multiple Myeloma/*drug therapy', 'Prednisone/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34344638/
1835,melphalan,37350429,"BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.","['Wu R', 'Ma L']","['Humans', 'Carmustine/therapeutic use', 'Transplantation, Autologous', 'Bendamustine Hydrochloride', '*Hematopoietic Stem Cell Transplantation', 'Cytarabine/therapeutic use', 'Etoposide/therapeutic use', 'Melphalan/therapeutic use', 'Cardiotoxicity', '*Mucositis', 'Retrospective Studies', 'Neoplasm Recurrence, Local', '*Lymphoma, Non-Hodgkin']",https://pubmed.ncbi.nlm.nih.gov/37350429/
1836,melphalan,24789622,Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.,"['Ghassemi F', 'Shields CL', 'Ghadimi H', 'Khodabandeh A', 'Roohipoor R']","['Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Intravitreal Injections', 'Male', 'Melphalan/*administration & dosage/adverse effects', '*Neoplasm Seeding', 'Recurrence', 'Retinal Neoplasms/*drug therapy', 'Retinoblastoma/drug therapy', 'Retrospective Studies', 'Topotecan/*administration & dosage/adverse effects', 'Vitreous Body/*pathology']",https://pubmed.ncbi.nlm.nih.gov/24789622/
1837,melphalan,32493164,"Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan.","['Sweiss K', 'Calip GS', 'Holden J', 'Lewkowski P', 'Mialik I', 'Johnson J', 'Galvin JP', 'Rondelli D', 'Patel P']","['Adult', 'Aged', 'Antineoplastic Agents/*administration & dosage/adverse effects/therapeutic use', 'Antineoplastic Agents, Alkylating/*administration & dosage/adverse effects/therapeutic use', 'Creatinine/metabolism', 'Diarrhea/epidemiology', 'Female', 'Hemoglobins/metabolism', 'Humans', 'Male', 'Melphalan/*administration & dosage/adverse effects/therapeutic use', 'Middle Aged', 'Neoplasms/drug therapy', 'Predictive Value of Tests', 'Recurrence', 'Retrospective Studies', 'Stem Cell Transplantation/*methods', 'Survival Analysis', 'Transplantation Conditioning', 'Treatment Outcome', 'Vidarabine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32493164/
1838,melphalan,39134959,"Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.","['Eltelbanei MA', 'El-Bassiouny NA', 'Abdalla MS', 'Khalaf M', 'Werida RH']","['Humans', '*Hematopoietic Stem Cell Transplantation/methods/adverse effects', 'Female', 'Male', '*Cytarabine/administration & dosage/adverse effects/therapeutic use', '*Etoposide/administration & dosage/adverse effects/therapeutic use', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', '*Melphalan/administration & dosage/adverse effects/therapeutic use', 'Adult', '*Lymphoma/therapy/mortality/drug therapy', '*Transplantation, Autologous', 'Middle Aged', '*Transplantation Conditioning/methods', '*Bendamustine Hydrochloride/administration & dosage/adverse effects', '*Carboplatin/administration & dosage/adverse effects/therapeutic use', 'Young Adult', 'Adolescent', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39134959/
1839,melphalan,17914442,Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects.,"['Kuhne A', 'Sezer O', 'Heider U', 'Meineke I', 'Muhlke S', 'Niere W', 'Overbeck T', 'Hohloch K', 'Trumper L', 'Brockmoller J', 'Kaiser R']","['Adult', 'Aged', 'Antineoplastic Agents, Alkylating/administration & dosage/adverse effects/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Female', 'Genotype', 'Glutathione S-Transferase pi/genetics/metabolism', 'Glutathione Transferase/*genetics/*metabolism', 'Humans', 'Male', 'Melphalan/administration & dosage/*adverse effects/*pharmacokinetics', 'Middle Aged', 'Polymorphism, Genetic']",https://pubmed.ncbi.nlm.nih.gov/17914442/
1840,Ranolazine,19737166,Chronic angina and the treatment with ranolazine: facts and recommendations.,"['Milne HC', 'Vallerand AH']","['Acetanilides/pharmacology/*therapeutic use', 'Angina Pectoris/*drug therapy/genetics', 'Chronic Disease', 'Enzyme Inhibitors/pharmacology/*therapeutic use', 'Humans', 'Piperazines/pharmacology/*therapeutic use', 'Ranolazine']",https://pubmed.ncbi.nlm.nih.gov/19737166/
1841,Ranolazine,26944071,Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease.,['Cacciapuoti F'],"['Angina, Stable/drug therapy/physiopathology', 'Benzazepines/pharmacology/*therapeutic use', 'Cardiovascular Agents/pharmacology/therapeutic use', 'Heart Rate/drug effects', 'Humans', 'Ivabradine', 'Myocardial Ischemia/*drug therapy/physiopathology', 'Oxygen Consumption/drug effects', 'Ranolazine/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26944071/
1842,Ranolazine,27653554,Formulation and Coating of Alginate and Alginate-Hydroxypropylcellulose Pellets Containing Ranolazine.,"['Segale L', 'Mannina P', 'Giovannelli L', 'Muschert S', 'Pattarino F']","['Alginates/*chemistry/pharmacokinetics', 'Cardiovascular Agents/chemistry/pharmacokinetics', 'Cellulose/*analogs & derivatives/chemistry/pharmacokinetics', 'Chemistry, Pharmaceutical/*methods', 'Drug Carriers/chemistry/pharmacokinetics', 'Drug Compounding', 'Drug Implants/*chemistry/pharmacokinetics', 'Drug Liberation', 'Glucuronic Acid/chemistry/pharmacokinetics', 'Hexuronic Acids/chemistry/pharmacokinetics', 'Methacrylates/chemistry/pharmacokinetics', 'Polymers/chemistry/pharmacokinetics', 'Polymethacrylic Acids/chemistry/pharmacokinetics', 'Ranolazine/*chemistry/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/27653554/
1843,Ranolazine,34841884,Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina.,"['Tamargo J', 'Lopez-Sendon J']","['Acetanilides/pharmacology/therapeutic use', '*Angina, Stable/drug therapy', '*Coronary Artery Disease/drug therapy', 'Humans', 'Piperazines/pharmacology', 'Quality of Life', 'Ranolazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34841884/
1844,Ranolazine,38411168,Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial.,"['Yusuf J', 'Prakash G', 'Safal S', 'Mehta V', 'Mukhopadhyay S']","['Humans', 'Nicorandil/therapeutic use', 'Ranolazine/therapeutic use', 'Coronary Angiography/adverse effects/methods', '*Percutaneous Coronary Intervention/adverse effects/methods', 'Stroke Volume', 'Ventricular Function, Left', 'Contrast Media/adverse effects', '*Acute Kidney Injury/chemically induced/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/38411168/
1845,Ranolazine,33518355,Pharmacokinetics and Safety of Extended-release Ranolazine in Korean and White Healthy Subjects.,"['Yoo H', 'Lee SW', 'Yoon DY', 'Yoon SH', 'Cho JY', 'Yu KS', 'Jang IJ', 'Lee S']","['Area Under Curve', 'Healthy Volunteers', 'Humans', 'Male', 'Ranolazine/adverse effects/*pharmacokinetics', 'Republic of Korea']",https://pubmed.ncbi.nlm.nih.gov/33518355/
1846,Ranolazine,34498453,Through the heart and beyond: a review on ranolazine.,['Uran C'],"['*Acetanilides/therapeutic use', 'Heart', 'Humans', '*Piperazines/pharmacology/therapeutic use', 'Ranolazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34498453/
1847,Ranolazine,28497941,Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis.,"['De Vecchis R', 'Ariano C', 'Giasi A', 'Cioppa C']","['Administration, Intravenous', 'Administration, Oral', 'Amiodarone/*administration & dosage/adverse effects', 'Anti-Arrhythmia Agents/administration & dosage/adverse effects', 'Atrial Fibrillation/drug therapy/*prevention & control', 'Cardiovascular Agents/administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Humans', 'Randomized Controlled Trials as Topic', 'Ranolazine/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28497941/
1848,Ranolazine,27056421,The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology.,"['Hartmann N', 'Mason FE', 'Braun I', 'Pabel S', 'Voigt N', 'Schotola H', 'Fischer TH', 'Dobrev D', 'Danner BC', 'Renner A', 'Gummert J', 'Belardinelli L', 'Frey N', 'Maier LS', 'Hasenfuss G', 'Sossalla S']","['Aged', 'Amiodarone/*analogs & derivatives/pharmacology', 'Atrial Function/*drug effects', 'Calcium/metabolism', 'Calcium Signaling/drug effects', 'Cardiovascular Agents/pharmacology', 'Dronedarone', 'Drug Therapy, Combination', 'Female', 'Heart Atria/*drug effects', 'Heart Ventricles/*drug effects', 'Humans', 'Male', 'Middle Aged', 'Myocardial Contraction/drug effects', 'Myocytes, Cardiac/drug effects/metabolism', 'Ranolazine/*pharmacology', 'Sarcomeres/drug effects/metabolism', 'Ventricular Function/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/27056421/
1849,Ranolazine,28182279,Ranolazine Added to Amiodarone Facilitates Earlier Conversion of Atrial Fibrillation Compared to Amiodarone-Only Therapy.,"['Tsanaxidis N', 'Aidonidis I', 'Hatziefthimiou A', 'Daskalopoulou SS', 'Giamouzis G', 'Triposkiadis F', 'Skoularigis I']","['Aged', 'Amiodarone/*administration & dosage', 'Anti-Arrhythmia Agents/administration & dosage', 'Atrial Fibrillation/*diagnosis/*drug therapy', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Synergism', 'Drug Therapy, Combination/methods', 'Female', 'Humans', 'Male', 'Ranolazine/*administration & dosage', 'Sodium Channel Blockers/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28182279/
1850,Ranolazine,35005029,Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study.,"['Nusca A', 'Bernardini F', 'Mangiacapra F', 'Maddaloni E', 'Melfi R', 'Ricottini E', 'Piccirillo F', 'Manfrini S', 'Ussia GP', 'Grigioni F']","['Analysis of Variance', 'Diabetes Mellitus/*drug therapy/physiopathology', 'Endothelial Cells/*drug effects/metabolism', 'Female', 'Glycemic Control/methods/*standards/statistics & numerical data', 'Heart Diseases/*drug therapy/physiopathology', 'Humans', 'Male', 'Middle Aged', 'Prospective Studies', 'Ranolazine/metabolism/*pharmacology/therapeutic use', 'Sodium Channel Blockers/metabolism/pharmacology/therapeutic use', 'Statistics, Nonparametric']",https://pubmed.ncbi.nlm.nih.gov/35005029/
1851,Ranolazine,25438492,"Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine.",['Mittal SR'],"['Acetanilides/*adverse effects/therapeutic use', 'Aged, 80 and over', 'Angina, Unstable/*drug therapy', 'Benzazepines/*adverse effects/therapeutic use', 'Bradycardia/*chemically induced/diagnosis', 'Diltiazem/*adverse effects/therapeutic use', 'Drug Interactions', 'Drug Substitution', 'Drug Therapy, Combination', 'Electrocardiography/*drug effects', 'Female', 'Humans', 'Ivabradine', 'Long QT Syndrome/*chemically induced/diagnosis', 'Piperazines/*adverse effects/therapeutic use', 'Ranolazine', 'Torsades de Pointes/*chemically induced/*diagnosis']",https://pubmed.ncbi.nlm.nih.gov/25438492/
1852,Capecitabine,36260828,Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).,"['Kunz PL', 'Graham NT', 'Catalano PJ', 'Nimeiri HS', 'Fisher GA', 'Longacre TA', 'Suarez CJ', 'Martin BA', 'Yao JC', 'Kulke MH', 'Hendifar AE', 'Shanks JC', 'Shah MH', 'Zalupski MM', 'Schmulbach EL', 'Reidy-Lagunes DL', 'Strosberg JR', ""O'Dwyer PJ"", 'Benson AB 3rd']","['Humans', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Capecitabine/therapeutic use', 'Dacarbazine/therapeutic use', '*Neuroendocrine Tumors/drug therapy', '*Pancreatic Neoplasms/drug therapy', 'Prospective Studies', 'Retrospective Studies', 'Temozolomide/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36260828/
1853,Capecitabine,28564564,Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.,"['Masuda N', 'Lee SJ', 'Ohtani S', 'Im YH', 'Lee ES', 'Yokota I', 'Kuroi K', 'Im SA', 'Park BW', 'Kim SB', 'Yanagita Y', 'Ohno S', 'Takao S', 'Aogi K', 'Iwata H', 'Jeong J', 'Kim A', 'Park KH', 'Sasano H', 'Ohashi Y', 'Toi M']","['Adult', 'Aged', 'Antimetabolites, Antineoplastic/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/mortality/surgery', 'Capecitabine/adverse effects/*therapeutic use', 'Chemotherapy, Adjuvant/adverse effects', 'Female', 'Hand-Foot Syndrome/etiology', 'Humans', 'Middle Aged', 'Neoadjuvant Therapy', 'Neoplasm Staging', 'Preoperative Care', 'Receptor, ErbB-2', 'Survival Analysis', 'Triple Negative Breast Neoplasms/drug therapy/mortality']",https://pubmed.ncbi.nlm.nih.gov/28564564/
1854,Capecitabine,38412399,Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.,"['Santhosh A', 'Sharma A', 'Bakhshi S', 'Kumar A', 'Sharma V', 'Malik PS', 'Pramanik R', 'Gogia A', 'Prasad CP', 'Sehgal T', 'Gund S', 'Dev A', 'Cheung WY', 'Pandey RM', 'Kumar S', 'Gupta I', 'Batra A']","['Humans', '*Capecitabine/adverse effects/administration & dosage/therapeutic use', 'Double-Blind Method', '*Hand-Foot Syndrome/prevention & control/etiology', '*Diclofenac/adverse effects/administration & dosage/analogs & derivatives', 'Female', 'Male', 'Middle Aged', 'Aged', '*Antimetabolites, Antineoplastic/adverse effects/administration & dosage', 'Breast Neoplasms/drug therapy', 'Administration, Topical', 'Adult', 'Gastrointestinal Neoplasms/drug therapy', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38412399/
1855,Capecitabine,30922733,"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.","['Primrose JN', 'Fox RP', 'Palmer DH', 'Malik HZ', 'Prasad R', 'Mirza D', 'Anthony A', 'Corrie P', 'Falk S', 'Finch-Jones M', 'Wasan H', 'Ross P', 'Wall L', 'Wadsley J', 'Evans JTR', 'Stocken D', 'Praseedom R', 'Ma YT', 'Davidson B', 'Neoptolemos JP', 'Iveson T', 'Raftery J', 'Zhu S', 'Cunningham D', 'Garden OJ', 'Stubbs C', 'Valle JW', 'Bridgewater J']","['Aged', 'Antimetabolites, Antineoplastic/*administration & dosage/adverse effects', 'Biliary Tract Neoplasms/mortality/pathology/*therapy', '*Biliary Tract Surgical Procedures/adverse effects/mortality', 'Capecitabine/*administration & dosage/adverse effects', 'Chemotherapy, Adjuvant', 'Disease Progression', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local', 'Progression-Free Survival', 'Time Factors', 'United Kingdom', '*Watchful Waiting']",https://pubmed.ncbi.nlm.nih.gov/30922733/
1856,Capecitabine,38710003,"Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.","['Jia R', 'Shan T', 'Zheng A', 'Zhang Y', 'Lu P', 'Zhang G', 'Wang F', 'Xu Z', 'Zheng G', 'Tang D', 'Zhang W', 'Li W', 'Li R', 'Guo Y', 'Liu L', 'Luo X', 'Zheng Y', 'Chang Z', 'Wang Q', 'Wang X', 'Yuan X', 'Kong G', 'Li S', 'Yang R', 'Zhou D', 'Ren J', 'Yin W', 'Li J', 'Zhang J', 'Wang Z', 'Sheng M', 'Xu B', 'Li L', 'Liu X', 'Lu Z', 'Wan L', 'Zhou F', 'Gao S']","['Humans', '*Capecitabine/administration & dosage/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Female', '*Fluorouracil/analogs & derivatives/administration & dosage/adverse effects/therapeutic use', '*Cisplatin/administration & dosage/adverse effects/therapeutic use', '*Esophageal Neoplasms/therapy/pathology/mortality', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Aged', '*Chemoradiotherapy/adverse effects', '*Esophageal Squamous Cell Carcinoma/therapy/mortality/pathology', '*Oxaliplatin/administration & dosage/therapeutic use/adverse effects', 'Adult', 'Oxaloacetates']",https://pubmed.ncbi.nlm.nih.gov/38710003/
1857,Capecitabine,29117285,Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine.,"['Cubiro X', 'Planas-Ciudad S', 'Garcia-Muret MP', 'Puig L']","['Administration, Topical', 'Aged', 'Angiolymphoid Hyperplasia with Eosinophilia/*chemically induced/*drug therapy', 'Antimetabolites, Antineoplastic/*adverse effects/therapeutic use', 'Capecitabine/*adverse effects/therapeutic use', 'Cohort Studies', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/drug therapy/pathology', 'Paronychia/*chemically induced/*drug therapy', 'Prognosis', 'Retrospective Studies', 'Timolol/*administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29117285/
1858,Capecitabine,33300950,Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.,"['Wang X', 'Wang SS', 'Huang H', 'Cai L', 'Zhao L', 'Peng RJ', 'Lin Y', 'Tang J', 'Zeng J', 'Zhang LH', 'Ke YL', 'Wang XM', 'Liu XM', 'Chen QJ', 'Zhang AQ', 'Xu F', 'Bi XW', 'Huang JJ', 'Li JB', 'Pang DM', 'Xue C', 'Shi YX', 'He ZY', 'Lin HX', 'An X', 'Xia W', 'Cao Y', 'Guo Y', 'Su YH', 'Hua X', 'Wang XY', 'Hong RX', 'Jiang KK', 'Song CG', 'Huang ZZ', 'Shi W', 'Zhong YY', 'Yuan ZY']","['Adult', 'Capecitabine/*administration & dosage/adverse effects', 'Chemotherapy, Adjuvant', 'Disease-Free Survival', 'Drug Administration Schedule', 'Female', 'Follow-Up Studies', 'Hand-Foot Syndrome/etiology', 'Humans', 'Maintenance Chemotherapy', 'Mastectomy', 'Middle Aged', 'Neoplasm Grading', 'Neoplasm Staging', 'Neoplasm, Residual', 'Observation', 'Triple Negative Breast Neoplasms/*drug therapy/mortality/pathology/surgery']",https://pubmed.ncbi.nlm.nih.gov/33300950/
1859,Capecitabine,37594133,5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review).,"['Alzahrani SM', 'Al Doghaither HA', 'Al-Ghafari AB', 'Pushparaj PN']","['Humans', 'Capecitabine/adverse effects', '*Fluorouracil/therapeutic use', 'Cell Division', 'Cell Membrane', '*Colorectal Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37594133/
1860,Capecitabine,33817933,Leukoencephalopathy with transient splenial lesions related to 5-fluorouracil or capecitabine.,"['Perrain V', 'Bihan K', 'Bompaire F', 'Houillier C', 'Jomier F', 'Leclercq D', 'Combret S', 'Mahe J', 'Ricard D', 'Berzero G', 'Psimaras D']","['Adult', 'Antimetabolites, Antineoplastic/adverse effects', 'Capecitabine/adverse effects', '*Fluorouracil/adverse effects', 'Humans', '*Leukoencephalopathies/chemically induced/diagnostic imaging', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/33817933/
1861,Capecitabine,30451997,5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration.,"['Brutcher E', 'Christensen D', 'Hennessey Smith M', 'Koutlas JB', 'Sellers JB', 'Timmons T', 'Thompson J']","['Acetates/therapeutic use', 'Adult', 'Aged', 'Antimetabolites, Antineoplastic/administration & dosage/*toxicity', 'Capecitabine/administration & dosage/*toxicity', 'Drug-Related Side Effects and Adverse Reactions/drug therapy/*mortality', 'Female', 'Fluorouracil/administration & dosage/*analogs & derivatives/toxicity', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/*drug therapy/mortality/parasitology', 'Patient Safety', 'Risk Assessment', 'Severity of Illness Index', 'Survival Analysis', 'Uridine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30451997/
1862,Capecitabine,33386659,Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine.,"['Schneider JJ', 'Galettis P', 'Martin JH']","['Antimetabolites, Antineoplastic/adverse effects', 'Capecitabine/adverse effects', '*Fluorouracil/adverse effects', 'Humans', '*Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33386659/
1863,Capecitabine,33683181,"5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations.","['Teperikidis E', 'Boulmpou A', 'Charalampidis P', 'Tsavousoglou C', 'Giannakoulas G', 'Papadopoulos CE', 'Vassilikos V']","['*Antineoplastic Agents/therapeutic use', 'Capecitabine/adverse effects', 'Cardiotoxicity/diagnosis/drug therapy/etiology', '*Fluorouracil/adverse effects', 'Humans', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/33683181/
1864,Capecitabine,33470162,Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer.,"['Visacri MB', 'Duarte NC', 'Lima TM', 'de Souza RN', 'Cobaxo TS', 'Teixeira JC', 'Barbosa CR', 'Dias LP', 'Tavares MG', 'Pincinato EC', 'Lima CS', 'Moriel P']","['Aged', 'Capecitabine/adverse effects', 'Fluorouracil/adverse effects', '*Gastrointestinal Neoplasms', 'Humans', 'Male', 'Middle Aged', '*Nausea', 'Prospective Studies', 'Vomiting']",https://pubmed.ncbi.nlm.nih.gov/33470162/
1865,Capecitabine,30313101,Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.,"['Lu Y', 'Zhao Z', 'Wang J', 'Lv W', 'Lu L', 'Fu W', 'Li W']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use', 'Capecitabine/administration & dosage/adverse effects/*therapeutic use', 'Dacarbazine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neoplasm Staging', 'Neuroendocrine Tumors/*drug therapy', 'Observational Studies as Topic', 'Survival Analysis', 'Temozolomide']",https://pubmed.ncbi.nlm.nih.gov/30313101/
1866,Capecitabine,33386926,Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.,"['Lunar N', 'Etienne-Grimaldi MC', 'Macaire P', 'Thomas F', 'Dalenc F', 'Ferrero JM', 'Pivot X', 'Milano G', 'Royer B', 'Schmitt A']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Middle Aged', '*Antimetabolites, Antineoplastic/adverse effects/pharmacokinetics', 'Area Under Curve', '*Breast Neoplasms/drug therapy', '*Capecitabine/adverse effects/pharmacokinetics', 'Deoxycytidine/analogs & derivatives/blood', 'Floxuridine/blood', 'Fluorouracil/blood', '*Models, Biological', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/33386926/
1867,Capecitabine,37027066,Fecal levels of SCFA and BCFA during capecitabine in patients with metastatic or unresectable colorectal cancer.,"['Ziemons J', 'Aarnoutse R', 'Heuft A', 'Hillege L', 'Waelen J', 'de Vos-Geelen J', 'Valkenburg-van Iersel L', 'van Hellemond IEG', 'Creemers GM', 'Baars A', 'Vestjens JHMJ', 'Penders J', 'Venema K', 'Smidt ML']","['Humans', 'Capecitabine/adverse effects', 'RNA, Ribosomal, 16S/genetics', 'Fatty Acids, Volatile/chemistry/metabolism/pharmacology', 'Fatty Acids/pharmacology', '*Colorectal Neoplasms/drug therapy', 'Bacteria/genetics/metabolism', '*Antineoplastic Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/37027066/
1868,Capecitabine,33555963,"Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option?","['Tomao F', 'Caruso G', 'Musacchio L', 'Di Donato V', 'Petrella MC', 'Verrico M', 'Tomao S', 'Benedetti Panici P', 'Muzii L', 'Palaia I']","['Antimetabolites, Antineoplastic/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects', 'Capecitabine/*administration & dosage/adverse effects', 'Combined Modality Therapy', 'Female', 'Humans', 'Neoplasm Recurrence, Local', 'Uterine Cervical Neoplasms/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/33555963/
1869,Capecitabine,39160369,Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.,"['Gupta N', 'Verma N', 'Patel B']","['Humans', '*Administration, Metronomic', 'Antimetabolites, Antineoplastic/administration & dosage/adverse effects', '*Capecitabine/administration & dosage/adverse effects', '*Carcinoma, Hepatocellular/drug therapy/pathology/mortality', '*Liver Neoplasms/drug therapy/pathology/mortality', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39160369/
1870,Fulvestrant,36183733,"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.","['Bidard FC', 'Hardy-Bessard AC', 'Dalenc F', 'Bachelot T', 'Pierga JY', 'de la Motte Rouge T', 'Sabatier R', 'Dubot C', 'Frenel JS', 'Ferrero JM', 'Ladoire S', 'Levy C', 'Mouret-Reynier MA', 'Lortholary A', 'Grenier J', 'Chakiba C', 'Stefani L', 'Plaza JE', 'Clatot F', 'Teixeira L', ""D'Hondt V"", 'Vegas H', 'Derbel O', 'Garnier-Tixidre C', 'Canon JL', 'Pistilli B', 'Andre F', 'Arnould L', 'Pradines A', 'Bieche I', 'Callens C', 'Lemonnier J', 'Berger F', 'Delaloge S']","['Humans', 'Female', 'Adolescent', 'Adult', 'Fulvestrant', 'Aromatase Inhibitors/adverse effects', '*Breast Neoplasms/drug therapy/genetics/pathology', 'Receptors, Estrogen/analysis', 'Receptor, ErbB-2/genetics/analysis', 'Prospective Studies', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Mutation', '*Neutropenia/chemically induced', '*Lymphopenia/chemically induced', 'Disease-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/36183733/
1871,Fulvestrant,37982575,ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.,"['Kingston B', 'Pearson A', 'Herrera-Abreu MT', 'Sim LX', 'Cutts RJ', 'Shah H', 'Moretti L', 'Kilburn LS', 'Johnson H', 'Macpherson IR', 'Ring A', 'Bliss JM', 'Hou Y', 'Toy W', 'Katzenellenbogen JA', 'Chandarlapaty S', 'Turner NC']","['Humans', 'Female', '*Breast Neoplasms/drug therapy/genetics/pathology', 'Fulvestrant/pharmacology/therapeutic use', 'Estrogen Receptor alpha/genetics/metabolism', '*Circulating Tumor DNA/genetics', 'Mutation']",https://pubmed.ncbi.nlm.nih.gov/37982575/
1872,Fulvestrant,30206110,The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.,"[""O'Leary B"", 'Cutts RJ', 'Liu Y', 'Hrebien S', 'Huang X', 'Fenwick K', 'Andre F', 'Loibl S', 'Loi S', 'Garcia-Murillas I', 'Cristofanilli M', 'Huang Bartlett C', 'Turner NC']","['Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Biomarkers, Tumor', 'Breast Neoplasms/drug therapy/*genetics/pathology', '*Clonal Evolution', 'Double-Blind Method', 'Drug Resistance, Neoplasm/*genetics', 'Estrogen Receptor alpha/*genetics', 'Female', 'Follow-Up Studies', 'Fulvestrant/administration & dosage', 'Humans', 'Mutation', 'Piperazines/administration & dosage', 'Prognosis', 'Pyridines/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/30206110/
1873,Fulvestrant,35671774,"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.","['Howell SJ', 'Casbard A', 'Carucci M', 'Ingarfield K', 'Butler R', 'Morgan S', 'Meissner M', 'Bale C', 'Bezecny P', 'Moon S', 'Twelves C', 'Venkitaraman R', 'Waters S', 'de Bruin EC', 'Schiavon G', 'Foxley A', 'Jones RH']","['Adolescent', 'Adult', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', '*Aromatase Inhibitors/therapeutic use', '*Breast Neoplasms/drug therapy/genetics/pathology', 'Double-Blind Method', 'Female', 'Fulvestrant', 'Humans', 'Neoplasm Recurrence, Local/pathology', 'Phosphatidylinositol 3-Kinases/genetics', 'Progression-Free Survival', 'Proto-Oncogene Proteins c-akt', 'Pyrimidines', 'Pyrroles', 'Receptor, ErbB-2/metabolism', 'Receptors, Estrogen/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35671774/
1874,Fulvestrant,34737452,"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.","['Xu B', 'Zhang Q', 'Zhang P', 'Hu X', 'Li W', 'Tong Z', 'Sun T', 'Teng Y', 'Wu X', 'Ouyang Q', 'Yan X', 'Cheng J', 'Liu Q', 'Feng J', 'Wang X', 'Yin Y', 'Shi Y', 'Pan Y', 'Wang Y', 'Xie W', 'Yan M', 'Liu Y', 'Yan P', 'Wu F', 'Zhu X', 'Zou J']","['Antineoplastic Agents, Hormonal/*therapeutic use', 'Breast Neoplasms/*drug therapy/pathology', 'Cell Proliferation/drug effects', 'Cyclin-Dependent Kinase 4/*antagonists & inhibitors', 'Cyclin-Dependent Kinase 6/*antagonists & inhibitors', 'Disease Progression', 'Double-Blind Method', 'Female', 'Fulvestrant/*therapeutic use', 'Humans', 'Middle Aged', 'Piperidines/*therapeutic use', 'Placebos/administration & dosage', 'Progression-Free Survival', 'Protein Kinase Inhibitors/*therapeutic use', 'Pyridines/*therapeutic use', 'Pyrimidines/*therapeutic use', 'Receptor, ErbB-2/metabolism', 'Receptors, Estrogen/metabolism', 'Receptors, Progesterone/metabolism']",https://pubmed.ncbi.nlm.nih.gov/34737452/
1875,Fulvestrant,39241495,"Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.","['Rugo HS', 'Oliveira M', 'Howell SJ', 'Dalenc F', 'Cortes J', 'Gomez HL', 'Hu X', 'Jhaveri KL', 'Krivorotko P', 'Loibl S', 'Morales Murillo S', 'Nowecki Z', 'Okera M', 'Park YH', 'Sohn J', 'Toi M', 'Iwata H', 'Yousef S', 'Zhukova L', 'Logan J', 'Twomey K', 'Khatun M', ""D'Cruz CM"", 'Turner NC']","['Humans', 'Female', '*Fulvestrant/pharmacology/therapeutic use', '*Breast Neoplasms/drug therapy/pathology', 'Middle Aged', 'Aged', '*Pyrroles/adverse effects/pharmacology/therapeutic use', 'Adult', 'Pyrimidines/pharmacology/adverse effects/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects/pharmacology', 'Receptors, Estrogen/metabolism', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/39241495/
1876,Fulvestrant,11398912,Fulvestrant.,"['Curran M', 'Wiseman L']","['Antineoplastic Agents, Hormonal/*therapeutic use', 'Breast Neoplasms/*drug therapy', 'Clinical Trials as Topic', 'Estrogen Antagonists/*therapeutic use', 'Female', 'Humans', 'Steroids/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11398912/
1877,Fulvestrant,35583555,"VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.","['Lindeman GJ', 'Fernando TM', 'Bowen R', 'Jerzak KJ', 'Song X', 'Decker T', 'Boyle F', 'McCune S', 'Armstrong A', 'Shannon C', 'Bertelli G', 'Chang CW', 'Desai R', 'Gupta K', 'Wilson TR', 'Flechais A', 'Bardia A']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects', '*Breast Neoplasms/drug therapy/genetics/pathology', 'Bridged Bicyclo Compounds, Heterocyclic', 'Class I Phosphatidylinositol 3-Kinases/genetics', 'Cyclin-Dependent Kinase 4/antagonists & inhibitors', 'Cyclin-Dependent Kinase 6/antagonists & inhibitors', 'Female', 'Fulvestrant/therapeutic use', 'Humans', '*Protein Kinase Inhibitors/therapeutic use', 'Proto-Oncogene Proteins c-bcl-2', 'Receptor, ErbB-2/metabolism', 'Receptors, Estrogen/metabolism', 'Sulfonamides']",https://pubmed.ncbi.nlm.nih.gov/35583555/
1878,Fulvestrant,38513188,"PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.","['Mayer EL', 'Ren Y', 'Wagle N', 'Mahtani R', 'Ma C', 'DeMichele A', 'Cristofanilli M', 'Meisel J', 'Miller KD', 'Abdou Y', 'Riley EC', 'Qamar R', 'Sharma P', 'Reid S', 'Sinclair N', 'Faggen M', 'Block CC', 'Ko N', 'Partridge AH', 'Chen WY', 'DeMeo M', 'Attaya V', 'Okpoebo A', 'Alberti J', 'Liu Y', 'Gauthier E', 'Burstein HJ', 'Regan MM', 'Tolaney SM']","['Humans', 'Female', '*Breast Neoplasms/drug therapy/pathology/mortality', '*Pyridines/therapeutic use', '*Piperazines/therapeutic use', '*Aromatase Inhibitors/therapeutic use', 'Middle Aged', '*Fulvestrant/therapeutic use', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Aged', '*Cyclin-Dependent Kinase 4/antagonists & inhibitors', '*Receptors, Estrogen/metabolism/analysis', '*Cyclin-Dependent Kinase 6/antagonists & inhibitors', 'Adult', '*Receptor, ErbB-2/metabolism', '*Receptors, Progesterone/metabolism', '*Antibodies, Monoclonal, Humanized/therapeutic use', 'Aged, 80 and over', 'Disease Progression', 'ErbB Receptors/antagonists & inhibitors/metabolism', 'Protein Kinase Inhibitors/therapeutic use', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/38513188/
1879,Fulvestrant,29860922,"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.","['Slamon DJ', 'Neven P', 'Chia S', 'Fasching PA', 'De Laurentiis M', 'Im SA', 'Petrakova K', 'Bianchi GV', 'Esteva FJ', 'Martin M', 'Nusch A', 'Sonke GS', 'De la Cruz-Merino L', 'Beck JT', 'Pivot X', 'Vidam G', 'Wang Y', 'Rodriguez Lorenc K', 'Miller M', 'Taran T', 'Jerusalem G']","['Adult', 'Aged', 'Aged, 80 and over', 'Aminopyridines/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Breast Neoplasms/*drug therapy/mortality', 'Double-Blind Method', 'Female', 'Fulvestrant/*administration & dosage/adverse effects', 'Humans', 'Kaplan-Meier Estimate', 'Middle Aged', 'Progression-Free Survival', 'Purines/*administration & dosage/adverse effects', 'Receptor, ErbB-2/biosynthesis', 'Receptors, Estrogen/biosynthesis', 'Receptors, Progesterone/biosynthesis']",https://pubmed.ncbi.nlm.nih.gov/29860922/
1880,Fulvestrant,29664714,"Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.","['Kornblum N', 'Zhao F', 'Manola J', 'Klein P', 'Ramaswamy B', 'Brufsky A', 'Stella PJ', 'Burnette B', 'Telli M', 'Makower DF', 'Cheema P', 'Truica CI', 'Wolff AC', 'Soori GS', 'Haley B', 'Wassenaar TR', 'Goldstein LJ', 'Miller KD', 'Sparano JA']","['Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Aromatase Inhibitors/administration & dosage', 'Biomarkers, Tumor/metabolism', 'Breast Neoplasms/*drug therapy/genetics/metabolism/pathology', 'Double-Blind Method', 'Drug Synergism', 'Everolimus/administration & dosage', 'Female', 'Fulvestrant/administration & dosage', 'Humans', 'Middle Aged', 'Postmenopause', 'Receptor, ErbB-2/metabolism', 'Receptors, Estrogen/metabolism', 'Response Evaluation Criteria in Solid Tumors', 'Survival Rate', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29664714/
1881,Fulvestrant,37906649,"Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients.","['Tolaney SM', 'Goel S', 'Nadal J', 'Denys H', 'Borrego MR', 'Litchfield LM', 'Liu J', 'Appiah AK', 'Chen Y', 'Andre F']","['Humans', 'Female', 'Trastuzumab/adverse effects', '*Breast Neoplasms/drug therapy/genetics/pathology', 'Fulvestrant/therapeutic use', 'Receptor, ErbB-2/genetics/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37906649/
1882,Fulvestrant,33246021,"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.","['Andre F', 'Ciruelos EM', 'Juric D', 'Loibl S', 'Campone M', 'Mayer IA', 'Rubovszky G', 'Yamashita T', 'Kaufman B', 'Lu YS', 'Inoue K', 'Papai Z', 'Takahashi M', 'Ghaznawi F', 'Mills D', 'Kaper M', 'Miller M', 'Conte PF', 'Iwata H', 'Rugo HS']","['*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Breast Neoplasms/drug therapy/genetics', 'Class I Phosphatidylinositol 3-Kinases/genetics', 'Female', 'Fulvestrant', 'Humans', 'Male', 'Receptor, ErbB-2/genetics', 'Receptors, Estrogen/genetics', 'Thiazoles']",https://pubmed.ncbi.nlm.nih.gov/33246021/
1883,Fulvestrant,35552673,"Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.","['Cristofanilli M', 'Rugo HS', 'Im SA', 'Slamon DJ', 'Harbeck N', 'Bondarenko I', 'Masuda N', 'Colleoni M', 'DeMichele A', 'Loi S', 'Iwata H', ""O'Leary B"", 'Andre F', 'Loibl S', 'Bananis E', 'Liu Y', 'Huang X', 'Kim S', 'Lechuga Frean MJ', 'Turner NC']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects', '*Breast Neoplasms/drug therapy/genetics/metabolism', 'Double-Blind Method', 'Female', 'Fulvestrant', 'Humans', 'Piperazines', 'Pyridines', '*Receptor, ErbB-2/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35552673/
1884,Fulvestrant,31826360,Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.,"['Slamon DJ', 'Neven P', 'Chia S', 'Fasching PA', 'De Laurentiis M', 'Im SA', 'Petrakova K', 'Bianchi GV', 'Esteva FJ', 'Martin M', 'Nusch A', 'Sonke GS', 'De la Cruz-Merino L', 'Beck JT', 'Pivot X', 'Sondhi M', 'Wang Y', 'Chakravartty A', 'Rodriguez-Lorenc K', 'Taran T', 'Jerusalem G']","['Aged', 'Aminopyridines/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/mortality', 'Drug Administration Schedule', 'Female', 'Fulvestrant/*administration & dosage/adverse effects', 'Humans', 'Kaplan-Meier Estimate', 'Middle Aged', 'Postmenopause', 'Progression-Free Survival', 'Purines/*administration & dosage/adverse effects', 'Receptor, ErbB-2', 'Receptors, Estrogen', 'Receptors, Progesterone']",https://pubmed.ncbi.nlm.nih.gov/31826360/
1885,Fulvestrant,26947331,"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.","['Cristofanilli M', 'Turner NC', 'Bondarenko I', 'Ro J', 'Im SA', 'Masuda N', 'Colleoni M', 'DeMichele A', 'Loi S', 'Verma S', 'Iwata H', 'Harbeck N', 'Zhang K', 'Theall KP', 'Jiang Y', 'Bartlett CH', 'Koehler M', 'Slamon D']","['Adult', 'Aged', 'Breast Neoplasms/*drug therapy/genetics/pathology', 'Class I Phosphatidylinositol 3-Kinases', 'Disease-Free Survival', 'Double-Blind Method', 'Estradiol/administration & dosage/*analogs & derivatives', 'Female', 'Fulvestrant', 'Humans', 'Middle Aged', 'Mutation', 'Neoplasm Metastasis', 'Neoplasm Recurrence, Local/genetics/pathology', 'Phosphatidylinositol 3-Kinases/*genetics', 'Piperazines/*administration & dosage', 'Pyridines/*administration & dosage', 'Receptor, ErbB-2/*genetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26947331/
1886,Fulvestrant,34102253,"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.","['Slamon DJ', 'Neven P', 'Chia S', 'Jerusalem G', 'De Laurentiis M', 'Im S', 'Petrakova K', 'Valeria Bianchi G', 'Martin M', 'Nusch A', 'Sonke GS', 'De la Cruz-Merino L', 'Beck JT', 'Ji Y', 'Wang C', 'Deore U', 'Chakravartty A', 'Zarate JP', 'Taran T', 'Fasching PA']","['Adolescent', 'Aminopyridines', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', '*Breast Neoplasms/drug therapy', 'Double-Blind Method', 'Female', 'Fulvestrant', 'Humans', 'Postmenopause', 'Purines', 'Receptor, ErbB-2', 'Receptors, Estrogen', 'Receptors, Progesterone']",https://pubmed.ncbi.nlm.nih.gov/34102253/
1887,Fulvestrant,31563959,"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.","['Sledge GW Jr', 'Toi M', 'Neven P', 'Sohn J', 'Inoue K', 'Pivot X', 'Burdaeva O', 'Okera M', 'Masuda N', 'Kaufman PA', 'Koh H', 'Grischke EM', 'Conte P', 'Lu Y', 'Barriga S', 'Hurt K', 'Frenzel M', 'Johnston S', 'Llombart-Cussac A']","['Aminopyridines/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Benzimidazoles', '*Breast Neoplasms/pathology', 'Female', 'Fulvestrant', 'Humans', 'Middle Aged', 'Receptor, ErbB-2', '*Triple Negative Breast Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31563959/
1888,Fulvestrant,33987967,Fatal acute hepatic failure secondary to thrombotic portal venopathy after commencing abemaciclib and fulvestrant treatment for advanced breast carcinoma: a unique autopsy finding.,"['Haynes HR', 'Mohan V', 'Mozayani B', 'Gallagher P']","['Aminopyridines', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Autopsy', 'Benzimidazoles', '*Breast Neoplasms/drug therapy', 'Female', 'Fulvestrant/adverse effects', 'Humans', '*Liver Failure, Acute', 'Receptor, ErbB-2']",https://pubmed.ncbi.nlm.nih.gov/33987967/
1889,Fulvestrant,36168844,"Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.","['Toi M', 'Huang CS', 'Im YH', 'Sohn J', 'Zhang W', 'Sakaguchi S', 'Haddad N', 'van Hal G', 'Sledge GW Jr']","['Female', 'Humans', '*Breast Neoplasms/metabolism', 'Fulvestrant', 'East Asian People', 'Receptor, ErbB-2/genetics/metabolism', 'Aminopyridines', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36168844/
1890,Ondansetron,28682150,Drug-drug interaction related to the use of pipamperon and ondansetron in a child treated for leukemia.,"['Bauters T', 'Buts S', 'Bordon V', 'Laureys G']","['Butyrophenones/administration & dosage/*adverse effects', 'Child', 'Drug Interactions', 'Electrocardiography/drug effects', 'Humans', 'Leukemia/drug therapy', 'Long QT Syndrome/*chemically induced', 'Male', 'Ondansetron/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28682150/
1891,Ondansetron,7795925,Ondansetron and opiate craving. A novel pharmacological approach to addiction.,"['Sell LA', 'Cowen PJ', 'Robson PJ']","['Female', 'Humans', 'Male', 'Methadone/administration & dosage/*therapeutic use', '*Narcotics', 'Ondansetron/administration & dosage/*therapeutic use', 'Substance Withdrawal Syndrome/diagnosis/*drug therapy', '*Substance-Related Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7795925/
1892,Ondansetron,24314899,Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis.,"['Freedman SB', 'Uleryk E', 'Rumantir M', 'Finkelstein Y']","['Antiemetics/administration & dosage/*adverse effects', 'Arrhythmias, Cardiac/*chemically induced', 'Emergency Treatment', 'Humans', 'Monitoring, Physiologic', 'Ondansetron/administration & dosage/*adverse effects', '*Product Surveillance, Postmarketing', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/24314899/
1893,Ondansetron,32526103,Major Congenital Malformation Risk After First Trimester Gestational Exposure to Oral or Intravenous Ondansetron.,['Andrade C'],"['Abnormalities, Drug-Induced/*etiology', 'Administration, Intravenous', 'Administration, Oral', 'Antiemetics/administration & dosage/therapeutic use/*toxicity', 'Female', 'Humans', 'Morning Sickness/drug therapy', 'Ondansetron/administration & dosage/therapeutic use/*toxicity', 'Pregnancy', 'Pregnancy Trimester, First', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/32526103/
1894,Ondansetron,30849498,Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis.,"['Kaplan YC', 'Richardson JL', 'Keskin-Arslan E', 'Erol-Coskun H', 'Kennedy D']","['Abnormalities, Drug-Induced/*epidemiology', 'Antiemetics/*therapeutic use', 'Case-Control Studies', 'Cohort Studies', 'Female', 'Humans', 'Ondansetron/*therapeutic use', 'Pregnancy', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/30849498/
1895,Ondansetron,29995744,Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects.,"['Parker SE', 'Van Bennekom C', 'Anderka M', 'Mitchell AA']","['Abnormalities, Drug-Induced/epidemiology/*etiology', 'Adult', 'Antiemetics/*adverse effects/therapeutic use', 'Case-Control Studies', 'Drug Administration Schedule', 'Female', 'Humans', 'Infant, Newborn', 'Male', 'Morning Sickness/*drug therapy', 'Odds Ratio', 'Ondansetron/*adverse effects/therapeutic use', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Trimester, First', 'Risk Factors', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/29995744/
1896,Ondansetron,21091329,Ondansetron is safe and effective for prehospital treatment of nausea and vomiting by paramedics.,"['Salvucci AA', 'Squire B', 'Burdick M', 'Luoto M', 'Brazzel D', 'Vaezazizi R']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Allied Health Personnel/*statistics & numerical data', 'Antiemetics/administration & dosage/adverse effects/*therapeutic use', 'California', 'Child', 'Child, Preschool', 'Confidence Intervals', 'Databases, Factual', 'Emergency Medical Services/*methods/statistics & numerical data', 'Female', 'Health Status Indicators', 'Humans', 'Infant', 'Infant, Newborn', 'Infusions, Intravenous', 'Injections, Intramuscular', 'Male', 'Middle Aged', 'Nausea/*drug therapy', 'Ondansetron/administration & dosage/adverse effects/*therapeutic use', 'Pain Measurement', 'Prospective Studies', 'Statistics, Nonparametric', 'Tablets', 'Vomiting/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21091329/
1897,Ondansetron,30501160,Effects of Ondansetron on Attenuating Spinal Anesthesia-Induced Hypotension and Bradycardia in Obstetric and Nonobstetric Subjects: A Systematic Review and Meta-Analysis.,"['Tubog TD', 'Kane TD', 'Pugh MA']","['Anesthesia, Spinal/*adverse effects', 'Antiemetics/administration & dosage/*therapeutic use', 'Bradycardia/etiology/*prevention & control', '*Delivery, Obstetric', 'Female', 'Humans', 'Hypotension/etiology/*prevention & control', 'Infusions, Intravenous', 'Nurse Anesthetists', 'Ondansetron/administration & dosage/*therapeutic use', 'Pregnancy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/30501160/
1898,Ondansetron,25960637,Efficacy and safety of ramosetron versus ondansetron for postoperative nausea and vomiting after general anesthesia: a meta-analysis of randomized clinical trials.,"['Gao C', 'Li B', 'Xu L', 'Lv F', 'Cao G', 'Wang H', 'Wang F', 'Wu G']","['Antiemetics/adverse effects/*therapeutic use', 'Benzimidazoles/adverse effects/*therapeutic use', 'Humans', 'Ondansetron/adverse effects/*therapeutic use', 'Postoperative Nausea and Vomiting/*drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/25960637/
1899,Ondansetron,7691500,Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.,"['Markham A', 'Sorkin EM']","['Antineoplastic Agents/*adverse effects', 'Cisplatin/adverse effects', 'Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Nausea/chemically induced/*drug therapy', 'Ondansetron/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Postoperative Complications/*drug therapy/prevention & control', 'Radiotherapy/*adverse effects', 'Vomiting/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7691500/
1900,Ondansetron,10887851,Systematic review of ondansetron for the prevention and treatment of postoperative nausea and vomiting in adults.,['Cox F'],"['Adult', 'Antiemetics/pharmacology/*therapeutic use', 'Double-Blind Method', 'Humans', 'Ondansetron/pharmacology/*therapeutic use', 'Patient Satisfaction', 'Postoperative Care/methods', 'Postoperative Nausea and Vomiting/*drug therapy/*prevention & control/psychology', 'Randomized Controlled Trials as Topic', 'Research Design', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10887851/
1901,Ondansetron,32382791,Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis.,"['Fugetto F', 'Filice E', 'Biagi C', 'Pierantoni L', 'Gori D', 'Lanari M']","['Acute Disease', 'Adolescent', 'Antiemetics/*administration & dosage/therapeutic use', 'Child', 'Drug Administration Schedule', 'Gastroenteritis/*complications', 'Humans', 'Models, Statistical', 'Ondansetron/*administration & dosage/therapeutic use', 'Treatment Outcome', 'Vomiting/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/32382791/
1902,Ondansetron,23578248,"Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia.","['Doggrell SA', 'Hancox JC']","['Antiemetics/*adverse effects/*therapeutic use', 'Antineoplastic Agents/adverse effects/therapeutic use', 'Arrhythmias, Cardiac/*chemically induced', 'Humans', 'Nausea/*drug therapy', 'Ondansetron/*adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/23578248/
1903,Ondansetron,28977021,Comparative efficacy of ramosetron and ondansetron in preventing postoperative nausea and vomiting: An updated systematic review and meta-analysis with trial sequential analysis.,"['Yokoi A', 'Mihara T', 'Ka K', 'Goto T']","['Antiemetics/*therapeutic use', 'Benzimidazoles/*therapeutic use', 'Humans', 'Ondansetron/*therapeutic use', 'Postoperative Nausea and Vomiting/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/28977021/
1904,Ondansetron,26835645,"Does Ondansetron Modify Sympathectomy Due to Subarachnoid Anesthesia?: Meta-analysis, Meta-regression, and Trial Sequential Analysis.","['Terkawi AS', 'Mavridis D', 'Flood P', 'Wetterslev J', 'Terkawi RS', 'Bin Abdulhak AA', 'Nunemaker MS', 'Tiouririne M']","['Anesthesia/*methods', 'Humans', 'Ondansetron/*pharmacology', 'Randomized Controlled Trials as Topic', 'Serotonin Antagonists/*pharmacology', 'Subarachnoid Space/drug effects', '*Sympathectomy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26835645/
1905,Ondansetron,34426397,Oral ondansetron for paediatric gastroenteritis in primary care: a randomised controlled trial.,"['Bonvanie IJ', 'Weghorst AA', 'Holtman GA', 'Russchen HA', 'Fickweiler F', 'Verkade HJ', 'Kollen BJ', 'Berger MY']","['Administration, Oral', '*Antiemetics/therapeutic use', 'Child', 'Child, Preschool', 'Double-Blind Method', '*Gastroenteritis/drug therapy', 'Humans', 'Infant', 'Ondansetron/therapeutic use', 'Primary Health Care', 'Treatment Outcome', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34426397/
1906,Ondansetron,27180992,"Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.","['Simino GP', 'Marra LP', 'Andrade EI', 'Acurcio Fde A', 'Reis IA', 'De Araujo VE', 'Cherchiglia ML']","['Antiemetics/adverse effects/pharmacology/therapeutic use', 'Antineoplastic Agents/adverse effects/therapeutic use', 'Humans', 'Nausea/chemically induced/*drug therapy', 'Neoplasms/drug therapy', 'Ondansetron/adverse effects/pharmacology/*therapeutic use', 'Quality of Life', 'Randomized Controlled Trials as Topic', 'Serotonin 5-HT3 Receptor Agonists/adverse effects/pharmacology/therapeutic use', 'Vomiting/chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27180992/
1907,Ondansetron,27634586,Long-term stability of dexamethasone and alizapride or ondansetron in sodium chloride 0.9% polyolefin bag at 5+/-3 degrees C.,"['Simar J', 'Godet M', 'Hecq JD', 'Closset M', 'Gillet P', 'Langhendries C', 'Bihin B', 'Jamart J', 'Galanti L']","['Antiemetics/*analysis', 'Dexamethasone/*analysis', 'Drug Combinations', 'Drug Stability', 'Drug Storage', 'Ondansetron/*analysis', 'Pharmaceutical Solutions', 'Polyenes', 'Pyrrolidines/*analysis', 'Sodium Chloride']",https://pubmed.ncbi.nlm.nih.gov/27634586/
1908,Olmesartan medoxomil,15013933,Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide.,"['Chrysant SG', 'Chrysant GS']","['Angiotensin II Type 2 Receptor Blockers', 'Antihypertensive Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Diuretics', 'Drug Therapy, Combination', 'Humans', 'Hydrochlorothiazide/administration & dosage/*therapeutic use', 'Hypertension/*drug therapy', 'Imidazoles/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Olmesartan Medoxomil', 'Randomized Controlled Trials as Topic', 'Sodium Chloride Symporter Inhibitors/administration & dosage/*therapeutic use', 'Tetrazoles/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15013933/
1909,Olmesartan medoxomil,21166525,"Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.",['Ram CV'],"['Amlodipine/adverse effects/pharmacology/*therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/*therapeutic use', 'Drug Combinations', 'Drug Therapy, Combination/adverse effects', 'Humans', 'Hydrochlorothiazide/adverse effects/pharmacology/*therapeutic use', 'Hypertension/*drug therapy', 'Imidazoles/adverse effects/pharmacology/*therapeutic use', 'Olmesartan Medoxomil', 'Tetrazoles/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21166525/
1910,Olmesartan medoxomil,23669062,Clinical effects of combined olmesartan medoxomil and amlodipine on clinic and ambulatory blood pressure in elderly patients with resistant hypertension.,"['Ding S', 'Liu J', 'Fu Q', 'Zheng Y']","['Aged', 'Amlodipine/administration & dosage/adverse effects/*therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Blood Pressure Monitoring, Ambulatory', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Imidazoles/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Olmesartan Medoxomil', 'Tetrazoles/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23669062/
1911,Olmesartan medoxomil,19210150,Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies.,['Ram CV'],"['Amlodipine/administration & dosage/*therapeutic use', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Humans', 'Hypertension/*drug therapy', 'Imidazoles/administration & dosage/*therapeutic use', 'Olmesartan Medoxomil', 'Placebos', 'Randomized Controlled Trials as Topic', 'Tetrazoles/administration & dosage/*therapeutic use', 'Valine/administration & dosage/*analogs & derivatives/therapeutic use', 'Valsartan']",https://pubmed.ncbi.nlm.nih.gov/19210150/
1912,Olmesartan medoxomil,17953473,Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists.,['Smith DH'],"['*Angiotensin Receptor Antagonists', 'Antihypertensive Agents/*pharmacology', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Humans', 'Imidazoles/*pharmacology', 'Olmesartan Medoxomil', 'Tetrazoles/*pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17953473/
1913,Olmesartan medoxomil,15291376,Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?,['Wehling M'],"['Angiotensin II Type 1 Receptor Blockers', 'Antihypertensive Agents/administration & dosage/adverse effects/*pharmacokinetics/therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Food-Drug Interactions', 'Humans', 'Hypertension/*drug therapy', 'Imidazoles/administration & dosage/adverse effects/*pharmacokinetics/therapeutic use', 'Olmesartan Medoxomil', 'Patient Compliance', 'Receptor, Angiotensin, Type 1/metabolism', 'Tetrazoles/administration & dosage/adverse effects/*pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15291376/
1914,Olmesartan medoxomil,12461321,A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?,['Greathouse M'],"['Angiotensin Receptor Antagonists', 'Antihypertensive Agents/*therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Humans', 'Hydrochlorothiazide/therapeutic use', 'Hypertension/drug therapy/epidemiology', 'Imidazoles/*therapeutic use', 'Olmesartan Medoxomil', 'Randomized Controlled Trials as Topic', 'Receptors, Angiotensin/therapeutic use', 'Tetrazoles/*therapeutic use', 'Treatment Outcome', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/12461321/
1915,Olmesartan medoxomil,17554345,"Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update.","['Chrysant SG', 'Dimas B', 'Shiraz M']","['Angiotensin II Type 1 Receptor Blockers/*therapeutic use', 'Clinical Trials as Topic', 'Diuretics/*administration & dosage', 'Drug Therapy, Combination', 'Humans', 'Hypertension/*drug therapy', 'Imidazoles/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Tetrazoles/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17554345/
1916,Olmesartan medoxomil,35972198,Permeability of olmesartan medoxomil from lipid based and suspension formulations using an optimized HDM-PAMPA model.,"['Komesli Y', 'Karasulu E']","['Alkanes', '*Carboxymethylcellulose Sodium', 'Lipids', '*Membranes, Artificial', 'Olmesartan Medoxomil', 'Permeability', 'Suspensions']",https://pubmed.ncbi.nlm.nih.gov/35972198/
1917,Telmisartan,32937023,Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.,"['Jin X', 'Kim MH', 'Han KH', 'Hong SJ', 'Ahn JC', 'Sung JH', 'Cho JM', 'Lee HC', 'Choi SY', 'Lee K', 'Kim WS', 'Rhee MY', 'Kim JH', 'Hong SP', 'Yoo BS', 'Cho EJ', 'Lee JH', 'Kim PJ', 'Park CG', 'Hyon MS', 'Shin JH', 'Lee SH', 'Sung KC', 'Hwang J', 'Kwon K', 'Chae IH', 'Seo JS', 'Kim H', 'Lee H', 'Cho Y', 'Kim HS']","['Aged', 'Amlodipine/*administration & dosage/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', '*Dyslipidemias/drug therapy', 'Female', 'Humans', '*Hypertension/drug therapy', 'Male', 'Middle Aged', 'Rosuvastatin Calcium/*administration & dosage/therapeutic use', 'Telmisartan/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32937023/
1918,Telmisartan,39426836,"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.","['Rodgers A', 'Salam A', 'Schutte AE', 'Cushman WC', 'de Silva HA', 'Di Tanna GL', 'Grobbee DE', 'Narkiewicz K', 'Ojji DB', 'Poulter NR', 'Schlaich MP', 'Oparil S', 'Spiering W', 'Williams B', 'Wright JT Jr', 'Lakshman P', 'Uluwattage W', 'Hay P', 'Pereira T', 'Amarasena N', 'Ranasinghe G', 'Gianacas C', 'Shanthakumar M', 'Liu X', 'Wang N', 'Gnanenthiran SR', 'Whelton PK']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Amlodipine/administration & dosage/adverse effects', '*Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', '*Hypertension/drug therapy', '*Indapamide/administration & dosage/adverse effects/therapeutic use', '*Telmisartan/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39426836/
1919,Telmisartan,35851888,"RP-HPLC method development and validation for simultaneous estimation of telmisartan, rosuvastatin calcium, and amlodipine besylate in combination.","['Mistry RP', 'Shah C', 'Jat R']","['*Amlodipine/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Chromatography, High Pressure Liquid', 'Humans', '*Hypertension/drug therapy', 'Rosuvastatin Calcium/therapeutic use', 'Telmisartan/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35851888/
1920,Telmisartan,38319595,"Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial.","['Lee CJ', 'Kang WC', 'Ihm SH', 'Sohn IS', 'Woo JS', 'Kim JW', 'Hong SJ', 'Choi JH', 'Suh JW', 'Seo JB', 'Doh JH', 'Son JW', 'Park JH', 'Lee JH', 'Hong YJ', 'Heo JH', 'Shin J', 'Kang SM']","['Humans', 'Anticholesteremic Agents/therapeutic use', 'Cholesterol, LDL', 'Double-Blind Method', 'Drug Therapy, Combination/adverse effects', '*Dyslipidemias/drug therapy', '*Ezetimibe/therapeutic use', '*Hypertension/drug therapy', '*Rosuvastatin Calcium/therapeutic use', '*Telmisartan/therapeutic use', 'Treatment Outcome', 'Antihypertensive Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38319595/
1921,Telmisartan,36577854,A Novel Hybrid of Telmisartan and Borneol Ameliorates Neuroinflammation and White Matter Injury in Ischemic Stroke Through ATF3/CH25H Axis.,"['Guan X', 'Wu J', 'Geng J', 'Ji D', 'Wei D', 'Ling Y', 'Zhang Y', 'Jiang G', 'Pang T', 'Huang Z']","['Humans', 'Telmisartan/therapeutic use/metabolism', '*Ischemic Stroke/drug therapy/metabolism', '*White Matter', 'Neuroinflammatory Diseases', '*Stroke/drug therapy/metabolism', '*Brain Injuries/metabolism', 'Microglia/metabolism', 'Activating Transcription Factor 3/metabolism/therapeutic use', '*Camphanes']",https://pubmed.ncbi.nlm.nih.gov/36577854/
1922,Telmisartan,12732865,"Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist.","['Pietrement C', 'Malot L', 'Santerne B', 'Roussel B', 'Motte J', 'Morville P']","['Acute Kidney Injury/chemically induced/*congenital', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects', 'Benzimidazoles/*adverse effects', 'Benzoates/*adverse effects', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Infant, Newborn', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/12732865/
1923,Telmisartan,38228033,Effects of telmisartan on metabolic syndrome components: a comprehensive review.,"['Imenshahidi M', 'Roohbakhsh A', 'Hosseinzadeh H']","['Humans', 'Telmisartan/pharmacology', 'Angiotensin Receptor Antagonists/pharmacology', '*Metabolic Syndrome/drug therapy', 'PPAR gamma/pharmacology', 'Prospective Studies', 'Angiotensin II Type 1 Receptor Blockers/pharmacology', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology', 'Benzimidazoles/pharmacology', '*Hypertension/drug therapy', 'Antihypertensive Agents/pharmacology', 'Blood Pressure', 'Benzoates/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/38228033/
1924,Telmisartan,35667505,"Simultaneous determination of hydrochlorothiazide, amlodipine, and telmisartan with spectrophotometric and HPLC green chemistry applications.","['Tiris G', 'Mehmandoust M', 'Lotfy HM', 'Erk N', 'Joo SW', 'Dragoi EN', 'Vasseghian Y']","['*Amlodipine/analysis', 'Chromatography, High Pressure Liquid/methods', 'Humans', 'Hydrochlorothiazide/analysis', '*Leukemia, Myeloid, Acute', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/35667505/
1925,Telmisartan,38871219,"Comparison of the efficacy, safety, and tolerability of the FDC of telmisartan + bisoprolol with telmisartan + metoprolol succinate ER combination therapy for stage 1 and stage 2 hypertension: A double-blind, multicentric, phase-III clinical study.","['Wander GS', 'Ram B', 'Kumar Sonkar S', 'Manjunath CN', 'Kamath P', 'Sreenivasamurthy L', 'Balamurugan R', 'Narasinga Rao S', 'Roy D', 'Vipulkumar Bachubhai P', 'S M', 'Kumar M K']","['Humans', 'Male', '*Hypertension/drug therapy/physiopathology', 'Female', '*Bisoprolol/administration & dosage/therapeutic use', 'Double-Blind Method', 'Middle Aged', 'Prospective Studies', 'Treatment Outcome', '*Blood Pressure/drug effects', '*Telmisartan/administration & dosage/therapeutic use', '*Metoprolol/administration & dosage/therapeutic use', 'Benzoates/administration & dosage/therapeutic use', 'Benzimidazoles/administration & dosage/therapeutic use', 'India', 'Dose-Response Relationship, Drug', 'Antihypertensive Agents/therapeutic use/administration & dosage', 'Drug Therapy, Combination', 'Adult', 'Drug Combinations', 'Follow-Up Studies']",https://pubmed.ncbi.nlm.nih.gov/38871219/
1926,Telmisartan,14513950,The telmisartan programme of research tO show Telmisartan End-organ proteCTION (PROTECTION) programme.,['Weber M'],"['Angiotensin-Converting Enzyme Inhibitors/*administration & dosage', 'Benzimidazoles/*administration & dosage', 'Benzoates/*administration & dosage', 'Cardiovascular Diseases/prevention & control', 'Clinical Trials as Topic', 'Humans', 'Hypertension/complications/*drug therapy', 'Kidney Diseases/prevention & control', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/14513950/
1927,Telmisartan,39443527,Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial.,"['Bonnet F', 'Doumbia A', 'Machault V', 'Ello FN', 'Bellecave P', 'Akpovo CB', 'Sidibe BT', 'Fernandez L', 'Kouame A', 'Adjogoua E', 'Dosso M', 'Niangoran S', 'Journot V', 'Eholie SP']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Antiviral Agents/therapeutic use', '*Atorvastatin/therapeutic use/administration & dosage', '*COVID-19/virology', '*COVID-19 Drug Treatment', 'Nasopharynx/virology', 'SARS-CoV-2/isolation & purification', '*Telmisartan/therapeutic use/administration & dosage', '*Viral Load/drug effects']",https://pubmed.ncbi.nlm.nih.gov/39443527/
1928,Telmisartan,37986329,"Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.","['Yoo YG', 'Lim MJ', 'Kim JS', 'Jeong HE', 'Ko H', 'Shin JY']","['Humans', 'Losartan/adverse effects', 'Irbesartan/adverse effects', 'Telmisartan/therapeutic use', 'Valsartan/therapeutic use', 'Angiotensin Receptor Antagonists', 'Retrospective Studies', 'Tetrazoles/adverse effects', 'Biphenyl Compounds', 'Benzimidazoles/adverse effects', 'Angiotensin-Converting Enzyme Inhibitors', '*Heart Failure/epidemiology', '*Myocardial Infarction/chemically induced/epidemiology', '*Cerebrovascular Disorders/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/37986329/
1929,Rosiglitazone,32828280,Rosiglitazone binds to RXRalpha to induce RXRalpha tetramerization and NB4 cell differentiation.,"['Huang F', 'Li Y', 'Chen J', 'Zhang XK', 'Zhou H']","['Cell Differentiation/*drug effects', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'HEK293 Cells', 'Humans', 'Hypoglycemic Agents/*pharmacology', 'Leukemia, Promyelocytic, Acute/metabolism', 'Protein Multimerization/*drug effects', 'Retinoid X Receptor alpha/*metabolism', 'Rosiglitazone/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32828280/
1930,Rosiglitazone,37318502,No causal effects between rosiglitazone and cardiovascular disease or risk factors: a Mendelian randomization study.,"['Li XM', 'Wu ZJ', 'Xu ZL', 'Li A', 'Liu MQ', 'Song CG', 'Wu K']","['Humans', '*Cardiovascular Diseases/chemically induced/epidemiology/genetics', 'Genome-Wide Association Study', 'Mendelian Randomization Analysis', 'Risk Factors', 'Polymorphism, Single Nucleotide', 'Rosiglitazone/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37318502/
1931,Rosiglitazone,32024657,Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.,"['Wallach JD', 'Wang K', 'Zhang AD', 'Cheng D', 'Grossetta Nardini HK', 'Lin H', 'Bracken MB', 'Desai M', 'Krumholz HM', 'Ross JS']","['Cardiovascular Diseases/*chemically induced/mortality', 'Humans', 'Hypoglycemic Agents/*adverse effects/pharmacology', 'Information Dissemination', 'Randomized Controlled Trials as Topic', 'Risk Factors', 'Rosiglitazone/*adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32024657/
1932,Rosiglitazone,26376779,Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.,"['Mendes D', 'Alves C', 'Batel-Marques F']","['Adverse Drug Reaction Reporting Systems/*standards', 'Cardiovascular Diseases/chemically induced/*epidemiology', 'Female', 'Humans', 'Hypoglycemic Agents/*adverse effects', 'Male', 'Patient Selection', 'Pioglitazone', 'Randomized Controlled Trials as Topic', 'Rosiglitazone', 'Thiazolidinediones/*adverse effects', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/26376779/
1933,Rosiglitazone,18376358,Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?,"['Stulc T', 'Ceska R']","['Cardiovascular Diseases/metabolism/*prevention & control', 'Diabetes Mellitus/metabolism/*prevention & control', 'Humans', 'PPAR gamma/agonists/metabolism', 'Risk Factors', 'Rosiglitazone', 'Thiazolidinediones/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/18376358/
1934,Rosiglitazone,30782959,Rosiglitazone remodels the lipid droplet and britens human visceral and subcutaneous adipocytes ex vivo.,"['Lee MJ', 'Jash S', 'Jones JEC', 'Puri V', 'Fried SK']","['Adipocytes/*drug effects/metabolism', 'Adipose Tissue/*drug effects/metabolism', 'Adult', 'Aged', 'Female', 'Humans', 'Hypoglycemic Agents/*pharmacology', 'Lipid Droplets/*drug effects/metabolism', 'Male', 'Middle Aged', 'Oxidation-Reduction', 'Phenotype', 'Rosiglitazone/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30782959/
1935,Rosiglitazone,37887306,Gene Expression Analyses in Models of Rosiglitazone-Induced Physiological and Pathological Mineralization Identify Novel Targets to Improve Bone and Vascular Health.,"['Bruedigam C', 'Leeuwen JPTMV', 'Peppel JV']","['Humans', 'Rosiglitazone/pharmacology', 'Cell Differentiation', '*Osteogenesis', 'Gene Expression Profiling', 'Muscle, Smooth, Vascular/metabolism', '*Calcinosis/pathology', 'Nuclear Proteins/metabolism', 'Adaptor Proteins, Signal Transducing/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37887306/
1936,Rosiglitazone,21116607,Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.,"['Gerstein HC', 'Mohan V', 'Avezum A', 'Bergenstal RM', 'Chiasson JL', 'Garrido M', 'MacKinnon I', 'Rao PV', 'Zinman B', 'Jung H', 'Joldersma L', 'Bosch J', 'Yusuf S']","['Aged', 'Diabetes Mellitus/*drug therapy/prevention & control', 'Female', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Male', 'Middle Aged', 'Ramipril/*therapeutic use', 'Rosiglitazone', 'Thiazolidinediones/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21116607/
1937,Rosiglitazone,21415383,"Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT.","['Kahn SE', 'Lachin JM', 'Zinman B', 'Haffner SM', 'Aftring RP', 'Paul G', 'Kravitz BG', 'Herman WH', 'Viberti G', 'Holman RR']","['Aged', 'Diabetes Mellitus, Type 2/*drug therapy/physiopathology', 'Female', 'Glyburide/*therapeutic use', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Insulin Resistance/physiology', 'Insulin-Secreting Cells/*drug effects', 'Male', 'Metformin/*therapeutic use', 'Middle Aged', 'Rosiglitazone', 'Thiazolidinediones/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21415383/
1938,Rosiglitazone,29573098,Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: A 1-year randomized study.,"['Piche ME', 'Laberge AS', 'Brassard P', 'Arsenault BJ', 'Bertrand OF', 'Despres JP', 'Costerousse O', 'Poirier P']","['Aged', 'Blood Glucose/metabolism', '*Blood Pressure', 'Coronary Artery Disease/complications', 'Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism', 'Double-Blind Method', '*Exercise', 'Exercise Test', 'Exercise Tolerance', 'Glycated Hemoglobin/metabolism', 'Humans', 'Hypertension/complications/*physiopathology', 'Hypoglycemic Agents/*therapeutic use', 'Insulin Resistance', 'Male', 'Middle Aged', 'PPAR gamma/agonists', 'Rest', 'Rosiglitazone/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29573098/
1939,Repaglinide,25005849,Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials.,"['Yin J', 'Deng H', 'Qin S', 'Tang W', 'Zeng L', 'Zhou B']","['Carbamates/adverse effects/*therapeutic use', 'Diabetes Mellitus, Type 2/blood/*drug therapy', 'Drug Therapy, Combination/adverse effects', 'Glycated Hemoglobin/analysis', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Metformin/adverse effects/*therapeutic use', 'Piperidines/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25005849/
1940,Repaglinide,25656849,A sensitive chemiluminescent immunoassay for point-of-care testing of repaglinide in natural dietary supplements and serum.,"['Zheng L', 'Wang J', 'Wang Y', 'Song Z', 'Dong Y', 'Yin Y', 'Eremin SA', 'Meng M', 'Xi R']","['Carbamates/*analysis/*blood', 'Chromatography, High Pressure Liquid', 'Dietary Supplements/*analysis', 'Humans', '*Immunoassay', 'Limit of Detection', '*Luminescence', 'Piperidines/*analysis/*blood', 'Point-of-Care Systems']",https://pubmed.ncbi.nlm.nih.gov/25656849/
1941,Repaglinide,35797718,"Principal Component Analysis and DoE-Based AQbD Approach to Multipurpose HPTLC Method for Synchronous Estimation of Multiple FDCs of Metformin HCl, Repaglinide, Glibenclamide and Pioglitazone HCl.","['Prajapati P', 'Radadiya K', 'Shah S']","['*Metformin', 'Pioglitazone', 'Glyburide', 'Chromatography, Thin Layer', 'Principal Component Analysis', 'Drug Combinations', 'Hypoglycemic Agents', 'Solvents', '*Carbamates', '*Piperidines']",https://pubmed.ncbi.nlm.nih.gov/35797718/
1942,Repaglinide,22752435,Validated stability-indicating spectrofluorimetric method with enhanced sensitivity for determination of repaglinide in tablets.,['El-Shaheny RN'],"['Carbamates/*analysis/chemistry', 'Drug Stability', 'Linear Models', 'Methanol/chemistry', 'Piperidines/*analysis/chemistry', 'Solvents/chemistry', 'Spectrometry, Fluorescence/*methods', 'Sulfuric Acids/chemistry', 'Tablets', 'Temperature', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/22752435/
1943,Repaglinide,30636597,Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis.,"['Zhou S', 'Xiang Q', 'Mu G', 'Ma L', 'Chen S', 'Xie Q', 'Zhang Z', 'Cui Y']","['Carbamates/metabolism/*pharmacokinetics', 'Cytochrome P-450 CYP2C8/*genetics/metabolism', 'Hypoglycemic Agents/metabolism/*pharmacokinetics', 'Liver-Specific Organic Anion Transporter 1/*genetics/metabolism', 'Piperidines/metabolism/*pharmacokinetics', '*Polymorphism, Genetic']",https://pubmed.ncbi.nlm.nih.gov/30636597/
1944,Repaglinide,20044909,Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method.,"['Rawat MK', 'Jain A', 'Mishra A', 'Muthu MS', 'Singh S']","['Biological Availability', 'Calorimetry, Differential Scanning', 'Carbamates/*chemistry/pharmacokinetics', '*Drug Carriers', 'Hypoglycemic Agents/*chemistry/pharmacokinetics', 'Lipids/*chemistry', 'Microscopy, Electron, Transmission', '*Nanostructures', 'Particle Size', 'Piperidines/*chemistry/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/20044909/
1945,Repaglinide,22268393,Repaglinide: a review of its use in type 2 diabetes mellitus.,['Scott LJ'],"['Carbamates/pharmacokinetics/pharmacology/*therapeutic use', 'Diabetes Mellitus, Type 2/*drug therapy', 'Humans', 'Hypoglycemic Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Piperidines/pharmacokinetics/pharmacology/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/22268393/
1946,Repaglinide,36168862,Characterization of binding by repaglinide and nateglinide with glycated human serum albumin using high-performance affinity microcolumns.,"['Ovbude ST', 'Tao P', 'Li Z', 'Hage DS']","['Humans', 'Nateglinide', '*Serum Albumin, Human', '*Albumins']",https://pubmed.ncbi.nlm.nih.gov/36168862/
1947,Repaglinide,32475902,"Efficacy and Safety of Miglitol- or Repaglinide-Based Combination Therapy with Alogliptin for Drug-Naive Patients with Type 2 Diabetes: An Open-Label, Single-Center, Parallel, Randomized Controlled Pilot Study.","['Okajima F', 'Sugihara H', 'Emoto N']","['1-Deoxynojirimycin/administration & dosage/adverse effects/*analogs & derivatives', 'Adult', 'Aged', 'Carbamates/*administration & dosage/adverse effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Dipeptidyl-Peptidase IV Inhibitors/*administration & dosage', 'Drug Therapy, Combination', 'Female', 'Glycoside Hydrolase Inhibitors/*administration & dosage', 'Humans', 'Male', 'Middle Aged', 'Pilot Projects', 'Piperidines/*administration & dosage/adverse effects', 'Safety', 'Treatment Outcome', 'Uracil/administration & dosage/adverse effects/*analogs & derivatives', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32475902/
1948,Repaglinide,31216051,Risk of Hypoglycemia and Concomitant Use of Repaglinide and Clopidogrel: A Population-Based Nested Case-Control Study.,"['Wei Y', 'Lin FJ', 'Lin SY', 'Wang CC']","['Aged', 'Aspirin/therapeutic use', 'Carbamates/*adverse effects', 'Case-Control Studies', 'Clopidogrel/*adverse effects', 'Drug Interactions', 'Female', 'Humans', 'Hypoglycemia/*chemically induced', 'Hypoglycemic Agents/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Nateglinide/therapeutic use', 'Piperidines/*adverse effects', 'Platelet Aggregation Inhibitors/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31216051/
1949,Repaglinide,35371345,Clinical Effects of Exercise Rehabilitation Combined with Repaglinide in the Treatment of Diabetes.,"['Li Y', 'Wang X', 'Zhang Y']","['Carbamates/pharmacology/therapeutic use', '*Diabetes Mellitus, Type 2', 'Humans', '*Hypoglycemic Agents/therapeutic use', 'Piperidines', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/35371345/
1950,Metolazone,37210742,Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics.,"['Yeoh SE', 'Osmanska J', 'Petrie MC', 'Brooksbank KJM', 'Clark AL', 'Docherty KF', 'Foley PWX', 'Guha K', 'Halliday CA', 'Jhund PS', 'Kalra PR', 'McKinley G', 'Lang NN', 'Lee MMY', 'McConnachie A', 'McDermott JJ', 'Platz E', 'Sartipy P', 'Seed A', 'Stanley B', 'Weir RAP', 'Welsh P', 'McMurray JJV', 'Campbell RT']","['Humans', '*Metolazone/therapeutic use/adverse effects', 'Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Furosemide/therapeutic use', '*Heart Failure/drug therapy/chemically induced', 'Diuretics/therapeutic use', 'Sodium']",https://pubmed.ncbi.nlm.nih.gov/37210742/
1951,Metolazone,32639593,A Systematic Review and Meta-Analysis of Metolazone Compared to Chlorothiazide for Treatment of Acute Decompensated Heart Failure.,"['Steuber TD', 'Janzen KM', 'Howard ML']","['Chlorothiazide/administration & dosage/*therapeutic use', 'Diuretics/administration & dosage/*therapeutic use', 'Heart Failure/*drug therapy', 'Humans', 'Metolazone/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32639593/
1952,Metolazone,5138749,Clinical experience with metolazone in fifty-two African patients: synergy with frusemide.,"['Gunstone RF', 'Wing AJ', 'Shani HG', 'Njemo D', 'Sabuka EM']","['Adult', 'Black People', 'Body Weight', 'Diuretics/*therapeutic use', '*Drug Synergism', 'Edema/drug therapy', 'Female', 'Furosemide/*therapeutic use', 'Humans', 'Ketones/therapeutic use', 'Male', 'Middle Aged', 'Quinazolines/*therapeutic use', 'Sulfonamides/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/5138749/
1953,Metolazone,23538300,Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure.,"['Ng TM', 'Konopka E', 'Hyderi AF', 'Hshieh S', 'Tsuji Y', 'Kim BJ', 'Han SY', 'Phan DH', 'Jeng AI', 'Lou M', 'Elkayam U']","['Acute Disease', 'Adult', 'Aged', 'Blood Urea Nitrogen', 'Bumetanide/adverse effects/*therapeutic use', 'Cohort Studies', 'Diuretics/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Furosemide/adverse effects/*therapeutic use', 'Heart Failure/*drug therapy/urine', 'Humans', 'Hyponatremia/epidemiology', 'Incidence', 'Male', 'Metolazone/adverse effects/*therapeutic use', 'Middle Aged', 'Regression Analysis', 'Retrospective Studies', 'Treatment Outcome', 'Urine/physiology']",https://pubmed.ncbi.nlm.nih.gov/23538300/
1954,Metolazone,3935455,Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man.,"['Marone C', 'Muggli F', 'Lahn W', 'Frey FJ']","['Calcium/urine', 'Diuretics/*pharmacology', 'Drug Synergism', 'Furosemide/*metabolism/pharmacology', 'Humans', 'Kinetics', 'Metolazone/*pharmacology', 'Sodium/urine']",https://pubmed.ncbi.nlm.nih.gov/3935455/
1955,Metolazone,319937,Metolazone and spironolactone in cirrhosis and the nephrotic syndrome.,"['Lang GR', 'Westenfelder C', 'Nascimento L', 'Dhupelia VB', 'Arruda JA', 'Kane RE']","['Adult', 'Aged', 'Blood Cell Count', 'Blood Glucose/metabolism', 'Blood Pressure/drug effects', 'Body Weight/drug effects', 'Chlorides/urine', 'Clinical Trials as Topic', 'Creatinine/blood', 'Diuresis/drug effects', 'Diuretics/*therapeutic use', 'Drug Interactions', 'Drug Therapy, Combination', 'Humans', 'Liver Cirrhosis/*drug therapy/metabolism/physiopathology', 'Male', 'Metolazone/adverse effects/pharmacology/*therapeutic use', 'Middle Aged', 'Nephrotic Syndrome/*drug therapy/metabolism/physiopathology', 'Potassium/blood/urine', 'Sodium/urine', 'Spironolactone/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/319937/
1956,Metolazone,27393709,Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance.,"['Shulenberger CE', 'Jiang A', 'Devabhakthuni S', 'Ivaturi V', 'Liu T', 'Reed BN']","['Acute Disease', 'Administration, Intravenous', 'Administration, Oral', 'Adult', 'Aged', 'Chlorothiazide/adverse effects/*therapeutic use', 'Cohort Studies', 'Diuretics/*therapeutic use', 'Drug Resistance', 'Female', 'Heart Failure/*drug therapy', 'Humans', 'Male', 'Metolazone/adverse effects/*therapeutic use', 'Middle Aged', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/27393709/
1957,Metolazone,34789407,"First-order derivative synchronous spectrofluorimetric determination of two antihypertensive drugs, metolazone and valsartan, in pharmaceutical and biological matrices.","['Zeid AM', 'Aboshabana R', 'Ibrahim FA']","['Antihypertensive Agents', '*Metolazone', '*Pharmaceutical Preparations', 'Spectrometry, Fluorescence', 'Valsartan']",https://pubmed.ncbi.nlm.nih.gov/34789407/
1958,Metolazone,1593359,Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia.,"['Segar JL', 'Robillard JE', 'Johnson KJ', 'Bell EF', 'Chemtob S']","['Bronchopulmonary Dysplasia/*drug therapy', 'Diuresis/drug effects', 'Drug Therapy, Combination', 'Drug Tolerance', 'Furosemide/*therapeutic use', 'Humans', 'Infant, Newborn', 'Metolazone/*therapeutic use', 'Water-Electrolyte Balance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1593359/
1959,Metolazone,849995,Antihypertensive and renin angiotensin effects of metolazone with and without propranolol.,"['Sambhi MP', 'Eggena P', 'Barrett JD', 'Thananopavarn C', 'Tuck M', 'Wiedman C']","['Angiotensin II/*blood', '*Antihypertensive Agents', 'Blood Pressure/drug effects', 'Diuretics/*pharmacology', 'Drug Interactions', 'Drug Therapy, Combination', 'Humans', 'Hypertension/drug therapy/metabolism/physiopathology', 'Metolazone/*pharmacology/therapeutic use', 'Potassium/metabolism', 'Propranolol/*pharmacology/therapeutic use', 'Renin/*blood', 'Sodium/metabolism', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/849995/
1960,Metolazone,16189620,Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature.,"['Rosenberg J', 'Gustafsson F', 'Galatius S', 'Hildebrandt PR']","['Aged', 'Aged, 80 and over', 'Blood Pressure/drug effects', 'Body Weight/drug effects', 'Bumetanide/therapeutic use', 'Diuretics/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Furosemide/therapeutic use', 'Heart Failure/*drug therapy', 'Humans', 'Male', 'Metolazone/*therapeutic use', 'Outpatients', 'Potassium/blood', 'Randomized Controlled Trials as Topic', 'Sodium/blood', 'Water-Electrolyte Balance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/16189620/
1961,Metolazone,25181459,Thiazide-like diuretic drug metolazone activates human pregnane X receptor to induce cytochrome 3A4 and multidrug-resistance protein 1.,"['Banerjee M', 'Chen T']","['Cell Survival/drug effects/physiology', 'Cytochrome P-450 CYP3A/*biosynthesis', 'Cytochrome P-450 CYP3A Inducers/*pharmacology', 'Diuretics/*pharmacology', 'Dose-Response Relationship, Drug', 'HEK293 Cells', 'Hep G2 Cells', 'Humans', 'Metolazone/*pharmacology', 'Multidrug Resistance-Associated Proteins/*biosynthesis', 'Pregnane X Receptor', 'Protein Binding/physiology', 'Receptors, Steroid/*metabolism', 'Thiazides/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25181459/
1962,Metolazone,31879759,Development and Validation of Two Robust Stability-Indicating Chromatographic Methods for Determination of Metolazone in Drug Substance and Pharmaceutical Dosage Form in the Presence of Its Degradation Products and Characterization of Main Degradation Products Based on LC-MS.,"['Zaazaa HE', 'Abdel-Ghany R', 'Abdelkawy M', 'Sayed M']","['Calibration', 'Chromatography, High Pressure Liquid/*methods', 'Chromatography, Reverse-Phase', 'Chromatography, Thin Layer/*methods', 'Drug Stability', 'Hydrolysis', 'Mass Spectrometry/methods', 'Metolazone/*analysis/*chemistry', 'Tablets/*analysis/chemistry']",https://pubmed.ncbi.nlm.nih.gov/31879759/
1963,Metolazone,7438679,Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.,"['Winchester JF', 'Kellett RJ', 'Boddy K', 'Boyle P', 'Dargie HJ', 'Mahaffey ME', 'Ward DM', 'Kennedy AC']","['Adolescent', 'Adult', 'Aged', 'Antihypertensive Agents/*therapeutic use', 'Bendroflumethiazide/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Diuretics/*therapeutic use', 'Female', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Metolazone/adverse effects/*therapeutic use', 'Middle Aged', 'Potassium/analysis']",https://pubmed.ncbi.nlm.nih.gov/7438679/
1964,Metolazone,31853105,Comparing the sodium excreting efficacy of furosemide and indapamide combination against furosemide and metolazone combination in congestive heart failure patients: A randomized control trial.,"['Salahudin M', 'Shah H', 'Jan MU', 'Altaf A']","['Administration, Intravenous', 'Administration, Oral', 'Aged', 'Body Weight', '*Diuretics/administration & dosage/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Female', '*Furosemide/administration & dosage/adverse effects/therapeutic use', 'Heart Failure/*drug therapy', 'Humans', '*Indapamide/administration & dosage/adverse effects/therapeutic use', 'Male', '*Metolazone/administration & dosage/adverse effects/therapeutic use', 'Middle Aged', 'Pakistan', 'Sodium/*urine']",https://pubmed.ncbi.nlm.nih.gov/31853105/
1965,Metolazone,23996979,Simultaneous determination of metolazone and losartan potassium in their binary mixtures using high-performance liquid chromatography with fluorimetric detection: application to combined tablets and spiked human plasma.,"['Walash MI', 'El-Enany NM', 'Eid MI', 'Fathy ME']","['Antihypertensive Agents/*blood', 'Chromatography, High Pressure Liquid/instrumentation/*methods', 'Diuretics/*blood', 'Drug Combinations', 'Fluorometry/*methods', 'Humans', 'Losartan/*blood', 'Metolazone/*blood', 'Tablets/analysis']",https://pubmed.ncbi.nlm.nih.gov/23996979/
1966,Metolazone,5123909,Use of metolazone in the treatment of ascites due to liver disease.,"['Hillenbrand P', 'Sherlock S']","['Adult', 'Ascites/*drug therapy/etiology', 'Chlorides/blood', 'Chronic Disease', 'Diuretics/adverse effects/*therapeutic use', 'Female', 'Hepatic Encephalopathy/chemically induced', 'Humans', 'Hypokalemia/chemically induced', 'Hyponatremia/chemically induced', 'Ketones/therapeutic use', 'Liver Diseases/*complications', 'Male', 'Middle Aged', 'Nitrogen/blood', 'Pyrazines/therapeutic use', 'Quinazolines/adverse effects/*therapeutic use', 'Spironolactone/therapeutic use', 'Sulfonamides/*therapeutic use', 'Uremia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/5123909/
1967,mercaptopurine,38417937,Mercaptopurine-induced Sweet's syndrome.,"['Commins N', 'Subhaharan D', 'Dettrick A', 'Patrick D']","['Male', 'Humans', '*Sweet Syndrome/chemically induced/diagnosis/drug therapy', 'Mercaptopurine/adverse effects', 'Skin/pathology', 'Adrenal Cortex Hormones/adverse effects', '*Crohn Disease/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38417937/
1968,mercaptopurine,2646222,6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis.,['Present DH'],"['Azathioprine/therapeutic use', 'Colitis, Ulcerative/*drug therapy', 'Crohn Disease/*drug therapy', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Mercaptopurine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2646222/
1969,mercaptopurine,32929576,"Phosphorene and Na-, Ca-, and Fe-doped phosphorene as candidates for delivery of mercaptopurine and fluorouracil anticancer drugs.","['Mahboobi T', 'Zardoost MR', 'Toosi MR']","['Antineoplastic Agents/administration & dosage', 'Calcium/*chemistry', 'Drug Carriers/*chemistry', 'Drug Delivery Systems', 'Fluorouracil/*administration & dosage/chemistry', 'Iron/*chemistry', 'Mercaptopurine/*administration & dosage/chemistry', 'Models, Molecular', 'Molecular Conformation', 'Molecular Structure', 'Phosphoranes/*chemistry', 'Sodium/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/32929576/
1970,mercaptopurine,3156615,Strength of the human mixed lymphocyte reaction (MLR) and its suppression by azathioprine or 6-mercaptopurine.,"['Al-Safi SA', 'Maddocks JL']","['Azathioprine/*pharmacology', 'Graft Survival/*drug effects', 'Humans', 'Kidney Transplantation', 'Lymphocyte Culture Test, Mixed', 'Mercaptopurine/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3156615/
1971,mercaptopurine,23680872,Modifying mesoporous silica nanoparticles to avoid the metabolic deactivation of 6-mercaptopurine and methotrexate in combinatorial chemotherapy.,"['Wang W', 'Fang C', 'Wang X', 'Chen Y', 'Wang Y', 'Feng W', 'Yan C', 'Zhao M', 'Peng S']","['Cell Proliferation/drug effects', 'Dithiothreitol/chemistry', 'Endocytosis', 'Humans', 'K562 Cells', 'Mercaptopurine/metabolism/therapeutic use/toxicity', 'Metal Nanoparticles/*chemistry', 'Methotrexate/metabolism/therapeutic use/toxicity', 'Neoplasms/drug therapy', 'Porosity', 'Silicon Dioxide/*chemistry', 'Surface Properties']",https://pubmed.ncbi.nlm.nih.gov/23680872/
1972,mercaptopurine,2207374,Determination of 6-mercaptopurine and its metabolites in plasma or serum by high performance liquid chromatography.,"['Sahnoun Z', 'Serre-Debeauvais F', 'Lang J', 'Faucon G', 'Gavend M']","['Azathioprine/administration & dosage/adverse effects', 'Chromatography, High Pressure Liquid', 'Humans', 'Mercaptopurine/*blood', 'Spectrophotometry, Ultraviolet', 'Sulfhydryl Reagents']",https://pubmed.ncbi.nlm.nih.gov/2207374/
1973,mercaptopurine,27648552,Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes.,"['Bjornsson ES', 'Gu J', 'Kleiner DE', 'Chalasani N', 'Hayashi PH', 'Hoofnagle JH']","['Adolescent', 'Adult', 'Aged', 'Alanine Transaminase/blood', 'Alkaline Phosphatase/blood', 'Azathioprine/administration & dosage/*adverse effects', 'Bilirubin/blood', 'Chemical and Drug Induced Liver Injury/*blood/etiology', 'Child', 'Cholestasis/*chemically induced', 'Databases, Factual', 'Female', 'Humans', 'Inflammatory Bowel Diseases/drug therapy', 'Male', 'Mercaptopurine/administration & dosage/*adverse effects', 'Middle Aged', 'Prospective Studies', 'Time Factors', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27648552/
1974,mercaptopurine,32185153,Adherence to Azathioprine/6-Mercaptopurine in Children and Adolescents with Inflammatory Bowel Diseases: A Multimethod Study.,"['Alsous MM', 'Hawwa AF', 'Imrie C', 'Szabo A', 'Alefishat E', 'Farha RA', 'Rwalah M', 'Horne R', 'McElnay JC']","['Adolescent', 'Antimetabolites/*therapeutic use', 'Azathioprine/blood/*therapeutic use', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Inflammatory Bowel Diseases/blood/*drug therapy', 'Male', 'Mercaptopurine/blood/*therapeutic use', 'Surveys and Questionnaires', '*Assessment of Medication Adherence']",https://pubmed.ncbi.nlm.nih.gov/32185153/
1975,mercaptopurine,35341387,6-Mercaptopurine and Macrophage Activation Syndrome Case Report and Review of the Literature.,"['Davenport L', 'Chin-Hon J', 'Chung J', 'Cindy Chen XJ', 'Schneider J']","['Humans', 'Female', 'Adult', '*Macrophage Activation Syndrome/chemically induced/diagnosis', 'Mercaptopurine/adverse effects', '*Clostridioides difficile', '*COVID-19', '*Lymphohistiocytosis, Hemophagocytic/diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/35341387/
1976,mercaptopurine,16048561,Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.,"['Gearry RB', 'Barclay ML']","['Antimetabolites, Antineoplastic/*therapeutic use', 'Azathioprine/adverse effects/metabolism/*therapeutic use', 'Bone Marrow/drug effects', 'Erythrocytes/metabolism', 'Guanine Nucleotides/metabolism', 'Humans', 'Inflammatory Bowel Diseases/*drug therapy/genetics/metabolism', 'Mercaptopurine/adverse effects/analogs & derivatives/*metabolism/*therapeutic use', 'Methyltransferases/deficiency/*genetics', 'Polymorphism, Genetic', 'Pyrophosphatases/deficiency', 'Thionucleotides/metabolism', 'Inosine Triphosphatase']",https://pubmed.ncbi.nlm.nih.gov/16048561/
1977,mercaptopurine,33750748,Allopurinol to Prevent Mercaptopurine Adverse Effects in Children and Young Adults With Acute Lymphoblastic Leukemia.,"['Kamojjala R', 'Bostrom B']","['Adolescent', 'Adult', 'Allopurinol/*therapeutic use', 'Antimetabolites, Antineoplastic/adverse effects/*therapeutic use', 'Child', 'Child, Preschool', 'Enzyme Inhibitors/*therapeutic use', 'Female', 'Humans', 'Male', 'Mercaptopurine/adverse effects/*therapeutic use', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy', 'Retrospective Studies', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33750748/
1978,mercaptopurine,25248004,Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.,"['Amin J', 'Huang B', 'Yoon J', 'Shih DQ']","['Azathioprine/*therapeutic use', 'Disease Management', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Inflammatory Bowel Diseases/*drug therapy', 'Mercaptopurine/*therapeutic use', 'Prognosis', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/25248004/
1979,mercaptopurine,32380641,Inhibition of Xanthine Oxidase-Catalyzed Xanthine and 6-Mercaptopurine Oxidation by Flavonoid Aglycones and Some of Their Conjugates.,"['Mohos V', 'Fliszar-Nyul E', 'Poor M']","['Allopurinol/pharmacology', 'Catalysis', 'Dose-Response Relationship, Drug', 'Flavonoids/*pharmacology', 'Mercaptopurine/*chemistry', 'Oxidation-Reduction/*drug effects', 'Xanthine/*chemistry', 'Xanthine Oxidase/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/32380641/
1980,mercaptopurine,35798387,Impact of SLC43A3/ENBT1 Expression and Function on 6-Mercaptopurine Transport and Cytotoxicity in Human Acute Lymphoblastic Leukemia Cells.,"['Ruel NM', 'Nguyen KH', 'Kim CS', 'Andrade LPS', 'Hammond JR']","['Amino Acid Transport Systems/metabolism', 'Biological Transport', 'HEK293 Cells', 'Humans', '*Mercaptopurine/pharmacology/therapeutic use', '*Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35798387/
1981,mercaptopurine,38072359,Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.,"['Bastida G', 'Alvarez-Sotomayor D', 'Aguas M', 'Iborra M', 'Del Hoyo J', 'Bejar-Serrano S', 'Garrido-Marin A', 'Valero-Perez E', 'Nos P']","['Humans', '*Azathioprine/adverse effects/therapeutic use', 'Male', 'Female', '*Mercaptopurine/adverse effects/administration & dosage/therapeutic use', 'Adult', 'Prospective Studies', '*Inflammatory Bowel Diseases/drug therapy', 'Middle Aged', '*Immunosuppressive Agents/adverse effects/therapeutic use', 'Young Adult', 'Gastrointestinal Diseases/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/38072359/
1982,Desloratadine,18336052,"Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.","['Devillier P', 'Roche N', 'Faisy C']","['Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Histamine H1 Antagonists, Non-Sedating/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Terfenadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18336052/
1983,Desloratadine,34517748,Efficiency and safety of desloratadine in combination with compound glycyrrhizin in the treatment of chronic urticaria: a meta-analysis and systematic review of randomised controlled trials.,"['Wen Y', 'Tang Y', 'Li M', 'Lai Y']","['Anti-Inflammatory Agents/administration & dosage/pharmacology', 'CD4-Positive T-Lymphocytes/cytology', 'CD8-Positive T-Lymphocytes/cytology', 'Chronic Urticaria/*drug therapy', 'Drug Therapy, Combination', 'Glycyrrhizic Acid/administration & dosage/*pharmacology', 'Histamine H1 Antagonists, Non-Sedating/administration & dosage/pharmacology', 'Humans', 'Immunoglobulin E/blood', 'Loratadine/administration & dosage/*analogs & derivatives/pharmacology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34517748/
1984,Desloratadine,23835058,Spectroscopic behavior of loratadine and desloratadine in different aqueous media conditions studied by means of TD-DFT calculations.,"['Brasca R', 'Romero MA', 'Goicoechea HC', 'Kelterer AM', 'Fabian WM']","['Electrons', 'Loratadine/*analogs & derivatives/*chemistry', '*Models, Molecular', 'Molecular Conformation', 'Protons', '*Quantum Theory', 'Spectrum Analysis', 'Thermodynamics', 'Time Factors', 'Water/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/23835058/
1985,Desloratadine,37452991,Proapoptotic and proautophagy effect of H1-receptor antagonist desloratadine in human glioblastoma cell lines.,"['Vidicevic-Novakovic S', 'Stanojevic Z', 'Tomonjic N', 'Karapandza K', 'Zekovic J', 'Martinovic T', 'Grujicic D', 'Ilic R', 'Raicevic S', 'Tasic J', 'Isakovic A']","['Humans', '*Glioblastoma/drug therapy/metabolism', 'Cell Line, Tumor', 'AMP-Activated Protein Kinases', 'TOR Serine-Threonine Kinases/metabolism', '*Antineoplastic Agents/therapeutic use', 'Apoptosis', 'Autophagy', 'Cell Proliferation']",https://pubmed.ncbi.nlm.nih.gov/37452991/
1986,Desloratadine,36197287,Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial.,"['Zhou T', 'Zhang Y', 'Ma Y', 'Ma W', 'Wu X', 'Huang L', 'Feng W', 'Zhou H', 'Liu J', 'Zhao H', 'Zhang L', 'Yang Y', 'Huang Y']","['Female', 'Humans', 'Male', 'Aprepitant/therapeutic use', '*Carcinoma, Non-Small-Cell Lung/drug therapy', 'ErbB Receptors', '*Lung Neoplasms/drug therapy', 'Protein Kinase Inhibitors/therapeutic use', 'Pruritus/chemically induced', 'Quality of Life', 'Middle Aged', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/36197287/
1987,Desloratadine,29380864,The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria.,"['Choonhakarn C', 'Chaowattanapanit S', 'Julanon N']","['Adult', 'Chronic Disease', 'Female', 'Histamine H1 Antagonists, Non-Sedating/*administration & dosage/adverse effects', 'Humans', 'Loratadine/administration & dosage/adverse effects/*analogs & derivatives', 'Maintenance Chemotherapy/methods', 'Male', 'Middle Aged', 'Recurrence', 'Remission Induction/methods', 'Retreatment', 'Retrospective Studies', 'Treatment Outcome', 'Urticaria/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29380864/
1988,Desloratadine,33582682,Comparative Efficacy of Fexofenadine Versus Levocetrizine Versus Desloratadine via 1% Histamine Wheal Suppression Test.,"['Kc S', 'Aryal A', 'Adhikary M', 'Karn D']","['Adult', 'Cetirizine', 'Double-Blind Method', '*Histamine', 'Humans', 'Loratadine/analogs & derivatives', 'Terfenadine/analogs & derivatives', '*Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33582682/
1989,Desloratadine,36353984,Antimicrobial and antibiofilm activities of desloratadine against multidrug-resistant Acinetobacter baumannii.,"['Eduvirgem J', 'Rossato L', 'Melo AL', 'Valiente AC', 'Placa LF', 'Wender H', 'Vaz MS', 'Ribeiro SM', 'Simionatto S']","['Anti-Bacterial Agents/pharmacology', '*Acinetobacter baumannii', 'Microbial Sensitivity Tests', '*Anti-Infective Agents/pharmacology', 'Biofilms', 'Drug Resistance, Multiple, Bacterial']",https://pubmed.ncbi.nlm.nih.gov/36353984/
1990,Desloratadine,16329713,The safety and efficacy of desloratadine for the management of allergic disease.,['Berger WE'],"['Histamine H1 Antagonists, Non-Sedating/adverse effects/*therapeutic use', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/therapeutic use', 'Product Surveillance, Postmarketing', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Perennial/*drug therapy/immunology', 'Rhinitis, Allergic, Seasonal/*drug therapy/immunology', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16329713/
1991,Desloratadine,38546101,"Oral isotretinoin with desloratadine compared with oral isotretinoin alone in the treatment of moderate to severe acne: a randomized, assessor-blinded study.","['Hazarika N', 'Yadav P', 'Bagri M', 'Chandrasekaran D', 'Bhatia R']","['Humans', '*Isotretinoin/administration & dosage/adverse effects', '*Acne Vulgaris/drug therapy', '*Loratadine/administration & dosage/analogs & derivatives/adverse effects', 'Female', 'Male', 'Administration, Oral', 'Young Adult', '*Severity of Illness Index', '*Dermatologic Agents/administration & dosage/adverse effects', 'Adolescent', 'Adult', '*Patient Satisfaction', 'Drug Therapy, Combination', 'Single-Blind Method', 'Treatment Outcome', 'Histamine H1 Antagonists, Non-Sedating/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38546101/
1992,Desloratadine,37904551,Hydroxypropyl Methylcellulose Orodispersible Film Containing Desloratadine for Geriatric Use: Formulation and Evaluation.,"['Al-Oran AYF', 'Yenilmez E']","['Humans', 'Aged', '*Hypromellose Derivatives/chemistry', 'Spectroscopy, Fourier Transform Infrared', 'Solubility', 'Solvents/chemistry', 'Administration, Oral']",https://pubmed.ncbi.nlm.nih.gov/37904551/
1993,Desloratadine,16503743,Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety.,"['Prenner B', 'Kim K', 'Gupta S', 'Khalilieh S', 'Kantesaria B', 'Manitpisitkul P', 'Lorber R', 'Wang Z', 'Lutsky B']","['Administration, Oral', 'Age Factors', 'Dose-Response Relationship, Drug', 'Electrocardiography', 'Histamine H1 Antagonists, Non-Sedating/adverse effects/*metabolism/*pharmacokinetics/therapeutic use', 'Loratadine/adverse effects/*analogs & derivatives/metabolism/pharmacokinetics/therapeutic use', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16503743/
1994,Acamprosate,28940866,"Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.","['Palpacuer C', 'Duprez R', 'Huneau A', 'Locher C', 'Boussageon R', 'Laviolle B', 'Naudet F']","['Acamprosate/*therapeutic use', 'Alcoholism/*drug therapy', 'Baclofen/*therapeutic use', 'Naltrexone/*analogs & derivatives/*therapeutic use', 'Narcotic Antagonists/*therapeutic use', 'Network Meta-Analysis', 'Topiramate/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28940866/
1995,Acamprosate,35113930,The rates and measurement of adherence to acamprosate in randomised controlled clinical trials: A systematic review.,"['Donoghue K', 'Hermann L', 'Brobbin E', 'Drummond C']","['Acamprosate/*therapeutic use', 'Adult', 'Alcohol Deterrents/*therapeutic use', 'Alcoholism/*drug therapy', 'Clinical Decision-Making', 'Humans', '*Medication Adherence', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/35113930/
1996,Acamprosate,36463765,"Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.","['Konstantelos N', 'Tourchian N', 'McCormack D', 'Lecce P', 'Tadrous M', 'Gomes T']","['Humans', 'Male', 'Female', 'Acamprosate/therapeutic use', 'Naltrexone/therapeutic use', '*Alcohol Deterrents/therapeutic use', 'Ontario', 'Taurine/therapeutic use', '*Alcoholism/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36463765/
1997,Acamprosate,37924307,Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT.,"['Donoghue K', 'Boniface S', 'Brobbin E', 'Byford S', 'Coleman R', 'Coulton S', 'Day E', 'Dhital R', 'Farid A', 'Hermann L', 'Jordan A', 'Kimergard A', 'Koutsou ML', 'Lingford-Hughes A', 'Marsden J', 'Neale J', ""O'Neill A"", 'Phillips T', 'Shearer J', 'Sinclair J', 'Smith J', 'Strang J', 'Weinman J', 'Whittlesea C', 'Widyaratna K', 'Drummond C']","['Adult', 'Humans', 'Acamprosate/therapeutic use', '*Alcoholism/drug therapy', 'Medication Therapy Management', 'Behavior Therapy', 'England', 'Cost-Benefit Analysis', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/37924307/
1998,Acamprosate,15200577,Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.,"['Bouza C', 'Angeles M', 'Munoz A', 'Amate JM']","['Acamprosate', 'Alcohol Deterrents/adverse effects/*therapeutic use', 'Alcoholism/*drug therapy', 'Humans', 'Naltrexone/adverse effects/*therapeutic use', 'Narcotic Antagonists/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Taurine/adverse effects/*analogs & derivatives/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15200577/
1999,Acamprosate,17956791,Treatment of tinnitus with acamprosate.,"['Azevedo AA', 'Figueiredo RR']","['Acamprosate', 'Alcohol Deterrents/*therapeutic use', 'Excitatory Amino Acid Antagonists', 'GABA Agents/therapeutic use', 'Humans', 'Taurine/*analogs & derivatives/therapeutic use', 'Tinnitus/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17956791/
2000,Acamprosate,32753686,TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response.,"['Ho MF', 'Zhang C', 'Zhang L', 'Wei L', 'Zhou Y', 'Moon I', 'Geske JR', 'Choi DS', 'Biernacka J', 'Frye M', 'Wen Z', 'Karpyak VM', 'Li H', 'Weinshilboum R']","['Acamprosate/*pharmacology', 'Alcohol Drinking', '*Alcoholism/drug therapy/genetics', '*Depressive Disorder, Major/drug therapy/genetics', 'Humans', 'Induced Pluripotent Stem Cells', '*Kynurenine', 'Neuroinflammatory Diseases', 'Pharmacogenetics', '*Serotonin', '*Tetraspanins/genetics', 'Tryptophan Hydroxylase/genetics']",https://pubmed.ncbi.nlm.nih.gov/32753686/
2001,Acamprosate,19170666,Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.,"['Mann K', 'Kiefer F', 'Smolka M', 'Gann H', 'Wellek S', 'Heinz A']","['Acamprosate', 'Adult', 'Alcohol Deterrents/pharmacology/*therapeutic use', 'Alcoholism/*drug therapy/physiopathology/*psychology', 'Combined Modality Therapy', 'Dopamine Agents/pharmacology/therapeutic use', 'Double-Blind Method', 'Excitatory Amino Acid Agents/pharmacology/therapeutic use', 'Female', 'Germany', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Middle Aged', 'Naltrexone/pharmacology/*therapeutic use', 'Positron-Emission Tomography', 'Predictive Value of Tests', 'Prognosis', '*Psychotherapy', 'Reflex/drug effects/physiology', 'Taurine/*analogs & derivatives/pharmacology/therapeutic use', 'United States', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19170666/
2002,Acamprosate,12377396,A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.,"['Mason BJ', 'Goodman AM', 'Dixon RM', 'Hameed MH', 'Hulot T', 'Wesnes K', 'Hunter JA', 'Boyeson MG']","['Acamprosate', 'Adolescent', 'Adult', 'Alcohol Deterrents/adverse effects/*pharmacokinetics', 'Alcoholism/*drug therapy/metabolism/psychology', 'Brain/*drug effects/metabolism', 'Cognition/*drug effects/physiology', 'Double-Blind Method', 'Drug Interactions/physiology', 'Drug Tolerance/physiology', 'Female', 'Humans', 'Male', 'Naltrexone/adverse effects/*pharmacokinetics', 'Narcotic Antagonists/adverse effects/*pharmacokinetics', 'Neuropsychological Tests', 'Reaction Time/drug effects/physiology', 'Taurine/adverse effects/*analogs & derivatives/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/12377396/
2003,Acamprosate,30251424,"Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.","['Chaignot C', 'Zureik M', 'Rey G', 'Dray-Spira R', 'Coste J', 'Weill A']","['Acamprosate/administration & dosage/adverse effects', 'Administrative Claims, Healthcare/statistics & numerical data', 'Adult', 'Aged', 'Alcohol Deterrents/*administration & dosage/adverse effects', 'Alcoholism/*drug therapy/mortality', 'Baclofen/administration & dosage/*adverse effects', 'Databases, Factual/statistics & numerical data', 'Dose-Response Relationship, Drug', 'Female', 'Follow-Up Studies', 'France/epidemiology', 'Hospitalization/*statistics & numerical data', 'Humans', 'Male', 'Middle Aged', 'Naltrexone/administration & dosage/adverse effects/analogs & derivatives', '*Off-Label Use', 'Risk Assessment', 'Socioeconomic Factors']",https://pubmed.ncbi.nlm.nih.gov/30251424/
2004,Acamprosate,12511176,"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.","['Kiefer F', 'Jahn H', 'Tarnaske T', 'Helwig H', 'Briken P', 'Holzbach R', 'Kampf P', 'Stracke R', 'Baehr M', 'Naber D', 'Wiedemann K']","['Acamprosate', 'Alcoholism/*drug therapy/*prevention & control', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Naltrexone/administration & dosage/*therapeutic use', 'Placebos', 'Secondary Prevention', 'Taurine/administration & dosage/*analogs & derivatives/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12511176/
2005,Acamprosate,27480445,Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.,"['Roos CR', 'Mann K', 'Witkiewitz K']","['Acamprosate', 'Adult', 'Alcohol Deterrents/therapeutic use', 'Alcohol Drinking/drug therapy/*psychology', 'Alcoholism/*drug therapy/*psychology', 'Female', 'Humans', 'Male', 'Naltrexone/*therapeutic use', 'Narcotic Antagonists/therapeutic use', 'Reproducibility of Results', '*Reward', 'Taurine/*analogs & derivatives/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27480445/
2006,Acamprosate,12826990,"Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.","['Johnson BA', ""O'Malley SS"", 'Ciraulo DA', 'Roache JD', 'Chambers RA', 'Sarid-Segal O', 'Couper D']","['Acamprosate', 'Adult', 'Alcoholism/blood/*drug therapy/psychology', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Naltrexone/blood/*pharmacokinetics/*therapeutic use', 'Neuropsychological Tests/statistics & numerical data', 'Taurine/analogs & derivatives/blood/*pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12826990/
2007,Dexpramipexole,37277072,Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial.,"['Siddiqui S', 'Wenzel SE', 'Bozik ME', 'Archibald DG', 'Dworetzky SI', 'Mather JL', 'Killingsworth R', 'Ghearing N', 'Schwartz JT', 'Ochkur SI', 'Jacobsen EA', 'Busse WW', 'Panettieri RA', 'Prussin C']","['Adult', 'Humans', 'Pramipexole/pharmacology/therapeutic use', 'Eosinophil Peroxidase', '*Asthma/drug therapy', '*Pulmonary Eosinophilia/drug therapy', 'Eosinophils', 'Treatment Outcome', 'Double-Blind Method', '*Anti-Asthmatic Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37277072/
2008,Dexpramipexole,29739754,Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes.,"['Panch SR', 'Bozik ME', 'Brown T', 'Makiya M', 'Prussin C', 'Archibald DG', 'Hebrank GT', 'Sullivan M', 'Sun X', 'Wetzler L', 'Ware J', 'Fay MP', 'Dunbar CE', 'Dworetzky SI', 'Khoury P', 'Maric I', 'Klion AD']","['Administration, Oral', 'Adult', 'Aged', 'Antioxidants/*administration & dosage', 'Eosinophils/*drug effects', 'Female', 'Follow-Up Studies', 'Humans', 'Hypereosinophilic Syndrome/*drug therapy/pathology', 'Male', 'Middle Aged', 'Pramipexole/*administration & dosage', 'Prognosis', 'Safety', '*Steroids']",https://pubmed.ncbi.nlm.nih.gov/29739754/
2009,Dexpramipexole,28178599,The targeted eosinophil-lowering effects of dexpramipexole in clinical studies.,"['Dworetzky SI', 'Hebrank GT', 'Archibald DG', 'Reynolds IJ', 'Farwell W', 'Bozik ME']","['Benzothiazoles/adverse effects/*pharmacology/therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Eosinophilia/drug therapy', 'Eosinophils/cytology/*drug effects', 'Humans', 'Hypereosinophilic Syndrome/drug therapy', 'Infections/chemically induced', 'Leukocyte Count', 'Pramipexole']",https://pubmed.ncbi.nlm.nih.gov/28178599/
2010,Dexpramipexole,24965504,Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function.,"['He P', 'Kerr D', 'Marbury T', 'Ries D', 'Farwell W', 'Stecher S', 'Dong Y', 'Wei D', 'Rogge M']","['Adult', 'Aged', 'Benzothiazoles/blood/*pharmacokinetics/urine', 'Female', 'Glomerular Filtration Rate', 'Humans', 'Male', 'Middle Aged', 'Neuroprotective Agents/blood/*pharmacokinetics/urine', 'Pramipexole', 'Renal Insufficiency/*metabolism/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/24965504/
2011,Dexpramipexole,30284267,Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size.,"['Laidlaw TM', 'Prussin C', 'Panettieri RA', 'Lee S', 'Ferguson BJ', 'Adappa ND', 'Lane AP', 'Palumbo ML', 'Sullivan M', 'Archibald D', 'Dworetzky SI', 'Hebrank GT', 'Bozik ME']","['Adult', 'Antioxidants/*therapeutic use', 'Chronic Disease', 'Eosinophilia/*drug therapy', 'Eosinophils/*drug effects', 'Female', 'Humans', 'Male', 'Nasal Polyps/*drug therapy', 'Pramipexole/*therapeutic use', 'Prospective Studies', 'Rhinitis/*drug therapy', 'Sinusitis/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30284267/
2012,Dexpramipexole,22101764,The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.,"['Cudkowicz M', 'Bozik ME', 'Ingersoll EW', 'Miller R', 'Mitsumoto H', 'Shefner J', 'Moore DH', 'Schoenfeld D', 'Mather JL', 'Archibald D', 'Sullivan M', 'Amburgey C', 'Moritz J', 'Gribkoff VK']","['Aged', 'Amyotrophic Lateral Sclerosis/*drug therapy', 'Benzothiazoles/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', 'Mitochondria/drug effects', 'Muscle Strength/drug effects', 'Muscles/*physiopathology', 'Pramipexole', 'Riluzole/therapeutic use', 'Single-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/22101764/
2013,Dexpramipexole,24067398,"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.","['Cudkowicz ME', 'van den Berg LH', 'Shefner JM', 'Mitsumoto H', 'Mora JS', 'Ludolph A', 'Hardiman O', 'Bozik ME', 'Ingersoll EW', 'Archibald D', 'Meyers AL', 'Dong Y', 'Farwell WR', 'Kerr DA']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Amyotrophic Lateral Sclerosis/*drug therapy', 'Antioxidants/administration & dosage/adverse effects/*pharmacology', 'Benzothiazoles/administration & dosage/adverse effects/*pharmacology', 'Double-Blind Method', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', 'Pilot Projects', 'Placebos', 'Pramipexole', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24067398/
2014,Desipramine,6337580,Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness.,"['Stewart JW', 'Quitkin FM', 'Liebowitz MR', 'McGrath PJ', 'Harrison WM', 'Klein DF']","['Adolescent', 'Adult', '*Ambulatory Care', 'Clinical Trials as Topic', 'Depression/drug therapy/psychology', 'Depressive Disorder/*drug therapy/psychology', 'Desipramine/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', 'Patient Dropouts', 'Placebos', 'Psychiatric Status Rating Scales', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/6337580/
2015,Desipramine,6798606,A comparison of plasma and serum levels of two tricyclic antidepressants: imipramine and desipramine.,"['Saady JJ', 'Bloom VL', 'Narasimhachari N', 'Goldberg SC', 'Friedel RO']","['Blood Chemical Analysis', 'Desipramine/*blood', 'Humans', 'Imipramine/*blood', 'Plasma/metabolism']",https://pubmed.ncbi.nlm.nih.gov/6798606/
2016,Desipramine,22115837,Reactive metabolites of desipramine and clomipramine: The kinetics of formation and reactivity with DNA.,"['Korobkova EA', 'Nemeth J', 'Cadougan M', 'Venkatratnam A', 'Bassit M', 'Azar N']","['Antidepressive Agents/chemistry/*metabolism', 'Biocatalysis', 'Clomipramine/chemistry/*metabolism', 'DNA/chemistry/*metabolism', 'Desipramine/chemistry/*metabolism', 'Horseradish Peroxidase/metabolism', 'Hydrogen Peroxide/metabolism', 'Kinetics', 'Oxidation-Reduction']",https://pubmed.ncbi.nlm.nih.gov/22115837/
2017,Desipramine,3949690,"Liquid chromatographic determination of identity, content, and content uniformity of desipramine, fluphenazine, and promazine.","['Beaulieu N', 'Gagne C', 'Lovering EG']","['Chromatography, Liquid', 'Desipramine/*analysis', 'Fluphenazine/*analysis', 'Promazine/*analysis']",https://pubmed.ncbi.nlm.nih.gov/3949690/
2018,Desipramine,3365915,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers.,"['Ciraulo DA', 'Barnhill JG', 'Jaffe JH']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Alcoholism/*metabolism', 'Blood Proteins/metabolism', 'Desipramine/*pharmacokinetics', 'Humans', 'Imipramine/*pharmacokinetics', 'Infusions, Intravenous', 'Male', 'Metabolic Clearance Rate', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/3365915/
2019,Desipramine,8407753,Side effects of methylphenidate and desipramine alone and in combination in children.,"['Pataki CS', 'Carlson GA', 'Kelly KL', 'Rapport MD', 'Biancaniello TM']","['Adolescent', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology', 'Child', 'Comorbidity', 'Depressive Disorder/*drug therapy/psychology', 'Desipramine/administration & dosage/*adverse effects', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Methylphenidate/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8407753/
2020,Desipramine,8444765,Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome.,"['Spencer T', 'Biederman J', 'Kerman K', 'Steingard R', 'Wilens T']","['Adolescent', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology', 'Child', 'Child, Preschool', 'Comorbidity', 'Desipramine/adverse effects/*therapeutic use', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Neurologic Examination/drug effects', 'Retrospective Studies', 'Tourette Syndrome/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/8444765/
2021,Desipramine,27254290,"UV-photodegradation of desipramine: Impact of concentration, pH and temperature on formation of products including their biodegradability and toxicity.","['Khaleel NDH', 'Mahmoud WMM', 'Olsson O', 'Kummerer K']","['Antidepressive Agents, Tricyclic/*chemistry/radiation effects', 'Bacteria/drug effects', 'Biodegradation, Environmental', 'Chromatography, Liquid', 'Desipramine/*chemistry/radiation effects', 'Dose-Response Relationship, Drug', 'Hydrogen-Ion Concentration', 'Kinetics', 'Mass Spectrometry', '*Photolysis', 'Quantitative Structure-Activity Relationship', 'Temperature', 'Toxicity Tests', '*Ultraviolet Rays', 'Water Pollutants, Chemical/*chemistry/radiation effects']",https://pubmed.ncbi.nlm.nih.gov/27254290/
2022,Desipramine,14529800,"Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder.","['Overtoom CC', 'Verbaten MN', 'Kemner C', 'Kenemans JL', 'van Engeland H', 'Buitelaar JK', 'van der Molen MW', 'van der Gugten J', 'Westenberg H', 'Maes RA', 'Koelega HS']","['Attention/*drug effects', 'Attention Deficit Disorder with Hyperactivity/blood/*drug therapy/physiopathology', 'Child', 'Choice Behavior/drug effects', 'Desipramine/analogs & derivatives/blood/*therapeutic use', 'Dopamine Agents/*therapeutic use', 'Double-Blind Method', 'Enzyme Inhibitors/blood/*therapeutic use', 'Humans', 'Hydroxyindoleacetic Acid/blood', '*Inhibition, Psychological', 'Levodopa/*therapeutic use', 'Male', 'Methylphenidate/*therapeutic use', 'Prolactin/blood', 'Reaction Time/drug effects']",https://pubmed.ncbi.nlm.nih.gov/14529800/
2023,Desipramine,3316312,"Alprazolam: an antidepressant? Alprazolam, desipramine, and an alprazolam-desipramine combination in the treatment of adult depressed outpatients.","['Fawcett J', 'Edwards JH', 'Kravitz HM', 'Jeffriess H']","['Adolescent', 'Adult', 'Alprazolam/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Desipramine/administration & dosage/adverse effects/therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Humans', 'Male', 'Middle Aged', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3316312/
2024,Theophylline,3315274,"Sustained-release theophylline and nocturnal asthma, once-daily and unequal dosing schedules.","['Smolensky MH', ""D'Alonzo GE"", 'Kunkel G', 'Barnes PJ']","['Asthma/*drug therapy/metabolism', 'Circadian Rhythm', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Food', 'Humans', 'Theophylline/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/3315274/
2025,Theophylline,6207849,"The stimulatory effects of caffeine, theophylline, lysine-theophylline and 3-isobutyl-1-methylxanthine on human sperm motility.","['Jiang CS', 'Kilfeather SA', 'Pearson RM', 'Turner P']","['1-Methyl-3-isobutylxanthine/pharmacology', 'Adolescent', 'Adult', 'Caffeine/pharmacology', 'Humans', 'In Vitro Techniques', 'Male', 'Sperm Motility/*drug effects', 'Theophylline/analogs & derivatives/pharmacology', 'Xanthines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6207849/
2026,Theophylline,7372953,"Utilization of intravenous dihydroxypropyl theophylline (dyphylline) in an aminophylline-sensitive patient, and its pharmacokinetic comparison with theophylline.","['Lawyer CH', 'Bardana EJ Jr', 'Rodgers R', 'Gerber N']","['Adult', 'Aminophylline/administration & dosage/*adverse effects', 'Asthma/drug therapy', 'Dyphylline/metabolism/*therapeutic use/urine', 'Female', 'Humans', 'Injections, Intravenous', 'Kinetics', 'Theophylline/*analogs & derivatives/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/7372953/
2027,Theophylline,3735090,Dissolution of theophylline monohydrate and anhydrous theophylline in buffer solutions.,"['de Smidt JH', 'Fokkens JG', 'Grijseels H', 'Crommelin DJ']","['Buffers', 'Crystallization', 'Diffusion', 'Hydrogen-Ion Concentration', 'Solubility', 'Spectrophotometry, Infrared', 'Spectrophotometry, Ultraviolet', 'Surface Properties', 'Theophylline/*analysis', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/3735090/
2028,Theophylline,7152739,Methods for evaluating optimal dosage regimens and their application to theophylline.,"['Richter O', 'Reinhardt D']","['Administration, Oral', '*Drug Administration Schedule', 'Humans', 'Injections, Intravenous', 'Kinetics', 'Models, Biological', 'Theophylline/*administration & dosage/metabolism']",https://pubmed.ncbi.nlm.nih.gov/7152739/
2029,Theophylline,23672674,Theophylline.,['Barnes PJ'],"['Asthma/drug therapy', 'Bronchodilator Agents/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', 'Pulmonary Disease, Chronic Obstructive/drug therapy', 'Theophylline/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23672674/
2030,Theophylline,6309681,Pharmacokinetics and pharmacodynamics of a short- and long-acting theophylline medication (Theolair and Theolair retard) in normals and patients with COLD. Part III: Plasma cyclic AMP.,"['Kreukniet J', 'Utama I', 'Hamelink ML']","['Adult', 'Cyclic AMP/*blood', 'Delayed-Action Preparations', 'Humans', 'Lung/physiopathology', 'Lung Diseases, Obstructive/*blood', 'Middle Aged', 'Theophylline/administration & dosage/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6309681/
2031,Theophylline,4008452,Theophylline-lithium interaction.,"['Cook BL', 'Smith RE', 'Perry PJ', 'Calloway RA']","['Adult', 'Drug Interactions', 'Female', 'Humans', 'Kinetics', 'Lithium/blood/metabolism/*pharmacology', 'Male', 'Theophylline/blood/metabolism/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/4008452/
2032,Theophylline,8228104,Theophylline toxicity.,['Cooling DS'],"['Cardiovascular Diseases/chemically induced', 'Charcoal/therapeutic use', 'Drug Interactions', 'Drug Overdose/therapy', 'Gastrointestinal Diseases/chemically induced', 'Hemoperfusion', 'Humans', 'Nervous System Diseases/chemically induced', 'Poisoning/therapy', 'Theophylline/pharmacology/*poisoning']",https://pubmed.ncbi.nlm.nih.gov/8228104/
2033,Theophylline,11775391,Theophylline revisited.,['Somerville LL'],"['Asthma/drug therapy', 'Bronchodilator Agents/pharmacokinetics/standards/*therapeutic use', 'Dose-Response Relationship, Drug', 'Humans', 'Phosphodiesterase Inhibitors/pharmacokinetics/standards/*therapeutic use', 'Practice Guidelines as Topic', 'Theophylline/pharmacokinetics/standards/*therapeutic use', 'Treatment Outcome', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/11775391/
2034,Theophylline,4054200,Pharmacokinetics of theophylline and enprofylline in patients requiring a high or low dose of theophylline.,"['Laursen LC', 'Johannesson N', 'Weeke B']","['Bronchodilator Agents/*metabolism', 'Female', 'Half-Life', 'Humans', 'Kinetics', 'Male', 'Theophylline/administration & dosage/*metabolism', 'Xanthines/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/4054200/
2035,Theophylline,6111606,A metabolic and pharmacokinetic comparison of theophylline and aminophylline (theophylline ethylenediamine).,"['Monks TJ', 'Smith RL', 'Caldwell J']","['Adult', 'Aminophylline/*metabolism', 'Biotransformation', 'Diet', 'Humans', 'Kinetics', 'Male', 'Theophylline/*metabolism', 'Xanthines/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6111606/
2036,Theophylline,3392510,Theophylline dosing and theophylline level testing in a family practice population.,"['Moore LD 3rd', 'Taylor AT']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Male', 'Middle Aged', 'Retrospective Studies', 'Smoking', 'Theophylline/administration & dosage/*blood']",https://pubmed.ncbi.nlm.nih.gov/3392510/
2037,Theophylline,6723760,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults.,"['Jonkman JH', 'van der Boon WJ', 'Balant LP', 'Schoenmaker R', 'Holtkamp A']","['Adult', 'Aminophylline/administration & dosage/metabolism', 'Biological Availability', 'Delayed-Action Preparations', 'Humans', 'Infusions, Parenteral', 'Intestinal Absorption', 'Kinetics', 'Theophylline/administration & dosage/blood/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/6723760/
2038,Theophylline,641777,Separation and spectrophotometric determination of theophylline and hydroxyethyltheophylline in a pharmaceutical syrup.,['De Fabrizio F'],"['Solutions/analysis', 'Spectrophotometry, Ultraviolet', 'Theophylline/*analogs & derivatives/*analysis/isolation & purification']",https://pubmed.ncbi.nlm.nih.gov/641777/
2039,Theophylline,2690704,Once-daily versus twice-daily dosing of theophylline. A decision analysis approach to evaluating theophylline blood levels and compliance.,"['Jordan TJ', 'Reichman LB']","['Asthma/drug therapy', 'Decision Support Techniques', 'Decision Trees', 'Drug Administration Schedule', 'Humans', 'Patient Compliance', 'Theophylline/*administration & dosage/blood/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2690704/
2040,Theophylline,12579577,Free energy calculations for theophylline binding to an RNA aptamer: Comparison of MM-PBSA and thermodynamic integration methods.,"['Gouda H', 'Kuntz ID', 'Case DA', 'Kollman PA']","['Binding Sites', 'Hydrogen Bonding', 'Magnetic Resonance Spectroscopy', 'Models, Molecular', 'Nucleic Acid Conformation', 'RNA/*chemistry/genetics/*metabolism', 'Theophylline/analogs & derivatives/*chemistry/*metabolism', 'Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/12579577/
2041,Lithium Aluminium Hydride,20683539,Microwave-assisted regioselective ring opening of non-activated aziridines by lithium aluminium hydride.,"['Stankovic S', ""D'hooghe M"", 'De Kimpe N']","['Aluminum Compounds/chemical synthesis/*chemistry', 'Amino Alcohols/chemical synthesis/chemistry', 'Aziridines/chemical synthesis/*chemistry', 'Lithium Compounds/chemical synthesis/*chemistry', 'Microwaves', 'Morpholines/chemical synthesis/*chemistry', 'Oxidation-Reduction', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/20683539/
2042,Lithium Aluminium Hydride,18362957,Reactivity of N-(omega-haloalkyl)-beta-lactams with regard to lithium aluminium hydride: novel synthesis of 1-(1-aryl-3-hydroxypropyl)aziridines and 3-aryl-3-(N-propylamino)propan-1-ols.,"[""D'hooghe M"", 'Dekeukeleire S', 'De Kimpe N']","['1-Propanol/*chemical synthesis/chemistry', 'Alkanes/*chemistry', 'Aluminum Compounds/*chemistry', 'Aziridines/*chemical synthesis/chemistry', 'Halogenation', 'Lithium Compounds/*chemistry', 'Molecular Structure', 'Reducing Agents/chemistry', 'beta-Lactams/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/18362957/
2043,Lithium Aluminium Hydride,10717654,Preparation of hydrogen from water by reduction with lithium aluminium hydride for the analysis of delta(2)H by isotope ratio mass spectrometry.,"['Ward S', 'Scantlebury M', 'Krol E', 'Thomson PJ', 'Sparling C', 'Speakman JR']","['Aluminum Compounds/*chemistry', 'Deuterium', 'Hydrogen/*chemistry', 'Lithium Compounds/*chemistry', 'Mass Spectrometry', 'Oxidation-Reduction', 'Reducing Agents', 'Reproducibility of Results', 'Seawater/analysis', 'Water/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/10717654/
2044,Dapsone,35249339,Efficacy and safety of dapsone gel for acne: a systematic review and meta-analysis.,"['Wang X', 'Wang Z', 'Sun L', 'Liu H', 'Zhang F']","['*Acne Vulgaris/chemically induced/drug therapy', 'Anti-Bacterial Agents/therapeutic use', 'Dapsone/adverse effects/therapeutic use', '*Eczema', 'Female', 'Humans', 'Treatment Outcome', 'United States']",https://pubmed.ncbi.nlm.nih.gov/35249339/
2045,Dapsone,28732451,Dapsone and azole interactions: A clinical perspective.,"['Corallo C', 'Coutsouvelis J', 'Avery S', 'Morgan S', 'Morrissey O']","['Anti-Infective Agents/adverse effects/*metabolism', 'Azoles/adverse effects/*metabolism', 'Dapsone/adverse effects/*metabolism', 'Drug Interactions/physiology', 'Hemolysis/drug effects/physiology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/28732451/
2046,Dapsone,22551309,Why dapsone stops seizures and may stop neutrophils' delivery of VEGF to glioblastoma.,"['Kast RE', 'Lefranc F', 'Karpel-Massler G', 'Halatsch ME']","['Anti-Bacterial Agents/pharmacology/therapeutic use', 'Anti-Infective Agents/therapeutic use', 'Dapsone/*pharmacology/*therapeutic use', 'Drug Delivery Systems/*methods', 'Glioblastoma/*drug therapy/*pathology', 'Humans', 'Neutrophils/*drug effects/*metabolism', 'Seizures/*drug therapy', 'Vascular Endothelial Growth Factors/drug effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22551309/
2047,Dapsone,14996397,Sneddon-Wilkinson disease resistant to dapsone and colchicine successfully controlled with PUVA.,"['Khachemoune A', 'Blyumin ML']","['Adult', 'Colchicine/therapeutic use', 'Dapsone/therapeutic use', 'Drug Resistance', 'Humans', 'Male', '*PUVA Therapy', 'Remission Induction', 'Skin Diseases, Vesiculobullous/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/14996397/
2048,Dapsone,1939403,Simultaneous high performance liquid chromatographic determination of dapsone and monoacetyldapsone in human plasma and urine.,"['Abuirjeie MA', 'Irshaid YM', 'al-Hadidi HF', 'Rawashdeh NM']","['Adult', 'Chromatography, High Pressure Liquid', 'Dapsone/*analogs & derivatives/*analysis/blood/urine', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/1939403/
2049,Dapsone,28870516,A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome.,"['Watanabe H', 'Watanabe Y', 'Tashiro Y', 'Mushiroda T', 'Ozeki T', 'Hashizume H', 'Sueki H', 'Yamamoto T', 'Utsunomiya-Tate N', 'Gouda H', 'Kusakabe Y']","['Computational Biology', 'Dapsone/adverse effects/immunology/*metabolism', 'Drug Hypersensitivity Syndrome/etiology/*immunology', 'HLA-B Antigens/immunology/*metabolism', 'Humans', 'Leprostatic Agents/adverse effects/*metabolism', 'Leprosy/*drug therapy', 'Molecular Docking Simulation', 'Molecular Dynamics Simulation', 'Protein Binding', 'Sequence Homology, Amino Acid']",https://pubmed.ncbi.nlm.nih.gov/28870516/
2050,Dapsone,11511841,Dapsone and sulfones in dermatology: overview and update.,"['Zhu YI', 'Stiller MJ']","['Anti-Infective Agents/chemistry/pharmacokinetics/*therapeutic use', 'Dapsone/chemistry/pharmacokinetics/*therapeutic use', 'Drug Interactions', 'Humans', 'Skin Diseases/*drug therapy', 'Sulfones/chemistry/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11511841/
2051,Dapsone,7586950,Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo.,"['Mitra AK', 'Thummel KE', 'Kalhorn TF', 'Kharasch ED', 'Unadkat JD', 'Slattery JT']","['Adult', 'Alcohol Deterrents/pharmacology', 'Anti-Bacterial Agents/pharmacology', 'Cytochrome P-450 CYP2E1', 'Cytochrome P-450 Enzyme System/*metabolism', 'Dapsone/*analogs & derivatives/*metabolism/pharmacokinetics', 'Disulfiram/pharmacology', 'Drug Interactions', 'Female', 'Humans', 'Hydroxylation/drug effects', 'Leprostatic Agents/*metabolism/pharmacokinetics', 'Male', 'Microsomes, Liver/drug effects/*metabolism', 'Oxidoreductases, N-Demethylating/*metabolism', 'Troleandomycin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7586950/
2052,Dapsone,32934050,A case of dapsone-induced methaemoglobinaemia.,"['Tan YA', 'Ng KC', 'Cheo SW', 'Khoo TT', 'Low QJ']","['Dapsone/adverse effects', 'Humans', '*Methemoglobinemia/chemically induced/diagnosis', 'Methylene Blue/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32934050/
2053,Dapsone,33657522,Impurity profiling of dapsone using gradient HPLC method.,"['Leistner A', 'Holzgrabe U']","['Chromatography, High Pressure Liquid', 'Chromatography, Liquid', '*Dapsone', '*Drug Contamination', 'Tandem Mass Spectrometry']",https://pubmed.ncbi.nlm.nih.gov/33657522/
2054,Dapsone,3403099,Pharmacokinetics of aspirin and chloramphenicol in normal and leprotic patients before and after dapsone therapy.,"['Garg SK', 'Kumar B', 'Shukla VK', 'Bakaya V', 'Lal R', 'Kaur S']","['Adult', 'Aspirin/*pharmacokinetics', 'Chloramphenicol/*pharmacokinetics', 'Dapsone/*adverse effects/therapeutic use', 'Drug Interactions', 'Female', 'Half-Life', 'Humans', 'Leprosy/drug therapy/*metabolism', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/3403099/
2055,Dapsone,27168264,"Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.","['Stein Gold LF', 'Jarratt MT', 'Bucko AD', 'Grekin SK', 'Berlin JM', 'Bukhalo M', 'Weiss JS', 'Berk DR', 'Chang-Lin JE', 'Lin V', 'Kaoukhov A']","['Acne Vulgaris/*diagnosis/*drug therapy', 'Adolescent', 'Adult', 'Anti-Infective Agents/*administration & dosage/chemistry', 'Child', 'Dapsone/*administration & dosage/chemistry', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Compounding', 'Female', 'Gels', 'Humans', 'Male', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27168264/
2056,Dapsone,23055729,Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies.,"['Monteiro LM', 'Lione VF', 'do Carmo FA', 'do Amaral LH', 'da Silva JH', 'Nasciutti LE', 'Rodrigues CR', 'Castro HC', 'de Sousa VP', 'Cabral LM']","['Administration, Oral', 'Anti-Infective Agents/administration & dosage/chemistry', 'Biological Availability', 'Caco-2 Cells', 'Computer Simulation', 'Dapsone/*administration & dosage/chemistry/*pharmacokinetics', 'Diffusion', 'Emulsions/chemistry', 'Humans', '*Models, Biological', '*Models, Chemical', 'Nanocapsules/*chemistry/ultrastructure', 'Particle Size', 'Permeability']",https://pubmed.ncbi.nlm.nih.gov/23055729/
2057,Dapsone,7979291,Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.,"['Falloon J', 'Lavelle J', 'Ogata-Arakaki D', 'Byrne A', 'Graziani A', 'Morgan A', 'Amantea MA', 'Ownby K', 'Polis M', 'Davey RT Jr', 'et al.']","['AIDS-Related Opportunistic Infections/*prevention & control', 'Adult', 'Biological Availability', 'Chromatography, High Pressure Liquid', 'Dapsone/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', 'Pneumonia, Pneumocystis/*prevention & control', 'Pyrimethamine/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7979291/
2058,alendronic acid,33159843,Adjuvant Alendronic Acid in the Management of Severe Cherubism: A Case Report and Literature Review.,"['Bradley D', 'Patel V', 'Honeyman C', 'McGurk M']","['Adolescent', '*Cherubism/diagnostic imaging/drug therapy', 'Humans', 'Male', 'Mandible', 'Maxilla/diagnostic imaging/surgery']",https://pubmed.ncbi.nlm.nih.gov/33159843/
2059,alendronic acid,33913339,Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial.,"['Pawade TA', 'Doris MK', 'Bing R', 'White AC', 'Forsyth L', 'Evans E', 'Graham C', 'Williams MC', 'van Beek EJR', 'Fletcher A', 'Adamson PD', 'Andrews JPM', 'Cartlidge TRG', 'Jenkins WSA', 'Syed M', 'Fujisawa T', 'Lucatelli C', 'Fraser W', 'Ralston SH', 'Boon N', 'Prendergast B', 'Newby DE', 'Dweck MR']","['Aged', 'Aged, 80 and over', 'Alendronate/*therapeutic use', 'Aortic Valve Stenosis/*diagnostic imaging/*drug therapy/metabolism', 'Bone Density Conservation Agents/*therapeutic use', 'Denosumab/*therapeutic use', '*Disease Progression', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', 'Positron Emission Tomography Computed Tomography', 'Treatment Outcome', 'Vascular Calcification/diagnostic imaging/drug therapy/metabolism']",https://pubmed.ncbi.nlm.nih.gov/33913339/
2060,alendronic acid,27824143,Engineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma.,"['Nguyen TD', 'Pitchaimani A', 'Aryal S']","['Alendronate/*administration & dosage', 'Biocompatible Materials', 'Bone Density Conservation Agents/*administration & dosage', 'Bone Neoplasms/*drug therapy', 'Calcium/chemistry', 'Cell Separation', 'Diffusion', 'Dose-Response Relationship, Drug', '*Drug Carriers', 'Drug Delivery Systems', 'Durapatite/chemistry', 'Flow Cytometry', 'Humans', 'Inhibitory Concentration 50', 'Ligands', 'Lipids', 'Magnetic Resonance Spectroscopy', 'Nanomedicine', 'Nanoparticles', 'Osteosarcoma/*drug therapy', 'Polyglycolic Acid/chemistry', 'Protein Engineering', 'Spectroscopy, Fourier Transform Infrared']",https://pubmed.ncbi.nlm.nih.gov/27824143/
2061,alendronic acid,38735917,The effect of long-term alendronic acid treatment on Modic changes in the lumbar spine: a gender and age-matched study.,"['Yiu K', 'Ahn H', 'Shea GK']","['Humans', 'Male', 'Female', '*Lumbar Vertebrae/diagnostic imaging', 'Case-Control Studies', 'Middle Aged', '*Bone Density Conservation Agents/therapeutic use/administration & dosage', 'Aged', '*Low Back Pain/drug therapy/etiology/diagnostic imaging', '*Magnetic Resonance Imaging', 'Alendronate/therapeutic use/administration & dosage', 'Time Factors', 'Adult', 'Administration, Oral', 'Age Factors', 'Treatment Outcome', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/38735917/
2062,alendronic acid,26618379,Efficacy and safety of alendronic acid in the treatment of osteoporosis in children.,"['Martin Siguero A', 'Areas Del Aguila VL', 'Franco Sereno MT', 'Fernandez Marchante AI', 'Perez Serrano R', 'Encinas Barrios C']","['Adolescent', 'Alendronate/adverse effects/*therapeutic use', 'Bone Density/drug effects', 'Bone Density Conservation Agents/adverse effects/*therapeutic use', 'Child', 'Female', 'Humans', 'Male', 'Off-Label Use', 'Osteoporosis/*drug therapy', 'Retrospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26618379/
2063,alendronic acid,18555931,"Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.","['Perkins AC', 'Blackshaw PE', 'Hay PD', 'Lawes SC', 'Atherton CT', 'Dansereau RJ', 'Wagner LK', 'Schnell DJ', 'Spiller RC']","['Aged', 'Alendronate/administration & dosage/*pharmacokinetics', 'Bone Density Conservation Agents/administration & dosage/*pharmacokinetics', 'Cross-Over Studies', 'Drugs, Generic/administration & dosage/*pharmacokinetics', 'Esophagus/diagnostic imaging/*physiology', 'Etidronic Acid/administration & dosage/*analogs & derivatives/pharmacokinetics', 'Female', '*Gastrointestinal Transit', 'Humans', 'Middle Aged', 'Posture', 'Radionuclide Imaging', 'Radiopharmaceuticals', 'Risedronic Acid', 'Single-Blind Method', 'Sodium Pertechnetate Tc 99m', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/18555931/
2064,alendronic acid,17163237,Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.,"['Reid DM', 'Hosking D', 'Kendler D', 'Brandi ML', 'Wark JD', 'Weryha G', 'Marques-Neto JF', 'Gaines KA', 'Verbruggen N', 'Melton ME']","['Aged', 'Alendronate/adverse effects/*therapeutic use', 'Bone Density/*drug effects', 'Bone Remodeling/*drug effects', 'Double-Blind Method', 'Etidronic Acid/adverse effects/*analogs & derivatives/therapeutic use', 'Female', 'Humans', 'Middle Aged', 'Osteoporosis, Postmenopausal/*drug therapy', 'Risedronic Acid']",https://pubmed.ncbi.nlm.nih.gov/17163237/
2065,alendronic acid,16964986,The problem of low levels of vitamin D and osteoporosis: use of combination therapy with alendronic acid and colecalciferol (vitamin D3).,['Epstein S'],"['Alendronate/*therapeutic use', 'Bone Density Conservation Agents/*therapeutic use', 'Bone and Bones/metabolism', 'Calcium/metabolism', 'Cholecalciferol/*therapeutic use', 'Drug Combinations', 'Humans', 'Osteoporosis/complications/*drug therapy/metabolism', 'Vitamin D/metabolism', 'Vitamin D Deficiency/complications/*drug therapy/metabolism']",https://pubmed.ncbi.nlm.nih.gov/16964986/
2066,alendronic acid,33998617,A fluorescence biosensor for Salmonella typhimurium detection in food based on the nano-self-assembly of alendronic acid modified upconversion and gold nanoparticles.,"['Chen M', 'Pan L', 'Tu K']","['*Biosensing Techniques', 'Fluorescence Resonance Energy Transfer', 'Gold', '*Metal Nanoparticles', 'Salmonella typhimurium']",https://pubmed.ncbi.nlm.nih.gov/33998617/
2067,alendronic acid,31587476,"Immobilization of BMP-2, BMP-7 and alendronic acid on titanium surfaces: Adhesion, proliferation and differentiation of bone marrow-derived stem cells.","['Kammerer PW', 'Pabst AM', 'Dau M', 'Staedt H', 'Al-Nawas B', 'Heller M']","['Alendronate/chemistry/*pharmacology', 'Biocompatible Materials/chemistry/*pharmacology', 'Bone Density Conservation Agents/chemistry/pharmacology', 'Bone Marrow Cells/cytology', 'Bone Morphogenetic Protein 2/chemistry/*pharmacology', 'Bone Morphogenetic Protein 7/chemistry/*pharmacology', 'Cell Adhesion/drug effects', 'Cell Differentiation/*drug effects', 'Cell Proliferation/drug effects', 'Cells, Cultured', 'Humans', 'Immobilized Proteins/chemistry/pharmacology', 'Osteogenesis/drug effects', 'Stem Cells/cytology/*drug effects', 'Surface Properties', 'Titanium/chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/31587476/
2068,alendronic acid,32534563,Using Alendronic Acid Coupled Fluorescently Labelled SM Liposomes as a Vehicle for Bone Targeting.,"['Medina OP', 'Medina TP', 'Humbert J', 'Qi B', 'Baum W', 'Will O', 'Damm T', 'Gluer C']","['*Alendronate', 'Fluorescent Dyes', 'Humans', 'Indocyanine Green', '*Liposomes', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/32534563/
2069,alendronic acid,30845365,Effect of Alendronic Acid on Fracture Healing: A Multicenter Randomized Placebo-Controlled Trial.,"['Duckworth AD', 'McQueen MM', 'Tuck CE', 'Tobias JH', 'Wilkinson JM', 'Biant LC', 'Pulford EC', 'Aldridge S', 'Edwards C', 'Roberts CP', 'Ramachandran M', 'McAndrew AR', 'Cheng KC', 'Johnston P', 'Shah NH', 'Mathew P', 'Harvie J', 'Hanusch BC', 'Harkess R', 'Rodriguez A', 'Murray GD', 'Ralston SH']","['Alendronate/*pharmacology/therapeutic use', 'Female', 'Fracture Healing/*drug effects', 'Fractures, Bone/diagnostic imaging/drug therapy', 'Humans', 'Male', 'Medication Adherence', 'Middle Aged', 'Patient Reported Outcome Measures', 'Placebos', 'Surveys and Questionnaires', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30845365/
2070,alendronic acid,38792228,Luminescent Alendronic Acid-Conjugated Micellar Nanostructures for Potential Application in the Bone-Targeted Delivery of Cholecalciferol.,"['Rizzi F', 'Panniello A', 'Comparelli R', 'Arduino I', 'Fanizza E', 'Iacobazzi RM', 'Perrone MG', 'Striccoli M', 'Curri ML', 'Scilimati A', 'Denora N', 'Depalo N']","['*Micelles', '*Cholecalciferol/chemistry', '*Nanostructures/chemistry', '*Bone and Bones/drug effects/metabolism', '*Alendronate/chemistry', 'Polyethylene Glycols/chemistry', 'Humans', 'Drug Delivery Systems', 'Luminescence', 'Nanoparticles/chemistry', 'Drug Carriers/chemistry', 'Quantum Dots/chemistry']",https://pubmed.ncbi.nlm.nih.gov/38792228/
2071,alendronic acid,39174042,Airway consequences of alendronic acid aspiration.,"['Lonsdale H', 'Sawant R', 'Kinshuck A', 'Fleming J']","['Humans', '*Bone Density Conservation Agents/adverse effects', 'Aged', '*Alendronate/adverse effects', 'Female', 'Respiratory Aspiration']",https://pubmed.ncbi.nlm.nih.gov/39174042/
2072,alendronic acid,24788629,Chemical injury caused by acute alendronic acid aspiration.,"['Ottaway ZV', 'Hammond C', 'Merritt S']","['Aged', '*Alendronate/therapeutic use', '*Bronchoscopy', 'Female', '*Foreign Bodies', 'Humans', 'Osteoporosis, Postmenopausal/drug therapy', '*Respiratory Aspiration', 'Respiratory System/*surgery', 'Respiratory Tract Diseases/etiology/*surgery', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/24788629/
2073,Tolbutamide,35077862,"Structural, thermal, vibrational, solubility and DFT studies of a tolbutamide co-amorphous drug delivery system for treatment of diabetes.","['R Sa M', 'Sarraguca JMG', 'de Sousa FF', 'Sarraguca MSC', 'Lopes JA', 'Lima ADDSG', 'Lage MR', 'Ribeiro PRS']","['Calorimetry, Differential Scanning', '*Diabetes Mellitus', 'Drug Delivery Systems', 'Drug Stability', 'Humans', 'Solubility', 'Spectroscopy, Fourier Transform Infrared', '*Tolbutamide', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/35077862/
2074,Tolbutamide,14764815,Acute insulin responses to calcium and tolbutamide do not differentiate focal from diffuse congenital hyperinsulinism.,"['Giurgea I', 'Laborde K', 'Touati G', 'Bellanne-Chantelot C', 'Nassogne MC', 'Sempoux C', 'Jaubert F', 'Khoa N', 'Chigot V', 'Rahier J', 'Brunelle F', 'Nihoul-Fekete C', 'Dunne MJ', 'Stanley C', 'Saudubray JM', 'Robert JJ', 'de Lonlay P']","['*Calcium Gluconate/administration & dosage', 'Child, Preschool', 'Diagnosis, Differential', 'Female', 'Glucose Tolerance Test', 'Humans', 'Hyperinsulinism/*classification/congenital/*diagnosis/metabolism', '*Hypoglycemic Agents', 'Infant', 'Infant, Newborn', 'Injections, Intravenous', 'Insulin/*metabolism', 'Insulin Secretion', 'Male', '*Tolbutamide']",https://pubmed.ncbi.nlm.nih.gov/14764815/
2075,Tolbutamide,6442088,Favorable effects of glibenclamide in a patient exhibiting idiosyncratic hepatotoxic reactions to both chlorpropamide and tolbutamide.,"['Rumboldt Z', 'Bota B']","['Adult', 'Chemical and Drug Induced Liver Injury/*etiology', 'Chlorpropamide/*adverse effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Female', 'Glyburide/*therapeutic use', 'Humans', 'Liver/*drug effects', 'Tolbutamide/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/6442088/
2076,Tolbutamide,16908425,Micronization and polymorphic conversion of tolbutamide and barbital by rapid expansion of supercritical solutions.,"['Shinozaki H', 'Oguchi T', 'Suzuki S', 'Aoki K', 'Sako T', 'Morishita S', 'Tozuka Y', 'Moribe K', 'Yamamoto K']","['Barbital/*chemistry', 'Calorimetry, Differential Scanning', 'Carbon Dioxide/chemistry', 'Drug Compounding/*methods', 'Particle Size', 'Solubility', 'Temperature', 'Tolbutamide/*chemistry', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/16908425/
2077,Tolbutamide,24604100,High heritability and genetic correlation of intravenous glucose- and tolbutamide-induced insulin secretion among non-diabetic family members of type 2 diabetic patients.,"['Gjesing AP', 'Hornbak M', 'Allin KH', 'Ekstrom CT', 'Urhammer SA', 'Eiberg H', 'Pedersen O', 'Hansen T']","['*Diabetes Mellitus, Type 2', 'Family', 'Female', 'Genotype', 'Glucose/*pharmacology', 'Glucose Tolerance Test', 'Humans', 'Insulin/*metabolism', 'Insulin Secretion', 'Insulin-Secreting Cells/drug effects/metabolism', 'Male', 'Tolbutamide/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/24604100/
2078,Tolbutamide,11875364,Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.,"['Kirchheiner J', 'Bauer S', 'Meineke I', 'Rohde W', 'Prang V', 'Meisel C', 'Roots I', 'Brockmoller J']","['Adult', 'Alleles', '*Aryl Hydrocarbon Hydroxylases', 'Blood Glucose/*metabolism', 'Cytochrome P-450 CYP2C19', 'Cytochrome P-450 CYP2C9', 'Cytochrome P-450 Enzyme System/*genetics', 'Drug Evaluation', 'Female', 'Genotype', 'Humans', 'Hypoglycemic Agents/*pharmacokinetics', 'Insulin/blood', 'Male', 'Mixed Function Oxygenases/*genetics', 'Polymorphism, Genetic/*genetics', 'Population Surveillance', '*Steroid 16-alpha-Hydroxylase', 'Steroid Hydroxylases/*genetics', 'Time Factors', 'Tolbutamide/*analogs & derivatives/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/11875364/
2079,Tolbutamide,20501911,"Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo.","['Donato MT', 'Hallifax D', 'Picazo L', 'Castell JV', 'Houston JB', 'Gomez-Lechon MJ', 'Lahoz A']","['Adenoviridae/*genetics', 'Alprazolam/*pharmacokinetics', 'Base Sequence', 'Cell Line', 'Cytochrome P-450 Enzyme System/*genetics', 'DNA Primers', 'Hepatocytes/*metabolism', 'Humans', 'Midazolam/*administration & dosage', 'Phenacetin/*pharmacokinetics', 'Tolbutamide/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/20501911/
2080,Tolbutamide,17050793,Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers.,"['Uchida S', 'Yamada H', 'Li XD', 'Maruyama S', 'Ohmori Y', 'Oki T', 'Watanabe H', 'Umegaki K', 'Ohashi K', 'Yamada S']","['Adult', 'Anti-Anxiety Agents/pharmacokinetics', 'Area Under Curve', '*Drug Interactions', 'Ginkgo biloba/*chemistry', 'Half-Life', 'Humans', 'Hypoglycemic Agents/pharmacokinetics', 'Male', 'Midazolam/*pharmacokinetics', 'Plant Extracts/*pharmacology', 'Tolbutamide/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/17050793/
2081,Tolbutamide,28067999,"Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide.","['Gillen M', 'Yang C', 'Wilson D', 'Valdez S', 'Lee C', 'Kerr B', 'Shen Z']","['Adult', 'Amlodipine/*pharmacokinetics', 'Area Under Curve', 'Carbamates/*pharmacokinetics', 'Cytochrome P-450 Enzyme System/metabolism', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Gene Expression Regulation/drug effects', 'Healthy Volunteers', 'Humans', 'In Vitro Techniques', 'Male', 'Middle Aged', 'Piperidines/*pharmacokinetics', 'Sildenafil Citrate/*pharmacokinetics', 'Thioglycolates/*administration & dosage/pharmacology', 'Tolbutamide/pharmacokinetics', 'Triazoles/*administration & dosage/pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28067999/
2082,Hexitol,11543583,Nonenzymatic synthesis of RNA and DNA oligomers on hexitol nucleic acid templates: the importance of the A structure.,"['Kozlov IA', 'Politis PK', 'Van Aerschot A', 'Busson R', 'Herdewijn P', 'Orgel LE']","['Catalysis', 'DNA/*chemistry', 'Exobiology', 'Guanosine Monophosphate/analogs & derivatives/chemistry', 'Lead', 'Molecular Structure', 'Oligonucleotides/*chemical synthesis', 'RNA/*chemistry', 'Sugar Alcohols/*chemistry', 'Templates, Genetic']",https://pubmed.ncbi.nlm.nih.gov/11543583/
2083,Hexitol,2339994,"Organic nitrates. O-(2,3-dihydroxypropyl)-1,4:3,6-dianhydro-hexitol-nitrates.","['Stoss P', 'Schluter G', 'Axmann R']","['Cardiotonic Agents/*chemical synthesis', 'Chemical Phenomena', 'Chemistry', 'Electrocardiography', 'Nitrates/*chemical synthesis/pharmacology', 'Stereoisomerism', 'Structure-Activity Relationship', 'Sugar Alcohols/*chemical synthesis/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2339994/
2084,Hexitol,12790513,Ribavirin derivatives with a hexitol moiety: synthesis and antiviral evaluation.,"['Van Aerschot A', 'Schepers G', 'Busson R', 'Rozenski J', 'Neyts J', 'De Clercq E', 'Herdewijn P']","['Antiviral Agents/*chemical synthesis/*pharmacology', 'Cell Line', 'Diarrhea Viruses, Bovine Viral/drug effects/growth & development', 'Herpesviridae/drug effects', 'Microbial Sensitivity Tests', 'Models, Chemical', 'Ribavirin/*analogs & derivatives/pharmacology', 'Sugar Alcohols/chemistry', 'Triazoles/chemistry', 'Yellow fever virus/drug effects/growth & development']",https://pubmed.ncbi.nlm.nih.gov/12790513/
2085,Hexitol,11542282,Efficient transfer of information from hexitol nucleic acids to RNA during nonenzymatic oligomerization.,"['Kozlov IA', 'De Bouvere B', 'Van Aerschot A', 'Herdewijn P', 'Orgel LE']","['Chromatography, High Pressure Liquid', 'DNA', 'Directed Molecular Evolution', '*Evolution, Molecular', 'Guanosine Monophosphate/analogs & derivatives/chemistry', 'Molecular Structure', 'Nucleic Acids/*chemistry', 'Nucleosides/chemistry', 'Oligonucleotides/*chemical synthesis', 'Polymers/chemical synthesis/chemistry', 'RNA/*chemistry', 'Sugar Alcohols/chemistry', 'Templates, Genetic']",https://pubmed.ncbi.nlm.nih.gov/11542282/
2086,Hexitol,10677582,Biological activity of hexitol nucleic acids targeted at Ha-ras and intracellular adhesion molecule-1 mRNA.,"['Vandermeeren M', 'Preveral S', 'Janssens S', 'Geysen J', 'Saison-Behmoaras E', 'Van Aerschot A', 'Herdewijn P']","['Cells, Cultured', 'Cytokines/pharmacology', 'Gene Expression/drug effects', 'Genes, ras/*drug effects/genetics', 'Humans', 'Intercellular Adhesion Molecule-1/*drug effects/genetics', 'Keratinocytes/drug effects/metabolism', 'Oligonucleotides/chemistry/*pharmacology', 'Protein Biosynthesis/drug effects', 'RNA, Messenger/drug effects']",https://pubmed.ncbi.nlm.nih.gov/10677582/
2087,Hexitol,15080997,Design and synthesis of conformationally frozen peptide nucleic acid backbone: chiral piperidine PNA as a hexitol nucleic acid surrogate.,"['Lonkar PS', 'Kumar VA']","['DNA/*chemistry', 'Peptide Nucleic Acids/*chemistry', 'Protein Conformation', 'Ultraviolet Rays']",https://pubmed.ncbi.nlm.nih.gov/15080997/
2088,Hexitol,6806830,The effect of sucrose and hexitol--containing chewing gums on plaque acidogenesis in vivo.,"['Vratsanos SM', 'Mandel ID']","['Acids/metabolism', 'Adult', '*Chewing Gum', 'Dental Caries Susceptibility', 'Dental Plaque/*metabolism', 'Humans', 'Hydrogen-Ion Concentration', 'Mannitol/*pharmacology', 'Sorbitol/*pharmacology', 'Sucrose/*pharmacology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6806830/
2089,Hexitol,11322725,Syntheses of neoglycolipids with hexitol spacers between the saccharidic and the lipidic parts.,"['Lafont D', 'Gross B', 'Kleinegesse R', 'Dumoulin F', 'Boullanger P']","['Galactose/chemistry', 'Glucosamine/chemistry', 'Glycolipids/*chemical synthesis/chemistry', 'Glycosylation', 'Mannitol/chemistry', 'Molecular Structure', 'Sorbitol/chemistry']",https://pubmed.ncbi.nlm.nih.gov/11322725/
2090,Hexitol,14565386,"Methylated hexitol nucleic acids, towards congeners with improved antisense potential.","['Van Aerschot A', 'Marchand A', 'Schepers G', 'Van den Eynde W', 'Rozenski J', 'Busson R', 'Herdewijn P']","['*Alcohols', 'Alkylation', 'Methylation', 'Nucleic Acids/*chemical synthesis', 'Nucleosides/chemical synthesis']",https://pubmed.ncbi.nlm.nih.gov/14565386/
2091,Hexitol,14565294,Synthesis and antiviral evaluation of ribavirin congeners containing a hexitol moiety.,"['Van Aerschot A', 'Schepers G', 'Busson R', 'Neyts J', 'De Clercq E', 'Herdewijn P']","['Alcohols', 'Antiviral Agents/*chemical synthesis/*pharmacology', 'Hepacivirus/*drug effects', 'Indicators and Reagents', 'Microbial Sensitivity Tests', 'Models, Molecular', 'Molecular Conformation', 'Ribavirin/*analogs & derivatives/chemical synthesis/pharmacology', 'Triazoles']",https://pubmed.ncbi.nlm.nih.gov/14565294/
2092,Hexitol,10989842,Evaluation of the cellular uptake of hexitol nucleic acids in HeLa cells.,"['Atkins D', 'Miller M', 'De Bouvere B', 'van Aerschot A', 'Herdewijn P']","['Fluorescent Dyes', 'HeLa Cells', 'Hexosephosphates/*metabolism', 'Humans', 'Nucleic Acids/*metabolism', 'Oligonucleotides, Antisense/*metabolism', 'Ribonuclease H/biosynthesis']",https://pubmed.ncbi.nlm.nih.gov/10989842/
2093,Hexitol,6401708,Regulation of hexitol catabolism in Streptococcus mutans.,"['Dills SS', 'Seno S']","['Biological Transport/drug effects', 'Deoxy Sugars/*pharmacology', 'Deoxyglucose/*pharmacology', 'Enzyme Induction', 'Escherichia coli Proteins', 'Glucose/metabolism/*pharmacology', 'Lactates/metabolism', 'Lactic Acid', 'Mannitol/*metabolism', 'Monosaccharide Transport Proteins', 'Phosphoenolpyruvate Sugar Phosphotransferase System/biosynthesis', 'Sorbitol/*metabolism', 'Streptococcus mutans/*metabolism', 'Sugar Alcohol Dehydrogenases/biosynthesis']",https://pubmed.ncbi.nlm.nih.gov/6401708/
2094,Hexitol,25853790,"1',5'-Anhydro-L-ribo-hexitol Adenine Nucleic Acids (alpha-L-HNA-A): Synthesis and Chiral Selection Properties in the Mirror Image World.","[""D'Alonzo D"", 'Froeyen M', 'Schepers G', 'Di Fabio G', 'Van Aerschot A', 'Herdewijn P', 'Palumbo G', 'Guaragna A']","['Adenine/*chemical synthesis/chemistry', 'Base Pairing', 'Models, Molecular', 'Nucleic Acid Conformation', 'Nucleic Acids/*chemical synthesis/chemistry', 'Oligonucleotides/*chemical synthesis/chemistry', 'RNA/chemistry', 'Stereoisomerism', 'Sugar Alcohols/*chemical synthesis/chemistry']",https://pubmed.ncbi.nlm.nih.gov/25853790/
2095,Hexitol,9784109,"5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase.","['Ostrowski T', 'Wroblowski B', 'Busson R', 'Rozenski J', 'De Clercq E', 'Bennett MS', 'Champness JN', 'Summers WC', 'Sanderson MR', 'Herdewijn P']","['Antiviral Agents/*chemical synthesis/chemistry/pharmacology', 'Arabinonucleosides/*chemical synthesis/chemistry/pharmacology', 'Cell Line', 'Crystallography, X-Ray', 'Cytomegalovirus/drug effects', 'Herpesvirus 1, Human/drug effects/enzymology', 'Herpesvirus 2, Human/drug effects', 'Herpesvirus 3, Human/drug effects', 'Models, Molecular', 'Molecular Conformation', 'Pyrimidines/*chemical synthesis/chemistry/pharmacology', 'Structure-Activity Relationship', 'Thymidine Kinase/chemistry']",https://pubmed.ncbi.nlm.nih.gov/9784109/
2096,Hexitol,21919455,"Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 3'-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides.","['Egli M', 'Pallan PS', 'Allerson CR', 'Prakash TP', 'Berdeja A', 'Yu J', 'Lee S', 'Watt A', 'Gaus H', 'Bhat B', 'Swayze EE', 'Seth PP']","['Models, Molecular', 'Molecular Conformation', 'Nucleic Acids/*chemistry', 'Oligonucleotides/*chemistry', 'RNA/*chemistry', 'Stereoisomerism', 'Sugar Alcohols/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/21919455/
2097,Hexitol,14746272,Replication of hexitol oligonucleotides as a prelude to the propagation of a third type of nucleic acid in vivo.,"['Pochet S', 'Kaminski PA', 'Van Aerschot A', 'Herdewijn P', 'Marliere P']","['*DNA Replication', 'DNA, Antisense/*genetics', 'Nucleic Acid Amplification Techniques', 'Oligonucleotides/*genetics']",https://pubmed.ncbi.nlm.nih.gov/14746272/
2098,Orphenadrine,37599333,"Spectrofluorometric determination of orphenadrine, dimenhydrinate, and cinnarizine using direct and synchronous techniques with greenness assessment.","['Ghonim R', 'Tolba MM', 'Ibrahim F', 'El-Awady MI']","['*Cinnarizine', '*Dimenhydrinate', 'Hydrochloric Acid', 'Laboratories', '*Orphenadrine', '*Spectrometry, Fluorescence/methods']",https://pubmed.ncbi.nlm.nih.gov/37599333/
2099,Orphenadrine,800383,A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy.,"['Capstick N', 'Pudney H']","['Clinical Trials as Topic', 'Depression/chemically induced/*drug therapy', 'Fluphenazine/*adverse effects', 'Humans', 'Orphenadrine/*analogs & derivatives/*therapeutic use', 'Parkinson Disease, Secondary/chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/800383/
2100,Orphenadrine,38363510,"Uptake, translocation, and metabolization of amitriptyline, lidocaine, orphenadrine, and tramadol by cress and pea.","['Detzlhofer A', 'Grechhamer C', 'Madikizela L', 'Himmelsbach M', 'Mlynek F', 'Buchberger W', 'Klampfl CW']","['Amitriptyline/metabolism', 'Pisum sativum', '*Brassicaceae', 'Orphenadrine/metabolism', '*Tramadol', 'Lidocaine/metabolism', 'Plants/metabolism', 'Vegetables', 'Pharmaceutical Preparations/metabolism', 'Plant Roots/metabolism']",https://pubmed.ncbi.nlm.nih.gov/38363510/
2101,Orphenadrine,31812988,"Development and Validation of Chromatographic Methods for Simultaneous Determination of Paracetamol, Orphenadrine Citrate and Caffeine in Presence of P-aminophenol; Quantification of P-aminophenol Nephrotoxic Impurity Using LC-MS/MS.","['Boltia SA', 'Soudi AT', 'Elzanfaly ES', 'Zaazaa HE']","['Acetaminophen/*analysis', 'Aminophenols/*analysis/toxicity', 'Caffeine/*analysis', 'Chromatography, High Pressure Liquid', 'Chromatography, Liquid/*methods', 'Chromatography, Reverse-Phase', 'Chromatography, Thin Layer', 'Densitometry/methods', 'Drug Contamination', 'Excipients', 'Orphenadrine/*analysis', 'Tablets', 'Tandem Mass Spectrometry/methods']",https://pubmed.ncbi.nlm.nih.gov/31812988/
2102,Orphenadrine,16981050,"Efficacy and safety of combined piroxicam, dexamethasone, orphenadrine, and cyanocobalamin treatment in mandibular molar surgery.","['Barroso AB', 'Lima V', 'Guzzo GC', 'Moraes RA', 'Vasconcellos MC', 'Bezerra MM', 'Viana FA', 'Bezerra RC', 'Santana GS', 'Frota-Bezerra FA', 'Moraes MO', 'Moraes ME']","['Adolescent', 'Adult', 'Anti-Inflammatory Agents/*administration & dosage/adverse effects', 'Dexamethasone/administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Therapy, Combination', 'Edema/prevention & control', 'Female', 'Humans', 'Male', 'Middle Aged', 'Molar, Third/*surgery', 'Muscle Relaxants, Central/*administration & dosage/adverse effects', 'Orphenadrine/administration & dosage/adverse effects', 'Pain Measurement', 'Pain, Postoperative/drug therapy', 'Piroxicam/administration & dosage/adverse effects', 'Prospective Studies', 'Severity of Illness Index', '*Tooth Extraction', 'Vitamin B 12/administration & dosage/adverse effects', 'Vitamin B Complex/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16981050/
2103,Orphenadrine,36976401,Investigations of the Interaction Mechanism Between Orphenadrine Hydrochloride and Bovine Serum Albumin by Spectroscopic and Voltammetric Techniques.,"['Gokavi NM', 'Nandibewoor ST', 'Gowda JI']","['*Serum Albumin, Bovine/chemistry', '*Orphenadrine', 'Spectrometry, Fluorescence', 'Spectrophotometry, Ultraviolet', 'Binding Sites', 'Thermodynamics', 'Protein Binding', 'Circular Dichroism']",https://pubmed.ncbi.nlm.nih.gov/36976401/
2104,Orphenadrine,29089169,"A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain.","['Friedman BW', 'Cisewski D', 'Irizarry E', 'Davitt M', 'Solorzano C', 'Nassery A', 'Pearlman S', 'White D', 'Gallagher EJ']","['Acute Pain/diagnosis/*drug therapy', 'Administration, Oral', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Therapy, Combination', 'Emergency Service, Hospital', 'Female', 'Follow-Up Studies', 'Humans', 'Low Back Pain/diagnosis/*drug therapy', 'Male', 'Methocarbamol/*administration & dosage', 'Muscle Relaxants, Central', 'Naproxen/*administration & dosage', 'Orphenadrine/*administration & dosage', 'Pain Measurement', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29089169/
2105,Orphenadrine,15991879,Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse) with its single active ingredients diclofenac and orphenadrine: a placebo-controlled study using laser-induced somatosensory-evoked potentials from capsaicin-induced hyperalgesic human skin.,"['Schaffler K', 'Reitmeir P', 'Gschanes A', 'Eggenreich U']","['Adult', 'Analgesics/administration & dosage/*therapeutic use', 'Capsaicin', 'Cross-Over Studies', 'Diclofenac/administration & dosage/*therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Evoked Potentials, Somatosensory', 'Female', 'Humans', 'Hyperalgesia/drug therapy', 'Infusions, Intravenous', 'Lasers', 'Male', 'Middle Aged', 'Orphenadrine/administration & dosage/*therapeutic use', 'Pain/chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15991879/
2106,Orphenadrine,925110,Sensitive and specific gas chromatographic and extraction method for the determination of orphenadrine in human body fluids.,"['Labout JJ', 'Thijssen CT', 'Hespe W']","['Biological Availability', 'Chromatography, Gas', 'Humans', 'Orphenadrine/*analysis/blood/urine']",https://pubmed.ncbi.nlm.nih.gov/925110/
2107,Orphenadrine,12408930,Spectrophotometric determination of phenylephrine HCl and orphenadrine citrate in pure and in dosage forms.,['Shama SA'],"['Chemistry, Pharmaceutical', 'Dosage Forms', 'Orphenadrine/*analysis/chemistry', 'Phenylephrine/*analysis/chemistry', 'Spectrometry, Gamma/methods']",https://pubmed.ncbi.nlm.nih.gov/12408930/
2108,Orphenadrine,1432628,Solid-state structure of orphenadrine hydrochloride and conformational comparisons with diphenhydramine hydrochloride and nefopam hydrochloride.,"['Glaser R', 'Donnell D', 'Maartmann-Moe K']","['Diphenhydramine/*chemistry', 'Magnetic Resonance Spectroscopy', 'Molecular Conformation', 'Nefopam/*chemistry', 'Orphenadrine/*chemistry', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/1432628/
2109,Orphenadrine,1103709,"A controlled clinical trial of chlormezanone, orphenadrine, orphenadrine/paracetamol and placebo in the treatment of painful skeletal muscle spasms.",['Valtonen EJ'],"['Acetaminophen/*therapeutic use', 'Chlormezanone/*therapeutic use', 'Clinical Trials as Topic', 'Drug Evaluation', 'Drug Therapy, Combination', 'Humans', 'Muscle Cramp/*drug therapy', 'Orphenadrine/*therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/1103709/
2110,Orphenadrine,791320,Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man.,"['Loga S', 'Curry S', 'Lader M']","['Adult', 'Antipyrine/metabolism', 'Chlorpromazine/blood/*pharmacology', 'Clinical Trials as Topic', 'Drug Interactions', 'Female', 'Half-Life', 'Humans', 'Male', 'Orphenadrine/blood/*pharmacology', 'Phenobarbital/blood/*pharmacology', 'Psychotic Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/791320/
2111,Orphenadrine,324238,"Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety.","['Gerlach J', 'Rasmussen PT', 'Hansen L', 'Kristjansen P']","['Administration, Oral', 'Adult', 'Aged', 'Antiparkinson Agents/administration & dosage/adverse effects/*therapeutic use', 'Anxiety/*drug therapy', 'Clinical Trials as Topic', 'Depression/*drug therapy', 'Dibenzazepines/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Evaluation', 'Dyskinesia, Drug-Induced', 'Humans', 'Middle Aged', 'Orphenadrine/administration & dosage/adverse effects/*therapeutic use', 'Parkinson Disease/*drug therapy', 'Placebos', 'Schizophrenia/*drug therapy', 'Tablets', 'Time Factors', 'Tranquilizing Agents/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/324238/
2112,Orphenadrine,22573364,Cu(II)-catalyzed asymmetric hydrosilylation of diaryl- and aryl heteroaryl ketones: application in the enantioselective synthesis of orphenadrine and neobenodine.,"['Sui YZ', 'Zhang XC', 'Wu JW', 'Li S', 'Zhou JN', 'Li M', 'Fang W', 'Chan AS', 'Wu J']","['Catalysis', 'Copper/*chemistry', 'Histamine Antagonists/*chemical synthesis/chemistry/pharmacology', 'Ketones/*chemistry', 'Ligands', 'Molecular Structure', 'Orphenadrine/*analogs & derivatives/*chemical synthesis/chemistry/pharmacology', 'Stereoisomerism', 'tert-Butyl Alcohol/chemistry']",https://pubmed.ncbi.nlm.nih.gov/22573364/
2113,Dicyclomine,28052111,"8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information.","['Zhang R', 'Persaud N']","['Cooperative Behavior', 'Dicyclomine/adverse effects/*therapeutic use', 'Doxylamine/adverse effects/*therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Nausea/*complications/*drug therapy', 'Physicians', 'Placebos', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Publication Bias', '*Publications', 'Pyridoxine/adverse effects/*therapeutic use', 'Research Report', 'Risk', 'Vomiting/*complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28052111/
2114,Dicyclomine,879205,"Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Benedectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score.","['Shapiro S', 'Heinonen OP', 'Siskind V', 'Kaufman DW', 'Monson RR', 'Slone D']","['*Abnormalities, Drug-Induced', 'Birth Weight/*drug effects', 'Cyclohexanecarboxylic Acids/*adverse effects', 'Dicyclomine/*adverse effects', 'Doxylamine/*adverse effects', 'Environmental Exposure', 'Female', 'Humans', '*Infant Mortality', 'Infant, Newborn', 'Intelligence/*drug effects', '*Maternal-Fetal Exchange', 'Pregnancy', 'Pyridines/*adverse effects', 'Retrospective Studies', 'United States']",https://pubmed.ncbi.nlm.nih.gov/879205/
2115,Dicyclomine,7254087,Congenital anomalies in relation to the use of doxylamine/dicyclomine and other antenatal factors: an ongoing prospective study.,"['Gibson GT', 'Colley DP', 'McMichael AJ', 'Hartshorne JM']","['Abnormalities, Drug-Induced/*epidemiology', 'Adult', 'Cyclohexanecarboxylic Acids/*adverse effects', 'Dicyclomine/*adverse effects', 'Doxylamine/*adverse effects', 'Drug Combinations', 'Epidemiologic Methods', 'Female', 'Humans', 'Infant, Newborn', 'Male', 'Maternal Age', 'Maternal-Fetal Exchange', 'Parity', 'Pregnancy', 'Pregnancy Trimester, First', 'Prospective Studies', 'Pyridines/*adverse effects', 'Pyridoxine/*adverse effects', 'Urogenital Abnormalities']",https://pubmed.ncbi.nlm.nih.gov/7254087/
2116,Dicyclomine,833958,The treatment of the uninhibited bladder with dicyclomine.,"['Awad SA', 'Bryniak S', 'Downie JW', 'Bruce AW']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Child', 'Cyclohexanecarboxylic Acids/*therapeutic use', 'Dicyclomine/administration & dosage/*therapeutic use', 'Female', 'Humans', 'Injections, Intramuscular', 'Male', 'Middle Aged', 'Urinary Bladder, Neurogenic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/833958/
2117,Dicyclomine,1102879,A comparative study of two dicyclomine preparations in functional bowel disorders.,['Hennessy WB'],"['Adult', 'Aged', 'Clinical Trials as Topic', 'Colonic Diseases, Functional/drug therapy', 'Cyclohexanecarboxylic Acids/*therapeutic use', 'Delayed-Action Preparations', 'Dicyclomine/administration & dosage/adverse effects/*therapeutic use', 'Diverticulitis, Colonic/drug therapy', 'Female', 'Gastrointestinal Diseases/*drug therapy', 'Humans', 'Male', 'Middle Aged', 'Patient Dropouts', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/1102879/
2118,Dicyclomine,29055706,"Inhibitory action of dicyclomine on lipase activity, kinetics and molecular study.","['Talebi M', 'Minai-Tehrani D', 'Fazilati M', 'Minai-Tehrani A']","['Cardiovascular System/drug effects/physiopathology', 'Dicyclomine/*chemistry/pharmacology', 'Gastrointestinal Tract/drug effects/physiopathology', 'Humans', 'Hydrogen Bonding/drug effects', 'Hydrophobic and Hydrophilic Interactions/drug effects', 'Lipase/antagonists & inhibitors/*chemistry', 'Muscle, Smooth/drug effects/physiopathology', 'Pseudomonas aeruginosa/*enzymology/pathogenicity', 'Spasm/*drug therapy/physiopathology', 'Temperature']",https://pubmed.ncbi.nlm.nih.gov/29055706/
2119,Dicyclomine,34670427,A First Report of HCTZ and Dicyclomine Induced Uncharacteristic Contraction Alkalosis.,"['Eid TJ', 'Horton M', 'Hendrix C', 'Yu JM', 'Browning EA', 'Malhotra A']","['Humans', 'Male', 'Adult', 'Telmisartan/pharmacology/therapeutic use', 'Hydrochlorothiazide/pharmacology/therapeutic use', 'Dicyclomine/pharmacology/therapeutic use', 'Chlorides/pharmacology/therapeutic use', 'Carbon Dioxide/pharmacology/therapeutic use', '*Hypertension/drug therapy', 'Blood Pressure', '*Alkalosis/drug therapy', 'Antihypertensive Agents', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/34670427/
2120,Dicyclomine,6530703,Two cases of death involving dicyclomine in infants. Measurement of therapeutic and toxic concentrations in blood.,"['Garriott JC', 'Rodriquez R', 'Norton LE']","['Adult', 'Cyclohexanecarboxylic Acids/*adverse effects', 'Dicyclomine/*adverse effects/blood', 'Dose-Response Relationship, Drug', 'Female', 'Gas Chromatography-Mass Spectrometry', 'Humans', 'Infant', 'Male']",https://pubmed.ncbi.nlm.nih.gov/6530703/
2121,chlortalidone,7137653,"Minoxidil in severe and moderately severe hypertension, in association with methyldopa and chlortalidone.","['Cotorruelo JG', 'Llamazares C', 'Florez J']","['Adult', 'Aged', 'Body Water/metabolism', 'Chlorthalidone/*therapeutic use', 'Creatinine/blood', 'Drug Therapy, Combination', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Methyldopa/*therapeutic use', 'Middle Aged', 'Minoxidil/adverse effects/*therapeutic use', 'Pyrimidines/*therapeutic use', 'Sodium/metabolism', 'Tachycardia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/7137653/
2122,chlortalidone,26528899,Identification and proportion of the enantiomers of the antihypertensive drug chlortalidone in its Form II by high quality single-crystal X-ray diffraction data.,"['Santos LM', 'Santos OMM', 'Mendes PF', 'Rosa IML', 'Silva CCD', 'Bonfilio R', 'de Araujo MB', 'Boralli VB', 'Doriguetto AC', 'Martins FT']","['Antihypertensive Agents/analysis/*chemistry', 'Chlorthalidone/analysis/*chemistry', 'Crystallography, X-Ray/methods', 'Stereoisomerism', 'X-Ray Diffraction/*methods']",https://pubmed.ncbi.nlm.nih.gov/26528899/
2123,chlortalidone,8263885,Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients.,"['Maharaj B', 'van der Byl K']","['Adult', 'Antihypertensive Agents/*therapeutic use', 'Atenolol/adverse effects/therapeutic use', '*Black People', 'Chlorthalidone/adverse effects/therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Humans', 'Hydroflumethiazide/adverse effects/therapeutic use', 'Hypertension/*drug therapy/*ethnology/physiopathology', 'Male', 'Reserpine/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8263885/
2124,chlortalidone,17687887,The control of impurities in chlortalidone using a reversed-phase stationary phase.,"['Douville V', 'Keller E', 'Lambertz K', 'Lodi A', 'Miller JH']","['Antihypertensive Agents/analysis/chemistry', 'Chlorthalidone/*analysis/chemistry', 'Chromatography, High Pressure Liquid/*methods', 'Drug Contamination/*prevention & control', 'Drug Stability', 'Molecular Structure', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/17687887/
2125,chlortalidone,10631756,Study of the photochemical and in vitro phototoxicity of chlortalidone [2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzene sulfonamide].,"['Vargas F', 'Mendez H']","['Chlorthalidone/*chemistry/radiation effects/*toxicity', 'Chromatography, High Pressure Liquid', 'Dermatitis, Phototoxic/*pathology', 'Diuretics/*chemistry/radiation effects/*toxicity', 'Electron Transport', 'Erythrocytes/drug effects', 'Free Radicals', 'Humans', 'In Vitro Techniques', 'Magnetic Resonance Spectroscopy', 'Photochemistry', 'Photolysis', 'Ultraviolet Rays']",https://pubmed.ncbi.nlm.nih.gov/10631756/
2126,chlortalidone,38374541,Elimination profile of low-dose chlortalidone and its detection in hair for doping analysis-Implication for unintentional non-therapeutic exposure.,"['Thieme D', 'Weigel K', 'Anielski P', 'Krumbholz A', 'Sporkert F', 'Keiler AM']","['Humans', '*Doping in Sports/prevention & control', '*Substance Abuse Detection/methods', '*Hair/chemistry', '*Chlorthalidone/analysis/administration & dosage', '*Tandem Mass Spectrometry/methods', 'Male', 'Chromatography, Liquid/methods', 'Adult', 'Hydrochlorothiazide/analysis/administration & dosage', 'Diuretics/analysis/administration & dosage/urine']",https://pubmed.ncbi.nlm.nih.gov/38374541/
2127,chlortalidone,21125811,Antioxidative effects of thiazide diuretics in refractory hypertensive patients. A randomized crossover trial of chlortalidone and trichlormethiazide.,"['Sato K', 'Dohi Y', 'Kojima M', 'Takase H', 'Suzuki S', 'Ito S']","['Aged', '*Antioxidants', 'Blood Chemical Analysis', 'Blood Pressure/drug effects', 'C-Reactive Protein/metabolism', 'Calcium Channel Blockers/pharmacology', 'Chlorthalidone/pharmacology/therapeutic use', 'Cross-Over Studies', 'Diuretics/*pharmacology/therapeutic use', 'Drug Resistance', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/drug therapy/*metabolism/physiopathology', 'Male', 'Middle Aged', 'Oxidative Stress/drug effects', 'Thiazides/*pharmacology/therapeutic use', 'Trichlormethiazide/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21125811/
2128,chlortalidone,11050696,Comparative bioavailability of two formulations containing atenolol and chlortalidone associated in a 4:1 fixed combination.,"['Marzo A', 'Monti NC', 'Dal Bo L', 'Mazzucchelli P', 'Crivelli F', 'Tettamanti RA', 'Ismaili S', 'Uhr MR', 'Ronchi C', 'Porziotta E']","['Adrenergic beta-Antagonists/administration & dosage/*pharmacokinetics', 'Adult', 'Antihypertensive Agents/administration & dosage/*pharmacokinetics', 'Area Under Curve', 'Atenolol/administration & dosage/*pharmacokinetics', '*Benzothiadiazines', 'Biological Availability', 'Chlorthalidone/administration & dosage/*pharmacokinetics', 'Diuretics', 'Drug Combinations', 'Female', 'Half-Life', 'Humans', 'Male', 'Sodium Chloride Symporter Inhibitors/administration & dosage/*pharmacokinetics', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/11050696/
2129,chlortalidone,30302936,Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial.,"['Collier DJ', 'Juhasz A', 'Agabiti-Rosei E', 'Lloyd E', 'Hisada M', 'Zhao L', 'Kupfer S', 'Caulfield MJ']","['Aged', 'Angiotensin II Type 1 Receptor Blockers/therapeutic use', 'Benzimidazoles/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects/physiology', 'Blood Pressure Monitoring, Ambulatory/methods', 'Chlorthalidone/administration & dosage/adverse effects/*therapeutic use', 'Drug Therapy, Combination/*methods', 'Essential Hypertension/classification/*drug therapy/epidemiology/ethnology', 'Female', 'Humans', 'Male', 'Middle Aged', 'Outcome Assessment, Health Care', 'Oxadiazoles/administration & dosage/adverse effects/*therapeutic use', 'Sodium Chloride Symporter Inhibitors/therapeutic use', 'Systole']",https://pubmed.ncbi.nlm.nih.gov/30302936/
2130,chlortalidone,8762212,Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes.,"['Schneider M', 'Lerch M', 'Papiri M', 'Buechel P', 'Boehlen L', 'Shaw S', 'Risen W', 'Weidmann P']","['Adrenergic beta-Antagonists/*administration & dosage/adverse effects', 'Adult', 'Aged', 'Antihypertensive Agents/*administration & dosage', 'Carbohydrate Metabolism', 'Chlorthalidone/*administration & dosage/adverse effects', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy/metabolism', 'Indoles/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Prospective Studies', 'Verapamil/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8762212/
2131,chlortalidone,39067499,Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: Case example with chlortalidone.,['Kintz P'],"['Humans', '*Hair/chemistry', '*Substance Abuse Detection/methods', 'Doping in Sports/prevention & control', 'Male', 'Female', 'Adult', 'Chlorthalidone/analysis/administration & dosage', 'Dose-Response Relationship, Drug', 'Limit of Detection']",https://pubmed.ncbi.nlm.nih.gov/39067499/
2132,Bexarotene,35243730,Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: A systematic review and meta-analysis.,"['Ginsburg E', 'Hennessy K', 'Mhaskar R', 'Seminario-Vidal L']","['Adult', 'Bexarotene/adverse effects', 'Female', 'Humans', 'Male', '*Mycosis Fungoides/drug therapy/pathology', 'Phototherapy/adverse effects/methods', 'Prospective Studies', 'Retrospective Studies', '*Skin Neoplasms/drug therapy/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35243730/
2133,Bexarotene,37041679,Impact of body mass index on the severity of bexarotene-associated hypertriglyceridemia: A post hoc analysis of an open-labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T-cell lymphoma.,"['Sanagawa A', 'Hayakawa T', 'Nishida E', 'Yamamoto A', 'Ikumi K', 'Mori Y', 'Hotta Y', 'Kimura K', 'Furukawa-Hibi Y', 'Morita A']","['Humans', 'Bexarotene/adverse effects', 'Body Mass Index', 'Tetrahydronaphthalenes/adverse effects', 'East Asian People', 'Overweight/chemically induced/drug therapy', '*Lymphoma, T-Cell, Cutaneous/drug therapy', '*Hypertriglyceridemia/chemically induced/epidemiology', '*Skin Neoplasms/pathology', 'Phototherapy/adverse effects', 'Obesity/epidemiology/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37041679/
2134,Bexarotene,36555852,"An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.","['Jurutka PW', 'di Martino O', 'Reshi S', 'Mallick S', 'Sausedo MA', 'Moen GA', 'Lee IJ', 'Ivan DJ', 'Krall TD', 'Peoples SJ', 'Perez A', 'Tromba L', 'Le A', 'Khadka I', 'Petros R', 'Savage BM', 'Salama E', 'Salama J', 'Ziller JW', 'Noh Y', 'Lee MY', 'Liu W', 'Welch JS', 'Marshall PA', 'Wagner CE']","['Humans', 'Bexarotene/pharmacology', 'Retinoid X Receptors/metabolism', 'Tetrahydronaphthalenes/pharmacology', '*Lymphoma, T-Cell, Cutaneous', 'Liver X Receptors', '*Skin Neoplasms', 'Retinoids/pharmacology', '*Leukemia', 'Triglycerides']",https://pubmed.ncbi.nlm.nih.gov/36555852/
2135,Bexarotene,18429646,Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.,"['Papadavid E', 'Antoniou C', 'Nikolaou V', 'Siakantaris M', 'Vassilakopoulos TP', 'Stratigos A', 'Stavrianeas N', 'Katsambas A']","['Adult', 'Aged', 'Anticarcinogenic Agents/adverse effects/therapeutic use', 'Bexarotene', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Mycosis Fungoides/*drug therapy', 'PUVA Therapy', 'Tetrahydronaphthalenes/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18429646/
2136,Bexarotene,29717863,"Bexarotene Binds to the Amyloid Precursor Protein Transmembrane Domain, Alters Its alpha-Helical Conformation, and Inhibits gamma-Secretase Nonselectively in Liposomes.","['Kamp F', 'Scheidt HA', 'Winkler E', 'Basset G', 'Heinel H', 'Hutchison JM', 'LaPointe LM', 'Sanders CR', 'Steiner H', 'Huster D']","['Amyloid Precursor Protein Secretases/*antagonists & inhibitors/metabolism', 'Amyloid beta-Protein Precursor/*metabolism', 'Bexarotene/chemistry/*pharmacology', 'Cholesterol/metabolism', 'HEK293 Cells', 'Humans', 'Liposomes/*metabolism', 'Molecular Structure', 'Neuroprotective Agents/chemistry/*pharmacology', 'Phosphatidylcholines/chemistry', 'Protein Conformation, alpha-Helical', 'Protein Domains', 'Receptor, Notch1/metabolism', 'Static Electricity']",https://pubmed.ncbi.nlm.nih.gov/29717863/
2137,Bexarotene,38871976,Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma.,"['Sanagawa A', 'Hayakawa T', 'Yamamoto A', 'Hotta Y', 'Furukawa-Hibi Y', 'Morita A']","['Humans', '*Bexarotene/adverse effects/therapeutic use/administration & dosage', '*Hypertriglyceridemia/chemically induced', 'Male', '*Body Mass Index', 'Female', 'Middle Aged', '*Lymphoma, T-Cell, Cutaneous/drug therapy', 'Aged', 'Administration, Oral', 'Japan', 'Phototherapy/adverse effects', 'Adult', 'Combined Modality Therapy', 'East Asian People']",https://pubmed.ncbi.nlm.nih.gov/38871976/
2138,Bexarotene,25833198,Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells.,"['Kong JN', 'He Q', 'Wang G', 'Dasgupta S', 'Dinkins MB', 'Zhu G', 'Kim A', 'Spassieva S', 'Bieberich E']","['ATP Binding Cassette Transporter, Subfamily G, Member 2', 'ATP-Binding Cassette Transporters/*metabolism', 'Bexarotene', 'Breast Neoplasms/*drug therapy/pathology', 'Cell Death/drug effects', 'Cell Line, Tumor', 'Ceramides/biosynthesis', 'Down-Regulation/drug effects', 'Doxorubicin/*pharmacology', 'Drug Resistance, Neoplasm', 'Drug Synergism', 'Exosomes/drug effects/metabolism', 'Humans', 'Neoplasm Proteins/*metabolism', 'Pregnenediones/*pharmacology', 'Tetrahydronaphthalenes/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25833198/
2139,Alfuzosin,27127315,"A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.","['Manjunatha R', 'Pundarikaksha HP', 'Madhusudhana HR', 'Amarkumar J', 'Hanumantharaju BK']","['Adrenergic alpha-1 Receptor Antagonists/*therapeutic use', 'Aged', 'Humans', 'Indoles/*therapeutic use', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/*drug therapy/physiopathology', 'Quinazolines/*therapeutic use', 'Sulfonamides/*therapeutic use', 'Tamsulosin', 'Treatment Outcome', 'Urological Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27127315/
2140,Alfuzosin,38896813,"Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men.","['Hart A', 'Aldridge G', 'Zhang Q', 'Narayanan NS', 'Simmering JE']","['Humans', 'Male', '*Doxazosin/therapeutic use', 'Aged', '*Prazosin/analogs & derivatives/therapeutic use', '*Lewy Body Disease/drug therapy', '*Adrenergic alpha-1 Receptor Antagonists/therapeutic use', '*Quinazolines/therapeutic use/adverse effects', 'Aged, 80 and over', 'Tamsulosin/therapeutic use', 'Prostatic Hyperplasia/drug therapy', 'Neuroprotective Agents/therapeutic use/pharmacology', 'Middle Aged', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/38896813/
2141,Alfuzosin,35751619,Use of alpha1-adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer's disease.,"['Latvala L', 'Tiihonen M', 'Murtola TJ', 'Hartikainen S', 'Tolppanen AM']","['*Adrenergic alpha-Antagonists/adverse effects', '*Alzheimer Disease/drug therapy/epidemiology', 'Case-Control Studies', 'Humans', 'Male', 'Quinazolines', 'Receptors, Adrenergic', 'Sulfonamides/adverse effects', 'Tamsulosin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35751619/
2142,Alfuzosin,11750253,"Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.",['Roehrborn CG'],"['Adrenergic alpha-Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Aged', 'Drug Administration Schedule', 'Humans', 'Male', 'Prostatic Hyperplasia/complications/*drug therapy', 'Quinazolines/adverse effects/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Urethral Obstruction/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/11750253/
2143,Alfuzosin,26244843,Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis.,"['Liu C', 'Zeng G', 'Kang R', 'Wu W', 'Li J', 'Chen K', 'Wan SP']","['Humans', 'Quinazolines/adverse effects/*therapeutic use', 'Sulfonamides/adverse effects/therapeutic use', 'Tamsulosin', 'Ureter/drug effects/pathology', 'Ureteral Calculi/*drug therapy/pathology', 'Urological Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26244843/
2144,Alfuzosin,7682910,"Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.","['Wilde MI', 'Fitton A', 'McTavish D']","['Adrenergic alpha-Antagonists/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Male', 'Prostatic Hyperplasia/*drug therapy/physiopathology', 'Quinazolines/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7682910/
2145,Alfuzosin,32770667,Pharmacokinetics and Bioequivalence Estimation of Two Formulations of Alfuzosin Extended-Release Tablets.,"['Al Bawab AQ', 'Alkhalidi BA', 'Albarahmieh E', 'Qassim SMA', 'Al-Saifi MAD', 'Al-Saifi B', 'Ling J', 'Al-Qerem W']","['Administration, Oral', 'Adult', 'Area Under Curve', 'Biological Availability', 'Cross-Over Studies', 'Cytochrome P-450 CYP3A/metabolism', 'Drug Compounding/methods/*statistics & numerical data', 'Drugs, Generic/pharmacokinetics', 'Half-Life', 'Healthy Volunteers', 'Humans', 'Male', 'Prostatic Hyperplasia/blood/*drug therapy', 'Quinazolines/administration & dosage/adverse effects/*pharmacokinetics', 'Therapeutic Equivalency', 'Urological Agents/administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/32770667/
2146,Alfuzosin,26104313,The beneficial effect of alpha-blockers for ureteral stent-related discomfort: systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo.,"['Kwon JK', 'Cho KS', 'Oh CK', 'Kang DH', 'Lee H', 'Ham WS', 'Choi YD', 'Lee JY']","['Adrenergic alpha-Antagonists/*administration & dosage', 'Bayes Theorem', 'Humans', 'Pain/*drug therapy/etiology', 'Pain Measurement', 'Quinazolines/*administration & dosage', 'Randomized Controlled Trials as Topic', 'Stents/*adverse effects', 'Sulfonamides/*administration & dosage', 'Tamsulosin', 'Treatment Outcome', 'Ureteral Obstruction/diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/26104313/
2147,Alfuzosin,16230138,Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.,"['MacDonald R', 'Wilt TJ']","['Adrenergic alpha-Antagonists/adverse effects/*therapeutic use', 'Humans', 'Male', 'Prostatic Hyperplasia/complications/*drug therapy', 'Quinazolines/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Urination Disorders/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/16230138/
2148,Alfuzosin,35754330,Green micellar liquid chromatographic analysis of alfuzosin hydrochloride and sildenafil citrate in a binary mixture compared to classical RPLC with stability indicating studies.,"['Ayad MM', 'Hosny MM', 'Metias YM']","['Chromatography, High Pressure Liquid/methods', 'Chromatography, Liquid', '*Micelles', 'Quinazolines', 'Sildenafil Citrate']",https://pubmed.ncbi.nlm.nih.gov/35754330/
2149,Alfuzosin,31967910,"Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development, in vitro characterization and gastroretentive monitoring in healthy volunteers via MRI.","['Abd El-Aziz MF', 'Ismail S', 'Tadros MI', 'Elnabarawi MA']","['Abdomen/diagnostic imaging', 'Adrenergic alpha-1 Receptor Antagonists/administration & dosage/*chemistry/pharmacokinetics', 'Biological Availability', 'Chitosan/chemistry', 'Drug Carriers/chemistry', 'Drug Compounding/*methods', 'Drug Delivery Systems/*methods', 'Drug Liberation', 'Drug Monitoring/instrumentation/*methods', 'Ferrosoferric Oxide/chemistry', 'Gastric Mucosa/metabolism', 'Healthy Volunteers', 'Humans', 'Hypromellose Derivatives/chemistry', '*Magnetic Resonance Imaging', 'Porosity', 'Quinazolines/administration & dosage/*chemistry/pharmacokinetics', 'Solubility', 'Surface Properties']",https://pubmed.ncbi.nlm.nih.gov/31967910/
2150,Alfuzosin,15555475,Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.,['Guay DR'],"['Adrenergic alpha-Antagonists/administration & dosage/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Drug Interactions', 'Humans', 'Male', 'Prostatic Hyperplasia/*drug therapy', 'Quinazolines/administration & dosage/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15555475/
2151,Alfuzosin,11893233,Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.,"['McKeage K', 'Plosker GL']","['Absorption', '*Adrenergic alpha-Antagonists/administration & dosage/pharmacokinetics/therapeutic use', 'Aged', 'Area Under Curve', 'Clinical Trials as Topic', 'Delayed-Action Preparations', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Half-Life', 'Humans', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/*drug therapy/epidemiology/physiopathology', '*Quinazolines/administration & dosage/pharmacokinetics/therapeutic use', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/11893233/
2152,Alfuzosin,2591463,Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin.,"['Scott MG', 'Deering AH', 'McMahon MT', 'Harron DW', 'Shanks RG']","['Adult', 'Antihypertensive Agents/administration & dosage/pharmacokinetics/*pharmacology', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Half-Life', 'Heart Rate/drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Male', 'Norepinephrine/blood', 'Prazosin/pharmacokinetics/*pharmacology', 'Quinazolines/administration & dosage/pharmacokinetics/*pharmacology', 'Random Allocation', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2591463/
2153,Alfuzosin,28937828,The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases with Benign Prostatic Hyperplasia.,"['Dogan M', 'Kutluksaman B', 'Keles I', 'Karalar M', 'Halat AO']","['Adrenergic alpha-1 Receptor Antagonists/*therapeutic use', 'Aged', 'Aged, 80 and over', 'Choroid/diagnostic imaging/*drug effects/pathology', 'Color Vision', 'Diagnostic Techniques, Ophthalmological', 'Humans', 'Iris/diagnostic imaging/drug effects/pathology', 'Male', 'Middle Aged', 'Night Vision', 'Organ Size', 'Prospective Studies', 'Prostatic Hyperplasia/*drug therapy', 'Pupil/*drug effects', 'Quinazolines/*therapeutic use', 'Sulfonamides/*therapeutic use', 'Tamsulosin', 'Tomography, Optical Coherence/methods']",https://pubmed.ncbi.nlm.nih.gov/28937828/
2154,Alfuzosin,36758367,Micellar-enhanced and green-assessed first-derivative synchronous spectrofluorimetric approach for concurrent determination of alfuzosin hydrochloride and solifenacin succinate in different matrices: Docking simulation.,"['Sayed RA', 'Mohamed AR', 'Shalaby A', 'Ibrahim H']","['Male', 'Humans', '*Solifenacin Succinate', '*Micelles', 'Spectrometry, Fluorescence/methods', 'Water']",https://pubmed.ncbi.nlm.nih.gov/36758367/
2155,Alfuzosin,10771467,Alfuzosin-induced hepatotoxicity.,"['Zabala S', 'Thomson C', 'Valdearcos S', 'Gascon A', 'Pina MA']","['Acute Disease', 'Antihypertensive Agents/*adverse effects', 'Chemical and Drug Induced Liver Injury/*physiopathology', 'Humans', 'Hypertension/drug therapy', 'Male', 'Middle Aged', 'Quinazolines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/10771467/
2156,Alfuzosin,35256148,A sensing platform of molecular imprinted polymer-based polyaniline/carbon paste electrodes for simultaneous potentiometric determination of alfuzosin and solifenacin in binary co-formulation and spiked plasma.,"['Wadie M', 'Marzouk HM', 'Rezk MR', 'Abdel-Moety EM', 'Tantawy MA']","['Aniline Compounds', 'Carbon/chemistry', 'Electrodes', 'Humans', 'Ion-Selective Electrodes', '*Molecular Imprinting', 'Polymers/chemistry', 'Quinazolines', 'Solifenacin Succinate']",https://pubmed.ncbi.nlm.nih.gov/35256148/
2157,Alfuzosin,30130627,"Effects of Alfuzosin, an alpha(1)-Adrenergic Antagonist, on Anal Pressures and Bowel Habits in Women With and Without Defecatory Disorders.","['Chakraborty S', 'Feuerhak K', 'Muthyala A', 'Harmsen WS', 'Bailey KR', 'Bharucha AE']","['Adrenergic alpha-1 Receptor Antagonists/therapeutic use', 'Adult', 'Anal Canal/*physiopathology', 'Constipation/*drug therapy/physiopathology', 'Defecation/drug effects/*physiology', 'Double-Blind Method', 'Female', 'Follow-Up Studies', '*Habits', 'Humans', 'Manometry', 'Middle Aged', 'Pressure', 'Quinazolines/*therapeutic use', 'Retrospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30130627/
2158,Sufentanil,32486875,An up-to-date overview of sublingual sufentanil for the treatment of moderate to severe pain.,"['Porela-Tiihonen S', 'Kokki H', 'Kokki M']","['Acute Pain/blood/*drug therapy', 'Administration, Sublingual', 'Analgesia, Patient-Controlled', 'Analgesics, Opioid/*administration & dosage/adverse effects/therapeutic use', 'Biological Availability', 'Drug Delivery Systems/*methods', 'Duration of Therapy', 'Female', 'Humans', 'Nausea/chemically induced', 'Pain Management/*methods', 'Pain Measurement', 'Pain, Postoperative/blood/*drug therapy', 'Sufentanil/*administration & dosage/adverse effects/therapeutic use', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/32486875/
2159,Sufentanil,34077940,Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates.,"['Pokorna P', 'Sima M', 'Koch B', 'Tibboel D', 'Slanar O']","['Analgesics, Opioid/administration & dosage/*pharmacokinetics', 'Body Weight', 'Dose-Response Relationship, Drug', 'Drug Monitoring/methods', 'Female', 'Gestational Age', 'Humans', 'Infant, Newborn', 'Male', '*Models, Biological', '*Respiration, Artificial', 'Retrospective Studies', 'Sufentanil/administration & dosage/*pharmacokinetics', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/34077940/
2160,Sufentanil,35072431,Gastroscopy sedation: clinical trial comparing propofol and sufentanil with or without remimazolam.,"['Xiao X', 'Xiao N', 'Zeng F', 'Chen H', 'Zhang L', 'He X']","['*Anesthesia', 'Benzodiazepines', 'Gastroscopy', 'Humans', 'Hypnotics and Sedatives/pharmacology', '*Propofol', 'Sufentanil/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/35072431/
2161,Sufentanil,31286476,Spinal and epidural sufentanil and fentanyl in early labour.,"['Vaananen A', 'Kuukasjarvi M', 'Tekay A', 'Ahonen J']","['Analgesia, Epidural/*methods', 'Analgesia, Obstetrical/*methods', 'Female', 'Fentanyl/*administration & dosage', 'Heart Rate, Fetal', 'Humans', 'Pregnancy', 'Sufentanil/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/31286476/
2162,Sufentanil,34284552,Combination of propofol and nasal sufentanil or intravenous midazolam for colonoscopy: a comparative study.,"['Akarsu Ayazoglu T', 'Uzman S']","['Colonoscopy', 'Conscious Sedation', 'Humans', 'Hypnotics and Sedatives/adverse effects', '*Midazolam/adverse effects', '*Propofol/adverse effects', 'Prospective Studies', 'Sufentanil/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34284552/
2163,Sufentanil,33653734,Efficacy and safety of sufentanil sublingual tablet system in postoperative pain management: a systematic review and meta-analysis.,"['Thangaraju P', 'Varthya SB', 'Venkatesan S', 'Tamilselvan T', 'Singh S']","['Adult', 'Humans', '*Sufentanil/adverse effects', '*Analgesics, Opioid/therapeutic use', 'Pain Management', 'Pain, Postoperative/drug therapy', 'Tablets/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33653734/
2164,Sufentanil,35550501,Safety and Efficacy of Sufentanil and Fentanyl Analgesia in Patients with Traumatic Brain Injury: A Retrospective Study.,"['Xia W', 'Yang C']","['*Analgesia', '*Brain Injuries, Traumatic/complications/drug therapy', 'Fentanyl/adverse effects', 'Humans', 'Pain/drug therapy', 'Retrospective Studies', 'Sufentanil/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35550501/
2165,Sufentanil,24782286,Efficacy and Safety of Sufentanil and Pethidine in Spinal Anesthesia for Painless Labor.,"['Salarian S', 'Fathi M', 'Farzanegan B', 'Bagheri B']","['Adult', 'Analgesics, Opioid/adverse effects/therapeutic use', '*Anesthesia, Spinal', 'Female', 'Humans', 'Labor Pain/*drug therapy', 'Meperidine/*adverse effects/*therapeutic use', 'Pregnancy', 'Sufentanil/*adverse effects/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24782286/
2166,Sufentanil,38357150,Effects of 0.15% ropivacaine alone and combination with sufentanil on epidural labor analgesia and adverse reactions.,"['Zhong H', 'Wang Y', 'Wang Y', 'Li H']","['Female', 'Humans', 'Infant, Newborn', 'Pregnancy', '*Analgesia, Obstetrical/adverse effects', 'Analgesics', 'Anesthetics, Local/adverse effects', 'Double-Blind Method', 'Ropivacaine/adverse effects', '*Sufentanil/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38357150/
2167,Sufentanil,28006928,Sufentanil and midazolam dosing and pharmacogenetic factors in pediatric analgosedation and withdrawal syndrome.,"['Hronova K', 'Pokorna P', 'Posch L', 'Slanar O']","['Adjuvants, Anesthesia/*administration & dosage/adverse effects', 'Child', 'Dose-Response Relationship, Drug', 'Female', 'Genetic Variation/genetics', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Midazolam/*administration & dosage/adverse effects', 'Pediatrics/*methods', 'Pharmacogenetics/*methods', 'Polymorphism, Single Nucleotide/genetics', 'Substance Withdrawal Syndrome/diagnosis/*genetics', 'Sufentanil/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28006928/
2168,Sufentanil,33523352,"Mechanisms contributing to hypotension after anesthetic induction with sufentanil, propofol, and rocuronium: a prospective observational study.","['Saugel B', 'Bebert EJ', 'Briesenick L', 'Hoppe P', 'Greiwe G', 'Yang D', 'Ma C', 'Mascha EJ', 'Sessler DI', 'Rogge DE']","['*Anesthetics', 'Anesthetics, Intravenous', 'Blood Pressure', 'Hemodynamics/physiology', 'Humans', '*Hypotension', '*Propofol', 'Rocuronium/pharmacology', 'Sufentanil/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33523352/
2169,Sufentanil,8896944,"Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.","['Scholz J', 'Steinfath M', 'Schulz M']","['Aging/metabolism', 'Alfentanil/*administration & dosage/*pharmacokinetics', 'Analgesics, Opioid/*administration & dosage/*pharmacokinetics', 'Fentanyl/*administration & dosage/*pharmacokinetics', 'Half-Life', 'Humans', 'Obesity/metabolism', 'Sufentanil/*administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8896944/
2170,Sufentanil,8387987,"Pharmacodynamics, pharmacokinetics, and clinical uses of fentanyl, sufentanil, and alfentanil.","['Willens JS', 'Myslinski NR']","['Alfentanil/administration & dosage/pharmacokinetics/*pharmacology', 'Fentanyl/administration & dosage/pharmacokinetics/*pharmacology', 'Humans', 'Pain, Postoperative/drug therapy/metabolism', 'Postoperative Care/nursing', 'Receptors, Opioid/physiology', 'Sufentanil/administration & dosage/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8387987/
2171,Sufentanil,35645107,Safety and efficacy of microwave ablation to treat pulmonary nodules under conscious analgosedation with sufentanil: A single-center clinical experience.,"['Cao P', 'Meng W', 'Xue G', 'Wang N', 'Li Z', 'Kong Y', 'Wei Z', 'Ye X']","['Dizziness', 'Humans', '*Microwaves/adverse effects', 'Nausea', '*Sufentanil/adverse effects', 'Vomiting']",https://pubmed.ncbi.nlm.nih.gov/35645107/
2172,Sufentanil,30549392,"Quality control and stability of ketamine, remifentanil, and sufentanil syringes in a pediatric operating theater.","['Bourdon F', 'Simon N', 'Lannoy D', 'Berneron C', 'Decaudin B', 'Reumaux L', 'Duhamel A', 'Richart P', 'Odou P']","['Anesthetics, Intravenous/analysis', 'Chromatography, High Pressure Liquid', 'Drug Stability', 'Ketamine/analysis/*chemistry', 'Pediatrics/methods', 'Quality Control', 'Remifentanil/analysis/*chemistry', 'Sufentanil/analysis/*chemistry', '*Syringes']",https://pubmed.ncbi.nlm.nih.gov/30549392/
2173,Sufentanil,39155580,The use of intranasal sufentanil and/or s-ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study.,"['Nielsen BN', 'Henneberg SW', 'Olsson EM', 'Lundeberg S']","['Humans', '*Ketamine/administration & dosage/adverse effects/therapeutic use', '*Sufentanil/administration & dosage/adverse effects', 'Retrospective Studies', 'Child', 'Child, Preschool', 'Male', '*Administration, Intranasal', 'Female', 'Infant', 'Adolescent', '*Analgesics/administration & dosage/therapeutic use', 'Pain, Procedural/prevention & control/etiology', 'Ambulatory Care']",https://pubmed.ncbi.nlm.nih.gov/39155580/
2174,Temozolomide,36260828,Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).,"['Kunz PL', 'Graham NT', 'Catalano PJ', 'Nimeiri HS', 'Fisher GA', 'Longacre TA', 'Suarez CJ', 'Martin BA', 'Yao JC', 'Kulke MH', 'Hendifar AE', 'Shanks JC', 'Shah MH', 'Zalupski MM', 'Schmulbach EL', 'Reidy-Lagunes DL', 'Strosberg JR', ""O'Dwyer PJ"", 'Benson AB 3rd']","['Humans', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Capecitabine/therapeutic use', 'Dacarbazine/therapeutic use', '*Neuroendocrine Tumors/drug therapy', '*Pancreatic Neoplasms/drug therapy', 'Prospective Studies', 'Retrospective Studies', 'Temozolomide/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36260828/
2175,Temozolomide,34419533,Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.,"['Tomar MS', 'Kumar A', 'Srivastava C', 'Shrivastava A']","['Antineoplastic Agents, Alkylating/pharmacology/*therapeutic use', 'Drug Resistance, Neoplasm', 'Glioblastoma/*drug therapy', 'Glioma/*drug therapy', 'Humans', 'Temozolomide/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34419533/
2176,Temozolomide,35836243,PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPbeta degradation to facilitate proneural-to-mesenchymal transition.,"['Gao Z', 'Xu J', 'Fan Y', 'Qi Y', 'Wang S', 'Zhao S', 'Guo X', 'Xue H', 'Deng L', 'Zhao R', 'Sun C', 'Zhang P', 'Li G']","['Antineoplastic Agents, Alkylating/pharmacology', '*Brain Neoplasms/drug therapy/genetics/pathology', 'Cell Line, Tumor', 'Drug Resistance, Neoplasm/genetics', 'Gene Expression Regulation, Neoplastic', '*Glioblastoma/drug therapy/genetics/pathology', 'Humans', '*MicroRNAs/genetics', '*RNA, Long Noncoding/genetics', 'Temozolomide/pharmacology/therapeutic use', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/35836243/
2177,Temozolomide,35522273,Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.,"['Crisafulli G', 'Sartore-Bianchi A', 'Lazzari L', 'Pietrantonio F', 'Amatu A', 'Macagno M', 'Barault L', 'Cassingena A', 'Bartolini A', 'Luraghi P', 'Mauri G', 'Battuello P', 'Personeni N', 'Zampino MG', 'Pessei V', 'Vitiello PP', 'Tosi F', 'Idotta L', 'Morano F', 'Valtorta E', 'Bonoldi E', 'Germano G', 'Di Nicolantonio F', 'Marsoni S', 'Siena S', 'Bardelli A']","['Antineoplastic Agents, Alkylating/pharmacology/therapeutic use', '*Brain Neoplasms/drug therapy', 'Cell Line, Tumor', '*Colorectal Neoplasms/drug therapy/genetics', 'DNA Mismatch Repair', 'DNA-Binding Proteins/genetics', 'Dacarbazine/therapeutic use', 'Humans', 'Mutation', 'O(6)-Methylguanine-DNA Methyltransferase/genetics/metabolism', 'Temozolomide/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35522273/
2178,Temozolomide,34343032,"Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.","['Defachelles AS', 'Bogart E', 'Casanova M', 'Merks JHM', 'Bisogno G', 'Calareso G', 'Gallego Melcon S', 'Gatz SA', 'Le Deley MC', 'McHugh K', 'Probst A', 'Rocourt N', 'van Rijn RR', 'Wheatley K', 'Minard-Colin V', 'Chisholm JC']","['Adolescent', 'Adult', 'Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use', 'Child', 'Child, Preschool', 'Europe', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Irinotecan/pharmacology/*therapeutic use', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local', 'Rhabdomyosarcoma/*drug therapy/pathology', 'Temozolomide/pharmacology/*therapeutic use', 'Vincristine/pharmacology/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34343032/
2179,Temozolomide,37651725,EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma.,"['Hong B', 'Yang E', 'Su D', 'Ju J', 'Cui X', 'Wang Q', 'Tong F', 'Zhao J', 'Yang S', 'Cheng C', 'Xin L', 'Xiao M', 'Yi K', 'Zhan Q', 'Ding Y', 'Xu H', 'Cui L', 'Kang C']","['Humans', 'Temozolomide/pharmacology/therapeutic use', '*Glioblastoma/genetics', 'Dacarbazine/therapeutic use', 'Antineoplastic Agents, Alkylating/pharmacology/therapeutic use', 'Caveolin 1/metabolism/pharmacology/therapeutic use', 'Cell Line, Tumor', 'DNA Repair Enzymes/genetics', 'DNA Modification Methylases/genetics', 'Autophagy', 'Drug Resistance, Neoplasm', 'Poly (ADP-Ribose) Polymerase-1/metabolism/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37651725/
2180,Temozolomide,37551745,"CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity.","['Bhutada I', 'Khambati F', 'Cheng SY', 'Tiek DM', 'Duckett D', 'Lawrence H', 'Vogelbaum MA', 'Mo Q', 'Chellappan SP', 'Padmanabhan J']","['Humans', 'Temozolomide/pharmacology/therapeutic use', '*Glioblastoma/genetics', 'Ribosomal Protein S6 Kinases, 70-kDa/pharmacology/therapeutic use', 'Drug Resistance, Neoplasm', 'Cell Line, Tumor', '*Glioma/drug therapy', '*Brain Neoplasms/genetics', 'Xenograft Model Antitumor Assays', 'Cyclin-Dependent Kinase 9/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37551745/
2181,Temozolomide,31311005,How and when to use temozolomide to treat aggressive pituitary tumours.,['Whitelaw BC'],"['Antineoplastic Agents, Alkylating/*therapeutic use', 'Humans', 'Neoplasm Recurrence, Local/*drug therapy/pathology', 'Pituitary Neoplasms/*drug therapy/pathology', 'Prognosis', 'Temozolomide/*therapeutic use', 'Time-to-Treatment']",https://pubmed.ncbi.nlm.nih.gov/31311005/
2182,Temozolomide,36100765,Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide.,"['Choo M', 'Mai VH', 'Kim HS', 'Kim DH', 'Ku JL', 'Lee SK', 'Park CK', 'An YJ', 'Park S']","['Humans', 'Temozolomide/therapeutic use', '*Glioblastoma/drug therapy', 'Cell Shape', 'Lipid Metabolism', 'Sterol Regulatory Element Binding Protein 1/metabolism', 'Drug Resistance, Neoplasm', 'Lipids', 'Cell Line, Tumor', '*Brain Neoplasms/drug therapy', 'Antineoplastic Agents, Alkylating/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/36100765/
2183,Temozolomide,37566307,Temozolomide and flavonoids against glioma: from absorption and metabolism to exosomal delivery.,"['Verma P', 'Joshi H', 'Singh T', 'Sharma B', 'Sharma U', 'Ramniwas S', 'Rana R', 'Gupta M', 'Kaur G', 'Tuli HS']","['Humans', 'Temozolomide/pharmacology/therapeutic use', 'Flavonoids/pharmacology/therapeutic use', 'Tissue Distribution', '*Glioma/drug therapy', '*Glioblastoma/drug therapy/metabolism', 'Cell Line, Tumor', 'Drug Resistance, Neoplasm', 'Antineoplastic Agents, Alkylating/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37566307/
2184,Temozolomide,38542190,A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance.,"['Karve AS', 'Desai JM', 'Gadgil SN', 'Dave N', 'Wise-Draper TM', 'Gudelsky GA', 'Phoenix TN', 'DasGupta B', 'Yogendran L', 'Sengupta S', 'Plas DR', 'Desai PB']","['Humans', 'Temozolomide/pharmacology/therapeutic use', '*Glioblastoma/metabolism', 'Antineoplastic Agents, Alkylating/adverse effects', 'Quality of Life', '*Brain Neoplasms/pathology', 'Neoplasm Recurrence, Local/drug therapy', 'DNA/pharmacology', 'Drug Resistance, Neoplasm/genetics', 'Cell Line, Tumor']",https://pubmed.ncbi.nlm.nih.gov/38542190/
2185,Temozolomide,36477472,Aporphine and isoquinoline derivatives block glioblastoma cell stemness and enhance temozolomide cytotoxicity.,"['Rodrigues-Junior DM', 'Raminelli C', 'Hassanie H', 'Trossini GHG', 'Perecim GP', 'Caja L', 'Moustakas A', 'Vettore AL']","['Humans', '*Temozolomide/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/36477472/
2186,Bumetanide,3511654,Disposition and response to bumetanide and furosemide.,['Brater DC'],"['Adult', 'Aged', 'Biological Availability', '*Bumetanide/metabolism/pharmacology', '*Diuretics/metabolism/pharmacology', '*Furosemide/metabolism/pharmacology', 'Heart Failure/metabolism', 'Humans', 'Kidney Diseases/metabolism', 'Kidney Transplantation', 'Kinetics', 'Liver Cirrhosis/metabolism', 'Middle Aged', 'Nephrotic Syndrome/metabolism']",https://pubmed.ncbi.nlm.nih.gov/3511654/
2187,Bumetanide,4550872,"Bumetanide: potent new ""loop"" diuretic.","['Asbury MJ', 'Gatenby PB', ""O'Sullivan S"", 'Bourke E']","['Administration, Oral', 'Adult', 'Aged', 'Butylamines/therapeutic use', 'Chlorides/urine', 'Clinical Trials as Topic', 'Diuretics/administration & dosage/adverse effects/*therapeutic use', 'Edema/drug therapy', 'Female', 'Furosemide/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Phenols/therapeutic use', 'Placebos', 'Potassium/urine', 'Sodium/urine', 'Sulfonamides/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/4550872/
2188,Bumetanide,35292925,A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.,"['Georgoula C', 'Ferrin M', 'Pietraszczyk-Kedziora B', 'Hervas A', 'Marret S', 'Oliveira G', 'Rosier A', 'Crutel V', 'Besse E', 'Severo CA', 'Ravel D', 'Fuentes J']","['Humans', 'Child', 'Male', 'Adolescent', 'Female', '*Autism Spectrum Disorder/drug therapy', 'Bumetanide/adverse effects', '*Autistic Disorder/diagnosis', 'Double-Blind Method', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35292925/
2189,Bumetanide,35657748,Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine.,"['Catry E', 'Colsoul ML', 'Closset M', 'Hubert J', 'Soumoy L', 'Bihin B', 'Thiry E', 'Jamart J', 'Hecq JD', 'Galanti L']","['*Bumetanide', 'Chromatography, High Pressure Liquid', 'Drug Stability', 'Drug Storage', 'Humans', 'Pharmaceutical Preparations', '*Polypropylenes/chemistry', 'Scopolamine', 'Syringes']",https://pubmed.ncbi.nlm.nih.gov/35657748/
2190,Bumetanide,3380083,"Demonstration of a [K+,Cl-]-cotransport system in human red cells by its sensitivity to [(dihydroindenyl)oxy]alkanoic acids: regulation of cell swelling and distinction from the bumetanide-sensitive [Na+,K+,Cl-]-cotransport system.","['Garay RP', 'Nazaret C', 'Hannaert PA', 'Cragoe EJ Jr']","[""4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid"", ""4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid/analogs & derivatives/pharmacology"", 'Biological Transport/drug effects', 'Bumetanide/*pharmacology', 'Carboxylic Acids/*pharmacology', 'Cells, Cultured', 'Chlorides/*blood', 'Diuretics/*pharmacology', 'Erythrocytes/*metabolism', 'Ethylmaleimide/pharmacology', 'Humans', 'Indenes/*pharmacology', 'Potassium/*blood', 'Sodium/*blood']",https://pubmed.ncbi.nlm.nih.gov/3380083/
2191,Bumetanide,37364772,Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets.,"['Shakleya D', 'Asmelash B', 'Alayoubi A', 'Abrigo N', 'Mohammad A', 'Wang J', 'Zhang J', 'Yang J', 'Marzan TA', 'Li D', 'Shaklah M', 'Alsharif FM', 'Desai S', 'Faustino PJ', 'Ashraf M', ""O'Connor T"", 'Vera M', 'Raw A', 'Sayeed VA', 'Keire D']","['Humans', '*Bumetanide', '*Nitrosamines/metabolism', 'Antioxidants/pharmacology', 'Ascorbic Acid', 'Nitrites/metabolism', 'Tablets', '*Caffeic Acids', '*Coumaric Acids']",https://pubmed.ncbi.nlm.nih.gov/37364772/
2192,Bumetanide,35524444,Clarifications regarding bumetanide for neonatal seizures.,['Staley KJ'],"['Bumetanide/therapeutic use', '*Epilepsy', 'Humans', 'Infant, Newborn', '*Infant, Newborn, Diseases', 'Seizures/drug therapy', 'Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Solute Carrier Family 12, Member 2']",https://pubmed.ncbi.nlm.nih.gov/35524444/
2193,Bumetanide,37021422,"Bumetanide, a Diuretic That Can Help Children with Autism Spectrum Disorder.","['Shaker E', 'El Agami O', 'Salamah A']","['Child', 'Humans', 'Bumetanide/therapeutic use', 'Diuretics/therapeutic use', '*Autism Spectrum Disorder/drug therapy', '*Autistic Disorder', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37021422/
2194,Bumetanide,22702741,Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.,['Pacifici GM'],"['Acetazolamide/therapeutic use', 'Bumetanide/pharmacokinetics/*pharmacology/therapeutic use', 'Drug Therapy, Combination', 'Ductus Arteriosus, Patent/drug therapy', 'Extracorporeal Membrane Oxygenation', 'Furosemide/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Hydrocephalus/drug therapy', 'Hypercalcemia/drug therapy', 'Ibuprofen/therapeutic use', 'Indomethacin/therapeutic use', 'Infant', 'Infant, Newborn', 'Infant, Premature', 'Sodium Potassium Chloride Symporter Inhibitors/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22702741/
2195,Bumetanide,23538300,Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure.,"['Ng TM', 'Konopka E', 'Hyderi AF', 'Hshieh S', 'Tsuji Y', 'Kim BJ', 'Han SY', 'Phan DH', 'Jeng AI', 'Lou M', 'Elkayam U']","['Acute Disease', 'Adult', 'Aged', 'Blood Urea Nitrogen', 'Bumetanide/adverse effects/*therapeutic use', 'Cohort Studies', 'Diuretics/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Furosemide/adverse effects/*therapeutic use', 'Heart Failure/*drug therapy/urine', 'Humans', 'Hyponatremia/epidemiology', 'Incidence', 'Male', 'Metolazone/adverse effects/*therapeutic use', 'Middle Aged', 'Regression Analysis', 'Retrospective Studies', 'Treatment Outcome', 'Urine/physiology']",https://pubmed.ncbi.nlm.nih.gov/23538300/
2196,Bumetanide,4448415,Use of bumetanide in the treatment of ascites due to liver disease.,"['Moult PJ', 'Lunzer MR', 'Trash DB', 'Sherlock S']","['Adolescent', 'Adult', 'Aged', 'Ascites/diet therapy/*drug therapy/etiology', 'Benzoates/*therapeutic use', 'Bilirubin/blood', 'Blood Glucose/analysis', 'Body Weight', 'Butylamines/therapeutic use', 'Chronic Disease', 'Diuretics/*therapeutic use', 'Female', 'Hepatic Encephalopathy/drug therapy', 'Humans', 'Liver Diseases/complications/*drug therapy', 'Male', 'Middle Aged', 'Natriuresis/drug effects', 'Phenyl Ethers/therapeutic use', 'Potassium/blood', 'Sodium/blood', '*Sulfonamides', 'Urea/blood']",https://pubmed.ncbi.nlm.nih.gov/4448415/
2197,Imatinib,33768564,Imatinib-induced eruptive nevi.,"['Hamie L', 'Sawaya RT', 'Abbas O']","['Adolescent', 'Humans', 'Male', '*Antineoplastic Agents/adverse effects/therapeutic use', '*Imatinib Mesylate/adverse effects/therapeutic use', '*Nevus, Pigmented/chemically induced/pathology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy', 'Protein Kinase Inhibitors/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33768564/
2198,Imatinib,30560342,"Synthesis, spectral characterization, docking studies and biological activity of urea, thiourea, sulfonamide and carbamate derivatives of imatinib intermediate.","['Chandrasekhar M', 'Prasad GS', 'Venkataramaiah C', 'Naga Raju C', 'Seshaiah K', 'Rajendra W']","['Anti-Infective Agents/chemical synthesis/chemistry/metabolism/pharmacology', 'Antioxidants/chemical synthesis/chemistry/metabolism/pharmacology', 'Aromatase/chemistry/metabolism', 'Carbamates/*chemistry', 'Chemistry Techniques, Synthetic', 'Imatinib Mesylate/*chemical synthesis/chemistry/metabolism/*pharmacology', '*Molecular Docking Simulation', 'Protein Conformation', 'Spectrum Analysis', 'Structure-Activity Relationship', 'Sulfonamides/*chemistry', 'Thiourea/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/30560342/
2199,Imatinib,35049365,Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy.,"['Ashraf S', 'Wolfson J', 'Vachhani P', 'Rangaraju S', 'Bachiashvili K', 'Bhatia R', 'Jamy O']","['Humans', 'Pregnancy', 'Adult', 'Female', 'Imatinib Mesylate/adverse effects', '*Philadelphia Chromosome', '*Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35049365/
2200,Imatinib,30504305,The argument for using imatinib in CML.,"['Claudiani S', 'Apperley JF']","['Clinical Trials as Topic', 'Humans', 'Imatinib Mesylate/adverse effects/*therapeutic use', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*drug therapy', '*Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/30504305/
2201,Imatinib,32893688,Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis.,"['Liakouli V', 'Ciaffi J', 'Ursini F', 'Ruscitti P', 'Meliconi R', 'Ciccia F', 'Cipriani P', 'Giacomelli R']","['Drug-Related Side Effects and Adverse Reactions', 'Humans', 'Imatinib Mesylate/adverse effects/*therapeutic use', 'Protein Kinase Inhibitors/adverse effects/*therapeutic use', 'Quality of Life', 'Scleroderma, Systemic/*drug therapy', 'Skin/drug effects/*pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32893688/
2202,Imatinib,36870577,Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19.,"['Baalbaki N', 'Duijvelaar E', 'Said MM', 'Schippers J', 'Bet PM', 'Twisk J', 'Fritchley S', 'Longo C', 'Mahmoud K', 'Maitland-van der Zee AH', 'Bogaard HJ', 'Swart EL', 'Aman J', 'Bartelink IH']","['Humans', 'Imatinib Mesylate/pharmacology/therapeutic use', 'Drug Repositioning', '*COVID-19', '*Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36870577/
2203,Imatinib,37955064,Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation.,"['Gagno S', 'Fratte CD', 'Posocco B', 'Buonadonna A', 'Fumagalli A', 'Guardascione M', 'Toffoli G', 'Cecchin E']","['Humans', 'Imatinib Mesylate/therapeutic use', '*Gastrointestinal Stromal Tumors/drug therapy/genetics', '*Antineoplastic Agents/adverse effects', 'Pharmacogenetics', 'Drug Monitoring']",https://pubmed.ncbi.nlm.nih.gov/37955064/
2204,Imatinib,38368446,Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib.,"['Klaihmon P', 'Lorthongpanich C', 'Kheolamai P', 'Saisaard W', 'Issaragrisil S']","['Humans', 'Imatinib Mesylate/pharmacology/therapeutic use', '*Drug Resistance, Neoplasm', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology', 'Fusion Proteins, bcr-abl/genetics', 'Protein Serine-Threonine Kinases', 'K562 Cells', 'Apoptosis', 'Tumor Suppressor Proteins']",https://pubmed.ncbi.nlm.nih.gov/38368446/
2205,Imatinib,37108337,LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib.,"['Ruiz-Demoulin S', 'Trenquier E', 'Dekkar S', 'Deshayes S', 'Boisguerin P', 'Serrano C', 'de Santa Barbara P', 'Faure S']","['Humans', '*Antineoplastic Agents/pharmacology/therapeutic use', 'Autophagy-Related Proteins/genetics', 'Drug Resistance, Neoplasm/genetics', '*Gastrointestinal Stromal Tumors/drug therapy/genetics/pathology', 'Imatinib Mesylate/pharmacology/therapeutic use', 'Mutation', 'Protein Kinase Inhibitors/pharmacology', 'Proto-Oncogene Proteins c-kit/metabolism', 'Sunitinib/pharmacology/therapeutic use', 'MAP Kinase Signaling System']",https://pubmed.ncbi.nlm.nih.gov/37108337/
2206,Imatinib,37563838,Therapeutic Drug Monitoring of Imatinib and N-Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC-MS/MS in a Cohort Study.,"['Huang X', 'Liu Y', 'Chen J', 'Zheng H', 'Ding Y', 'He Z']","['Adolescent', 'Humans', 'Imatinib Mesylate/therapeutic use', '*Antineoplastic Agents/therapeutic use', 'Chromatography, Liquid', 'Drug Monitoring', 'Cohort Studies', 'Tandem Mass Spectrometry', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy', 'Protein Kinase Inhibitors/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37563838/
2207,Imatinib,16573254,Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate.,['Scheinfeld N'],"['Antineoplastic Agents/*adverse effects', 'Benzamides', 'Drug Eruptions/*etiology/pathology', 'Humans', 'Imatinib Mesylate', 'Piperazines/*adverse effects', 'Protein-Tyrosine Kinases/*antagonists & inhibitors', 'Pyrimidines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16573254/
2208,Imatinib,30022700,Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment.,"['Jose A', 'Ninave KM', 'Karnam S', 'Venuganti VVK']","['1,2-Dipalmitoylphosphatidylcholine/*chemistry', 'Antineoplastic Agents/*administration & dosage/pharmacology', 'Breast Neoplasms/*drug therapy', 'Cell Line, Tumor', 'Cell Survival/drug effects', 'Drug Compounding/methods', 'Drug Liberation', 'Female', 'Humans', 'Imatinib Mesylate/*administration & dosage/pharmacology', 'Liposomes/*chemistry', 'Lysophosphatidylcholines/*chemistry', 'Nanoparticles/chemistry', 'Tamoxifen/*administration & dosage/pharmacology', 'Temperature']",https://pubmed.ncbi.nlm.nih.gov/30022700/
2209,Imatinib,38536418,Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring.,"['Omran MM', 'Ibrahim AB', 'Abdelfattah R', 'Shouman SA', 'Hamza MS']","['Humans', '*Imatinib Mesylate/pharmacokinetics/therapeutic use/blood', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/blood', 'Female', 'Male', 'Middle Aged', 'Adult', '*Antineoplastic Agents/pharmacokinetics/therapeutic use/blood', '*Creatine Kinase/blood', 'Aged', '*Drug Monitoring/methods', 'Protein Kinase Inhibitors/pharmacokinetics/therapeutic use/blood', 'Young Adult', 'Treatment Outcome', 'Creatine Kinase, MB Form/blood', 'Tandem Mass Spectrometry', 'Aged, 80 and over', 'Chromatography, Liquid']",https://pubmed.ncbi.nlm.nih.gov/38536418/
2210,Imatinib,26942271,p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?,"['Noujaim J', 'Gonzalez D', 'Thway K', 'Jones RL', 'Judson I']","['Female', 'Gastrointestinal Stromal Tumors/*drug therapy', 'Humans', 'Imatinib Mesylate/administration & dosage/pharmacology/*therapeutic use', 'Male', 'Mutation', 'Prognosis']",https://pubmed.ncbi.nlm.nih.gov/26942271/
2211,Imatinib,37902257,"Therapeutic drug monitoring to personalize dosing of imatinib, sunitinib, and pazopanib: A mixed methods study on barriers and facilitators.","['Westerdijk K', 'Steeghs N', 'Tacke CSJ', 'van der Graaf WTA', 'van Erp NP', 'van Oortmerssen G', 'Hermens RPMG', 'Desar IME']","['Humans', 'Imatinib Mesylate/therapeutic use', 'Sunitinib', '*Drug Monitoring', 'Pharmaceutical Preparations']",https://pubmed.ncbi.nlm.nih.gov/37902257/
2212,Imatinib,38695123,Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN.,"['Cortes JE', 'Jiang Q', 'Wang J', 'Weng J', 'Zhu H', 'Liu X', 'Hochhaus A', 'Kim DW', 'Radich J', 'Savona M', 'Martin-Regueira P', 'Sy O', 'Saglio G']","['Humans', '*Dasatinib/therapeutic use/administration & dosage', '*Imatinib Mesylate/therapeutic use/administration & dosage', 'Male', 'Female', 'Middle Aged', 'Aged', '*Leukemia, Myeloid, Chronic-Phase/drug therapy/mortality', 'Adult', 'Treatment Outcome', 'Follow-Up Studies', 'Protein Kinase Inhibitors/therapeutic use/adverse effects/administration & dosage', 'Antineoplastic Agents/therapeutic use', 'Aged, 80 and over', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/38695123/
2213,Lamivudine,38005918,Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis.,"['Henriquez-Camacho C', 'Hijas-Gomez AI', 'Risco Risco C', 'Ruiz Lapuente MA', 'Escudero-Sanchez R', 'Cuerda VM']","['Adult', 'Humans', 'Lamivudine/therapeutic use', 'Antiviral Agents/pharmacology', 'Hepatitis B Surface Antigens', '*Hepatitis B/complications', 'Hepatitis B virus/genetics', '*Hepatitis B, Chronic', 'Treatment Outcome', 'DNA, Viral']",https://pubmed.ncbi.nlm.nih.gov/38005918/
2214,Lamivudine,11374710,Hepatic decompensation associated with lamivudine: a case report and review of lamivudine-induced hepatotoxicity.,"['Ormseth EJ', 'Holtzmuller KC', 'Goodman ZD', 'Colonna JO', 'Batty DS', 'Sjogren MH']","['Hepatitis B, Chronic/drug therapy', 'Humans', 'Lamivudine/*adverse effects/therapeutic use', 'Liver/*drug effects/pathology', 'Liver Failure/*chemically induced/pathology/surgery', 'Liver Transplantation', 'Male', 'Middle Aged', 'Reverse Transcriptase Inhibitors/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11374710/
2215,Lamivudine,27561199,Synthesis of (125) I-lamivudine and (125) I-lamivudine-ursodeoxycholic acid codrug.,"['Motaleb MA', 'Abo-Kul M', 'Ibrahim SM', 'Saad SM', 'Arafat M']","['Antiviral Agents/*chemical synthesis/*chemistry', 'Chemistry Techniques, Synthetic', 'Iodine Radioisotopes/*chemistry', 'Lamivudine/*chemical synthesis/*chemistry', 'Radiochemistry', 'Ursodeoxycholic Acid/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/27561199/
2216,Lamivudine,37311224,"Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.","['Martinez-Serra A', 'De Lazzari E', 'Berrocal L', 'Foncillas A', 'De La Mora L', 'Inciarte A', 'Chivite I', 'Gonzalez-Cordon A', 'Martinez-Rebollar M', 'Torres B', 'Laguno M', 'Blanco JL', 'Martinez E', 'Mallolas J', 'Ambrosioni J']","['Adult', 'Female', 'Humans', 'Lamivudine/therapeutic use', 'Retrospective Studies', '*HIV Infections/drug therapy', '*Anti-HIV Agents/therapeutic use', 'Drug Therapy, Combination', 'Heterocyclic Compounds, 3-Ring/therapeutic use', 'Oxazines/therapeutic use', 'Pyridones/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37311224/
2217,Lamivudine,31180906,Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.,"['Radford M', 'Parks DC', 'Ferrante S', 'Punekar Y']","['Anti-HIV Agents/adverse effects/*therapeutic use', 'CD4 Lymphocyte Count', 'Drug Therapy, Combination', 'HIV Infections/*drug therapy', 'HIV-1', 'Heterocyclic Compounds, 3-Ring/adverse effects/*therapeutic use', 'Humans', 'Lamivudine/adverse effects/*therapeutic use', 'Oxazines', 'Piperazines', 'Pyridones', 'RNA, Viral/blood', 'Randomized Controlled Trials as Topic', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/31180906/
2218,Lamivudine,26631576,Preparation and characterization of isoniazid and lamivudine co-loaded polymeric microspheres.,"['Pandey G', 'Yadav SK', 'Mishra B']","['Caco-2 Cells', '*Drug Carriers/chemistry/pharmacokinetics/pharmacology', 'Humans', '*Isoniazid/chemistry/pharmacokinetics/pharmacology', '*Lamivudine/chemistry/pharmacokinetics/pharmacology', 'Materials Testing', '*Microspheres']",https://pubmed.ncbi.nlm.nih.gov/26631576/
2219,Lamivudine,39047063,Female Genital Tract Host Factors and Tenofovir and Lamivudine Active Metabolites.,"['Lantz AM', 'Kiweewa Matovu F', 'Johnson R', 'Isingel E', 'Nakalega R', 'Kabwigu S', 'Beksinska ME', 'Nicol MR']","['Humans', 'Female', '*Tenofovir/therapeutic use/pharmacokinetics', '*Lamivudine/pharmacokinetics/therapeutic use', 'Adult', '*HIV Infections/drug therapy', '*Anti-HIV Agents/pharmacokinetics/therapeutic use', '*Cytokines/metabolism', 'Cervix Uteri/drug effects/metabolism', 'Uganda', 'Young Adult', 'Vagina/drug effects/immunology']",https://pubmed.ncbi.nlm.nih.gov/39047063/
2220,Lamivudine,39092932,Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation study.,"['Bekker A', 'Capparelli EV', 'Mirochnick M', 'Clarke DF', 'Cotton MF', 'Shapiro R', 'McCarthy K', 'Moye J', 'Violari A', 'Chokephaibulkit K', 'Abrams E', 'Penazzato M', 'Ruel TD', 'Cressey TR']","['Humans', '*Lamivudine/pharmacokinetics/administration & dosage', '*HIV Infections/drug therapy', 'Female', 'Infant, Newborn', '*Infant, Premature', '*Anti-HIV Agents/pharmacokinetics/administration & dosage/therapeutic use', 'Male', 'Infant', 'Gestational Age', 'Computer Simulation']",https://pubmed.ncbi.nlm.nih.gov/39092932/
2221,Lamivudine,25666155,Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.,"['Singhroy DN', 'Wainberg MA', 'Mesplede T']","['Anti-HIV Agents/pharmacology', 'Drug Resistance, Viral/genetics', 'HIV Integrase Inhibitors/*pharmacology', 'HIV-1/drug effects/pathogenicity', 'Heterocyclic Compounds, 3-Ring/*pharmacology', 'Humans', 'Lamivudine/*pharmacology', 'Oxazines', 'Piperazines', 'Pyridones', 'Virus Replication/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25666155/
2222,Lamivudine,17413701,"Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.","['Laurent C', 'Kouanfack C', 'Koulla-Shiro S', 'Njoume M', 'Nkene YM', 'Ciaffi L', 'Brulet C', 'Peytavin G', 'Vergne L', 'Calmy A', 'Mpoudi-Ngole E', 'Delaporte E']","['Adult', 'Anti-HIV Agents/adverse effects/blood/*therapeutic use', 'CD4 Lymphocyte Count', 'Drug Resistance, Viral', 'Drug Therapy, Combination', 'Female', 'Humans', 'Lamivudine/adverse effects/blood/*therapeutic use', 'Long-Term Care/methods', 'Male', 'Nevirapine/adverse effects/blood/*therapeutic use', 'Reverse Transcriptase Inhibitors/therapeutic use', 'Stavudine/adverse effects/blood/*therapeutic use', 'Treatment Outcome', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/17413701/
2223,Lamivudine,10432731,Comparison of anti-HBV activity of beta-D- and beta-L-DDA-5'monophosphate prodrugs and effectiveness in combination with lamivudine.,"['Loi AG', 'Faraj A', 'Pierra C', 'Gosselin G', 'Imbach JL', 'Locarnini SA', 'Groman EV', 'Schinazi RF', 'Sommadossi JP']","['Antiviral Agents/*pharmacology', 'Cell Line', 'Deoxyadenine Nucleotides/*pharmacology', 'Dideoxynucleotides', 'Hepatitis B virus/*drug effects/physiology', 'Lamivudine/*pharmacology', 'Microbial Sensitivity Tests', 'Stereoisomerism', 'Virus Replication/drug effects']",https://pubmed.ncbi.nlm.nih.gov/10432731/
2224,Lamivudine,37604629,"Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark.","['Pedersen KBH', 'Knudsen A', 'Moller S', 'Siebner HR', 'Hove JD', 'Gerstoft J', 'Benfield T']","['Humans', 'Body Composition', 'Body Weight', '*Cardiovascular Diseases', 'Denmark', '*HIV Infections/drug therapy', 'Lamivudine/therapeutic use', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/37604629/
2225,Lamivudine,37632082,Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV.,"['Mazzitelli M', 'Sasset L', 'Gardin S', 'Leoni D', 'Trunfio M', 'Scaglione V', 'Mengato D', 'Agostini E', 'Vania E', 'Putaggio C', 'Cattelan A']","['Aged', 'Male', 'Humans', 'Female', '*Lamivudine/therapeutic use', 'Silver', 'Heterocyclic Compounds, 3-Ring/adverse effects', '*HIV Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37632082/
2226,Lamivudine,38271846,Derivative spectroscopy and wavelet transform as green spectrophotometric methods for abacavir and lamivudine measurement.,"['Alsharif ST', 'Almalki AH', 'Ramzy S', 'Sultan Alqahtani A', 'Abduljabbar MH', 'Algarni MA', 'Serag A']","['Humans', '*Lamivudine/chemistry', '*Wavelet Analysis', 'Reproducibility of Results', 'Spectrophotometry', 'Pharmaceutical Preparations', '*Cyclopropanes', 'Dideoxyadenosine/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/38271846/
2227,Lamivudine,31503008,Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.,"['Vannappagari V', 'Ragone L', 'Henegar C', 'van Wyk J', 'Brown D', 'Demarest J', 'Quercia R', 'St Clair M', 'Underwood M', 'Gatell JM', 'de Ruiter A', 'Aboud M']","['Anti-HIV Agents/*pharmacology/therapeutic use', 'Antiretroviral Therapy, Highly Active', '*Drug Resistance, Viral', '*Genome, Viral', 'Global Health', 'HIV Infections/drug therapy/*epidemiology/*virology', 'HIV-1/*drug effects/*genetics', 'Humans', 'Lamivudine/pharmacology/therapeutic use', '*Mutation', 'Prevalence', 'Rilpivirine/pharmacology/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31503008/
2228,Lamivudine,34293960,"Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults.","['Mendoza I', 'Lazaro A', 'Torralba M']","['Adult', '*Anti-HIV Agents/adverse effects', 'Dideoxynucleosides', '*HIV Infections/drug therapy', 'Heterocyclic Compounds, 3-Ring/adverse effects', 'Humans', 'Lamivudine/adverse effects', 'Oxazines', 'Piperazines', 'Pyridones/therapeutic use', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/34293960/
2229,Lamivudine,20503923,"Identification, isolation, and characterization of potential degradation products in a triple combination lamivudine, zidovudine, and nevirapine tablet for oral suspension.","['Aparna P', 'Rao SV', 'Thomas KM', 'Mukkanti K', 'Badarinadh Gupta P', 'Rangarao K', 'Narayan GK', 'Sandip T', 'Upendra K']","['Anti-HIV Agents/*analysis', 'Chromatography, High Pressure Liquid', 'Drug Contamination', 'Indicators and Reagents', 'Lamivudine/*analysis', 'Magnetic Resonance Spectroscopy', 'Nevirapine/*analysis', 'Spectrometry, Mass, Electrospray Ionization', 'Spectrophotometry, Ultraviolet', 'Spectroscopy, Fourier Transform Infrared', 'Suspensions', 'Tablets', 'Zidovudine/*analysis']",https://pubmed.ncbi.nlm.nih.gov/20503923/
2230,Lamivudine,18184191,Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis.,"['Katz LH', 'Fraser A', 'Gafter-Gvili A', 'Leibovici L', 'Tur-Kaspa R']","['Antiviral Agents/administration & dosage/pharmacology/*therapeutic use', 'Hepatitis B/immunology/mortality/*prevention & control', 'Hepatitis B Surface Antigens/blood', 'Hepatitis B virus/drug effects', 'Humans', 'Immunocompromised Host', 'Lamivudine/administration & dosage/*pharmacology/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18184191/
2231,Lamivudine,34983415,Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.,"['Deng L', 'Li C', 'Chen P', 'Luo X', 'Zheng X', 'Zhou L', 'Zhou Y', 'Xia J', 'Hong Z']","['Alkynes', '*Anti-HIV Agents/adverse effects', 'Benzoxazines/adverse effects', 'Cyclopropanes', '*HIV Infections/drug therapy', '*HIV-1', 'Heterocyclic Compounds, 3-Ring', 'Humans', 'Lamivudine/therapeutic use', 'Oxazines', 'Piperazines', 'Prospective Studies', 'Pyridones', 'Tenofovir/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34983415/
2232,Perphenazine,27916696,Molecular mobility in the supercooled and glassy states of nizatidine and perphenazine.,"['Sailaja U', 'Shahin Thayyil M', 'Krishna Kumar NS', 'Govindaraj G', 'Ngai KL']","['Dielectric Spectroscopy/methods', 'Glass/chemistry', 'Motion', 'Nizatidine/*chemistry', 'Perphenazine/*chemistry', 'Pharmaceutical Preparations/*chemistry', 'Temperature', 'Transition Temperature']",https://pubmed.ncbi.nlm.nih.gov/27916696/
2233,Perphenazine,16195121,"Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.","['Andersen TH', 'Bech P', 'Larsen NE']","['Adult', 'Antipsychotic Agents/*therapeutic use', 'Basal Ganglia Diseases/*chemically induced', 'Benzodiazepines/therapeutic use', 'Buspirone/*therapeutic use', 'Denmark', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Olanzapine', 'Perphenazine/*therapeutic use', 'Pilot Projects', 'Risperidone/*therapeutic use', 'Schizophrenia/*drug therapy', '*Schizophrenic Psychology', 'Serotonin Receptor Agonists/*therapeutic use', 'Weight Loss/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/16195121/
2234,Perphenazine,31172223,Antimelanoma activity of perphenazine and prochlorperazine in human COLO829 and C32 cell lines.,"['Otreba M', 'Pajor M', 'Warncke JD']","['Antineoplastic Agents/administration & dosage/pharmacology', 'Antipsychotic Agents/administration & dosage/pharmacology', 'Cell Line, Tumor', 'Cell Movement/drug effects', 'Cell Survival/drug effects', 'Dose-Response Relationship, Drug', 'Humans', 'Melanoma/*drug therapy/pathology', 'Microphthalmia-Associated Transcription Factor/metabolism', 'Monophenol Monooxygenase/metabolism', 'Perphenazine/administration & dosage/*pharmacology', 'Prochlorperazine/administration & dosage/*pharmacology', 'Skin Neoplasms/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/31172223/
2235,Perphenazine,20739894,Efficacy of perphenazine to prevent postoperative nausea and vomiting: a quantitative systematic review.,"['Schnabel A', 'Eberhart LH', 'Muellenbach R', 'Morin AM', 'Roewer N', 'Kranke P']","['Adult', 'Antiemetics/adverse effects/*therapeutic use', 'Child', 'Humans', 'Perphenazine/adverse effects/*therapeutic use', 'Postoperative Nausea and Vomiting/*prevention & control', 'Randomized Controlled Trials as Topic', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/20739894/
2236,Perphenazine,36542544,Perphenazine-Macrocycle Conjugates Rapidly Sequester the Abeta42 Monomer and Prevent Formation of Toxic Oligomers and Amyloid.,"['Ball SR', 'Adamson JSP', 'Sullivan MA', 'Zimmermann MR', 'Lo V', 'Sanz-Hernandez M', 'Jiang X', 'Kwan AH', 'McKenzie ADJ', 'Werry EL', 'Knowles TPJ', 'Kassiou M', 'Meisl G', 'Todd MH', 'Rutledge PJ', 'Sunde M']","['Humans', '*Perphenazine', 'Amyloid beta-Peptides', 'Amyloid', '*Alzheimer Disease', 'Amyloidogenic Proteins', 'Peptide Fragments']",https://pubmed.ncbi.nlm.nih.gov/36542544/
2237,Perphenazine,29648716,FLUPHENAZINE AND PERPHENAZINE IMPACT ON MELANOGENESIS AND ANTIOXIDANT ENZYMES ACTIVITY IN NORMAL HUMAN MELANOCYTES.,"['Otreba M', 'Wrzesniok D', 'Beberok A', 'Rok J', 'Buszman E']","['Catalase/metabolism', 'Cells, Cultured', 'Fluphenazine/*pharmacology', 'Humans', 'Melanins/*biosynthesis', 'Melanocytes/*drug effects/metabolism', 'Oxidative Stress/drug effects', 'Perphenazine/*pharmacology', 'Superoxide Dismutase/metabolism']",https://pubmed.ncbi.nlm.nih.gov/29648716/
2238,Perphenazine,35933777,Simultaneous spectrophotometric determination of fluphenazine HCl and nortriptyline HCl in presence of their potential impurities perphenazine and dibenzosuberone in bulk and pharmaceutical formulation.,"['Magdy MA', 'Abdelhamid NS', 'Anwar BH', 'Farid NF']","['Dibenzocycloheptenes', 'Drug Compounding', 'Fluphenazine', '*Nortriptyline', '*Perphenazine', 'Spectrophotometry/methods']",https://pubmed.ncbi.nlm.nih.gov/35933777/
2239,Perphenazine,7365497,Low dose perphenazine and levodopa/carbidopa therapy in a patient with Parkinsonism and a psychotic illness.,"['Hale MS', 'Bellizzi J']","['Carbidopa/*therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Humans', 'Levodopa/*therapeutic use', 'Male', 'Middle Aged', 'Parkinson Disease/*drug therapy', 'Perphenazine/*therapeutic use', 'Psychotic Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7365497/
2240,Perphenazine,2316231,Perphenazine-induced priapism.,"['Chan J', 'Alldredge BK', 'Baskin LS']","['Adult', 'Humans', 'Male', 'Perphenazine/*adverse effects/therapeutic use', 'Priapism/*chemically induced/surgery', 'Schizophrenia, Paranoid/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2316231/
2241,Perphenazine,17102980,Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.,"['Gunes A', 'Scordo MG', 'Jaanson P', 'Dahl ML']","['Adolescent', 'Adult', 'Aged', 'Antipsychotic Agents/*adverse effects', 'Dopamine Antagonists/*adverse effects', 'Dyskinesia, Drug-Induced/etiology/*genetics', 'Female', 'Gene Frequency', 'Genetic Predisposition to Disease', 'Genotype', 'Humans', 'Male', 'Middle Aged', 'Odds Ratio', 'Perphenazine/*adverse effects', 'Polymorphism, Genetic', 'Receptor, Serotonin, 5-HT2A/genetics', 'Receptor, Serotonin, 5-HT2C/genetics', 'Receptors, Dopamine/*genetics', 'Receptors, Dopamine D2/genetics', 'Receptors, Dopamine D3/genetics', 'Receptors, Serotonin/*genetics', 'Risk Factors', 'Schizophrenia/*drug therapy/genetics', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17102980/
2242,Perphenazine,25535080,PLGA biodegradable nanoparticles containing perphenazine or chlorpromazine hydrochloride: effect of formulation and release.,"['Halayqa M', 'Domanska U']","['Chemistry, Pharmaceutical', 'Chlorpromazine/*administration & dosage/chemistry', '*Delayed-Action Preparations', 'Dopamine Antagonists/*administration & dosage/chemistry', 'Hydrogen-Ion Concentration', 'Kinetics', 'Lactic Acid/*chemistry', 'Nanoparticles/*chemistry/ultrastructure', 'Particle Size', 'Perphenazine/*administration & dosage/chemistry', 'Polyglycolic Acid/*chemistry', 'Polylactic Acid-Polyglycolic Acid Copolymer']",https://pubmed.ncbi.nlm.nih.gov/25535080/
2243,Perphenazine,29710513,"Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone.","['Hendouei N', 'Farnia S', 'Mohseni F', 'Salehi A', 'Bagheri M', 'Shadfar F', 'Barzegar F', 'Hoseini SD', 'Charati JY', 'Shaki F']","['Adolescent', 'Adult', 'Aged', 'Antipsychotic Agents/*pharmacology/therapeutic use', 'Biomarkers/blood', 'Clozapine/*pharmacology/therapeutic use', 'Humans', 'Middle Aged', 'Oxidative Stress/*drug effects', 'Perphenazine/*pharmacology/therapeutic use', 'Psychiatric Status Rating Scales', 'Risperidone/*pharmacology/therapeutic use', 'Schizophrenia/blood/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29710513/
2244,Perphenazine,26660173,"Quantitation of Haloperidol, Fluphenazine, Perphenazine, and Thiothixene in Serum or Plasma Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).","['Slawson MH', 'Johnson-Davis KL']","['Antipsychotic Agents/*blood', 'Chromatography, High Pressure Liquid/methods', 'Drug Monitoring/methods', 'Fluphenazine/*blood', 'Haloperidol/*blood', 'Humans', 'Perphenazine/*blood', 'Tandem Mass Spectrometry/*methods', 'Thiothixene/*blood']",https://pubmed.ncbi.nlm.nih.gov/26660173/
2245,Perphenazine,11870012,"Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.","['Pollock BG', 'Mulsant BH', 'Rosen J', 'Sweet RA', 'Mazumdar S', 'Bharucha A', 'Marin R', 'Jacob NJ', 'Huber KA', 'Kastango KB', 'Chew ML']","['Aged', 'Aged, 80 and over', 'Antipsychotic Agents/*therapeutic use', 'Behavioral Symptoms/*drug therapy/psychology', 'Citalopram/*therapeutic use', 'Dementia/*drug therapy/psychology', 'Donepezil', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', '*Hospitalization', 'Humans', 'Indans/therapeutic use', 'Male', 'Perphenazine/*therapeutic use', 'Piperidines/therapeutic use', 'Placebos', 'Psychotic Disorders/*drug therapy/psychology', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11870012/
2246,Perphenazine,36089313,A ratiometric electrochemical sensor based on Cu-coordinated molecularly imprinted polymer and porous carbon supported Ag nanoparticles for highly sensitive and selective detection of perphenazine.,"['Liu Y', 'Xia Y', 'Tang Y', 'Chen Y', 'Cao J', 'Zhao F', 'Zeng B']","['Carbon/chemistry', 'Electrochemical Techniques/methods', 'Humans', '*Metal Nanoparticles', '*Molecular Imprinting/methods', 'Molecularly Imprinted Polymers', 'Perphenazine', 'Porosity', 'Reproducibility of Results', 'Silver']",https://pubmed.ncbi.nlm.nih.gov/36089313/
2247,Perphenazine,7112329,Treatment of post-herpetic neuralgia and acute herpetic pain with amitriptyline and perphenazine.,"['Weis O', 'Sriwatanakul K', 'Weintraub M']","['Adult', 'Aged', 'Amitriptyline/*therapeutic use', 'Drug Combinations', 'Female', 'Herpes Zoster/*complications', 'Humans', 'Male', 'Middle Aged', 'Neuralgia/*drug therapy/etiology', 'Pain/*drug therapy', 'Perphenazine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7112329/
2248,Perphenazine,3907278,"Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.","['Knudsen P', 'Hansen LB', 'Auken G', 'Waehrens J', 'Hojholdt K', 'Larsen NE']","['Adult', 'Clinical Trials as Topic', 'Delayed-Action Preparations', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', 'Perphenazine/adverse effects/*analogs & derivatives/therapeutic use', 'Psychiatric Status Rating Scales', 'Random Allocation', 'Schizophrenia/*drug therapy', 'Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/3907278/
2249,Perphenazine,18075468,CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.,"['Aklillu E', 'Kalow W', 'Endrenyi L', 'Harper P', 'Miura J', 'Ozdemir V']","['Antipsychotic Agents/*pharmacology', 'Area Under Curve', 'Cytochrome P-450 CYP2D6/*genetics/metabolism', 'Double-Blind Method', 'Genotype', 'Humans', 'Perphenazine/*pharmacology', 'Pituitary Gland/*drug effects/metabolism', 'Polymorphism, Genetic', 'Prolactin/*metabolism', 'Receptors, Dopamine D2/*genetics/metabolism', 'Taq Polymerase/metabolism', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/18075468/
2250,gadoversetamide,10077031,"Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function.","['Swan SK', 'Baker JF', 'Free R', 'Tucker RM', 'Barron B', 'Barr R', 'Seltzer S', 'Gazelle GS', 'Maravilla KR', 'Barr W', 'Stevens GR', 'Lambrecht LJ', 'Pierro JA']","['Adult', 'Central Nervous System/pathology', 'Central Nervous System Diseases/*diagnosis', '*Contrast Media/administration & dosage/pharmacokinetics', 'Double-Blind Method', 'Female', 'Gadolinium/adverse effects/pharmacokinetics', 'Humans', 'Injections, Intravenous', 'Liver/pathology', 'Liver Diseases/*diagnosis', 'Magnetic Resonance Imaging/*methods', 'Male', 'Middle Aged', '*Organometallic Compounds/adverse effects/pharmacokinetics', 'Renal Insufficiency/*physiopathology', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/10077031/
2251,gadoversetamide,18212288,"Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial.","['Kim RJ', 'Albert TS', 'Wible JH', 'Elliott MD', 'Allen JC', 'Lee JC', 'Parker M', 'Napoli A', 'Judd RM']","['Acute Disease', 'Adult', 'Aged', 'Chronic Disease', 'Contrast Media', 'Double-Blind Method', 'Europe', 'Female', 'Humans', 'Image Enhancement/*methods', 'Magnetic Resonance Imaging/*methods', 'Male', 'Middle Aged', 'Myocardial Infarction/*diagnosis', 'Organometallic Compounds/*therapeutic use', 'Patient Selection', 'Sensitivity and Specificity', 'South America', 'United States']",https://pubmed.ncbi.nlm.nih.gov/18212288/
2252,gadoversetamide,10077020,"A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial.","['Rubin DL', 'Desser TS', 'Semelka R', 'Brown J', 'Nghiem HV', 'Stevens WR', 'Bluemke D', 'Nelson R', 'Fultz P', 'Reimer P', 'Ho V', 'Kristy RM', 'Pierro JA']","['*Contrast Media/adverse effects', 'Double-Blind Method', 'Female', '*Gadolinium DTPA/adverse effects', 'Humans', 'Injections, Intravenous', 'Liver/pathology', 'Liver Diseases/*diagnosis', 'Magnetic Resonance Imaging/*methods', 'Male', 'Middle Aged', '*Organometallic Compounds/adverse effects', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/10077020/
2253,gadoversetamide,35184618,Genotoxic effects of gadobutrol and gadoversetamide active substances used in magnetic resonance imaging in human peripheral lymphocytes in vitro.,"['Akbas E', 'Unal F', 'Yuzbasioglu D']","['Humans', 'Micronucleus Tests', '*Contrast Media/toxicity', '*Gadolinium/pharmacology', 'Sister Chromatid Exchange', 'Lymphocytes', 'DNA Damage', 'Chromosome Aberrations/chemically induced', 'Magnetic Resonance Imaging']",https://pubmed.ncbi.nlm.nih.gov/35184618/
2254,gadoversetamide,17166334,The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients.,"['Lowe LH', 'Kearns GL', 'Wible JH Jr']","['Adolescent', 'Central Nervous System Diseases/*diagnosis', 'Child', 'Child, Preschool', 'Contrast Media/administration & dosage/*adverse effects', 'Electrocardiography', 'Female', 'Heart/drug effects/physiopathology', 'Humans', 'Injections, Intravenous/adverse effects', '*Magnetic Resonance Imaging', 'Male', 'Organometallic Compounds/administration & dosage/*adverse effects', 'Sensitivity and Specificity']",https://pubmed.ncbi.nlm.nih.gov/17166334/
2255,gadoversetamide,18287415,Clinical and economic impact of falsely decreased calcium values caused by gadoversetamide interference.,"['Gandhi MJ', 'Narra VR', 'Brown JJ', 'Guo A', 'Grosu DS', 'Parvin CA', 'Scott MG']","['Blood Chemical Analysis', 'Calcium/*blood', 'Colorimetry', 'Contrast Media/*pharmacology', 'False Positive Reactions', 'Female', '*Health Care Costs', 'Humans', 'Hypocalcemia/*diagnosis/*economics/therapy', 'Magnetic Resonance Imaging', 'Male', 'Organometallic Compounds/*pharmacology', 'Prospective Studies', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/18287415/
2256,gadoversetamide,15167099,Pharmacokinetics and safety of the MRI contrast agent gadoversetamide injection (OptiMARK) in healthy pediatric subjects.,"['Baker JF', 'Kratz LC', 'Stevens GR', 'Wible JH Jr']","['Adolescent', 'Age Factors', 'Child', 'Child, Preschool', 'Contrast Media/administration & dosage/*pharmacokinetics', 'Humans', 'Infant', 'Injections, Intravenous', '*Magnetic Resonance Imaging', 'Organometallic Compounds/administration & dosage/*pharmacokinetics', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/15167099/
2257,gadoversetamide,18814985,"Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients.","['Wible JH Jr', 'Tata PN', 'Napoli AM', 'Lowe LH', 'Kearns GL']","['Adolescent', 'Child', 'Child, Preschool', 'Contrast Media/administration & dosage/pharmacokinetics', 'Female', 'Humans', 'Injections, Intra-Arterial', 'Magnetic Resonance Imaging/*methods', 'Male', 'Metabolic Clearance Rate', 'Organometallic Compounds/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/18814985/
2258,gadoversetamide,19025944,Safety of gadoversetamide in patients with acute and chronic myocardial infarction.,"['Huber S', 'Muthupillai R', 'Cheong B', 'Wible JH Jr', 'Shah D', 'Woodard P', 'Grothues F', 'Mahrholdt H', 'Rochitte CE', 'Masoli O', 'Kim RJ', 'Schwaiger CM', 'Fuisz A', 'Kramer C', 'van Rossum AC', 'Biederman R', 'Lombardi M', 'Martin E', 'Kevorkian R', 'Flamm SD']","['Acute Disease', 'Adult', 'Aged', 'Aged, 80 and over', 'Analysis of Variance', 'Chi-Square Distribution', 'Chronic Disease', 'Contrast Media/administration & dosage/adverse effects', 'Electroencephalography', 'Female', 'Humans', 'Male', 'Middle Aged', 'Myocardial Infarction/*diagnosis', '*Organometallic Compounds/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19025944/
2259,gadoversetamide,19022548,Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate.,"['Kadiyala D', 'Roer DA', 'Perazella MA']","['Adult', 'Chelating Agents/pharmacology/*therapeutic use', 'Contrast Media/*adverse effects', 'Female', 'Humans', 'Joints/drug effects', 'Male', 'Middle Aged', 'Nephrogenic Fibrosing Dermopathy/*chemically induced/*drug therapy', 'Organometallic Compounds/*adverse effects', 'Skin/drug effects', 'Thiosulfates/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19022548/
2260,gadoversetamide,14696230,Safety assessment of gadoversetamide (OptiMARK) administered by power injector.,"['Abdou N', 'Napoli AM', 'Hynes MR', 'Allen JC Jr', 'Wible JH Jr']","['Analysis of Variance', 'Contrast Media/*administration & dosage/adverse effects', 'Female', 'Humans', 'Injections, Intravenous/methods', '*Magnetic Resonance Imaging', 'Male', 'Organometallic Compounds/*administration & dosage/adverse effects', 'Poisson Distribution', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/14696230/
2261,Ofloxacin,9338498,"In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.",['Hoogkamp-Korstanje JA'],"['Anti-Infective Agents/*pharmacology', 'Ciprofloxacin/pharmacology', '*Fluoroquinolones', 'Gram-Negative Bacteria/*drug effects', 'Gram-Positive Bacteria/*drug effects', 'Humans', 'In Vitro Techniques', 'Levofloxacin', 'Microbial Sensitivity Tests', 'Naphthyridines/pharmacology', 'Ofloxacin/pharmacology', 'Pefloxacin/pharmacology', 'Quinolones/pharmacology', 'Respiratory Tract Infections/*microbiology']",https://pubmed.ncbi.nlm.nih.gov/9338498/
2262,Ofloxacin,23716899,Ofloxacin-induced hallucinations.,"['Chauhan U', 'Shanbag P', 'Kashid P']","['Anti-Bacterial Agents/*adverse effects', 'Child, Preschool', 'Female', 'Hallucinations/*chemically induced', 'Humans', 'Ofloxacin/*adverse effects', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/23716899/
2263,Ofloxacin,11821176,"In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.","['Pendland SL', 'Messick CR', 'Jung R']","['Anti-Infective Agents/*pharmacology', 'Aztreonam/pharmacology', 'Ceftazidime/pharmacology', 'Cephalosporins/pharmacology', 'Ciprofloxacin/*pharmacology', 'Drug Synergism', 'Humans', 'Lactams/*pharmacology', '*Levofloxacin', 'Microbial Sensitivity Tests', 'Monobactams/pharmacology', 'Ofloxacin/*pharmacology', 'Penicillins/pharmacology', 'Piperacillin/pharmacology', 'Pseudomonas aeruginosa/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/11821176/
2264,Ofloxacin,36328279,Fractionation of levofloxacin and ofloxacin during their transport in NOM-goethite: Batch and column studies.,"['Qin X', 'Zhong X', 'Wang B', 'Wang G', 'Liu F', 'Weng L']","['*Levofloxacin/chemistry', 'Ofloxacin', '*Iron Compounds/chemistry', 'Adsorption', 'Humic Substances/analysis']",https://pubmed.ncbi.nlm.nih.gov/36328279/
2265,Ofloxacin,8243083,"Oral ciprofloxacin, ofloxacin, and lomefloxacin as alternatives to intravenous antimicrobial therapy.","['Belliveau P', 'Nightingale CH', 'Quintiliani R', 'Crowe H', 'Gousee G']","['Administration, Oral', 'Anti-Bacterial Agents/*pharmacology', 'Ciprofloxacin/administration & dosage/pharmacology/*therapeutic use', 'Drug Costs', 'Drug Tolerance', 'Female', '*Fluoroquinolones', 'Gram-Negative Aerobic Bacteria/*drug effects', 'Gram-Negative Bacterial Infections/*drug therapy', 'Gram-Positive Cocci/drug effects', 'Humans', 'Male', 'Ofloxacin/administration & dosage/pharmacology/*therapeutic use', 'Quinolones/administration & dosage/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/8243083/
2266,Ofloxacin,38454837,Simultaneous identification and enantioseparation of ofloxacin and duloxetine without the single standard and computational calculation of their inclusion complexes.,"['Chen L', 'Li X']","['Duloxetine Hydrochloride', '*Ofloxacin/analysis', 'Stereoisomerism', '*Electrophoresis, Capillary/methods']",https://pubmed.ncbi.nlm.nih.gov/38454837/
2267,Ofloxacin,26100699,"Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.","['Willby M', 'Sikes RD', 'Malik S', 'Metchock B', 'Posey JE']","['Antitubercular Agents/*pharmacology', 'DNA Gyrase/genetics', 'Drug Resistance, Bacterial/genetics', 'Fluoroquinolones/*pharmacology', 'Levofloxacin/*pharmacology', 'Microbial Sensitivity Tests', 'Moxifloxacin', 'Mycobacterium tuberculosis/*drug effects/enzymology/genetics']",https://pubmed.ncbi.nlm.nih.gov/26100699/
2268,Ofloxacin,33218729,Ofloxacin induces etiolation in Welsh onion leaves.,"['Liu X', 'Lv Y', 'Gao S', 'Xu K']","['Anti-Bacterial Agents/toxicity', 'Etiolation', '*Ofloxacin/toxicity', '*Onions', 'Photosynthesis', 'Plant Leaves']",https://pubmed.ncbi.nlm.nih.gov/33218729/
2269,Ofloxacin,28868575,"Co-contaminant effects on ofloxacin adsorption onto activated carbon, graphite, and humic acid.","['Wang C', 'Ma L', 'Liu B', 'Zhang D', 'Pan B']","['Adsorption', 'Charcoal/*chemistry', 'Graphite/*chemistry', 'Humic Substances/*analysis', 'Hydrophobic and Hydrophilic Interactions', '*Models, Theoretical', 'Ofloxacin/*analysis/chemistry', 'Water Pollutants, Chemical/*analysis/chemistry']",https://pubmed.ncbi.nlm.nih.gov/28868575/
2270,Ofloxacin,1646700,"Ofloxacin, a bactericidal antibacterial.",['Smith JT'],"['Anti-Infective Agents/metabolism/*pharmacology', 'Bacteria/*drug effects/metabolism', 'DNA, Bacterial/drug effects', 'Drug Resistance, Microbial', 'Escherichia coli/drug effects/metabolism', 'Humans', 'Microbial Sensitivity Tests', 'Ofloxacin/metabolism/*pharmacology', 'Oxygen/metabolism', 'Pseudomonas Infections/drug therapy/metabolism', 'Staphylococcal Infections/drug therapy/metabolism', 'Topoisomerase II Inhibitors']",https://pubmed.ncbi.nlm.nih.gov/1646700/
2271,Ofloxacin,24598151,Co-sorption of ofloxacin and Cu(II) in soils before and after organic matter removal.,"['Wu D', 'Li H', 'Liao S', 'Sun X', 'Peng H', 'Zhang D', 'Pan B']","['Adsorption', 'Anti-Bacterial Agents/analysis/chemistry', 'Copper/analysis/*chemistry', 'Environmental Restoration and Remediation', 'Hydrophobic and Hydrophilic Interactions', 'Models, Chemical', 'Ofloxacin/analysis/*chemistry', 'Soil/*chemistry', 'Soil Pollutants/analysis/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/24598151/
2272,Ofloxacin,19230750,"Rapid and sensitive spectrofluorimetric determination of enrofloxacin, levofloxacin and ofloxacin with 2,3,5,6-tetrachloro-p-benzoquinone.",['Ulu ST'],"['Anti-Bacterial Agents/*analysis', 'Chloranil/*chemistry', 'Enrofloxacin', 'Fluoroquinolones/*analysis', 'Fungicides, Industrial/*chemistry', '*Levofloxacin', 'Molecular Structure', 'Ofloxacin/*analysis', 'Reproducibility of Results', 'Sensitivity and Specificity', 'Spectrometry, Fluorescence/methods']",https://pubmed.ncbi.nlm.nih.gov/19230750/
2273,Ofloxacin,24550337,Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.,"['Thee S', 'Garcia-Prats AJ', 'McIlleron HM', 'Wiesner L', 'Castel S', 'Norman J', 'Draper HR', 'van der Merwe PL', 'Hesseling AC', 'Schaaf HS']","['Adolescent', 'Antitubercular Agents/*pharmacokinetics/*therapeutic use', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Levofloxacin/*pharmacokinetics/*therapeutic use', 'Male', 'Ofloxacin/*pharmacokinetics/*therapeutic use', 'Prospective Studies', 'Tuberculosis, Multidrug-Resistant/blood/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24550337/
2274,Ofloxacin,28211325,Impact of concentration and species of sulfamethoxazole and ofloxacin on their adsorption kinetics on sediments.,"['Wang P', 'Zhang D', 'Zhang H', 'Li H', 'Ghosh S', 'Pan B']","['Adsorption', 'Anti-Bacterial Agents/*chemistry', 'Geologic Sediments/*chemistry', 'Hydrogen-Ion Concentration', 'Hydrophobic and Hydrophilic Interactions', 'Kinetics', 'Ofloxacin/*chemistry', 'Sulfamethoxazole/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/28211325/
2275,Ofloxacin,8580559,Ofloxacin-induced vasculitis.,"['Ceyhan BB', 'Lawrence R', 'Sungur M', 'Ahiskali R', 'Celikel T']","['Aged', 'Anti-Infective Agents/*adverse effects', 'Humans', 'Male', 'Ofloxacin/*adverse effects', 'Vasculitis/*chemically induced/diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/8580559/
2276,Aliskiren,18340340,Aliskiren: the first renin inhibitor for clinical treatment.,"['Jensen C', 'Herold P', 'Brunner HR']","['Amides/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Cardiovascular Diseases/*drug therapy', 'Fumarates/*therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Renin/*antagonists & inhibitors', 'Renin-Angiotensin System/drug effects']",https://pubmed.ncbi.nlm.nih.gov/18340340/
2277,Aliskiren,19279548,Aliskiren-induced QT interval prolongation.,"['Peitz GJ', 'Malesker MA', 'Sojka SG']","['Aged', 'Amides/*adverse effects', 'Anti-Arrhythmia Agents/adverse effects', 'Antihypertensive Agents/*adverse effects', 'Female', 'Fumarates/*adverse effects', 'Humans', 'Long QT Syndrome/*chemically induced', 'Sotalol/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19279548/
2278,Aliskiren,25285791,Conception and evolution of stereocontrolled strategies toward functionalized 8-aryloctanoic acids related to the total synthesis of aliskiren.,"['Hanessian S', 'Chenard E', 'Guesne S', 'Cusson JP']","['Amides/*chemical synthesis/chemistry', 'Caprylates/*chemistry', 'Catalysis', 'Crystallography, X-Ray', 'Esters', 'Fumarates/*chemical synthesis/chemistry', 'Lactones/*chemistry', 'Molecular Structure', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/25285791/
2279,Aliskiren,22475518,Rapid HILIC method with fluorescence detection using derivatization reaction utilizing o-phthaldialdehyde for determination of degradation product of aliskiren.,"['Dousa M', 'Brichac J', 'Svoboda J', 'Klvana R']","['Amides/*analysis/chemistry', 'Amino Acids/*analysis', 'Antihypertensive Agents/*analysis/chemistry', 'Chromatography, Liquid/*methods', 'Fumarates/*analysis/chemistry', 'Mass Spectrometry/methods', 'Sensitivity and Specificity', 'Spectrometry, Fluorescence/methods', 'Time Factors', 'o-Phthalaldehyde/chemistry']",https://pubmed.ncbi.nlm.nih.gov/22475518/
2280,Aliskiren,27043774,"Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.","['McMurray JJ', 'Krum H', 'Abraham WT', 'Dickstein K', 'Kober LV', 'Desai AS', 'Solomon SD', 'Greenlaw N', 'Ali MA', 'Chiang Y', 'Shao Q', 'Tarnesby G', 'Massie BM']","['Aged', 'Amides/adverse effects/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use', 'Chronic Disease', 'Diabetes Mellitus, Type 2/complications/drug therapy', 'Double-Blind Method', 'Drug Therapy, Combination', 'Enalapril/adverse effects/*therapeutic use', 'Female', 'Follow-Up Studies', 'Fumarates/adverse effects/*therapeutic use', 'Heart Failure/complications/*drug therapy', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Renin/*antagonists & inhibitors', 'Stroke Volume', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/27043774/
2281,Aliskiren,20235519,"Total synthesis of ""aliskiren"": the first Renin inhibitor in clinical practice for hypertension.","['Hanessian S', 'Guesne S', 'Chenard E']","['Amides/*chemical synthesis/chemistry/*pharmacology/therapeutic use', 'Antihypertensive Agents/chemical synthesis/chemistry/pharmacology/therapeutic use', 'Fumarates/*chemical synthesis/chemistry/*pharmacology/therapeutic use', 'Hypertension/*drug therapy', 'Protease Inhibitors/chemical synthesis/chemistry/pharmacology/therapeutic use', 'Renin/*antagonists & inhibitors', 'Stereoisomerism', 'Substrate Specificity']",https://pubmed.ncbi.nlm.nih.gov/20235519/
2282,Aliskiren,17999872,Aliskiren: the first direct renin inhibitor for hypertension.,"['van den Meiracker AH', 'Jan Danser AH']","['Amides/pharmacology/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Blood Pressure/drug effects', 'Fumarates/pharmacology/*therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Receptors, Cell Surface/drug effects', 'Renin/*antagonists & inhibitors/drug effects', 'Renin-Angiotensin System/drug effects', 'Vacuolar Proton-Translocating ATPases/drug effects']",https://pubmed.ncbi.nlm.nih.gov/17999872/
2283,Aliskiren,22975662,"Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists.","['Lanier G', 'Sankholkar K', 'Aronow WS']","['Amides/*administration & dosage', 'Angiotensin II Type 1 Receptor Blockers/*administration & dosage', 'Antihypertensive Agents/*administration & dosage', 'Benzimidazoles/*administration & dosage', 'Calcium Channel Blockers/administration & dosage', 'Diuretics/administration & dosage', 'Drug Therapy, Combination', 'Fumarates/*administration & dosage', 'Humans', 'Hypertension/*drug therapy', 'Oxadiazoles/*administration & dosage', 'Renin/*antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/22975662/
2284,Aliskiren,23872160,Highly sensitive HPLC method for assay of aliskiren in human plasma through derivatization with 1-naphthyl isocyanate using UV detection.,"['Belal F', 'Walash M', 'El-Enany N', 'Zayed S']","['Amides/*blood', 'Antihypertensive Agents/*blood', 'Chromatography, High Pressure Liquid/*methods', 'Drug Monitoring', 'Fumarates/*blood', 'Humans', 'Isocyanates/chemistry', 'Limit of Detection', 'Naphthalenes/chemistry', 'Spectrophotometry, Ultraviolet/*methods']",https://pubmed.ncbi.nlm.nih.gov/23872160/
2285,Aliskiren,19279535,"Successful utilization of aliskiren, a direct renin inhibitor in Bartter syndrome.",['Bell DS'],"['Amides/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Bartter Syndrome/*drug therapy', 'Female', 'Fumarates/*therapeutic use', 'Humans', 'Middle Aged', 'Renin-Angiotensin System/drug effects']",https://pubmed.ncbi.nlm.nih.gov/19279535/
2286,Aliskiren,29470612,Efficacy of aliskiren supplementation for heart failure : A meta-analysis of randomized controlled trials.,"['Luo Y', 'Chen Q']","['*Amides/therapeutic use', '*Antihypertensive Agents/therapeutic use', 'Dietary Supplements', 'Female', '*Fumarates/therapeutic use', '*Heart Failure/drug therapy', 'Humans', 'Male', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29470612/
2287,Aliskiren,16776501,Formal total synthesis of the potent renin inhibitor aliskiren: application of a SmI2-promoted acyl-like radical coupling.,"['Lindsay KB', 'Skrydstrup T']","['Amides/*chemical synthesis/chemistry/pharmacology', 'Enzyme Inhibitors/*chemical synthesis/chemistry/pharmacology', 'Free Radicals/chemistry', 'Fumarates/*chemical synthesis/chemistry/pharmacology', 'Molecular Conformation', 'Renin/*antagonists & inhibitors', 'Stereoisomerism', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/16776501/
2288,Aliskiren,30631130,The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis.,"['Bjerre HL', 'Christensen JB', 'Buus NH', 'Simonsen U', 'Su J']","['Amides/adverse effects/*therapeutic use', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Blood Pressure/*drug effects', 'Fumarates/adverse effects/*therapeutic use', 'Humans', 'Hypertension/diagnosis/*drug therapy/mortality/physiopathology', 'Randomized Controlled Trials as Topic', 'Renin/*antagonists & inhibitors', 'Renin-Angiotensin System/*drug effects', 'Risk Factors', 'Signal Transduction', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30631130/
2289,Aliskiren,33687953,Efficacy and safety of aliskiren combination therapy: a protocol for an umbrella review.,"['Shen J', 'Feng W', 'Wang Y', 'Zhao Q', 'Flavorta BL', 'Lu J']","['Amides/adverse effects', 'Antihypertensive Agents/adverse effects', '*Fumarates/adverse effects', 'Humans', '*Research Design', 'Review Literature as Topic', 'Systematic Reviews as Topic']",https://pubmed.ncbi.nlm.nih.gov/33687953/
2290,Aliskiren,21059822,A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension.,"['Zhenfeng Zheng', 'Huilan Shi', 'Junya Jia', 'Dong Li', 'Shan Lin']","['Amides/administration & dosage/adverse effects/*therapeutic use', 'Angiotensin Receptor Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Fumarates/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Hypertension/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/21059822/
2291,Glycopyrrolate,31605923,A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 mug and 160/18/9.6 mug using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.,"['Rabe KF', 'Martinez FJ', 'Ferguson GT', 'Wang C', 'Singh D', 'Wedzicha JA', 'Trivedi R', 'St Rose E', 'Ballal S', 'McLaren J', 'Darken P', 'Reisner C', 'Dorinsky P']","['Administration, Inhalation', 'Adult', 'Aged', 'Aged, 80 and over', 'Budesonide/*administration & dosage', '*Drug Delivery Systems', 'Female', 'Formoterol Fumarate/*administration & dosage', 'Glycopyrrolate/*administration & dosage', 'Humans', 'Male', '*Metered Dose Inhalers', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31605923/
2292,Glycopyrrolate,30232048,"Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.","['Ferguson GT', 'Rabe KF', 'Martinez FJ', 'Fabbri LM', 'Wang C', 'Ichinose M', 'Bourne E', 'Ballal S', 'Darken P', 'DeAngelis K', 'Aurivillius M', 'Dorinsky P', 'Reisner C']","['Administration, Inhalation', 'Adult', 'Aged', 'Aged, 80 and over', 'Budesonide/*administration & dosage', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Forced Expiratory Volume/drug effects', 'Formoterol Fumarate/*administration & dosage', 'Glycopyrrolate/*administration & dosage', 'Humans', 'Male', 'Metered Dose Inhalers', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Respiratory Function Tests', 'Respiratory System Agents/*administration & dosage', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30232048/
2293,Glycopyrrolate,38797902,Efficacy and Safety of Glycopyrrolate in the Management of Organophosphate and Carbamate Poisoning: A Systematic Review.,"['Rashid M', 'Poojari PG', 'Chandran VP', 'Shetty R', 'Kaur H', 'Nair S', 'Thunga G']","['*Glycopyrrolate/therapeutic use', 'Humans', '*Organophosphate Poisoning/drug therapy', '*Carbamates/therapeutic use/adverse effects/poisoning', 'Antidotes/therapeutic use/administration & dosage', 'Muscarinic Antagonists/therapeutic use/adverse effects', 'Poisoning/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38797902/
2294,Glycopyrrolate,27871593,Atropine and glycopyrrolate do not support bacterial growth-safety and economic considerations.,"['Ittzes B', 'Weiling Z', 'Batai IZ', 'Kerenyi M', 'Batai I']","['Acinetobacter baumannii/drug effects/growth & development', 'Adjuvants, Anesthesia/pharmacology', 'Atropine/*pharmacology', 'Bacterial Load/*drug effects', 'Equipment Contamination/*prevention & control', 'Escherichia coli/drug effects/growth & development', 'Glycopyrrolate/*pharmacology', 'Pseudomonas aeruginosa/drug effects/growth & development', 'Staphylococcus aureus/drug effects/growth & development']",https://pubmed.ncbi.nlm.nih.gov/27871593/
2295,Glycopyrrolate,33252985,"Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.","['Martinez FJ', 'Rabe KF', 'Ferguson GT', 'Wedzicha JA', 'Singh D', 'Wang C', 'Rossman K', 'St Rose E', 'Trivedi R', 'Ballal S', 'Darken P', 'Aurivillius M', 'Reisner C', 'Dorinsky P']","['Aged', 'Bronchodilator Agents/*therapeutic use', 'Budesonide/*therapeutic use', 'Cause of Death', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Forced Expiratory Volume', 'Formoterol Fumarate/*therapeutic use', 'Glucocorticoids/*therapeutic use', 'Glycopyrrolate/*therapeutic use', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', '*Mortality', 'Muscarinic Antagonists/*therapeutic use', 'Proportional Hazards Models', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/33252985/
2296,Glycopyrrolate,6990948,"Evaluation of glycopyrrolate and atropine as adjuncts to reversal of non-depolarizing neuromuscular blocking agents in a ""true-to-life"" situation.","['Cozanitis DA', 'Dundee JW', 'Merrett JD', 'Jones CJ', 'Mirakhur RK']","['*Atropine/pharmacology', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', '*Glycopyrrolate/pharmacology', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Neostigmine/pharmacology', 'Neuromuscular Blocking Agents/*antagonists & inhibitors', 'Neuromuscular Junction/drug effects', '*Pyrrolidines/pharmacology', 'Random Allocation', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6990948/
2297,Glycopyrrolate,7004254,Glycopyrrolate in children. A comparison between the effects of glycopyrrolate and atropine administered before induction of anaesthesia.,"['Lavis DM', 'Lunn JN', 'Rosen M']","['*Atropine/pharmacology', 'Body Temperature/drug effects', 'Child', 'Child, Preschool', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', '*Glycopyrrolate/pharmacology', 'Heart Rate/drug effects', 'Humans', 'Intraoperative Period', 'Male', '*Preanesthetic Medication', '*Pyrrolidines/pharmacology', 'Salivation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/7004254/
2298,Glycopyrrolate,7370144,Comparative study of atropine and glycopyrrolate on suxamethonium-induced changes in cardiac rate and rhythm.,"['Cozanitis DA', 'Dundee JW', 'Khan MM']","['Adult', 'Atropine/*therapeutic use', 'Bradycardia/chemically induced/physiopathology/*prevention & control', 'Double-Blind Method', 'Female', 'Glycopyrrolate/*therapeutic use', 'Heart Rate/drug effects', 'Humans', 'Male', '*Preanesthetic Medication', 'Pyrrolidines/*therapeutic use', 'Random Allocation', 'Succinylcholine/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7370144/
2299,Glycopyrrolate,34085852,An ultrasensitive LC-MS/MS method and application to clinical dose-range finding for glycopyrrolate via an e-Nebulizer.,"['Chen YL', 'Wang W', 'Shi L', 'Eddy J']","['Humans', 'Chromatography, High Pressure Liquid/methods', 'Dose-Response Relationship, Drug', '*Glycopyrrolate/blood/pharmacokinetics/administration & dosage', 'Limit of Detection', 'Nebulizers and Vaporizers', 'Pulmonary Disease, Chronic Obstructive/drug therapy/blood', 'Reproducibility of Results', 'Solid Phase Extraction', '*Tandem Mass Spectrometry/methods']",https://pubmed.ncbi.nlm.nih.gov/34085852/
2300,Glycopyrrolate,31868101,Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting beta(2)-agonist fixed-dose combinations in COPD.,"['Siddiqui MK', 'Shukla P', 'Jenkins M', 'Ouwens M', 'Guranlioglu D', 'Darken P', 'Biswas M']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/administration & dosage/adverse effects', 'Drug Combinations', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Glycopyrrolate/*administration & dosage/adverse effects', 'Humans', 'Metered Dose Inhalers', 'Muscarinic Antagonists/administration & dosage/adverse effects', 'Network Meta-Analysis', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/31868101/
2301,Glycopyrrolate,27871302,Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): study protocol for a randomised controlled feasibility study.,"['Qurashi I', 'Chu S', 'Husain N', 'Drake RJ', 'Chaudhry I', 'Deakin JF']","['Adolescent', 'Adult', 'Aged', 'Antipsychotic Agents/*adverse effects', 'Clinical Protocols', 'Clozapine/*adverse effects', 'Double-Blind Method', 'Feasibility Studies', 'Female', 'Glycopyrrolate/adverse effects/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Muscarinic Antagonists/adverse effects/*therapeutic use', 'Research Design', 'Salivation/*drug effects', 'Schizophrenia/*drug therapy', 'Scopolamine/adverse effects/*therapeutic use', 'Sialorrhea/chemically induced/diagnosis/physiopathology/*prevention & control', 'Time Factors', 'Treatment Outcome', 'United Kingdom', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27871302/
2302,Glycopyrrolate,32917556,Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease.,"['Gon Y', 'Nishi K', 'Sato K', 'Maes A', 'Siddiqui S', 'Hayashi N', 'Hirata H', 'Martin UJ', 'Reisner C']","['Administration, Inhalation', 'Adult', 'Aged', 'Aged, 80 and over', 'Asian People', 'Delayed-Action Preparations', 'Double-Blind Method', 'Drug Delivery Systems/*methods', 'Female', 'Formoterol Fumarate/*administration & dosage', 'Glycopyrrolate/*administration & dosage', 'Humans', 'Male', 'Metered Dose Inhalers', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Safety', 'Severity of Illness Index', 'Suspensions', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32917556/
2303,Glycopyrrolate,34210340,Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.,"['van den Berge M', 'De Backer J', 'Van Holsbeke C', 'De Backer W', 'Trivedi R', 'Jenkins M', 'Dorinsky P', 'Aurivillius M']","['Administration, Inhalation', 'Adrenal Cortex Hormones/administration & dosage', 'Adult', 'Aged', 'Aged, 80 and over', 'Bronchodilator Agents/administration & dosage', 'Budesonide/*administration & dosage', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Formoterol Fumarate/*administration & dosage', 'Glycopyrrolate/*administration & dosage', 'Humans', 'Male', '*Metered Dose Inhalers', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/*diagnostic imaging/*drug therapy', 'Tomography, X-Ray Computed/*methods']",https://pubmed.ncbi.nlm.nih.gov/34210340/
2304,Glycopyrrolate,33907393,Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD.,"['Putcha N', 'Ozol-Godfrey A', 'Sanjar S', 'Sharma S']","['Administration, Inhalation', 'Bronchodilator Agents/therapeutic use', '*Cardiovascular Diseases/diagnosis/drug therapy/epidemiology', 'Comorbidity', 'Forced Expiratory Volume', 'Glycopyrrolate/therapeutic use', 'Humans', 'Muscarinic Antagonists/therapeutic use', 'Prevalence', '*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology', 'Quality of Life', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33907393/
2305,Glycopyrrolate,6739187,"Anticholinergic premedication in infants: a comparison of atropine and glycopyrrolate on heart rate, demeanor, and facial flushing.","['Cozanitis DA', 'Jones CJ', 'Erkola O']","['*Akathisia, Drug-Induced', 'Atropine/*pharmacology', 'Face', '*Flushing', 'Glycopyrrolate/*pharmacology', 'Heart Rate/*drug effects', 'Humans', 'Infant, Newborn', 'Parasympatholytics/*pharmacology', '*Premedication', 'Pyrrolidines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6739187/
2306,Glycopyrrolate,27916620,Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.,"['Martinez FJ', 'Rabe KF', 'Ferguson GT', 'Fabbri LM', 'Rennard S', 'Feldman GJ', 'Sethi S', 'Spangenthal S', 'Gottschlich GM', 'Rodriguez-Roisin R', 'Arora S', 'Siler TM', 'Siddiqui S', 'Darken P', 'Fischer T', 'Maes A', 'Golden M', 'Orevillo C', 'Reisner C']","['Administration, Inhalation', 'Adult', 'Aged', 'Aged, 80 and over', 'Bronchodilator Agents/*administration & dosage', 'Budesonide/therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', 'Female', 'Fluticasone/therapeutic use', 'Forced Expiratory Volume', 'Formoterol Fumarate/*administration & dosage', 'Glucocorticoids/therapeutic use', 'Glycopyrrolate/*administration & dosage', 'Humans', 'Male', 'Metered Dose Inhalers', 'Middle Aged', 'Muscarinic Antagonists/*administration & dosage', 'Prednisone/therapeutic use', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology', 'Suspensions', 'Vital Capacity']",https://pubmed.ncbi.nlm.nih.gov/27916620/
2307,Glycopyrrolate,32021143,Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.,"['Chen R', 'Zhong N', 'Wang HY', 'Zhao L', 'Mei X', 'Qin Z', 'Huang J', 'Assam PN', 'Maes A', 'Siddiqui S', 'Martin UJ', 'Reisner C']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/administration & dosage/adverse effects/*therapeutic use', 'Aged', 'Bronchodilator Agents/administration & dosage/adverse effects', 'China', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Forced Expiratory Volume', 'Formoterol Fumarate/administration & dosage/adverse effects/*therapeutic use', 'Glycopyrrolate/adverse effects/*therapeutic use', 'Humans', 'Lung/*drug effects/physiopathology', 'Male', '*Metered Dose Inhalers', 'Middle Aged', 'Muscarinic Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy/physiopathology', 'Recovery of Function', 'Severity of Illness Index', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32021143/
2308,Glycopyrrolate,31841699,Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.,"['Dunn LJ', 'Kerwin EM', 'DeAngelis K', 'Darken P', 'Gillen M', 'Dorinsky P']","['Administration, Inhalation', 'Adult', 'Aged', 'Aged, 80 and over', 'Bronchodilator Agents/*administration & dosage/blood/pharmacokinetics', 'Budesonide/administration & dosage/blood/*pharmacokinetics', 'Double-Blind Method', 'Drug Combinations', 'Drug Delivery Systems/*methods', 'Female', 'Formoterol Fumarate/administration & dosage/blood/*pharmacokinetics', 'Glycopyrrolate/administration & dosage/blood/*pharmacokinetics', 'Humans', 'Male', 'Metered Dose Inhalers', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/metabolism', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/31841699/
2309,Fluphenazine,692838,Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.,"['MacCrimmon DJ', 'Saxena B', 'Foley P', 'Grof P']","['Adult', '*Ambulatory Care', 'Chronic Disease', 'Decanoic Acids', 'Delayed-Action Preparations', 'Double-Blind Method', 'Drug Evaluation', 'Female', 'Fluphenazine/administration & dosage/adverse effects/*therapeutic use', 'Heptanoates', 'Humans', 'Injections, Intramuscular', 'Male', 'Middle Aged', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/692838/
2310,Fluphenazine,3154530,Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia.,['Glazer WM'],"['Adult', 'Dyskinesia, Drug-Induced/blood/*metabolism', 'Female', 'Fluphenazine/adverse effects/*analogs & derivatives/blood/pharmacokinetics', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/3154530/
2311,Fluphenazine,394794,Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients.,"['Knights A', 'Okasha MS', 'Salih MA', 'Hirsch SR']","['Adolescent', 'Adult', 'Aged', 'Basal Ganglia Diseases/*chemically induced', 'Clinical Trials as Topic', 'Depression/*chemically induced', 'Flupenthixol/adverse effects/*therapeutic use', 'Fluphenazine/adverse effects/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Schizophrenia/*drug therapy', 'Schizophrenic Psychology', 'Social Adjustment', 'Thioxanthenes/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/394794/
2312,Fluphenazine,800383,A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy.,"['Capstick N', 'Pudney H']","['Clinical Trials as Topic', 'Depression/chemically induced/*drug therapy', 'Fluphenazine/*adverse effects', 'Humans', 'Orphenadrine/*analogs & derivatives/*therapeutic use', 'Parkinson Disease, Secondary/chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/800383/
2313,Fluphenazine,37702508,CWHM-974 is a fluphenazine derivative with improved antifungal activity against Candida albicans due to reduced susceptibility to multidrug transporter-mediated resistance mechanisms.,"['Miron-Ocampo A', 'Beattie SR', 'Guin S', 'Conway T', 'Meyers MJ', 'Moye-Rowley WS', 'Krysan DJ']","['*Antifungal Agents/pharmacology/metabolism', '*Candida albicans', 'Fluconazole/pharmacology/metabolism', 'Fluphenazine/pharmacology/metabolism', 'Fungal Proteins/genetics/metabolism', 'Microbial Sensitivity Tests', 'Membrane Transport Proteins/genetics/metabolism', 'Drug Resistance, Multiple', 'Candida', 'Drug Resistance, Fungal/genetics']",https://pubmed.ncbi.nlm.nih.gov/37702508/
2314,Fluphenazine,32804597,"Based on Principles and Insights of COVID-19 Epidemiology, Genome Sequencing, and Pathogenesis: Retrospective Analysis of Sinigrin and Prolixin(RX) (Fluphenazine) Provides Off-Label Drug Candidates.","['Nazeam J', 'Mohammed EZ', 'Raafat M', 'Houssein M', 'Elkafoury A', 'Hamdy D', 'Jamil L']","['Antiviral Agents/chemistry/*pharmacology', 'Bayes Theorem', 'Biological Products/chemistry/pharmacology', 'COVID-19/*epidemiology/etiology', 'Coronavirus/genetics', 'Fluphenazine/chemistry/*pharmacology', 'Genetic Predisposition to Disease', 'Genetic Variation', 'Genome, Viral', 'Glucosinolates/chemistry/*pharmacology', 'Host-Pathogen Interactions', 'Humans', 'Middle East Respiratory Syndrome Coronavirus/pathogenicity', 'Molecular Docking Simulation', 'Off-Label Use', 'Pneumonia, Viral/etiology', 'Retrospective Studies', 'SARS-CoV-2/*genetics/pathogenicity', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/32804597/
2315,Fluphenazine,29648716,FLUPHENAZINE AND PERPHENAZINE IMPACT ON MELANOGENESIS AND ANTIOXIDANT ENZYMES ACTIVITY IN NORMAL HUMAN MELANOCYTES.,"['Otreba M', 'Wrzesniok D', 'Beberok A', 'Rok J', 'Buszman E']","['Catalase/metabolism', 'Cells, Cultured', 'Fluphenazine/*pharmacology', 'Humans', 'Melanins/*biosynthesis', 'Melanocytes/*drug effects/metabolism', 'Oxidative Stress/drug effects', 'Perphenazine/*pharmacology', 'Superoxide Dismutase/metabolism']",https://pubmed.ncbi.nlm.nih.gov/29648716/
2316,Fluphenazine,36952079,"Repurposing fluphenazine to suppress melanoma brain, lung and bone metastasis by inducing G0/G1 cell cycle arrest and apoptosis and disrupting autophagic flux.","['Xi H', 'Wu M', 'Ma H', 'Li S', 'Huang Q', 'Zhang Y', 'Xia Y']","['Humans', 'Fluphenazine/pharmacology', 'G1 Phase Cell Cycle Checkpoints', 'CD8-Positive T-Lymphocytes/pathology', 'Drug Repositioning', '*Melanoma/drug therapy/pathology', 'Brain/pathology', '*Brain Neoplasms/drug therapy', 'Lung/pathology', 'Apoptosis', 'Cell Line, Tumor', 'Cell Proliferation']",https://pubmed.ncbi.nlm.nih.gov/36952079/
2317,Fluphenazine,3693869,Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.,"['Norman TR', 'Marriott PF', 'Kimber NM', 'Burrows GD']","['Adult', 'Female', 'Fluphenazine/*analogs & derivatives/*blood/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Prolactin/*blood', 'Schizophrenia/blood/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3693869/
2318,Fluphenazine,10842546,Combined fluphenazine and lidocaine for pain relief in head and neck cancers.,"['Desai PM', 'Desai KP']","['Anesthetics, Local/*therapeutic use', 'Dopamine Antagonists/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Fluphenazine/*therapeutic use', 'Head and Neck Neoplasms/*complications', 'Humans', 'Injections, Intralesional', 'Lidocaine/*therapeutic use', 'Male', 'Nerve Block/methods', 'Pain Measurement', 'Pain, Intractable/*etiology/*prevention & control', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10842546/
2319,Fluphenazine,37110626,"Improvement of the In Vitro Cytotoxic Effect on HT-29 Colon Cancer Cells by Combining 5-Fluorouacil and Fluphenazine with Green, Red or Brown Propolis.","['Falcao SI', 'Duarte D', 'Diallo M', 'Santos J', 'Ribeiro E', 'Vale N', 'Vilas-Boas M']","['Humans', '*Propolis/pharmacology/chemistry', 'HT29 Cells', 'Fluphenazine', '*Antineoplastic Agents/pharmacology', '*Colonic Neoplasms/drug therapy', 'Fluorouracil/pharmacology', 'Phenols/pharmacology/chemistry']",https://pubmed.ncbi.nlm.nih.gov/37110626/
2320,Fluphenazine,35933777,Simultaneous spectrophotometric determination of fluphenazine HCl and nortriptyline HCl in presence of their potential impurities perphenazine and dibenzosuberone in bulk and pharmaceutical formulation.,"['Magdy MA', 'Abdelhamid NS', 'Anwar BH', 'Farid NF']","['Dibenzocycloheptenes', 'Drug Compounding', 'Fluphenazine', '*Nortriptyline', '*Perphenazine', 'Spectrophotometry/methods']",https://pubmed.ncbi.nlm.nih.gov/35933777/
2321,Fluphenazine,1860020,Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.,"['Marder SR', 'Midha KK', 'Van Putten T', 'Aravagiri M', 'Hawes EM', 'Hubbard JW', 'McKay G', 'Mintz J']","['Adult', 'Akathisia, Drug-Induced', 'Delayed-Action Preparations', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Dyskinesia, Drug-Induced/blood/etiology', 'Fluphenazine/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics', 'Humans', 'Male', '*Psychiatric Status Rating Scales', 'Psychomotor Agitation/blood', 'Risk Factors', 'Schizophrenia/blood/*drug therapy', '*Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/1860020/
2322,Fluphenazine,26021642,Fluphenazine.HCl and Epigallocatechin Gallate Modulate the Rate of Formation and Structural Properties of Apolipoprotein C-II Amyloid Fibrils.,"['Zlatic CO', 'Mao Y', 'Ryan TM', 'Mok YF', 'Roberts BR', 'Howlett GJ', 'Griffin MD']","['Amyloid/chemistry/*drug effects/metabolism/ultrastructure', 'Antipsychotic Agents/adverse effects/*pharmacology', 'Apolipoprotein C-II/*chemistry/genetics/metabolism/ultrastructure', 'Benzothiazoles', 'Binding, Competitive', 'Catechin/*analogs & derivatives/pharmacology/therapeutic use', 'Drug Discovery', 'Drugs, Investigational/adverse effects/*pharmacology/therapeutic use', 'Fluphenazine/adverse effects/*pharmacology', 'Humans', 'Kinetics', 'Microscopy, Electron, Transmission', 'Neuroprotective Agents/*pharmacology/therapeutic use', 'Particle Size', 'Protein Aggregates/drug effects', 'Protein Conformation/drug effects', 'Proteostasis Deficiencies/chemically induced/drug therapy/metabolism/pathology', 'Recombinant Proteins/chemistry/metabolism/ultrastructure', 'Small Molecule Libraries', 'Thiazoles/antagonists & inhibitors/metabolism', 'Ultracentrifugation']",https://pubmed.ncbi.nlm.nih.gov/26021642/
2323,Fluphenazine,3949690,"Liquid chromatographic determination of identity, content, and content uniformity of desipramine, fluphenazine, and promazine.","['Beaulieu N', 'Gagne C', 'Lovering EG']","['Chromatography, Liquid', 'Desipramine/*analysis', 'Fluphenazine/*analysis', 'Promazine/*analysis']",https://pubmed.ncbi.nlm.nih.gov/3949690/
2324,Fluphenazine,1375019,Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.,"['Pickar D', 'Owen RR', 'Litman RE', 'Konicki E', 'Gutierrez R', 'Rapaport MH']","['Adult', 'Antipsychotic Agents/therapeutic use', 'Clozapine/*therapeutic use', 'Dopamine/physiology', 'Double-Blind Method', 'Female', 'Fluphenazine/therapeutic use', 'Homovanillic Acid/cerebrospinal fluid', 'Humans', 'Hydroxyindoleacetic Acid/cerebrospinal fluid', 'Male', 'Placebos', 'Schizophrenia/cerebrospinal fluid/*drug therapy/physiopathology', 'Schizophrenic Psychology', 'Serotonin/physiology']",https://pubmed.ncbi.nlm.nih.gov/1375019/
2325,Fluphenazine,26660173,"Quantitation of Haloperidol, Fluphenazine, Perphenazine, and Thiothixene in Serum or Plasma Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).","['Slawson MH', 'Johnson-Davis KL']","['Antipsychotic Agents/*blood', 'Chromatography, High Pressure Liquid/methods', 'Drug Monitoring/methods', 'Fluphenazine/*blood', 'Haloperidol/*blood', 'Humans', 'Perphenazine/*blood', 'Tandem Mass Spectrometry/*methods', 'Thiothixene/*blood']",https://pubmed.ncbi.nlm.nih.gov/26660173/
2326,nevirapine,24596282,"Transmission of nevirapine-resistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, Mozambique.","['Micek MA', 'Dross S', 'Blanco AJ', 'Beck IA', 'Matunha L', 'Seidel K', 'Montoya P', 'Matediana E', 'Gantt S', 'Gloyd S', 'Frenkel L']","['Anti-HIV Agents/administration & dosage/adverse effects', 'Breast Feeding/adverse effects', 'Drug Resistance, Viral', 'Female', 'HIV Infections/drug therapy/*transmission/virology', 'HIV-1/*isolation & purification', 'Humans', '*Infectious Disease Transmission, Vertical', 'Milk, Human/*virology', 'Mozambique', 'Nevirapine/*administration & dosage/*adverse effects', 'Pregnancy', 'Pregnancy Complications, Infectious/virology', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/24596282/
2327,nevirapine,14562852,HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors.,['Wainberg MA'],"['*Drug Resistance, Viral/genetics', 'HIV-1/*drug effects/genetics', 'Humans', 'Mutation', 'Nevirapine/*pharmacology', 'Reverse Transcriptase Inhibitors/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/14562852/
2328,nevirapine,17725424,Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.,"['Kassaye S', 'Lee E', 'Kantor R', 'Johnston E', 'Winters M', 'Zijenah L', 'Mateta P', 'Katzenstein D']","['Adolescent', 'Adult', 'Anti-HIV Agents/administration & dosage/pharmacology/therapeutic use', 'Drug Resistance, Viral/*genetics', 'Female', 'HIV Infections/drug therapy/virology', 'HIV-1/drug effects/*genetics', 'Humans', 'Milk, Human/*virology', 'Molecular Sequence Data', '*Mutation', 'Nevirapine/*administration & dosage/pharmacology/therapeutic use', 'Pregnancy', 'Pregnancy Complications, Infectious/drug therapy/virology', 'Reverse Transcriptase Inhibitors/administration & dosage/pharmacology/therapeutic use', 'Zimbabwe']",https://pubmed.ncbi.nlm.nih.gov/17725424/
2329,nevirapine,39266781,"Exploring Co-Amorphous Formulations Of Nevirapine: Insights From Computational, Thermal, And Solubility Analyses.","['Dos Santos KA', 'Chaves LL', 'Nadvorny D', 'de La Roca Soares MF', 'Sobrinho JLS']","['*Nevirapine/chemistry', '*Solubility', '*Calorimetry, Differential Scanning/methods', '*X-Ray Diffraction/methods', '*Chemistry, Pharmaceutical/methods', 'Spectroscopy, Fourier Transform Infrared/methods', 'Drug Compounding/methods', 'Lamivudine/chemistry', 'Hydrogen Bonding', 'Anti-HIV Agents/chemistry']",https://pubmed.ncbi.nlm.nih.gov/39266781/
2330,nevirapine,17961859,Is it safe to switch between efavirenz and nevirapine in the event of toxicity?,"['Mehta U', 'Maartens G']","['Alkynes', 'Benzoxazines/adverse effects/immunology/*therapeutic use', 'Chemical and Drug Induced Liver Injury/etiology', 'Cross Reactions', 'Cyclopropanes', 'Drug Eruptions/etiology', 'HIV Infections/*drug therapy', 'Humans', 'Nevirapine/adverse effects/immunology/*therapeutic use', 'Reverse Transcriptase Inhibitors/adverse effects/immunology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17961859/
2331,nevirapine,32184040,Synthesis and evaluation of nevirapine analogs to study the metabolic activation of nevirapine.,"['Tateishi Y', 'Ohe T', 'Yasuda D', 'Takahashi K', 'Nakamura S', 'Kazuki Y', 'Mashino T']","['Cell Survival/drug effects', 'Dose-Response Relationship, Drug', 'Hep G2 Cells', 'Humans', 'Microsomes, Liver/chemistry/metabolism', 'Molecular Structure', 'Nevirapine/chemical synthesis/*metabolism/pharmacology', 'Reverse Transcriptase Inhibitors/chemical synthesis/*metabolism/pharmacology', 'Structure-Activity Relationship', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/32184040/
2332,nevirapine,16109442,"Effect of system variables involved in packed column SFC of nevirapine as model analyte using response surface methodology: application to retention thermodynamics, solute transfer kinetic study and binary diffusion coefficient determination.","['Kaul N', 'Agrawal H', 'Paradkar AR', 'Mahadik KR']","['Anti-HIV Agents/chemistry/isolation & purification', 'Biophysical Phenomena', 'Biophysics', 'Calibration', 'Chromatography', 'Chromatography, High Pressure Liquid', 'Chromatography, Supercritical Fluid/*methods', 'Diffusion', 'Kinetics', 'Models, Chemical', 'Models, Theoretical', 'Nevirapine/chemistry/*isolation & purification', 'Pressure', 'Regression Analysis', 'Reproducibility of Results', 'Sensitivity and Specificity', 'Spectrophotometry', 'Temperature', 'Thermodynamics', 'Ultraviolet Rays']",https://pubmed.ncbi.nlm.nih.gov/16109442/
2333,nevirapine,29441880,Crystal form conversion of nevirapine solvates subjected to elevated temperature and humidity: a qualitative study.,"['Stieger N', 'Caira MR', 'Wessels JC', 'Liebenberg W']","['Anti-HIV Agents/*chemistry', 'Crystallization', 'Hot Temperature', 'Humidity', 'Hydrophobic and Hydrophilic Interactions', 'Models, Molecular', 'Molecular Weight', 'Nevirapine/*chemistry', 'Thermogravimetry', 'Water/chemistry']",https://pubmed.ncbi.nlm.nih.gov/29441880/
2334,nevirapine,27284987,Nevirapine prophylaxis to prevent HIV-1 mother-to-child transmission: pharmacokinetic considerations in preterm infants.,"['Capretti MG', 'Marsico C', 'Conti M', 'Corvaglia LT', 'Arcuri S', 'Faldella G', 'Re MC']","['Anti-HIV Agents/pharmacokinetics/therapeutic use', 'Female', 'HIV Infections/*prevention & control/*transmission', '*HIV-1', 'Humans', 'Infant, Newborn', 'Infant, Premature', 'Infectious Disease Transmission, Vertical/*prevention & control', 'Nevirapine/*pharmacokinetics/*therapeutic use', 'Oligopeptides/therapeutic use', 'Pregnancy', 'RNA, Viral']",https://pubmed.ncbi.nlm.nih.gov/27284987/
2335,nevirapine,16779754,Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.,"['Manosuthi W', 'Sungkanuparph S', 'Thakkinstian A', 'Rattanasiri S', 'Chaovavanich A', 'Prasithsirikul W', 'Likanonsakul S', 'Ruxrungtham K']","['Adult', 'Anti-HIV Agents/*blood/therapeutic use', 'Antiretroviral Therapy, Highly Active/methods', 'Antitubercular Agents/*therapeutic use', 'Drug Interactions', 'Female', 'HIV Infections/complications/*drug therapy', 'Humans', 'Male', 'Nevirapine/*blood/therapeutic use', 'Prospective Studies', 'Rifampin/*therapeutic use', 'Treatment Outcome', 'Tuberculosis/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16779754/
2336,nevirapine,10723513,"dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.",['Skowron G'],"['Anti-HIV Agents/adverse effects/pharmacokinetics/therapeutic use', 'CD4 Lymphocyte Count', 'Drug Therapy, Combination', 'HIV Infections/*drug therapy', 'Humans', 'Nelfinavir/adverse effects/pharmacokinetics/*therapeutic use', 'Nevirapine/adverse effects/pharmacokinetics/*therapeutic use', 'RNA, Viral/blood', 'Research Design', 'Reverse Transcriptase Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Stavudine/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10723513/
2337,nevirapine,36460185,Assessing the potential for nevirapine removal and its ecotoxicological effects on Coelastrella tenuitheca and Tetradesmus obliquus in aqueous environment.,"['Reddy K', 'Renuka N', 'Kumari S', 'Ratha SK', 'Moodley B', 'Pillay K', 'Bux F']","['Nevirapine/metabolism', '*Chlorophyceae/metabolism', 'Water/metabolism', 'Pharmaceutical Preparations/metabolism', '*Microalgae/metabolism']",https://pubmed.ncbi.nlm.nih.gov/36460185/
2338,nevirapine,20503923,"Identification, isolation, and characterization of potential degradation products in a triple combination lamivudine, zidovudine, and nevirapine tablet for oral suspension.","['Aparna P', 'Rao SV', 'Thomas KM', 'Mukkanti K', 'Badarinadh Gupta P', 'Rangarao K', 'Narayan GK', 'Sandip T', 'Upendra K']","['Anti-HIV Agents/*analysis', 'Chromatography, High Pressure Liquid', 'Drug Contamination', 'Indicators and Reagents', 'Lamivudine/*analysis', 'Magnetic Resonance Spectroscopy', 'Nevirapine/*analysis', 'Spectrometry, Mass, Electrospray Ionization', 'Spectrophotometry, Ultraviolet', 'Spectroscopy, Fourier Transform Infrared', 'Suspensions', 'Tablets', 'Zidovudine/*analysis']",https://pubmed.ncbi.nlm.nih.gov/20503923/
2339,nevirapine,16940117,"Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.","['DeJesus E', 'Piliero PJ', 'Summers K', 'Wire MB', 'Stein DS', 'Masterman A', 'Lou Y', 'Min SS', 'Shelton MJ']","['Adult', 'Anti-HIV Agents/*pharmacology', 'Carbamates/*pharmacology', 'Drug Interactions', 'Female', 'Furans', '*HIV', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/pharmacology', 'Humans', 'Male', 'Nevirapine/*pharmacology', 'Organophosphates/*pharmacology', 'Reverse Transcriptase Inhibitors/pharmacology', 'Ritonavir/*pharmacology', 'Sulfonamides/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/16940117/
2340,nevirapine,23343913,Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.,"['Shubber Z', 'Calmy A', 'Andrieux-Meyer I', 'Vitoria M', 'Renaud-Thery F', 'Shaffer N', 'Hargreaves S', 'Mills EJ', 'Ford N']","['Adult', 'Alkynes', 'Anti-HIV Agents/administration & dosage/*adverse effects', 'Benzoxazines/administration & dosage/*adverse effects', 'Child', 'Cyclopropanes', 'HIV Infections/*drug therapy', 'Humans', 'Nevirapine/administration & dosage/*adverse effects', 'Randomized Controlled Trials as Topic', 'Reverse Transcriptase Inhibitors/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/23343913/
2341,nevirapine,23970648,"Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both?","['Saxon CJ', 'Helbert MR', 'Komolafe AJ', 'Higgins SP']","['Adult', 'Anti-HIV Agents/*adverse effects/therapeutic use', 'CD4 Lymphocyte Count', 'Diagnosis, Differential', 'Exanthema/*chemically induced', 'HIV Infections/*drug therapy', 'Hepatitis/complications/drug therapy', 'Humans', 'Hypersensitivity/complications/drug therapy', 'Kenya', 'Nevirapine/*adverse effects/therapeutic use', 'Syphilis/*diagnosis/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23970648/
2342,nevirapine,15247339,Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.,"['Jourdain G', 'Ngo-Giang-Huong N', 'Le Coeur S', 'Bowonwatanuwong C', 'Kantipong P', 'Leechanachai P', 'Ariyadej S', 'Leenasirimakul P', 'Hammer S', 'Lallemant M']","['Adult', 'Anti-Retroviral Agents/administration & dosage/*therapeutic use', '*Antiretroviral Therapy, Highly Active', 'CD4 Lymphocyte Count', 'Double-Blind Method', '*Drug Resistance, Viral/genetics', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Genotype', 'HIV Infections/*drug therapy/prevention & control/transmission', '*HIV-1/genetics', 'Humans', 'Labor, Obstetric', 'Logistic Models', 'Mutation', 'Nevirapine/administration & dosage/*therapeutic use', 'Pregnancy', 'Pregnancy Complications, Infectious/*drug therapy', 'Pregnancy Trimester, Third', 'RNA, Viral/blood', 'Risk Factors', 'Treatment Failure', 'Viral Load', 'Zidovudine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15247339/
2343,Diazepam,1505149,"Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time.","['Friedman H', 'Greenblatt DJ', 'Peters GR', 'Metzler CM', 'Charlton MD', 'Harmatz JS', 'Antal EJ', 'Sanborn EC', 'Francom SF']","['Administration, Oral', 'Adult', 'Conscious Sedation', 'Diazepam/blood/*pharmacokinetics/pharmacology', 'Dose-Response Relationship, Drug', 'Electroencephalography/drug effects', 'Female', 'Humans', 'Male', 'Motor Activity/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1505149/
2344,Diazepam,6592306,"Comparison of sedation, amnesia, and patient comfort produced by intravenous and rectal diazepam.","['Lundgren S', 'Rosenquist JB']","['Adolescent', 'Adult', 'Anesthesia, Dental/*methods', 'Anesthesia, Intravenous/*methods', 'Anesthesia, Rectal/*methods', 'Consumer Behavior', 'Diazepam/*administration & dosage/adverse effects', 'Female', 'Humans', 'Hypnotics and Sedatives', 'Male', 'Memory', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6592306/
2345,Diazepam,6383447,"Sedation for endoscopy: a comparison between diazepam, and diazepam plus pethidine with naloxone reversal.","['Boldy DA', 'English JS', 'Lang GS', 'Hoare AM']","['Adolescent', 'Adult', 'Aged', 'Clinical Trials as Topic', '*Diazepam/administration & dosage/antagonists & inhibitors', 'Double-Blind Method', '*Endoscopy', 'Female', 'Humans', '*Hypnotics and Sedatives', 'Male', '*Meperidine/administration & dosage/antagonists & inhibitors', 'Middle Aged', 'Naloxone/pharmacology', 'Random Allocation', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6383447/
2346,Diazepam,27534563,Deposition of diazepam and its metabolites in hair following a single dose of diazepam.,"['Wang X', 'Johansen SS', 'Zhang Y', 'Jia J', 'Rao Y', 'Jiang F', 'Linnet K']","['Adult', 'Asian People', 'Chromatography, Liquid', 'Diazepam/administration & dosage/*analysis', 'Female', 'Hair/*chemistry', 'Healthy Volunteers', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*analysis', 'Male', 'Nordazepam/analysis', 'Oxazepam/analogs & derivatives/analysis', 'Tandem Mass Spectrometry', 'Temazepam/analogs & derivatives/analysis', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27534563/
2347,Diazepam,28508332,Occurrence of diazepam and its metabolites in wastewater and surface waters in Beijing.,"['Wang C', 'Hou L', 'Li J', 'Xu Z', 'Gao T', 'Yang J', 'Zhang H', 'Li X', 'Du P']","['Beijing', 'Cities', 'Diazepam/*analysis', 'Nordazepam', '*Wastewater', 'Water Pollutants, Chemical/*analysis']",https://pubmed.ncbi.nlm.nih.gov/28508332/
2348,Diazepam,14550883,Convergent synthesis and antibacterial activity of pyrazole and pyrazoline derivatives of diazepam.,"['Berghot MA', 'Moawad EB']","['Anti-Bacterial Agents/*chemical synthesis/*pharmacology', 'Bacteria/*drug effects', 'Diazepam/*analogs & derivatives/chemical synthesis/*pharmacology', 'Gram-Negative Bacteria/drug effects', 'Gram-Positive Bacteria/drug effects', 'Indicators and Reagents', 'Magnetic Resonance Spectroscopy', 'Microbial Sensitivity Tests', 'Pyrazoles/*chemical synthesis/*pharmacology', 'Spectrophotometry, Infrared']",https://pubmed.ncbi.nlm.nih.gov/14550883/
2349,Diazepam,36117,Comparison of the actions of diazepam and lorazepam.,"['Dundee JW', 'McGowan WA', 'Lilburn JK', 'McKay AC', 'Hegarty JE']","['Amnesia', 'Anti-Anxiety Agents/*pharmacology', 'Diazepam/blood/*pharmacology', 'Humans', 'Lorazepam/blood/*pharmacology', 'Middle Aged', 'Preanesthetic Medication', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/36117/
2350,Diazepam,35533144,Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling of Diazepam: Unbound Interstitial Brain Concentrations Correspond to Clinical End Points.,['Burkat PM'],"['Benzodiazepines/pharmacology', 'Brain', '*Diazepam/pharmacology', 'Humans', '*Nordazepam', 'gamma-Aminobutyric Acid']",https://pubmed.ncbi.nlm.nih.gov/35533144/
2351,Diazepam,32065672,Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers.,"['Hogan RE', 'Gidal BE', 'Koplowitz B', 'Koplowitz LP', 'Lowenthal RE', 'Carrazana E']","['Administration, Intranasal', 'Administration, Oral', 'Administration, Rectal', 'Adolescent', 'Adult', 'Biological Availability', 'Diazepam/*administration & dosage/*pharmacokinetics', 'Female', 'Gels', 'Healthy Volunteers', 'Humans', 'Male', 'Middle Aged', 'Nasal Sprays', 'Sleepiness', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32065672/
2352,Diazepam,3445811,Diazepam and fentanyl as adjuncts to local anesthesia.,"['Michelson LN', 'Lindenthal JJ', 'Peck GC', 'Agresti CJ', 'Ship AG', 'Weiss PR']","['*Adjuvants, Anesthesia', '*Anesthesia, Local', 'Diazepam/administration & dosage/adverse effects/*pharmacology', 'Fentanyl/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Infusions, Intravenous', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/3445811/
2353,Diazepam,24217684,Conscious sedation with diazepam and midazolam for dental patient: priority to diazepam.,"['Zanette G', 'Manani G', 'Favero L', 'Stellini E', 'Mazzoleni S', 'Cocilovo F', 'Modolo O', 'Ferrarese N', 'Facco E']","['Adult', '*Conscious Sedation', 'Diazepam/*therapeutic use', 'Female', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Male', 'Midazolam/*therapeutic use', 'Middle Aged', '*Oral Surgical Procedures']",https://pubmed.ncbi.nlm.nih.gov/24217684/
2354,Diazepam,21298417,Reduction of temazepam to diazepam and lorazepam to delorazepam during enzymatic hydrolysis.,"['Fu S', 'Molnar A', 'Bowron P', 'Lewis J', 'Wang H']","['Benzodiazepines/*metabolism', 'Chromatography, Liquid', 'Diazepam/*metabolism', 'Glucuronidase/*metabolism', 'Humans', 'Hydrolysis', 'Lorazepam/*metabolism', 'Mass Spectrometry', 'Nordazepam/*analogs & derivatives/metabolism', 'Reference Standards', 'Temazepam/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/21298417/
2355,Diazepam,3045792,Actions and interactions of indomethacin and diazepam on performance in healthy volunteers.,"['Nuotto E', 'Saarialho-Kere U']","['Clinical Trials as Topic', 'Diazepam/administration & dosage/adverse effects/*pharmacology', 'Double-Blind Method', 'Drug Synergism', 'Female', 'Humans', 'Indomethacin/administration & dosage/adverse effects/*pharmacology', 'Male']",https://pubmed.ncbi.nlm.nih.gov/3045792/
2356,Diazepam,1126114,Placental transfer to diazepam and its disposition in the newborn.,"['Mandelli M', 'Morselli PL', 'Nordio S', 'Pardi G', 'Principi N', 'Sereni F', 'Tognoni G']","['Administration, Oral', 'Diazepam/administration & dosage/*blood', 'Female', 'Fetal Blood/metabolism', 'Fetus/metabolism', 'Half-Life', 'Humans', 'Infant, Newborn', 'Injections, Intramuscular', 'Injections, Intravenous', 'Kinetics', '*Maternal-Fetal Exchange', 'Pregnancy', 'Pregnancy Trimester, Third']",https://pubmed.ncbi.nlm.nih.gov/1126114/
2357,Diazepam,3096681,Diazepam and methadone blood levels following concurrent administration of diazepam and methadone.,"['Preston KL', 'Griffiths RR', 'Cone EJ', 'Darwin WD', 'Gorodetzky CW']","['Adult', 'Chromatography, Thin Layer', 'Diazepam/administration & dosage/*blood', 'Drug Interactions', 'Humans', 'Immunoenzyme Techniques', 'Kinetics', 'Male', 'Meiosis/drug effects', 'Methadone/administration & dosage/*blood', 'Nordazepam/blood']",https://pubmed.ncbi.nlm.nih.gov/3096681/
2358,Diazepam,2702793,"Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo.","['Greenblatt DJ', 'Ehrenberg BL', 'Gunderman J', 'Locniskar A', 'Scavone JM', 'Harmatz JS', 'Shader RI']","['Adult', 'Diazepam/blood/*pharmacokinetics', 'Double-Blind Method', '*Electroencephalography', 'Female', 'Half-Life', 'Humans', 'Infusions, Intravenous', 'Male', 'Metabolic Clearance Rate', 'Midazolam/blood/*pharmacokinetics', 'Placebos', 'Regression Analysis']",https://pubmed.ncbi.nlm.nih.gov/2702793/
2359,Diazepam,7628181,Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam.,"['Mould DR', 'DeFeo TM', 'Reele S', 'Milla G', 'Limjuco R', 'Crews T', 'Choma N', 'Patel IH']","['Adult', 'Cross-Over Studies', 'Diazepam/blood/*pharmacokinetics/*pharmacology', 'Drug Administration Schedule', 'Drug Interactions', 'Humans', 'Infusions, Intravenous', 'Male', 'Midazolam/blood/*pharmacokinetics/*pharmacology', 'Psychomotor Performance/drug effects', 'Sensitivity and Specificity', 'Single-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/7628181/
2360,procainamide,27354046,Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study.,"['Ortiz M', 'Martin A', 'Arribas F', 'Coll-Vinent B', 'Del Arco C', 'Peinado R', 'Almendral J']","['Aged', 'Amiodarone/*administration & dosage/adverse effects', 'Anti-Arrhythmia Agents/*administration & dosage/adverse effects', 'Cardiomyopathies/complications', 'Drug Administration Schedule', 'Female', 'Humans', 'Infusions, Intravenous', 'Male', 'Middle Aged', 'Patient Selection', 'Procainamide/*administration & dosage/adverse effects', 'Tachycardia, Ventricular/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27354046/
2361,procainamide,37075496,Generic detection of organophosphorus nerve agent adducts to butyrylcholinesterase in plasma using liquid chromatography-tandem mass spectrometry combined with an improved procainamide-gel separation and pepsin digestion method.,"['Liu CC', 'Liang LH', 'Yan L', 'Chen B', 'Liu XJ', 'Yang Y', 'Liu SL', 'Xi HL']","['Humans', 'Aged', '*Nerve Agents/analysis', 'Butyrylcholinesterase', 'Tandem Mass Spectrometry/methods', 'Procainamide/analysis', 'Pepsin A', 'Organophosphorus Compounds', 'Chromatography, Liquid/methods', 'Digestion']",https://pubmed.ncbi.nlm.nih.gov/37075496/
2362,procainamide,2476614,Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.,"['Funck-Brentano C', 'Light RT', 'Lineberry MD', 'Wright GM', 'Roden DM', 'Woosley RL']","['Acecainide/*adverse effects/pharmacokinetics/therapeutic use', 'Acetylation', 'Adult', 'Aged', 'Arrhythmias, Cardiac/drug therapy', 'Drug Interactions', 'Electrocardiography', 'Female', 'Half-Life', 'Humans', 'Infusions, Intravenous', 'Male', 'Middle Aged', 'Phenotype', 'Procainamide/*adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2476614/
2363,procainamide,26335213,"Continuous intravenous antiarrhythmic agents in the intensive care unit: strategies for safe and effective use of amiodarone, lidocaine, and procainamide.","['Samarin MJ', 'Mohrien KM', 'Oliphant CS']","['Amiodarone/*therapeutic use', 'Anti-Arrhythmia Agents/adverse effects/*therapeutic use', 'Arrhythmias, Cardiac/*drug therapy', 'Drug Interactions', 'Humans', 'Infusions, Intravenous', 'Intensive Care Units', 'Lidocaine/*therapeutic use', 'Procainamide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26335213/
2364,procainamide,2456755,Metabolites of procainamide and practolol inhibit complement components C3 and C4.,"['Sim E', 'Stanley L', 'Gill EW', 'Jones A']","['Acecainide/pharmacology', 'Complement C3/*antagonists & inhibitors', 'Complement C4/*antagonists & inhibitors', 'Humans', 'Practolol/*analogs & derivatives/*pharmacology', 'Procainamide/*analogs & derivatives/*pharmacology', 'Protein Binding/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2456755/
2365,procainamide,2244779,Intrahepatic cholestasis due to hypersensitivity reaction to procainamide.,"['Ahn CS', 'Tow DE']","['Aged', 'Cholestasis/*chemically induced/physiopathology', 'Drug Hypersensitivity/*physiopathology', 'Humans', 'Liver/enzymology/metabolism', 'Male', 'Procainamide/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2244779/
2366,procainamide,2979715,Metabolism of procainamide to a hydroxylamine by human neutrophils and mononuclear leukocytes.,"['Uetrecht J', 'Zahid N', 'Rubin R']","['Biotransformation', 'Humans', 'Hydroxylamines/*blood', 'In Vitro Techniques', 'Kinetics', 'Leukocytes, Mononuclear/drug effects/*metabolism', 'Neutrophils/drug effects/*metabolism', 'Procainamide/*blood', 'Prostaglandin Antagonists/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2979715/
2367,procainamide,3409498,Comparison of individual and combined effects of procainamide and amiodarone in patients with sustained ventricular tachyarrhythmias.,"['Marchlinski FE', 'Buxton AE', 'Kindwall KE', 'Miller JM', 'Rosenthal ME', 'Gottlieb CD', 'Bloom RB', 'Josephson ME']","['Adult', 'Aged', 'Amiodarone/*therapeutic use', 'Cardiac Pacing, Artificial', 'Drug Combinations', 'Electrocardiography', 'Female', 'Heart Conduction System/physiopathology', 'Humans', 'Male', 'Middle Aged', 'Procainamide/*therapeutic use', 'Refractory Period, Electrophysiological', 'Tachycardia, Supraventricular/*drug therapy/etiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/3409498/
2368,procainamide,3354563,Procainamide-associated pancytopenia.,"['Shields AF', 'Berenson JA']","['Adult', 'Bone Marrow/pathology', 'Erythrocyte Count', 'Hemoglobins/analysis', 'Humans', 'Leukocyte Count', 'Male', 'Pancytopenia/blood/*chemically induced', 'Platelet Count', 'Procainamide/*adverse effects', 'Reticulocytes/cytology']",https://pubmed.ncbi.nlm.nih.gov/3354563/
2369,procainamide,2396315,Procainamide-induced myasthenic crisis.,"['Godley PJ', 'Morton TA', 'Karboski JA', 'Tami JA']","['Aged', 'Humans', 'Injections, Intravenous', 'Male', 'Myasthenia Gravis/*complications', 'Procainamide/administration & dosage/*adverse effects', 'Respiratory Insufficiency/*chemically induced/complications']",https://pubmed.ncbi.nlm.nih.gov/2396315/
2370,procainamide,8844445,Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization.,"['Yang BB', 'Abel RB', 'Uprichard AC', 'Smithers JA', 'Forgue ST']","['Acecainide/administration & dosage/blood/*pharmacokinetics', 'Anti-Arrhythmia Agents/administration & dosage/blood/*pharmacokinetics', 'Arrhythmias, Cardiac/drug therapy/metabolism', 'Chemistry, Pharmaceutical', 'Cross-Over Studies', 'Delayed-Action Preparations', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Procainamide/administration & dosage/blood/*pharmacokinetics', 'Tablets', 'Ventricular Premature Complexes']",https://pubmed.ncbi.nlm.nih.gov/8844445/
2371,procainamide,3134699,Procainamide-induced lupus anticoagulant.,"['Heyman MR', 'Flores RH', 'Edelman BB', 'Carliner NH']","['Aged', 'Autoantibodies/biosynthesis', 'Blood Coagulation/drug effects', 'Blood Coagulation Factors/biosynthesis/*immunology', 'Female', 'Humans', 'Lupus Coagulation Inhibitor', 'Male', 'Partial Thromboplastin Time', 'Procainamide/*adverse effects', 'Prothrombin Time']",https://pubmed.ncbi.nlm.nih.gov/3134699/
2372,Desflurane,39121786,"Desflurane versus sevoflurane anesthesia and postoperative recovery in older adults undergoing minor- to moderate-risk noncardiac surgery - A prospective, randomized, observer-blinded, clinical trial.","['Taschner A', 'Fleischmann E', 'Horvath K', 'Adamowitsch N', 'Emler D', 'Christian T', 'Hantakova N', 'Hochreiter B', 'Hofer L', 'List M', 'Rossi B', 'Zenz FW', 'Zanvettor G', 'Zotti O', 'Graf A', 'Fraunschiel M', 'Reiterer C']","['Humans', '*Sevoflurane/administration & dosage/adverse effects', '*Desflurane/administration & dosage/adverse effects', '*Anesthetics, Inhalation/administration & dosage/adverse effects', '*Anesthesia Recovery Period', 'Aged', 'Male', 'Prospective Studies', 'Female', '*Postoperative Nausea and Vomiting/epidemiology/prevention & control', '*S100 Calcium Binding Protein beta Subunit/blood', 'Single-Blind Method', 'Consciousness Monitors', 'Methyl Ethers/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39121786/
2373,Desflurane,24110878,"Classification of EEG bursts in deep sevoflurane, desflurane and isoflurane anesthesia using AR-modeling and entropy measures.","['Lipping T', 'Stalnacke J', 'Olejarczyk E', 'Marciniak R', 'Jantti V']","['Algorithms', '*Anesthesia', 'Anesthetics, Inhalation/*pharmacology', 'Cluster Analysis', 'Desflurane', '*Electroencephalography', '*Entropy', 'Humans', 'Isoflurane/*analogs & derivatives/*pharmacology', 'Methyl Ethers/*pharmacology', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/24110878/
2374,Desflurane,26198766,Desflurane and sevoflurane use during low- and minimal-flow anesthesia at fixed vaporizer settings.,"['Horwitz M', 'Jakobsson JG']","['Adult', 'Aged', 'Anesthesia, Inhalation/*methods', 'Anesthetics, Inhalation/adverse effects/*pharmacology', 'Desflurane', 'Female', 'Humans', 'Isoflurane/adverse effects/*analogs & derivatives/pharmacology', 'Laparoscopy', 'Male', 'Methyl Ethers/adverse effects/*pharmacology', 'Middle Aged', 'Nebulizers and Vaporizers', 'Sevoflurane', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26198766/
2375,Desflurane,34620093,Effects of desflurane and sevoflurane on somatosensory-evoked and motor-evoked potential monitoring during neurosurgery: a randomized controlled trial.,"['Xiang B', 'Jiao S', 'Zhang Y', 'Wang L', 'Yao Y', 'Yuan F', 'Chen R', 'Zhou Q']","['Adult', 'Anesthetics, Inhalation/pharmacology', 'Desflurane/*pharmacology', 'Evoked Potentials, Motor/*drug effects', 'Evoked Potentials, Somatosensory/*drug effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Monitoring, Intraoperative/*methods', '*Neurosurgical Procedures', 'Sevoflurane/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34620093/
2376,Desflurane,37481911,Systematic review with meta-analysis of relative risk of prolonged times to tracheal extubation with desflurane versus sevoflurane or isoflurane.,"['Dexter F', 'Hindman BJ']","['Humans', '*Isoflurane/adverse effects', 'Sevoflurane', 'Desflurane/adverse effects', 'Risk', 'Airway Extubation/adverse effects', '*Anesthetics, Inhalation/adverse effects', '*Methyl Ethers/adverse effects', 'Anesthesia Recovery Period']",https://pubmed.ncbi.nlm.nih.gov/37481911/
2377,Desflurane,33673181,Sevoflurane and Desflurane Exposure Enhanced Cell Proliferation and Migration in Ovarian Cancer Cells via miR-210 and miR-138 Downregulation.,"['Ishikawa M', 'Iwasaki M', 'Zhao H', 'Saito J', 'Hu C', 'Sun Q', 'Sakamoto A', 'Ma D']","['Cell Line, Tumor', 'Cell Movement/*drug effects', 'Cell Proliferation/*drug effects', 'Desflurane/*pharmacology', 'Down-Regulation/*drug effects', 'Female', 'Gene Expression Regulation, Neoplastic/*drug effects', 'Humans', 'Hypoxia-Inducible Factor 1, alpha Subunit/metabolism', 'MicroRNAs/*biosynthesis', 'Neoplasm Proteins/metabolism', 'Ovarian Neoplasms/*metabolism/pathology', 'RNA, Neoplasm/*biosynthesis', 'Sevoflurane/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33673181/
2378,Desflurane,35845953,The Effects of Switching from Sevoflurane to Short-Term Desflurane prior to the End of General Anesthesia on Patient Emergence and Recovery: A Randomized Controlled Trial.,"['Kim JW', 'Lee JY', 'Hwang SW', 'Kang DH', 'Ryu SJ', 'Kim DS', 'Kim JD']","['Aged', 'Anesthesia Recovery Period', 'Anesthesia, General', '*Anesthetics, Inhalation/pharmacology', 'Desflurane', 'Humans', '*Isoflurane/pharmacology', '*Methyl Ethers', 'Postoperative Nausea and Vomiting', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/35845953/
2379,Desflurane,8536556,Desflurane. A review of its pharmacodynamic and pharmacokinetic properties and its efficacy in general anaesthesia.,"['Patel SS', 'Goa KL']","['Adolescent', 'Adult', 'Aged', 'Anesthesia, General', 'Anesthesia, Obstetrical', 'Anesthetics, Inhalation/pharmacokinetics/*pharmacology', 'Child', 'Clinical Trials as Topic', 'Desflurane', 'Female', 'Humans', 'Isoflurane/*analogs & derivatives/pharmacokinetics/pharmacology', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/8536556/
2380,Desflurane,36814199,Hemodynamic responses to 1 MAC desflurane inhalation during anesthesia induction with propofol bolus and remifentanil continuous infusion: a prospective randomized single-blind clinical investigation.,"['Lee JW', 'Kim MK', 'Kim JY']","['Adult', 'Humans', 'Young Adult', 'Remifentanil/pharmacology', '*Propofol/pharmacology', 'Desflurane/pharmacology', 'Sevoflurane/pharmacology', 'Prospective Studies', 'Single-Blind Method', 'Piperidines/adverse effects', 'Hemodynamics', 'Anesthesia, General', 'Heart Rate', '*Anesthetics, Inhalation/pharmacology', 'Anesthetics, Intravenous/pharmacology', '*Isoflurane/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/36814199/
2381,Desflurane,27871572,The effects of sevoflurane and desflurane on the hemodynamics and respiratory functions in laparoscopic sleeve gastrectomy.,"['Ozdogan HK', 'Cetinkunar S', 'Karateke F', 'Cetinalp S', 'Celik M', 'Ozyazici S']","['Adult', 'Anesthetics, Inhalation/pharmacology', 'Cohort Studies', 'Desflurane', 'Female', '*Gastrectomy', 'Hemodynamics/*drug effects', 'Humans', 'Isoflurane/*analogs & derivatives/pharmacology', 'Laparoscopy', 'Male', 'Methyl Ethers/*pharmacology', 'Obesity, Morbid/*surgery', 'Prospective Studies', 'Respiration/*drug effects', 'Respiratory Function Tests', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/27871572/
2382,Desflurane,40016655,Minimising the usage of desflurane only by education and removal of the vaporisers - a before-and-after-trial.,"['Lehmann F', 'Mader J', 'Koch C', 'Markmann M', 'Leicht D', 'Sander M']","['*Desflurane/administration & dosage', '*Anesthetics, Inhalation/administration & dosage', 'Humans', 'Prospective Studies', '*Nebulizers and Vaporizers', 'Germany', 'Hospitals, University', 'Male', 'Isoflurane/analogs & derivatives/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/40016655/
2383,Desflurane,35445895,Relationship between ANI and qNOX and between MAC and qCON during outpatient laparoscopic cholecystectomy using remifentanil and desflurane without muscle relaxants: a prospective observational preliminary study.,"['Pantalacci T', 'Allaouchiche B', 'Boselli E']","['Adult', 'Humans', 'Remifentanil', 'Desflurane', 'Anesthetics, Intravenous', 'Outpatients', '*Cholecystectomy, Laparoscopic', 'Piperidines', 'Anesthesia, General', 'Vasodilator Agents', 'Muscles', '*Isoflurane/pharmacology', '*Anesthetics, Inhalation']",https://pubmed.ncbi.nlm.nih.gov/35445895/
2384,Desflurane,33578509,Prediction of expiratory desflurane and sevoflurane concentrations in lung-healthy patients utilizing cardiac output and alveolar ventilation matched pharmacokinetic models: A comparative observational study.,"['Weber J', 'Missbach C', 'Schmidt J', 'Wenzel C', 'Schumann S', 'Philip JH', 'Wirth S']","['Adult', 'Aged', 'Algorithms', 'Anesthetics, Inhalation/administration & dosage/pharmacokinetics', 'Cardiac Output/*drug effects/physiology', 'Clinical Trials as Topic', 'Computer Simulation/statistics & numerical data', 'Desflurane/administration & dosage/*pharmacokinetics', 'Drug Therapy, Combination', 'Exhalation/*physiology', 'Female', 'Humans', 'Lung/metabolism/physiology', 'Male', 'Middle Aged', 'Predictive Value of Tests', 'Pulmonary Alveoli/drug effects/metabolism/physiology', 'Pulmonary Ventilation/*physiology', 'Sevoflurane/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/33578509/
2385,Desflurane,37791946,"Comparison of the Effects of Desflurane and Sevoflurane on Variations in Salivary Melatonin and Sleep Disturbance After Total Knee Arthroplasty: A Single-center, Prospective, Randomized, Controlled, Open-label Study.","['Mori K', 'Komatsu T', 'Fujiwara Y', 'Fujita Y']","['Adult', 'Humans', 'Anesthetics, Inhalation/pharmacology', '*Arthroplasty, Replacement, Knee/adverse effects', '*Desflurane/pharmacology', 'Melatonin/metabolism', 'Prospective Studies', '*Sevoflurane/pharmacology', 'Sleep Wake Disorders', 'Saliva/chemistry']",https://pubmed.ncbi.nlm.nih.gov/37791946/
2386,Sildenafil,36141480,Sildenafil during the 2nd and 3rd Trimester of Pregnancy: Trials and Tribulations.,"['De Bie FR', 'Basurto D', 'Kumar S', 'Deprest J', 'Russo FM']","['Female', 'Fetal Growth Retardation', '*Hernias, Diaphragmatic, Congenital/chemically induced/drug therapy', 'Humans', '*Hypertension, Pulmonary', 'Phosphodiesterase 5 Inhibitors/pharmacology/therapeutic use', '*Pre-Eclampsia/chemically induced', 'Pregnancy', 'Sildenafil Citrate/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36141480/
2387,Sildenafil,38863262,Prophylactic sildenafil to prevent bronchopulmonary dysplasia: A systematic review and meta-analysis.,"['Hirata K', 'Nakahari A', 'Takeoka M', 'Watanabe M', 'Nishimura Y', 'Katayama Y', 'Isayama T']","['Humans', '*Sildenafil Citrate/therapeutic use/administration & dosage', '*Bronchopulmonary Dysplasia/prevention & control', 'Infant, Newborn', 'Phosphodiesterase 5 Inhibitors/therapeutic use/administration & dosage', 'Treatment Outcome', 'Randomized Controlled Trials as Topic', 'Infant, Extremely Premature', 'Vasodilator Agents/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38863262/
2388,Sildenafil,36861763,Differences in Efficacy and Safety of Sirolimus and Sildenafil in Pediatric Lymphatic Malformations.,"['Wang J', 'Zhang X', 'Sun N', 'Liu Q', 'Li Y', 'Peng Y', 'Cheng X', 'Zhang J', 'Liu Y', 'Feng G', 'Liu Z', 'Ji T', 'Li X', 'Liu Y', 'Wang S', 'Ni X']","['Child', 'Humans', 'Sildenafil Citrate/adverse effects', 'Sirolimus/adverse effects', 'Retrospective Studies', 'Treatment Outcome', '*Lymphatic Abnormalities/drug therapy', '*Vascular Malformations']",https://pubmed.ncbi.nlm.nih.gov/36861763/
2389,Sildenafil,34685745,"Sildenafil-Mediated Neuroprotection from Adult to Neonatal Brain Injury: Evidence, Mechanisms, and Future Translation.","['Zinni M', 'Pansiot J', 'Leger PL', 'El Kamouh M', 'Baud O']","['Adult', 'Brain Injuries/*drug therapy', 'Humans', 'Infant, Newborn', '*Neuroprotection/drug effects', 'Nitric Oxide/metabolism', 'Sex Characteristics', 'Sildenafil Citrate/pharmacology/*therapeutic use', '*Translational Research, Biomedical']",https://pubmed.ncbi.nlm.nih.gov/34685745/
2390,Sildenafil,28341580,Efficacy and Safety of Sildenafil in Men With Sexual Dysfunction and Spinal Cord Injury.,"['Ohl DA', 'Carlsson M', 'Stecher VJ', 'Rippon GA']","['Humans', 'Male', 'Ejaculation/drug effects', '*Erectile Dysfunction/drug therapy/etiology', 'Penile Erection/drug effects', '*Phosphodiesterase 5 Inhibitors/adverse effects/therapeutic use', '*Sildenafil Citrate/adverse effects/therapeutic use', '*Spinal Cord Injuries/complications/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/28341580/
2391,Sildenafil,36849042,Histone deacetylase inhibitors synergize with sildenafil to suppress purine metabolism and proliferation in pulmonary hypertension.,"['Zhang H', ""D'Alessandro A"", 'Li M', 'Reisz JA', 'Riddle S', 'Muralidhar A', 'Bull T', 'Zhao L', 'Gerasimovskaya E', 'Stenmark KR']","['Humans', 'Sildenafil Citrate/pharmacology/therapeutic use', '*Hypertension, Pulmonary/metabolism', 'Histone Deacetylase Inhibitors/pharmacology/therapeutic use/metabolism', 'Vascular Remodeling', 'Vasodilator Agents/pharmacology', 'Pulmonary Artery', 'Purines/metabolism/pharmacology/therapeutic use', 'Cell Proliferation']",https://pubmed.ncbi.nlm.nih.gov/36849042/
2392,Sildenafil,35462261,Assessment of correlations between sildenafil use and comorbidities and lifestyle factors using wastewater-based epidemiology.,"['Shao XT', 'Zhang PY', 'Liu SY', 'Lin JG', 'Tan DQ', 'Wang DG']","['Cities', 'Humans', 'Life Style', 'Sildenafil Citrate/analysis', 'Wastewater/chemistry', '*Wastewater-Based Epidemiological Monitoring', '*Water Pollutants, Chemical/analysis']",https://pubmed.ncbi.nlm.nih.gov/35462261/
2393,Sildenafil,31339910,The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis.,"['Ferreira RDDS', 'Negrini R', 'Bernardo WM', 'Simoes R', 'Piato S']","['Birth Weight', 'Delivery, Obstetric', 'Female', 'Fetus/*drug effects', 'Gestational Age', 'Headache/chemically induced', 'Humans', 'Infant', 'Infant Mortality', 'Labor, Obstetric', 'Pregnancy', '*Pregnancy Outcome', 'Publication Bias', 'Risk', 'Sildenafil Citrate/adverse effects/*pharmacology', 'Umbilical Arteries/physiology']",https://pubmed.ncbi.nlm.nih.gov/31339910/
2394,Sildenafil,33856119,Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension.,"['Chen T', 'Chen J', 'Chen C', 'Zheng H', 'Chen Y', 'Liu M', 'Zheng B']","['Bosentan', 'Child', 'Cost-Benefit Analysis', 'Humans', '*Hypertension, Pulmonary/drug therapy', '*Pharmaceutical Preparations', '*Pulmonary Arterial Hypertension', 'Quality of Life', 'Sildenafil Citrate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33856119/
2395,Sildenafil,34461080,"Method development and validation of sildenafil, N-desmethylsildenafil and N1,N4-desmethylsildenafil by LC-MS/MS and its application.","['Xu YY', 'Qin F', 'Dai YX', 'Zhong XF', 'Yan J', 'Xu SM', 'Xu PS']","['Administration, Oral', 'Adolescent', 'Adult', 'Blood Chemical Analysis/methods', 'Calibration', 'Chromatography, Liquid/*methods', 'Drug Stability', 'Humans', 'Limit of Detection', 'Male', 'Middle Aged', 'Sensitivity and Specificity', 'Sildenafil Citrate/administration & dosage/*blood/metabolism/*pharmacokinetics', 'Tandem Mass Spectrometry/*methods', 'Therapeutic Equivalency', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34461080/
2396,Sildenafil,26756977,Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension.,"['Hakamata A', 'Odagiri K', 'Miyakawa S', 'Irisawa H', 'Takeuchi K', 'Inui N', 'Tanaka S', 'Uchida S', 'Watanabe H']","['Adult', 'Bosentan', 'Drug Therapy, Combination', 'Exercise', 'Female', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Male', 'Middle Aged', 'Phenylpropionates/adverse effects/*pharmacokinetics/pharmacology/*therapeutic use', 'Pyridazines/adverse effects/*pharmacokinetics/pharmacology/*therapeutic use', 'Sildenafil Citrate/adverse effects/*pharmacokinetics/pharmacology/*therapeutic use', 'Sulfonamides/adverse effects/*pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26756977/
2397,Sildenafil,32822614,"Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.","['Behr J', 'Nathan SD', 'Wuyts WA', 'Mogulkoc Bishop N', 'Bouros DE', 'Antoniou K', 'Guiot J', 'Kramer MR', 'Kirchgaessler KU', 'Bengus M', 'Gilberg F', 'Perjesi A', 'Harari S', 'Wells AU']","['Aged', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension, Pulmonary/*prevention & control', 'Idiopathic Pulmonary Fibrosis/*drug therapy', 'Male', 'Pyridones/administration & dosage/adverse effects/*therapeutic use', 'Sildenafil Citrate/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32822614/
2398,Sildenafil,32713951,Use of sildenafil for pulmonary hypertension in neonates.,"['Marquez-Gonzalez H', 'Rios DI', 'Jean Tron MG', 'Barajas-Nava LA']","['Humans', 'Hypertension, Pulmonary/*drug therapy/mortality', 'Infant, Newborn', 'Randomized Controlled Trials as Topic', 'Sildenafil Citrate/*therapeutic use', 'Vasodilator Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32713951/
2399,Sildenafil,30911094,Vascular Response to Sildenafil Citrate in Aging and Age-Related Macular Degeneration.,"['Yiu G', 'Vuong VS', 'Tran S', 'Migacz J', 'Cunefare D', 'Farsiu S', 'Khandelwal N', 'Agrawal R', 'Cheung CMG']","['Aged', 'Aged, 80 and over', 'Aging/*pathology', 'Case-Control Studies', 'Choroid/blood supply/diagnostic imaging/drug effects/pathology', 'Female', 'Fluorescein Angiography', 'Humans', 'Macula Lutea/diagnostic imaging/metabolism/pathology', 'Macular Degeneration/*diagnosis/*drug therapy/etiology/metabolism', 'Male', 'Phosphodiesterase 5 Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Retinal Vessels/diagnostic imaging/drug effects/metabolism/pathology', 'Sildenafil Citrate/administration & dosage/adverse effects/*therapeutic use', 'Tomography, Optical Coherence/methods', 'Vasodilator Agents/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30911094/
2400,Sildenafil,28093934,Efficacy and safety of oral sildenafil in treatment of pediatric head and neck lymphatic malformations.,"['Wang S', 'Zhang J', 'Ge W', 'Liu Y', 'Guo Y', 'Liu Y', 'Wang N', 'He Y', 'Tai J', 'Ni X']","['Child', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Lymphatic Abnormalities/*drug therapy', 'Male', 'Phosphodiesterase 5 Inhibitors/*therapeutic use', 'Prospective Studies', 'Sildenafil Citrate/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28093934/
2401,Sildenafil,26179419,Application of Orbitrap-mass spectrometry to differentiate isomeric sildenafil- and thiosildenafil-like analogues used for the adulteration of dietary supplements.,"['Kee CL', 'Ge X', 'Low MY']","['Dietary Supplements/*analysis', 'Drug Contamination', 'Food Safety', 'Humans', 'Isomerism', 'Phosphodiesterase 5 Inhibitors/chemistry/*isolation & purification', 'Pyrimidines/chemistry/*isolation & purification', 'Sildenafil Citrate/analogs & derivatives/*isolation & purification', 'Sulfones/chemistry/*isolation & purification', 'Tandem Mass Spectrometry/instrumentation/*methods', 'Urological Agents/chemistry/*isolation & purification']",https://pubmed.ncbi.nlm.nih.gov/26179419/
2402,Thalidomide,15172781,Thalidomide.,"['Franks ME', 'Macpherson GR', 'Figg WD']","['Clinical Trials as Topic', 'Gastrointestinal Diseases/drug therapy', 'HIV Infections/complications', 'Humans', 'Neoplasms/drug therapy', 'Rheumatic Diseases/drug therapy', 'Skin Diseases/drug therapy', 'Thalidomide/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15172781/
2403,Thalidomide,37585660,From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation.,"['Oleinikovas V', 'Gainza P', 'Ryckmans T', 'Fasching B', 'Thoma NH']","['Humans', '*Thalidomide/pharmacology/therapeutic use', 'Proteolysis', '*Ubiquitin-Protein Ligases/metabolism', 'Proteasome Endopeptidase Complex/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37585660/
2404,Thalidomide,37913505,Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia.,"['Chen H', 'Wu S', 'Tang M', 'Zhao R', 'Zhang Q', 'Dai Z', 'Gao Y', 'Yang S', 'Li Z', 'Du Y', 'Yang A', 'Zhong L', 'Lu L', 'Xu L', 'Shen X', 'Liu S', 'Zhong J', 'Li X', 'Lu H', 'Xiong H', 'Shen Y', 'Chen H', 'Gong S', 'Xue H', 'Ge Z']","['Humans', '*Angiodysplasia/complications/drug therapy', 'China', 'Double-Blind Method', '*Gastrointestinal Hemorrhage/drug therapy/etiology', '*Thalidomide/administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome', '*Intestinal Diseases/complications/drug therapy', 'Recurrence', '*Intestine, Small/blood supply', 'Administration, Oral', '*Hematologic Agents/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37913505/
2405,Thalidomide,17139107,Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity.,"['Nakamura T', 'Noguchi T', 'Kobayashi H', 'Miyachi H', 'Hashimoto Y']","['Antineoplastic Agents/chemical synthesis/pharmacology', 'Cell Line, Tumor', 'Humans', 'Molecular Structure', 'Thalidomide/*analogs & derivatives/*chemical synthesis/chemistry/*metabolism/pharmacology', 'Tumor Necrosis Factor-alpha/*antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/17139107/
2406,Thalidomide,37226469,"Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations.","['Vargesson N', 'Hooper G', 'Giddins G', 'Hunter A', 'Stirling P', 'Lam W']","['Adult', 'Humans', 'Child', 'Female', 'Thalidomide/adverse effects', '*Abnormalities, Multiple', 'Upper Extremity', '*Fetal Diseases']",https://pubmed.ncbi.nlm.nih.gov/37226469/
2407,Thalidomide,25858208,Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease.,"['Yang C', 'Singh P', 'Singh H', 'Le ML', 'El-Matary W']","['Adult', 'Child', 'Colitis, Ulcerative/*drug therapy', 'Crohn Disease/*drug therapy', 'Humans', 'Inflammatory Bowel Diseases/drug therapy', 'Remission Induction', 'Thalidomide/analogs & derivatives/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25858208/
2408,Thalidomide,35278515,Binding and thermodynamic study of thalidomide with calf thymus DNA: Spectroscopic and computational approaches.,"['Yasmeen S', 'Qais FA', 'Rana M', 'Islam A', 'Rahisuddin']","['Circular Dichroism', '*DNA/chemistry', 'Molecular Docking Simulation', 'Nucleic Acid Conformation', 'Spectrometry, Fluorescence', 'Spectrophotometry, Ultraviolet', 'Spectroscopy, Fourier Transform Infrared', '*Thalidomide/pharmacology', 'Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/35278515/
2409,Thalidomide,11155589,Thalidomide.,"['Radomsky CL', 'Levine N']","['Dermatologic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Immunosuppressive Agents/adverse effects/pharmacokinetics/therapeutic use', 'Practice Guidelines as Topic', 'Skin Diseases/*drug therapy', 'Thalidomide/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11155589/
2410,Thalidomide,39342210,Efficacy and safety of thalidomide for recurrent aphthous stomatitis: a systematic review and meta-analysis of randomized controlled trials.,"['Jian Y', 'Wang F', 'Zhao M', 'Han X', 'Wang X']","['Humans', 'Randomized Controlled Trials as Topic', 'Recurrence', '*Stomatitis, Aphthous/drug therapy', '*Thalidomide/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39342210/
2411,Thalidomide,28469241,A HAND to TBX5 Explains the Link Between Thalidomide and Cardiac Diseases.,"['Khalil A', 'Tanos R', 'El-Hachem N', 'Kurban M', 'Bouvagnet P', 'Bitar F', 'Nemer G']","['Basic Helix-Loop-Helix Transcription Factors/chemistry/genetics/*metabolism', 'DNA', 'Female', 'Genotype', 'HEK293 Cells', 'HeLa Cells', 'Heart Defects, Congenital/*chemically induced/genetics/*metabolism', 'Humans', 'Male', 'Molecular Docking Simulation', 'Pedigree', 'Phenotype', 'Protein Binding', 'Protein Structure, Tertiary', 'T-Box Domain Proteins/chemistry/*metabolism', 'Thalidomide/chemistry/*metabolism/*toxicity']",https://pubmed.ncbi.nlm.nih.gov/28469241/
2412,Thalidomide,34314371,Efficacy and Safety of Thalidomide in Patients with Complicated Central Nervous System Tuberculosis: A Systematic Review and Meta-Analysis.,"['Panda PK', 'Panda P', 'Dawman L', 'Sihag RK', 'Sharawat IK']","['Immunosuppressive Agents/*adverse effects/*therapeutic use', 'Thalidomide/*adverse effects/*therapeutic use', 'Tuberculosis, Central Nervous System/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34314371/
2413,Thalidomide,19370685,Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.,"['Akobeng AK', 'Stokkers PC']","['Crohn Disease/*drug therapy', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Lenalidomide', 'Remission Induction', 'Thalidomide/analogs & derivatives/*therapeutic use', 'Tumor Necrosis Factor-alpha/antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/19370685/
2414,Thalidomide,16755058,"Effects of immunomodulatory derivatives of thalidomide (IMiDs) and their analogs on cell-differentiation, cyclooxygenase activity and angiogenesis.","['Fujimoto H', 'Noguchi T', 'Kobayashi H', 'Miyachi H', 'Hashimoto Y']","['Angiogenesis Inhibitors/pharmacology', 'Cell Differentiation/*drug effects', 'Cyclooxygenase 1/*drug effects', 'HL-60 Cells', 'Humans', 'Immunologic Factors/pharmacology', 'Thalidomide/analogs & derivatives/*pharmacology', 'Tumor Cells, Cultured', 'Umbilical Veins/pathology']",https://pubmed.ncbi.nlm.nih.gov/16755058/
2415,Thalidomide,31487824,New Thalidomide-Resembling Dicarboximides Target ABC50 Protein and Show Antileukemic and Immunomodulatory Activities.,"['Cieslak M', 'Kazmierczak-Baranska J', 'Krolewska-Golinska K', 'Napiorkowska M', 'Stukan I', 'Wojda U', 'Nawrot B']","['ATP-Binding Cassette Transporters/*antagonists & inhibitors/metabolism', 'Antineoplastic Agents/chemical synthesis/chemistry/*pharmacology', 'Apoptosis/drug effects', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Dose-Response Relationship, Drug', 'Drug Screening Assays, Antitumor', 'Humans', 'Immunologic Factors/chemical synthesis/chemistry/*pharmacology', 'K562 Cells', 'Molecular Structure', 'Structure-Activity Relationship', 'Thalidomide/chemical synthesis/chemistry/*pharmacology', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/31487824/
2416,chlorphenamine,594118,"Physical parameters of chlorphenamine maleate suppositories and its release as a function of particle size, concentration and nature of the base.","['el-Din EN', 'Mursi NM', 'Elbary AA', 'Foda N']","['Chemistry, Pharmaceutical', '*Chlorpheniramine/analysis', 'Hardness', 'Ointment Bases', 'Particle Size', 'Solubility', 'Suppositories', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/594118/
2417,chlorphenamine,21175434,"Dextromethorphan, chlorphenamine and serotonin toxicity: case report and systematic literature review.","['Monte AA', 'Chuang R', 'Bodmer M']","['Antitussive Agents/*poisoning', 'Chlorpheniramine/*poisoning', 'Dextromethorphan/*poisoning', 'Drug Overdose', 'Humans', 'Male', 'Serotonin Agents/*poisoning', 'Suicide, Attempted', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21175434/
2418,chlorphenamine,7849134,"Experimental design for the rapid selection of separation conditions for methyl and propyl parahydroxybenzoate, phenylephrine hydrochloride and chlorphenamine maleate by ion-pair liquid chromatography.","['De Beer JO', 'Vandenbroucke CV', 'Massart DL']","['Analysis of Variance', 'Chlorpheniramine/chemistry/*isolation & purification', 'Chromatography, Liquid/*methods', 'Parabens/chemistry/*isolation & purification', 'Phenylephrine/chemistry/*isolation & purification', 'Regression Analysis']",https://pubmed.ncbi.nlm.nih.gov/7849134/
2419,chlorphenamine,39484821,Pharmacology of chlorphenamine and pseudoephedrine use in the common cold: a narrative review.,"['Douhard R', 'Humbert P', 'Milon JY', 'Pegahi R']","['Humans', '*Common Cold/drug therapy', '*Pseudoephedrine/adverse effects/therapeutic use/administration & dosage', '*Chlorpheniramine/therapeutic use/adverse effects', 'Pharmacovigilance', 'Nasal Decongestants/therapeutic use/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39484821/
2420,chlorphenamine,37848799,Chlorphenamine adsorption on commercial activated carbons: Effect of Operating Conditions and Surface Chemistry.,"['Martinez-Espinosa JA', 'Leyva-Ramos R', 'Medina DI', 'Aragon-Pina A', 'Villela-Martinez DE', 'Carrales-Alvarado DH']","['*Charcoal/chemistry', 'Adsorption', '*Chlorpheniramine', 'Hydrogen-Ion Concentration', 'Temperature', 'Surface Properties']",https://pubmed.ncbi.nlm.nih.gov/37848799/
2421,chlorphenamine,24254834,"Simultaneous quantitative analysis of dextromethorphan, dextrorphan and chlorphenamine in human plasma by liquid chromatography-electrospray tandem mass spectrometry.","['Ding Y', 'Huang K', 'Chen L', 'Yang J', 'Xu WY', 'Xu XJ', 'Duan R', 'Zhang J', 'He Q']","['Adult', 'Chlorpheniramine/*blood/chemistry/pharmacokinetics', 'Chromatography, High Pressure Liquid/*methods', 'Dextromethorphan/*blood/chemistry/pharmacokinetics', 'Dextrorphan/*blood/chemistry/pharmacokinetics', 'Drug Stability', 'Female', 'Humans', 'Least-Squares Analysis', 'Male', 'Reproducibility of Results', 'Sensitivity and Specificity', 'Spectrometry, Mass, Electrospray Ionization/methods', 'Tandem Mass Spectrometry/*methods', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24254834/
2422,chlorphenamine,11332874,Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally.,"['Van Toor BS', 'Buchwald A', 'Stengele E', 'Trenk D', 'Gercek C', 'de Mey CM']","['Administration, Intranasal', 'Administration, Oral', 'Adult', 'Area Under Curve', 'Biological Availability', 'Chlorpheniramine/administration & dosage/*pharmacokinetics', 'Cross-Over Studies', 'Half-Life', 'Histamine H1 Antagonists/administration & dosage/*pharmacokinetics', 'Humans', 'Male', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/11332874/
2423,chlorphenamine,24261438,"Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial.","['Picon PD', 'Costa MB', 'da Veiga Picon R', 'Fendt LC', 'Suksteris ML', 'Saccilotto IC', 'Dornelles AD', 'Schmidt LF']","['Acetaminophen/*administration & dosage', 'Adolescent', 'Adult', 'Chlorpheniramine/*administration & dosage', 'Common Cold/*drug therapy', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Humans', 'Male', 'Middle Aged', 'Phenylephrine/*administration & dosage', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24261438/
2424,chlorphenamine,12946529,"HPLC determination of aminophylline, methoxyphenamine hydrochloride, noscapine and chlorphenamine maleate in compound dosage forms with an aqueous-organic mobile phase.","['Yin C', 'Tang C', 'Wu X']","['Adrenergic beta-Agonists/*analysis', 'Aminophylline/*analysis', 'Antitussive Agents/*analysis', 'Bronchodilator Agents/*analysis', 'Capsules', 'Chlorpheniramine/*analysis', 'Chromatography, High Pressure Liquid', 'Drug Combinations', 'Indicators and Reagents', 'Methamphetamine/*analogs & derivatives/*analysis', 'Noscapine/*analysis', 'Reference Standards', 'Reproducibility of Results', 'Solutions', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/12946529/
2425,chlorphenamine,21899852,Coupling frontal elution paper chromatography with desorption corona beam ionization mass spectrometry for rapid analysis of chlorphenamine in herbal medicines and dietary supplements.,"['Huang YQ', 'You JQ', 'Zhang J', 'Sun W', 'Ding L', 'Feng YQ']","['Chlorpheniramine/*analysis', 'Chromatography, Liquid/*methods', 'Dietary Supplements/*analysis', 'Drugs, Chinese Herbal/*chemistry', 'Ethanol', 'Linear Models', 'Mass Spectrometry/*methods', 'Paper', 'Reproducibility of Results', 'Sensitivity and Specificity', 'Tablets/chemistry']",https://pubmed.ncbi.nlm.nih.gov/21899852/
2426,Megestrol,23543530,Megestrol acetate for treatment of anorexia-cachexia syndrome.,"['Ruiz Garcia V', 'Lopez-Briz E', 'Carbonell Sanchis R', 'Gonzalvez Perales JL', 'Bort-Marti S']","['Acquired Immunodeficiency Syndrome/complications', 'Anorexia/*drug therapy/etiology', 'Appetite Stimulants/adverse effects/*therapeutic use', 'Cachexia/*drug therapy/etiology', 'Humans', 'Megestrol Acetate/adverse effects/*therapeutic use', 'Neoplasms/complications', 'Randomized Controlled Trials as Topic', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/23543530/
2427,Megestrol,12357484,Adrenal insufficiency and testicular failure secondary to megestrol acetate therapy in a patient with cystic fibrosis.,"['McKone EF', 'Tonelli MR', 'Aitken ML']","['Adrenal Insufficiency/*chemically induced', 'Anorexia/drug therapy', 'Cystic Fibrosis/complications/*drug therapy/physiopathology', 'Humans', 'Male', 'Megestrol Acetate/*adverse effects', 'Middle Aged', 'Testicular Diseases/*chemically induced', 'Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/12357484/
2428,Megestrol,26776251,The Efficacy and Safety of Megestrol Acetate in Protein-Energy Wasting due to Chronic Kidney Disease: A Systematic Review.,"['Wazny LD', 'Nadurak S', 'Orsulak C', 'Giles-Smith L', 'Tangri N']","['Appetite', '*Appetite Stimulants', 'Body Weight', 'Humans', 'Megestrol Acetate/*adverse effects/*therapeutic use', 'Nutritional Status', 'Quality of Life', 'Renal Dialysis', 'Renal Insufficiency, Chronic/*complications/physiopathology', 'Serum Albumin/analysis', 'Treatment Outcome', 'Wasting Syndrome/*drug therapy/etiology', 'Weight Gain']",https://pubmed.ncbi.nlm.nih.gov/26776251/
2429,Megestrol,29400904,Clinical Inquiry: Is megestrol acetate safe and effective for malnourished nursing home residents?,"['Wen FK', 'Millar J', 'Oberst-Walsh L', 'Nashelsky J']","['Appetite Stimulants/*adverse effects', 'Humans', 'Malnutrition/*drug therapy', 'Megestrol Acetate/*adverse effects', '*Nursing Homes', 'Risk Factors', 'Venous Thrombosis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/29400904/
2430,Megestrol,7889638,Megestrol-induced Cushing's syndrome.,"['Steer KA', 'Kurtz AB', 'Honour JW']","['Adenocarcinoma/drug therapy', 'Adult', 'Cushing Syndrome/*chemically induced', 'Diabetes Mellitus, Type 1/complications', 'Female', 'Humans', 'Megestrol/*adverse effects', 'Uterine Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7889638/
2431,Megestrol,24456823,Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.,"['Fleming GF', 'Filiaci VL', 'Marzullo B', 'Zaino RJ', 'Davidson SA', 'Pearl M', 'Makker V', 'Burke JJ 2nd', 'Zweizig SL', 'Van Le L', 'Hanjani P', 'Downey G', 'Walker JL', 'Reyes HD', 'Leslie KK']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Disease-Free Survival', 'Drug Administration Schedule', 'Endometrial Neoplasms/*drug therapy/metabolism/pathology', 'Female', 'Humans', 'Immunohistochemistry', 'Megestrol Acetate/administration & dosage/adverse effects', 'Middle Aged', 'Neoplasm Metastasis', 'Neoplasm Recurrence, Local/drug therapy/metabolism/pathology', 'Sirolimus/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Tamoxifen/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/24456823/
2432,Megestrol,36333773,"Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.","['Zhao X', 'Niu J', 'Shi C', 'Liu Z']","['Female', 'Humans', 'Pregnancy', '*Endometrial Hyperplasia/drug therapy', '*Endometrial Neoplasms/drug therapy', '*Intrauterine Devices, Medicated/adverse effects', '*Levonorgestrel/adverse effects', 'Megestrol Acetate/therapeutic use', 'Metformin/therapeutic use', 'Obesity', 'Prospective Studies', 'Randomized Controlled Trials as Topic', '*Antineoplastic Combined Chemotherapy Protocols/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/36333773/
2433,Megestrol,7959340,Estrogen and progesterone receptor expression of decidual endometrium in a postmenopausal woman treated with tamoxifen and megestrol acetate.,"['Cohen I', 'Shulman A', 'Altaras M', 'Tepper R', 'Cordoba M', 'Beyth Y']","['Breast Neoplasms/drug therapy', 'Carcinoma, Ductal, Breast/drug therapy', 'Endometrium/*drug effects', 'Estrogens/agonists', 'Female', 'Humans', 'Megestrol/*analogs & derivatives/pharmacology/therapeutic use', 'Megestrol Acetate', 'Middle Aged', '*Postmenopause', 'Receptors, Estrogen/*drug effects', 'Receptors, Progesterone/*drug effects', 'Tamoxifen/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7959340/
2434,Megestrol,15579914,"Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids.","['Lofgren L', 'Wallberg B', 'Wilking N', 'Fornander T', 'Rutqvist LE', 'Carlstrom K', 'von Schoultz B', 'von Schoultz E']","['Aged', 'Antineoplastic Agents, Hormonal/administration & dosage/adverse effects/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/pathology', 'Chemotherapy, Adjuvant', 'Female', 'Humans', 'Insulin-Like Growth Factor I/analysis', 'Megestrol Acetate/administration & dosage/adverse effects/*therapeutic use', 'Middle Aged', 'Postmenopause', 'Prospective Studies', 'Sex Hormone-Binding Globulin/analysis', 'Tamoxifen/administration & dosage/adverse effects/*therapeutic use', 'Testosterone/blood']",https://pubmed.ncbi.nlm.nih.gov/15579914/
2435,Megestrol,9250225,Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature.,"['Mann M', 'Koller E', 'Murgo A', 'Malozowski S', 'Bacsanyi J', 'Leinung M']","['Adrenal Insufficiency/chemically induced', 'Antineoplastic Agents, Hormonal/*adverse effects', 'Appetite Stimulants/*adverse effects', 'Cushing Syndrome/chemically induced', 'Diabetes Mellitus/chemically induced', 'Glucocorticoids/*adverse effects', 'Humans', 'Megestrol/*adverse effects', 'Megestrol Acetate/adverse effects', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/9250225/
2436,Megestrol,31961463,Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.,"['Yang BY', 'Gulinazi Y', 'Du Y', 'Ning CC', 'Cheng YL', 'Shan WW', 'Luo XZ', 'Zhang HW', 'Zhu Q', 'Ma FH', 'Liu J', 'Sun L', 'Yu M', 'Guan J', 'Chen XJ']","['Adolescent', 'Adult', 'Antineoplastic Agents, Hormonal/*administration & dosage', 'China', 'Drug Therapy, Combination', 'Endometrial Hyperplasia/complications/*drug therapy', 'Endometrial Neoplasms/complications/*drug therapy', 'Female', 'Fertility Preservation/*methods', 'Humans', 'Megestrol Acetate/*administration & dosage', 'Metformin/*administration & dosage', 'Middle Aged', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31961463/
2437,Megestrol,12203099,Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate.,"['Matin K', 'Egorin MJ', 'Ballesteros MF', 'Smith DC', 'Lembersky B', 'Day RS', 'Johnson CS', 'Trump DL']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Male', 'Megestrol Acetate/administration & dosage/adverse effects/pharmacokinetics', 'Middle Aged', 'Neoplasms/*drug therapy', 'Pituitary-Adrenal System/drug effects', 'Vinblastine/administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/12203099/
2438,Megestrol,31451262,Ten years of Croatian national guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome - Evaluation of awareness and implementation among Croatian oncologists.,"['Krznaric Z', 'Juretic A', 'Domislovic V', 'Barisic A', 'Kekez D', 'Vranesic Bender D']","['Cachexia/*drug therapy', 'Eicosapentaenoic Acid/analogs & derivatives/*pharmacology', 'Humans', 'Megestrol Acetate/*pharmacology', 'Neoplasms/complications/*drug therapy', 'Nutritional Support/standards', 'Oncologists/*psychology', 'Surveys and Questionnaires', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/31451262/
2439,Megestrol,24167059,"A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy.","['Cuvelier GD', 'Baker TJ', 'Peddie EF', 'Casey LM', 'Lambert PJ', 'Distefano DS', 'Wardle MG', 'Mychajlunow BA', 'Romanick MA', 'Dix DB', 'Wilson BA']","['Adolescent', 'Adult', 'Appetite/*drug effects', 'Appetite Stimulants/*therapeutic use', 'Child', 'Child, Preschool', 'Double-Blind Method', 'Female', 'Follow-Up Studies', 'Humans', 'Infant', 'Male', 'Megestrol Acetate/*therapeutic use', 'Neoplasm Staging', 'Neoplasms/*complications/therapy', 'Nutrition Disorders/diagnosis/*drug therapy/etiology', 'Prognosis', 'Quality of Life', 'Weight Loss/*drug effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24167059/
2440,Megestrol,27016228,"Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.","['Myers AP', 'Filiaci VL', 'Zhang Y', 'Pearl M', 'Behbakht K', 'Makker V', 'Hanjani P', 'Zweizig S', 'Burke JJ 2nd', 'Downey G', 'Leslie KK', 'Van Hummelen P', 'Birrer MJ', 'Fleming GF']","['Class I Phosphatidylinositol 3-Kinases', 'Endometrial Neoplasms/drug therapy/*genetics/mortality', 'Female', 'Humans', 'Megestrol Acetate/*administration & dosage', '*Mutation', 'PTEN Phosphohydrolase/genetics', 'Phosphatidylinositol 3-Kinases/genetics', 'Prospective Studies', 'Proto-Oncogene Proteins c-akt/genetics', 'Sirolimus/administration & dosage/*analogs & derivatives/therapeutic use', 'Tamoxifen/*administration & dosage', 'Tuberous Sclerosis Complex 1 Protein', 'Tumor Suppressor Proteins/genetics']",https://pubmed.ncbi.nlm.nih.gov/27016228/
2441,Megestrol,11994348,Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial.,"['Lambert CP', 'Sullivan DH', 'Freeling SA', 'Lindquist DM', 'Evans WJ']","['Aged', 'Aging/*physiology', 'Body Composition/*drug effects', 'Drug Therapy, Combination', 'Gonadal Steroid Hormones/*therapeutic use', 'Humans', 'Male', 'Megestrol Acetate/*therapeutic use', 'Middle Aged', 'Muscle, Skeletal/physiology', 'Testosterone/*therapeutic use', 'Weight Gain/*drug effects', '*Weight Lifting']",https://pubmed.ncbi.nlm.nih.gov/11994348/
2442,Cinacalcet,37777840,Hypocalcemia and cardiovascular mortality in cinacalcet users.,"['Goto S', 'Hamano T', 'Fujii H', 'Taniguchi M', 'Abe M', 'Nitta K', 'Nishi S']","['Humans', 'Cinacalcet', '*Hypocalcemia/chemically induced', 'Calcium', 'Prospective Studies', 'Renal Dialysis/adverse effects', 'Parathyroid Hormone', '*Hyperparathyroidism, Secondary/etiology', 'Calcimimetic Agents', '*Heart Failure/etiology']",https://pubmed.ncbi.nlm.nih.gov/37777840/
2443,Cinacalcet,36848027,Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.,"['Bernardor J', 'De Mul A', 'Bacchetta J', 'Schmitt CP']","['Adult', 'Humans', 'Child', 'Cinacalcet/therapeutic use', 'Renal Dialysis', 'Calcium/therapeutic use', '*Chronic Kidney Disease-Mineral and Bone Disorder/drug therapy/complications', '*Cardiovascular Diseases', '*Hyperparathyroidism, Secondary/drug therapy/etiology', 'Calcimimetic Agents/therapeutic use', 'Parathyroid Hormone', 'Vitamin D/therapeutic use', '*Renal Insufficiency, Chronic/complications/therapy', 'Minerals', 'Phosphates/metabolism']",https://pubmed.ncbi.nlm.nih.gov/36848027/
2444,Cinacalcet,37459863,Spectrofluorometric determination of cinacalcet hydrochloride: greenness assessment and application to biological fluids andin-vitrodissolution testing.,"['Abo Zaid MH', 'El-Enany N', 'Mostafa AE', 'Hadad GM', 'Belal F']","['Humans', '*Tablets', 'Cinacalcet', 'Limit of Detection']",https://pubmed.ncbi.nlm.nih.gov/37459863/
2445,Cinacalcet,28630081,Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.,"['Moe SM', 'Wetherill L', 'Decker BS', 'Lai D', 'Abdalla S', 'Long J', 'Vatta M', 'Foroud TM', 'Chertow GM']","['Adult', 'Aged', 'Alkaline Phosphatase/blood', 'Biomarkers/blood', 'Black People/genetics', 'Calcimimetic Agents/adverse effects/*therapeutic use', 'Chronic Kidney Disease-Mineral and Bone Disorder/blood/*drug therapy/ethnology/genetics', 'Cinacalcet/adverse effects/*therapeutic use', 'Female', 'Fibroblast Growth Factor-23', 'Gene Frequency', 'Humans', 'Kidney Diseases/blood/ethnology/genetics/*therapy', 'Linkage Disequilibrium', 'Male', 'Middle Aged', 'Parathyroid Hormone/blood', 'Pharmacogenetics', '*Pharmacogenomic Variants', '*Polymorphism, Single Nucleotide', 'Receptors, Calcitriol/genetics', 'Receptors, Calcium-Sensing/*genetics', '*Renal Dialysis/adverse effects', 'Time Factors', 'Treatment Outcome', 'White People/genetics']",https://pubmed.ncbi.nlm.nih.gov/28630081/
2446,Cinacalcet,35041148,The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies.,"['Chandran M', 'Bilezikian JP', 'Lau J', 'Rajeev R', 'Yang SP', 'Samuel M', 'Parameswaran R']","['*Cinacalcet/adverse effects/therapeutic use', 'Humans', '*Hyperparathyroidism, Primary/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/35041148/
2447,Cinacalcet,30935461,Pharmacokinetics and pharmacodynamics of cinacalcet in patients with renal failure receiving hemodialysis and hemodiafiltration therapy .,"['Shi W', 'Tan X', 'Li Z', 'Zhang M', 'Huang B', 'Lu F', 'Jia J', 'Chen J', 'Zhong M']","['China', 'Cinacalcet/*pharmacokinetics', '*Hemodiafiltration', 'Humans', 'Parathyroid Hormone/blood', '*Renal Dialysis', 'Renal Insufficiency/*therapy', 'Tandem Mass Spectrometry']",https://pubmed.ncbi.nlm.nih.gov/30935461/
2448,Cinacalcet,35840839,"Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions.","['Kilford P', 'Khoshaein N', 'Southall R', 'Gardner I']","['Acetanilides/pharmacokinetics', 'Cinacalcet/pharmacokinetics', 'Computer Simulation', '*Cytochrome P-450 CYP2D6/metabolism', '*Cytochrome P-450 CYP2D6 Inhibitors/pharmacokinetics', 'Drug Interactions', 'Humans', 'Models, Biological', 'Nebivolol/pharmacokinetics', 'Thiazoles/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/35840839/
2449,Cinacalcet,28097356,Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.,"['Block GA', 'Bushinsky DA', 'Cheng S', 'Cunningham J', 'Dehmel B', 'Drueke TB', 'Ketteler M', 'Kewalramani R', 'Martin KJ', 'Moe SM', 'Patel UD', 'Silver J', 'Sun Y', 'Wang H', 'Chertow GM']","['Administration, Oral', 'Biomarkers/blood', 'Calcimimetic Agents/administration & dosage/adverse effects/*pharmacology', 'Calcium/administration & dosage/blood', 'Cinacalcet/administration & dosage/adverse effects/*pharmacology', 'Double-Blind Method', 'Female', 'Fibroblast Growth Factor-23', 'Fibroblast Growth Factors/blood', 'Humans', 'Hyperparathyroidism, Secondary/blood/*drug therapy/etiology', 'Infusions, Intravenous', 'Kidney Failure, Chronic/complications/therapy', 'Male', 'Middle Aged', 'Nausea/chemically induced', 'Parathyroid Hormone/*blood', 'Peptides/administration & dosage/adverse effects/*pharmacology', '*Renal Dialysis', 'Time Factors', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/28097356/
2450,Cinacalcet,25988877,The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet.,"['Lorenzoni V', 'Trieste L', 'Turchetti G']","['Adult', 'Chelating Agents/administration & dosage/economics/therapeutic use', 'Cinacalcet/administration & dosage/economics/*therapeutic use', 'Cost-Benefit Analysis', 'Ergocalciferols/administration & dosage/economics/*therapeutic use', 'Humans', 'Hyperparathyroidism, Secondary/*drug therapy/economics/etiology', 'Kidney Failure, Chronic/complications', 'Phosphates/metabolism', 'Vitamin D/administration & dosage/economics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25988877/
2451,Cinacalcet,36316798,"Evaluating the clinical and mechanistic effects of eplerenone and amiloride monotherapy, and combination therapy with cinacalcet, in primary hyperparathyroidism: A placebo-controlled randomized trial.","['Parksook WW', 'Heydarpour M', 'Brown JM', 'Turchin A', 'Mannstadt M', 'Vaidya A']","['Humans', 'Female', 'Male', 'Eplerenone/therapeutic use', 'Cinacalcet/pharmacology', '*Amiloride/therapeutic use', 'Aldosterone', 'Calcium', 'Renin', '*Hyperparathyroidism, Primary', 'Parathyroid Hormone']",https://pubmed.ncbi.nlm.nih.gov/36316798/
2452,Cinacalcet,33757437,A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism.,"['Eddington H', 'Chinnadurai R', 'Alderson H', 'Ibrahim ST', 'Chrysochou C', 'Green D', 'Erekosima I', 'Hutchison A', 'Bubtana A', 'Hegarty J', 'Kalra PA']","['Adult', 'Calcinosis/*prevention & control', 'Calcium-Regulating Hormones and Agents/adverse effects/*therapeutic use', 'Carotid Intima-Media Thickness', 'Cinacalcet/adverse effects/*therapeutic use', 'Heart Ventricles/anatomy & histology', 'Humans', 'Hyperparathyroidism, Secondary/*drug therapy/etiology', 'Kidney Failure, Chronic/blood/*complications/therapy', 'Middle Aged', 'Parathyroid Hormone/blood', 'Phosphates/blood', 'Prospective Studies', 'Renal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/33757437/
2453,Cinacalcet,37964112,Safety of cinacalcet in children and adolescents with chronic kidney disease-mineral bone disorder: systematic review and proportional meta-analysis of case series.,"['Zamoner SMS', 'Takase HM', 'Riyuzo MC', 'Caramori JCT', 'de Andrade LGM']","['Adolescent', 'Child', 'Child, Preschool', 'Humans', 'Infant', 'Infant, Newborn', '*Bone Diseases', 'Calcimimetic Agents/adverse effects', 'Calcium', '*Chronic Kidney Disease-Mineral and Bone Disorder/etiology/complications', 'Cinacalcet/adverse effects', '*Hyperparathyroidism, Secondary/drug therapy/etiology', '*Hypocalcemia/etiology', 'Minerals/therapeutic use', 'Parathyroid Hormone', 'Renal Dialysis/adverse effects', '*Renal Insufficiency, Chronic/therapy']",https://pubmed.ncbi.nlm.nih.gov/37964112/
2454,Cinacalcet,23548469,Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients.,"['Kilpatrick RD', 'Newsome BB', 'Zaun D', 'Liu J', 'Solid CA', 'Nieman K', 'St Peter WL']","['Adolescent', 'Adult', 'Aged', 'Calcium/blood', 'Cinacalcet', 'Female', 'Humans', 'Hyperparathyroidism, Secondary/blood/*drug therapy/etiology', 'Injections, Intravenous', 'Male', 'Middle Aged', 'Naphthalenes/*therapeutic use', 'Parathyroid Neoplasms/blood', 'Phosphorus/blood', '*Renal Dialysis', 'United States', 'Vitamin D/*administration & dosage', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/23548469/
2455,Cinacalcet,23121374,Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.,"['Chertow GM', 'Block GA', 'Correa-Rotter R', 'Drueke TB', 'Floege J', 'Goodman WG', 'Herzog CA', 'Kubo Y', 'London GM', 'Mahaffey KW', 'Mix TC', 'Moe SM', 'Trotman ML', 'Wheeler DC', 'Parfrey PS']","['Adult', 'Aged', 'Cardiovascular Diseases/etiology/mortality/*prevention & control', 'Cinacalcet', 'Female', 'Humans', 'Hyperparathyroidism, Secondary/*drug therapy/etiology', 'Hypocalcemia/chemically induced', 'Intention to Treat Analysis', 'Kidney Failure, Chronic/complications/*drug therapy/therapy', 'Male', 'Middle Aged', 'Naphthalenes/adverse effects/*therapeutic use', 'Odds Ratio', 'Parathyroid Hormone/blood', '*Renal Dialysis/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/23121374/
2456,Cinacalcet,29391567,"Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism.","['Evans M', 'Methven S', 'Gasparini A', 'Barany P', 'Birnie K', 'MacNeill S', 'May MT', 'Caskey FJ', 'Carrero JJ']","['Aged', 'Calcimimetic Agents/*adverse effects', 'Cardiovascular Diseases/chemically induced/epidemiology/*mortality', 'Cinacalcet/*adverse effects', 'Female', 'Fractures, Bone/chemically induced/epidemiology/*mortality', 'Humans', 'Hyperparathyroidism, Secondary/complications/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Renal Dialysis', 'Renal Insufficiency, Chronic/complications/*drug therapy/physiopathology', 'Sweden/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/29391567/
2457,Cinacalcet,38254024,"Comparative efficacy of sodium thiosulfate, bisphosphonates, and cinacalcet for the treatment of vascular calcification in patients with haemodialysis: a systematic review and network meta-analysis.","['He L', 'Li Y', 'Jin J', 'Cheng M', 'Bai Y', 'Xu J']","['Humans', '*Diphosphonates/therapeutic use', 'Cinacalcet/therapeutic use', 'Network Meta-Analysis', 'Calcium', '*Vascular Calcification/drug therapy', 'Randomized Controlled Trials as Topic', '*Thiosulfates']",https://pubmed.ncbi.nlm.nih.gov/38254024/
2458,Cinacalcet,34787825,A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride.,"['Nakamura H', 'Tokumoto M', 'Anayama M', 'Kurihara S', 'Makino Y', 'Tamura K', 'Nagasawa M']","['*Calcium/therapeutic use', 'Cinacalcet/therapeutic use', 'Humans', '*Hyperparathyroidism, Secondary/drug therapy/etiology', 'Parathyroid Hormone/therapeutic use', 'Peptides', 'Renal Dialysis/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34787825/
2459,Acitretin,28961283,Annular atrophic lichen planus responds to hydroxychloroquine and acitretin.,"['Eyler JT', 'Garib G', 'Thompson KR', 'Dahiya M', 'Swan JW']","['Acitretin/*therapeutic use', 'Aged', 'Dermatologic Agents/therapeutic use', 'Humans', 'Hydroxychloroquine/*therapeutic use', 'Lichen Planus/*drug therapy/pathology', 'Male', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28961283/
2460,Acitretin,32276295,Keratoacanthoma centrifugum marginatum associated with mechanical trauma: Response to acitretin-A case report and review of the literature.,"['Gavric G', 'Lekic B', 'Milinkovic Sreckovic M', 'Bosic M', 'Zivanovic D']","['*Acitretin/therapeutic use', 'Aged', 'Cicatrix', 'Female', 'Humans', '*Keratoacanthoma/diagnosis/drug therapy', 'Leg', 'Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/32276295/
2461,Acitretin,38734848,Plexin B2 tissue expression and related gene polymorphisms in psoriasis and their relation to NB-UVB and Acitretin therapy.,"['Hegazy EM', 'Taieb MAE', 'Hassan MH', 'Ibrahim AK', 'El-Din EA', 'Ibrahim HM']","['Humans', '*Psoriasis/genetics/drug therapy/diagnosis', 'Male', 'Female', 'Adult', '*Nerve Tissue Proteins/genetics', 'Middle Aged', '*Severity of Illness Index', '*Acitretin/therapeutic use/administration & dosage', 'Ultraviolet Therapy/methods', 'Single-Blind Method', 'Polymorphism, Single Nucleotide', 'Young Adult', 'Skin/pathology/metabolism/drug effects', 'Receptors, Immunologic/genetics', 'Treatment Outcome', 'Receptors, Cell Surface/genetics/metabolism', 'Keratolytic Agents/therapeutic use/administration & dosage', 'Combined Modality Therapy']",https://pubmed.ncbi.nlm.nih.gov/38734848/
2462,Acitretin,8435906,Acitretin and etretinate. How and when they should be used.,"['Geiger JM', 'Saurat JH']","['Acitretin/pharmacology/*therapeutic use', 'Algorithms', 'Clinical Protocols', 'Drug Interactions', 'Drug Therapy, Combination', 'Etretinate/pharmacology/*therapeutic use', 'Humans', 'Mucous Membrane/drug effects', 'PUVA Therapy', 'Skin/drug effects', 'Skin Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8435906/
2463,Acitretin,30712052,D-penicillamine-induced pseudo-pseudoxanthoma elasticum and extensive elastosis perforans serpiginosa with excellent response to acitretin.,"['Chisti MA', 'Binamer Y', 'Alfadley A', 'Almutawa A']","['Acitretin/*therapeutic use', 'Adult', 'Hepatolenticular Degeneration/drug therapy', 'Humans', 'Keratolytic Agents/*therapeutic use', 'Male', 'Penicillamine/*adverse effects', 'Pseudoxanthoma Elasticum/chemically induced/*drug therapy', 'Skin Diseases/chemically induced/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30712052/
2464,Acitretin,21611678,Acitretin revisited.,"['Lynde CW', 'Kraft JN', 'Lynde CB']","['Acitretin/pharmacology/*therapeutic use', 'Humans', 'Keratolytic Agents/pharmacology/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Skin Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21611678/
2465,Acitretin,27828646,Primary localized cutaneous amyloidosis with lichen and poikiloderma-like lesions and an excellent response to systemic acitretin.,"['Ma H', 'Su X', 'Zhu G', 'Yin S', 'Lu C', 'Lai W']","['Acitretin/*therapeutic use', 'Amyloidosis, Familial/complications/diagnosis/*drug therapy', 'Female', 'Humans', 'Keratolytic Agents/*therapeutic use', 'Lichenoid Eruptions/complications/drug therapy', 'Skin Diseases, Genetic/complications/diagnosis/*drug therapy', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27828646/
2466,Acitretin,10523731,Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine.,"['Roeder C', 'Driesch PV']","['Acitretin/*therapeutic use', 'Azathioprine/*therapeutic use', 'Dermatitis, Exfoliative/drug therapy/pathology', 'Drug Therapy, Combination', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Keratolytic Agents/*therapeutic use', 'Male', 'Middle Aged', 'Pemphigoid, Bullous/drug therapy/pathology', 'Psoriasis/drug therapy/pathology', 'Skin/*drug effects/pathology', 'Skin Diseases/*drug therapy/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10523731/
2467,Acitretin,29704247,Clinical and molecular characterization and response to acitretin in three families with Sjogren-Larsson syndrome.,"['Vural S', 'Vural A', 'Akcimen F', 'Bagci IS', 'Tunca C', 'Gundogdu Eken A', 'Ruzicka T', 'Basak AN']","['Acitretin/*therapeutic use', 'Adolescent', 'Aldehyde Oxidoreductases/genetics', 'Child', 'Child, Preschool', 'DNA Mutational Analysis', 'Exome', 'Female', 'Humans', 'Ichthyosis, Lamellar/*drug therapy/genetics', 'Keratolytic Agents/*therapeutic use', 'Magnetic Resonance Imaging', 'Male', 'Musculoskeletal Abnormalities/genetics', 'Neuroimaging', 'Paraparesis, Spastic/genetics', 'Pedigree', 'Quality of Life', 'Sjogren-Larsson Syndrome/diagnostic imaging/*drug therapy/*genetics']",https://pubmed.ncbi.nlm.nih.gov/29704247/
2468,Acitretin,37906397,Use of Acitretin Among Girls and Women of Childbearing Age and Occurrence of Acitretin-Exposed Pregnancies in Germany.,"['Reinold J', 'Kollhorst B', 'Temme HL', 'Wentzell N', 'Haug U']","['Pregnancy', 'Child', 'Humans', 'Female', '*Acitretin/adverse effects', '*Abnormalities, Drug-Induced/epidemiology/etiology/drug therapy', 'Germany/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/37906397/
2469,Acitretin,36763783,"Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.","['Alabas OA', 'Mason KJ', 'Yiu ZZN', 'Hampton PJ', 'Reynolds NJ', 'Owen CM', 'Bewley A', 'Laws PM', 'Warren RB', 'Lunt M', 'Smith CH', 'Grif fi ths CEM']","['Humans', 'Male', 'Methotrexate/therapeutic use', 'Acitretin/adverse effects', 'Cyclosporine/therapeutic use', 'Cohort Studies', 'Prospective Studies', 'Fumarates/adverse effects', '*Dermatologic Agents/adverse effects', '*Psoriasis/drug therapy/chemically induced', 'Biological Factors/therapeutic use', 'Immunologic Factors/therapeutic use', 'Adjuvants, Immunologic/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36763783/
2470,Acitretin,12125942,Vascular variant of keratosis lichenoides chronica associated with hypothyroidism and response to tacalcitol and acitretin.,"['Nijsten T', 'Mentens G', 'Lambert J']","['Acitretin/*administration & dosage', 'Chronic Disease', 'Dermatologic Agents/*administration & dosage', 'Dihydroxycholecalciferols/*administration & dosage', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypothyroidism/*complications', 'Keratolytic Agents/*administration & dosage', 'Keratosis/complications/drug therapy/*pathology', 'Lichenoid Eruptions/complications/drug therapy/*pathology', 'Middle Aged', 'Skin Diseases, Vascular/complications/drug therapy/*pathology']",https://pubmed.ncbi.nlm.nih.gov/12125942/
2471,Acitretin,8731684,Coexistence of palmoplantar lichen planus and lupus erythematosus with response to treatment using acitretin.,"['De Jong EM', 'Van De Kerkhof PC']","['Acitretin/*therapeutic use', 'Foot Dermatoses/complications/drug therapy', 'Hand Dermatoses/complications/drug therapy', 'Humans', 'Keratolytic Agents/*therapeutic use', 'Lichen Planus/*complications/*drug therapy', 'Lupus Erythematosus, Cutaneous/*complications/therapy', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/8731684/
2472,Acitretin,21455552,Depression and acitretin: a true association or a class labeling?,"['Hayes J', 'Koo J']","['Acitretin/*adverse effects/therapeutic use', 'Depression/*chemically induced/etiology', 'Dermatologic Agents/*adverse effects/therapeutic use', '*Drug Labeling', 'Humans', 'Isotretinoin/adverse effects/therapeutic use', 'Mood Disorders/chemically induced/etiology', 'Psoriasis/drug therapy', 'Suicidal Ideation', 'Suicide', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/21455552/
2473,Acitretin,24601982,Acitretin in psoriasis: an evolving scenario.,"['Dogra S', 'Yadav S']","['Acitretin/*therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Psoriasis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24601982/
2474,Acitretin,8864375,Acrodermatitis continua of Hallopeau: response to combined treatment with acitretin and calcipotriol ointment.,"['Kuijpers AL', 'van Dooren-Greebe RJ', 'van de Kerkhof PC']","['Acitretin/*therapeutic use', 'Acrodermatitis/*drug therapy/immunology', 'Aged', 'Calcitriol/administration & dosage/*analogs & derivatives/therapeutic use', 'Dermatologic Agents/administration & dosage/*therapeutic use', 'Drug Synergism', 'Drug Therapy, Combination', 'Female', 'Humans', 'Neutrophils/drug effects', 'Ointments']",https://pubmed.ncbi.nlm.nih.gov/8864375/
2475,Acitretin,31281982,Adipocyte Fatty Acid-Binding Protein as a Novel Marker of Psoriasis and Clinical Response to Acitretin.,"['Baran A', 'Kiluk P', 'Swiderska M', 'Maciaszek M', 'Mysliwiec H', 'Flisiak I']","['Acitretin/pharmacology/*therapeutic use', 'Adipocytes/*chemistry/metabolism', 'Adult', 'Biomarkers/blood', 'Body Mass Index', 'Fatty Acid-Binding Proteins/*blood', 'Female', 'Humans', 'Inflammation/blood', 'Male', 'Middle Aged', 'Psoriasis/*blood/*drug therapy/metabolism', 'Risk Factors', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/31281982/
2476,Lidocaine,29536530,The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders.,"['Berk T', 'Silberstein SD']","['Anesthetics/administration & dosage/metabolism/pharmacokinetics/*pharmacology', 'Headache Disorders/*drug therapy', 'Humans', 'Lidocaine/administration & dosage/metabolism/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29536530/
2477,Lidocaine,3443650,High-performance liquid chromatography of lidocaine and nine of its metabolites in human plasma and urine.,"['Tam YK', 'Tawfik SR', 'Ke J', 'Coutts RT', 'Gray MR', 'Wyse DG']","['Acetylation', 'Biotransformation', 'Chromatography, High Pressure Liquid', 'Humans', 'Indicators and Reagents', 'Lidocaine/*analysis/blood/urine', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/3443650/
2478,Lidocaine,35569627,Exploiting hydrogen bonding to enhance lidocaine loading and stability in a poly ethylene-co-vinyl acetate carrier matrix.,"['Agarwal P', 'Nieuwoudt MK', 'Li S', 'Procter G', 'Andrews GP', 'Jones DS', 'Svirskis D']","['Ethylenes', '*Excipients/chemistry', 'Hydrogen Bonding', '*Lidocaine', 'Myristic Acid', 'Polymers/chemistry', 'Vinyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/35569627/
2479,Lidocaine,3992772,Plasma concentrations of lidocaine resulting from instillation of lidocaine jelly into genitourinary tract prior to cystoscopy.,"['Ouellette RD', 'Blute R Sr', 'Jaffee S', 'Bahde C']","['Adult', 'Aged', '*Cystoscopy', 'Female', 'Humans', 'Lidocaine/administration & dosage/*blood', 'Male', 'Middle Aged', '*Urogenital System']",https://pubmed.ncbi.nlm.nih.gov/3992772/
2480,Lidocaine,26671412,"Chromatographic Determination of Aminoacridine Hydrochloride, Lidocaine Hydrochloride and Lidocaine Toxic Impurity in Oral Gel.","['Bebawy LI', 'Elghobashy MR', 'Abbas SS', 'Shokry RF']","['Administration, Oral', 'Aminacrine/*analysis', 'Chromatography, High Pressure Liquid', '*Drug Contamination', 'Gels', 'Lidocaine/administration & dosage/*analysis/chemistry', 'Pharmaceutical Preparations']",https://pubmed.ncbi.nlm.nih.gov/26671412/
2481,Lidocaine,15277825,Pharmacokinetics and safety of lidocaine and monoethylglycinexylidide in liposuction: a microdialysis study.,"['Kenkel JM', 'Lipschitz AH', 'Shepherd G', 'Armstrong VW', 'Streit F', 'Oellerich M', 'Luby M', 'Rohrich RJ', 'Brown SA']","['Adipose Tissue/metabolism', 'Adult', 'Anesthetics, Local/administration & dosage/*pharmacokinetics/toxicity', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Lidocaine/administration & dosage/*analogs & derivatives/*pharmacokinetics/toxicity', '*Lipectomy', 'Metabolic Clearance Rate/physiology', '*Microdialysis', 'Postoperative Period', 'Risk Assessment']",https://pubmed.ncbi.nlm.nih.gov/15277825/
2482,Lidocaine,4067534,Concentrations of lidocaine and monoethylglycylxylidide (MEGX) in lidocaine associated deaths.,"['Peat MA', 'Deyman ME', 'Crouch DJ', 'Margot P', 'Finkle BS']","['Autopsy', 'Humans', 'Lidocaine/*analogs & derivatives/*metabolism/*poisoning', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/4067534/
2483,Lidocaine,27720093,Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes.,"['Houlihan S', 'Decarie D', 'Benes C', 'Cleve R', 'Vidler M', 'Magee LA', 'Ensom MHH', 'von Dadelszen P']","['Drug Stability', 'Hot Temperature', 'Lidocaine/*analysis/*chemistry', 'Magnesium Sulfate/*analysis/*chemistry', 'Syringes']",https://pubmed.ncbi.nlm.nih.gov/27720093/
2484,Lidocaine,2055080,Endotracheal and endobronchial lidocaine administration: effects on plasma lidocaine concentration and blood gases.,"['Prengel AW', 'Lindner KH', 'Hahnel J', 'Ahnefeld FW']","['Adult', 'Blood Gas Analysis', '*Bronchi', 'Chromatography, High Pressure Liquid', 'Female', 'Humans', '*Instillation, Drug', '*Intubation, Intratracheal', 'Lidocaine/*administration & dosage/blood/pharmacokinetics', 'Middle Aged', '*Trachea']",https://pubmed.ncbi.nlm.nih.gov/2055080/
2485,Lidocaine,2068827,Lidocaine absorption and metabolism after oropharyngeal application in young and young-elderly adults.,"['Watson WA', 'Sands MF', 'Barlow JC', 'Lener ME', 'Wilton JH']","['Absorption', 'Adult', 'Age Factors', 'Aged', 'Dosage Forms', 'Gels', 'Humans', 'Lidocaine/administration & dosage/analogs & derivatives/blood/*pharmacokinetics', 'Middle Aged', 'Oropharynx/metabolism', 'Sputum/chemistry', 'Vocal Cords/metabolism']",https://pubmed.ncbi.nlm.nih.gov/2068827/
2486,Lidocaine,17358099,"Effects of esmolol, lidocaine and fentanyl on haemodynamic responses to endotracheal intubation: a comparative study.","['Ugur B', 'Ogurlu M', 'Gezer E', 'Nuri Aydin O', 'Gursoy F']","['Blood Pressure/*drug effects', 'Double-Blind Method', 'Fentanyl/*pharmacology', 'Heart Rate/*drug effects', 'Humans', '*Intubation, Intratracheal', 'Lidocaine/*pharmacology', 'Propanolamines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/17358099/
2487,Lidocaine,7175699,Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man.,"['Bennett PN', 'Aarons LJ', 'Bending MR', 'Steiner JA', 'Rowland M']","['Administration, Oral', 'Adult', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Injections, Intravenous', 'Kinetics', 'Lidocaine/administration & dosage/*analogs & derivatives/*metabolism', 'Male', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7175699/
2488,Lidocaine,1441877,Lidocaine hydrocarbonate and lidocaine hydrochloride for cesarean section: transplacental passage and neonatal effects.,"['Guay J', 'Gaudreault P', 'Boulanger A', 'Tang A', 'Lortie L', 'Dupuis C']","['Adaptation, Physiological/drug effects', 'Adult', '*Anesthesia, Epidural', '*Anesthesia, Obstetrical', 'Apgar Score', '*Cesarean Section', 'Female', 'Fetal Blood/chemistry', 'Fetus/*drug effects', 'Heart Rate, Fetal/drug effects', 'Humans', 'Infant, Newborn', 'Lidocaine/administration & dosage/blood/metabolism/*pharmacology', '*Maternal-Fetal Exchange', 'Neurophysiology', 'Placenta/*metabolism', 'Pregnancy', 'Reflex/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1441877/
2489,Lidocaine,3354875,Effects of aerosolized and/or intravenous lidocaine on hemodynamic responses to laryngoscopy and intubation in outpatients.,"['Laurito CE', 'Baughman VL', 'Becker GL', 'Polek WV', 'Riegler FX', 'VadeBoncouer TR']","['Aerosols', 'Ambulatory Surgical Procedures', 'Double-Blind Method', 'Hemodynamics/*drug effects', 'Humans', 'Injections, Intravenous', '*Intubation, Intratracheal', '*Laryngoscopy', 'Lidocaine/*administration & dosage/pharmacology', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3354875/
2490,Lidocaine,29496229,Intravenous lidocaine infusion.,"['Soto G', 'Naranjo Gonzalez M', 'Calero F']","['*Anesthesia', 'Anesthetics, Local/*administration & dosage/pharmacology', 'Chronic Pain/prevention & control', 'Humans', 'Infusions, Intravenous', 'Lidocaine/*administration & dosage/pharmacology', 'Neoplasm Recurrence, Local/prevention & control', 'Pain, Postoperative/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/29496229/
2491,Dofetilide,25634399,"Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.","['Jaiswal A', 'Goldbarg S']","['Anti-Arrhythmia Agents/*adverse effects', 'Electrocardiography', 'Humans', 'Phenethylamines/*adverse effects', 'Risk Factors', 'Sulfonamides/*adverse effects', 'Torsades de Pointes/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25634399/
2492,Dofetilide,27261832,"Dofetilide: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias.","['Shenasa F', 'Shenasa M']","['*Anti-Arrhythmia Agents', 'Arrhythmias, Cardiac/*drug therapy', 'Humans', '*Phenethylamines', '*Sulfonamides']",https://pubmed.ncbi.nlm.nih.gov/27261832/
2493,Dofetilide,29450893,Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review.,"['Moore JC', 'Trager L', 'Anzia LE', 'Saliba W', 'Bassiouny M', 'Bhargava M', 'Chung M', 'Desai M', 'Garberich R', 'Lever H', 'Lindsay BD', 'Sengupta J', 'Tchou P', 'Wazni O', 'Wilkoff BL']","['Anti-Arrhythmia Agents/*therapeutic use', 'Atrial Fibrillation/complications/*drug therapy', 'Cardiomyopathy, Hypertrophic/complications/*drug therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Phenethylamines/*therapeutic use', 'Retrospective Studies', 'Sulfonamides/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29450893/
2494,Dofetilide,11698075,[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.,"['Finlayson K', 'Turnbull L', 'January CT', 'Sharkey J', 'Kelly JS']","['Anti-Arrhythmia Agents/*metabolism', 'Benzimidazoles/pharmacology', 'Binding, Competitive', '*Cation Transport Proteins', 'Cell Line', 'Cell Membrane/*metabolism', '*DNA-Binding Proteins', 'Drug Evaluation, Preclinical/methods', 'ERG1 Potassium Channel', 'Electrocardiography', 'Ether-A-Go-Go Potassium Channels', 'Haloperidol/pharmacology', 'Humans', 'Patch-Clamp Techniques', 'Phenethylamines/*metabolism', 'Pimozide/pharmacology', 'Potassium Channel Blockers', 'Potassium Channels/genetics/*metabolism', '*Potassium Channels, Voltage-Gated', 'Quaternary Ammonium Compounds/pharmacology', 'Sulfanilamides/pharmacology', 'Sulfonamides/*metabolism', 'Terfenadine/pharmacology', '*Trans-Activators', 'Transcriptional Regulator ERG', 'Transfection', 'Tritium']",https://pubmed.ncbi.nlm.nih.gov/11698075/
2495,Dofetilide,35976119,Dofetilide Dose Reductions and Discontinuation in Obese Compared with Nonobese Patients.,"['Anderson K', 'Greenlee K', 'Matteo M', 'Wilkoff B']","['Humans', 'Female', '*Drug Tapering', '*Obesity/diagnosis', 'Body Weight']",https://pubmed.ncbi.nlm.nih.gov/35976119/
2496,Dofetilide,33736527,Safety of Inpatient Dofetilide Initiation per Cardiology Services: A Retrospective Review.,"['Cicirale C', 'Jackson J', 'Gothard D']","['Anti-Arrhythmia Agents/adverse effects', '*Atrial Fibrillation/drug therapy', '*Cardiology', '*Heart Arrest/chemically induced/epidemiology', 'Humans', 'Inpatients', 'Phenethylamines', 'Retrospective Studies', 'Sulfonamides']",https://pubmed.ncbi.nlm.nih.gov/33736527/
2497,Dofetilide,17588691,Late dofetilide-associated life-threatening proarrhythmia.,"['Kolb C', 'Ndrepepa G', 'Zrenner B']","['Anti-Arrhythmia Agents/*adverse effects', 'Atrial Fibrillation/*therapy', 'Defibrillators, Implantable/*adverse effects', 'Electrocardiography', 'Humans', 'Male', 'Middle Aged', 'Phenethylamines/*adverse effects', 'Sulfonamides/*adverse effects', 'Tachycardia, Ventricular/*chemically induced', 'Ventricular Fibrillation/*etiology']",https://pubmed.ncbi.nlm.nih.gov/17588691/
2498,Dofetilide,29940780,A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?,"['Wolbrette DL', 'Hussain S', 'Maraj I', 'Naccarelli GV']","['Anti-Arrhythmia Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Atrial Fibrillation/diagnosis/*drug therapy/mortality/physiopathology', 'Atrial Flutter/diagnosis/*drug therapy/mortality/physiopathology', 'Clinical Decision-Making', 'Heart Conduction System/*drug effects/physiopathology', 'Heart Rate/*drug effects', 'Humans', 'Patient Selection', 'Phenethylamines/adverse effects/pharmacokinetics/*therapeutic use', 'Potassium Channel Blockers/adverse effects/pharmacokinetics/*therapeutic use', 'Risk Factors', 'Sulfonamides/adverse effects/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29940780/
2499,Dofetilide,25453194,QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation.,"['Chung EH', 'Guise KD']","['Anti-Arrhythmia Agents/therapeutic use', 'Atrial Fibrillation/*diagnosis/*drug therapy', 'Electrocardiography/drug effects/*instrumentation', 'Equipment Design', 'Equipment Failure Analysis', 'Humans', '*Mobile Applications', 'Phenethylamines/*therapeutic use', 'Reproducibility of Results', 'Sensitivity and Specificity', '*Smartphone', 'Sulfonamides/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25453194/
2500,Dofetilide,32347108,Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.,"['Ting C', 'Malloy R', 'Knowles D']","['*Academic Medical Centers', 'Aged', 'Anti-Arrhythmia Agents/*administration & dosage/adverse effects', 'Atrial Fibrillation/diagnosis/*drug therapy/physiopathology', 'Boston', '*Drug Dosage Calculations', 'Drug Monitoring', 'Female', 'Heart Rate/*drug effects', 'Humans', 'Long QT Syndrome/chemically induced/physiopathology', 'Male', 'Middle Aged', 'Phenethylamines/*administration & dosage/adverse effects', ""Practice Patterns, Physicians'"", 'Retrospective Studies', 'Risk Assessment', 'Risk Factors', 'Sotalol/*administration & dosage/adverse effects', 'Sulfonamides/*administration & dosage/adverse effects', 'Torsades de Pointes/chemically induced/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/32347108/
2501,Dofetilide,33812835,Comparative Efficacy of Dofetilide Versus Amiodarone in Patients With Atrial Fibrillation.,"['Shantha G', 'Chugh A', 'Crawford T', 'Latchamsetty R', 'Ghanbari H', 'Ghannam M', 'Liang J', 'Batul A', 'Chung E', 'Saeed M', 'Cunnane R', 'Jongnarangsin K', 'Bogun F', 'Pelosi F Jr', 'Morady F', 'Oral H']","['Aged', 'Aged, 80 and over', '*Amiodarone/adverse effects', 'Anti-Arrhythmia Agents/adverse effects', '*Atrial Fibrillation/drug therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Phenethylamines', 'Stroke Volume', 'Sulfonamides', 'Ventricular Function, Left']",https://pubmed.ncbi.nlm.nih.gov/33812835/
2502,Dofetilide,34894807,Refractory Torsades de Pointes Due to Dofetilide Overdose.,"['Crosby J', 'Bhopalwala H', 'Kharawala A', 'Dewaswala N', 'Ganti SS', 'Bhopalwala A']","['Female', 'Humans', 'Middle Aged', 'Phenethylamines', 'Sulfonamides/adverse effects', '*Torsades de Pointes/chemically induced/therapy']",https://pubmed.ncbi.nlm.nih.gov/34894807/
2503,Dofetilide,33484394,Outpatient initiation of dofetilide: insights from the complexities of atrial fibrillation management during the COVID-19 lockdown.,"['Mascarenhas DAN', 'Mudumbi PC', 'Kantharia BK']","['Adult', 'Aged', 'Aged, 80 and over', 'Anti-Arrhythmia Agents/therapeutic use', '*Atrial Fibrillation/drug therapy', '*COVID-19', 'Communicable Disease Control', 'Female', 'Humans', 'Outpatients', 'Phenethylamines', 'SARS-CoV-2', 'Sulfonamides']",https://pubmed.ncbi.nlm.nih.gov/33484394/
2504,Dofetilide,8269312,"Sequential bilateral bundle branch block during dofetilide, a new class III antiarrhythmic agent, in a patient with atrial fibrillation.","['Crijns HJ', 'Kingma JH', 'Gosselink AT', 'Dalrymple HW', 'De Langen CD', 'Lie K']","['Adult', 'Anti-Arrhythmia Agents/*adverse effects', 'Atrial Fibrillation/*drug therapy/physiopathology', 'Bundle-Branch Block/*chemically induced', 'Electrocardiography', 'Heart Conduction System/drug effects', 'Humans', 'Male', 'Phenethylamines/*adverse effects', 'Sulfonamides/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8269312/
2505,Dofetilide,11326815,Dofetilide (Tikosyn): a new drug to control atrial fibrillation.,['Saliba WI'],"['Anti-Arrhythmia Agents/*pharmacology/therapeutic use', 'Atrial Fibrillation/*drug therapy', 'Drug Interactions', 'Humans', 'Patient Selection', 'Phenethylamines/*pharmacology/therapeutic use', '*Potassium Channel Blockers', 'Sulfonamides/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11326815/
2506,Dofetilide,29038104,Safety of Oral Dofetilide Reloading for Treatment of Atrial Arrhythmias.,"['Cho JH', 'Youn SJ', 'Moore JC', 'Kyriakakis R', 'Vekstein C', 'Militello M', 'Poe SM', 'Wolski K', 'Tchou PJ', 'Varma N', 'Niebauer MJ', 'Bhargava M', 'Saliba WI', 'Wazni OM', 'Lindsay BD', 'Wilkoff BL', 'Chung MK']","['Administration, Oral', 'Aged', 'Aged, 80 and over', 'Anti-Arrhythmia Agents/*administration & dosage/adverse effects', 'Arrhythmias, Cardiac/diagnosis/*drug therapy/physiopathology', 'Drug Administration Schedule', 'Drug Dosage Calculations', 'Electrocardiography, Ambulatory', 'Female', 'Heart Atria/drug effects/physiopathology', 'Heart Rate/*drug effects', 'Humans', 'Male', 'Medical Records', 'Middle Aged', 'Patient Admission', 'Phenethylamines/*administration & dosage/adverse effects', 'Predictive Value of Tests', 'Retrospective Studies', 'Risk Factors', 'Sulfonamides/*administration & dosage/adverse effects', 'Time Factors', 'Torsades de Pointes/chemically induced/diagnosis/physiopathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29038104/
2507,Dofetilide,29573040,F463L increases the potential of dofetilide on human ether-a-go-go-related gene (hERG) channels.,"['Cheng G', 'Wu J', 'Han W', 'Sun C']","['Cell Line', 'Ether-A-Go-Go Potassium Channels/*genetics/*metabolism', 'HEK293 Cells', 'Humans', 'Long QT Syndrome/*genetics', 'Microscopy, Confocal', 'Mutation/genetics', 'Patch-Clamp Techniques', 'Phenethylamines/*pharmacology', 'Plasmids/genetics', 'Potassium Channel Blockers/*pharmacology', 'Sulfonamides/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29573040/
2508,Dofetilide,28233630,Practice variation in the re-initiation of dofetilide: An observational study.,"['Turagam MK', 'Afzal MR', 'Reddy M', 'Pillarisetti J', 'Lavu M', 'Atkins D', 'Jeffrey C', 'Christensen K', 'Pimentel R', 'Dendi R', 'Vacek J', 'Hurwitz J', 'Di Biase L', 'Natale A', 'Lakkireddy D']","['Anti-Arrhythmia Agents/*therapeutic use', 'Atrial Fibrillation/diagnosis/*drug therapy', 'Cardiologists/*standards', 'Humans', 'Phenethylamines/*therapeutic use', 'Practice Guidelines as Topic/*standards', 'Sulfonamides/*therapeutic use', 'Surveys and Questionnaires', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28233630/
2509,miglustat,14609352,Miglustat.,"['McCormack PL', 'Goa KL']","['Clinical Trials as Topic', 'Gaucher Disease/*drug therapy', 'Glucosylceramidase/pharmacokinetics/pharmacology/*therapeutic use', 'Glucosyltransferases/*antagonists & inhibitors', 'Humans', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/14609352/
2510,miglustat,34800400,"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.","['Schoser B', 'Roberts M', 'Byrne BJ', 'Sitaraman S', 'Jiang H', 'Laforet P', 'Toscano A', 'Castelli J', 'Diaz-Manera J', 'Goldman M', 'van der Ploeg AT', 'Bratkovic D', 'Kuchipudi S', 'Mozaffar T', 'Kishnani PS']","['1-Deoxynojirimycin/analogs & derivatives', 'Adolescent', 'Double-Blind Method', '*Glycogen Storage Disease Type II/chemically induced/drug therapy', 'Humans', 'Treatment Outcome', 'alpha-Glucosidases/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34800400/
2511,miglustat,30111334,Miglustat in Niemann-Pick disease type C patients: a review.,"['Pineda M', 'Walterfang M', 'Patterson MC']","['1-Deoxynojirimycin/analogs & derivatives/therapeutic use', 'Biomarkers/metabolism', 'Enzyme Inhibitors/therapeutic use', 'Humans', 'Niemann-Pick Disease, Type C/*drug therapy/metabolism/mortality/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30111334/
2512,miglustat,38418563,104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).,"['Schoser B', 'Kishnani PS', 'Bratkovic D', 'Byrne BJ', 'Claeys KG', 'Diaz-Manera J', 'Laforet P', 'Roberts M', 'Toscano A', 'van der Ploeg AT', 'Castelli J', 'Goldman M', 'Holdbrook F', 'Sitaraman Das S', 'Wasfi Y', 'Mozaffar T']","['Humans', 'Male', 'Female', '*Glycogen Storage Disease Type II/drug therapy', 'Middle Aged', 'Adult', '*1-Deoxynojirimycin/*analogs & derivatives/administration & dosage/adverse effects/therapeutic use', 'Double-Blind Method', '*Enzyme Replacement Therapy/methods', 'alpha-Glucosidases/adverse effects/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Treatment Outcome', 'Aged', 'Enzyme Inhibitors/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38418563/
2513,miglustat,38057636,Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).,"['Byrne BJ', 'Schoser B', 'Kishnani PS', 'Bratkovic D', 'Clemens PR', 'Goker-Alpan O', 'Ming X', 'Roberts M', 'Vorgerd M', 'Sivakumar K', 'van der Ploeg AT', 'Goldman M', 'Wright J', 'Holdbrook F', 'Jain V', 'Benjamin ER', 'Johnson F', 'Das SS', 'Wasfi Y', 'Mozaffar T']","['Adult', 'Humans', '*Glycogen Storage Disease Type II/therapy', 'Treatment Outcome', 'alpha-Glucosidases/therapeutic use', 'Indoles', 'Enzyme Replacement Therapy/methods', '*Propionates', '1-Deoxynojirimycin/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/38057636/
2514,miglustat,16247743,Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.,"['Weinreb NJ', 'Barranger JA', 'Charrow J', 'Grabowski GA', 'Mankin HJ', 'Mistry P']","['1-Deoxynojirimycin/adverse effects/*analogs & derivatives/therapeutic use', 'Contraindications', 'Gaucher Disease/*drug therapy', 'Glucosylceramidase/therapeutic use', 'Glucosyltransferases/antagonists & inhibitors', 'Humans', 'Practice Guidelines as Topic']",https://pubmed.ncbi.nlm.nih.gov/16247743/
2515,miglustat,20821051,Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up.,"['Masciullo M', 'Santoro M', 'Modoni A', 'Ricci E', 'Guitton J', 'Tonali P', 'Silvestri G']","['1-Deoxynojirimycin/*analogs & derivatives/therapeutic use', 'Disease Progression', 'Enzyme Inhibitors/*therapeutic use', 'Glucosyltransferases/*antagonists & inhibitors/metabolism', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Middle Aged', 'Muscle Weakness/diagnosis/drug therapy/etiology', 'Muscular Atrophy, Spinal/diagnosis/drug therapy/etiology', 'Neurologic Examination', 'Predictive Value of Tests', 'Sandhoff Disease/complications/diagnosis/*drug therapy/enzymology/genetics', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20821051/
2516,miglustat,15262277,Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C.,"['Lachmann RH', 'te Vruchte D', 'Lloyd-Evans E', 'Reinkensmeier G', 'Sillence DJ', 'Fernandez-Guillen L', 'Dwek RA', 'Butters TD', 'Cox TM', 'Platt FM']","['Adult', 'Boron Compounds', 'Cells, Cultured', 'Endocytosis', 'Endosomes/metabolism', 'Female', 'Fibroblasts/cytology/metabolism', 'Fluorescent Dyes', 'Glucosylceramidase/*administration & dosage', 'Glycolipids/biosynthesis/*metabolism', 'Humans', 'Lysosomes/metabolism', 'Niemann-Pick Diseases/*drug therapy/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/15262277/
2517,miglustat,22515974,Unexpected cure from cutaneous leukocytoclastic vasculitis in a patient treated with N-butyldeoxynojirimycin (miglustat) for Gaucher disease.,"['Machaczka M', 'Klimkowska M', 'Hagglund H']","['1-Deoxynojirimycin/*therapeutic use', 'Aged', 'Gaucher Disease/*drug therapy', 'Humans', 'Male', 'Treatment Outcome', 'Vasculitis, Leukocytoclastic, Cutaneous/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22515974/
2518,miglustat,36243834,Cost-effectiveness of miglustat versus symptomatic therapy of Niemann-Pick disease type C.,"['Gutic M', 'Milosavljevic MN', 'Jankovic SM']","['Adolescent', 'Humans', '*Niemann-Pick Disease, Type C/diagnosis/drug therapy', 'Cost-Benefit Analysis', 'Enzyme Inhibitors/therapeutic use', '1-Deoxynojirimycin/therapeutic use/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/36243834/
2519,miglustat,37480097,Effects of miglustat therapy on neurological disorder and survival in early-infantile Niemann-Pick disease type C: a national French retrospective study.,"['Freihuber C', 'Dahmani-Rabehi B', 'Brassier A', 'Broue P', 'Cances C', 'Chabrol B', 'Eyer D', 'Labarthe F', 'Latour P', 'Levade T', 'Pichard S', 'Sevin C', 'Vanier MT', 'Heron B']","['Female', 'Pregnancy', 'Humans', 'Infant', 'Child, Preschool', 'Child', 'Adolescent', 'Young Adult', 'Adult', '*Niemann-Pick Disease, Type C/drug therapy', 'Retrospective Studies', '*Nervous System Diseases', '1-Deoxynojirimycin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37480097/
2520,miglustat,39287071,Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data.,"['Shohet S', 'Hummel N', 'Fu S', 'Keyzor I', 'MacCulloch A', 'Johnson N', 'Castelli J', 'Czarny-Ozga I', 'Mozaffar T', 'Thom H']","['*Glycogen Storage Disease Type II/drug therapy', 'Humans', '*Enzyme Replacement Therapy/methods', '*1-Deoxynojirimycin/analogs & derivatives/therapeutic use', '*Network Meta-Analysis', 'alpha-Glucosidases/therapeutic use', 'Randomized Controlled Trials as Topic', 'Walk Test']",https://pubmed.ncbi.nlm.nih.gov/39287071/
2521,miglustat,21978771,"Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form--no positive effects after 2-years of miglustat therapy.","['Tylki-Szymanska A', 'Groener JE', 'Kaminski ML', 'Lugowska A', 'Jurkiewicz E', 'Czartoryska B']","['1-Deoxynojirimycin/*analogs & derivatives/therapeutic use', 'Adult', 'Diagnostic Errors', 'Enzyme Inhibitors/*therapeutic use', 'Female', 'Gaucher Disease/complications/*diagnosis/*drug therapy', 'Hepatomegaly/drug therapy/etiology', 'Humans', 'Male', 'Saposins/*deficiency', 'Splenomegaly/drug therapy/etiology', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/21978771/
2522,Risedronic acid,33300108,Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.,"[""Dell'Anno I"", 'Martin SA', 'Barbarino M', 'Melani A', 'Silvestri R', 'Bottaro M', 'Paolicchi E', 'Corrado A', 'Cipollini M', 'Melaiu O', 'Giordano A', 'Luzzi L', 'Gemignani F', 'Landi S']","['Antineoplastic Agents/*pharmacology', 'Cell Line', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Drug Repositioning', 'Gene Expression Regulation, Neoplastic/drug effects', 'Humans', 'Mesothelioma/*drug therapy/genetics/metabolism', 'Pleural Neoplasms/*drug therapy/genetics/metabolism', 'Risedronic Acid/*pharmacology', 'STAT1 Transcription Factor/*antagonists & inhibitors/metabolism', 'Vidarabine/*analogs & derivatives/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33300108/
2523,Risedronic acid,34333172,Hydroxyapatite surface-functionalized monolithic column for selective in-tube solid phase microextraction of zoleronic acid and risedronic acid.,"['Wang J', 'Ni B', 'Li W', 'Sun J', 'Tao Y', 'Chen L']","['Chromatography, High Pressure Liquid', '*Durapatite', '*Hydroxyapatites', 'Limit of Detection', 'Reproducibility of Results', '*Risedronic Acid', '*Solid Phase Microextraction']",https://pubmed.ncbi.nlm.nih.gov/34333172/
2524,Risedronic acid,17163237,Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.,"['Reid DM', 'Hosking D', 'Kendler D', 'Brandi ML', 'Wark JD', 'Weryha G', 'Marques-Neto JF', 'Gaines KA', 'Verbruggen N', 'Melton ME']","['Aged', 'Alendronate/adverse effects/*therapeutic use', 'Bone Density/*drug effects', 'Bone Remodeling/*drug effects', 'Double-Blind Method', 'Etidronic Acid/adverse effects/*analogs & derivatives/therapeutic use', 'Female', 'Humans', 'Middle Aged', 'Osteoporosis, Postmenopausal/*drug therapy', 'Risedronic Acid']",https://pubmed.ncbi.nlm.nih.gov/17163237/
2525,Risedronic acid,19366276,Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.,"['Zhong ZM', 'Chen JT']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Bone Density Conservation Agents/*therapeutic use', 'Etidronic Acid/*analogs & derivatives/therapeutic use', 'Follow-Up Studies', 'Fractures, Bone/etiology/*prevention & control', 'Humans', 'Male', 'Middle Aged', 'Osteoporosis/complications/*drug therapy', 'Randomized Controlled Trials as Topic', 'Risedronic Acid', 'Risk', 'Spinal Fractures/etiology/prevention & control', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19366276/
2526,Valproic acid,35170557,Meropenem to Treat Valproic Acid Intoxication.,"['Smolders EJ', 'Ter Heine R', 'Natsch S', 'Kramers K']","['Anti-Bacterial Agents/therapeutic use', '*Anticonvulsants/therapeutic use', 'Drug Interactions', 'Humans', 'Meropenem/therapeutic use', '*Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35170557/
2527,Valproic acid,30931853,Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update.,"['Guo HL', 'Jing X', 'Sun JY', 'Hu YH', 'Xu ZJ', 'Ni MM', 'Chen F', 'Lu XP', 'Qiu JC', 'Wang T']","['Anticonvulsants/*adverse effects/therapeutic use', 'Antioxidants/therapeutic use', 'Carnitine/therapeutic use', '*Chemical and Drug Induced Liver Injury', 'Epilepsy', 'Humans', 'Liver/drug effects/pathology', 'Valproic Acid/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30931853/
2528,Valproic acid,35251569,Valproic Acid Inhibits Glioma and Its Mechanisms.,"['Yang ZY', 'Wang XH']","['*Brain Neoplasms/drug therapy', 'Cell Line, Tumor', 'Epithelial-Mesenchymal Transition/genetics', '*Glioma/drug therapy', 'Humans', 'Valproic Acid/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35251569/
2529,Valproic acid,6421770,Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.,"['Bialer M', 'Hussein Z', 'Dubrovsky J', 'Raz I', 'Abramsky O']","['Administration, Oral', 'Adult', 'Biological Availability', 'Capsules', 'Delayed-Action Preparations', 'Half-Life', 'Humans', 'Kinetics', 'Male', 'Tablets', 'Valproic Acid/administration & dosage/blood/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/6421770/
2530,Valproic acid,21373707,"Real-time, in vivo monitoring and pharmacokinetics of valproic acid via a novel biomarker in exhaled breath.","['Gamez G', 'Zhu L', 'Disko A', 'Chen H', 'Azov V', 'Chingin K', 'Kramer G', 'Zenobi R']","['Biomarkers/*analysis', 'Breath Tests/*methods', 'Epilepsy/drug therapy', 'Exhalation', 'Humans', 'Monitoring, Physiologic/methods', 'Protein Binding', 'Spectrometry, Mass, Electrospray Ionization/*methods', 'Valproic Acid/administration & dosage/*analysis/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/21373707/
2531,Valproic acid,21975791,Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults.,"['Gill D', 'Derry S', 'Wiffen PJ', 'Moore RA']","['Adult', 'Analgesics/*therapeutic use', 'Diabetic Neuropathies/*drug therapy', 'Fibromyalgia/*drug therapy', 'Humans', 'Neuralgia, Postherpetic/*drug therapy', 'Randomized Controlled Trials as Topic', 'Valproic Acid/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21975791/
2532,Valproic acid,32748626,Prescribing Practices of Valproic Acid for Agitation and Delirium in the Intensive Care Unit.,"['Quinn NJ', 'Hohlfelder B', 'Wanek MR', 'Duggal A', 'Torbic H']","['Aged', 'Anticonvulsants/pharmacology/*therapeutic use', 'Antipsychotic Agents/*therapeutic use', 'Cohort Studies', 'Female', 'Humans', 'Incidence', 'Intensive Care Units/*standards', 'Male', 'Middle Aged', 'Psychomotor Agitation/*drug therapy', 'Retrospective Studies', 'Valproic Acid/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32748626/
2533,Valproic acid,28060221,Valproic Acid: Special Considerations and Targeted Monitoring.,"['Collins-Yoder A', 'Lowell J']","['Anticonvulsants/*therapeutic use', 'Drug Monitoring/*methods', 'Humans', 'Mutation', 'Neuroscience Nursing', 'Polypharmacy', 'Valproic Acid/blood/*pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28060221/
2534,Valproic acid,25302991,Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase.,"['Star K', 'Edwards IR', 'Choonara I']","['Adverse Drug Reaction Reporting Systems', 'Anticonvulsants/*adverse effects/therapeutic use/toxicity', 'Chemical and Drug Induced Liver Injury/*epidemiology', 'Child', 'Drug-Related Side Effects and Adverse Reactions/epidemiology', 'Epilepsy/drug therapy', 'Humans', 'Liver/drug effects', 'Valproic Acid/*adverse effects/therapeutic use/toxicity']",https://pubmed.ncbi.nlm.nih.gov/25302991/
2535,Valproic acid,26715390,Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion.,"['Cook AM', 'Zafar MS', 'Mathias S', 'Stewart AM', 'Albuja AC', 'Bensalem-Owen M', 'Kapoor S', 'Baumann RJ']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anticonvulsants/*administration & dosage/adverse effects/*blood/therapeutic use', 'Child', 'Child, Preschool', 'Cohort Studies', 'Data Interpretation, Statistical', 'Female', 'Humans', 'Infant', 'Infusions, Intravenous', 'Male', 'Medical Records', 'Middle Aged', 'Migraine Disorders/drug therapy', 'Retrospective Studies', 'Seizures/drug therapy', 'Treatment Outcome', 'Valproic Acid/*administration & dosage/adverse effects/*blood/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26715390/
2536,Valproic acid,24076030,Metabolic and endocrine effects of valproic acid chronic treatment.,"['Belcastro V', ""D'Egidio C"", 'Striano P', 'Verrotti A']","['Anticonvulsants/*adverse effects/pharmacology/therapeutic use', 'Epilepsy/blood/*drug therapy', 'Humans', 'Hyperinsulinism/*chemically induced/complications', '*Insulin Resistance', 'Leptin/blood', 'Metabolic Syndrome/blood/*chemically induced', 'Valproic Acid/*adverse effects/pharmacology/therapeutic use', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/24076030/
2537,Valproic acid,6799283,"The free fraction of valproic acid in tears, saliva, and cerebrospinal fluid.","['Monaco F', 'Piredda S', 'Mutani R', 'Mastropaolo C', 'Tondi M']","['Adult', 'Child', 'Epilepsy/metabolism', 'Humans', 'Immunoenzyme Techniques', 'Protein Binding', 'Saliva/*analysis', 'Tears/*analysis', 'Valproic Acid/*analysis/blood/cerebrospinal fluid']",https://pubmed.ncbi.nlm.nih.gov/6799283/
2538,Gemfibrozil,1888257,Gemfibrozil-induced myopathy.,"['Magarian GJ', 'Lucas LM', 'Colley C']","['Clofibrate/adverse effects', 'Drug Therapy, Combination', 'Gemfibrozil/*adverse effects/therapeutic use', 'Humans', 'Hypertriglyceridemia/drug therapy', 'Lovastatin/adverse effects', 'Male', 'Middle Aged', 'Muscular Diseases/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/1888257/
2539,Gemfibrozil,7956717,Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.,['Wolf HR'],"['Cholesterol/blood', 'Cholesterol, HDL/blood', 'Clofibric Acid/adverse effects/*analogs & derivatives/therapeutic use', 'Female', 'Gemfibrozil/adverse effects/*therapeutic use', 'Humans', 'Hyperlipidemias/blood/*drug therapy', 'Hypolipidemic Agents/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Single-Blind Method', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/7956717/
2540,Gemfibrozil,36139056,"Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges.",['Shah MB'],"['Cholesterol', 'Clopidogrel/pharmacology', 'Cytochrome P-450 CYP2C8/metabolism', '*Gemfibrozil/metabolism/pharmacology', '*Glucuronides/metabolism', 'Heme', 'Platelet Aggregation Inhibitors', 'Triglycerides']",https://pubmed.ncbi.nlm.nih.gov/36139056/
2541,Gemfibrozil,26378985,Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-beta-Glucuronide.,"['Kimoto E', 'Li R', 'Scialis RJ', 'Lai Y', 'Varma MV']","['Biological Transport', 'Chromatography, Liquid', 'Gemfibrozil/*metabolism', 'Glucuronides/*metabolism', 'HEK293 Cells', 'Hepatocytes/*metabolism', 'Humans', 'Hypolipidemic Agents/*metabolism', 'Liver/*metabolism', 'Models, Theoretical', 'Multidrug Resistance-Associated Protein 2', 'Multidrug Resistance-Associated Proteins/metabolism', 'Organic Anion Transporters/metabolism', 'Tandem Mass Spectrometry']",https://pubmed.ncbi.nlm.nih.gov/26378985/
2542,Gemfibrozil,22180293,"Occurrence, fate, and persistence of gemfibrozil in water and soil.","['Fang Y', 'Karnjanapiboonwong A', 'Chase DA', 'Wang J', 'Morse AN', 'Anderson TA']","['Biodegradation, Environmental', 'Environmental Monitoring', 'Gemfibrozil/*analysis', 'Groundwater/*chemistry', 'Hypolipidemic Agents/*analysis', 'Soil/chemistry', 'Soil Pollutants/*analysis', 'Waste Disposal, Fluid', 'Water Pollutants, Chemical/*analysis']",https://pubmed.ncbi.nlm.nih.gov/22180293/
2543,Gemfibrozil,28623936,Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders.,"['Kim K', 'Kleinman HK', 'Lee HJ', 'Pahan K']","['Child', 'Gemfibrozil/*adverse effects/*therapeutic use', 'Humans', 'Neuronal Ceroid-Lipofuscinoses/*drug therapy', 'Tripeptidyl-Peptidase 1']",https://pubmed.ncbi.nlm.nih.gov/28623936/
2544,Gemfibrozil,2045526,Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.,"['Zimetbaum P', 'Frishman WH', 'Kahn S']","['Bezafibrate/pharmacology', 'Cholesterol, HDL', 'Clofibric Acid/analogs & derivatives/pharmacology', 'Diabetes Mellitus, Type 2/blood', 'Fenofibrate/adverse effects/pharmacology', 'Fibric Acids', 'Gemfibrozil/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Hypercholesterolemia/blood/*drug therapy', 'Hypertriglyceridemia/blood/*drug therapy', 'Hypolipidemic Agents/adverse effects/*blood/pharmacology', 'Kidney Diseases/blood', 'Lipoproteins, VLDL/*biosynthesis/blood', 'Metabolic Clearance Rate', 'Triglycerides/*blood']",https://pubmed.ncbi.nlm.nih.gov/2045526/
2545,Gemfibrozil,8420296,Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.,"['Wiklund O', 'Angelin B', 'Bergman M', 'Berglund L', 'Bondjers G', 'Carlsson A', 'Linden T', 'Miettinen T', 'Odman B', 'Olofsson SO', 'et al.']","['Adult', 'Aged', 'Analysis of Variance', 'Apolipoproteins B/analysis', 'Cholesterol/blood', 'Drug Therapy, Combination', 'Female', 'Gemfibrozil/adverse effects/*therapeutic use', 'Humans', 'Hypercholesterolemia/blood/*drug therapy', 'Male', 'Middle Aged', 'Pravastatin/adverse effects/*therapeutic use', 'Single-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/8420296/
2546,Gemfibrozil,34303168,Modeling degradation kinetics of gemfibrozil and naproxen in the UV/chlorine system: Roles of reactive species and effects of water matrix.,"['Liu H', 'Hou Z', 'Li Y', 'Lei Y', 'Xu Z', 'Gu J', 'Tian S']","['Chlorine', 'Gemfibrozil', 'Kinetics', 'Naproxen', 'Oxidation-Reduction', 'Ultraviolet Rays', 'Water', '*Water Pollutants, Chemical/analysis', '*Water Purification']",https://pubmed.ncbi.nlm.nih.gov/34303168/
2547,Gemfibrozil,3056692,"Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia.","['Todd PA', 'Ward A']","['*Gemfibrozil/pharmacokinetics/pharmacology/therapeutic use', 'Humans', 'Hyperlipidemias/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3056692/
2548,Gemfibrozil,2381138,Gemfibrozil absorption and elimination in kidney and liver disease.,"['Knauf H', 'Kolle EU', 'Mutschler E']","['Adult', 'Aged', 'Chromatography, High Pressure Liquid', 'Female', 'Gemfibrozil/*pharmacokinetics', 'Half-Life', 'Humans', '*Intestinal Absorption', 'Kidney Diseases/*metabolism', 'Kidney Failure, Chronic/metabolism', 'Liver Cirrhosis/metabolism', 'Liver Diseases/*metabolism', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2381138/
2549,Gemfibrozil,7661873,"Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination.","['Vanhanen HT', 'Miettinen TA']","['Absorption', 'Apolipoproteins/blood', 'Cholestanol/blood', 'Cholesterol/biosynthesis/*metabolism', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Gemfibrozil/*therapeutic use', 'Humans', 'Hyperlipidemias/drug therapy/*metabolism', 'Lipoproteins/blood', 'Male', 'Middle Aged', 'Pravastatin/*therapeutic use', 'Squalene/blood', 'Sterols/metabolism', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/7661873/
2550,Doxazosin,26414968,"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.","['Williams B', 'MacDonald TM', 'Morant S', 'Webb DJ', 'Sever P', 'McInnes G', 'Ford I', 'Cruickshank JK', 'Caulfield MJ', 'Salsbury J', 'Mackenzie I', 'Padmanabhan S', 'Brown MJ']","['Adrenergic alpha-1 Receptor Antagonists/*therapeutic use', 'Adrenergic beta-1 Receptor Antagonists/*therapeutic use', 'Aged', 'Bisoprolol/*therapeutic use', 'Cross-Over Studies', 'Double-Blind Method', 'Doxazosin/*therapeutic use', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Mineralocorticoid Receptor Antagonists/*therapeutic use', 'Spironolactone/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26414968/
2551,Doxazosin,17563267,Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia.,"['Bhardwa J', 'Goldstraw M', 'Tzortzis S', 'Kirby R']","['5-alpha Reductase Inhibitors', 'Adrenergic alpha-Antagonists/administration & dosage/*therapeutic use', 'Aged', 'Doxazosin/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Finasteride/administration & dosage/*therapeutic use', 'Humans', 'Male', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17563267/
2552,Doxazosin,38206436,The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas.,"['Ohmachi Y', 'Yamamoto M', 'Inaba Y', 'Makino S', 'Urai S', 'Matsumoto R', 'Bando H', 'Kanie K', 'Tsujimoto Y', 'Motomura Y', 'Sasaki Y', 'Oi-Yo Y', 'Yamamoto N', 'Suzuki M', 'Takahashi M', 'Iguchi G', 'Kanzawa M', 'Furukawa J', 'Shigemura K', 'Mizobuchi S', 'Ogawa W', 'Fukuoka H']","['Humans', '*Doxazosin/therapeutic use/administration & dosage', 'Female', 'Male', '*Pheochromocytoma/surgery/drug therapy', 'Middle Aged', '*Adrenal Gland Neoplasms/surgery/drug therapy', 'Retrospective Studies', '*Paraganglioma/drug therapy/surgery', 'Adult', 'Aged', '*alpha-Methyltyrosine/therapeutic use/administration & dosage/pharmacology', '*Adrenergic alpha-1 Receptor Antagonists/therapeutic use/administration & dosage', 'Drug Therapy, Combination', 'Preoperative Care/methods', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38206436/
2553,Doxazosin,36883885,A Double-Blind Randomized Controlled Trial of Doxazosin for Co-Occurring PTSD and Alcohol Use Disorder in Veterans.,"['Back SE', 'Flanagan JC', 'Mintz J', 'Brady KT', 'Jones J', 'Jarnecke AM', 'Joseph JE', 'Shirley DW', 'Malcolm RJ', 'Hamner M', 'Litz BT', 'Niles BL', 'Young-McCaughan S', 'Keane TM', 'Peterson AL']","['Humans', '*Veterans', '*Stress Disorders, Post-Traumatic/complications/diagnosis/drug therapy', 'Doxazosin/therapeutic use', '*Alcoholism/diagnosis/drug therapy/epidemiology', 'Treatment Outcome', 'Adrenergic alpha-1 Receptor Antagonists/adverse effects', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/36883885/
2554,Doxazosin,38896813,"Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men.","['Hart A', 'Aldridge G', 'Zhang Q', 'Narayanan NS', 'Simmering JE']","['Humans', 'Male', '*Doxazosin/therapeutic use', 'Aged', '*Prazosin/analogs & derivatives/therapeutic use', '*Lewy Body Disease/drug therapy', '*Adrenergic alpha-1 Receptor Antagonists/therapeutic use', '*Quinazolines/therapeutic use/adverse effects', 'Aged, 80 and over', 'Tamsulosin/therapeutic use', 'Prostatic Hyperplasia/drug therapy', 'Neuroprotective Agents/therapeutic use/pharmacology', 'Middle Aged', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/38896813/
2555,Doxazosin,14634256,Protonation site and hydrogen bonding in anhydrous and hydrated crystalline forms of doxazosin mesylate from powder data.,"['Chernyshev VV', 'Machon D', 'Fitch AN', 'Zaitsev SA', 'Yatsenko AV', 'Shmakov AN', 'Weber HP']","['Crystallization', 'Doxazosin/*chemistry', 'Hydrogen Bonding', 'Models, Chemical', 'Models, Molecular', 'Molecular Conformation', 'Protons', 'Water/chemistry']",https://pubmed.ncbi.nlm.nih.gov/14634256/
2556,Doxazosin,34515895,"The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof.","['Veldhuizen GP', 'Alnazer RM', 'de Leeuw PW', 'Kroon AA']","['Humans', 'Aldosterone/therapeutic use', 'Renin/therapeutic use', 'Doxazosin/adverse effects', '*Hyperaldosteronism/diagnosis/drug therapy', 'Verapamil/pharmacology/therapeutic use', 'Retrospective Studies', '*Hypertension/diagnosis/drug therapy', 'Antihypertensive Agents/adverse effects', 'Hydralazine/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34515895/
2557,Doxazosin,28440105,Effect of doxazosin on stress reactivity and the ability to resist smoking.,"['Verplaetse TL', 'Weinberger AH', 'Oberleitner LM', 'Smith KM', 'Pittman BP', 'Shi JM', 'Tetrault JM', 'Lavery ME', 'Picciotto MR', 'McKee SA']","['Adrenergic alpha-1 Receptor Antagonists/administration & dosage/*pharmacology', 'Adult', 'Craving/*drug effects', 'Doxazosin/administration & dosage/*pharmacology', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pilot Projects', 'Smoking/*drug therapy/metabolism/physiopathology', '*Stress, Psychological/metabolism/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/28440105/
2558,Doxazosin,32869260,Efficacy and Safety of Doxazosin in Medical Expulsive Therapy for Distal Ureteral Stones: A Systematic Review and Meta-analysis.,"['Ma L', 'Zou S', 'Yang L', 'Wang F']","['Adrenergic alpha-1 Receptor Antagonists/adverse effects/*therapeutic use', 'Doxazosin/adverse effects/*therapeutic use', 'Humans', 'Treatment Outcome', 'Ureteral Calculi/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/32869260/
2559,Doxazosin,8733335,Doxazosin: a new approach to hypertension and benign prostatic hyperplasia.,['Pool JL'],"['Adrenergic alpha-Antagonists/*therapeutic use', 'Aged', 'Antihypertensive Agents/*therapeutic use', 'Clinical Trials as Topic', 'Doxazosin/*therapeutic use', 'Humans', 'Male', 'Prostatic Hyperplasia/*drug therapy', 'Sympatholytics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8733335/
2560,Doxazosin,16469026,Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health.,"['Kaplan SA', 'DE Rose AF', 'Kirby RS', ""O'leary MP"", 'McVary KT']","['Adrenergic alpha-Antagonists/*administration & dosage', 'Adult', 'Aged', 'Aged, 80 and over', 'Delayed-Action Preparations/administration & dosage', 'Doxazosin/*administration & dosage', 'Erectile Dysfunction/*drug therapy', 'Humans', 'Hypertension/*drug therapy', 'Libido/drug effects', 'Male', 'Middle Aged', 'Patient Satisfaction', 'Prostatic Hyperplasia/*drug therapy', 'Quality of Life', 'Treatment Outcome', 'Vasodilation/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/16469026/
2561,Doxazosin,37980865,"Cardiovascular drugs and suicide death: Determination of carvedilol, amlodipine, doxazosin and diltiazem in two fatal cases.","['Santunione AL', 'Palazzoli F', 'Verri P', 'Vandelli D', 'Castagnetti V', 'Profeta C', 'Silingardi E']","['Humans', 'Amlodipine', 'Diltiazem', 'Carvedilol', 'Doxazosin', '*Cardiovascular Agents', '*Suicide']",https://pubmed.ncbi.nlm.nih.gov/37980865/
2562,Doxazosin,34414962,Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis.,"['Guo J', 'Tang R']","['Humans', 'Male', '*Doxazosin/adverse effects/therapeutic use', '*Lower Urinary Tract Symptoms/drug therapy/etiology', '*Prostatic Hyperplasia/complications', '*Tamsulosin/adverse effects/therapeutic use', 'Treatment Outcome', '*Urological Agents/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34414962/
2563,Doxazosin,34463000,Doxazosin and erlotinib have anticancer effects in the endometrial cancer cell and important roles in ERalpha and Wnt/beta-catenin signaling pathways.,"['Karaca B', 'Bakir E', 'Yerer MB', 'Cumaoglu A', 'Hamurcu Z', 'Eken A']","['Antineoplastic Agents/administration & dosage/*therapeutic use', 'Doxazosin/administration & dosage/*therapeutic use', 'Endometrial Neoplasms/*drug therapy/metabolism/pathology', 'Erlotinib Hydrochloride/administration & dosage/*therapeutic use', 'Estrogen Receptor alpha/*drug effects/metabolism', 'Female', 'Humans', 'Wnt Signaling Pathway/*drug effects', 'beta Catenin/*drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/34463000/
2564,Doxazosin,24509125,"Doxazosin to treat hypertension: it's time to take it personally--a retrospective analysis of 19, 495 patients.","['Wolak T', 'Toledano R', 'Novack V', 'Sharon A', 'Shalev A', 'Wolak A']","['Aged', 'Antihypertensive Agents/*therapeutic use', 'Doxazosin/*therapeutic use', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Retrospective Studies', 'Tomography, Emission-Computed, Single-Photon']",https://pubmed.ncbi.nlm.nih.gov/24509125/
2565,Doxazosin,30145268,Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans.,"['Back SE', 'Flanagan JC', 'Jones JL', 'Augur I', 'Peterson AL', 'Young-McCaughan S', 'Shirley DW', 'Henschel A', 'Joseph JE', 'Litz BT', 'Hancock AK', 'Roache JD', 'Mintz J', 'Wachen JS', 'Keane TM', 'Brady KT']","['Humans', '*Adrenergic alpha-1 Receptor Antagonists/therapeutic use', '*Alcoholism/diagnostic imaging/drug therapy/psychology', 'Brain/diagnostic imaging', 'Double-Blind Method', '*Doxazosin/therapeutic use', 'Functional Neuroimaging', 'Magnetic Resonance Imaging', 'Randomized Controlled Trials as Topic', '*Stress Disorders, Post-Traumatic/diagnostic imaging/drug therapy/psychology', 'Treatment Outcome', '*Veterans', 'Clinical Trials, Phase II as Topic']",https://pubmed.ncbi.nlm.nih.gov/30145268/
2566,Doxazosin,16550731,Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure.,['Os I'],"['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anticholesteremic Agents/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Doxazosin/administration & dosage/adverse effects/*therapeutic use', 'Drug Carriers', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Prospective Studies', 'Technology, Pharmaceutical/methods', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/16550731/
2567,Doxazosin,32621102,The use of doxazosin before adrenalectomy for pheochromocytoma: is the duration related to intraoperative hemodynamics and postoperative complications?,"['Kong H', 'Li N', 'Tian J', 'Bao Z', 'Liu L', 'Wu K', 'Gao Y', 'Jin B', 'Zhang Z', 'Fang D', 'Zhang J', 'Zhou L']","['Adrenal Gland Neoplasms/*surgery', '*Adrenalectomy', 'Adrenergic alpha-1 Receptor Antagonists/*administration & dosage', 'Adult', 'Aged', 'Doxazosin/*administration & dosage', 'Duration of Therapy', 'Female', 'Hemodynamics', 'Humans', 'Intraoperative Period', 'Male', 'Middle Aged', 'Pheochromocytoma/physiopathology/*surgery', 'Postoperative Complications/*epidemiology', 'Preoperative Period', 'Retrospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32621102/
2568,Darunavir,35460601,"Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.","['Paton NI', 'Musaazi J', 'Kityo C', 'Walimbwa S', 'Hoppe A', 'Balyegisawa A', 'Asienzo J', 'Kaimal A', 'Mirembe G', 'Lugemwa A', 'Ategeka G', 'Borok M', 'Mugerwa H', 'Siika A', 'Odongpiny ELA', 'Castelnuovo B', 'Kiragga A', 'Kambugu A']","['*Anti-HIV Agents/adverse effects', 'Darunavir', 'Drug Therapy, Combination', '*HIV Infections/drug therapy', '*HIV-1', 'Heterocyclic Compounds, 3-Ring', 'Humans', 'Lamivudine/adverse effects', 'Oxazines', 'Piperazines', 'Prospective Studies', 'Pyridones', 'RNA/therapeutic use', 'Ritonavir', 'Tenofovir', 'Viral Load', 'Zidovudine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35460601/
2569,Darunavir,33221868,Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.,"['Meriglier E', 'Rivoisy C', 'Hessamfar M', 'Bernard N', 'Aureau I', 'Lapoirie J', 'Contis A', 'Sacher F', 'Sacristan B', 'Lahouati M', 'Pedeboscq S', 'Vandenhende MA', 'Bouchet S', 'Bonnet F']","['Antiviral Agents/administration & dosage/*adverse effects/blood/therapeutic use', 'COVID-19/epidemiology', 'Cohort Studies', 'Darunavir/administration & dosage/*adverse effects/blood/therapeutic use', 'Drug Therapy, Combination', 'Electrocardiography', 'France', 'Humans', 'Hydroxychloroquine/administration & dosage/*adverse effects/blood/therapeutic use', 'Long QT Syndrome/chemically induced/epidemiology', 'Lopinavir/administration & dosage/*adverse effects/blood/therapeutic use', 'SARS-CoV-2', 'Severity of Illness Index', 'Treatment Outcome', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33221868/
2570,Darunavir,34289276,Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.,"['Paton NI', 'Musaazi J', 'Kityo C', 'Walimbwa S', 'Hoppe A', 'Balyegisawa A', 'Kaimal A', 'Mirembe G', 'Tukamushabe P', 'Ategeka G', 'Hakim J', 'Mugerwa H', 'Siika A', 'Asienzo J', 'Castelnuovo B', 'Kiragga A', 'Kambugu A']","['Adolescent', 'Adult', 'Anti-HIV Agents/*administration & dosage/adverse effects', 'Child', 'Darunavir/*administration & dosage/adverse effects', 'Drug Resistance', 'Drug Therapy, Combination', 'Female', 'HIV Infections/*drug therapy/virology', '*HIV-1/isolation & purification', 'Heterocyclic Compounds, 3-Ring/*administration & dosage/adverse effects', 'Humans', 'Male', 'Middle Aged', 'Oxazines/*administration & dosage/adverse effects', 'Piperazines/*administration & dosage/adverse effects', 'Pyridones/*administration & dosage/adverse effects', 'Reverse Transcriptase Inhibitors/*administration & dosage/adverse effects', 'Tenofovir/*administration & dosage', 'Viral Load', 'Young Adult', 'Zidovudine/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/34289276/
2571,Darunavir,29237008,Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.,"['Molto J', 'Curran A', 'Miranda C', 'Challenger E', 'Santos JR', 'Ribera E', 'Khoo S', 'Valle M', 'Clotet B']","['Adult', 'Anti-HIV Agents/administration & dosage/blood/*pharmacokinetics', 'Cobicistat/administration & dosage/blood/*pharmacokinetics', 'Cohort Studies', 'Darunavir/administration & dosage/blood/*pharmacokinetics', 'Drug Therapy, Combination', 'Female', 'HIV/drug effects', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/administration & dosage/blood/*pharmacokinetics', 'Humans', 'Male', 'Middle Aged', 'Nitriles', 'Pyridazines/administration & dosage/blood/*pharmacokinetics', 'Pyrimidines', 'RNA, Viral/blood', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29237008/
2572,Darunavir,28193650,Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro.,"['Roberts O', 'Khoo S', 'Owen A', 'Siccardi M']","['Antirheumatic Agents/*pharmacokinetics/therapeutic use', 'Antitubercular Agents/*pharmacokinetics/therapeutic use', 'Cells, Cultured', 'Cobicistat/*pharmacokinetics/therapeutic use', 'Darunavir/*pharmacokinetics/therapeutic use', 'Drug Interactions', 'Drug Therapy, Combination', 'HIV Infections/*drug therapy/virology', 'HIV-1/drug effects', 'Hepatocytes/drug effects', 'Humans', 'Metabolic Clearance Rate/drug effects', 'Mycobacterium tuberculosis/drug effects', 'Rifampin/*pharmacokinetics/therapeutic use', 'Ritonavir/*pharmacokinetics/therapeutic use', 'Tuberculosis, Pulmonary/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/28193650/
2573,Darunavir,34076612,Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.,"['Momper JD', 'Wang J', 'Stek A', 'Shapiro DE', 'Scott GB', 'Paul ME', 'Febo IL', 'Burchett S', 'Smith E', 'Chakhtoura N', 'Denson K', 'Rungruengthanakit K', 'George K', 'Yang DZ', 'Capparelli EV', 'Mirochnick M', 'Best BM']","['*Anti-HIV Agents/therapeutic use', 'Child', 'Cobicistat/therapeutic use', 'Darunavir/therapeutic use', 'Female', '*HIV Infections/drug therapy', 'Humans', 'Infectious Disease Transmission, Vertical', 'Placenta', 'Postpartum Period', 'Pregnancy', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/34076612/
2574,Darunavir,37955446,"Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/Rifapentine.","['Brooks KM', 'Pau AK', 'Swaim D', 'Bunn HT', 'Adeojo L', 'Peloquin CA', 'Kumar P', 'Kovacs JA', 'George JM']","['Humans', 'Cobicistat/therapeutic use', 'Cross-Over Studies', '*Darunavir/pharmacokinetics/therapeutic use', '*HIV Infections/drug therapy', 'Isoniazid/therapeutic use', 'Drug Combinations']",https://pubmed.ncbi.nlm.nih.gov/37955446/
2575,Darunavir,38399959,Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen.,"['Stam AJ', 'Buchholtz NVEJ', 'Bierman WFW', 'van Crevel R', 'Hoepelman AIM', 'Claassen MAA', 'Ammerlaan HSM', 'van Welzen BJ', 'van Kasteren MEE', 'van Lelyveld SFL', 'de Jong D', 'Tesselaar K', 'van Luin M', 'Nijhuis M', 'Wensing AMJ', 'Lowerit Study Team']","['Humans', 'Darunavir/therapeutic use/pharmacology', 'Viremia', '*HIV Infections/drug therapy', 'Antiretroviral Therapy, Highly Active', 'Sequence Analysis', 'Viral Load', '*Anti-HIV Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/38399959/
2576,Darunavir,17987220,Darunavir.,"['El-Atrouni WI', 'Temesgen Z']","['Clinical Trials as Topic', 'Darunavir', 'Drug Interactions', 'Drug Resistance, Viral', 'Drug Therapy, Combination', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/adverse effects/pharmacology/*therapeutic use', 'Humans', 'Sulfonamides/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17987220/
2577,Darunavir,36115063,"Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV.","['Ferrara M', 'Cusato J', 'Salvador E', 'Trentalange A', 'Alcantarini C', 'Trunfio M', 'Cannizzo ES', 'Bono V', 'Nozza S', 'De Nicolo A', 'Ianniello A', 'De Vivo E', ""D'Avolio A"", 'Di Perri G', 'Bonora S', 'Marchetti G', 'Calcagno A']","['Humans', 'Tenofovir/therapeutic use', 'Emtricitabine/therapeutic use/pharmacokinetics', 'Darunavir', '*Anti-HIV Agents', 'Lipopolysaccharide Receptors/therapeutic use', 'Interleukin-6', 'Lipopolysaccharides', '*HIV Infections/drug therapy', 'Inflammation/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36115063/
2578,Darunavir,37243208,Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naive AIDS- or Late-Presenting HIV-Infected Patients.,"['Fabbiani M', 'Masini M', 'Rossetti B', 'Ciccullo A', 'Borghi V', 'Lagi F', 'Capetti A', 'Colafigli M', 'Panza F', 'Baldin G', 'Mussini C', 'Sterrantino G', 'Farinacci D', 'Montagnani F', 'Tumbarello M', 'Di Giambenedetto S']","['Male', 'Humans', 'Adult', 'Female', 'Darunavir/therapeutic use', '*HIV Infections/drug therapy', '*Acquired Immunodeficiency Syndrome/drug therapy', 'Heterocyclic Compounds, 3-Ring/adverse effects', 'RNA', '*Anti-HIV Agents/adverse effects', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/37243208/
2579,Darunavir,32878571,"Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV.","['Adrian S', 'Miao H', 'Feng H', 'Scherzinger A', 'Nardini G', 'Beghetto B', 'Roncaglia E', 'Ligabue G', 'Milic J', 'Guaraldi G', 'Lake JE', 'Erlandson KM']","['Adipose Tissue/*drug effects', 'Adult', 'Anti-HIV Agents/*therapeutic use', 'Atazanavir Sulfate/*therapeutic use', 'Darunavir/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'HIV Infections/*drug therapy', 'HIV-1/drug effects', 'Hospitals, Teaching/statistics & numerical data', 'Humans', 'Italy', 'Male', 'Middle Aged', 'Muscles/*drug effects', 'Raltegravir Potassium/*therapeutic use', 'Retrospective Studies', 'Viral Load/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32878571/
2580,Darunavir,34496848,Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance.,"['Wolf E', 'Boesecke C', 'Balogh A', 'Bidner H', 'Cordes C', 'Heiken H', 'Krznaric I', 'Kummerle T', 'Stellbrink HJ', 'Schneider J', 'Spinner CD']","['*Anti-HIV Agents/therapeutic use', 'Darunavir/therapeutic use', 'Drug Resistance', 'Female', '*HIV Infections/drug therapy', '*HIV-1/genetics', 'Heterocyclic Compounds, 3-Ring', 'Humans', 'Male', 'Middle Aged', 'Oxazines', 'Piperazines', 'Pyridones']",https://pubmed.ncbi.nlm.nih.gov/34496848/
2581,Darunavir,36059130,Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.,"['Nakalema S', 'Chappell CA', 'Pham M', 'Byakika-Kibwika P', 'Kaboggoza J', 'Walimbwa SI', 'Musaazi J', 'Nakijoba R', 'Mbabazi L', 'Kyohairwe I', 'Nassiwa S', 'Jeppson J', 'Winchester L', 'Siccardi M', 'Fletcher CV', 'Scarsi KK', 'Lamorde M']","['Female', 'Humans', 'Darunavir/adverse effects', '*Levonorgestrel/adverse effects/pharmacokinetics', 'Rilpivirine/adverse effects', 'Ritonavir', 'Progestins', '*HIV Infections/drug therapy', 'Contraceptive Agents']",https://pubmed.ncbi.nlm.nih.gov/36059130/
2582,Darunavir,39066245,Reversibility of Neuropsychiatric Adverse Events after Switching to Darunavir/Cobicistat or Doravirine in Men on INSTI-Based Regimen.,"['Mata-Marin JA', 'Juarez-Contreras CA', 'Rodriguez-Evaristo MS', 'Martinez-Carrizales OC', 'Pompa-Mera E', 'Chaparro Sanchez A', 'Triana-Gonzalez S', 'Cano-Diaz AL', 'Gaytan-Martinez JE']","['Humans', 'Male', '*Darunavir/adverse effects/therapeutic use/administration & dosage', '*HIV Infections/drug therapy', 'Middle Aged', 'Prospective Studies', 'Adult', '*Cobicistat/adverse effects/therapeutic use/administration & dosage', '*Pyridones/adverse effects', 'HIV Integrase Inhibitors/adverse effects/therapeutic use/administration & dosage', 'Heterocyclic Compounds, 3-Ring/adverse effects/therapeutic use/administration & dosage', 'Sleep Initiation and Maintenance Disorders/chemically induced', 'Drug Substitution/adverse effects', 'Anti-HIV Agents/adverse effects/therapeutic use', 'Piperazines/adverse effects', 'Triazoles']",https://pubmed.ncbi.nlm.nih.gov/39066245/
2583,Darunavir,30873741,Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.,"['Crauwels HM', 'Osiyemi O', 'Zorrilla C', 'Bicer C', 'Brown K']","['Adult', 'Cobicistat/administration & dosage/*pharmacokinetics', 'Darunavir/administration & dosage/*pharmacokinetics', 'Drug Therapy, Combination', 'Female', 'Gestational Age', 'HIV Infections/*drug therapy', 'Humans', 'Infant, Newborn', 'Infectious Disease Transmission, Vertical/statistics & numerical data', 'Maternal Age', 'Postpartum Period/blood', 'Pregnancy', 'Pregnancy Complications, Infectious/*drug therapy', 'Pregnancy Trimester, Second/blood', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30873741/
2584,Darunavir,29365125,Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.,"['Pressiat C', 'Hirt D', 'Treluyer JM', 'Zheng Y', 'Morlat P', 'Naqvi A', 'Tran L', 'Viard JP', 'Avettand-Fenoel V', 'Rouzioux C', 'Meyer L', 'Cheret A']","['Adult', 'Anti-HIV Agents/administration & dosage/*pharmacokinetics', 'Darunavir/administration & dosage/*pharmacokinetics', 'Female', 'HIV Infections/drug therapy', 'HIV-1/isolation & purification', 'Humans', 'Male', 'Maraviroc/administration & dosage/*pharmacokinetics', 'Middle Aged', 'Models, Statistical', 'Plasma/*chemistry', 'Raltegravir Potassium/administration & dosage/*pharmacokinetics', 'Ritonavir/administration & dosage/pharmacokinetics', 'Viral Load', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29365125/
2585,Darunavir,30605006,Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.,"['Mena A', 'Cid P', 'Duenas C', 'Garcinuno MA', 'Lorenzo JF', 'Margusino L', 'Quinones M', 'Grande C', 'Rodriguez-Osorio I', 'Castro A']","['Adult', 'Cobicistat/administration & dosage/*therapeutic use', 'Cohort Studies', 'Darunavir/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'HIV Infections/*drug therapy', 'Humans', 'Male', 'Middle Aged', 'Prospective Studies', 'Ritonavir/administration & dosage/*therapeutic use', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/30605006/
2586,Darunavir,25202920,Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.,"['Malvestutto CD', 'Ma Q', 'Morse GD', 'Underberg JA', 'Aberg JA']","['Adolescent', 'Adult', 'Alkynes', 'Anti-HIV Agents/*pharmacokinetics', 'Benzoxazines/*pharmacokinetics', 'Cyclopropanes', 'Darunavir', 'Drug Interactions', 'Female', 'HIV Protease Inhibitors/*pharmacokinetics', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacokinetics', 'Male', 'Middle Aged', 'Quinolines/*pharmacokinetics', 'Ritonavir/*pharmacokinetics', 'Sulfonamides/*pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25202920/
2587,Darunavir,29395300,"Effect of body weight and composition on efavirenz, atazanavir or darunavir concentration.","['Lloret-Linares C', 'Rahmoun Y', 'Lopes A', 'Chopin D', 'Simoneau G', 'Green A', 'Delhotal B', 'Sauvageon H', 'Mouly S', 'Bergmann JF', 'Sellier PO']","['Adult', 'Aged', 'Alkynes', 'Anti-HIV Agents/*pharmacokinetics', 'Atazanavir Sulfate/*pharmacokinetics', 'Benzoxazines/*pharmacokinetics', 'Body Composition/*physiology', 'Body Weight/*physiology', 'Cyclopropanes', 'Darunavir/*pharmacokinetics', 'Female', 'Humans', 'Male', 'Middle Aged', 'Overweight/metabolism']",https://pubmed.ncbi.nlm.nih.gov/29395300/
2588,oxybutynin,24369895,Fesoterodine fumarate and the oxybutynin ring for the treatment of urinary incontinence in women.,"['Rantell A', 'Cardozo L', 'Srikrishna S']","['Benzhydryl Compounds/pharmacology/*therapeutic use', 'Cholinergic Antagonists/pharmacology/*therapeutic use', 'Contraceptive Devices, Female', 'Drug Delivery Systems', 'Female', 'Humans', 'Mandelic Acids/pharmacology/*therapeutic use', 'Urinary Bladder, Overactive/drug therapy', 'Urinary Incontinence/*drug therapy', 'Urological Agents/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24369895/
2589,oxybutynin,30395486,"The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.","['Taranto-Montemurro L', 'Messineo L', 'Sands SA', 'Azarbarzin A', 'Marques M', 'Edwards BA', 'Eckert DJ', 'White DP', 'Wellman A']","['Adrenergic Uptake Inhibitors/*therapeutic use', 'Atomoxetine Hydrochloride/*therapeutic use', 'Cross-Over Studies', 'Double-Blind Method', '*Drug Combinations', 'Female', 'Humans', 'Male', 'Mandelic Acids/*therapeutic use', 'Middle Aged', 'Parasympatholytics/*therapeutic use', 'Placebo Effect', 'Sleep/*drug effects', 'Sleep Apnea, Obstructive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30395486/
2590,oxybutynin,26852022,Combinatorial synthesis of deuterium-enriched (S)-oxybutynin.,"['Li F', 'Jiang W', 'Czarnik AW', 'Li W']","['Combinatorial Chemistry Techniques', 'Deuterium/*chemistry', 'Mandelic Acids/*chemical synthesis/chemistry', 'Molecular Structure']",https://pubmed.ncbi.nlm.nih.gov/26852022/
2591,oxybutynin,19901914,Intravesical oxybutynin in the pediatric neurogenic bladder.,['Lazarus J'],"['Administration, Intravesical', 'Child', 'Humans', 'Mandelic Acids/*administration & dosage', 'Muscarinic Antagonists/*administration & dosage', 'Urinary Bladder, Neurogenic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19901914/
2592,oxybutynin,358527,Effect of oxybutynin chloride on bladder spasm following transurethral surgery.,"['Wein AJ', 'Hanno PM', 'Raezer DM', 'Benson GS']","['Aged', 'Clinical Trials as Topic', 'Cyclohexanes/therapeutic use', 'Double-Blind Method', 'Drug Evaluation', 'Humans', 'Male', 'Mandelic Acids/*therapeutic use', 'Middle Aged', 'Parasympatholytics/*therapeutic use', 'Placebos', 'Postoperative Complications/drug therapy', 'Prostatectomy/adverse effects', 'Spasm/*drug therapy', 'Urinary Bladder/surgery', 'Urinary Bladder Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/358527/
2593,oxybutynin,28538882,Oxybutynin as an alternative treatment for hyperhidrosis.,"['Delort S', 'Marchi E', 'Correa MA']","['Humans', 'Hyperhidrosis/*drug therapy', 'Mandelic Acids/adverse effects/*therapeutic use', 'Muscarinic Antagonists/adverse effects/*therapeutic use', 'Sweat Glands/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28538882/
2594,oxybutynin,34041778,Hematohidrosis of the mid-face and hands treated with oral oxybutynin.,"['Tirthani K', 'Sardana K', 'Mathachan SR']","['Adolescent', 'Female', 'Hand', '*Hemorrhage', 'Humans', 'Mandelic Acids', '*Sweat Gland Diseases']",https://pubmed.ncbi.nlm.nih.gov/34041778/
2595,oxybutynin,7006730,The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride.,"['Moisey CU', 'Stephenson TP', 'Brendler CB']","['Adult', 'Aged', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Mandelic Acids/*therapeutic use', 'Middle Aged', 'Parasympatholytics/*therapeutic use', 'Urinary Bladder, Neurogenic/complications', 'Urination Disorders/*drug therapy/etiology/physiopathology', 'Urodynamics/drug effects']",https://pubmed.ncbi.nlm.nih.gov/7006730/
2596,oxybutynin,36869926,Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials.,"['El-Samahy M', 'Mouffokes A', 'Badawy MM', 'Amro S', 'Fayad T', 'Abdelwahab OA']","['Humans', 'Treatment Outcome', '*Quality of Life', 'Randomized Controlled Trials as Topic', '*Hyperhidrosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36869926/
2597,oxybutynin,26321038,The value of oxybutynin in transdermal patches for treating overactive bladder.,"['Salinas-Casado J', 'Esteban-Fuertes M', 'Serrano O', 'Galvan J']","['Humans', 'Mandelic Acids/*administration & dosage', 'Muscarinic Antagonists/*administration & dosage', '*Transdermal Patch', 'Urinary Bladder, Overactive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26321038/
2598,oxybutynin,8365449,Comparison of urodynamic findings and response to oxybutynin in nocturnal enuresis.,"['Persson-Junemann C', 'Seemann O', 'Kohrmann KU', 'Junemann KP', 'Alken P']","['Adolescent', 'Child', 'Enuresis/*drug therapy/physiopathology', 'Female', 'Humans', 'Male', 'Mandelic Acids/pharmacology/*therapeutic use', 'Muscle Contraction/drug effects', 'Parasympatholytics/pharmacology/*therapeutic use', 'Urodynamics/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/8365449/
2599,oxybutynin,38296001,Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment.,"['Chancellor MB', 'Lucioni A', 'Staskin D']","['Humans', '*Urinary Bladder, Overactive/drug therapy', 'Cholinergic Antagonists/adverse effects', 'Mandelic Acids/adverse effects', '*Cognitive Dysfunction/chemically induced', 'Muscarinic Antagonists/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38296001/
2600,oxybutynin,36538809,"One Month Dosing of Atomoxetine plus Oxybutynin in Obstructive Sleep Apnea: A Randomized, Placebo-controlled Trial.","['Aishah A', 'Loffler KA', 'Toson B', 'Mukherjee S', 'Adams RJ', 'Altree TJ', 'Ainge-Allen HW', 'Yee BJ', 'Grunstein RR', 'Carberry JC', 'Eckert DJ']","['Male', 'Humans', 'Atomoxetine Hydrochloride/adverse effects', '*Muscarinic Antagonists/adverse effects', '*Sleep Apnea, Obstructive/drug therapy', 'Oxygen/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36538809/
2601,oxybutynin,17329869,The effects of external heating on the permeation of oxybutynin through human epidermal membrane.,"['Mizushima H', 'Inoue K', 'Ishizuka H']","['Administration, Cutaneous', 'Algorithms', 'Cadaver', 'Drug Delivery Systems', 'Electricity', 'Epidermis/*metabolism', 'Heating/*methods', 'Humans', 'In Vitro Techniques', 'Isosorbide Dinitrate/administration & dosage/pharmacokinetics', 'Mandelic Acids/administration & dosage/chemistry/*pharmacokinetics', 'Muscarinic Antagonists/administration & dosage/chemistry/pharmacokinetics', '*Skin Absorption', 'Solubility', 'Stereoisomerism', 'Temperature', 'Thermodynamics', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/17329869/
2602,oxybutynin,35575444,Oxybutynin nanosuspension gel for enhanced transdermal treatment for overactive bladder syndrome.,"['Sheng Y', 'Zhang S', 'Ling J', 'Hu C', 'Zhang Z', 'Lv H']","['Administration, Cutaneous', 'Gels', 'Humans', 'Mandelic Acids/adverse effects', 'Muscarinic Antagonists/adverse effects', '*Urinary Bladder, Overactive/chemically induced/drug therapy/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35575444/
2603,oxybutynin,19732583,Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases.,"['Gish P', 'Mosholder AD', 'Truffa M', 'Johann-Liang R']","['Adolescent', 'Adult', 'Adverse Drug Reaction Reporting Systems/*statistics & numerical data', 'Age Factors', 'Central Nervous System/drug effects', 'Child', 'Child, Preschool', 'Databases as Topic', 'Humans', 'Infant', 'Mandelic Acids/administration & dosage/*adverse effects', 'Middle Aged', 'Muscarinic Antagonists/administration & dosage/*adverse effects', 'Nervous System Diseases/*chemically induced', 'Nocturnal Enuresis/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19732583/
2604,oxybutynin,37555595,The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome.,"['Combs D', 'Edgin J', 'Hsu CH', 'Bottrill K', 'Van Vorce H', 'Gerken B', 'Matloff D', 'La Rue S', 'Parthasarathy S']","['Child', 'Humans', 'Atomoxetine Hydrochloride/therapeutic use', '*Down Syndrome/complications', 'Quality of Life', '*Sleep Apnea, Obstructive/complications/drug therapy', 'Treatment Outcome', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37555595/
2605,oxybutynin,39225443,An Updated Structure of Oxybutynin Hydrochloride.,"['Lin J', 'Bu G', 'Unge J', 'Gonen T']","['*Mandelic Acids/chemistry', '*Molecular Docking Simulation/methods', '*Muscarinic Antagonists/chemistry/pharmacology', 'X-Ray Diffraction/methods', 'Models, Molecular', 'Receptor, Muscarinic M3/chemistry/metabolism']",https://pubmed.ncbi.nlm.nih.gov/39225443/
2606,Palonosetron,21752467,Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients.,"['Rigacci L', 'Landi C', 'Caruso JP', 'Puccini B', 'Alterini R', 'Carrai V', 'Perrone T', 'Bosi A']","['Adult', 'Aged', 'Antiemetics/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects', 'Bleomycin/adverse effects', 'Dacarbazine/adverse effects', 'Dexamethasone/*administration & dosage', 'Doxorubicin/adverse effects', 'Drug Therapy, Combination', 'Female', 'Hodgkin Disease/*drug therapy', 'Humans', 'Isoquinolines/*administration & dosage', 'Male', 'Middle Aged', 'Nausea/chemically induced/*prevention & control', 'Palonosetron', 'Prospective Studies', 'Quinuclidines/*administration & dosage', 'Serotonin Antagonists/administration & dosage', 'Treatment Outcome', 'Vinblastine/adverse effects', 'Vomiting/chemically induced/*prevention & control', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21752467/
2607,Palonosetron,34292534,Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.,['Shirley M'],"['Administration, Intravenous', 'Administration, Oral', 'Antiemetics/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Antineoplastic Agents/adverse effects', 'Clinical Trials as Topic', 'Dexamethasone/therapeutic use', 'Drug Combinations', 'Drug Interactions', 'Humans', 'Isoquinolines/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Nausea/chemically induced/*drug therapy', 'Pyridines/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Quinuclidines/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Vomiting/chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34292534/
2608,Palonosetron,33617380,Efficacy of palonosetron-dexamethasone combination compared to palonosetron alone for prophylaxis against postoperative nausea and vomiting.,"['Jin Z', 'Kowa CY', 'Gan S', 'Lin J', 'Gan TJ']","['Adult', '*Anesthesia', '*Antiemetics/therapeutic use', 'Dexamethasone/therapeutic use', 'Humans', 'Palonosetron', 'Postoperative Nausea and Vomiting/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/33617380/
2609,Palonosetron,35570542,Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.,"['Aapro M', 'Jordan K', 'Scotte F', 'Celio L', 'Karthaus M', 'Roeland E']","['*Antiemetics/adverse effects/therapeutic use', '*Antineoplastic Agents/adverse effects', 'Benzeneacetamides', 'Dexamethasone', 'Humans', 'Nausea/chemically induced/prevention & control', 'Palonosetron/adverse effects/therapeutic use', 'Piperazines', 'Pyridines', 'Quality of Life', 'Vomiting/chemically induced/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/35570542/
2610,Palonosetron,31865713,A narrative review of tropisetron and palonosetron for the control of chemotherapy-induced nausea and vomiting.,"['Yang Y', 'Zhang L']","['Antineoplastic Agents/*adverse effects', 'Female', 'Humans', 'Male', 'Nausea/chemically induced/*drug therapy', 'Neoplasms/*complications', 'Palonosetron/pharmacology/*therapeutic use', 'Tropisetron/pharmacology/*therapeutic use', 'Vomiting/chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31865713/
2611,Palonosetron,26296300,Efficacy of palonosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis.,"['Xiong C', 'Liu G', 'Ma R', 'Xue J', 'Wu A']","['Antiemetics/*therapeutic use', 'Humans', 'Isoquinolines/*therapeutic use', 'Ondansetron/therapeutic use', 'Palonosetron', 'Postoperative Nausea and Vomiting/epidemiology/*prevention & control', 'Quinuclidines/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/26296300/
2612,Palonosetron,33993343,Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.,"['Hsu YC', 'Chen CY', 'Tam KW', 'Hsu CY']","['Antiemetics/*therapeutic use', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Granisetron/adverse effects/*therapeutic use', 'Humans', 'Nausea/chemically induced/*drug therapy', 'Palonosetron/adverse effects/*therapeutic use', 'Quality of Life', 'Randomized Controlled Trials as Topic', 'Serotonin 5-HT3 Receptor Antagonists/therapeutic use', 'Vomiting/chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33993343/
2613,Palonosetron,27992509,Palonosetron and Ramosetron Compared for Effectiveness in Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis.,"['Ahn E', 'Choi G', 'Kang H', 'Baek C', 'Jung Y', 'Woo Y', 'Lee S', 'Chang Y']","['Benzimidazoles/adverse effects/*therapeutic use', 'Female', 'Humans', 'Isoquinolines/adverse effects/*therapeutic use', 'Male', 'Palonosetron', 'Postoperative Nausea and Vomiting/*prevention & control', 'Quinuclidines/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/27992509/
2614,Palonosetron,26613606,Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.,['Keating GM'],"['Antiemetics/administration & dosage/adverse effects/*therapeutic use', 'Antineoplastic Agents/adverse effects', 'Drug Combinations', 'Humans', 'Isoquinolines/administration & dosage/adverse effects/*therapeutic use', 'Nausea/chemically induced/prevention & control', 'Practice Guidelines as Topic', 'Pyridines/administration & dosage/adverse effects/*therapeutic use', 'Quinuclidines/administration & dosage/adverse effects/*therapeutic use', 'Vomiting/chemically induced/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/26613606/
2615,Palonosetron,36810240,Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting.,"['Yip CC', 'Li L', 'Lau TKH', 'Chan VTC', 'Kwok CCH', 'Suen JJS', 'Mo FKF', 'Yeo W']","['Humans', 'Female', '*Antiemetics/adverse effects', 'Palonosetron/adverse effects', 'Olanzapine/adverse effects', 'Quality of Life', 'Retrospective Studies', 'Dexamethasone', 'Vomiting', 'Nausea', '*Breast Neoplasms/drug therapy', '*Antineoplastic Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/36810240/
2616,Palonosetron,28718727,Effects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery.,"['Liu Q', 'Zhou C', 'Bao Z', 'Zhu Y']","['Anesthesia, General/adverse effects', 'Antiemetics/*therapeutic use', 'Humans', 'Isoquinolines/*therapeutic use', 'Laparoscopy/*rehabilitation', 'Ondansetron/*therapeutic use', 'Palonosetron', 'Postoperative Nausea and Vomiting/etiology/physiopathology/*prevention & control', 'Quinuclidines/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28718727/
2617,Palonosetron,35068277,Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting.,"['Halloush S', 'Alhifany AA', 'Alkhatib NS', 'Al Bawab AQ', 'Al-Qawasmeh B', 'Al Shawakri E', 'Koeller J']","['*Antiemetics/therapeutic use', '*Antineoplastic Agents/adverse effects', 'Cost-Benefit Analysis', 'Dexamethasone/therapeutic use', 'Humans', 'Nausea/chemically induced/drug therapy/prevention & control', 'Palonosetron/therapeutic use', 'Quinuclidines/therapeutic use', 'Vomiting/chemically induced/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/35068277/
2618,Palonosetron,21282670,A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.,"['Likun Z', 'Xiang J', 'Yi B', 'Xin D', 'Tao ZL']","['Adult', 'Antiemetics/adverse effects/therapeutic use', 'Antineoplastic Agents/adverse effects/therapeutic use', 'Constipation/chemically induced', 'Dexamethasone/*adverse effects/therapeutic use', 'Headache/chemically induced', 'Humans', 'Infusions, Intravenous', 'Isoquinolines/adverse effects/*therapeutic use', 'Nausea/*chemically induced/*drug therapy/prevention & control', 'Neoplasms/drug therapy', 'Palonosetron', 'Quinuclidines/adverse effects/*therapeutic use', 'Serotonin 5-HT3 Receptor Antagonists/adverse effects/*therapeutic use', 'Treatment Outcome', 'Vomiting/*chemically induced/*drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/21282670/
2619,Palonosetron,39621965,"Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT.","['Zhou H', 'Zhao Y', 'Zhang M', 'Yao J', 'Leng S', 'Li X', 'Lin L', 'Chen J', 'Zhang S', 'Qin X', 'Qin Z', 'Yi T', 'Wang R', 'Li X', 'Yu Y', 'Wang Z', 'Zheng Q', 'Mei J', 'Zang A', 'Li N', 'Cao F', 'Cao K', 'Li W', 'Lu Y', 'Lin D', 'Zhou Y', 'Yang R', 'Fang W', 'Zhou N', 'Yang Y', 'Zhang Y', 'Chen G', 'Zhou T', 'Yang X', 'Wang H', 'Wang Y', 'Huang Y', 'Zhang L']","['Humans', 'Male', 'Female', '*Vomiting/chemically induced/prevention & control/drug therapy', '*Nausea/chemically induced/prevention & control/drug therapy', '*Cisplatin/adverse effects', 'Middle Aged', '*Palonosetron/therapeutic use', '*Antiemetics/therapeutic use/administration & dosage', '*Dexamethasone/administration & dosage/therapeutic use', 'Aged', 'Adult', '*Morpholines/therapeutic use/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Drug Combinations', 'Isoquinolines/therapeutic use/administration & dosage', 'Quinuclidines/administration & dosage/therapeutic use', 'Antineoplastic Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39621965/
2620,Palonosetron,38206711,Comparison of the antiemetic efficacy of a combination of midazolam with ramosetron and midazolam with palonosetron for postoperative nausea and vomiting prophylaxis in laparoscopic cholecystectomy.,"['Lim JA', 'Jo S', 'Choi EK']","['Humans', '*Antiemetics/therapeutic use', 'Palonosetron', 'Postoperative Nausea and Vomiting/drug therapy/prevention & control', 'Midazolam/therapeutic use', '*Cholecystectomy, Laparoscopic/adverse effects', 'Double-Blind Method', '*Benzimidazoles']",https://pubmed.ncbi.nlm.nih.gov/38206711/
2621,Palonosetron,32735029,"Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.","['van der Vorst MJDL', 'Toffoli EC', 'Beusink M', 'van Linde ME', 'van Voorthuizen T', 'Brouwer S', 'van Zweeden AA', 'Vrijaldenhoven S', 'Berends JC', 'Berkhof J', 'Verheul HMW']","['Aged', '*Antiemetics/therapeutic use', '*Antineoplastic Agents/adverse effects', 'Dexamethasone/therapeutic use', 'Double-Blind Method', 'Humans', 'Male', 'Metoclopramide/adverse effects', 'Nausea/chemically induced/drug therapy/prevention & control', 'Palonosetron/therapeutic use', 'Quality of Life', 'Quinuclidines/therapeutic use', 'Vomiting/chemically induced/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/32735029/
2622,Palonosetron,29764184,"Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.","['Chow R', 'Tsao M', 'Chiu L', 'Popovic M', 'Milakovic M', 'Lam H', 'DeAngelis C']","['Adult', 'Aged', 'Aged, 80 and over', 'Antiemetics/therapeutic use', 'Dexamethasone/*therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Isoquinolines/*therapeutic use', 'Male', 'Middle Aged', 'Nausea/*drug therapy/etiology', 'Neoplasms/*radiotherapy', 'Neurokinin-1 Receptor Antagonists/*therapeutic use', 'Palonosetron', 'Quinuclidines/*therapeutic use', 'Radiotherapy/*adverse effects', 'Randomized Controlled Trials as Topic', 'Serotonin Antagonists/therapeutic use', 'Vomiting/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/29764184/
2623,Amlodipine,37551050,Amlodipine in the current management of hypertension.,"['Wang JG', 'Palmer BF', 'Vogel Anderson K', 'Sever P']","['Humans', 'Aged', '*Amlodipine/adverse effects', '*Hypertension', 'Antihypertensive Agents/adverse effects', 'Calcium Channel Blockers/adverse effects', 'Blood Pressure']",https://pubmed.ncbi.nlm.nih.gov/37551050/
2624,Amlodipine,36737518,"Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation.","['Honda A', 'Tahara N', 'Tahara A', 'Bekki M', 'Maeda-Ogata S', 'Sugiyama Y', 'Igata S', 'Nishino Y', 'Matsui T', 'Kurata S', 'Abe T', 'Yamagishi SI', 'Fukumoto Y']","['Humans', 'Middle Aged', 'Aged', '*Amlodipine/pharmacology/therapeutic use', 'Antihypertensive Agents/pharmacology/therapeutic use', 'Blood Pressure', '*Hypertension/diagnostic imaging/drug therapy/complications', 'Angiotensin Receptor Antagonists/pharmacology/therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology/therapeutic use', 'Calcium Channel Blockers/pharmacology/therapeutic use', 'Essential Hypertension/complications/drug therapy', 'Inflammation/diagnostic imaging/complications', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/36737518/
2625,Amlodipine,35667505,"Simultaneous determination of hydrochlorothiazide, amlodipine, and telmisartan with spectrophotometric and HPLC green chemistry applications.","['Tiris G', 'Mehmandoust M', 'Lotfy HM', 'Erk N', 'Joo SW', 'Dragoi EN', 'Vasseghian Y']","['*Amlodipine/analysis', 'Chromatography, High Pressure Liquid/methods', 'Humans', 'Hydrochlorothiazide/analysis', '*Leukemia, Myeloid, Acute', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/35667505/
2626,Amlodipine,23669062,Clinical effects of combined olmesartan medoxomil and amlodipine on clinic and ambulatory blood pressure in elderly patients with resistant hypertension.,"['Ding S', 'Liu J', 'Fu Q', 'Zheng Y']","['Aged', 'Amlodipine/administration & dosage/adverse effects/*therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Blood Pressure Monitoring, Ambulatory', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Imidazoles/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Olmesartan Medoxomil', 'Tetrazoles/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23669062/
2627,Amlodipine,19436661,Amlodipine and valsartan as components of a rational and effective fixed-dose combination.,"['Waeber B', 'Ruilope LM']","['Age Factors', 'Aged', 'Amlodipine/adverse effects/*therapeutic use', 'Amlodipine, Valsartan Drug Combination', 'Angiotensin II Type 1 Receptor Blockers/adverse effects/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Blood Pressure/drug effects', 'Calcium Channel Blockers/adverse effects/*therapeutic use', 'Diuretics/therapeutic use', 'Drug Combinations', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Medication Adherence', 'Middle Aged', 'Tetrazoles/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19436661/
2628,Amlodipine,27731568,Amlodipine-Induced Gingival Overgrowth.,"['Jayanthi R', 'Rajan PB']","['Adult', 'Aged', 'Amlodipine/administration & dosage/*adverse effects', 'Antihypertensive Agents/therapeutic use', 'Calcium Channel Blockers/administration & dosage/*adverse effects', 'Female', 'Gingival Overgrowth/*chemically induced', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/27731568/
2629,Amlodipine,38557512,Comparative Efficacy and Safety of Amlodipine and Losartan Potassium in Essential Hypertension in a Tertiary Hospital of Bangladesh.,"['Shimu RN', 'Majumder S', 'Tarannum F', 'Chowdhury DP', 'Nahar A', 'Afrin A', 'Akter M', 'Nahar S', 'Jahan S', 'Hossain MA']","['Male', 'Humans', 'Female', 'Losartan/therapeutic use/pharmacology', 'Amlodipine/therapeutic use/pharmacology', 'Bangladesh', 'Tertiary Care Centers', 'Antihypertensive Agents/therapeutic use', '*Hypertension/drug therapy', 'Essential Hypertension/drug therapy/chemically induced', 'Blood Pressure', 'Treatment Outcome', '*Mercury/pharmacology/therapeutic use', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/38557512/
2630,Amlodipine,30704023,Study of Interactions between Amlodipine and Quercetin on Human Serum Albumin: Spectroscopic and Modeling Approaches.,"['Vanekova Z', 'Hubcik L', 'Toca-Herrera JL', 'Furtmuller PG', 'Valentova J', 'Mucaji P', 'Nagy M']","['Amlodipine/*chemistry/metabolism/pharmacokinetics', 'Drug Interactions', 'Humans', 'Models, Molecular', 'Molecular Conformation', 'Molecular Structure', 'Protein Binding', '*Quantitative Structure-Activity Relationship', 'Quercetin/*chemistry/metabolism/pharmacokinetics', 'Serum Albumin, Human/*chemistry/metabolism', 'Spectrum Analysis']",https://pubmed.ncbi.nlm.nih.gov/30704023/
2631,Amlodipine,23959544,The effects of amlodipine and S(-)-amlodipine on vascular endothelial function in patients with hypertension.,"['He Y', 'Si D', 'Yang C', 'Ni L', 'Li B', 'Ding M', 'Yang P']","['Amlodipine/chemistry/*therapeutic use', 'Antihypertensive Agents/chemistry/*therapeutic use', 'Blood Pressure/drug effects', 'Calcium Channel Blockers/chemistry/*therapeutic use', 'Cells, Cultured', 'China', 'Cross-Over Studies', 'Endothelium, Vascular/*drug effects/metabolism/physiopathology', 'Female', 'Human Umbilical Vein Endothelial Cells/*drug effects/metabolism', 'Humans', 'Hypertension/diagnosis/*drug therapy/metabolism/physiopathology', 'Male', 'Middle Aged', 'Nitric Oxide/metabolism', 'Nitric Oxide Synthase Type III/antagonists & inhibitors/metabolism', 'Phosphorylation', 'Protein Kinase C/antagonists & inhibitors/metabolism', 'Protein Kinase Inhibitors/pharmacology', 'Time Factors', 'Treatment Outcome', 'Vasodilation/*drug effects', 'Vasodilator Agents/chemistry/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23959544/
2632,Amlodipine,25007309,Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study.,"['Sison J', 'Assaad-Khalil SH', 'Najem R', 'Kitchlew AR', 'Cho B', 'Ueng KC', 'Shete A', 'Knap D']","['Adult', 'Aged', '*Amlodipine/administration & dosage/adverse effects', 'Amlodipine, Valsartan Drug Combination', 'Antihypertensive Agents/administration & dosage', 'Asia', 'Blood Pressure/*drug effects', 'Double-Blind Method', 'Drug Combinations', 'Drug Monitoring', 'Female', 'Heart Failure/drug therapy', 'Humans', 'Hydrochlorothiazide/*administration & dosage', 'Hypertension/diagnosis/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Prospective Studies', 'Research Design', '*Tetrazoles/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25007309/
2633,Amlodipine,24746411,Taste acceptability of pulverized brand-name and generic drugs containing amlodipine or candesartan.,"['Uestuener P', 'Ferrarini A', 'Santi M', 'Mardegan C', 'Bianchetti MG', 'Simonetti GD', 'Milani GP', 'Lava SA']","['Adult', 'Amlodipine/*administration & dosage', 'Angiotensin II Type 1 Receptor Blockers/*administration & dosage', 'Antihypertensive Agents/*administration & dosage', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds', 'Calcium Channel Blockers/*administration & dosage', 'Chemistry, Pharmaceutical', 'Drugs, Generic/*pharmacology', 'Female', 'Humans', 'Male', 'Middle Aged', '*Patient Satisfaction', 'Single-Blind Method', 'Taste Perception/*drug effects', 'Tetrazoles/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/24746411/
2634,Amlodipine,20108992,Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.,['Curran MP'],"['*Amlodipine/administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Anticholesteremic Agents/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Blood Pressure/drug effects', 'Cardiovascular Diseases/*prevention & control', 'Clinical Trials as Topic', 'Drug Combinations', 'Dyslipidemias/*drug therapy', '*Heptanoic Acids/administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Humans', 'Hypertension/*drug therapy', 'Lipoproteins, LDL/drug effects', 'Patient Compliance', '*Pyrroles/administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20108992/
2635,Amlodipine,7636894,The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension.,"['Ajayi AA', 'Akintomide AO']","['Amlodipine/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Drug Tolerance', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hydrochlorothiazide/administration & dosage/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Hypokalemia/chemically induced', 'Male', 'Middle Aged', 'Nigeria', 'Posture', 'Potassium/blood', 'Safety', 'Single-Blind Method', 'Supine Position', 'Urea/blood']",https://pubmed.ncbi.nlm.nih.gov/7636894/
2636,Amlodipine,37322624,Comparison of antihypertensive drugs amlodipine and perindopril on blood pressure variability after long-term treatment of hypertension induced by apatinib and bevacizumab.,"['Zhao W', 'Liu L', 'Chen L']","['Humans', '*Antihypertensive Agents/therapeutic use/pharmacology', 'Perindopril/therapeutic use/pharmacology', 'Amlodipine/therapeutic use/pharmacology', 'Blood Pressure', 'Bevacizumab/adverse effects', '*Hypertension/chemically induced/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37322624/
2637,Sodium chloride,34609547,"Sodium chloride or Plasmalyte-148 evaluation in severe diabetic ketoacidosis (SCOPE-DKA): a cluster, crossover, randomized, controlled trial.","['Ramanan M', 'Attokaran A', 'Murray L', 'Bhadange N', 'Stewart D', 'Rajendran G', 'Pusapati R', 'Petty M', 'Garrett P', 'Kruger P', 'Peake S', 'Billot L', 'Venkatesh B']","['Adult', 'Cross-Over Studies', '*Diabetic Ketoacidosis/drug therapy', 'Fluid Therapy', 'Humans', 'Saline Solution', 'Sodium Chloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34609547/
2638,Sodium chloride,32824070,Reaction of Aldoximes with Sodium Chloride and Oxone under Ball-Milling Conditions.,"['Chen K', 'Niu C', 'Wang GW']","['Chemistry Techniques, Synthetic', 'Oximes/*chemistry', 'Sodium Chloride/*chemistry', 'Solvents/*chemistry', 'Sulfuric Acids/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/32824070/
2639,Sodium chloride,39571221,"Effects of sodium chloride on the textural attributes, rheological properties, microstructure, and 3D printing performance of rice starch-curdlan composite gel.","['Li W', 'Zhang K', 'Qin Y', 'Li M', 'Li H', 'Guo M', 'Xu T', 'Sun Q', 'Ji N', 'Xie F']","['*Oryza/chemistry', '*Starch/chemistry', '*Rheology', '*Sodium Chloride/chemistry', '*Gels/chemistry', '*beta-Glucans/chemistry', '*Printing, Three-Dimensional']",https://pubmed.ncbi.nlm.nih.gov/39571221/
2640,Sodium chloride,25916895,Promoting Effect of Sodium Chloride on the Solubilization and Depolymerization of Cellulose from Raw Biomass Materials in Water.,"['Jiang Z', 'Yi J', 'Li J', 'He T', 'Hu C']","['*Biomass', 'Cellulose/*chemistry', 'Cost-Benefit Analysis', '*Polymerization', 'Sodium Chloride/*chemistry', 'Solubility', 'Solvents/chemistry', 'Water/*chemistry', 'Zea mays/chemistry']",https://pubmed.ncbi.nlm.nih.gov/25916895/
2641,Sodium chloride,5675504,Differential tolerance of streptomycetes to sodium chloride as a taxonomic aid.,"['Tresner HD', 'Hayes JA', 'Backus EJ']","['Culture Media', 'Pigments, Biological/biosynthesis', 'Sodium Chloride/*pharmacology', 'Streptomyces/*classification/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/5675504/
2642,Sodium chloride,29018256,Sodium chloride effect on the aggregation behaviour of rhamnolipids and their antifungal activity.,"['Rodrigues AI', 'Gudina EJ', 'Teixeira JA', 'Rodrigues LR']","['Antifungal Agents/*pharmacology', 'Aspergillus/drug effects', 'Fungi/drug effects/growth & development', 'Glycolipids/*chemistry/isolation & purification/*pharmacology', 'Micelles', 'Microbial Sensitivity Tests', 'Pseudomonas aeruginosa/drug effects', 'Sodium Chloride/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29018256/
2643,Sodium chloride,10746580,"Inhibitory combinations of nisin, sodium chloride, and pH on Listeria monocytogenes ATCC 15313 in broth by an experimental design approach.","['Bouttefroy A', 'Mansour M', 'Linder M', 'Milliere JB']","['Anti-Bacterial Agents/*pharmacology', '*Food Microbiology', 'Hydrogen-Ion Concentration', '*Listeria monocytogenes/drug effects', 'Nisin/*pharmacology', 'Sodium Chloride/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10746580/
2644,Sodium chloride,34742411,"Kinetics of denaturation and renaturation processes of double-stranded helical polysaccharide, xanthan in aqueous sodium chloride.","['Tomofuji Y', 'Matsuo K', 'Terao K']","['Carbohydrate Conformation', 'Circular Dichroism/methods', 'Kinetics', 'Molecular Conformation', 'Polysaccharides, Bacterial/*chemistry', 'Scattering, Small Angle', 'Sodium Chloride/*chemistry', 'Temperature', 'Water/*chemistry', 'X-Ray Diffraction/methods']",https://pubmed.ncbi.nlm.nih.gov/34742411/
2645,Sodium chloride,38159714,Comparison of the effect of Sodium Chloride concentration on protein determination: Bradford and Biuret methods.,['Miranda MP'],"['*Biuret/analysis', 'Sodium Chloride', 'Proteins/analysis', 'Spectrophotometry/methods']",https://pubmed.ncbi.nlm.nih.gov/38159714/
2646,Sodium chloride,25133748,Effect of sodium chloride on hydration structures of PMEA and P(MPC-r-BMA).,"['Morita S', 'Tanaka M']","['Acrylates/*chemistry', 'Polymers/*chemistry', 'Sodium Chloride/*chemistry', 'Water/chemistry']",https://pubmed.ncbi.nlm.nih.gov/25133748/
2647,Sodium chloride,7365456,Effect of sodium chloride on the activity and production of staphylococcal exonuclease.,"['Udou T', ""Ichik'awa Y""]","['Calcium/pharmacology', 'Dose-Response Relationship, Drug', 'Hydrogen-Ion Concentration', 'Micrococcal Nuclease/*biosynthesis', 'Sodium Chloride/*pharmacology', 'Staphylococcus aureus/*enzymology']",https://pubmed.ncbi.nlm.nih.gov/7365456/
2648,Sodium chloride,25466549,Sodium chloride toxicity and the cellular basis of salt tolerance in halophytes.,"['Flowers TJ', 'Munns R', 'Colmer TD']","['Salinity', '*Salt Tolerance', 'Salt-Tolerant Plants/*drug effects', 'Sodium Chloride/*toxicity', 'Stress, Physiological']",https://pubmed.ncbi.nlm.nih.gov/25466549/
2649,Sodium chloride,34842759,"Sodium Chloride, Migraine and Salt Withdrawal: Controversy and Insights.",['Brown RB'],"['*Headache Disorders, Secondary', 'Humans', '*Migraine Disorders/drug therapy', 'Pain', 'Sodium Chloride/adverse effects', 'Sodium Chloride, Dietary/adverse effects', '*Substance Withdrawal Syndrome', '*Substance-Related Disorders']",https://pubmed.ncbi.nlm.nih.gov/34842759/
2650,Sodium chloride,22728959,Sodium chloride affects propidium monoazide action to distinguish viable cells.,"['Barth VC Jr', 'Cattani F', 'Ferreira CA', 'de Oliveira SD']","['Azides/*pharmacology', 'DNA, Bacterial/genetics', 'Genome, Bacterial/genetics', 'Halobacterium salinarum/*cytology/*drug effects/genetics', 'Microbial Viability/*drug effects', 'Polymerase Chain Reaction', 'Propidium/*analogs & derivatives/pharmacology', 'Sodium Chloride/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/22728959/
2651,Sodium chloride,3966472,Sodium chloride pica secondary to iron-deficiency anemia.,"['Shapiro MD', 'Linas SL']","['Adult', 'Anemia, Hypochromic/*complications', 'Female', 'Humans', 'Hypernatremia/etiology', 'Pica/*etiology', '*Sodium Chloride']",https://pubmed.ncbi.nlm.nih.gov/3966472/
2652,Sodium chloride,7299654,"Sodium chloride equivalents, cryoscopic properties, and hemolytic effects of certain medicinals in aqueous solution IV: Supplemental values.",['Hammarlund ER'],"['Chemical Phenomena', 'Chemistry, Pharmaceutical', 'Chemistry, Physical', 'Freezing', 'Hemolysis/*drug effects', 'Humans', 'Hydrogen-Ion Concentration', 'In Vitro Techniques', '*Osmolar Concentration', 'Sodium Chloride/pharmacology', 'Solubility', '*Solutions']",https://pubmed.ncbi.nlm.nih.gov/7299654/
2653,Sodium chloride,5713452,The thermodynamic activity of calcium ion in sodium chloride-calcium chloride electrolytes.,['Butler JN'],"['*Calcium', '*Calcium Chloride', 'Electrolytes', 'Osmolar Concentration', '*Sodium Chloride', '*Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/5713452/
2654,Sodium chloride,446652,Adhesion of human red blood cells to polystyrene. Influence of sodium chloride concentration and of neuraminidase treatment.,['Horisberger M'],"['Cell Adhesion/drug effects', 'Electrophysiology', 'Erythrocytes/drug effects/*physiology', 'Humans', 'In Vitro Techniques', 'Neuraminidase/*pharmacology', 'Osmolar Concentration', '*Polystyrenes', 'Sodium Chloride/*blood']",https://pubmed.ncbi.nlm.nih.gov/446652/
2655,Sodium chloride,36566700,High extracellular sodium chloride concentrations induce resistance to LPS signal in human dendritic cells.,"['Al-Hajj S', 'Lemoine R', 'Chadet S', 'Goumard A', 'Legay L', 'Roxburgh E', 'Heraud A', 'Deluce N', 'Lamendour L', 'Burlaud-Gaillard J', 'Gatault P', 'Buchler M', 'Roger S', 'Halimi JM', 'Baron C']","['Humans', '*Sodium Chloride/pharmacology/metabolism', '*Lipopolysaccharides/pharmacology/metabolism', 'Cell Differentiation', 'Chlorides/metabolism/pharmacology', 'Dendritic Cells', 'Cytokines/metabolism', 'Sodium/metabolism/pharmacology', 'Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/36566700/
2656,Sorafenib,37814030,Binding of berberine to PEBP1 synergizes with sorafenib to induce the ferroptosis of hepatic stellate cells.,"['Xie Z', 'Zhou Y', 'Lin M', 'Huang C']","['Humans', 'Sorafenib/pharmacology/metabolism/therapeutic use', 'Hepatic Stellate Cells/metabolism/pathology', '*Berberine/pharmacology/metabolism/therapeutic use', '*Ferroptosis', 'Liver Cirrhosis/drug therapy/metabolism', 'Phosphatidylethanolamine Binding Protein/genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37814030/
2657,Sorafenib,37499670,"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.","['Qin S', 'Chan SL', 'Gu S', 'Bai Y', 'Ren Z', 'Lin X', 'Chen Z', 'Jia W', 'Jin Y', 'Guo Y', 'Hu X', 'Meng Z', 'Liang J', 'Cheng Y', 'Xiong J', 'Ren H', 'Yang F', 'Li W', 'Chen Y', 'Zeng Y', 'Sultanbaev A', 'Pazgan-Simon M', 'Pisetska M', 'Melisi D', 'Ponomarenko D', 'Osypchuk Y', 'Sinielnikov I', 'Yang TS', 'Liang X', 'Chen C', 'Wang L', 'Cheng AL', 'Kaseb A', 'Vogel A']","['Humans', '*Carcinoma, Hepatocellular/drug therapy', 'Sorafenib/therapeutic use', '*Liver Neoplasms/drug therapy', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37499670/
2658,Sorafenib,32532960,The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.,"['Tang W', 'Chen Z', 'Zhang W', 'Cheng Y', 'Zhang B', 'Wu F', 'Wang Q', 'Wang S', 'Rong D', 'Reiter FP', 'De Toni EN', 'Wang X']","['Apoptosis/drug effects', 'Carcinoma, Hepatocellular/*drug therapy/genetics/pathology', 'Cell Proliferation/drug effects', 'Drug Resistance, Neoplasm/drug effects/*genetics', 'Humans', 'Liver Neoplasms/*drug therapy/genetics/pathology', 'Sorafenib/adverse effects/*therapeutic use', 'Tumor Microenvironment/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32532960/
2659,Sorafenib,38458013,Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.,"['Dong R', 'Wang T', 'Dong W', 'Zhu H', 'Liu Q', 'Liang H', 'Chen X', 'Zhang B', 'Zhang X']","['Humans', 'Sorafenib/pharmacology/therapeutic use', '*Carcinoma, Hepatocellular/pathology', '*Antineoplastic Agents/pharmacology/therapeutic use', '*Liver Neoplasms/pathology', 'Cell Line, Tumor', 'Cell Proliferation', 'Drug Resistance, Neoplasm']",https://pubmed.ncbi.nlm.nih.gov/38458013/
2660,Sorafenib,30575484,Sorafenib for Advanced and Refractory Desmoid Tumors.,"['Gounder MM', 'Mahoney MR', 'Van Tine BA', 'Ravi V', 'Attia S', 'Deshpande HA', 'Gupta AA', 'Milhem MM', 'Conry RM', 'Movva S', 'Pishvaian MJ', 'Riedel RF', 'Sabagh T', 'Tap WD', 'Horvat N', 'Basch E', 'Schwartz LH', 'Maki RG', 'Agaram NP', 'Lefkowitz RA', 'Mazaheri Y', 'Yamashita R', 'Wright JJ', 'Dueck AC', 'Schwartz GK']","['Adolescent', 'Adult', 'Aged', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Desmoid Tumors/*drug therapy/mortality', 'Follow-Up Studies', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Progression-Free Survival', 'Sorafenib/adverse effects/*therapeutic use', 'Survival Rate', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30575484/
2661,Sorafenib,31029219,Sorafenib.,"['Abdelgalil AA', 'Alkahtani HM', 'Al-Jenoobi FI']","['Antineoplastic Agents/chemistry/*pharmacology', 'Sorafenib/chemistry/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/31029219/
2662,Sorafenib,31918403,The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.,"['Xia S', 'Pan Y', 'Liang Y', 'Xu J', 'Cai X']","['Carcinoma, Hepatocellular/*drug therapy/*metabolism/pathology', '*Drug Resistance, Neoplasm/drug effects', 'Epigenesis, Genetic/drug effects', 'Humans', 'Liver Neoplasms/*drug therapy/*metabolism/pathology', 'Sorafenib/pharmacology/*therapeutic use', '*Tumor Microenvironment/drug effects/genetics']",https://pubmed.ncbi.nlm.nih.gov/31918403/
2663,Sorafenib,38147732,From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma.,"['Wang Z', 'Zhou C', 'Zhang Y', 'Tian X', 'Wang H', 'Wu J', 'Jiang S']","['Humans', '*Carcinoma, Hepatocellular/pathology', 'Sorafenib/pharmacology/therapeutic use', '*Liver Neoplasms/pathology', '*Ferroptosis', '*Antineoplastic Agents/pharmacology/therapeutic use', 'Cell Line, Tumor']",https://pubmed.ncbi.nlm.nih.gov/38147732/
2664,Sorafenib,35946175,ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma.,"['Shi Y', 'Shang J', 'Li Y', 'Zhong D', 'Zhang Z', 'Yang Q', 'Lai C', 'Feng T', 'Yao Y', 'Huang X']","['Humans', '*Carcinoma, Hepatocellular/pathology', 'Sorafenib/therapeutic use', '*Liver Neoplasms/pathology', 'Drug Resistance, Neoplasm/genetics', 'Cell Line, Tumor', 'Hypoxia']",https://pubmed.ncbi.nlm.nih.gov/35946175/
2665,Sorafenib,33127619,(11)C-Sorafenib and (15)O-H(2)O PET for Early Evaluation of Sorafenib Therapy.,"['Mammatas LH', 'Yaqub M', 'Hendrikse NH', 'Hoekstra OS', 'Honeywell RJ', 'Schuit RC', 'Meijerink M', 'Schwarte LA', 'Peters GJ', 'Verheul HMW', 'Lammertsma AA', 'Menke-van der Houven van Oordt CW']","['*Sorafenib/therapeutic use', 'Humans', 'Male', '*Positron-Emission Tomography', 'Female', 'Middle Aged', 'Aged', 'Treatment Outcome', 'Oxygen Radioisotopes', 'Neoplasms/drug therapy/diagnostic imaging', 'Carbon Radioisotopes', 'Antineoplastic Agents/therapeutic use', 'Adult', 'Prospective Studies', 'Phenylurea Compounds/therapeutic use/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/33127619/
2666,Sorafenib,31931920,Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.,"['Fleeman N', 'Houten R', 'Bagust A', 'Richardson M', 'Beale S', 'Boland A', 'Dundar Y', 'Greenhalgh J', 'Hounsome J', 'Duarte R', 'Shenoy A']","['Antineoplastic Agents/*therapeutic use', '*Cost-Benefit Analysis', 'Humans', 'Iodine Radioisotopes/therapeutic use', 'Phenylurea Compounds/*therapeutic use', 'Quality-Adjusted Life Years', 'Quinolines/*therapeutic use', 'Sorafenib/*therapeutic use', 'Technology Assessment, Biomedical', 'Thyroid Neoplasms/*drug therapy', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/31931920/
2667,Sorafenib,34185551,"Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.","['Qin S', 'Bi F', 'Gu S', 'Bai Y', 'Chen Z', 'Wang Z', 'Ying J', 'Lu Y', 'Meng Z', 'Pan H', 'Yang P', 'Zhang H', 'Chen X', 'Xu A', 'Cui C', 'Zhu B', 'Wu J', 'Xin X', 'Wang J', 'Shan J', 'Chen J', 'Zheng Z', 'Xu L', 'Wen X', 'You Z', 'Ren Z', 'Liu X', 'Qiu M', 'Wu L', 'Chen F']","['Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use', 'Carcinoma, Hepatocellular/*drug therapy', 'Female', 'Humans', 'Liver Neoplasms/*drug therapy', 'Male', 'Middle Aged', 'Neoplasm Metastasis', 'Pyridines/pharmacology/*therapeutic use', 'Sorafenib/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34185551/
2668,Sorafenib,35473892,Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma.,"['Wang L', 'Wang L', 'Xiao B', 'Cui M', 'Zhang B']","['*Antineoplastic Agents/pharmacology/therapeutic use', '*Carcinoma, Hepatocellular/drug therapy/genetics/pathology', 'Humans', '*Liver Neoplasms/drug therapy/genetics/pathology', '*MicroRNAs', 'Phenylurea Compounds', 'Quinolines', 'Sorafenib/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35473892/
2669,Carmustine,20873990,Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.,"['Nagaiah G', 'Almubarak M', 'Khan M', 'Altaha R']","['Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal/administration & dosage/adverse effects', 'Antibodies, Monoclonal, Humanized', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects', 'Bevacizumab', 'Brain Neoplasms/*cerebrospinal fluid/drug therapy', 'Camptothecin/administration & dosage/adverse effects/analogs & derivatives', 'Carmustine/administration & dosage/*adverse effects', 'Drug Implants/adverse effects', 'Female', 'Glioblastoma/*cerebrospinal fluid/drug therapy', 'Humans', 'Irinotecan', 'Male', 'Neoplasm Recurrence, Local/drug therapy', 'Oligodendroglioma/*cerebrospinal fluid/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20873990/
2670,Carmustine,7044535,"Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.","['Abramson N', 'Lurie P', 'Mietlowski WL', 'Schilling A', 'Bennett JM', 'Horton J']","['Aged', 'Antineoplastic Agents/*administration & dosage/adverse effects', '*Antineoplastic Combined Chemotherapy Protocols', 'Carmustine/administration & dosage/adverse effects', 'Clinical Trials as Topic', 'Cyclophosphamide/administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Melphalan/administration & dosage/adverse effects', 'Middle Aged', 'Multiple Myeloma/*drug therapy', 'Prednisone/administration & dosage/adverse effects', 'Prognosis', 'Prospective Studies', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/7044535/
2671,Carmustine,7833095,"Elevated doses of carmustine and mitomycin C, with lonidamine enhancement and autologous bone marrow transplantation in the treatment of advanced colorectal cancer: results from a pilot study.","['Franchi F', 'Seminara P', 'Codacci Pisanelli G', 'Guazzugli Bonaiuti VP', 'Giovagnorio F', 'Gualdi G']","['Adult', 'Antineoplastic Agents/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', '*Bone Marrow Transplantation', 'Carmustine/administration & dosage', 'Colonic Neoplasms/drug therapy/mortality/*therapy', 'Combined Modality Therapy', 'Drug Administration Schedule', 'Female', 'Humans', 'Indazoles/administration & dosage', 'Male', 'Middle Aged', 'Mitomycin/administration & dosage', 'Pilot Projects', 'Rectal Neoplasms/drug therapy/mortality/*therapy', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/7833095/
2672,Carmustine,38438773,CDKN2A promoter methylation enhances self-renewal of glioblastoma stem cells and confers resistance to carmustine.,"['Wang J', 'Xi YF', 'Zhao Q', 'Guo JH', 'Zhang Z', 'Zhang MB', 'Chang J', 'Wu YQ', 'Su W']","['Humans', '*Carmustine/pharmacology', '*Glioblastoma/drug therapy/genetics', 'Stem Cells', 'Genes, p16', 'Methylation', 'Cyclin-Dependent Kinase Inhibitor p16/genetics']",https://pubmed.ncbi.nlm.nih.gov/38438773/
2673,Carmustine,39527165,"Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection.","['Kanamori M', 'Shibahara I', 'Shimoda Y', 'Akiyama Y', 'Beppu T', 'Ohba S', 'Enomoto T', 'Ono T', 'Mitobe Y', 'Hanihara M', 'Mineharu Y', 'Ishida J', 'Asano K', 'Yoshida Y', 'Natsumeda M', 'Nomura S', 'Abe T', 'Yonezawa H', 'Katakura R', 'Shibui S', 'Kuroiwa T', 'Suzuki H', 'Takei H', 'Matsushita H', 'Saito R', 'Arakawa Y', 'Sonoda Y', 'Hirose Y', 'Kumabe T', 'Yamaguchi T', 'Endo H', 'Tominaga T']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', '*Bevacizumab/therapeutic use/administration & dosage/adverse effects', '*Brain Neoplasms/diagnosis/drug therapy/pathology/radiotherapy', '*Carmustine/administration & dosage/therapeutic use/adverse effects', '*Chemoradiotherapy', '*Glioblastoma/diagnosis/drug therapy/pathology/surgery', 'Magnetic Resonance Imaging', 'Prospective Studies', 'Survival Rate', '*Temozolomide/therapeutic use/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39527165/
2674,Carmustine,2986069,Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas.,"['Miller DF', 'Bay JW', 'Lederman RJ', 'Purvis JD', 'Rogers LR', 'Tomsak RL']","['Adult', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Brain Neoplasms/*drug therapy', 'Carmustine/*adverse effects', 'Carotid Arteries', 'Cisplatin/*adverse effects', 'Conjunctivitis/chemically induced', 'Eye Diseases/*chemically induced', 'Female', 'Glioblastoma/drug therapy', 'Glioma/*drug therapy', 'Humans', 'Infusions, Intra-Arterial', 'Intraocular Pressure/drug effects', 'Neoplasm Recurrence, Local/drug therapy', 'Reflex, Pupillary/drug effects', 'Retinal Diseases/chemically induced', 'Visual Acuity/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2986069/
2675,Carmustine,33952587,Physicochemical stability of carmustine-containing medicinal products after reconstitution and after dilution to ready-to-administer infusion solutions stored refrigerated or at room temperature.,"['Knoll L', 'Kraemer I', 'Thiesen J']","['*Carmustine', 'Temperature', '*Antineoplastic Agents', 'Europe', 'Drug Stability']",https://pubmed.ncbi.nlm.nih.gov/33952587/
2676,Carmustine,36252775,"CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme.","['Radtke L', 'Majchrzak-Celinska A', 'Awortwe C', 'Vater I', 'Nagel I', 'Sebens S', 'Cascorbi I', 'Kaehler M']","['Humans', 'Temozolomide/pharmacology/therapeutic use', '*Glioblastoma/drug therapy/genetics/pathology', 'Carmustine/pharmacology/therapeutic use', 'ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism', 'Lomustine/therapeutic use/pharmacology', 'CRISPR-Cas Systems', 'ATP-Binding Cassette Transporters/metabolism', 'Neoplasm Proteins/metabolism', 'Cell Line, Tumor', 'Drug Resistance, Neoplasm', 'ATP Binding Cassette Transporter, Subfamily B/genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/36252775/
2677,Carmustine,32810491,"microRNA-181a mediates the chemo-sensitivity of glioblastoma to carmustine and regulates cell proliferation, migration, and apoptosis.","['Rezaei T', 'Hejazi M', 'Mansoori B', 'Mohammadi A', 'Amini M', 'Mosafer J', 'Rezaei S', 'Mokhtarzadeh A', 'Baradaran B']","['Antineoplastic Agents, Alkylating/pharmacology/therapeutic use', 'Apoptosis/drug effects/physiology', 'Brain Neoplasms/drug therapy/genetics/*metabolism', 'Carmustine/*pharmacology/therapeutic use', 'Cell Line, Tumor', 'Cell Movement/*drug effects/physiology', 'Cell Proliferation/*drug effects/physiology', 'Dose-Response Relationship, Drug', 'Glioblastoma/drug therapy/genetics/*metabolism', 'Humans', 'MicroRNAs/genetics/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/32810491/
2678,Carmustine,31432377,Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas.,"['Yerram P', 'Reiss SN', 'Modelevsky L', 'Gavrilovic IT', 'Kaley T']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects', 'Bevacizumab/administration & dosage', 'Brain Neoplasms/*drug therapy/pathology', 'Carmustine/administration & dosage', 'Chemical and Drug Induced Liver Injury/*etiology', 'Female', 'Follow-Up Studies', 'Glioma/*drug therapy/pathology', 'Hematologic Diseases/*chemically induced', 'Humans', 'Male', 'Middle Aged', 'Neoplasm Grading', 'Neoplasm Recurrence, Local/*drug therapy/pathology', 'Retrospective Studies', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31432377/
2679,Carmustine,8541728,"Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.","['Lattanzi SC', 'Tosteson T', 'Chertoff J', 'Maurer LH', ""O'Donnell J"", 'LeMarbre PJ', 'Mott L', 'DelPrete SA', 'Forcier RJ', 'Ernstoff MS']","['Adult', 'Age Factors', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Carmustine/administration & dosage', 'Cisplatin/administration & dosage', 'Dacarbazine/administration & dosage', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Melanoma/*drug therapy/secondary', 'Middle Aged', 'Sex Characteristics', 'Survival Rate', 'Tamoxifen/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/8541728/
2680,Carmustine,29476996,Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.,"['Akiyama Y', 'Kimura Y', 'Enatsu R', 'Mikami T', 'Wanibuchi M', 'Mikuni N']","['Adult', 'Aged', 'Angiogenesis Inhibitors/administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use', 'Bevacizumab/administration & dosage/adverse effects', 'Brain Neoplasms/*drug therapy/radiotherapy/surgery', 'Carmustine/administration & dosage/adverse effects', 'Combined Modality Therapy', 'Cranial Irradiation/adverse effects', 'Craniotomy', 'Cysts/etiology', 'Dacarbazine/administration & dosage/adverse effects/analogs & derivatives', 'Disease-Free Survival', 'Drug Administration Schedule', 'Drug Evaluation', 'Drug Implants', 'Drug Synergism', 'Female', 'Follow-Up Studies', 'Glioblastoma/*drug therapy/radiotherapy/surgery', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local/surgery', 'Neurosurgical Procedures', 'Postoperative Hemorrhage/etiology', 'Proportional Hazards Models', 'Retrospective Studies', 'Temozolomide', 'Treatment Outcome', 'Tumor Microenvironment']",https://pubmed.ncbi.nlm.nih.gov/29476996/
2681,Carmustine,38385909,"Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.","['Xin X', 'Lin L', 'Yang Y', 'Wang N', 'Wang J', 'Xu J', 'Wei J', 'Huang L', 'Zheng M', 'Xiao Y', 'Meng F', 'Cao Y', 'Zhu X', 'Zhang Y']","['Humans', 'Male', '*Carmustine/therapeutic use/administration & dosage', '*Melphalan/therapeutic use/administration & dosage', '*Cytarabine/therapeutic use/administration & dosage', 'Female', '*Hematopoietic Stem Cell Transplantation/methods', 'Middle Aged', 'Adult', '*Transplantation, Autologous/methods', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Etoposide/therapeutic use/administration & dosage', '*Vidarabine/*analogs & derivatives/administration & dosage/therapeutic use', 'Prognosis', 'Aged', 'Lymphoma, B-Cell/therapy/mortality', 'Podophyllotoxin/therapeutic use/administration & dosage', 'Immunotherapy, Adoptive/methods', 'Young Adult', 'Combined Modality Therapy', 'Transplantation Conditioning/methods', 'Receptors, Chimeric Antigen/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38385909/
2682,Carmustine,29035395,Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma.,"['Joffe E', 'Rosenberg D', 'Rozovski U', 'Perry C', 'Kirgner I', 'Trestman S', 'Gur O', 'Aviv F', 'Sarid N', 'Kolomansky A', 'Gepstein L', 'Herishanu Y', 'Naparstek E']","['Adult', 'Antineoplastic Agents, Alkylating/pharmacology/*therapeutic use', 'Carmustine/pharmacology/*therapeutic use', 'Cyclophosphamide/pharmacology/*therapeutic use', 'Female', 'Hematopoietic Stem Cell Transplantation/*methods', 'Hodgkin Disease/mortality/*therapy', 'Humans', 'Lymphoma, Non-Hodgkin/mortality/*therapy', 'Male', 'Middle Aged', 'Progression-Free Survival', 'Retrospective Studies', 'Thiotepa/pharmacology/*therapeutic use', 'Transplantation, Autologous/*methods']",https://pubmed.ncbi.nlm.nih.gov/29035395/
2683,Carmustine,39069458,Cisplatin as a Viable and Secure Alternative to Carmustine in BEAM-Based Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma.,"['Acosta-Maldonado BL', 'Padilla-Ortega A', 'Fernandez-Vargas OE', 'Rivera-Fong L', 'Valero-Saldana LM', 'Calderon-Flores E']","['Humans', '*Hematopoietic Stem Cell Transplantation', 'Adult', 'Male', 'Female', '*Carmustine/administration & dosage/therapeutic use', 'Retrospective Studies', '*Cytarabine/administration & dosage/therapeutic use', '*Melphalan/administration & dosage/therapeutic use', '*Transplantation, Autologous', '*Transplantation Conditioning/methods', '*Cisplatin/administration & dosage/therapeutic use', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Middle Aged', 'Young Adult', 'Hodgkin Disease/therapy/mortality', 'Etoposide/administration & dosage', 'Lymphoma/therapy/mortality', 'Adolescent', 'Lymphoma, Non-Hodgkin/therapy/mortality', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39069458/
2684,Carmustine,26806465,AN in vitro evaluation of a carmustine-loaded Nano-co-Plex for potential magnetic-targeted intranasal delivery to the brain.,"['Akilo OD', 'Choonara YE', 'Strydom AM', 'du Toit LC', 'Kumar P', 'Modi G', 'Pillay V']","['Administration, Intranasal', 'Antineoplastic Agents, Alkylating/*administration & dosage/chemistry/pharmacology', 'Brain/metabolism', 'Carmustine/*administration & dosage/chemistry/pharmacology', 'Cell Line, Tumor', 'Cell Survival/drug effects', '*Drug Delivery Systems', 'Drug Liberation', 'Fluorescein-5-isothiocyanate/administration & dosage/chemistry/pharmacology', 'Fluorescent Dyes/administration & dosage/chemistry/pharmacology', 'Humans', 'Magnetite Nanoparticles/*administration & dosage/chemistry', 'Particle Size', 'Polyethyleneimine/administration & dosage/chemistry/pharmacology', 'Polyvinyl Alcohol/administration & dosage/chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/26806465/
2685,Carmustine,37932468,"CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients.","['Wang T', 'Liu P', 'Xu L', 'Gao L', 'Ni X', 'Tang G', 'Chen L', 'Chen J', 'Wang L', 'Wang Y', 'Fu W', 'Yue W', 'Liu N', 'Li R', 'Lu G', 'Luo Y', 'Yang J']","['Humans', 'Carmustine/adverse effects', '*Hematopoietic Stem Cell Transplantation/methods', 'Melphalan/adverse effects', 'Etoposide/adverse effects', 'Semustine', 'Cohort Studies', 'Propensity Score', 'Transplantation, Autologous/methods', 'Neoplasm Recurrence, Local', 'Cyclophosphamide/adverse effects', 'Cytarabine/adverse effects', '*Lymphoma, Large B-Cell, Diffuse/therapy', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37932468/
